<SEC-DOCUMENT>0001104659-25-014838.txt : 20250218
<SEC-HEADER>0001104659-25-014838.hdr.sgml : 20250218
<ACCEPTANCE-DATETIME>20250218171352
ACCESSION NUMBER:		0001104659-25-014838
CONFORMED SUBMISSION TYPE:	S-4
PUBLIC DOCUMENT COUNT:		109
FILED AS OF DATE:		20250218
DATE AS OF CHANGE:		20250218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-285035
		FILM NUMBER:		25636100

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4
<SEQUENCE>1
<FILENAME>glyc-20241231xs4.htm
<DESCRIPTION>FORM-S-4
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 2/18/2025 9:21:26 PM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: 3b6d4724-c266-4092-920f-31d2910d799e -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:glyc="http://glyc.com/20241231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>GLYCOMIMETICS, INC.</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" xs:nil="true" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" name="us-gaap:PreferredStockValue" id="Hidden_D7vkSyJr-EqQ_vMdm49tQQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" xs:nil="true" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" name="us-gaap:PreferredStockValue" id="Hidden_iYvC6zUDDkeqXWNTByTQFA"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden__sNpJ6kWbEi0MrQEFcD_Vw">http://fasb.org/us-gaap/2024#RestructuringCostsAndAssetImpairmentCharges</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_e7QLV2rjm0K6BIn7F2EDZw">http://fasb.org/us-gaap/2024#RestructuringCostsAndAssetImpairmentCharges</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_Cl5USwoH3E2-Yiysk554yw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_wYseKlUGHEeUkGQbXltD3Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" xs:nil="true" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" name="us-gaap:DeferredTaxAssetsNet" id="Hidden_458vb9MY1EioLUCUnC-NFg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" xs:nil="true" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" name="us-gaap:DeferredIncomeTaxLiabilities" id="Hidden_eA0MLaJIrUmo4aiKeTHJNw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" xs:nil="true" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Hidden_hdWUWzn18kiagf-L_qnDbQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" xs:nil="true" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Hidden_NTBSQbNInE69YpwADs5_rw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_svfYtyytSku_5hVzJCGpwg" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_rkMRBeyC_Ee79e86m5b6WA">0.02083</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="Hidden_vgZVo8BJJ0aed1tCmLrUPw">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Fj8fd_U170aoblyabwgvVw" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" id="Hidden_wztLkP3Lm02MgfrAQ67r5g">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_29jmlAx-Ok-3Yvf3ByU8Qg" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" id="Hidden_L7HqH2SU6UKyZQDrUHawow">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_gI4hA-RNTEmj4Ln9TxOBNw" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" id="Hidden_OZBgsrfjlECTU_mCo2b-RA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_YUjaMxLsuk-X-7qE4Kk97w" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" id="Hidden_dvRw_F9A4E-8M7P2Y-W2Tg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Fj8fd_U170aoblyabwgvVw" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" id="Hidden_dPj4OlAFHU2hlppffVMjow">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_29jmlAx-Ok-3Yvf3ByU8Qg" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" id="Hidden_TfZ5_WmvLk69osJya5oqwQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_i4KFkDItQU-W7JjpHj8jIQ">64483958</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" name="us-gaap:LeasePracticalExpedientLessorSingleLeaseComponent" id="Hidden_-J90KSXgGUSREtmuyxhLCA">true</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_GQx9LJBBZk6tvQkeC5S2pg">64393744</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_VaSlxAOYBU-VdhWjQiAv6g" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_36PO8EraXkq8olRkBZDjHw">0.0025</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Hidden_QkjKoOCR1UixNvOHv0BEAQ">true</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="Hidden_gisLThAx_kmBXJrqV8ibaQ">http://fasb.org/us-gaap/2024#RestructuringCostsAndAssetImpairmentCharges</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="dei:EntityCentralIndexKey" id="Tc_3sI6Ro4BHk6YmGfxcbTz3g_6_1">0001253689</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="dei:AmendmentFlag" id="Tc_XfHy7xS8SkOi7WvG1PgsfQ_7_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="glyc-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_SHUtEQJ4gEmeTUN1FXH1Jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_ZY2boBNI1ES9pXTrZe4dfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_TkPU169fb0a115F1Jhn1kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tjhcHjf3qUCUEAGiJHVx7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cIbtCfNf7EazwoGlwZilVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MVa3Xane0EWGuB31zaHGLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_74z7jNQFhUKDHc5lm0MsVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KsS5cukmYkiHF4C6-dXYBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YguH7JjiPk21kMLGoxNsYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wERsIdAgWE-wQCQ81ui9CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AwOVplV_P0mDzPrhrPFQXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSdHWh91dUS21LGrb3eG2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_onqX81APG0Ghn54y5zgaMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_glyc_OtherAwardsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-V6DN7K7xkqKAShmvSchFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:OtherAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K4GuybjZVEmN-yz3jNQQZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_QC2B5nm5zE6wl4KPu8GzAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NeI1DrJAfU2Pdw5yL4hyCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_SGKk_W-IqEa8wgIaEyiQyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JTfAygcVu0yXRQjZySO8fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_V8Yc464DDEuqsw28B2LXXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_KEVqEI1mz0alUnOYmZkAMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_g8Jzg9x9fkCHME1NaPv5rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_svfYtyytSku_5hVzJCGpwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_R_eQJnbT5kGlzY8X-rGidQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_VaSlxAOYBU-VdhWjQiAv6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_l6-d0WjB2EWKO9FwgF6G9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2016_srt_StatementGeographicalAxis_glyc_RockvilleMarylandMember_BcWT7OTHpEyojUQYM5l-wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glyc:RockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_U4gkV-b8YE6xJmFs08VMbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ezQHd-wQf0--shnHTiwUGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_31_2024_kOgWP4JoZ0qcll1HUFWAMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_M5J3K2r_hUe_T0x0UXRjpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_VcdbkkEL90CR6p-GileFsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_glyc_FederalAndStateAuthoritiesMember_0VDyvQ7ZGE6FKTRNibG9Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">glyc:FederalAndStateAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TMq5bdXLv0uPMiT_XpYChA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_R9ETDiIjiEmYnIZRVb5HJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_fba-gQlZbEu4aT4dU-Zdgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_DKDfj7hCjUu3mShq3nI3Gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_28_2024_srt_OwnershipAxis_glyc_CrescentBiopharmaIncMember_srt_StatementScenarioAxis_glyc_PriorToClosingOfPrivatePlacementMember_9Nw2kINcWkOS08dTHYx78Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">glyc:CrescentBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">glyc:PriorToClosingOfPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_28_2024_srt_OwnershipAxis_glyc_CrescentBiopharmaIncMember_srt_StatementScenarioAxis_glyc_PostClosingOfPrivatePlacementMember_vPM54hGTmUeMioQHoVKWoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">glyc:CrescentBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">glyc:PostClosingOfPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_28_2024_srt_OwnershipAxis_glyc_GlycoMimeticsIncMember_srt_StatementScenarioAxis_glyc_PriorToClosingOfPrivatePlacementMember_Tm8848Kss0eZks2g6Tisbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">glyc:GlycoMimeticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">glyc:PriorToClosingOfPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_28_2024_srt_OwnershipAxis_glyc_GlycoMimeticsIncMember_srt_StatementScenarioAxis_glyc_PostClosingOfPrivatePlacementMember_A1VjOonYZ0mFZlFMgXfwHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">glyc:GlycoMimeticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">glyc:PostClosingOfPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8hSvq-SHI0KxvBm4TVYLQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_wZeRx6oRpUKbM_22ALjCXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_J7qgUFtkl0Wo9KigpKzqfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_v6lQTXiXUUmyixAKiaaFgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_mfEME_8KIEOUdPf0enFlBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_J_TWX_FgbkyiMy1gXdMchw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_29jmlAx-Ok-3Yvf3ByU8Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_YUjaMxLsuk-X-7qE4Kk97w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Fj8fd_U170aoblyabwgvVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_gI4hA-RNTEmj4Ln9TxOBNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_goAAe-HQTkGa8mwVYUZwOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_vGzIZ8H2gUCh6mmnJZxOfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_8LGYnV6fdkuBJAJjiuhDlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pj61R-BVG0mAA7jRopE9Lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qaEaEVpgsk2gHQo8gXVEfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_T5bkeU0TREKgcAs7V6M9TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aWlLHTyMG0CvFZ6zPAULSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_R7XVHwnd7U6Sd_9oTQ_uFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EjDnsR2epkyuZXXhTKnIHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2023_srt_StatementGeographicalAxis_glyc_SecondPortionSquareFeetRockvilleMarylandMember_XXtFnEFv6EaiyeUhpgD3cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glyc:SecondPortionSquareFeetRockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2023_srt_StatementGeographicalAxis_glyc_FirstPortionSquareFeetRockvilleMarylandMember_omYj33019EaIg4e-nOCwbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glyc:FirstPortionSquareFeetRockvilleMarylandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HyhkPdyGmU6UnG8nxVmM2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_GranteeStatusAxis_glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_nWojf5k1XEuW7zoLkHsxkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">glyc:ShareBasedPaymentArrangementNewlyHiredEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_1XsemFUZukWboPPsX0QU9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_t2wb_CLKRESBcc-YEXDRlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iGa9kvr1_0OCIlThV88zBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_28_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8BLdTfohekutDmOuRqt3RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lEn5z0QjVECg-jhVCra21w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_28_2024_TP4f-xHx2E2A5iRUPIKLLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_SmdQHOUz5UqCH4SGTEpEHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_Lgi28lfrs0-59NK1_KFagw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_a1VBadA-40-Zv384mN5EKA"><xbrli:measure>glyc:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_employee__mI-PxD8qU-9RiyVThW_0Q"><xbrli:measure>glyc:employee</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_xM6my3fUa0iIeeFWVwoxkA"><xbrli:measure>glyc:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_c5PYJCWbn0-rXPVafi2irQ"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_hVrhBvSi7EWHtMESRprj8Q"><xbrli:measure>glyc:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:9.2pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As filed with the Securities and Exchange Commission on February 18, 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">No. 333-</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk190537201"></a><a id="_2eb53f5a_532f_43f0_9fd5_a7867992d7fe"></a><a id="_Hlk190564412"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="dei:DocumentType" id="Narr_iDrnSZ41mk6K4nMcDQ3qGA"><b style="font-weight:bold;">S-4</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REGISTRATION STATEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">UNDER</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">THE SECURITIES ACT OF 1933</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="dei:EntityRegistrantName" id="Narr_3ND9X9pXrkmq0YXsmPTYLQ"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:12pt;"><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Delaware</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"/><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2834</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"/><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">06-1686563</b></p></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(State or other jurisdiction of <br/>incorporation or organization)</p></td><td style="vertical-align:top;white-space:nowrap;width:2%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"/><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Primary Standard Industrial <br/>Classification Code Number)</p></td><td style="vertical-align:top;white-space:nowrap;width:2%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"/><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(I.R.S. Employer <br/>Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">P.O. Box 65</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Monrovia, Maryland 21770</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (240) 243-1201</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="white-space:pre-wrap;"> (Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Harout Semerjian</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">President and Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">GlycoMimetics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> P.O. Box 65</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Monrovia, Maryland 21770</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (240) 243-1201</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-style:italic;font-weight:bold;">Copies of all communications, including communications sent to agent for service, should be sent to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:12pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Asher M. Rubin, Esq.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">John H. Butler, Esq.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Kostian Ciko, Esq.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Kori M. Cooper, Esq.</b><br/><b style="font-weight:bold;">Sidley Austin LLP</b><br/><b style="font-weight:bold;">787 Seventh Avenue</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">New York, New York 10019</b><br/><b style="font-weight:bold;">(212) 839-5300</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"/><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ryan A. Murr, Esq. </b><br/><b style="font-weight:bold;">Branden C. Berns, Esq. </b><br/><b style="font-weight:bold;">Chris W. Trester, Esq. </b><br/><b style="font-weight:bold;">Gibson, Dunn &amp; Crutcher LLP </b><br/><b style="font-weight:bold;">One Embarcadero Center, Suite 2600 </b><br/><b style="font-weight:bold;">San Francisco, California 94111 </b><br/><b style="font-weight:bold;">(415) 393-8373</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Approximate date of commencement of proposed sale of the securities to the public:  </b>As soon as practicable after the effective date of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;">If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_5ec91ea4_cf9c_4843_91a3_1d2ce40a36c6"></a><a id="Tc_NoCTSNh0g0aBp4X-T60nJw_1_0"></a><a id="Tc_FK8GbE8PvUekwzMBBKSHPw_2_0"></a><a id="Tc_GsCVYPiwfEuult5ioM4Hrg_2_1"></a><a id="Tc_ilwMT9S5A0Gs_6DjU9p91A_2_2"></a><a id="Tc_oN1Z-WfCz0KxctrCr4-OyQ_2_3"></a><a id="Tc_0x3NncECeEOlKGuy9AR3_g_3_1"></a><a id="Tc_USnQRpY1N0aQc3U4PsiOSQ_3_2"></a><a id="Tc_-xiO3IFY7EmBvQx9av699g_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:86.65%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15.38%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:37.68%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:18.08%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:28.83%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15.38%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">GlycoMimetics, Inc.</b></p></td><td style="vertical-align:bottom;width:37.68%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.08%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:28.83%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.38%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:bottom;width:37.68%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:18.08%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:bottom;width:28.83%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:15.38%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="dei:EntityFilerCategory" id="Tc_U9qblJHfckOn8rQVg4th7w_3_0"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:37.68%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:bottom;width:18.08%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:bottom;width:28.83%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt:fixed-true" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="dei:EntitySmallBusiness" id="Tc_rmeuyciYBEiZAELZG5Zctw_3_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:15.38%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"/><td style="vertical-align:bottom;width:37.68%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"/><td style="vertical-align:bottom;width:18.08%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:28.83%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="dei:EntityEmergingGrowthCompany" id="Tc_gOrkuzVz4k-QXMtGtysk7g_4_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 3pt 0pt;">Exchange Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer) <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="height:615.2pt;left:-0.08%;position:absolute;top:17.7pt;width:30pt;z-index:251658240;"><div style="height:615.2pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:29pt;"><div style="left:0pt;max-height:100%;position:relative;text-indent:0pt;top:0pt;transform:rotate(180.1deg);width:29pt;writing-mode:vertical-rl;-ms-writing-mode:tb-rl;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;width:100%;margin:0pt 0pt 12pt 0pt;"><span style="color:#d2232a;">The information in this preliminary proxy statement/prospectus is not complete and may be changed. GlycoMimetics, Inc. may not sell the securities described in this preliminary proxy statement/prospectus until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary proxy statement/prospectus is not an offer to sell and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;width:100%;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:662.9pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e8a5f2eb_c310_4168_97cc_c14352347505"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 36pt;"><b style="color:#d2232a;font-weight:bold;">PRELIMINARY PROXY STATEMENT/PROSPECTUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 36pt;"><b style="color:#d2232a;font-weight:bold;">SUBJECT TO COMPLETION, DATED FEBRUARY 18, 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:52.51%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:47.48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:52.51%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;"><img src="glyc-20241231xs4007.jpg" alt="Graphic" style="display:inline-block;height:47.2pt;width:218.2pt;"/></b></p></td><td style="vertical-align:middle;width:47.48%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;"><img src="glyc-20241231xs4008.jpg" alt="Graphic" style="display:inline-block;height:80.05pt;width:153.2pt;"/></b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">PROPOSED MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">YOUR VOTE IS VERY IMPORTANT</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">To the Stockholders of GlycoMimetics, Inc. and Crescent Biopharma, Inc.,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">GlycoMimetics, Inc., a Delaware corporation (&#8220;GlycoMimetics&#8221;), and Crescent Biopharma, Inc., a Delaware corporation (&#8220;Crescent&#8221;), entered into an Agreement and Plan of Merger and Reorganization on October 28, 2024, which agreement was subsequently amended on February 14, 2025 (as amended, the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Gemini Merger Sub Corp., a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Crescent, with Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Crescent will merge with and into Gemini Merger Sub II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). After the completion of the Merger, Second Merger Sub will change its corporate name to &#8220;Crescent Biopharma Operating Company, LLC&#8221; and GlycoMimetics will change its name to &#8220;Crescent Biopharma, Inc.&#8221; The term &#8220;Combined Company&#8221; when used in the accompanying proxy statement/prospectus refers to the post-Merger corporate structure including Crescent Biopharma, Inc. (f/k/a GlycoMimetics, Inc.) as the parent entity and Crescent Biopharma Operating Company, LLC as its wholly-owned subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">At the closing of the First Merger (the &#8220;First Effective Time&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement: (i) each then-outstanding share of Crescent common stock (including shares of Crescent common stock issued in the Crescent Pre-Closing Financing (as defined below) and excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of GlycoMimetics common stock equal to the Exchange Ratio as described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Exchange Ratio</i>&#8221; beginning on page 135 of the accompanying proxy statement/prospectus (the &#8220;Exchange Ratio&#8221;); (ii) each then-outstanding share of Crescent preferred stock will be converted into the right to receive a number of shares of GlycoMimetics Series A non-voting convertible preferred stock, par value $0.001 per share (&#8220;GlycoMimetics Series A Preferred Stock&#8221;), equal to the Exchange Ratio divided by 1,000; (iii) each then-outstanding option to purchase Crescent common stock will be assumed by GlycoMimetics, subject to adjustment as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Crescent Options</i>&#8221; beginning on page 138 of the accompanying proxy statement/prospectus; (iv) each then-outstanding warrant to purchase shares of Crescent common stock will be converted into a warrant to purchase shares of GlycoMimetics common stock, subject to adjustment as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Crescent Warrants</i>&#8221; beginning on page 139 of the accompanying proxy statement/prospectus; (v) each in-the-money option to acquire shares of GlycoMimetics common stock (the &#8220;GlycoMimetics In the Money Option&#8221;) that is issued and outstanding (whether vested or unvested) will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of shares underlying such option; (vi) each GlycoMimetics restricted stock unit will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of unsettled shares of GlycoMimetics common stock underlying such GlycoMimetics restricted stock unit; and (vii) each share of GlycoMimetics common stock that is issued and outstanding at the First Effective Time will remain issued and outstanding in accordance with its terms and such shares, subject to the proposed reverse stock split, and will be unaffected by the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_09e31670_7690_4a23_b9a9_a0ec1baa37bf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on GlycoMimetics&#8217; capitalization as of September 30, 2024 and Crescent&#8217;s capitalization as of October 28, 2024 (the date the Merger Agreement was executed) and taking into account GlycoMimetics&#8217; current cash position, each share of Crescent common stock is currently estimated to be entitled to receive approximately 14.9149 shares of GlycoMimetics common stock. Each share of Crescent preferred stock will be converted into the right to receive a number of shares of GlycoMimetics Series A Preferred Stock, equal to the Exchange Ratio divided by 1,000. This estimated Exchange Ratio does not give effect to the proposed GlycoMimetics reverse stock split and is subject to adjustment based on GlycoMimetics&#8217; estimated net cash at the closing of the First Merger as described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Exchange Ratio</i>&#8221; beginning on page 135 of the accompanying proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, on February 14, 2025, Crescent and GlycoMimetics entered into an amended and restated subscription agreement (the &#8220;Subscription Agreement&#8221;) with certain institutional and accredited investors for the purchase of shares of Crescent common stock and Crescent pre-funded warrants for an aggregate purchase price of approximately $200.0 million (which includes $37.5 million of proceeds previously received by Crescent from the issuance of its convertible notes in October 2024 (the &#8220;Convertible Notes&#8221;) and accrued interest on such note), immediately prior to the closing of the Merger (referred to herein as the &#8220;Crescent Pre-Closing Financing&#8221;). The shares of Crescent common stock and Crescent pre-funded warrants that are issued in the Crescent Pre-Closing Financing will be converted into the right to receive a number of shares of GlycoMimetics common stock and warrants to purchase shares of GlycoMimetics common stock, respectively, equal to the Exchange Ratio described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Exchange Ratio</i>&#8221; beginning on page 135 of the accompanying proxy statement/prospectus. Crescent and the investors participating in the Crescent Pre-Closing Financing have also agreed to enter into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) at the closing of the Crescent Pre-Closing Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Crescent common stock that are held by the investors participating in the Crescent Pre-Closing Financing from time to time pursuant to Rule 415 under the Securities Act (&#8220;Rule 415&#8221;). The Crescent Pre-Closing Financing is more fully described in the sections titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Subscription Agreement</i>&#8221; and &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Registration Rights Agreement</i>&#8221; beginning on pages 151 and 153, respectively, of the accompanying proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately after the Merger, based solely on the estimated Exchange Ratio as described in the accompanying proxy statement/prospectus, GlycoMimetics securityholders as of immediately prior to the Merger are expected to own approximately 3.10% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis, and subject to dilution from any equity issued by Crescent after the date of the Merger Agreement and before the closing), and former holders of Crescent securities (including those issued in the Crescent Pre-Closing Financing) are expected to own approximately 96.90% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, GlycoMimetics&#8217; net cash as of closing being equal to $1.8 million. Under certain circumstances described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Exchange Ratio</i>&#8221; beginning on page 135 of the accompanying proxy statement/prospectus, the ownership percentages may be adjusted up or down including, but not limited to, if GlycoMimetics&#8217; net cash as of closing is less than $1.725 million or more than $1.875 million. GlycoMimetics currently estimates that its net cash as of closing will be approximately $1.8 million, and the currently estimated ownership percentages reflect this projection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shares of GlycoMimetics common stock are currently listed on Nasdaq under the symbol &#8220;GLYC.&#8221; GlycoMimetics plans to file an initial listing application for the Combined Company with Nasdaq. After completion of the Merger, GlycoMimetics will be renamed &#8220;Crescent Biopharma, Inc.&#8221; and it is expected that the common stock of the Combined Company will trade on Nasdaq under the symbol &#8220;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.&#8221; It is a condition to the consummation of the Merger that GlycoMimetics will receive confirmation from Nasdaq that the Combined Company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that GlycoMimetics will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties. On &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, the last trading day before the date of the accompanying proxy statement/prospectus, the closing sale price of GlycoMimetics common stock was $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics stockholders are cordially invited to attend the special meeting in lieu of the annual meeting of GlycoMimetics stockholders. GlycoMimetics is holding its special meeting in lieu of the annual meeting of stockholders (the &#8220;GlycoMimetics Special Meeting&#8221;) on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Eastern Time, unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the Merger and related matters. At the GlycoMimetics Special Meeting, GlycoMimetics will ask its stockholders to:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Approve (i) the issuance of shares of GlycoMimetics common stock (including the shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series A Preferred Stock), which will represent more than 20% of the shares of GlycoMimetics common stock outstanding immediately prior to the Merger, to stockholders of Crescent, pursuant to the terms of the Merger Agreement, a copy of which is attached as <i style="font-style:italic;">Annex A</i>, including the amendment thereto, to the accompanying proxy statement/prospectus, and (ii) the change of control of GlycoMimetics resulting from the Merger, </p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal No. 1&#8221;);</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Approve an amendment to the amended and restated certificate of incorporation of GlycoMimetics, as amended (the &#8220;GlycoMimetics Charter&#8221;), to increase the number of shares of GlycoMimetics common stock that GlycoMimetics is authorized to issue from 150,000,000&#160;shares to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the form attached as <i style="font-style:italic;">Annex G</i> to the accompanying proxy statement/prospectus (the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal No. 2&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Approve an amendment to the GlycoMimetics Charter to effect a reverse stock split of GlycoMimetics&#8217; issued and outstanding common stock at a ratio in the range between &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, inclusive, in the form attached as <i style="font-style:italic;">Annex H </i>to the accompanying proxy statement/prospectus, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by the GlycoMimetics board of directors (the &#8220;GlycoMimetics Board&#8221;) and the Crescent board of directors (the &#8220;Crescent Board&#8221;) prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by GlycoMimetics stockholders, determined solely by the GlycoMimetics Board (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal No. 3&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Elect the Class II directors, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, to the GlycoMimetics Board and to hold office until GlycoMimetics&#8217; 2028 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal No. 4&#8221;), provided that if the Merger is consummated, the approval of Proposal No. 4 will only have an effect until the completion of the Merger because the composition of the GlycoMimetics Board will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Ratify the appointment of Ernst &amp; Young LLP as GlycoMimetics&#8217; independent registered public accounting firm for fiscal year ending December 31, 2025, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed, as the Combined Company&#8217;s independent registered public accounting firm (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal No. 5&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Approve the Crescent Biopharma, Inc. 2025 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal No. 6&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Approve the Crescent Biopharma, Inc. 2025 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal No. 7&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Approve, on an advisory basis, certain compensation arrangements for GlycoMimetics named executive officers that are based on or otherwise relate to the Merger (the &#8220;the Merger Compensation Proposal&#8221; or &#8220;Proposal No. 8&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">9.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Approve an adjournment of the GlycoMimetics Special Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal No. 9&#8221;); and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">10.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Transact such other business as may properly come before the stockholders at the GlycoMimetics Special Meeting or any adjournment or postponement thereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described in the accompanying proxy statement/prospectus, the directors and officers of GlycoMimetics who in the aggregate owned approximately 10.7% of the outstanding shares of GlycoMimetics capital stock as of February 7, 2025, and certain Crescent stockholders who in the aggregate owned approximately 98.5% of the outstanding shares of Crescent capital stock as of February 7, 2025, are parties to stockholder support agreements with GlycoMimetics and Crescent, respectively, whereby such stockholders have agreed to vote in favor of the adoption of the Merger Agreement and the approval of the Merger and related transactions contemplated by the Merger Agreement, subject to the terms of the support agreements. Following the effectiveness of the registration statement on Form S-4 of which the accompanying proxy statement/prospectus is a part and pursuant to the Merger Agreement, Crescent stockholders holding a sufficient number of shares of Crescent capital stock to adopt the Merger Agreement and approve the Merger and related transactions will be asked to execute written consents providing for such adoption and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While the Combined Company will not be considered a &#8220;controlled company&#8221; under the relevant listing rules of Nasdaq, it is anticipated that the Combined Company executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % of the Combined Company&#8217;s outstanding shares of common stock (on a fully-diluted basis). As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the Combined Company stockholders for approval, as well as the Combined Company&#8217;s management and affairs, though they have no agreement to do so nor any expectation of entering into such an agreement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After careful consideration, each of the GlycoMimetics and the Crescent boards of directors has approved the Merger Agreement and has determined that it is advisable to consummate the Merger. The GlycoMimetics Board has approved the proposals described in the accompanying proxy statement/prospectus and recommends that its stockholders vote &#8220;FOR&#8221; the proposals described in the accompanying proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">More information about GlycoMimetics, Crescent, the Merger Agreement and transactions contemplated thereby and the foregoing proposals is contained in the accompanying proxy statement/prospectus. GlycoMimetics urges you to read the accompanying proxy statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;RISK FACTORS&#8221; BEGINNING ON PAGE</b><b style="font-weight:bold;"> </b><span style="font-weight:bold;">16</span><b style="font-weight:bold;"> </b><b style="font-weight:bold;">OF THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">GlycoMimetics and Crescent are excited about the opportunities the Merger brings to GlycoMimetics&#8217; and Crescent&#8217;s stockholders and thank you for your consideration and continued support.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:21.6pt;"><td style="vertical-align:middle;width:58.43%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Harout Semerjian</p></td><td style="vertical-align:middle;width:41.56%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jonathan Violin</p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:top;width:58.43%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td><td style="vertical-align:top;width:41.56%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Chief Executive Officer and President</i></p></td></tr><tr style="height:18.45pt;"><td style="vertical-align:top;width:58.43%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">GlycoMimetics, Inc.</i></p></td><td style="vertical-align:top;width:41.56%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Crescent Biopharma, Inc.</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy statement/prospectus. Any representation to the contrary is a criminal offense.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying proxy statement/prospectus is dated &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2025, and is first being mailed to GlycoMimetics&#8217; stockholders on or about &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2025.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_903c1181_8a5d_4871_864a_f361c74ce322"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">P.O. Box 65</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Monrovia, MD 21770</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS IN LIEU OF ANNUAL MEETING OF STOCKHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To the stockholders of GlycoMimetics, Inc.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTICE IS HEREBY GIVEN</b> that a virtual special meeting in lieu of annual meeting of stockholders (the &#8220;GlycoMimetics Special Meeting&#8221;) will be held on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Eastern Time, unless postponed or adjourned to a later date. The GlycoMimetics Special Meeting will be held exclusively online. You will be able to attend and participate in the GlycoMimetics Special Meeting online by visiting <i style="font-style:italic;">www. </i>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i style="font-style:italic;">.com</i>, where you will be able to listen to the meeting live, submit questions and vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The GlycoMimetics Special Meeting will be held for the following purposes:</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To approve (i) the issuance of shares of GlycoMimetics common stock (including the shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series A Preferred Stock), which will represent more than 20% of the shares of GlycoMimetics common stock outstanding immediately prior to the Merger, to stockholders of Crescent, pursuant to the terms of the Merger Agreement, a copy of which is attached as <i style="font-style:italic;">Annex A</i>, including the amendment thereto, to the accompanying proxy statement/prospectus, and (ii) the change of control of GlycoMimetics resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To approve an amendment to the amended and restated certificate of incorporation of GlycoMimetics, as amended (the &#8220;GlycoMimetics Charter&#8221;), to increase the number of shares of GlycoMimetics common stock that GlycoMimetics is authorized from 150,000,000 to issue to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , in the form attached as <i style="font-style:italic;">Annex G</i> to the accompanying proxy statement/prospectus;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To approve an amendment to the GlycoMimetics Charter to effect a reverse stock split of GlycoMimetics&#8217; issued and outstanding common stock at a ratio in the range between &#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160; , inclusive, in the form attached as <i style="font-style:italic;">Annex H </i>to the accompanying proxy statement/prospectus, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by the GlycoMimetics Board and the Crescent Board prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by GlycoMimetics stockholders, determined solely by the GlycoMimetics Board;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To elect the Class II directors, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , &#160;&#160;&#160;&#160;&#160;&#160;&#160; , and &#160;&#160;&#160;&#160;&#160; , to the GlycoMimetics Board and to hold office until GlycoMimetics&#8217; 2028 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal, provided that if the Merger is consummated, the approval of Proposal No. 4 will only have an effect until the completion of the Merger because the composition of the GlycoMimetics Board will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To ratify the appointment of Ernst &amp; Young LLP as GlycoMimetics&#8217; independent registered public accounting firm for fiscal year ending December 31, 2025, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed as the Combined Company&#8217;s independent registered public accounting firm;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To approve the Crescent Biopharma, Inc. 2025 Stock Incentive Plan;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To approve the Crescent Biopharma, Inc. 2025 Employee Stock Purchase Plan;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To approve, on an advisory basis, certain compensation arrangements for GlycoMimetics named executive officers that are based on or otherwise relate to the Merger;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">9.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To approve an adjournment of the GlycoMimetics Special Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">10.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To transact such other business as may properly come before the stockholders at the GlycoMimetics Special Meeting or any adjournment or postponement thereof.</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These proposals are collectively referred to as the &#8220;Proposals.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Board has fixed &#160;&#160;&#160;&#160;&#160;&#160;, 2025 as the record date (the &#8220;Record Date&#8221;) for the determination of stockholders entitled to notice of, and to vote at, the GlycoMimetics Special Meeting and any adjournment or postponement thereof. Only holders of record of shares of GlycoMimetics common stock at the close of business on the Record Date are entitled to notice of, and to vote at, the GlycoMimetics Special Meeting. At the close of business on the Record Date, GlycoMimetics had &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of common stock outstanding and entitled to vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Your vote is important. The affirmative vote of a majority of the shares of GlycoMimetics common stock entitled to vote on the subject matter and present at the GlycoMimetics Special Meeting, assuming a quorum is present, is required for approval of Proposal No.&#160;1, Proposal No.&#160;5, Proposal No.&#160;6, Proposal No.&#160;7, Proposal No. 8 and Proposal No. 9. The affirmative vote of at least sixty-six and two-thirds percent (66</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">2/3</sup><b style="font-weight:bold;">%) of the voting power of all then-outstanding shares of GlycoMimetics capital stock entitled to vote generally in the election of directors, voting together as a single class, is required for approval of Proposal No. 2 and Proposal No. 3 at the GlycoMimetics Special Meeting, assuming a quorum is present. With respect to Proposal No.&#160;</b><b style="font-weight:bold;">4</b><b style="font-weight:bold;">, the directors are elected by a plurality of the votes properly cast at the GlycoMimetics Special Meeting, and the three nominees for director receiving the highest numbers of affirmative votes properly cast will be elected. Proposal No. 1 is conditioned on the approval of Proposal No. 2. Notwithstanding the approval of Proposal No.&#160;1, if Proposal No. 2 is not approved, the actions contemplated by Proposal No. 1 will not be effected and the Merger will not be consummated.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">All stockholders are cordially invited to attend the special meeting. Even if you plan to attend the GlycoMimetics Special Meeting, GlycoMimetics requests that you sign and return the enclosed proxy or vote by mail or online to ensure that your shares will be represented at the GlycoMimetics Special Meeting if you are unable to attend. You may change or revoke your proxy at any time before it is voted at the GlycoMimetics Special Meeting.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE GLYCOMIMETICS BOARD HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, IN THE BEST INTERESTS OF, AND ADVISABLE TO GLYCOMIMETICS AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. THE GLYCOMIMETICS BOARD RECOMMENDS THAT GLYCOMIMETICS STOCKHOLDERS VOTE &#8220;FOR&#8221; EACH SUCH PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#8217; Meeting to Be Held on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Eastern Time.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The proxy statement/prospectus, which also serves as the annual report to stockholders in connection with the special meeting in lieu of annual meeting, is available at <i style="font-style:italic;">www.glycomimetics.com.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">By Order of the GlycoMimetics Board of Directors,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Harout Semerjian</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_ca63fcdc_a983_4918_8d98_c3325b06c2c3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXPLANATORY NOTE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The issuances of (i) all shares of GlycoMimetics common stock in exchange for each share of Crescent common stock (including shares of Crescent common stock issued in the Crescent Pre-Closing Financing), (ii) all shares of GlycoMimetics common stock issuable upon exercise of pre-funded warrants issued in exchange for pre-funded warrants to purchase shares of Crescent common stock sold in the Crescent Pre-Closing Financing, and (iii) all shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series A Preferred Stock issued in exchange for each share of Crescent preferred stock, are intended to be covered by this registration statement on Form S-4 of which the accompanying proxy statement/prospectus is a part. There is no difference between the shares of GlycoMimetics common stock that will be issued in exchange for each share of Crescent common stock issued in the Crescent Pre-Closing Financing, the shares of GlycoMimetics common stock that will be issued in exchange for each other share of Crescent common stock, the shares of GlycoMimetics common stock that will be issuable upon the exercise of pre-funded warrants that will be issued in exchange for pre-funded warrants to purchase shares of Crescent common stock sold in the Crescent Pre-Closing Financing and the shares of GlycoMimetics common stock that will be issuable upon conversion of GlycoMimetics Series A Preferred Stock that will be issued in exchange for each share of Crescent preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_261acb02_91ba_41ea_b5f7_7c02fd375bf6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REFERENCES TO ADDITIONAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying proxy statement/prospectus incorporates important business and financial information about GlycoMimetics, Inc. that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission (&#8220;SEC&#8221;) website (<i style="font-style:italic;">www.sec.gov</i>) or upon your written or oral request by contacting P.O. Box 65, Monrovia, MD 21770, Attention: &#160;&#160;&#160; , or by calling (240) 243-1201. GlycoMimetics also maintains a website at <i style="font-style:italic;">www.glycomimetics.com</i>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. However, the information contained in or accessible through GlycoMimetics&#8217; website is not part of the accompanying proxy statement/prospectus or the registration statement of which the accompanying proxy statement/prospectus forms a part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">To ensure timely delivery of these documents, any request should be made no later than &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2025 to receive them before the GlycoMimetics Special Meeting.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For additional details about where you can find information about GlycoMimetics, please see the section titled &#8220;<i style="font-style:italic;">Where You Can Find More Information</i>&#8221; beginning on page 315 of the accompanying proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9e027e51_e184_4ef9_bcdb_30a64c3c626a"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PAGE</b></p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#QUESTIONSANDANSWERSABOUTTHEMERGER_430584"><span style="font-style:normal;font-weight:normal;">QUESTIONS AND ANSWERS ABOUT THE MERGER</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">iii</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#PROSPECTUSSUMMARY_804771"><span style="font-style:normal;font-weight:normal;">PROSPECTUS SUMMARY</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#MARKETPRICEANDDIVIDENDINFORMATION_791020"><span style="font-style:normal;font-weight:normal;">MARKET PRICE AND DIVIDEND INFORMATION</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#RISKFACTORS_941803"><span style="font-style:normal;font-weight:normal;">RISK FACTORS</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"><span style="font-style:normal;font-weight:normal;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#THESPECIALMEETINGINLIEUOFANNUALMEETINGOF"><span style="font-style:normal;font-weight:normal;">THE SPECIAL MEETING IN LIEU OF ANNUAL MEETING OF GLYCOMIMETICS STOCKHOLDERS</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">94</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#THEMERGER_985712"><span style="font-style:normal;font-weight:normal;">THE MERGER</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">99</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#THEMERGERAGREEMENT_134884"><span style="font-style:normal;font-weight:normal;">THE MERGER AGREEMENT</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">134</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#AGREEMENTSRELATEDTOTHEMERGER_119864"><span style="font-style:normal;font-weight:normal;">AGREEMENTS RELATED TO THE MERGER</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">151</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#GLYCOMIMETICSDIRECTORSOFFICERSANDCORPORA"><span style="font-style:normal;font-weight:normal;">GLYCOMIMETICS DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">154</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#ADDITIONALINFORMATIONREGARDINGTHEBOARDOF"><span style="font-style:normal;font-weight:normal;">ADDITIONAL INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">159</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#GLYCOMIMETICSEXECUTIVECOMPENSATION_82177"><span style="font-style:normal;font-weight:normal;">GLYCOMIMETICS EXECUTIVE COMPENSATION</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">161</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#GLYCOMIMETICSNONEMPLOYEEDIRECTORCOMPENSA"><span style="font-style:normal;font-weight:normal;">GLYCOMIMETICS NON-EMPLOYEE DIRECTOR COMPENSATION</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">168</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#GLYCOMIMETICSEQUITYCOMPENSATIONPLANINFOR"><span style="font-style:normal;font-weight:normal;">GLYCOMIMETICS EQUITY COMPENSATION PLAN INFORMATION</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">170</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#CRESCENTEXECUTIVECOMPENSATION_819535"><span style="font-style:normal;font-weight:normal;">CRESCENT EXECUTIVE COMPENSATION</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">171</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#CRESCENTDIRECTORCOMPENSATION_207818"><span style="font-style:normal;font-weight:normal;">CRESCENT DIRECTOR COMPENSATION</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">174</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#MATTERSBEINGSUBMITTEDTOAVOTEOFGLYCOMIMET"><span style="font-style:normal;font-weight:normal;">MATTERS BEING SUBMITTED TO A VOTE OF GLYCOMIMETICS STOCKHOLDERS</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">175</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#PROPOSALNO1THENASDAQSTOCKISSUANCEPROPOSA"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 1 - THE NASDAQ STOCK ISSUANCE PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">175</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#PROPOSALNO2THEAUTHORIZEDSHAREINCREASEPRO"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 2 - THE AUTHORIZED SHARE INCREASE PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">177</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#PROPOSALNO3THEREVERSESTOCKSPLITPROPOSAL_"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 3 - THE REVERSE STOCK SPLIT PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">180</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#PROPOSALNO4THEDIRECTORELECTIONPROPOSAL_4"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 4 - THE DIRECTOR ELECTION PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">187</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#PROPOSALNO5THEAUDITORRATIFICATIONPROPOSA"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 5 - THE AUDITOR RATIFICATION PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">188</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#PROPOSALNO6THESTOCKPLANPROPOSAL_793387"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 6 - THE STOCK PLAN PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">189</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#PROPOSALNO7THEESPPPROPOSAL_216161"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 7 - THE ESPP PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">194</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#PROPOSALNO8THEMERGERCOMPENSATIONPROPOSAL"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 8 - THE MERGER COMPENSATION PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">198</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#PROPOSALNO9THEADJOURNMENTPROPOSAL_23903"><span style="font-style:normal;font-weight:normal;">PROPOSAL NO. 9 - THE ADJOURNMENT PROPOSAL</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">199</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#GLYCOMIMETICSBUSINESS_353440"><span style="font-style:normal;font-weight:normal;">GLYCOMIMETICS&#8217; BUSINESS</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">200</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#CRESCENTSBUSINESS_189691"><span style="font-style:normal;font-weight:normal;">CRESCENT&#8217;S BUSINESS</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">216</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#GLYCOMIMETICSMANAGEMENTSDISCUSSIONANDANA"><span style="font-style:normal;font-weight:normal;">GLYCOMIMETICS&#8217; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">254</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#CRESCENTSMANAGEMENTSDISCUSSIONANDANALYSI"><span style="font-style:normal;font-weight:normal;">CRESCENT&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">260</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#MANAGEMENTFOLLOWINGTHEMERGER_867307"><span style="font-style:normal;font-weight:normal;">MANAGEMENT FOLLOWING THE MERGER</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">274</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#CERTAINRELATIONSHIPSANDRELATEDPARTYTRANS"><span style="font-style:normal;font-weight:normal;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED COMPANY</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">279</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#UNAUDITEDPROFORMACONDENSEDCOMBINEDFINANC"><span style="font-style:normal;font-weight:normal;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">284</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#NOTESTOUNAUDITEDPROFORMACONDENSEDCOMBINE"><span style="font-style:normal;font-weight:normal;">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">288</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#DESCRIPTIONOFGLYCOMIMETICSCAPITALSTOCK_1"><span style="font-style:normal;font-weight:normal;">DESCRIPTION OF GLYCOMIMETICS CAPITAL STOCK</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">295</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#COMPARISONOFRIGHTSOFHOLDERSOFGLYCOMIMETI"><span style="font-style:normal;font-weight:normal;">COMPARISON OF RIGHTS OF HOLDERS OF GLYCOMIMETICS CAPITAL STOCK AND CRESCENT CAPITAL STOCK</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">298</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#PRINCIPALSTOCKHOLDERSOFGLYCOMIMETICS_268"><span style="font-style:normal;font-weight:normal;">PRINCIPAL STOCKHOLDERS OF GLYCOMIMETICS</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">308</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#PRINCIPALSTOCKHOLDERSOFCRESCENT_564460"><span style="font-style:normal;font-weight:normal;">PRINCIPAL STOCKHOLDERS OF CRESCENT</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">310</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#PRINCIPALSTOCKHOLDERSOFTHECOMBINEDCOMPAN"><span style="font-style:normal;font-weight:normal;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">312</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#LEGALMATTERS_200163"><span style="font-style:normal;font-weight:normal;">LEGAL MATTERS</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">314</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#EXPERTS_986908"><span style="font-style:normal;font-weight:normal;">EXPERTS</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">314</p></td></tr><tr><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#WHEREYOUCANFINDMOREINFORMATION_403864"><span style="font-style:normal;font-weight:normal;">WHERE YOU CAN FIND MORE INFORMATION</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">315</p></td></tr><tr><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><a href="#STOCKHOLDERPROPOSALSORDIRECTORNOMINATION"><span style="font-style:normal;font-weight:normal;">STOCKHOLDER PROPOSALS OR DIRECTOR NOMINATIONS FOR 2025 ANNUAL MEETING</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">316</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:9.2pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e93d4b31_be5e_44f9_9682_7b305dae2049"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"/><td style="vertical-align:bottom;width:5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PAGE</b></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#INDEXTOGLYCOMIMETICSINCSFINANCIALSTATEME"><span style="font-style:normal;font-weight:normal;">INDEX TO FINANCIAL STATEMENTS</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexA_529116"><span style="font-style:normal;font-weight:normal;">ANNEX A: AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, AND THE AMENDMENT THERETO</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-1</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexB_979236"><span style="font-style:normal;font-weight:normal;">ANNEX B: OPINION OF LUCID CAPITAL MARKETS</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">B-1</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexC_190262"><span style="font-style:normal;font-weight:normal;">ANNEX C: FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">C-1</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexD_955409"><span style="font-style:normal;font-weight:normal;">ANNEX D: FORM OF GLYCOMIMETICS STOCKHOLDER SUPPORT AGREEMENT</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">D-1</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexE_977427"><span style="font-style:normal;font-weight:normal;">ANNEX E: FORM OF LOCK-UP AGREEMENT</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">E-1</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexF_238963"><span style="font-style:normal;font-weight:normal;">ANNEX F: CERTIFICATE OF DESIGNATION OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXG_146265"><span style="font-style:normal;font-weight:normal;">ANNEX G: FORM OF CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GLYCOMIMETICS, INC. TO REFLECT INCREASE IN AUTHORIZED SHARES</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">G-1</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ANNEXH_824276"><span style="font-style:normal;font-weight:normal;">ANNEX H: FORM OF CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GLYCOMIMETICS, INC. TO REFLECT REVERSE STOCK SPLIT</span></a></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">H-1</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexI_679679"><span style="font-style:normal;font-weight:normal;">ANNEX I: APPRAISAL RIGHTS (SECTION 262 OF THE DELAWARE GENERAL CORPORATION LAW)</span></a></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">I-1</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANNEX J: FORM OF CRESCENT BIOPHARMA, INC. 2025 STOCK INCENTIVE PLAN*</p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">J-1</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANNEX K: FORM OF CRESCENT BIOPHARMA, INC. 2025 EMPLOYEE STOCK PURCHASE PLAN *</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">K-1</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:95%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANNEX L: FORM OF GLYCOMIMETICS, INC. PROXY CARD*</p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">L-1</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1.5pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* To be filed by amendment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e7475543_06af_4097_b4aa_b9472c705a15"></a><a id="QUESTIONSANDANSWERSABOUTTHEMERGER_430584"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">QUESTIONS AND ANSWERS ABOUT THE MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal No.&#160;3 of this proxy statement/prospectus</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">All references to Crescent&#8217;s &#8220;product candidates,&#8221; &#8220;programs,&#8221; &#8220;portfolio&#8221; and &#8220;pipeline&#8221; in this proxy statement/prospectus refer to the research programs with respect to which Crescent has the option to acquire intellectual property license rights to pursuant to each of that certain (i)&#160;Antibody Discovery and Option Agreement, dated September&#160;19, 2024 (the &#8220;Antibody Paragon Option Agreement&#8221;), and (ii)&#160;ADC Discovery and Option Agreement, dated October&#160;28, 2024 (the &#8220;ADC Paragon Option Agreement,&#8221; and together with the Antibody Paragon Option Agreement, the &#8220;Paragon Option Agreements&#8221;), each by and among Crescent, Paragon Therapeutics,&#160;Inc. (&#8220;Paragon&#8221;) and Parascent Holding LLC (&#8220;Parascent&#8221;). As of the date of this proxy statement/prospectus, Crescent has not exercised any such option or obtained any such license pursuant to the Paragon Option Agreements. While Crescent has not yet entered into an option agreement for the CR-003 program, Crescent expects to amend the ADC Paragon Option Agreement to include CR-003 prior to the time that this registration statement on Form&#160;S-4 is declared effective by the SEC.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following section provides answers to frequently asked questions about the Merger. This section, however, provides only summary information. For a more complete response to these questions and for additional information, please refer to the cross-referenced sections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">What is the Merger?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On October&#160;28, 2024, GlycoMimetics, Crescent, First Merger Sub and Second Merger Sub entered into the Merger Agreement, which agreement was subsequently amended on February&#160;14, 2025. A copy of the Merger Agreement is attached as <i style="font-style:italic;">Annex A</i>, including the amendment thereto. The Merger Agreement contains the terms and conditions of the proposed Merger. Pursuant to the Merger Agreement, First Merger Sub will merge with and into Crescent, with Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the First Merger. Crescent will then merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger. This entire transaction is referred to in this proxy statement/prospectus as the Merger. In connection with the Merger, GlycoMimetics will change its corporate name to &#8220;Crescent Biopharma,&#160;Inc.&#8221;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then-outstanding share of Crescent common stock (including shares of Crescent common stock issued in the Crescent Pre-Closing Financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of GlycoMimetics common stock equal to the Exchange Ratio (described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Exchange Ratio</i>&#8221; beginning on page&#160;135 of this proxy statement/prospectus), (ii)&#160;each then-outstanding share of Crescent preferred stock will be converted into the right to receive a number of shares of GlycoMimetics Series&#160;A Preferred Stock equal to the Exchange Ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then-outstanding option to purchase Crescent common stock will be assumed by GlycoMimetics, subject to adjustment as set forth in the Merger Agreement, (iv)&#160;each then-outstanding warrant to purchase shares of Crescent common stock will be converted into a warrant to purchase shares of GlycoMimetics common stock, subject to adjustment as set forth in the Merger Agreement and the form of warrant, (v)&#160;each in-the-money option to acquire shares of GlycoMimetics common stock that is issued and outstanding (whether vested or unvested) will be cancelled and converted into the right to receive immediately prior to the First Effective Time a number of shares of GlycoMimetics common stock equal to the number of shares underlying such option, and (vi)&#160;each GlycoMimetics restricted stock unit will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of unsettled shares of GlycoMimetics common stock underlying such GlycoMimetics restricted stock unit.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Each share of GlycoMimetics common stock that is issued and outstanding at the First Effective Time will remain issued and outstanding in accordance with its terms and such shares, subject to the proposed reverse stock split, will be unaffected by the Merger. Immediately after the Merger and prior to closing of the Crescent Pre-Closing Financing, based solely on the estimated Exchange Ratio as described in this proxy statement/prospectus, GlycoMimetics securityholders as of immediately prior to the Merger are expected to own approximately 3.10% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis, and subject to dilution from any equity issued by Crescent after the date of the Merger Agreement and before the closing), and former holders of Crescent securities (including those issued in the Crescent Pre-Closing Financing) are expected to own approximately 96.90% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, GlycoMimetics&#8217; net cash as of closing being equal to $1.8 million. Under certain circumstances described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Exchange Ratio</i>&#8221; beginning on page&#160;135 of this proxy statement/prospectus, the ownership&#160;percentages may be adjusted up or down including, but not limited to, if GlycoMimetics&#8217; net cash as of closing is less than $1.725 million or more than $1.875 million. GlycoMimetics currently estimates that its net cash as of closing will be approximately $1.8&#160;million, and the currently estimated ownership&#160;percentages reflect this projection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">Why are the two companies proposing to merge?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">GlycoMimetics and Crescent believe that combining the two companies will result in a company with a promising pipeline, a strong leadership team and substantial capital resources, focused on developing novel biologics designed to set a new standard for the treatment of solid tumors. For a more complete description of the reasons for the Merger, please see the sections titled &#8220;<i style="font-style:italic;">The Merger&#8212;GlycoMimetics&#8217; Reasons for the Merger</i>&#8221; and &#8220;<i style="font-style:italic;">The Merger&#8212;Crescent&#8217;s Reasons for the Merger</i>&#8221; beginning on pages&#160;106 and 110, respectively, of this proxy statement/prospectus.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">What will </b><b style="font-weight:bold;">happen</b><b style="font-weight:bold;"> to GlycoMimetics if, for any reason, the Merger with Crescent does not close?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">GlycoMimetics has invested significant time and incurred, and expects to continue to incur, significant expenses related to the proposed Merger with Crescent. In the event the Merger does not close, GlycoMimetics will have a limited ability to continue its current operations without obtaining additional financing. Although the GlycoMimetics Board may elect, among other things, to attempt to complete another strategic transaction if the Merger with Crescent does not close, the GlycoMimetics Board may instead divest all or a portion of GlycoMimetics&#8217; business or take steps necessary to liquidate or dissolve GlycoMimetics&#8217; business and assets if a viable alternative strategic transaction is not available. If GlycoMimetics decides to dissolve and liquidate its assets, GlycoMimetics would be required to pay all of its contractual obligations, and to set aside certain reserves for potential future claims, and there can be no assurance as to the amount of and the timing of such liquidation and distribution of available cash left to distribute to stockholders after paying the obligations of GlycoMimetics and setting aside funds for reserves.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">Why am I </b><b style="font-weight:bold;">receiving</b><b style="font-weight:bold;"> this proxy statement/prospectus?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">You are receiving this proxy statement/prospectus because you have been identified as a stockholder of GlycoMimetics as of the applicable Record Date, and you are entitled to vote to approve the matters set forth herein. This document serves as:</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a proxy statement of GlycoMimetics used to solicit proxies for the GlycoMimetics Special Meeting to vote on the matters set forth herein;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a prospectus of GlycoMimetics used to offer (i)&#160;shares of GlycoMimetics common stock issued in exchange for shares of Crescent common stock (including shares of Crescent common stock issued in the Crescent Pre-Closing Financing), (ii)&#160;shares of GlycoMimetics common stock issuable upon exercise of pre-funded warrants issued in exchange for pre-funded warrants to purchase shares of Crescent common stock sold in the Crescent Pre-Closing Financing, and (iii)&#160;shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock issued in exchange for shares of Crescent preferred stock in the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the annual report of GlycoMimetics provided in connection with the special meeting in lieu of annual meeting.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iv</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">What is the </b><b style="font-weight:bold;">Crescent</b><b style="font-weight:bold;"> </b><b style="font-weight:bold;">P</b><b style="font-weight:bold;">re-</b><b style="font-weight:bold;">C</b><b style="font-weight:bold;">losing </b><b style="font-weight:bold;">F</b><b style="font-weight:bold;">inancing?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">In connection with the Merger, Crescent and GlycoMimetics entered into the Subscription Agreement with certain investors named therein, including, among others, Fairmount, Venrock Healthcare Capital Partners, BVF Partners, Paradigm BioCapital, RTW Investments, Blackstone Multi-Asset Investing, Frazier Life Sciences, Commodore Capital, Perceptive Advisers, Deep Track Capital, Boxer Capital Management, Soleus, Logos Capital, Driehaus Capital Management, Braidwell LP, and Wellington Management, pursuant to which such investors agreed to purchase shares of Crescent common stock and pre-funded warrants to purchase shares of Crescent common stock for an aggregate purchase price of approximately $200.0 million (which includes $37.5 million of proceeds previously received by Crescent from the issuance of its Convertible Notes&#160;and accrued interest on such note). Shares of Crescent common stock and pre-funded warrants issued pursuant to this financing transaction will be converted into shares of GlycoMimetics common stock and pre-funded warrants to acquire shares GlycoMimetics common stock, in accordance with the Exchange Ratio and the Merger Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Immediately after the First Merger, the shares of Crescent common stock and Crescent pre-funded warrants issued in the Crescent Pre-Closing Financing are expected to represent approximately 77.52% of the outstanding shares of common stock of the Combined Company (on a fully-diluted basis, and subject to dilution from any equity issued by Crescent after the date of the Merger Agreement and before the closing). GlycoMimetics, Crescent and the investors participating in the Crescent Pre-Closing Financing have also agreed to enter into a Registration Rights Agreement at the closing of the Crescent Pre-Closing Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of GlycoMimetics common stock that are held by the investors participating in the Crescent Pre-Closing Financing from time to time pursuant to Rule&#160;415. The closing of the Crescent Pre-Closing Financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the Merger as well as certain other conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">For a more complete description of the Crescent Pre-Closing Financing, please see the sections titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Subscription Agreement</i>&#8221; and &#8220;<i style="font-style:italic;">&#8212;Registration Rights Agreement</i>&#8221; beginning on pages&#160;151 and 153 of this proxy statement/prospectus, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">What proposals will be voted on at the GlycoMimetics Special Meeting in connection with the Merger?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Pursuant to the terms of the Merger Agreement, the following proposals must be approved by the requisite stockholder vote at the GlycoMimetics Special Meeting in order for the Merger to close:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;1&#160;- The Nasdaq Stock Issuance Proposal</b> to approve (i)&#160;the issuance of shares of GlycoMimetics common stock (including the shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock), which will represent more than 20% of the shares of GlycoMimetics common stock outstanding immediately prior to the Merger, to stockholders of Crescent, pursuant to the terms of the Merger Agreement, a copy of which is attached as <i style="font-style:italic;">Annex A, </i>including the amendment thereto, to this proxy statement/prospectus, and (ii)&#160;the change of control of GlycoMimetics resulting from the Merger, pursuant to Nasdaq Listing Rules&#160;5635(a)&#160;and 5635(b), respectively;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;2&#160;- Authorized Share Increase Proposal</b> to approve an amendment to the GlycoMimetics Charter to increase the number of shares of GlycoMimetics common stock that GlycoMimetics is authorized to issue from 150,000,000 to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the form attached as <i style="font-style:italic;">Annex G</i> to this proxy statement/prospectus;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Additionally, Proposal No.&#160;2 must be approved to have an adequate number of authorized but unissued shares of GlycoMimetics common stock to complete the Merger; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;3&#160;- Reverse Stock Split Proposal</b> to approve an amendment to the GlycoMimetics Charter to effect a reverse stock split of GlycoMimetics&#8217; issued and outstanding common stock at a ratio in the range between&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, inclusive, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by the GlycoMimetics Board and the Crescent Board prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by GlycoMimetics stockholders, determined solely by the GlycoMimetics Board, the form attached as <i style="font-style:italic;">Annex H</i> to this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Each of Proposal No.&#160;1 and Proposal No.&#160;2 is a condition to completion of the Merger. The issuance of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock, and GlycoMimetics Series&#160;A Preferred Stock in connection with the Merger and the change of control of GlycoMimetics resulting </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">v</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">from the Merger will not take place unless Proposal No.&#160;1 and Proposal No.&#160;2 are approved by GlycoMimetics stockholders and the Merger is consummated. The GlycoMimetics Board may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal No.&#160;1 is not approved by GlycoMimetics stockholders, following the special meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">In addition to the requirement of obtaining GlycoMimetics stockholder approval of Proposal No.&#160;1 and Proposal No.&#160;2, the closing of the Merger is subject to the satisfaction or waiver of each of the other closing conditions set forth in the Merger Agreement. For a more complete description of the closing conditions under the Merger Agreement, please see the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Conditions to the Completion of the Merger</i>&#8221; beginning on page&#160;147 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The presence, by attending or being represented by proxy, at the GlycoMimetics Special Meeting of the holders of at least one-third of the shares of GlycoMimetics common stock outstanding and entitled to vote at the GlycoMimetics Special Meeting is necessary to constitute a quorum at the meeting for the Proposals.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What proposals are to be voted on at the GlycoMimetics Special Meeting, other than the Nasdaq Stock Issuance Proposal, </b><b style="font-weight:bold;">the</b><b style="font-weight:bold;"> Reverse Stock Split Proposal and the Authorized Share Increase Proposal?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">At the GlycoMimetics Special Meeting, the holders of GlycoMimetics common stock will also be asked to consider the following proposals:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;4&#160;- The Director Election Proposal</b> to elect three Class&#160;II director nominees named in the accompany proxy statement/prospectus to the GlycoMimetics Board, to serve until GlycoMimetics&#8217; 2028 annual meeting of stockholders or until their successors have been duly elected and qualified, or until their earlier death, resignation or removal;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;5&#160;- The Auditor Ratification Proposal</b> to ratify the selection of Ernst&#160;&amp; Young LLP as GlycoMimetics&#8217; independent registered public accounting firm for the fiscal&#160;year ending December&#160;31, 2025;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;6&#160;- The Stock Plan Proposal</b> to approve the Crescent Biopharma,&#160;Inc. 2025 Stock Incentive Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;7&#160;- The ESPP Proposal</b> to approve the Crescent Biopharma,&#160;Inc. 2025 Employee Stock Purchase Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;8&#160;- The Merger Compensation Proposal</b> to approve, on an advisory basis, certain compensation arrangements for GlycoMimetics named executive officers that are based on or otherwise relate to the Merger; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Proposal No.&#160;9&#160;- The Adjournment Proposal</b> to approve an adjournment of the GlycoMimetics Special Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The approval of Proposal Nos.&#160;3,&#160;4,&#160;5,&#160;6,&#160;7,&#160;8 and 9 are not a condition to the Merger. GlycoMimetics does not expect that any matter other than the Proposals will be brought before the GlycoMimetics Special Meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The presence, by attending or being represented by proxy, at the GlycoMimetics Special Meeting of the holders of at least one-third of the shares of GlycoMimetics common stock outstanding and entitled to vote at the GlycoMimetics Special Meeting is necessary to constitute a quorum at the meeting for the purpose of approving the Proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">What stockholder votes are required to approve the Proposals at the GlycoMimetics Special Meeting?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The affirmative vote of a majority of the shares of GlycoMimetics common stock entitled to vote on the subject matter and present at the GlycoMimetics Special Meeting, assuming a quorum is present, is required for approval of Proposal Nos.&#160;1,&#160;5,&#160;6,&#160;7, 8 and 9. The affirmative vote of at least sixty-six and two-thirds&#160;percent (66<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2/3</sup>%) of the voting power of all then-outstanding shares of GlycoMimetics capital stock entitled to vote generally in the election of directors, voting together as a single class, is required for approval of Proposal No.&#160;2 and Proposal No.&#160;3 at the GlycoMimetics Special Meeting, assuming a quorum is present. With respect to Proposal No.&#160;4, directors are elected by a plurality of the votes properly cast at the GlycoMimetics Special Meeting, and the three nominees for director receiving the highest numbers of affirmative votes properly cast will be elected. </p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">vi</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Proposal No.&#160;1 is conditioned on the approval of Proposal No.&#160;2. Notwithstanding the approval of Proposal No.&#160;1, if Proposal No.&#160;2 is not approved, the actions contemplated by Proposal No.&#160;1 will not be effected and the Merger will not be consummated.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What will Crescent stockholders, participants in Crescent&#8217;s 202</b><b style="font-weight:bold;">4</b><b style="font-weight:bold;"> Equity Incentive Plan, option holders and warrant holders receive in the Merger?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Crescent stockholders will receive shares of GlycoMimetics common stock. GlycoMimetics will assume Crescent&#8217;s 2024 Equity Incentive Plan, as amended, along with issued and outstanding awards under such plan. Outstanding and unexercised options to purchase shares of Crescent common stock immediately prior to the First Effective Time will be converted into options to purchase shares of GlycoMimetics common stock, with necessary adjustments being made to the number of shares and exercise price underlying such options in order to reflect the economic equivalent of the prior equity award in light of the Exchange Ratio. Crescent warrant holders&#8217; outstanding and unexercised warrants to purchase shares of Crescent common stock immediately prior to the First Effective Time will be assumed by GlycoMimetics and each outstanding and unexercised warrant will be converted into a warrant to purchase shares of GlycoMimetics common stock, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio. Applying the Exchange Ratio, the former Crescent securityholders immediately before the Merger are expected to own approximately 96.90% of the aggregate number of shares of the Combined Company&#8217;s capital stock following the Merger (on a fully-diluted basis, and subject to dilution from any equity issued by Crescent after the date of the Merger Agreement and before the closing), and GlycoMimetics securityholders immediately before the Merger are expected to own approximately 3.10% of the aggregate number of shares of the Combined Company capital stock following the Merger (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, GlycoMimetics&#8217; net cash as of closing being equal to $1.8 million. Under certain circumstances further described in the Merger Agreement, the ownership&#160;percentages may be adjusted up or down including, but not limited to, if GlycoMimetics&#8217; net cash is less than $1.725 million or more than $1.875 million. GlycoMimetics&#8217; management currently anticipates GlycoMimetics&#8217; net cash as of closing will be approximately $1.8 million, and the currently estimated ownership&#160;percentages reflect this projection.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">For a more complete description of the treatment of Crescent common stock, Crescent&#8217;s 2024 Equity Incentive Plan, Crescent options and Crescent warrants in the Merger, please see the sections titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Merger Consideration</i>&#8221;<i style="font-style:italic;">&#160;</i>and<i style="font-style:italic;">&#160;&#8221;The Merger Agreement&#8212;Exchange Ratio</i>&#8221; beginning on pages&#160;134 and 135, respectively, of this proxy statement/prospectus. For a description of the effect of the Crescent Pre-Closing Financing on GlycoMimetics&#8217; and Crescent&#8217;s current securityholders, please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Subscription Agreement</i>&#8221; beginning on page&#160;151 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">Will the common stock of the Combined Company trade on an exchange?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Shares of GlycoMimetics common stock are currently listed on Nasdaq under the symbol &#8220;GLYC.&#8221; GlycoMimetics intends to file an initial listing application for the common stock of the Combined Company with Nasdaq. After completion of the Merger, GlycoMimetics will be renamed &#8220;Crescent Biopharma,&#160;Inc.&#8221; and it is expected that the common stock of the Combined Company will trade on Nasdaq under the symbol &#8220;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.&#8221; It is a condition to the consummation of the Merger that GlycoMimetics will receive confirmation from Nasdaq that the Combined Company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that GlycoMimetics will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, the last trading day before the date of this proxy statement/prospectus, the closing sale price of GlycoMimetics common stock was $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">Who will be the directors of the Combined Company immediately following the Merger?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Immediately following the Merger, the Combined Company&#8217;s board of directors will be composed of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; members, all of whom will have been designated by Crescent.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Effective as of the First Effective Time, the GlycoMimetics Board will appoint the following Crescent designees: Jonathan Violin, Alexandra Balcom, Peter Harwin, Susan Moran, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to the board of directors of the Combined Company, and concurrent therewith all of GlycoMimetics&#8217; current directors will resign from their positions as directors of the GlycoMimetics Board effective as of the First Effective Time. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;is expected to be appointed as Chair of the board of directors of the Combined Company.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">vii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The staggered structure of three classes of directors of the GlycoMimetics Board will remain in place for the Combined Company following the completion of the Merger. See the section titled &#8220;<i style="font-style:italic;">Management Following the Merger</i>&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">Who will be the executive officers of the Combined Company immediately following the Merger?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Immediately following the Merger, the executive management team of the Combined Company is expected to consist of the following members of the Crescent executive management team:</p></td></tr></table><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr><td style="vertical-align:top;width:33.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:63.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:33.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jonathan Violin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:63.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, President and Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Christopher Doughty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:63.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Business Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Ryan Lynch</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:63.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer, Senior Vice President of Finance and Chief Accounting Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Barbara Bispham</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:63.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Counsel and Corporate Secretary</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">As an GlycoMimetics stockholder, how does the GlycoMimetics Board recommend that I vote?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The GlycoMimetics Board, in consultation with financial and legal advisors and management, evaluated the terms of the Merger Agreement and the related transactions contemplated thereby and: (i)&#160;determined that the Merger and the related transactions contemplated by the Merger Agreement are fair to, advisable and in the best interests of GlycoMimetics and its stockholders; (ii)&#160;approved and declared advisable the Merger Agreement and the related transactions contemplated by the Merger Agreement and the Subscription Agreement, including the issuance of shares of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock, in connection with the Merger and the Crescent Pre-Closing Financing, respectively; and (iii)&#160;recommends that GlycoMimetics&#8217; stockholders vote &#8220;<b style="font-weight:bold;">FOR</b>&#8221; each of the Proposals.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">What risks should I consider in deciding whether to vote in favor of the Merger?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">You should carefully review the section titled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; beginning on page&#160;16 of this proxy statement/prospectus and the documents incorporated by reference herein, which set forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the Combined Company&#8217;s business will be subject, and risks and uncertainties to which each of GlycoMimetics and Crescent, as independent companies, are subject.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">When do you expect the Merger to be consummated?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Merger is anticipated to close in the late second quarter of 2025, but the exact timing cannot be predicted. For more information, please see the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Conditions to the Completion of the Merger</i>&#8221; beginning on page&#160;147 of this proxy statement/prospectus.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">What do I need to do now?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">GlycoMimetics urges you to read this proxy statement/prospectus carefully, including the annexes and the documents incorporated by reference, and to consider how the Merger affects you.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Stockholder</i><i style="font-style:italic;"> of Record: Shares Registered in Your Name</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">If you are a stockholder of record, you may vote at the GlycoMimetics Special Meeting, vote by proxy over the telephone, vote by proxy through the Internet or vote by proxy using a proxy card that you may request or that we may elect to deliver at a later time, the form of which is attached as <i style="font-style:italic;">Annex </i><i style="font-style:italic;">L</i>. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote even if you have already voted by proxy.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To vote, come to the Special Meeting and we will give you a ballot when you arrive.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To vote using the proxy card, simply complete, sign and date the proxy card that you may request or that we may elect to deliver at a later time and return it promptly in the envelope provided. If you return your signed proxy card to us before the special meeting, we will vote your shares as you direct.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">viii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To vote over the telephone, dial toll-free</span><span style="display:inline-block;width:0.12pt;"></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;&#160;&#160;&#160;&#160;&#160;using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number found on the Notice. Your vote must be received by&#160;&#160;&#160;&#160;&#160;&#160;, 2025 at&#160;&#160;&#160;&#160;&#160;Eastern Time to be counted.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To vote through the Internet, go to </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">www. &#160;&#160;&#160;&#160;&#160;&#160;.com </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to complete an electronic proxy card. You will be asked to provide the company number and control number from the Notice. Your vote must be received by&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 at&#160;&#160;&#160;&#160;&#160;&#160;Eastern Time to be counted.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Beneficial Owner: Shares Registered in the </i><i style="font-style:italic;">Name</i><i style="font-style:italic;"> of Broker or Bank</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a Notice containing voting instructions from that organization rather than from GlycoMimetics. Simply follow the voting instructions in the Notice to ensure that your vote is counted. You may vote by telephone or over the Internet as instructed by your broker or bank. To vote at the GlycoMimetics Special Meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">What if I return a proxy card or otherwise vote but do not make specific choices?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, &#8220;For&#8221; the Nasdaq Stock Issuance Proposal, &#8220;For&#8221; the Authorized Share Proposal, &#8220;For&#8221; the Reverse Stock Split Proposal, &#8220;For&#8221; the Director Election Proposal, &#8220;For&#8221; the Auditor Ratification Proposal, &#8220;For&#8221; the Stock Plan Proposal, &#8220;For&#8221; the ESPP Proposal, &#8220;For&#8221; the Merger Compensation Proposal, and &#8220;For&#8221; the Adjournment Proposal. If any other matter is properly presented at the meeting, your proxy holder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">What happens if I do not return a proxy card or otherwise vote or provide proxy instructions, as applicable?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">If you are an GlycoMimetics stockholder, the failure to return your proxy card or otherwise vote or provide proxy instructions will reduce the aggregate number of votes required to approve Proposal Nos.&#160;1,&#160;5,&#160;6,&#160;7,&#160;8, and 9.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">If my GlycoMimetics shares are held in &#8220;street name&#8221; by my broker and I do not provide my broker or bank with voting instructions, what happens?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent may still be able to vote your shares in its discretion or your shares may constitute &#8220;broker non-votes.&#8221;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">If an GlycoMimetics stockholder does not return voting instructions to their broker on how to vote their shares of GlycoMimetics common stock, such broker may be prevented from voting, or may otherwise choose not to vote, such shares held by such broker, resulting in broker non-votes with respect to such shares. To make sure that your vote is counted, you should instruct your broker to vote your shares of GlycoMimetics common stock, following the procedures provided by your broker.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">What are broker non-votes and do they count for determining a quorum?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Generally, a &#8220;broker non-vote&#8221; occurs when shares held by a broker are not voted with respect to a particular proposal because the broker has not received voting instructions from its client(s)&#160;with respect to such shares on how to vote and does not have or did not exercise discretionary authority to vote on the matter.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Broker non-votes, if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the GlycoMimetics Special Meeting. Broker non-votes, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal Nos.&#160;1,&#160;2,&#160;3,&#160;4,&#160;5,&#160;6,&#160;7, 8 and&#160;9.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ix</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">May&#160;I revoke and/or change my vote after I have submitted a proxy or provided proxy instructions?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">GlycoMimetics stockholders of record, unless such stockholder&#8217;s vote is subject to a support agreement, may revoke and/or change their vote at any time before their proxy is voted at the GlycoMimetics Special Meeting in one of four ways:</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You may submit another properly completed proxy with a later date by mail or via the internet.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You can provide your proxy instructions via telephone at a later date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You may send a notice that you are revoking your proxy over the internet, following the instructions provided on your proxy card.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You may attend the GlycoMimetics Special Meeting and vote during the meeting. Simply attending the GlycoMimetics Special Meeting will not, by itself, revoke your proxy and/or change your vote.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What are the material U.S. federal income tax considerations of the Merger to a U.S. Holder of Crescent common stock and Crescent preferred stock?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Subject to the limitations and qualifications described in the section titled &#8220;<i style="font-style:italic;">The Merger&#8212;U.S. Federal Income Tax Considerations of the Merger</i>&#8221; beginning on page&#160;128 of this proxy statement/prospectus, each of GlycoMimetics and Crescent intend that the Merger qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) for U.S. federal income tax purposes. Assuming the Merger so qualifies, a U.S. Holder of Crescent stock (as defined therein) will not recognize gain or loss upon the exchange of its Crescent stock for GlycoMimetics stock. For a more detailed discussion of the U.S. federal income tax considerations of the Merger, see the section titled &#8220;<i style="font-style:italic;">The Merger&#8212;U.S. Federal Income Tax Considerations of the Merger</i>&#8221; beginning on page&#160;128.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Q:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">What are the U.S. federal income tax considerations of the reverse stock split to a U.S. Holders of GlycoMimetics common stock?</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A U.S. Holder of GlycoMimetics common stock should not recognize gain or loss upon the reverse stock split, except to the extent such holder receives cash in lieu of a fractional share of GlycoMimetics common stock, and subject to the discussion in the section titled &#8220;<i style="font-style:italic;">Proposal No.&#160;3&#8212;The Reverse Stock Split Proposal&#8212;U.S. Federal Income Tax Considerations of the Reverse Stock Split</i>&#8221; &#8220; beginning on page&#160;184 of this proxy statement/prospectus. Please review the information in the section titled &#8220;<i style="font-style:italic;">Proposal No.&#160;3&#8212;The Reverse Stock Split Proposal&#8212;U.S. Federal Income Tax Considerations of the Reverse Stock Split</i>&#8221; beginning on page&#160;184 of this proxy statement/prospectus for a more complete description of the U.S. federal income tax considerations of the reverse stock split to a U.S. Holder of GlycoMimetics common stock.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q:</b></span><b style="font-weight:bold;">Who can help answer my questions?</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">A:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">If you are an GlycoMimetics stockholder and would like additional copies of this proxy statement/prospectus without charge or if you have questions about the Merger or related matters, including the procedures for voting your shares, you should contact:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Banks and Brokers Call:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Stockholders Call Toll Free:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">x</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6f1900ef_49aa_4b9b_9a58_b2f300bb4677"></a><a id="PROSPECTUSSUMMARY_804771"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PROSPECTUS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the GlycoMimetics Special Meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement and the other annexes to which you are referred in this proxy statement/prospectus, and the documents incorporated by reference therein. For more information, please see the section titled &#8220;<i style="font-style:italic;">Where You Can Find More Information</i>&#8221; beginning on page 315 of this proxy statement/prospectus. Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal No.<i style="font-style:italic;">&#160;</i>3 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Companies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics is a biotechnology company that was previously developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation. GlycoMimetics&#8217; previous lead glycomimetic drug candidate, uproleselan, is a specific E-selectin antagonist that it was developing to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (&#8220;AML&#8221;), a life-threatening hematologic cancer, and potentially other hematologic cancers. GlycoMimetics conducted a randomized, double-blind, placebo-controlled Phase 3 pivotal clinical trial to evaluate uproleselan in individuals with relapsed/refractory (R/R) AML. In May 2024, GlycoMimetics reported topline results from the Phase 3 trial, in which uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone. GlycoMimetics has concluded, following feedback from the U.S. Food and Drug Administration (&#8220;FDA&#8221;), that the regulatory path forward for its lead product candidate uproleselan for the treatment of relapsed and refractory acute myeloid leukemia would require an additional clinical trial. At this time, GlycoMimetics does not intend to continue development of uproleselan or any other product candidates. In July 2024, GlycoMimetics announced a streamlined operating plan that includes the exploration of strategic alternatives focused on maximizing shareholder value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; executive officers and employees work remotely, and its mailing address is P.O. Box 65, Monrovia, MD 21770. Its telephone number is (240) 243-1201.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab, marketed by Merck as Keytruda&#174;, the best-selling drug in the world and approved for the treatment of numerous cancers. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics Inc. that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer (&#8220;NSCLC&#8221;). Crescent believes the emerging data from the clinical development of ivonescimab allows for the acceleration of the development of CR-001. Following the precedents set by traditional PD-1 inhibitors, such as Keytruda and Opdivo&#174;, Crescent plans to systematically seek regulatory approvals for CR-001 to treat multiple solid tumor indications, both as a monotherapy and in combination with other mechanisms of action. Crescent intends to submit an Investigational New Drug (&#8220;IND&#8221;), application to the FDA for CR-001 in the fourth quarter of 2025, with initial clinical data anticipated in the second half of 2026. Crescent plans to complement CR-001 with a portfolio of product candidates that have potential activity against solid tumors both as a monotherapy as well as in combination with CR-001. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (&#8220;ADCs&#8221;) against validated oncology targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s principal executive offices are located at 221 Crescent Street Building 23, Suite 105, Waltham, MA 02453, and its telephone number is (617) 430-5595.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">First Merger Sub</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">First Merger Sub is a direct, wholly owned subsidiary of GlycoMimetics and was formed solely for the purpose of carrying out the Merger. First Merger Sub&#8217;s executive officers and employees work remotely, and its mailing address is P.O. Box 65, Monrovia, MD 21770. Its telephone number is (240) 243-1201.</p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Second Merger Sub</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Second Merger Sub is a direct, wholly owned subsidiary of GlycoMimetics and was formed solely for the purpose of carrying out the Merger. Second Merger Sub&#8217;s executive officers and employees work remotely, and its mailing address is P.O. Box 65, Monrovia, MD 21770. Its telephone number is (240) 243-1201.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Merger </b>(see page 99)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with the Delaware General Corporation Law (&#8220;DGCL&#8221;), (i) at the First Effective Time, First Merger Sub will merge with and into Crescent, with Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the First Merger and (ii) immediately following the First Merger and as part of the same overall transaction as the First Merger, Crescent will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GlycoMimetics&#8217; Reasons for the Merger</b> (see page 106)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, the GlycoMimetics Board considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the GlycoMimetics Board believes that the Merger will create a Combined Company with a promising pipeline of novel biologics designed to set a new standard for the treatment of solid tumors, leveraging Crescent&#8217;s expertise in antibody and ADC discovery and development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the GlycoMimetics Board believes that the Merger will provide GlycoMimetics stockholders with an opportunity to participate in the potential value creation of the Combined Company, which will have a stronger financial position and greater access to capital markets than GlycoMimetics as a standalone entity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the GlycoMimetics Board believes that the Merger will enhance the Combined Company&#8217;s ability to attract and retain talented employees, collaborators, and partners in the highly competitive oncology field;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the GlycoMimetics Board believes that the Merger will enable GlycoMimetics to avoid the substantial costs, risks, and uncertainties associated with continuing its current operations without obtaining additional financing, pursuing another strategic transaction, or liquidating or dissolving its business and assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the GlycoMimetics Board believes that the terms and conditions of the Merger Agreement are fair and reasonable to GlycoMimetics and its stockholders, taking into account the Exchange Ratio, the Crescent Pre-Closing Financing, the Support Agreements, and the absence of any superior alternative proposals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the GlycoMimetics Board received the opinion of Lucid Capital Markets, its financial advisor, that as of the date of the Merger Agreement and based upon and subject to the assumptions, qualifications, and limitations set forth therein, the Exchange Ratio was fair, from a financial point of view, to GlycoMimetics and its stockholders.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing information is not intended to be exhaustive, but is believed to include a summary of all of the material factors considered by the GlycoMimetics Board in its consideration of the Merger Agreement and the transactions contemplated thereby. After conducting an overall analysis of these and other factors, including thorough discussions with, and questioning of, GlycoMimetics&#8217; senior management and legal counsel, the GlycoMimetics Board concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on this overall analysis of the factors described above, the GlycoMimetics Board unanimously approved the Merger Agreement, the Merger, and the other transactions contemplated by the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Crescent&#8217;s Reasons for the Merger</b> (see page 110)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the course of reaching its decision to approve the Merger and the Crescent Pre-Closing Financing, the Crescent Board held numerous meetings, consulted with Crescent&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety </p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of factors. Ultimately, the Crescent Board concluded that a merger with GlycoMimetics, together with the additional financing committed from the Crescent Pre-Closing Financing, was the best option to generate capital resources to support the advancement of Crescent&#8217;s pipeline and fund the combined organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional factors the Crescent Board considered included the following (which factors are not necessarily presented in any order of relative importance):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Merger will potentially expand the access to capital and the range of investors available as a public company to support the preclinical and clinical development of Crescent&#8217;s pipeline, compared to the capital and investors Crescent could otherwise gain access to if it continued to operate as a privately-held company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Crescent Pre-Closing Financing will generate capital resources to fund the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits from increased public market awareness of Crescent and its pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical and current information concerning Crescent&#8217;s business, including its financial performance and condition, operations, management, and preclinical and clinical data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the competitive nature of the industry in which Crescent operates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Crescent Board&#8217;s fiduciary duties to Crescent stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Crescent Board&#8217;s belief that no alternatives to the Merger, together with the additional financing committed from the Crescent Pre-Closing Financing, were reasonably likely to create greater value for Crescent stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Crescent Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Crescent Board&#8217;s expectation that the Merger, together with the additional financing committed from the Crescent Pre-Closing Financing, would be a higher probability and more cost-effective means to access capital than other options considered, including an initial public offering;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected financial position, operations, management structure and operating plans of the Combined Company (including the ability to support the Combined Company&#8217;s current and planned preclinical studies and clinical trials);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the business, history, operations, financial resources and credibility of GlycoMimetics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of appraisal rights under the DGCL to holders of Crescent capital stock who comply with the required procedures under the DGCL, which allow such holders to seek appraisal of the fair value of their shares of Crescent capital stock as determined by the Delaware Court of Chancery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and conditions of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the shares of GlycoMimetics common stock issued to Crescent stockholders, including shares of GlycoMimetics common stock issued in exchange for shares of Crescent common stock sold in the Crescent Pre-Closing Financing, will be registered on a Form S-4 registration statement and will become freely tradable for Crescent stockholders who are not affiliates of Crescent and who are not parties to lock-up agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Support Agreements, pursuant to which certain directors, officers and stockholders of Crescent and GlycoMimetics, respectively, have agreed, solely in their capacity as stockholders of Crescent and GlycoMimetics, respectively, to vote all of their shares of Crescent capital stock or GlycoMimetics common stock in favor of the adoption or approval, respectively, of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to obtain a Nasdaq listing and the change of the combined organization&#8217;s name to Crescent Biopharma, Inc. prior to or upon the closing of the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the likelihood that the Merger will be consummated on a timely basis.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Crescent Board also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that the Merger or Crescent Pre-Closing Financing might not be completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there is no adjustment to the Exchange Ratio if GlycoMimetics&#8217; net cash as of closing is between $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.725 million and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.875 million;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for purposes of calculating the Exchange Ratio, GlycoMimetics&#8217; valuation will be equal to at least 3% of the sum of (i) Crescent&#8217;s valuation immediately prior to the Merger (including the Crescent Pre-Closing Financing) plus (ii) $8 million, subject to further adjustment based on GlycoMimetics&#8217; net cash;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential effect of the termination fee of up to $2.0 million payable by Crescent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential reduction of GlycoMimetics&#8217; net cash prior to the closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that GlycoMimetics could consider certain unsolicited acquisition proposals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, time and effort involved in connection with completing the Merger, related disruptions or potential disruptions to Crescent&#8217;s business and related administrative challenges associated with combining the companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the additional expenses and obligations to which Crescent&#8217;s business will be subject following the Merger as a public company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk Factors</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; in this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recommendation of the GlycoMimetics Board of Directors </b>(see page 95)</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board has determined and declared that the issuance of shares of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series A Preferred Stock, pursuant to the Merger Agreement is fair to, in the best interests of, and advisable to, GlycoMimetics and its stockholders. The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">&#160;</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval of Nasdaq Stock Issuance Proposal as described in this proxy statement/prospectus.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board has determined and declared that it is advisable and in the best interests of GlycoMimetics and its stockholders to approve the amendment to the GlycoMimetics Charter to effect the increase in authorized shares. The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; the Authorized Share Increase Proposal as described in this proxy statement/prospectus.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board has determined and declared that it is advisable and in the best interests of GlycoMimetics and its stockholders to approve the amendment to the GlycoMimetics Charter to effect the reverse stock split, if necessary. The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">&#160;</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Reverse Stock Split Proposal as described in this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">The GlycoMimetics Board has determined and believes that it is advisable to, and in the best interests of, GlycoMimetics and its stockholders to elect                     ,                    , and                     to serve on the GlycoMimetics Board in the class of directors with terms expiring at GlycoMimetics&#8217; 2028 annual meeting of stockholders, provided that if the Merger is consummated, the approval of Proposal No. 4 will only have an effect until the completion of the Merger because the composition of the GlycoMimetics Board will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement. The GlycoMimetics Board that GlycoMimetics stockholders vote &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">&#160;</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the director nominees named in the Director Election Proposal as described in this proxy statement/prospectus.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board has determined and believes that it is advisable to, and in the best interests of, GlycoMimetics and its stockholders to ratify the selection of Ernst &amp; Young LLP as GlycoMimetics&#8217; independent registered public accounting </span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">firm for the fiscal year ending December&#160;31, 2025, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed. The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">&#160;</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Auditor Ratification Proposal as described in this proxy statement/prospectus.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board has determined and believes that it is advisable to, and in the best interests of, GlycoMimetics and its stockholders to approve the 2025 Stock Incentive Plan, as described in this proxy statement/prospectus. The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; the Stock Plan Proposal as described in this proxy statement/prospectus.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board has determined and believes that it is advisable to, and in the best interests of, GlycoMimetics and its stockholders to approve the 2025 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; the ESPP Proposal as described in this proxy statement/prospectus.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board has determined and believes that it is advisable to, and in the best interests of, GlycoMimetics and its stockholders to approve certain compensation arrangements for GlycoMimetics named executive officers that are based on or otherwise relate to the Merger. The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; the Merger Compensation Proposal as described in this proxy statement/prospectus.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board has determined and believes that adjourning the GlycoMimetics Special Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal is fair to, in the best interests of, and advisable to, GlycoMimetics and its stockholders and has approved and adopted the proposal. The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">FOR</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; the Adjournment Proposal, if necessary, as described in this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of GlycoMimetics&#8217; Directors and Executive Officers in the Merger</b> (see page 122)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In considering the recommendation of the GlycoMimetics Board with respect to approving the Merger, stockholders should be aware that GlycoMimetics&#8217; directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of GlycoMimetics stockholders generally. These interests may present them with actual or potential conflicts of interest. These interests include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under the terms of the Merger Agreement, (i) prior to the closing of the Merger, the GlycoMimetics Board will accelerate the vesting of all equity awards of GlycoMimetics then outstanding but not then vested or exercisable, and cancel each option to acquire shares of GlycoMimetics common stock with an exercise price per share greater than the GlycoMimetics Closing Price and (ii) at the closing of the First Merger, (a) each option to acquire shares of GlycoMimetics common stock with an exercise price less than or equal to the GlycoMimetics Closing Price (a &#8220;GlycoMimetics In the Money Option&#8221;) will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of shares underlying such option, (b) each GlycoMimetics restricted stock unit will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of unsettled shares of GlycoMimetics common stock underlying such GlycoMimetics restricted stock unit, and (c) each other option to acquire shares of GlycoMimetics common stock will be cancelled for no consideration; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">executive officers of GlycoMimetics are eligible to receive severance benefits under the terms of their employment agreements in the event they experience a qualifying termination of employment in connection with the Mergers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the GlycoMimetics stockholders approve the Merger as contemplated by this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of Crescent&#8217;s Directors and Executive Officers in the Merger</b> (see page 125)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In considering the recommendation of the Crescent Board with respect to approving the Merger, stockholders should be aware that Crescent&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of </p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Crescent stockholders generally. These interests may present them with actual or potential conflicts of interest. These interests include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as of February 7, 2025, Crescent&#8217;s current non-employee directors and executive officers beneficially owned, in the aggregate, approximately 80.0% of the shares of Crescent capital stock, which for purposes of this subsection excludes any Crescent shares issuable upon exercise or settlement of Crescent options held by such individual;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Fairmount Healthcare Fund II L.P. (&#8220;Fairmount Fund II&#8221;), an affiliate of Peter Harwin, a Crescent director, currently holds shares of Crescent capital stock and an unsecured convertible promissory note with an initial principal amount of $15.0 million at an interest rate of 12% per annum of Crescent and has agreed to purchase shares and pre-funded warrants in the Crescent Pre-Closing Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in connection with the Merger, each option to purchase shares of Crescent common stock held by Crescent&#8217;s executive officers and directors, whether or not vested, will be converted into an option to purchase shares of the Combined Company&#8217;s common stock, on the same terms and conditions (including any vesting and acceleration provisions);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s directors and executive officers are expected to become directors and executive officers of the Combined Company upon completion of the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger Agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Crescent Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Crescent stockholders approve the Merger as contemplated by this proxy statement/prospectus.</p><a id="OpinionofLucidCapitalMarketstotheGlycoMi"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion of Lucid Capital Markets to the GlycoMimetics Board</b> (see page B-1)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; retained Lucid Capital Markets, LLC (&#8220;Lucid&#8221;) as its financial advisor in connection with the Merger and the other transactions contemplated by the Merger Agreement. On October 28, 2024, Lucid rendered to the GlycoMimetics Board its oral opinion, which was subsequently confirmed by delivery of a written opinion to the GlycoMimetics Board dated October 28, 2024, that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the review undertaken by Lucid in preparing its opinion, the Exchange Ratio proposed to be paid by GlycoMimetics pursuant to the Merger Agreement was fair, from a financial point of view, to GlycoMimetics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The full text of the written opinion of Lucid, dated October 28, 2024, which describes the assumptions made and the qualifications and limitations upon the review undertaken by Lucid in preparing its opinion, is attached as <i style="font-style:italic;">Annex B</i> to this proxy statement/prospectus and is incorporated herein by reference. <b style="font-weight:bold;">Lucid&#8217;s financial advisory services and opinion were provided for the information and assistance of the GlycoMimetics Board (in their capacity as directors and not in any other capacity) in connection with and for purposes of the GlycoMimetics Board&#8217;s consideration of the Merger and the opinion of Lucid addressed only the fairness, from a financial point of view, as of the date thereof, to GlycoMimetics of the Exchange Ratio proposed to be paid by GlycoMimetics pursuant to the terms of the Merger Agreement. The opinion of Lucid did not address any other term or aspect of the Merger Agreement or the Merger and does not constitute a recommendation to any stockholder of GlycoMimetics as to whether or how such holder should vote with respect to the Merger or otherwise act with respect to the Merger or any other matter.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The full text of the written opinion of Lucid should be read carefully in its entirety for a description of the assumptions </b><b style="font-weight:bold;">made</b><b style="font-weight:bold;"> and limitations upon the review undertaken by Lucid in preparing its opinion.</b></p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Merger Agreement</b> (see page 134)</p><a id="MergerConsideration_280873"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Merger Consideration</span> (see page 134)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i) each then-outstanding share of Crescent common stock (including shares of Crescent common stock issued in the Crescent Pre-Closing Financing and excluding shares to be canceled pursuant to the Merger Agreement and dissenting shares) will be automatically converted solely into the right to receive a number of shares of GlycoMimetics common stock equal to the Exchange Ratio (described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Exchange Ratio</i>&#8221; beginning on page 135 of this proxy statement/prospectus), (ii) each then-outstanding share of Crescent preferred stock will be converted into the right to receive a number of shares of GlycoMimetics Series A Preferred Stock equal to the Exchange Ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii) each then-outstanding option to purchase Crescent common stock will be assumed by GlycoMimetics, subject to adjustment based on the Exchange Ratio as set forth in the Merger Agreement, and (iv) each then-outstanding warrant to purchase shares of Crescent common stock will be converted into a warrant to purchase shares of GlycoMimetics common stock, subject to adjustment based on the Exchange Ratio as set forth in the Merger Agreement and the form of warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately after the Merger, GlycoMimetics securityholders as of immediately prior to the Merger are expected to own approximately 3.10% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis, and subject to dilution from any equity issued by Crescent after the date of the Merger Agreement and before the closing), and former holders of Crescent securities are expected to own approximately 96.90% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis). Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if GlycoMimetics&#8217; net cash as of closing is less than $1.725 million or more than $1.875 million. GlycoMimetics&#8217; management currently anticipates GlycoMimetics&#8217; net cash as of closing will be approximately $1.8 million, and the currently estimated ownership percentages reflect this projection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent Options </span>(see page <span style="font-weight:bold;">138</span>)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, GlycoMimetics will assume Crescent&#8217;s 2024 Equity Incentive Plan and each option to purchase shares of Crescent common stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of GlycoMimetics common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, from and after the First Effective Time: (i) each outstanding Crescent stock option assumed by GlycoMimetics may be exercised solely for shares of GlycoMimetics common stock; (ii) the number of shares of GlycoMimetics common stock subject to each outstanding Crescent stock option assumed by GlycoMimetics will be determined by multiplying (A) the number of shares of Crescent common stock that were subject to such Crescent stock option assumed by GlycoMimetics, as in effect immediately prior to the First Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of GlycoMimetics common stock; and (iii) the per share exercise price of each Crescent stock option assumed by GlycoMimetics will be determined by dividing (A) the per share exercise price of such Crescent stock option, as in effect immediately prior to the First Effective Time, by (B) the Exchange Ratio and rounding the resulting exercise price up to the nearest whole cent. Each Crescent stock option assumed by GlycoMimetics will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Crescent stock option will otherwise remain unchanged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each Crescent stock option shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of GlycoMimetics common stock subsequent to the First Effective Time. In addition, the Combined Company&#8217;s compensation committee will succeed to the authority and responsibility of the Crescent Board as administrator of the Crescent 2024 Equity Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent Warrants</span> (see page 139)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, each warrant to purchase shares of Crescent capital stock that is outstanding and unexercised immediately prior to the First Effective Time (including any pre-funded warrant issued pursuant to the Crescent Pre-Closing Financing), whether or not vested, will be converted into a warrant to purchase shares of GlycoMimetics common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accordingly, from and after the First Effective Time: (i) each outstanding Crescent warrant assumed by GlycoMimetics may be exercised solely for shares of GlycoMimetics common stock; (ii) the number of shares of GlycoMimetics common stock subject to </p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">each outstanding Crescent warrant assumed by GlycoMimetics will be determined by multiplying (A) the number of shares of Crescent common stock that were subject to such Crescent warrant, as in effect immediately prior to the First Effective Time, by (B) the Exchange Ratio, and rounding the resulting number up to the next whole number of shares of GlycoMimetics common stock to the extent the aggregate amount of fractional shares of GlycoMimetics common stock such holder of the assumed warrants would otherwise be entitled to is equal to or exceeds 0.50, and otherwise rounded down; and (iii) the per share exercise price of each Crescent warrant assumed by GlycoMimetics will be determined by dividing (A) the per share exercise price of such Crescent warrant, as in effect immediately prior to the First Effective Time, by (B) the Exchange Ratio and rounding the resulting exercise price up to the nearest whole cent. Each Crescent warrant assumed by GlycoMimetics will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Crescent warrant will otherwise remain unchanged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each Crescent warrant shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of GlycoMimetics common stock subsequent to the First Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics Common Stock, GlycoMimetics Options and GlycoMimetics Restricted Stock Units </span>(see page 139)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as contemplated by the proposed increase in the number of authorized shares of GlycoMimetics common stock described in Proposal No. 2 of this proxy statement/prospectus and the proposed reverse stock split of issued and outstanding GlycoMimetics common stock described in Proposal No. 3 of this proxy statement/prospectus, GlycoMimetics common stock will remain unaffected by the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, the GlycoMimetics Board will accelerate the vesting of all equity awards of GlycoMimetics then outstanding but not then vested or exercisable, and cancel each option to acquire shares of GlycoMimetics common stock with an exercise price per share greater than the volume weighted average closing trading price of a share of GlycoMimetics common stock on Nasdaq for the five (5) consecutive trading days ending three (3) trading days immediately prior to the closing of the First Merger (the &#8220;GlycoMimetics Closing Price&#8221;), such options known as GlycoMimetics Out of the Money Options. At the closing of the First Merger, (i) each option to acquire shares of GlycoMimetics common stock with an exercise price less than or equal to the GlycoMimetics Closing Price will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of shares underlying such option, (ii) each GlycoMimetics restricted stock unit will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of unsettled shares of GlycoMimetics common stock underlying such GlycoMimetics restricted stock unit, and (iii) each other option to acquire shares of GlycoMimetics common stock will be cancelled for no consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conditions to the Completion of the Merger</span> (see page 147)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To complete the Merger, GlycoMimetics stockholders must approve Proposal No. 1 and Proposal No. 2 and Crescent stockholders must adopt the Merger Agreement and approve the Merger and the related transactions contemplated by the Merger Agreement. Additionally, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived.</p><a id="NonSolicitation_84341"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Non-Solicitation</span> (see page 144)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains non-solicitation provisions prohibiting GlycoMimetics and Crescent from soliciting a competing transaction. Each of GlycoMimetics and Crescent has agreed that, subject to certain exceptions, GlycoMimetics and Crescent and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize or permit any of the directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any acquisition proposal or acquisition inquiry or take any action that could reasonably be expected to lead to an acquisition proposal or acquisition inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">furnish any non-public information with respect to it to any person in connection with or in response to an acquisition proposal or acquisition inquiry;</span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">engage in discussions or negotiations with any person with respect to any acquisition proposal or acquisition inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">execute or enter into any letter of intent or any contract contemplating or otherwise relating to any acquisition transaction; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicly propose to do any of the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement expressly permits Crescent to take any action with respect to an Interim Financing or a Crescent Acquisition (each as defined below).</p><a id="BoardRecommendationChange_457511"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Board Recommendation Change</span> (see page 145)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Neither the Crescent Board nor the GlycoMimetics Board may change its recommendation in favor of the Merger, except that prior to receipt by such party of its stockholder approval, such party&#8217;s board of directors may effect a change in recommendation as a result of a material development or change in circumstances (&#8220;Intervening Event&#8221;) or with respect to a superior offer that did not result from a material breach of the Merger Agreement if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such party&#8217;s board of directors shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to effect such change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such party has provided at least four business days&#8217; prior written notice to the other party that it intends to effect a change in recommendation, and during such period has, and has caused its lead financial advisor and outside legal counsel to, negotiate with the other party in good faith to make such adjustments to the terms and conditions so that the acquisition proposal ceases to constitute a superior offer; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if after the other party shall have delivered to such party a written offer to alter the terms or conditions of the Merger Agreement during the four-business day period referred to above, such party&#8217;s board of directors shall have determined in good faith (based on the advice of its outside legal counsel), that the failure to effect a change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of any material amendment to any superior offer, the party considering the superior offer would be required to provide the other party with notice of such material amendment and there would be a new three-business day period following such notification during which the parties would be obligated to comply again with the requirements described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the case of an Intervening Event, the party suffering such event shall promptly notify the other party before effecting a change in recommendation. The written notice is required to state the material facts and circumstances related to the applicable Intervening Event and that such party&#8217;s board of directors intends to make a change in recommendation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement</span> (see page 148)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Either GlycoMimetics or Crescent may terminate the Merger Agreement under certain circumstances, which would prevent the Merger from being consummated.</p><a id="TerminationFee_620082"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination Fees Payable by GlycoMimetics and Termination Fees Payable by Crescent</span> (see page 150)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger Agreement is terminated under certain circumstances, GlycoMimetics could be required to pay Crescent a termination fee of $320,000 or Crescent could be required to pay GlycoMimetics a termination fee of up to $2.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Support Agreements</span> (see page 151)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Certain Crescent stockholders holding approximately 98.5% of the outstanding shares of Crescent capital stock, without giving effect to the Crescent Pre-Closing Financing, have entered into support agreements with GlycoMimetics and Crescent to vote all of their shares of Crescent capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative acquisition proposals (the &#8220;Crescent Support Agreements&#8221;). The directors and officers of GlycoMimetics holding approximately 10.7% of the outstanding shares of GlycoMimetics common stock have entered into support agreements with GlycoMimetics and Crescent to vote all of their shares of GlycoMimetics common stock in favor of the </p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal and against any alternative acquisition proposals (the &#8220;GlycoMimetics Support Agreements,&#8221; and, together with the Crescent Support Agreements, the &#8220;Support Agreements&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lock-Up Agreements</span> (see page <span style="font-weight:bold;">Error! Bookmark not defined.</span>)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of Crescent&#8217;s executive officers, directors and stockholders have entered into lock-up agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of GlycoMimetics common stock or any securities convertible into or exercisable or exchangeable for GlycoMimetics common stock, currently or thereafter owned, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series A Preferred Stock issued in exchange for shares of Crescent preferred stock in the Merger, but excluding, as applicable, shares purchased in the Crescent Pre-Closing Financing (including any shares of GlycoMimetics common stock issuable upon exercise of pre-funded warrants issued in exchange for pre-funded warrants to purchase shares of Crescent common stock sold in the Crescent Pre-Closing Financing), until 180 days following the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Subscription Agreement and Registration Rights Agreement</span> (see pages 151 and 153)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, Crescent and GlycoMimetics entered into the Subscription Agreement with certain new and existing investors of Crescent, pursuant to which such investors have agreed to purchase Crescent common stock or, in lieu thereof, Crescent pre-funded warrants, representing an aggregate commitment of $200.0 million (which includes $37.5 million of proceeds previously received by Crescent from the issuance of its Convertible Notes and accrued interest on such note) in the Crescent Pre-Closing Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The shares of Crescent common stock and Crescent pre-funded warrants that are issued in the Crescent Pre-Closing Financing will be or will have the right to be, respectively, converted into shares of GlycoMimetics common stock in the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Subscription Agreement contains customary representations and warranties of Crescent and also contains customary representations and warranties of the purchaser parties thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Subscription Agreement also contemplates GlycoMimetics, Crescent and the investors participating in the Crescent Pre-Closing Financing entering into the Registration Rights Agreement at the closing of the Crescent Pre-Closing Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Crescent common stock that are held by the investors participating in the Crescent Pre-Closing Financing from time to time pursuant to Rule 415.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Management Following the Merger</b> (see page 274)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table sets forth the name, age as of February 7, 2025 and position of each of the individuals who are expected to serve as executives and directors of the Combined Company following completion of the Merger:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:5.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:65.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:25.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:5.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:65.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Position</b></p></td></tr><tr><td style="vertical-align:top;width:25.26%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Executive Officers</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:65.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Jonathan Violin</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">49</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Chief Executive Officer, President and Director</span></p></td></tr><tr><td style="vertical-align:top;width:25.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Christopher Doughty</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">38</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Chief Business Officer</span></p></td></tr><tr><td style="vertical-align:top;width:25.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Ryan Lynch</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">41</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Treasurer, Senior Vice President of Finance and Chief Accounting Officer</span></p></td></tr><tr><td style="vertical-align:top;width:25.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Barbara Bispham</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">39</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">General Counsel and Corporate Secretary</span></p></td></tr><tr><td style="vertical-align:top;width:25.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Non-Employee Directors:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Peter Harwin</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">39</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Director</span></p></td></tr><tr><td style="vertical-align:top;width:25.26%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Alexandra Balcom</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">41</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Director</span></p></td></tr><tr><td style="vertical-align:top;width:25.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Susan Moran</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">55</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Director</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">U.S. Federal Income Tax Considerations of the Merger</b> (see page 128)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As discussed in detail in the section titled &#8220;<i style="font-style:italic;">The Merger&#8212;U.S. Federal Income Tax Considerations of the Merge</i>r&#8221; beginning on page 128 of this proxy statement/prospectus and subject to the limitations and qualifications described therein, Crecent and GlycoMimetics intend the Merger to qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code. Assuming the Merger so qualifies, a U.S. Holder of Crecent stock (as defined therein) will not recognize gain or loss upon the exchange of its Crecent stock for GlycoMimetics stock. For a more detailed discussion of the U.S. federal income tax considerations of the Merger, see the section titled &#8220;<i style="font-style:italic;">The Merger&#8212;U.S. Federal Income Tax Considerations of the Merger</i>,&#8221; beginning on page 128 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risk Factors</b> (see page 16)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Both GlycoMimetics and Crescent are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility that the Merger may not be completed, poses a number of risks to each company and its respective securityholders, including the following risks:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to the Proposed Merger</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Failure to complete, or delays in completing, the potential Merger with Crescent could materially and adversely affect GlycoMimetics&#8217; results of operations, business, financial results and/or common stock price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Exchange Ratio will not change or otherwise be adjusted based on the market price of GlycoMimetics common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The issuance of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series A Preferred Stock, to Crescent stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger must be approved by GlycoMimetics stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Crescent stockholders. Failure to obtain these approvals would prevent the closing of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If GlycoMimetics completes the Merger, the Combined Company will need to raise additional capital and satisfy certain contractual obligations by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the Combined Company&#8217;s stockholders or restrict the Combined Company&#8217;s operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics is expected to be deemed a shell company. As a result, if GlycoMimetics completes the Merger, the Combined Company may be subject to more stringent reporting requirements, offering limitations and resale restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Some of the GlycoMimetics and Crescent directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics stockholders and Crescent stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Crescent common stock issued in the Crescent Pre-Closing Financing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to the Proposed Reverse Stock Split</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The reverse stock split may not increase the Combined Company&#8217;s stock price over the long term;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The reverse stock split may decrease the liquidity of the Combined Company&#8217;s common stock; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The reverse stock split may lead to a decrease in the Combined Company&#8217;s overall market capitalization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to GlycoMimetics</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Failure to complete, or delays in completing, the Merger with Crescent could expose GlycoMimetics to other operational and financial risks;</span></td></tr></table></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If GlycoMimetics does not successfully consummate the Merger or another strategic transaction, the GlycoMimetics Board may decide to pursue a dissolution and liquidation of GlycoMimetics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics has a limited operating history, no history of commercializing products, has not generated any product revenue, has incurred significant operating losses since inception, expects to continue to incur losses and may never achieve or maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If GlycoMimetics decides to resume development of its drug candidates, GlycoMimetics would need substantial additional funding. If GlycoMimetics was unable to raise that capital when needed, GlycoMimetics may not be able to continue as a going concern and could be forced to delay, reduce or eliminate drug development programs or potential commercialization efforts; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If GlycoMimetics fails to comply or regain compliance with Nasdaq&#8217;s continued listing standards, its common stock may be delisted and the price of its common stock, its ability to access the capital markets and its financial condition could be negatively impacted.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Crescent</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent has concluded there is substantial doubt about its ability to continue as a going concern for at least twelve months from the date its financial statements as of December 31, 2024 are available to be issued. Even if the Merger and Crescent Pre-Closing Financing are successful, Crescent will need to raise additional capital, and if it is unable to do so when needed, that will raise substantial doubt about Crescent&#8217;s ability to continue as a going concern;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent has never generated any revenue from product sales and may never be profitable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent is a preclinical-stage biopharmaceutical company with a limited operating history on which to assess its business; it has not initiated, conducted or completed any clinical trials, has no products approved for commercial sale, has historically incurred losses, and anticipates that it will continue to incur significant losses for the foreseeable future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s programs are in preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If Crescent or its current or future collaborators are unable to complete development of or commercialize Crescent&#8217;s product candidates, or experience significant delays in doing so, Crescent&#8217;s business will be materially harmed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent is substantially dependent on the success of its lead program, CR-001, and its anticipated clinical trials of such programs may not be successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent currently relies on licensing arrangements with Paragon through the Paragon Option Agreements. If Crescent is unable to maintain collaborations or licensing arrangements, or if its collaborations or licensing arrangements are not successful, Crescent&#8217;s business could be negatively impacted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In order to successfully implement Crescent&#8217;s plans and strategies, Crescent will need to grow the size of its organization and it may experience difficulties in managing this growth;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent does not currently own any issued patents or pending patent applications. Therefore, Crescent&#8217;s ability to obtain and protect its patent rights, and protect other proprietary rights, is uncertain, exposing Crescent to the possible loss of competitive advantage; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If Crescent is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Crescent will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to the Combined Company</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market price of the Combined Company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company may incur losses for the foreseeable future and may never achieve profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Provisions that will be in the Combined Company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the Combined Company more difficult and may prevent attempts by its stockholders to replace or remove its management;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">After completion of the Merger, the Combined Company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the Combined Company stockholders for approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company will have broad discretion in the use of the cash and cash equivalents of the Combined Company and the proceeds from the Crescent Pre-Closing Financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These risks and other risks are discussed in greater detail under the section titled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; beginning on page 16 of this proxy statement/prospectus. GlycoMimetics and Crescent both encourage you to read and consider all of these risks carefully.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Regulatory Approvals</b> (see page 128)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics and Crescent do not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nasdaq Stock Market Listing</b> (see page 130)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics intends to file an initial listing application for the common stock of the Combined Company with Nasdaq. After completion of the Merger, GlycoMimetics will be renamed &#8220;Crescent Biopharma, Inc.&#8221; and it is expected that the common stock of the Combined Company will trade on Nasdaq under the symbol &#8220;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.&#8221; It is a condition to the consummation of the Merger that GlycoMimetics will receive confirmation from Nasdaq that the Combined Company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that GlycoMimetics will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Anticipated Accounting Treatment</b> (see page 130)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is expected to be treated by GlycoMimetics as a reverse merger and will be accounted for as an in-substance reverse recapitalization of GlycoMimetics by Crescent in accordance with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) as, at close, the transaction is, in essence, the issuance of equity for GlycoMimetics&#8217; net assets, which primarily consist of cash and other nominal non-operating assets and liabilities. For accounting purposes, Crescent is considered to be acquiring the assets and liabilities of GlycoMimetics in this transaction based on the terms of the Merger Agreement and other factors, including: (i) Crescent&#8217;s equity holders will own a substantial majority of the voting rights in the Combined Company; (ii) Crescent&#8217;s largest stockholder will retain the largest interest in the Combined Company; (iii) Crescent will designate all of the initial members of the board of directors of the Combined Company; and (iv) Crescent&#8217;s executive management team will become the management of the Combined Company. The Combined Company will be named Crescent Biopharma, Inc. Accordingly, the Merger is expected to be treated as the equivalent of Crescent issuing stock to acquire the net assets of GlycoMimetics. As a result of the Merger, the net assets of GlycoMimetics will be stated at fair value, which approximates carrying value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Crescent. The direct and incremental costs related to the transaction will be treated as a reduction of the net proceeds received within additional paid-in-capital. See the &#8220;<i style="font-style:italic;">Unaudited Pro Forma Condensed Combined Financial Information</i>&#8221; elsewhere in this proxy statement/prospectus for additional information.</p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:20.6pt 5.22% 0pt 5.22%;padding:1pt 0.65% 1pt 0.65%;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights</b> (see page 131)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the DGCL, GlycoMimetics stockholders are not entitled to appraisal rights in connection with the Merger. Crescent stockholders are entitled to appraisal rights in connection with the Merger under Section 262 of the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Comparison of Rights of Holders of GlycoMimetics Capital Stock and Crescent Capital Stock</b> (see page 298)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Both GlycoMimetics and Crescent are incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the DGCL. If the Merger is completed, Crescent stockholders will become GlycoMimetics stockholders, and their rights will be governed by the DGCL, the amended and restated bylaws of GlycoMimetics (the &#8220;GlycoMimetics Bylaws&#8221;) and the GlycoMimetics Charter, as may be further amended by Proposal Nos.&#160;2 and 3 if approved by the GlycoMimetics stockholders at the GlycoMimetics Special Meeting. The rights of GlycoMimetics stockholders contained in the GlycoMimetics Charter and GlycoMimetics Bylaws differ from the rights of Crescent stockholders under the amended and restated certificate of incorporation of Crescent (the &#8220;Crescent Charter&#8221;) and bylaws of Crescent (the &#8220;Crescent Bylaws&#8221;), as more fully described under the section titled &#8220;<i style="font-style:italic;">Comparison of Rights of Holders of GlycoMimetics Capital Stock and Crescent Capital Stock</i>&#8221; beginning on page 298 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5369a6b9_73d3_4308_a309_de4073f95681"></a><a id="MARKETPRICEANDDIVIDENDINFORMATION_791020"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">MARKET PRICE AND DIVIDEND INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;GLYC.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The closing price of the GlycoMimetics common stock on October&#160;25, 2024, the last day of trading prior to the announcement of the Merger, as reported on The Nasdaq Capital Market, was $0.17 per share. The closing price of the GlycoMimetics common stock on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, as reported on The Nasdaq Capital Market, was $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the market price of the GlycoMimetics common stock is subject to fluctuation, the market value of the shares of the GlycoMimetics common stock that the Crescent stockholders will be entitled to receive in the Merger may increase or decrease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is a private company, and its shares of common stock and preferred stock are not publicly traded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming approval of Proposal Nos. 1 and 2 and successful application for initial listing with Nasdaq, following the consummation of the Merger, shares of GlycoMimetics common stock will trade on Nasdaq under GlycoMimetics&#8217; new name, &#8220;Crescent Biopharma,&#160;Inc.,&#8221; and new trading symbol &#8220;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, the Record Date for the GlycoMimetics Special Meeting, there were approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;registered holders of record of the GlycoMimetics common stock. As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, Crescent had&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;holders of record of Crescent common stock and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;holder(s)&#160;of record of Crescent preferred stock. For detailed information regarding the beneficial ownership of certain GlycoMimetics and Crescent stockholders, see the sections of this proxy statement/prospectus titled &#8220;<i style="font-style:italic;">Principal Stockholders of GlycoMimetics</i>,&#8221; &#8220;<i style="font-style:italic;">Principal Stockholders of Crescent</i>&#8221; and &#8220;<i style="font-style:italic;">Principal Stockholders of the Combined Company</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividends</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has never declared or paid any cash dividends on the GlycoMimetics common stock and does not anticipate paying cash dividends on the GlycoMimetics common stock for the foreseeable future. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Merger will be at the discretion of the combined organization&#8217;s then-current board of directors and will depend upon a number of factors, including the combined organization&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then-current board of directors deems relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent has never paid or declared any cash dividends on Crescent capital stock. If the Merger does not occur, Crescent does not anticipate paying any cash dividends on the Crescent capital stock in the foreseeable future, and Crescent intends to retain all available funds and any future earnings to fund the development and expansion of its business. Any future determination to pay dividends will be at the discretion of the Crescent Board and will depend upon a number of factors, including its results of operations, financial condition, future prospects, contractual restrictions, and restrictions imposed by applicable laws and other factors the Crescent Board deems relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_75e47c03_5694_4dd5_ace1_33ca0b1770da"></a><a id="RISKFACTORS_941803"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Combined Company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information contained or incorporated by reference in this proxy statement/prospectus, you should carefully consider the material risks described below before deciding how to vote your shares of GlycoMimetics common stock. You should also read and consider the other information in this proxy statement/prospectus. Please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page&#160;</i>315<i style="font-style:italic;"> of this proxy statement/prospectus for further information.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Proposed Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to complete, or delays in completing, the potential Merger with Crescent could materially and adversely affect GlycoMimetics&#8217; results of operations, business, financial results and/or common stock price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;28, 2024, GlycoMimetics entered into the Merger Agreement with Crescent, which agreement was subsequently amended on February&#160;14, 2025, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Crescent, with Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the First Merger and, immediately following the First Merger and as part of the same overall transaction as the First Merger, Crescent will merge with and into Second Merger Sub as part of the Second Merger, with Second Merger Sub continuing as a wholly owned subsidiary of GlycoMimetics and the surviving entity of the Second Merger. Consummation of the Merger is subject to certain closing conditions, a number of which are not within GlycoMimetics&#8217; control. Any failure to satisfy these required conditions to closing may prevent, delay or otherwise materially adversely affect the completion of the transaction. GlycoMimetics cannot predict with certainty whether or when any of the required closing conditions will be satisfied or if another uncertainty may arise and cannot assure you that it will be able to successfully consummate the Merger as currently contemplated under the Merger Agreement or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; efforts to complete the Merger could cause substantial disruptions in, and create uncertainty surrounding, its business, which may materially adversely affect its results of operation and its business. Uncertainty as to whether the Merger will be completed in a timely manner or at all may affect GlycoMimetics&#8217; ability to retain and motivate existing employees. Uncertainty as to whether the Merger will be completed in a timely manner or at all could adversely affect GlycoMimetics&#8217; business and its relationship with collaborators, suppliers, vendors, regulators and other business partners. The adverse effects of the pendency of the transaction could be exacerbated by any delays in completion of the transaction or termination of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the conditions to the Merger are not satisfied or waived, the Merger may not occur.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if the Merger is approved by the stockholders of Crescent and GlycoMimetics, specified conditions must be satisfied or, to the extent permitted by applicable law, waived to complete the Merger. These conditions are set forth in the Merger Agreement and described further in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement</i>&#8221; of this proxy statement/prospectus. GlycoMimetics cannot assure you that all of the conditions to the consummation of the Merger will be satisfied or waived. If the conditions are not satisfied or waived, the Merger may not occur or the closing may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Exchange Ratio for the Merger will not change or otherwise be adjusted based on the market price of GlycoMimetics common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Applying the Exchange Ratio, based on GlycoMimetics&#8217; capitalization as of September&#160;30, 2024 and Crescent&#8217;s capitalization as of October&#160;28, 2024 (the date the Merger Agreement was executed) and taking into account GlycoMimetics&#8217; current cash position, each share of Crescent common stock is currently estimated to be entitled to receive approximately 14.9149 shares of GlycoMimetics common stock. Each share of Crescent preferred stock will be converted into the right to receive a number of shares of GlycoMimetics Series A Preferred Stock, equal to the Exchange Ratio divided by 1,000. Applying the Exchange Ratio, the former Crescent securityholders immediately before the Merger are expected to own approximately 96.90% of the aggregate number of shares of the Combined Company&#8217;s capital stock following the Merger (on a fully-diluted basis, and subject to dilution from any equity issued by Crescent after the date of the Merger Agreement and before the closing), and GlycoMimetics securityholders immediately before the Merger are expected to own approximately 3.10% of the aggregate number of shares of the Combined Company capital stock following the Merger (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, GlycoMimetics&#8217; net cash as of closing being equal to $1.8 million. In the event GlycoMimetics&#8217; net cash is below $1.725 million, the Exchange Ratio will be </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">adjusted such that the number of shares issued to Crescent&#8217;s pre-closing securityholders will be increased, and GlycoMimetics stockholders will own a smaller&#160;percentage of the Combined Company following the consummation of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any changes in the market price of GlycoMimetics&#8217; stock before the completion of the First Merger will not affect the number of shares Crescent stockholders will be entitled to receive pursuant to the Merger Agreement. Therefore, if before the completion of the First Merger, the market price of GlycoMimetics common stock increases from the market price on the date of the Merger Agreement, then Crescent stockholders could receive merger consideration with substantially more value for their shares of Crescent capital stock than the parties had negotiated when they established the Exchange Ratio. Similarly, if before the completion of the First Merger, the market price of GlycoMimetics common stock declines from the market price on the date of the Merger Agreement, then Crescent stockholders could receive merger consideration with substantially lower value. The Merger Agreement does not include a price-based termination right.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The issuance of GlycoMimetics common stock, including the shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock, to Crescent stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger must be approved by GlycoMimetics stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Crescent stockholders. Failure to obtain these approvals would prevent the closing of the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before the Merger can be completed, GlycoMimetics stockholders must approve, among other things, the issuance of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock, to Crescent stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger, and Crescent stockholders must adopt the Merger Agreement and approve the Merger and the related transactions. Failure to obtain the required stockholder approvals may result in a material delay in, or the abandonment of, the Merger. Any delay in completing the Merger may materially adversely affect the timing and benefits that are expected to be achieved from the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, neither GlycoMimetics nor Crescent is obligated to complete the Merger if there is a material adverse effect affecting the other party between October&#160;28, 2024, the date of the Merger Agreement, and the closing of the Merger. However, certain types of causes are excluded from the concept of a &#8220;material adverse effect.&#8221; Such exclusions include, but are not limited to, changes in general economic or political conditions, industry-wide changes, changes resulting from the announcement of the Merger, natural disasters, pandemics, other public health events or force majeure events and changes in U.S. generally accepted accounting principles. Therefore, if any of these events were to occur and adversely affect GlycoMimetics or Crescent, the other party would still be obliged to consummate the closing of the Merger notwithstanding such material adverse effect. If any such adverse effects occur and GlycoMimetics consummates the closing of the Merger, the stock price of the Combined Company may suffer. This in turn may reduce the value of the Merger to the stockholders of GlycoMimetics, Crescent or both.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Merger is not completed, GlycoMimetics&#8217; stock price may decline significantly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The market price of GlycoMimetics common stock is subject to significant fluctuations. Market prices for securities of pharmaceutical, biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of GlycoMimetics common stock will likely be volatile based on whether stockholders and other investors believe that GlycoMimetics can complete the Merger or otherwise raise additional capital to support GlycoMimetics&#8217; operations if the Merger is not consummated and another strategic transaction cannot be identified, negotiated and consummated in a timely manner, if at all. The volatility of the market price of GlycoMimetics common stock has been and may be exacerbated by low trading volume. Additional factors that may cause the market price of GlycoMimetics common stock to fluctuate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of the results of its clinical trials, discussions with regulators, and regulatory approval decisions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the entry into, or termination of, key agreements, including commercial partner agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by commercial partners or competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the loss of key employees;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future sales of GlycoMimetics common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general and industry-specific economic conditions that may affect GlycoMimetics&#8217; research and development expenditures; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">period-to-period fluctuations in financial results.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of GlycoMimetics common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If GlycoMimetics completes the Merger, the Combined Company will need to raise additional capital and satisfy certain contractual obligations by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the Combined Company&#8217;s stockholders or restrict the Combined Company&#8217;s operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, Crescent and GlycoMimetics entered into the Subscription Agreement with certain investors, including existing investors of Crescent, pursuant to which the investors agreed to purchase, in the aggregate, $200.0 million (which includes $37.5 million of proceeds previously received by Crescent from the issuance of its Convertible Notes&#160;and accrued interest on such note) in shares of common stock and pre-funded warrants of Crescent in the Crescent Pre-Closing Financing immediately prior to the closing of the Merger. The closing of the Crescent Pre-Closing Financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the Merger as well as certain other conditions. The shares of Crescent common stock and pre-funded warrants issued in the Crescent Pre-Closing Financing will result in dilution to all securityholders of the Combined Company (i.e., both GlycoMimetics&#8217; pre-Merger securityholders and former Crescent securityholders).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional financing may not be available to the Combined Company when it is needed or may not be available on favorable terms. To the extent that the Combined Company raises additional capital by issuing equity securities, such financing will cause additional dilution to all securityholders of the Combined Company, including GlycoMimetics&#8217; pre-Merger securityholders and Crescent&#8217;s former securityholders. It is also possible that the terms of any new equity securities may have preferences over the Combined Company&#8217;s common stock. Any debt financing the Combined Company enters into may involve covenants that restrict its operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the Combined Company&#8217;s assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make investments. In addition, if the Combined Company raises additional funds through licensing arrangements, it may be necessary to grant licenses on terms that are not favorable to the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, as a result of GlycoMimetics&#8217; assumption of the Paragon Option Agreements in connection with the Merger, the Combined Company will be subject to the obligation to grant to Parascent, on each of December&#160;31, 2025 and December&#160;31, 2026, warrants to purchase a number of shares equal to 1.00% of the outstanding shares of GlycoMimetics common stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares on the grant date. Such warrants granted will result in further dilution to all securityholders of the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transfers of the Combined Company&#8217;s securities utilizing Rule&#160;144 of the Securities Act may be limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Combined Company&#8217;s securities will be restricted from immediate resale. Holders should be aware that transfers of the Combined Company&#8217;s securities pursuant to Rule&#160;144 may be limited as Rule&#160;144 is not available, subject to certain exceptions, for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company. GlycoMimetics&#8217; expected disposal of GlycoMimetics&#8217; historical assets and operations in connection with the Merger is expected to make GlycoMimetics a shell company. GlycoMimetics anticipates that following the consummation of the Merger, the Combined Company will no longer be a shell company. As a result, GlycoMimetics anticipates that holders will not be able to sell their restricted Combined Company securities pursuant to Rule&#160;144 without registration until one&#160;year after GlycoMimetics files the Current Report on Form&#160;8-K following the closing that includes the required Form&#160;10 information that reflects that the Combined Company is no longer a shell company.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics&#8217; is expected to be deemed a shell company. As a result, if GlycoMimetics completes the Merger, the Combined Company will be subject to more stringent reporting requirements, offering limitations and resale restrictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; or the Combined Company&#8217;s expected disposal of GlycoMimetics&#8217; historical assets and operations prior to or following the Merger is expected to make GlycoMimetics a shell company. As such, the Combined Company would be subject to the requirements applicable to shell company business combinations. The requirements applicable to shell company business combinations are as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Combined Company will need to file a Form&#160;8-K to report the Form&#160;10 type information after closing with the SEC reflecting its status as an entity that is not a shell company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics is not, and the Combined Company will not be, eligible to use a Form&#160;S-3 until 12 full calendar&#160;months after closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Combined Company will need to wait at least 60 calendar&#160;days after closing to file a Form&#160;S-8 for any equity plans or awards;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Combined Company will be an &#8220;ineligible issuer&#8221; for three&#160;years following the closing, which will prevent the Combined Company from (i)&#160;incorporating by reference in its Form&#160;S-1 filings, (ii)&#160;using a free writing prospectus, or (iii)&#160;taking advantage of well-known seasoned issuer status despite its public float;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investors who (i)&#160;are affiliates of Crescent at the time the Merger is submitted for the vote or consent of Crescent stockholders, (ii)&#160;receive securities of the Combined Company in the Merger (i.e., Rule&#160;145(c)&#160;securities) and (iii)&#160;publicly offer or sell such securities, will be deemed to be engaged in a distribution of such securities, and therefore to be underwriters with respect to resales of those securities, and accordingly such securities may not be included in the Form&#160;S-1 resale registration statement anticipated to be filed after the closing of the Merger unless such securities are sold only in a fixed price offering in which such investors are named as underwriters in the prospectus; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Rule&#160;144(i)(2)&#160;will limit the ability to publicly resell Rule&#160;145(c)&#160;securities per Rule&#160;145(d), as well as any other &#8220;restricted&#8221; or &#8220;control&#8221; securities of the Combined Company per Rule&#160;144 (i.e., holders of restricted securities and any affiliates of the public company are also affected) until one&#160;year after the Form&#160;10 information is filed with the SEC.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing SEC requirements would increase the Combined Company&#8217;s time and cost of raising capital, offering stock under equity plans, and complying with securities laws. Further, such requirements will add burdensome restrictions on the resale of Combined Company shares by affiliates of Crescent and any holders of &#8220;restricted&#8221; or &#8220;control&#8221; securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Some of GlycoMimetics&#8217; and Crescent&#8217;s directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Directors and executive officers of GlycoMimetics and Crescent may have interests in the Merger that are different from, or in addition to, the interests of other GlycoMimetics stockholders generally. These interests with respect to GlycoMimetics&#8217; directors and executive officers may include, among others, retention bonus payments, extension of exercisability periods of previously issued stock option grants, severance payments if employment is terminated in a qualifying termination in connection with the Merger and rights to continued indemnification, expense advancement and insurance coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, certain current members of the Crescent Board will continue as directors of the Combined Company after the effective time, and, following the closing of the Merger, will be eligible to be compensated as non-employee directors of the Combined Company pursuant to GlycoMimetics&#8217; non-employee director compensation policy that is expected to remain in place following the effective time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Board was aware of and considered those interests, among other matters, in reaching their decisions to approve and adopt the Merger Agreement, approve the Merger, and recommend the approval of the Merger Agreement to GlycoMimetics and Crescent stockholders. These interests, among other factors, may have influenced the directors and executive officers of each company to support or approve the Merger.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics stockholders and Crescent stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Crescent common stock issued in the Crescent Pre-Closing Financing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Combined Company is unable to realize the full strategic and financial benefits currently anticipated from the Merger, GlycoMimetics stockholders and Crescent stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the Combined Company is able to realize only part of the strategic and financial benefits currently anticipated from the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics securityholders will generally have a reduced ownership and voting interest in, and will exercise less influence over the management of, the Combined Company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the completion of the Merger, GlycoMimetics&#8217; current stockholders will generally own a smaller&#160;percentage of the Combined Company than their ownership of GlycoMimetics prior to the Merger. Immediately after the Merger, GlycoMimetics securityholders as of immediately prior to the Merger are expected to own approximately 3.10% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis, and subject to dilution from any equity issued by Crescent after the date of the Merger Agreement and before the closing), and former holders of Crescent securities are expected to own approximately 96.90% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, GlycoMimetics&#8217; net cash as of closing being equal to $1.8 million. The Chief Executive Officer of Crescent will serve as the Chief Executive Officer of the Combined Company following the completion of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While the Merger Agreement is in effect, each party is generally prohibited from, among other things, soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any acquisition proposal or acquisition inquiry. In addition, GlycoMimetics&#8217; current directors and executive officers and certain significant stockholders have entered into support agreements pursuant to the terms of the Merger Agreement, and as an inducement to Crescent&#8217;s willingness to enter into the Merger Agreement, by which they have agreed to vote all of their shares of GlycoMimetics capital stock in favor of the Merger Agreement and the transactions contemplated thereby and against any competing proposals, subject to certain limited exceptions. These provisions could discourage a potential competing acquirer from considering or proposing an acquisition or merger, even if it were prepared to pay consideration with a higher value than that implied by the merger consideration in the combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because the lack of a public market for Crescent common stock makes it difficult to evaluate the fair market value of its capital stock, the value of GlycoMimetics common stock to be issued to Crescent stockholders may be more or less than the fair market value of Crescent common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The outstanding capital stock of Crescent is privately held and is not traded on any public market. The lack of a public market makes it difficult to determine the fair market value of Crescent capital stock. Because the&#160;percentage of GlycoMimetics&#8217; equity to be issued to Crescent stockholders was determined based on negotiations between the parties, it is possible that the value of GlycoMimetics common stock and GlycoMimetics Series&#160;A Preferred Stock to be issued to Crescent stockholders will be more or less than the fair market value of Crescent capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lawsuits may be filed against GlycoMimetics, Crescent, or any of the members of their respective boards of directors arising out of the Merger, which may delay or prevent the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against GlycoMimetics, the GlycoMimetics Board, Crescent, the Crescent Board and others in connection with the transactions contemplated by the Merger Agreement. The outcome of litigation is uncertain, and GlycoMimetics or Crescent may not be successful in defending against any such future claims. Lawsuits that may be filed against GlycoMimetics, the GlycoMimetics Board, Crescent, or the Crescent Board could delay or prevent the Merger, divert the attention of GlycoMimetics&#8217; and Crescent&#8217;s management and employees from their day-to-day business and otherwise adversely affect GlycoMimetics and Crescent financially.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics has never paid and, other than in connection with the Merger with Crescent, does not intend to pay any cash dividends in the foreseeable future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has never paid cash dividends on any of its capital stock. GlycoMimetics does not currently anticipate declaring or paying cash dividends on its capital stock in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If GlycoMimetics does not successfully consummate the Merger or another strategic transaction, the GlycoMimetics Board may decide to pursue a dissolution and liquidation of GlycoMimetics. In such an event, the amount of cash available for distribution to GlycoMimetics stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities, as to which GlycoMimetics can give you no assurance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the Merger will be completed. If the Merger is not completed, the GlycoMimetics Board may decide to pursue a dissolution and liquidation of GlycoMimetics. In such an event, the amount of cash available for distribution to GlycoMimetics stockholders will depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of cash available for distribution continues to decrease as GlycoMimetics funds its operations while pursuing the Merger. In addition, if the GlycoMimetics Board were to approve and recommend, and GlycoMimetics stockholders were to approve, a dissolution and liquidation of GlycoMimetics, GlycoMimetics would be required under Delaware law to pay GlycoMimetics&#8217; outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to stockholders. GlycoMimetics&#8217; commitments and contingent liabilities may include obligations under GlycoMimetics&#8217; employment and related agreements with certain employees that provide for severance and other payments following a termination of employment occurring for various reasons, including a change in control of GlycoMimetics, litigation against GlycoMimetics, and other various claims and legal actions arising in the ordinary course of business, and other unexpected and/or contingent liabilities. As a result of this requirement, a portion of GlycoMimetics&#8217; assets would need to be reserved pending the resolution of such obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, GlycoMimetics may be subject to litigation or other claims related to a dissolution and liquidation of GlycoMimetics. If a dissolution and liquidation were to be pursued, the GlycoMimetics Board, in consultation with GlycoMimetics&#8217; advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of GlycoMimetics common stock could lose all or a significant portion of their investment in the event of liquidation, dissolution or winding up of GlycoMimetics. A liquidation would be a lengthy and uncertain process with no assurance of any value ever being returned to GlycoMimetics stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Proposed Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The </span><span style="font-style:italic;font-weight:bold;">r</span><span style="font-style:italic;font-weight:bold;">everse </span><span style="font-style:italic;font-weight:bold;">s</span><span style="font-style:italic;font-weight:bold;">tock </span><span style="font-style:italic;font-weight:bold;">s</span><span style="font-style:italic;font-weight:bold;">plit could result in a significant devaluation of GlycoMimetics&#8217; market capitalization and the trading price of GlycoMimetics </span><span style="font-style:italic;font-weight:bold;">c</span><span style="font-style:italic;font-weight:bold;">ommon </span><span style="font-style:italic;font-weight:bold;">s</span><span style="font-style:italic;font-weight:bold;">tock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although GlycoMimetics expects that the reverse stock split will result in an increase in the market price of GlycoMimetics common stock, GlycoMimetics cannot assure stockholders that the reverse stock split, if implemented, will increase the market price of GlycoMimetics common stock in proportion to the reduction in the number of shares of GlycoMimetics common stock outstanding or result in a permanent increase in the market price. Accordingly, the total market capitalization of GlycoMimetics common stock after either or both of the reverse stock split may be lower than the total market capitalization before such reverse stock split and, in the future, the market price of GlycoMimetics common stock following such reverse stock split may not exceed or remain higher than the market price prior to the corresponding reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The effect the reverse stock split may have upon the market price of GlycoMimetics common stock cannot be predicted with any certainty. The market price of GlycoMimetics common stock is dependent on many factors, including GlycoMimetics&#8217; business and financial performance, general market conditions, prospects for future success and other factors detailed from time to time in the reports GlycoMimetics files with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The reverse </span><span style="font-style:italic;font-weight:bold;">s</span><span style="font-style:italic;font-weight:bold;">tock </span><span style="font-style:italic;font-weight:bold;">s</span><span style="font-style:italic;font-weight:bold;">plit may result in some stockholders owning &#8220;odd lots&#8221; that may be more difficult to sell or require greater transaction costs per share to sell.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The reverse stock split may result in some stockholders owning &#8220;odd lots&#8221; of less than 100 shares of GlycoMimetics common stock on a post-split basis. These odd lots may be more difficult to sell, or require greater transaction costs per share to sell, than shares in &#8220;round lots&#8221; of even multiples of 100 shares.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The </span><span style="font-style:italic;font-weight:bold;">r</span><span style="font-style:italic;font-weight:bold;">everse </span><span style="font-style:italic;font-weight:bold;">s</span><span style="font-style:italic;font-weight:bold;">tock </span><span style="font-style:italic;font-weight:bold;">s</span><span style="font-style:italic;font-weight:bold;">plit may not generate additional investor interest.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While the GlycoMimetics Board believes that a higher stock price may help generate investor interest, there can be no assurance that the reverse stock split will result in a per share price that will attract institutional investors or investment funds or that such share price will satisfy the investing guidelines of institutional investors or investment funds. As a result, the trading liquidity of GlycoMimetics common stock may not necessarily improve.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The reverse stock split may not increase the Combined Company&#8217;s stock price over the long term.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The principal purposes of the reverse stock split are to (i)&#160;increase the per-share market price of GlycoMimetics common stock above the minimum bid price requirement under the Nasdaq rules&#160;so that the listing of GlycoMimetics and the shares of GlycoMimetics common stock being issued in the Merger on Nasdaq will be approved and (ii)&#160;increase the number of authorized and unissued shares available for future issuance in connection with the Merger, though such increase will not alone be sufficient to complete the Merger. It cannot be assured, however, that the reverse stock split will accomplish any increase in the per share market price of GlycoMimetics common stock for any meaningful period of time. While it is expected that the reduction in the number of outstanding shares of GlycoMimetics common stock will proportionally increase the market price of GlycoMimetics common stock, it cannot be assured that the reverse stock split will increase the market price of GlycoMimetics common stock by a multiple of the reverse stock split ratio mutually agreed by GlycoMimetics and Crescent, or result in any permanent or sustained increase in the market price of GlycoMimetics common stock, which is dependent upon many factors, including GlycoMimetics&#8217; business and financial performance, general market conditions and prospects for future success. Thus, while the stock price of GlycoMimetics common stock might meet the listing requirements for Nasdaq initially after the reverse stock split, it cannot be assured that it will continue to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The reverse stock split may decrease the liquidity of the Combined Company&#8217;s common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although the GlycoMimetics Board believes that the anticipated increase in the market price of the Combined Company&#8217;s common stock resulting from the proposed reverse stock split could encourage interest in its common stock and possibly promote greater liquidity for its stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the reverse stock split. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market makers for the Combined Company&#8217;s common stock. In addition, the reverse stock split may not result in an increase in the Combined Company&#8217;s stock price necessary to satisfy Nasdaq&#8217;s initial listing requirements for the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The reverse stock split may lead to a decrease in the Combined Company&#8217;s overall market capitalization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Should the market price of the Combined Company&#8217;s common stock decline after the reverse stock split, the&#160;percentage decline will be greater, due to the smaller number of shares outstanding, than it would have been prior to the reverse stock split. A reverse stock split is often viewed negatively by the market and, consequently, can lead to a decrease in the Combined Company&#8217;s overall market capitalization. If the per share market price does not increase in proportion to the reverse stock split ratio, then the value of the Combined Company, as measured by its stock capitalization, will be reduced. In some cases, the per-share stock price of companies that have effected reverse stock splits subsequently declined back to pre-reverse split levels, and accordingly, it cannot be assured that the total market value of the Combined Company&#8217;s common stock will remain the same after the reverse stock split is effected, or that the reverse stock split will not have an adverse effect on the Combined Company&#8217;s stock price due to the reduced number of shares outstanding after the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to GlycoMimetics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to GlycoMimetics&#8217; Financial Position and Capital Needs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics ha</span><span style="font-style:italic;font-weight:bold;">s</span><span style="font-style:italic;font-weight:bold;"> incurred significant losses since </span><span style="font-style:italic;font-weight:bold;">its</span><span style="font-style:italic;font-weight:bold;"> inception. GlycoMimetics expect</span><span style="font-style:italic;font-weight:bold;">s</span><span style="font-style:italic;font-weight:bold;"> to continue to incur losses and may never achieve or maintain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has incurred significant losses since its inception and, as of December&#160;31, 2024, GlycoMimetics had an accumulated deficit of $494.4 million. In recent&#160;years, GlycoMimetics has financed its operations primarily with proceeds from public offerings of its common stock.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has devoted substantially all of its financial resources and efforts to research and development, including preclinical studies and clinical trials. However, GlycoMimetics has not completed development of any drugs, and in July&#160;2024, following the announcement of the data from its Phase 3 pivotal trial and its discussions with the FDA, GlycoMimetics announced that GlycoMimetics would initiate a review of strategic alternatives focused on maximizing stockholder value. GlycoMimetics also reduced its workforce by approximately 80% in order to conserve its cash resources as part of a streamlined operating plan while GlycoMimetics undertook its strategic review. Following the strategic review, GlycoMimetics entered into an acquisition agreement with Crescent to consummate the proposed Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the termination of GlycoMimetics&#8217; clinical programs, its research and development expenses have decreased. GlycoMimetics expects to continue to incur costs and expenditures in connection with the merger process. Based on its current operating plan, which includes the ceasing of its clinical development programs, GlycoMimetics expects that its current cash and cash equivalents will fund its operations until the closing of the Merger; however, GlycoMimetics has based this estimate on assumptions that may prove to be wrong, and GlycoMimetics could use its capital resources sooner than GlycoMimetics expects. There can be no assurance that the proposed Merger with Crescent, or any other course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated or lead to increased stockholder value. If GlycoMimetics is unable to close the Merger or raise additional capital, GlycoMimetics will need to eliminate some or all of its operations or liquidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics expects to continue to incur significant expenses in connection with its ongoing activities, including continuing to operate as a public company. If GlycoMimetics were to resume clinical development activities in the future, GlycoMimetics would expect to incur significant additional expenses and operating losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To become and remain profitable, GlycoMimetics must succeed in developing and eventually commercializing drugs that generate significant revenue. This would require GlycoMimetics to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of its drug candidates, obtaining regulatory approval for these drug candidates and manufacturing and commercializing any drugs for which GlycoMimetics may obtain regulatory approval, as well as discovering additional drug candidates. If GlycoMimetics were to resume its development programs, GlycoMimetics may never succeed in these activities and, even if GlycoMimetics did, GlycoMimetics may never generate revenue that is significant enough to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if GlycoMimetics achieves profitability, GlycoMimetics may not be able to sustain or increase profitability on a quarterly or annual basis. GlycoMimetics&#8217; failure to become and remain profitable would depress the value of GlycoMimetics and could impair its ability to raise capital, expand its business, maintain its research and development efforts or even continue its operations. A decline in the value of GlycoMimetics could also result in significant harm to its financial position and adversely affect its stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If GlycoMimetics decides to resume development of its drug candidates, GlycoMimetics would need substantial additional funding. If GlycoMimetics </span><span style="font-style:italic;font-weight:bold;">was</span><span style="font-style:italic;font-weight:bold;"> unable to raise that capital when needed, GlycoMimetics may not be able to continue as a going concern and could be forced to delay, reduce or eliminate drug development programs or potential commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics were to resume development of drug candidates, its capital requirements would depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and development requirements of other drug candidates that GlycoMimetics may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of its drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of its drug candidates for which GlycoMimetics receives marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of its drug candidates for which GlycoMimetics receives marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing its intellectual property rights and defending any intellectual property-related claims; and</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which GlycoMimetics acquire</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">s</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or in-licenses other drug candidates and technologies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Identifying potential drug candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes&#160;years to complete, and GlycoMimetics or any current or future collaborators may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, drug candidates, if approved, may not achieve commercial success. Accordingly, if GlycoMimetics were to resume development activities, GlycoMimetics&#8217; ability to fund its operations would be dependent upon management&#8217;s plans, which could include raising additional capital through a combination of equity and debt financings, collaborations and strategic alliances. However, there can be no assurances that new financings or other transactions will be available to GlycoMimetics on commercially acceptable terms, or at all. GlycoMimetics&#8217; ability to raise additional capital could also be adversely impacted by global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide. If GlycoMimetics is unable to raise capital to fund its operations when needed or on attractive terms, GlycoMimetics could be forced to delay, reduce the scope of or eliminate its research and development programs or any future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to GlycoMimetics&#8217; stockholders, restrict its operations or require GlycoMimetics to relinquish rights to its drug candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics were to resume its development activities, GlycoMimetics would expect to finance its cash needs through a combination of equity offerings, debt financings and license and development agreements until such time, if ever, as GlycoMimetics could generate substantial commercial revenues. To the extent that GlycoMimetics raises additional capital through the sale of equity or convertible debt securities, your ownership interest would be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics were to raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, GlycoMimetics may be required to relinquish valuable rights to its research programs or drug candidates or grant licenses on terms that may not be favorable to GlycoMimetics or that may be at less than the full potential value of such rights. If GlycoMimetics is unable to raise additional funds through equity or debt financings or other arrangements with third parties when needed, GlycoMimetics may be required to delay, limit, reduce or terminate its drug development or future commercialization efforts or grant rights to third parties to develop and market drug candidates that GlycoMimetics would otherwise prefer to develop and market itself.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If GlycoMimetics fails to comply or regain compliance with Nasdaq&#8217;s continued listing standards, its common stock may be delisted and the price of its common stock, its ability to access the capital markets and its financial condition could be </span><span style="font-style:italic;font-weight:bold;">negatively</span><span style="font-style:italic;font-weight:bold;"> impacted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics common stock was previously listed on The Nasdaq Global Market, and GlycoMimetics was required to meet certain listing requirements, including with respect to minimum closing bid prices, market value of publicly held shares, stockholders&#8217; equity and market value of listed securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2024, GlycoMimetics received notice from the Listing Qualifications Department of The Nasdaq Stock Market, or Nasdaq, that GlycoMimetics was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market. Pursuant to Nasdaq listing rules, GlycoMimetics was provided an initial compliance period until December&#160;18, 2024 to regain compliance. In order to qualify for additional time to regain compliance, GlycoMimetics transferred the listing of GlycoMimetics common stock from The Nasdaq Global Market to The Nasdaq Capital Market, which became effective as of December&#160;20, 2024. In connection with that transfer, on December&#160;19, 2024, GlycoMimetics received notice from Nasdaq that GlycoMimetics had been granted an additional 180 calendar&#160;days, or until June&#160;16, 2025, to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule&#160;5550(a)(2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If necessary to regain compliance with Nasdaq listing standards, GlycoMimetics may, subject to approval of the GlycoMimetics Board and stockholders, implement a reverse stock split. However, there can be no assurance that a reverse stock split, or any other alternatives GlycoMimetics may consider to regain compliance with the minimum bid price requirement, would be approved or would result in a sustained higher stock price that would allow GlycoMimetics to meet the Nasdaq stock price listing requirements.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Separately, Nasdaq listing rules&#160;requires companies listed on the Nasdaq Capital Market to maintain a stockholders&#8217; equity of at least $2.5 million. As of December&#160;31, 2024, GlycoMimetics had stockholders&#8217; equity of $5.3 million. As a result of GlycoMimetics&#8217; expected decrease in stockholders&#8217; equity prior to the Merger due to continued net losses, there can be no assurance that GlycoMimetics will be able to maintain the minimum required stockholders&#8217; equity under the Nasdaq continued listing standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics is not able to maintain compliance within the compliance periods allotted by Nasdaq, its common stock could be delisted, which would have a further material adverse effect on the market price of its common stock and on stockholder liquidity. GlycoMimetics intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the listing requirement; however, there can be no assurance that GlycoMimetics will be able to regain compliance with the listing requirement or will otherwise be in compliance with the other Nasdaq listing criteria. If Nasdaq delists its common stock for failure to meet its listing standards, and its common stock is not eligible for quotation or listing on another market or exchange, GlycoMimetics and its stockholders could face significant negative consequences, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading of its common stock being conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities, such as the Pink Sheets or the OTC Bulletin Board, which could result in limited availability of market quotations for its common stock and increased difficulty of disposing of shares of common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination that the common stock is a &#8220;penny stock,&#8221; which would require brokers trading in the common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for shares of its common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited amount of analyst coverage; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decreased ability to issue additional securities or obtain additional financing in the future.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Discovery and Development of GlycoMimetics&#8217; Drug Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Should GlycoMimetics resume development of its drug candidates, its focus on discovering and developing novel glycomimetic drugs and its approach to discovering and developing drugs may never lead to marketable drugs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A key element of GlycoMimetics&#8217; prior development strategy was to use and expand its platform to build a pipeline of novel glycomimetic drug candidates and progress these drug candidates through clinical development for the treatment of a variety of diseases. The discovery of therapeutic drugs based on molecules that mimic the structure of carbohydrates is an emerging field, and the scientific discoveries that form the basis for GlycoMimetics&#8217; past efforts to discover and develop drug candidates are relatively new. The scientific evidence to support the feasibility of developing drug candidates based on these discoveries is both preliminary and limited. Although its research and development efforts resulted in a pipeline of glycomimetic drug candidates, GlycoMimetics was unable to successfully progress those drug candidates through clinical trials. If GlycoMimetics were to resume its development activities, the drug candidates that GlycoMimetics identifies may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and achieve market acceptance. If GlycoMimetics does not successfully develop and commercialize drug candidates based upon its glycomimetics platform, GlycoMimetics will not be able to obtain product revenue in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If GlycoMimetics were to resume development activities, GlycoMimetics would need to conduct additional clinical trials. All of its other drug candidates other than uproleselan were in earlier stages of clinical trials or in preclinical development.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Uproleselan is GlycoMimetics&#8217; only drug candidate that was recently in a Phase 2 or Phase 3 clinical trial. In the second quarter of 2024, GlycoMimetics announced results of its pivotal Phase 3 clinical trial of uproleselan in R/R AML. The study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population. Following the announcement of the data from the Phase 3 trial, GlycoMimetics requested and held a meeting with the FDA to discuss whether any of the results summarized above could serve as a basis for a submission for regulatory approval. Based on the feedback received, GlycoMimetics concluded that any potential regulatory path for uproleselan in this patient population would require an additional clinical trial, the conduct of which would require capital resources beyond those available to it.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">GlycoMimetics&#8217; other drug candidates were in earlier stages of clinical trials or in preclinical development. GlycoMimetics has not completed the development of any drug candidates, GlycoMimetics currently generates no revenue from the sale of any drugs, and </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">even if GlycoMimetics were to resume its development activities, GlycoMimetics may never be able to develop a marketable drug. As a company, GlycoMimetics has no experience in submitting and obtaining FDA approval for an NDA. GlycoMimetics previously invested substantially all of its efforts and financial resources in the development of its glycomimetics platform, the identification of potential drug candidates using that platform and the development of its drug candidates. If GlycoMimetics were to resume development, its ability to generate revenue from its other drug candidates, would depend heavily on their successful development and eventual commercialization. The success of those drug candidates would depend on several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for its drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making arrangements with third-party manufacturers for, or establishing, commercial manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales of the drugs, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the drugs, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively competing with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining healthcare coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protecting its rights in its intellectual property portfolio; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of the drugs following approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical</span><span style="font-style:italic;font-weight:bold;"> drug development involves a lengthy and expensive process, with an uncertain outcome. Should GlycoMimetics resume development of its drug candidates, GlycoMimetics may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of its drug candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The risk of failure of GlycoMimetics&#8217; drug candidates is high. It is impossible to predict when or if any of its drug candidates will prove safe or effective in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, GlycoMimetics or a collaborator must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of the drug candidate in humans. Clinical testing is expensive, difficult to design and implement, can take many&#160;years to complete and is uncertain as to outcome. For example, in May&#160;2024, GlycoMimetics announced results of its pivotal Phase 3 clinical trial of uproleselan in R/R AML. Even though GlycoMimetics observed favorable results in earlier trials of uproleselan, uproleselan combined with chemotherapy did not meet the primary endpoint of overall survival in the intent to treat population in its Phase 3 trial. A failure of one or more clinical trials can occur at any stage of development. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. In addition, changes in patient treatment options over time may make the relevance of historical control data for a given indication less relevant to the drug candidate being studied, which could impact the success of the trial or, even if successful, the desirability of a successful drug candidate versus other available treatment options. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their drug candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics were to resume development activities, GlycoMimetics or its current or future collaborators may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent its or their ability to receive marketing approval or commercialize its drug candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators or institutional review boards may not authorize GlycoMimetics or its investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of its drug candidates may produce negative or inconclusive results, including failure to demonstrate statistical significance, and GlycoMimetics may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs as GlycoMimetics has done with respect to uproleselan following the Phase 3 pivotal clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials of its drug candidates may be larger than GlycoMimetics anticipates, enrollment in these clinical trials may be slower than GlycoMimetics anticipates or participants may drop out of these clinical trials at a higher rate than GlycoMimetics anticipates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to GlycoMimetics in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators or institutional review boards may require that GlycoMimetics or its investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of its drug candidates may be greater than GlycoMimetics anticipates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of its drug candidates or other materials necessary to conduct clinical trials of its drug candidates may be insufficient or inadequate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its drug candidates may have undesirable side effects or other unexpected characteristics, causing GlycoMimetics or its investigators, regulators or institutional review boards to suspend or terminate the trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; drug development costs would also increase if GlycoMimetics experiences delays in testing or marketing approvals. Preclinical studies or clinical trials may not begin as planned, could need to be restructured or may not be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which GlycoMimetics may have the exclusive right to commercialize its drug candidates or allow its competitors to bring drugs to market before GlycoMimetics does, and thereby impair its ability to successfully commercialize its drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Should GlycoMimetics resume development of its drug candidates, serious adverse or unacceptable side effects could be identified, in which case GlycoMimetics would need to abandon or limit their development.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics were to resume the development of its drug candidates and those candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, GlycoMimetics may need to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many drug candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented their further development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If GlycoMimetics were to resume development of its drug candidates, GlycoMimetics may expend its limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Even if GlycoMimetics resumes its drug development activities, GlycoMimetics would have limited financial and management resources and as a result would need to focus on a limited number of research programs and drug candidates. As a result, GlycoMimetics may forego or delay pursuit of opportunities with other drug candidates or for other indications that later prove to have greater commercial potential. GlycoMimetics&#8217; resource allocation decisions could cause GlycoMimetics to fail to capitalize on viable commercial drugs or profitable market opportunities. GlycoMimetics&#8217; spending on research and development programs and drug candidates for specific indications may not yield any commercially viable drugs. If GlycoMimetics does not accurately evaluate the commercial potential or target market for a particular drug candidate, GlycoMimetics may relinquish valuable rights to that drug </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">candidate through collaboration, licensing or other arrangements in cases in which it would have been more advantageous for GlycoMimetics to retain sole development and commercialization rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to GlycoMimetics&#8217; Dependence on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Should GlycoMimetics resume development activities, its success would depend in part on collaborations. If GlycoMimetics is unable to maintain any of these collaborations, or if these collaborations are not successful, its business could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even before its decision to cease development activities, GlycoMimetics had limited capabilities for drug development and do not have any capabilities for sales, marketing or distribution. If GlycoMimetics were to resume drug development, it expects that it would need to engage collaborators to support its operations. GlycoMimetics cannot assure you that collaborators will develop its drug candidates in a timely manner, or at all, or, if regulatory approval for a drug candidate is achieved, that such collaborator will successfully commercialize the candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any collaborations GlycoMimetics might enter into may pose a number of risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue the commercialization of any drug candidates that achieve regulatory approval or may elect not to pursue, continue or renew development or commercialization of drug candidates based on clinical trial results, changes in such collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could experience delays in initiating or conducting clinical trials for any number of reasons;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with its drugs or drug candidates if such collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than GlycoMimetics</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">drug candidates discovered in collaboration with GlycoMimetics may be viewed by its collaborators as competitive with their own drug candidates or drugs, which may cause such collaborators to cease to devote resources to the commercialization of its drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more of its drug candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such drug or drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of drug candidates, might lead to additional responsibilities for GlycoMimetics with respect to drug candidates or might result in litigation or arbitration, any of which would be time consuming and expensive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend its or their intellectual property rights or may use its or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose GlycoMimetics to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose GlycoMimetics to litigation and potential liability; and</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated for the convenience of the collaborator and, if terminated, GlycoMimetics could be required to raise additional capital to pursue further development or commercialization of the applicable drug candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any collaborations GlycoMimetics might enter into do not result in the successful development and commercialization of drugs, or if one of its collaborators terminates its agreement with GlycoMimetics, GlycoMimetics may not receive any future research funding or milestone or royalty payments under the collaboration. For example, in 2020, GlycoMimetics&#8217; former collaborator Pfizer terminated its license agreement with GlycoMimetics for the worldwide development and commercialization of its prior drug candidate rivipansel, thereby eliminating its right to receive any future development or commercialization milestones or royalty payments for sales of that drug candidate. In addition, even if GlycoMimetics is eligible to receive any such payments from a collaborator, they could be substantially delayed. If GlycoMimetics does not receive the funding it expects under these agreements, the development of its drug candidates could be delayed and GlycoMimetics may need additional resources to develop its drug candidates. All of the risks relating to drug development, regulatory approval and commercialization described in this report also apply to the activities of its collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a current or future collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate development or commercialization of any drug candidate licensed to it by GlycoMimetics. If one of its collaborators terminates its agreement with GlycoMimetics, GlycoMimetics may find it more difficult to attract new collaborators and its reputation in the business and financial communities could be adversely affected. GlycoMimetics may in the future determine to collaborate with pharmaceutical and biotechnology companies for their development and potential commercialization of its drug candidates. GlycoMimetics faces significant competition in seeking appropriate collaborators. GlycoMimetics&#8217; ability to reach a definitive agreement for a collaboration will depend, among other things, upon its assessment of a collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If GlycoMimetics is unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, GlycoMimetics may have to curtail the development of a drug candidate, reduce or delay its development or one or more of its other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities or increase its expenditures and undertake development or commercialization activities at its own expense. If GlycoMimetics elects to fund and undertake development or commercialization activities on its own, GlycoMimetics may need to obtain additional expertise and additional capital, which may not be available to GlycoMimetics on acceptable terms or at all. If GlycoMimetics fails to enter into collaborations and does not have sufficient funds or expertise to undertake the necessary development and commercialization activities, GlycoMimetics may not be able to further develop its drug candidates or bring them to market, which would impair its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Should GlycoMimetics resume development of its drug candidates, GlycoMimetics would expect to rely on third parties to conduct additional clinical trials for its drug candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics previously engaged a third-party contract research organization, or CRO, to conduct its clinical trials for uproleselan. If GlycoMimetics were to resume clinical development, GlycoMimetics would expect to engage CROs with respect to any further clinical trials of uproleselan or any of its other drug candidates that may progress to clinical development. GlycoMimetics would also expect to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct those clinical trials. Agreements with such third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If GlycoMimetics needs to enter into alternative arrangements, that would delay its drug development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; reliance on these third parties for research and development activities would reduce its control over these activities, but would not relieve GlycoMimetics of its responsibilities. For example, GlycoMimetics would remain responsible for ensuring that each of its clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires GlycoMimetics to comply with standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. GlycoMimetics also is required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and significant civil and criminal sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Furthermore, these third parties may also have relationships with other entities, some of which may be GlycoMimetics&#8217; competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct GlycoMimetics&#8217; clinical trials in accordance with regulatory requirements or its stated protocols, GlycoMimetics will not be able to </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">obtain, or may be delayed in obtaining, marketing approvals for its drug candidates and will not be able to, or may be delayed in its efforts to, successfully commercialize its drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics also expects to rely on other third parties to store and distribute drug supplies for any further clinical trials that GlycoMimetics were to conduct. Any performance failure on the part of its distributors could delay clinical development or marketing approval of its drug candidates or commercialization of GlycoMimetics&#8217;drugs, producing additional losses and depriving GlycoMimetics of potential revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics previously contracted with third parties for the manufacturing of </span><span style="font-style:italic;font-weight:bold;">its</span><span style="font-style:italic;font-weight:bold;"> drug candidates for preclinical and clinical testing, and if GlycoMimetics were to resume development activities and pursue commercialization, GlycoMimetics would expect to continue to do so. This reliance on third parties increases the risk that GlycoMimetics would not have sufficient quantities of </span><span style="font-style:italic;font-weight:bold;">its</span><span style="font-style:italic;font-weight:bold;"> drug candidates or drugs, or such quantities at an acceptable cost, which could delay, prevent or impair its potential development or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics does not have any manufacturing facilities or personnel. GlycoMimetics has in the past relied on third parties for the manufacturing of its drug candidates for preclinical and clinical testing, as well as for potential commercial manufacture. If GlycoMimetics were to resume its drug development activities, GlycoMimetics would need to re-engage those third parties. Its reliance on third parties would increase the risk that GlycoMimetics will not have sufficient quantities of its drug candidates or drugs, or such quantities at an acceptable cost or quality, which could delay, prevent or impair its ability to timely conduct clinical trials or its other potential development or commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics would also expect to rely on third-party manufacturers or third-party collaborators for the manufacturing of commercial supply of any other drug candidates for which GlycoMimetics or its collaborators obtain marketing approval. For example, in January&#160;2024 GlycoMimetics entered into an agreement with Patheon Manufacturing Services LLC, or Patheon, for manufacture and supply of uproleselan for commercial sale. Pursuant to the agreement, Patheon was to manufacture commercial quantities of injectable uproleselan from active pharmaceutical ingredient GlycoMimetics was to supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics were to resume its development activities, GlycoMimetics may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if GlycoMimetics is able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on the third party for regulatory compliance and quality assurance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible breach of the manufacturing agreement by the third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible misappropriation of GlycoMimetics&#8217; proprietary information, including its trade secrets and know-how; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for GlycoMimetics.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations or similar regulatory requirements outside the United States. GlycoMimetics&#8217; failure, or the failure of its third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on GlycoMimetics, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of drug candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of its drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, in the event that any of its third-party manufacturers fails to comply with such requirements or to perform its obligations to GlycoMimetics in relation to quality, timing or otherwise, or if its supply of components or other materials becomes limited or interrupted for other reasons, GlycoMimetics may be forced to manufacture the materials itself, for which GlycoMimetics currently does not have the capabilities or resources, or enter into an agreement with another third party, which GlycoMimetics may not be able to do on commercially reasonable terms, if at all. If its contract manufacturers cannot perform as agreed, GlycoMimetics may be required to replace such manufacturers and GlycoMimetics may incur added costs and delays in identifying and qualifying any such replacement. Any replacement of GlycoMimetics&#8217; manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. If GlycoMimetics is required to change manufacturers for any reason, GlycoMimetics will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect GlycoMimetics&#8217; ability to develop its drug candidates in a timely manner or within budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; dependence upon others for the manufacturing of its drug candidates or drugs may adversely affect its ability to commercialize any drugs that receive marketing approval on a timely and competitive basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the </b><b style="font-weight:bold;">Potential </b><b style="font-weight:bold;">Commercialization of GlycoMimetics&#8217; Drug Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Should GlycoMimetics resume development of drug candidates, if any of those drug candidates were to receive marketing approval, it may still fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics does not intend to continue development of uproleselan or any of its other product candidates. However, should GlycoMimetics decide to resume development activities and any of its drug candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If its drug candidates do not achieve an adequate level of acceptance, GlycoMimetics may not generate significant revenue from drug sales and it may not become profitable. The degree of market acceptance of GlycoMimetics&#8217; drug candidates, even if approved for commercial sale, would depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and potential advantages compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; ability to offer its drugs for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of third-party coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any restrictions on the use of GlycoMimetics&#8217; drugs together with other medications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Should GlycoMimetics resume development of its drug candidates, GlycoMimetics would need to establish sales, marketing and distribution capabilities for its drug candidates and may not be successful in commercializing those drug candidates if approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even prior to its decision to cease drug development and commercialization activities, GlycoMimetics did not have a sales or marketing infrastructure and had no experience in the sale, marketing or distribution of pharmaceutical drugs. If GlycoMimetics were to resume development, GlycoMimetics would need to establish a sales and marketing organization to market or co-promote any drugs that achieve marketing approval. There are risks involved with establishing sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a drug candidate for which GlycoMimetics recruits a sales force and establish marketing capabilities is delayed or does not occur for any reason, GlycoMimetics would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and its investment would be lost if GlycoMimetics cannot retain or reposition its sales and marketing personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other factors that could inhibit GlycoMimetics&#8217; efforts to commercialize drugs on its own include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of sales personnel to obtain access to physicians or its failure to educate adequate numbers of physicians on the benefits of any future drugs;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of complementary drugs to be offered by sales personnel, which could put GlycoMimetics at a competitive disadvantage relative to companies with more products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics is unable to establish its own sales, marketing and distribution capabilities and therefore enter into arrangements with third parties to perform these services, its revenue and its profitability, if any, would likely be lower than if GlycoMimetics were to sell, market and distribute any drugs that GlycoMimetics develops itself. In addition, GlycoMimetics may not be successful in entering into arrangements with third parties to sell, market and distribute its drug candidates or may be unable to do so on terms that are favorable to GlycoMimetics. GlycoMimetics likely would have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market its drugs effectively. Even if GlycoMimetics were to resume drug development, in the event that GlycoMimetics does not establish sales, marketing and distribution capabilities successfully, either on its own or in collaboration with third parties, GlycoMimetics would not be successful in commercializing its drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Should GlycoMimetics resume drug development, GlycoMimetics would face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than GlycoMimetics does.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development and commercialization of new drugs is highly competitive. GlycoMimetics has faced competition with respect to its drug candidates, and should GlycoMimetics resume drug development GlycoMimetics would face competition with respect to any drug candidates that GlycoMimetics may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Should any competitors&#8217; drug candidates receive regulatory or marketing approval prior to GlycoMimetics&#8217;, they may establish a strong market position and diminish the need for GlycoMimetics&#8217; drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The key competitive factors affecting the success of all of GlycoMimetics&#8217; drug candidates, if approved, are likely to be their safety, efficacy, convenience, price, the level of generic competition and the availability of coverage and reimbursement from government and other third-party payors. To the extent that competitive drugs or drug candidates developed by others are successful in treating GlycoMimetics&#8217; target indications, it would reduce the market opportunity for its drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of the companies against which GlycoMimetics may compete in the future, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than GlycoMimetics does. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of GlycoMimetics&#8217; competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with GlycoMimetics in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, its programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; commercial opportunity could be reduced or eliminated if its competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any drugs that GlycoMimetics may develop. GlycoMimetics&#8217; competitors also may obtain FDA or other regulatory approval for their drugs more rapidly than GlycoMimetics may obtain approval for its, which could result in its competitors establishing a strong market position before GlycoMimetics is able to enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, because GlycoMimetics has no patents with respect to its glycomimetics platform, its competitors may use its methods, or acquire similar expertise, in order to develop glycomimetic drug candidates and progress these drug candidates through clinical development and commercialization, which could impair its ability to successfully commercialize its drug candidates or otherwise limit its commercial opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if GlycoMimetics or its collaborators are able to commercialize any of its drug candidates, the drugs may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">GlycoMimetics&#8217; and its collaborators&#8217; ability to commercialize any of its drug candidates successfully would depend, in part, on the extent to which coverage and adequate reimbursement for these drugs and related treatments will be available from government payor programs at the federal and state levels authorities, including Medicare and Medicaid, private health insurers, managed care </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">plans and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for drugs. Coverage and reimbursement may not be available for any drug that GlycoMimetics or its collaborators commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Inadequate reimbursement levels may adversely affect the demand for, or the price of, any drug candidate for which GlycoMimetics or its collaborators obtain marketing approval. Obtaining and maintaining adequate reimbursement for its drugs may be difficult. GlycoMimetics may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, GlycoMimetics or its collaborators may not be able to successfully commercialize any drug candidates for which marketing approval is obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers GlycoMimetics&#8217; costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover GlycoMimetics&#8217; costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, one payor&#8217;s determination to provide coverage for a drug does not assure that other payors will also provide coverage for the drug. GlycoMimetics&#8217; or its collaborators&#8217; inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved drugs that GlycoMimetics develops could adversely affect its operating results, its ability to raise capital needed to commercialize drugs and its overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, GlycoMimetics or its collaborators might obtain marketing approval for a drug in a particular country, but then be subject to price regulations that delay commercial launch of the drug, possibly for lengthy time periods, and negatively impact its ability to generate revenue from the sale of the drug in that country. Adverse pricing limitations may hinder GlycoMimetics&#8217; ability to recoup its investment in one or more drug candidates, even if its drug candidates obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that GlycoMimetics&#8217; drug candidates, if they are approved for sale in the United States or in other countries, will be considered medically reasonable and necessary for a specific indication, that they will be considered cost-effective by third-party payors, that coverage or an adequate level of reimbursement will be available or that third-party payors&#8217; reimbursement policies will not adversely affect its ability to sell its drug candidates profitably if they are approved for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits against GlycoMimetics could cause GlycoMimetics to incur substantial liabilities and to limit commercialization of any drugs that GlycoMimetics may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics faces an inherent risk of product liability exposure related to the testing of its drug candidates in human clinical trials, and will face an even greater risk if GlycoMimetics commercially sells any drugs that GlycoMimetics may develop. If GlycoMimetics cannot successfully defend itself against claims that its drug candidates or drugs caused injuries, GlycoMimetics will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any drug candidates or drugs that GlycoMimetics may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to its reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards paid to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced resources of its management to pursue its business strategy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any drugs that GlycoMimetics may develop.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has carried clinical trial insurance coverage in an amount that GlycoMimetics believes was sufficient in relation to its clinical trials that were conducted in the United States and in foreign countries where GlycoMimetics had sites. The use of its drug candidates in clinical trials may result in liability claims for which its insurance would not be adequate to cover all liabilities that GlycoMimetics may incur. In addition, if GlycoMimetics were to resume drug development activities, GlycoMimetics may need to increase its insurance coverage as GlycoMimetics expands its clinical trials or if GlycoMimetics commences commercialization of its drug candidates. Insurance coverage is increasingly expensive. GlycoMimetics may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to GlycoMimetics&#8217; Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Should GlycoMimetics resume drug development activities but are unable to obtain and maintain patent protection for its drug candidates, or if the scope of the patent protection obtained is not sufficiently broad, its competitors could develop and commercialize drug candidates similar or identical to ours, and its ability to successfully commercialize its drug candidates may be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics elects to resume its drug development activities, its success would depend in large part on its ability to obtain and maintain patent protection in the United States and other countries with respect to its drug candidates. GlycoMimetics has in the past sought to protect its proprietary position by filing patent applications in the United States and abroad related to its drug candidates and would need to maintain its intellectual property rights should GlycoMimetics decide to further pursue the development of any of those drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is expensive and time consuming, and GlycoMimetics may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that GlycoMimetics will fail to identify patentable aspects of its research and development output before it is too late to obtain patent protection. GlycoMimetics may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of GlycoMimetics&#8217; business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent&#160;years been the subject of much litigation. In addition, the laws of foreign countries may not protect GlycoMimetics&#8217; rights to the same extent as the laws of the United States, or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing or, in some cases, not at all. Therefore, GlycoMimetics cannot know with certainty whether GlycoMimetics was the first to make the inventions claimed in its patents or pending patent applications, or that GlycoMimetics was the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of its patent rights are highly uncertain. GlycoMimetics&#8217; pending and future patent applications may not result in patents being issued that protect its drug candidates, in whole or in part, or which effectively prevent others from commercializing competitive drug candidates. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of GlycoMimetics&#8217; patents or narrow the scope of its patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of GlycoMimetics&#8217; patent applications and the enforcement or defense of its issued patents. On September&#160;16, 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, became effective on March&#160;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of GlycoMimetics&#8217; business if GlycoMimetics were to continue the development of its drug candidates. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of GlycoMimetics&#8217; patent applications and the enforcement or defense of GlycoMimetics&#8217; issued patents, all of which could have a material adverse effect on GlycoMimetics&#8217; business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, GlycoMimetics may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging its patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, GlycoMimetics&#8217; patent rights, allow third parties to commercialize its drug candidates and compete directly with GlycoMimetics, without payment to GlycoMimetics, or result in its inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by its patents and patent applications is threatened, it could dissuade companies from collaborating with GlycoMimetics to license, develop or commercialize current or future drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if GlycoMimetics&#8217; patent applications issue as patents, they may not issue in a form that will provide GlycoMimetics with any meaningful protection, prevent competitors from competing with GlycoMimetics or otherwise provide GlycoMimetics with any competitive advantage. GlycoMimetics&#8217; competitors may be able to circumvent its patents by developing similar or alternative drug candidates in a non-infringing manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and GlycoMimetics&#8217; patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit GlycoMimetics&#8217; ability to stop others from using or commercializing similar or identical drug candidates, or limit the duration of the patent protection of GlycoMimetics&#8217; drug candidates. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, GlycoMimetics&#8217; patent portfolio may not provide it with sufficient rights to exclude others from commercializing drugs similar or identical to its drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics may become involved in lawsuits to protect or enforce its patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe GlycoMimetics&#8217; issued patents or other intellectual property. To counter infringement or unauthorized use, GlycoMimetics may be required to file infringement claims, which can be expensive and time consuming. Any claims GlycoMimetics asserts against perceived infringers could provoke these parties to assert counterclaims against GlycoMimetics alleging that GlycoMimetics infringes their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that GlycoMimetics&#8217; patents do not cover the technology. An adverse result in any litigation proceeding could put one or more of GlycoMimetics&#8217; patents at risk of being invalidated or interpreted narrowly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A third party may hold intellectual property, including patent, rights that are important or necessary to the development of GlycoMimetics&#8217; drug candidates should GlycoMimetics elect to resume such activities. It may be necessary for GlycoMimetics to use patented or proprietary technology of third parties to commercialize its drug candidates, in which case GlycoMimetics would be required to obtain a license from these third parties on commercially reasonable terms, or GlycoMimetics&#8217; business could be harmed, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that GlycoMimetics is infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of its business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If GlycoMimetics were to resume drug development, its commercial success would depend upon its ability, and the ability of its collaborators, to develop, manufacture, market and sell its drug candidates without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. GlycoMimetics may become </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to its drug candidates, including interference or derivation proceedings before the USPTO. Third parties may assert infringement claims against GlycoMimetics based on existing patents or patents that may be granted in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics is found to infringe a third party&#8217;s intellectual property rights, GlycoMimetics could be required to obtain a license from such third party to continue developing and marketing its drug candidates. However, GlycoMimetics may not be able to obtain any required license on commercially reasonable terms or at all. Even if GlycoMimetics was able to obtain a license, it could be non-exclusive, thereby giving its competitors access to the same technologies licensed to GlycoMimetics. GlycoMimetics could be forced, including by court order, to cease commercializing the infringing drug. In addition, GlycoMimetics could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if GlycoMimetics is found to have willfully infringed a patent. A finding of infringement could prevent GlycoMimetics from commercializing its drug candidates or force GlycoMimetics to cease some of its business operations. Claims that GlycoMimetics has misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics may be subject to claims by third parties asserting that GlycoMimetics or its employees have misappropriated their intellectual property, or claiming ownership of what GlycoMimetics regards as its own intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of GlycoMimetics&#8217; current and former employees were previously employed at universities or other biotechnology or pharmaceutical companies. Although GlycoMimetics has tried to ensure that its employees do not use the proprietary information or know-how of others in their work for it, GlycoMimetics may be subject to claims that these employees or GlycoMimetics has used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, while it is GlycoMimetics&#8217; policy to require its employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to GlycoMimetics, GlycoMimetics may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that GlycoMimetics regards as its own. GlycoMimetics&#8217; assignment agreements may not be self-executing or may be breached, and GlycoMimetics may be forced to bring claims against third parties, or defend claims they may bring against GlycoMimetics, to determine the ownership of what GlycoMimetics regards as its intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics fails in prosecuting or defending any such claims, in addition to paying monetary damages, GlycoMimetics may lose valuable intellectual property rights or personnel. Even if GlycoMimetics is successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property litigation could cause GlycoMimetics to spend substantial resources and distract its personnel from their normal responsibilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if resolved in its favor, litigation or other legal proceedings relating to intellectual property claims may cause GlycoMimetics to incur significant expenses and could distract its technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative it could have a substantial adverse effect on the price of GlycoMimetics common stock. Such litigation or proceedings could substantially increase GlycoMimetics&#8217; operating losses and reduce the resources available for potential development activities or any future sales, marketing or distribution activities. GlycoMimetics may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of its competitors may be able to sustain the costs of such litigation or proceedings more effectively than GlycoMimetics can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise its ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If GlycoMimetics is unable to protect the confidentiality of its trade secrets, its business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to seeking patents for its drug candidates, GlycoMimetics has also relied on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain its historical competitive position. For example, its platform was based on trade secrets that consist largely of expertise in carbohydrate chemistry and knowledge of carbohydrate biology. GlycoMimetics does not believe that GlycoMimetics can obtain patent protection for its platform. Thus, GlycoMimetics&#8217; competitors may use its methods, or acquire similar expertise, in order to develop glycomimetic drug candidates and progress these drug candidates through clinical development and commercialization, which could impair its ability to successfully commercialize its drug candidates.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has sought to protect its trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as its employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. GlycoMimetics has also entered into confidentiality and invention or patent assignment agreements with its current and former employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose GlycoMimetics&#8217; proprietary information, including its trade secrets, and GlycoMimetics may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of its trade secrets were to be lawfully obtained or independently developed by a competitor, GlycoMimetics would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with GlycoMimetics. If any of GlycoMimetics&#8217; trade secrets were to be disclosed to or independently developed by a competitor, its competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Regulatory Approval of GlycoMimetics&#8217; Drug Candidates and Other Legal Compliance Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Should GlycoMimetics resume development of its drug candidates but GlycoMimetics or its collaborators are not able to obtain, or if there are delays in obtaining, required regulatory approvals, GlycoMimetics or they would not be able to commercialize its drug </span><span style="font-style:italic;font-weight:bold;">candidates</span><span style="font-style:italic;font-weight:bold;"> and its ability to generate revenue would be materially impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that GlycoMimetics resumes development of its drug candidates, the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, would be subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar regulatory authorities outside the United States. Failure to obtain marketing approval for a drug candidate would prevent GlycoMimetics or its collaborators from commercializing the drug candidate. GlycoMimetics has not received approval to market any of its drug candidates from regulatory authorities in any jurisdiction. GlycoMimetics has only limited experience in filing and supporting the applications necessary to gain marketing approvals and would expect to rely on third-party CROs to assist GlycoMimetics in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the drug candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, applicable regulatory authorities. GlycoMimetics&#8217; drug candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude its ability to obtain marketing approval or prevent or limit commercial use. If any of GlycoMimetics&#8217; drug candidates receives marketing approval, the accompanying label may limit the approved use of its drug, which could limit sales of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many&#160;years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the drug candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted drug application may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application, or may decide that GlycoMimetics&#8217; data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a drug candidate. Any marketing approval GlycoMimetics ultimately obtains may be limited or subject to restrictions or post-approval commitments that render the approved drug not commercially viable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics resumes development activities but experiences delays in obtaining approval or if GlycoMimetics fails to obtain approval of its drug candidates, the commercial prospects for its drug candidates may be harmed and its ability to generate revenue will be materially impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even though GlycoMimetics previously obtained Orphan Drug designation for several of its drug candidates, GlycoMimetics may not be able to obtain orphan drug marketing exclusivity for these or any of its other drug candidates should </span><span style="font-style:italic;font-weight:bold;">GlycoMimetics</span><span style="font-style:italic;font-weight:bold;"> resume their development.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Regulatory authorities in some jurisdictions, including the United States and the European Union, or EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">annually in the United States. GlycoMimetics previously obtained Orphan Drug designation from the FDA for some of its drug candidates. However, in order to obtain marketing exclusivity in a particular jurisdiction, GlycoMimetics must receive the first marketing approval of the drug for its intended indication. In addition, the orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, if a drug with an orphan designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same drug for the same indication for that time period. The applicable period is seven&#160;years in the United States and 10&#160;years in the EU. The EU exclusivity period can be reduced to six&#160;years if a drug no longer meets the criteria for orphan designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even though GlycoMimetics has obtained orphan drug exclusivity for a drug candidate, that exclusivity may not effectively protect the candidate from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve another drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if </span><span style="font-style:italic;font-weight:bold;">GlycoMimetics</span><span style="font-style:italic;font-weight:bold;"> were to resume the development of uproleselan, the FDA fast track designation and additional breakthrough therapy designation for uproleselan may not actually lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a drug is intended for the treatment of a serious or life-threatening disease or condition and the drug demonstrates the potential to address unmet medical needs for this disease or condition, the drug sponsor may apply for the FDA fast track designation. If fast track designation is obtained, the FDA may initiate review of sections of a NDA before the application is complete. This &#8220;rolling review&#8221; is available if the applicant provides, and the FDA approves, a schedule for submission of the individual sections of the application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although GlycoMimetics previously obtained a fast track designation from the FDA for uproleselan to treat AML and breakthrough therapy designation for uproleselan to treat AML, even if GlycoMimetics were to continue to advance uproleselan toward potential regulatory approval, GlycoMimetics may not experience a faster development process, review or approval compared to conventional FDA procedures. Its fast track designation may be withdrawn by the FDA if it believes that the designation is no longer supported by data from its clinical development programs. Its fast track designation does not guarantee that GlycoMimetics will qualify for or be able to take advantage of the expedited review procedures or obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to obtain marketing approval in international jurisdictions would prevent </span><span style="font-style:italic;font-weight:bold;">GlycoMimetics</span><span style="font-style:italic;font-weight:bold;"> drug candidates from being marketed abroad.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to market and sell its drugs in the EU and any other jurisdictions, GlycoMimetics or its collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the drug be approved for reimbursement before it can be approved for sale in that country. If GlycoMimetics resumes development activities, GlycoMimetics or its collaborators may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, failure to obtain approval in one jurisdiction may impact GlycoMimetics&#8217; ability to obtain approval elsewhere. GlycoMimetics or its collaborators may not be able to file for marketing approvals and may not receive necessary approvals to commercialize its drugs in any market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Should GlycoMimetics resume drug development activities, a variety of risks associated with developing and marketing its drug candidates internationally could hurt its business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If GlycoMimetics were to continue the development of its drug candidates, GlycoMimetics or its collaborators may seek regulatory approval for its drug candidates outside of the United States and, accordingly, GlycoMimetics expects that GlycoMimetics </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">will be subject to additional risks related to operating in foreign countries if GlycoMimetics obtains the necessary approvals, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">differing regulatory requirements in foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market with low or lower prices rather than buying them locally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic weakness, including inflation or political instability in particular foreign economies and markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign taxes, including withholding of payroll taxes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations related to doing business in another country;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties staffing and managing foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential liability under the Foreign Corrupt Practices Act or comparable foreign regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">challenges enforcing its contractual and intellectual property rights, especially in foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from pandemic, epidemic or disease outbreaks or geo-political actions, including war and terrorism.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any drug candidate for which GlycoMimetics obtains marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and GlycoMimetics may therefore be subject to penalties if GlycoMimetics fail</span><span style="font-style:italic;font-weight:bold;">s</span><span style="font-style:italic;font-weight:bold;"> to comply with regulatory requirements or if GlycoMimetics experiences unanticipated problems with its drug candidates, </span><span style="font-style:italic;font-weight:bold;">when</span><span style="font-style:italic;font-weight:bold;"> and if any of them are approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any drug candidate for which GlycoMimetics obtains marketing approval, along with manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such drug candidate, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a drug candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions of approval, including the requirement to implement a risk evaluation and mitigation strategy. If any of GlycoMimetics&#8217; drug candidates receives marketing approval, the accompanying label may limit the approved use of GlycoMimetics&#8217; drug, which could limit its sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the drug. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if GlycoMimetics does not market its drugs for their approved indications, GlycoMimetics may be subject to enforcement action for off-label marketing. Violations of the Federal Food, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Drug, and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, later discovery of previously unknown adverse events or other problems with GlycoMimetics&#8217; drugs, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may have negative consequences, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on such drugs, manufacturers or manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of a drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall or withdrawal of the drugs from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that GlycoMimetics submit</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">s</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical holds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of revenue or profit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of GlycoMimetics&#8217; drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-compliance with the EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of drugs for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the EU&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics&#8217; business and relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health </span><span style="font-style:italic;font-weight:bold;">information</span><span style="font-style:italic;font-weight:bold;"> privacy and security and other healthcare laws and regulations, which could expose GlycoMimetics to significant penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which GlycoMimetics obtains marketing approval. Any arrangements with third-party payors and customers may expose GlycoMimetics to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which GlycoMimetics conducts clinical research, sell, market and distribute any drugs for which GlycoMimetics obtains marketing approval. In addition, GlycoMimetics may be subject to transparency laws and patient data privacy and security regulation by the U.S. federal and state governments and by governments in foreign jurisdictions in which GlycoMimetics conducts its business. The applicable federal, state and foreign healthcare laws and regulations that may affect its ability to operate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal healthcare programs, such as Medicare and Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, and civil monetary penalty laws that prohibit individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates and covered subcontractors that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Open Payments program, pursuant to the Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;) information related to &#8220;payments or other transfers of value&#8221; made to physicians, which is defined to include doctors, dentists, optometrists, podiatrists and chiropractors, other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members, with disclosure of such information to be made by CMS on a publicly available website; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that GlycoMimetics&#8217; business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that GlycoMimetics&#8217; business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If GlycoMimetics&#8217; operations are found to be in violation of any of these laws or any other governmental regulations that may apply to GlycoMimetics, it may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, individual imprisonment, additional reporting requirements and oversight if GlycoMimetics becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of GlycoMimetics&#8217; operations, which could have a material adverse effect on GlycoMimetics&#8217; business. If any of the physicians or other healthcare providers or entities with whom GlycoMimetics expects to do business, including its collaborators, is found not to be in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect its business.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if GlycoMimetics were to resume drug development activities, recently enacted and future legislation may increase the difficulty and cost for GlycoMimetics to obtain marketing approval of and commercialize its drug candidates and affect the prices GlycoMimetics may obtain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States and some foreign jurisdictions, there have been a number of enacted and proposed legislative and regulatory changes regarding the healthcare system that could prevent or delay marketing approval of GlycoMimetics&#8217; drug candidates, restrict or regulate post-approval activities and affect its ability to profitably sell any drug candidates for which GlycoMimetics obtains marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts, which include major legislative initiatives to reduce the cost of care through changes in the healthcare system, including limits on the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;PRACA&#8221;), is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, improve quality of care, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The PPACA, among other things, increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, under which they must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded the types of entities eligible for the 340B drug discount program; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There have been amendments and judicial and Congressional challenges to certain aspects of PPACA. For example, in 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan&#160;year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part&#160;D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the PPACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and additional reform measures of the second Trump administration will impact the PPACA. Additional legislative proposals to reform healthcare and government insurance programs, along with the trend toward managed healthcare in the United States, could influence the purchase of medicines and reduce reimbursement and/or coverage of GlycoMimetics&#8217; product candidates, if approved. Current and future healthcare reform measures may result in more rigorous coverage criteria and in additional downward pressure on the price that GlycoMimetics receives for any approved drug. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, the IRA, among other things (i)&#160;directs HHS to negotiate the price of certain high-expenditure, single-source drugs that have been on the market for at least seven&#160;years and covered under Medicare, known as the Medicare Drug Price Negotiation Program, and (ii)&#160;imposes rebates under Medicare Part&#160;B and Medicare Part&#160;D to penalize price increases that outpace inflation. These provisions began to take effect progressively in fiscal&#160;year 2023. In August&#160;2024, HHS announced the agreed-upon prices of the first 10 drugs that were subject to price negotiations, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. On January&#160;17, 2025, HHS selected fifteen additional drugs covered under Part&#160;D for price negotiation in 2025. Each&#160;year thereafter more Part&#160;B and Part&#160;D products will become subject to the Medicare Drug Price Negotiation Program.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, on December&#160;7, 2023, an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act was announced. On December&#160;8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing. The implementation of cost containment measures or other healthcare reforms may prevent GlycoMimetics from being able to generate revenue, attain profitability or commercialize its drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for drugs. GlycoMimetics cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of its drug candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject GlycoMimetics to more stringent product labeling and post-marketing testing and other requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Governments outside the United States tend to impose strict price controls, which may adversely affect GlycoMimetics&#8217; revenue, if any, from the potential commercialization of drug candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some countries, particularly in the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain coverage and reimbursement or pricing approval in some countries, GlycoMimetics may be required to conduct a clinical trial that compares the cost-effectiveness of its drug candidate to other available therapies. If reimbursement of GlycoMimetics&#8217; drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, its business could be harmed, possibly materially, to the extent that GlycoMimetics seeks to commercialize drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If GlycoMimetics fails to comply with environmental, health and safety laws and regulations, GlycoMimetics could become subject to fines or penalties or incur costs that could harm its business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. GlycoMimetics&#8217; prior operations involved the use of hazardous and flammable materials, including chemicals and biological materials. GlycoMimetics&#8217; prior operations also produced hazardous waste products. GlycoMimetics has generally contracted with third parties for the disposal of these materials and wastes. GlycoMimetics cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from its use of hazardous materials, GlycoMimetics could be held liable for any resulting damages, and any liability could exceed its resources. GlycoMimetics also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although GlycoMimetics has historically maintained workers&#8217; compensation insurance to cover GlycoMimetics for costs and expenses GlycoMimetics may incur due to injuries to its employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. GlycoMimetics does not maintain insurance for environmental liability or toxic tort claims that may be asserted against GlycoMimetics in connection with its storage or disposal of biological, hazardous or radioactive materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, to the extent GlycoMimetics resumes significant drug development activities, GlycoMimetics may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair its research, development or production efforts. GlycoMimetics&#8217; failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to GlycoMimetics&#8217; Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics&#8217; employees and employees of its collaborators may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">GlycoMimetics and its collaborators are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">manufacturing standards GlycoMimetics has established, to comply with federal and state healthcare fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to GlycoMimetics. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to GlycoMimetics&#8217; reputation. GlycoMimetics has adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct, and the precautions GlycoMimetics takes to detect and prevent improper activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting GlycoMimetics from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against GlycoMimetics, and GlycoMimetics is not successful in defending itself or asserting its rights, or any such actions are instituted against any of its collaborators, those actions could have a significant impact on its business, including the imposition of significant fines or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If GlycoMimetics&#8217; information technology systems or data, or those of third parties upon which GlycoMimetics relies, are or were compromised, GlycoMimetics could experience adverse consequences resulting from such compromise, including, but not limited to, regulatory investigations or actions; litigation; fines and penalties; a disruption of its business operations, including its clinical trials; reputational harm; loss of revenue and profits; and other adverse consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of its business, GlycoMimetics and the third parties upon which GlycoMimetics has relied collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, and trade secrets. GlycoMimetics has also relied upon third parties, such as service providers, for its data processing&#8211;related activities and has shared or received sensitive data with or from third parties. To the extent GlycoMimetics resumes its drug development activities, GlycoMimetics will be increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate its business. Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent and continue to increase. These threats are becoming increasingly difficult to detect. These threats come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During times of war and other major conflicts, GlycoMimetics and the third parties upon which GlycoMimetics may rely could be vulnerable to a heightened risk of these attacks, including cyber-attacks that could materially disrupt its systems and operations, supply chain, and ability to operate clinical trials and develop its drug candidates. GlycoMimetics and the third parties upon which GlycoMimetics may rely could also be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by artificial intelligence (AI), telecommunications failures, earthquakes, fires, floods, and other similar threats. Ransomware attacks, including those perpetrated by organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in GlycoMimetics&#8217; operations, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but GlycoMimetics may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If GlycoMimetics resumes its drug development activities, GlycoMimetics expects that GlycoMimetics would need to rely on third parties and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, content delivery to customers, and other functions. GlycoMimetics would also rely on CROs and CMOs. GlycoMimetics&#8217; ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If the third parties GlycoMimetics may rely upon experience a security incident or other interruption, GlycoMimetics could experience adverse consequences. While GlycoMimetics may be entitled to damages if the third parties it relies upon fail to satisfy their privacy or security-related obligations to GlycoMimetics, any award may be insufficient to cover its damages, or GlycoMimetics may be unable to recover such award. Similarly, supply-chain attacks have increased in frequency and severity, and GlycoMimetics cannot guarantee that third parties and infrastructure in its potential supply chain or its third-party partners&#8217; supply </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to its information technology systems or the third-party information technology systems that would support GlycoMimetics and its services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Remote work has also increased risks to GlycoMimetics&#8217; information technology systems and data, as its current and former employees have utilized network connections, computers and devices outside its premises or network, including working at home, while in transit and in public locations. Future or past business transactions could expose GlycoMimetics to additional cybersecurity risks and vulnerabilities, as its systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, GlycoMimetics may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into its information technology environment and security program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While GlycoMimetics previously implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. GlycoMimetics has taken steps designed to detect, mitigate, and remediate vulnerabilities in its information systems (such as its hardware and/or software, including that of third parties upon which GlycoMimetics has relied). GlycoMimetics may not, however, have detected and remediated all such vulnerabilities on a timely basis. GlycoMimetics may experience further delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of the previously identified or similar threats could cause a security incident. A security incident could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to data. A security incident could disrupt its ability (and that of third parties upon whom GlycoMimetics relies) to conduct its business. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in its regulatory approval efforts and significantly increase its costs to recover or reproduce the data. GlycoMimetics may expend significant resources or modify its business activities (including its clinical trial activities) in an effort to protect against security incidents. Certain data privacy and security obligations may require GlycoMimetics to implement and maintain specific security measures, industry-standard or reasonable security measures to protect its information technology systems and data. Applicable data privacy and security obligations may require GlycoMimetics to notify relevant stakeholders of security incidents, including affected individuals, customers, regulators, and investors. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If GlycoMimetics (or a third party upon whom GlycoMimetics relies) experiences a security incident or are perceived to have experienced a security incident, GlycoMimetics may experience adverse consequences. These consequences may include government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); interruptions in GlycoMimetics&#8217; operations, including disruption of GlycoMimetics&#8217; development programs, if any; additional reporting requirements and/or oversight; interruptions or restrictions on processing sensitive data (which could result in delays in obtaining, or GlycoMimetics&#8217; inability to obtain, regulatory approvals and significantly increase GlycoMimetics&#8217; costs to recover or reproduce the data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in GlycoMimetics&#8217; operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may negatively impact GlycoMimetics&#8217; ability to grow and operate GlycoMimetics&#8217; business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in its contracts are sufficient to protect GlycoMimetics from liabilities, damages, or claims related to its data privacy and security obligations. Additionally, GlycoMimetics cannot be sure that its insurance coverage will be adequate or sufficient to protect GlycoMimetics from or to mitigate liabilities arising out of its privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about GlycoMimetics from public sources, data brokers, or other means that reveals competitively sensitive details about GlycoMimetics&#8217; organization and could be used to undermine GlycoMimetics&#8217; competitive advantage or market position. Additionally, sensitive information of GlycoMimetics could be leaked, disclosed, or revealed as a result of or in connection with use of generative AI technologies by GlycoMimetics&#8217; employees, personnel or vendors.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics and the third parties with whom GlycoMimetics has worked are subject to stringent and changing U.S. and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. GlycoMimetics&#8217; actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration; fines and penalties; disruptions of GlycoMimetics&#8217; business operations; reputational harm; loss of revenue and profits; and other adverse business impacts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of its business, GlycoMimetics has processed personal data and other sensitive data, including proprietary and confidential business data, trade secrets, intellectual property, clinical trial participant data, and other sensitive third-party data. The data processing activities related to its work subject GlycoMimetics and the third parties with whom GlycoMimetics has worked to numerous data privacy and security obligations, such as federal, state, local and foreign laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations governing the processing and security of personal data. These obligations may change, are subject to differing interpretations and may be inconsistent among jurisdictions or conflict. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in GlycoMimetics&#8217; business; affect GlycoMimetics&#8217; (or the third parties upon which GlycoMimetics relies) ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal data; necessitate the acceptance of more onerous obligations in GlycoMimetics&#8217; contracts; result in liability; or impose additional costs on GlycoMimetics. These obligations may necessitate changes to GlycoMimetics&#8217; information technologies, systems, and practices and to those of any third parties that process personal data on GlycoMimetics&#8217; behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outside the U.S., an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation (GDPR) (EU) 2016/679, or the EU GDPR and the United Kingdom&#8217;s GDPR (the &#8220;UK GDPR&#8221;), or collectively GDPR, impose strict requirements on the processing of personal data. Under the GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines in the event of violations. Under the GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics may transfer personal data from Europe and other jurisdictions to the United States or other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (the &#8220;EEA&#8221;) and the UK have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions have adopted or may adopt similarly stringent data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the U.S. in compliance with law, such as the EEA standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that GlycoMimetics can satisfy or rely on these measures to lawfully transfer personal data to the U.S. If there is no lawful manner for GlycoMimetics to transfer personal data from the EEA, the UK, or other jurisdictions to the U.S., or if the requirements for a legally-compliant transfer are too onerous, GlycoMimetics could face significant adverse consequences, including the interruption or degradation of its operations, the need to relocate part of or all of its business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against its processing or transferring of personal data necessary to operate its business. Some EEA regulators have prevented companies from transferring personal data out of the EEA for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section&#160;5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health data. See the risk factor captioned &#8220;<i style="font-style:italic;">GlycoMimetics&#8217; business and relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose GlycoMimetics to significant penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.&#8221;</i></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Numerous U.S. states have also enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact GlycoMimetics&#8217; business and ability to provide its products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, or CPRA, collectively CCPA, applies to personal data of consumers, business representatives, and employees who are California residents. These obligations include, but are not limited to, providing specific disclosures in privacy notices and honoring requests of such individuals certain rights related to their personal data. The CCPA provide for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. While the CCPA and other comprehensive state privacy laws contain limited exceptions for clinical trial data, these developments may further complicate compliance efforts, and increase legal risk and compliance costs for GlycoMimetics and the third parties upon whom GlycoMimetics relies. Similar laws are being considered in several other states, as well as at the federal and local levels, and GlycoMimetics expects more states to pass similar laws in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to data privacy and security laws, GlycoMimetics may be contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future. GlycoMimetics is also bound by other contractual obligations related to data privacy and security, and its efforts to comply with such obligations may not be successful. For example, clinical trial participants or research subjects about whom GlycoMimetics or its vendors obtain information, as well as the providers who share this information with GlycoMimetics, may contractually limit its ability to use and disclose the information.&#160;GlycoMimetics has published privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of its practices, GlycoMimetics may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires GlycoMimetics to devote significant resources, which may necessitate changes to its services, information technologies, systems, and practices and to those of any third parties that process personal data on its behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is possible that, in the future, GlycoMimetics may fail or be perceived to have failed to comply with applicable data privacy and security obligations. Moreover, despite GlycoMimetics&#8217; best compliance efforts, its personnel or third parties whom it relies on could fail to comply with such obligations, which could negatively impact its business operations and compliance posture. If GlycoMimetics or the third parties on which it relies fail, or are perceived to have failed, to address or comply with data privacy and security obligations, GlycoMimetics could face significant consequences. These consequences may include, but are not limited to, government enforcement actions; litigation (including class claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on GlycoMimetics&#8217; reputation, business, or financial condition, including but not limited to: interruptions or stoppages&#160;in GlycoMimetics&#8217; business operations including, as relevant, clinical trials; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize uproleselan; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of GlycoMimetics&#8217; operations.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics may become involved in litigation, including securities class action litigation, that could divert management&#8217;s attention and harm its business, and insurance coverage may not be sufficient to cover all costs and damages.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the past, litigation, including securities class action litigation, has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, or the announcement of negative events, such as negative results from clinical trials. These events may also result in investigations by the SEC. GlycoMimetics may be exposed to such litigation, even if no wrongdoing occurred. Litigation is usually expensive, uncertain, and diverts management&#8217;s attention and resources, which could adversely affect GlycoMimetics&#8217; business and cash resources and its ability to consummate the Merger with Crescent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unfavorable global economic conditions could adversely affect GlycoMimetics&#8217; business, financial condition or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn, or additional global financial crises, including related to health epidemics or armed conflicts and geopolitical tensions around the world, could result in a variety of risks to GlycoMimetics&#8217; business, including weakened demand for its product candidates, if approved, or its ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain GlycoMimetics&#8217; suppliers, possibly resulting in supply disruption. Any of the foregoing could harm GlycoMimetics&#8217; business and GlycoMimetics cannot anticipate all of the ways in which the economic climate and financial market conditions could adversely impact its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, GlycoMimetics&#8217; available cash and cash equivalents are held in accounts managed by third-party financial institutions and consist of cash in its operating accounts and cash invested in U.S. Government money market funds. At any point in time, the funds in GlycoMimetics&#8217; operating accounts may exceed the Federal Deposit Insurance Corporation insurance limits. While GlycoMimetics monitors the cash balances in its operating accounts and adjusts the cash balances as appropriate, these cash balances could be impacted if the underlying financial institutions fail. GlycoMimetics can provide no assurances that access to its operating cash or invested cash and cash equivalents will not be impacted by adverse conditions in the financial markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If GlycoMimetics fails to comply or regain compliance with Nasdaq&#8217;s continued listing standards prior to the consummation of the Merger, GlycoMimetics common stock may be delisted and the price of its common stock, its ability to access the capital markets and its financial condition could be negatively impacted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics common stock was previously listed on the Nasdaq Global Market, and it was required to meet certain listing requirements, including with respect to minimum closing bid prices, market value of publicly held shares, stockholders&#8217; equity and market value of listed securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June 2024, GlycoMimetics received notice from the Listing Qualifications Department of The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) that it was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market. Pursuant to Nasdaq listing rules, GlycoMimetics was provided an initial compliance period until December 18, 2024 to regain compliance. In order to qualify for additional time to regain compliance, GlycoMimetics transferred the listing of its common stock from the Nasdaq Global Market to the Nasdaq Capital Market, which became effective as of December 20, 2024. In connection with that transfer, on December 19, 2024, GlycoMimetics received notice from Nasdaq that it had been granted an additional 180 calendar days, or until June 16, 2025, to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If necessary to regain compliance with Nasdaq listing standards, GlycoMimetics may, subject to approval of the GlycoMimetics Board and stockholders, implement a reverse stock split. However, there can be no assurance that a reverse stock split, or any other alternatives GlycoMimetics may consider to regain compliance with the minimum bid price requirement, would be approved or would result in a sustained higher stock price that would allow GlycoMimetics to meet the Nasdaq stock price listing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Separately, Nasdaq listing rules requires companies listed on the Nasdaq Capital Market to maintain a stockholders&#8217; equity of at least $2.5 million. As of December 31, 2024, GlycoMimetics had stockholders&#8217; equity of $5.3 million. As a result of GlycoMimetics&#8217; expected decrease in stockholders&#8217; equity prior to the Merger due to continued net losses, there can be no assurance that GlycoMimetics will be able to maintain the minimum required stockholders&#8217; equity under the Nasdaq continued listing standards.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics is not able to maintain compliance within the compliance periods allotted by Nasdaq, its common stock could be delisted, which would have a further material adverse effect on the market price of its common stock and on stockholder liquidity. GlycoMimetics intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the listing requirement; however, there can be no assurance that GlycoMimetics will be able to regain compliance with the listing requirement or will otherwise be in compliance with the other Nasdaq listing criteria. If Nasdaq delists GlycoMimetics common stock for failure to meet its listing standards, and GlycoMimetics common stock is not eligible for quotation or listing on another market or exchange, GlycoMimetics and GlycoMimetics stockholders could face significant negative consequences, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading of GlycoMimetics common stock being conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities, such as the Pink Sheets or the OTC Bulletin Board, which could result in limited availability of market quotations for GlycoMimetics common stock and increased difficulty of disposing of shares of common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination that the common stock is a &#8220;penny stock,&#8221; which would require brokers trading in GlycoMimetics common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for shares of GlycoMimetics common stock; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited amount of analyst coverage; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decreased ability to issue additional securities or obtain financing in the future.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">An active trading market for GlycoMimetics common stock may not be sustained.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although GlycoMimetics common stock is listed on The Nasdaq Capital Market, GlycoMimetics cannot assure you that an active trading market for GlycoMimetics&#8217; shares will be sustained. If an active market for GlycoMimetics common stock is not sustained, it may be difficult for investors in GlycoMimetics common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The trading price of GlycoMimetics common stock has been and is likely to continue to be volatile.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; stock price from time to time has been volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The market price for GlycoMimetics common stock may be influenced by many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations regarding the consummation of the Merger with Crescent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements relating to development, regulatory approvals or commercialization of GlycoMimetics&#8217; drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated variations in GlycoMimetics&#8217; operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in financial estimates by GlycoMimetics or by any securities analysts who might cover GlycoMimetics&#8217; stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conditions or trends in GlycoMimetics&#8217; industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in laws or other regulatory actions affecting GlycoMimetics or its industry, such as drug pricing and reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the biopharmaceutical industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by GlycoMimetics or its competitors of significant acquisitions, strategic partnerships or divestitures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of investigations or regulatory scrutiny of GlycoMimetics&#8217; operations or lawsuits filed against GlycoMimetics;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investors&#8217; general perception of GlycoMimetics and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes concerning GlycoMimetics&#8217; intellectual property or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruitment or departure of key personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of GlycoMimetics common stock, including sales by its directors and officers or specific stockholders.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies, which has resulted in volatile stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, including worsening economic conditions and other adverse effects or developments relating to political, regulatory and other market conditions, may negatively affect the market price of shares of GlycoMimetics common stock, regardless of GlycoMimetics&#8217; actual operating performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against GlycoMimetics, could cause GlycoMimetics to incur substantial costs and divert management&#8217;s attention and resources from its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about GlycoMimetics, its business or its market, its stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading market for GlycoMimetics common stock is influenced by the research and reports that equity research analysts publish about GlycoMimetics and its business. GlycoMimetics has only limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of GlycoMimetics common stock, and such lack of research coverage may adversely affect the market price of GlycoMimetics common stock. Even if GlycoMimetics has equity research analyst coverage, GlycoMimetics will not have any control over the analysts or the content and opinions included in their reports. The price of GlycoMimetics common stock could decline if one or more equity research analysts downgrade GlycoMimetics common stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of GlycoMimetics or fails to publish reports on GlycoMimetics regularly, demand for its stock could decrease, which in turn could cause GlycoMimetics common stock price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The issuance of additional stock in connection with financings, acquisitions, investments, GlycoMimetics&#8217; stock incentive plan, GlycoMimetics&#8217; employee stock purchase plan or otherwise will dilute all other stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; certificate of incorporation authorizes GlycoMimetics to issue up to 150,000,000 shares of common stock and up to 5,000,000 shares of preferred stock with such rights and preferences as may be determined by the GlycoMimetics Board. Subject to compliance with applicable rules&#160;and regulations, GlycoMimetics may issue its shares of common stock or securities convertible into its common stock from time to time in connection with a financing, acquisition, investment, its stock incentive plan, its employee stock purchase plan or otherwise. Any such issuance could result in substantial dilution to GlycoMimetics&#8217; existing stockholders and cause the trading price of GlycoMimetics common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If a substantial number of GlycoMimetics&#8217; total outstanding shares are sold into the market, or if the market perceives that such sales may occur, it could cause the market price of GlycoMimetics common stock to drop significantly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of GlycoMimetics common stock in the public market could occur at any time. If GlycoMimetics&#8217; stockholders sell, or if the market perceives that GlycoMimetics&#8217; stockholders intend to sell, substantial amounts of GlycoMimetics common stock in the public market, the market price of GlycoMimetics common stock could decline significantly. All of GlycoMimetics&#8217; outstanding shares of common stock are available for sale in the public market, subject only to the restrictions of Rule&#160;144 under the Securities Act in the case of GlycoMimetics&#8217; affiliates.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, GlycoMimetics has filed registration statements on Form&#160;S-8 registering the issuance of shares of common stock subject to options or other equity awards issued or reserved for future issuance under its equity incentive plans. Shares registered under these registration statements are available for sale in the public market subject to vesting arrangements and exercise of options, as well as Rule&#160;144 in the case of GlycoMimetics&#8217; affiliates. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of GlycoMimetics common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in GlycoMimetics&#8217; corporate charter documents and under Delaware law may prevent or frustrate attempts by GlycoMimetics&#8217; stockholders to change its management and hinder efforts to acquire a controlling interest in it, and the market price of its common stock may be lower as a result.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provisions in GlycoMimetics&#8217; certificate of incorporation and bylaws that could make it difficult for a third party to acquire, or attempt to acquire, control of GlycoMimetics, even if a change in control was considered favorable by some or all of its stockholders. For example, the GlycoMimetics Board has the authority to issue up to 5,000,000 shares of preferred stock. The GlycoMimetics Board can fix the price, rights, preferences, privileges and restrictions of the preferred stock without any further vote or action by GlycoMimetics&#8217; stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction. As a result, the market price of GlycoMimetics common stock and the voting and other rights of GlycoMimetics&#8217; stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; charter documents also contain other provisions that could have an anti-takeover effect, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">only one of GlycoMimetics&#8217; three classes of directors is elected each&#160;year;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholders are not entitled to remove directors other than by a 66</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">2/3</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">% vote and only for cause;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholders are not permitted to take actions by written consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholders cannot call a special meeting of stockholders; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stockholders must give advance notice to nominate directors or submit proposals for consideration at stockholder meetings.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, GlycoMimetics is subject to the anti-takeover provisions of Section&#160;203 of the Delaware General Corporation Law, which regulates corporate acquisitions by prohibiting Delaware corporations from engaging in specified business combinations with particular stockholders of those companies. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for GlycoMimetics common stock, including transactions that may be in your best interests. These provisions may also prevent changes in GlycoMimetics&#8217; management or limit the price that investors are willing to pay for GlycoMimetics&#8217; stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; certificate of incorporation also provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between GlycoMimetics and its stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If GlycoMimetics fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics is subject to the reporting requirements of the Securities Exchange Act of 1934, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the rules&#160;and regulations of The Nasdaq Capital Market. The Sarbanes-Oxley Act requires, among other things, that GlycoMimetics maintains effective disclosure controls and procedures and internal control over financial reporting and perform system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal control over financial reporting. This requires that GlycoMimetics incur substantial additional professional fees and internal costs to expand its accounting and finance functions and that GlycoMimetics expends significant management efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">GlycoMimetics may discover areas of its internal financial and accounting controls and procedures that need improvement. GlycoMimetics&#8217; internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics is unable to maintain proper and effective internal controls in the future, GlycoMimetics may not be able to produce timely and accurate financial statements, and GlycoMimetics may conclude that its internal controls over financial reporting are not effective. If that were to happen, the market price of its stock could decline and GlycoMimetics could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics does not anticipate paying any cash dividends on its common stock, and its stock may not appreciate in value.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has never declared or paid cash dividends on its common stock. GlycoMimetics intends to retain all available funds to continue its operations through the Merger and do not anticipate declaring or paying any cash dividends on its common stock. Any return to stockholders will therefore be limited to the appreciation of their stock, if any. There is no guarantee that shares of GlycoMimetics common stock will appreciate in value or that the price at which GlycoMimetics&#8217; stockholders have purchased their shares will be able to be maintained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics&#8217; ability to use net operating loss carryforwards may be subject to limitations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, GlycoMimetics had federal and state net operating loss carryforwards of $351.8 million, research and development tax credit carryforwards of $10.9 million and $44.1 million of orphan drug tax credit carryforwards. The federal and state net operating loss carryforwards will begin to expire, if not utilized, beginning in 2025, the research and development tax credits in 2025 and the orphan drug tax credit in 2033. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under federal income tax laws, federal net operating losses incurred in 2018 and in future&#160;years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited.&#160;In addition, under Section&#160;382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. The Merger with Crescent, if consummated, could result in an ownership change that would limit the ability of the Combined Company to use GlycoMimetics&#8217; net operating loss carryforwards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Crescent</b></p><a id="RisksRelatedtoCrescentsFinancialConditio"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Crescent&#8217;s Financial Condition and Capital Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent has concluded there is substantial doubt about its ability to continue as a going concern for at least twelve months from the date its financial statements as of December 31, 2024 are available to be issued. Even if the Merger and Crescent Pre-Closing Financing are successful, Crescent will need to raise additional capital, and if it is unable to do so when needed, that will raise substantial doubt about Crescent&#8217;s ability to continue as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, Crescent had $34.8 million of cash. Should this Merger and Crescent Pre-Closing Financing be successful, Crescent will need to raise additional capital to continue to fund its operations and service its debt obligations in the future. If Crescent is unable to raise additional capital when needed, that will raise substantial doubt about Crescent&#8217;s ability to continue as a going concern. As a result, Crescent has concluded there is substantial doubt about its ability to continue as a going concern for at least twelve&#160;months from the date its financial statements as of December&#160;31, 2024 are available to be issued. In light of these concerns, Crescent&#8217;s independent registered public accounting firm included in its opinion on the financial statements an explanatory paragraph expressing substantial doubt about Crescent&#8217;s ability to continue as a going concern beyond twelve&#160;months from the date Crescent&#8217;s financial statements are available to be issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Developing Crescent&#8217;s product candidates requires a substantial amount of capital. Following the Merger and Crescent Pre-Closing Financing, the Combined Company will also incur additional costs associated with operating as a public company. Crescent expects its research and development expenses to increase in connection with its ongoing activities, particularly as it advances its product candidates through preclinical studies and clinical trials. Crescent will need to raise additional capital to fund its operations, and such funding may not be available to Crescent on acceptable terms, or at all, and such funding may become even more difficult to obtain due to rising interest rates and the current downturn in the U.S. capital markets and the biotechnology sector in general. </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Competition for additional capital among biotechnology companies may be particularly intense during economic downturns. Crescent may be unable to raise capital through public offerings of its common stock and may need to turn to alternative financing arrangements. Such arrangements, if Crescent pursues them, could involve the issuance of one or more types of securities, including common stock, preferred stock, convertible debt, warrants to acquire common stock or other securities. These securities could be issued at or below the then prevailing market price for Crescent common stock. In addition, if Crescent issues debt securities, the holders of the debt would have a claim to Crescent&#8217;s assets that would be superior to the rights of stockholders until the principal, accrued and unpaid interest and any premium or make-whole has been paid. Interest on any newly-issued debt securities and/or newly-incurred borrowings would increase Crescent&#8217;s operating costs and reduce its net income (or increase its net loss), and these impacts may be material. If the issuance of new securities results in diminished rights to holders of Crescent common stock, the market price of Crescent common stock could be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent does not currently have any products approved for sale and does not generate any revenue from product sales. Accordingly, Crescent expects to rely primarily on equity and/or debt financings to fund its continued operations. Crescent&#8217;s ability to raise additional funds will depend, in part, on the success of its preclinical studies and clinical trials and other product development activities, regulatory events, its ability to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect its value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond Crescent&#8217;s control. There can be no assurances that sufficient funds will be available to Crescent when required or on acceptable terms, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Crescent is unable to raise additional capital when required or on acceptable terms, it may be required to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significantly delay, scale back, or discontinue the development or commercialization of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek strategic partnerships, or amend existing partnerships, for research and development programs at an earlier stage than otherwise would be desirable or that Crescent otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">dispose of technology assets, or relinquish or license on unfavorable terms, Crescent&#8217;s rights to technologies or any of its product candidates that it otherwise would seek to develop or commercialize itself;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursue the sale of the company to a third party at a price that may result in a loss on investment for Crescent&#8217;s stockholders; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">file for bankruptcy or cease operations altogether (and face any related legal proceedings).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these events could have a material adverse effect on Crescent&#8217;s business, operating results, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if successful in raising new capital, Crescent could be limited in the amount of capital it raises due to investor demand restrictions placed on the amount of capital it raises or other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, any capital raising efforts are subject to significant risks and contingencies, as described in more detail under the risk factor titled &#8220;<i style="font-style:italic;">Raising additional capital may cause dilution to Crescent&#8217;s stockholders, restrict its operations, or require it to relinquish rights.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent has never generated any revenue from product sales and may never be profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent has no products approved for commercialization and has never generated any revenue from product sales. Crescent&#8217;s ability to generate revenue and achieve profitability depends on its ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize, one or more of its product candidates. Crescent does not anticipate generating revenue from product sales for the foreseeable future. Crescent&#8217;s ability to generate future revenue from product sales depends heavily on its success in many areas, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completing research and development of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory and marketing approvals for its product candidates for which it completes clinical trials;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that are commercially feasible, meet regulatory requirements and Crescent&#8217;s supply needs in sufficient quantities to meet market demand for its product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">qualifying for adequate coverage and reimbursement by government and third-party payors for any product candidates for which Crescent obtains regulatory and marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing, launching, and commercializing product candidates for which Crescent obtains regulatory and marketing approval, either directly or with a collaborator or distributor;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">gaining market acceptance of Crescent&#8217;s product candidates as treatment options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any competing products and technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">implementing internal systems and infrastructure, as needed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protecting and enforcing Crescent&#8217;s intellectual property rights, including patents, trade secrets, and know-how;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which Crescent may enter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining coverage and adequate reimbursement from third-party payors and maintaining pricing for Crescent&#8217;s product candidates that supports profitability; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attracting, hiring, and retaining qualified personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if one or more of the product candidates that Crescent develops is approved for commercial sale, Crescent anticipates incurring significant costs associated with commercializing any approved product candidate. Crescent&#8217;s expenses could increase beyond expectations if it is required by regulatory authorities to perform clinical and other studies in addition to those that Crescent anticipates. Even if Crescent is able to generate revenues from the sale of any approved products, it may not become profitable and may need to obtain additional funding to continue operations. Crescent will also have to develop or acquire manufacturing capabilities or continue to contract with contract manufacturers in order to continue development and potential commercialization of its product candidates. For instance, if the costs of manufacturing Crescent&#8217;s drug product are not commercially feasible, Crescent will need to develop or procure its drug product in a commercially feasible manner in order to successfully commercialize a future approved product, if any. Additionally, if Crescent is not able to generate revenue from the sale of any approved products, it may never become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent is a preclinical-stage biopharmaceutical company with a limited operating history on which to assess its business; it has not initiated, conducted or completed any clinical trials, has no products approved for commercial sale, has historically incurred losses, and anticipates that it will continue to incur significant losses for the foreseeable future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is a preclinical-stage biopharmaceutical company with a limited operating history. Since September&#160;19, 2024 (inception), Crescent has incurred significant operating losses. For the period between September&#160;19, 2024 (inception) to December&#160;31, 2024, Crescent reported a net loss of $17.9 million and had an accumulated deficit of $17.9 million. Crescent will need to raise substantial additional capital to continue to fund its operations in the future. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on Crescent&#8217;s financial condition and its ability to develop its product candidates. Changing circumstances may cause Crescent to consume capital significantly faster or slower than it currently anticipates. If Crescent is unable to acquire additional capital or resources, it will be required to modify its operational plans to complete future milestones and it may be required to delay, limit, reduce or eliminate development or future commercialization efforts of product candidates and/or programs. Crescent has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Crescent may be forced to reduce its operating expenses and raise additional funds to meet its working capital needs, principally through the additional sales of its securities or debt financings or entering into strategic collaborations.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent has devoted substantially all of its financial resources to identify, acquire, and develop its product candidates, organizing and staffing its company, and providing general and administrative support for its operations. To date, Crescent has funded its operations primarily from the sale and issuance of convertible preferred and common equity securities and unsecured convertible notes. The amount of Crescent&#8217;s future net losses will depend, in part, on the rate of its future expenditures and its ability to obtain funding through equity or debt financings, strategic collaborations, or grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. Crescent expects its losses to increase as its product candidates enter more advanced clinical trials. It may be several&#160;years, if ever, before Crescent completes pivotal clinical trials and/or has a product candidate approved for commercialization. Crescent expects to invest significant funds into the research and development of its current programs to determine the potential to advance product candidates to regulatory approval. If Crescent obtains regulatory approval to market a product candidate, its future revenue will depend upon the size of any markets in which its product candidates may receive approval, and its ability to achieve sufficient market acceptance, pricing, coverage and adequate reimbursement from third-party payors, and adequate market share for its product candidates in those markets. Even if Crescent obtains adequate market share for its product candidates, because the potential markets in which its product candidates may ultimately receive regulatory approval could be very small, Crescent may never become profitable despite obtaining such market share and acceptance of its products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent expects to continue to incur significant expenses and increasing operating losses for the foreseeable future and its expenses will increase substantially if and as it:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continues the preclinical development and initiates the clinical development of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continues efforts to discover and develop new product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continues the manufacturing of its product candidates or increases volumes manufactured by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advances its product candidates into larger, more expensive clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiates additional preclinical studies or clinical trials for its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks regulatory and marketing approvals and reimbursement for its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishes a sales, marketing, and distribution infrastructure to commercialize any products for which it may obtain regulatory and marketing approval and market for itself;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks to identify, assess, acquire, and/or develop other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">makes milestone, royalty, or other payments under third-party license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks to maintain, protect, and expand its intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is required to pay penalties under its Registration Rights Agreement for failing to timely register the applicable securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks to attract and retain skilled personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">experiences any delays or encounters issues with the development and potential regulatory approval of its clinical and product candidates such as safety issues, manufacturing delays, clinical trial accrual delays, longer follow-up for planned studies or trials, additional major studies or trials, or supportive trials necessary to support regulatory and marketing approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and incurs additional costs associated with operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Crescent has no significant experience as a company in initiating, conducting or completing clinical trials. In part because of this lack of experience, Crescent cannot be certain that its planned clinical trials will begin or be completed on time, if at all. In addition, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Crescent has not yet demonstrated an ability to obtain regulatory and marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on its behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about Crescent&#8217;s future success or viability may not be as accurate as they could be if Crescent had a longer operating history. Further, the net losses Crescent incurs may fluctuate significantly from quarter to quarter and&#160;year to&#160;year, such that a period-to-period comparison of its results of operations may not be a good indication of its future performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to Crescent&#8217;s stockholders, restrict its operations, or require it to relinquish rights.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as Crescent can generate substantial revenue from the sale of its product candidates, Crescent expects to finance its cash needs through a combination of equity offerings, debt financings and license and development agreements. To the extent that Crescent raises additional capital through the sale of equity securities or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of Crescent common stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting Crescent&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Crescent raises additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, it may be required to relinquish valuable rights to its research programs or product candidates or grant licenses on terms that may not be favorable to it. If Crescent is unable to raise additional funds through equity or debt financings or other arrangements with third parties when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that Crescent would otherwise prefer to develop and market itself.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent that Crescent raises additional capital through the sale of equity, including pursuant to any sales under convertible debt or other securities convertible into equity, the ownership interest of its stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of its stockholders. For instance, at its inception in September&#160;2024, Crescent sold an aggregate of 20,000,000 shares of Series&#160;Seed Preferred Stock, and in October&#160;2024, it sold the Convertible Notes&#160;for gross proceeds of $37.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Debt financing, if available, would likely involve agreements that include covenants limiting or restricting Crescent&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. If Crescent raises additional funds through strategic collaborations or licensing arrangements with third parties, Crescent may have to relinquish valuable rights to its product candidates or future revenue streams or grant licenses on terms that are not favorable to Crescent. Crescent cannot assure that it will be able to obtain additional funding if and when necessary to fund its entire portfolio of product candidates to meet its projected plans. If Crescent is unable to obtain funding on a timely basis, it may be required to delay or discontinue one or more of its development programs or the commercialization of any product candidates or be unable to expand its operations or otherwise capitalize on potential business opportunities, which could materially harm Crescent&#8217;s business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Discovery, Development and Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent faces competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed by Crescent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The development and commercialization of drugs is highly competitive. Product candidates developed by Crescent, if approved, will face significant competition and Crescent&#8217;s failure to effectively compete may prevent it from achieving significant market penetration. Crescent competes with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, including Merck, Bristol Myers Squibb, Genetech, AstraZeneca, Summit Therapeutics&#160;Inc., BioNTech SE, LaNova Medicines&#160;Ltd., and Compass Therapeutics,&#160;Inc., as well as academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which Crescent is currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing regulatory approved products than Crescent does, and are further along in the clinical development and/or commercialization process than Crescent is. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of Crescent&#8217;s competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">collaborative arrangements with large and established companies. These competitors also compete with Crescent in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, raising capital, registering patients for clinical trials, establishing and defending rights to intellectual property, as well as in acquiring technologies complementary to, or necessary for, Crescent&#8217;s product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s competitors have developed, are developing or may in the future develop programs and processes competitive with Crescent&#8217;s programs and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any potential new treatments, including those currently under clinical development. Crescent&#8217;s success will depend partially on its ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or presentation profile. Crescent&#8217;s commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation or are less expensive than the products Crescent develops, or if Crescent&#8217;s competitors develop competing products or if biosimilars enter the market more quickly than Crescent does and are able to gain market acceptance. Conversely, the lack of commercial success of other competing programs may raise concerns about the financial viability of Crescent&#8217;s programs. Please see the section titled &#8220;<i style="font-style:italic;">Crescent&#8217;s Business&#8212;Competition</i>&#8221; beginning on page&#160;232 of this proxy statement/prospectus for a more detailed description of Crescent&#8217;s competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent&#8217;s programs are in preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If Crescent or its current or future collaborators are unable to complete development of or commercialize Crescent&#8217;s product candidates, or experience significant delays in doing so, Crescent&#8217;s business will be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent has no products on the market, and all of its programs are in preclinical stages of development and have not been tested in humans. As a result, Crescent expects it will be many&#160;years before it commercializes any product candidate, if ever. Crescent&#8217;s ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing, its product candidates, either alone or with third parties, and Crescent cannot guarantee you that it will ever obtain regulatory approval for any of its product candidates. Crescent has not yet demonstrated its ability to initiate or complete any clinical trials, obtain regulatory approvals, manufacture a clinical or commercial scale product or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary for successful product commercialization. Before obtaining regulatory approval for the commercial distribution of Crescent&#8217;s product candidates, Crescent or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of Crescent&#8217;s programs and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent or its collaborators may experience delays in initiating or completing clinical trials. Crescent or its collaborators also may experience numerous unforeseen events during, or as a result of, any clinical trials that they could conduct that could delay or prevent Crescent&#8217;s ability to receive regulatory and marketing approval or commercialize its product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators or institutional review boards (&#8220;IRBs&#8221;), the FDA or ethics committees may not authorize Crescent or its investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results, and Crescent may decide, or regulators may require it, to conduct additional preclinical studies or clinical trials or Crescent may decide to abandon product development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of subjects required for clinical trials of any product candidates may be larger than Crescent anticipates, especially if regulatory bodies require completion of non-inferiority or superiority trials, enrollment in these clinical trials may be slower than Crescent anticipates or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than Crescent anticipates;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to Crescent in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that Crescent add new clinical trial sites or investigators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent may elect to, or regulators, IRBs or ethics committees may require that Crescent or its investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the patients in Crescent&#8217;s trials are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of any of Crescent&#8217;s programs may be greater than Crescent anticipates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quality of Crescent&#8217;s product candidates or other materials necessary to conduct clinical trials of Crescent&#8217;s product candidates may be inadequate to initiate or complete a given clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s inability to manufacture sufficient quantities of its product candidates for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reports from clinical testing of other therapies may raise safety or efficacy concerns about Crescent&#8217;s programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidates as well as data emerging from other therapies in the same class as Crescent&#8217;s product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or other regulatory authorities may require Crescent to submit additional data such as long-term toxicology studies, or impose other requirements before permitting Crescent to initiate a clinical trial.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Commencing clinical trials in the United States is subject to acceptance by the FDA of an IND application, biologics license application (&#8220;BLA&#8221;) or similar application and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires Crescent to complete additional preclinical studies or it is required to satisfy other FDA or foreign regulatory authority requests, respectively, prior to commencing clinical trials, the start of Crescent&#8217;s first clinical trials may be delayed. Even after Crescent receives and incorporates guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that Crescent has satisfied their requirements to commence any clinical trial or change their position on the acceptability of Crescent&#8217;s trial design or the clinical endpoints selected, which may require Crescent to complete additional preclinical studies or clinical trials, delay the enrollment of Crescent&#8217;s clinical trials or impose stricter approval conditions than Crescent currently expects. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union (&#8220;EU&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if it experiences any issues that delay or prevent regulatory approval of, or its ability to commercialize, its product candidates. Crescent or its current or future collaborators&#8217; inability to complete development of, or commercialize Crescent&#8217;s product candidates, or significant delays in doing so, could have a material and adverse effect on Crescent&#8217;s business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent is substantially dependent on the success of its lead program, CR-001, and its anticipated clinical trials of such program may not be successful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s future success is substantially dependent on its ability to timely obtain regulatory and marketing approval for, and then successfully commercialize, its lead program, CR-001. Crescent is also advancing its CR-002 and CR-003 programs. Crescent is investing a majority of its efforts and financial resources into the research and development of these programs. Crescent anticipates that the IND for CR-001 will be submitted by the fourth quarter of 2025 followed by a Phase 1 clinical trial with results expected in the second half of 2026 in patients with solid tumors. Crescent anticipates that the IND for CR-002 will be submitted by mid-2026. The success of Crescent&#8217;s CR-001 is dependent on observing in CR-001 the targeting, binding, cooperativity and pharmacokinetics of ivonescimab, an anti-PD-1/anti-VEGF bispecific antibody that demonstrated efficacy superior to market-leading pembrolizumab in a large Phase 3 clinical trial, while avoiding the mechanistic risks that could perturb the balance of efficacy and safety that define this new class of immunotherapy, assuming Crescent successfully completes clinical development and obtains regulatory and marketing approval for CR-001. To the extent Crescent does not observe this recapitulation of ivonescimab in CR-001, it would significantly and adversely affect the clinical and commercial potential of CR-001.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s programs will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, product development, regulatory and marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before Crescent generates any revenues from product sales. Crescent is not permitted to market or promote these programs, or any other programs, before it receives regulatory and marketing approval from the FDA and comparable foreign regulatory authorities, and Crescent may never receive such regulatory or marketing approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The success of Crescent&#8217;s product candidates will depend on a variety of factors. Crescent does not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to Crescent&#8217;s intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator. Accordingly, Crescent cannot assure you that it will ever be able to generate revenue through the sale of these product candidates, even if approved. If Crescent is not successful in obtaining regulatory approval and commercializing its CR-001, CR-002 or CR-003 programs, or is significantly delayed in doing so, Crescent&#8217;s business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Crescent does not achieve its projected development goals in the time frames it announces and expects, the commercialization of Crescent&#8217;s product candidates may be delayed and its expenses may increase and, as a result, its stock price may decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, Crescent estimates the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which it sometimes refers to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected timing for the anticipated commencement of Crescent&#8217;s Phase 1 studies, and clinical trials in solid tumor and other target indications, as well as the receipt of clinical data, and submission of regulatory filings. From time to time, Crescent may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to Crescent&#8217;s estimates, in some cases for reasons beyond Crescent&#8217;s control. If Crescent does not meet these milestones as publicly announced, or at all, the commercialization of its product candidates may be delayed or never achieved and, as a result, its stock price may decline. Additionally, delays relative to Crescent&#8217;s projected timelines are likely to cause overall expenses to increase, which may require Crescent to raise additional capital sooner than expected and prior to achieving targeted development milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any drug delivery device that Crescent potentially uses to deliver its product candidates may have its own regulatory, development, supply and other risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent expects to deliver its product candidates via a drug delivery device, such as an injector or other delivery system. There may be unforeseen technical complications related to the development activities required to bring such a product to market, including primary container compatibility and/or dose volume requirements. Crescent&#8217;s product candidates may not be approved or may be substantially delayed in receiving approval if the devices that Crescent chooses to develop do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single-source unaffiliated third-party companies. Crescent may be dependent on the sustained cooperation and effort of those third-party companies both to supply the devices and, in some cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, Crescent may also be dependent on those third-party companies continuing to maintain such approvals or clearances once they have been received. Failure of third-party companies to supply the devices, to successfully complete studies on the devices in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching the market or in gaining approval or clearance for expanded labels for new indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent&#8217;s approach to the discovery and development of its programs is unproven, and Crescent may not be successful in its efforts to build a pipeline of programs with commercial value.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s approach to the discovery and development of its programs, particularly CR-001, leverages clinically validated mechanisms of action and incorporates the targeting, binding, cooperativity and pharmacokinetics of ivonescimab, an anti-PD-1/anti-VEGF bispecific antibody that demonstrated efficacy superior to market-leading pembrolizumab in a large Phase 3 clinical trial. Crescent&#8217;s programs are purposefully designed to avoid mechanistic risks that could perturb the balance of efficacy and safety that defines this new class of immunotherapy. However, the scientific research that forms the basis of Crescent&#8217;s efforts to develop programs using ivonescimab-like technologies is ongoing and may not result in viable programs. There is limited clinical data available on product candidates utilizing the same mechanism of action as ivonescimab, especially in solid tumor indications, demonstrating whether they are safe or effective for long-term treatment in humans. The long-term safety and efficacy of these technologies and exposure profile of Crescent&#8217;s programs compared to currently approved products is unknown.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent may ultimately discover that reproducing ivonescimab&#8217;s established pharmacology for its specific targets and indications and any programs resulting therefrom does not possess certain properties required for therapeutic effectiveness. Crescent currently has only preclinical data regarding the ivonescimab-like properties of its programs and the same results may not be seen in humans. In addition, programs using ivonescimab-like technologies may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. Many product candidates that appeared highly promising in preclinical studies or in early-stage clinical trials have failed when advanced into, or further in, clinical development. In addition, the failure of companies that are developing products similar to Crescent or targeting the same indications as Crescent to demonstrate safety and efficacy of their product candidates may be harmful to Crescent&#8217;s business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, Crescent may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven. If Crescent&#8217;s discovery or business development activities fail to identify novel targets or technologies for drug development, or such targets prove to be unsuitable for treating human disease, Crescent may not be able to develop viable additional programs. Crescent and its existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if Crescent or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as Crescent intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from Crescent&#8217;s programs prove to be ineffective, unsafe or commercially unviable, such programs would have little, if any, value, which would have a material and adverse effect on Crescent&#8217;s business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If Crescent&#8217;s preclinical studies and clinical trials are not sufficient to support regulatory approval of any of its product candidates, Crescent may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before obtaining regulatory and marketing approval from regulatory authorities for the sale of any product candidate, Crescent must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Crescent&#8217;s clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. For example, Crescent depends on the availability of non-human primates (&#8220;NHPs&#8221;)to conduct certain preclinical studies that it is required to complete prior to submitting an IND and initiating clinical development. There is currently a global shortage of NHPs available for drug development. This could cause the cost of obtaining NHPs for Crescent&#8217;s future preclinical studies to increase significantly and, if the shortage continues, could also result in delays to Crescent&#8217;s development timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory and marketing approval of their product candidates. In addition, Crescent expects to rely on patients to provide feedback on measures such as measures of quality of life, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of Crescent&#8217;s control, and can vary widely from day-to-day for a particular patient, and from patient to patient and from site to site within a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Crescent cannot be sure that the FDA or comparable foreign regulatory authorities will agree with its clinical development plan. Crescent plans to design a Phase 1 clinical trial for CR-001 based on the clinical profile of ivonescimab. If the FDA or comparable foreign regulatory authorities require Crescent to conduct additional trials or enroll additional patients, Crescent&#8217;s development timelines may be delayed. Crescent cannot be sure that submission of an IND, BLA or similar application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other <i style="font-style:italic;">in vivo </i>or <i style="font-style:italic;">in vitro </i>data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required IRB approval or positive ethics </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">committee opinions at each clinical trial site; delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of Crescent&#8217;s product candidates for use in clinical trials or the inability to do any of the foregoing; failure by Crescent&#8217;s CROs, other third parties or Crescent to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s current Good Clinical Practice requirements (&#8220;GCPs&#8221;) or applicable regulatory guidelines in other countries; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to facilities operated by a contract manufacturing organization (&#8220;CMO&#8221;) and delays or failure by Crescent&#8217;s CMOs or Crescent to make any necessary changes to such manufacturing process; and third parties being unwilling or unable to satisfy their contractual obligations to Crescent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent could also encounter delays if a clinical trial is suspended or terminated by it, by the IRBs or ethics committees of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or Crescent&#8217;s clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If Crescent is required to conduct additional clinical trials or other testing of its product candidates beyond those that Crescent currently contemplates, if Crescent is unable to successfully complete clinical trials of its product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, Crescent&#8217;s business and results of operations may be adversely affected and it may incur significant additional costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Crescent encounters difficulties enrolling patients in its future clinical trials, its clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent may experience difficulties in patient enrollment in its future clinical trials for a variety of reasons, including the competitive landscape for solid tumor indications and competition for establishing trial sites and clinical trial enrollment. The timely completion of clinical trials in accordance with their protocols depends, among other things, on Crescent&#8217;s ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients in future trials for any of Crescent&#8217;s programs will depend on many factors, including if patients choose to enroll in clinical trials, rather than using approved products, or if Crescent&#8217;s competitors have ongoing clinical trials for programs that are under development for the same indications as its programs, and patients instead enroll in such clinical trials. Additionally, the number of patients required for clinical trials of Crescent&#8217;s programs may be larger than Crescent anticipates, especially if regulatory bodies require the completion of non-inferiority or superiority trials. Even if Crescent is able to enroll a sufficient number of patients for its future clinical trials, it may have difficulty maintaining patients in its clinical trials. Crescent&#8217;s inability to enroll or maintain a sufficient number of patients would result in significant delays in completing clinical trials or receipt of regulatory and marketing approvals and increased development costs or may require Crescent to abandon one or more clinical trials altogether.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preliminary, &#8220;topline&#8221; or interim data from Crescent&#8217;s clinical trials that it announces or publishes from time to time may change as more patient data become available and are subject to audit and verification procedures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, Crescent may publicly disclose preliminary or topline data from its preclinical studies and clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. Crescent also makes assumptions, estimations, calculations and conclusions as part of its analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results that Crescent reports may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Any preliminary or topline data should be viewed with caution until the final data are available. From time to time, Crescent may also disclose interim data from its preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from Crescent&#8217;s clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with Crescent&#8217;s assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular product candidate and Crescent in general. In addition, the information Crescent chooses to publicly disclose regarding a particular preclinical </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">study or clinical trial is based on what is typically extensive information, and you or others may not agree with what Crescent determines is material or otherwise appropriate information to include in its disclosure. As a result, you or others may have reached different conclusions based on such extensive information in comparison to Crescent&#8217;s publicly disclosed conclusion regarding a particular preclinical study or clinical trial. If the preliminary, topline or interim data that Crescent reports differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, Crescent&#8217;s ability to obtain approval for, and commercialize, its product candidates may be harmed, which could harm its business, operating results, prospects or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent&#8217;s future clinical trials or those of its future collaborators may reveal significant adverse events or undesirable side effects not seen in Crescent&#8217;s preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of any of Crescent&#8217;s product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Results of Crescent&#8217;s clinical trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. While preclinical studies conducted with respect to Crescent&#8217;s programs have not shown any such characteristics to date, Crescent has not yet initiated any clinical trials in humans. If significant adverse events or other side effects are observed in any of Crescent&#8217;s future clinical trials, Crescent may have difficulty recruiting patients to such trials, patients may drop out of the trials, or Crescent may be required to abandon the trials or its development efforts of one or more programs altogether. For example, clinical experience in NSCLC with anti-VEGF inhibitors, such as bevacizumab, identified serious adverse events, including fatal pulmonary hemorrhage, that have limited the number of patients eligible for treatment. Other adverse events associated with bevacizumab include proteinuria and hypertension. Crescent, the FDA or other applicable regulatory authorities, or an IRB, may suspend any clinical trials of any program at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies and trials have later been found to cause side effects that prevented their further development. Other potential products have shown side effects in preclinical studies, which side effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining or maintaining regulatory and marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Treatment-emergent adverse events could also affect patient recruitment or the ability of enrolled subjects to complete Crescent&#8217;s clinical trials or could result in potential product liability claims. Potential side effects associated with Crescent&#8217;s product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from Crescent&#8217;s product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences could harm Crescent&#8217;s business, financial condition, results of operations and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, even if Crescent successfully advances its product candidates or any future product candidates through clinical trials, such trials will only include a limited number of patients and limited duration of exposure to Crescent&#8217;s product candidates. As a result, Crescent cannot be assured that adverse effects of its product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using Crescent&#8217;s product candidates over a multi-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of the foregoing events occur or if one or more of Crescent&#8217;s programs proves to be unsafe, Crescent&#8217;s entire pipeline could be affected, which would have a material adverse effect on its business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent may expend its limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because Crescent has limited financial and managerial resources, it focuses its research and development efforts on certain selected programs. For example, Crescent is initially focused on its lead program, CR-001, and other programs, CR-002 and CR-003. As a result, Crescent may forgo or delay pursuit of opportunities with other programs that later prove to have greater commercial potential. Crescent&#8217;s resource allocation decisions may cause it to fail to capitalize on viable commercial products or profitable market opportunities. Crescent&#8217;s spending on current and future research and development programs for specific indications may not yield any commercially viable product candidates. If Crescent does not accurately evaluate the commercial potential or target market for a particular product candidate, it may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for it to retain sole development and commercialization rights to such product candidate. In addition, Crescent selects product candidates amongst a variety of potential product candidates from Paragon, and the product candidates it selects may fail to be viable commercial products or the product candidates it does not select may have a greater likelihood of success.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any approved products resulting from Crescent&#8217;s current programs or any future program may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and Crescent may not generate any future revenue from the sale or licensing of such products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if regulatory approval is obtained for a product candidate resulting from one of Crescent&#8217;s current or future programs, they may not gain market acceptance among physicians, healthcare professionals, patients, healthcare payors or the medical community. Crescent may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. There are several approved products and product candidates in later stages of development for the treatment of solid tumors, including pembrolizumab. In addition, Opdivo, a PD-1 inhibitor, and Yervoy&#174;, a CTLA-4 inhibitor, in combination are approved by the FDA for treating various cancers, including metastatic melanoma, advanced renal cell carcinoma, and certain types of colorectal cancer. Crescent&#8217;s CR-001 utilizes a proprietary anti-PD-1/anti-VEGF bispecific antibody for its method of action, and is designed to recapitulate the targeting, binding, cooperativity and pharmacokinetics of ivonescimab, an anti-PD-1/anti-VEGF bispecific antibody that demonstrated efficacy superior to market-leading pembrolizumab in a large Phase 3 clinical trial. Although checkpoint inhibitors are highly effective in some patients, most patients with solid tumors fail to respond to these therapies. Furthermore, patients who do respond do not always achieve durable responses. Market participants with significant influence over acceptance of new treatments, such as clinicians and third-party payors, may not adopt a biologic that uses cooperative binding qualities for Crescent&#8217;s targeted indications, and Crescent may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any programs developed by it or its existing or future collaborators. Serious adverse events, including fatal pulmonary hemorrhage, observed in anti-VEGF inhibitors, such as bevacizumab, may adversely affect Crescent&#8217;s ability to gain market acceptance. Market acceptance of Crescent&#8217;s product candidates may be negatively impacted by potential poor performance of its competitors, including the occurrence of serious adverse events in such competitors&#8217; clinical trials or failure by such competitors to obtain and maintain regulatory approval for their product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sales of medical products also depend on the willingness of clinicians to prescribe the treatment. Crescent cannot predict whether clinicians, clinicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that its product is safe, therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any of Crescent&#8217;s product candidates is approved but does not achieve an adequate level of acceptance by such parties, Crescent may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable. Market acceptance of Crescent&#8217;s product candidates will depend on many factors, including factors that are not within its control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain of Crescent&#8217;s programs may compete with its other programs, which could negatively impact Crescent&#8217;s business and reduce its future revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is developing product candidates for the same indication, solid tumors, and may in the future develop its programs for other oncology indications. Each such program targets a different mechanism of action. However, developing multiple programs for a single indication may negatively impact Crescent&#8217;s business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the same time, they could compete for the enrollment of patients. In addition, if multiple product candidates are approved for the same indication, they may compete for market share, which could limit Crescent&#8217;s future revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent may conduct clinical trials for programs at sites outside the United States, and the FDA may not accept data from trials conducted in such locations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent may choose to conduct one or more of its future clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. If the FDA does not accept the data from any trial that Crescent conducts outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt Crescent&#8217;s development of the applicable product candidates. Even if the FDA accepted such data, it could require Crescent to modify its planned clinical trials to receive clearance to initiate such trials in the United States or to continue such trials once initiated.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, conducting international clinical trials presents additional risks that may delay completion of Crescent&#8217;s clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit Crescent&#8217;s ability to conduct its clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, foreign exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant to foreign countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If Crescent is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Crescent will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes many&#160;years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Crescent cannot commercialize product candidates in the United States without first obtaining regulatory approval from the FDA. Similarly, Crescent cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of Crescent&#8217;s product candidates, including its lead program, CR-001, and other programs, CR-002 and CR-003, Crescent must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that its product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, Crescent&#8217;s product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude Crescent&#8217;s obtaining regulatory and marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that Crescent&#8217;s data are insufficient for approval and require additional preclinical, clinical or other data. Crescent&#8217;s product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of Crescent&#8217;s clinical trials; Crescent may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related side effects may be experienced by patients in Crescent&#8217;s clinical trials or by individuals using drugs similar to Crescent&#8217;s product candidates; Crescent may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; the FDA or comparable foreign regulatory authorities may disagree with Crescent&#8217;s interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of Crescent&#8217;s product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere, and Crescent may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of Crescent&#8217;s product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which Crescent contracts for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering Crescent&#8217;s clinical data insufficient for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of the large number of drugs in development, only a small&#160;percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in Crescent&#8217;s failing to obtain regulatory approval to market its product candidates, which would significantly harm Crescent&#8217;s business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Crescent were to obtain approval, regulatory authorities may approve any of Crescent&#8217;s product candidates for fewer or more limited indications than Crescent requests, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. If Crescent is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Crescent will not be able to commercialize, or will be delayed in commercializing, its product candidates and its ability to generate revenue will be materially impaired.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent may not be able to meet requirements for the chemistry, manufacturing and control of its programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to receive approval of its products by the FDA and comparable foreign regulatory authorities, Crescent must show that it and its contract manufacturing partners are able to characterize, control and manufacture its drug products safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that Crescent&#8217;s drug products meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If Crescent is not able to meet the chemistry, manufacturing and control requirements, it may not be successful in getting its products approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent&#8217;s product candidates for which it intends to seek approval as biologics may face competition sooner than anticipated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Act, as amended by the Healthcare and Education Reconciliation Act (the &#8220;ACA&#8221;), includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four&#160;years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent believes that any of its product candidates approved as biologics under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider Crescent&#8217;s product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if Crescent receives regulatory approval of its product candidates, Crescent will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and Crescent may be subject to penalties if it fails to comply with regulatory requirements or experiences unanticipated problems with its product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any regulatory approvals that Crescent may receive for its product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) in order to approve Crescent&#8217;s product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or comparable foreign regulatory authorities approve Crescent&#8217;s product candidates, its product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with current cGMPs and GCPs for any clinical trials that Crescent conducts following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If Crescent or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or Crescent, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, restrictions on Crescent&#8217;s ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. The occurrence of any event or penalty described above </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">may inhibit Crescent&#8217;s ability to commercialize its product candidates and generate revenue and could require Crescent to expend significant time and resources in response and could generate negative publicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent may face difficulties from healthcare legislative reform measures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of Crescent&#8217;s product candidates. Crescent cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If Crescent is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if it is not able to maintain regulatory compliance, Crescent may lose any regulatory and marketing approval that it may have obtained and it may not achieve or sustain profitability. See the section titled &#8220;<i style="font-style:italic;">Crescent&#8217;s Business&#8212;Government Regulation&#8212;Healthcare Reform</i>&#8221; for a more detailed description of healthcare reform measures that may prevent or limit Crescent&#8217;s ability to generate revenue, attain profitability, or commercialize its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose Crescent to penalties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose Crescent to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which Crescent conducts its operations, including how Crescent researches, markets, sells and distributes its product candidates, if approved. See the section titled &#8220;<i style="font-style:italic;">Crescent&#8217;s Business&#8212;Government Regulation&#8212;Other Healthcare Laws and Compliance Requirements</i>&#8221; for a more detailed description of the laws that may affect Crescent&#8217;s ability to operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ensuring that Crescent&#8217;s internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If Crescent&#8217;s operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to it, Crescent may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of Crescent&#8217;s operations. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if Crescent is successful in defending against any such actions that may be brought against it, its business may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if Crescent is able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, it may not be able to offer such product candidates at competitive prices which would seriously harm its business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent intends to seek approval to market its product candidates in both the United States and in selected foreign jurisdictions. If Crescent obtains approval in one or more foreign jurisdictions for its product candidates, Crescent will be subject to rules&#160;and regulations in those jurisdictions. Crescent&#8217;s ability to successfully commercialize any product candidates that it may develop will depend in part on the extent to which reimbursement for these product candidates and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitor&#8217;s product, including a branded or generic/biosimilar product, over Crescent&#8217;s products in an attempt to reduce their costs, which may reduce Crescent&#8217;s commercial opportunity. Additionally, if any of Crescent&#8217;s product candidates are approved and Crescent is found to have improperly promoted off-label uses of those product candidates, Crescent may become subject to significant liability, which would materially adversely affect its business and financial condition. See the sections titled &#8220;<i style="font-style:italic;">Crescent&#8217;s Business&#8212;Government Regulation&#8212;Coverage and Reimbursement</i>&#8221; and &#8220;<i style="font-style:italic;">Crescent&#8217;s Business&#8212;Other Government Regulation Outside of the United States&#8212;Regulation in the European Union</i>&#8221; for a more detailed description of the government regulations and third-party payor practices that may affect Crescent&#8217;s ability to commercialize its product candidates.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent is subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Crescent can face criminal liability and other serious consequences for violations, which can harm its business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which Crescent conducts activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. Crescent may engage third parties to sell its products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. Crescent has direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. Crescent can be held liable for the corrupt or other illegal activities of its employees, agents, contractors, and other collaborators, even if Crescent does not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Governments outside the United States tend to impose strict price controls, which may adversely affect Crescent&#8217;s revenue, if any.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some countries, particularly member states of the EU (&#8220;EU Member States&#8221;), the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory and marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced EU Member States, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, Crescent or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of Crescent&#8217;s product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, Crescent&#8217;s business, financial condition, results of operations or prospects could be materially and adversely affected. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations, including those related to the pricing of prescription pharmaceuticals, as the United Kingdom (&#8220;UK&#8221;) determines which EU laws to replicate or replace. If the UK were to significantly alter its regulations affecting the pricing of prescription pharmaceuticals, Crescent could face significant new costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent may attempt to obtain accelerated approval of its product candidates. If Crescent is unable to obtain accelerated approval, Crescent may be required to conduct clinical trials beyond those that it contemplates, or the size and duration of Crescent&#8217;s pivotal clinical trials could be greater than currently planned, which could increase the expense of obtaining, reduce the likelihood of obtaining, and/or delay the timing of obtaining necessary regulatory approvals. Even if Crescent receives accelerated approval from the FDA or comparable foreign regulatory authorities, the FDA or comparable foreign regulatory authorities may require that Crescent conducts confirmatory trials to verify clinical benefit. If Crescent&#8217;s confirmatory trials do not verify clinical benefit, or if Crescent does not comply with rigorous post-approval requirements, the FDA may seek to withdraw accelerated approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Crescent may seek accelerated approval for Crescent&#8217;s product candidates. The FDA may grant accelerated approval to a product designed to treat a serious or life-threatening condition that provides meaningful therapeutic advantage over available therapies and demonstrates an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease. If granted, accelerated approval may be contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s predicted effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022, the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. The FDA may require that any such confirmatory study be initiated or substantially underway prior to the submission of an application for accelerated approval. If such post-approval studies fail to confirm the drug&#8217;s clinical benefits relative to its risks, the FDA may withdraw its </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">approval of the drug. If Crescent chooses to pursue accelerated approval, there can be no assurance that the FDA will agree that Crescent&#8217;s proposed primary endpoint is an appropriate surrogate endpoint. Similarly, there can be no assurance that after subsequent FDA feedback that Crescent will continue to pursue accelerated approval or any other form of expedited development, review, or approval, even if Crescent initially decides to do so. Furthermore, if Crescent submits an application for accelerated approval, there can be no assurance that such application will be accepted or that approval will be granted on a timely basis, or at all. The FDA also could require Crescent to conduct further studies or trials prior to considering Crescent&#8217;s application or granting approval of any type. Crescent might not be able to fulfill the FDA&#8217;s requirements in a timely manner, which would cause delays, or approval might not be granted because Crescent&#8217;s submission is deemed incomplete by the FDA. Comparable considerations apply outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if Crescent receives accelerated approval from the FDA, Crescent will be subject to rigorous post-approval requirements, including submission to the FDA of all promotional materials prior to their dissemination. The FDA will require Crescent to conduct a confirmatory study to verify the predicted clinical benefit. The FDA could withdraw accelerated approval for multiple reasons, including Crescent&#8217;s failure to conduct any required post-approval study with due diligence, or the inability of such study to confirm the predicted clinical benefit. A failure to obtain accelerated approval or any other form of expedited review or approval for a product candidate could result in a longer time period prior to commercializing such product candidate, increase the cost of development of such product candidate, and harm Crescent&#8217;s competitive position in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A breakthrough therapy, fast track, or other expedited designation for Crescent&#8217;s product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that those product candidates will receive regulatory and marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent may seek a breakthrough therapy, fast track, or other designation for appropriate product candidates. Designations such as these are within the discretion of the FDA, or other comparable regulatory authorities. The receipt of a designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of Crescent&#8217;s product candidates qualifies under one of FDA&#8217;s designation programs, the FDA may later decide that the products no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. See the section titled &#8220;<i style="font-style:italic;">Crescent&#8217;s Business</i><span style="font-style:italic;font-weight:bold;">&#8212;</span><i style="font-style:italic;">Government Regulation</i><span style="font-style:italic;font-weight:bold;">&#8212;</span><i style="font-style:italic;">Expedited Development and Review Programs</i>&#8221; for a more detailed description of the process for seeking expedited designations such as fast track or breakthrough therapy designations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Disruptions at the FDA, the SEC and other government agencies and regulatory authorities caused by funding shortages, changes or reductions in agency personnel, or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of Crescent&#8217;s business may rely, which could negatively impact Crescent&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA to review regulatory filings and Crescent&#8217;s ability to commence human clinical trials can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent&#160;years as a result. In addition, government funding of the SEC, and other government agencies on which Crescent&#8217;s operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other agencies or comparable foreign regulatory authorities may also slow the time necessary for the review and approval of applications for clinical trial or marketing authorization, which would adversely affect Crescent&#8217;s business. For example, in previous&#160;years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process Crescent&#8217;s regulatory submissions, which could have a material adverse effect on Crescent&#8217;s business. Further, future government shutdowns or changes or reductions in agency personnel could impact Crescent&#8217;s ability to access the public markets and obtain necessary capital in order to properly capitalize and continue Crescent&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a prolonged government shutdown occurs, if there is a significant change or reduction in agency personnel, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process Crescent&#8217;s regulatory submissions, which could have a material adverse effect on its business.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Crescent&#8217;s Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent does not currently own any issued patents or pending patent applications. Therefore, Crescent&#8217;s ability to obtain and protect its patent rights, and protect other proprietary rights, is uncertain, exposing Crescent to the possible loss of competitive advantage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s success depends in large part on its ability to obtain and maintain patent protection for its platform technologies, programs and their uses, as well as its ability to operate without infringing on or violating the proprietary rights of others. Crescent&#8217;s ability to protect its technologies from unauthorized making, using, selling, offering to sell or importing by third parties is dependent on the extent to which Crescent has rights under valid and enforceable patents that cover these activities. Crescent relies upon a combination of future patents, trademarks, trade secret protection, confidentiality agreements and the Paragon Option Agreements to protect the intellectual property related to its programs and technologies. Crescent does not currently own any patents, but it expects to license certain patent rights from Paragon and, in the future, prosecute underlying intellectual property for some or all of the in-licensed or owned product candidates that it develops. Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target PD-1 and VEGF, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including CR-001. In addition, Paragon intends to file one or more additional provisional patent applications directed to ADCs, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including CR-002 and CR-003. However, Crescent may not be able to protect its intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets, and other intellectual property. Filing, prosecuting and defending patents on programs worldwide would be expensive and Crescent&#8217;s intellectual property rights in some foreign jurisdictions can be less extensive than those in the United States; the reverse may also occur. As such, Crescent may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if it applies for them. Crescent&#8217;s competitors may operate in countries where Crescent does not have patent protection and can freely use Crescent&#8217;s technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where Crescent does have patent protection or pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s intellectual property portfolio is at an early stage. Crescent does not currently own any issued patents or pending patent applications. Crescent&#8217;s future optioned in-licensed or owned patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of Crescent&#8217;s programs or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or programs. Even if these patents are granted, they may be difficult to enforce. If Crescent does not obtain patent coverage for the work it is conducting, or if Crescent obtains such rights but they are invalidated or rendered unenforceable, it may be unable to exclude competitors from pursuing and marketing the same or similar product candidates. Other risks Crescent faces if it is not able to obtain and maintain patent coverage for its product candidates are the reduction in valuation of Crescent&#8217;s product candidates, and ultimately of Crescent as a company, by potential investors, and Crescent&#8217;s inability to assert claims for infringement against third parties or counterclaim against such third parties or negotiate more advantageous settlement parameters Further, any issued patents that Crescent may license or own covering Crescent&#8217;s programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the United States Patent and Trademark Office (&#8220;USPTO&#8221;). Further, if Crescent encounters delays in its clinical trials or delays in obtaining regulatory approval, the period of time during which Crescent could market its product candidates under patent protection would be reduced. Thus, the patents that Crescent may own and license may not afford Crescent any meaningful competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition to seeking patents for some of its technology and programs, Crescent may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain its competitive position. Any disclosure, either intentional or unintentional, by Crescent&#8217;s employees, the employees of third parties with whom Crescent shares its facilities or third-party consultants and vendors that Crescent engages to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of Crescent&#8217;s trade secrets or proprietary information could enable competitors to duplicate or surpass Crescent&#8217;s technological achievements, thus eroding Crescent&#8217;s competitive position in its market. In order to protect Crescent&#8217;s proprietary technology and processes, it relies in part on confidentiality agreements and, if applicable, material transfer agreements, consulting agreements, or other similar agreements prior to beginning research or disclosing proprietary information with parties, such as collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. Crescent also enters into confidentiality and invention or patent assignment agreements with its employees and consultants under which they are obligated to maintain confidentiality and to assign their inventions to Crescent. These agreements typically limit the rights of the third parties to use or disclose Crescent&#8217;s confidential information, including Crescent&#8217;s </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">trade secrets. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Crescent may need to share its proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition, while Crescent undertakes efforts to protect its trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, Crescent may not be able to assert any trade secret rights against such party. Enforcing a claim that a party disclosed or misappropriated Crescent&#8217;s trade secrets, or securing title to an employee- or consultant-developed invention if a dispute arises, is challenging and the outcome is unpredictable. In addition, courts outside of the United States may be less willing to protect trade secrets. Costly and time-consuming litigation could be necessary to enforce and determine the scope of Crescent&#8217;s proprietary rights and failure to obtain or maintain trade secret protection could adversely affect Crescent&#8217;s competitive business position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. In addition, these agreements typically restrict the ability of Crescent&#8217;s advisors, employees, third-party contractors and consultants to publish data potentially relating to Crescent&#8217;s trade secrets, although Crescent&#8217;s agreements may contain certain limited publication rights. Despite Crescent&#8217;s efforts to protect its trade secrets, competitors may discover Crescent&#8217;s trade secrets, either through breach of its agreements with third parties, independent development or publication of information by any of its third-party collaborators. A competitor&#8217;s discovery of Crescent&#8217;s trade secrets would impair its competitive position and have an adverse impact on its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lastly, if Crescent&#8217;s trademarks and trade names are not registered or adequately protected, then Crescent may not be able to build name recognition in its markets of interest and its business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Crescent is unable to obtain or maintain necessary rights to its programs through acquisitions and in-licenses, its business may be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because Crescent&#8217;s development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of Crescent&#8217;s business may depend in part on its ability to acquire, in-license, or use these third-party proprietary rights. Crescent may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that it identifies as necessary for its programs. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that Crescent may consider attractive or necessary. These established companies may have a competitive advantage over Crescent due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Crescent to be a competitor may be unwilling to assign or license rights to Crescent. Crescent also may be unable to license or acquire third-party intellectual property rights on commercially reasonable terms or at all. If Crescent is unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights it does obtain, Crescent&#8217;s ability to commercialize any of its targeted therapeutics, if approved, would likely be delayed, or Crescent may have to abandon development of the relevant program, which could have a material adverse effect on its business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While Crescent plans to obtain the right to control prosecution, defense, maintenance and enforcement of the patents relating to its programs, there may be times when the filing and prosecution activities for patents and patent applications relating to Crescent&#8217;s programs are controlled by future licensors or collaboration partners. For example, Paragon currently has the right to file patent applications and control prosecution with respect to any inventions that may fall within the Paragon Option Agreements, including those that may apply to CR-001, CR-002 and, when the expected option agreement is entered into, CR-003. If Crescent, Paragon or any of Crescent&#8217;s future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of Crescent&#8217;s business, including by payment of all applicable fees for patents covering its product candidates, Crescent could lose its rights to the intellectual property or its exclusivity with respect to those rights, its ability to develop and commercialize those product candidates may be adversely affected and it may not be able to prevent competitors from making, using and selling competing products. In addition, even where Crescent is granted the right to control patent prosecution of patents and patent applications it has licensed to and from third parties, Crescent may still be adversely affected or prejudiced by actions or inactions of its licensees, its future licensors and their counsel that took place prior to the date upon which Crescent assumed control over patent prosecution. For example, because Crescent has not yet entered into a license agreement for CR-001, CR-002 or CR-003, Paragon is currently responsible for the prosecution, defense, maintenance and enforcement of patents related to such programs. Subsequent to entering into a license agreement with Paragon for each such program, Crescent expects to control patent prosecution over such program following the trigger for transfer of prosecution control to Crescent.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s future licensors may rely on third-party consultants or collaborators or on funds from third parties such that Crescent&#8217;s future licensors are not the sole and exclusive owners of the patents Crescent in-licenses. If other third parties have ownership rights to Crescent&#8217;s future in-licensed patents, they may be able to license such patents to Crescent&#8217;s competitors, and Crescent&#8217;s competitors could market competing products and technology. This could have a material adverse effect on Crescent&#8217;s competitive position, business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is possible that Crescent may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if Crescent is able to obtain a license, it may be non-exclusive, including with respect to the use, field or territory of the licensed intellectual property, thereby giving Crescent&#8217;s competitors access to the same technologies licensed to Crescent. In that event, Crescent may be required to expend significant time and resources to redesign its technology, programs, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If Crescent is unable to do so, it may be unable to develop or commercialize the affected product candidates, which could harm its business, financial condition, results of operations, and prospects significantly. Crescent cannot provide any assurances that third-party patents do not exist which might be enforced against Crescent&#8217;s current technology, manufacturing methods, programs, or future methods or products resulting in either an injunction prohibiting Crescent&#8217;s manufacture or future sales, or, with respect to its future sales, an obligation on Crescent&#8217;s part to pay royalties and/or other forms of compensation to third parties, which could be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Disputes may arise between Crescent and its future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation-related issues; whether and the extent to which Crescent&#8217;s technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; Crescent&#8217;s right to sublicense patents and other rights to third parties; Crescent&#8217;s right to transfer or assign the license; the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by Crescent&#8217;s future licensors and it and its partners; and the priority of invention of patented technology. If Crescent or its future licensors breach the terms of its license agreements, such breach may have a material adverse effect on Crescent&#8217;s business and the commercialization efforts for Crescent&#8217;s programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent may be subject to patent infringement claims or may need to file claims to protect its intellectual property, which could result in substantial costs and liability and prevent Crescent from commercializing its potential products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess Crescent&#8217;s freedom to operate and guarantee that Crescent can operate without infringing on or violating third-party rights. If certain of Crescent&#8217;s product candidates are ultimately granted regulatory approval, patent rights held by third parties, if found to be valid and enforceable, could be alleged to render one or more of Crescent&#8217;s product candidates infringing. If a third party successfully brings a claim against Crescent, Crescent may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret misappropriation) brought against Crescent, whether or not successful, may cause Crescent to incur significant legal expenses and divert the attention of its management and key personnel from other business concerns. Crescent cannot be certain that future patents, if filed and issued, owned or licensed by it will not be challenged by others, whether in the course of litigation or in agencies like the USPTO. Some of Crescent&#8217;s competitors may be able to sustain the costs of complex intellectual property litigation more effectively than Crescent can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on Crescent&#8217;s ability to raise funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe or otherwise violate Crescent&#8217;s future patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, Crescent may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties to assert counterclaims against Crescent, including claims alleging that Crescent infringes their patents or other intellectual property rights and/or that Crescent&#8217;s patents are invalid and/or unenforceable. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents Crescent asserts is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that Crescent&#8217;s patents do not cover the technology. Similarly, if Crescent asserts trademark infringement claims, a court or administrative body may determine that the marks Crescent has asserted are invalid or unenforceable or that the party against whom Crescent has asserted trademark infringement has superior rights to the marks in question. In such a case, Crescent could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if Crescent is successful, any award of monetary damages or other remedy Crescent receives may not be commercially valuable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Further, Crescent may be required to protect its future patents, if filed and issued, through procedures created to challenge the validity of a patent before administrative bodies in the United States such as the USPTO or abroad. Such mechanisms include re-</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">examination, post grant review and equivalent proceedings in foreign jurisdictions, <i style="font-style:italic;">e.g.</i>, opposition proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, Crescent&#8217;s patent rights, which could adversely affect Crescent&#8217;s competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if Crescent&#8217;s programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against Crescent&#8217;s future licensees and other parties with whom Crescent has business relationships and Crescent may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require Crescent to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, Crescent may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to Crescent&#8217;s intellectual property rights, there is a risk that some of Crescent&#8217;s confidential information could be compromised by disclosure during this type of litigation or other proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent may be subject to claims that it has wrongfully hired an employee from a competitor or that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As is common in the biotechnology industry, in addition to Crescent&#8217;s employees, Crescent engages the services of consultants to assist it in the development of its programs. Many of these consultants, and many of Crescent&#8217;s employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including Crescent&#8217;s competitors or potential competitors. Crescent could in the future be subject to claims that it or its employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although Crescent tries to ensure that its employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for Crescent, Crescent may become subject to claims that it caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that Crescent or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While Crescent may litigate to defend itself against these claims, even if it is successful, litigation could result in substantial costs and could be a distraction to management. If Crescent&#8217;s defenses to these claims fail, in addition to requiring it to pay monetary damages, a court could prohibit Crescent from using technologies or features that are essential to its programs, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect Crescent&#8217;s reputation, its ability to form strategic alliances or sublicense its rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on Crescent&#8217;s business, results of operations and financial condition. Even if Crescent is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing Crescent&#8217;s ability to protect its products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Although Crescent does not currently own or in-license any patents or applications, if it obtains such patents and applications in the future, changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith Act could increase the uncertainties and costs surrounding the prosecution of Crescent&#8217;s owned and in-licensed patent applications, if any, and the maintenance, enforcement or defense of its owned and in-licensed issued patents, if any. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Assuming that other requirements for patentability are met, prior to March&#160;2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March&#160;2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of Crescent&#8217;s patent applications, if any, and the enforcement or defense of its issued patents, if any, all of which could have a material adverse effect on Crescent&#8217;s business, financial condition, results of operations and prospects. Additionally, the USPTO and patent offices in other jurisdictions have often required that patent applications directed to pharmaceutical and/or biotechnology-related inventions be limited or narrowed substantially to cover only the specific innovations exemplified in the patent application, thereby limiting the scope of protection against competitive challenges. Accordingly, even if Crescent or its licensors are able to obtain patents, the patents might be substantially narrower than anticipated. Thus, there is no assurance as to the degree and range of protections any of Crescent&#8217;s patents, if issued, may afford Crescent or whether patents will be issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S. Supreme Court and U.S. Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United States Supreme Court in <i style="font-style:italic;">Amgen,&#160;Inc. v. Sanofi</i> (<i style="font-style:italic;">Amgen</i>) recently held that Amgen&#8217;s patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement where the patent specification provided twenty-six exemplary antibodies, but the claimed class of antibodies covered a &#8220;vast number&#8221; of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that Crescent will be granted U.S. patents with composition of matter claims directed to antibodies functionally defined by their ability to bind a particular antigen. Even if Crescent is granted claims directed to functionally defined antibodies, it is possible that a third party may challenge Crescent&#8217;s patents, when issued, relying on the reasoning in <i style="font-style:italic;">Amgen</i> or other recent precedential court decisions. Additionally, there have been proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact Crescent&#8217;s ability to enforce its proprietary technology. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on Crescent&#8217;s patent rights and its ability to protect, defend and enforce its patent rights in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Geopolitical instability in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United States and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on Crescent&#8217;s business. In addition, a decree was adopted by the Russian government in March&#160;2022 allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, Crescent would not be able to prevent third parties from practicing its inventions in Russia or from selling or importing products made using its inventions in and into Russia. Accordingly, Crescent&#8217;s competitive position may be impaired, and its business, financial condition, results of operations and prospects may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, a European Unified Patent Court (&#8220;UPC&#8221;) entered into force on June&#160;1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for EU Member States. The broad geographic reach of the UPC could enable third parties to seek revocation of any of Crescent&#8217;s future European patents in a single proceeding at the UPC rather than through multiple proceedings in each of the individual European Union member states in which the European patent is validated. Under the UPC, a successful revocation proceeding for a European Patent under the UPC would result in loss of patent protection in those European Union countries. Accordingly, a single proceeding under the UPC could result in the partial or complete loss of patent protection in numerous European Union countries. Such a loss of patent protection could have a material adverse impact on Crescent&#8217;s business and its ability to commercialize its technology and product candidates and, resultantly, on its business, financial condition, prospects and results of operations. Moreover, the controlling laws and regulations of the UPC will develop over time and Crescent cannot predict what the outcomes of cases tried before the UPC will be. The case law of the UPC may adversely affect Crescent&#8217;s ability to enforce or defend the validity of its European patents. Patent owners have the option to opt-out their European patents from the jurisdiction of the UPC, defaulting to pre-UPC enforcement mechanisms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Although Crescent does not currently own any European patents or applications, if it obtains such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on Crescent&#8217;s business and its ability to </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">commercialize or license its technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect Crescent&#8217;s ability to enforce or defend the validity of any European patents it may obtain. Crescent may decide to opt out from the UPC any future European patent applications that it may file and any patents it may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. Crescent cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if Crescent decides to opt out of the UPC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and Crescent&#8217;s patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If Crescent fails to maintain any future patents and patent applications, if filed and issued, covering its programs, Crescent&#8217;s competitive position would be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect Crescent&#8217;s ability to develop and market its products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent cannot guarantee that any of its patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can Crescent be certain that it has identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of its product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent, the patent&#8217;s prosecution history and in some cases certain extrinsic evidence of the meaning of terms in a claim. Crescent&#8217;s interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, Crescent may incorrectly determine that its products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Crescent&#8217;s determination of the expiration date of any patent in the United States or abroad that it considers relevant may be incorrect. Crescent&#8217;s failure to identify and correctly interpret relevant patents may negatively impact its ability to develop and market its products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18&#160;months after filing, and publications in the scientific literature often lag behind actual discoveries, Crescent cannot be certain that others have not filed patent applications for technology covered by Crescent&#8217;s future issued patents or its pending applications, if filed, or that Crescent was the first to invent the technology. Crescent&#8217;s competitors may have filed, and may in the future file, patent applications covering products or technology similar to Crescent&#8217;s. Any such patent application may have priority over Crescent&#8217;s future patent applications or patents, if filed and issued, which could require Crescent to obtain rights to issued patents covering such technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent may become subject to claims challenging the inventorship or ownership of its patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Crescent may be subject to claims that former employees, collaborators or other third parties have an interest in Crescent&#8217;s future patents, if filed and issued, or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being invalid or unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing Crescent&#8217;s programs or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. While Crescent typically requires employees, consultants and contractors who may develop intellectual property on its behalf to execute agreements assigning such intellectual property to Crescent, Crescent may be unsuccessful in obtaining execution of assignment agreements with each party who in fact develops intellectual property that Crescent regards as its own. Moreover, even when Crescent obtains agreements assigning </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">intellectual property to it, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached. In either case, Crescent may be forced to bring claims against third parties, or defend claims that they may bring against Crescent, to determine the ownership of what Crescent regards as its intellectual property. If Crescent fails in defending any such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on Crescent&#8217;s business. Even if Crescent is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect the competitive position of Crescent&#8217;s product candidates for an adequate amount of time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest United States non-provisional filing date or international Patent Cooperation Treaty Filing. The patent term of a U.S. patent may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier-filed patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering Crescent&#8217;s product candidates are obtained, once the patent life has expired, Crescent may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, Crescent&#8217;s owned and licensed patent portfolio may not provide it with sufficient rights to exclude others from commercializing products similar or identical to Crescent&#8217;s.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a Patent Term Extension (&#8220;PTE&#8221;) of up to five&#160;years beyond the normal expiration of the patent to compensate patent owners for loss of an enforceable patent term due to the lengthy regulatory approval process. A PTE grant cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of the product approval. Further, PTE may only be applied once per product, and only with respect to an approved indication&#8201;-&#8201;in other words, only one patent (for example, covering the product itself, an approved use of said product, or a method of manufacturing said product) can be extended by PTE. Crescent anticipates applying for PTE in the United States. Similar extensions may be available in other countries where anticipates is prosecuting patents, and Crescent likewise anticipates applying for such extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The granting of a PTE is not guaranteed and is subject to numerous requirements. Crescent might not be granted an extension because of, for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant patents or otherwise failure to satisfy any of the numerous applicable requirements. In addition, to the extent Crescent wishes to pursue a PTE based on a patent that it in-licenses from a third party, Crescent would need the cooperation of that third party. Moreover, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with Crescent&#8217;s assessment of whether such extensions are available, and may refuse to grant extensions to Crescent&#8217;s patents, or may grant more limited extensions than Crescent requests. If this occurs, Crescent&#8217;s competitors may be able to obtain approval of competing products following its patent expiration by referencing Crescent&#8217;s clinical and preclinical data and launch their product earlier than might otherwise be the case. If this were to occur, it could have a material adverse effect on Crescent&#8217;s ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent&#8217;s technology licensed from various third parties in the future, including Paragon, may be subject to retained rights.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s future licensors may retain certain rights under the relevant agreements with Crescent, including the right to use or license the licensed technology outside of the scope of Crescent&#8217;s license, use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether Crescent&#8217;s licensors limit their use of the technology to these uses, and Crescent could incur substantial expenses to enforce its rights to its licensed technology in the event of misuse. In addition, while there are certain restrictions on Paragon&#8217;s ability to develop products that could be competitive with Crescent&#8217;s, these restrictions may not prevent the possible future license or development by Paragon of certain technology that could lead to product candidates competitive with Crescent&#8217;s. This could have a material adverse effect on Crescent&#8217;s competitive position, business, financial condition, results of operations, and prospects.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Crescent&#8217;s Reliance on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent expects to rely on licensing arrangements with Paragon through the Paragon Option Agreements. If Crescent is unable to maintain collaborations or licensing arrangements, or if its collaborations or licensing arrangements are not successful, Crescent&#8217;s business could be negatively impacted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent expects to rely on its current and future licensing arrangements with Paragon, including through the Paragon Option Agreements, for a substantial portion of its discovery capabilities, including for CR-001, CR-002 and CR-003, and in-licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Collaborations or licensing arrangements that Crescent enters into may not be successful, including in connection with the Paragon Option Agreements and any potential agreement with Paragon for the development of CR-003, and any success will depend heavily on the efforts and activities of such collaborators or licensors. If any of Crescent&#8217;s current or future collaborators or licensors experiences delays in performance of, or fails to perform its obligations under their agreement with Crescent, disagrees with Crescent&#8217;s interpretation of the terms of such agreement or terminates their agreement with Crescent, Crescent&#8217;s programs could be adversely affected. If Crescent fails to comply with any of the obligations under its collaborations or license agreements, including payment terms and diligence terms, Crescent&#8217;s collaborators or licensors may have the right to terminate such agreements, in which event Crescent may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by its agreements or may face other penalties under its agreements. Crescent&#8217;s collaborators and licensors may also fail to properly maintain or defend the intellectual property Crescent has licensed from them, if required by Crescent&#8217;s agreement with them, or even infringe upon, Crescent&#8217;s intellectual property rights, leading to the potential invalidation of Crescent&#8217;s intellectual property or subjecting it to litigation or arbitration, any of which would be time-consuming and expensive and could harm Crescent&#8217;s ability to commercialize its product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with Crescent&#8217;s programs and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than Crescent&#8217;s.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of Crescent&#8217;s strategy, Crescent plans to evaluate additional opportunities to enhance its capabilities and expand its development pipeline or provide development or commercialization capabilities that complement Crescent&#8217;s. Crescent may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships may require Crescent to incur non-recurring and other charges, increase its near and long-term expenditures, issue securities that dilute its existing stockholders or disrupt its management and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that Crescent considers attractive. These companies may have a competitive advantage over Crescent due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Crescent to be a competitor may be unwilling to assign or license rights to Crescent. Whether Crescent reaches a definitive agreement for a collaboration, including with respect to CR-003, will depend upon, among other things, its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators. Crescent may not be able to negotiate additional collaborations, including with respect to CR-003, on a timely basis, on acceptable terms or at all. If Crescent fails to enter into collaborations, including with respect to CR-003, and does not have sufficient funds or expertise to undertake the necessary development and commercialization activities, it may not be able to further develop its product candidates or bring them to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent currently relies, and plans to rely in the future, on third parties to conduct and support its preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, Crescent may not be able to obtain regulatory approval of or commercialize its product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Crescent has utilized and plans to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs and strategic partners, to conduct and support its preclinical studies and clinical trials under agreements with Crescent. Crescent will rely heavily on these third parties over the course of its preclinical studies and clinical trials, and Crescent controls only certain aspects of their activities. As a result, Crescent will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if it were relying entirely upon its own staff. Nevertheless, Crescent is responsible for ensuring that each of its studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and its reliance on these third parties does not relieve Crescent of its regulatory responsibilities. Crescent and its third-party </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of Crescent&#8217;s programs in clinical development. If Crescent or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in Crescent&#8217;s clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require Crescent to perform additional clinical trials before approving Crescent&#8217;s marketing applications. Crescent cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of Crescent&#8217;s clinical trials comply with GCP regulations. In addition, Crescent&#8217;s clinical trials must be conducted with products produced under cGMP regulations. Crescent&#8217;s failure to comply with these regulations may require it to repeat clinical trials, which would delay the regulatory approval process. Moreover, Crescent&#8217;s business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any third parties conducting Crescent&#8217;s clinical trials will not be Crescent&#8217;s employees and, except for remedies available to Crescent under its agreements with such third parties, Crescent cannot control whether they devote sufficient time and resources to Crescent&#8217;s programs. These third parties may be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including Crescent&#8217;s competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect their performance on Crescent&#8217;s behalf and the timing thereof and could lead to products that compete directly or indirectly with Crescent&#8217;s product candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to Crescent&#8217;s clinical protocols or regulatory requirements or for other reasons, Crescent&#8217;s clinical trials may be extended, delayed or terminated and Crescent may not be able to complete development of, obtain regulatory approval of or successfully commercialize its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, Crescent currently relies on foreign CROs and CMOs, including WuXi Biologics (Hong Kong) Limited (&#8220;WuXi&#8221;) for formulation and manufacturing of Crescent&#8217;s stage 1 clinical trial materials, and will likely continue to rely on foreign CROs and CMOs in the future. WuXi is a subsidiary or affiliate of WuXi Biologics, which is identified in the proposed U.S. legislation known as the BIOSECURE Act as a biotechnology &#8220;company of concern.&#8221; The BIOSECURE Act, if passed, would prohibit federal agencies from entering into procurement contracts with an entity that uses biotechnology equipment or services from a biotechnology company of concern. Foreign CMOs may be subject to U.S. legislation, including the proposed BIOSECURE Act, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to Crescent, delay the procurement or supply of such material or have an adverse effect on Crescent&#8217;s ability to secure significant commitments from governments to purchase its potential therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For example, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on Crescent&#8217;s collaborators in China which could have an adverse effect on Crescent&#8217;s business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, such as the United States and the UK, could also negatively impact Crescent&#8217;s ability to manufacture its product candidates for its planned clinical trials or have an adverse effect on its ability to secure government funding, which could adversely affect Crescent&#8217;s financial condition and cause it to delay its clinical development programs. Furthermore, if the BIOSECURE Act is passed and one or more of Crescent&#8217;s collaborators or vendors in China, including WuXi, is deemed to be a biotechnology company of concern, Crescent&#8217;s operations and financial condition may be negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements affecting such collaborators. In addition, while Crescent has established relationships with CROs and CMOs outside of China, moving to those suppliers in the event of a geopolitical instability affecting Crescent&#8217;s collaborators in China could introduce delays into the development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent currently relies and expects to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture its product candidates, and Crescent may rely on third parties to produce and process its products, if approved. Crescent&#8217;s business could be adversely affected if it is unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Crescent does not currently own any facility that may be used as its clinical or commercial manufacturing and processing facility and must currently rely on CMOs to manufacture its product candidates. Crescent has not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any of its product candidates, if approved. Crescent currently has a sole source relationship for its supply of the CR-001, CR-002 programs and expects to have a sole source relationship for the supply of the CR-003 program. If there should be any disruption in such supply arrangement, including any adverse events affecting </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s sole supplier, it could have a negative effect on the clinical development of Crescent&#8217;s programs and other operations while Crescent works to identify and qualify an alternate supply source. Crescent may not control the manufacturing process of, and may be completely dependent on, its contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory authorities for the manufacture of its product candidates. Beyond periodic audits, Crescent has limited control over the ability of its CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of Crescent&#8217;s product candidates or if it withdraws any approval in the future, Crescent may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs, delays, and materially adversely affect Crescent&#8217;s ability to develop, obtain regulatory approval for or market its product candidates, if approved. Similarly, Crescent&#8217;s failure, or the failure of its CMOs, to comply with applicable regulations could result in sanctions being imposed on Crescent, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Crescent&#8217;s product candidates or drugs and harm Crescent&#8217;s business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, Crescent&#8217;s CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, or as a result of labor disputes or unstable political environments. If any CMOs on which Crescent will rely fail to manufacture quantities of Crescent&#8217;s product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows Crescent to achieve profitability, Crescent&#8217;s business, financial condition and prospects could be materially and adversely affected. In addition, Crescent&#8217;s CMOs are responsible for transporting temperature-controlled materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, Crescent&#8217;s integrity and purity specifications. Crescent and any of its CMOs may also face product seizure or detention or refusal to permit the import or export of products. Crescent&#8217;s business could be materially adversely affected by business disruptions to its third-party providers that could materially adversely affect its anticipated timelines, potential future revenue and financial condition and increase its costs and expenses. Each of these risks could delay or prevent the completion of Crescent&#8217;s preclinical studies and clinical trials or the approval of any of its product candidates by the FDA, result in higher costs or adversely impact commercialization of its product candidates. See the section titled &#8220;<i style="font-style:italic;">Crescent&#8217;s Business&#8212;Manufacturing</i>&#8221; for a more detailed description of Crescent&#8217;s manufacturing plans and assumptions and the factors that may affect the success of Crescent&#8217;s programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Crescent&#8217;s Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">In order to successfully implement Crescent&#8217;s plans and strategies, Crescent will need to grow the size of its organization and it may experience difficulties in managing this growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent expects to experience significant growth in the number of its employees and the scope of its operations, particularly in the areas of preclinical and clinical drug development, technical operations, clinical operations, regulatory affairs and, potentially, sales and marketing. To manage Crescent&#8217;s anticipated future growth, Crescent must continue to implement and improve its managerial, operational and financial personnel and systems, expand its facilities and continue to recruit and train additional qualified personnel. Due to Crescent&#8217;s limited financial resources and the limited experience of its management team working together in managing a company with such anticipated growth, Crescent may not be able to effectively manage the expansion of its operations or recruit and train additional qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent is highly dependent on its key personnel and anticipates hiring new key personnel. If Crescent is not successful in attracting and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is a preclinical stage biotechnology company with a limited operating history, and, as of February&#160;7, 2025, it had six full-time employees. Crescent has been and will continue to be highly dependent on the research and development, clinical and business development expertise of its executive officers, as well as the other principal members of its management, scientific and clinical team. Any of Crescent&#8217;s management team members may terminate their employment with Crescent at any time. Crescent does not maintain &#8220;key person&#8221; insurance for any of its executives or other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Attracting and retaining qualified personnel will also be critical to Crescent&#8217;s success, including with respect to any strategic transaction that it may pursue. The loss of the services of Crescent&#8217;s executive officers or other key employees could impede the achievement of its research, development and commercialization objectives and seriously harm its ability to successfully implement its business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in Crescent&#8217;s industry with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and commercialize product candidates. Competition to hire from this limited </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">pool is intense, and Crescent may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. Crescent also experiences competition for the hiring of scientific and clinical personnel from universities and research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, Crescent relies on consultants and advisors, including scientific and clinical advisors, to assist it in formulating its discovery and nonclinical and clinical development and commercialization strategy. Crescent&#8217;s consultants and advisors may be employed by employers other than Crescent and may have commitments under consulting or advisory contracts with other entities that may limit their availability to Crescent. If Crescent is unable to continue to attract and retain high quality personnel, its ability to pursue its growth strategy will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent&#8217;s future growth may depend, in part, on its ability to operate in foreign markets, where it would be subject to additional regulatory burdens and other risks and uncertainties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s future growth may depend, in part, on its ability to develop and commercialize its product candidates in foreign markets for which it may rely on collaboration with third parties. Crescent is not permitted to market or promote any of its product candidates before it receives regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any of its product candidates. To obtain separate regulatory approval in many other countries, Crescent must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of its product candidates, and Crescent cannot predict success in these jurisdictions. If Crescent fails to comply with the regulatory requirements in international markets and receive applicable regulatory and marketing approvals, its target market will be reduced and its ability to realize the full market potential of its product candidates will be harmed and its business will be adversely affected. Moreover, even if Crescent obtains approval of its product candidates and ultimately commercializes its product candidates in foreign markets, Crescent would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent&#8217;s estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which Crescent competes achieve the forecasted growth, its business may not grow at similar rates, or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Crescent&#8217;s estimates and forecasts relating to size and expected growth of its target market may prove to be inaccurate. Even if the markets in which Crescent competes meet Crescent&#8217;s size estimates and growth forecasts, Crescent&#8217;s business may not grow at similar rates, or at all. Crescent&#8217;s growth is subject to many factors, including its success in implementing its business strategy, which is subject to many risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s revenue will be dependent, in part, upon the size of the markets in the territories for which it gains regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether Crescent owns the commercial rights for that territory. If the number of Crescent&#8217;s addressable patients is not as significant as it estimates, the indication approved by regulatory authorities is narrower than it expects or the treatment population is narrowed by competition, physician choice or treatment guidelines, Crescent may not generate significant revenue from sales of such products, even if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent&#8217;s employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is exposed to the risk that its employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on its behalf may engage in misconduct or other improper activities. Crescent will adopt a code of conduct, which will become effective as of the Closing, but it is not always possible to identify and deter misconduct by these parties and the precautions Crescent takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Crescent from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent&#8217;s internal information technology systems, or those of any of its CROs, manufacturers, other contractors or consultants, third-party service providers, or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of Crescent&#8217;s proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to Crescent&#8217;s brand and material disruption of its operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of its business, Crescent and the third parties upon which it relies collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, sensitive information).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite the implementation of security measures in an effort to protect systems that store Crescent&#8217;s information, given their size and complexity and the increasing amounts of information maintained on Crescent&#8217;s internal information technology systems and those of its third-party CROs, other contractors (including sites performing Crescent&#8217;s clinical trials), third-party service providers and supply chain companies, and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by Crescent&#8217;s employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties, which may compromise Crescent&#8217;s system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, Crescent&#8217;s data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, Crescent, and the third parties upon which it relies, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt Crescent&#8217;s systems and operations, supply chain, and ability to produce, sell and distribute its goods and services. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in Crescent&#8217;s operations, ability to provide its products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but Crescent may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, Crescent&#8217;s data or applications, or for it to be believed or reported that any of these occurred, Crescent could incur liability and reputational damage and the development and commercialization of its product candidates could be delayed. Further, Crescent&#8217;s insurance policies may not be adequate to compensate it for the potential losses arising from any such disruption in, or failure or security breach of, its systems or third-party systems where information important to Crescent&#8217;s business operations or commercial development is stored.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s fully-remote workforce may create additional risks for its information technology systems and data because its employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business transactions (such as acquisitions or integrations) could expose Crescent to additional cybersecurity risks and vulnerabilities, as its systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While Crescent has implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Crescent may be unable in the future to detect vulnerabilities in its information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, Crescent may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require Crescent to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Crescent relies on third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts. Crescent&#8217;s ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If Crescent&#8217;s third-party service providers experience a security incident or other interruption, Crescent could experience adverse consequences. While Crescent may be entitled to damages if its third-party service providers fail to satisfy their privacy or security-related obligations to it, any award may be insufficient to cover Crescent&#8217;s damages, or Crescent may be unable to recover such award. In addition, supply-chain attacks have </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">increased in frequency and severity, and Crescent cannot guarantee that third parties&#8217; infrastructure in its supply chain or its third-party partners&#8217; supply chains have not been compromised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Crescent (or a third party upon whom it relies) experiences a security incident or are perceived to have experienced a security incident, Crescent may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in Crescent&#8217;s operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting Crescent&#8217;s platform, deter new customers from products, and negatively impact Crescent&#8217;s ability to grow and operate its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in Crescent&#8217;s contracts are sufficient to protect Crescent from liabilities, damages, or claims related to its data privacy and security obligations. Crescent cannot be sure that its insurance coverage will be adequate or sufficient to protect it from or to mitigate liabilities arising out of its privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent is subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect Crescent&#8217;s operating results and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent and third parties who it works with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. Crescent is or may become subject to the terms of contractual obligations related to privacy, data protection and data security. Crescent&#8217;s obligations may also change or expand as its business grows. The actual or perceived failure by Crescent or third parties related to Crescent to comply with such laws, regulations and obligations could increase Crescent&#8217;s compliance and operational costs, expose it to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on its business, financial condition, and results of operations. See the section titled &#8220;<i style="font-style:italic;">Crescent&#8217;s Business</i><span style="font-style:italic;font-weight:bold;">&#8212;</span><i style="font-style:italic;">Government Regulation</i><span style="font-style:italic;font-weight:bold;">&#8212;</span><i style="font-style:italic;">Data Privacy and Security</i>&#8221; for a more detailed description of the laws that may affect Crescent&#8217;s ability to operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Crescent fails to comply with environmental, health and safety laws and regulations, it could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of its business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Crescent&#8217;s operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, Crescent may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair Crescent&#8217;s research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent may be subject to adverse legislative or regulatory tax changes that could negatively impact its financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The rules&#160;dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which may have retroactive application) could adversely affect Crescent&#8217;s stockholders or Crescent. Crescent assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where it has operations to determine the potential effect on its business and any assumptions it has made about its future taxable income. Crescent cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. For example, the United States enacted the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;), which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and Jobs Act eliminated the previously available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five&#160;years for research activities conducted in the United States and over 15&#160;years for research activities conducted outside the United States. The U.S. Congress is considering legislation that would restore the current deductibility of research and development </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">expenditures; however, Crescent has no assurance that the provision will be repealed or otherwise modified. Such changes, among others, may adversely affect Crescent&#8217;s effective tax rate, results of operation and general business condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that it believes will complement or augment its existing business. If Crescent acquires businesses with promising markets or technologies, it may not be able to realize the benefit of acquiring such businesses if it is unable to successfully integrate them with its existing operations and company culture. Crescent may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition that delay or prevent it from realizing their expected benefits or enhancing Crescent&#8217;s business. There is no assurance that, following any such acquisition, Crescent will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on Crescent&#8217;s business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent maintains its cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect Crescent&#8217;s ability to pay its operational expenses or make other payments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s cash held in non-interest-bearing and interest-bearing accounts exceeds the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were to fail, Crescent could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank on March&#160;10, 2023. The Federal Reserve subsequently announced that account holders would be made whole. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that Crescent may experience in the future or inability for a material time period to access its cash and cash equivalents could have an adverse effect on its ability to pay its operational expenses or make other payments, which could adversely affect its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent&#8217;s estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which Crescent competes achieve the forecasted growth, its business may not grow at similar rates, or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Crescent&#8217;s estimates and forecasts relating to size and expected growth of its target market may prove to be inaccurate. Even if the markets in which Crescent competes meet its size estimates and growth forecasts, Crescent&#8217;s business may not grow at similar rates, or at all. Crescent&#8217;s growth is subject to many factors, including its success in implementing its business strategy, which is subject to many risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s revenue will be dependent, in part, upon the size of the markets in the territories for which Crescent gains regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether Crescent owns the commercial rights for that territory. If the number of its addressable patients is not as significant as Crescent estimates, the indication approved by regulatory authorities is narrower than Crescent expects or the treatment population is narrowed by competition, physician choice or treatment guidelines, Crescent may not generate significant revenue from sales of such products, even if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial stage, and its product liability insurance may not cover all damages from such claims.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Crescent is exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. While Crescent currently has no products that have been approved for commercial sale, the future use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose Crescent to liability claims. These claims may be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such product. Any claims against Crescent, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the market for Crescent&#8217;s products or any prospects for commercialization of its products. Although Crescent intends to obtain product liability insurance for its future clinical trials, it is possible that any liabilities could exceed Crescent&#8217;s insurance coverage or that in the future Crescent may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">liability claim or series of claims is brought against Crescent for uninsured liabilities or in excess of insured liabilities, Crescent&#8217;s assets may not be sufficient to cover such claims and its business operations could be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Litigation costs and the outcome of litigation could have a material adverse effect on Crescent&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time Crescent may be subject to litigation claims through the ordinary course of its business operations regarding, but not limited to, employment matters, security of patient and employee personal information, contractual relations with collaborators and intellectual property rights. Litigation to defend itself against claims by third parties, or to enforce any rights that Crescent may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of its resources, causing a material adverse effect on its business, financial condition, results of operations or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent&#8217;s business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on its results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates, and uncertainty about economic stability. Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), tighter credit, fluctuating interest rates, volatility in financial markets, high unemployment, labor availability constraints, currency fluctuations and other challenges in the global economy have in the past adversely affected, and may in the future adversely affect, Crescent and Crescent&#8217;s business partners and suppliers. The Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. For example, trade policies and geopolitical disputes (including as a result of China-Taiwan relations) and other international conflicts can result in tariffs, sanctions and other measures that restrict international trade, and can materially adversely affect Crescent&#8217;s business, particularly if these measures occur in regions where Crescent sources its components or raw materials. In addition, tensions between the United States and China have led to a series of tariffs being imposed by the United States on imports from China mainland, as well as other business restrictions. Tariffs increase the costs of the components and raw materials Crescent sources. Countries may also adopt other measures, such as controls on imports or exports of goods, technology or data, that could adversely impact Crescent&#8217;s operations and supply chain. Any such volatility and disruptions may adversely affect Crescent&#8217;s business or the third parties on whom Crescent relies. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect Crescent by increasing its costs, including labor and employee benefit costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on Crescent&#8217;s results of operations and financial condition.</p><a id="RisksRelatedtotheCombinedCompany_572546"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Combined Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If any of the events described in &#8220;Risks Related to GlycoMimetics&#8221; or &#8220;Risks Related to Crescent&#8221; occur, those events could cause potential benefits of the Merger not to be realized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following completion of the Merger, the Combined Company will be susceptible to many of the risks described in the sections herein entitled &#8220;<i style="font-style:italic;">Risks Related to GlycoMimetics</i>&#8221; and &#8220;<i style="font-style:italic;">Risks Related to Crescent</i>.&#8221; To the extent any of the events in the risks described in those sections occur, the potential benefits of the Merger may not be realized and the results of operations and financial condition of the Combined Company could be adversely affected in a material way. This could cause the market price of the Combined Company common stock to decline.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price of the Combined Company common stock is expected to be volatile, and the market price of the common stock may drop following the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The market price of the Combined Company common stock following the Merger could be subject to significant fluctuations. Some of the factors that may cause the market price of the Combined Company common stock to fluctuate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical trials and preclinical studies of the Combined Company&#8217;s product candidates, or those of the Combined Company&#8217;s competitors or the Combined Company&#8217;s existing or future collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed financial and development projections the Combined Company may provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed the financial and development projections of the investment community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if the Combined Company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the Combined Company or its competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actions taken by regulatory agencies with respect to the Combined Company&#8217;s product candidates, clinical studies, manufacturing process or sales and marketing terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and the Combined Company&#8217;s ability to obtain patent protection for its technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or stockholder litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if securities or industry analysts do not publish research or reports about the Combined Company&#8217;s business, or if they issue adverse or misleading opinions regarding its business and stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of securities by the Combined Company or its securityholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if the Combined Company fails to raise an adequate amount of capital to fund its operations or continued development of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of the Combined Company common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction of technological innovations or new therapies that compete with the products and services of the Combined Company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">period-to-period fluctuations in the Combined Company&#8217;s financial results.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the Combined Company common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect the Combined Company&#8217;s business and the value of its common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if the Combined Company experiences a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the Combined Company&#8217;s strategic direction or seek changes in the composition of its board of directors could have an adverse effect on its operating results, financial condition and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company may incur losses for the foreseeable future and may never achieve profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company may never become profitable, even if it is able to complete clinical development for one or more product candidates and eventually commercialize such product candidates. The Combined Company will need to successfully complete significant research, development, testing and regulatory compliance activities that, together with projected general and administrative expenses, is expected to result in substantial increased operating losses for at least the next several&#160;years. Even if the Combined Company does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Combined Company fails to attract and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its product candidates or otherwise implement its business plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company&#8217;s ability to compete in the highly competitive pharmaceuticals industry depends on its ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. The Combined Company will be highly dependent on its management and scientific personnel. The loss of the services of any of these individuals could impede, delay, or prevent the successful development of the Combined Company&#8217;s product pipeline, completion of its planned clinical trials, commercialization of its product candidates or in-licensing or acquisition of new assets and could impact negatively its ability to implement successfully its business plan. If the Combined Company loses the services of any of these individuals, it might not be able to find suitable replacements on a timely basis or at all, and its business could be harmed as a result. The Combined Company might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company will require substantial additional funds to conduct the costly and time-consuming clinical efficacy trials necessary to pursue regulatory approval of each potential product candidate and to continue the development of CR-001, CR-002, CR-003 and Crescent&#8217;s future programs and future product candidates. The Combined Company&#8217;s future capital requirements will depend upon a number of factors, including: the number and timing of future product candidates in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance. Raising additional capital may be costly or difficult to obtain and could, for example, through the sale of common stock or securities convertible or exchangeable into common stock, significantly dilute the Combined Company stockholders&#8217; ownership interests or inhibit the Combined Company&#8217;s ability to achieve its business objectives. If the Combined Company raises additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely the rights of its common stockholders. In addition, any debt financing may subject the Combined Company to fixed payment obligations and covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the Combined Company raises additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, the Combined Company may have to relinquish certain valuable intellectual property or other rights to its product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to it. Even if the Combined Company were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to the Combined Company or its stockholders.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company will incur significant legal, accounting and other expenses as a public company that Crescent did not incur as a private company, including costs associated with public company reporting obligations under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The Combined Company&#8217;s management team will consist of the executive officers of Crescent prior to the Merger. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that the Combined Company complies with all of these requirements. Any changes the Combined Company makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules&#160;and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for the Combined Company to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Upon completion of the Merger, failure by the Combined Company to comply with the initial listing standards of Nasdaq will prevent its stock from being listed on Nasdaq.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon completion of the Merger, GlycoMimetics, under the new name &#8220;Crescent Biopharma,&#160;Inc.,&#8221; will be required to meet the initial listing requirements to maintain the listing and continued trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements. Pursuant to the Merger Agreement, GlycoMimetics agreed to use its commercially reasonable efforts to cause the shares of GlycoMimetics common stock being issued in the Merger (including any common stock issuable upon conversion of the GlycoMimetics Series&#160;A Preferred Stock) to be approved for listing on Nasdaq at or prior to the effective time of the Merger. Based on information currently available to GlycoMimetics, GlycoMimetics anticipates that its stock will be unable to meet the $4.00 minimum bid price initial listing requirement at the closing of the Merger unless it effects a reverse stock split. The GlycoMimetics Board intends to effect a reverse stock split of the shares of GlycoMimetics common stock at a ratio of between to . In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split. Following the Merger, if the Combined Company is unable to satisfy Nasdaq listing requirements, Nasdaq may notify the Combined Company that its shares of common stock will not be listed on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon a potential delisting from Nasdaq, if the Combined Company common stock is not then eligible for quotation on another market or exchange, trading of the shares could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of the Combined Company common stock; decreases in institutional and other investor demand for the shares, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker dealers willing to execute trades in the Combined Company common stock. Also, it may be difficult for the Combined Company to raise additional capital if the Combined Company common stock is not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of the Combined Company common stock and could have a material adverse effect on the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Once the Combined Company is no longer a smaller reporting company or otherwise no longer qualifies for applicable exemptions, the Combined Company will be subject to additional laws and regulations affecting public companies that will increase the Combined Company&#8217;s costs and the demands on management and could harm the Combined Company&#8217;s operating results and cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Combined Company will be subject to the reporting requirements of the Exchange Act, which requires, among other things, that the Combined Company file with the SEC, annual, quarterly and current reports with respect to the Combined Company&#8217;s business and financial condition as well as other disclosure and corporate governance requirements. However, as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule&#160;12b-2 under the Exchange Act, in at least the near term, the Combined Company may take advantage of exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this proxy statement/prospectus and in the Combined Company&#8217;s periodic reports and proxy statements. Once the Combined Company is no longer a smaller reporting company or otherwise no longer qualifies for these exemptions, the Combined Company will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If the Combined Company is not able to comply with the requirements in a timely manner or at all, the Combined Company&#8217;s financial condition or the market price of the Combined Company common stock may be harmed. </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For example, if the Combined Company or its independent auditor identifies deficiencies in the Combined Company&#8217;s internal control over financial reporting that are deemed to be material weaknesses the Combined Company could face additional costs to remedy those deficiencies, the market price of the Combined Company stock could decline or the Combined Company could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the Combined Company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provided the Combined Company continues to be listed on Nasdaq, the Combined Company will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules&#160;and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that the Combined Company maintain effective disclosure controls and procedures and internal control over financial reporting. The Combined Company must perform system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal controls over financial reporting in its Annual Report on Form&#160;10-K filing for that&#160;year, as required by Section&#160;404 of the Sarbanes-Oxley Act. As a private company, Crescent has not been required to document and test its internal controls over financial reporting nor has its management been required to certify the effectiveness of its internal controls and its auditors have not been required to opine on the effectiveness of its internal control over financial reporting. Following the Merger, the Combined Company will be required to incur substantial professional fees and internal costs to expand its accounting and finance functions and expend significant management efforts. The Combined Company may experience difficulty in meeting these reporting requirements in a timely manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company may discover weaknesses in its system of internal control over financial reporting that could result in a material misstatement of its financial statements. The Combined Company&#8217;s internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Combined Company is not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act, or if it is unable to maintain proper and effective internal controls, the Combined Company may not be able to produce timely and accurate financial statements. If that were to happen, the market price of its common stock could decline and it could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The unaudited pro forma condensed combined financial information for GlycoMimetics and Crescent included in this proxy statement/prospectus are preliminary, and the Combined Company&#8217;s actual financial position and operations after the Merger may differ materially from the unaudited pro forma financial information included in this proxy statement/prospectus.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma financial information for GlycoMimetics and Crescent included in this proxy statement/prospectus are presented for illustrative purposes only and is not necessarily indicative of the Combined Company&#8217;s actual financial condition or results of operations of future periods, or the financial condition or results of operations that would have been realized had the entities been combined during the period presented. The Combined Company&#8217;s actual results and financial position after the Merger may differ materially and adversely from the unaudited pro forma financial information included in this proxy statement/prospectus. The Exchange Ratio reflected in this proxy statement/prospectus is preliminary. The final Exchange Ratio could differ materially from the preliminary Exchange Ratio used to prepare the pro forma adjustments. For more information see the section titled &#8220;<i style="font-style:italic;">Unaudited Pro Forma Condensed Combined Financial Information</i>&#8221; beginning on page&#160;284.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions that will be in the Combined Company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the Combined Company more difficult and may prevent attempts by its stockholders to replace or remove its management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Provisions that will be included in the Combined Company&#8217;s certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the Combined Company that stockholders may consider favorable, including transactions in which its common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of the Combined Company common stock, thereby depressing the market price of its common stock. In addition, because the Combined Company board of directors will be responsible for appointing the members of the Combined Company management team, these provisions may frustrate or prevent any </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">attempts by the Combined Company stockholders to replace or remove its current management by making it more difficult for stockholders to replace members of the Combined Company board of directors. Among other things, these provisions will:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue the use of a classified board of directors such that not all members of the Combined Company board of directors are elected at one time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow the authorized number of the Combined Company directors to be changed only by resolution of its board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit the manner in which stockholders can remove directors from the Combined Company&#8217;s board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide for advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by its stockholders by written consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit who may call a special meeting of stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize the Combined Company board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the Combined Company board of directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the approval of the holders of at least 66</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">2/3</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">% of the votes that all Combined Company stockholders would be entitled to cast to amend or repeal certain provisions of the Combined Company&#8217;s certificate of incorporation or bylaws.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, because the Combined Company will be incorporated in Delaware, it is governed by the provisions of Section&#160;203 of the DGCL, which prohibits stockholders owning in excess of 15% of the outstanding Combined Company voting stock from merging or combining with the Combined Company. Although GlycoMimetics and Crescent believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with the Combined Company board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by the Combined Company stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics and Crescent expect the Combined Company to amend its bylaws to provide that, unless the Combined Company consents in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain legal actions between Combined Company and its stockholders, which could limit its stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the Combined Company or its directors, officers, employees or stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">GlycoMimetics and Crescent expect the Combined Company to amend its bylaws to provide that, unless the Combined Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the sole and exclusive forum for the following types of proceedings (i)&#160;any derivative action or proceeding brought on the Combined Company&#8217;s behalf, (ii)&#160;any action asserting a claim of or based on a breach of a fiduciary duty owed by any of the Combined Company&#8217;s current or former directors, officers, employees or stockholders to the Combined Company or its stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (iv)&#160;any action asserting a claim arising pursuant to any provision of the Combined Company&#8217;s certificate of incorporation or its bylaws (in each case, as they may be amended from time to time) or that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers to herein as the &#8220;Delaware Forum Provision.&#8221; The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act and the Exchange Act. GlycoMimetics and Crescent expect the Combined Company to also amend its bylaws to provide that, unless it consents in writing to an alternative forum, federal district courts of the United States will be the sole and exclusive forum for any complaint asserting a cause of action arising under the Securities Act, which for purposes of this risk factor is referred to herein as the &#8220;Federal Forum Provision.&#8221; There is uncertainty as to whether a court would enforce such a provision. In addition, the bylaws of the Combined Company will provide that </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">any person or entity purchasing or otherwise acquiring any interest in shares of its capital stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived the Combined Company&#8217;s compliance with the U.S. federal securities laws and the rules&#160;and regulations thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Delaware Forum Provision and the Federal Forum Provision may impose additional costs on stockholders of the Combined Company in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or were permitted to select another jurisdiction. Additionally, the forum selection clauses in the bylaws of the Combined Company may limit its stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with the Combined Company or its directors, officers, employees or stockholders, which may discourage such lawsuits against the Combined Company and its directors, officers, employees and stockholders even though an action, if successful, might benefit its stockholders. Alternatively, if a court were to find the Delaware Forum Provision or the Federal Forum Provision contained in the Combined Company&#8217;s bylaws to be inapplicable or unenforceable in an action, the Combined Company may incur additional costs associated with resolving such action in other jurisdictions, which could materially and adversely affect its business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics and Crescent do not anticipate that the Combined Company will pay any cash dividends in the foreseeable future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The current expectation is that the Combined Company will retain its future earnings, if any, to fund the growth of the Combined Company&#8217;s business as opposed to paying dividends. As a result, capital appreciation, if any, of the Combined Company common stock will be your sole source of gain, if any, for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">An active trading market for the Combined Company common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Merger, there had been no public market for shares of Crescent capital stock. An active trading market for the Combined Company shares of common stock may never develop or be sustained. If an active market for the Combined Company common stock does not develop or is not sustained, it may be difficult for the Combined Company stockholders to sell their shares at an attractive price or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future sales of shares by existing stockholders could cause the Combined Company stock price to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If existing securityholders of GlycoMimetics and Crescent sell, or indicate an intention to sell, substantial amounts of the Combined Company common stock in the public market after legal restrictions on resale discussed in this proxy statement/prospectus lapse, the trading price of the common stock of the Combined Company could decline. Based on shares outstanding as of September&#160;30, 2024 for GlycoMimetics and October&#160;28, 2024 for Crescent, after giving effect to the estimated Exchange Ratio and the shares of Crescent common stock to be issued in the Crescent Pre-Closing Financing and shares expected to be issued upon completion of the Merger and prior to giving effect to the anticipated GlycoMimetics Reverse Stock Split, the Combined Company is expected to have outstanding a total of approximately 1,509,530,971 shares of common stock immediately following the completion of the Merger (or approximately 2,081,711,797 shares of common stock after giving effect to the conversion of the GlycoMimetics Series&#160;A Preferred Stock and the exercise of the Crescent pre-funded warrants to be issued in the Crescent Pre-Closing Financing). Approximately million shares will be freely tradeable upon completion of the Merger and approximately million shares (or approximately million, if the GlycoMimetics Series&#160;A Preferred Stock is converted and the Crescent pre-funded warrants are exercised) will become available for sale in the public market beginning 180&#160;days after the closing of the Merger as a result of the expiration of lock-up agreements between GlycoMimetics on the one hand and certain securityholders of Crescent on the other hand (and without giving effect to any restrictions on resale under securities laws). In addition, shares of common stock that are subject to outstanding options or warrants of Crescent (excluding the pre-funded warrants issued in the Crescent Pre-Closing Financing) will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules&#160;144 and 701 under the Securities Act. If these shares are sold, the trading price of the Combined Company common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">After completion of the Merger, the Combined Company executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the Combined Company stockholders for approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Upon the completion of the Merger, and giving effect to the issuance of the shares of Crescent common stock and the Crescent pre-funded warrants prior to the closing of the Merger pursuant to the Crescent Pre-Closing Financing, it is anticipated that the Combined Company executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately % of the Combined Company&#8217;s outstanding shares of common stock (on a fully-diluted basis), subject to certain assumptions, including, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">but not limited to, GlycoMimetics&#8217; net cash as of closing being $1.8 million. GlycoMimetics&#8217; management currently anticipates GlycoMimetics&#8217; net cash as of closing will be approximately $1.8 million, and the currently estimated ownership&#160;percentages reflect this projection. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the Combined Company stockholders for approval, as well as the Combined Company management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of the Combined Company&#8217;s assets. This concentration of voting power could delay or prevent an acquisition of the Combined Company on terms that other stockholders may desire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the Combined Company, its business or its market, its stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading market for the Combined Company common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect to not provide research coverage of the Combined Company common stock after the completion of the Merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the Combined Company will not have any control over the analysts or the content and opinions included in their reports. The price of the Combined Company common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the Combined Company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company will have broad discretion in the use of the cash and cash equivalents of the Combined Company and the proceeds from the Crescent Pre-Closing Financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company will have broad discretion over the use of the cash and cash equivalents of the Combined Company and the proceeds from the Crescent Pre-Closing Financing. You may not agree with the Combined Company&#8217;s decisions, and its use of the proceeds may not yield any return on your investment. The Combined Company&#8217;s failure to apply these resources effectively could compromise its ability to pursue its growth strategy and the Combined Company might not be able to yield a significant return, if any, on its investment of these net proceeds. You will not have the opportunity to influence its decisions on how to use the Combined Company&#8217;s cash resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company may be subject to adverse legislative or regulatory tax changes that could negatively impact its financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The rules&#160;dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect the Combined Company or its stockholders. The Combined Company will assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where the Combined Company has operations to determine the potential effect on its business and any assumptions the Combined Company will make about its future taxable income. It cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. For example, the United States enacted the IRA, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Act eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five&#160;years. The U.S. Congress is considering legislation that would restore the current deductibility of research and development expenditures, however, there is no assurance that the provision will be repealed or otherwise modified. Such changes, among others, may adversely affect its effective tax rate, results of operation and general business condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Combined Company&#8217;s ability to use NOL carryforwards and other tax attributes may be limited, including as a result of the Merger.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">GlycoMimetics has incurred losses during its history, and the Combined Company does not expect to become profitable in the near future and may never achieve profitability. As of December&#160;31, 2024, GlycoMimetics had NOL carryforwards of approximately $351.8 million, and approximately $10.9 million of research and development credits that may be used to offset future taxable income. GlycoMimetics had operating loss carryforwards of $351.8 million generated prior to 2018, which will expire beginning in 2025 if not utilized. Under current law, GlycoMimetics&#8217; U.S. federal NOLs of $351.8 million incurred in tax&#160;years beginning after December&#160;31, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2017 may be carried forward indefinitely, but the deductibility of such net operating loss carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal law. In addition, under Sections 382 and 383 of the Code, U.S. federal net operating loss carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An &#8220;ownership change&#8221; pursuant to Section&#160;382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50&#160;percentage points over their lowest ownership&#160;percentage within a rolling three-year period. The Combined Company&#8217;s ability to utilize its net operating loss carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed above, in connection with the Merger or other transactions. Similar rules&#160;may apply under state tax laws. If the Combined Company earns taxable income, such limitations could result in increased future income tax liability to the Combined Company, and the Combined Company&#8217;s future cash flows could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unfavorable global economic conditions could adversely affect the Combined Company&#8217;s business, financial condition, results of operations or cash flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company&#8217;s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to the Combined Company&#8217;s business, including weakened demand for the Combined Company&#8217;s product candidates and the Combined Company&#8217;s ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain the Combined Company&#8217;s suppliers, possibly resulting in supply disruption, or cause the Combined Company&#8217;s customers to delay making payments for its services. Any of the foregoing could harm the Combined Company&#8217;s business and the Combined Company cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Hlk190565239"></a><a id="_3275b619_8b76_40d9_b3f1_4e3b4940929c"></a><a id="CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">This proxy statement/prospectus contains or incorporates statements that constitute forward-looking statements within the meaning of the federal securities laws in relation to GlycoMimetics, Crescent, the Merger and the other proposed transactions contemplated thereby.  Any express or implied statements that do not relate to historical or current facts or matters are forward-looking statements.  In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.  These forward-looking statements include, but are not limited to, express or implied statements regarding GlycoMimetics&#8217; or Crescent&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;target,&#8221; &#8220;endeavor,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;contemplate&#8221; or the negative of these terms or other comparable terminology, but the absence of these words does not mean that a statement is not forward-looking.  These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects.  There can be no assurance that future developments affecting GlycoMimetics, Crescent or the proposed transaction will be those that have been anticipated.  These forward-looking statements involve a number of risks, uncertainties (some of which are beyond GlycoMimetics&#8217; or Crescent&#8217;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.  In addition to other factors and matters contained in or incorporated by reference in this document, GlycoMimetics and Crescent believe the following factors could cause actual results to differ materially from those discussed in the forward-looking statements:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the conditions to the closing of the Merger are not satisfied, including the failure to obtain stockholder approval required to complete the Merger and transactions contemplated thereby;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; and Crescent&#8217;s ability to meet expectations regarding the timing and completion of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the Crescent Pre-Closing Financing is not completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainties as to the timing and costs of the consummation of the Merger and the ability of each of GlycoMimetics and Crescent to consummate the Merger and the transactions contemplated thereby, including the Crescent Pre-Closing Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to GlycoMimetics&#8217; continued listing on the Nasdaq until closing of the proposed Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations regarding the strategies, prospects, plans expectations and objectives of management of GlycoMimetics or Crescent for future operations of the Combined Company following the closing of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of the Combined Company to recognize the benefits that may be derived from the Merger, including the commercial or market opportunity of the product candidates of Crescent and the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to GlycoMimetics&#8217; and Crescent&#8217;s ability to correctly estimate their respective operating expenses and expenses associated with the transaction, uncertainties regarding the impact any delay in the closing of the Merger would have on the anticipated cash resources of the Combined Company upon closing and other events and unanticipated spending and costs that could reduce the Combined Company&#8217;s cash resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the accuracy of the parties&#8217; estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the fact that under the terms of the Merger Agreement, GlycoMimetics and Crescent are restrained from soliciting other acquisition proposals during the pendency of the Merger, except in certain circumstances;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of the announcement or pendency of the Merger on GlycoMimetics&#8217; or Crescent&#8217;s business relationships, operating results and business generally, including disruption of GlycoMimetics&#8217; and Crescent&#8217;s management&#8217;s attention from ongoing business operations due to the Merger and potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the Merger Agreement may be terminated in circumstances that require GlycoMimetics or Crescent to pay a termination fee;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome of any legal proceedings that may be instituted against GlycoMimetics, Crescent or any of their respective directors or officers related to the Merger Agreement or the transactions contemplated thereby;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of GlycoMimetics and Crescent to protect their respective intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive responses to the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">legislative, regulatory, political and economic developments beyond the parties&#8217; control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, timing and success of clinical trials for Crescent&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">success in retaining, or changes required in, GlycoMimetics&#8217; and Crescent&#8217;s officers, key employees or directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; public securities&#8217; potential liquidity and trading;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory actions with respect to GlycoMimetics&#8217; and Crescent&#8217;s product candidates or their respective competitors&#8217; products and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s ability to manufacture their product candidates in conformity with the FDA&#8217;s requirements and to scale up manufacturing of their product candidates to commercial scale, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s reliance on third-party contract development and manufacturer organizations to manufacture and supply product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of Crescent&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected potential benefits of strategic collaboration with third parties and Crescent&#8217;s ability to attract collaborators with development, regulatory and commercialization expertise;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s ability to successfully commercialize product candidates, if approved, and the rate and degree of market acceptance of such product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments and projections relating to Crescent&#8217;s competitors or industry.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Should one or more of these risks or uncertainties materialize, or should any of GlycoMimetics&#8217; or Crescent&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.  There may be additional risks that GlycoMimetics or Crescent considers immaterial or which are unknown.  You are urged to carefully review the disclosures GlycoMimetics and Crescent make concerning these risks and other factors that may affect GlycoMimetics&#8217; and Crescent&#8217;s business and operating results under the section titled &#8220;</span><i style="font-style:italic;">Risk Factors</i>&#8221; beginning on page 16<span style="white-space:pre-wrap;"> of this proxy statement/prospectus.  Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in reports filed with the SEC by GlycoMimetics and incorporated by reference herein.  Please see the section titled &#8220;</span><i style="font-style:italic;">Where You Can Find More Information</i>&#8221; beginning on page 315<span style="white-space:pre-wrap;"> of this proxy statement/prospectus.  There can be no assurance that the Merger will be completed, or if it is completed, that it will be completed within the anticipated time period or that the expected benefits of the Merger will be realized.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of GlycoMimetics, Crescent or the Combined C<span style="white-space:pre-wrap;">ompany could differ materially from the forward-looking statements.  Any public statements or disclosures by GlycoMimetics and Crescent following this proxy statement/prospectus that modify or impact any of the forward-looking statements contained in this proxy statement/prospectus will be deemed to modify or supersede such statements in this proxy statement/prospectus.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein.  GlycoMimetics and Crescent do not intend, and undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, unless required by law to do so.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d0334126_7a2a_43dd_afd9_5184889b6237"></a><a id="THESPECIALMEETINGINLIEUOFANNUALMEETINGOF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">THE SPECIAL MEETING IN LIEU OF ANNUAL MEETING OF GlycoMimetics STOCKHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Date, Time and Place</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Special Meeting will be held on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, commencing at &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  Eastern Time, unless postponed or adjourned to a later date.  The GlycoMimetics Special Meeting will be held exclusively online. You will be able to attend and participate in the GlycoMimetics Special Meeting online by visiting <i style="font-style:italic;">www.</i>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i style="font-style:italic;">.com</i><span style="white-space:pre-wrap;">, where you will be able to listen to the meeting live, submit questions and vote. GlycoMimetics is sending this proxy statement/prospectus to its stockholders in connection with the solicitation of proxies by the GlycoMimetics Board for use at the GlycoMimetics Special Meeting and any adjournments or postponements of the GlycoMimetics Special Meeting.  This proxy statement/prospectus is first being furnished to GlycoMimetics stockholders on or about &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Purpose of the GlycoMimetics Special Meeting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purposes of the GlycoMimetics Special Meeting are:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Approve (i) the issuance of shares of GlycoMimetics common stock (including the shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series A Preferred Stock), which will represent more than 20% of the shares of GlycoMimetics common stock outstanding immediately prior to the Merger, to stockholders of Crescent, pursuant to the terms of the Merger Agreement, a copy of which is attached as <i style="font-style:italic;">Annex A, </i>including the amendment thereto, to this proxy statement/prospectus, and (ii) the change of control of GlycoMimetics resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal No. 1&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Approve an amendment to the amended and restated certificate of incorporation of GlycoMimetics (the &#8220;GlycoMimetics Charter&#8221;) to increase the number of shares of GlycoMimetics common stock that GlycoMimetics is authorized to issue from 150,000,000&#160;shares to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the form attached as <i style="font-style:italic;">Annex G</i> to this proxy statement/prospectus (the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal No. 2&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Approve an amendment to the GlycoMimetics Charter to effect a reverse stock split of GlycoMimetics&#8217; issued and outstanding common stock at a ratio in the range between &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, inclusive, in the form attached as <i style="font-style:italic;">Annex H </i>to this proxy statement/prospectus, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by the GlycoMimetics Board and the Crescent Board prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by GlycoMimetics stockholders, determined solely by the GlycoMimetics Board (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal No. 3&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Elect the Class II directors,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, to the GlycoMimetics Board and to hold office until GlycoMimetics&#8217; 2028 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal No. 4&#8221;), provided that if the Merger is consummated, the approval of Proposal No. 4 will only have an effect until the completion of the Merger because the composition of the GlycoMimetics Board will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Ratify the appointment of Ernst &amp; Young LLP as GlycoMimetics&#8217; independent registered public accounting firm for fiscal year ending December 31, 2025, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal No. 5&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Approve the Crescent Biopharma, Inc. 2025 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal No. 6&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Approve the Crescent Biopharma, Inc. 2025 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal No. 7&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Approve, on an advisory basis, certain compensation arrangements for GlycoMimetics named executive officers that are based on or otherwise relate to the Merger (the &#8220;the Merger Compensation Proposal&#8221; or &#8220;Proposal No. 8&#8221;);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">9.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Approve an adjournment of the GlycoMimetics Special Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal No. 9&#8221;); and</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">10.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Transact such other business as may properly come before the stockholders at the GlycoMimetics Special Meeting or any adjournment or postponement thereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Each of Proposal No. 1 and Proposal No. 2 is a condition to completion of the Merger.  The issuance of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series A Preferred Stock, and GlycoMimetics Series A Preferred Stock in connection with the Merger and the change of control of GlycoMimetics resulting from the Merger will not take place unless Proposal No. 1 and Proposal No. 2 are approved by GlycoMimetics stockholders and the Merger is consummated.  The amendment to the GlycoMimetics Charter to increase the number of authorized shares of GlycoMimetics common stock will not take place unless Proposal No. 2 is approved by the requisite GlycoMimetics stockholders.  The amendment to the GlycoMimetics Charter to effect a reverse stock split of GlycoMimetics&#8217; issued and outstanding common stock will not take place unless Proposal No. 3 is approved by the requisite GlycoMimetics stockholders.  The GlycoMimetics Board may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal No. 1 is not approved by GlycoMimetics stockholders, following the special meeting.</span></p><a id="RecommendationoftheGlycoMimeticsBoardofD"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recommendation of the GlycoMimetics Board of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">The GlycoMimetics Board recommends that you vote:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="white-space:pre-wrap;">The GlycoMimetics Board has determined and declared that the issuance of shares of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series A Preferred Stock, pursuant to the Merger Agreement is fair to, in the best interests of, and advisable to, GlycoMimetics and its stockholders.  The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-weight:bold;">FOR</b>&#8221;<b style="font-weight:bold;">&#160;</b>the approval of Nasdaq Stock Issuance Proposal as described in this proxy statement/prospectus.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="white-space:pre-wrap;">The GlycoMimetics Board has determined and declared that it is advisable and in the best interests of GlycoMimetics and its stockholders to approve the amendment to the GlycoMimetics Charter to effect the increase in authorized shares.  The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-weight:bold;">FOR</b>&#8221; the Authorized Share Increase Proposal as described in this proxy statement/prospectus.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="white-space:pre-wrap;">The GlycoMimetics Board has determined and declared that it is advisable and in the best interests of GlycoMimetics and its stockholders to approve the amendment to the GlycoMimetics Charter to effect the reverse stock split, if necessary.  The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-weight:bold;">FOR</b>&#8221;<b style="font-weight:bold;">&#160;</b>the Reverse Stock Split Proposal as described in this proxy statement/prospectus.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The GlycoMimetics Board has determined and believes that it is advisable to, and in the best interests of, GlycoMimetics and its stockholders to elect &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="white-space:pre-wrap;"> to serve on the GlycoMimetics Board in the class of directors with terms expiring at GlycoMimetics&#8217; 2028 annual meeting of stockholders, provided that if the Merger is consummated, the approval of Proposal No. 4 will only have an effect until the completion of the Merger because the composition of the GlycoMimetics Board will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement.  The GlycoMimetics Board that GlycoMimetics stockholders vote &#8220;</span><b style="font-weight:bold;">FOR</b>&#8221;<b style="font-weight:bold;">&#160;</b>the director nominees named in the Director Election Proposal as described in this proxy statement/prospectus.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The GlycoMimetics Board has determined and believes that it is advisable to, and in the best interests of, GlycoMimetics and its stockholders to ratify the selection of Ernst &amp; Young LLP as GlycoMimetics&#8217; independent registered public accounting firm for the fiscal year ending December&#160;<span style="white-space:pre-wrap;">31, 2025, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed.  The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-weight:bold;">FOR</b>&#8221;<b style="font-weight:bold;">&#160;</b>the Auditor Ratification Proposal as described in this proxy statement/prospectus.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="white-space:pre-wrap;">The GlycoMimetics Board has determined and believes that it is advisable to, and in the best interests of, GlycoMimetics and its stockholders to approve the 2025 Stock Incentive Plan, as described in this proxy statement/prospectus.  The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-weight:bold;">FOR</b>&#8221; the Stock Plan Proposal as described in this proxy statement/prospectus.</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The GlycoMimetics Board has determined and believes that it is advisable to, and in the best interests of, GlycoMimetics and its stockholders to approve the 2025 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the ESPP Proposal as described in this proxy statement/prospectus.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="white-space:pre-wrap;">The GlycoMimetics Board has determined and believes that it is advisable to, and in the best interests of, GlycoMimetics and its stockholders to approve certain compensation arrangements for GlycoMimetics named executive officers that are based on or otherwise relate to the Merger.  The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-weight:bold;">FOR</b>&#8221; the Merger Compensation Proposal as described in this proxy statement/prospectus.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="white-space:pre-wrap;">The GlycoMimetics Board has determined and believes that adjourning the GlycoMimetics Special Meeting, if necessary, to solicit additional proxies if there is not a sufficient number of votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal is fair to, in the best interests of, and advisable to, GlycoMimetics and its stockholders and has approved and adopted the proposal.  The GlycoMimetics Board recommends that GlycoMimetics stockholders vote &#8220;</span><b style="font-weight:bold;">FOR</b>&#8221; the Adjournment Proposal, if necessary, as described in this proxy statement/prospectus.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Record Date and Voting Power</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Only holders of record of GlycoMimetics common stock at the close of business on the Record Date of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="white-space:pre-wrap;">, 2025, are entitled to notice of, and to vote at, the GlycoMimetics Special Meeting.  At the close of business on the Record Date, there were &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; registered holders of record of GlycoMimetics common stock and there were &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="white-space:pre-wrap;">shares of GlycoMimetics common stock issued and outstanding.  Each share of GlycoMimetics common stock entitles the holder thereof to one vote on each matter submitted for stockholder approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Voting and Revocation of Proxies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The proxy accompanying this proxy statement/prospectus is solicited on behalf of the GlycoMimetics Board for use at the GlycoMimetics Special Meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">If, as of the Record Date referred to above, your shares were registered directly in your name with the transfer agent for GlycoMimetics common stock, Equiniti, then you are a stockholder of record.  As a stockholder of record, you may vote at the GlycoMimetics Special Meeting or vote by proxy.  Whether or not you plan to attend the GlycoMimetics Special Meeting, we urge you to vote by proxy over the telephone or on the Internet as instructed below or return the proxy card we may mail to you to ensure your vote is counted, the form of which is attached hereto as </span><i style="font-style:italic;">Annex </i><i style="font-style:italic;">L</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The procedures for voting are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">If you are a stockholder of record, you may vote at the GlycoMimetics Special Meeting.  Alternatively, you may vote by proxy by using the accompanying proxy card, over the internet or by telephone.  Whether or not you plan to attend the GlycoMimetics Special Meeting, GlycoMimetics encourages you to vote by proxy to ensure your vote is counted.  Even if you have submitted a proxy before the GlycoMimetics Special Meeting, you may still attend the GlycoMimetics Special Meeting and vote.  In such case, your previously submitted proxy will be disregarded.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="white-space:pre-wrap;">To vote, come to the GlycoMimetics Special Meeting and we will give you a ballot when you arrive.  If you attend the GlycoMimetics Special Meeting and vote, your vote will revoke any proxy that you have previously submitted.  Simply attending the GlycoMimetics Special Meeting will not, by itself, revoke your proxy.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="white-space:pre-wrap;">To vote using the proxy card, simply complete, sign and date the proxy card that you may request or that we may elect to deliver at a later time and return it promptly in the envelope provided.  If you return your signed proxy card to GlycoMimetics before the special meeting, we will vote your shares as you direct.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">You can vote by proxy over the telephone by calling the toll-free number found on the proxy card.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">You can vote by proxy over the internet by following the instructions provided on the proxy card.</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a voting instruction card and voting instructions with these proxy materials from that organization rather than from GlycoMimetics.  Simply complete and mail the voting instruction card to ensure that your vote is counted.  To vote at the GlycoMimetics Special Meeting, you must obtain a valid proxy from your broker, bank or other agent.  Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other agent to request a proxy form.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">GlycoMimetics provides internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions.  However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">If you hold shares beneficially in street name and do not provide your broker or other agent with voting instructions, your shares may constitute &#8220;broker non-votes.&#8221; A &#8220;broker non-vote&#8221; occurs when shares held by a broker are not voted with respect to a particular proposal because the broker has not received voting instructions from its client(s) with respect to such shares on how to vote and does not have or did not exercise discretionary authority to vote on the matter.  Abstentions will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the GlycoMimetics Special Meeting.  Abstentions will be counted towards the vote totals for each proposal, and will have the same effect of a vote &#8220;AGAINST&#8221; Proposal Nos.&#160;1,&#160;5,&#160;6,&#160;</span><span style="white-space:pre-wrap;">7, 8 and 9.  Broker non-votes, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal Nos.&#160;1,&#160;2,&#160;3,&#160;4,&#160;5,&#160;6,&#160;7, 8 and&#160;</span><span style="white-space:pre-wrap;">9.  If an GlycoMimetics stockholder does not return voting instructions to their broker on how to vote their shares of GlycoMimetics common stock, such broker may be prevented from voting, or may otherwise choose not to vote, such shares held by such broker, resulting in broker non-votes with respect to such shares.  To make sure that your vote is counted, you should instruct your broker to vote your shares of GlycoMimetics common stock, following the procedures provided by your broker.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">All properly executed proxies that are not revoked will be voted at the GlycoMimetics Special Meeting and at any adjournments or postponements of the GlycoMimetics Special Meeting in accordance with the instructions contained in the proxy.  </span><b style="font-weight:bold;">If a holder of GlycoMimetics common stock executes and returns a proxy and does not specify otherwise, the shares represented by that proxy will be voted &#8220;FOR&#8221; all of the proposals in accordance with the recommendation of the GlycoMimetics Board.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The presence at the GlycoMimetics Special Meeting of the holders of a majority of the shares of GlycoMimetics common stock outstanding and entitled to vote at the GlycoMimetics Special Meeting is necessary to constitute a quorum at the meeting.  Abstentions and broker non-votes, if any, will be counted towards the presence of a quorum.  The affirmative vote of a majority of the shares of GlycoMimetics common stock entitled to vote on the subject matter and present at the GlycoMimetics Special Meeting, assuming a quorum is present, is required for approval of Proposal Nos.&#160;1,&#160;5,&#160;6,&#160;</span><span style="white-space:pre-wrap;">7, 8 and 9.  The affirmative vote of at least sixty-six and two-thirds percent (66</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2/3</sup><span style="white-space:pre-wrap;">%) of the voting power of all then-outstanding shares of GlycoMimetics capital stock entitled to vote generally in the election of directors, voting together as a single class, is required for approval of Proposal No. 2 and Proposal No. 3 at the GlycoMimetics Special Meeting, assuming a quorum is present. With respect to Proposal No. 4, directors are elected by a plurality of the votes properly cast at the GlycoMimetics Special Meeting, and the three nominees for director receiving the highest numbers of affirmative votes properly cast will be elected.  Proposal No. 1 is conditioned on the approval of Proposal No. 2.  Notwithstanding the approval of Proposal No.&#160;1, if Proposal No. 2 is not approved, the actions contemplated by Proposal No. 1 will not be effected and the Merger will not be consummated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Each of Proposal No. 1 and Proposal No. 2 is a condition to completion of the Merger.  The issuance of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series A Preferred Stock, and GlycoMimetics Series A Preferred Stock in connection with the Merger and the change of control of GlycoMimetics resulting from the Merger will not take place unless Proposal No. 1 and Proposal No. 2 are approved by GlycoMimetics stockholders and the Merger is consummated.  The amendment to the GlycoMimetics Charter to increase the number of authorized shares of GlycoMimetics common stock will not take place unless Proposal No. 2 is approved by the requisite GlycoMimetics stockholders.  The amendment to the GlycoMimetics Charter to effect a reverse stock split of GlycoMimetics&#8217; issued and outstanding common stock, will not take place unless Proposal No. 3 is approved by the requisite GlycoMimetics stockholders.  The GlycoMimetics Board may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal No. 1 is not approved by GlycoMimetics stockholders, following the special meeting.</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Votes will be counted by the inspector of election appointed for the meeting, who will separately count &#8220;FOR,&#8221; &#8220;AGAINST&#8221; and &#8220;WITHHOLD&#8221; votes, abstentions and broker non-votes, if any, as applicable to each proposal.  Abstentions and broker non-votes, if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the GlycoMimetics Special Meeting.  Abstentions will be counted towards the vote totals for each proposal, and will have the same effect of a vote &#8220;AGAINST&#8221; Proposal Nos.&#160;1,&#160;5,&#160;6,&#160;7, 8 and 9. Broker non-votes, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal Nos.&#160;1,&#160;2,&#160;3,&#160;4,&#160;5,&#160;6,&#160;7, 8 and&#160;9.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, the directors and executive officers of GlycoMimetics owned or controlled &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="white-space:pre-wrap;">% of the outstanding shares of GlycoMimetics common stock entitled to vote at the GlycoMimetics Special Meeting.  As of </span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, the GlycoMimetics stockholders that are party to a support agreement, including the directors, executive officers and certain stockholders of GlycoMimetics, owned an aggregate number of shares of GlycoMimetics common stock representing approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="white-space:pre-wrap;">% of the outstanding shares of GlycoMimetics common stock.  Each stockholder that entered into a support agreement, including the directors and executive officers of GlycoMimetics, has agreed to vote all shares of GlycoMimetics common stock owned by him or her as of the Record Date in favor of the adoption of the Merger Agreement and the transactions contemplated thereby, including the Merger, the issuance of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series A Preferred Stock, to the stockholders of Crescent pursuant to the Merger Agreement and the change of control resulting from the First Merger, and against any alternative acquisition proposals.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Solicitation of Proxies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition to solicitation by mail, the directors, officers, employees and agent of GlycoMimetics may solicit proxies from GlycoMimetics stockholders by personal interview, telephone, email, fax or otherwise.  GlycoMimetics and Crescent will share equally the costs of printing and filing this proxy statement/prospectus and proxy card.  Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of GlycoMimetics common stock for the forwarding of solicitation materials to the beneficial owners of GlycoMimetics common stock.  GlycoMimetics will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out of pocket expenses they incur in connection with the forwarding of solicitation materials.  GlycoMimetics has retained Innisfree M&amp;A Incorporated as its proxy solicitor.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">As of the date of this proxy statement/prospectus, the GlycoMimetics Board does not know of any business to be presented at the GlycoMimetics Special Meeting other than as set forth in the notice accompanying this proxy statement/prospectus.  If any other matters should properly come before the GlycoMimetics Special Meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_ffc2d3dd_3385_4a8c_bdd5_d99286f2644e"></a><a id="THEMERGER_985712"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">THE MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This section and the section titled &#8220;The Merger Agreement&#8221; beginning on page </i><span style="font-style:italic;">134</span><i style="font-style:italic;white-space:pre-wrap;"> of this proxy statement/prospectus describe the material aspects of the Merger and the Merger Agreement.  While GlycoMimetics and Crescent believe that this description covers the material terms of the Merger and the Merger Agreement, it may not contain all of the information that is important to you.  You should read carefully this entire proxy statement/prospectus for a more complete understanding of the Merger and the Merger Agreement and the other documents to which you are referred in this proxy statement/prospectus.  See the section titled &#8220;Where You Can Find More Information&#8221; beginning on page </i><span style="font-style:italic;">315</span><i style="font-style:italic;"> of this proxy statement/prospectus.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Background of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following chronology is a summary description of the background of the negotiations and the proposed merger and does not purport to</i><i style="font-style:italic;"> document </i><i style="font-style:italic;">every </i><i style="font-style:italic;">discussion </i><i style="font-style:italic;">among representatives of </i><i style="font-style:italic;">GlycoMimetics</i><i style="font-style:italic;">, </i><i style="font-style:italic;">Crescent</i><i style="font-style:italic;"> and other parties. In addition to formal meetings of the </i><i style="font-style:italic;">GlycoMimetics </i><i style="font-style:italic;">Board, </i><i style="font-style:italic;">GlycoMimetics&#8217; </i><i style="font-style:italic;">management had </i><i style="font-style:italic;">periodic and other </i><i style="font-style:italic;">informal discussions with members of the </i><i style="font-style:italic;">GlycoMimetics </i><i style="font-style:italic;">Board throughout the process</i><i style="font-style:italic;">,</i><i style="font-style:italic;"> and </i><i style="font-style:italic;">GlycoMimetics&#8217; </i><i style="font-style:italic;">management held weekly calls with</i><i style="font-style:italic;"> various </i><i style="font-style:italic;">advisors, and ultimately with </i><i style="font-style:italic;">Crescent</i><i style="font-style:italic;"> and its advisors. The terms of the Merger Agreement are the result of extensive arm&#8217;s-length negotiations among </i><i style="font-style:italic;">GlycoMimetics&#8217; </i><i style="font-style:italic;">and </i><i style="font-style:italic;">Crescent</i><i style="font-style:italic;">&#8217;s management and members of the </i><i style="font-style:italic;">GlycoMimetics </i><i style="font-style:italic;">Board and </i><i style="font-style:italic;">the Crescent Board</i><i style="font-style:italic;">, </i><i style="font-style:italic;">as well as </i><i style="font-style:italic;">with </i><i style="font-style:italic;">GlycoMimetics&#8217; </i><i style="font-style:italic;">and </i><i style="font-style:italic;">Crescent</i><i style="font-style:italic;">&#8217;s respective financial advisors and legal counsel.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the GlycoMimetics Board&#8212;assisted by GlycoMimetics senior management and outside advisors&#8212;regularly considers and reviews the strategy, performance (including clinical trial outcomes), and prospects of GlycoMimetics with a view toward maximizing stockholder value. These reviews have included, from time to time, discussions of opportunities and risks associated with GlycoMimetics&#8217; product candidates, its financial condition and market conditions generally, with a view toward strategic alternatives, financing opportunities, business collaborations and licensing opportunities potentially available to GlycoMimetics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On May 4, 2024, at a meeting of the GlycoMimetics Board with members of GlycoMimetics&#8217; management, an external biostatistical consultant, and a representative of GlycoMimetics&#8217; legal advisor, Sidley Austin LLP (&#8220;Sidley&#8221;), in attendance, members of the GlycoMimetics Board and management reviewed the topline results of GlycoMimetics&#8217; Phase 3 global pivotal study of uproleselan in patients with relapsed/refractory acute myeloid leukemia (the &#8220;Clinical Trial&#8221;). The results of the Clinical Trial indicated that uproleselan combined with chemotherapy did not achieve a statistically significant improvement in the primary endpoint of overall survival in the intent to treat population versus chemotherapy alone.  The topline results further indicated potential significant benefit in a subset patient group that, if statistically significant and validated through additional analysis, could merit investigation as a potential pathway for regulatory approval. The GlycoMimetics Board discussed potential next steps regarding Clinical Trial data analysis, including possibly pursuing a strategy for regulatory approval pathway following receipt and analysis of the full dataset for the Clinical Trial, as well as the potential for a positive readout from an adaptive Phase 2/3 study being conducted by the National Cancer Institute (the &#8220;NCI&#8221;) with uproleselan in adults with newly diagnosed AML who are 60 years or older and fit for intensive chemotherapy (the &#8220;NCI Trial&#8221;).  GlycoMimetics Board also considered and discussed potential strategic alternatives available to GlycoMimetics in light of the negative Clinical Trial results, including out-licensing or divestiture of GlycoMimetics&#8217; other development programs.  GlycoMimetics&#8217; management presented the outline of a near-term plan to address the Clinical Trial results, including public announcement of topline results, expectations regarding receipt of the full dataset and plans for additional analysis and development of a briefing document to the FDA, and a corporate review and reduction of financial commitments to include a work force reduction.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Prior to market open on May 6, 2024, GlycoMimetics publicly announced the Clinical Trial results.  In the same release, GlycoMimetics also announced preliminary financial results for the first quarter of 2024, which showed that, as of March 31, 2024, GlycoMimetics had cash and cash equivalents of $31.3 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On May 8, 2024, the GlycoMimetics Board held a videoconference meeting with members of GlycoMimetics&#8217; management and a representative of Sidley in attendance to further review and discuss the topline results from the Clinical Trial, including the potential utility of conducting additional analysis based on data signals in the specified patient subsets referred to previously. The GlycoMimetics Board also considered and discussed a proposal prepared by GlycoMimetics&#8217; management regarding: (i) an initial 30-day period to include Clinical Trial data analysis and potential public presentation of results via an investor call, planned engagement with the FDA on a potential regulatory pathway to submit a New Drug Application based on subset analysis, engagement with the NCI regarding potential modification of the NCI Trial in light of the Clinical Trial results, outreach to potential partners regarding a sale or licensing of the company&#8217;s pipeline programs, development of a planned reduction in force, and identification of a preferred </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">financial advisor to assist with a potential strategic option process; (ii) a subsequent two month period to implement the planned reduction in force, discuss Clinical Trial data with the FDA and evaluate potential registration pathways, if any, close out the Clinical Trial and update the company&#8217;s budget, and execute any potential partnering opportunities for GlycoMimetics pipeline assets; and (iii) a final, additional two month period to either continue to engage with the FDA or, should a registrational pathway not be feasible, to engage a financial advisor to assist with strategic options, or carry out a wind-down of the company.  The GlycoMimetics Board and management discussed the proposed phased approach to business operations over the subsequent six month period and directed management to begin preparatory work on the strategic review process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 24, 2024, GlycoMimetics&#8217; management updated the GlycoMimetics Board on GlycoMimetics&#8217; progress in development of a regulatory strategy based on subset analysis of data from the Clinical Trial, recent interactions with regulatory agencies regarding potential data publication at a medical conference, and engagement efforts with the NCI regarding the NCI Trial to assess whether such NCI Trial would be capable of modification in light of the results of the Clinical Trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 4, 2024, GlycoMimetics&#8217; management presented comprehensive results from the Clinical Trial during an investor call and in a concurrent press release. GlycoMimetics&#8217; management announced its intention to explore a potential path forward for uproleselan in multiple AML settings based on observed Clinical Trial efficacy results, as well as efforts to engage with the NCI regarding potential modification of the NCI Trial in light of the observed Clinical Trial efficacy results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 18, 2024, GlycoMimetics&#8217; management submitted a Type B briefing package to the FDA in anticipation of a meeting with the FDA scheduled for July 18, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 21, 2024, GlycoMimetics received a notice from The Nasdaq Stock Market that GlycoMimetics was not in compliance with Nasdaq&#8217;s listing rules because the minimum bid price of GlycoMimetics common stock had been below $1.00 per share for 30 consecutive business days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">At a videoconference meeting on June 28, 2024, the GlycoMimetics Board met with members of GlycoMimetics&#8217; management and a representative of Sidley in attendance to discuss and consider GlycoMimetics&#8217; potential strategic scenarios pending the outcome of the upcoming FDA Type B meeting.  The GlycoMimetics Board considered the company&#8217;s potential pathways in scenarios including full FDA approval, accelerated approval, and no approval, including with or without a confirmatory trial. The GlycoMimetics Board discussed potential outcomes in an approval scenario, including out-licensing of ex-US rights to uproleselan, partnering of pipeline assets, and potential acquisition of GlycoMimetics by a third party.  The GlycoMimetics Board further discussed potential strategic alternatives available to GlycoMimetics in a non-approval scenario, including a broad outreach to potential reverse merger counterparties or a liquidation of GlycoMimetics, and considered the projected timing of such alternatives against the company&#8217;s existing cash runway.  The GlycoMimetics Board determined that while awaiting FDA feedback GlycoMimetics should explore and evaluate its strategic alternatives and discussed the retention of a financial advisor to assist the GlycoMimetics Board.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Between June 28, 2024, and July 26, 2024, members of GlycoMimetics&#8217; management interviewed several investment banking firms to assess their suitability to act as GlycoMimetics&#8217; financial advisor in connection with a review of potential strategic alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 12, 2024, the FDA provided preliminary comments in response to GlycoMimetics&#8217; Type B briefing package, which comments indicated the agency would most likely require one or more additional clinical trials for potential regulatory approval of uproleselan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The GlycoMimetics Board met on July 15, 2024 via videoconference with members of GlycoMimetics&#8217; management and a representative of Sidley in attendance.  GlycoMimetics&#8217; management briefed the GlycoMimetics Board on the FDA&#8217;s preliminary comments and the company&#8217;s preparations for the upcoming in-person meeting, as well as the status of GlycoMimetics&#8217; discussions with the NCI on a potential modification of the NCI Trial. The GlycoMimetics Board discussed GlycoMimetics&#8217; cash position, current partnering efforts, and the projected timelines for various strategic alternatives, including a potential dissolution or a reverse merger.  The GlycoMimetics Board then discussed potential reverse merger candidates, including licensees of Paragon.  The GlycoMimetics Board also discussed the previously-interviewed potential candidates to act as financial advisor to GlycoMimetics in connection with a potential strategic transaction and, following discussion, directed GlycoMimetics&#8217; management to contact Lucid regarding a potential engagement.</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On July 19, 2024, the GlycoMimetics Board held a videoconference meeting with members of GlycoMimetics&#8217; management and a representative of Sidley in attendance to receive an update and discuss the outcome of GlycoMimetics&#8217; Type B meeting with the FDA.  The GlycoMimetics Board also discussed the update from GlycoMimetics&#8217; management regarding discussions with Lucid.  Based on these discussions, and after consideration of the relative qualifications and expertise of the other potential candidates, including industry expertise, knowledge, access to potential transaction counterparties, and recent transaction experience, as well as the terms of the proposed engagement letter with Lucid and the recommendation of GlycoMimetics&#8217; management, the GlycoMimetics Board approved the selection of Lucid as GlycoMimetics&#8217; financial advisor to assist GlycoMimetics in its review of potential strategic alternatives and authorized and directed GlycoMimetics&#8217; management to seek to finalize an engagement letter with Lucid.  The board of directors also discussed a proposed press release to announce GlycoMimetics&#8217; most recent corporate developments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Thereafter, on July 25, 2024, GlycoMimetics issued a press release regarding recent corporate developments, including the FDA&#8217;s feedback on the potential regulatory pathway for uproleselan, GlycoMimetics&#8217; initiation of an engagement of Lucid as GlycoMimetics&#8217; financial advisor for the strategic review, continuation of discussions with the NCI regarding potential modification of the NCI Trial, and an additional, significant workforce reduction. Based on the corporate restructuring and streamlining of operations, GlycoMimetics also announced its expectation of a significant reduction in future operating expenses that would extend its cash runway into the second quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Board held a videoconference meeting on July 26, 2024 with members of GlycoMimetics&#8217; management and a representative of Sidley in attendance.The GlycoMimetics Board received updates regarding feedback to the July 25 announcement of a strategic review and initiation of a corporate restructuring plan. Among other things, the GlycoMimetics Board discussed the feasibility of GlycoMimetics raising the additional funds that would be required to conduct the additional clinical trials that management anticipated would be required in order to achieve regulatory approval of uproleselan, including a discussion regarding the feedback from certain of GlycoMimetics&#8217; major investors that they were unwilling to provide additional funding to GlycoMimetics based on the development opportunities then available to GlycoMimetics, and the GlycoMimetics Board determined that pursuing such a financing was not a viable strategy for GlycoMimetics. The GlycoMimetics Board also discussed management&#8217;s ongoing efforts to monetize GlycoMimetics&#8217; pipeline products, including a discussion of the terms of a non-binding term sheet submitted by a third party for potential acquisition of GlycoMimetics&#8217; GMI-1687 program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On August 2, 2024, the GlycoMimetics Board held a meeting at which members of management, representatives from Lucid, and a representative from Sidley were present. The GlycoMimetics Board reviewed cash projections provided by the company&#8217;s management based on expected timelines to complete a reverse merger, and considered the terms of in-process business development negotiations for the potential sale of GlycoMimetics pipeline programs that could result in additional cash generation.  At this meeting, Lucid reviewed the process it proposed to undertake in order to identify and evaluate potential strategic alternatives and potential counterparties that it believed may be interested in pursuing a reverse merger transaction with GlycoMimetics. The GlycoMimetics Board discussed the anticipated timeline for contacting and receiving and evaluating proposals from interested parties in connection with a strategic transaction. The GlycoMimetics Board authorized Lucid to begin outreach to all of the potential counterparties presented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Beginning on August 9, 2024, Lucid initiated a process of identifying and evaluating potential counterparties for a strategic transaction with assistance from the GlycoMimetics Board and members of GlycoMimetics&#8217; management. In their outreach, members of the GlycoMimetics Board, GlycoMimetics&#8217; management, and representatives of Lucid contacted over 200 potential buyers that might be suitable candidates for a reverse merger with GlycoMimetics, with various interested parties entering into confidentiality agreements to prepare bid letters that were due on August 21, 2024.  On that date, Lucid received 32 bid letters from counterparties that indicated interest in a reverse merger transaction.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Following receipt of bid letters on August 21, 2024, Lucid reviewed the proposals and selected 11 potential counterparties that most strongly aligned with GlycoMimetics&#8217; stated requirements and projected closing cash levels.  Lucid engaged in discussions with each of the 11 finalists to assess their interest in moving forward with a potential transaction and based on those conversations, identified that 5 of the 11 potential counterparties would be interested in presenting to GlycoMimetics&#8217; management.  Based on discussions with the management of GlycoMimetics regarding GlycoMimetics&#8217; updated expense budgets and anticipated cash forecasts through the potential closing of a reverse merger transaction, Lucid reprioritized discussions with the potential counterparties to focus on 10 candidates believed to be most interested in and reasonably able to consummate a reverse merger with GlycoMimetics. After diligence calls with each of these 10 counterparties, three viable targets were identified and the remaining seven potential counterparties were deprioritized due to transactability issues, including cash needs, milestone timing, free float considerations, and valuation concerns. GlycoMimetics&#8217; management reviewed with Lucid the non-binding proposals provided by the three remaining potential counterparties and, during the week of September 2, 2024, met with representatives of each potential counterparty.  </span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Following the counterparty management presentations and after further diligence, Lucid worked with GlycoMimetics&#8217; management to refine GlycoMimetics&#8217; estimate of closing cash deliverable at a projected closing and determined that two of the three potential counterparties would not be viable choices.  With respect to the remaining potential counterparty (&#8220;Party A&#8221;), on September 10, 2024, GlycoMimetics&#8217; management directed Lucid to present Party A with a proposed term sheet for a reverse merger reflecting, among other items, the anticipated closing cash deliverable by GlycoMimetics and a reduced equity valuation for Party A.  Thereafter, on September 12, 2024, Party A presented a further revised proposed term sheet with additional proposed revisions, including a readjusted Party A valuation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the announcement of topline results, GlycoMimetics&#8217; management continued to explore potential monetization transactions for GlycoMimetics&#8217; other programs but was unable to identify any other viable transactions. On September 5, 2024, following extensive marketing efforts and discussion with multiple potentially interested parties, GlycoMimetics sold its rivipansel program to Biossil Inc. for approximately $1 million in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 13, 2024, the GlycoMimetics Board held a meeting at which members of management, representatives from Lucid, and a representative from Sidley were present. The GlycoMimetics Board reviewed the proposed reverse merger process to date, the potential candidates considered during the process, the proposed terms of a merger with Party A and Lucid&#8217;s analysis of the viability of Party A as a viable merger candidate, anticipated timelines to completion of a potential merger, and the potential pros and cons of pursuing a dissolution of GlycoMimetics instead of a reverse merger transaction with Party A. As part of this discussion, Lucid provided GlycoMimetics Board with additional context regarding Party A&#8217;s willingness to engage in a low-cash merger transaction, the anticipated post-merger financing needs of the Combined Company, and a preliminary valuation analysis of Party A. The GlycoMimetics Board, GlycoMimetics&#8217; management and Lucid further considered and assessed the potential closing risk to a merger transaction with Party A given that such transaction would require approval from Chinese regulatory authorities and discussed potential protections that could be included in a merger agreement to help mitigate such risks. Following additional discussion, the GlycoMimetics Board directed GlycoMimetics&#8217; management and Lucid to continue with negotiation of the Party A term sheet, incorporating such additional protections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 15, 2024, representatives from Wedbush Securities Inc. (&#8220;Wedbush&#8221;), the financial advisor to Crescent, contacted Lucid to express interest in submitting a proposal for a merger transaction between GlycoMimetics and Crescent, a company that would be setup and in-license product candidates from Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 17, 2024, Lucid representatives conducted a call with Party A&#8217;s financial advisor to provide an update on GlycoMimetics&#8217; process and deliberations regarding Party A&#8217;s proposed term sheet. On that same date, GlycoMimetics and Paragon executed a confidentiality agreement, after which representatives of Crescent presented Lucid and GlycoMimetics&#8217; management with a written indication of interest for a merger transaction (the &#8220;Crescent Proposal&#8221;). Following receipt of the Crescent Proposal on September 17 and throughout the following day, Lucid and GlycoMimetics&#8217; management met multiple times to review and discuss the Crescent Proposal as well as to conduct diligence on the anticipated Crescent assets, including a review of other recent reverse merger transactions involving affiliates of Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 18, 2024, following additional discussions regarding the Crescent Proposal, including the relative merits of the proposal in relation to the Party A term sheet and in light of the post-merger strength of prior similarly-situated merger partners of Paragon licensees, GlycoMimetics&#8217; management directed Lucid to prepare a draft term sheet reflecting the Crescent Proposal for consideration by the GlycoMimetics Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The GlycoMimetics Board convened at a meeting on September 19, 2024, at which members of management, representatives from Lucid, and a representative from Sidley were present. While considering the best interests of GlycoMimetics stockholders, the GlycoMimetics Board reviewed and assessed the Crescent Proposal and the proposed Crescent term sheet (&#8220;Crescent Term Sheet&#8221;) in the context of the existing Party A term sheet as well as being a potential alternative to a wind-down or dissolution of GlycoMimetics.  Lucid then provided a more detailed description of its recent interactions with Wedbush and Paragon in respect of the Crescent Proposal, including a company overview and an assessment of the company&#8217;s proposed Private Investment in Public Equity (&#8220;PIPE&#8221;) financing and expected post-merger valuation.  The GlycoMimetics Board then considered and discussed the relative merits and risks of the Crescent Proposal, Crescent Term Sheet and Party A term sheet, including the respective GlycoMimetics valuations, post-merger ownership percentages, financing needs, and risks to completion of a merger with both counterparties.  At that point of the meeting, representatives of Crescent then joined the videoconference to respond to due diligence questions from GlycoMimetics&#8217; management, the GlycoMimetics Board and their advisors, including questions about Crescent&#8217;s technology, development plans and milestones, expected clinical inflection points, and expected financial resources from a proposed concurrent PIPE transaction. </span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Paragon&#8217;s representatives also joined the videoconference and described their experience with recent reverse merger transactions and fitness as a strategic transaction partner.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Following Crescent&#8217;s presentation, the GlycoMimetics Board determined that Crescent was a counterparty that merited serious consideration because (i) it required a minimal amount of GlycoMimetics&#8217; cash and would therefore allow for sufficient time to complete the proposed transaction, (ii) the company was backed by a reputable investor with a history of successful reverse merger transactions, and (iii) the company was confident that it could secure strong interest with respect to an investment that would be contemplated to close concurrently with the closing of the proposed merger. As a result, the GlycoMimetics Board focused its efforts on pursuing a transaction with Crescent while continuing to discuss a potential transaction with Party A in case a transaction with Crescent did not come to fruition. The GlycoMimetics Board determined that it should pursue a transaction with Crescent in light of the GlycoMimetics Board&#8217;s view that (i) the liquidation of GlycoMimetics was not reasonably likely to result in superior value to GlycoMimetics&#8217; stockholders when compared to the proposed transaction; (ii) the $8 million enterprise value ascribed to GlycoMimetics would give GlycoMimetics&#8217; stockholders a significant opportunity to participate in the potential growth of the Combined Company following the merger at the negotiated exchange ratio; (iii) the preliminary due diligence performed to date and the recommendations of its advisors with respect to the viability of Crescent&#8217;s assets, including the proposed concurrent $125 million PIPE financing, would provide a meaningful opportunity to GlycoMimetics&#8217; stockholders; (iv) the likelihood of consummation of the proposed transaction would be high given Paragon licensees&#8217; recent record of successful reverse merger transactions and substantial capital resources; and (v) the proposal from Crescent was more favorable to GlycoMimetics than the potential value that might have resulted from further pursuing other strategic transactions available to GlycoMimetics, including with Party A, in light of the extensive outreach process undertaken to date. To assist with the potential transaction, the GlycoMimetics Board discussed the establishment of a special transaction committee for the purpose of reviewing, negotiating and making recommendations to the GlycoMimetics Board regarding subsequent changes to the Crescent Term Sheet (the &#8220;Term Sheet Committee&#8221;). The Term Sheet Committee was formed for convenience of the GlycoMimetics Board and not because of any conflicts-related concerns with Crescent or Paragon.  The GlycoMimetics Board approved the formation of the Term Sheet Committee and appointed Mr. Junius and Mr. Pearson to serve on the Term Sheet Committee. The GlycoMimetics Board delegated to the Term Sheet Committee the full power and authority of the GlycoMimetics Board to, among other things, consider, evaluate, negotiate and make recommendations to the GlycoMimetics Board regarding the Crescent Term Sheet.  It was also discussed and concluded that the Term Sheet Committee would update and seek input from the GlycoMimetics Board as appropriate; and members of the GlycoMimetics Board who were not also members of the Term Sheet Committee would have timely access to the Crescent Term Sheet and any subsequent changes thereto.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On September 19, 2024 and September 20, 2024, GlycoMimetics&#8217; management and the legal representatives and financial advisors to each of GlycoMimetics and Crescent continued to perform due diligence on Crescent and the potential strategic opportunity and held multiple discussions regarding, among other things, the form of the proposed transaction and related timelines; Crescent&#8217;s proposed increase of the level of concurrent PIPE financing with no concomitant change to GlycoMimetics valuation; the proposed development plan for Crescent&#8217;s technology and the indication under development; the potential contribution of additional assets to Crescent, including GlycoMimetics&#8217; existing pipeline; the substantive economic terms of a potential reverse merger transaction; and the relative valuations to be ascribed to each party.  Following these discussions, a revised Crescent Term Sheet was circulated to the Term Sheet Committee for approval, which was granted.  Thereafter, on the evening of September 20, 2024, Lucid delivered a revised draft of the Crescent Term Sheet to Wedbush, proposing a reverse merger transaction ascribing an $8,000,000 enterprise valuation to GlycoMimetics, a $50,000,000 enterprise valuation of Crescent, a concurrent PIPE financing in the amount of $125,000,000, and setting forth certain other material terms including (1) conditions to execution of any definitive agreement, (2) conditions to the closing of the business combination transaction; and (3) the exclusivity period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 22, 2024, representatives of Wedbush delivered a revised Crescent Term Sheet to Lucid that included proposed changes to the cash deliverable collar, post-closing board representation, a shortening of the exclusivity period, and a number of the other legal terms, while leaving the respective enterprise values and concurrent financing requirements unchanged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">On September 23, 2024, multiple discussions were held between GlycoMimetics&#8217; management and the Term Sheet Committee regarding the revised Crescent Term Sheet, including an update on negotiations and the anticipated timeline for a potential transaction with Crescent.  The members of the Term Sheet Committee provided feedback and direction to GlycoMimetics&#8217; management on these matters, and authorized GlycoMimetics&#8217; management to continue to negotiate and to execute the non-binding term sheet consistent with such feedback. The revised Crescent Term Sheet was shared with Wedbush that afternoon, and later that day was returned to Lucid and GlycoMimetics&#8217; management with minor adjustments to the board representation provision and amount of the collar for net cash to be delivered at closing. GlycoMimetics&#8217; management met once again with the members of the Term Sheet Committee regarding these additional changes, which were approved.  Thereafter, GlycoMimetics and Crescent executed the non-binding Crescent Term Sheet.  The executed Crescent Term Sheet proposed a reverse merger transaction that provided an ascribed value of </span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Crescent of $50 million, with an implied ownership interest in the Combined Company of approximately 86.2% for Crescent equityholders and an ascribed value of GlycoMimetics of $8 million (assuming closing net cash of $1 million) with an implied ownership interest in the Combined Company of approximately 13.8% for existing GlycoMimetics equityholders, in each case, prior to accounting for the proposed $125 million concurrent PIPE investment. The GlycoMimetics valuation was based on (i) $1 million of net cash at closing, plus (ii) a non-cash enterprise value of $7 million. The term sheet also provided for a concurrent financing at closing of no less than $125 million. The executed term sheet also provided for an exclusive negotiation period of an additional 21 days from execution of the Crescent Term Sheet.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 24, 2024, GlycoMimetics made the decision not to pursue a transaction with Party A. Party A is owned by a Chinese parent and GlycoMimetics was concerned about the unknown time it would take for Chinese regulatory bodies to clear the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following execution of the Crescent Term Sheet, on September 25, 2024, GlycoMimetics&#8217; management and their representatives from Lucid and Sidley met with Crescent management and representatives of Wedbush and Gibson, Dunn &amp; Crutcher LLP (&#8220;Gibson&#8221;), Crescent&#8217;s legal advisor, via video conference to discuss the timeline and process for signing definitive agreements providing for a potential business combination and a concurrent private placement financing, including the status of Gibson&#8217;s discussions with the SEC regarding the preferred form of the merger, and discussed and tentatively agreed on a work plan for such definitive agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On September 27, 2024, Gibson provided their formal due diligence request list to GlycoMimetics, and thereafter GlycoMimetics provided Crescent and its advisors with access to an online data room for purposes of conducting further business, financial, legal, tax, intellectual property, insurance and other due diligence with respect to GlycoMimetics and its business.  Between September 27, 2024 and October 28, 2024, representatives of GlycoMimetics&#8217; management team conducted further business and financial due diligence with respect to Crescent, its business and the market for its pipeline products, and, over the same period of time, GlycoMimetics&#8217; legal and financial advisors conducted due diligence with respect to Crescent and its business based on verbal and written responses from Crescent&#8217;s management team and its financial and legal advisors.  During the same period, GlycoMimetics&#8217; advisors negotiated the terms and conditions of the Merger Agreement at the direction of and in coordination with the GlycoMimetics Board and GlycoMimetics&#8217; management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 16, 2024, GlycoMimetics executed an indemnity letter with Jefferies LLC, TD Securities (USA) LLC and Stifel, Nicolaus &amp; Company, Incorporated as placement agents in respect of the sale of securities underlying the proposed $125 million concurrent PIPE financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 17, 2024, the GlycoMimetics Board held a meeting with GlycoMimetics&#8217; management to discuss the status of the reverse merger negotiations and the ongoing discussions regarding the structuring of the transaction. The GlycoMimetics Board reviewed the proposed transaction timeline and GlycoMimetics&#8217; existing cash resources, the proposed PIPE financing for the transaction, including the potential dilution to GlycoMimetics shareholders as a result of the proposed PIPE financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 17, 2024, representatives of Sidley and Lucid discussed with Gibson the potential terms of the preferred stock to be issued in the merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 19, 2024, Gibson delivered draft documentation for the PIPE financing to Sidley.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 21, 2024, members of GlycoMimetics Board met with Sidley and Lucid and discussed the drafts of the Merger Agreement and the PIPE documentation, and following such discussion Sidley sent to Gibson an issues list for negotiation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later, on October 21, 2024, representatives of Sidley and Lucid and representatives of Gibson had a teleconference to negotiate the terms of the PIPE financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 22, 2024, representatives of Gibson delivered to Sidley drafts of certain ancillary agreements and documents relating to the merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later in the day on October 22, 2024, representatives of Gibson and representatives of Sidley had a videoconference call to negotiate the terms of the merger agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 23, 2024, GlycoMimetics&#8217; management participated in a due diligence call with the placement agents for the PIPE and their advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 24, 2024, representatives of Lucid and representatives of Wedbush had a videoconference to discuss the merger consideration calculation and Lucid requested the addition of a floor concept to protect GlycoMimetics in the event Crescent engaged in a dilutive acquisition during the pre-closing period. On October 24, 2024, representatives of Gibson provided to Sidley a proposed approach to addressing the concerns raised by GlycoMimetics regarding the impact of dilutive acquisitions and GlycoMimetics&#8217; potential cash needs through closing. Management of GlycoMimetics, Sidley and Lucid discussed the proposed approach, and later in the day representatives of Sidley provided a revised draft of the merger agreement to Gibson, which included updates providing that: (1) for purposes of determining the value of GlycoMimetics in the calculation of the exchange ratio, GlycoMimetics would be valued, at a minimum, at 3% of the value of the combined company (including the amount received in the PIPE), subject to certain assumptions and an adjustment for GlycoMimetics net cash delivered at closing, (2) a time-based adjustment for the amount of GlycoMimetics net cash required to be delivered at closing would be made if the closing of the merger were to occur after June 30, 2024, and (3) if the merger agreement were to be terminated by Crescent after May 30, 2024 in certain situations where GlycoMimetics would not otherwise receive a termination fee, GlycoMimetics would nonetheless be entitled to receive a set fee for each month between May 30, 2024 and the termination, up to $2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the evening of October 24, 2024, representatives of Gibson provided a revised draft of the merger agreement to Sidley.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On the morning of October 25, 2024, management of GlycoMimetics discussed the revised draft merger agreement with Sidley and Lucid.  Throughout the day GlycoMimetics&#8217; management and advisors had numerous calls with Crescent and its advisors to negotiate the terms of the merger agreement and ancillary agreements, and in the early evening on October 25, 2024, the representatives of Sidley provided a revised draft of the merger agreement to Gibson.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Negotiations on the merger agreement included the structure of the merger, involving a two-step process to achieve desired tax and legal outcomes, and the conversion of securities, detailing the exchange ratio and treatment of options and warrants. In addition, valuation and financial adjustments were crucial, with specific procedures for determining Crescent&#8217;s valuation and GlycoMimetics&#8217; net cash position, and terms for financing. Governance changes, such as board and officer appointments and amendments to organizational documents, were negotiated alongside employee benefits, including the termination of GlycoMimetics&#8217; 401(k) plans and acceleration of vesting for options. Regulatory compliance, ensuring the merger qualifies as a reorganization under Section 368(a) of the Internal Revenue Code, and indemnification provisions for directors and officers were also key points. Termination provisions, stockholder consents, and miscellaneous provisions like amendments and waivers were meticulously detailed to address both parties&#8217; interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 25, 2024, the GlycoMimetics Board held a video conference meeting with members of GlycoMimetics&#8217; management team in attendance. At the meeting, the GlycoMimetics Board was provided with an overview of the proposed merger (including the potential benefits and the risks related thereto), the key terms of the draft merger agreement and related ancillary documents, and its fiduciary duties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Over the course of the next several days, GlycoMimetics and its advisors had rolling negotiations with Crescent and its advisors regarding the terms of the merger agreement and the ancillary agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 28, 2024, the parties entered into the Merger Agreement and the related ancillary documents and the private placement investors executed and delivered the Subscription Agreement for the $125&#160;million Crescent Pre-Closing Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 29, 2024, GlycoMimetics and Crescent issued a joint press release announcing the execution and delivery of the Merger Agreement, and GlycoMimetics filed a Current Report on Form 8-K, which filed as an exhibit (a) the Merger Agreement, (b) the form of Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock, (c) the form of Crescent Support Agreement, (d) the form of GlycoMimetics Support Agreement, (e) the form of GlycoMimetics Securities Purchase Agreement, (f) the form of Registration Rights Agreement, (g) the form of Lock-up Agreement, (h) a press release and a joint press release, dated October 29, 2024, respectively (i) an investor presentation providing information on Crescent, and (j) a transcript of a conference call held to announce the proposed transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Over the course of second half of January 2025, Gibson, Crescent, Sidley and GlycoMimetics discussed potential amendments to the merger agreement and the securities purchase agreement, and on February 3, 2025, representatives of Gibson provided drafts of an amendment to the merger agreement and an amended and restated securities purchase agreement related to the PIPE financing. The amended and restated securities purchase agreement provided, among other things, for the purchase of securities of Crescent immediately prior to the closing of the merger in lieu of the purchase of securities of GlycoMimetics immediately following the closing of the merger. The price and other economic terms of the financing remained materially unchanged. The amendment to the merger agreement adjusted, among other things, (i) the structure of PIPE financing described in the merger agreement (as described above) and (ii) the filings contemplated to be made with the SEC in connection with the transactions contemplated by the merger agreement. Relative to the terms of the merger agreement signed on October 28, 2024, the amendment to the merger agreement did not result in a change to the expected exchange ratio or ownership of the combined company by GlycoMimetics securityholders as of immediately prior to the merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Over the course of the next several days, GlycoMimetics and its advisors had rolling negotiations with Crescent and its advisors regarding the terms of the amendment to the merger agreement and the amended and restated securities purchase agreement. On February 13, 2025, representatives of Sidley and representatives of Gibson and Crescent proposed that the amendment to the merger agreement contain a covenant that Crescent would, if necessary, obtain additional support agreements for investors participating in any interim financings by Crescent, such that the Crescent stock subject to support agreements would exceed a majority of Crescent&#8217;s outstanding shares (measured immediately following the closing of such interim financing).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 14, 2025, the parties entered into the amendment to the merger agreement and the amended and restated securities purchase agreement (along with the investors in the PIPE financing), and GlycoMimetics filed a Current Report on Form 8-K related thereto.</p><a id="GlycoMimeticsReasonsfortheMerger_246864"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">GlycoMimetics&#8217; Reasons for the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During the course of its evaluation of the Merger Agreement and the transactions contemplated thereby, the GlycoMimetics Board held numerous meetings, consulted with GlycoMimetics&#8217; senior management and with financial and legal advisors and consultants to the GlycoMimetics Board. In reaching its decision to approve the Merger Agreement and the transactions contemplated thereby, the GlycoMimetics Board considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the then-current and historical trading prices of GlycoMimetics common stock, and the possibility that GlycoMimetics common stock could be delisted from the Nasdaq and only trade through the over-the-counter markets, if at all;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the GlycoMimetics Board&#8217;s belief that GlycoMimetics&#8217; business development efforts were not reasonably likely to result in any significant developments or events in the near term that could reasonably be expected to serve as a meaningful catalyst for GlycoMimetics&#8217; stock price;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the extensive efforts of the GlycoMimetics Board and GlycoMimetics&#8217; management over an extended period of time to identify a fundable business model for GlycoMimetics that could reasonably be expected to enhance and create long-term shareholder value;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the risks associated with GlycoMimetics&#8217; business plan, including execution risk, funding risk, technology risk, regulatory risk, risks relating to the potential size and/or profitability of GlycoMimetics&#8217; potential target markets, and risks relating to the evolving competitive landscape relating for GlycoMimetics&#8217; products and services;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">GlycoMimetics&#8217; liquidity position, extremely limited funding runway and repeated inability to raise material amounts of additional capital;</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the comprehensive and thorough process of reviewing and analyzing potential strategic alternatives undertaken by the GlycoMimetics Board and management, including the exploration of potential sale of the company transactions, licensing transactions, transactions for the sale of key assets or businesses, and financing transactions, the GlycoMimetics Board&#8217;s belief that no commercially viable alternative financing, strategic investment, merger, asset sale or licensing transaction was reasonably available to GlycoMimetics, and the GlycoMimetics Board&#8217;s belief that the only reasonably executable alternative to the Merger was a liquidation and dissolution of GlycoMimetics that could not be reasonably expected to provide any dividend, liquidating distribution or other payments or value to GlycoMimetics stockholders;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the GlycoMimetics Board&#8217;s belief that the Exchange Ratio for the Merger is the highest Exchange Ratio to which Crescent was willing to agree and that the other terms of the Merger Agreement represent in the aggregate the most favorable terms to GlycoMimetics and its stockholders to which Crescent was willing to agree;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">that following the Merger, the pre-Merger GlycoMimetics stockholders will continue to own common equity in Crescent and the GlycoMimetics Board&#8217;s belief that this continuing equity interest will provide the existing GlycoMimetics stockholders with an opportunity to participate following the Merger in the potential equity value of the Combined Company, which will focus on Crescent&#8217;s product pipeline;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the GlycoMimetics Board&#8217;s view, based on the scientific, regulatory and technical due diligence conducted by GlycoMimetics&#8217; management and advisors of the potential market opportunity of Crescent&#8217;s product candidates, which the GlycoMimetics Board anticipates will be the focus of the Combined Company;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the GlycoMimetics Board&#8217;s view, following review with GlycoMimetics&#8217; management and advisors, of Crescent&#8217;s anticipated fundraising and development plans and the potential ability of the Combined Company to successfully raise additional funds to enable the continued development of Crescent&#8217;s product pipeline through anticipated future value inflection points;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the GlycoMimetics Board&#8217;s belief that the funding advances by Crescent provided for in the Merger Agreement are reasonably likely to provide sufficient funding to GlycoMimetics to allow GlycoMimetics to close the Merger and should provide a cash cushion that, in the event the Merger Agreement is terminated, will substantially enhance the ability of GlycoMimetics to conduct an orderly dissolution and liquidation; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the ability of the GlycoMimetics Board to respond to unsolicited acquisition proposals that third parties may make before GlycoMimetics stockholders approve the Merger, including the GlycoMimetics Board&#8217;s ability to change its recommendation regarding the Merger and (subject to payment of the breakup fee described elsewhere in this proxy statement/prospectus) terminate the Merger Agreement in response to a superior proposal.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Board also considered the terms of the Merger Agreement and related transaction documents, including those described below, and concluded that the terms of the Merger Agreement and related transaction documents, in the aggregate, were fair to and in the best interests of GlycoMimetics and its stockholders under the circumstances:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">that under the terms of the Merger Agreement, the pre-Merger GlycoMimetics stockholders are anticipated (subject to dilution from any equity issued by Crescent after the date of the Merger Agreement and before the closing) to own approximately 3.10% of the fully-diluted equity interests of Crescent at the closing;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the nature of the conditions to GlycoMimetics&#8217; and Crescent&#8217;s respective obligations to complete the Merger, as more fully described below under the caption &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Conditions to the Completion of the Merger</i>,&#8221; beginning on page 147 in this proxy statement/prospectus, and the GlycoMimetics Board&#8217;s view of the likelihood that the Merger will be completed on a timely basis;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the respective rights of, and limitations on, GlycoMimetics and Crescent under the Merger Agreement to consider and engage in discussions regarding unsolicited acquisition proposals under certain circumstances, and the limitations on the board of directors of each party to change its recommendation in favor of the Merger, as more fully described below under the caption &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Non-Solicitation</i>&#8221; and &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;</i><i style="font-style:italic;">Board Recommendation Change</i>,&#8221; beginning on pages 144 and 145 in this proxy statement/prospectus;</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the potential termination fee plus reimbursement certain of expenses, which could become payable by Crescent to GlycoMimetics if the Merger Agreement is terminated in certain circumstances, as more fully described below under the caption &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Termination and Termination Fees</i>,&#8221; beginning on page 148 in this proxy statement/prospectus;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the GlycoMimetics Support Agreements, pursuant to which certain stockholders of GlycoMimetics agreed, solely in their capacities as stockholders, to vote their shares of GlycoMimetics common stock in favor of the Merger and against any alternative acquisition proposals, and that such voting obligations terminate if the GlycoMimetics Board changes its recommendation with respect to the Merger, all as more fully described below under the caption &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Support Agreements</i>,&#8221; beginning on page 151 in this proxy statement/prospectus;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the provisions of the Merger Agreement relating to the officers and employees of GlycoMimetics, including the treatment of employee stock options and restricted stock units in the Merger, the treatment of GlycoMimetics&#8217; obligations to pay severance to officers and employees, and the provisions relating to GlycoMimetics&#8217; ability to change the compensation of officers and employees and/or make any bonus payment or equity awards following the signing of the Merger Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the course of its deliberations, the GlycoMimetics Board also considered a variety of risks and other countervailing factors related to entering into the Merger, including:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the termination fee payable by GlycoMimetics upon the occurrence of certain events and the potential effect of such termination fee in deterring other potential acquirors from proposing an alternative acquisition that may be more advantageous to GlycoMimetics stockholders;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the substantial expenses to be incurred by GlycoMimetics in connection with the Merger and the potential for events out of the control of GlycoMimetics to delay the vote of GlycoMimetics stockholders or Crescent stockholders and/or delay or prevent the closing;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the risk that GlycoMimetics does not have sufficient liquidity to fund expenses and options through the closing, including if the closing were to be delayed;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the risk that one of more of the conditions to the closing will not be satisfied, including among others the risk that Crescent stockholders do not approve the Merger; the risk that GlycoMimetics common stock is delisted by Nasdaq and/or the risk that a material adverse effect occurs with respect to GlycoMimetics; and the related risk that in the event the Merger Agreement is terminated without the closing occurring (and without GlycoMimetics entering into an agreement for a superior proposal), GlycoMimetics will not have sufficient remaining cash to be able to fund an orderly dissolution and liquidation;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the restrictions on GlycoMimetics soliciting alternative acquisition proposals during the pendency of the Merger, as more fully described below under the caption &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Non-Solicitation</i>,&#8221; beginning on page 144 in this proxy statement/prospectus;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">that the trading of GlycoMimetics common stock, both prior to the Merger and following the completion of the Merger, will likely be materially impacted by matters relating to Crescent and its financial condition, operating results, pipeline and prospects; that Crescent is not currently a public company and limited information available relating to Crescent is publicly available; that there is no established trading market or market prices for Crescent common stock; and that as a result the price of GlycoMimetics common stock could increase, decrease and/or be volatile;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">that the ability of the Combined Company to execute on its business plan will be subject to substantial challenges, some of which will be beyond the control of the Combined Company, including risks and challenges relating to execution, technology, regulatory matters, funding needs and the fact that the Combined Company is not anticipated to generate any material amount of revenue in the near future, risks relating to the development and/or commercialization of Crescent&#8217;s product pipeline, and inherent uncertainties as to the extent to which the Combined Company will be able to successfully execute its business plan on a timely basis, if at all, and achieve its projections;</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the interests that GlycoMimetics&#8217; directors and executive officers have with respect to the transactions that are or may be different from, or in addition to, the interests of GlycoMimetics stockholders generally, including those interests described in the sections entitled &#8220;<i style="font-style:italic;">The Merger&#8212;Interests of GlycoMimetics&#8217; Directors and Executive Officers in the Merger</i>&#8221; beginning on page 122 in this proxy statement/prospectus; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">the various other risks associated with the Combined Company and the proposed transactions, including those described in the sections entitled &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; and &#8220;<i style="font-style:italic;">Cautionary Note Regarding Forward-Looking Statements</i>&#8221; beginning on pages 16 and 92, respectively, in this proxy statement/prospectus.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing information and factors considered by the GlycoMimetics Board are not intended to be exhaustive but are believed to include all of the material factors considered by the GlycoMimetics Board. In view of the wide variety of factors considered in connection with its evaluation of the Merger and the complexity of these matters, the GlycoMimetics Board did not find it useful to attempt, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of the GlycoMimetics Board may have given different weight to different factors. The GlycoMimetics Board conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, GlycoMimetics&#8217; senior management team and financial and legal advisors and consultants to the GlycoMimetics Board, and considered the factors overall to be favorable to, and to support, its determination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GlycoMimetics Liquidation Analysis</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the evaluation of the Merger by the GlycoMimetics Board, GlycoMimetics&#8217; management prepared an analysis with respect to the estimated value of the liquidation or dissolution of GlycoMimetics as a potential alternative to the Merger, including for such purposes GlycoMimetics&#8217; estimated cash position at the time of the potential dissolution or liquidation, GlycoMimetics&#8217; estimated expenses in connection with any such liquidation or dissolution, and estimated amount of cash available to be distributed to GlycoMimetics stockholders in connection with any such proposed future dissolution or liquidation (the &#8220;Liquidation Analysis&#8221;). Although the Liquidation Analysis assumes that the entirety of GlycoMimetics cash balance at the time of the dissolution or liquidation would be available for distribution to GlycoMimetics stockholders, it is unlikely that the entirety of such cash balance would be available at the time of an actual dissolution or liquidation due to the requirements of applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The inclusion of the Liquidation Analysis should not be deemed an admission or representation by GlycoMimetics or any of its officers, directors, affiliates, advisors, or other representatives with respect to the Liquidation Analysis. The Liquidation Analysis is not included to influence your views on the Merger, the Merger Agreement and the transactions contemplated thereby and is summarized in this proxy statement/prospectus solely to provide stockholders access to certain information considered by the GlycoMimetics Board in connection with its evaluation of the Merger, the Merger Agreement and the transactions contemplated thereby. Any estimates contained in these analyses are not necessarily indicative of actual values or predictive of future results or values, which may be significantly more or less favorable than as set forth below. In addition, analyses relating to the value of GlycoMimetics do not purport to be appraisals or reflect the prices at which shares of GlycoMimetics common stock may actually be valued or trade, either before or after the consummation of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Liquidation Analysis is prospective financial information and was not prepared with a view toward public disclosure, nor was it prepared with a view toward compliance with published guidelines of the SEC, the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information, or GAAP. Neither the independent registered public accounting firm of GlycoMimetics nor any other independent accountant has audited, reviewed, compiled, examined or performed any procedures with respect to the accompanying unaudited prospective financial information for the purpose of its inclusion herein, and accordingly, neither the independent registered public accounting firm of GlycoMimetics nor any other independent accountant expresses an opinion or provides any form of assurance with respect thereto for the purpose of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The prospective financial information included in this proxy statement/prospectus has been prepared by, and is the responsibility of, GlycoMimetics&#8217; management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled nor applied agreed-upon procedures with respect to the accompanying prospective financial information and, accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. The PricewaterhouseCoopers LLP report included in this proxy statement/prospectus relates to Crescent&#8217;s previously issued financial statements. It does not extend to the prospective financial information and should not be read to do so.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Liquidation Analysis includes estimates of cash and of certain expenditures, which for the purpose of the Liquidation Analysis were not calculated in accordance with GAAP. Non-GAAP financial measures should not be viewed as a substitute for GAAP financial measures and may be different from non-GAAP financial measures used by other companies. Furthermore, there are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation. Accordingly, non-GAAP financial measures should be considered together with, and not as an alternative to, financial measures prepared in accordance with GAAP. The SEC rules, which otherwise would require a reconciliation of a non-GAAP financial measure to a GAAP financial measure, do not apply to non-GAAP financial measures provided to a board of directors or financial advisors in connection with a proposed business combination transaction such as the Merger if the disclosure is included in a document such as this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">In light of the foregoing factors and the uncertainties inherent in estimated cash balances, stockholders are cautioned not to place undue reliance, if any, on the Liquidation Analysis.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The below summary of the Liquidation Analysis is subject to the statements above, and it represents estimates prepared by GlycoMimetics&#8217; management of the cash which could be distributed to stockholders as permitted under applicable law pursuant to a plan of dissolution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Key assumptions underlying the Liquidation Analysis included: (i) that the entire distribution of GlycoMimetics&#8217; net cash would be made in November 2024 (the &#8220;Deemed Liquidation Date&#8221;)&#894; (ii) that GlycoMimetics would have approximately $3.87 million of net cash and cash equivalents as of the Deemed Liquidation Date, after satisfying its liabilities and paying the costs and expenses of the liquidation and dissolution&#894; and (iii) that approximately 64.5 million total shares of GlycoMimetics common stock would be issued and outstanding on the Deemed Liquidation Date.  The analysis resulted in an estimated cash distribution per share of GlycoMimentics common stock of $0.06 per share.</span></p><a id="CrescentsReasonsfortheMerger_810443"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Crescent&#8217;s Reasons for the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In the course of reaching its decision to approve the Merger and the Crescent Pre-Closing Financing, the Crescent Board held numerous meetings, consulted with Crescent&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors.  Ultimately, the Crescent Board concluded that a merger with GlycoMimetics, together with the additional financing committed from the Crescent Pre-Closing Financing, was the best option to generate capital resources to support the advancement of Crescent&#8217;s pipeline and fund the combined organization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional factors the Crescent Board considered included the following (which factors are not necessarily presented in any order of relative importance):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of Crescent&#8217;s pipeline, compared to the capital and investors Crescent could otherwise gain access to if it continued to operate as a privately-held company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Crescent Pre-Closing Financing will generate capital resources to fund the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits from increased public market awareness of Crescent and its pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical and current information concerning Crescent&#8217;s business, including its financial performance and condition, operations, management and preclinical and clinical data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the competitive nature of the industry in which Crescent operates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Crescent Board&#8217;s fiduciary duties to Crescent stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Crescent Board&#8217;s belief that no alternatives to the Merger, together with the additional financing committed from the Crescent Pre-Closing Financing, were reasonably likely to create greater value for Crescent stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Crescent Board;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Crescent Board&#8217;s expectation that the Merger, together with the additional financing committed from the Crescent Pre-Closing Financing, would be a higher probability and more cost-effective means to access capital than other options considered, including an IPO;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected operations, management structure and operating plans of the Combined Company (including the ability to support the Combined Company&#8217;s current and planned preclinical studies and clinical trials);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the business, history, operations, financial resources and credibility of GlycoMimetics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of appraisal rights under the DGCL to holders of Crescent capital stock who comply with the required procedures under the DGCL, which allow such holders to seek appraisal of the fair value of their shares of Crescent capital stock as determined by the Delaware Court of Chancery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and conditions of the Merger Agreement, including the following:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the determination that the expected relative percentage ownership of GlycoMimetics stockholders and Crescent stockholders in the combined organization was appropriate, based on the Crescent Board&#8217;s judgment and assessment of the approximate valuations of GlycoMimetics (including the value of the net cash GlycoMimetics is expected to provide to the combined organization) and Crescent (including the value of the amount of proceeds from the Crescent Pre-Closing Financing);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expectation that the Merger will be treated as a reorganization for U.S. federal income tax purposes, with the result that the Crescent stockholders will generally not recognize taxable gain or loss for U.S. federal income tax purposes with respect to the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the limited number and nature of the conditions of the obligation of GlycoMimetics to consummate the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rights of Crescent under the Merger Agreement to consider certain unsolicited acquisition proposals under certain circumstances should Crescent receive a superior offer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rights of Crescent under the Merger Agreement to effect a change in recommendation in favor of the Merger as a result of a material development or change in circumstances (i.e., applicable Intervening Events);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the conclusion of the Crescent Board that the potential termination fees payable by GlycoMimetics or Crescent to the other party, and the circumstances when such fee may be payable, were reasonable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the belief that the other terms of the Merger Agreement, including the parties&#8217; representations, warranties and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the shares of GlycoMimetics common stock issued to Crescent stockholders, including shares of GlycoMimetics common stock issued in exchange for shares of Crescent common stock sold in the Crescent Pre-Closing Financing, will be registered on a Form S-4 registration statement and will become freely tradable for Crescent stockholders who are not affiliates of Crescent and who are not parties to lock-up agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Support Agreements, pursuant to which certain directors, officers and stockholders of Crescent and GlycoMimetics, respectively, have agreed, solely in their capacity as stockholders of Crescent and GlycoMimetics, respectively, to vote all of their shares of Crescent capital stock or GlycoMimetics common stock in favor of the adoption or approval, respectively, of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to obtain a Nasdaq listing and the change of the combined organization&#8217;s name to Crescent Biopharma, Inc. prior to or upon the closing of the Merger; and</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the likelihood that the Merger will be consummated on a timely basis.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Crescent Board also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that the Merger might not be completed and the potential adverse effect of the public announcement of the Merger on the reputation of Crescent and the ability of Crescent to obtain financing in the future in the event the Merger is not completed; the possibility that the Crescent Pre-Closing Financing might not be completed or completed in accordance with the terms of the Merger Agreement and the potential adverse effect of the public announcement of the Crescent Pre-Closing Financing on the reputation of Crescent and the ability of Crescent to obtain financing in the future in the event the Crescent Pre-Closing Financing is not completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Exchange Ratio used to establish the number of shares of GlycoMimetics common stock to be issued to Crescent stockholders in the Merger is fixed, except for adjustments due to GlycoMimetics&#8217; net cash balances, the amount of proceeds from the Crescent Pre-Closing Financing and outstanding capital stock at closing, and thus the relative percentage ownership of GlycoMimetics stockholders and Crescent stockholders in the combined organization immediately following the completion of the Merger is similarly fixed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential reduction of GlycoMimetics&#8217; net cash prior to the closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility that GlycoMimetics could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Merger or change its recommendation to approve the Merger upon certain events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the Merger might not be consummated in a timely manner or at all, for a variety of reasons, such as the failure of GlycoMimetics to obtain the required stockholder vote or the failure of Crescent to close the Crescent Pre-Closing Financing, and the potential adverse effect on the reputation of Crescent and the ability of Crescent to obtain financing in the future in the event the Merger is not completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in connection with completing the Merger, the time and effort of Crescent senior management required to complete the Merger, the related disruptions or potential disruptions to Crescent&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with Crescent, and related administrative challenges associated with combining the companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the additional expenses and obligations to which Crescent&#8217;s business will be subject to following the Merger that Crescent has not previously been subject to, and the operational changes to Crescent&#8217;s business, in each case that may result from being a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the fact that the representations and warranties in the Merger Agreement do not survive the closing of the Merger and the potential risk of liabilities that may arise post-closing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that future sales of common stock by existing GlycoMimetics stockholders may cause the price of GlycoMimetics common stock to fall, thus reducing the potential value of GlycoMimetics common stock received by Crescent stockholders following the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Risk Factors</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; in this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The foregoing information is not intended to be exhaustive, but is believed to include a summary of all of the material factors considered by the Crescent Board in its consideration of the Merger Agreement, the Crescent Pre-Closing Financing, and the transactions contemplated thereby.  After conducting an overall analysis of these and other factors, including thorough discussions with, and questioning of, Crescent&#8217;s senior management and legal counsel, the Crescent Board concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above.  Based on this overall analysis of the factors described above, the Crescent Board unanimously approved the Merger Agreement, the Merger, the Crescent Pre-Closing Financing and the other transactions contemplated by the Merger Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion of Lucid, GlycoMimetics&#8217; Financial Advisor, to the GlycoMimetics Board of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As stated above, pursuant to an engagement letter dated July 24, 2024 (the &#8220;Engagement Letter&#8221;), GlycoMimetics retained Lucid to act as its financial advisor in connection with the Merger and to render an opinion to the GlycoMimetics Board as to the fairness of the Exchange Ratio, from a financial point of view, to the holders of common stock of GlycoMimetics (the &#8220;Lucid Opinion&#8221;).&#160;On October 28, 2024, at the request of the GlycoMimetics Board, Lucid rendered an oral opinion, subsequently confirmed by delivery of the Lucid Opinion dated October 28, 2024, to the GlycoMimetics Board, that the Exchange Ratio was fair, from a financial point of view, to the holders of common stock of GlycoMimetics as of the date of the Lucid Opinion and based upon the various assumptions, qualifications and limitations set forth therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The full text of the Lucid Opinion is attached as </b><span style="font-style:italic;font-weight:bold;">Annex&#160;B</span><b style="font-weight:bold;"> to this proxy statement/prospectus and is incorporated by reference. GlycoMimetics encourages its stockholders to read the Lucid Opinion in its entirety for the assumptions made, procedures followed, other matters considered and limits of the review by Lucid. The summary of the Lucid Opinion set forth herein is qualified by reference to the full text of the Lucid Opinion. Lucid provided the Lucid Opinion for the benefit and use of the GlycoMimetics Board in its consideration of the financial terms of the Merger. The Lucid Opinion is not a recommendation to the GlycoMimetics Board or to any stockholder as to how to vote or act with respect to the Merger or any other matter.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">As described elsewhere in this proxy statement/prospectus, concurrent with the execution and delivery of the Merger Agreement, certain institutional and accredited investors entered into a Securities Purchase Agreement with GlycoMimetics, pursuant to which they agreed, subject to the terms and conditions of such agreement, to purchase immediately following the consummation of the Merger, shares of GlycoMimetics common stock and pre-funded warrants for an aggregate purchase price of approximately $200.0 million in a private placement. The Merger Agreement and the Securities Purchase Agreement were amended on February 14, 2025 to, among other things, contemplate that the investors would instead receive, immediately prior to the consummation of the Merger, shares of Crescent common stock and pre-funded warrants for an aggregate purchase price of approximately $200.0 million, which is referred to in this proxy statement/prospectus as the Crescent Pre-Closing Financing. This &#8220;Opinion of GlycoMimetics&#8217; Financial Advisor&#8221; reflects the current structure of the Merger and Crescent Pre-Closing Financing. The Lucid Opinion attached as Annex B includes language regarding the original form of the Merger Agreement and Securities Purchase Agreement. Lucid has confirmed with the GlycoMimetics Board that this change to the Crescent Pre-Closing Financing (i) does not impact the conclusions of its opinion and (ii) does not require an amendment to its opinion.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Lucid Opinion, Lucid took into account an assessment of general economic, market and financial conditions as well as its experience in connection with similar transactions and securities valuations generally and, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed a draft of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain publicly available financial and other information for each of GlycoMimetics and Crescent, respectively, including equity research on comparable companies, and certain relevant financial and operating data furnished to Lucid by the management of GlycoMimetics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain relevant historical financial and operating data concerning Crescent furnished to Lucid by the management of Crescent and its financial advisors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Discussed with certain members of the management of GlycoMimetics the historical and current business operations, financial condition and prospects of GlycoMimetics and Crescent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed the reported price and trading histories of certain publicly traded companies that Lucid deemed relevant;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain financial terms of the Merger Agreement as compared to the publicly available financial terms of certain selected business combinations that Lucid deemed relevant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain financial terms of completed initial public offerings for certain companies that Lucid deemed relevant; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as Lucid deemed relevant for purposes of this Opinion</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In conducting Lucid&#8217;s review and arriving at the Lucid Opinion, Lucid has, with GlycoMimetics&#8217; consent, relied upon the assumption that all information provided to Lucid by GlycoMimetics and Crescent was accurate and complete in all material respects. Lucid did not undertaken any responsibility for the accuracy, completeness or reasonableness of, or independent verification of, such information. Furthermore, Lucid assumed, with GlycoMimetics&#8217; consent, that the Exchange Ratio will be 14.7507.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid expressly disclaimed any undertaking or obligation to advise any person of any change in any fact or matter affecting the Lucid Opinion of which Lucid becomes aware after the date of the Lucid Opinion. Lucid assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of GlycoMimetics or Crescent since the date of the last financial statements made available to Lucid. Lucid did not obtain any independent evaluations, valuations or appraisals of the assets or liabilities of GlycoMimetics or Crescent, nor was Lucid furnished with such materials. In addition, Lucid did not evaluate the solvency or fair value of GlycoMimetics or Crescent under any state or federal laws relating to bankruptcy, insolvency or similar matters. The Lucid Opinion did not address any legal, tax or accounting matters related to the Merger, as to which Lucid assumed that GlycoMimetics and the GlycoMimetics Board received such advice from legal, tax and accounting advisors as each determined appropriate. The Lucid Opinion addressed only the fairness of the Exchange Ratio, from a financial point of view, to the holders of common stock of GlycoMimetics. Lucid expressed no view as to any other aspect or implication of the Merger or any other agreement or arrangement entered into in connection with the Merger. The Lucid Opinion was necessarily based upon economic and market conditions and other circumstances as they existed and could be evaluated by Lucid on the date of the Lucid Opinion. It should be understood that although subsequent developments may affect the Lucid Opinion, Lucid does not have any obligation to update, revise or reaffirm the Lucid Opinion and Lucid expressly disclaimed any responsibility to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid did not consider any potential legislative or regulatory changes currently being considered or recently enacted by the United States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the U.S. Securities and Exchange Commission, the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">For purposes of rendering the Lucid Opinion, Lucid assumed, with the consent of the GycoMimetics board of directors, that except as would not be in any way meaningful to Lucid&#8217;s analysis, the final form of the Merger Agreement would not differ from the draft agreement Lucid reviewed; the representations and warranties of each party contained in the Merger Agreement were true and correct in all respects; each party would perform all of the covenants and agreements required to be performed by it under the Merger Agreement; and the transactions contemplated by the Merger Agreement would be consummated in accordance with the terms of the Merger Agreement, without any waiver or amendment of any term or condition thereof.  Lucid also assumed that all governmental, regulatory and other consents and approvals contemplated by the Merger Agreement or otherwise required for the transactions contemplated thereby would be obtained and that in the course of obtaining any of those consents no restrictions would be imposed or waivers made that would have an adverse effect on GlycoMimetics, Crescent or the contemplated benefits of the Merger. Lucid assumed that the Merger would be consummated in a manner that complies with the applicable provisions of the Securities Act, the Exchange&#160;Act, and all other applicable federal and state statutes and the rules and regulations promulgated thereunder.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of rendering the Lucid Opinion, Lucid, with the consent of the GlycoMimetics Board, assumed that (i) prior to the closing of the Merger, Crescent would receive approximately $200.0 million in proceeds from the Crescent Pre-Closing Financing and that no Interim Financing (as defined in the Merger Agreement) would occur, (ii) the Exchange Ratio would be 14.7507, and (iii) upon closing of the Merger, the holders of Crescent common stock and Crescent preferred stock, Crescent options and Crescent warrants would in the aggregate hold approximately 86.2% of the fully-diluted shares of GlycoMimetics common stock (excluding certain GlycoMimetics options) immediately following the Merger (19.4% after giving effect to the Crescent Pre-Closing Financing), the holders of GlycoMimetics common stock would in the aggregate hold approximately 13.8% of the fully-diluted shares of GlycoMimetics common stock (excluding certain GlycoMimetics options) immediately following the Merger (3.1% after giving effect to the Crescent Pre-Closing Financing) and (iv) the investors in the Crescent Pre-Closing Financing would in the aggregate hold approximately 77.5% of the fully-diluted shares of GlycoMimetics common stock (excluding certain GlycoMimetics options).</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Lucid Opinion was intended for the benefit and use of the GlycoMimetics Board in its consideration of the financial terms of the Merger and, except as set forth in the Engagement Letter, may not be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose without Lucid&#8217;s prior written consent, except that the Lucid Opinion may be included in its entirety in any filing related to the Merger to be filed with the U.S. Securities and Exchange Commission and the proxy statement/prospectus to be mailed to the GlycoMimetics stockholders. The Lucid Opinion does not constitute a recommendation to the GlycoMimetics Board of whether to approve the Merger or to any GlycoMimetics stockholder or any other person as to how to vote or act with respect to the transactions contemplated by the Merger Agreement (including the Merger) or any other matter. The Lucid Opinion did not address GlycoMimetics&#8217; underlying business decision to proceed with the Merger or the relative merits of the Merger compared to other alternatives available to GlycoMimetics. Lucid expressed no opinion as to the prices or ranges of prices at which shares or the securities of any person, including GlycoMimetics, would trade at any time, including following the announcement or consummation of the Merger. Lucid was requested to opine as to, and the Lucid Opinion did not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the Merger, or any class of such persons, relative to the compensation to be paid to the holders of GlycoMimetics common stock in connection with the Merger or with respect to the fairness of any such compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Principal Financial Analyses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the principal financial analyses performed by Lucid to arrive at the Lucid Opinion. Some of the summaries of financial analyses include information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data set forth in the tables without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of the financial analyses. Lucid performed certain procedures, including each of the financial analyses described below and reviewed with the GlycoMimetics Board the assumptions on which such analyses were based and other factors, including the historical and projected financial results of GlycoMimetics and Crescent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transaction Overview as of the Date of the Lucid Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based upon the Exchange Ratio of 14.7507 at the time of the signing of the Merger Agreement, it was estimated that at the closing: (a)&#160;Crescent equity holders as of immediately prior to the Merger (including the shares issued in the approximately $200.0&#160;million Crescent Pre-Closing Financing) would own approximately 96.9% of the fully-diluted&#160;shares of GlycoMimetics common stock at the closing of the Merger, and (b)&#160;the GlycoMimetics equity holders as of immediately prior to the Merger will own approximately 3.1% of the fully-diluted&#160;shares of GlycoMimetics common stock at the closing of the Merger, in each case, subject to adjustment of the Exchange Ratio as set forth in the Merger Agreement and described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent Valuation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the purpose of the Lucid Opinion, Lucid utilized a Crescent Valuation of $50.0 million, which was the pre-money valuation utilized in the Crescent Pre-Closing Financing and the Merger Agreement. The post-money Crescent valuation is calculated by adding the negotiated value of $50.0 million plus $200.0 million raised in the Crescent Pre-Closing Financing totaling $250.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Analysis of Selected Initial Public Offering Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid reviewed certain publicly available information for the IPOs of 20 solid tumor-focused biopharmaceutical companies that have completed an IPO since September 2018 and whose lead product at the time of IPO was in early-stage of clinical development. Although the companies referred to below were used for comparison purposes, none of these companies are directly comparable to Crescent. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. These companies, which are referred to as the &#8220;Selected Precedent IPO Companies,&#8221; were:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Adagene</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bicara Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bicycle Therapeutics</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Black Diamond Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bolt Biotherapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CureVac N.V.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gritstone Bio</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Janux Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lyell Immunopharma</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Nuvectis Pharma</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Omega Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ORIC Pharmaceuticals</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prelude Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pyxis Oncology</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Relay Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tharimmune</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Turnstone Biologics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tyra Biosciences</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Werewolf Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Xilio Therapeutics</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The total enterprise value at IPO is defined as the pre-money equity value plus indebtedness, liquidation value of preferred stock and non-controlling interest, minus cash and cash equivalents at the time of its IPO. The Selected Precedent IPO Companies had total enterprise values between $32.1&#160;million and $3.1 billion. Lucid derived a median total enterprise value of $321.5&#160;million for the Selected Precedent IPO Companies. Using the 25th percentile and the 75th percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for Crescent (by adding an estimated $4.0&#160;million in net cash at closing), which was approximately $225.4&#160;million to $577.1&#160;million. This compares to the Crescent Valuation as per the Merger Agreement of $50.0&#160;million.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Precedent IPO Companies</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:37.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Filing Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Enterprise</b><br/><b style="font-weight:bold;">Value&#160;($M)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/13/24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Bicara Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">412.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2/9/24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Adagene</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">786.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">7/21/23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Turnstone Biologics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">137.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2/4/22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Nuvectis Pharma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">41.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1/13/22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Tharimmune</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">32.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10/22/21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Xilio Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">218.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10/7/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pyxis Oncology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">222.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/15/21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Tyra Biosciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">346.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">7/29/21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Omega Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">557.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">6/17/21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Lyell Immunopharma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,098.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">6/11/21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Janux Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">413.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">5/4/21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Werewolf Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">236.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2/4/21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Bolt Biotherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">437.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/25/20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Prelude Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">618.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">8/14/20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CureVac N.V.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,619.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">7/16/20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Relay Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,025.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4/24/20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">ORIC Pharmaceuticals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">261.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1/30/20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Black Diamond Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">296.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">5/22/19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Bicycle Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">127.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.47%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/27/18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:41.82%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Gritstone Bio</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">278.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Analysis of Selected Publicly Traded Companies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on its experience and professional judgment and using financial screening sources and databases to find companies that share similar business characteristics to Crescent within the biopharmaceutical industry, Lucid selected financial data of 13 publicly traded companies (referred to as the &#8220;Selected Publicly Traded Companies&#8221;). Each of the Selected Publicly Traded Companies had a lead candidate in the early stages of clinical development and focused on the solid tumor space. Furthermore, Lucid concentrated its analysis on comparable companies reporting cash balances exceeding $75.0 million, aligning with Crescent&#8217;s anticipated cash balance of over $200.0 million following the closing of the Crescent Pre-Closing Financing. Although the companies referred to below were used for comparison purposes, none of those companies is directly comparable to Crescent. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. The total enterprise values are based on closing stock prices on October 25, 2024. The Selected Publicly Traded Companies were:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Bicara Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Context Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Corbus Pharmaceuticals</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CytomX Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enliven Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Fate Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Immatics</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">InstilBio</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Janux Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mersana Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ORIC Pharmaceuticals</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">TScan Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tyra Biosciences</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Selected Publicly Traded Companies had implied total enterprise values between negative $56.7&#160;million and $2.1&#160;billion. Lucid derived a median implied total enterprise value of $135.2&#160;million for the Selected Publicly Traded Companies. Using the 25th&#160;percentile and the 75th&#160;percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for Crescent (by adding an estimated $4.0&#160;million in net cash at closing), which was approximately $64.2&#160;million to $661.8&#160;million. This compares to the Crescent Valuation as per the Merger Agreement of $50.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Publicly Traded Companies</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:86.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Company Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Enterprise</b><br/><b style="font-weight:bold;">Value&#160;($M)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Janux Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,139.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.08%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Enliven Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,048.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.08%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Tyra Biosciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">784.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.08%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Bicara Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">657.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.08%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Immatics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">386.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.08%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">ORIC Pharmaceuticals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">266.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.08%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Instil Bio</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">135.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.08%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mersana Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">95.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.08%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Context Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">74.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.08%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Corbus Pharmaceuticals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">60.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.08%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">TScan Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(9.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.08%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fate Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(50.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.08%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">CytomX Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(56.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Analysis of Selected Fairmount-Backed Publicly Traded Companies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on its experience and professional judgment, Lucid selected financial data of 6 publicly traded companies previously backed by the Fairmount team (referred to as the &#8220;Selected Fairmount-Backed Publicly Traded Companies&#8221;). The selection criteria for these companies was based on Crescent&#8217;s affiliation with Fairmount. Although the companies referred to below were used for comparison purposes, none of those companies is directly comparable to Crescent. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. The total enterprise values are based on closing stock prices on October 25, 2024. The Selected Publicly Traded Companies were:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Apogee Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Astria Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cogent Biosciences</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Oruka Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Spyre Therapeutics</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Viridian Therapeutics</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Selected Fairmount-Backed Publicly Traded Companies had implied total enterprise values between $292.5&#160;million and $2.3&#160;billion. Lucid derived a median implied total enterprise value of $952.0&#160;million for the Selected Fairmount-Backed Publicly Traded Companies. Using the 25th&#160;percentile and the 75th&#160;percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for Crescent (by adding an estimated $4.0&#160;million in net cash at closing), which was approximately $612.5&#160;million to $1.3&#160;billion. This compares to the Crescent Valuation as per the Merger Agreement of $50.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Selected Publicly Traded Companies</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Company Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Enterprise</b><br/><b style="font-weight:bold;">Value&#160;($M)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Apogee Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,323.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Spyre Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,346.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Viridian Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">983.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cogent Biosciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">920.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Oruka Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">504.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Astria Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">292.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Selected Precedent M&amp;A Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of the 9 most recent qualifying merger transactions of companies in the biopharmaceutical industry, which had a lead candidate in the early-stage of clinical development and focused on the solid tumor space (referred to as the &#8220;Selected Precedent M&amp;A Transactions&#8221;). Although the precedent transactions referred to below were used for comparison purposes, none of the target companies is directly comparable to Crescent. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the companies involved and other factors that could affect the merger value of such companies and Crescent to which they are being compared. Lucid reviewed the total enterprise values of the target companies (not inclusive of future milestone payments). These transactions, including the date each was closed, were as follows below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Selected Precedent M&amp;A Transactions had total implied enterprise values between $110.0&#160;million and $2.4&#160;billion. Lucid derived a median total enterprise value of $509.0&#160;million for the Selected Precedent M&amp;A Transactions. Using the 25th&#160;percentile and the 75th&#160;percentile of the implied total enterprise values, Lucid then calculated a range of implied total enterprise values for Crescent (by adding an estimated $4.0&#160;million in net cash at closing), which was approximately $204.0&#160;million to $1.2&#160;billion. This compares to Crescent&#8217;s Valuation as per the Merger Agreement of $50.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Selected Precedent M&amp;A Transactions</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Closed Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Target</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Acquirer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Implied&#160;Enterprise</b><span style="text-decoration-line:none;"><br/></span><b style="font-weight:bold;">Value&#160;($M)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">7/29/24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Nerio Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,300.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">5/2/24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Mariana Oncology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Novartis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,000.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4/3/24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Kinnate Biopharma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">XOMA Royalty Corp</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">115.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">11/22/23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">T3 Pharma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">509.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1/16/23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Neogene</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">AstraZeneca</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">200.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">9/7/22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Good Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Roche</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">250.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12/10/21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NBE Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Boehringer Ingelheim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,180.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1/23/20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Synthorx</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Sanofi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,350.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">5/31/2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">AurKa Pharma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.58%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Eli Lilly</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.7%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">110.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics Valuation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Analysis of Precedent Reverse Merger Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of life sciences reverse merger transactions dating back to January 2018 (referred to as the &#8220;Selected Precedent Reverse Merger Transactions&#8221;). Lucid reviewed the total premium to cash delivered to each target. These transactions, including the date each was closed, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Selected Precedent Reverse Merger Transactions</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Closed Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Surviving Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Public Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value Delivered</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">for Public</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Vehicle Net of Cash</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($ mm&#8217;s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">10/17/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">TuHURA Biosciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Kintara Therapeutics (Nasdaq: KTRA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">10/9/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Wex Pharmaceuticals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Virios Therapeutics (Nasdaq: VIRI)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">9/3/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Oruka Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">ARCA Biopharma (Nasdaq: ABIO)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">8/12/24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Firefly Neurosciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">WaveDancer (Nasdaq: WAVD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">6/20/24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Tetonic Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">AVROBIO (Nasdaq: AVRO)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">4/1/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Tawsfynydd Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Onconova Therapeutics (Nasdaq: ONTX)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">3/26/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Serina Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">AgeX Therapeutics (Nasdaq: AGE)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Q32 Bio</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Homology Medicines (Nasdaq: FIXX)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">3/21/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">LENZ Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Graphite Bio (Nasdaq: GRPH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">3/14/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Immunogenx</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">First Wave BioPharma (FWBI)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">3/6/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Adaptive Phage Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Biomx (NYSEAM: PHGE)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">NA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">12/27/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Cyclo Therapeutics (Nasdaq: CYTH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Applied Molecular Transport (Nasdaq: AMTI)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">12/18/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Neurogene</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Neoleukin Therapeutics (Nasdaq: NLTX)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">12/15/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">ProteoMedix (Onconetix)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Blue Water Biotech (Nasdaq: BWV)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">NA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">11/13/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Cartesian Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Selecta Biosciences (Nasdaq: RNAC)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">11/3/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Korro Bio</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Frequency Therapeutics (Nasdaq: FREQ)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">10/31/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Lung Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Aileron Therapeutics (Nasdaq: ALRN)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">10/16/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Notable Labs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Vascular Biogenics Ltd. (Nasdaq: VBLT)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">9/11/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Dianthus Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Magenta Therapeutics (Nasdaq: MGTA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">8/16/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">EIP Pharma (CervoMed)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Diffusion Pharmaceuticals (Nasdaq: DFFN)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">6/29/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">TeraImmune</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Baudax Bio (Nasdaq: BXRX)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">6/22/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Spyre Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Aeglea BioTherapeutics (Nasdaq: AGLE)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">6/1/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Elicio Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Angion Biomedica (Nasdaq: ANGN)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">4/22/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">GRI Bio</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Vallon Pharmaceuticals (Nasdaq: VLON)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">3/20/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">CalciMedica</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Graybug Vision (Nasdaq: GRAY)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">3/7/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Carisma Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Sesen Bio (Nasdaq: SESN)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">2/23/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Enliven Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Imara (Nasdaq: IMRA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">1/9/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Catheter Precision, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Ra Medical Systems (NYSE: RMED)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">12/29/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Disc Medicine</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Gemini Therapeutics (Nasdaq: GMTX)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">12/27/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">GNI Group (Gyre Therapeutics)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Catalyst Biosciences (Nasdaq: CBIO)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">12/19/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Kineta, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Yumanity Therapeutics (Nasdaq: YMTX)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">11/8/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">ARS Pharmaceuticals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Silverback Therapeutics (Nasdaq: SBTX)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">9/28/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Aceragen, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Idera Pharmaceuticals (Nasdaq: IDRA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">9/15/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Lisata Therapeutics (Cend)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Caladrius Biosciences (Nasdaq: CLBS)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">8/30/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Vivani Medical (Nano Precision)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Second Sight Medical (Nasdaq: EYES)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">NA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">7/5/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Syros Pharmaceuticals (Nasdaq: SYRS)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Tyme Technologies (Nasdaq: TYME)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">5/16/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Aprea Therapeutics, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Atrin Pharmaceuticals (NasdaqGS: APRE)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">10/24/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Quoin Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Cellect Biotechnology Ltd. (Nasdaq: APOP)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">8/26/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Aadi Bioscience, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">8/3/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Decoy Biosystems, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Indaptus Therapeutics (Intec) (Nasdaq: INDP)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">7/27/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Cytocom, Inc. (Statera)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Cleveland BioLabs, Inc. (Nasdaq: CBLI)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">NA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">6/28/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Tempest Therapeutics Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Millendo Therapeutics, Inc. (Nasdaq: MLND)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">6/15/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">ReShape Lifesciences Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Obalon Therapeutics, Inc. (Nasdaq: OBLN)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">4/27/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Leading BioSciences, Inc. (Palisade)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Seneca Biopharma, Inc. (Nasdaq: SNCA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">4/16/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">MyMD Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Akers Biosciences, Inc. (Nasdaq: AKER)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">3/31/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">StemoniX Inc. (Vyant Bio)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Cancer Genetics, Inc. (Nasdaq: CGIX)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">3/16/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">ChemomAb Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Anchiano Therapeutics Ltd. (Nasdaq: ANCN)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">2/24/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Viracta Therapeutics, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Sunesis Pharmaceuticals (Nasdaq: SNSS)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">1/28/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Quellis Biosciences, Inc. (Astria)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Catabasis Pharmaceuticals (Nasdaq: CATB)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">12/22/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Yumanity Therapeutics Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Proteostasis Therapeutics (Nasdaq: PTI)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.54%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">12/1/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Petros Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Neurotrope, Inc. (NasdaqCM: NTRP)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0046310425%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Closed Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Surviving Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Public Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Value Delivered</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">for Public</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Vehicle Net of Cash</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($ mm&#8217;s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">11/23/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">F-star Therapeutics, Limited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Spring Bank Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">11/5/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Ocuphire Pharma, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Rexahn Pharmaceuticals (Nasdaq: REXN)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">10/27/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Viridian Therapeutics, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Miragen Therapeutics, Inc. (NasdaqCM: MGEN)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">9/15/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Adicet Bio, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">resTORbio, Inc. (NasdaqGS: TORC)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">9/14/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Anelixis Therapeutics (Eledon)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Novus Therapeutics, Inc. (NasdaqCM: NVUS)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">7/6/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Kiq Bio (Cogent)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Unum Therapeutics, Inc. (NASDAQ: UMRX)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">6/15/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Forte Biosciences, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Tocagen Inc. (NasdaqGS: TOCA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">5/28/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Larimar Therapeutics, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Zafgen, Inc. (NasdaqGS: ZFGN)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">5/26/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Histogen, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Conatus Pharmaceuticals (Nasdaq: CNAT)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">5/22/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Qualigen, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Ritter Pharmaceuticals (Nasdaq: RTTR)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">NA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">5/18/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Timber Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">BioPharmX Corporation (AMEX: BPMX)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">4/1/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Curetis NV (Euronext: CURE)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">OpGen, Inc. (NasdaqCM: OPGN)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">1/9/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Protara Therapeutics, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Proteon Therapeutics, Inc. (NASDAQ: PRTO)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">12/30/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">NeuroBo Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Gemphire Therapeutics Inc. (NASDAQ: GEMP)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">11/7/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Venus Concept Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Restoration Robotics, Inc. (NASDAQ: HAIR)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">9/27/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Ocugen, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Histogenics Corporation (NASDAQ: HSGX)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">NA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">8/31/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Brickell Biotech, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Vical Incorporated (NASDAQ: VICL)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">7/31/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">ESSA Pharma (NASDAQ: EPIX)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Realm Therapeutics plc (NASDAQ: RLM)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">7/22/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Salarius Pharmaceuticals, LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Flex Pharma, Inc. (NASDAQ: FLKS)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">7/15/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">NeuBase Therapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Ohr Pharmaceutical (NASDAQ: OHRP)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">6/10/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Oncternal Therapeutics, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">GTx, Inc. (NASDAQ: GTXI)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">6/9/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Edesa Biotech Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Stellar Biotechnologies, Inc. (NASDAQ: SBOT)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">5/9/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Armata Pharmaceuticals (f.k.a C3J)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Ampliphi Biosciences (NYSE: APHB)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">5/6/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Adynxx, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Alliqua BioMedical, Inc. (NASDAQ: ALQA)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">4/23/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Mereo BioPharma (AIM: MPH)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Oncomed Pharmaceuticals (NASDAQ: OMED)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">4/12/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Immunic AG</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Vital Therapies, Inc. (NASDAQ: VTL)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">3/26/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Enlivex Therapeutics Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Bioblast Pharma Ltd. (NASDAQ: ORPN)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">3/18/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">PDS Biotechnology Corporation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Edge Therapeutics, Inc. (NASDAQ: EDGE)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">3/13/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">X4 Pharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Arsanis, Inc. (NASDAQ: ASNS)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">1/24/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Seelos Therapeutics, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Apricus Biosciences, Inc. (NASDAQ: APRI)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">12/7/2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Millendo Therapeutics, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">OvaScience, Inc. (NASDAQ: OVAS)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">10/12/2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Aravive Biologics, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Versartis, Inc. (NASDAQ: VSAR)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">2/13/2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Vaxart, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Aviragen Therapeutics, Inc. (NASDAQ: AVIR)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">1/30/2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Innovate Biopharmaceuticals, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Monster Digital, Inc. (NASDAQ: MSDI)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">1/17/2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Evofem Biosciences, Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Neothetics, Inc. (NASDAQ: NEOT)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">1/4/2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Rocket Pharmaceuticals, Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:29.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Inotek Pharmaceuticals Corp (NASDAQ: ITEK)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Lucid reviewed the value delivered for the public vehicle (net of cash) from the Selected Precedent Reverse Merger Transactions, which ranged from $0.0&#160;million to $44.0&#160;million. Lucid derived the median for the value delivered for the public vehicle (net of cash) to be $10.0 million. This compares to the GlycoMimetics Valuation as per the Merger Agreement of $8.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The summary set forth above does not purport to be a complete description of all the analyses performed by Lucid. The preparation of a fairness opinion involves various determinations as to the most appropriate and relevant methods of financial analysis and the application of these methods to the particular circumstances. Therefore, such an opinion is not readily susceptible to partial analysis or summary description. Lucid did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Accordingly, notwithstanding the separate factors summarized above, Lucid believes, and advised the GlycoMimetics Board, that its analyses must be considered as a whole. Selecting portions of its analyses and the factors considered by it without considering all analyses and factors could create an incomplete view of the process underlying the Lucid Opinion. In performing its analyses, Lucid made numerous assumptions with respect to industry performance, business and economic conditions and other matters, many of which are beyond the control of GlycoMimetics and Crescent. These analyses performed by Lucid are not necessarily indicative of actual values or future results, which may be significantly more or less favorable than suggested by such analyses. In addition, analyses relating to the value of businesses do not purport to be appraisals or to reflect the prices at which businesses or securities may actually be sold. Accordingly, such analyses and estimates are inherently subject to uncertainty, being based upon numerous factors or events beyond the control of the parties or their respective advisors. None of GlycoMimetics, Crescent, Lucid or any other person assumes responsibility if future results are materially different from those projected. The analyses supplied by Lucid and the Lucid Opinion were among several factors taken into consideration by the GlycoMimetics Board in making its decision to enter into the Merger Agreement and should not be considered as determinative of such a decision.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Lucid was selected by the GlycoMimetics Board to render an opinion to the GlycoMimetics Board because Lucid is a nationally recognized investment banking firm and as part of its investment banking business, Lucid is regularly engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. In addition, in the ordinary course of its business, Lucid or certain of its affiliates, as well as investment funds in which Lucid or its affiliates may have financial interests, may acquire, hold or sell long or short positions, or trade or otherwise effect transactions in debt, equity, and other securities and financial instruments (including bank loans and other obligations) of, or investments in, GlycoMimetics, Crescent or any other party that may be involved in the Merger and/or their respective affiliates. In the two years preceding the date of the Lucid Opinion, Lucid had not had a relationship GlycoMimetics or its affiliates and had not received any fees from GlycoMimetics or any of its affiliates.  In the two years preceding the date of the Lucid Opinion, Lucid had not had a relationship with Crescent or any of its affiliates and had not received any fees from Crescent or any of its affiliates. Lucid and its affiliates may in the future seek to provide investment banking or financial advisory services to GlycoMimetics and Crescent and/or their respective affiliates and expect to receive fees for the rendering of these services.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Engagement Letter between Lucid and GlycoMimetics, as of the time the Merger Agreement was approved, if the Merger is consummated, Lucid will be entitled to receive a transaction fee of $1,100,000 payable in cash at the closing of the transaction. Lucid received a $150,000 upfront initial fee and a fee for the Lucid Opinion of $350,000 upon delivery of the Lucid Opinion, that were non-creditable to the $1,100,000 transaction fee. Additionally, GlycoMimetics has agreed to reimburse Lucid for its&#160;out-of-pocket expenses and has agreed to indemnify Lucid against certain liabilities, including liabilities under the federal securities laws. The terms of the fee arrangement with Lucid, which are customary in transactions of this nature, were negotiated at arm&#8217;s length between GlycoMimetics and Lucid, and the GlycoMimetics Board was aware of the arrangement.</p><a id="InterestsofGlycoMimeticsDirectorsandExec"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of GlycoMimetics&#8217; Directors and Executive Officers in the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In considering the recommendation of the GlycoMimetic Board with respect to approving the Merger, stockholders should be aware that GlycoMimetic&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of GlycoMimetics&#8217; stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the GlycoMimetic&#8217;s stockholders approve the Merger as contemplated by this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Treatment of GlycoMimetics Options and Restricted Stock Units</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Under the terms of the Merger Agreement, prior to the closing of the Merger, the GlycoMimetics Board will accelerate the vesting of all equity awards of GlycoMimetics then outstanding but not then vested or exercisable, and cancel each option to acquire shares of GlycoMimetics common stock with an exercise price per share greater than the GlycoMimetics Closing Price.  At the closing of the First Merger, (i) each option to acquire shares of GlycoMimetics common stock with an exercise price less than or equal to the GlycoMimetics Closing Price will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of shares underlying such option, (ii) each GlycoMimetics restricted stock unit will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of unsettled shares of GlycoMimetics common stock underlying such GlycoMimetics restricted stock unit, and (iii) each other option to acquire shares of GlycoMimetics common stock will be cancelled for no consideration.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below sets forth information regarding the GlycoMimetics stock options and restricted stock units held as of February 7, 2025 by each of GlycoMimetics&#8217; current executive officers and non-employee directors.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.95%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:30.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Participant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Vested Options</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Held (#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise Price of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Vested Options ($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Unvested</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options Held (#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise Price of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Unvested Options ($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Unvested Restricted</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Stock Units Held (#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:30.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Executive Officers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Harout Semerjian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,536,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2,402,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Brian Hahn</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">771,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">659,524</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Non-Employee Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Patricia Andrews</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">141,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Mark Goldberg, M.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">167,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Scott Jackson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">130,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Rachel King</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,494,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Daniel Junius</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">163,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Scott Koenig, M.D., Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">121,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Timothy Pearson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">152,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Potential Payments upon Termination or Change in Control</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Messrs. Semerjian and Hahn have entered into employment agreements with GlycoMimetics which provide that, in the event the executive&#8217;s employment is terminated by GlycoMimetics without &#8220;cause&#8221;, or for &#8220;good reason&#8221; (each as defined in the employment agreements and as described in more detail in the section titled &#8220;<i style="font-style:italic;">GlycoMimetics Executive Compensation</i>&#8221; on page 161), subject to the executive&#8217;s execution and non-revocation of a release, the executive is entitled to 12 months of salary continuation payable in equal installments via payroll (18 months in the case of Mr. Semerjian) and continued payment of the employer portion of the executive&#8217;s medical, dental and vision benefits for up to 12 months (18 months in the case of Mr. Semerjian).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In the event the employment of Mr. Semerjian or Mr. Hahn  is terminated without cause or for good reason within 12 months following a &#8220;change in control&#8221; (as defined in the employment agreements and as described in more detail in the section titled </span>&#8220;<i style="font-style:italic;">GlycoMimetics Executive Compensation</i>&#8221; on page 161), subject to the executive&#8217;s execution and non-revocation of a release, the executive is instead entitled to receive a lump sum payment equal to 12 months (18 months in the case of Mr. Semerjian) of the sum of his base salary and his then current target annual bonus, continued payment of the employer portion of the executive&#8217;s medical, dental and vision benefits for up to 12 months (18 months in the case of Mr. Semerjian), and full acceleration of any unvested GlycoMimetics equity awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2024, GlycoMimetics entered a Retention Agreement and Offer of Revised Severance Eligibility with each of Messrs. Semerjian and Hahn (the &#8220;Retention Agreements&#8221;). The Retention Agreements provide for a cash retention payment equal to the executive&#8217;s 2024 target bonus if the executive remains employed through December 31, 2024, payable on the next regularly scheduled payroll date, which each executive earned based on their continued service through December 31, 2024. If an executive received the cash retention payment, he is not eligible to receive a 2024 target bonus, but he is eligible to receive a prorated target bonus based on the number of months the executive is employed by GlycoMimetics in 2025. The Retention Agreements also provide that Messrs. Semerjian and Hahn are entitled to the benefits they would have been eligible to receive pursuant to their employment agreements if their employment was terminated following a change in control if, within 3 months following their separation date, GlycoMimetics enters a definitive agreement that results in a change in control within the 12 months following their separation date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger will constitute a &#8220;change in control&#8221; for purposes of the employment agreements and Retention Agreements.</p><a id="GoldenParachuteCompensation_435892"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Golden Parachute Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information set forth in the table below is intended to comply with Item 402(t) of Regulation S-K, which requires disclosure of compensation that each named executive officer could receive that is based on or otherwise relates to the Merger. This compensation is referred to as &#8220;golden parachute&#8221; compensation by the applicable SEC disclosure rules, and in this section GlycoMimetics uses such term to describe the Merger-related compensation payable to GlycoMimetics&#8217; named executive officers. For additional details regarding the terms of the payments and benefits described below, see the discussion above. This Merger-related compensation is subject to a non-binding advisory vote of GlycoMimetics stockholders, as set forth in Proposal 8 to this proxy statement. See the section entitled &#8220;<i style="font-style:italic;">Proposal No. 8&#8212;The Merger Compensation Proposal</i>&#8221; on page 198.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:9.2pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The amounts indicated below are estimates based on multiple assumptions that may or may not actually occur or be accurate on the relevant date, including assumptions described below, and do not reflect certain compensation actions that may occur before the consummation of the Merger. For purposes of calculating such amounts, the Company has assumed:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the relevant price per share of GlycoMimetics common stock is $0.41 per share, which is the average closing market price of GlycoMimetics common stock over the first five business days following the first public announcement of the transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">February 7, 2025 as the date the Mergers are consummated; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a termination of each named executive officer&#8217;s employment by the Company without cause or by the applicable named executive officer for good reason (in each case, as defined in the applicable employment agreement) on February 7, 2025, based on the terms of employment agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="15" style="vertical-align:bottom;width:99.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">G</b><b style="font-weight:bold;">olden Parachute Payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:29.27%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pension/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">NQDC</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Perquisites/</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Benefits</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"><br/></sup><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Tax</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Reimbursement</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.27%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Harout Semerjian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,548,627</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">56,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,604,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Brian Hahn</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">673,387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">37,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">710,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Edwin Rock, M.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The amounts reported in the &#8220;Cash&#8221; column are attributable to double-trigger arrangements (i.e., the amounts are triggered by the change in control that will occur upon completion of the Merger and payment is conditioned upon the named executive officer&#8217;s qualifying termination of employment within one year following the change in control).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Amounts reflect cash severance benefits under the employment agreements that would be payable in lump sum, assuming termination of the named executive officer&#8217;s employment without cause or for good reason, as described in the employment agreements, in each case, within 12 months following a change in control and subject to the executive officer&#8217;s execution and non-revocation of a release of claims in favor of GlycoMimetics. Under the employment agreements, Messrs. Semerjian and Hahn would be entitled to receive a lump sum payment equal to 18 months of his base salary in the case of Mr. Semerjian and 12 months of his base salary in the case of Mr. Hahn plus each executive officer&#8217;s respective current target annual bonus, as follows:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:57.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annual</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Base&#160;Salary&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annual</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Target&#160;Bonus&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Harout Semerjian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.19%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 3.6pt;">666,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.67%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 3.6pt;">366,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Brian Hahn</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 3.6pt;">480,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:19.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 3.6pt;">192,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Amounts reflect the acceleration value of unvested option and restricted stock unit awards held by the executive officers. The amounts reported in this column are attributable to single-trigger arrangements (i.e., the amounts are triggered by the change in control alone). Under the terms of the Merger Agreement, prior to the closing of the Merger, the GlycoMimetics Board will accelerate the vesting of all equity awards of GlycoMimetics then outstanding but not then vested or exercisable, and cancel each option to acquire shares of GlycoMimetics common stock with an exercise price per share greater than the GlycoMimetics Closing Price. At the closing of the First Merger, (i) each option to acquire shares of GlycoMimetics common stock with an exercise price less than or equal to the GlycoMimetics Closing Price will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of shares underlying such option, (ii) each GlycoMimetics restricted stock unit will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of unsettled shares of GlycoMimetics common stock underlying such GlycoMimetics restricted stock unit, and (iii) each other option to acquire shares of GlycoMimetics common stock will be cancelled for no consideration. Amounts are calculated assuming a price of $0.41 per share of GlycoMimetics common stock. Because none of the named executive officers hold outstanding restricted stock units and the exercise price per share for each outstanding stock option held by the named executive officers exceeds the assumed purchase price of $0.41, no amounts are included in this column.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:52.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 3.6pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restricted</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Stock&#160;Units&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.14%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Harout Semerjian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:17.24%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:25.4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Brian Hahn</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:17.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:25.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Edwin Rock, M.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:17.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:25.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:9.2pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(4)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Represents the value of the continued payment of the employer portion of the named executive officer&#8217;s medical, dental and vision benefits for up to 12 months (18 months in the case of Mr. Semerjian), with the value based on the current active employee rates under the Company&#8217;s health plans. This benefit is &#8220;double-trigger&#8221; (i.e., it is not solely contingent upon a change in control but instead requires a termination without cause or for good reason, whether or not following the consummation of a change in control) and is subject to the named executive officer&#8217;s execution and effectiveness of a release of claims.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(5)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">As Dr. Rock separated from employment effective August 1, 2024 and has received severance payments in accordance with the terms of his employment agreement; he is not eligible for severance payments in connection with the Merger.</p></td></tr></table><a id="InterestsofCrescentsDirectorsandExecutiv"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Interests of Crescent&#8217;s Directors and Executive Officers in the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In considering the recommendation of the Crescent Board with respect to approving the Merger, stockholders should be aware that Crescent&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Crescent stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Crescent Board was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Crescent stockholders approve the Merger as contemplated by this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent Ownership Interests</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of February 7, 2025, Crescent&#8217;s current non-employee directors and executive officers beneficially owned, in the aggregate approximately 80.0% of the shares of Crescent capital stock, which for purposes of this subsection excludes any Crescent shares issuable upon exercise or settlement of Crescent options held by such individual. Each of Crescent&#8217;s officers, directors and affiliated stockholders have also entered into a support agreement in connection with the Merger. For a more detailed discussion of the support agreements, please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Support Agreements</i>&#8221; beginning on page 151 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As noted above, Fairmount Fund II, an affiliate of Peter Harwin, a Crescent director, Jonathan Violin, Crescent&#8217;s President and Chief Executive Officer and a director, and Christopher Doughty, Crescent&#8217;s Chief Business Officer, also currently hold shares of Crescent capital stock. The table below sets forth the ownership of Crescent capital stock by Fairmount Fund II, Jonathan Violin and Christopher Doughty as of February 7, 2025. Fairmount Fund II also holds a portion of the Convertible Notes and has agreed to purchase shares and pre-funded warrants in the Crescent Pre-Closing Financing. For a more detailed discussion of these relationships, please see the section titled &#8220;<i style="font-style:italic;">Certain Relationships and Related Party Transactions of the Combined Company&#8212;Crescent Transactions&#8212;</i><i style="font-style:italic;">Crescent Pre-Closing Financing</i>&#8221; beginning on page 280 of this proxy statement/prospectus.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Stockholder</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Capital&#160;Stock&#160;held</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:75.53%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fairmount Healthcare Fund II L.P.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:22.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">20,000,000<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:75.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jonathan Violin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:22.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,366,120<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:75.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Christopher Doughty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:22.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">273,224<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of 20,000,000 shares of Crescent common stock issuable upon conversion of 20,000,000 shares of Crescent preferred stock held directly by Fairmount Fund II. Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) serves as the investment manager for Fairmount Fund II. Fairmount Fund II has delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fairmount Fund II&#8217;s portfolio. The general partner of Fairmount is Fairmount Funds Management GP LLC (&#8220;Fairmount GP&#8221;). As a managing member of Fairmount GP, Peter Harwin may be deemed to have voting and investment power over the shares held by Fairmount Fund II. Fairmount, Fairmount GP, and Mr. Harwin disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of 1,366,120 shares of Crescent common stock held by Jonathan Violin. Of such shares, 1,024,590 were purchased by Dr. Violin, in anticipation of his service as Chief Executive Officer and President and director of Crescent, at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on September 28, 2025 and in equal monthly installments for the 36 months thereafter.</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of 273,224 shares of Crescent common stock held by Christopher Doughty. Such shares were purchased by Mr. Doughty, in anticipation of his service as Crescent&#8217;s Chief Business Officer, at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on September 28, 2025 and in equal monthly installments for the 36 months thereafter.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Violin and Doughty Anti-Dilution Provision</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the consulting agreement between Crescent and Dr. Violin and the offer letter between Crescent and Mr. Doughty, Crescent is obligated to issue additional options to purchase shares of Crescent common stock in order to maintain (i) Dr. Violin&#8217;s ownership in Crescent at approximately 5% on a fully-diluted basis, and (ii) Mr. Doughty&#8217;s ownership in Crescent at approximately 1% on a fully-diluted basis, in each case, until Crescent has raised an aggregate of $200.0 million in financing. Pursuant to these anti-dilution provisions, in connection with the entry into the Subscription Agreement, on December 11, 2024, Crescent issued Dr. Violin and Mr. Doughty options to purchase shares of Crescent common stock in full satisfaction of such obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, each option to purchase shares of Crescent common stock that is outstanding and unexercised immediately prior to the effective time of the First Merger under Crescent&#8217;s 2024 Equity Incentive Plan and that, following assumption by GlycoMimetics at the effective time of the First Merger, will be eligible to be registered on Form S-8, whether or not vested, will be converted into an option to purchase shares of GlycoMimetics common stock. GlycoMimetics will assume Crescent&#8217;s 2024 Equity Incentive Plan and each such outstanding option to purchase shares of Crescent common stock in accordance with the terms (as in effect as of the date of the Merger Agreement) of Crescent&#8217;s 2024 Equity Incentive Plan and the terms of the stock option agreement by which such option to purchase shares of Crescent common stock is evidenced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below sets forth information regarding the Crescent stock options held as of February 7, 2025 by each of Crescent&#8217;s current executive officers and non-employee directors. The number of shares of common stock underlying such options and the exercise price will be adjusted appropriately to reflect the Exchange Ratio. All outstanding Crescent stock options are unvested as of February 7, 2025.</p><a id="_Hlk190518439"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Participant</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:20.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Vested Options</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Held (#)</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:18.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Average</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise Price</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">of Vested</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options ($)</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:18.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Unvested</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options Held (#)</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise Price</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">of Unvested</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options ($)</b></p></td></tr><tr><td style="vertical-align:top;width:20.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Executive Officers</b></p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Jonathan Violin</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> 1,541,925</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0.89</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> 3,744,675</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0.89</p></td></tr><tr><td style="vertical-align:top;width:20.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Christopher Doughty</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> 44,055</span></p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0.89</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> 1,013,265</span></p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0.89</p></td></tr><tr><td style="vertical-align:top;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Ryan Lynch</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> 731,535</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0.89</p></td></tr><tr><td style="vertical-align:top;width:20.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Barbara Bispham</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">735,193</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0.89</p></td></tr><tr><td style="vertical-align:top;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Non-Employee Directors</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:20.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Alexandra Balcom</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7,752</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0.89</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">131,793</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0.89</p></td></tr><tr><td style="vertical-align:top;width:20.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Peter Harwin</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0.89</p></td></tr><tr style="height:12.6pt;"><td style="vertical-align:top;width:20.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Susan Moran</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7,752</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:10.05pt;"></span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0.89</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">131,793</p></td><td style="vertical-align:top;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">0.89</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent Management Following the Merger</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described in the section captioned &#8220;<i style="font-style:italic;">Management Following the Merger</i>&#8221; beginning on page 274 of this proxy statement/prospectus certain of Crescent&#8217;s directors and executive officers are expected to become the directors and executive officers of the Combined Company upon the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Indemnification and Insurance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a discussion of the indemnification and insurance provisions related to the Crescent directors and officers under the Merger Agreement, please see the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Indemnification and Insurance for Directors and Officers</i>&#8221; beginning on page 146 of this proxy statement/prospectus.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Form of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with the DGCL, (i) at the First Effective Time, First Merger Sub will merge with and into Crescent, with Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the First Merger and (ii) immediately following the First Merger and as part of the same overall transaction as the First Merger (the &#8220;Second Effective Time&#8221;), Crescent will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity.</p><a id="MergerConsiderationandAdjustment_21272"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Merger Consideration and Adjustment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i) each then-outstanding share of Crescent common stock (including shares of Crescent common stock issued in the Crescent Pre-Closing Financing and excluding shares to be canceled pursuant to the Merger Agreement and dissenting shares) will be automatically converted solely into the right to receive a number of shares of GlycoMimetics common stock equal to the Exchange Ratio (described in more detail in the section titled &#8220;<i style="font-style:italic;">The Merger Agreement&#8212;Exchange Ratio</i>&#8221; beginning on page 135 of this proxy statement/prospectus), (ii) each then-outstanding share of Crescent preferred stock will be converted into the right to receive a number of shares of GlycoMimetics Series A Preferred Stock equal to the Exchange Ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii) each then-outstanding option to purchase Crescent common stock will be assumed by GlycoMimetics, subject to adjustment based on the Exchange Ratio as set forth in the Merger Agreement, and (iv) each then-outstanding warrant to purchase shares of Crescent common stock will be converted into a warrant to purchase shares of GlycoMimetics common stock, subject to adjustment based on the Exchange Ratio as set forth in the Merger Agreement and the form of warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">No fractional shares of GlycoMimetics common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued.  Any fractional shares of GlycoMimetics common stock resulting from the conversion of shares of Crescent common stock (including shares of Crescent common stock issued in the Crescent Pre-Closing Financing) shall be issued as follows:  (i) one share of GlycoMimetics common stock if the aggregate amount of fractional shares of GlycoMimetics common stock of any individual holder of Crescent capital stock if upon conversion is equal to or exceeds 0.50 or (ii) no shares of GlycoMimetics common stock if the aggregate amount of fractional shares of GlycoMimetics common stock of any individual holder of Crescent capital stock if upon conversion is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding.  Any fractional shares of GlycoMimetics Series A Preferred Stock that a holder of Crescent preferred stock would otherwise be entitled to receive will be aggregated with all fractional shares of GlycoMimetics preferred stock issuable to such holder and rounded up to the nearest whole share of GlycoMimetics&#8217; convertible preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Procedures for Exchanging Stock Certificates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On or prior to the closing date, GlycoMimetics and Crescent will select an exchange agent (the &#8220;Exchange Agent&#8221;) and, at the First Effective Time (as defined herein), GlycoMimetics will deposit with the Exchange Agent evidence of book-entry shares representing the shares of GlycoMimetics common stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Crescent common stock (including shares of Crescent common stock issued in the Crescent Pre-Closing Financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) and the shares of GlycoMimetics Series A Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Crescent preferred stock calculated in accordance with the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Promptly after the First Effective Time, the Exchange Agent will mail to each record holder of Crescent common stock (including shares of Crescent common stock issued in the Crescent Pre-Closing Financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) and each record holder of Crescent preferred stock who will receive GlycoMimetics Series A Preferred Stock issuable in exchange for such Crescent preferred stock pursuant to the terms, and calculated in accordance with, the Merger Agreement (i) a letter of transmittal and (ii) instructions for surrendering the record holder&#8217;s stock certificates in exchange for the merger consideration.  Upon delivery to the Exchange Agent of a duly executed letter of transmittal in accordance with the Exchange Agent&#8217;s instructions and the declaration for tax withholding purposes, the surrender of the record holder&#8217;s stock certificates, if applicable, and delivery to the Exchange Agent of such other documents as may be reasonably required by the Exchange Agent or GlycoMimetics, the record holder of such stock certificates or book-entry shares, as applicable, will be entitled to receive in exchange therefor book-entry shares representing the number of whole shares of GlycoMimetics common stock or GlycoMimetics Series A Preferred Stock issuable to such holder pursuant to the Merger Agreement.  The surrendered certificates representing shares of Crescent common stock or Crescent preferred stock will be canceled.</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the First Effective Time, each certificate representing Crescent common stock or Crescent preferred stock that has not been surrendered will represent only the right to receive shares of GlycoMimetics common stock or GlycoMimetics Series A Preferred Stock, as applicable, issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">HOLDERS OF CRESCENT COMMON STOCK OR CRESCENT PREFERRED STOCK SHOULD NOT SEND IN THEIR CRESCENT STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF CRESCENT STOCK CERTIFICATES.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">First Effective Time and Second Effective Time</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two business days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Crescent stockholders and the approval by the GlycoMimetics stockholders of the issuance of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series A Preferred Stock, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger.  The First Merger will become effective upon the filing of a certificate of merger (the &#8220;First Certificate of Merger&#8221;) with the Secretary of State of the State of Delaware or at such later time as is agreed by GlycoMimetics and Crescent and specified in the First Certificate of Merger.  The Second Merger will become effective upon the filing of a certificate of merger (the &#8220;Second Certificate of Merger&#8221;) with the Secretary of State of the State of Delaware or at such later time as is agreed by GlycoMimetics and Crescent and specified in the Second Certificate of Merger.  Neither GlycoMimetics nor Crescent can predict the exact timing of the consummation of the Merger.</span></p><a id="RegulatoryApprovals_941376"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Regulatory Approvals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In the United States, GlycoMimetics must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of shares of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series A Preferred Stock, to Crescent&#8217;s stockholders in connection with the transactions contemplated by the Merger Agreement and the filing of this proxy statement/prospectus with the SEC.  GlycoMimetics and Crescent do not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</span></p><a id="USFederalIncomeTaxConsiderationsoftheMer"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">U.S. Federal Income Tax Considerations of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following discussion is a summary of U.S. federal income tax considerations to U.S. Holders (as defined below) of Crescent common stock of Crescent preferred stock (collectively, &#8220;Crescent stock&#8221;) of the Merger. The discussion does not purport to be a complete analysis of all potential tax considerations. The considerations of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws, are not discussed. This discussion is based on the Code, Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. Holder. Crescent has not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax considerations of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion is limited to a U.S. Holder that holds Crescent stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax considerations relevant to a U.S. Holder&#8217;s particular circumstances, including, without limitation, the effect of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules under Section 451(b) of the Code. In addition, it does not address considerations relevant to U.S. Holders subject to special rules, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. expatriates and former citizens or long-term residents of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders whose functional currency is not the U.S. dollar;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons holding Crescent stock as part of a hedge, straddle or other risk-reduction strategy or as part of a conversion transaction or other integrated investment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">banks, insurance companies and other financial institutions;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">real estate investment trusts or regulated investment companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">brokers, dealers or traders in securities or other persons that elect to use a mark-to-market method of accounting for their holdings in Crescent stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partnerships or other entities or arrangements classified as partnerships, passthroughs, or disregarded entities for U.S. federal income tax purposes (and investors therein), S corporations or other passthrough entities (including hybrid entities);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-exempt organizations or governmental organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons deemed to sell Crescent stock under the constructive sale provisions of the Code;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons who hold or receive Crescent stock pursuant to the exercise of any employee stock option or otherwise as compensation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-qualified retirement plans; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons that ow</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">n, or have owned, actually or constructively, more than 5% of Crescent stock;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If an entity or arrangement classified as a partnership for U.S. federal income tax purposes holds Crescent stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, a partnership holding Crescent stock and each partner in such partnership is urged to consult its tax advisor regarding the U.S. federal income tax considerations to it of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">This discussion is for informational purposes only and is not tax advice. Each prospective investor is urged to consult its tax advisor with respect to the application of the U.S. federal income tax laws to its particular situation as well as any tax considerations of the Merger arising under U.S. federal estate or gift tax laws, the laws of any state, local or non-U.S. taxing jurisdiction or any applicable income tax treaty.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purpose of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of Crescent stock that, for U.S. federal income tax purposes, is or is treated as any of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an individual who is a citizen or resident of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a trust that: (i) is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; (within the meaning of Section 7701(a)(30) of the Code); or (ii) has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of Crescent and GlycoMimetics intends that the Merger qualifies as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code. Assuming the Merger so qualifies, a U.S. Holder will not recognize gain or loss upon the exchange of its Crescent stock for GlycoMimetics common stock or GlycoMimetics Series A Preferred Stock (collectively, &#8220;GlycoMimetics stock&#8221;). A U.S. Holder will have the same aggregate basis in its GlycoMimetics stock after the Merger as such U.S. Holder had in the corresponding Crescent stock immediately prior to the Merger. A U.S. Holder&#8217;s holding period in the GlycoMimetics stock immediately following the Merger will include such U.S. Holder&#8217;s holding period in the corresponding Crescent stock immediately prior to the Merger. If a U.S. Holder holds different blocks of Crescent stock (generally, Crescent stock acquired on different dates or at different prices), such U.S. Holder is urged to consult its tax advisor with respect to the determination of the tax bases and/or holding periods of the shares of GlycoMimetics stock received in the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each U.S. Holder is urged to consult its tax advisor regarding the U.S. federal income tax considerations of the Merger in light of its personal circumstances and the considerations to them under state, local and non-U.S. tax laws and other federal tax laws.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Information Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each U.S.&#160;Holder who receives GlycoMimetics stock in the Merger is required to retain permanent records pertaining to the Merger and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property, and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. Each U.S.&#160;Holder who owned immediately before the Merger at least one percent (by vote or value) of the total outstanding stock of Crescent or who owned securities in Crescent with a basis of $1,000,000 or more is required to attach a statement to its tax return for the year in which the Merger is consummated that contains the information listed in Treasury Regulation&#160;Section&#160;1.368-3(b). Such statement must include the U.S.&#160;Holder&#8217;s tax basis in such U.S.&#160;Holder&#8217;s Crescent stock surrendered in the Merger, the fair market value of such Crescent stock, the date of the Merger, and the name and employer identification number of each of Crescent and GlycoMimetics.&#160;Each U.S. Holder is urged to consult with its tax advisor to comply with these rules.</p><a id="NasdaqStockMarketListing_590667"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nasdaq Stock Market Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shares of GlycoMimetics common stock are currently listed on Nasdaq under the symbol &#8220;GLYC.&#8221; GlycoMimetics has agreed to use commercially reasonable efforts to (a) maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq; (b) to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of GlycoMimetics common stock to be issued in connection with the Merger and transactions contemplated thereunder, and to cause such shares to be approved for listing (subject to official notice of issuance); (c) prepare and timely submit to Nasdaq a notification form for the proposed reverse stock split (if required) and to submit a copy of the amendment to the GlycoMimetics Charter effecting the proposed reverse stock split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the closing date of the Merger; and (d) to the extent required by Nasdaq Marketplace Rule 5110, assist Crescent in preparing and filing an initial listing application for the GlycoMimetics common stock issued to Crescent stockholders (including any common stock issuable upon conversion of the GlycoMimetics Series A Preferred Stock) (the &#8220;Nasdaq Listing Application&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, under the Merger Agreement, each of GlycoMimetics&#8217; and Crescent&#8217;s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the closing of the Merger, of various conditions, including that the Nasdaq Listing Application shall have been approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Nasdaq Listing Application is approved, GlycoMimetics anticipates that the common stock of the Combined Company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.&#8221; In order for the Nasdaq Listing Application to be accepted, among other requirements, the Combined Company must maintain a bid price of $4.00 or higher for a certain period of time following the proposed reverse stock split.</p><a id="AnticipatedAccountingTreatment_928907"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Anticipated Accounting Treatment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is expected to be treated by GlycoMimetics as a reverse merger and will be accounted for as an in-substance reverse recapitalization of GlycoMimetics by Crescent in accordance with U.S. GAAP as, at close, the transaction is, in essence, the issuance of equity for GlycoMimetics&#8217; net assets<span style="white-space:pre-wrap;">, which primarily consist of cash and other nominal non-operating assets and liabilities.  Immediately prior to the Merger, Crescent is not a variable interest entity as it has sufficient equity at risk in order to fund its next development milestones. For accounting purposes, Crescent is considered to be acquiring the assets and liabilities of GlycoMimetics in this transaction based on the terms of the Merger Agreement and other factors, including:  (i) Crescent&#8217;s equity holders will own a substantial majority of the voting rights in the Combined Company; (ii) Crescent&#8217;s largest stockholder will retain the largest interest in the Combined Company; (iii) Crescent will designate all of the initial members of the board of directors of the Combined Company; and (iv) Crescent&#8217;s executive management team will become the management of the Combined Company.  The Combined Company will be named Crescent Biopharma, Inc.  Accordingly, the Merger is expected to be treated as the equivalent of Crescent issuing stock to acquire the net assets of GlycoMimetics.  As a result of the Merger, the net assets of GlycoMimetics will be stated at fair value, which approximates carrying value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Crescent.  The direct and incremental costs related to the transaction will be treated as a reduction of the net proceeds received within additional paid-in-capital.  See the &#8220;</span><i style="font-style:italic;">Unaudited Pro Forma Condensed Combined Financial Information</i>&#8221; elsewhere in this proxy statement/prospectus for additional information.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="AppraisalRightsandDissentersRights_23852"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Under the DGCL, GlycoMimetics stockholders are not entitled to appraisal rights in connection with the Merger.  Crescent stockholders are entitled to appraisal rights in connection with the Merger under Section 262 of the DGCL.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The discussion below is not a complete summary regarding Crescent&#8217;s stockholders&#8217; appraisal rights under Delaware law and is qualified in its entirety by reference to the text of the relevant provisions of Delaware law, which are attached as <i style="font-style:italic;">Annex </i><i style="font-style:italic;">I</i><span style="white-space:pre-wrap;"> in this proxy statement/prospectus.  Stockholders intending to exercise appraisal rights should carefully review </span><i style="font-style:italic;">Annex </i><i style="font-style:italic;">I</i><span style="white-space:pre-wrap;">.  Failure to follow precisely any of the statutory procedures set forth in </span><i style="font-style:italic;">Annex </i><i style="font-style:italic;">I</i><span style="white-space:pre-wrap;"> may result in a termination or waiver of these rights.  This summary does not constitute legal or other advice, nor does it constitute a recommendation that Crescent stockholders exercise their appraisal rights under Delaware law.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Section 262, where a merger is adopted by stockholders by written consent in lieu of a meeting of stockholders pursuant to Section 228 of the DGCL, either the constituent corporation before the effective date of such merger or the surviving corporation, within ten days after the effective date of such merger, must notify each stockholder of the constituent corporation entitled to appraisal rights of the approval of such merger, the effective date of such merger and that appraisal rights are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">If the Merger is completed, within ten days after the effective date of the Merger, Crescent will notify its stockholders that the Merger has been approved, the effective date of the Merger and that appraisal rights are available to any stockholder who has not approved the Merger.  Holders of shares of Crescent capital stock who desire to exercise their appraisal rights must deliver a written demand for appraisal to Crescent within 20 days after the date of mailing of that notice, and that stockholder must not have delivered a written consent approving the Merger.  A demand for appraisal must reasonably inform Crescent of the identity of the stockholder and that such stockholder intends thereby to demand appraisal of the shares of Crescent capital stock held by such stockholder.  Failure to deliver a written consent approving the Merger will not in and of itself constitute a written demand for appraisal satisfying the requirements of Section 262.  All demands for appraisal should be addressed to c/o Crescent Biopharma, Inc., 221 Crescent Street Building 23, Suite 105</span>, Waltham, MA 02453 and should be executed by, or on behalf of, the record holder of shares of Crescent capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ALL DEMANDS MUST BE RECEIVED BY CRESCENT WITHIN 20 DAYS AFTER THE DATE CRESCENT MAILS A NOTICE TO ITS STOCKHOLDERS NOTIFYING THEM THAT THE MERGER HAS BEEN APPROVED, THE EFFECTIVE DATE OF THE MERGER AND THAT APPRAISAL RIGHTS ARE AVAILABLE TO ANY STOCKHOLDER WHO HAS NOT APPROVED THE MERGER.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you fail to deliver a written demand for appraisal within the time period specified above, you will be entitled to receive the merger consideration for your shares of Crescent capital stock as provided for in the Merger Agreement, but you will have no appraisal rights with respect to your shares of Crescent capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">To be effective, a demand for appraisal by a holder of shares of Crescent capital stock must be made by, or in the name of, the registered stockholder, fully and correctly, as the stockholder&#8217;s name appears on the stockholder&#8217;s stock certificate(s).  Beneficial owners who do not also hold the shares of record may not directly make appraisal demands to Crescent.  The beneficial owner must, in these cases, have the registered owner, such as a broker, bank or other custodian, submit the required demand in respect of those shares.  If shares are owned of record in a fiduciary capacity, such as by a trustee, guardian or custodian, execution of a demand for appraisal should be made by or for the fiduciary; and if the shares are owned of record by more than one person, as in a joint tenancy or tenancy in common, the demand should be executed by or for all joint owners.  An authorized agent, including an authorized agent for two or more joint owners, may execute the demand for appraisal for a stockholder of record; however, the agent must identify the record owner or owners and expressly disclose the fact that, in executing the demand, he or she is acting as agent for the record owner.  A record owner, such as a broker, who holds shares as a custodian for others, may exercise the record owner&#8217;s right of appraisal with respect to the shares held for one or more beneficial owners, while not exercising this right for other beneficial owners.  In that case, the written demand should state the number of shares as to which appraisal is sought.  Where no number of shares is expressly mentioned, the demand will be presumed to cover all shares held in the name of the record owner.  In addition, the stockholder must continuously hold the shares of record from the date of making the demand through the effective time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you hold your shares of Crescent capital stock in a brokerage account or in other custodian form and you wish to exercise appraisal rights, you should consult with your bank, broker or other custodian to determine the appropriate procedures for the making of a demand for appraisal by the custodian.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">At any time within 60 days after the effective time, any stockholder who has demanded an appraisal, but has neither commenced an appraisal proceeding or joined an appraisal proceeding as a named party, has the right to withdraw such stockholder&#8217;s demand and accept the terms of the Merger by delivering a written withdrawal to Crescent.  If, following a demand for appraisal, you have withdrawn your demand for appraisal in accordance with Section 262, you will have the right to receive the merger consideration for your shares of Crescent capital stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Within 120 days after the effective date of the Merger, any stockholder who has delivered a demand for appraisal in accordance with Section 262 will, upon written request to the surviving corporation, be entitled to receive a written statement setting forth the aggregate number of shares not voted in favor of the Merger Agreement and with respect to which demands for appraisal rights have been received and the aggregate number of holders of these shares.  This written statement will be mailed to the requesting stockholder within 10 days after the stockholder&#8217;s written request is received by the surviving corporation or within 10 days after expiration of the period for delivery of demands for appraisal, whichever is later.  Within 120 days after the effective date of the Merger, either the surviving corporation or any stockholder who has delivered a demand for appraisal in accordance with Section 262 may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares held by all such stockholders.  Upon the filing of the petition by a stockholder, service of a copy of the petition must be made upon the surviving corporation.  The surviving corporation has no obligation to file a petition in the Delaware Court of Chancery in the event there are dissenting stockholders, and GlycoMimetics, which is expected to be the surviving corporation, has no present intent to file a petition in the Delaware Court of Chancery.  Accordingly, the failure of a stockholder to file a petition within the period specified could nullify the stockholder&#8217;s previously written demand for appraisal.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">If a petition for appraisal is duly filed by a stockholder and a copy of the petition is delivered to the surviving corporation, the surviving corporation will then be obligated, within 20 days after receiving service of a copy of the petition, to provide the Delaware Court of Chancery with a duly verified list containing the names and addresses of all stockholders who have demanded an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the surviving corporation.  After notice to dissenting stockholders who demanded appraisal of their shares, the Delaware Court of Chancery is empowered to conduct a hearing upon the petition, and to determine those stockholders who have complied with Section 262 and who have become entitled to the appraisal rights provided thereby.  The Delaware Court of Chancery may require the stockholders who have demanded appraisal for their shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with that direction, the Delaware Court of Chancery may dismiss the proceedings as to that stockholder.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">After determination of the stockholders entitled to appraisal of their shares, the Delaware Court of Chancery will appraise the &#8220;fair value&#8221; of the shares owned by those stockholders.  This value will be exclusive of any element of value arising from the accomplishment or expectation of the Merger, but may include a fair rate of interest, if any, upon the amount determined to be the fair value.  When the value is determined, the Delaware Court of Chancery will direct the payment of the value, with interest thereon accrued during the pendency of the proceeding, if the Delaware Court of Chancery so determines, to the stockholders entitled to receive the same, upon surrender by the holders of the certificates representing those shares.  At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter only upon the sum of (i) the difference, if any, between the amount so paid and the fair value of the shares subject to appraisal as determined by the Delaware Court of Chancery and (ii) interest theretofore accrued, unless paid at that time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In determining fair value and, if applicable, a fair rate of interest, the Delaware Court of Chancery is required to take into account all relevant factors. In <i style="font-style:italic;">Weinberger v. UOP, Inc.</i>, the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#8220;proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#8221; should be considered, and that &#8220;fair price obviously requires consideration of all relevant factors involving the value of a company.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section 262 provides that fair value is to be &#8220;exclusive of any element of value arising from the accomplishment or expectation of the merger.&#8221; <i style="font-style:italic;">In Cede &amp; Co. v. Technicolor, Inc.</i>, the Delaware Supreme Court stated that this exclusion is a &#8220;narrow exclusion [that] does not encompass known elements of value,&#8221; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In <i style="font-style:italic;">Weinberger</i>, the Delaware Supreme Court construed Section 262 to mean that &#8220;elements of future value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#8221;</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should be aware that the fair value of your shares as determined under Section 262 could be more than, the same as, or less than the value that you are entitled to receive under the terms of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Costs of the appraisal proceeding may be imposed upon the surviving corporation and the stockholders participating in the appraisal proceeding by the Delaware Court of Chancery as the Court deems equitable in the circumstances.  Upon the application of a stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorneys&#8217; fees and the fees and expenses of experts, to be charged pro rata against the value of all shares entitled to appraisal.  In the absence of such a determination of assessment, each party bears its own expenses.  Any stockholder who had demanded appraisal rights will not, after the effective time, be entitled to vote shares subject to that demand for any purpose or to receive payments of dividends or any other distribution with respect to those shares, other than with respect to payment as of a record date prior to the effective time; however, if no petition for appraisal is filed within 120 days after the effective time, or if the stockholder delivers a written withdrawal of his or her demand for appraisal and an acceptance of the terms of the Merger within 60 days after the effective time, then the right of that stockholder to appraisal will cease and that stockholder will be entitled to receive the merger consideration for shares of his or her Crescent capital stock pursuant to the Merger Agreement.  Any withdrawal of a demand for appraisal made more than 60 days after the effective time may only be made with the written approval of the surviving corporation.  No appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the court.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Failure to follow the steps required by Section 262 for perfecting appraisal rights may result in the loss of appraisal rights.  In view of the complexity of Section 262, stockholders who may wish to dissent from the Merger and pursue appraisal rights should consult their legal advisors.</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c0c01418_b375_4fbb_907f_7d167066a1ea"></a><a id="THEMERGERAGREEMENT_134884"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">THE MERGER AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement, including the amendment thereto, is attached to this proxy statement/prospectus as Annex A and is incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its terms. It is not intended to provide any other factual information about GlycoMimetics, Crescent, First Merger Sub or Second Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Merger Agreement contains representations and warranties that GlycoMimetics, First Merger Sub and Second Merger Sub, on the one hand, and Crescent, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in confidential disclosure letters exchanged by the parties in connection with signing the Merger Agreement. While GlycoMimetics and Crescent do not believe that these disclosure letters contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure letters do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about GlycoMimetics or Crescent, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between GlycoMimetics, First Merger Sub, Second Merger Sub and Crescent and are modified by the disclosure letters.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Structure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with Delaware law, at the closing of the Merger, (i)&#160;First Merger Sub, a wholly owned subsidiary of GlycoMimetics formed by GlycoMimetics in connection with the Merger, will merge with and into Crescent, with Crescent surviving as a wholly owned subsidiary of GlycoMimetics, and (ii)&#160;immediately following the First Merger and as part of the same overall transaction as the First Merger, Crescent will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Completion and Effectiveness of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two business&#160;days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Crescent stockholders and the approval by the GlycoMimetics stockholders of the issuance of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger. The Merger will become effective upon the filing of certificates of Merger with the Secretary of State of the State of Delaware or at such later time as is agreed by GlycoMimetics and Crescent and specified in the certificates of Merger. Neither GlycoMimetics nor Crescent can predict the exact timing of the consummation of the Merger.</p><a id="MergerConsideration_601615"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Merger Consideration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, each share of Crescent common stock (including any shares of Crescent common stock issued pursuant to Crescent&#8217;s Pre-Closing Financing) outstanding immediately prior to the First Effective Time (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of GlycoMimetics common stock equal to the Exchange Ratio described in more detail below, and each share of Crescent&#8217;s preferred stock outstanding immediately prior to the First Effective Time (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of GlycoMimetics&#8217; convertible preferred stock equal to (x)&#160;the Exchange Ratio described in more details below <i style="font-style:italic;">divided by</i> (y)&#160;<span style="white-space:pre-wrap;">1,000. No fractional shares of GlycoMimetics common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of GlycoMimetics common stock resulting from the conversion of shares of Crescent common stock (including shares of Crescent common stock issued in the Crescent Pre-Closing Financing) shall be issued as follows:  (i)&#160;one </span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">share of GlycoMimetics common stock if the aggregate amount of fractional shares of GlycoMimetics common stock of any individual holder of Crescent capital stock if upon conversion is equal to or exceeds 0.50 or (ii)&#160;no shares of GlycoMimetics common stock if the aggregate amount of fractional shares of GlycoMimetics common stock of any individual holder of Crescent capital stock if upon conversion is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of GlycoMimetics Series&#160;A Preferred Stock that a holder of Crescent preferred stock would otherwise be entitled to receive will be aggregated with all fractional shares of GlycoMimetics Series&#160;A Preferred Stock issuable to such holder and rounded up to the nearest whole share of GlycoMimetics Series&#160;A Preferred Stock.</span></p><a id="ExchangeRatio_869762"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exchange Ratio</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Exchange Ratio is calculated using a formula intended to allocate existing GlycoMimetics and Crescent securityholders a&#160;percentage of the Combined Company. Based on GlycoMimetics&#8217; capitalization as of September&#160;30, 2024 and Crescent&#8217;s capitalization as of October&#160;28, 2024, the date the Merger Agreement was executed, the Exchange Ratio was estimated to be equal to approximately 14.9149 shares of GlycoMimetics common stock for each share of Crescent common stock. Each share of Crescent preferred stock will be converted into the right to receive a number of shares of GlycoMimetics Series A Preferred Stock, equal to the Exchange Ratio divided by 1,000. This estimate of the Exchange Ratio is subject to adjustment prior to closing of the First Merger for net cash as of 11:59&#160;p.m. Eastern Time on the business day prior to the anticipated closing date (and as a result, GlycoMimetics securityholders could own less, and Crescent securityholders (including, for this purpose, investors in the Crescent Pre-Closing Financing) could own more, or vice versa, of the Combined Company). GlycoMimetics&#8217; management currently anticipates that GlycoMimetics&#8217; net cash as of closing will be approximately $1.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the estimates set forth above, after giving effect to the Crescent Pre-Closing Financing, and certain other assumptions, immediately following the completion of the Merger, GlycoMimetics securityholders would own approximately 3.10% of the capital stock of the Combined Company post-Merger, and Crescent securityholders, including shares of Crescent common stock and Crescent warrants purchased in the Crescent Pre-Closing Financing, would own approximately 96.90% of the capital stock of the Combined Company post-Merger. Under certain circumstances further described in the Merger Agreement, the ownership&#160;percentages may be adjusted up or down including, but not limited to, if GlycoMimetics&#8217; net cash as of closing is less than $1.725 million or more than $1.875 million. GlycoMimetics&#8217; management currently anticipates GlycoMimetics&#8217; net cash as of closing will be approximately $1.8 million, and the currently estimated ownership&#160;percentages reflect this projection. There can be no assurances any of these assumptions will be accurate at closing when the final Exchange Ratio is determined. For more information on the Crescent Pre-Closing Financing, please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Subscription Agreement</i>&#8221; beginning on page&#160;151 in this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Exchange Ratio formula is the quotient obtained (rounded to four decimal places) by dividing the number of Crescent Merger Shares (defined below) by the Crescent Outstanding Shares (defined below), in which:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Aggregate Valuation&#8221; means the sum of (i)&#160;the Crescent Valuation plus (ii)&#160;the GlycoMimetics Valuation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Company</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Acquisition&#8221; means any acquisition or license of, by purchase or otherwise, a portion of, or all or substantially all of, (i)&#160;the property or assets, (ii)&#160;the equity securities or other evidence of beneficial ownership, or (iii)&#160;any division, line of business or other business unit, in each case, of any person other than GlycoMimetics and its subsidiaries.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Crescent Allocation&#160;Percentage&#8221; means the&#160;percentage (rounded to four decimal places) determined by subtracting the GlycoMimetics Allocation&#160;Percentage from 100%.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Crescent Merger Shares&#8221; means the product determined by multiplying (i)&#160;the Post-Closing GlycoMimetics Shares by (ii)&#160;the Crescent Allocation&#160;Percentage.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Crescent Outstanding Shares&#8221; means, without duplication, the total number of shares of Crescent capital stock outstanding immediately prior to the First Effective Time, (including any shares of Crescent common stock or Crescent preferred stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Crescent Pre-Closing Financing, any Interim Financing or Crescent Acquisition), expressed on a fully diluted and as-converted-to-Crescent common stock basis, assuming, without limitation or duplication, the exercise of all options and warrants to acquire Crescent&#8217;s capital stock and other rights or commitments to receive shares of Crescent common stock or Crescent preferred stock (or securities convertible or exercisable into shares of Crescent common stock or Crescent preferred stock, including the convertible promissory note convertible into Crescent common stock), whether conditional or unconditional or vested or unvested, that are outstanding (on a treasury share method basis) as of immediately prior to the First Effective Time. The calculation of Crescent outstanding shares excludes, (i)&#160;any Crescent options, Crescent warrants and any other equity awards issued under Crescent&#8217;s 2024 Equity Incentive Plan (including any shares of Crescent common stock issuable upon the exercise of such Crescent options, Crescent warrants or other equity awards) issued to directors, employees, consultants or other service providers following October&#160;28, 2024 but prior to the Closing and (ii)&#160;any shares of Crescent common stock underlying the Convertible Notes&#160;that are to be contributed as consideration in the Crescent Pre-Closing Financing pursuant to the Subscription Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Crescent Valuation&#8221; means (i)&#160;$50.0 million, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">plus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (ii)&#160;the amount of proceeds actually received by Crescent from the Crescent Pre-Closing Financing (including in the proceeds actually received from any convertible promissory notes convertible into Crescent common stock, and any interest thereon, contributed as consideration in the Crescent Pre-Closing Financing), </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">plus </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)&#160;the fair market value of each Company Acquisition, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">plus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (iv)&#160;the fair market value of any Interim Financing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;GlycoMimetics Allocation&#160;Percentage&#8221; means the quotient (expressed as a&#160;percentage and rounded to four decimal places) determined by dividing (i)&#160;the GlycoMimetics Valuation by (ii)&#160;the Aggregate Valuation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;GlycoMimetics Net Cash Lower Amount&#8221; means if GlycoMimetics net cash is less than $1.725 million, then the difference, if any, between $1.8 million and GlycoMimetics net cash.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;GlycoMimetics Net Cash Upper Amount&#8221; means if GlycoMimetics net cash is more than $1.875 million, then the difference, if any, between $1.8 million and GlycoMimetics net cash.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;GlycoMimetics Outstanding Shares&#8221; means, without duplication, (including, without limitation, the effects of any reverse split, if completed) the total number of shares of GlycoMimetics common stock outstanding immediately prior to the First Effective Time expressed on a fully-diluted basis and as converted to GlycoMimetics common stock basis, and assuming, without limitation or duplication, (i)&#160;the issuance of shares of GlycoMimetics common stock in respect of all options, warrants or other rights or commitments to receive shares of GlycoMimetics common stock or GlycoMimetics preferred stock (or securities convertible or exercisable into shares of GlycoMimetics common stock or GlycoMimetics preferred stock, but excluding any GlycoMimetics convertible preferred stock issuable as a result of the Merger or as a result of the Crescent Pre-Closing Financing), whether conditional or unconditional, that are outstanding (on a treasury share method basis) as of immediately prior to the First Effective Time, and (ii)&#160;the settlement in shares of GlycoMimetics common stock of GlycoMimetics restricted stock units outstanding as of immediately prior to the Effective Time on a net settlement basis, and excludes GlycoMimetics Out of the Money Options.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;GlycoMimetics Valuation&#8221; means the greater of (x)(i)&#160;$8</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.0 million</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">minus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (ii)&#160;the GlycoMimetics Net Cash Lower Amount (if any) </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">plus </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(iii)&#160;the GlycoMimetics Net Cash Upper Amount (if any), and (y)(i)&#160;the GlycoMimetics Valuation Floor, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">minus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (ii)&#160;the GlycoMimetics Net Cash Lower Amount (if any) </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">plus</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (iii)&#160;the GlycoMimetics Net Cash Upper Amount (if any).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;GlycoMimetics Valuation Floor&#8221; means an amount equal to (i)&#160;0.03, multiplied by (ii)&#160;the sum of (A)&#160;Crescent Valuation (as of immediately prior to the closing) and (B)&#160;$8.0 million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Interim Financing&#8221; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">means</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> any sale (or series of related sales) by Crescent of its common stock or preferred stock, as applicable, that is completed following October&#160;28, 2024; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">however</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, that neither the issuance of Convertible Notes&#160;nor the Crescent Pre-Closing Financing is an Interim Financing.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Post-Closing GlycoMimetics Shares&#8221; means the quotient determined by dividing (i)&#160;the GlycoMimetics Outstanding Shares by (ii)&#160;the GlycoMimetics Allocation&#160;Percentage. The estimated Exchange Ratio for purposes of the unaudited pro forma condensed combined financial information was derived on a fully-diluted basis as of October&#160;28, 2024 using a stipulated value of Crescent of approximately $50.0 million (excluding the Crescent Pre-Closing Financing) and of GlycoMimetics of approximately $8.0 million. For more information, see &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Calculation of GlycoMimetics&#8217; Net Cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Merger Agreement, GlycoMimetics&#8217; &#8220;net cash&#8221; means, as of 11:59&#160;p.m. Eastern Time on the last business day prior to the anticipated closing date, the sum (without duplication) of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; unrestricted cash and cash equivalents and marketable securities determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in GlycoMimetics&#8217; SEC filings or GlycoMimetics&#8217; balance sheet; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Certain GlycoMimetics prepaid expenses set forth in GlycoMimetics&#8217; disclosure letter; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$300,000 for each&#160;month, or portion thereof, after June&#160;30, 2025 by which closing is delayed (except where such delay is caused primarily by the actions of GlycoMimetics), which amount shall begin accruing on July&#160;1, 2025.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</i> the sum (without duplication) of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; consolidated short-term and long-term contractual obligations and liabilities accrued at the closing date, in each case determined in accordance with GAAP and, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the GlycoMimetics&#8217; SEC reports and its balance sheet;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The aggregate amount (without duplication) of all fees and expenses incurred by GlycoMimetics prior to the First Effective Time in connection with the contemplated transactions, in each case (excluding certain fees and expenses incurred by GlycoMimetics prior to the First Effective Time in connection with certain transactions), to the extent unpaid as of the First Effective Time, including;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any fees and expenses of legal counsel, accountants, financial advisors, investment bankers, brokers, consultants, tax advisors, and other professional advisors of GlycoMimetics in connection with the transactions contemplated by the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">50% of the fees paid to the SEC in connection with filing this registration statement and any amendments and supplements thereto, with the SEC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">50% of the fees and expenses in connection with the printing, mailing and distribution of this proxy statement and any amendments and supplements thereto;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">50% of the fees associated with the filing of the Combined Company&#8217;s initial listing application with Nasdaq;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any bonus, retention payments, severance, change-in-control payments or similar payment obligations (including payments with &#8220;single-trigger&#8221; provisions triggered at and as of the consummation of the transactions contemplated hereby) that become due or payable to any director, officer, employee or consultant in connection with the consummation of the contemplated transactions, together with any payroll taxes associated therewith;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with obtaining the &#8220;D&amp;O tail policy&#8221; pursuant to Section&#160;6.7 of the Merger Agreement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount by which the actual amount of any Parent Net Cash Excluded Expense at closing exceeds the estimate set forth on Schedule 1.1(b)&#160;of GlycoMimetics disclosure letter.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All remaining rent payments and any other liabilities under GlycoMimetics&#8217; lease obligations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any unpaid taxes of GlycoMimetics and its subsidiaries for tax periods (or portions thereof) ending on or before the closing date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No later than five business&#160;days prior to the anticipated closing date, (i)&#160;GlycoMimetics will deliver to Crescent a net cash schedule setting forth, in reasonable detail, GlycoMimetics&#8217; good faith estimated calculation of the components of its net cash, including any GlycoMimetics Net Cash Lower Amount or GlycoMimetics Net Cash Upper Amount and (ii)&#160;Crescent will deliver to GlycoMimetics a Crescent valuation schedule setting forth, in reasonable detail, Crescent&#8217;s good faith estimated calculations of the components of Crescent&#8217;s valuation, in each case, as of 11:59&#160;p.m. Eastern Time on the last business day prior to the anticipated closing date, prepared and certified by GlycoMimetics&#8217; and Crescent&#8217;s chief financial officer (or if there is no chief financial officer, the principal financial and accounting officer), as the case may be, and, if requested, the relevant work papers and back-up materials used or useful in preparing the net cash schedule and Crescent valuation schedule, respectively. No later than three business&#160;days after delivery of such net cash schedule (the last day of such period referred to as the response date), Crescent will have the right to dispute any part of the net cash schedule by delivering a written notice to that effect to GlycoMimetics (referred to herein as a dispute notice). Any dispute notice will identify, in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to GlycoMimetics&#8217; net cash calculation. No later than three business&#160;days after delivery of such Crescent valuation schedule (the last day of such period referred to as the response date), GlycoMimetics will have the right to dispute any part of such schedule by delivering a written notice to that effect to Crescent (referred to herein as an Crescent valuation dispute notice). Any dispute notice will identify, in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to Crescent&#8217;s valuation calculation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Crescent disputes the net cash schedule or GlycoMimetics disputes the Crescent valuation schedule, the parties shall attempt in good faith to resolve the disputed items and negotiate an agreed-upon determination of net cash and/or Crescent&#8217;s valuation, as the case may be. If the parties are unable to negotiate an agreed-upon determination of the disputed items or component thereof within three&#160;days after the delivery of the relevant dispute notice, any remaining disagreements will be referred to an independent auditor of recognized national standing mutually agreed upon by GlycoMimetics and Crescent. The determination of the amount of net cash or Crescent valuation made by such auditor shall be final and binding on GlycoMimetics and Crescent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; net cash balance is subject to numerous factors, some of which are outside of GlycoMimetics&#8217; control. The actual amount of net cash will depend significantly on the timing of the closing of the Merger. In addition, the closing of the Merger could be delayed if GlycoMimetics and Crescent are not able to agree upon the amount of GlycoMimetics&#8217; net cash as of 11:59&#160;p.m. Eastern Time on the last business day prior to the anticipated closing date.</p><a id="CrescentOptions_773564"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Crescent Options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, each option to purchase shares of Crescent common stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of GlycoMimetics common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Accordingly, from and after the First Effective Time:  (i)&#160;each outstanding Crescent stock option assumed by GlycoMimetics may be exercised solely for shares of GlycoMimetics common stock; (ii)&#160;the number of shares of GlycoMimetics common stock subject to each outstanding Crescent stock option assumed by GlycoMimetics will be determined by multiplying (A)&#160;the number of shares of Crescent common stock that were subject to such Crescent stock option assumed by GlycoMimetics, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of GlycoMimetics common stock; and (iii)&#160;the per share exercise price of each Crescent stock option assumed by will be determined by dividing (A)&#160;the per share exercise price of such Crescent stock option, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio and rounding the resulting exercise price up to the nearest whole cent. Each Crescent stock option assumed by GlycoMimetics will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Crescent stock option will otherwise remain unchanged.</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent provided under the terms of a Crescent stock option assumed by GlycoMimetics in accordance with the terms of the Merger Agreement, such Crescent stock option shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of GlycoMimetics common stock subsequent to the First Effective Time. In addition, the GlycoMimetics Board or a committee thereof will succeed to the authority and responsibility of the Crescent Board or any committee thereof with respect to each Crescent option assumed by GlycoMimetics in accordance with the terms of the Merger Agreement.</p><a id="CrescentWarrants_481334"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Crescent Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, each warrant to purchase shares of Crescent capital stock (including any pre-funded Crescent warrants issued pursuant to the Crescent Pre-Closing Financing) that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be converted into a warrant to purchase shares of GlycoMimetics common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Accordingly, from and after the First Effective Time:  (i)&#160;each outstanding Crescent warrant assumed by GlycoMimetics may be exercised solely for shares of GlycoMimetics common stock; (ii)&#160;the number of shares of GlycoMimetics common stock subject to each outstanding Crescent warrant assumed by GlycoMimetics will be determined by multiplying (A)&#160;the number of shares of Crescent common stock issuable upon exercise of the Crescent warrant that were subject to such Crescent warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio, and rounding the resulting number up to the next whole number of shares of GlycoMimetics common stock to the extent the aggregate amount of fractional shares of GlycoMimetics common stock such holder of the assumed warrants would otherwise be entitled to is equal to or exceeds 0.50, and otherwise rounded down; and (iii)&#160;the per share exercise price for the GlycoMimetics common stock issuable upon exercise of each Crescent warrant assumed by GlycoMimetics will be determined by dividing (A)&#160;the per share exercise price of GlycoMimetics common stock subject to such Crescent warrant as in effect immediately prior to the First Effective Time, by (B)&#160;the Exchange Ratio and rounding the resulting exercise price up to the nearest whole cent. Each Crescent warrant assumed by GlycoMimetics will otherwise continue in full force and effect and the term, any restriction on the exercise and other provisions of such Crescent warrant will otherwise remain unchanged.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent provided under the terms of a Crescent warrant assumed by GlycoMimetics in accordance with the terms of the Merger Agreement, such Crescent warrant shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of GlycoMimetics common stock subsequent to the First Effective Time. In addition, the GlycoMimetics Board or a committee thereof will succeed to the authority and responsibility of the Crescent Board or any committee thereof with respect to each Crescent warrant assumed by GlycoMimetics in accordance with the terms of the Merger Agreement.</p><a id="GlycoMimeticsCommonStockGlycoMimeticsOpt"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GlycoMimetics Common Stock, GlycoMimetics Options and GlycoMimetics Restricted Stock Units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as contemplated by the proposed increase in the number of authorized shares of GlycoMimetics common stock described in Proposal No.&#160;2 of this proxy statement/prospectus and<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;</sup>the proposed reverse stock split of issued and outstanding GlycoMimetics common stock described in Proposal No.&#160;3 of this proxy statement/prospectus, GlycoMimetics common stock will remain unaffected by the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, the GlycoMimetics Board will accelerate the vesting of all equity awards of GlycoMimetics then outstanding but not then vested or exercisable, and cancel each GlycoMimetics Out of the Money Option. At the closing of the First Merger, (i)&#160;each GlycoMimetics In the Money Option will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of shares underlying such option, (ii)&#160;each GlycoMimetics restricted stock unit will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of unsettled shares of GlycoMimetics common stock underlying such GlycoMimetics restricted stock unit, and (iii)&#160;each other option to acquire shares of GlycoMimetics common stock will be cancelled for no consideration.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Procedures for Exchanging Crescent Stock Certificates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the closing date of the First Merger, GlycoMimetics will select an Exchange Agent and, at the First Effective Time, GlycoMimetics will deposit with the Exchange Agent evidence of book-entry shares representing the shares of GlycoMimetics common stock and GlycoMimetics Series&#160;A Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Crescent common stock and Crescent preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Promptly after the First Effective Time, the Exchange Agent will mail to each record holder of Crescent common stock or Crescent preferred stock (i)&#160;a letter of transmittal and (ii)&#160;instructions for surrendering the record holder&#8217;s stock certificates in exchange for the merger consideration. Upon delivery to the Exchange Agent of a duly executed letter of transmittal in accordance with the Exchange Agent&#8217;s instructions and the declaration for tax withholding purposes, the surrender of the record holder&#8217;s stock certificates, if applicable, and delivery to the Exchange Agent of such other documents as may be reasonably required by the Exchange Agent or GlycoMimetics, the record holder of such stock certificates or book-entry shares, as applicable, will be entitled to receive in exchange therefor book-entry shares representing the number of whole shares of GlycoMimetics common stock issuable to such holder pursuant to the Merger Agreement. The surrendered certificates representing shares of Crescent common stock or Crescent preferred stock will be canceled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the First Effective Time, each certificate representing Crescent common stock or Crescent preferred stock that has not been surrendered will represent only the right to receive shares of GlycoMimetics common stock or preferred stock (as applicable) issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">HOLDERS OF CRESCENT COMMON STOCK OR CRESCENT PREFERRED STOCK SHOULD NOT SEND IN THEIR CRESCENT STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF CRESCENT STOCK CERTIFICATES.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Directors and Officers of GlycoMimetics Following the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Merger Agreement, each of the directors and officers of GlycoMimetics will resign effective as of the First Effective Time and the GlycoMimetics Board will thereafter consist of a total of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;new directors designated by Crescent. Crescent has designated Jonathan Violin, Alexandra Balcom, Peter Harwin, Susan Moran, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to serve as members of the GlycoMimetics Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, upon the closing of the Merger, Jonathan Violin will serve as Chief Executive Officer and President, Christopher Doughty will serve as Chief Business Officer, Ryan Lynch will serve as Treasurer, Senior Vice President of Finance and Chief Accounting Officer, and Barbara Bispham will serve as General Counsel and Corporate Secretary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Amendment of the Amended and Restated Certificate of Incorporation of GlycoMimetics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics agreed to amend its amended and restated certificate of incorporation to (i)&#160;change GlycoMimetics&#8217; name to &#8220;Crescent Biopharma,&#160;Inc.&#8221;, (ii)&#160;effect the proposed reverse stock split, if needed, (iii)&#160;authorize a sufficient number of shares of common stock to issue the merger consideration and (iv)&#160;increase the number of shares of GlycoMimetics common stock that GlycoMimetics is authorized to the amount proposed in this Proxy Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Representations and Warranties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement contains customary representations and warranties of GlycoMimetics, First Merger Sub and Second Merger Sub, on one hand, and Crescent, on the other hand, for a transaction of this type relating to, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">corporate organization and power, and similar corporate matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">due organization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">organizational documents;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authority to enter into the Merger Agreement and the related agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">votes required for completion of the Merger and approval of the proposals that will come before the GlycoMimetics Special Meeting of stockholders and that will be the subject of the Crescent stockholder approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">except as otherwise specifically disclosed in the Merger Agreement, the fact that the consummation of the Merger would not contravene the organizational documents, certain laws, governmental authorizations or certain contracts of the parties; result in any encumbrances on the parties&#8217; assets or require the consent of any third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the parties&#8217; efforts with respect to ensuring the inapplicability of Section&#160;203 of the DGCL and other similar takeover laws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">capitalization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial statements and, with respect to GlycoMimetics, documents filed with the SEC and the accuracy of information contained in those documents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">material changes or events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">title to assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">real property and leaseholds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">material contracts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the validity of material contracts to which the parties or their subsidiaries are a party and any violation, default or breach of such contracts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory compliance, permits and restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">legal proceedings and orders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee and labor matters and benefit plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">environmental matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">insurance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial advisors fees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain transactions or relationships with affiliates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">privacy and data security;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with respect to GlycoMimetics, the valid issuance in the Merger of GlycoMimetics common stock; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with respect to Crescent, the lack of ownership of GlycoMimetics common stock.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The representations and warranties are, in many respects, qualified by materiality and knowledge, and will not survive the Merger. The accuracy of the representations and warranties of the Company form the basis of certain of the conditions to the obligations of GlycoMimetics and Crescent to complete the Merger, subject to materiality thresholds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Covenants; Conduct of Business Pending the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has agreed that, except as permitted by the Merger Agreement, as required by law, or unless Crescent has provided written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, GlycoMimetics and its subsidiaries will use commercially reasonable efforts to conduct their business and operations in the ordinary course consistent with past practices and in compliance with all applicable laws, regulations and certain material contracts. GlycoMimetics has also agreed that, subject to certain limited exceptions, without the consent of Crescent, it will not, and will not cause or permit any of its subsidiaries to, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of capital stock; or repurchase, redeem or otherwise reacquire any shares of capital stock or other securities (except for shares of GlycoMimetics common stock from terminated employees, directors or consultants of GlycoMimetics);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of any capital stock or other security (except for GlycoMimetics common stock issued upon the valid exercise of outstanding GlycoMimetics options or GlycoMimetics restricted stock units), any option, warrant or right to acquire any capital stock or any other security or any instrument convertible into or exchangeable for any capital stock or other security;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">except as required to give effect to anything in contemplation of the closing, amend the certificate of incorporation, bylaws or other similar organizational documents of GlycoMimetics or its subsidiaries, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">form any subsidiary or acquire any equity interest or other interest in any other entity or enter into any joint venture with any other entity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lend money to any person or entity; incur or guarantee any indebtedness for borrowed money; guarantee any debt securities of others; or make any capital expenditure or commitment in excess of $25,000;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adopt, establish or enter into certain agreements, plans or arrangements relating to employment or benefits matters; cause or permit any such agreement, plan or arrangement to be amended other than as required by law or in order to make amendments for purposes of Section&#160;409A of the Code; pay any bonus or make any profit-sharing or similar payment to, or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers, employees or independent contractors; increase the severance or change of control benefits offered to any current or new employees, directors or consultants; or hire any officer, employee or consultant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any encumbrance with respect to such assets or properties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, assign, transfer, license, sublicense or otherwise dispose of any material intellectual property rights of GlycoMimetics (other than pursuant to non-exclusive licenses in the ordinary course of business);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">other than in the ordinary course of business:  make, change or revoke any material tax election; file any amended income or other material tax return; adopt or change any material accounting method in respect of taxes; enter into any material tax closing agreement or settle any material tax claim or assessment; consent to any extension or waiver of the limitation period applicable to or relating to any material tax claim or assessment; or surrender any material claim for refund;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">waive, settle or compromise any pending or threatened legal proceeding against GlycoMimetics or any of its subsidiaries, other than waivers, settlements or agreements for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and that do not impose any material restrictions on the </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operations or businesses of GlycoMimetics or its subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by GlycoMimetics or any of its subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or fail to repay when due any material obligation, including accounts payable and accrued expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">forgive any loans to any person, including its employees, officers, directors or affiliate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">terminate or modify in any material respect, or fail to exercise renewal rights to, any material insurance policy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">materially change pricing or royalties or other payments set or charged by GlycoMimetics or any of subsidiaries to its customers or licensees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agree to materially change pricing or royalties or other payments set or charged by persons who have licensed intellectual property to GlycoMimetics or any of subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter into, amend in a manner adverse to GlycoMimetics or terminate any of GlycoMimetics&#8217; material contracts outside the ordinary course of business; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agree, resolve or commit to do any of the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent has agreed that, except as permitted by the Merger Agreement (including in connection with any Interim Financing or Crescent Acquisition), as required by law, or unless GlycoMimetics shall have provided its written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, Crescent will use commercially reasonable efforts to conduct its business and operations in the ordinary course consistent with past practices and in compliance with all applicable laws, regulations and certain contracts. Crescent has also agreed that, subject to certain limited exceptions, without the consent of GlycoMimetics, it will not, and will not cause or permit its subsidiary to, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of capital stock; or repurchase, redeem or otherwise reacquire any shares of capital stock or other securities (except for shares of common stock from terminated employees, directors or consultants of Crescent);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">except as required to give effect to anything in contemplation of the closing, amend the certificate of incorporation, bylaws or other organizational documents of Crescent or its subsidiaries, or effect or be a party to any Merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">other than in the ordinary course of its business, sell, issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing actions with respect to more than 25% of the shares of Crescent capital stock outstanding as of the date the Merger Agreement was signed:  any capital stock or other security of Crescent or its subsidiaries (except for shares of outstanding Crescent common stock issued upon the valid exercise or settlement of Crescent options or warrants in accordance with their terms as in effect as of the date of the Merger Agreement); any option, warrant or right to acquire any capital stock or any other security; or any instrument convertible into or exchangeable for any capital stock or other security of Crescent or its subsidiaries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other than in the ordinary course of its business, acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lend money to any person or entity; incur or guarantee any indebtedness for borrowed money; guarantee any debt securities of others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any encumbrance with respect to such assets or properties, except in the ordinary course of business;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, assign, transfer, license, sublicense or otherwise dispose of any material intellectual property rights owned by Crescent, other than pursuant to non-exclusive licenses in the ordinary course of business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">waive, settle or compromise any pending or threatened legal proceeding against Crescent, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of Crescent or any equitable relief on, or the admission of wrongdoing by Crescent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter into, amend in a manner adverse to Crescent or terminate any material contract outside of the ordinary course of its business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agree, resolve or commit to do any of the foregoing.</span></td></tr></table><div style="margin-top:9pt;"><a id="NonSolicitation_638714"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Non-Solicitation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Each of GlycoMimetics and Crescent have agreed that, except as described below, GlycoMimetics and Crescent and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize any of the directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any Acquisition Proposal (as defined below) or Acquisition Inquiry (as defined below) or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">furnish any non-public information with respect to it to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">engage in discussions or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">execute or enter into any letter of intent or any contract contemplating or otherwise relating to an Acquisition Proposal; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicly propose to do any of the foregoing.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">An &#8220;Acquisition Inquiry&#8221; means, with respect to a party, an inquiry, indication of interest or request for non-public information (other than an inquiry, indication of interest or request for information made or submitted by Crescent, on the one hand, or GlycoMimetics on the other hand, to the other party) that would reasonably be expected to lead to an Acquisition Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">An &#8220;Acquisition Proposal&#8221; means, with respect to a party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of Crescent or any of its affiliates, on the one hand, or by or on behalf of GlycoMimetics or any of its affiliates, on the other hand, to the other party) contemplating or otherwise relating to any Acquisition Transaction with such party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">An &#8220;Acquisition Transaction&#8221; means any transaction or series of related transactions (other than the Crescent Pre-Closing Financing, any Interim Financing, or any Company Acquisition) involving:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">any merger, consolidation, amalgamation, share exchange, business combination, issuance or acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or similar transaction:  (i)&#160;in which any individual, entity, governmental entity, or &#8220;group,&#8221; as defined under applicable securities laws, directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of GlycoMimetics or Crescent or any of their respective subsidiaries or (ii)&#160;in which GlycoMimetics, Crescent or Merger Subs or any of their respective subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such party or any of its subsidiaries or issues securities convertible into more than 20% of the outstanding securities of any class of voting securities; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of GlycoMimetics or Crescent and their respective subsidiaries, as applicable, taken as a whole.</span></td></tr></table><div style="margin-top:9pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Notwithstanding the foregoing, before obtaining the applicable approvals of the GlycoMimetics stockholders or Crescent stockholders required to consummate the Merger, each party may furnish non-public information regarding such party and its subsidiaries to, and may enter into discussions or negotiations with, any third party in response to a bona fide written Acquisition Proposal, which such party&#8217;s board of directors determines in good faith, after consultation with such party&#8217;s financial advisors and outside legal counsel, constitutes or is reasonably likely to result in a Superior Offer (as defined below) (and is not withdrawn), if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such party&#8217;s board of directors concludes in good faith, based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the fiduciary duties of such board of directors under applicable law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least two business&#160;days prior to furnishing any non-public information or entering into discussions with a third party, such party gives the other party written notice of the identity of the third party and of that party&#8217;s intention to furnish non-public information to, or enter into discussions with, such third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such party receives from the third party an executed confidentiality agreement containing provisions at least as favorable to such party as those contained in the confidentiality agreement between GlycoMimetics and Crescent; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least two business&#160;days prior to furnishing any non-public information to a third party, such party furnishes the same non-public information to the other party to the extent not previously furnished.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">A &#8220;Superior Offer&#8221; means an unsolicited <i style="font-style:italic;">bona fide</i> written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that (a)&#160;was not obtained or made as a direct or indirect result of a breach of the Merger Agreement, (b)&#160;is on terms and conditions that the board of directors of the party receiving the offer determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other party to the Merger Agreement to amend the terms of the Merger Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to that party&#8217;s stockholders than the terms of the transactions contemplated by the Merger Agreement, (c)&#160;is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party) and (d)&#160;is reasonably capable of being completed on the terms proposed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">The Merger Agreement also provides that each party will promptly (and in no event later than one business day after such party receives any such Acquisition Proposal or Acquisition Inquiry) advise the other party of the status and terms of, and keep the other party reasonably informed with respect to, any Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">The Merger Agreement expressly permits Crescent to take any action with respect to an Interim Financing or a Crescent Acquisition.</p><a id="BoardRecommendationChange_946099"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Board Recommendation Change</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Under the Merger Agreement, subject to certain exceptions described below, both Crescent and GlycoMimetics agreed that their respective board of directors may not withhold, amend, withdraw or modify (or publicly propose to withhold, amend, withdraw or modify) the recommendation of such party&#8217;s board of directors in a manner adverse to the other party except for in limited circumstances described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">At any time prior to the approval of the Merger by each party&#8217;s respective stockholders, if (i)&#160;such party has received a bona fide written Acquisition Proposal that the such party&#8217;s board of directors determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii)&#160;a material development or change in circumstances (other than any such event, development or change to the extent related to any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, the fact, in and of itself, that such party meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of such party and occurs or arises after the date the Merger Agreement was executed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">In the case of a change recommendation due to a material development or change in circumstance, such party&#8217;s board of directors must first promptly notify the other party, in writing, at least four business&#160;days before making a change in its recommendation, stating the material facts and circumstances related to the applicable material development or change in circumstance and that such party&#8217;s board of directors intends to make a change in its recommendation.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">In the case of a change its recommendation due to a Superior Offer, such party&#8217;s board of directors must first:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determine in good faith, based on the advice of its outside legal counsel, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negotiate with the other party in good faith to make such adjustments to the terms and conditions of the Merger Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, during the required four business day notice period and provide the other party with certain information regarding such Superior Offer.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">If the other party delivers a written offer to alter the terms or conditions of the Merger Agreement during the required four business day notice period, the party considering a change in the recommendation of its board of directors must redetermine in good faith, based on the advice of its outside legal counsel and financial advisors, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Required Stockholder Approvals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">GlycoMimetics is obligated under the Merger Agreement to take all action necessary under applicable law to call, give notice of and hold a meeting of the holders of GlycoMimetics common stock for the purpose of considering and voting to approve the Merger Agreement and the transactions contemplated thereby (including the Merger) and an amendment to the GlycoMimetics Charter as further described herein (collectively, the &#8220;Merger proposals&#8221;). The GlycoMimetics Special Meeting will be held as promptly as practicable after this registration statement on Form&#160;S-4 is declared effective under the Securities Act, and in any event no later than 45&#160;days after the effective date of this registration statement on Form&#160;S-4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Promptly after this registration statement on Form&#160;S-4 has been declared effective, and no later than two business&#160;days thereafter, Crescent is required to obtain the approval by written consent from the holders of a majority of the outstanding shares of Crescent&#8217;s capital stock, voting as a single class on an as-converted basis and the holders of a majority of the outstanding shares of Crescent Series&#160;Seed Preferred Stock, voting as a separate class, in each case, to (x)&#160;adopt and approve the Merger Agreement and the Merger or the transactions contemplated thereby (including the Merger), (y)&#160;acknowledge that the approval given thereby is irrevocable and that such stockholders are aware of their rights to demand appraisal for their shares pursuant to Section&#160;262 of the DGCL, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (z)&#160;acknowledge that by their approval of the Merger, they are not entitled to appraisal rights with respect to their shares in connection with the Merger and thereby waive any rights to receive payment of the fair value of their capital stock under the DGCL. Reasonably promptly following receipt of such consents, Crescent will prepare, and cause to be mailed to its stockholders who did not execute such consents, a notice in accordance with the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Regulatory Approvals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Each party agreed to use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of the Merger Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party with or otherwise submitted by such party to any governmental authority with respect to the transactions contemplated by the Merger Agreement, and to submit promptly any additional information requested by any such governmental authority. GlycoMimetics and Crescent do not intend to seek any regulatory approval from antitrust or other regulatory authorities to consummate the transactions.</p><a id="IndemnificationandInsuranceforDirectorsa"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Indemnification and Insurance for Directors and Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Under the Merger Agreement, from the First Merger Effective Time through the sixth anniversary of the date on which the First Merger Effective Time occurs, GlycoMimetics and the surviving entity in the Second Merger agreed to indemnify and hold harmless each person who is now, or has been at any time prior to the date of the Merger Agreement, or who becomes prior to the First Merger Effective Time, a director or officer of GlycoMimetics or Crescent, respectively, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the indemnified officer or director is or was a director or officer of GlycoMimetics or of Crescent, whether asserted or claimed prior to, at or after the First Merger Effective Time. From and after the First Merger Effective Time, GlycoMimetics and the surviving corporation in the Merger will also fulfill GlycoMimetics&#8217; and Crescent&#8217;s indemnity obligations, respectively, to each person who is, has been, or who becomes prior to the First Merger Effective Time, a director or officer of GlycoMimetics or Crescent.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">The certificate of formation and limited liability company agreement of the surviving entity will contain provisions no less favorable with respect to indemnification and advancement of expenses as those presently set forth in the GlycoMimetics Charter and GlycoMimetics Bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">From and after the First Merger Effective Time, GlycoMimetics will maintain director and officers&#8217; liability insurance policies, with an effective date as of the closing date of the First Merger, on commercially available terms and conditions and with coverage limits customary for U.S. public companies similarly situated to GlycoMimetics. In addition, GlycoMimetics will secure and purchase a six&#160;year &#8220;tail policy&#8221; on GlycoMimetics&#8217; existing directors&#8217; and officers&#8217; liability insurance policy with an effective date as of the date of the closing of the First Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Additional Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Each of GlycoMimetics and Crescent has agreed to use its commercially reasonable efforts to cause to be taken all actions necessary to consummate the Merger and the other transactions contemplated by the Merger Agreement. In connection therewith, each party has agreed to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such party in connection with the transactions contemplated by the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use commercially reasonable efforts to obtain each consent (if any) reasonably required to be obtained (pursuant to any applicable law or contract, or otherwise) in connection with the Merger and the other transactions contemplated by the Merger Agreement or for such contract to remain in full force and effect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the transactions contemplated by the Merger Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use commercially reasonable efforts to satisfy the conditions precedent to the consummation of the Merger Agreement.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Pursuant to the Merger Agreement, GlycoMimetics and Crescent have further agreed that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics will use its commercially reasonable efforts to maintain its listing on Nasdaq and cause the shares of GlycoMimetics common stock (including any shares of GlycoMimetics common stock issuable upon conversion of the GlycoMimetics Series&#160;A Preferred Stock) being issued in the Merger to be approved for listing on Nasdaq at or prior to the First Merger Effective Time.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics will keep Crescent reasonably informed regarding any stockholder litigation against GlycoMimetics or any of its directors relating to the Merger Agreement or the transactions contemplated thereby.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 36pt;">GlycoMimetics will (i)&#160;give Crescent the opportunity to participate in, but not control, the defense, settlement or prosecution of any such litigation (to the extent that the attorney-client privilege is not undermined or otherwise adversely affected), (ii)&#160;consult with Crescent with respect to the defense, settlement and prosecution of any such litigation and (iii)&#160;consider in good faith Crescent&#8217;s advice with respect to such litigation.</p><a id="ConditionstotheCompletionoftheMerger_946"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Conditions to the Completion of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">The following contains a description of all material conditions to the completion of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Each party&#8217;s obligation to complete the Merger is subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the closing, of various conditions, which include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any applicable waiting periods (or any extensions thereof) under the U.S. Hart Scott-Rodino Antitrust Improvements Act of 1976, as amended, (if applicable) shall have expired or otherwise been terminated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the registration statement on Form&#160;S-4, of which this proxy statement/prospectus is a part, must have been declared effective by the SEC in accordance with the Securities Act and must not be subject to any stop order or any proceeding seeking a stop order that has not been withdrawn;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any material state securities laws applicable to the issuance of the shares of GlycoMimetics&#8217; capital stock in connection with the Merger or any of the other transactions contemplated by the Merger Agreement shall have been complied with;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there must not have been issued, and remain in effect, any order preventing the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement by any governmental authority of competent jurisdiction, and no law, statute, rule, regulation, ruling or decree will be in effect which has the effect of making the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement illegal;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the holders of a majority of the outstanding shares of Crescent common stock, voting as a single class on an as-converted basis and the holders of a majority of the outstanding shares of Crescent Series&#160;Seed Preferred Stock, voting as a separate class, must have adopted and approved the Merger Agreement and the transactions contemplated thereby by written consent (the &#8220;Crescent stockholder approval&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the holders of the shares of GlycoMimetics common stock constituting a majority of the votes properly cast at the GlycoMimetics Special Meeting must have approved the Merger Agreement and the transactions contemplated thereby;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initial listing application for GlycoMimetics common stock on Nasdaq (including any shares of GlycoMimetics common stock issuable upon conversion of the shares of GlycoMimetics Series&#160;A Preferred Stock) shall have been approved by Nasdaq;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lock-up agreements executed by certain stockholders of Crescent will continue to be in full force and effect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the GlycoMimetics Charter amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing at least such amendments as are necessary to consummate the transactions contemplated by the Merger Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics shall have filed a Certificate of Designation with the Secretary of State of the State of Delaware designating the GlycoMimetics Series&#160;A Preferred Stock.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">In addition, each party&#8217;s obligation to complete the Merger is further subject to the satisfaction or waiver by that party of the following additional conditions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other party&#8217;s representations and warranties being true and correct as of the closing date, subject to applicable materiality qualifiers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other party to the Merger Agreement must have performed or complied with in all material respects all of such party&#8217;s agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior to the First Effective Time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of a material adverse effect that is continuing with respect to the other party; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other party having delivered certain certificates and other documents required under the Merger Agreement for the closing.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">In addition, the obligation of GlycoMimetics and Merger Subs to complete the Merger is further subject to the Subscription Agreement being in full force and effect and cash proceeds of not less than $100.0 million, less the amount of proceeds actually received by the Company in connection with any Interim Financing prior to the Closing, having been received by Crescent, substantially simultaneously with the closing of the First Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Termination and Termination Fees</b></p><a id="TerminationoftheMergerAgreement_43944"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">The Merger Agreement may be terminated at any time before the First Merger Effective Time, whether before or after the required stockholder approvals to complete the Merger have been obtained, as set forth below:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by mutual written consent of GlycoMimetics and Crescent;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by either GlycoMimetics or Crescent, if the Merger has not been consummated by September&#160;30, 2025 (subject to possible extension as provided in the Merger Agreement); </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided, however</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, that this right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal cause of the failure of the Merger to occur on or before September&#160;30, 2025 and such action or failure to act constitutes a breach of the Merger Agreement; and </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided, further</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, that such date may be extended by 60&#160;days by either party in the event that the SEC has not declared effective the registration statement on Form&#160;S-4, of which this proxy statement/prospectus is a part, by the date which is 60&#160;days prior to September&#160;30, 2025;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by either GlycoMimetics or Crescent, if a court of competent jurisdiction or governmental entity has issued a final and non-appealable order, decree or ruling or having the effect of permanently restrains, enjoins or otherwise prohibits the Merger or any of the transactions contemplated by the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by GlycoMimetics, if the Crescent stockholder approval has not been obtained within two business&#160;days of the date of the registration statement on Form&#160;S-4, of which this proxy statement/prospectus is a part, becoming effective; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> that this right to terminate the Merger Agreement will not be available to GlycoMimetics once Crescent obtains such stockholder approval (whether timely or not);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(e)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by either GlycoMimetics or Crescent, if the GlycoMimetics Special Meeting has been held and completed and GlycoMimetics stockholders have taken a final vote on the Merger proposals set forth herein to be considered at the GlycoMimetics Special Meeting, and such proposals have not been approved by the GlycoMimetics stockholders; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> that GlycoMimetics may not terminate the Merger Agreement pursuant to this provision if the failure to obtain the approval of GlycoMimetics stockholders was caused by the action or failure to act of GlycoMimetics and such action or failure to act constitutes a material breach by GlycoMimetics of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(f)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Crescent, at any time prior to obtaining the approval by GlycoMimetics stockholders of the Merger proposals set forth herein to be considered at the GlycoMimetics Special Meeting, if any of the following circumstances shall occur:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics fails to include in this proxy statement/prospectus the GlycoMimetics Board&#8217;s recommendation that GlycoMimetics stockholders vote to approve the Merger proposals set forth herein to be considered at the GlycoMimetics Special Meeting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board, or any committee thereof, makes an GlycoMimetics board recommendation change or publicly approves, endorses or recommends any Acquisition Proposal; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal, other than a confidentiality agreement permitted pursuant to the Merger Agreement;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(g)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by GlycoMimetics, at any time prior to obtaining the Crescent stockholder approval, if any of the following circumstances shall occur:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Crescent Board makes a Crescent board recommendation change or publicly proposes, endorses or recommends any Acquisition Proposal; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(h)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by Crescent, if GlycoMimetics or Merger Subs have breached any of their representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of GlycoMimetics has become inaccurate, in either case such that the conditions to the closing would not be satisfied as of time of such breach or inaccuracy; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> that Crescent is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided, further</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, if such breach or inaccuracy is curable, then GlycoMimetics shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of the expiration of a 30-day period after delivery of written notice of such breach or inaccuracy from Crescent to GlycoMimetics or Merger Subs and Crescent&#8217;s intention to terminate pursuant to this paragraph (it being understood that GlycoMimetics shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by GlycoMimetics or Merger Subs is cured prior to such termination becoming effective);</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by GlycoMimetics, if Crescent has breached any of its representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of Crescent has become inaccurate, in either case such that the conditions to the closing would not be satisfied as of time of such breach or inaccuracy; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that GlycoMimetics is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">provided, further</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, if such breach or inaccuracy is curable, then GlycoMimetics shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of the expiration of a 30-day period after delivery of written notice of such breach or inaccuracy from GlycoMimetics to Crescent and GlycoMimetics&#8217; intention to terminate pursuant to this paragraph (it being understood that the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Crescent is cured prior to such termination becoming effective); or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(j)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by GlycoMimetics (at any time prior to obtaining the GlycoMimetics stockholder approval), upon the GlycoMimetics Board authorizing GlycoMimetics to enter into a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that constitutes a superior offer, subject to certain conditions.</span></td></tr></table><div style="margin-top:12pt;"><a id="TerminationFeesPayablebyGlycoMimetics_98"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination Fees Payable by GlycoMimetics</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics must pay Crescent a termination fee of $320,000 if (i)&#160;the Merger Agreement is terminated by GlycoMimetics or Crescent pursuant to clause (e)&#160;above or by Crescent pursuant to clause (f)&#160;above, (ii)&#160;at any time after the date of the Merger Agreement and prior to the GlycoMimetics Special Meeting, a bona fide third party Acquisition Proposal for a change of control transaction with respect to GlycoMimetics will have been publicly announced, disclosed or otherwise communicated to the GlycoMimetics Board (and will not have been withdrawn), and (iii)&#160;within 12&#160;months after the date of such termination, GlycoMimetics enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction (excluding in each case any transactions occurring in connection with the liquidation, dissolution and winding up of GlycoMimetics).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination Fees Payable by Crescent</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent must pay GlycoMimetics a termination fee of $2.0 million if (i)&#160;the Merger Agreement is terminated by GlycoMimetics pursuant to clause (d)&#160;or (g)&#160;above, (ii)&#160;at any time after the date of the Merger Agreement and before obtaining the Crescent stockholder approval, an Acquisition Proposal with respect to Crescent will have been publicly announced, disclosed or otherwise communicated to the Crescent Board (and will not have been withdrawn), and (iii)&#160;within 12&#160;months after the date of such termination, Crescent enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Crescent terminates the Merger Agreement other than pursuant to clause (e)&#160;or (f)&#160;above, Crescent must pay GlycoMimetics a non-refundable fee in an amount equal to $500,000 for each&#160;month (or portion thereof) that has elapsed after May&#160;30, 2025 at the time of such payment; provided that in no event shall the amount of the fee payable by Crescent exceed $2.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Amendment and Waiver</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties to the Merger Agreement and authorized by such party&#8217;s boards of directors at any time, unless the Merger Agreement has been adopted and approved by any party&#8217;s stockholders, in which case no amendment which by law requires further approval by the such party&#8217;s stockholders, may be made without such further approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any provision of the Merger Agreement may be waived by any party solely on that party&#8217;s behalf, without the consent of any other party. The waiver must be expressly set forth in a written instrument duly executed and delivered on behalf of such party, which will only be valid in the specific instance in which it is given. No failure or delay on the part of any party with respect to the exercise of any power, right, privilege or remedy under the Merger Agreement will operate as a waiver of such power, right, privilege or remedy. Furthermore, no single or partial exercise of any such power, right, privilege or remedy will preclude any other or further exercise thereof or of any other power, right, privilege or remedy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a6f0c489_ce06_4775_83f4_a84f9f60f765"></a><a id="AGREEMENTSRELATEDTOTHEMERGER_119864"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">AGREEMENTS RELATED TO THE MERGER</b></p><a id="SupportAgreements_917428"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Support Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain Crescent stockholders holding approximately 98.5% of the outstanding shares of Crescent capital stock as of February&#160;7, 2025 have entered into Crescent Support Agreements with GlycoMimetics and Crescent to vote all of their shares of Crescent capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative acquisition proposals. The directors and officers of GlycoMimetics holding approximately 10.7% of the outstanding shares of GlycoMimetics common stock as of February&#160;7, 2025 have entered into GlycoMimetics Support Agreements with GlycoMimetics and Crescent to vote all of their shares of GlycoMimetics common stock in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal and against any alternative acquisition proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Lock-Up Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of Crescent&#8217;s executive officers, directors and stockholders have entered into lock-up agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of GlycoMimetics common stock or any securities convertible into or exercisable or exchangeable for GlycoMimetics common stock, currently or thereafter owned, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock issued in exchange for shares of Crescent preferred stock in the Merger, but excluding, as applicable, shares purchased by existing Crescent stockholders in the Crescent Pre-Closing Financing (including any shares of GlycoMimetics common stock issuable upon exercise of pre-funded warrants issued in exchange for pre-funded warrants to purchase shares of Crescent common stock sold in the Crescent Pre-Closing Financing), until 180&#160;days after the effective time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Crescent stockholders who have executed lock-up agreements as of February&#160;7, 2025 owned, in the aggregate, approximately 98.5% of the shares of Crescent&#8217;s outstanding capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing description of the lock-up agreements does not purport to be complete and is qualified in its entirety by the full text of the form of lock-up agreement, which is attached hereto as <i style="font-style:italic;">Annex E</i>.</p><a id="SubscriptionAgreement_341407"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Subscription Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, Crescent and GlycoMimetics entered into the Subscription Agreement with certain new and existing investors of Crescent, pursuant to which such investors have agreed to purchase immediately prior to the First Merger, shares of Crescent common stock or, in lieu thereof, Crescent pre-funded warrants, representing an aggregate commitment of approximately $200.0 million (which includes $37.5 million of proceeds previously received by Crescent from the issuance of its Convertible Notes&#160;and accrued interest on such note) in the Crescent Pre-Closing Financing. Under the Subscription Agreement, the number of shares of Crescent common stock or pre-funded warrants, as applicable, shall be determined at a purchase price per share or warrant equal to (i)&#160;a valuation for Crescent equal to approximately $50.0 million, (ii)&#160;divided by the number of shares of Crescent common stock outstanding immediately prior to the First Effective Time of the Merger (but excluding the securities being issued under the Subscription Agreement). Each share of Crescent preferred stock will be converted into the right to receive a number of shares of GlycoMimetics Series&#160;A Preferred Stock calculated in accordance with the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The shares of Crescent common stock and Crescent pre-funded warrants that are issued in the Crescent Pre-Closing Financing will be or will have the right to be, respectively, converted into shares of GlycoMimetics common stock in the Merger. Accordingly, by approving Proposal No.&#160;1 relating to the Merger, GlycoMimetics stockholders will also be approving the issuance of shares of GlycoMimetics common stock to be issued in exchange for all shares of Crescent common stock and pre-funded warrants that are sold in the Crescent Pre-Closing Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Subscription Agreement contains customary representations and warranties of Crescent and also contains customary representations and warranties of the purchaser parties thereto.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each purchaser&#8217;s obligation to purchase shares of Crescent common stock and/or Crescent pre-funded warrants from Crescent pursuant to the Subscription Agreement is subject to the satisfaction or waiver of certain conditions, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s representations and warranties in the Subscription Agreement being true and correct in all respects as of the effective date of the Subscription Agreement and true and correct in all material respects as of the closing date for the Crescent Pre-Closing Financing, subject to certain exceptions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent having performed and complied in all material respects with all covenants, agreements, obligations and conditions required to be performed or complied with by it;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of a compliance certificate by the chief executive officer of Crescent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all registrations, qualifications, permits and approvals, if any, required under applicable state securities laws having been obtained;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of a secretary&#8217;s certificate by the secretary of Crescent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the satisfaction or waiver of all conditions to the closing of the Merger set forth in the Merger Agreement (other than the condition regarding the Crescent Pre-Closing Financing) and the closing of Merger being set to occur substantially concurrent with the closing of the Crescent Pre-Closing Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no injunction having been issued prohibiting the consummation of the Crescent Pre-Closing Financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent having delivered the Registration Rights Agreement required by the Subscription Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">this registration statement on Form&#160;S-4 shall have been become effective under the Securities Act, no stop order shall be suspending the effectiveness of this registration statement and no proceeding for that purpose shall have been initiated or threatened in writing by the SEC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Nasdaq Listing Application shall have been approved by Nasdaq;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no material adverse effect shall have occurred that is continuing, since the date of the Subscription Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent shall receive at closing aggregate proceeds from the purchase of securities pursuant to the Subscription Agreement of not less than $100</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.0 million</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (including in such proceeds any convertible securities contributed as consideration in accordance with the Subscription Agreement)</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, less the amount of proceeds actually received by the Company in connection with any Interim Financing prior to the Closing </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(excluding in proceeds any convertible securities contributed as consideration in accordance with the Subscription Agreement); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an opinion from Company counsel, dated as of the closing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s obligation to sell shares of Crescent common stock to each purchaser pursuant to the Subscription Agreement is subject to the satisfaction or waiver of certain conditions, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the representations and warranties made by the purchasers being true and correct as of the effective date of the Subscription Agreement and true and correct in all material respects as of the closing date of the Crescent Pre-Closing Financing, subject to certain exceptions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each purchaser having performed and complied with all covenants, agreements, obligations and conditions required to be performed or complied with by each purchaser;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all registrations, qualifications, permits and approvals, if any, required under applicable state securities laws having been obtained; and</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the satisfaction or waiver of all conditions to the closing of the Merger set forth in the Merger Agreement (other than those conditions which are to be satisfied at the closing of the transactions contemplated by the Merger Agreement) and the closing of Merger being set to occur substantially concurrent with the closing of the Crescent Pre-Closing Financing.</span></td></tr></table><div style="margin-top:12pt;"><a id="RegistrationRightsAgreement_53171"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Registration Rights Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Subscription Agreement contemplates GlycoMimetics, Crescent and the investors participating in the Crescent Pre-Closing Financing entering into a Registration Rights Agreement at the closing of the Crescent Pre-Closing Financing, pursuant to which, among other things, the Combined Company will agree to provide for the registration and resale of certain shares of Crescent common stock that are held by the investors participating in the Crescent Pre-Closing Financing from time to time, including the shares of GlycoMimetics common stock issued in exchange for shares of Crescent common stock sold in the Crescent Pre-Closing Financing and GlycoMimetics pre-funded warrants assumed upon conversion of the Crescent pre-funded warrants sold in the Crescent Pre-Closing Financing (including shares issuable upon exercise of such warrants).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Registration Rights Agreement, the Combined Company will agree to prepare and file a resale registration statement covering the resale of the GlycoMimetics common stock within 30&#160;days of the closing of the Crescent Pre-Closing Financing pursuant to Rule&#160;415 and to use its reasonable best efforts to have the registration statement declared effective within 60&#160;days of the closing of the Crescent Pre-Closing Financing, subject to certain exceptions, and to keep such registration statement continuously effective under the Securities Act until the earlier of (a)&#160;the date that all registrable securities covered by such registration statement (i)&#160;have been sold, thereunder or pursuant to Rule&#160;144 of the Securities Act (&#8220;Rule&#160;144&#8221;), or (ii)&#160;may be sold without volume or manner-of-sale restrictions pursuant to Rule&#160;144 and without the requirement for the Combined Company to be in compliance with the current public information requirement under Rule&#160;144, and (b)&#160;five&#160;years after the date of the Registration Rights Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Registration Rights Agreement, the Combined Company will agree that neither the Combined Company nor securityholders of the Combined Company (other than the investors participating in the Crescent Pre-Closing Financing and party to the Registration Rights Agreement) may have &#8220;piggyback&#8221; registration rights and that the Combined Company will be prohibited from filing any other registration statements until all of the registerable securities subject to the Registration Rights Agreement are registered pursuant to an effective registration statement, subject to certain exceptions. The Registration Rights Agreement also provides that the Combined Company will pay certain expenses relating to such registrations and indemnify the applicable securityholders against certain liabilities. The form of Registration Rights Agreement is filed as Exhibit&#160;10.4 to this registration statement on Form&#160;S-4 of which this proxy statement/prospectus is a part, and the foregoing description of the Registration Rights Agreement is qualified in its entirety by reference thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2ee92e48_c7d9_4073_a615_47dcea39c43c"></a><a id="GLYCOMIMETICSDIRECTORSOFFICERSANDCORPORA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">GLYCOMIMETICS DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following sets forth certain information, as of February&#160;7, 2025, concerning GlycoMimetics&#8217; directors and executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; directors, executive officers and key employees as of February&#160;7, 2025 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:35.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.43%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Timothy Pearson</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.58%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director and Chairman</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Mark Goldberg, M.D.</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Patricia Andrews</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Scott Koenig, M.D., Ph.D.</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Scott Jackson</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Rachel King</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Daniel Junius</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Harout Semerjian</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director, President, and CEO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Brian Hahn</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer and Sr. VP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:47.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Edwin Rock, M.D. </b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">64</p></td><td style="vertical-align:top;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:35.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Medical Officer and Sr. VP </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Member of the Audit Committee</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Member of the Compensation Committee</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Member of the Nominating and Corporate Governance Committee</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Non-employee Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Timothy Pearson</b>. Mr.&#160;Pearson has served as has served as a member of the GlycoMimetics Board since 2014 and as its Chairperson since 2019. Mr.&#160;Pearson has served as the chief executive officer of Carrick Therapeutics, a privately held oncology company, since July&#160;2019. He previously served as executive vice president and the chief financial officer of TESARO,&#160;Inc., an oncology-focused biopharmaceutical company, from 2014 until its acquisition by GlaxoSmithKline in February&#160;2019. Mr.&#160;Pearson was also executive vice president and chief financial officer of Catalyst Health Solutions, a publicly held pharmacy benefit management company, from 2011 until its acquisition by SXC Health Solutions in 2012. Prior to joining Catalyst, Mr.&#160;Pearson served as the chief financial officer and executive vice president of MedImmune,&#160;Inc. Mr.&#160;Pearson also currently serves on the board of Korro Bio, a public company. He previously served on the board of directors of Ra Pharmaceuticals,&#160;Inc., until it was acquired by UCB in 2020. Mr.&#160;Pearson is a Certified Public Accountant and holds dual B.S. degrees in Business Administration from the University of Delaware and in Accounting from the University of Maryland, University College, as well as an M.S. in Finance from Loyola College. As a result of Mr.&#160;Pearson&#8217;s educational background and professional experiences, the GlycoMimetics Board believes Mr.&#160;Pearson possesses particularly impactful knowledge and experience in accounting and finance; corporate strategy, leadership of complex organizations and human capital management, all of which strengthen the Board&#8217;s collective qualifications, skills and experience.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Mark Goldberg, M.D. </b>Dr.&#160;Goldberg has served as a member of the GlycoMimetics Board since 2014. Dr.&#160;Goldberg served in a number of capacities of increasing responsibility at Synageva BioPharma Corp., a biopharmaceutical company, between 2011 and 2015, including as Executive Vice President, Medical and Regulatory Strategy. Prior to joining Synageva he served in various management capacities of increasing responsibility at Genzyme Corporation, a biopharmaceutical company, from 1996 to 2011, most recently as Senior Vice President, Clinical Development and Global Therapeutic Head, Oncology and Personalized Genetic Health, and as Chairman of Genzyme&#8217;s Early Product Development Board. Prior to working at Genzyme, he was a full-time staff physician at Brigham and Women&#8217;s Hospital and the Dana-Farber Cancer Institute. He still holds an appointment at Brigham and Women&#8217;s Hospital. Dr.&#160;Goldberg has also been on the faculty of Harvard Medical School since 1987 and serves as a Lecturer in Medicine (part-time). He is a board certified medical oncologist and hematologist. Dr.&#160;Goldberg serves on the boards of directors of the public biopharmaceutical companies Blueprint Medicines Corporation and Avacta Group&#160;plc. Within the last five&#160;years, he also served on the boards of directors of the public biopharmaceutical companies Audentes Therapeutics,&#160;Inc., ImmunoGen,&#160;Inc. and Idera Pharmaceuticals (now known as Aceragen,&#160;Inc.). He has also served as a member of the board of directors of the American Cancer Society since January&#160;2019. Dr.&#160;Goldberg received his A.B. from Harvard College and his M.D. from Harvard Medical School. The GlycoMimetics Board believes that Dr.&#160;Goldberg&#8217;s prestigious medical background and significant clinical experience allow him to make particularly valuable contributions to GlycoMimetics&#8217; research and development efforts, while his public company board experience provides GlycoMimetics with valuable strategic and operational expertise and leadership skills.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Patricia Andrews</b><i style="font-style:italic;">. </i>Ms.&#160;Andrews has served as a member of the GlycoMimetics Board since 2017. Ms.&#160;Andrews has served as the chief executive officer of Sumitomo Pharma Oncology,&#160;Inc. (and its predecessor, Boston Biomedical,&#160;Inc.), an oncology drug research and development company, and as an executive officer of its parent company, Sumitomo Pharma Co.&#160;Ltd. from 2017 until her retirement in July&#160;2023. Ms.&#160;Andrews joined Boston Biomedical in 2013. From 2008 to 2012, she served as the chief commercial officer of Incyte Corporation, a publicly held biopharmaceutical company. From 1991 to 2008, Ms.&#160;Andrews served in various roles of increasing responsibility at Pfizer&#160;Inc., culminating in her role as a vice president and the general manager of Pfizer&#8217;s U.S. Oncology business unit. Ms.&#160;Andrews serves on the board of Oncolytics Biotech,&#160;Inc. Ms.&#160;Andrews received her B.A. degree from Brown University and her M.B.A. degree from the University of Michigan. The GlycoMimetics Board believes Ms.&#160;Andrews&#8217; qualifications to serve on the Board include her strong leadership and demonstrated management experience within the pharmaceutical industry, including serving as a chief executive officer and a chief commercial officer, as well as her in-depth knowledge of operations and commercial strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Scott Koenig, M.D.. Ph.D. </b>Dr.&#160;Koenig has served as a member of the GlycoMimetics Board since 2017. Dr.&#160;Koenig is the co-founder of and has been the president and chief executive officer and a director of MacroGenics,&#160;Inc., a publicly held pharmaceutical company, since 2001. Previously, Dr.&#160;Koenig served as a senior vice president at MedImmune,&#160;Inc., where he participated in the selection and maturation of their product pipeline. From 1984 to 1990, he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Dr.&#160;Koenig served as chairman of the board of directors of Applied Genetic Technologies Corporation, or AGTC, a publicly held pharmaceutical company, until its acquisition in November&#160;2022. He is also a member of the board of directors of the Biotechnology Innovation Organization (BIO) and the International Biomedical Research Alliance. Dr.&#160;Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston. The GlycoMimetics Board believes that Dr.&#160;Koenig&#8217;s deep experience in the biopharmaceutical industry, specifically in the BioHealth Capital Region of Maryland, Virginia, and Washington, DC, his service on committees and boards of local institutions and organizations, and his strategic and operational expertise and leadership skills make him highly qualified to serve as a member of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Scott Jackson</b><span style="font-style:italic;font-weight:bold;">. </span>Mr.&#160;Jackson has served as a member of the GlycoMimetics Board since November&#160;2018. Mr.&#160;Jackson served as the chief executive officer and as a member of the board of directors of Celator Pharmaceuticals,&#160;Inc. from 2008 until 2016, when GlycoMimetics was acquired by Jazz Pharmaceuticals&#160;plc. Mr.&#160;Jackson has more than 30&#160;years of experience in the pharmaceutical and biotechnology industries and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly&#160;&amp; Co., SmithKline Beecham, ImClone Systems&#160;Inc., Centocor&#160;Inc. (a division of Johnson&#160;&amp; Johnson), Eximias Pharmaceutical and YM BioSciences. Mr.&#160;Jackson currently serves on the board of directors of MacroGenics,&#160;Inc., and Spero Therapeutics,&#160;Inc., and as chairperson of the board of directors of Mural Oncology,&#160;plc., all of which are publicly traded pharmaceutical companies. Mr.&#160;Jackson also serves on the board of directors of Philabundance, a non-profit organization addressing food insecurity in the Philadelphia region. He holds a B.S. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. The GlycoMimetics Board believes Mr.&#160;Jackson&#8217;s extensive experience in the pharmaceutical and biotechnology industries, including service as an executive officer and board member, as well as his management expertise and significant background in business and commercial development, sales and marketing and clinical development, make him highly qualified to serve as a member of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Rachel King</b><i style="font-style:italic;">. </i>Ms.&#160;King co-founded GlycoMimetics and has served as a member of the Board since GlycoMimetics&#8217; inception in 2003. Ms.&#160;King served as GlycoMimetics&#8217; president and chief executive officer from GlycoMimetics&#8217; inception in 2003 until August&#160;2021. Ms.&#160;King has served as the interim president and chief executive officer of the Biotechnology Innovation Organization (BIO) from October&#160;2022 to March&#160;2024 and has served on its board of directors since 2005, including as chair of the board of BIO from 2013 to 2015. Previously, Ms.&#160;King was an Executive in Residence at New Enterprise Associates (NEA), an investment firm, from 2001 to 2003. From 1999 to 2001, Ms.&#160;King served as a senior vice president of Novartis Corporation, a pharmaceutical company. Before joining Novartis, Ms.&#160;King spent 10&#160;years with Genetic Therapy,&#160;Inc., a biotechnology company, where she served in a number of roles as part of the executive team, which included GlycoMimetics&#8217; initial public offering and later acquisition by Novartis. After the acquisition by Novartis, she served as the chief executive officer of Genetic Therapy, which was then a wholly owned subsidiary of Novartis. Ms.&#160;King previously worked at Alza Corporation, a pharmaceutical and medical systems company that was later acquired by Johnson&#160;&amp; Johnson, as well as at Bain and Company, a management consulting firm. Ms.&#160;King currently serves on the board of directors of Novavax,&#160;Inc., a publicly traded biotechnology company. Ms.&#160;King was appointed by Maryland&#8217;s governor as chair of the Maryland Life Sciences Advisory Board and served in that capacity from 2013 to 2015. She also currently serves on the board of the University of Maryland BioPark. She received a B.A. from Dartmouth College and an M.B.A. from Harvard Business School. The GlycoMimetics Board believes that Ms.&#160;King&#8217;s detailed knowledge of GlycoMimetics as one of GlycoMimetics&#8217; co-founders and her experience with biotechnology companies prior to founding GlycoMimetics, in addition to her leadership skills, allow her to make valuable contributions to the Board.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Daniel Junius</b>. Mr.&#160;Junius has served as a member of the GlycoMimetics Board since 2016. Mr.&#160;Junius served as the president and chief executive officer of ImmunoGen,&#160;Inc., formerly a publicly held biotechnology company recently acquired by AbbVie, from 2009 until his retirement in 2016. He also served as ImmunoGen&#8217;s president and chief operating officer and acting chief financial officer from July&#160;2008 to December&#160;2008, as an executive vice president and the chief financial officer from 2006 to July&#160;2008, and as a senior vice president and the chief financial officer from 2005 to 2006. Mr.&#160;Junius also served as a director of ImmunoGen from 2008 until June&#160;2018. Before joining ImmunoGen, Mr.&#160;Junius was an executive vice president and the chief financial officer of New England Business Service,&#160;Inc., or NEBS, a business-to-business direct marketing company, from 2002 until its acquisition by Deluxe Corporation in 2004 and a senior vice president and the chief financial officer of NEBS from 1998 to 2002. Prior to NEBS, he was a vice president and the chief financial officer of Nashua Corporation, a manufacturer and marketer of specialty imaging paper and label products and services. He joined Nashua Corporation in 1984 and held financial management positions of increasing responsibility before becoming chief financial officer in 1996. Mr.&#160;Junius has served on the board of directors and as chair of the audit committee of IDEXX Laboratories,&#160;Inc., a publicly held pet healthcare company, since 2014. Mr.&#160;Junius holds a Bachelor of Arts in Political Science from Boston College and a master&#8217;s degree in Management from Northwestern University&#8217;s Kellogg School of Management. The GlycoMimetics Board believes that Mr.&#160;Junius&#8217; extensive experience, including service as chief executive officer and chief financial officer of public companies, in addition to his financial expertise and depth of knowledge of the biopharmaceutical industry, allows him to make valuable contributions to the Board and to bolster the Board&#8217;s overall skills and experience.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Executive Officers and Employee Director</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Harout Semerjian</b>. Mr.&#160;Semerjian has served as the GlycoMimetics President and Chief Executive Officer and as a member of the Board since August&#160;2021. Prior to joining GlycoMimetics, he was an independent advisor to private equity firms focused on investments in healthcare companies. He previously served as president and chief executive officer of Immunomedics,&#160;Inc., a pharmaceutical company, during April&#160;and May&#160;of 2020. From March&#160;2018 to April&#160;2020, he served as an executive vice president and chief commercial officer at Ipsen Pharma, where he was accountable for that company&#8217;s worldwide commercialization and portfolio strategy across oncology, neurosciences and rare diseases. From February&#160;2017 to February&#160;2018, he served as president and head of Ipsen&#8217;s Specialty Care International Region&#160;&amp; Global Franchises. Mr.&#160;Semerjian previously spent 16&#160;years at Novartis Oncology, where he held various worldwide strategic and operational positions, culminating in his last role as a senior vice president and global head for Ribociclib, accountable for worldwide launch preparations. During his tenure at Novartis, Mr.&#160;Semerjian worked on numerous launches and commercial activities for various therapies, including Gleevec, Tasigna, Exjade/Jadenu, Promacta, Zometa, and Femara. He has also served as a member of the board of directors of the Biotechnology Innovation Organization (BIO) since October&#160;2023. Mr.&#160;Semerjian holds an M.B.A. from Cornell University, an M.B.A. from Queen&#8217;s University, Canada, and a B.S. in Biology from the Lebanese American University in Lebanon. The GlycoMimetics Board believes that Mr.&#160;Semerjian&#8217;s long-time experience as an executive officer in the pharmaceutical industry and his significant background in commercialization activities provide a valuable contribution to the Board, in addition to his role as Chief Executive Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Brian Hahn</b>. Mr.&#160;Hahn has served as the GlycoMimetics Chief Financial Officer and Senior Vice President since January&#160;2019, Chief Financial Officer from 2012 until January&#160;2019, and Director of Finance and Administration from 2010 to 2012. From 2009 to 2010 he served in the position of Assistant Controller for OpGen,&#160;Inc., a biotechnology company, and from 2002 to 2009, Mr.&#160;Hahn served in the position of Executive Director of Finance at MiddleBrook Pharmaceuticals,&#160;Inc. (formerly Advancis Pharmaceutical), a specialty pharmaceutical company. From 1998 to 2001, he was a senior accountant with Bering Truck Corporation. Mr.&#160;Hahn currently serves as Co-Chair of the Biotechnology Industry Organization (BIO)&#8217;s Finance and Tax Committee. In 2015, Mr.&#160;Hahn testified on behalf of BIO before the House Subcommittee on Capital Markets and Government Sponsored Enterprises in support of the Fostering Innovation Act. Mr.&#160;Hahn received a B.B.A. from Shenandoah University and an M.B.A. from the University of Maryland.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Edwin Rock, M.D.</b> Dr. Rock has served as the GlycoMimetics Chief Medical Officer and Senior Vice President since September 2022. Prior to joining GlycoMimetics, Dr. Rock was the Chief Medical Officer at Partner Therapeutics from September 2020 to September 2022. Previously, he served as the Vice President of Clinical Development at MacroGenics, Inc. from 2017 to September 2020, where he led that company&#8217;s program culminating in FDA approval of its product Margenza. From 2016 to 2017, he served as Executive Director, Clinical Research at Astex, a subsidiary of Otsuka Pharmaceutical Co., Ltd., having previously served from 2009 to 2016 as Otsuka&#8217;s Senior Director, Global Clinical Development. Earlier in his career he worked in clinical development for GSK and as a Medical Officer in the FDA&#8217;s Office of Oncology Drug Products. Dr. Rock holds a B.A. in Biology and Economics from Swarthmore College. He earned Ph.D. and M.D. degrees from the Stanford University School of Medicine before completing his Internal Medicine residency at Brigham and Women&#8217;s Hospital and his Medical Oncology fellowship at the University of Pennsylvania.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BOARD DIVERSITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While GlycoMimetics does not have a formal diversity policy in place, GlycoMimetics&#8217; Nominating and Corporate Governance Committee considers the diversity of the GlycoMimetics Board overall with respect to age, disability, gender identity or expression, ethnicity, military veteran status, national origin, race, religion, sexual orientation, and other backgrounds and experiences. GlycoMimetics&#8217; Nominating and Corporate Governance Committee is committed to actively seeking out and will instruct any search firm it engages to identify, individuals who will contribute to the overall diversity of the GlycoMimetics Board to be included in the pool of candidates from which nominees to the GlycoMimetics Board are selected. GlycoMimetics Board monitors the mix of skills and experience of its directors to help ensure it has the necessary tools to perform its oversight function effectively. The GlycoMimetics Board fully appreciates the value of a diversity of viewpoints, background and experiences as important to the selection of directors to enhance the GlycoMimetics Board&#8217;s cognitive diversity and quality of dialogue in its discussions.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:12.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:16.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:17.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Board Diversity Matrix (as of February 7, 2025)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total Number of Directors:</b></p></td><td colspan="10" style="vertical-align:bottom;width:60%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">8</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.13%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Did Not</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Female</b></p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Male</b></p></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-Binary</b></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:17.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Disclose</b></p></td></tr><tr><td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Part I: Gender Identity</b></p></td><td style="vertical-align:bottom;width:8.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.42%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Directors</p></td><td style="vertical-align:bottom;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Part II: Demographic Background</b></p></td><td style="vertical-align:bottom;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">White</p></td><td style="vertical-align:bottom;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td><td style="vertical-align:top;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;6**</p></td><td style="vertical-align:top;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:17.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Includes one director who identifies as Middle Eastern.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Code of Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has adopted a Code of Business Conduct and Ethics, which is applicable to all of its directors, officers and employees, including its CEO, Chief Financial Officer and other senior financial officers. The Code of Business Conduct and Ethics provides a framework for sound ethical business decisions and sets forth GlycoMimetics&#8217; expectations on a number of topics, including conflicts of interest, compliance with laws, use of its assets and business ethics. GlycoMimetics&#8217; Code of Business Conduct and Ethics is posted in the &#8220;Corporate Governance&#8221; section of the &#8220;Investors&#8221; tab of its website located at www.glycomimetics.com. If GlycoMimetics ever were to amend or waive any provision of the Code of Business Conduct and Ethics that applies to its principal executive officer, principal financial officer, principal accounting officer or any person performing similar functions, GlycoMimetics intends to satisfy its disclosure obligations, if any, with respect to any such waiver or amendment by posting such information on its website set forth above rather than by filing a Current Report on Form&#160;8-K. In the case of a waiver for an executive officer or a director, the disclosure required under applicable Nasdaq listing standards also will be made available on GlycoMimetics&#8217; website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Hedging And Pledging Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under GlycoMimetics Insider Trading Policy, GlycoMimetics directors, executive officers, employees, and their designees may not hedge their ownership of GlycoMimetics&#8217; stock, including but not limited to trading in options, puts, calls, or other derivative instruments related to GlycoMimetics&#8217; stock or debt. Additionally, directors, executive officers, employees, and their designees may not purchase GlycoMimetics&#8217; stock on margin, borrow against GlycoMimetics&#8217; stock held in a margin account, or pledge GlycoMimetics&#8217; stock as collateral for a loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Audit Committee and Audit Committee Financial Experts</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All members of the GlycoMimetics Audit Committee are &#8220;independent&#8221; in accordance with Nasdaq listing standards and SEC rules&#160;applicable to boards of directors in general and audit committee members in particular. The GlycoMimetics Board has determined that Ms.&#160;Andrews, Mr.&#160;Junius and Mr.&#160;Pearson each qualify as an &#8220;audit committee financial expert&#8221; as defined by the applicable SEC rules&#160;and that each member of the Audit Committee is financially sophisticated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Family Relationships</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are no family relationships among any of GlycoMimetics&#8217; executive officers or directors.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Audit Committee Report </b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Audit Committee consists solely of independent directors, as required by and in compliance with SEC rules&#160;and regulations and Nasdaq listing standards. The Audit Committee operates pursuant to a written charter adopted by the GlycoMimetics Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Audit Committee is responsible for assisting the Board in its oversight responsibilities related to accounting policies, internal controls, financial reporting, and legal and regulatory compliance. Management of GlycoMimetics has the primary responsibility for its financial reporting processes, proper application of accounting principles, and internal controls as well as the preparation of its financial statements. GlycoMimetics&#8217; independent registered public accounting firm is responsible for performing an audit of GlycoMimetics&#8217; financial statements and expressing an opinion as to the conformity of such financial statements with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Audit Committee has reviewed and discussed GlycoMimetics&#8217; audited financial statements for the fiscal&#160;year ended December&#160;31, 2024 with management and the independent registered public accounting firm. The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) and the SEC. In addition, the Audit Committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent registered public accounting firm&#8217;s communications with the Audit Committee concerning independence and has discussed with the independent registered public accounting firm its independence. Based on the review and discussions described above, the Audit Committee recommended to the Board that GlycoMimetics&#8217; audited financial statements be included in its Annual Report on Form&#160;10-K for the fiscal&#160;year ended December&#160;31, 2024, for filing with the SEC.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mr. Daniel Junius, Chair </p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ms. Patricia Andrews</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mr. Tim Pearson</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The material in this report is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC and is not to be incorporated by reference in any filing of GlycoMimetics under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a1599460_e06c_4909_9040_b53207c0e5fe"></a><a id="ADDITIONALINFORMATIONREGARDINGTHEBOARDOF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">ADDITIONAL INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE</b><b style="font-weight:bold;text-transform:uppercase;"><br/></b><b style="font-weight:bold;text-transform:uppercase;">GOVERNANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Independence of the Board of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As required under the Nasdaq listing standards, a majority of the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively determined by the board of directors. The GlycoMimetics Board consults with GlycoMimetics&#8217; counsel to ensure that the board of directors&#8217; determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent listing standards of the Nasdaq, as in effect from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and GlycoMimetics, its senior management and its independent registered public accounting firm, the Board of Directors has affirmatively determined that the following directors are independent directors within the meaning of the applicable Nasdaq listing standards: Ms.&#160;Andrews, Drs.&#160;Goldberg and Koenig, and Messrs.&#160;Jackson, Junius and Pearson. In making this determination, the Board found that none of the directors had a material or other disqualifying relationship with GlycoMimetics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board Leadership Structure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has structured its Board in a way that GlycoMimetics believes effectively serves its objectives of corporate governance and management oversight. GlycoMimetics separates the roles of President and Chairman of the board of directors in recognition of the differences between the two roles. GlycoMimetics believes that the President should be responsible for the day-to-day leadership and performance of GlycoMimetics, while the Chairman of the board of directors should work with the President and the rest of the board of directors to set the strategic direction for GlycoMimetics and provide guidance to, and oversight of the President. The Chairman also sets the agenda for meetings of the board of directors and presides over them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Pearson, who is an independent director, was elected Chairman of the board of directors in 2019. In this capacity, Mr.&#160;Pearson, among other things, calls and presides over board meetings, including meetings of the independent directors, and sets meeting agendas. In this role, Mr.&#160;Pearson can effectively coordinate between the board of directors and management regarding risk management issues and the implementation of appropriate responses, and can help ensure the effective independent functioning of the board of directors in its oversight responsibilities. Accordingly, the Chairman has substantial ability to shape the work of the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Role of the Board of Directors in Risk Oversight and Risk Management</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">One of the Board&#8217;s key functions is informed oversight of GlycoMimetics&#8217; risk management process. The Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various standing committees of the Board that address risks inherent in their respective areas of oversight.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Meetings of The Board of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics Board met 16 times during the 2024 fiscal&#160;year. The independent members of the Board met separately as a group at each of the board meetings in 2024. All members of the Board attended at least 75% of the aggregate of (i)&#160;the total number of meetings of the board of directors held during the period for which each director served and (ii)&#160;the total number of meetings held by all committees of the board of directors of which each director was a member during the periods that they served. All of GlycoMimetics&#8217; directors then on the board of directors attended GlycoMimetics&#8217; 2024 annual meeting of stockholders (the &#8220;2024 Annual Meeting&#8221;) whether in person or via telephone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Election of Board of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors at GlycoMimetics&#8217; annual stockholders&#8217; meetings.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Code of Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has adopted the GlycoMimetics Code of Business Conduct and Ethics that applies to all officers, directors and employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Insider Trading Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has adopted an Insider Trading Policy that governs the purchase, sale and/or other dispositions of its securities by its directors, officers and employees, as well as their immediate family members and entities owned or controlled by them, and that is designed to promote compliance with insider trading laws, rules&#160;and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9daf0807_d8db_4ab0_99d0_36e0e8fa2a76"></a><a id="GLYCOMIMETICSEXECUTIVECOMPENSATION_82177"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">GLYCOMIMETICS EXECUTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This section discusses the material components of the executive compensation program for GlycoMimetics&#8217; current and former executive offices who are named in the 2024 Summary Compensation Table below. In 2024, GlycoMimetics&#8217; &#8220;named executive officers&#8221; and their positions were as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Harout Semerjian, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">President and Chief Executive Officer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Brian Hahn, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Chief Financial Officer and Senior Vice President; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Edwin Rock, M.D., </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">former Chief Medical Officer and Senior Vice President.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2024 Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information concerning the compensation of GlycoMimetics&#8217; named executive officers for the&#160;years presented.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NON-EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INCENTIVE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTION</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PLAN</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ALL&#160;OTHER</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SALARY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BONUS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AWARDS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMPENSATION</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMPENSATION</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TOTAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">NAME AND PRINCIPAL POSITION</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">YEAR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">)(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.43%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Harout Semerjian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">663,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">376,910</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,822,638</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">59,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,923,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:29.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">638,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,263,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">376,910</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,389,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Brian Hahn</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">479,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">196,004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">655,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">52,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,383,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Chief Financial Officer and Senior Vice President</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">461,009</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">154,679</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">477,822</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">196,004</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,425</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,299,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Edwin Rock, M.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">282,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">655,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">555,582</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,494,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Chief Medical Officer and Senior Vice President</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">2023</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">466,620</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">474,912</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">198,779</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,000</p></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,152,311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For Mr.&#160;Semerjian, the amount for 2023 represents a discretionary bonus awarded, in part, to assist with commuter expenses, and the amount for 2024 represents a retention bonus earned on December&#160;31, 2024. For Mr.&#160;Hahn, amounts in this column represent the remaining 60% of a retention bonus that was paid in August&#160;2023 and the amount for 2024 represents a retention bonus earned on December&#160;31, 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The amounts reflect the full grant date fair value for stock option awards granted during the indicated&#160;year. The grant date fair value was computed in accordance with ASC Topic 718, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Compensation&#8212;Stock Compensation, </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with the performance-based option awards valued based on the probable achievement level of the performance conditions at the time of grant. Because there was only one vesting level of the 2024 performance-based options, there is no grant date fair value in in excess of the amount reported in the table above. This calculation does not give effect to any estimate of forfeitures related to service-based vesting but assumes that the executive will perform the requisite service for the award to vest in full. The assumptions GlycoMimetics used in valuing stock options are described in Note&#160;9 to its audited financial statements included in this proxy statement/prospectus. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon vesting or exercise of the stock options, or the sale of the common stock underlying the stock options.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The amounts reflect the portion of each officer&#8217;s target bonus paid based on the achievement of pre-specified corporate and/or individual performance goals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amounts in this column reflect matching contributions under GlycoMimetics&#8217; 401(k)&#160;plan and supplemental compensation for cell phone expenses as well as vacation accrual payments and, in the case of Mr.&#160;Hahn, long-term care insurance premiums. For Dr.&#160;Rock only, the amount reported for 2024 also includes severance payments and company reimbursements for COBRA medical and dental insurance premiums in the aggregate amount of $503,365 and consulting fees of $7,125. See &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Former Chief Medical Officer</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; below for additional information.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Narrative Disclosure to Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2024 Salaries</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; named executive officers receive a base salary to compensate them for services rendered to GlycoMimetics. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role, and responsibilities. The base salaries of GlycoMimetics&#8217; named executive officers are reviewed from time to time and adjusted when the GlycoMimetics Board or the Compensation Committee of the GlycoMimetics Board (the &#8220;Compensation Committee&#8221;) determines an adjustment is appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During 2024, the Compensation Committee increased the annual base salary for Mr.&#160;Semerjian from $640,458 to $666,076, the annual salary for Mr.&#160;Hahn from $462,491 to $480,991, and the annual base salary for Dr.&#160;Rock from $469,040 to $487,802, each effective February&#160;2024, in recognition of the executive&#8217;s individual performance and based on compensation data provided by GlycoMimetics&#8217; compensation consultant, Alpine Rewards, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2024 Bonuses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics seeks to motivate and reward its executives for achievements relative to GlycoMimetics&#8217; corporate goals and expectations for each fiscal&#160;year. Each named executive officer has a target bonus opportunity, defined as a&#160;percentage of his annual salary. The following table presents the target bonus of each of GlycoMimetics&#8217; named executive officers for 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TARGET&#160;BONUS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">NAME</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(%&#160;OF&#160;SALARY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Harout Semerjian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Brian Hahn</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Edwin Rock, M.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To reinforce the importance of integrated and collaborative leadership, bonuses for executives other than the Chief Executive Officer have been based primarily on company performance, but also contain an individual performance component. GlycoMimetics&#8217; Chief Executive Officer&#8217;s bonus has historically been based exclusively on company performance. In no event may a bonus awarded to an executive exceed 150% of such executive&#8217;s target bonus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; corporate performance objectives for 2024 included certain accomplishments in clinical, non-clinical development, as well as financial and administrative goals. Considering the financial situation of GlycoMimetics, no bonuses would be paid for 2024 performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Retention Bonuses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2022, the Compensation Committee approved a cash retention program for selected employees, including GlycoMimetics&#8217; executive officers other than the Chief Executive Officer. Under the program, each participant had the opportunity to receive an individual cash award up to 1.5 times the amount of such participant&#8217;s 2021 annual bonus target. Of the cash award, 40% was paid in a lump sum in August&#160;2022 to participants who were employed at that time and the remaining 60% was paid in a lump sum in August&#160;2023. Mr.&#160;Hahn is the only named executive officer who was eligible to participate in the cash retention program. His cash retention award is described in the Summary Compensation Table above under the &#8220;Bonus&#8221; column.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2024, the Compensation Committee approved a cash retention program for selected employees, including GlycoMimetics&#8217; executive officers. Under the program, each participant had the opportunity to receive an individual cash award up to 1.0 time the amount of such participant&#8217;s 2023 annual bonus target. The award is payable to those employed on December&#160;31, 2024. The cash retention award is described in the 2024 Summary Compensation Table above under the &#8220;Bonus&#8221; column.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Long-Term Incentives</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has historically granted stock options to its named executive officers and in some prior&#160;years also awarded restricted stock units. GlycoMimetics awards stock options on the date the Compensation Committee approves the grant. GlycoMimetics sets the option exercise price and grant date fair value based on the closing price of its common stock on the Nasdaq Capital Market on the date of grant. GlycoMimetics typically grants stock options at the start of employment and annually as part of its Compensation Committee review process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2024, in connection with its annual compensation review for 2023, the Compensation Committee granted options to purchase shares of GlycoMimetics common stock to GlycoMimetics&#8217; named executive officers. The shares of common stock subject to the option grants in the table below vest as to one-fourth of the shares one&#160;year after the date of grant, with the balance of the shares vesting in 36 successive equal&#160;monthly installments thereafter, subject to the named executive officer&#8217;s service with GlycoMimetics as of each such date. Each option has an exercise price of $3.11 per share, the closing price of GlycoMimetics common stock on the grant date.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:26.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NUMBER&#160;OF&#160;SHARES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">UNDERLYING&#160;JANUARY&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTION&#160;GRANT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Harout Semerjian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.23%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">695,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Brian Hahn</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Edwin Rock, M.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2024, the Compensation Committee granted options to purchase shares of GlycoMimetics common stock with performance-based vesting. The performance-based options are scheduled to vest in full upon FDA approval of GlycoMimetics&#8217; product candidate uproleselan, subject to the recipient&#8217;s continued service through the vesting date. Mr.&#160;Semerjian was awarded a performance-based option for an aggregate of 521,250 shares, Mr.&#160;Hahn was awarded a performance-based option for an aggregate of 187,500 shares common stock, and Dr.&#160;Rock was awarded a performance-based option for an aggregate of 187,500 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">163</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Outstanding Equity Awards at 2024 Fiscal&#160;Year-End</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table provides information about outstanding stock options and restricted stock units held by each of GlycoMimetics&#8217; named executive officers on December&#160;31, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:63.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTION&#160;AWARDS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STOCK&#160;AWARDS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EQUITY&#160;INCENTIVE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PLAN&#160;AWARDS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NUMBER&#160;OF</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NUMBER&#160;OF</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MARKET&#160;VALUE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NUMBER&#160;OF</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NUMBER&#160;OF</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SHARES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF&#160;SHARES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNDERLYING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR&#160;UNITS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR&#160;UNITS&#160;OF</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNDERLYING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNDERLYING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNEXERCISED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTION</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF&#160;STOCK</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STOCK&#160;THAT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNEXERCISED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNEXERCISED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNEARNED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTION</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THAT&#160;HAVE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">HAVE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS&#160;(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS&#160;(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS&#160;(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXPIRATION</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOT&#160;VESTED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOT&#160;VESTED&#160;</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">NAME</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISABLE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNEXERCISABLE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNEXERCISABLE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DATE</b>&#160;<sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Harout Semerjian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">915,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">183,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">08/02/2031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">549,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">08/02/2031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">308,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">114,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/20/2032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">312,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">339,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/18/2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">695,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/12/2034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">521,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">06/09/2034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Brian Hahn</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">61,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/07/2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">65,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/06/2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">65,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/03/2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">65,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/09/2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">90,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10.59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/16/2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">120,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/21/2030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">67,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">1,437</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/19/2031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">120,094</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">44,606</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/20/2032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">118,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">128,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/18/2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">47,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/20/2032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(9)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/12/2034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">187,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">06/09/2034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Edwin Rock, M.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">112,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">87,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(10)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">09/01/2032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">117,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">127,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/18/2033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">01/12/2034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">187,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">06/09/2034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In each case the option expiration date is ten&#160;years after the date of grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Market value of restricted stock units that have not vested was determined by multiplying the number of shares by $0.25, the closing price of GlycoMimetics common stock on December&#160;31, 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These shares will vest&#160;monthly through August&#160;3, 2025, in each case subject to the officer&#8217;s continued service through the applicable vesting date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This option will vest upon achievement of specified development and commercialization milestones.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These shares will vest&#160;monthly through January&#160;21, 2026, subject to the officer&#8217;s continued service through each applicable vesting date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25% of the total shares underlying this option vested on January&#160;19, 2024. The remaining shares will vest&#160;monthly through January&#160;19, 2027, subject to the officer&#8217;s continued service through each applicable vesting date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25% of the total shares underlying this option vested on January&#160;12, 2025. The remaining shares will vest&#160;monthly through January&#160;12, 2028, subject to the officer&#8217;s continued service through each applicable vesting date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These shares vested on January&#160;20, 2025, subject to the officer&#8217;s continued service through each applicable vesting date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(9)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These shares vested on January&#160;20, 2025, subject to the officer&#8217;s continuous service as of that date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(10)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These shares will vest&#160;monthly through September&#160;2, 2026, in each case subject to the officer&#8217;s continued service through the applicable vesting date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pension Benefits and Nonqualified Deferred Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; named executive officers did not participate in, or otherwise receive any benefits under, any pension plan or nonqualified deferred compensation plan sponsored by GlycoMimetics during 2024.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">164</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employment Agreements and Potential Payments upon Termination of Employment or upon Change in Control</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to their employment agreements with GlycoMimetics, each continuing named executive officer is eligible for severance benefits in specified circumstances. Under the terms of the agreements, upon execution and effectiveness of a severance agreement and release of claims, each such named executive officer will be entitled to severance payments if GlycoMimetics terminates such executive&#8217;s employment without cause, or such executive terminates employment with GlycoMimetics for good reason.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following definitions have been adopted in the current employment agreements with GlycoMimetics&#8217; named executive officers:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;cause&#8221; means that </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">has determined in its sole discretion that any of the following occurred: (a)&#160;the executive officer&#8217;s breach of fiduciary duty or substantial misconduct with respect to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business and affairs, (b)&#160;the executive officer&#8217;s neglect of duties or failure to act which can reasonably be expected to materially adversely affect </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business or affairs, (c)&#160;the executive officer&#8217;s material breach of the employment agreement, or of any provision of the proprietary information, assignment of inventions, noncompetition and non-solicitation agreement to which the executive is a party which, to the extent curable, is not cured within 15&#160;days after written notice thereof is given to the executive officer, (d)&#160;the commission by the executive officer of an act involving moral turpitude or fraud, (e)&#160;the executive officer&#8217;s conviction of any felony, or of any misdemeanor involving fraud, theft, embezzlement, forgery or moral turpitude, (f)&#160;other conduct by the executive officer that is materially harmful to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business or reputation, including but not limited to conduct found to be in violation of its policies prohibiting harassment or discrimination, or (g)&#160;the expiration of the employment agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;good reason&#8221; means any of the following without the executive officer&#8217;s prior written consent: (a)&#160;any material diminution of the executive officer&#8217;s duties or responsibilities under the employment agreement (except in each case in connection with a termination for cause or as a result of the executive officer&#8217;s death or disability), or the assignment to the executive officer of duties or responsibilities that are materially inconsistent with the executive officer&#8217;s then-current position, with the exception of certain situations involving the acquisition of GlycoMimetics; (b)&#160;a reduction of at least 10% of the executive&#8217;s base salary unless pursuant to a salary reduction program applicable generally to similarly-situated employees; (c)&#160;any material breach of the employment agreement by </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which it has not cured within 15 business&#160;days after written notice thereof is given to it; or (d)&#160;a relocation of the executive officer from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">principal office to a location more than 35 miles from the location of its principal office, other than on required travel by the executive officer on business or on a temporary basis not to exceed a period equal to two calendar&#160;months; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;change in control&#8221; means any of the following: (a)&#160;a sale, lease, exchange or other transfer in one transaction or a series of related transactions of all or substantially all of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assets, other than the transfer of its assets to a majority-owned subsidiary corporation; (b)&#160;a merger or consolidation in which </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is not the surviving corporation, unless the holders of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing at least 50% of the voting power of the corporation or other entity surviving such transaction; (c)&#160;a reverse merger in which </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is the surviving corporation but the shares of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">common stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise, unless the holders of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding voting stock immediately prior to such transaction own, immediately after such transaction, securities representing at least 50% of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">voting power; or (d)&#160;any transaction or series of related transactions in which in excess of 50% of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">voting power is transferred; provided that, where required to avoid additional taxation under Section&#160;409A of the Internal Revenue Code, the event that occurs must also be a &#8220;change in the ownership or effective control of a corporation, or a change in the ownership of a substantial portion of the assets of a corporation&#8221; as defined under applicable regulations.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">165</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the schedule of severance payments each of GlycoMimetics&#8217; named executive officers would receive in the event of a qualifying termination.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTINUATION&#160;OF</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EMPLOYER&#160;PORTION</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF&#160;MEDICAL,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ACCELERATION&#160;OF</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SALARY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DENTAL&#160;AND&#160;VISION</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNVESTED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">TERMINATION SCENARIO</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTINUATION</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BONUS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BENEFIT&#160;PREMIUMS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EQUITY&#160;AWARDS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Prior to or More than 12&#160;Months Following a Change in Control</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 23.05pt;">Harout Semerjian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">None</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">None</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:2.9pt;text-indent:-2.9pt;margin:0pt 0pt 0pt 23.05pt;">Brian Hahn</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">None</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">None</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:2.9pt;text-indent:-2.9pt;margin:0pt;">Within 12&#160;Months Following a Change in Control</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 23.05pt;">Harout Semerjian</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Target&#160;Bonus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Full&#160;Acceleration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 23.05pt;">Brian Hahn</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Target&#160;Bonus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Full&#160;Acceleration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the termination is prior to, or more than 12&#160;months following a change, in control, the executive officer&#8217;s salary continuation will be paid on GlycoMimetics&#8217; regular payroll dates, less applicable withholdings and deductions. If the termination is within 12&#160;months following a change in control, the executive officer&#8217;s salary continuation will be paid in a lump-sum cash payment, less applicable withholdings and deductions, within 60&#160;days following the change in control termination.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The executive officer will receive payment of the executive officer&#8217;s target bonus award for the 18&#160;months, in the case of Mr.&#160;Semerjian, or 12&#160;months, in the case of Mr.&#160;Hahn and Dr.&#160;Rock, immediately prior to the executive officer&#8217;s change in control termination, payable in a lump-sum cash payment, less applicable withholdings and deductions, within 60&#160;days following the change in control termination.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The executive officer will receive accelerated vesting of all then unvested equity awards that he may have, if any.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Health and Welfare Benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; named executive officers are eligible to participate in all of its employee benefit plans, such as medical, dental, vision, group life and disability insurance, in each case on the same basis as its other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics also maintains a defined contribution employee retirement plan for its employees, including its named executive officers. GlycoMimetics&#8217; 401(k)&#160;plan is intended to qualify as a tax-qualified plan under Section&#160;401 of the Internal Revenue Code so that contributions to GlycoMimetics&#8217; 401(k)&#160;plan, and income earned on such contributions, are not taxable to participants until withdrawn or distributed from the 401(k)&#160;plan. GlycoMimetics&#8217; 401(k)&#160;plan provides that each participant may contribute a portion of his or her pre-tax compensation, up to a statutory limit, which was $22,500 for 2023 and is $23,000 for 2024. Participants who are at least 50&#160;years old can also make &#8220;catch-up&#8221; contributions, which was and is up to an additional $7,500 for 2023 and 2024. Under GlycoMimetics&#8217; 401(k)&#160;plan, each employee is fully vested in his or her deferred salary contributions. Employee contributions are held and invested by the plan&#8217;s trustee, subject to participants&#8217; ability to give investment directions by following specified procedures. In 2024, GlycoMimetics provided matching contributions of up to 50% of the first 6% of each employee&#8217;s eligible contributions to the 401(k)&#160;plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics does not provide perquisites or personal benefits to its named executive officers. GlycoMimetics does, however, pay the premiums for term life insurance for all of its employees, including its named executive officers. GlycoMimetics previously paid premiums for long-term care insurance for all of its employees; GlycoMimetics no longer does so, although GlycoMimetics <span style="white-space:pre-wrap;">continues to pay such premiums for continuing employees for whom it  previously did so. Due to his tenure with </span>GlycoMimetics, Mr.&#160;Hahn is the only named executive officer for whom GlycoMimetics continues to pay such long-term care insurance premiums.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">166</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Clawbacks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a public company, if GlycoMimetics is required to restate its financial results due to its material noncompliance with any financial reporting requirements under the federal securities laws as a result of misconduct, the Chief Executive Officer and Chief Financial Officer may be legally required to reimburse GlycoMimetics for any bonus or other incentive-based or equity-based compensation they receive in accordance with the provisions of section 304 of the Sarbanes-Oxley Act of 2002, as amended. Additionally, GlycoMimetics has implemented a Dodd-Frank Act-compliant clawback policy, as required by SEC rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;"><b style="font-weight:bold;">Former Chief Medical Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Rock&#8217;s position was eliminated in connection with the workforce reduction, and he separated from employment with GlycoMimetics effective August&#160;1, 2024. In connection with Dr.&#160;Rock&#8217;s separation, GlycoMimetics entered into a separation agreement with Dr.&#160;Rock pursuant to which he became eligible to receive the severance payments and benefits under his employment agreement with GlycoMimetics, which includes his base salary continuation for a period of 12&#160;months and reimbursement for continued health coverage pursuant to COBRA for up to 12&#160;months. GlycoMimetics entered into a separate agreement with Dr.&#160;Rock (the &#8220;Consulting Agreement&#8221;), effective as of the Separation Date, pursuant to which Dr.&#160;Rock will, at the request of Mr.&#160;Hahn or his designee, provide GlycoMimetics with consulting services through January&#160;31, 2025 (the &#8220;Consulting Period&#8221;). During the Consulting Period, Dr.&#160;Rock will be paid a specified hourly rate, subject to obtaining advance approval from an authorized representative of GlycoMimetics to provide such consulting services. Dr.&#160;Rock&#8217;s provision of services under the Consulting Agreement constituted &#8220;Continuous Service&#8221; for purposes of continued vesting and exercising of his outstanding equity awards under GlycoMimetics&#8217; equity incentive plans. The severance payments, benefits and consulting fees paid to Dr.&#160;Rock by GlycoMimetics with respect to 2024 are set forth in the &#8220;All Other Compensation&#8221; column of the 2024 Summary Compensation Table above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pay Versus Performance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics will provide information about the relationship between executive compensation actually paid and certain financial performance of GlycoMimetics as required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K in an amendment to this proxy statement/joint prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Policies and Practices Regarding </b><b style="font-weight:bold;">Long-Term Incentive </b><b style="font-weight:bold;">Awards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Compensation Committee and senior management monitor GlycoMimetics&#8217; equity grant practices to evaluate whether such policies comply with governing regulations and are consistent with good corporate practices. When making regular annual equity grants, the GlycoMimetics Compensation Committee&#8217;s practice is to approve them at its meeting in January&#160;of each&#160;year as part of the annual compensation review and after results for the preceding fiscal&#160;year become available. Because the GlycoMimetics Compensation Committee&#8217;s regular meeting schedule is determined in the prior fiscal&#160;year, the proximity of any awards to other significant corporate events is coincidental. In addition, the GlycoMimetics Compensation Committee may make grants at any time during the&#160;year it deems appropriate, including with respect to new hires or transitions or for general retentive or incentive needs. GlycoMimetics attempts to make equity awards during periods when it does not have material non-public information (&#8220;MNPI&#8221;) that could impact GlycoMimetics&#8217; stock price and GlycoMimetics does not time the release of MNPI based on equity grant dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">During 2024, no stock option grants were made to any of GlycoMimetics&#8217; named executive officers during any period beginning four business&#160;days before the filing or furnishing of a periodic report or current report (other than a current report on Form&#160;8-K disclosing a material new option award grant under Item&#160;5.02(e)&#160;of that form) and ending one business day after the filing or furnishing of any such report with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">167</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_026a6171_ea67_4ad7_96ce_c078b9487977"></a><a id="GLYCOMIMETICSNONEMPLOYEEDIRECTORCOMPENSA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">GLYCOMIMETICS NON-EMPLOYEE DIRECTOR COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As compensation for serving on the GlycoMimetics Board, each director who is not an employee of GlycoMimetics receives a cash retainer for service on the GlycoMimetics Board and for service on each committee on which the director is a member. The compensation of GlycoMimetics&#8217; directors is based on market practice information provided by GlycoMimetics&#8217; independent compensation consultant. This compensation is periodically reviewed with respect to cash retainers and equity incentives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The retainers paid to non-employee directors for service on the Board and for service on each committee of the Board on which the director is a member are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CHAIRMAN&#160;ADDITIONAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MEMBER&#160;ANNUAL&#160;SERVICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ANNUAL&#160;SERVICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RETAINER</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RETAINER</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Board of Directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">30,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Audit Committee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Compensation Committee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Nominating and Corporate Governance Committee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These retainers are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment is prorated for any portion of such quarter that the director is not serving on the GlycoMimetics Board. GlycoMimetics also reimbursed its non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending GlycoMimetics Board and committee meetings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2023, GlycoMimetics amended its non-employee director compensation policy to allow for each director to make an election to receive all or a portion of the annual cash compensation payable above in the form of fully vested shares of common stock. Elections must be delivered before the start of the fiscal&#160;year to which the election relates. Elections cannot be altered with respect to a fiscal&#160;year once the fiscal&#160;year begins and, once made, such election remains in effect for all subsequent fiscal&#160;years unless and until revised or revoked.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, any new non-employee director receives an option grant to purchase 80,000 shares of common stock upon becoming a director. This grant will vest in three equal installments on the first, second and third anniversaries of the grant date. Further, on the date of the 2024 annual meeting of stockholders, each non-employee director that continues to serve as a non-employee member on the GlycoMimetics Board will receive an option to purchase 40,000 shares of common stock. The annual grant to the non-employee director vests on the first full anniversary of the date of grant. The exercise price of options granted to directors is equal to the closing price of GlycoMimetics common stock on the Nasdaq Capital Market the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2024 Director Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table shows the compensation earned by each of GlycoMimetics non-employee directors for the&#160;year ended December&#160;31, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FEES&#160;EARNED&#160;OR&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTION&#160;AWARDS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PAID&#160;IN&#160;CASH&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TOTAL&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Patricia Andrews<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">49,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">51,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mark Goldberg, M.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">55,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">51,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">106,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Scott Jackson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">49,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">51,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Daniel Junius</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">62,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">51,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">114,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Rachel King <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">51,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">91,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Scott Koenig, M.D., Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">44,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">51,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">96,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Timothy Pearson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">88,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">51,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">139,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reflects the aggregate grant date fair value of options and restricted stock units granted during the fiscal&#160;year ended December&#160;31, 2024 calculated in accordance with FASB ASC Topic 718. For a discussion of valuation assumptions, see Note&#160;9 to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics&#8217; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">audited consolidated financial statements included in this proxy statement/prospectus. These amounts do not reflect the actual economic value that will be realized by the director upon vesting or exercise of the stock options or the sale of the common stock underlying the stock options.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">168</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This director elected to receive quarterly retainers for the first and second quarters of 2024, equal to one-half of the amounts reported in the &#8220;Fees Earned or Paid in Cash&#8221; column, in the form of unrestricted shares of common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, GlycoMimetics&#8217; non-employee directors held the following restricted stock units and stock options:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SHARE&#160;SUBJECT&#160;TO&#160;UNVESTED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SHARE&#160;SUBJECT&#160;TO&#160;OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RESTRICTED&#160;STOCK&#160;UNITS&#160;(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS&#160;(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Patricia Andrews</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">181,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mark Goldberg, M.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">192,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Scott Jackson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">170,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Daniel Junius</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">203,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Rachel King</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,534,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Scott Koenig, M.D., Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">161,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Timothy Pearson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">192,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">169</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_315a3a8a_dea4_4354_bc13_6f933930eb77"></a><a id="GLYCOMIMETICSEQUITYCOMPENSATIONPLANINFOR"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">GLYCOMIMETICS EQUITY COMPENSATION PLAN INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table provides certain information regarding GlycoMimetics&#8217; equity compensation plans in effect as of December&#160;31, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining&#160;available&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">future&#160;issuance&#160;under</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;securities&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equity&#160;compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">be&#160;issued&#160;upon&#160;exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price&#160;of&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">plans</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of&#160;outstanding&#160;options,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(excluding&#160;securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants&#160;and&#160;rights</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants&#160;and&#160;rights</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reflected&#160;in&#160;column&#160;(a))</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Plan Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(a)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(b)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(c)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Equity compensation plans approved by security holders </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12,427,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.77%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,624,710</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Equity compensation plans not approved by security holders <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,720,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">299,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,148,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,923,818</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes shares issuable upon exercise of outstanding options and shares issuable upon settlement of outstanding restricted stock units (&#8220;RSUs&#8221;) under GlycoMimetics&#8217; Amended and Restated 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Excludes RSUs that convert to shares of GlycoMimetics common stock from determination of Weighted Average Exercise Price.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 2,531,613 shares available under the 2013 Plan and 3,554,364 shares available under GlycoMimetics&#8217; 2013 Employee Stock Purchase Plan (&#8220;2013 ESPP&#8221;). On January&#160;1 of each&#160;year, the number of shares reserved under the 2013 Plan is automatically increased by 4% of the total number of shares of common stock that are outstanding at that time, or a lesser number of shares as may be determined by the GlycoMimetics Board. An additional 2,575,749 shares were added to the number of available shares under the 2013 Plan, effective January&#160;1, 2025. No shares were added to the reserve under the 2013 ESPP on January&#160;1, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents shares issuable under GlycoMimetics&#8217; Inducement Plan. A description of the Inducement Plan is contained in Note&#160;9 to GlycoMimetics&#8217; consolidated financial statements included in this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">170</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a2ff9e78_2338_4e62_a2fa_3233eb48a769"></a><a id="CRESCENTEXECUTIVECOMPENSATION_819535"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT EXECUTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following completion of the Merger, the executive officers of Crescent will become executive officers of the Combined Company. This section sets forth the fiscal&#160;year 2024 compensatory arrangements for the following executive officers of Crescent who are expected to become executive officers of the Combined Company (the &#8220;<span style="font-style:italic;font-weight:bold;">Crescent NEOs</span>&#8221;):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Appointment&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:40.83%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jonathan Violin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:40%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Executive Officer and President<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15.46%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">October&#160;21, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Christopher Doughty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Business Officer<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">October&#160;21, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:40.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Ryan Lynch</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:40%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Treasurer, Senior Vice President of Finance and<br/>Chief Accounting Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:15.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;10, 2024 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr.&#160;Violin and Mr.&#160;Doughty were appointed on October&#160;21, 2024. From September&#160;28, 2024 until October&#160;21, 2024, the date of their appointment, Dr.&#160;Violin and Mr.&#160;Doughty provided services to Crescent as consultants.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents information regarding the total compensation awarded to, earned by, and paid to the Crescent NEOs for the 2024 fiscal&#160;year.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:4.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:5.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name and Principal Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Salary</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Bonus</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock&#160;Awards</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Awards&#160;($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.76%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Jonathan Violin</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:6.57%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">155,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.64%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.59%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">273,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,700,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,128,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer and President</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Christopher Doughty</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">109,791</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:5.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">54,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">750,697 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">929,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">Chief Business Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Ryan Lynch</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:4.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:5.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">519,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">538,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">Treasurer, Senior Vice President of Finance and Chief Accounting Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amounts in this column for 2024 for Dr.&#160;Violin represent consulting fees paid for services provided to Crescent and for Mr.&#160;Doughty includes $74,374 of consulting fees related to services provided to Crescent prior to his commencement of employment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amounts in this column represent annual cash bonus compensation paid for performance in 2024, as described in more information under &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Narrative to Summary Compensation Table&#8212;Annual Bonuses</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; below.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amounts in this column represent the aggregate grant date fair value of common stock and restricted stock awarded to the Crescent NEOs during 2024, calculated in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718 (&#8220;FASB ASC Topic 718&#8221;). See Note&#160;7 to Crescent&#8217;s financial statements included elsewhere in this proxy statement/prospectus for more information on the assumptions used in calculating such amounts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amounts in this column represent the aggregate grant date fair value of stock options awarded to the Crescent NEOs during 2024, calculated in accordance with FASB ASC Topic 718. See Note&#160;7 to Crescent&#8217;s financial statements included elsewhere in this proxy statement/prospectus for more information on the assumptions used in calculating such amounts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Narrative to Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Base Salary</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The base salary for each Crescent NEO was established in connection with the commencement of their employment with Crescent after taking into account market compensation rates, responsibilities, and experience. Crescent expects to review base salaries for the Crescent NEOs annually and may adjust salaries from time to time to realign with market levels after taking into account individual responsibilities, internal equity, performance, and experience. As of December&#160;31, 2024, the annual base salary (or, for Dr.&#160;Violin, the annual consulting fees) of each Crescent NEO was $600,000 for Dr.&#160;Violin, $425,000 for Mr.&#160;Doughty and $340,000 for Mr.&#160;Lynch.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">171</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Annual Bonus</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each Crescent NEO other than Dr.&#160;Violin is eligible to participate in Crescent&#8217;s annual bonus program with target bonuses equal to 40% for Mr.&#160;Doughty and 35% for Mr.&#160;Lynch. For 2024, Mr.&#160;Doughty&#8217;s target bonus was pro-rated based on his start date, and Mr.&#160;Lynch was not eligible to receive an annual bonus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2024 bonuses were paid out based on a holistic evaluation of Crescent&#8217;s performance and the Crescent NEOs&#8217; contributions to Crescent during 2024. Based on such performance, the Crescent Board approved the annual bonuses set forth in the &#8220;<i style="font-style:italic;">Summary Compensation Table</i>&#8221; above, which were paid in 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Long-Term Incentives</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s equity grant program is intended to align the interests of the Crescent NEOs with those of Crescent&#8217;s stockholders and to motivate them to make important contributions to Crescent&#8217;s performance. In connection with their commencement of services with Crescent in September&#160;2024: (i)&#160;Dr.&#160;Violin received a grant of 341,530 shares of stock that were fully vested on the date of grant and purchased 1,024,590 shares of restricted stock at $0.20 per share, representing the fair market value on such date, which shares vest 25% on September&#160;28, 2025 and&#160;monthly thereafter through September&#160;28, 2028; and (ii)&#160;Mr.&#160;Doughty purchased 273,224 shares of restricted stock at $0.20 per share, representing the fair market value on such date, which shares vest 25% on September&#160;28, 2025 and&#160;monthly thereafter through September&#160;28, 2028. On December&#160;11, 2024, Dr.&#160;Violin and Mr.&#160;Doughty received options to purchase 5,286,600 shares and 1,057,320 shares, respectively, which (i)&#160;for Dr.&#160;Violin, vested 25% on the grant date with the remaining 75% vesting&#160;monthly through December&#160;11, 2028, and (ii)&#160;for Mr.&#160;Doughty, vest&#160;monthly through December&#160;11, 2028. In connection with the commencement of his employment, on December&#160;27, 2024, Mr.&#160;Lynch received options to purchase 731,535 shares of Crescent common stock, which vest 25% on December&#160;27, 2025 and&#160;monthly thereafter until December&#160;27, 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Consulting Agreements and Offer Letters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the commencement of their services and/or employment with Crescent, Crescent entered into consulting agreements and/or offer letters with each of the Crescent NEOs, as described below. For purposes of the following descriptions, &#8220;cause,&#8221; &#8220;change in control,&#8221; and &#8220;good reason&#8221; have the meanings provided under the respective offer letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="font-style:italic;font-weight:bold;">Dr.&#160;Violin</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Violin provides services to Crescent under a consulting agreement. Pursuant to the consulting agreement, he is eligible to receive a&#160;monthly consulting fee equal to $50,000 per&#160;month and received the Crescent equity grants as described above under &#8220;<i style="font-style:italic;">Long-Term Equity Incentives</i>.&#8221; The consulting agreement also provides for periodic grants of stock options sufficient to maintain Dr.&#160;Violin&#8217;s ownership at approximately 5% on a fully-diluted basis until Crescent has raised an aggregate of $200 million in financing, to vest 25% on the date of grant and 75% in equal&#160;monthly installments for the 48&#160;months after the date of grant. The options granted to Dr.&#160;Violin on December&#160;11, 2024 were in full satisfaction of such obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="font-style:italic;font-weight:bold;">Mr.&#160;Doughty</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the commencement of his employment with Crescent, Mr.&#160;Doughty provided services pursuant to a consulting agreement with Crescent. Under the consulting agreement, Mr.&#160;Doughty received&#160;monthly consulting fees equal to $35,416 per&#160;month and received an initial grant of stock options as described above under &#8220;<i style="font-style:italic;">Long-Term Equity Incentives</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Doughty&#8217;s offer letter provides for an annual base salary of $425,000 and an annual target bonus equal to 40% of his base salary, pro-rated for 2024. The offer letter also provides for periodic grants of stock options sufficient to maintain Mr.&#160;Doughty&#8217;s ownership at approximately 1.0% on a fully-diluted basis until Crescent has raised an aggregate of $200 million in financing, to vest in equal&#160;monthly installments for the 48&#160;months after the applicable date of grant. The options granted to Mr.&#160;Doughty on December&#160;11, 2024 were in full satisfaction of such obligation.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">172</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under Mr.&#160;Doughty&#8217;s offer letter, in the event of Mr.&#160;Doughty&#8217;s termination by Crescent without cause more than three&#160;months before or 12&#160;months following a change in control of Crescent, he is eligible for the following severance benefits, subject to his execution and non-revocation of a release of claims: (i)&#160;severance payments equal to 12&#160;months of his base salary, (ii)&#160;any earned but unpaid bonus for the&#160;year prior to the&#160;year of termination, and (iii)&#160;Crescent-subsidized continued health coverage for up to 12&#160;months. Upon a termination by Crescent without cause or his resignation for good reason within three&#160;months before or 12&#160;months following a change in control, he will be eligible to receive the foregoing severance benefits as well as the full acceleration of his outstanding time-based equity awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Mr.&#160;Lynch</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Mr.&#160;Lynch&#8217;s offer letter provides for an annual base salary of $340,000 and an annual target bonus equal to 35% of his base salary beginning with 2025 (Mr.&#160;Lynch was not eligible for a 2024 annual bonus). The offer letter also provides for an initial grant of stock options as described above under &#8220;<i style="font-style:italic;">Long-Term Equity Incentives</i><span style="white-space:pre-wrap;">.&#8221;  Mr.&#160;Lynch is also eligible to receive the same severance benefits as described above for Mr.&#160;Doughty, except the change in control reference period is limited to the 12&#160;months following a change in control, the cash severance payments will be equal to nine&#160;months of his base salary, and the Crescent-subsidized continued health coverage will continue for up to nine&#160;months.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Outstanding Equity Awards at 2024 Fiscal&#160;Year-End</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The following table sets forth information concerning outstanding equity awards held by each of the Crescent NEOs as of December&#160;31, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:36.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option&#160;Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:23.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock&#160;Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Securities</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Underlying</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Unexercised</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options&#160;(#)</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Securities</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Underlying</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Unexercised</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Options&#160;(#)</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Unexercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Exercise</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Price&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Expiration</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Shares&#160;or</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Units&#160;of&#160;Stock</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">That&#160;Have&#160;Not</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Vested</b><br/><b style="font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Market&#160;Value&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Shares&#160;or&#160;Units&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Stock&#160;That&#160;Have</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Not&#160;Vested</b><br/><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.38%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jonathan Violin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,321,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3,964,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:5.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/11/2034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.38%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,024,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:11.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">204,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Christopher Doughty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,057,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.89 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/11/2034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">273,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">54,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:36.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Ryan Lynch</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">731,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.89 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12/27/2034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amounts in this column reflect the value of restricted stock as of December&#160;31, 2024, based on a per share price of $0.20.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These options vest in approximately equal&#160;monthly installments through December&#160;11, 2028, subject to the Crescent NEO&#8217;s continued service through the applicable vesting date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These shares of restricted stock vest as to 25% on September&#160;28, 2025 and thereafter in approximately equal&#160;monthly installments for 36&#160;months, subject to the Crescent NEO&#8217;s continued service through the applicable vesting date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The options vest as to 25% on December&#160;27, 2025 and thereafter in approximately equal&#160;monthly installments for 36&#160;months, subject to the Crescent NEO&#8217;s continued service through the applicable vesting date.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Additional Narrative Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Retirement Benefits</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Crescent provides employees, including the Crescent NEOs, the opportunity to participate in a tax-qualified defined contribution 401(k)&#160;retirement plan; however, Crescent does not provide any matching or other contributions under such plan. Crescent does not provide any non-qualified deferred compensation plans or defined benefit plans.</p><a id="a2024EquityIncentivePlan_113054"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">2024 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent also maintains a 2024 Equity Incentive Plan, the purpose of which is to advance the interests of Crescent&#8217;s stockholders by enhancing Crescent&#8217;s ability to attract, retain and motivate persons who are expected to make important contributions to Crescent and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of Crescent&#8217;s stockholders. Crescent&#8217;s 2024 Equity Incentive Plan provides for the issuance of up to 11,094,669 shares of Crescent common stock, which may be granted as stock options, restricted stock, restricted stock units and other stock-based awards to eligible employees, officers, directors, consultants and advisors of Crescent on such terms and conditions as approved by the Crescent Board or any committee appointed by the Crescent Board to administer Crescent&#8217;s 2024 Equity Incentive Plan. No grants will be made under Crescent&#8217;s 2024 Equity Incentive Plan following consummation of the Merger.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">173</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e68fda5b_668b_48fc_9f8f_90d86d0d1831"></a><a id="CRESCENTDIRECTORCOMPENSATION_207818"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT DIRECTOR COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During 2024, Crescent granted each of Ms.&#160;Balcom and Ms.&#160;Moran stock options to acquire 139,545 shares of Crescent common stock, which vest&#160;monthly over three&#160;years commencing with December&#160;11, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No members of the Crescent Board received any cash retainers or other fees during 2024. Crescent did not implement a formal non-employee director compensation policy during 2024. It is expected that the Combined Company will implement a non-employee director compensation program that is expected to include an annual cash retainer and annual equity grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2024 Director Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents the total compensation for each person who served as a non-employee member of the Crescent Board and received compensation for such service during fiscal&#160;year 2024. Directors who also serve as employees received no additional compensation for their service as directors.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option&#160;Awards</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.59%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Alexandra Balcom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">97,682</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">97,682</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Peter Harwin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Susan Moran</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">97,682</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">97,682</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jonathan Violin served as a director and Chief Executive Officer and President during 2024. Dr.&#160;Violin did not receive any additional compensation for services as a director and thus, pursuant to applicable SEC rules, is omitted from this table.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The amounts reported represent the aggregate grant date fair value of the stock options awarded to Crescent non-employee directors during 2024, calculated in accordance with FASB ASC Topic 718. See Note&#160;7 to Crescent&#8217;s financial statements included elsewhere in this proxy statement/prospectus for more information on the assumptions used in calculating such amounts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As of December&#160;31, 2024, Ms.&#160;Balcom and Ms.&#160;Moran each held outstanding options to acquire 139,545 shares of Crescent common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">174</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_14cb697d_20ae_4cdb_9894_bde3bb640e28"></a><a id="MATTERSBEINGSUBMITTEDTOAVOTEOFGLYCOMIMET"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">MATTERS BEING SUBMITTED TO A VOTE OF GLYCOMIMETICS STOCKHOLDERS</b></p><a id="PROPOSALNO1THENASDAQSTOCKISSUANCEPROPOSA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PROPOSAL NO.&#160;1&#160;- THE NASDAQ STOCK ISSUANCE PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the GlycoMimetics Special Meeting, GlycoMimetics will ask its stockholders to approve (i)&#160;the issuance of shares of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock, to the stockholders of Crescent pursuant to the Merger Agreement, which shares of GlycoMimetics common stock will represent more than 20% of the shares of GlycoMimetics common stock outstanding immediately prior to the First Merger and (ii)&#160;the change of control of GlycoMimetics resulting from the First Merger, pursuant to Nasdaq Listing Rules&#160;5635(a)&#160;and 5635(b), respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately after the First Merger, GlycoMimetics securityholders as of immediately prior to the First Merger are expected to own approximately 3.10% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis, and subject to dilution from any equity issued by Crescent after the date of the Merger Agreement and before the closing), and former holders of Crescent securities are expected to own approximately 96.90% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, GlycoMimetics&#8217; net cash as of closing being equal to $1.8 million. Under certain circumstances further described in the Merger Agreement, the ownership&#160;percentages may be adjusted up or down, including if GlycoMimetics&#8217; net cash as of closing is less than $1.725 million or more than $1.875 million. GlycoMimetics&#8217; management currently anticipates GlycoMimetics&#8217; net cash as of closing will be approximately $1.8 million, and the currently estimated ownership&#160;percentages reflect this projection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics will assume outstanding and unexercised options and warrants to purchase shares of Crescent common stock, and such securities will be converted into options and warrants, as applicable, to purchase shares of GlycoMimetics common stock, subject to certain adjustments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The terms of, reasons for and other aspects of the Merger Agreement and the Merger are described in detail in the section of this proxy statement/prospectus titled &#8220;<i style="font-style:italic;">The Merger Agreement</i>.&#8221; A copy of the Merger Agreement, including the amendment thereto, is attached as <i style="font-style:italic;">Annex A</i> to this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reason for the Proposal</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Nasdaq Listing Rule&#160;5635(a)(1), a company listed on Nasdaq is required to obtain stockholder approval prior to the issuance of common stock, among other things, in connection with the acquisition of another company&#8217;s stock, if the number of shares of common stock to be issued is in excess of 20% of the number of shares of common stock then outstanding. The potential issuance of the shares of GlycoMimetics common stock in the Merger exceeds the 20% under the Nasdaq Listing Rules&#160;and is expected to represent approximately 96.90% of GlycoMimetics common stock (on a fully-diluted basis, and subject to dilution from any equity issued by Crescent after the date of the Merger Agreement and before the closing) immediately following the Merger. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(a)(1), GlycoMimetics must obtain the approval of GlycoMimetics stockholders for the issuance of these shares of common stock in the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Nasdaq Listing Rule&#160;5635(b), a company listed on Nasdaq is required to obtain stockholder approval prior to an issuance of stock that will result in a &#8220;change of control&#8221; of the listed company. It is expected that Nasdaq will determine that the Merger constitutes a &#8220;change of control&#8221; of the listed company. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(b), GlycoMimetics must obtain the approval of GlycoMimetics stockholders of the change of control resulting from the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of a majority of the shares of GlycoMimetics common stock entitled to vote on the subject matter and present or represented by proxy at the GlycoMimetics Special Meeting is required to approve the Nasdaq Stock Issuance Proposal. Abstentions will have the same effect as votes &#8220;<b style="font-weight:bold;">AGAINST</b>&#8221; the Nasdaq Stock Issuance Proposal and broker non-votes, if any, will have no effect on the Nasdaq Stock Issuance Proposal.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">175</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is conditioned upon the approval of the Nasdaq Stock Issuance Proposal. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Nasdaq Stock Issuance Proposal is conditioned on the approval of the Authorized Share Increase Proposal. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Authorized Share Increase Proposal is not approved, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected and the Merger will not be consummated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain GlycoMimetics stockholders have agreed to vote any shares of GlycoMimetics common stock owned by them in favor of the Nasdaq Stock Issuance Proposal. See &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Support Agreements</i>&#8221; beginning on page&#160;151 of this proxy statement/prospectus for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the approval of the Nasdaq Stock Issuance Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE GLYCOMIMETICS BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE NASDAQ STOCK ISSUANCE</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">176</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d31b5824_cde5_40ad_9cef_568d6ee2d6aa"></a><a id="PROPOSALNO2THEAUTHORIZEDSHAREINCREASEPRO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PROPOSAL NO.&#160;2&#160;- THE AUTHORIZED SHARE INCREASE PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><a id="_Hlk190523510"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the GlycoMimetics Special Meeting, GlycoMimetics will ask its stockholders to approve an amendment to the GlycoMimetics Charter to increase the number of authorized shares of GlycoMimetics common stock (the &#8220;GlycoMimetics Share Increase Amendment&#8221;). On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, the GlycoMimetics Board approved a proposal to amend the GlycoMimetics Charter to increase the number of authorized shares of GlycoMimetics common stock from 150,000,000&#160;shares to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, which would also have the effect of increasing the total number of authorized shares from 155,000,000, including GlycoMimetics preferred stock, to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(the &#8220;GlycoMimetics Share Increase&#8221;), in the form attached as <i style="font-style:italic;">Annex G</i> to this proxy statement/prospectus. On the Record Date, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of GlycoMimetics common stock issued and outstanding, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of GlycoMimetics common stock reserved for issuance. Accordingly, approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of the total number of GlycoMimetics common stock currently authorized remain available for issuance or may be reserved for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Form&#160;of the GlycoMimetics Share Increase Amendment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Share Increase Amendment would amend and restate the first paragraph of Article&#160;IV of the GlycoMimetics Charter in its entirety as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;The Company is authorized to issue two classes of stock to be designated, respectively, &#8220;Common Stock&#8221; and &#8220;Preferred Stock.&#8221; The total number of shares of all classes of capital stock which the Company shall have authority to issue is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares, of which &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares shall be Common Stock (the &#8220;Common Stock&#8221;), each having a par value of one-tenth of one cent ($0.001), and Five Million (5,000,000) shares shall be Preferred Stock (the &#8220;Preferred Stock&#8221;), each having a par value of one-tenth of one cent ($0.001).&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Background and Reasons for the GlycoMimetics Share Increase Amendment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Charter currently authorizes the issuance of up to 150,000,000&#160;shares of GlycoMimetics common stock and 5,000,000&#160;shares of preferred stock. As of the close of business on the Record Date, there were&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of GlycoMimetics common stock issued and outstanding, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of GlycoMimetics common stock reserved for issuance. Accordingly, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of the total number of GlycoMimetics common stock currently authorized remain available for issuance or may be reserved for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described in greater detail in the section of this proxy statement/prospectus titled &#8220;<i style="font-style:italic;">The Merger Agreement</i>,&#8221; pursuant to the Merger Agreement, GlycoMimetics will be required to issue shares of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock, to Crescent stockholders and to assume Crescent&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Crescent common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The number of shares of GlycoMimetics common stock currently authorized and unissued and not reserved for issuance is not sufficient for (i)&#160;the issuance of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock, pursuant to the Merger Agreement and (ii)&#160;the assumption of Crescent&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Crescent common stock. In addition, there will not be sufficient shares of GlycoMimetics common stock available for issuance in connection with possible future acquisitions, equity and equity-based financings, possible future awards under employee benefit plans and other corporate purposes that the GlycoMimetics Board may determine to be desirable. Therefore, the GlycoMimetics Board has determined that the GlycoMimetics Share Increase Amendment is in the best interests of GlycoMimetics and its stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the GlycoMimetics Share Increase Amendment is approved by stockholders, upon its effectiveness, and without giving effect to the proposed reverse stock split described in Proposal No.&#160;3 of this proxy statement/prospectus, GlycoMimetics will have a total of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; authorized shares of GlycoMimetics common stock, with&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of GlycoMimetics common stock issued and outstanding (as of the Record Date), and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares reserved for issuance (as of the Record Date), leaving a balance of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of GlycoMimetics common stock authorized and unissued and not reserved for any specific purpose. Such outstanding share amounts will be correspondingly adjusted to the extent the proposed reverse stock split is effected prior to effectiveness of the GlycoMimetics Share Increase Amendment, but the reverse stock split will not change the number of authorized shares of common or preferred stock. The GlycoMimetics Share Increase Amendment will have no effect on the authorized shares of GlycoMimetics Preferred Stock.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">177</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Except for (i)&#160;the issuance of shares of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock, and (ii)&#160;the issuance of shares of GlycoMimetics common stock that may result from the assumption of Crescent&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Crescent common stock, each pursuant to the terms of the Merger Agreement, GlycoMimetics does not currently have any plans, proposals or arrangement to issue any of its authorized but unissued shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Possible Effects of the GlycoMimetics Share Increase Amendment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the GlycoMimetics Share Increase Amendment is approved and becomes effective, the additional authorized shares would be available for issuance at the discretion of the GlycoMimetics Board and without further stockholder approval, except as may be required by law or Nasdaq rules. The additional shares of authorized GlycoMimetics common stock would have the same rights and privileges as the shares of GlycoMimetics common stock currently issued and outstanding. Holders of GlycoMimetics common stock have no preemptive rights. The GlycoMimetics Share Increase would not change the number of shares of common stock outstanding, nor will it have any immediate dilutive effect; however, the issuance of additional shares of GlycoMimetics common stock authorized by the GlycoMimetics Share Increase may, among other things, have a dilutive effect on earnings per share and on stockholders&#8217; equity and voting rights. Furthermore, future sales of substantial amounts of GlycoMimetics common stock, or the perception that these sales might occur, could adversely affect the prevailing market price of GlycoMimetics common stock or limit GlycoMimetics&#8217; ability to raise additional capital. GlycoMimetics stockholders should recognize that, as a result of this proposal, they will own a smaller&#160;percentage of shares relative to the total authorized shares of the company than they presently own.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Appraisal or Dissenters&#8217; Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the DGCL, stockholders are not entitled to appraisal rights or dissenter&#8217;s rights with respect to the GlycoMimetics Share Increase Amendment or the GlycoMimetics Share Increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effectiveness of Amendment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">If the GlycoMimetics Share Increase Amendment is approved by the stockholders at the GlycoMimetics Special Meeting, it will become effective upon the filing of a certificate of amendment, a copy of which is attached as <i style="font-style:italic;">Annex G </i>to this proxy statement/prospectus, with the Delaware Secretary of State or such later effective date and time as specified in the certificate of amendment in accordance with Delaware law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Copies of the GlycoMimetics Charter and the certificates of amendment to the GlycoMimetics Charter are available as exhibits to this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The affirmative vote of a at least sixty-six and two-thirds&#160;percent (66<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2/3</sup>%) of the voting power of all then-outstanding shares of GlycoMimetics capital stock entitled to vote generally in the election of directors, voting together as a single class, assuming a quorum is present, properly cast for or against the Authorized Share Increase Proposal by the holders of GlycoMimetics common stock is required to approve the Authorized Share Increase Proposal. Abstentions and broker non-votes, if any, will have no effect on the Authorized Share Increase Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Nasdaq Stock Issuance Proposal and the Merger are conditioned upon the approval of the Authorized Share Increase Proposal. In order to have an adequate number of available shares to effect the Merger, the stockholders of GlycoMimetics will need to approve the Authorized Share Increase Proposal. Additionally, the GlycoMimetics Board may determine to effect the Authorized Share Increase Proposal, if approved, even if the Nasdaq Stock Issuance Proposal is not approved by the GlycoMimetics stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Certain GlycoMimetics stockholders have agreed to vote any shares of GlycoMimetics common stock owned by them in favor of the Authorized Share Increase Proposal. See &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Support Agreements</i>&#8221; beginning on page&#160;151 of this proxy statement/prospectus for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the approval of the Authorized Share Increase Proposal.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">178</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE GLYCOMIMETICS BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE AUTHORIZED SHARE INCREASE PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">179</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4c447476_9b70_4736_808c_b8f1f77a7e02"></a><a id="PROPOSALNO3THEREVERSESTOCKSPLITPROPOSAL_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PROPOSAL NO.&#160;3&#160;- THE REVERSE STOCK SPLIT PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the GlycoMimetics Special Meeting, GlycoMimetics will ask its stockholders to approve an amendment to the GlycoMimetics Charter to effect a reverse stock split of GlycoMimetics&#8217; issued and outstanding common stock at a ratio in the range of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to<span style="display:inline-block;width:0.89pt;"></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, to be determined mutually by the GlycoMimetics Board and the Crescent Board (the &#8220;Split Ratio&#8221;). The final Split Ratio and effectiveness of such amendment and the abandonment of such amendment will be mutually agreed by the GlycoMimetics Board and the Crescent Board prior to the First Effective Time, assuming this proposal is approved by GlycoMimetics&#8217; stockholders. On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, the GlycoMimetics Board adopted resolutions approving the proposed certificate of amendment to the GlycoMimetics Charter in the form attached as <i style="font-style:italic;">Annex H</i> to this proxy statement/prospectus. If this certificate of amendment is filed with the Secretary of State of the State of Delaware, upon its effectiveness (the &#8220;reverse stock split effective time&#8221;), it will effect the reverse stock split by the Split Ratio but will not increase the par value of GlycoMimetics common stock. At the reverse stock split effective time, the issued and outstanding shares of GlycoMimetics common stock immediately prior to the reverse stock split effective time will automatically without further action on the part of GlycoMimetics be combined into a smaller number of shares in accordance with the final Split Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">By approving the Reverse Stock Split Proposal, GlycoMimetics stockholders will approve the amendment to the GlycoMimetics Charter pursuant to which any whole number of issued and outstanding shares of GlycoMimetics common stock, between and including&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, would be combined into one share of GlycoMimetics common stock, and will authorize the GlycoMimetics Board to file the certificate of amendment. As of the Record Date, 150,000,000&#160;shares of GlycoMimetics common stock were authorized, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of GlycoMimetics common stock were outstanding and no shares of GlycoMimetics common stock were held in treasury.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The reverse stock split will not change the number of authorized shares of GlycoMimetics common stock or preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All holders of GlycoMimetics common stock will be affected proportionately by the reverse stock split. No fractional shares of GlycoMimetics common stock will be issued as a result of the reverse stock split. Instead, GlycoMimetics stockholders who otherwise would be entitled to receive fractional shares will be entitled to receive cash as set forth below under the caption &#8220;No Fractional Shares.&#8221; Each GlycoMimetics stockholder will hold the same&#160;percentage of the outstanding GlycoMimetics common stock immediately following the reverse stock split as that GlycoMimetics stockholder did immediately prior to the reverse stock split, except to the extent that the reverse stock split results in GlycoMimetics stockholders receiving cash in lieu of fractional shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Reasons for the Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Board approved the proposal approving the amendment to the GlycoMimetics Charter effecting the reverse stock split for the following reasons:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board believes effecting the reverse stock split will result in an increase in the minimum bid price of GlycoMimetics common stock and reduce the risk of a delisting of GlycoMimetics common stock from Nasdaq in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board believes a higher stock price may help generate investor interest in GlycoMimetics, and ultimately the Combined Company, and help GlycoMimetics attract and retain employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board believes a higher stock price may increase trading volume in GlycoMimetics common stock and facilitate future financings by the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board believes that the resulting increase in the number of authorized and unissued shares available for future issuance will be necessary for the issuance of shares to the stockholders of Crescent pursuant to the Merger Agreement, as described in the Nasdaq Stock Issuance Proposal, the issuance of shares of GlycoMimetics common stock that may result from the assumption of Crescent&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Crescent common stock, pursuant to the Merger Agreement, and ultimately the consummation of the Merger; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The GlycoMimetics Board believes that a range of reverse stock split ratios provides it with the most flexibility to achieve the desired results of the reverse stock split.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">180</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Requirements for Listing on Nasdaq</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;GLYC.&#8221; GlycoMimetics intends to file an initial listing application pursuant to the terms of the Merger Agreement for the Combined Company to list the securities of the Combined Company on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Nasdaq rules, an issuer must, in a case such as this, apply for initial inclusion following a transaction whereby the issuer combines with a non-Nasdaq entity, resulting in a change of control of the issuer and potentially allowing the non-Nasdaq entity to obtain a Nasdaq listing. Accordingly, the listing standards of Nasdaq will require GlycoMimetics to have, among other things, a $4.00 per share minimum bid price for a certain number of trading&#160;days preceding the closing of the Merger. Therefore, the reverse stock split may be necessary in order to satisfy Nasdaq requirements and consummate the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, it is a condition to the closing of the Merger that the shares of GlycoMimetics common stock to be issued in the Merger pursuant to the Merger Agreement have been approved for listing on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">One of the effects of the reverse stock split will be to effectively increase the proportion of authorized shares which are unissued relative to those which are issued. This could result in GlycoMimetics&#8217; management being able to issue more shares without further stockholder approval. The reverse stock split will not affect the number of authorized shares of GlycoMimetics capital stock, which will continue to be authorized pursuant to the GlycoMimetics Charter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Potential Increased Investor Interest</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, GlycoMimetics common stock closed at $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per share. An investment in GlycoMimetics common stock may not appeal to brokerage firms that are reluctant to recommend lower priced securities to their clients. Investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a&#160;percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide research coverage of lower priced stocks. Also, the GlycoMimetics Board believes that most investment funds are reluctant to invest in lower priced stocks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are risks associated with the reverse stock split, including that the reverse stock split may not result in an increase in the per share price of GlycoMimetics common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics cannot predict whether the reverse stock split will increase the market price for GlycoMimetics common stock. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market price per share of GlycoMimetics common stock after the reverse stock split will rise in proportion to the reduction in the number of shares of GlycoMimetics common stock outstanding before the reverse stock split;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the reverse stock split will result in a per share price that will attract brokers and investors who do not trade in lower priced stocks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the reverse stock split will result in a per share price that will increase the ability of GlycoMimetics to attract and retain employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market price per share will either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq for continued listing; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market price per share will achieve and maintain the $4.00 minimum bid price requirement for a sufficient period of time for the Combined Company&#8217;s common stock to be approved for listing by Nasdaq.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The market price of GlycoMimetics common stock will also be based on the performance of GlycoMimetics, and after the Merger, on the performance of the Combined Company, and other factors, some of which are unrelated to the number of shares outstanding. If the reverse stock split is effected and the market price of GlycoMimetics common stock declines, the&#160;percentage decline as an absolute number and as a&#160;percentage of the overall market capitalization of GlycoMimetics may be greater than would occur in the absence of a reverse stock split. Furthermore, the liquidity of GlycoMimetics common stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">181</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Effects of the Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the reverse stock split is implemented, after the reverse stock split effective time, the issued and outstanding shares of GlycoMimetics common stock immediately prior to the reverse stock split effective time will automatically, without further action on the part of GlycoMimetics, be combined into a smaller number of shares proportionately based on the Split Ratio and each GlycoMimetics stockholder will own a reduced number of shares of GlycoMimetics common stock. The reverse stock split will affect all GlycoMimetics stockholders uniformly and will not affect any stockholder&#8217;s&#160;percentage ownership interests in GlycoMimetics, except that GlycoMimetics stockholders who would have otherwise received fractional shares will receive cash in lieu of such fractional shares. After the reverse stock split, each share of GlycoMimetics common stock will have the same voting rights and rights to dividends and distributions and will be identical in all other respects to the GlycoMimetics common stock now authorized, and GlycoMimetics common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split is not intended as, and will not have the effect of, a &#8220;going private transaction&#8221; covered by Rule&#160;13e-3 under the Exchange Act. GlycoMimetics will continue to be subject to the periodic reporting requirements of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Effect on Shares of GlycoMimetics Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The reverse stock split will not change the number of authorized shares of GlycoMimetics common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the reverse stock split effective time, GlycoMimetics common stock would have a new committee on uniform securities identification procedures number, which is used to identify GlycoMimetics common stock. GlycoMimetics common stock is currently registered under Section&#160;12(b)&#160;of the Exchange Act and GlycoMimetics is subject to the periodic reporting and other requirements of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Effect on GlycoMimetics Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The reverse stock split will not change the number of authorized shares of GlycoMimetics preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reduction in Stated Capital</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The reverse stock split will not affect the par value of GlycoMimetics common stock. As a result, after the reverse stock split effective time, the stated capital on GlycoMimetics&#8217; balance sheet attributable to GlycoMimetics common stock will be reduced proportionately based on the Split Ratio, subject to a minor adjustment in respect of the treatment of fractional shares, and the additional paid-in capital account will be credited with the amount by which the stated capital is reduced. GlycoMimetics stockholders&#8217; equity, in the aggregate, will remain unchanged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Effect on Equity Plans and Outstanding Derivative and Convertible Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Proportionate adjustments will be made to the per share exercise price, the number of shares issuable upon the exercise, vesting or settlement of all outstanding options and warrants to purchase or acquire, as applicable, shares of GlycoMimetics common stock, and the number of shares reserved for issuance pursuant to GlycoMimetics&#8217; existing equity incentive, stock option and employee stock purchase plans will be reduced proportionately based on the Split Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If (i)&#160;the GlycoMimetics stockholders approve the Nasdaq Stock Issuance Proposal and the Reverse Stock Split Proposal, (ii)&#160;the GlycoMimetics Board and the Crescent Board mutually agree that a reverse stock split is necessary, and (iii)&#160;the GlycoMimetics Board still believes that a reverse stock split is in the best interests of GlycoMimetics and its stockholders, GlycoMimetics will file the certificate of amendment to the GlycoMimetics Charter with the Secretary of State of the State of Delaware at such time as the GlycoMimetics Board has determined to be the appropriate reverse stock split effective time at the Split Ratio. If the Reverse Stock Split Proposal is approved and the Nasdaq Stock Issuance Proposal is not approved by GlycoMimetics stockholders, the GlycoMimetics Board and the Crescent Board may mutually agree to delay effecting the reverse stock split without resoliciting stockholder approval or abandon effecting the reverse stock split; otherwise, the GlycoMimetics Board may, in its sole discretion, delay without resolicitation of stockholder approval or abandon effecting the reverse stock split. Beginning at the reverse stock split </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">182</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">effective time, each stock certificate representing pre-split shares will be deemed for all corporate purposes to evidence ownership of post-split shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Beneficial Owners of Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the implementation of the reverse stock split, GlycoMimetics intends to treat shares held by stockholders in &#8220;street name&#8221; (i.e., through a bank, broker, custodian or other nominee), in the same manner as registered stockholders whose shares are registered in their names. Banks, brokers, custodians or other nominees will be instructed to effect the reverse stock split for their beneficial holders holding GlycoMimetics common stock in street name. However, these banks, brokers, custodians or other nominees may have different procedures than registered stockholders for processing the reverse stock split and making payment for fractional shares. If a stockholder holds shares of GlycoMimetics common stock with a bank, broker, custodian or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker, custodian or other nominee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Registered Holders of Common Stock in Book-Entry Form</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of GlycoMimetics&#8217; registered holders of common stock hold some or all of their shares electronically in book-entry form with GlycoMimetics&#8217; transfer agent,<i style="font-style:italic;">&#160;</i>Equiniti. These stockholders do not hold physical stock certificates evidencing their ownership of GlycoMimetics common stock. However, they are provided with a statement reflecting the number of<i style="font-style:italic;">&#160;</i>shares of GlycoMimetics common stock registered in their accounts. If a stockholder holds registered shares in book-entry form with GlycoMimetics&#8217; transfer agent, no action needs to be taken to receive post-reverse stock split shares or payment in lieu of fractional shares, if applicable. If a stockholder is entitled to post-reverse stock split shares, a transaction statement will automatically be sent to the stockholder&#8217;s address of record indicating the number of shares of GlycoMimetics common stock held following the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Registered Holders of Common Stock in Certificate Form</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As soon as practicable after the reverse stock split effective time, the GlycoMimetics stockholders will be notified that the reverse stock split has been effected. GlycoMimetics expects that the GlycoMimetics transfer agent will act as Exchange Agent for purposes of implementing the exchange of stock certificates. Holders of pre-split shares will be asked to surrender to the Exchange Agent certificates representing pre-split shares held in certificated form in exchange for certificates representing post-split shares in accordance with the procedures to be set forth in a letter of transmittal to be sent by GlycoMimetics. No new certificates will be issued to a stockholder until such stockholder has surrendered such stockholder&#8217;s outstanding certificate(s)&#160;together with the properly completed and executed letter of transmittal to the Exchange Agent. Any pre-split shares submitted for transfer, whether pursuant to a sale or other disposition, or otherwise, will automatically be exchanged for post-split shares. <b style="font-weight:bold;">Stockholders should not destroy any stock certificate(s)&#160;and should not submit any certificate(s)&#160;unless and until requested to do so</b><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">No Fractional Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No fractional shares will be issued in connection with the reverse stock split. Stockholders of record who otherwise would be entitled to receive fractional shares because they hold a number of pre-split shares not evenly divisible by the number of pre-split shares for which each post-split share is to be reclassified, will be entitled, upon surrender to the Exchange Agent of certificates representing such shares, to a cash payment in lieu thereof at a price equal to the fraction of a share to which the stockholder would otherwise be entitled multiplied by the closing price of the common stock on Nasdaq on the date of the filing of the certificate of amendment to the GlycoMimetics Charter effecting the reverse stock split. For the foregoing purposes, all shares of common stock held by a holder will be aggregated (thus resulting in no more than one fractional share per holder). The ownership of a fractional interest will not give the holder thereof any voting, dividend or other rights except to receive payment therefor as described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where GlycoMimetics is domiciled and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the effective date of the split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence has been received by GlycoMimetics or the Exchange Agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">183</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Potential Anti-Takeover Effect</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although the increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have an anti-takeover effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the GlycoMimetics Board or contemplating a tender offer or other transaction for the combination of GlycoMimetics with another company, the reverse stock split is not being proposed in response to any effort of which GlycoMimetics is aware to accumulate shares of GlycoMimetics common stock or obtain control of GlycoMimetics, other than in connection with the Merger, nor is it part of a plan by management to recommend a series of similar amendments to the GlycoMimetics Board and stockholders. Other than the proposals being submitted to the GlycoMimetics stockholders for their consideration at the GlycoMimetics Special Meeting, the GlycoMimetics Board does not currently contemplate recommending the<i style="font-style:italic;">&#160;</i>adoption of any other actions that could be construed to affect the ability of third parties to take over or change<i style="font-style:italic;">&#160;</i>control of GlycoMimetics. For more information, please see the section titled &#8220;<i style="font-style:italic;">Risk Factors&#8212;Risks Related to the Combined Company</i>&#8221; beginning on page&#160;83 of this proxy statement/prospectus.</p><a id="USFederalIncomeTaxConsiderationsoftheRev"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">U.S. Federal Income Tax Considerations of the Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following discussion is a summary of U.S. federal income tax considerations to U.S. Holders (as defined below) of GlycoMimetics common stock of the reverse stock split. The discussion does not purport to be a complete analysis of all potential tax considerations. The considerations of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws, are not discussed. This discussion is based on the Code, Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a U.S. Holder. GlycoMimetics has not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax considerations of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion is limited to a U.S. Holder that holds GlycoMimetics common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax considerations relevant to a U.S. Holder&#8217;s particular circumstances, including without limitation the effect of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules&#160;under Section&#160;451(b)&#160;of the Code. In addition, it does not address considerations relevant to U.S. Holders subject to special rules, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. expatriates and former citizens or long-term residents</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders whose functional currency is not the U.S. dollar;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons holding </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GlycoMimetics </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">common stock as part of a hedge, straddle or other risk-reduction strategy or as part of a conversion transaction or other integrated investment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">banks, insurance companies and other financial institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">real estate investment trusts or regulated investment companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">brokers, dealers or traders in securities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or other persons that elect to use a mark-to-market method of accounting for their holdings in GlycoMimetics common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partnerships or other entities or arrangements classified as partnerships, passthroughs, or disregarded entities for U.S. federal income tax purposes (and investors therein), S corporations or other passthrough entities (including hybrid entities);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-exempt organizations or governmental organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons deemed to sell GlycoMimetics common stock under the constructive sale provisions of the Code;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons who hold or receive GlycoMimetics common stock pursuant to the exercise of any employee stock option or otherwise as compensation;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">184</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-qualified retirement plans; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons that own, or have owned, actually or constructively, more than 5%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of GlycoMimetics common stock</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If an entity or arrangement classified as a partnership for U.S. federal income tax purposes holds GlycoMimetics common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, a partnership holding GlycoMimetics common stock and each partner in such partnership is urged to consult its tax advisor regarding the U.S. federal income tax considerations to it of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purpose of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of GlycoMimetics common stock that, for U.S. federal income tax purposes, is or is treated as any of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an individual who is a citizen or resident of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate, the income of which is subject to U.S. federal income tax regardless of its source</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a trust that: (i)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> the meaning of Section&#160;7701(a)(30) of the Code); or (ii)&#160;has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">This discussion is for informational purposes only and is not tax advice. Each prospective investor is urged to consult its tax advisor with respect to the application of the U.S. federal income tax laws to its particular situation as well as any tax considerations of the reverse stock split arising under U.S. federal estate or gift tax laws, the laws of any state, local or non-U.S. taxing jurisdiction or any applicable income tax treaty.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Tax Considerations of the Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The proposed reverse stock split is intended to qualify as a &#8220;recapitalization&#8221; for U.S. federal income tax purposes pursuant to Section&#160;368(a)(1)(E)&#160;of the Code. As a result, a U.S. Holder generally should not recognize gain or loss upon the proposed reverse stock split, except with respect to cash received in lieu of a fractional share of GlycoMimetics common stock, as discussed below. A U.S. Holder&#8217;s aggregate adjusted tax basis in the shares of GlycoMimetics common stock received pursuant to the proposed reverse stock split should equal the aggregate adjusted tax basis of the shares of the GlycoMimetics common stock surrendered (excluding any portion of such basis that is allocated to any fractional share of GlycoMimetics common stock), and such U.S. Holder&#8217;s holding period in the shares of GlycoMimetics common stock received should include the holding period in the shares of GlycoMimetics common stock surrendered. U.S. Treasury Regulations provide detailed rules&#160;for allocating the tax basis and holding period of the shares of GlycoMimetics common stock surrendered to the shares of GlycoMimetics common stock received in a recapitalization pursuant to the proposed reverse stock split. Each U.S. Holder of shares of GlycoMimetics common stock acquired on different dates and at different prices is urged to consult its tax advisor regarding the allocation of the tax basis and holding period of such shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash in Lieu of Fractional Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A U.S. Holder that receives cash in lieu of a fractional share of GlycoMimetics common stock pursuant to the proposed reverse stock split should recognize capital gain or loss in an amount equal to the difference between the amount of cash received and the U.S. Holder&#8217;s tax basis in the shares of GlycoMimetics common stock surrendered that is allocated to such fractional share of GlycoMimetics common stock. Such capital gain or loss should be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for GlycoMimetics common stock surrendered exceeded one&#160;year at the effective time of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Tax Reporting Regarding the Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Assuming the reverse stock split qualifies as a recapitalization within the meaning of Section&#160;368(a)&#160;of the Code, each U.S. Holder who receives shares of GlycoMimetics common stock in the reverse stock split is required to retain permanent records pertaining to the reverse stock split and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. Each U.S. Holder who owned at least five&#160;percent (by </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">185</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">vote or value) of the total outstanding stock of GlycoMimetics or who owned securities in GlycoMimetics with a basis of $1,000,000 or more are required to attach a statement to their tax returns for the&#160;year in which the reverse stock split is consummated that contains the information listed in Treasury Regulations Section&#160;1.368-3(b). Such statement must include the holder&#8217;s tax basis in the U.S. Holder&#8217;s GlycoMimetics common stock and the fair market value of such stock. Each U.S. Holder is urged to consult with its tax advisor to comply with these rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">This discussion of U.S. federal income tax considerations of the reverse stock split is for general information purposes only and is not intended to be, and should not be construed as, tax advice. Determining the actual tax consequences of the reverse stock split to you may be complex and will depend on your specific situation and on factors that are not within GlycoMimetics&#8217; knowledge or control. Each prospective investor is urged to consult its tax advisor with respect to the application of U.S. federal income tax laws to its specific situation as well as any tax considerations arising under the U.S. federal estate or gift tax rules&#160;or under the laws of any state, local, non-U.S. or other taxing jurisdiction.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Appraisal or Dissenters&#8217; Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the DGCL, stockholders are not entitled to appraisal rights or dissenter&#8217;s rights with respect to the proposed amendment to the GlycoMimetics Charter to effect the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of a at least sixty-six and two-thirds&#160;percent (66<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2/3</sup>%) of the voting power of all then-outstanding shares of GlycoMimetics capital stock entitled to vote generally in the election of directors, voting together as a single class, assuming a quorum is present, properly cast for or against the Reverse Stock Split Proposal by the holders of GlycoMimetics common stock is required to approve the Reverse Stock Split Proposal. Abstentions and broker non-votes, if any, will have no effect on the Reverse Stock Split Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</b> conditioned upon the approval of the Reverse Stock Split Proposal. Additionally, the GlycoMimetics Board may determine to effect the Reverse Stock Split Proposal, if approved, even if Proposal No.&#160;1 is not approved by the GlycoMimetics stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain GlycoMimetics stockholders have agreed to vote any shares of GlycoMimetics common stock owned by them in favor of the Reverse Stock Split Proposal. See &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Support Agreements</i>&#8221; beginning on page&#160;151 of this proxy statement/prospectus for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the approval of the Reverse Stock Split Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE GLYCOMIMETICS BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE REVERSE STOCK SPLIT</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">186</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_fb224c99_3566_4a96_b571_d69a433ab69f"></a><a id="PROPOSALNO4THEDIRECTORELECTIONPROPOSAL_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PROPOSAL NO.&#160;4&#160;- THE DIRECTOR ELECTION PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Board currently consists of eight members. In accordance with the terms of the GlycoMimetics Charter and GlycoMimetics Bylaws, the GlycoMimetics Board is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with members of each class serving staggered three-year terms. The members of the classes are divided as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;I directors are Daniel Junius and Rachel King, whose terms will expire at GlycoMimetics&#8217; annual meeting of stockholders to be held in 2027;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;II directors are Scott Jackson, Scott Koenig, and Harout Semerjian, whose term will expire at GlycoMimetics&#8217; annual meeting of stockholders to be held in 2025;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;III directors are Patricia Andrews, Mark Goldberg, and Timothy Pearson, whose term will expire at GlycoMimetics&#8217; annual meeting of stockholders to be held in 2026.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the expiration of the term of a class of the GlycoMimetics Board, any director in that class will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the&#160;year in which their term expires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Charter and GlycoMimetics Bylaws provide that the authorized number of directors may be set and changed only by resolution of the GlycoMimetics Board. GlycoMimetics Bylaws also provide that GlycoMimetics&#8217; directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds of the voting rights of the shares of capital stock then entitled to vote in an annual election of directors, and that any vacancy on the GlycoMimetics Board, including a vacancy resulting from an increase in the size of the GlycoMimetics Board, may be filled only by vote of a majority of its directors then in office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Board has nominated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; for election as a Class&#160;II director at the GlycoMimetics Special Meeting. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; are currently directors and have consented to continue to serve as directors if elected. If &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; become unable or unwilling to serve, however, the proxies may be voted for substitute nominees selected by the GlycoMimetics Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics stockholders should understand, however, that if the Merger is consummated, the approval of the director nominees named in the Director Election Proposal will only have an effect until the completion of the Merger because the composition of the GlycoMimetics Board will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement. Following the Merger, the Combined Company&#8217;s board of directors will consist of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;members designated by Crescent, including Peter Harwin, Jonathan Violin, Alexandra Balcom, Susan Moran, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. All of GlycoMimetics&#8217; current directors are expected to resign from their positions as directors of GlycoMimetics, effective as of the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The nominees for Class&#160;II director who receive the most votes properly cast (also known as a plurality) will be elected. You may either vote &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the nominees or &#8220;<b style="font-weight:bold;">WITHHOLD</b>&#8221; your vote from the nominees. Withheld votes and broker non-votes, if any, will have no effect on the Director Election Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</b> conditioned upon the election of the director nominees named in the Director Election Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the election of the director nominees named in the Director Election Proposal. However, if the nominees are unable to serve or for good cause will not serve as a director, the proxies will be voted for the election of such substitute nominees as the GlycoMimetics Board may designate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE GLYCOMIMETICS BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE DIRECTOR NOMINEES NAMED IN THE DIRECTOR ELECTION PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">187</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_83cad55f_8fd1_4cbb_b0ec_34b9530f2f6e"></a><a id="PROPOSALNO5THEAUDITORRATIFICATIONPROPOSA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PROPOSAL NO.&#160;5&#160;- THE AUDITOR RATIFICATION PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the GlycoMimetics Special Meeting, GlycoMimetics will ask its stockholders to ratify the appointment by the audit committee of the GlycoMimetics Board (the &#8220;GlycoMimetics audit committee&#8221;) of Ernst&#160;&amp; Young LLP as GlycoMimetics&#8217; independent registered public accounting firm for the fiscal&#160;year ending December&#160;31, 2025, provided that PricewaterhouseCoopers LLP is expected to be appointed for the fiscal&#160;year ending December&#160;31, 2025 if the Merger is completed. Ernst&#160;&amp; Young LLP has served as GlycoMimetics&#8217; independent registered public accounting firm since 2011.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics audit committee is solely responsible for selecting GlycoMimetics&#8217; independent registered public accounting firm for the fiscal&#160;year ending December&#160;31, 2025. Stockholder approval is not required to appoint Ernst&#160;&amp; Young LLP as GlycoMimetics&#8217; independent registered public accounting firm. However, the GlycoMimetics Board believes that submitting the selection of Ernst&#160;&amp; Young LLP to GlycoMimetics stockholders for ratification is good corporate governance. If GlycoMimetics stockholders do not ratify this appointment, the GlycoMimetics audit committee will reconsider whether to retain Ernst&#160;&amp; Young&#160;LLP. If the selection of Ernst&#160;&amp; Young LLP is ratified, the GlycoMimetics audit committee, at its discretion, may direct the selection of a different independent registered public accounting firm at any time it decides that such a change would be in the best interest of GlycoMimetics and its stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A representative of Ernst&#160;&amp; Young LLP is expected to be present at the GlycoMimetics Special Meeting and will have an opportunity to make a statement if he or she desires to do so and to respond to appropriate questions from GlycoMimetics stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of a majority of the shares of GlycoMimetics common stock entitled to vote on the subject matter and present or represented by proxy at the GlycoMimetics Special Meeting required to approve the Auditor Ratification Proposal. Abstentions will have the same effect as votes &#8220;<b style="font-weight:bold;">AGAINST</b>&#8221; the Auditor Ratification Proposal and broker non-votes, if any, will have no effect on the Auditor Ratification Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</b> conditioned upon the approval of the Auditor Ratification Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the Auditor Ratification Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE GLYCOMIMETICS BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE AUDITOR RATIFICATION PROPOSAL, PROVIDED THAT PRICEWATERHOUSECOOPERS LLP IS EXPECTED TO BE APPOINTED FOR THE FISCAL&#160;YEAR ENDING DECEMBER&#160;31, 2025 IF THE MERGER IS COMPLETED.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">188</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_844cd118_c3e6_43c0_ae58_d8d160715e8a"></a><a id="PROPOSALNO6THESTOCKPLANPROPOSAL_793387"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PROPOSAL NO.&#160;6&#160;- THE STOCK PLAN PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the GlycoMimetics Special Meeting, GlycoMimetics will ask its stockholders to approve the Crescent Biopharma,&#160;Inc. 2025 Stock Incentive Plan (the &#8220;2025 Stock Plan&#8221;) to be effective on the closing date of the Merger. The 2025 Stock Plan was approved by the GlycoMimetics Board on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, subject to stockholder approval and the consummation of the Merger. If the 2025 Stock Plan is approved by stockholders and the Merger is consummated, no further awards will be granted under GlycoMimetics&#8217; Amended and Restated 2013 Equity Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of the 2025 Stock Plan is to promote and closely align the interests of employees, officers, non-employee directors and other individual service providers of the Combined Company and its stockholders by providing stock-based compensation and other performance-based compensation. The objectives of the 2025 Stock Plan are to attract and retain the best available employees, officers, non-employee directors and other individual service providers for positions of substantial responsibility and to motivate participants to optimize the profitability and growth of the Combined Company through incentives that are consistent with the Combined Company&#8217;s goals and that link the personal interests of participants to those of the Combined Company&#8217;s stockholders. The 2025 Stock Plan allows for the grant of stock options, stock appreciation rights (&#8220;SARs&#8221;), restricted stock, restricted stock units (&#8220;RSUs&#8221;), other stock-based awards and incentive bonuses (collectively, &#8220;Awards&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of the 2025 Stock Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following description of the 2025 Stock Plan is not intended to be complete and is qualified in its entirety by the complete text of the 2025 Stock Plan, a copy of which is attached as <i style="font-style:italic;">Annex J</i> to this proxy statement/prospectus. Stockholders are urged to read the 2025 Stock Plan in its entirety.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Administration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2025 Stock Plan will be administered by the compensation committee of the Combined Company board of directors (the &#8220;Board&#8221;), or another committee designated by the Board to administer the 2025 Stock Plan, which is referred to herein as the &#8220;Administrator.&#8221; The Administrator will have broad authority, subject to the provisions of the 2025 Stock Plan, to administer and interpret the 2025 Stock Plan and Awards granted thereunder. All decisions and actions of the Administrator will be final.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Subject to 2025 Stock Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The initial share pool under the 2025 Stock Plan will be&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % of the total number of shares of outstanding capital stock immediately following the consummation of the Merger (including Combined Company common stock, preferred stock and unexercised pre-funded warrants), subject to certain adjustments in the event of a change in the Combined Company&#8217;s capitalization. The shares that may be issued under the 2025 Stock Plan will be automatically increased on January&#160;1 of each&#160;year beginning in 2026 and ending with a final increase on January&#160;1, 2035 in an amount equal to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % of the diluted stock (including Combined Company common stock, preferred stock and unexercised pre-funded warrants) on the preceding December&#160;31, unless a lower, or no, increase is determined by the Administrator. Only&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of Combined Company common stock may be issued under the 2025 Stock Plan as incentive stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shares of Combined Company common stock issued under the 2025 Stock Plan may be either authorized and unissued shares or previously issued shares acquired by the Combined Company. On termination or expiration of an Award under the 2025 Stock Plan, in whole or in part, the number of shares of Combined Company common stock subject to such Award but not issued thereunder or that are otherwise forfeited back to the Combined Company will again become available for grant under the 2025 Stock Plan. Additionally, shares retained or withheld in payment of any exercise price, purchase price, or tax withholding obligation of an Award will again become available for grant under the 2025 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, the closing price of a share of GlycoMimetics was $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, as reported on the Nasdaq Stock Market.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">189</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Eligibility</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Current or prospective employees, officers, non-employee directors, and other independent service providers of the Combined Company and its subsidiaries will be eligible to participate in the 2025 Stock Plan, if selected by the Administrator. Following the Merger, it is expected that approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; employees (including&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; executive officers), &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; non-employee directors and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; other individual service providers of the Combined Company will be eligible to participate in the 2025 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Types of Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span>. All stock options granted under the 2025 Stock Plan will be evidenced by a written agreement with the participant, which provides, among other things, whether the option is intended to be an incentive stock option or a non-qualified stock option, the number of shares subject to the option, the exercise price, exercisability (or vesting), the term of the option, which may not generally exceed ten&#160;years, and other terms and conditions. Subject to the express provisions of the 2025 Stock Plan, options generally may be exercised over such period, in installments or otherwise, as the Administrator may determine. The exercise price for any stock option granted may not generally be less than the fair market value of the Combined Company common stock subject to that option on the grant date. The exercise price may be paid in cash or such other method as determined by the Administrator, including an irrevocable commitment by a broker to pay over such amount from a sale of the shares issuable under an option, the delivery of previously owned shares, or withholding of shares deliverable upon exercise. The 2025 Stock Plan permits, without stockholder approval, the Administrator to reduce the exercise price of a previously awarded option or cancel and re-grant or exchange such option for cash or a new Award with a lower (or no) exercise price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Appreciation Rights</span>. SARs may be granted alone or in conjunction with all or part of a stock option. Upon exercising a SAR, the participant is entitled to receive the amount by which the fair market value of the Combined Company common stock at the time of exercise exceeds the exercise price of the SAR. This amount is payable in Combined Company common stock, cash, restricted stock, or a combination thereof, at the Administrator&#8217;s discretion. The 2025 Stock Plan permits, without stockholder approval, the Administrator to reduce the exercise price of a previously awarded SAR or cancel and re-grant or exchange such SAR for cash or a new Award with a lower (or no) exercise price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock and RSUs</span>. Awards of restricted stock consist of shares of stock that are transferred to the participant subject to restrictions that may result in forfeiture if specified conditions are not satisfied. RSUs result in the transfer of shares of cash or stock to the participant only after specified conditions are satisfied. The Administrator will determine the restrictions and conditions applicable to each award of restricted stock or RSUs, which may include performance vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Stock-Based Awards</span>. Other stock-based awards are Awards denominated in or payable in, valued in whole or in part by reference to, or otherwise based on or related to, the value of Combined Company common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Incentive Bonuses</span>. Each incentive bonus will confer upon the participant the opportunity to earn a payment, which may be subject to vesting or performance criteria established by the Administrator. Payment of the amount due under an incentive bonus may be made in cash or shares, as determined by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Performance Criteria</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Administrator may specify certain performance criteria which must be satisfied before Awards will be granted or will vest. The performance goals may vary from participant to participant, group to group, and period to period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transferability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Awards generally may not be sold, transferred for value, pledged, assigned, or otherwise alienated or hypothecated by a participant other than by will or the laws of descent and distribution, and each option or SAR may be exercisable only by the participant during his or her lifetime.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">190</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clawback</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Awards will be subject to recoupment in accordance with any clawback policy adopted by the Combined Company, including the GlycoMimetics Incentive Compensation Recoupment Policy (or any successor or other clawback policy adopted by the Combined Company).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adjustments Upon a Change in Capitalization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of a change in capitalization of the Combined Company, including any reorganization, reclassification, combination of shares, stock split, reverse stock split, spin-off, dividend or distribution (other than quarterly cash dividends), the share pool and outstanding Awards will be equitably adjusted by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Change in Control</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of a change in control of the Combined Company, the Administrator may (i)&#160;provide for the assumption of outstanding Awards, (ii)&#160;issue substitute awards, (iii)&#160;accelerate vesting or waiver any forfeiture conditions, (iv)&#160;accelerate the exercisability of the award, (v)&#160;make any other adjustments to outstanding Awards as deemed to be appropriate or (vi)&#160;provide for the cancellation and cash-out of outstanding Awards; however, if Awards are not assumed, continued or substituted for, then all outstanding Awards will become fully vested and exercisable (with performance based on target or actual achievement as determined by the Administrator).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendment and Termination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company board of directors will have the right to amend, alter, suspend, or terminate the 2025 Stock Plan at any time, provided certain enumerated material amendments may not be made without stockholder approval. No amendment or alteration to the 2025 Stock Plan or an Award or Award agreement will be made that would materially impair the rights of the holder, without such holder&#8217;s consent; however, no consent will be required if the Administrator determines in its sole discretion and prior to the date of any change in control that such amendment or alteration either is required or advisable in order for the Combined Company, the 2025 Stock Plan, or such Award to satisfy any law or regulation or to meet the requirements of or avoid adverse financial accounting consequences under any accounting standard, or is not reasonably likely to significantly diminish the benefits provided under such Award, or that any such diminishment has been adequately compensated. The 2025 Stock Plan will automatically terminate as to the grant of future awards, unless earlier terminated by the Combined Company board of directors, on<span style="display:inline-block;width:2.78pt;"></span><span style="display:inline-block;width:18pt;"></span>, 2035.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Federal Income Tax Consequences</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the U.S. federal income tax treatment applicable to the Combined Company and the participants who receive Awards under the 2025 Stock Plan based on the federal income tax laws in effect on the date of this proxy statement/prospectus. This summary is not intended to be exhaustive and does not address all matters relevant to a particular participant based on their specific circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The summary expressly does not discuss the income tax laws of any state, municipality, or non-U.S. taxing jurisdiction, or the gift, estate, excise (including the rules&#160;applicable to deferred compensation under Section&#160;409A of the Code), or tax laws other than U.S. federal income tax law. Because individual circumstances may vary, each participant is urged to consult their own tax advisor concerning the tax implications of Awards granted under the 2025 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Incentive Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Options granted under the 2025 Stock Plan may be either incentive stock options, which are intended to satisfy the requirements of Section&#160;422 of the Code, or non-qualified stock options, which are not intended to meet such requirements. No taxable income is recognized by the optionee at the time of the option grant, and no taxable income is recognized for ordinary income tax purposes at the time the option is exercised, although taxable income may arise at that time for alternative minimum tax purposes. Unless there is a &#8220;disqualifying disposition&#8221;, as described below, the optionee will recognize long-term capital gain in an amount equal to the excess of (i)&#160;the amount realized upon the sale or other disposition of the purchased shares over (ii)&#160;the exercise price paid for the shares. A disqualifying disposition occurs if the disposition is less than two&#160;years after the date of grant or less than one&#160;year after the exercise date. If there is a disqualifying disposition of the shares, then the excess of (i)&#160;the fair market value of those shares on the exercise date or (if less) the amount realized upon such sale or disposition over (ii)&#160;the exercise price paid for the shares will be taxable as ordinary </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">191</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">income to the optionee. Any additional gain or loss recognized upon the disposition will be a capital gain or loss. If the optionee makes a disqualifying disposition of the purchased shares, then the Combined Company (or, if applicable, the affiliate employer) will be entitled to an income tax deduction for the taxable&#160;year in which such disposition occurs equal to the amount of ordinary income recognized by the optionee as a result of the disposition. The Combined Company will not be entitled to any income tax deduction if the optionee makes a qualifying disposition of the shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nonqualified Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No taxable income is recognized by an optionee upon the grant of a non-qualified stock option. The optionee in general will recognize ordinary income, in the&#160;<span style="white-space:pre-wrap;">year in which the option is exercised, equal to the excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares, and the optionee will be required to satisfy the tax withholding requirements applicable to such income. The Combined Company  (or, if applicable, the affiliate employer) will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the optionee with respect to the exercised non-qualified stock option.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Appreciation Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No taxable income is recognized upon receipt of a SAR. The participant will recognize ordinary income in the&#160;year in which the SAR is exercised, in an amount equal to the excess of the fair market value of the underlying shares of common stock on the exercise date over the base price in effect for the exercised right, and the participant will be required to satisfy the tax withholding requirements applicable to such income. The Combined Company (or, if applicable, the affiliate employer) will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant in connection with the exercise of the SAR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A participant who receives unvested shares of Combined Company common stock will not recognize any taxable income at the time those shares are granted but will have to report as ordinary income, as and when the restrictions constituting a substantial risk of forfeiture lapse, an amount equal to the excess of (i)&#160;the fair market value of the shares on the vesting date over (ii)&#160;the amount paid (if any) for the shares. The participant may, however, elect under Section&#160;83(b)&#160;of the Code to include as ordinary income in the&#160;year the unvested shares are issued an amount equal to the excess of (a)&#160;the fair market value of those shares on the issue date over (b)&#160;the amount paid (if any) for such shares. If the Section&#160;83(b)&#160;<span style="white-space:pre-wrap;">election is made, the participant will not recognize any additional income as and when the shares subsequently vest. The Combined Company  (or, if applicable, the affiliate employer) will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time such ordinary income is recognized by the participant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Units, Other Stock-Based Awards, Incentive Bonuses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, no taxable income is recognized upon the grant of RSUs, other stock-based awards or incentive bonuses. The participant will recognize ordinary income in the&#160;<span style="white-space:pre-wrap;">year in which the award is settled in shares or cash. The amount of that income will be equal to the fair market value of the shares on the date of issuance or the amount of the cash paid in settlement of the award, and the participant will be required to satisfy the tax withholding requirements applicable to the income. The Combined Company  (or, if applicable, the affiliate employer) will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time the shares are issued or the cash amount is paid.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deductibility of Executive Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;162(m)&#160;of the Code limits the deductibility for federal income tax purposes of certain compensation paid to any &#8220;covered employee&#8221; in excess of $1.0 million. It is expected that compensation deductions for any covered employee with respect to awards granted under the 2025 Stock Plan will be subject to the $1.0 million annual deduction limitation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">New Plan Benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics cannot currently determine the benefits or number of shares subject to Awards that may be granted in the future to eligible participants under the 2025 Stock Plan because the grant of Awards and terms of such Awards are to be determined in the sole discretion of the Administrator.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">192</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of a majority of the shares of GlycoMimetics common stock entitled to vote on the subject matter and present or represented by proxy at the GlycoMimetics Special Meeting required to approve the Stock Plan Proposal. Abstentions will have the same effect as votes &#8220;<b style="font-weight:bold;">AGAINST</b>&#8221; the Stock Plan Proposal and broker non-votes, if any, will have no effect on the Stock Plan Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</b> conditioned upon the approval of the Stock Plan Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the Stock Plan Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE GLYCOMIMETICS BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE STOCK PLAN PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">193</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_753e22d3_18c8_4817_8cf4_f100ff2bd2d8"></a><a id="PROPOSALNO7THEESPPPROPOSAL_216161"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PROPOSAL NO.&#160;7&#160;- THE ESPP PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the GlycoMimetics Special Meeting, GlycoMimetics will ask its stockholders to approve the Crescent Biopharma,&#160;Inc. 2025 Employee Stock Purchase Plan (the &#8220;2025 ESPP&#8221;) to be effective on the closing date of the Merger. The 2025 ESPP was approved by the GlycoMimetics Board on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, subject to stockholder approval and the consummation of the Merger. If the 2025 ESPP is approved by stockholders and the Merger is consummated, GlycoMimetics&#8217; 2013 Employee Stock Purchase Plan will be terminated and no further shares will be issued thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of the 2025 ESPP is to provide employees of the Combined Company and its designated subsidiaries with an opportunity to purchase shares of the Combined Company common stock through accumulated contributions. The 2025 ESPP, and the rights of participants to make purchases thereunder, is intended to qualify under Section&#160;423 of the Code; however, sub-plans that do not meet the requirements of Section&#160;423 of the Code may be established for the benefit of eligible employees of non-U.S. subsidiaries of the Combined Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of the ESPP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following description of the 2025 ESPP is not intended to be complete and is qualified in its entirety by the complete text of the 2025 ESPP, a copy of which is attached as <i style="font-style:italic;">Annex K</i> to this proxy statement. Stockholders are urged to read the 2025 ESPP in its entirety.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Administration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2025 ESPP will be administered by the compensation committee of the Board or another committee designated by the Board to administer, which is referred to herein as the &#8220;ESPP Administrator.&#8221; All questions of interpretation of the 2025 ESPP are determined by the ESPP Administrator, whose decisions are final and binding upon all participants. The ESPP Administrator may delegate, subject to applicable law, its responsibilities under the 2025 ESPP to one or more other persons. The ESPP Administrator may adopt rules&#160;or procedures relating to the operation and administration of the 2025 ESPP to accommodate the specific requirements of local laws and procedures, including to adopt sub-plans for participants outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Subject to ESPP</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The initial share pool under the 2025 ESPP will be the lesser of (i) &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % of the total number of shares of outstanding capital stock immediately following the consummation of the Merger (including Combined Company common stock, preferred stock and unexercised pre-funded warrants) or (ii) &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares, subject to certain adjustments in the event of a change in the Combined Company&#8217;s capitalization. The shares that may be issued under the 2025 ESPP will be automatically increased on January&#160;1 of each&#160;year beginning in 2026 and ending with a final increase on January&#160;1, 2035 in an amount equal to the lesser of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % of the diluted stock (including Combined Company common stock, preferred stock and unexercised pre-funded warrants) on the preceding December&#160;31 or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, unless a lower, or no, increase is determined by the ESPP Administrator. Shares of Combined Company common stock issued under the 2025 ESPP may either be shares of authorized but unissued Combined Company common stock, Combined Company common stock held as treasury shares, or Combined Company common stock acquired in an open-market transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the total number of shares to be purchased by all participants on any exercise date (as defined below) exceeds the number of shares remaining available for issuance under the 2025 ESPP, the ESPP Administrator may make a pro rata allocation of the remaining available number of shares in as uniform a manner as possible and as the ESPP Administrator determines to be equitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, the closing price of a share of GlycoMimetics was $ &#160;&#160;&#160;&#160;&#160;&#160;&#160; per share, as reported on the Nasdaq Stock Market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Eligibility</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">All employees of the Combined Company or a designated subsidiary of the Combined Company (as defined in the 2025 ESPP) who customarily work for more than 20 hours per week and more than five&#160;months in any calendar&#160;<span style="white-space:pre-wrap;">year and satisfy the requirements set forth in the 2025 ESPP will be eligible to participate in the 2025 ESPP.  However, any employee who would own (or pursuant to </span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">194</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Section&#160;424(d)&#160;of the Code would be deemed to own) more than 5% of the voting power or value of the Combined Company common stock immediately after a grant under the 2025 ESPP is not eligible to participate, and no participant may purchase more than $25,000 of Combined Company common stock in any one calendar&#160;year. Following the Merger, it is expected that approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; employees will be eligible to participate in the 2025 ESPP.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Offering Periods</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2025 ESPP is generally implemented by a series of &#8220;offering periods&#8221;. Unless otherwise specified by the ESPP Administrator, the first offering period and the first purchase period will begin on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and end on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, with subsequent offering periods and purchase periods lasting for&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and ending every&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Payroll Deductions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To participate in an offering period, an eligible employee must execute and submit a properly completed subscription agreement on or before a date determined by the ESPP Administrator prior to the applicable enrollment date. Once enrolled in the 2025 ESPP, a participant can purchase shares of the Combined Company&#8217;s common stock with payroll deductions at the end of the applicable offering period. Once an offering period is over, a participant is automatically enrolled in the next offering period unless the participant chooses to withdraw from the 2025 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each subscription agreement will request a deduction in an amount expressed as a whole&#160;percentage between 1% and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; % and all payroll deductions will be credited to the eligible employee&#8217;s account. No interest will be paid on any amount held in the account of any eligible employee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Option Grant</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On the first trading day of each offering period, each eligible employee automatically will be granted an option to acquire shares of Combined Company common stock on the exercise date. All participants granted options under the 2025 ESPP will have the same rights and privileges consistent with the requirements set forth in Section&#160;423 of the Code. No eligible employee will be permitted to purchase more than&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of Combined Company common stock during each purchase period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Purchase Price</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The price per share at which shares are purchased under the 2025 ESPP is determined by the ESPP Administrator, but in no event will be less than 85% of the fair market value of the Combined Company common stock on the first or the last day of the offering period, whichever is lower.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exercise of Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the end of each offering period, unless the participant has withdrawn from the 2025 ESPP, payroll deductions are applied automatically to purchase shares of common stock at the price described above. The number of shares purchased is determined by dividing the payroll deductions by the applicable purchase price, rounded down to the nearest whole share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any payroll deductions accumulated in a participant&#8217;s account that are not sufficient to purchase a full share will be retained in the participant&#8217;s account for the subsequent option period (subject to earlier withdrawal in accordance with the terms of the 2025 ESPP). Any other amounts of payroll deductions in a participant&#8217;s account that are not used for the purchase of shares of Combined Company common stock, whether because of the participant&#8217;s withdrawal, because the amount would enable the participant to purchase more than the maximum number of shares, or for any other reason, will be returned to the participant, without interest, as soon as administratively practicable after such withdrawal, exercise date or other event, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cancellation and Withdrawal</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Participants may cancel all (but not less than all) of their option and terminate their subscription agreement by delivering a written notice revoking their subscription to the Combined Company or by following an electronic or other withdrawal procedure determined by the ESPP Administrator. Upon such termination and cancellation, the balance in the participant&#8217;s account will be returned to the participant, without interest, as soon as administratively practicable thereafter.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">195</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Termination of Employment or Eligibility</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the termination of a participant&#8217;s employment with the Combined Company (or a designated subsidiary, as applicable) for any reason or if a participant loses eligibility to participate in the 2025 ESPP, the participant&#8217;s option will be deemed cancelled, the balance in the participant&#8217;s account will be returned to the participant (or his or her estate or designated beneficiary in the event of the participant&#8217;s death), without interest, as soon as administratively practicable, and the participant will have no other rights under the 2025 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transferability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Rights to purchase Combined Company common stock under the 2025 ESPP may not be transferred by a participant and may be exercised during a participant&#8217;s lifetime only by the participant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adjustments Upon a Change in Capitalization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of any reorganizations, recapitalizations, stock splits, reverse stock splits, stock dividends, extraordinary dividends or distributions, or similar events, the ESPP Administrator will appropriately adjust the number and class of shares available under the 2025 ESPP and the applicable purchase price of such shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Merger or Other Corporate Transaction</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of a merger, sale, or other similar corporate transaction involving the Combined Company, each outstanding option will be assumed or an equivalent option substituted by the successor corporation or a parent or subsidiary of the successor corporation. If the successor corporation refuses to assume or substitute for the option, the offering period with respect to which such option relates will be shortened by setting a new exercise date on which such offering period shall end. The new exercise date will occur before the date of the Combined Company&#8217;s proposed merger, sale, or other similar corporate transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendment and Termination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ESPP Administrator may amend, suspend or terminate the 2025 ESPP at any time and, in the event of a termination of the 2025 ESPP, may terminate all outstanding offering periods (and return each participant&#8217;s account balance to the participant) or allow outstanding offering periods to expire in accordance with their terms. The 2025 ESPP will continue in effect until terminated by the ESPP Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Federal Income Tax Consequences</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a brief description of the federal income tax treatment that will generally apply to the grant and exercise of rights under the 2025 ESPP, based on federal income tax laws in effect on the date of this proxy statement/prospectus. The exact federal income tax treatment of options under the 2025 ESPP will depend on the specific nature of any such option and the individual tax attributes of the participant. The following summary is not intended to be exhaustive and, among other considerations, does not describe gift, estate, social security, state, local or international tax consequences. In addition, if one or more sub-plans are established for employees of non-U.S. subsidiaries, the tax rules&#160;may be different than discussed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2025 ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code and, as a result, employees who participate in the 2025 ESPP will be afforded favorable tax treatment subject to meeting certain requirements specified by the Code. In general, there are no federal income tax consequences to a participant upon the grant of the option to purchase shares under the 2025 ESPP at the beginning of an option period or upon its exercise on the exercise date at the end of an option period. Upon the disposition of shares of common stock acquired upon exercise of an option, the participant will generally be subject to tax and the nature and amount of the tax will depend on whether the employee has satisfied the statutory holding period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the employee holds shares acquired under the 2025 ESPP for at least two&#160;years from the grant date of his or her option and at least one&#160;year from the date he or she acquired the shares (referred to as the &#8220;statutory holding period&#8221;), any gain on the sale of the shares will be taxed as ordinary income to the extent of the lesser of (i)&#160;the amount by which the fair market value of the shares on the grant date (i.e., the first day of the option period) exceeded the exercise price for the option, or (ii)&#160;the amount by which the fair market value of the shares on the date of sale exceeds the exercise price of the option. Any additional gain or loss will be taxed as long-term capital gain or loss.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">196</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the participant sells or otherwise disposes of the shares before the expiration of the statutory holding period, then in the&#160;year of such &#8220;disqualifying&#8221; disposition, the participant will be required to recognize ordinary income equal to the difference between the fair market value of the shares on the date of the exercise of the option and the exercise price of the option. Any additional gain or loss will be short-term or long-term capital gain or loss depending on the length of time the employee has held the shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Combined Company is not entitled to any deduction with respect to the difference between the fair market value of the common stock and the option exercise price if the participant satisfies the statutory holding period described above. If shares are sold before the statutory holding period is satisfied, the Combined Company (or, if applicable, the affiliate employer) is entitled to  a tax deduction for any ordinary income recognized by the participant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">New Plan Benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The benefits that will be received by or allocated to eligible employees under the 2025 ESPP cannot be determined at this time because the amount of payroll deductions contributed to purchase shares of Combined Company common stock under the 2025 ESPP is entirely within the discretion of each participant (subject to the limitations discussed above).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of a majority of the shares of GlycoMimetics common stock entitled to vote on the subject matter and present or represented by proxy at the GlycoMimetics Special Meeting required to approve the ESPP Proposal. Abstentions will have the same effect as votes &#8220;<b style="font-weight:bold;">AGAINST</b>&#8221; the ESPP Proposal and broker non-votes, if any, will have no effect on the ESPP Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</b> conditioned upon the approval of the ESPP Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the ESPP Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE GLYCOMIMETICS BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE ESPP PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">197</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_78a29c5e_79b3_4cdb_a306_f1d9f1e9fca2"></a><a id="PROPOSALNO8THEMERGERCOMPENSATIONPROPOSAL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PROPOSAL NO.&#160;8&#160;- THE MERGER COMPENSATION PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Section&#160;14A of the Exchange Act and Rule&#160;14a-21(c)&#160;thereunder, GlycoMimetics is seeking non-binding, advisory stockholder approval of certain compensation arrangements for GlycoMimetics named executive officers that are based on or otherwise relate to the Merger, as disclosed pursuant to Item&#160;402(t)&#160;of Regulation S-K in the section titled &#8220;<i style="font-style:italic;">The Merger&#8212;Interests of GlycoMimetics&#8217; Directors and Executive Officers in the Merger&#8212;</i> <i style="font-style:italic;">Golden Parachute Compensation</i>&#8221; beginning on page&#160;123 of this proxy statement/prospectus. At the GlycoMimetics Special Meeting, GlycoMimetics will therefore ask its stockholders to adopt the following resolution:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;white-space:pre-wrap;">&#8220;RESOLVED:  That certain compensation arrangements for GlycoMimetics named executive officers in connection with the Merger, as disclosed pursuant to Item&#160;402(t)&#160;of Regulation S-K in the section titled &#8220;</b><span style="font-style:italic;font-weight:bold;">The Merger&#8212;Interests of GlycoMimetics&#8217; Directors and Executive Officers in the Merger&#8212;</span> <span style="font-style:italic;font-weight:bold;">Golden Parachute Compensation</span><b style="font-weight:bold;">&#8221; in the proxy statement/prospectus, are hereby APPROVED on a non-binding, advisory basis.&#8221;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the vote is advisory in nature only, it will not be binding on GlycoMimetics. Accordingly, to the extent GlycoMimetics is contractually obligated to pay the compensation, the compensation will be payable to the named executive officers, subject only to the conditions applicable thereto, if the Merger is completed, regardless of the outcome of the advisory vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The affirmative vote of a majority of the shares of GlycoMimetics common stock entitled to vote on the subject matter and present or represented by proxy at the GlycoMimetics common stock is required to approve the Merger Compensation Proposal. Abstentions will have the same effect as votes &#8220;<b style="font-weight:bold;">AGAINST</b>&#8221; the Merger Compensation Proposal and broker non-votes, if any, will have no effect on the Merger Compensation Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</b> conditioned upon the approval of the Merger Compensation Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the approval of the Merger Compensation Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE GLYCOMIMETICS BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE MERGER COMPENSATION</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">PROPOSAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">198</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_84680a72_5ee8_497e_a2b4_f2862dbb9686"></a><a id="PROPOSALNO9THEADJOURNMENTPROPOSAL_23903"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PROPOSAL NO.&#160;9&#160;- THE ADJOURNMENT PROPOSAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics fails to receive a sufficient number of votes to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal, GlycoMimetics may propose to adjourn the GlycoMimetics Special Meeting, for a period of not more than 60&#160;days, for the purpose of soliciting additional proxies to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal. GlycoMimetics currently does not intend to propose adjournment at the GlycoMimetics Special Meeting if there are sufficient votes to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a quorum is not present at the GlycoMimetics Special Meeting, under GlycoMimetics Bylaws, stockholders holding a majority of the shares present or by proxy and entitled to vote, or if no stockholders are present any officer entitled to preside at or act as secretary of the special meeting, will have the power to adjourn the special meeting until a quorum is present or represented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Required Vote</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a quorum is present, the affirmative vote of a majority of the shares of GlycoMimetics common stock entitled to vote on the subject matter and present or represented by proxy at the GlycoMimetics Special Meeting is required to approve the Adjournment Proposal. Abstentions will have the same effect as votes &#8220;<b style="font-weight:bold;">AGAINST</b>&#8221; the Adjournment Proposal and broker non-votes, if any, will have no effect on the Adjournment Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Merger is <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</b> conditioned upon the approval of the Adjournment Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<b style="font-weight:bold;">FOR</b>&#8221; the approval of the Adjournment Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THE GLYCOMIMETICS BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE ADJOURNMENT PROPOSAL,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">IF NECESSARY.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">199</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3a48402f_4e05_4fc2_bab4_2d80c4140cf1"></a><a id="GLYCOMIMETICSBUSINESS_353440"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">GLYCOMIMETICS&#8217; BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics is a biotechnology company that was previously developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in cancers and inflammation. GlycoMimetics&#8217; previous lead glycomimetic drug candidate, uproleselan, is a specific E-selectin antagonist that GlycoMimetics was developing to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics conducted a randomized, double-blind, placebo-controlled Phase 3 pivotal clinical trial to evaluate uproleselan in individuals with relapsed/refractory (R/R) AML. In the second quarter of 2024, GlycoMimetics reported results from the Phase 3 trial showing that uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat (ITT) population versus chemotherapy alone. GlycoMimetics has concluded, following subsequent feedback from the U.S. Food and Drug Administration, that the regulatory path forward for uproleselan for the treatment of relapsed and refractory acute myeloid leukemia would require an additional clinical trial. In July&#160;2024, GlycoMimetics announced a streamlined operating plan that included the exploration of strategic alternatives focused on maximizing shareholder value and a corporate restructuring that included a reduction in its workforce by 26 employees, or approximately 80% of its headcount. At this time, GlycoMimetics does not intend to continue development of uproleselan or any other drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the strategic review, on October&#160;28, 2024, GlycoMimetics, Gemini Merger Sub Corp., a Delaware corporation and GlycoMimetics&#8217; wholly-owned subsidiary, Gemini Merger Sub II, LLC, a Delaware limited liability company and GlycoMimetics&#8217; wholly-owned subsidiary, and Crescent Biopharma,&#160;Inc., a Delaware corporation, entered into an Agreement and Plan of Merger and Reorganization, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, (i)&#160;First Merger Sub will merge with and into Crescent, with Crescent continuing as GlycoMimetics&#8217; wholly owned subsidiary and the surviving corporation of the merger and (ii)&#160;immediately following the First Merger and as part of the same overall transaction as the First Merger, Crescent will merge with and into Second Merger Sub.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Exchange Ratio formula in the Merger Agreement, and based on GlycoMimetics&#8217; capitalization as of September&#160;30, 2024 and Crescent&#8217;s capitalization as of October&#160;28, 2024 (the date the Merger Agreement was executed), upon the closing of the Merger (and prior to closing of the Crescent Pre-Closing Financing described below), on a pro forma basis and based upon the number of shares of GlycoMimetics common stock expected to be issued in the Merger, pre-Merger Crescent stockholders will own approximately 86.21% of the Combined Company and pre-Merger GlycoMimetics stockholders will own approximately 13.79% of the Combined Company. After giving further effect to the Crescent Pre-Closing Financing, the pre-Merger Crescent stockholders (inclusive of those investors participating in the Crescent Pre-Closing Financing) are expected to own approximately 96.9% of the Combined Company and GlycoMimetics&#8217; pre-Merger stockholders are expected to own approximately 3.1% of the Combined Company. The Exchange Ratio may be further adjusted as described in the Merger Agreement. GlycoMimetics and Crescent have agreed to customary representations, warranties and covenants in the Merger Agreement and the consummation of the Merger is subject to customary closing conditions, including, among other things, approval by GlycoMimetics&#8217; stockholders and the Crescent stockholders of the transaction, Nasdaq and SEC approvals, and completion of a concurrent private placement of at least $100 million (as described below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, in connection with the Merger, GlycoMimetics will establish the terms of a new series of preferred stock designated as GlycoMimetics Series&#160;A Preferred Stock. Holders of the GlycoMimetics Series&#160;A Preferred Stock will be entitled to receive dividends on shares of GlycoMimetics Series&#160;A Preferred Stock equal to, on an as-if-converted-to-GlycoMimetics common stock basis, and in the same form as dividends actually paid on shares of the GlycoMimetics common stock. Except as otherwise required by the Certificate of Designation or law, the GlycoMimetics Series&#160;A Preferred Stock will not have voting rights. The Certificate of Designation will provide however that for so long at least 30% of the GlycoMimetics Series&#160;A Preferred Stock remains issued and outstanding, the holders of GlycoMimetics Series&#160;A Preferred Stock exclusively and voting together as a separate class on an as-converted to common stock basis, shall be entitled to elect two directors (the &#8220;Preferred Directors&#8221;); and the holders of record of the shares of common stock and of any other class or series of voting stock (including the GlycoMimetics Series&#160;A Preferred Stock), exclusively and voting together as a single class on an as-converted to common stock basis, shall be entitled to elect the balance of the total number of directors.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">200</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon completion of the Merger, GlycoMimetics plans to operate under the name Crescent Biopharma,&#160;Inc. The Merger is expected to close in the late second quarter of 2025, subject to certain closing conditions, including, among other things, approval by the stockholders of each company and the satisfaction of customary closing conditions. The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended. Following the Merger, the current business of Crescent will become the primary business of GlycoMimetics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrently with the execution and delivery of the Merger Agreement, certain institutional and accredited investors have entered into a securities purchase agreement, with GlycoMimetics, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase, immediately following the consummation of the Merger, shares of GlycoMimetics common stock and pre-funded warrants for an aggregate purchase price of approximately $200.0 million in the Crescent Pre-Closing Financing. The closing of the Crescent Pre-Closing Financing is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement (in addition to other customary closing conditions) and is expected to occur immediately prior to the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, on February&#160;14, 2025, Crescent and GlycoMimetics entered into the Subscription Agreement with certain institutional and accredited investors pursuant to which such investors have agreed, subject to the terms and conditions of such agreements, to purchase, immediately prior to the consummation of the Merger, shares of GlycoMimetics common stock and pre-funded warrants for an aggregate purchase price of approximately $200.0 million in the Crescent Pre-Closing Financing. The closing of the Crescent Pre-Closing Financing is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement (in addition to other customary closing conditions) and is expected to occur immediately prior to the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrent with the execution of the Merger Agreement, GlycoMimetics&#8217; directors and officers and certain stockholders of Crescent (solely in their respective capacities as Crescent stockholders) holding approximately 98.5% of the outstanding shares of Crescent capital stock have entered into support agreements to vote all of their shares in favor of the adoption and approval of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that GlycoMimetics does not complete the Merger, GlycoMimetics may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Glyco</b><b style="font-weight:bold;">M</b><b style="font-weight:bold;">imetics</b><b style="font-weight:bold;">&#8217; </b><b style="font-weight:bold;">Historical Platform and Drug Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; proprietary glycomimetics platform was based on its expertise in carbohydrate chemistry and its understanding of the role carbohydrates play in key biological processes. Most human proteins are modified by the addition of complex carbohydrate structures to the surface of such proteins, which affects the functions of the proteins and their interactions with other molecules. GlycoMimetics&#8217; prior research and development efforts focused on drug candidates targeting selectins, which are proteins that serve as adhesion molecules and bind to carbohydrates that are involved in the inflammatory component and progression of a wide range of diseases, including hematologic disorders, cancer and cardiovascular disease. For example, GlycoMimetics believes that members of the selectin family play a key role in tumor metastasis and resistance to chemotherapy. Inhibiting specific carbohydrates from binding to selectins has long been viewed as a potentially attractive approach for therapeutic intervention. The ability to successfully develop drug-like carbohydrate compounds that inhibit binding with selectins, known as selectin antagonists, has historically been limited by their potency and the complexities of carbohydrate chemistry. GlycoMimetics believes its expertise in the rational design of potent glycomimetic antagonists with drug-like properties and in carbohydrate chemistry enabled GlycoMimetics to identify highly effective selectin antagonists and other glycomimetics that may inhibit the disease-related functions of certain carbohydrates in order to develop novel drug candidates to address orphan diseases with high unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The status of GlycoMimetics&#8217; current drug candidates is summarized below. GlycoMimetics is no longer actively pursuing the development of any of these drug candidates. GlycoMimetics retained the worldwide development and commercialization rights to each of its drug candidates, except with respect to uproleselan and GMI-1687, for which GlycoMimetics has exclusively licensed development and commercialization rights to Apollomics (Hong Kong) Limited, or Apollomics, in Mainland China, Hong Kong, Macau and Taiwan, collectively referred to as Greater China. Although those agreements remain in force, Apollomics has announced its intention to wind down its clinical development program and GlycoMimetics does not anticipate those agreements to continue following the consummation of the Merger.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">201</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Uproleselan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics was previously developing uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Uproleselan received Orphan Drug designation from the FDA in 2015 for treatment of patients with AML. In 2016, uproleselan received Fast Track designation from the FDA for treatment of adult patients with relapsed or refractory AML and elderly patients aged 60&#160;years or older with AML. In 2017, uproleselan received Breakthrough Therapy designation from the FDA for treatment of adult patients with relapsed or refractory AML. In 2017, the European Commission, based on a favorable recommendation from the EMA Committee for Orphan Medicinal Products, granted Orphan Designation for uproleselan for treatment of patients with AML. In January&#160;2021, the China National Medical Products Administration Center for Drug Evaluation granted Breakthrough Therapy designation to uproleselan for treatment of relapsed/refractory AML.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">E-selectin plays a critical role in binding cancer cells within vascular niches in the bone marrow, which prevents the cells from entering circulation where they can be more readily killed by chemotherapy. In animal studies, uproleselan mobilized AML cancer cells out of the bone marrow, making them more sensitive to chemotherapy. In these studies, tumor burden was significantly reduced in the animals treated with a combination of chemotherapy and uproleselan as compared to animals treated with chemotherapy alone. In addition, the combination of uproleselan with chemotherapy resulted in improved survival rates for the treated animals compared to chemotherapy alone. In other animal studies, uproleselan appeared to also protect normal cells from some of the side effects of chemotherapy. Common side effects of chemotherapy include bone marrow toxicity resulting in neutropenia, which is an abnormally low number of neutrophils, the white blood cells that serve as the primary defense against infection, and mucositis, which is the inflammation and sloughing of the mucous membranes lining the digestive tract. Animals treated with uproleselan and chemotherapy had less severe neutropenia and mucositis and lower bone marrow toxicity as compared to animals treated with chemotherapy alone. GlycoMimetics believes that treatment with uproleselan results in lower bone marrow toxicity due to its inhibition of E-selectin, this inhibition makes stem cells in the bone marrow divide less frequently, thereby protecting them from chemotherapy agents that target rapidly dividing cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2018, GlycoMimetics dosed the first patient in a Phase 3 clinical trial to evaluate uproleselan in adults with relapsed/refractory AML. In 2021, GlycoMimetics completed enrollment of 388 patients in a randomized, double-blind, placebo-controlled Phase 3 pivotal clinical trial to evaluate uproleselan in individuals with relapsed/refractory AML, the design of which was based on guidance received from the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2022, GlycoMimetics submitted a request to the FDA to amend the protocol for the trial to conduct an interim analysis and have the findings reviewed by the trial&#8217;s Independent Data Monitoring Committee, or IDMC, as blinded pooled survival data showed patients living longer than expected based on the historical benchmarks used to design the trial. The statistical plan agreed to with the FDA was for the IDMC to review efficacy and safety data at 80% of survival events, which was reached at the end of 2022. When designing the interim analysis, GlycoMimetics amended the protocol to create the opportunity to achieve unblinding at approximately 80% of survival events while maintaining the statistical integrity of the final analysis should the IDMC recommend the trial continue to the final overall events trigger. The interim analysis plan required a high statistical threshold to be met for the IDMC to recommend unblinding, reserving approximately 95% of the trial&#8217;s statistical power for the final analysis. In February&#160;2023, the IDMC reviewed the interim utility analysis and recommended that the pivotal Phase 3 clinical trial continue to the originally planned final overall survival events trigger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2024, GlycoMimetics reported topline results from the Phase 3 trial, in which uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat, or ITT, population versus chemotherapy alone. In June&#160;2024, GlycoMimetics announced comprehensive results of the Phase 3 trial. Following the announcement of the data from the Phase 3 trial, GlycoMimetics requested and held a meeting with the FDA to discuss whether any of the results summarized above could serve as a basis for a submission for regulatory approval. Based on the feedback received, GlycoMimetics concluded that any potential regulatory path for uproleselan in this patient population would require an additional clinical trial, the conduct of which would require capital resources beyond those available to GlycoMimetics. The decision to not conduct an additional clinical trial did not relate to any safety or medical issues or negative regulatory feedback related to GlycoMimetics&#8217; programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">GlycoMimetics also entered into a Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute, or NCI, part of the National Institutes of Health, to conduct a Phase 2/3 randomized, controlled clinical trial evaluating the addition of uproleselan to a standard chemotherapy regimen in older adults with previously untreated AML who are eligible for </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">202</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">intensive chemotherapy. On October&#160;29, 2024, GlycoMimetics announced data from the Phase 2 portion of the trial showing no statistically significant improvement in event-free survival, or EFS, for patients receiving uproleselan in combination with chemotherapy versus chemotherapy alone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GMI-1687</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics designed an innovative antagonist of E-selectin, GMI-1687, that could be a subcutaneously administered treatment. Initially developed as a potential life-cycle extension to uproleselan, GMI-1687 was being developed to broaden the clinical usefulness of an E-selectin antagonist to conditions where outpatient treatment is preferred or required. As described below, GlycoMimetics has entered into a collaboration with Apollomics (Hong Kong) Limited for the development of GMI-1687, as well as uproleselan, in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China, but GlycoMimetics is not otherwise actively developing GMI-1687.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">GlycoMimetics&#8217; Collaboration with Apollomics for Uproleselan and GMI-1687</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020, GlycoMimetics entered into an exclusive collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687 for all fields and all uses in Greater China. GlycoMimetics and Apollomics were also collaborating to advance the preclinical and clinical development of GMI-1687. In December&#160;2024 Apollomics announced that its Phase 3 bridging trial of uproleselan did not demonstrate favorable benefit and that Apollomics would be winding down the program. GlycoMimetics does not expect the collaboration and license agreement to remain in effect following the consummation of the Merger, and does not have anticipate having any material ongoing obligations under the agreement for supplying drug for any trials being conducted by Apollomics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the exclusive collaboration and license agreement, which currently remains in effect, GlycoMimetics is eligible to receive potential milestone payments totaling approximately&#160;$180.0 million based on the achievement of specified development, regulatory and commercial milestones, as well as tiered royalties ranging from the high single digits to 15% based on net sales. Apollomics will be responsible for all costs related to development, regulatory approvals and commercialization in Greater China for uproleselan and GMI-1687. GlycoMimetics&#160;retains all rights for both compounds in the rest of the world and has agreed to supply uproleselan and GMI-1687 to Apollomics pursuant to clinical and commercial supply agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has also entered into a clinical supply agreement with Apollomics under which GlycoMimetics will manufacture and supply uproleselan product to Apollomics at agreed-upon prices. Apollomics has the option to begin manufacture after appropriate material transfer requirements are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020, the China National Medical Products Administration, or NMPA,&#160;Center for Drug Evaluation, or CDE, granted IND approval for uproleselan (also referred to as APL-106), enabling the initiation of a Phase 1 PK and tolerability study. The IND approval also included acceptance of a Phase 3 bridging study of APL-106 in combination with chemotherapy in relapsed/refractory AML. In January&#160;2021, APL-106 was granted Breakthrough Therapy designation from the China NMPA CDE for the treatment of relapsed/refractory acute myeloid leukemia. In January&#160;2024, Apollomics announced the completion of enrollment in the Phase 3 bridging study. A total of 140 adult patients across 20 sites in Greater China with primary refractory AML or relapsed AML (first or second untreated relapse) and eligible to receive induction chemotherapy were randomized to receive either uproleselan combined with chemotherapy or placebo plus chemotherapy. The primary endpoint for the Phase 3 bridging study is overall survival. Secondary outcome measures include the rate and duration of remission and whether uproleselan can reduce the rate of oral mucositis, a chemotherapy-related side effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics and Apollomics established a joint development committee to oversee activities under the collaboration and license agreement. The collaboration and license agreement will terminate on a region-by-region basis upon the expiration of the royalty term for each region, unless earlier terminated by either party. Either party may terminate the collaboration and license agreement upon prior written notice, subject to specified conditions, including uncured material breach, or upon bankruptcy or insolvency of the other party. Apollomics may terminate the collaboration and license agreement upon prior written notice for any reason. As noted above, in December&#160;2024 Apollomics announced that its Phase 3 bridging trial of uproleselan did not demonstrate favorable benefit and that Apollomics would be winding down the program. GlycoMimetics does not expect the collaboration and license agreement to remain in effect following the consummation of the Merger, and GlycoMimetics does not anticipate having any material ongoing obligations under the agreement for supplying drug for any trials being conducted by Apollomics.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">203</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics strives to protect the intellectual property that GlycoMimetics believes is important to its business, including seeking and maintaining patent protection intended to cover the composition of matter of its drug candidates and their methods of use. GlycoMimetics has issued patents which cover uproleselan and methods of use that are expected to expire between 2032 and 2039. In addition, GlycoMimetics has several pending patent applications covering uproleselan and/or methods of using it, the last expiring of which, if issued, currently would be predicted to expire in 2041. GlycoMimetics also has two issued patents covering GMI-1687 that are expected to expire in 2037. In addition, GlycoMimetics has several pending patent applications covering GMI-1687 and/or methods of using it, the last expiring of which, if issued, currently would be predicted to expire in 2041. GlycoMimetics also has several pending patent applications directed to its lead galectin antagonist compounds and their methods of use, the last of which, if issued, currently would be predicted to expire in 2042. GlycoMimetics has also relied on trade secret protection for its confidential and proprietary information and careful monitoring of such information to protect aspects of its business, as well as know-how and continuing technological innovation to develop, strengthen and maintain its proprietary position in the field of glycomimetics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics were to resume its historical business of drug development, GlycoMimetics&#8217; success would depend significantly on its ability to obtain and maintain patent and other proprietary protection for commercially important inventions and know-how related to its business, defend and enforce its patents, preserve confidentiality of its trade secrets and operate without infringing valid and enforceable patents and other proprietary rights of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A third party may hold intellectual property, including patent rights that are important or necessary to the development of GlycoMimetics&#8217; drug candidates. It may be necessary for GlycoMimetics to use the patented or proprietary technology of third parties to commercialize its drug candidates, in which case GlycoMimetics would be required to obtain a license from these third parties. If GlycoMimetics is not able to obtain such a license, or is not able to obtain such a license on commercially reasonable terms, its business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent positions of biotechnology companies like GlycoMimetics are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance, including where a reissue application is filed in relation to an issued patent to correct issues or errors arising during prosecution that may render claims of the issued patent either wholly or partially invalid or unenforceable. Consequently, GlycoMimetics does not know whether any of its drug candidates will be protectable or remain protected by enforceable patents. GlycoMimetics cannot predict whether the patent applications GlycoMimetics is currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that GlycoMimetics holds may be challenged, circumvented or invalidated by third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18&#160;months, and since publication of discoveries in scientific or patent literature often lags behind actual discoveries, GlycoMimetics cannot be certain of the priority of inventions covered by pending patent applications. Moreover, GlycoMimetics may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office, or USPTO, or a foreign patent office to determine priority of invention or in post-grant challenge proceedings, such as oppositions, that challenge priority of invention or other features of patentability. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to GlycoMimetics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics does not have any manufacturing facilities or personnel. GlycoMimetics relied on third parties for the manufacturing of its drug candidates for preclinical and clinical testing, as well as for potential commercial manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2024, GlycoMimetics entered into a project agreement with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific, or Patheon, for manufacture and supply of uproleselan for commercial sale. Pursuant to the agreement, Patheon was to manufacture commercial supplies of injectable uproleselan from active pharmaceutical ingredients GlycoMimetics supplies, and was also to be responsible for supplying the other required raw materials and other supportive manufacturing services such as quality control testing for raw materials, packaging components and finished product. The initial term of the agreement is through&#160;year-end 2026; however, following GlycoMimetics&#8217; decision to cease the development and potential commercialization of uproleselan GlycoMimetics has paused all activities under this project agreement and expects that it may be terminated following the consummation of the Merger with Crescent.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">204</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to entering into the agreement with Crescent for the Merger, GlycoMimetics had not yet established a sales, marketing or drug distribution infrastructure. GlycoMimetics generally retained commercial rights in the United States for its drug candidates. If GlycoMimetics were to resume drug development activities, then subject to receiving marketing approvals, GlycoMimetics believes that it would be possible for GlycoMimetics to access the U.S. market for those drug candidates through a focused, specialized, key account sales force. GlycoMimetics believes that such an organization would be able to target the community of physicians who are the key specialists in treating the patient populations for which its drug candidates were being developed. With respect to uproleselan and GMI-1687, GlycoMimetics granted Apollomics exclusive commercialization rights in Greater China. GlycoMimetics would expect to enter into distribution and other marketing arrangements with third parties for any other drug candidates that obtain marketing approval outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While GlycoMimetics believes that its technology, knowledge, experience and scientific resources have in the past provided it with competitive advantages, GlycoMimetics would face potential competition from many different sources, including large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, and medical technology companies, in the event that GlycoMimetics resumes its drug development activities. Any product candidates that GlycoMimetics successfully develops and commercializes would compete with existing therapies and new therapies that may become available in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If GlycoMimetics resumes its development activities and seek any regulatory approvals and pursue commercialization, GlycoMimetics believes that the key competitive factors affecting success of its drug candidates are likely to be their safety, efficacy, convenience, price, generic competition, and availability of coverage and reimbursement from government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of the companies against which GlycoMimetics would compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than GlycoMimetics does. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of GlycoMimetics&#8217; competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors would also compete with GlycoMimetics in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, its programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation and Product Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States, at the federal, state and local levels, and in other countries, extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products, such as those GlycoMimetics is developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">United States Government Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic (&#8220;FDCA&#8221;), and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the drug development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending new drug applications, or NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">205</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before a drug may be marketed in the United States generally involves:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of human clinical trials, including adequate and well-controlled clinical trials, in accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug for each indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an NDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices, or cGMP, and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity, as well as satisfactory completion of an FDA inspection of selected clinical sites to determine GCP compliance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the NDA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Preclinical Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must continue to oversee the clinical trial while it is being conducted. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their ClinicalTrials.gov website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined. In Phase 1, the drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an initial indication of its effectiveness. In Phase 2, the drug typically is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. In Phase 3, the drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the safety and efficacy of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">206</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted, at least annually, to the FDA, and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements, or if the drug has been associated with unexpected serious harm to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Marketing Approval</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has agreed to certain performance goals regarding the timing of its review of an application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, under the Pediatric Research Equity Act, an NDA or supplement to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans and elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA conducts a preliminary review of all NDAs within the first 60&#160;days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA typically refers questions regarding novel drugs to an external advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The testing and approval process for an NDA requires substantial time, effort and financial resources, and could take several&#160;years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval of an NDA on a timely basis, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">207</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Special FDA Expedited Review and Approval Programs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has various programs, including fast track designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and the FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six&#160;months, rather than the standard review of 10&#160;months under current PDUFA guidelines. These six- and ten-month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two&#160;months to the timeline for review and decision from the date of submission. Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval. Such products may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. Alternatively, the approval may be on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. Approvals may also take into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A sponsor can also request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. GlycoMimetics may explore some of these opportunities for its product candidates as appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Post-Approval Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications, manufacturing changes or other labeling claims, are subject to further testing requirements and prior FDA review and approval. There also are continuing annual user fee requirements for any marketed products, as well as application fees for supplemental applications with clinical data.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">208</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, including a boxed warning, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications, pharmaceutical companies generally are required to promote their drug products only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Drug Supply Chain Security Act and state laws that limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Federal and State Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state healthcare laws and regulations restrict business practices in the biopharmaceutical industry. These laws include, but are not limited to, anti-kickback and false claims laws and regulations, data privacy and security, and transparency laws and regulations.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">209</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting some common activities from prosecution, the exemptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare-covered business, the statute has been violated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The reach of the federal Anti-Kickback Statute was also broadened by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively PPACA, which, among other things, amended the intent requirement of the federal Anti-Kickback Statute such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or the civil monetary penalties statute, which imposes penalties against any person or entity who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Federal false claims laws, including the federal civil False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Companies also have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non-reimbursable, uses. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, GlycoMimetics may be subject to data privacy and security regulation by both the federal government and the states in which GlycoMimetics conducts its business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, imposes specified requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities (or other business associates) that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity, and their covered subcontractors. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which are not pre-empted by HIPAA, differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">210</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, as well as state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of GlycoMimetics&#8217; business activities could be subject to challenge under one or more of such laws. If GlycoMimetics&#8217; operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to GlycoMimetics, GlycoMimetics may be subject to significant penalties, including administrative, criminal and civil monetary penalties, damages, fines, disgorgement, imprisonment, additional reporting requirements and oversight if GlycoMimetics becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare programs and the curtailment or restructuring of GlycoMimetics&#8217; operations, any of which could adversely affect its ability to operate its business and its results of operations. To the extent that any of its products are sold in a foreign country, GlycoMimetics may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Coverage and Reimbursement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The future commercial success of GlycoMimetics&#8217; drug candidates or any of its collaborators&#8217; ability to commercialize any approved drug candidates successfully will depend in part on the extent to which governmental payor programs at the federal and state levels, including Medicare and Medicaid, private health insurers and other third-party payors provide coverage for and establish adequate reimbursement levels for its drug candidates. Government health administration authorities, private health insurers and other organizations generally decide which drugs they will pay for and establish reimbursement levels for healthcare. In particular, in the United States, private health insurers and other third-party payors often provide reimbursement for products and services based on the level at which the government, through the Medicare or Medicaid programs, provides reimbursement for such treatments. In the United States, the European Union, or EU, and other potentially significant markets for GlycoMimetics&#8217; drug candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which often has resulted in average selling prices lower than they would otherwise be. Further, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect GlycoMimetics&#8217; future product sales and results of operations. These pressures can arise from rules&#160;and practices of managed care groups, judicial decisions and laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical coverage and reimbursement policies and pricing in general.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third-party payors are increasingly imposing additional requirements and restrictions on coverage and limiting reimbursement levels for medical products. For example, federal and state governments reimburse covered prescription drugs at varying rates generally below average wholesale price. These restrictions and limitations influence the purchase of healthcare services and products. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drug products for a particular indication. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. GlycoMimetics may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of its products, in addition to the costs required to obtain the FDA approvals. GlycoMimetics&#8217; drug candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party reimbursement may not be available to enable GlycoMimetics to maintain price levels sufficient to realize an appropriate return on its investment in drug development. Legislative proposals to reform healthcare or reduce costs under government insurance programs may result in lower reimbursement for GlycoMimetics&#8217; drugs and drug candidates or exclusion of GlycoMimetics&#8217; drugs and drug candidates from coverage. The cost containment measures that healthcare payors and providers are instituting and any healthcare reform could significantly reduce GlycoMimetics&#8217; revenues from the sale of any approved drug candidates. GlycoMimetics cannot provide any assurances that GlycoMimetics will be able to obtain and maintain third-party coverage or adequate reimbursement for its drug candidates in whole or in part.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">211</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Impact of Healthcare Reform on GlycoMimetics&#8217; Business</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The United States and some foreign jurisdictions are considering enacting or have enacted a number of additional legislative and regulatory proposals to change the healthcare system in ways that could affect GlycoMimetics&#8217; ability to sell its products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts, which include major legislative initiatives to reduce the cost of care through changes in the healthcare system, including limits on the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There have been several U.S. government initiatives over the past few&#160;years to fund and incentivize certain comparative effectiveness research, including creation of the Patient-Centered Outcomes Research Institute under PPACA. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of any product, if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#8217;s product could adversely affect the sales of GlycoMimetics&#8217; product candidates. If third-party payors do not consider GlycoMimetics&#8217; drug candidates to be cost-effective compared to other available therapies, they may not cover its drug candidates, once approved, as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow GlycoMimetics to sell its drugs on a profitable basis. The PPACA substantially changed the way healthcare is financed by both governmental and private insurers. Among other measures that may have an impact on GlycoMimetics&#8217; business, PPACA established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; a new Medicare Part&#160;D coverage gap discount program; and a new formula that increases the rebates a manufacturer must pay under the Medicaid Drug Rebate Program. Additionally, PPACA extends manufacturers&#8217; Medicaid rebate liability, expands eligibility criteria for Medicaid programs and expands entities eligible for discounts under the Public Health Service pharmaceutical pricing program. There have been judicial and Congressional challenges to certain aspects of PPACA, as well as efforts by the executive branch at various times to repeal or replace certain aspects of the PPACA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been judicial, administrative, executive, and Congressional legislative challenges to certain aspects of the PPACA. For example, in August&#160;2022, the Inflation Reduction Act of 2022, or IRA was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan&#160;year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part&#160;D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how any such challenges and additional reform measures of the second Trump administration will impact the PPACA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, the IRA, among other things (i)&#160;directs the U.S. Department of Health and Human Services, or HHS, to negotiate the price of certain high-expenditure, single-source drugs that have been on the market for at least seven&#160;years and covered under Medicare, known as the Medicare Drug Price Negotiation Program, and (ii)&#160;imposes rebates under Medicare Part&#160;B and Medicare Part&#160;D to penalize price increases that outpace inflation. These provisions began to take effect progressively in fiscal&#160;year 2023. In August&#160;2024, HHS announced the agreed-upon prices of the first 10 drugs that were subject to price negotiations, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. On January&#160;17, 2025, HHS selected fifteen additional drugs covered under Part&#160;D for price negotiation in 2025. Each&#160;year thereafter more Part&#160;B and Part&#160;D products will become subject to the Medicare Drug Price Negotiation Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, on December&#160;7, 2023, an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act was announced. On December&#160;8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">212</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January&#160;5, 2024, the FDA approved Florida&#8217;s Section&#160;804 Importation Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of PPACA, Medicare payments are increasingly tied to quality of care and value measures, and reporting of related data by providers such as physicians and hospitals. So-called &#8220;value-based reimbursement&#8221; measures may present challenges as well as potential opportunities for biopharmaceutical manufacturers. Medicare incentives for providers meeting certain quality measures may ultimately prove beneficial for manufacturers that are able to establish that their products may help providers to meet such measures. However, manufacturers&#8217; ability to market their drug products based on quality or value is highly regulated and not always permissible. In addition, the potentially decreased Medicare reimbursement to those providers that fail to adequately comply with quality reporting requirements could translate to decreased resources available to purchase products and may negatively impact marketing or utilization of GlycoMimetics&#8217; drug candidates if they are approved for marketing. GlycoMimetics cannot predict at this time what impact, if any, the longer-term shift towards value-based reimbursement will have on any of its drug candidates in either the Medicare program, or in any other third-party payor programs that may similarly tie payment to provider quality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additional legislative proposals to reform healthcare and government insurance programs, along with the trend toward managed healthcare in the United States, could influence the purchase of medicines and reduce reimbursement and/or coverage of GlycoMimetics&#8217; product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Exclusivity and Approval of Competing Products</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Hatch-Waxman Patent Listing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug application, or ANDA, or 505(b)(2)&#160;NDA. Generally, an ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths, dosage form and route of administration as the listed drug and has been shown to be bioequivalent through <i style="font-style:italic;">in vitro </i>or <i style="font-style:italic;">in vivo </i>testing or otherwise to the listed drug. ANDA applicants are not required to conduct or submit results of preclinical or clinical tests to prove the safety or efficacy of their drug product, other than the requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug. 505(b)(2)&#160;NDAs generally are submitted for changes to a previously approved drug product, such as a new dosage form or indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ANDA or 505(b)(2)&#160;NDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. Specifically, the applicant must certify with respect to each patent that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the required patent information has not been filed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent has expired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the listed patent is invalid, unenforceable or will not be infringed by the new product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, the ANDA or 505(b)(2)&#160;NDA cannot be approved until all listed patents have expired, except when the ANDA or 505(b)(2)&#160;NDA applicant challenges a listed drug. A certification that the proposed product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2)&#160;NDA application will not be approved until all the listed patents claiming the referenced product have expired.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">213</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the ANDA or 505(b)(2)&#160;NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45&#160;days after the receipt of notice of the Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2)&#160;NDA until the earlier of 30&#160;months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Hatch-Waxman Non-Patent Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Market and data exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications for competing products. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the activity of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2)&#160;NDA submitted by another company that contains the previously approved active moiety. However, an ANDA or 505(b)(2)&#160;NDA may be submitted after four&#160;years if it contains a certification of patent invalidity or noninfringement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDCA also provides three&#160;years of marketing exclusivity for an NDA, 505(b)(2)&#160;NDA or supplement to an existing NDA or 505(b)(2)&#160;NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant, are deemed by the FDA to be essential to the approval of the application or supplement. Three-year exclusivity may be awarded for changes to a previously approved drug product, such as new indications, dosages, strengths or dosage forms of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and, as a general matter, does not prohibit the FDA from approving ANDAs or 505(b)(2)&#160;NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Orphan Drug Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug or biological product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA or biologics license application. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a product that has orphan designation subsequently receives the first FDA approval for such drug for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. If a drug or biological product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity. Orphan drug status in the EU has similar, but not identical, benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Pediatric Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six&#160;months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan drug exclusivity periods described above. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or Orange Book listed patent protection cover the drug are extended by six&#160;months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">214</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">an ANDA or 505(b)(2)&#160;application owing to regulatory exclusivity or listed patents. If any of its drug candidates is approved, GlycoMimetics anticipates seeking pediatric exclusivity when it is appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Foreign Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to market any product outside of the United States, GlycoMimetics would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of its drug candidates. For example, in the EU, GlycoMimetics must obtain authorization of a clinical trial application, or CTA, in each member state in which GlycoMimetics intends to conduct a clinical trial. Whether or not GlycoMimetics obtains FDA approval for a drug, GlycoMimetics would need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before GlycoMimetics can commence clinical trials or marketing of the drug in those countries. The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employees and Human Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2024, in connection with its streamlined operating plan, GlycoMimetics announced a corporate restructuring that included a reduction in its workforce by 26 employees, or approximately 80% of its headcount. GlycoMimetics substantially completed the reduction in the third quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of January&#160;31, 2025, GlycoMimetics had four full-time employees, all of whom are located in the United States. None of GlycoMimetics&#8217; employees is represented by a labor union or covered by a collective bargaining agreement. GlycoMimetics considers its relationship with its employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to GlycoMimetics&#8217; corporate restructuring and the ceasing of its drug development activities, GlycoMimetics&#8217; human capital resources objectives included, as applicable, identifying, recruiting, retaining, incentivizing and integrating its existing and new employees. The principal purposes of GlycoMimetics&#8217; equity incentive plans were to attract, retain and reward high performing employees through the granting of equity-based compensation awards in order to motivate employees to perform to the best of their abilities and achieve GlycoMimetics&#8217; objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics was incorporated under the laws of the State of Delaware in 2003. GlycoMimetics&#8217; executive officers and employees work remotely, and its mailing address is P.O.&#160;Box 65, Monrovia, MD 21770. GlycoMimetics&#8217; telephone number is (240) 243-1201.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;GlycoMimetics,&#8221; the GlycoMimetics logo and other trademarks or service marks of GlycoMimetics,&#160;Inc. appearing in this proxy statement/prospectus are the property of GlycoMimetics,&#160;Inc. This proxy statement/prospectus contains additional trade names, trademarks and service marks of others, which are the property of their respective owners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; internet website address is www.glycomimetics.com. In addition to the information contained in this proxy statement/prospectus, information about GlycoMimetics can be found on its website. GlycoMimetics&#8217; website and information included in or linked to its website are not part of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended, are available free of charge through its website as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission, or SEC. Additionally the SEC maintains an internet site that contains reports, proxy and information statements and other information. The address of the SEC&#8217;s website is www.sec.gov.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">215</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0f9a49db_9a8d_40b5_918d_b2daf82ff325"></a><a id="CRESCENTSBUSINESS_189691"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT&#8217;S BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">All references to Crescent&#8217;s &#8220;product candidates,&#8221; &#8220;programs,&#8221; &#8220;portfolio&#8221; and &#8220;pipeline&#8221; in this proxy statement/prospectus refer to the research programs with respect to which Crescent has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements. While Crescent has not yet entered into an option agreement for the CR-003 program, Crescent expects to amend the ADC Paragon Option Agreement to include CR-003 prior to the time that this registration statement on Form&#160;S-4 is declared effective by the SEC.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody, which Crescent believes has the potential to deliver improved clinical efficacy and safety over pembrolizumab, marketed by Merck as Keytruda&#174;, the best-selling drug in the world and approved for the treatment of numerous cancers. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, an anti-PD-1/anti-VEGF bispecific antibody in development by Akeso Biopharma and Summit Therapeutics Inc. that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer (&#8220;NSCLC&#8221;). Crescent believes the emerging data from the clinical development of ivonescimab allows for the acceleration of the development of CR-001. Following the precedents set by traditional PD-1 inhibitors, such as Keytruda and Opdivo&#174;, Crescent plans to systematically seek regulatory approvals for CR-001 to treat multiple solid tumor indications, utilizing monotherapies and combination treatment options. Crescent intends to submit an IND application to the FDA for CR-001 in the fourth quarter of 2025, with initial clinical data anticipated in the second half of 2026. Crescent plans to complement CR-001 with a portfolio of product candidates that have potential activity against solid tumors both as a monotherapy as well as in combination with CR-001.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immune checkpoint inhibitors have revolutionized the treatment landscape for various solid tumors by reactivating the body&#8217;s immune system to target and destroy cancer cells. These inhibitors, which are antibodies against targets such as CTLA-4 and PD-1/PD-L1, have shown unprecedented anti-tumor activity, and have become standard-of-care treatments for a number of malignancies, including advanced metastatic melanoma and microsatellite instability-high tumors. These inhibitors have led to significant clinical outcomes, with notable improvements in survival rates and durable responses in patients who previously had limited treatment options. These products have also been successful commercially, with worldwide sales estimated to be in excess of $50 billion, over half of which are driven by sales of Keytruda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although checkpoint inhibitors are highly effective in some patients, many patients with solid tumors fail to respond to these therapies. Furthermore, patients who do respond do not always achieve long-lasting benefit. There have been broad efforts by the pharmaceutical industry to identify immuno-oncology products able to address this unmet clinical need. Ivonescimab is the first drug candidate to demonstrate improved clinical efficacy compared to pembrolizumab (Keytruda) in a head-to-head Phase 3 clinical trial for the treatment of na&#239;ve, or not previously treated, advanced and metastatic NSCLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CR-001 was designed to build upon the success of ivonescimab through the creation of a proprietary anti-PD-1/anti-VEGF bispecific antibody designed to mimic the PD-1 and VEGF binding and functional activity of ivonescimab, with additional proprietary design focused on stability and manufacturability. Unlike traditional antibody drug products, such as the marketed anti-PD-1 and anti-VEGF antibodies, the bispecific binding of CR-001 to its targets is cooperative. Binding of VEGF, an angiogenic growth factor that stimulates the growth of blood vessels and is overexpressed in many tumors, to CR-001 leads to the formation of molecular complexes through polymerization of CR-001. This increases its binding to PD-1 on immune cells and is designed to lead to more potent antitumor activity. Results from the ivonescimab Phase 3 trial in NSCLC showed that, compared to pembrolizumab, not only was there a significant improvement in overall progression-free survival (&#8220;PFS&#8221;) in the treated population, but that these benefits extended to patients with tumors that had low levels of PD-L1 expression, a class of patients where response to anti-PD-1 therapy has historically been modest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent plans to submit an IND for CR-001 in the fourth quarter of 2025 followed thereafter by commencement of a Phase 1 trial. Because the properties of CR-001 are closely aligned with those of ivonescimab, Crescent intends to apply clinical findings from ivonescimab to design the CR-001 Phase 1 trial such that it has the potential to serve as strong validation for the clinical potential of CR-001. Crescent anticipates results from this trial to be available in the second half of 2026, setting the stage for pivotal trials in multiple solid tumors.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">216</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:220.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The range of solid tumor indications for which PD-1/PD-L1 checkpoint inhibitors or VEGF inhibitors have been approved is vast, numbering over thirty. Multiple inhibitors in both of these classes are approved for the treatment of solid tumors, generating revenue of many tens of billions. A new therapy that demonstrates superior efficacy in one or more of these indications could participate in this market in a significant way. Crescent believes that ivonescimab and anti-PD-1/anti-VEGF bispecific antibodies that share the precise cooperative mechanism of ivonescimab, such as CR-001, have the potential to do this. Although, to date, the superiority of ivonescimab over pembrolizumab has been demonstrated only in treatment-na&#239;ve advanced and metastatic NSCLC, clinical experience with checkpoint inhibitors suggests that molecules that enhance checkpoint inhibition, such as ivonescimab and CR-001, may improve antitumor responses in other solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Key to maximizing the clinical and commercial success of other PD-1/PD-L1 checkpoint pathway inhibitors is their use in combination with other therapies, including other immunotherapies. This is best illustrated by Opdivo, a PD-1 inhibitor, and Yervoy&#174;, a CTLA-4 inhibitor, both marketed by Bristol Myers Squibb. This combination of immuno-oncology drugs is approved by the FDA for treating various cancers, including metastatic melanoma, advanced renal cell carcinoma, and certain types of colorectal cancer. Crescent plans to follow this model by developing CR-001 both as a monotherapy and in combination with molecules that target different mechanisms of action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is advancing its second and third programs, CR-002 and CR-003, which are ADCs against validated oncology targets. Crescent&#8217;s plan is to use these ADCs to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001. The identity of the targets of these ADCs will be disclosed as they advance, which is expected in mid-2026 for CR-002.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent believes that bispecific anti-PD-1/anti-VEGF molecules, such as CR-001, have the potential to displace leading traditional checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 inhibitors, which represent some of the most successful drugs in the market. The combination of CR-001 with wholly owned products, such as those Crescent expects to develop from its CR-002 and CR-003 programs, provides the opportunity for Crescent to command a significant share of this emerging market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Crescent&#8217;s Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="glyc-20241231xs4027.jpg" alt="Graphic" style="display:inline-block;height:220.05pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:468.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Crescent&#8217;s Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s goal is to establish CR-001 as the backbone for the treatment of a broad set of solid tumors. Crescent plans to complement CR-001 with a portfolio of product candidates that have potential monotherapy activity as well as combination activity with CR-001. Crescent&#8217;s strategy is to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Obtain clinical proof-of-concept data with CR-001 in a Phase 1 trial</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The similarity in binding and functional properties of CR-001 with ivonescimab provides Crescent with the opportunity to design a Phase 1 trial of CR-001 based on the clinical </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">217</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">profile of ivonescimab. Crescent believes that, because CR-001 replicates the functional properties of ivonescimab, early clinical data from ivonescimab can serve as important validation of potential efficacy and safety of both, thereby allowing Crescent to move quickly into late-stage development with a level of speed and confidence that would not exist if CR-001 did not mimic the PD-1 and VEGF binding affinity, potency, and cooperativity of ivonescimab.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Develop CR-001 in multiple indications</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Crescent has identified a number of solid tumors in which PD-1 checkpoint inhibitors and VEGF inhibitors have demonstrated clinical activity. Crescent intends to develop CR-001 in multiple solid tumors, prioritized based on existing clinical evidence for the potential of CR-001, the size of the market opportunity, and the feasibility to streamline the generation of the data that Crescent believes will be sufficient to obtain regulatory approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Advance Crescent&#8217;s internal ADC programs into clinical development</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Crescent is developing two ADC programs, CR-002 and CR-003, against validated oncology targets. Crescent believes that each of these programs has the potential to provide therapeutic benefit when used as a monotherapy and in combination with CR-001. Crescent intends to disclose the identity of the molecular targets for these programs as the programs advance.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Develop CR-001 in combination with a portfolio of internal drug candidates</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Crescent believes that, similar to traditional PD-1 checkpoint inhibitors, CR-001 has the potential to have meaningful clinical activity both as a monotherapy and in combination with other therapies. Crescent believes that the ability to combine CR-001 with current and future internal drug candidates provides it with a distinct competitive advantage.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Expand its portfolio of product candidates</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Crescent will consider opportunities to expand its pipeline by obtaining access to additional product candidates that have potential activity against solid tumors both as a monotherapy and in combination with CR-001.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Limitations of current immune checkpoint inhibitors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immune checkpoint inhibitors have revolutionized the treatment of cancer, offering new hope to patients with previously limited options. These groundbreaking therapies work by reactivating the body&#8217;s own immune system to target and destroy cancer cells. Checkpoint inhibitors, such as CTLA-4 and PD-1/PD-L1 inhibitors, have demonstrated unprecedented anti-tumor activity, and have become standard treatments for various malignancies, including advanced metastatic melanoma, NSCLC, renal cell carcinoma, and microsatellite instability-high tumors. These inhibitors have led to significant clinical outcomes, with notable improvements in survival rates and durable responses in patients who previously had only limited treatment options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The remarkable impact of immune checkpoint inhibitors on cancer treatment is reflected in their commercial success. For example, Yervoy, a CTLA-4 inhibitor that was approved in 2011, achieved worldwide sales of $2.2 billion in 2024. Keytruda, a PD-1 inhibitor, has received 40 FDA approvals and 30 European Commission approvals in a variety of different indications. Worldwide sales of Keytruda in 2024 were $29.5 billion. Despite the commercial dominance of Keytruda, at least six other PD-1/PD-L1 inhibitors have been approved by the FDA, including two that received initial approvals in 2024. Sales of this class of checkpoint inhibitors continue to grow&#160;year-over-year, with worldwide sales in 2024 estimated to be $51 billion.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">218</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:278.2pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="glyc-20241231xs4028.jpg" alt="Graphic" style="display:inline-block;height:278.2pt;width:468.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 1. Global sales of PD-1/PD-L1 inhibitors</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite these therapies&#8217; remarkable success, only a fraction of patients treated with checkpoint inhibitors obtain meaningful benefit. For example, treatment of patients with unresectable or metastatic melanoma with pembrolizumab resulted in a 6% complete response (&#8220;CR&#8221;) rate, and a 27% partial response (&#8220;PR&#8221;) rate. A meta-analysis of 91 clinical trials found that the objective response rate to checkpoint inhibitors was less than 20%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Multiple approaches have been taken to improve this response rate, including the clinical testing of potential therapies against other immune checkpoint targets, and combination therapies. Emerging targets, such as LAG-3, TIM-3, and TIGIT, are being evaluated in preclinical studies and clinical trials, with the hope of providing additional options for patients with refractory or resistant cancers. However, none of these approaches has yet demonstrated clinical efficacy as a monotherapy that matches the established success rates of PD-1/PD-L1 inhibitors. More promising results have been obtained when these agents are combined with PD-1/PD-L1 inhibitors. For example, Opdualag&#174;, a fixed dose combination of relatlimab, a LAG-3 inhibitor, and nivolumab, was approved in 2022 for the treatment of unresectable or metastatic melanoma. The overall response rate with the combination drug in the RELATIVITY-047 trial was 43% versus 33% with nivolumab monotherapy. Combination with other agents thus offers new and potentially profound improvement in the ability of checkpoint inhibitors to meaningfully impact more patients and more tumor types.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The breakthrough potential of ivonescimab, an anti-PD-1/anti-VEGF bispecific molecule</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ivonescimab, a cooperative anti-PD-1/anti-VEGF bispecific molecule, has demonstrated promising clinical results that highlight its breakthrough potential in oncology. Ivonescimab was designed to synergistically combine the mechanisms of angiogenesis inhibition and immune checkpoint blockade in a single molecule by targeting both PD-1 and VEGF pathways. In a Phase 3 clinical trial in NSCLC, ivonescimab demonstrated a statistically significant and clinically meaningful improvement in PFS compared to pembrolizumab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">HARMONi-2 is a randomized, double-blind Phase 3 trial sponsored by Akeso Biopharma comparing the efficacy of ivonescimab with pembrolizumab as first-line treatment with PD-L1 expressing locally advanced or metastatic NSCLC. Both ivonescimab and pembrolizumab were dosed by intravenous infusion every three weeks. A planned interim analysis found that patients treated with ivonescimab had a statistically significant improvement in median PFS of 5.3&#160;months compared to pembrolizumab, with p&lt;0.0001. Ivonescimab-treated patients had a median PFS of 11.1&#160;months, compared to 5.8&#160;months with pembrolizumab. The median PFS of pembrolizumab in this trial is consistent with the 5.4&#160;month PFS observed in the pembrolizumab monotherapy arm of the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">219</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:249pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">KEYNOTE-042 trial conducted in a similar patient population, providing additional support for observed improved efficacy of ivonescimab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="glyc-20241231xs4029.jpg" alt="Graphic" style="display:inline-block;height:248.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:468.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 2. Ivonescimab monotherapy led to an improvement in median progression-free survival or mPFS over pembrolizumab as a first-line treatment in advanced and metastatic NSCLC</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to this improvement in PFS over pembrolizumab, two other observations from this trial highlight the potential of ivonescimab. First is that improved benefit was observed in patients where pembrolizumab has historically had modest efficacy. This includes patients with low levels of PD-L1 expression and in squamous cell tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="glyc-20241231xs4030.jpg" alt="Graphic" style="display:inline-block;height:79.5pt;width:341pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 3. Ivonescimab provided improved PFS compared to pembrolizumab including in patients with low levels of PD-L1 expression and in squamous cell cancers, both of which have historically been associated with poor response to pembrolizumab. The benefits of ivonescimab are represented by the hazard ratio, a statistical measure of the relative risk of disease progression in patients in separate groups. A hazard ratio of 0.54 means that ivonescimab-treated patients had a 46% lower chance of disease progression than those treated with pembrolizumab. PD-L1 expression was assessed by the Tumor Proportion Score, or TPS, which quantifies the&#160;percentage of viable tumor cells showing partial or complete membrane staining of PD-L1.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Second, treatment with ivonescimab was well-tolerated with the frequency and severity of immune-related adverse events comparable to those observed in the pembrolizumab arm. Clinical experience in NSCLC with anti-VEGF inhibitors, such as bevacizumab, identified serious adverse events, including fatal pulmonary hemorrhage, that have limited the number of patients eligible for treatment. Other adverse events associated with bevacizumab include proteinuria and hypertension. The majority of these VEGF-related adverse events were Grade 1 or Grade 2 in the data presented from the interim analysis of the HARMONi-2 trial. There were no adverse events greater than Grade 3. The frequency of Grade 3 events were 1% hemorrhage, 3% proteinuria, and 5% hypertension. There were no increases in treatment discontinuation or death associated with ivonescimab compared to pembrolizumab.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">220</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:142.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our solution, CR-001</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CR-001 is a bispecific antibody designed by Paragon to build upon the transformative clinical efficacy observed with ivonescimab by replicating its functional properties with a proprietary new molecule. Crescent plans to submit an IND for CR-001 in the fourth quarter of 2025 followed by a Phase 1 trial, with results expected in the second half of 2026 in patients with solid tumors. Crescent intends to incorporate insights from clinical results of ivonescimab in the design of this trial to obtain early clinical proof-of-concept efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The rationale for targeting PD-1 and VEGF</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Both PD-1 and VEGF are targets of approved drugs for multiple indications. However, the potential for combining the inhibition of both targets is not widely appreciated. Data from The Cancer Genome Atlas indicates that these targets are co-expressed in various human tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">VEGF is well-recognized for its angiogenesis-inducing activity, promoting the formation of new blood vessels to help tumors overcome oxygen deficits and nutrient starvation. However, it also has an important immunosuppressive role. VEGF can inhibit the maturation of key immune cells known as dendritic cells and promote the accumulation of another key population of immune cells, the myeloid-derived suppressor cells. Other reports indicate that blocking VEGF signaling may promote antitumor immune responses by inhibiting the accumulation of regulatory T cells. Because immunosuppressive microenvironments also drive angiogenesis, VEGF plays a central role in driving further immunosuppression. A number of preclinical studies and clinical trials have explored the potential of inhibiting both PD-1 and VEGF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The design of ivonescimab drives its efficacy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The antitumor activity of ivonescimab observed in the HARMONi-2 trial was higher than expected for the combination treatments containing both an anti-PD-1 and anti-VEGF antibody in NSCLC. For example, in the Lung-MAP S1800A trial, the combination of ramucirumab, a VEGF receptor inhibitor, and pembrolizumab led to a modest median PFS of 4.5&#160;months compared to 5.2&#160;months reported for patients treated with standard of care. In the ImPower150 trial, the addition of atezolizumab, a PD-L1 inhibitor, to a combination of bevacizumab and chemotherapy, led to a modest increase in median PFS from 6.8&#160;months to 8.3&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">In vitro</i> studies reported by scientists at Akeso Biopharma and Summit Therapeutics&#160;Inc. at the Society for Immunotherapy of Cancer conference in 2023 found that ivonescimab binding to both PD-1 and to VEGF was cooperative. Each molecule of ivonescimab is capable of binding to two PD-1 and two VEGF molecules. Due to inherent dimerization of VEGF, its binding to ivonescimab can lead to the formation of ivonescimab complexes, effectively increasing the local concentration of anti-PD-1 binding sites. Similarly, binding of ivonescimab to PD-1 on immune cells leads to a local increase in anti-VEGF binding sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="glyc-20241231xs4031.jpg" alt="Graphic" style="display:inline-block;height:142.25pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:468.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 4. VEGF binding to ivonescimab leads to the formation of ivonescimab-VEGF complexes.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The presence of both PD-1 and VEGF expressing immune cells in tumors leads to cooperative binding of ivonescimab resulting in increased binding to both targets, which is hypothesized to be the driver of increased efficacy.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">221</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:187.8pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The design of CR-001</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CR-001 is a new molecular entity designed to match the targeting, binding, cooperativity, and pharmacokinetics of ivonescimab in order to maximize the likelihood of demonstrating superior efficacy compared to approved PD-1 and PD-L1 therapies. The VEGF binding domain is that of bevacizumab, an FDA-approved anti-VEGF antibody. This domain was incorporated into CR-001 to match the VEGF binding affinity of ivonescimab, which contains the same domain. The PD-1 binding domain of CR-001 is a proprietary scFv sequence that was designed to match the affinity of the PD-1 binding domain of ivonescimab while benefiting from increased stability engineered by Paragon. Crescent has filed composition of matter claims for the CR-001 sequence based in part on Crescent&#8217;s proprietary scFv engineering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="glyc-20241231xs4032.jpg" alt="Graphic" style="display:inline-block;height:187.8pt;width:468.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 5. Structure of CR-001</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CR-001 was designed to match the pharmacokinetics of ivonescimab. Similar to ivonescimab, the IgG Fc domain of CR-001 was modified to reduce its ability to bind to Fc&#947;RIIIA, a receptor on natural killer (&#8220;NK&#8221;) cells that drives antibody dependent cellular cytotoxicity. The resulting reduction in antibody-dependent cellular cytotoxicity is designed to protect CR-001 from driving NK cell dependent destruction of T cells. The affinity of CR-001 for the FcRn receptor matches that of ivonescimab, helping to prolong its half-life in circulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">In vitro activity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ability of VEGF to drive cooperative binding of CR-001 to PD-1 was investigated in cellular assays conducted by Paragon. CR-001 led to the concentration-dependent activation of the nuclear factor of activated T cell, gene by PD-1-expressing cells upon exposure to PD-L1 expressing cells. In the presence of exogenous VEGF, the potency of CR-001 was increased by approximately 30-fold. The activity of CR-0001 in this assay closely matched that of ivonescimab, and was synthesized by Paragon based on publicly available information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="glyc-20241231xs4033.jpg" alt="Graphic" style="display:inline-block;height:163pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:468.3pt;"/></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">222</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:201pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 6. CR-001 led to cooperative binding to PD-1 in the presence of VEGF</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A direct measure of CR-001 binding to PD-1 expressed on a Jurkat T cell line showed that the increased sensitivity to T cell activation upon VEGF addition was consistent with higher binding to PD-1. In the presence of VEGF, binding of CR-001 and ivonescimab to PD-1 were both greatly enhanced, directly demonstrating the cooperative binding nature of CR-001 and ivonescimab. The presence of VEGF creates daisy chains of drug molecules so that multiple drug molecules are bound to each PD-1 molecule, increasing signal amplitude.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical potential for CR-001</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Whereas, to date, the superiority of ivonescimab over pembrolizumab has been demonstrated only in treatment-na&#239;ve advanced and metastatic NSCLC, clinical experience with checkpoint inhibitors suggests that molecules that enhance checkpoint inhibition, such as ivonescimab and CR-001, may improve antitumor responses in other solid tumors. Ivonescimab has been or is currently being investigated in clinical trials in 16 indications, and has been granted marketing approval by the China National Medical Products Administration (&#8220;NMPA&#8221;) of China for the treatment of EGFR mutated locally advanced or metastatic NSCLC patients who have progressed after EGFR TKI treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Access to solid tumor indications and the lucrative market opportunities they present is a critical objective for Crescent with CR-001. Crescent intends to prioritize the development of CR-001 in indications for which clinical evidence supports potential efficacy, and for which there is an efficient path to market, high unmet medical need, and favorable competitive intensity. This approach provides the potential to establish CR-001 as a first-in-class therapy in these indications. Crescent may also develop CR-001 in other indications where it believes that CR-001 may compete favorably with ivonescimab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="glyc-20241231xs4034.jpg" alt="Graphic" style="display:inline-block;height:201pt;width:468.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 7. PD-1/PD-L1 checkpoint inhibitors and anti-VEGF antibodies have demonstrated antitumor activity across multiple solid tumors, both as a monotherapy and in combination.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Planned clinical development of CR-001</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent plans to submit an IND for CR-001 in the fourth quarter of 2025 and then to conduct a Phase 1 trial in patients with solid tumors. Crescent believes that the similarity between CR-001 and ivonescimab will enable it to apply insights from the clinical development of ivonescimab to that of CR-001. Specifically, the company believes this prior experience will help it to obtain early proof-of-concept data in the initial Phase 1 trial as well as to accelerate its development in later-stage trials.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">223</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:152.05pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="glyc-20241231xs4035.jpg" alt="Graphic" style="display:inline-block;height:152.05pt;width:468.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 8. Outline of the clinical development plan for CR-001</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">CR-001 has the potential to serve as the core of a growing portfolio</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cancer treatment often depends on the use of combination therapies. Traditionally, these have been combinations of cytotoxic drugs. However, new treatment modalities are transforming the treatment landscape resulting in combinations of biologics. Drug candidates such as ivonescimab and CR-001 not only have the potential to improve efficacy, but they can also do so with good tolerability. This provides the opportunity to combine these drug candidates with other antitumor drugs. Ivonescimab has already demonstrated in multiple clinical trials that it can be safely dosed in combination with other anticancer drugs to deliver meaningful antitumor activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A promising advancement in cancer therapy is the use of ADCs, which are designed to combine the targeting capabilities of antibodies with the cell-killing power of cytotoxic drugs. By specifically targeting cancer cells and delivering the cytotoxic agent directly to them, ADCs can minimize damage to healthy cells and reduce side effects. An emerging therapeutic approach combines the use of ADCs and checkpoint inhibitors. Examples of synergistic activity between these two classes of biologics have been reported in cancers such as NSCLC and urogenital cancers. In December&#160;2023, the FDA approved the combination of enfortumab vedotin, an ADC targeting nectin-4, and pembrolizumab for patients with locally advanced or metastatic urothelial cancer.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">224</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:325.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="glyc-20241231xs4036.jpg" alt="Graphic" style="display:inline-block;height:324.85pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:464.25pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 9. Crescent plans to seek synergistic antitumor activity by combining CR-001 with ADCs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent plans to develop additional ADC programs, including CR-002 and CR-003, with the potential to have both monotherapy activity as well as synergistic activity with CR-001. These programs, including CR-002 and CR-003, are designed to deliver a toxin that targets topoisomerase I, a toxin that has been incorporated into multiple other product candidates, including some approved drugs. Crescent anticipates submitting an IND application for, and revealing the target of, CR-002 in mid-2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="glyc-20241231xs4037.jpg" alt="Graphic" style="display:inline-block;height:168.2pt;width:468.3pt;"/></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">225</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 10. Design of the CR-002 ADC product candidate</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Crescent&#8217;s pipeline expansion opportunities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is focused on developing additional programs that have the potential:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for a product profile to be best-in-class and best-in-indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for the product to rapidly demonstrate clinical proof-of-concept;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for broad utility across multiple solid tumor indications; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to be combined with CR-001 to provide additive or synergistic efficacy that is superior to either product alone.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Crescent&#8217;s Team, Investors, and Paragon Collaboration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent was founded in September&#160;2024 and launched to research and develop antibody and ADC candidates licensed from Paragon, an antibody discovery engine founded by Fairmount Funds Management LLC (&#8220;Fairmount&#8221;), and led by industry veterans with extensive experience in drug discovery. Crescent holds options to acquire intellectual property rights with respect to certain research programs, including CR-001 and CR-002, from Paragon. Following the exercise of the Options (defined below) under the Paragon Option Agreements and execution of the respective license agreements, Crescent will have exclusive worldwide development and commercialization rights to its programs, including two selected targets for CR-001: PD-1 and VEGF; and one undisclosed target for CR-002.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent entered into the Paragon Option Agreements with Paragon and Parascent pursuant to which Paragon agreed to perform certain research activities to discover, generate, identify, and characterize antibody or ADC candidates, as applicable, directed to the selected targets PD-1 and VEGF for CR-001, and targets for CR-002. Under the Paragon Option Agreements, Crescent has the exclusive option to, on a research program-by-research program basis, be granted (a)&#160;an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the monospecific antibodies or ADCs, as applicable, and products directed to the selected target(s), and (b)&#160;an exclusive (in the case of the Antibody Paragon Option Agreement) or non-exclusive (in the case of the ADC Paragon Option Agreement), worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize multispecific antibodies or ADCs, as applicable, and products direct to the selected target(s)&#160;(an &#8220;Option&#8221;). Crescent&#8217;s Options to acquire the intellectual property rights to the research programs under the Paragon Option Agreements, including CR-001 and CR-002, currently remain unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is led by an experienced management team. Crescent&#8217;s Chief Executive Officer and President, Jonathan Violin, Ph.D., who also serves as a Director of the Company, brings deep experience in company building, business strategy, and product development. Dr.&#160;Violin serves as a Venture Partner at Fairmount Funds and previously served as President and CEO of Viridian Therapeutics. Christopher Doughty, Crescent&#8217;s Chief Business Officer, served in a similar role at Prometheus Biosciences, and as Vice President Strategy&#160;&amp; Business Development at Strata Oncology. Crescent&#8217;s remaining management team includes Barbara Bispham, who serves as General Counsel and Secretary, and Ryan Lynch, who serves as Treasurer, Senior Vice President of Finance and Chief Accounting Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent has secured financing commitments that, upon closing of the Crescent Pre-Closing Financing, are expected to result in total gross proceeds of approximately $200 million from a syndicate of healthcare investors led by Fairmount, Venrock Healthcare Capital Partners, BVF Partners, and a large investment management firm, with participation from Paradigm BioCapital, RTW Investments, Blackstone Multi-Asset Investing, Frazier Life Sciences, Commodore Capital, Perceptive Advisers, Deep Track Capital, Boxer Capital Management, Soleus, Logos Capital, Driehaus Capital Management, Braidwell LP, and Wellington Management. The financing includes common stock and pre-funded warrants to purchase additional shares of common stock and reflects the conversion of previously issued $37.5 million Convertible Notes together with accrued interest of such Convertible Notes, and is expected to close immediately prior to the Closing. Crescent expects to use the proceeds to fund the development of CR-001 and other programs in its pipeline.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">226</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Paragon Option Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is party to the Paragon Option Agreements with Paragon and Parascent. Paragon and Parascent each beneficially own more than 5% of a class of Crescent&#8217;s voting securities through their respective holdings of Crescent common stock, although neither are expected to own more than 5% following the closing of the Merger. Fairmount beneficially owns more than 5% of a class of Crescent&#8217;s voting securities, one of Crescent&#8217;s directors is affiliated with Fairmount (Peter Harwin) and Fairmount beneficially owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon. Parascent is an entity formed by Paragon as a vehicle to hold equity in Crescent in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreements other than to receive warrants granted to Parascent under the Paragon Option Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September&#160;19, 2024, Crescent entered into the Antibody Paragon Option Agreement with Paragon and Parascent. On October&#160;28, 2024, Crescent entered into the ADC Paragon Option Agreement with Paragon and Parascent. Under the terms of the Paragon Option Agreements, Paragon agreed to perform certain research activities to discover, generate, identify, and characterize one or more antibody candidates, in the case of the Antibody Paragon Option Agreement, and one or more antibody-drug conjugates, in the case of the ADC Paragon Option Agreement, directed to certain mutually agreed therapeutic targets of interest to Crescent (each, a &#8220;Research Program&#8221;). The Antibody Paragon Option Agreement includes two selected targets for CR-001: PD-1 and VEGF. The ADC Paragon Option Agreement initially includes one undisclosed target for CR-002. From time to time, Crescent can choose to add additional targets to the ADC Paragon Option Agreement by mutual agreement with Paragon and Parascent. While Crescent has not yet entered into an option agreement for the CR-003 program, Crescent expects to amend the ADC Paragon Option Agreement to include CR-003 prior to the time that this registration statement on Form&#160;S-4 is declared effective by the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Paragon Option Agreements require Crescent, Paragon, and Parascent to develop a research plan for each target that includes design, modeling, synthesis, evaluation, and other mutually agreed activities (each, a &#8220;Research Plan&#8221;), which activities primarily include performing preclinical studies. Paragon will perform the activities set forth in each Research Plan on the timelines set forth in such Research Plan and in compliance with a mutually agreed budget. Each Research Program will be overseen and coordinated by a joint development committee consisting of two employees from Crescent and two employees from Paragon, with Crescent and Paragon each having one vote with respect to decisions of the committee. When Paragon and Parascent have produced an antibody or ADC, as applicable, against a selected target, and upon the completion of each Research Program, Paragon and Parascent will deliver to Crescent a data package that includes sequence information for all then-existing antibodies or ADCs, as applicable, and information directed to such target. Crescent, Paragon, and Parascent have developed a Research Plan for CR-001 and CR-002 consistent with the foregoing, and Paragon and Parascent have delivered an antibody against PD-1 and VEGF in accordance with such Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Paragon Option Agreements, Crescent has an &#8220;Option&#8221;, on a Research Program-by-Research Program basis, to enter into a separate agreement with Paragon consistent with a set of pre-negotiated terms (a &#8220;License Agreement&#8221;). Each License Agreement will include (a)&#160;an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and commercialize the monospecific antibodies or ADCs, as applicable, and products directed to the selected target(s), and (b)&#160;an exclusive (in the case of the Antibody Paragon Option Agreement) or non-exclusive (in the case of the ADC Paragon Option Agreement), worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and commercialize multispecific antibodies or ADCs, as applicable, and products directed to the selected target(s). Additionally, each License Agreement under the ADC Paragon Option Agreement will include a non-exclusive, worldwide license to certain patents controlled by Paragon or its affiliates that (i)&#160;include a claim that expressly recites the sequence of the monospecific antibody included in the ADC, or derived from the ADC, applicable to the Research Program, and (ii)&#160;are necessary to develop, manufacture, commercialize or otherwise exploit the ADC or derived ADCs applicable to the Research Program, but exclude any patents owned or otherwise controlled by Paragon or its affiliates that cover the composition of matter of, or any method of specifically making or using, a multispecific ADC or a multispecific product directed to targets other than the undisclosed CR-002 target that is developed, manufactured, commercialized or otherwise exploited by Paragon or its affiliate or sublicensee (other than Crescent and its affiliates and sublicensees). Each License under the ADC Paragon Option Agreement will further include a right of first negotiation for a set period of time after the execution of the License Agreement with regard to any multispecific ADCs or products that are developed by Paragon. The Option with respect to each Research Program is exercisable at Crescent&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following the delivery of the data package from Paragon related to the results of the Research Program (an &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements. Activities under a Research Plan may continue past the exercise of an Option or entry into a License Agreement. Crescent&#8217;s Options to acquire the intellectual property rights to the Research Programs under the Paragon Option Agreements, including CR-001 and CR-002, currently remain unexercised.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">227</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of an Option with respect to a Research Program, the parties are obligated to use reasonable efforts to finalize and execute a License Agreement within 30&#160;days. Under the terms of a License Agreement, Crescent expects that it will have sole authority over and control of the development, regulatory approval, manufacturing and commercialization of such in-licensed intellectual property worldwide. In addition, Crescent expects to have sole authority over and control of the application for and issuance of all regulatory approvals related to such in-licensed intellectual property. Prior to entry into a License Agreement, Paragon is responsible for the prosecution, defense, maintenance and enforcement of patents related to the Research Program. Following entry into a License Agreement, Crescent expects to control prosecution, defense, maintenance and enforcement of patents in-licensed under such License Agreement. However, there is no assurance that Crescent will successfully negotiate future License Agreements with Paragon or that the terms will not differ from those described in this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Paragon Option Agreements shall continue in force on a Research Program- by-Research Program basis until the later of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by Crescent; (ii)&#160;if Crescent exercises its Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 30&#160;days, the expiration of such 30-day period (subject to any mutually agreed extension of such period); and (iii)&#160;the expiration of the applicable Research Term (as defined under the applicable Paragon Option Agreement). Crescent may terminate any Paragon Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon; provided, that Crescent must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Paragon Option Agreements or any Research Program immediately upon written notice to Crescent if, as a result of any action or failure to act by Crescent or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate any Paragon Option Agreement or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30-day period and (ii)&#160;the other party&#8217;s bankruptcy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon signing of the Antibody Paragon Option Agreement, Crescent was required to reimburse Paragon $1.5 million for upfront research and development costs related to CR-001 and other general and administrative costs incurred by Paragon prior to September 19, 2024. Contemporaneously, Crescent also issued an aggregate of 5,000,000 shares of Crescent common stock to Paragon for aggregate non-cash upfront consideration of Paragon&#8217;s entry into the Antibody Paragon Option Agreement, valued at $0.20 per share, for a total of $1.0 million. Paragon subsequently contributed 2,500,000 of such shares to Parascent. The $1.5 million of research and development costs related to CR-001 reflects the actual historical direct costs incurred by Paragon as well as a 20% mark-up on the direct costs to approximate the indirect costs incurred by Paragon from the inception of the CR-001 program to the entry into the Paragon Option Agreement. All of the costs reflected in the upfront amount were incurred by Paragon between January 1, 2024 and the parties&#8217; entry into the Paragon Option Agreement. Such direct costs were related to development activities. Of these upfront development costs related to CR-001 incurred by Paragon prior to September 19, 2024, a total of $1.5 million was recognized as research and development expense and less than $0.1 million was recognized as general and administrative expense during the period from September 19, 2024 (inception) to December 31, 2024. Crescent paid $1.5 million to Paragon in November 2024. The non-cash upfront consideration was recorded as research and development expense in Crescent&#8217;s consolidated statement of operations and comprehensive loss during the period from September 19, 2024 (inception) to December 31, 2024 as related IP license fees associated with entering into the Option Agreement. Crescent is also required to pay Paragon for certain development fees and costs on a Research Program-by-Research Program basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is also required to pay Paragon for certain development fees and costs on a Research Program-by-Research Program basis. Under the Paragon Option Agreements, Crescent is required to pay Paragon a one-time, non-refundable research initiation fee within 30&#160;days following finalization of a Research Plan in the amount of $1.3 million for CR-001 and $2.5 million for CR-002, which amounts were paid by Crescent in December&#160;2024 for each of CR-001 and CR-002. Under the Paragon Option Agreements, on a Research Program-by-Research Program basis, Crescent is required to make one-time non-refundable milestone payments to Paragon of up to a total of $22.0 million for CR-001 and $46.0 million for CR-002 upon the achievement of certain clinical development and regulatory milestones. Crescent paid a $1.5 million milestone payment to Paragon in connection with the achievement of a development candidate for CR-001, which was expensed as development costs for the fiscal&#160;year ended December&#160;31, 2024 and paid in January&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Upon exercise of the Option with respect to a Research Program, the parties are obligated to use reasonable efforts to finalize and execute a License Agreement within 30&#160;days. Any License Agreement entered into with respect to a given Research Program shall contain the same milestone payment obligations as the applicable Paragon Option Agreement, provided that any milestone set in such Paragon Option Agreement that has not yet been achieved and is duplicated in such License Agreement shall no longer be achievable and payable under the terms of such Paragon Option Agreement and shall only be achievable under the terms of the License </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">228</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Agreement. For the avoidance of doubt, if a milestone is achieved and paid by Crescent pursuant to a Paragon Option Agreement for a certain Research Program, then there shall be no milestone payment due for the achievement of such milestone under a subsequently executed License Agreement for such Research Program. Further, under a License Agreement, Crescent would also be required to make royalty payments to Paragon in the low single-digit&#160;percentage range based on net sales of products, subject to certain reductions. The royalty term will terminate on a product-by-product and country-by-country basis upon the later of the expiration of the last-to-expire valid claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, as part of the Paragon Option Agreements, on each of December&#160;31, 2025 and December&#160;31, 2026, Crescent will grant Parascent warrants to purchase a number of shares equal to 1.00% of Crescent&#8217;s outstanding capital stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares of Crescent common stock on each respective grant date. Parascent is an entity formed by Paragon as a vehicle to hold equity in Crescent in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreements other than to receive such warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this proxy statement/prospectus, Crescent has paid Paragon (i)&#160;$6.2 million under the Antibody Paragon Option Agreement for development costs related to PD-1 and VEGF incurred by Paragon through the effective date of the agreement, including pre-development costs, and (ii)&#160;$0.8 million under the ADC Paragon Option Agreement for development costs related to the undisclosed CR-002 target incurred by Paragon through the effective date of the agreement. Crescent considers Paragon and Fairmount to be related parties. Please see the section titled &#8220;<i style="font-style:italic;">Certain Relationships and Related Party Transactions of the Combined Company</i>&#8221; beginning on page&#160;279 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent strives to protect the proprietary programs and technologies that it believes are important to its business, including seeking and maintaining patent protection intended to cover the composition of matter of its programs, their methods of use and manufacture, related technologies, diagnostics, and other inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Paragon has filed provisional patent applications, and intends to file one or more additional provisional patent applications directed to antibodies that target PD-1 and VEGF, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including CR-001. In addition, Paragon has filed provisional patent applications, and intends to file one or more additional provisional patent applications directed to ADCs against various oncology targets, including applications covering composition of matter, pharmaceutical formulations, and methods of using such ADCs, including CR-002. Crescent has not yet exercised its option to acquire exclusive rights to any PD-1 or VEGF patent applications, but retains the right to do so. When the provisional patent applications are pursued non-provisionally and mature into one or more issued patents covering CR-001 or CR-002, Crescent would expect those patents to expire in 2045, absent any applicable patent term adjustments or extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s commercial success will depend in significant part upon obtaining and maintaining patent protection and trade secret protection for its targeted therapeutics and the methods used to develop and manufacture them, as well as successfully defending these patents against third-party challenges and operating without infringing on the proprietary rights of others. Crescent&#8217;s ability to stop third parties from making, using, selling, offering to sell, or importing its products depends on the extent to which Crescent has rights under valid and enforceable patents or trade secrets that cover these activities. Crescent cannot be sure that patents will be granted with respect to any of its pending patent applications or with respect to any patent applications filed by it in the future, nor can Crescent be sure that any of its existing patents, or any patents granted to it in the future will be commercially useful in protecting its targeted therapeutics, current programs and processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which Crescent files, including the United States, the patent term is 20&#160;years from the earliest date of filing a non-provisional patent application. In the United States, a patent&#8217;s term may potentially be lengthened by patent term adjustment (&#8220;PTA&#8221;), which compensates a patentee for administrative delays by the USPTO in examining and granting a patent. In the United States, the patent term of a patent that covers an FDA-approved drug may also be eligible for PTE, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits PTE of up to five&#160;years beyond the expiration of the patent. The length of the PTE accorded a patent is related to the length of time the drug is under regulatory review by the FDA. PTE cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval. Further, only one patent applicable to an approved drug may be extended, and only those claims covering the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">229</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions for extending the term of a patent that covers an approved drug are available in multiple European countries and other foreign jurisdictions. In the future, if and when Crescent&#8217;s products receive FDA approval, it expects to apply for patent term extensions on patents covering those products. Crescent expects to seek patent term extensions to all of its issued patents in any jurisdiction where these are available; however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with Crescent&#8217;s assessment of whether such extensions should be granted, and if granted, the length of such extensions. Patent term in the U.S. may be shortened if a patent is terminally disclaimed over an earlier-filed patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some instances, Crescent files provisional patent applications directly in the USPTO. Provisional patent applications are designed to provide a lower-cost first patent filing in the United States. Corresponding non-provisional patent applications must be filed not later than 12&#160;months after the provisional application filing date. The corresponding non-provisional application benefits in that the priority date(s)&#160;of the non-provisional patent application is/are the earlier provisional application filing date(s), and the patent term of the finally issued patent is calculated from the earliest non-provisional application filing date. This system allows Crescent to obtain an early priority date, obtain a later start to the patent term and to delay prosecution costs, which may be useful in the event that Crescent decides not to pursue examination in a subsequent non-provisional application. While Crescent intends, as appropriate, to timely file non-provisional patent applications relating to its provisional patent applications, it cannot predict whether any such non-provisional patent applications will result in the issuance of patents that provide it with any competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent intends to file U.S. non-provisional applications and/or international Patent Cooperation Treaty (&#8220;PCT&#8221;) applications that claim the benefit of the priority date of earlier filed provisional or non-provisional applications, when applicable. The PCT system allows for a single PCT application to be filed within 12&#160;months of the priority filing date of a corresponding priority patent application, such as a U.S. provisional or non-provisional application, and to designate all of the 157 PCT contracting states in which national phase patent applications can later be pursued based on the PCT application. The PCT International Searching Authority performs a patentability search and issues a non-binding patentability opinion, which can be used to evaluate the chances of success for the national applications in foreign countries prior to having to incur the filing fees. Although a PCT application does not issue as a patent, it allows the applicant to establish a patent application filing date in any of the member states and then seek patents through later-filed national-phase applications. No later than either 30 or 31&#160;months from the earliest priority date of the PCT application, separate national phase patent applications can be pursued in any of the PCT member states, depending on the deadline set by individual contracting states. National phase entry can generally be accomplished through direct national filing or, in some cases, through a regional patent organization, such as the European Patent Organization. The PCT system delays application filing expenses, allows a limited evaluation of the chances of success for national/regional patent applications and allows for substantial savings in comparison to having filed individual countries rather than a PCT application in the event that no national phase applications are filed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For all patent applications, Crescent determines claiming strategy on a case-by-case basis. Advice of counsel and Crescent&#8217;s business model and needs are always considered. Crescent files patent applications containing claims for protection of all commercially relevant uses of its proprietary technologies and any products, as well as all new applications and/or uses it discovers for existing technologies and products, assuming these are strategically valuable. Crescent may periodically reassess the number and type of patent applications, as well as the pending and issued patent claims to ensure that coverage and value are obtained for its processes, and compositions, given existing patent law and court decisions. Further, claims may be modified during patent prosecution to meet Crescent&#8217;s intellectual property and business needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent recognizes that the ability to obtain patent protection and the degree of such protection depends on a number of factors, including the extent of the prior art, the novelty and non-obviousness of the invention, and the ability to satisfy subject matter, written description, and enablement requirements of the various patent jurisdictions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted or further altered even after patent issuance. Consequently, Crescent may not obtain or maintain adequate patent protection for any of its targeted therapeutics. Crescent cannot predict whether the patent applications it is currently pursuing will be issued as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that it holds may be challenged, circumvented or invalidated by third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition to patents, Crescent relies upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain its competitive position. However, trade secrets and know-how can be difficult to protect. Crescent seeks to protect its proprietary information, in part by executing confidentiality agreements with its collaborators and scientific advisors, and non-competition, non-solicitation, confidentiality and invention assignment agreements with its employees and consultants. Crescent has also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements Crescent enters into are designed to protect its proprietary information and the agreements or clauses </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">230</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">requiring assignment of inventions to Crescent are designed to grant Crescent ownership of technologies that are developed through its relationship with the respective counterparty. Crescent cannot guarantee, however, that it has executed such agreements with all applicable counterparties, that such agreements will not be breached, or that these agreements will afford Crescent adequate protection of its intellectual property and proprietary rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent positions of biotechnology companies like Crescent&#8217;s are generally uncertain and involve complex legal, scientific and factual questions. Crescent&#8217;s commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require Crescent to alter its development or commercial strategies, or its products or processes, obtain licenses or cease certain activities. Crescent&#8217;s breach of any license agreements or its failure to obtain a license to proprietary rights required to develop or commercialize its future products may have a material adverse impact on it. If third parties prepare and file patent applications in the United States that also claim technology to which Crescent has rights, Crescent may have to participate in interference or derivation proceedings in the USPTO to determine priority of invention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">When available to expand market exclusivity, Crescent&#8217;s strategy is to obtain, or license additional intellectual property related to current or contemplated development platforms, core elements of technology and/or programs and targeted therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For more information regarding the risks related to Crescent&#8217;s intellectual property, see the section titled &#8220;<i style="font-style:italic;">Risk Factor</i><i style="font-style:italic;">s</i><i style="font-style:italic;">&#8212;</i><i style="font-style:italic;">Risks Related to Crescent&#8217;s Intellectual Property</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Commercial</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Should any of its product candidates be approved for commercialization, Crescent intends to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable Crescent to realize the full commercial value of its programs. Given its stage of development, Crescent has not yet established a commercial organization or distribution capabilities. Crescent currently holds exclusive Options (as defined below) to acquire worldwide development and commercialization rights to all of its programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent does not currently own or operate facilities for product manufacturing, testing, storage, and distribution. Crescent has contracted and expects to continue to contract with third parties for the manufacture and distribution of its product candidates. Because Crescent relies on contract manufacturers, it employs personnel with extensive technical, manufacturing, analytical and quality experience. Crescent&#8217;s team has deep knowledge and understanding of the regulations that govern manufacturing, documentation, quality assurance, and quality control of drug supply that are required to support Crescent&#8217;s regulatory filings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and biopharmaceutical industries are characterized by continuing technological advancement and significant competition. While Crescent believes that its programs, technology, development experience and scientific knowledge provide it with competitive advantages, Crescent faces competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others. Any product candidates that Crescent successfully develops and commercialize will compete with existing therapies and new therapies that may become available in the future. Many of the companies with which Crescent is currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than Crescent does. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of Crescent&#8217;s competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Crescent in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, patient enrollment for clinical trials as well as in acquiring technologies complementary to, or necessary for, Crescent&#8217;s programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Key competitive factors affecting the success of all of Crescent&#8217;s product candidates that it develops, if approved, are likely to be efficacy, safety, convenience, presentation, price, the level of generic competition, and the availability of reimbursement from government and other third-party payors. Crescent&#8217;s competitors may also obtain FDA or other regulatory approval for their products more rapidly than Crescent may obtain approval for its products, which could result in Crescent&#8217;s competitors establishing a strong market position before Crescent is able to enter the market.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">231</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Specifically, there are several companies developing or marketing treatments that may be approved for the same indications and/or diseases as Crescent&#8217;s most advanced program, CR-001, including major pharmaceutical companies. Crescent does not yet have clinical data for any of its programs and there can be no assurance that its programs will have similar or comparable results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are several approved immuno-oncology biologic therapies for the treatment of solid tumor indications, including, but not limited to, anti-PD-1 therapies Keytruda (pembrolizumab; Merck) and Opdivo (nivolumab; Bristol Myers Squibb), as well as approved anti-PD-L1 therapies Tecentriq&#174; (atezolizumab; Genetech) and Imfinzi&#174; (durvalumab; AstraZeneca). Future biosimilars and other therapies in development may also serve as competition for Crescent&#8217;s product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, Crescent is aware of several anti-PD-(L)1/VEGF bispecific product candidates in clinical development for solid tumor indications, including, but not limited to, ivonescimab (Summit Therapeutics&#160;Inc.), BNT327 (BioNTech SE), LM-299 (LaNova Medicines&#160;Ltd.; in-licensed by Merck), and CTX-10726 (Compass Therapeutics,&#160;Inc.).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those Crescent is developing. Crescent, along with its third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory authorities of the countries in which Crescent wishes to conduct studies or seek approval or licensure of its product candidates. Generally, before a new therapeutic product can be marketed, considerable data demonstrating a biological product candidate&#8217;s quality, safety, purity and potency, or a small molecule drug candidate&#8217;s quality, safety and efficacy, must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. For biological product candidates, potency is similar to efficacy and is interpreted to mean the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in the manner intended, to effect a given result.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-marketing may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications from the sponsor, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on Crescent and its products or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Biologics Regulation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, biological products (or &#8220;biologics&#8221;) are subject to regulation under the FDCA, the Public Health Service Act (&#8220;PHSA&#8221;) and other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;) regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board (&#8220;IRB&#8221;), or ethics committee at each clinical site before the trial is commenced; manufacture of the proposed biologic candidate in accordance with current good manufacturing practices (&#8220;cGMPs&#8221;);</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">232</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with GCP requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation of and submission to the FDA of a BLA, after completion of all pivotal clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60&#160;days of its receipt of a BLA to file the application for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical and Clinical Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to beginning any clinical trial with a product candidate, in the United States, Crescent must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and <i style="font-style:italic;">in vitro</i> studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor, and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">233</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">BLA Submission and Review</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Within 60&#160;days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within 10&#160;months after the filing date, or, if the application qualifies for priority review, six&#160;months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">234</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Combination Therapy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Combination therapy is a treatment modality that involves the use of two or more drugs to be used in combination to treat a disease or condition. If those drugs are combined in one dosage form, such as one pill, that is known as a fixed dose combination product and it is reviewed pursuant to the FDA&#8217;s Combination Rule&#160;at 21 CFR 300.50. The rule&#160;provides that two or more drugs may be combined in a single dosage form when each component contributes to the claimed effects and the dosage of each component (amount, frequency, duration) is such that the combination is safe and effective for a significant patient population requiring such concurrent therapy as defined in the labeling for the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">But not all combination therapy falls under the category of a fixed dose combination. For example, the FDA recognizes that two drugs in separate dosage forms and in separate packaging, that otherwise might be administered as a monotherapy for an indication, also may be used in combination for the same indication. In 2013, the FDA issued guidance to assist sponsors that were developing the range of combination therapies that fall outside the category of fixed dose combinations. That guidance provides recommendations and advice on such topics as: (1)&#160;assessment at the outset whether two or more therapies are appropriate for use in combination; (2)&#160;guiding principles for nonclinical and clinical development of the combination; (3)&#160;options for regulatory pathways to seek marketing approval of the combination; and (4)&#160;post-marketing safety monitoring and reporting obligations. Given the wide range of potential combination therapy variations, the FDA indicated it intends to assess each potential combination on a case-by case basis and encouraged sponsors to engage in early and regular consultation with the relevant review division at the agency throughout the development process for its proposed combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation of Combination Products</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Certain therapeutic products are comprised of multiple components, such as drug components, biologic components, and device components, that would normally be subject to different regulatory frameworks by the FDA and frequently regulated by different centers at the FDA. These products are known as combination products. Under the FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. The determination of which center will be the lead center is based on the &#8220;primary mode of action&#8221; of the combination product. Thus, if the primary mode of action of a drug/biologic-device combination product is attributable to the drug or biological product, the FDA center responsible for premarket review of the drug or biological product would have primary jurisdiction for the combination product. The FDA has also established the Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute. A combination product with a primary mode of action attributable to the drug or biologic component generally would be reviewed and approved pursuant to the drug or biologic approval processes set forth in the FDCA. In reviewing the NDA or BLA for such a product, however, FDA reviewers </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">235</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">would consult with their counterparts in the FDA&#8217;s Center for Devices and Radiological Health to ensure that the device component of the combination product met applicable requirements regarding safety, effectiveness, durability and performance. In addition, under FDA regulations, combination products are subject to cGMP requirements applicable to both drugs and devices, including the Quality System Regulation applicable to medical devices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Post-Approval Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any products manufactured or distributed by Crescent pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record- keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. After a BLA is approved for a biological product, the product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, and potency or effectiveness of biologics. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon Crescent and its third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon Crescent and any third-party manufacturers that it may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal of the FDA to permit the import or export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mandated modification of promotional materials and labelling and the issuance of corrective information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">236</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by Crescent and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biosimilars and Reference Product Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The BPCIA created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA- approved reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. The FDA has issued guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A reference biologic is granted 12&#160;years of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval pathway for the lesser of (i)&#160;one&#160;year after the first commercial marketing, (ii)&#160;18&#160;months after approval if there is no legal challenge, (iii)&#160;18&#160;months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv)&#160;42&#160;months after the application has been approved if a lawsuit is ongoing within the 42-month period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six&#160;months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In July&#160;2018, the FDA announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics and biosimilars. On December&#160;20, 2020, Congress amended the PHSA as part of the COVID-19 relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">237</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As discussed below, the IRA is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent Term Extension</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, after a BLA is approved, owners of relevant drug patents may apply for up to a five-&#160;year patent extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory process. The allowable patent term extension is typically calculated as one-half the time between (1)&#160;the latter of (a)&#160;the effective date of an IND and (b)&#160;issue date of the patent for which extension is sought, and (2)&#160;the submission date of a BLA, plus the time between BLA submission date and the BLA approval date, up to a maximum of five&#160;years. The time can be shortened if the FDA determines that the applicant did not pursue licensure with due diligence. The total patent term after the extension may not exceed 14&#160;years from the date of product licensure. Only one patent applicable to a licensed biological product is eligible for extension and only those claims covering the product, a method for using it, or a method for manufacturing it may be extended, and the application for the extension must be submitted prior to the expiration of the patent in question. However, Crescent may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Some, but not all, foreign jurisdictions possess patent term extension or other additional patent exclusivity mechanisms that may be more or less stringent and comprehensive than those of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Healthcare Laws and Compliance Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute (&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); HIPAA and similar foreign, federal and state fraud, abuse and transparency laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Crescent&#8217;s practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that caused the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">238</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicaid&#160;&amp; Medicare Services (&#8220;CMS&#8221;) information related to payments or other transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning on January&#160;1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is also subject to federal price reporting laws and federal consumer protection and unfair competition laws. Federal price reporting laws require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/ or discounts on approved products. Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If Crescent&#8217;s operations are found to be in violation of any of such laws or any other governmental regulations that apply, Crescent may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of its operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data Privacy and Security</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information could apply to Crescent&#8217;s operations or the operations of Crescent&#8217;s partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For example, HIPAA, as amended by the HITECH Act, and their respective implementing regulations imposes data privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable protected health information (&#8220;PHI&#8221;) for or on behalf of such covered entities. These requirements imposed by HIPAA and the HITECH Act on covered entities and business associates include entering into agreements that require business associates protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the privacy of PHI, which limit the disclosure of a patient&#8217;s past, present, or future physical or mental health or condition or information about a patient&#8217;s receipt of health care if the information identifies, or could reasonably be used to identify, the individual; ensuring the confidentiality, integrity, and availability of all PHI created, received, maintained, or transmitted in electronic form, to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of such PHI; and reporting of breaches of PHI to individuals and regulators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. A covered entity or business associate is also liable for civil money penalties for a violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. To the extent that Crescent submits electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to Crescent may be delayed or denied.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">239</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, state health information privacy laws, such as California&#8217;s Confidentiality of Medical Information Act and Washington&#8217;s My Health My Data Act, govern the privacy and security of health-related information, specifically, may apply even when HIPAA does not and impose additional requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even when HIPAA and state health information privacy laws do not apply, according to the FTC and state Attorneys General, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5(a)&#160;of the Federal Trade Commission Act and state consumer protection laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, certain state laws, such as the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (CCPA), govern the privacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA in various ways. Numerous other states have passed similar laws, but many differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. The CCPA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, and affords rights to California residents in relation to their personal information. Health information falls under the CCPA&#8217;s definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked, directly or indirectly, with a particular consumer or household&#8212;unless it is subject to HIPAA&#8212;and is included under a new category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. The numerous other comprehensive privacy laws that have passed or are being considered in other states, as well as at the federal and local levels, also exempt some data processed in the context of clinical trials; but others exempt covered entities and business associates subject to HIPAA altogether, further complicating compliance efforts, and increasing legal risk and compliance costs for Crescent and the third parties upon whom Crescent relies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Coverage and Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the U.S. and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Crescent&#8217;s ability to successfully commercialize its product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow it to establish or maintain pricing sufficient to realize a sufficient return on its investment. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which Crescent obtains regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of Crescent&#8217;s product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require Crescent to provide scientific and clinical support for the use of its product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Factors payors consider in determining reimbursement are based on whether the product is:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a covered benefit under its health plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safe, effective and medically necessary;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">240</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost-effective; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">neither experimental nor investigational.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able to directly negotiate prescription drug prices and to cap out-of-pocket costs. Each&#160;year, CMS will select and negotiate a preset number of high-spend drugs and biologics that are covered under Medicare Part&#160;B and Part&#160;D that do not have generic or biosimilar competition. On August&#160;29, 2023, HHS announced the list of the first ten drugs subject to price negotiations. These price negotiations occurred in 2024. In January&#160;2025, CMS announced a list of 15 additional Medicare Part&#160;D drugs that will be subject to price negotiations. The IRA also provides a new &#8220;inflation rebate&#8221; covering Medicare patients that took effect in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation rebate provision requires drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Part&#160;B and Part&#160;D increases faster than the rate of inflation. To support biosimilar competition, beginning in October&#160;2022, qualifying biosimilars may receive a Medicare Part&#160;B payment increase for a period of five&#160;years. Separately, if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two&#160;years, CMS will be authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA&#8217;s impact on commercialization and competition remains largely uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Crescent cannot be sure that reimbursement will be available for any product candidate that Crescent may commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finally, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of Crescent&#8217;s product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">241</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare Reform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For example, the ACA, which was enacted in March&#160;2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and Crescent expects there will be additional challenges and amendments to the ACA in the future. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan&#160;year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part&#160;D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of on average 2% per fiscal&#160;year as part of the federal budget sequestration under the Budget Control Act of 2011. These reductions went into effect in April&#160;2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional action is taken by Congress. In addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point-of-sale discounts that manufacturers must agree to offer under the Medicare Part&#160;D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare Part&#160;D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May&#160;2019, CMS adopted a final rule&#160;allowing Medicare Advantage Plans the option to use step therapy for Part&#160;B drugs, permitting Medicare Part&#160;D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part&#160;D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January&#160;1, 2021. In response to the Biden administration&#8217;s October&#160;2022 executive order, on February&#160;14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December&#160;7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December&#160;8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the IRA, continued legislative and enforcement interest exists in the United States with respect to specialty drug pricing practices. Crescent expects regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Individual states in the U.S. have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">242</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">harm Crescent&#8217;s business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for its drugs or put pressure on its drug pricing, which could negatively affect Crescent&#8217;s business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other Government Regulation Outside of the United States</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to regulations in the United States, Crescent is subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of its products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Whether or not Crescent obtains FDA approval for a product, it must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation in the European Union</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">European Data Laws</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (GDPR), which came into force in May&#160;2018, and related data protection laws in individual EU Member States. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the personal data breaches which may have to be notified to the national data protection authorities and data subjects, the measures to be taken when engaging processors, and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the European Economic Area (EEA) that are not considered by the European Commission (EC) to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (&#8220;SCCs&#8221;). When relying on SCCs, data exporters are also required to conduct a transfer risk assessment to verify if anything in the law and/or practices of the third country may impinge on the effectiveness of the SCCs in the context of the transfer at stake and, if so, to identify and adopt supplementary measures that are necessary to bring the level of protection of the data transferred to the EU standard of essential equivalence. Where no supplementary measure is suitable, the data exporter should avoid, suspend or terminate the transfer. With regard to the transfer of data from the EEA to the United States, on July&#160;10, 2023, the EC adopted its adequacy decision for the EU-US Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to U.S. companies participating in the framework. With regard to the transfer of data from the EU to the United Kingdom (UK), personal data may freely flow from the EEA to the UK since the UK is deemed to have an adequate data protection level. However, the adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four&#160;years after their entry into force, unless renewed.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">243</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, there are specific requirements relating to processing health data from clinical trials, including public disclosure obligations provided in the EU Clinical Trials Regulation No.&#160;536/2014 (CTR), EMA disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against Crescent, harm to Crescent&#8217;s reputation, and adversely impact its business and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, following the UK&#8217;s withdrawal from the EU and the EEA, companies also have to comply with the UK&#8217;s data protection laws (including the UK GDPR (as defined in section 3(10)&#160;(as supplemented by section 205(4)) of the Data Protection Act 2018 (the DPA 2018)), the DPA 2018, and related data protection laws in the UK). Separate from the fines that can be imposed by the GDPR, the UK regime has the ability to fine up to the greater of &#163;17.5 million or 4% of global turnover. Companies are subject to specific transfer rules&#160;under the UK regime which broadly mirror the GDPR rules. On February&#160;2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (IDTA) and the international data transfer addendum to the EC&#8217;s standard contractual clauses for international data transfers (Addendum) and a document setting out transitional provisions. The IDTA and Addendum came into force on March&#160;21, 2022 and replaced the old SCCs for the purposes of the UK regime. Regarding transfers from the UK to the EEA, personal data may flow freely since the EEA is deemed to have an adequate data protection level for purposes of the UK regime. With regard to the transfer of personal data from the UK to the United States, the UK government has adopted an adequacy decision for the United States, the UK-US Data Bridge, which came into force on October&#160;12, 2023. The UK-US Data Bridge recognizes the United States as offering an adequate level of data protection where the transfer is to a U.S. company participating in the EU-US Data Privacy Framework and the UK Extension.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Drug and Biologic Development Process</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regardless of where they are conducted, all clinical trials included in applications for marketing authorization for human medicines in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the EU CTR (EU) No.&#160;536/2014, which entered into force on January&#160;31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the former regime, which will expire after a transition period of three&#160;years, as outlined below in more detail, before a clinical trial can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more Ethics Committees. The NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU member state where they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">A more unified procedure will apply under the new CTR. A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal. One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application and consult and coordinate with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member state may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules&#160;on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">244</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">three-&#160;year transition period. EU Member States will work in CTIS immediately after the system has gone live. Since January&#160;31, 2023, submission of initial clinical trial applications via CTIS is mandatory and CTIS serves as the single entry point for submission of clinical trial-related information and data. By January&#160;31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS. On July&#160;19, 2023, the EC published guidance concerning the steps to be taken in this transition. This guidance provides, among other things, that (i)&#160;documentation which was previously assessed will not be reassessed, (ii)&#160;templates that were developed and endorsed by the EU Clinical Trials Expert Group to provide compliance with the CTR do not need to be updated and (iii)&#160;there is no need to retrospectively create a site suitability form, which are only necessary for new trial sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on GCP and the ethical principles that have their origin in the Declaration of Helsinki.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party. A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Drug Marketing Authorization</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a MA. To obtain an MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized or decentralized procedure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To be used or sold in the UK, a drug must have an effective MA obtained by a centralized application through EMA or a national application. National applications are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the Medicines and Healthcare products Regulatory Agency (the &#8220;MHRA&#8221;) Submissions Portal. The process from application to authorizations generally takes up to 210&#160;days, excluding time taken to provide any additional information or data required by the MHRA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August&#160;30, 2023, the MHRA published detailed guidance on its recently announced new International Reliance Procedure (the &#8220;IRP&#8221;) for MAAs. The IRP applies since January&#160;1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international regulators (e.g. Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a MA in the UK. Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line extensions, variations and renewals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Centralized Authorization Procedure</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application by the EMA that is valid for all EU Member States as well as in the three additional EEA member states. The centralized procedure is compulsory for certain types of medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (&#8220;ATMP&#8221;) and medicinal products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May&#160;20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a marketing authorization through the centralized procedure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the timeframe for the evaluation of an MAA by </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">245</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the EMA&#8217;s CHMP is, in principle, 210&#160;days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a&#160;year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150&#160;days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67&#160;days after receipt of the CHMP opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Decentralized Authorization Procedure</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i)&#160;they can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii)&#160;they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii)&#160;they can be authorized in an EU member state in accordance with that state&#8217;s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization (mutual recognition procedure).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a marketing authorization for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk Management Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All new MAAs must include a RMP describing the risk management system that a company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i)&#160;at the request of EMA or a national competent authority, or (ii)&#160;whenever the risk-management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October&#160;20, 2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">MA Validity Period</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Marketing Authorizations have an initial duration of five&#160;years. After these five&#160;years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine&#160;months before the five-year period expires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three&#160;years after authorization ceases to be valid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the UK, the period of three&#160;years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion to a Great Britain MA. Conversion refers to the procedure by which, as of January&#160;1, 2021, MAs granted on the basis of a centralized procedure in the EU are only valid in Northern Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically converted into UK MAs effective in Great Britain only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period starting when the UK left the EU on January&#160;31, 2020 and ending on December&#160;31, 2020 (the &#8220;Brexit Transition Period&#8221;) </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">246</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">will be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining EU Member States, the three-year period will start running from the last date the drug was placed on the UK market before the end of the Brexit Transition Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exceptional Circumstances/Conditional Approval</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar to accelerated approval regulations in the United States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number of criteria are fulfilled: (i)&#160;the benefit/risk balance of the product is positive, (ii)&#160;it is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii)&#160;unmet medical needs will be fulfilled by the grant of the MA and (iv)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. Once a conditional MA has been granted, the MA holder must fulfil specific obligations within defined timelines. A conditional MA is valid for one&#160;year and must be renewed annually, but it can be converted into a standard MA once the MA holder fulfils the obligations imposed and the complete data confirm that the medicine&#8217;s benefits continue to outweigh its risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Data and Market Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. New Chemical Entities (&#8220;NCEs&#8221;) approved in the EU qualify for eight&#160;years of data exclusivity and 10&#160;years of marketing exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An additional non-cumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight&#160;years of the 10-year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU. After eight&#160;years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two&#160;years later (or a total of 10&#160;years after the first MA in the EU of the innovator product), or three&#160;years later (or a total of 11&#160;years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another noncumulative one-year period of data exclusivity can be added to the eight&#160;years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant preclinical or clinical studies were carried out in relation to the new indication. Another&#160;year of data exclusivity may be added to the eight&#160;years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre- trial tests or clinical trials (when examining an application by another applicant for or holder of market authorization for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one&#160;year after the initial change was authorized).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to include an NCE. Even if a compound is considered to be a NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April&#160;26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages, e.g., a shortening of the periods of data exclusivity; however, there is currently neither a final version of this draft nor a date for its entry into force. While the European Parliament adopted its approving position on the reform on April&#160;10, 2024, no further required legislative steps have been taken since.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a pediatric improvement plan (&#8220;PIP&#8221;) together with a request for agreement to the EMA. The EMA issues a decision on the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">247</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PIP based on an opinion of the EMA&#8217;s Pediatric Committee. Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g., until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g., because the relevant disease or condition occurs only in adults) has been granted by the EMA. The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted an MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six-month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two-&#160;year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January&#160;1, 2021 have been adopted as UK PIPs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">PRIME Designation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling non-clinical data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or from CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-Approval Regulation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and marketing authorizations. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules&#160;and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure by Crescent or by any of its third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holder of MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">These pharmacovigilance rules&#160;can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">248</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">expensive and could impact Crescent&#8217;s profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">More generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The manufacturing process for pharmaceutical products in the European Union is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the European Union with the intention to import the active pharmaceutical ingredients into the European Union. Similarly, the distribution of pharmaceutical products into and within the European Union is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the European Union or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sales and Marketing Regulations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The advertising and promotion of Crescent&#8217;s products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s summary of product characteristics (&#8220;SmPC&#8221;) as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription-only medicines is also prohibited in the EU. Violations of the rules&#160;governing the promotion of medicinal products in the European Union could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of Crescent&#8217;s products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">EU regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA. Following Brexit, the requirements to display the common logo no longer apply to UK-based online sellers, except for those established in Northern Ireland.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Anti-Corruption Legislation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">249</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the scope of the Bribery Act 2010. Due to the Bribery Act 2010&#8217;s far-reaching territorial application, the potential penalized act does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the person&#8217;s act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still have been committed. The Bribery Act 2010 is comprised of four offenses that cover (i)&#160;individuals, companies and partnerships that give, promise or offer bribes, (ii)&#160;individuals, companies and partnerships that request, agree to receive or accept bribes, (iii)&#160;individuals, companies and partnerships that bribe foreign public officials, and (iv)&#160;companies and partnerships that fail to prevent persons acting on their behalf from paying bribes. The penalties imposed under the Bribery Act 2010 depend on the offence committed, harm and culpability and penalties range from unlimited fines to imprisonment for a maximum term of 10&#160;years and in some cases both.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Regulations in the UK and Other Markets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The UK formally left the EU on January&#160;31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long-term set of arrangements for the supply of medicines into Northern Ireland. The EU and the UK agreed on a trade and cooperation agreement, which includes provisions affecting the life sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP issued documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The UK government has adopted the Medicines and Medical Devices Act 2021 (the MMDA) to enable the UK&#8217;s regulatory frameworks to be updated following the UK&#8217;s departure from the EU. The MMDA introduces regulation-making, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The MHRA has since been consulting on future regulations for medicines and medical devices in the UK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The MMDA supplements the UK Medical Devices Regulations 2002 (the &#8220;Regulations&#8221;), which are based on the EU Medical Devices Directive as amended to reflect the United Kingdom&#8217;s post-Brexit regulatory regime. Notably, the Regulations do not include any of the revisions that have been made by the EU Medical Devices Regulation (EU) 2017/745, which has gained full application in all EU Member States since May&#160;26, 2021 but is not applicable in the UK as &#8220;retained law&#8221;. Additionally, the MHRA launched a comprehensive consultation in 2021 with proposals to amend the regulatory framework for medical devices in the United Kingdom. The stated objectives of the proposals include expansion of the scope of the Regulations (for example, by expanding the <i style="font-style:italic;">in vitro</i> diagnostic medical device definition to include software and other products, including products without an intended medical purpose but with similar functioning and risk profiles) and potentially through use of internationally recognized definitions (for example, by excluding products that contain viable biological substances and excluding food), remove trade barriers, further the availability of medical devices and improve the favorability of the UK market. The consultation period closed on November&#160;25, 2021 and on June&#160;26, 2022, the MHRA published a response to its consultation, which sets out the proposed new UK regulatory framework for medical devices and <i style="font-style:italic;">in vitro</i> diagnostic medical devices. The proposals are intended to improve patient safety and public health through appropriate regulatory oversight, improve the traceability of medical devices, improve the regulation of the rules&#160;governing software and AI as medical devices and introduce alternative routes to market to ensure the UK aligns with any superior international best practices. Core aspects of the new framework are expected to apply from July&#160;1, 2025 with appropriate transitional measures and the introduction of secondary legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Crescent fails to comply with applicable foreign regulatory requirements, Crescent may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">250</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation of Medicinal Products in Australia</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Australian Therapeutic Goods Administration (&#8220;TGA&#8221;) and the National Health and Medical Research Council (&#8220;NHMRC&#8221;) set the GCP requirements for clinical research in Australia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Compliance with the regulations, standards and codes set by the TGA and NHMRC is mandatory. Under the Therapeutic Goods Act 1989 (Cth) and the Therapeutic Goods Regulations 1990 (Cth), it is a condition (amongst other conditions) of all clinical trials involving investigational medicinal products to comply with the National Statement on Ethical Conduct in Research Involving Humans, published by the NHMRC (the &#8220;National Statement&#8221;), and the Guideline for Good Clinical Practice published by the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (&#8220;ICH Guidelines&#8221;). The ICH Guidelines have been adopted in Australia and must be complied with across all fields of clinical research involving therapeutic goods, including those related to pharmaceutical quality, nonclinical and clinical data requirements and trial designs. The basic requirements for preclinical data to support a first-in-human trial under ICH Guidelines are applicable in Australia. Requirements related to adverse event reporting in Australia are generally similar to those required in other major jurisdictions, although reporting timeframes may differ to other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials conducted using &#8220;unapproved therapeutic goods&#8221; in Australia, being those which have not yet been evaluated by the TGA for quality, safety and efficacy (and including unapproved indications of therapeutic goods which have otherwise been approved for use in Australia) must occur pursuant to either the Clinical Trial Notification Scheme (&#8220;CTN Scheme&#8221;) or the Clinical Trial Approval Scheme (&#8220;CTA Scheme&#8221;). In each case, the trial is supervised by a Human Research Ethics Committee (&#8220;HREC&#8221;), an independent review committee constituted in accordance with the National Statement that ensures the protection of rights, safety and well-being of human subjects involved in a clinical trial. An HREC reviews, approves and provides continuing oversight of trial protocols (including any amendments), methods and materials intended to be used in obtaining and documenting informed consent of the clinical trial subjects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The CTN Scheme broadly involves:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to an HREC, of all material relating to the proposed clinical trial, including the trial protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the HREC reviews the scientific validity of the trial design, the balance of risk versus harm of the therapeutic good, the ethical acceptability of the trial process, and approves the trial protocol. The HREC is also responsible for monitoring the conduct of the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the institution or organization at which the trial will be conducted (the &#8220;Approving Authority&#8221;) giving final approval for the conduct of the trial at the site, in terms no less restrictive to those advised by the HREC; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the investigator submitting a &#8216;Notification of Intent to Conduct a Clinical Trial&#8217; form (&#8220;CTN Form&#8221;) to the TGA. The CTN Form&#160;must be signed by the sponsor, the principal investigator, the chairman of the HREC and a person responsible from the Approving Authority. The TGA does not review any data relating to the clinical trial however CTN trials cannot commence until the trial has been notified to the TGA. It is the responsibility of the sponsor to ensure that all relevant approvals are in place before supplying the &#8220;unapproved&#8221; therapeutic goods in clinical trials in Australia.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the CTA Scheme:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a sponsor submits an application to conduct a clinical trial to the TGA for evaluation and comment, which includes payment of relevant fees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the TGA will undertake a preliminary assessment to ensure that there is sufficient data to begin evaluation. If critical data is missing, the TGA may request further information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a sponsor must forward any comments made by the TGA delegate to the HREC(s)&#160;at the sites where the trial will be conducted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the HREC is responsible for considering the scientific and ethical issues of the proposed trial protocol.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">251</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A sponsor cannot commence a trial under the CTA Scheme until written advice has been received from the TGA regarding the application and approval for the conduct of the trial has been obtained from an ethics committee and the institution at which the trial will be conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Approval for inclusion in the Australian Register of Therapeutic Goods (&#8220;ARTG&#8221;) is required before a therapeutic good (including pharmaceutical product) may be marketed (or supplied, imported, exported or manufactured) in Australia. Exceptions apply to therapeutic goods/pharmaceutical products that are supplied, imported, and exported to and from Australia for the purposes of a clinical trial, on the basis that certain conditions are met (e.g., the trial is conducted in accordance with the CTN or CTA Scheme).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once a sponsor decides to register a therapeutic good/pharmaceutical product in Australia, in order to obtain registration of the product on the ARTG, it is required that (amongst others):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sponsor submits appropriate documentation, including the outcomes of clinical trials and studies, to allow the TGA to assess the quality, safety and efficacy of the therapeutic product/ pharmaceutical product; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sponsor submits evidence which demonstrates that the manufacture of the therapeutic product/ pharmaceutical product complies with the applicable GMP requirements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The TGA has the ultimate discretion to decide whether to include the therapeutic product/ pharmaceutical product in the ARTG.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation of Medical Products in New Zealand</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials in New Zealand are regulated under the Medicines Act 1981 (&#8220;Medicines Act&#8221;) and Medicines Regulations 1984.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trial Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The New Zealand Medicines and Medical Devices Safety Authority (&#8220;Medsafe&#8221;) is the regulatory authority that administers the application and approval process for medicines and clinical trials in New Zealand (under delegation from the Director-General of Health). Approval from Medsafe is required in the following two circumstances:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">before a medicine can be distributed in New Zealand&#8201;-&#8201;see &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Approval for Distribution</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221; below; however, there is an exemption from this approval requirement for medicines that are imported or manufactured for the sole purpose of use in a clinical trial (including pharmacokinetic, bioequivalence and first-in-human studies); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for all clinical trials involving unapproved medicines carried out in New Zealand; however, if a medicine is already approved by Medsafe for distribution in New Zealand, then there is no separate requirement to obtain approval for clinical trials with that medicine (including if the medicine is being tested for a use not provided for under its existing authorization).</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Medsafe also expects all clinical trials to be carried out in accordance with internationally accepted standards for good clinical practice as published by the EMA in its Guideline for Good Clinical Practice, to the extent that these standards are compatible with the Medicines Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trial Approval Process</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The clinical trial approval process requires submission of an online application to Medsafe. The application must include information about the nature of the medicine, the purpose of the trial, details of the investigators conducting the trial, written consent to nomination from each investigator, copies of information supplied to the investigators, a protocol of the trial, and details of the sites and facilities used. The application must be made by the actual or intended importer, manufacturer, packer, or supplier of the medicine in New Zealand. Once approved, the applicant becomes the &#8220;sponsor&#8221; and assumes responsibility and legal liability for the trial in New Zealand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Once an application is received, Medsafe provides it to the Health Research Council of New Zealand (&#8220;HRC&#8221;). One of two HRC standing committees will consider the application and make a recommendation to Medsafe as to whether the clinical trial should be approved (with or without conditions) or declined. The Standing Committee on Therapeutic Trials considers pharmaceutical medicine trial applications, while the Gene Technology Advisory Committee considers applications for trials involving gene and other </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">252</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">biotechnology therapies. Both standing committees undertake a similar scientific assessment process, and consider factors such as trial protocol and design, data collection, and general compliance with the Guideline for Good Practice before making a recommendation to Medsafe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Ethical Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Medsafe expects all clinical trials to be approved by the Health and Disability Ethics Committee (&#8220;HDEC&#8221;), regardless of whether Medicines Act approval is required. HDEC reviews and approves applications and provides ongoing oversight of clinical trials to ensure alignment with good ethical practice. HDEC approval can be sought before, during, or after Medicines Act approval is sought from Medsafe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Registration</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A clinical trial&#8217;s sponsor may register a trial with the Australian New Zealand Clinical Trials Registry (&#8220;ANZCTR&#8221;), an online public registry of clinical trials undertaken in New Zealand, Australia, and elsewhere. While not mandatory, the ANZCTR is a recognized part of the World Health Organisation Registry Network and registration is encouraged by the World Health Organisation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Approval for Distribution</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a sponsor decides to distribute the new medicine product in New Zealand after the clinical trial, the sponsor must apply for distribution approval. This is separate to the approval process for clinical trials and involves submitting an application to Medsafe for consideration. Medsafe assesses the safety, efficacy, quality and risk profile of the medicine, and makes a recommendation to the Minister of Health as to whether the medicine should be approved for distribution (in practice, the Minister follows Medsafe&#8217;s recommendation).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employees and Human Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of February&#160;7, 2025, Crescent had six full-time employees. Crescent also engages temporary employees and consultants to augment its existing workforce. None of Crescent&#8217;s employees are represented by a labor union or covered under a collective bargaining agreement. Crescent considers its relationship with its employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent recognizes that attracting, motivating, and retaining talent at all levels is vital to continuing its success. Crescent invests in its employees through high-quality benefits, professional development opportunities, and various health and wellness initiatives and offers competitive compensation packages (base salary and incentive plans), ensuring fairness in internal compensation practices. The principal purposes of Crescent&#8217;s incentive plans (bonus and equity) are to align with the long-term interests of its stakeholders and stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Properties and Facilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent currently operates as a virtual company and does not maintain physical corporate offices. Crescent&#8217;s employees currently work remotely. Crescent believes these arrangements support its current needs. Crescent maintains a mailing address at 221 Crescent Street Building 23, Suite&#160;105, Waltham, MA 02453.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, Crescent may become involved in legal proceedings. Crescent is not currently a party to or aware of any proceedings that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on Crescent because of defense and settlement costs, diversion of management resources and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">253</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6f4d872c_c756_4007_99df_df9cd0074e22"></a><a id="GLYCOMIMETICSMANAGEMENTSDISCUSSIONANDANA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">GLYCOMIMETICS&#8217; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS</b><b style="font-weight:bold;text-transform:uppercase;"> OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion of GlycoMimetics&#8217; financial condition and results of operations in conjunction with the financial statements and the related notes thereto and other financial information included elsewhere in this proxy statement/prospectus. The following discussion contains forward-looking statements that reflect GlycoMimetics&#8217; current plans, estimates and beliefs. GlycoMimetics&#8217; historical results are not necessarily indicative of the results that may be expected for any period in the future. GlycoMimetics&#8217; actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this proxy statement/prospectus, particularly in the section titled &#8220;Risk Factors.&#8221; Please also see the section titled &#8220;Cautionary Note&#160;Regarding Forward-Looking Statements.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview and Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics is a biotechnology company that was previously developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation. GlycoMimetics&#8217; previous lead glycomimetic drug candidate, uproleselan, is a specific E-selectin antagonist that GlycoMimetics was developing to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. GlycoMimetics conducted a randomized, double-blind, placebo-controlled Phase 3 pivotal clinical trial to evaluate uproleselan in individuals with relapsed/refractory (R/R) AML. In May&#160;2024, GlycoMimetics reported topline results from the Phase 3 trial, in which uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat (&#8220;ITT&#8221;) population versus chemotherapy alone. In June&#160;2024, GlycoMimetics announced comprehensive results of the Phase 3 trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the announcement of the data from the Phase 3 trial, GlycoMimetics requested and held a meeting with the FDA to discuss whether any of the results summarized above could serve as a basis for a submission for regulatory approval. Based on the feedback received, GlycoMimetics concluded that any potential regulatory path for uproleselan in this patient population would require an additional clinical trial, the conduct of which would require capital resources beyond those available to GlycoMimetics. The decision to not conduct an additional clinical trial did not relate to any safety or medical issues or negative regulatory feedback related to its programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2024, following the announcement of the data from its Phase 3 pivotal trial and its discussions with the FDA, GlycoMimetics announced that GlycoMimetics would initiate a review of strategic alternatives focused on maximizing stockholder value, which could include, but are not limited to, a merger, sale, divestiture of assets, licensing, or other strategic transaction. GlycoMimetics also reduced its workforce by approximately 80% in the third quarter of 2024 in order to conserve its cash resources as part of a streamlined operating plan while GlycoMimetics undertook its strategic review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics also previously entered into a Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute, or NCI, part of the National Institutes of Health, to conduct a Phase 2/3 randomized, controlled clinical trial testing the addition of uproleselan to a standard chemotherapy regimen. On October&#160;29, 2024 GlycoMimetics announced data from the Phase 2 portion of the trial showing no statistically significant improvement in event-free survival (&#8220;EFS&#8221;) for patients receiving uproleselan in combination with chemotherapy versus chemotherapy alone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following these outcomes of its clinical trials and regulatory discussions GlycoMimetics does not currently intend to continue development of uproleselan or any of its other drug candidates. GlycoMimetics currently does not have any ongoing clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Merger Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the strategic review described above, on October&#160;28, 2024 GlycoMimetics entered into the Merger Agreement with Crescent, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors, pursuant to which Crescent will become a wholly owned subsidiary of GlycoMimetics and GlycoMimetics will operate under the name Crescent Biopharma,&#160;Inc. following the Merger. GlycoMimetics anticipates that the Merger will close in the late second quarter of 2025, subject to certain closing conditions, along with the concurrent Crescent Pre-Closing Financing. Following the Merger, the current business of Crescent will become the primary business of GlycoMimetics.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">254</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on its current operating plan, GlycoMimetics expects that its current cash and cash equivalents will fund its operations until the closing of the contemplated Merger, which is subject to approval by its stockholders and the stockholders of Crescent and other customary closing conditions; however, GlycoMimetics has based this estimate on assumptions that may prove to be wrong, and GlycoMimetics could use its capital resources sooner than GlycoMimetics expects. If the contemplated Merger does not close by the third quarter of 2025, GlycoMimetics may seek other strategic alternatives or liquidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; management&#8217;s discussion and analysis of its financial condition and results of operations is based on its financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements requires GlycoMimetics to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the balance sheets and the reported amounts of revenue and expenses during the reporting periods. In accordance with GAAP, GlycoMimetics bases its estimates on historical experience and on various other assumptions that GlycoMimetics believes are reasonable under the circumstances at the time such estimates are made. Actual results may differ materially from its estimates and judgments under different assumptions or conditions. GlycoMimetics periodically reviews its estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in GlycoMimetics&#8217; financial statements prospectively from the date of the change in estimate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics defines its critical accounting policies as those accounting principles generally accepted in the United States that require GlycoMimetics to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on its financial condition and results of operations, as well as the specific manner in which GlycoMimetics applies those principles. While its significant accounting policies are more fully described in Note&#160;3 to its financial statements appearing elsewhere in this proxy statement/prospectus, GlycoMimetics believes the following are the critical accounting policies used in the preparation of its financial statements that require significant judgments and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has issued stock-based compensation awards to its employees and non-employee directors, including stock options. GlycoMimetics measures stock-based compensation expense related to these awards based on the fair value of the award, utilizing the Black-Scholes-Merton option pricing model, on the date of grant and recognize stock-based compensation expense on a straight-line basis over the requisite service period of the awards, which generally equals the vesting period. GlycoMimetics accounts for forfeitures as they occur. GlycoMimetics previously granted stock options with exercise prices equal to the estimated fair value of its common stock on the date of grant. The Black-Scholes-Merton option pricing model requires the input of various assumptions that require management to apply judgment and make assumptions and estimates, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risk-Free Interest Rate</b>&#8212;The risk-free interest rate assumption is based on observed interest rates for constant maturity U.S. Treasury securities consistent with the expected life of GlycoMimetics&#8217; employee stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Expected Term</b>&#8212;The expected life represents the period of time the stock options are expected to be outstanding and is based on the simplified method. Under the simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the contractual term. GlycoMimetics used the simplified method due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Expected Volatility</b>&#8212;Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. GlycoMimetics based the expected volatility on the historical volatility of its publicly traded common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Expected Dividend Yield</b>&#8212;GlycoMimetics has assumed no dividend yield because it does not expect to pay dividends in the future, which is consistent with its history of not paying dividends.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">255</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Components of Operating Results</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has not generated any revenue from the sale of its drug candidates and does not expect to generate any revenue from the sale of drugs in the near future. Substantially all of its historical revenue consisted of upfront and milestone payments under license and collaboration agreements. GlycoMimetics does not expect to recognize revenue in the future under any current license or collaboration agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses have consisted of expenses incurred in performing research and development activities, including compensation and benefits for full-time research and development employees, facilities expenses, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, fees paid to CROs and other consultants and other outside expenses. Other preclinical research and platform programs have included activities related to exploratory efforts, target validation, lead optimization for GlycoMimetics&#8217; earlier programs and its proprietary glycomimetics platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has not utilized a formal time allocation system to capture expenses on a project-by-project basis because GlycoMimetics was organized and recorded expense by functional department and its employees allocated time to more than one development project. Accordingly, GlycoMimetics has only allocated a portion of its research and development expenses by functional area and by drug candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities were deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses have consisted primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, accounting, business development and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters and fees for accounting and consulting services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other income consists of interest income earned on GlycoMimetics&#8217; cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth GlycoMimetics&#8217; results of operations:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.94%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:bottom;width:22.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Increase/(Decrease)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(5,812)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(964)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Restructuring and asset impairment charges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">40,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">39,285</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(40,039)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(39,275)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(764)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Gain on sale of asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(1,441)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(61)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total other income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(216)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(37,879)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(36,899)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(980)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">256</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2024 and 2023, GlycoMimetics recognized $0 and $10,000, respectively, in revenue from its license agreements with Apollomics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes GlycoMimetics&#8217; research and development expense by functional area:</p><a id="tblDLtable"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:bottom;width:22.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Increase/(Decrease)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Clinical development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(3,443)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(53)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Manufacturing and formulation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,145</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Contract research services, consulting and other costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(608)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(34)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Laboratory costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">780</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(768)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel-related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(3,798)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">910</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(5,812)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes GlycoMimetics&#8217; research and development expense by drug candidate:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:bottom;width:22.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Increase/(Decrease)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Uproleselan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(116)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">GMI-1687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(1,429)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(82)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other research&#160;and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(830)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(37)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel-related and stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(3,437)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(40)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(5,812)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; research and development expense for the&#160;year ended December&#160;31, 2024 decreased by $5.8 million compared to 2023 primarily due to GlycoMimetics&#8217; winding down of operations beginning in June&#160;2024 following the results from its clinical trials. During 2023, GlycoMimetics accrued amounts for the expected payments of&#160;year-end bonuses to employees; as no bonuses are payable for the&#160;year ended December&#160;31, 2024, GlycoMimetics did not record any further accruals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the components of GlycoMimetics&#8217; general and administrative expense:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.92%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(dollars in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:bottom;width:22.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Increase/(Decrease)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel-related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,434</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,927</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(1,493)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Legal, consulting and other professional expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(303)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(26)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:47.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.95%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(964)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses decreased by $1.0 million for the&#160;year ended December&#160;31, 2024 as compared 2023. This decrease was primarily due to lower personnel-related expenses, including no bonus accruals for 2024. These decreases were offset by higher stock-based compensation expenses incurred 2024 as compared to 2023 due to stock options granted in 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Gain on Sale of Asset</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2024, GlycoMimetics sold the rights to one of its prior drug candidates, rivipansel, for cash proceeds of $1.2 million. As GlycoMimetics had previously written down this asset to zero value in the prior&#160;year, GlycoMimetics recorded a $1.2 million gain on sale of asset during the&#160;year ended December&#160;31, 2024.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">257</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restructuring and Asset Impairment Charges</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2024 GlycoMimetics undertook a reduction of its headcount and incurred $7.0 million of severance and related expenses. GlycoMimetics also recorded $0.5 million of charges related to the restructuring.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2024, interest income decreased by $1.4 million due to lower invested cash and cash equivalent balances as compared to the same period in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sources of Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics historically financed its operations primarily through public offerings and private placements of its capital stock, including at-the-market equity sales agreements and upfront and milestone payments from its license and collaboration agreements. As of December&#160;31, 2024, GlycoMimetics had $10.7 million in cash and cash equivalents. Based on its current operating plan, GlycoMimetics expects that its current cash and cash equivalents will fund its operations until the closing of the Merger, which is subject to approval by its stockholders and the stockholders of Crescent and other customary closing conditions; however, GlycoMimetics has based this estimate on assumptions that may prove to be wrong, and GlycoMimetics could use its capital resources sooner than GlycoMimetics expects. If GlycoMimetics is unable to close the Merger or raise additional capital, GlycoMimetics will need to eliminate some or all of its operations or liquidate. The Crescent Pre-Closing Financing is subject to the satisfaction or waiver of the closing conditions of the Merger and would close immediately prior to the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2022, GlycoMimetics filed a shelf registration statement with the SEC, which was declared effective on April&#160;22, 2022. In April&#160;2022, GlycoMimetics entered into an at-the-market sales agreement, or the Sales Agreement, with Cowen and Company. Under the Sales Agreement, GlycoMimetics may sell up to $100.0 million in shares of its common stock. During the&#160;years ended December&#160;31, 2023 and 2022, GlycoMimetics sold shares of common stock under the Sales Agreement, for aggregate net proceeds of $28.7 million and $4.2 million, respectively, after deducting commissions and offering expenses. There were no shares sold in the&#160;year ended December&#160;31, 2024. As of December&#160;31, 2024, $66.0 million remained available to be sold under the Sales Agreement, although GlycoMimetics has no current plans to sell additional shares under the Sales Agreement prior to the closing of the Merger, and the shelf registration will expire in April&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics entered into a collaboration and license agreement with Apollomics in 2020 and are potentially eligible to earn milestone payments and royalties under that agreement. However, GlycoMimetics&#8217; ability to earn milestone payments and potential royalty payments and their timing will be dependent upon the outcome of Apollomics&#8217; activities and is therefore uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Funding Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics&#8217; primary uses of capital were historically compensation and related expenses, third-party clinical research and development services, clinical costs, legal and other regulatory expenses and general overhead costs. Now that GlycoMimetics has suspended all of its research and development activities in anticipation of the Merger with Crescent, its operations will be limited and GlycoMimetics expects that its expenses will decrease significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, GlycoMimetics&#8217; only contractual obligation consisted of the remaining rent obligation of $67,000 for office space that expired at the end of January&#160;2025. Due to the outcome of GlycoMimetics&#8217; Phase 3 clinical trial, GlycoMimetics does not anticipate any funding requirements to arise under GlycoMimetics&#8217; collaboration and license agreement with Apollomics&#8217; or other manufacturing agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The accompanying financial statements have been prepared assuming that GlycoMimetics will continue as a going concern within one&#160;year after the date that the financial statements are issued. During 2024, GlycoMimetics incurred a net loss of $37.9 million and had net cash flows used in operating activities of $31.1 million. At December&#160;31, 2024, GlycoMimetics had $10.7 million in cash and cash equivalents and had no committed source of additional funding. Management believes that given GlycoMimetics&#8217; current cash position and forecasted negative cash flows from operating activities over the next twelve&#160;months, there is substantial doubt about its </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">258</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ability to continue as a going concern after the date that is one&#160;year from the date that these financial statements are issued without the closing of the contemplated Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the contemplated Merger does not close by the late second quarter of 2025, GlycoMimetics may seek other strategic alternatives or liquidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes GlycoMimetics&#8217; cash flows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash provided by (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(31,098)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(34,880)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(31,073)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(6,078)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was $31.1 million during the&#160;year ended December&#160;31, 2024 compared to $34.9 million during the&#160;year ended December&#160;<span style="white-space:pre-wrap;">31, 2023.  The decrease is due to GlycoMimetics&#8217; winding down of operations beginning in June&#160;2024 following the results from its clinical trials, offset in part by increased costs for GlycoMimetics&#8217; corporate restructuring.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by investing activities for the&#160;year ended December&#160;31, 2024 was from proceeds from the sale of laboratory equipment net of purchases of computer, office and laboratory equipment. Net cash used in investing activities for the&#160;year ended December&#160;31, 2023 was from the purchases of computer, office and laboratory equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities during the&#160;year ended December&#160;31, 2024 consisted of proceeds received from stock option exercises. Net cash provided by financing activities during the&#160;year ended December&#160;31, 2023 primarily consisted of the net proceeds received from sales of GlycoMimetics common stock under the Sales Agreement of $28.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">259</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_76524114_d6c7_4cff_8bb4_dff5819aca16"></a><a id="CRESCENTSMANAGEMENTSDISCUSSIONANDANALYSI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF</b><b style="font-weight:bold;text-transform:uppercase;"> OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion of Crescent&#8217;s financial condition and results of operations in conjunction with the financial statements and the related notes thereto and other financial information included elsewhere in this proxy statement/prospectus. The following discussion contains forward-looking statements that reflect Crescent&#8217;s current plans, estimates and beliefs. Crescent&#8217;s historical results are not necessarily indicative of the results that may be expected for any period in the future. Crescent&#8217;s actual results and the timing of events could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this proxy statement/prospectus, particularly in the section titled &#8220;Risk Factors.&#8221; Please also see the section titled &#8220;Cautionary Note&#160;Regarding Forward-Looking Statements.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab, marketed by Merck as Keytruda&#174;, the best-selling drug in the world and approved for the treatment of numerous cancers. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti - PD - 1/anti - VEGF antibody in development by Akeso Biopharma and Summit Therapeutics Inc. that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent believes the emerging data from the clinical development of ivonescimab allows for the acceleration of the development of CR-001. Following the precedents set by traditional PD-1 inhibitors, such as Keytruda and Opdivo&#174;, Crescent plans to systematically seek regulatory approvals for CR-001 to treat multiple solid tumor indications, both as a monotherapy and in combination with other mechanisms of action. Crescent intends to submit an Investigational New Drug application to the FDA for CR-001 in the fourth quarter of 2025, with initial clinical data anticipated in the second half of 2026. Crescent plans to complement CR-001 with a portfolio of product candidates that have potential activity against solid tumors both as a monotherapy as well as in combination with CR-001. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates against validated oncology targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its inception in September&#160;2024, Crescent has devoted substantially all of its resources to raising capital, organizing and staffing Crescent, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties, and providing general and administrative support for these operations. Crescent does not have any programs approved for sale and has not generated any revenue from product sales. To date, Crescent has funded its operations primarily with proceeds from the issuance of its Convertible Notes&#160;and convertible preferred stock. In September&#160;2024, Crescent received $4.0 million in gross proceeds from the issuance of Series&#160;Seed Preferred Stock. Additionally, in October&#160;2024, Crescent received gross proceeds of $37.5 million, with a total commitment up to $75.0 million, from the issuance of the Convertible Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent has incurred operating losses since inception. Crescent&#8217;s ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs Crescent may develop. Crescent incurred net losses of $17.9 million for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024. As of December&#160;31, 2024, Crescent had an accumulated deficit of $17.9 million. Crescent expects to continue to incur significantly increased expenses for the foreseeable future if and as it:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advances its existing and future research and development and discovery-related development of its CR-001 and CR-002 programs, including potential expansion into additional indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks and identifies additional research programs and product candidates and initiates discovery- related activities and preclinical studies for those programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completes future preclinical studies for Crescent&#8217;s pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursues investigational new drug applications or comparable foreign applications that allow commencement of Crescent&#8217;s planned clinical trials or future clinical trials for any programs Crescent may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiates enrollment and successfully completes clinical trials;</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">260</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursues positive results from Crescent&#8217;s future clinical trials that support a finding of safety and effectiveness, an acceptable risk-benefit profile in the intended populations and a competitive efficacy, safety and half-life profile;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hires research and development, clinical, manufacturing and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adds operational, financial and management information systems and personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">experiences any delays, challenges, or other issues associated with the preclinical and clinical development of Crescent&#8217;s programs, including with respect to its regulatory strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develops, maintains and enhances a sustainable, scalable, reproducible and transferable clinical and commercial-scale cGMP capabilities through a third-party or Crescent&#8217;s own manufacturing facility for the programs Crescent may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeks, obtains and maintains regulatory approvals for any product candidates for which Crescent successfully completes clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ultimately establishes a sales, marketing and distribution infrastructure to commercialize any programs for which Crescent may obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">generates revenue from commercial sales of product candidates for which Crescent receives regulatory approval, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintains safety, tolerability and efficacy profile of any product Crescent may develop in additional indications following approval in one indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintains, expands, enforces, defends and protects Crescent&#8217;s intellectual property portfolio and other intellectual property protection or regulatory exclusivity for any products Crescent may develop and defends any intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">further acquires or in-licenses product candidates or programs, intellectual property and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishes and maintains any future collaborations, including making milestone, royalty or other payments thereunder; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incurs additional costs of operating as a public company, including increased costs of audit, legal, regulatory and tax-related services associated with maintaining compliance with an exchange listing and SEC requirements, director and officer insurance premiums and investor and public relations costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any changes in the outcome of any of these variables with respect to the development of programs that Crescent may identify could mean a significant change in the costs and timing associated with the development of such programs. For example, if the U.S. Food and Drug Administration or another comparable regulatory authority were to require Crescent to conduct clinical trials beyond those that Crescent currently anticipates will be required to complete clinical development and obtain regulatory approval of one or more product candidates, or if Crescent experiences significant delays in Crescent&#8217;s preclinical studies or clinical trials, Crescent would be required to expend significant additional financial resources and time to advance and complete clinical development. Crescent may never obtain regulatory approval for any of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent will not generate revenue from product sales unless and until it successfully initiates and completes clinical development and obtains regulatory approval for any product candidates. If Crescent obtains regulatory approval for any of its product candidates and does not enter into a commercialization partnership, it expects to incur significant expenses related to developing Crescent&#8217;s commercialization capability to support product sales, manufacturing, marketing, and distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As a result of all the foregoing, Crescent expects to need substantial additional funding to support its continued operations and growth strategy. Until such a time as Crescent can generate significant revenue from product sales, if ever, it expects to finance its operations through the sale of equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. Crescent may be unable to raise additional funds or enter into such other agreements on favorable terms, or at </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">261</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">all. If Crescent fails to raise capital or enter into such agreements as, and when needed, Crescent may have to significantly delay, scale back or discontinue the development and commercialization of one or more of its programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks associated with product development, Crescent is unable to accurately predict the timing or amount of increased expenses or when or if Crescent will be able to achieve or maintain profitability. Even if Crescent is able to generate product sales, Crescent may not become profitable. If Crescent fails to become profitable or is unable to sustain profitability on a continuing basis, then Crescent may be unable to continue its operations at planned levels and be forced to reduce or terminate its operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, Crescent had cash of $34.8 million. Based on its current operating plan, Crescent has concluded that there is substantial doubt about its ability to continue as a going concern within the 12&#160;months after the date Crescent&#8217;s financial statements for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024 are available to be issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics and Crescent entered into the Merger Agreement on October&#160;28, 2024, which agreement was subsequently amended on February&#160;<span style="white-space:pre-wrap;">14, 2025, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Gemini Merger Sub Corp.,  the First Merger Sub, will merge with and into Crescent, with Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the First Merger, and Crescent will merge with and into Gemini Merger Sub II, LLC, the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger. After the completion of the Merger, Second Merger Sub will change its corporate name to &#8220;Crescent Biopharma Operating Company, LLC&#8221; and GlycoMimetics will change its name to &#8220;Crescent Biopharma,&#160;Inc.&#8221; The term Combined Company refers to the post-Merger corporate structure including Crescent Biopharma,&#160;Inc. (f/k/a GlycoMimetics,&#160;Inc.) as the parent entity and Crescent Biopharma Operating Company, LLC as its wholly-owned subsidiary. The Combined Company will be led by Crescent&#8217;s management team and will focus on developing differentiated oncology therapeutics for patients living with solid tumors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, Crescent and GlycoMimetics entered into the Subscription Agreement with certain institutional and accredited investors, pursuant to which such investors have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the Merger, shares of Crescent common stock and pre-funded warrants for an aggregate purchase price of $200.0 million (which includes $37.5 million of proceeds previously received by Crescent from the issuance of its Convertible Notes&#160;and accrued interest on such notes) in the Crescent Pre-Closing Financing. The closing of the Crescent Pre-Closing Financing is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and is expected to occur immediately prior to the closing of the Merger. The proceeds from the Subscription Agreement are expected to advance the Combined Company&#8217;s pipeline and will be used for research and development, business development, working capital, and other general corporate purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent estimates that the net proceeds from the Merger and the Crescent Pre-Closing Financing, together with Crescent&#8217;s existing cash as of the date of this proxy statement/prospectus, will be sufficient to enable Crescent to fund its operating expenses and capital expenditure requirements through 2027. Crescent has based this estimate on assumptions that may prove to be wrong, Crescent&#8217;s operating plan may change as a result of many factors currently unknown to Crescent and Crescent could exhaust its available capital resources sooner than Crescent expects. See the sections titled &#8220;&#8212;<i style="font-style:italic;">Liquidity and Capital Resources</i>&#8221; below and &#8220;<i style="font-style:italic;">Risk Factors&#8212;Risks Related to Crescent</i>&#8212;<i style="font-style:italic;">Risks Related to Crescent&#8217;s Financial Condition and Capital Requirements</i>&#8221; beginning on page&#160;52 of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Impact of General Economic Risk Factors on Crescent&#8217;s Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Uncertainty in the global economy presents significant risks to Crescent&#8217;s business. Crescent is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including increases in inflation, fluctuating interest rates, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), recent bank failures, geopolitical factors, including the ongoing conflicts between Russia and Ukraine and in the Middle East and the responses thereto, and supply chain disruptions. While Crescent is closely monitoring the impact of the current macroeconomic and geopolitical conditions on all aspects of Crescent&#8217;s business, including the impacts on participants in any future clinical trials and its employees, suppliers, vendors and business partners and Crescent&#8217;s future access to capital, the ultimate extent of the impact on Crescent&#8217;s business remains highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are outside Crescent&#8217;s control and could exist for an extended period of time. Crescent will continue to evaluate the nature and extent of the potential impacts to its business, results of operations, liquidity and capital resources. For additional information, see the section titled &#8220;<i style="font-style:italic;">Risk Factors&#8212;Risks Related to Crescent&#8212;General Risk Factors</i>.&#8221;</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">262</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Components of Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, Crescent has not generated revenue from any sources, including product sales, and does not expect to generate any revenue from the sale of products in the foreseeable future. If Crescent&#8217;s development efforts for its product candidates are successful and result in regulatory approval, Crescent may generate revenue in the future from product sales or payments from future collaboration or license agreements that Crescent may enter into with third parties, or any combination thereof. Crescent cannot predict if, when, or to what extent it will generate revenue from the commercialization and sale of Crescent&#8217;s product candidates. Crescent may never succeed in obtaining regulatory approval for any of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s operating expenses consist of (i)&#160;research and development expenses and (ii)&#160;general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred in connection with the research and development of Crescent&#8217;s programs. These expenses include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of funding research performed by third parties, including Paragon, that conduct research and development activities on Crescent&#8217;s behalf and services rendered under the Paragon Option Agreements for CR-001 and CR-002;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred in connection with continuing Crescent&#8217;s current research programs and discovery-phase development of any programs Crescent may identify, including under future agreements with third parties, such as consultants and contractors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expenses, including recruiting costs, salaries, bonuses, benefits and equity-based compensation expense.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent expenses research and development costs as incurred. For the period from September&#160;19, 2024 (inception) to December&#160;31, 2024, Crescent recognized $13.2 million of expenses in connection with services provided by Paragon under the Paragon Option Agreements in Crescent&#8217;s statement of operations and comprehensive loss. See the section titled &#8220;<i style="font-style:italic;">Contractual Obligations and Commitments</i>&#8221; below for further details on Crescent&#8217;s research plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel-related expenses, including recruiting costs, salaries, bonuses, benefits, and equity-based compensation, for individuals in Crescent&#8217;s executive, finance, operations, human resources, business development and other administrative functions. Other significant general and administrative expenses include legal fees relating to corporate matters and patent-related activities, insurance costs, information technology, and professional and consulting fees associated with accounting, audit, tax and investor and public relations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent expects that its general and administrative expenses will increase substantially for the foreseeable future as Crescent increases its headcount and potentially establishes office space to support its expected growth. Crescent also expects to incur increased expenses associated with the Merger and Crescent Pre-Closing Financing transactions and becoming a public company, including transactional costs and increased costs of accounting, audit, legal, regulatory and tax related services associated with maintaining compliance with SEC requirements, additional director and officer insurance costs, and investor and public relations costs. Crescent also expects to incur additional intellectual property-related expenses as Crescent files patent applications to protect innovations arising from its research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Expense, net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Other expense, net includes interest income of $0.2 million earned for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024 relating to Crescent&#8217;s money market account and interest expense of $0.9 million incurred for the period from </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">263</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:5.75pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">September&#160;19, 2024 (inception) to December&#160;31, 2024 relating to Crescent&#8217;s Convertible Notes&#160;issued to various investors in October&#160;2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No provision for income taxes was recorded for the period from September&#160;19, 2024 (inception) through December&#160;31, 2024. Crescent has recorded a full valuation allowance against its net deferred tax assets as of the balance sheet date, as Crescent believes it is not more likely than not that the benefit will be realized due to its cumulative losses generated to date and expectation of future losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations for the Period from September&#160;19, 2024 (Inception) to December&#160;31, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes Crescent&#8217;s statement of operations and comprehensive loss for the period presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;from</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">September&#160;19,&#160;2024</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Inception)&#160;to</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Research and development<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,034 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">General and administrative<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,157 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.5pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,191 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.5pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(17,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other income/(expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">176 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Interest expense <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(852)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.5pt;">Total other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(676)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(17,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes related party amount of $13,185 for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes related party amount of $571 for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes related party amount of $341 for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes Crescent&#8217;s research and development expenses incurred for the period presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;from</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">September&#160;19,&#160;2024</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Inception)&#160;to</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">External research and development costs by selected target:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">CR-001 <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,510 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">CR-002 <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,251 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other research and development costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">207 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Personnel-related (including stock-based compensation)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">61 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Other<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 11.5pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,034 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes related party amount of $9,868 for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes related party amount of $3,251 for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes related party amount of $61 for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024.</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">264</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:5.75pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes related party amount of $5 for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $14.0 million for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024 and consisted primarily of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$9.9 million of research and development expense due to Paragon for services rendered under the Antibody Paragon Option Agreement for CR-001, including $2.5 million of research and development expense due to Paragon for pre-development costs associated with CR-001;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.6 million of research and development expense related to chemistry, manufacturing, and development costs for CR-001 with a third-party contract development and manufacturing organization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.3 million of research and development expense due to Paragon for services rendered under the ADC Paragon Option Agreement for CR-002; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.2 million of professional fees related to hiring of Crescent&#8217;s research and development team.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes Crescent&#8217;s total general and administrative expenses for the period presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.95%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;from</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">September&#160;19,&#160;2024&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Inception)&#160;to</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Professional and consulting fees<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,774</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel-related (including stock-based compensation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,153</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Legal fees related to patent<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">147</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">83</p></td></tr><tr><td style="vertical-align:bottom;width:82.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Total general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.6%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,157</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes related party amount of $405 for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes related party amount of $140 for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes related party amount of $26 for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $3.2 million for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024 and consisted primarily of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.8 million of professional and consulting fees associated with accounting, audit, investor and public relations, and legal fees due to an increase in Crescent&#8217;s business activity and as Crescent began preparing to become a public company, including $0.4 million reimbursed to Paragon for such services provided;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.2 million of personnel-related costs related to recruiting costs, salaries, benefits and other compensation-related costs, including stock-based compensation of $1.1 million;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1 million of legal fees due to Paragon associated with patent-related activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1 million of other business expenses.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">265</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sources of Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its inception, Crescent has incurred significant operating losses. Crescent expects to incur significant expenses and operating losses for the foreseeable future as Crescent continues the preclinical development of its programs and commences clinical development of CR-001 and CR-002. Crescent has not yet commercialized any products and Crescent does not expect to generate revenue from sales of products for several&#160;years, if at all. To date, Crescent has funded its operations primarily with proceeds from the issuance of Series&#160;Seed convertible preferred stock and the sale of Crescent&#8217;s Convertible Notes. In September&#160;2024, Crescent issued and sold 20,000,000 shares of Series&#160;Seed Preferred Stock to Fairmount, through an affiliate fund, at a purchase price of $0.20 per share, for total gross proceeds of $4.0 million, which qualifies as a related party transaction. In October&#160;2024, Crescent received $37.5 million in net proceeds from the issuance of its Convertible Notes&#160;to several investors, of which Fairmount, through an affiliate fund, holds a convertible note with an initial principal amount of $15.0 million, which qualifies as a related party transaction. As of December&#160;31, 2024, Crescent had cash of $34.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes Crescent&#8217;s cash flows for the period presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;from</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">September&#160;19,&#160;2024&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Inception)&#160;to&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(6,269)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">41,035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Net increase in cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.5%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">34,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.64%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Used in Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From September&#160;19, 2024 (inception) to December&#160;31, 2024, net cash used in operating activities was $6.3 million, which was primarily attributable to a net loss of $17.9 million, offset by non-cash charges of $2.1 million and net cash provided by changes in operating activities of $9.5 million. Non-cash charges consisted of a $1.1 million increase in stock-based compensation expense and $1.0 million in non-cash research and development expense. Net cash provided by changes in Crescent&#8217;s operating activities primarily consisted of a $0.1 million increase in accounts payable, $2.2 million increase in accrued expenses and other current liabilities, $7.2 million increase in related parties accounts payable and other current liabilities, partially offset by less than $0.1 million increase in prepaid expenses and other current assets. The increase in amounts due to related parties, accounts payable, and accrued expenses and other current liabilities was primarily due to an increase in Crescent&#8217;s business activity, as well as vendor invoicing and payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Provided by Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From September&#160;19, 2024 (inception) to December&#160;31, 2024, net cash provided by financing activities was $41.0 million, consisting of $4.0 million of net proceeds from the issuance of Crescent&#8217;s Series&#160;Seed Preferred Stock, $0.3 million of proceeds from the issuance of common stock and $37.5 million of gross proceeds from the issuance of the Convertible Notes, partially offset by $0.8 million of payments in deferred offering costs and less than $0.1 million of debt issuance costs associated with the Convertible notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future Funding Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, Crescent has not generated any revenue from product sales. Crescent does not expect to generate revenue from product sales unless and until Crescent successfully completes preclinical and clinical development of, receives regulatory approval for, and commercializes a product candidate. Crescent does not know when, or if, that will occur. Crescent expects its expenses to increase substantially in connection with its ongoing activities, particularly as Crescent advances the preclinical activities and studies and initiates clinical trials. In addition, if Crescent obtains regulatory approval for any programs, Crescent expects to incur significant expenses related to product sales, marketing, and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. Further, upon the completion of the Merger, Crescent expects to incur additional costs associated with operating as a public company. The timing and amount of Crescent&#8217;s operating expenditures will depend largely on the factors set out above. For more information, see the section titled &#8220;<i style="font-style:italic;">Risk Factors</i><i style="font-style:italic;">&#8212;</i><i style="font-style:italic;">Risks Related to Crescent</i><i style="font-style:italic;">&#8212;</i><i style="font-style:italic;">Risks Related to Crescent&#8217;s Financial Condition and Capital Requirements&#8221;</i> beginning on page&#160;52 of this proxy statement/prospectus.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">266</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s funding requirements and timing and amount of its operating expenditures will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate of progress in the development of Crescent&#8217;s existing and future research and development and discovery-related development of its CR-001 and CR-002 programs, including potential expansion into additional indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of additional research programs and product candidates and discovery-related activities and preclinical studies for those programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of Crescent to successfully file investigational new drug applications or comparable foreign applications and obtain authorization to commence Crescent&#8217;s planned clinical trials or future clinical trials for any programs Crescent may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of enrollment and successful completion of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs necessary to pursue positive results from Crescent&#8217;s future clinical trials that support a finding of safety and effectiveness, an acceptable risk-benefit profile in the intended populations and a competitive efficacy, safety and half-life profile;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of hiring research and development, clinical, manufacturing and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of adding operational, financial and management information systems and personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs necessary to obtain regulatory approvals, if any, for any approved products in the United States and other jurisdictions, and the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of developing, maintaining and enhancing sustainable, scalable, reproducible and transferable clinical and commercial-scale cGMP capabilities through a third-party or Crescent&#8217;s own manufacturing facility for the programs Crescent may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including establishing sales, marketing and distribution infrastructure to commercialize any programs, for any of Crescent&#8217;s product candidates for which Crescent receives regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of Crescent&#8217;s product candidates for which Crescent receives marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, maintaining, expanding, enforcing, defending and protecting Crescent&#8217;s intellectual property rights and protection or regulatory exclusivity for any products Crescent may develop and defending any intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and payment of milestone, royalty or other payments Crescent must make pursuant to its existing and potential future collaborations and licensing arrangements with third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs Crescent incurs in maintaining business operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with being a public company, including costs of audit, legal, regulatory and tax- related services associated with maintaining compliance with an exchange listing and SEC requirements, director and officer insurance premiums and investor and public relations costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of competing technological and market developments; and</span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">267</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which Crescent acquires or invests in businesses, products and technologies, including entering into licensing or collaboration arrangements for programs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Identifying potential programs and product candidates and conducting preclinical studies and clinical trials is a time consuming, expensive and uncertain process that takes&#160;years to complete, and Crescent may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, Crescent&#8217;s programs, if approved, may not achieve commercial success. Crescent&#8217;s commercial revenues, if any, will be derived from sales of products that Crescent does not expect to be commercially available for many&#160;years, if ever. Accordingly, Crescent will need to obtain substantial additional funds to achieve its business objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Adequate additional funds may not be available to Crescent on acceptable terms, or at all. Crescent does not currently have any committed external source of funds. To the extent that Crescent raises additional capital through the sale of equity or convertible debt securities, ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of Crescent&#8217;s existing stockholders. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting Crescent&#8217;s ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute ownership interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Crescent raises additional funds through strategic collaborations or licensing arrangements with third parties, Crescent may have to relinquish valuable rights to its technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to Crescent. If Crescent is unable to raise additional funds through equity or debt financings when needed, Crescent may be required to delay, limit or terminate its product development programs or any future commercialization efforts or grant rights to develop and market product candidates to third parties that Crescent would otherwise prefer to develop and market itself.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, Crescent had cash of $34.8 million. Based on its current operating plan, Crescent has concluded that there is substantial doubt about its ability to continue as a going concern for at least 12&#160;months from the date Crescent&#8217;s financial statements for the period September&#160;19, 2024 (inception) to December&#160;31, 2024 are available to be issued. Crescent estimates that the net proceeds from the Merger and the Crescent Pre-Closing Financing, together with Crescent&#8217;s existing cash as of the date of this proxy statement/prospectus, will be sufficient to enable Crescent to fund Crescent&#8217;s operating expenses and capital expenditure obligations requirements through 2027. Crescent has based this estimate on assumptions that may prove to be wrong, Crescent&#8217;s operating plan may change as a result of many factors currently unknown to Crescent and Crescent could exhaust its available capital resources sooner than Crescent expects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contractual Obligations and Other Commitments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Paragon Option Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2024, Crescent entered into the Antibody Paragon Option Agreement with Paragon and Parascent for CR-001 for the selected targets PD-1 and VEGF, and in October&#160;2024, Crescent entered into the ADC Paragon Option Agreement with Paragon and Parascent for CR-002 for an undisclosed target for Crescent&#8217;s initial research programs. Parascent is an entity formed by Paragon as a vehicle to hold equity in Crescent in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreements other than to receive such warrants. Under the Paragon Option Agreements, Crescent has the Option, on a Research Program-by-Research Program basis, to enter into a separate agreement with Paragon consistent with a set of pre-negotiated terms (a &#8220;License Agreement&#8221;). If Crescent exercises its Options and finalizes the related license agreements, it will be required to make non-refundable milestone payments to Paragon of up to $22.0 million for CR-001 and up to $46.0 million for CR-002 upon the achievement of certain clinical development and regulatory milestones, as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale of each developed product. From time to time, Crescent can choose to add additional targets by mutual agreement with Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Paragon Option Agreements require Crescent, Paragon, and Parascent to develop a Research Plan for each target that includes design, modeling, synthesis, evaluation, and other mutually agreed activities, which activities primarily include performing preclinical studies. Paragon will perform the activities set forth in each Research Plan on the timelines set forth in such Research Plan and in compliance with a mutually agreed budget. Each Research Program will be overseen and coordinated by a joint development committee consisting of two employees from Crescent and two employees from Paragon, with Crescent and Paragon each having one vote with respect to decisions of the committee. When Paragon and Parascent have produced an antibody or ADC, as applicable, </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">268</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">against a selected target, and upon the completion of each Research Program, Paragon and Parascent will deliver to Crescent a data package that includes sequence information for all then-existing antibodies or ADCs, as applicable, and information directed to such target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Paragon Option Agreements, each License Agreement will include (a)&#160;an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and commercialize the monospecific antibodies or ADCs, as applicable, and products directed to the selected target(s), and (b)&#160;an exclusive (in the case of the Antibody Paragon Option Agreement) or non-exclusive (in the case of the ADC Paragon Option Agreement), worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and commercialize multispecific antibodies or ADCs, as applicable, and products directed to the selected target(s). Additionally, each License Agreement under the ADC Paragon Option Agreement will include a non-exclusive, worldwide license to certain patents controlled by Paragon or its affiliates that (i)&#160;include a claim that expressly recites the sequence of the monospecific antibody included in the ADC, or derived from the ADC, applicable to the Research Program, and (ii)&#160;are necessary to develop, manufacture, commercialize or otherwise exploit the ADC or derived ADCs applicable to the Research Program, but exclude any patents owned or otherwise controlled by Paragon or its affiliates that cover the composition of matter of, or any method of specifically making or using, a multispecific ADC or a multispecific product directed to targets other than the undisclosed CR-002 target that is developed, manufactured, commercialized or otherwise exploited by Paragon or its affiliate or sublicensee (other than Crescent and its affiliates and sublicensees). Each License under the ADC Paragon Option Agreement will further include a right of first negotiation for a set period of time after the execution of the License Agreement with regard to any multispecific ADCs or products that are developed by Paragon. The Option with respect to each Research Program is exercisable at Crescent&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following the delivery of the data package from Paragon related to the results of the Research Program (an &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements. Activities under a Research Plan may continue past the exercise of an Option or entry into a License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s Options to acquire the intellectual property rights to the Research Programs under the Paragon Option Agreements, including CR-001 and CR-002, currently remain unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of an Option with respect to a Research Program, the parties are obligated to use reasonable efforts to finalize and execute a License Agreement within 30&#160;days. Under the terms of a License Agreement, Crescent expects that it will have sole authority over and control of the development, regulatory approval, manufacturing and commercialization of such in-licensed intellectual property worldwide. In addition, Crescent expects to have sole authority over and control of the application for and issuance of all regulatory approvals related to such in-licensed intellectual property. Prior to entry into a License Agreement, Paragon is responsible for the prosecution, defense, maintenance and enforcement of patents related to the Research Program. Following entry into a License Agreement, Crescent expects to control prosecution, defense, maintenance and enforcement of patents licensed under such License Agreement. However, there is no assurance that Crescent will successfully negotiate future License Agreements with Paragon or that the terms will not differ from those described in this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Paragon Option Agreements shall continue in force on a Research Program- by-Research Program basis until the later of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by Crescent; (ii)&#160;if Crescent exercises its Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 30&#160;days, the expiration of such 30-day period (subject to any mutually agreed extension of such period); and (iii)&#160;the expiration of the applicable Research Term (as defined under the applicable Paragon Option Agreement). Crescent may terminate any Paragon Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon; provided, that Crescent must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Paragon Option Agreements or any Research Program immediately upon written notice to Crescent if, as a result of any action or failure to act by Crescent or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate any Paragon Option Agreement or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30-day period and (ii)&#160;the other party&#8217;s bankruptcy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Upon signing of the Antibody Paragon Option Agreement, Crescent was required to reimburse Paragon $1.5 million for upfront research and development costs related to CR-001 and other general and administrative costs incurred by Paragon prior to September&#160;19, 2024. Contemporaneously, Crescent also issued an aggregate of 5,000,000 shares of Crescent common stock to Paragon for aggregate non-cash upfront consideration of Paragon&#8217;s entry into the Antibody Paragon Option Agreement, valued at </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">269</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">$0.20 per share, for a total of $1.0 million. Paragon subsequently contributed 2,500,000 of such shares to Parascent. The $1.5 million of research and development costs related to CR-001 reflects the actual historical direct costs incurred by Paragon as well as a 20% mark-up on the direct costs to approximate the indirect costs incurred by Paragon from the inception of the CR-001 program to the entry into the Paragon Option Agreement. All of the costs reflected in the upfront amount were incurred by Paragon between January&#160;1, 2024 and the parties&#8217; entry into the Paragon Option Agreement. Such direct costs were related to development activities. Of these upfront development costs related to CR-001 incurred by Paragon prior to September&#160;19, 2024, a total of $1.5 million was recognized as research and development expense and less than $0.1 million was recognized as general and administrative expense during the period from September&#160;19, 2024 (inception) to December&#160;31, 2024. Crescent paid $1.5 million to Paragon in November&#160;2024. The non-cash upfront consideration was recorded as research and development expense in Crescent&#8217;s consolidated statement of operations and comprehensive loss during the period from September&#160;19, 2024 (inception) to December&#160;31, 2024 as related IP license fees associated with entering into the Option Agreement. Crescent is also required to pay Paragon for certain development fees and costs on a Research Program-by-Research Program basis. Under the Antibody Paragon Option Agreement, Crescent is also responsible for certain additional development costs incurred by Paragon, which from September&#160;19, 2024 (inception) to December&#160;31, 2024, totaled $4.7 million, and of which $4.6 million was recognized as research and development expense and $0.1 million was recognized as general and administrative expense in Crescent&#8217;s consolidated statements of operations and comprehensive loss for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024. An amount of $6.2 million is included in related party accounts payable and other current liabilities within Crescent&#8217;s balance sheet as of December&#160;31, 2024. Under the Antibody Paragon Option Agreement, Crescent is obligated to pay Paragon $1.3 million following finalization of the research plan for CR-001, which was paid in December&#160;2024. Crescent also paid a $1.5 million milestone payment to Paragon in January&#160;2025 in connection with the selection of a development candidate for CR-001.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the ADC Paragon Option Agreement, Crescent was required to pay Paragon a one-time, non-refundable research initiation fee in the amount of $2.5 million for CR-002, which was paid in December&#160;2024 and recognized as research and development expense in Crescent&#8217;s consolidated statements of operations and comprehensive loss for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024. Under the ADC Paragon Option Agreement, Crescent is required to reimburse Paragon $0.8 million for costs related to CR-002 incurred by Paragon through December&#160;31, 2024, which $0.8 million was recognized as research and development expense and less than $0.1 million was recognized in general and administrative expense in Crescent&#8217;s consolidated statement of operations and comprehensive loss during the period from September&#160;19, 2024 (inception) to December&#160;31, 2024. An amount of $0.8 million is included in related party accounts payable and other current liabilities within Crescent&#8217;s balance sheet as of December&#160;31, 2024 for development costs related to CR-002. No pre-development costs were incurred for CR-002 for periods prior to September&#160;19, 2024 (inception).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any License Agreement entered into with respect to a given Research Program shall contain the same milestone payment obligations as the applicable Paragon Option Agreement, provided that any milestone set in such Paragon Option Agreement that has not yet been achieved and is duplicated in such License Agreement shall no longer be achievable and payable under the terms of such Paragon Option Agreement and shall only be achievable under the terms of the License Agreement. For the avoidance of doubt, if a milestone is achieved and paid by Crescent pursuant to a Paragon Option Agreement for a certain Research Program, then there shall be no milestone payment due for the achievement of such milestone under a subsequently executed License Agreement for such Research Program. Further, under a License Agreement, Crescent would also be required to make royalty payments to Paragon in the low single-digit&#160;percentage range based on net sales of products, subject to certain reductions. The royalty term will terminate on a product-by-product and country-by-country basis upon the later of the expiration of the last-to-expire valid claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, on each of December&#160;31, 2025 and December&#160;31, 2026, Crescent will grant Parascent warrants to purchase a number of shares equal to 1.00% of Crescent&#8217;s outstanding capital stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares of Crescent common stock on each respective grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent considers Paragon, Parascent and Fairmount to be related parties. See the section titled &#8220;<i style="font-style:italic;">Certain Relationships and Related Party Transactions of the Combined Company&#8212;Crescent&#8217;s Relationships with Paragon, Parascent and Fairmount</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Convertible Notes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In October&#160;2024, Crescent completed convertible note financings in which Crescent issued and sold to certain investors an aggregate principal amount of $37.5 million (of which $15.0 million is from Fairmount), with a total commitment up to $75.0 million aggregate principal in Convertible Notes&#160;at an interest rate of 12% per annum. Upon a &#8220;Next Equity Financing&#8221; under the terms of the Convertible Notes, the principal amount and all accrued interest under each convertible note will convert into a number of shares of </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">270</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Crescent common stock equal to the quotient obtained by dividing the purchase price by the conversion price in connection with the Next Equity Financing. All unpaid interest and principal is scheduled to mature on December&#160;31, 2026. Prepayment is not permitted without prior written consent of the investor. Pursuant to the Subscription Agreement, the holders of the Convertible Notes&#160;have agreed to contribute such notes as consideration in exchange for shares of Crescent common stock and pre-funded warrants to purchase shares of Crescent common stock in the Crescent Pre-Closing Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, the aggregate principal amount of outstanding borrowings under Crescent&#8217;s Convertible Notes&#160;was $37.5 million, with up to $75.0 million of borrowings to withdraw in total until the maturity date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s management&#8217;s discussion and analysis of its financial condition and results of operations is based on Crescent&#8217;s financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires Crescent to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues recognized and expenses incurred during the reporting periods. Crescent&#8217;s estimates are based on its historical experience and on various other factors that Crescent believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While Crescent&#8217;s significant accounting policies are described in more detail in Note&#160;2 to its financial statements for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024 included elsewhere in this proxy statement/prospectus, Crescent believes the following accounting policies used in the preparation of Crescent&#8217;s financial statements require the most significant judgments and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Contract Costs Accruals</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of Crescent&#8217;s research and development expenses, with a substantial portion of Crescent&#8217;s ongoing research and development activities conducted by third-party service providers, including contract research organizations and contract manufacturing organizations, and Crescent&#8217;s related party Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent accrues for expenses resulting from obligations under Paragon Option Agreements between Paragon, Parascent, and Crescent and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to Crescent. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. Crescent makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to Crescent&#8217;s accruals could materially affect its results of operations. As of December&#160;31, 2024, Crescent has not experienced any material deviations between accrued and actual research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent measures stock-based awards granted to employees, directors, and non-employees in the form of stock options to purchase shares of Crescent&#8217;s common stock, based on their fair value on the date of the grant using the Black-Scholes model. Crescent measures restricted common stock awards using the difference, if any, between the purchase price per share of the award and the fair value of Crescent&#8217;s common stock at the date of grant. Compensation expense for those awards is recognized using the straight-line method over the requisite service period, which is generally the vesting period of the respective award for employees. Compensation expense for awards to non-employees with service-based vesting conditions is recognized in the same manner as if Crescent had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Crescent accounts for forfeitures as they occur. Crescent classifies its stock-based compensation expenses in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">271</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes model uses inputs that are determined by the Crescent Board on the date of grant and assumptions Crescent makes for the volatility of stock-based awards, the expected term of stock- based awards, the risk-free interest rate for a period that approximates the expected term of Crescent&#8217;s stock-based awards and its expected dividend yield. Crescent has historically been a private company and lacks company-specific historical and implied volatility information of Crescent&#8217;s stock. Therefore, Crescent estimates its expected stock volatility based on the historical volatility of a representative group of public companies in the biotechnology industry for a term equal to the remaining time of the expected term. The expected term of Crescent&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the options on the date of measurement. Crescent has estimated a 0% dividend yield based on the expected dividend yield and the fact that Crescent has never paid, and does not expect to pay, any cash dividends in the foreseeable future. See Note&#160;2 to Crescent&#8217;s financial statements included elsewhere in this proxy statement/prospectus for information concerning certain of the specific assumptions Crescent used in applying the Black-Scholes model to determine the estimated fair value of its stock options granted in the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Determination of Fair Value of Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As there has been no public market for Crescent&#8217;s common stock from September&#160;19, 2024 (inception) to December&#160;31, 2024, the estimated fair value of stock-based awards has been determined by the Crescent Board as of the date of grant, with input from management, and with consideration of additional objective and subjective factors that Crescent believed were relevant. In addition, the board of directors considered various objective and subjective factors to determine the fair value of Crescent&#8217;s share-based awards as of each grant date, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prices at which Crescent sold shares of Crescent preferred stock and preferences of the Crescent preferred stock relative to its stock-based awards at the time of each grant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s common stock valuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of Crescent&#8217;s research and development programs, including the status of discovery-phase studies for Crescent&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s stage of development and business strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external market conditions affecting the biotechnology industry and trends within the biotechnology industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s financial position, including cash on hand, and its historical and forecasted performance and operating results; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of an active public market for Crescent&#8217;s common stock and Crescent preferred stock at the grant dates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent&#8217;s common stock valuations were prepared using a hybrid method, including an option pricing method (&#8220;OPM&#8221;). The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted expected return method (&#8220;PWERM&#8221;), where the equity value in one or more of the scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for a company, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if Crescent had used significantly different assumptions or estimates, the fair value of Crescent&#8217;s incentive shares and its stock-based compensation expense could have been materially different.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">272</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once a public trading market for Crescent&#8217;s common stock has been established in connection with the completion of the Merger, it is no longer necessary for the board of directors to estimate the fair value of Crescent&#8217;s stock-based awards in connection with its accounting for granted stock-based awards or other such awards Crescent may grant, as the fair value of its common stock and share-based awards is determined based on the quoted market price of Crescent&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Convertible Notes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2024, Crescent has issued $37.5 million in convertible notes to certain investors. Crescent accounts for its convertible notes under Accounting Standard Codification (&#8220;ASC&#8221;) No.&#160;815, Derivatives and Hedging (&#8220;ASC 815&#8221;). Under ASC 815-15-25, the election can be at the inception of a financial instrument to account for the instrument under ASC No.&#160;825, Fair Value Measurements and Disclosures (Including the Fair Value Option) (&#8220;ASC 825&#8221; and the &#8220;Fair Value Option&#8221;). Crescent performed an analysis of all of the terms and features of the convertible notes and has not elected the Fair Value Option. Crescent assessed all terms and features of the Convertible Note&#160;in order to identify any potential embedded features that would require bifurcation. As part of this analysis, Crescent assessed the economic characteristics and risks of the embedded features. Crescent determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting. Crescent determined that the conversion options of the Convertible Note, including the conversion features related to a defaulting purchaser and highest interest rate, were not clearly and closely associated with a debt host. However, these features did not meet the definition of a derivative under ASC 815, Derivatives and Hedging, and as a result, did not require separate accounting as a derivative liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Issued Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A description of recently issued accounting pronouncements that may potentially impact Crescent&#8217;s financial position, results of operations or cash flows is disclosed in Note&#160;2 to Crescent&#8217;s financial statements as of December&#160;31, 2024 included elsewhere in this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the periods presented Crescent did not have, nor does Crescent currently have, any off-balance sheet arrangements as defined in the rules&#160;and regulations of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Rate Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Convertible Notes&#160;bear interest until December&#160;2026 at a fixed rate per annum equal to 12%. An immediate 10% change in the prime rate would not have a material impact on Crescent&#8217;s debt-related obligations, financial position or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inflation Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Crescent&#8217;s results of operations and financial condition are presented based on historical cost. While it is difficult to accurately measure the impact of inflation due to the imprecise nature of the estimates required, Crescent believes the effects of inflation, if any, on its business, results of operations, financial condition or financial statements included elsewhere in this proxy statement/prospectus have been immaterial. Crescent cannot assure you its business will not be affected in the future by inflation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">273</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9f98d230_8209_4e1a_8692_3702b0c2e85b"></a><a id="MANAGEMENTFOLLOWINGTHEMERGER_867307"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">MANAGEMENT FOLLOWING THE MERGER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Executive Officers and Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the completion of the Merger, the business and affairs of the Combined Company will be managed under the direction of the Combined Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company&#8217;s board of directors will initially be fixed at members, consisting of current Crescent board members, namely Jonathan Violin, Alexandra Balcom, Peter Harwin, Dr.&#160;Susan Moran and . The staggered structure of the current GlycoMimetics Board will remain in place for the Combined Company following the completion of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each executive officer of the Combined Company will serve at the discretion of the Combined Company&#8217;s board of directors and holds office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal. There are no family relationships among any of the proposed Combined Company&#8217;s directors or executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of GlycoMimetics&#8217; current directors are expected to resign from their positions as directors of GlycoMimetics, effective as of the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the name, age as of February&#160;7, 2025 and position of each of the individuals who are expected to serve as executives and directors of the Combined Company following completion of the Merger:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:37.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:3.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;white-space:nowrap;width:55.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:37.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Executive Officers</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:55.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jonathan Violin, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:55.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Christopher Doughty</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:55.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Business Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Ryan Lynch</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:55.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer, Senior Vice President of Finance and Chief Accounting Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Barbara Bispham</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:55.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Counsel and Corporate Secretary</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Non-Employee Directors:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:55.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Peter Harwin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:55.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Alexandra Balcom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:55.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:37.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Susan Moran, M.D., MSCE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:55.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Executive Officers and Employee Director</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Jonathan Violin, Ph.D</b>. Dr.&#160;Violin has served as Crescent&#8217;s Chief Executive Officer and President and as a member of the Crescent Board since October&#160;2024. Dr.&#160;Violin has served as a Venture Partner at Fairmount Funds Management LLC, a healthcare investment firm, since June&#160;2023. Prior to joining Fairmount, Dr.&#160;Violin served as President, Chief Executive Officer and member of the board of directors of Viridian Therapeutics,&#160;Inc. (Nasdaq: VRDN), a biopharmaceutical company, from January&#160;2021 to February&#160;2023, and he previously served as President and Chief Operating Officer of Viridian from October&#160;2020 until January&#160;2021. He was the Co-Founder of Viridian&#8217;s predecessor and led its operations from April&#160;2020 to its acquisition. Dr.&#160;Violin has served as a member of the board of directors of Dianthus Therapeutics,&#160;Inc. (formerly Magenta Therapeutics,&#160;Inc.) (Nasdaq: DNTH) since the completion of its business combination in September&#160;2023 with Dianthus Therapeutics,&#160;Inc., a biotechnology company he co-founded in 2019. Dr.&#160;Violin also co-founded Quellis Biosciences,&#160;Inc., a biotechnology company (acquired by Astria Therapeutics,&#160;Inc. (Nasdaq: ATXS), formerly Catabasis Pharmaceuticals,&#160;Inc.), in 2018 and, since January&#160;2021, has served on the Astria Therapeutics board of directors. Prior to that, he co-founded and helped lead Trevena&#160;Inc. (Nasdaq: TRVN), a biotechnology company, in various roles from 2008 until November&#160;2018, including most recently as Senior Vice President, Scientific Affairs and Investor Relations Officer. Dr.&#160;Violin received a Ph.D. from the Department of Pharmacology in the Biomedical Sciences Program at the University of California, San Diego, a M.B.A. with a concentration in Health Sector Management from the Fuqua School of Business at Duke University, and a B.S. in Chemical Pharmacology from Duke University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent believes that Dr.&#160;Violin is qualified to serve as a member of the Combined Company&#8217;s board of directors because of his extensive experience and innovations in the field of biotechnology and his academic expertise and accomplishments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Christopher Doughty</b>. Mr.&#160;Doughty has served as Crescent&#8217;s Chief Business Officer since October&#160;2024. From February&#160;2021 to October&#160;2024, Mr.&#160;Doughty served as Chief Business Officer at Prometheus Biosciences,&#160;Inc., a Nasdaq-listed biotechnology company that was acquired by Merck&#160;&amp; Co.,&#160;Inc. in June&#160;2023, where he was responsible for business development, corporate </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">274</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">development, strategic planning, and competitive intelligence related activities. Prior to joining Prometheus, Mr.&#160;Doughty served as Vice President Strategy and Business Development at Strata Oncology,&#160;Inc., a biotechnology company, from May&#160;2017 to February&#160;2021, where he was responsible for leading business development. Prior to joining Strata, Mr.&#160;Doughty served as an Engagement Manager at McKinsey&#160;&amp; Company. Mr.&#160;Doughty received an M.B.A. from the University of Michigan Ross School of Business and a B.S. in Industrial and Operations Engineering from the University of Michigan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Ryan Lynch</b>. Mr.&#160;Lynch has served as Crescent&#8217;s Treasurer, Senior Vice President of Finance and Chief Accounting Officer since December&#160;2024. Prior to joining Crescent, Mr.&#160;Lynch served as VP Finance at Kelonia Therapeutics,&#160;Inc., a biotechnology company, from November&#160;2021 to December&#160;2024, where he was responsible for overseeing the company&#8217;s finance and accounting functions. Prior to Kelonia, from December&#160;2019 to November&#160;2021, Mr.&#160;Lynch served as Senior Director, Corporate Controller at Morphic Therapeutic,&#160;Inc., a biopharmaceutical company and wholly owned subsidiary of Morphic Holding, Inc, a Nasdaq-listed biopharmaceutical company that was acquired by Eli Lilly and Company in 2024, where he was responsible for overseeing the company&#8217;s finance and accounting functions. Prior to joining Morphic, Mr.&#160;Lynch held positions of increasing responsibility at Concert Pharmaceuticals,&#160;Inc. from May&#160;2014 to November&#160;2019, most recently serving as Senior Director, Corporate Controller. Mr.&#160;Lynch received an M.S. in Accounting from the University of Massachusetts Amherst and a B.B.A. in Accounting from the University of Massachusetts Amherst. Mr.&#160;Lynch is a licensed certified public accountant in Massachusetts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Barbara Bispham</b>. Ms.&#160;Bispham has served as Crescent&#8217;s General Counsel and Corporate Secretary since January&#160;2025. Prior to joining Crescent, Ms.&#160;Bispham served as Senior Vice President, General Counsel and Corporate Secretary at Sail Biomedicines, a biotechnology company and subsidiary of Flagship Pioneering,&#160;Inc., from October&#160;2023 to January&#160;2025, where she was responsible for overseeing the company&#8217;s legal and intellectual property operations. Prior to Sail, Ms.&#160;Bispham served as Senior Vice President, General Counsel and Corporate Secretary at Senda Biosciences,&#160;Inc., a biotechnology company and subsidiary of Flagship Pioneering,&#160;Inc., from October&#160;2022 until it merged with LARONDE,&#160;Inc., also a subsidiary of Flagship Pioneering,&#160;Inc., to form Sail Biomedicines in October&#160;2023, where she was responsible for overseeing the company&#8217;s legal and intellectual property operations. Prior to joining Senda, Ms.&#160;Bispham held positions of increasing responsibility at BridgeBio Pharma,&#160;Inc. (Nasdaq: BBIO), a biopharmaceutical company, from August&#160;2020 to September&#160;2022, most recently serving as Vice President, Head of Legal, where she was responsible for overseeing the company&#8217;s legal, transactional, employment, governance, litigation, privacy, compliance, and intellectual property operations. While at BridgeBio Pharma, Ms.&#160;Bispham supported key activities in connection with the commercialization of the company&#8217;s first two FDA-approved drugs, NULIBRY&#174; (fosdenopterin) and TRUSELTIQ&#174; (infigratinib). Prior to joining BridgeBio, Ms.&#160;Bispham was an associate at Goodwin Procter LLP, where she was a member of the firm&#8217;s Tech&#160;&amp; Life Sciences Group, and, before that, a corporate associate at Cooley LLP, where she was a member of the public companies and emerging companies practice groups. Ms.&#160;Bispham received a B.A. from the University of Pennsylvania and a J.D. from Cornell Law School.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Non-employee Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Alexandra Balcom</b>. Ms.&#160;Balcom has served as a member of the Crescent Board since November&#160;2024. Ms.&#160;Balcom has served as Chief Financial Officer at Nuvalent,&#160;Inc. (Nasdaq: NUVL), a biotechnology company, since January&#160;2021. From April&#160;2017 to March&#160;2021, Ms.&#160;Balcom held positions of increasing responsibility at SQZ Biotechnologies Company, formerly a NYSE-listed biotechnology company, most recently serving as Vice President of Finance from January&#160;2019 to March&#160;2021. Prior to joining SQZ Biotechnologies, Ms.&#160;Balcom held positions of increasing responsibility at Agios Pharmaceuticals&#160;Inc. (Nasdaq: AGIO), a biopharmaceutical company, from January&#160;2011 to April&#160;20217, most recently serving as Corporate Controller. Ms.&#160;Balcom received a B.B.A. in Finance from the University of Massachusetts, Amherst, and a M.B.A. from Boston College. Ms.&#160;Balcom is a Certified Public Accountant in Massachusetts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent believes Ms.&#160;Balcom is qualified to serve as a member of the Combined Company&#8217;s board of directors because of her experience as an executive officer of life sciences companies, her expertise in finance and her background in business development and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Peter Harwin</b>. Mr.&#160;Harwin has served as a member of the Crescent Board since September&#160;2024. Mr.&#160;Harwin is a Managing Member at Fairmount, a healthcare investment firm he co-founded in April&#160;2016. Prior to Fairmount, Mr.&#160;Harwin served as a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr.&#160;Harwin also serves as chairman of the board of directors of Cogent Biosciences,&#160;Inc. (Nasdaq: COGT) and as a member of the board of directors of Apogee Therapeutics,&#160;Inc. (Nasdaq: APGE), Oruka Therapeutics,&#160;Inc. (Nasdaq: Oruka), Spyre Therapeutics,&#160;Inc. (Nasdaq: SYRE), Viridian Therapeutics,&#160;Inc. (Nasdaq: VRDN) and Paragon Therapeutics,&#160;Inc. Mr.&#160;Harwin received a B.B.A. from Emory University.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">275</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent believes Mr.&#160;Harwin is qualified to serve as a member of the Combined Company&#8217;s board of directors because of his experience advising and serving as a director of biotechnology companies and as a manager of funds specializing in the area of life sciences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Susan Moran, M.D., MSCE</b>. Dr.&#160;Moran has served as a member of the Crescent Board since November&#160;2024. From July&#160;2021 to May&#160;2024, Dr.&#160;Moran served as Chief Medical Officer of RayzeBio,&#160;Inc., a Nasdaq-listed radiopharmaceutical therapeutics company that was acquired by the Bristol-Myers Squibb Company in 2024. Prior to joining RayzeBio, Dr.&#160;Moran served as Chief Medical Officer at QED Therapeutics,&#160;Inc., a biotechnology company and subsidiary of BridgeBio Pharma,&#160;Inc. (Nasdaq: BBIO), from March&#160;2018 to June&#160;2021. Prior to joining QED, Dr.&#160;Moran held positions of increasing responsibility at Puma Biotechnology,&#160;Inc. (Nasdaq: PBYI), a biopharmaceutical company, from 2014 to 2018, most recently serving as Vice President and Head of Clinical Development. Prior to joining Puma, Dr.&#160;Moran served as Medical Director at Takeda Oncology from 2011 until 2014 and as Senior Medical Director at Sanofi Genzyme from 2007 until 2011. Dr.&#160;Moran is a board-certified internist and previously held faculty appointments at the University of Pennsylvania School of Medicine and Harvard Medical School. Dr.&#160;Moran currently serves on the board of directors of Tyra Biosciences,&#160;Inc. (Nasdaq: TYRA) and BioAtla,&#160;Inc. (Nasdaq: BCAB). Dr.&#160;Moran received a B.A. from the University of Virginia, a M.D. from Duke University, and a M.S. in Clinical Epidemiology from the University of Pennsylvania School of Medicine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent believes Dr.&#160;Moran is qualified to serve as a member of the Combined Company&#8217;s board of directors because of her leadership, scientific, medical and academic experience in the biotechnology industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Composition of the Board of Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Board currently consists of eight members, divided into three staggered classes, with one class to be elected at each annual meeting to serve for a three-year term. The staggered structure of the board of directors will remain in place for the Combined Company following the completion of the Merger, with Class&#160;I directors holding terms expiring at the 2028 annual meeting of stockholders, Class&#160;II directors holding terms expiring at the 2026 annual meeting of stockholders and Class&#160;<span style="white-space:pre-wrap;">III directors holding terms expiring at the 2027 annual meeting of stockholders. It is anticipated that the incoming directors will be appointed to classes of the Combined Company board of directors following the completion of the Merger as follows:        are expected to be Class&#160;</span><span style="white-space:pre-wrap;">I directors;        are expected to be Class&#160;</span><span style="white-space:pre-wrap;">II directors; and        are expected to be Class&#160;III directors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Director Independence</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nasdaq listing rules&#160;have objective tests and a subjective test for determining who is an &#8220;independent director.&#8221; The subjective test states that an independent director must be a person who lacks a relationship that, in the opinion of the board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating committees must be independent, and audit and compensation committee members must satisfy additional independence criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on information provided by each proposed director concerning her or his background, employment and affiliations, GlycoMimetics and Crescent expect that the Combined Company&#8217;s board of directors will determine that&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;qualify as &#8220;independent directors&#8221; as defined under Nasdaq listing rules. Jonathan Violin, Crescent&#8217;s current Chief Executive Officer, is not expected to qualify as an independent director of the Combined Company. In making these determinations, the Combined Company&#8217;s board of directors will consider the current and prior relationships that each director has with GlycoMimetics and Crescent and all other facts and circumstances that the Combined Company&#8217;s board of directors deems relevant in determining the independence of each proposed director, including the interests of each Combined Company director in the Merger, any relevant related party transactions and the beneficial ownership of securities of GlycoMimetics, Crescent or the Combined Company by each Combined Company director. See also the sections titled &#8220;<i style="font-style:italic;">The Merger&#8212;Interests of Crescent&#8217;s Directors and Executive Officers in the Merger</i>,&#8221; &#8220;<i style="font-style:italic;">Certain Relationships and Related Party Transactions of the Combined Company</i>&#8221; and &#8220;<i style="font-style:italic;">Principal Stockholders of Crescent</i>&#8221; beginning on pages&#160;125, 279 and 310, respectively, of this proxy statement/prospectus for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board Leadership Structure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Following the completion of the Merger,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;is expected to serve as Chair of the Combined Company&#8217;s board of directors (&#8220;Chair&#8221;). Although the Combined Company&#8217;s governance documents will not require that the Combined Company separate the Chief Executive Officer and Chair positions, Crescent believes that having the positions be separate is the appropriate leadership structure for the Combined Company at this time as it helps facilitate independent board oversight of management and allows the Chief </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">276</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Executive Officer to focus on strategy execution and managing the business while the Chair focuses on corporate governance and managing the Combined Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Crescent Board recognizes that, depending on future circumstances, other leadership models, such as combining the roles of Chief Executive Officer and Chair, might be appropriate. Accordingly, the Combined Company&#8217;s board may periodically review its leadership structure. At any time when a non- independent director is serving as Chair, Crescent anticipates that the independent directors of the Combined Company will designate a lead independent director to preside at all meetings of the board of directors of the Combined Company at which the Chair is not present, preside over executive sessions of the independent directors, which will occur regularly throughout each&#160;year, serve as a liaison between the Chair and independent directors, and perform such additional duties as the Combined Company&#8217;s board of directors may otherwise determine and delegate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board Committees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the completion of the Merger, GlycoMimetics and Crescent anticipate that the Combined Company&#8217;s board of directors will establish an audit committee, a compensation committee and a nominating and governance committee (&#8220;governance committee&#8221;), each of which will operate pursuant to a charter adopted by the Combined Company&#8217;s board of directors. GlycoMimetics and Crescent believe that following the completion of the Merger the functioning and composition of these committees of the Combined Company will comply with the requirements of Nasdaq listing rules&#160;and SEC rules&#160;and regulations. The Combined Company&#8217;s board of directors may also establish other committees from time to time to assist the Combined Company and its board of directors. Each of the audit committee, compensation committee and the governance committee is expected to have the responsibilities described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Audit Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the completion of the Merger, the members of the Combined Company&#8217;s audit committee are expected to be&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, each of whom is expected to qualify as an independent director for audit committee purposes as defined under the rules&#160;of the SEC and the applicable Nasdaq listing rules&#160;and has sufficient knowledge in financial and auditing matters to serve on the Combined Company&#8217;s audit committee.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;is expected to chair the audit committee. In addition, the Combined Company&#8217;s board of directors is expected to determine that&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;is an &#8220;audit committee financial expert&#8221; as defined under the rules&#160;of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The primary responsibilities of the Combined Company&#8217;s audit committee will be to oversee the Combined Company&#8217;s accounting and financial reporting processes, including the audits of the financial statements, and the internal and external audit processes. The audit committee will oversee the system of internal controls established by management and the Combined Company&#8217;s compliance with legal and regulatory requirements. The audit committee will also be responsible for the review, consideration and approval or ratification of related party transactions. The audit committee will oversee the independent auditors, including their independence and objectivity. The audit committee will be empowered to retain outside legal counsel and other advisors as it deems necessary or appropriate to assist it in fulfilling its responsibilities and to approve the fees and other retention terms of the advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Compensation Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the consummation of the Merger, the members of the Combined Company&#8217;s compensation committee are expected to be&#160;&#160;&#160;&#160;,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, each of whom is expected to qualify as an independent director for compensation committee purposes as defined under the rules&#160;of the SEC and the applicable Nasdaq listing rules.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;is expected to chair the compensation committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The primary responsibilities of the Combined Company&#8217;s compensation committee will be to periodically review and approve the compensation and other benefits for the Combined Company&#8217;s senior officers and directors. This will include reviewing and approving corporate goals and objectives relevant to the compensation of the Combined Company&#8217;s executive officers, evaluating the performance of these officers in light of the goals and objectives and setting the officers&#8217; compensation. The compensation committee will also administer and make recommendations to the Combined Company&#8217;s board of directors regarding equity incentive plans that are subject to the board of directors&#8217; approval and approve the grant of equity awards under the plans to executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Governance Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the consummation of the Merger, the members of the Combined Company&#8217;s governance committee are expected to be&#160;&#160;&#160;&#160;,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, each of whom is expected to qualify as an independent director as defined under applicable Nasdaq listing rules.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;is expected to chair the governance committee.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">277</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Combined Company&#8217;s governance committee will be responsible for engaging in succession planning for the Combined Company&#8217;s board of directors, developing and recommending to the Combined Company&#8217;s board of directors criteria for identifying and evaluating qualified director candidates and making recommendations to the Combined Company&#8217;s board of directors regarding candidates for election or reelection to the Combined Company&#8217;s board of directors at each annual stockholders&#8217; meeting. In addition, the governance committee will be responsible for overseeing corporate governance matters. The governance committee will also be responsible for overseeing the structure, composition and functioning of the Combined Company&#8217;s board of directors and its committees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Compensation Committee Interlocks and Insider Participation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None of the expected members of the Combined Company&#8217;s compensation committee has at any time been one of the officers or employees of the Combined Company. None of the Combined Company&#8217;s expected executive officers currently serves, or in the past fiscal&#160;year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers that is or are expected to serve on the Combined Company&#8217;s board of directors or compensation committee following the completion of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Code of Conduct and Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Following the completion of the Merger, the Combined Company will adopt a Code of Conduct and Ethics that establishes the standards of ethical conduct applicable to all of the Combined Company&#8217;s directors, officers and employees. The full text of the Combined Company&#8217;s Code of Conduct and Ethics will be posted on the Combined Company&#8217;s website at        . It is expected to address, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting, external communications, confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. The Combined Company intends to disclose any amendments to the Code of Conduct and Ethics, or any waivers of its requirements, on its website to the extent required by applicable rules. The Combined Company&#8217;s audit committee will be responsible for applying and interpreting the Code of Conduct and Ethics in situations where questions are presented to it. Information contained on, or that can be accessed through, the Combined Company&#8217;s website is not incorporated by reference into this proxy statement/prospectus, and you should not consider information on the Combined Company&#8217;s website to be part of this proxy statement/prospectus.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">278</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_eafeae88_ee02_484d_9a52_91df845c43b7"></a><a id="CERTAINRELATIONSHIPSANDRELATEDPARTYTRANS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED COMPANY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with Crescent&#8217;s and GlycoMimetics&#8217; directors and executive officers, including those discussed in the sections titled &#8220;<i style="font-style:italic;">Management Following the Merger</i>,&#8221; &#8220;<i style="font-style:italic;">Crescent Executive Compensation</i>&#8221; and &#8220;<i style="font-style:italic;">GlycoMimetics Executive Compensation</i>,&#8221; the following is a description of each transaction involving GlycoMimetics since January&#160;1, 2023, each transaction involving Crescent since September&#160;19, 2024 (inception) and each currently proposed transaction in which:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">either Crescent or GlycoMimetics has been or is to be a participant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Crescent&#8217;s or GlycoMimetics&#8217; total assets at&#160;year-end for the last two completed fiscal&#160;years, as applicable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any of Crescent&#8217;s or GlycoMimetics&#8217; directors, executive officers or holders of more than 5% of Crescent&#8217;s or GlycoMimetics&#8217; capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GlycoMimetics Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There have been no transactions since January&#160;1, 2024 to which GlycoMimetics has been a participant in which the amount involved exceeded or will exceed $120,000 (which amount is less than one&#160;percent of the average of GlycoMimetics&#8217; total assets at&#160;year-end for the last two completed fiscal&#160;years), and in which any of GlycoMimetics&#8217; directors, executive officers or holders of more than 5% of capital stock, or any members of their immediate family, had or will have a direct or indirect material interest, other than compensation arrangements that are described under &#8220;Executive Compensation&#8221; and &#8220;Non-Employee Director Compensation.&#8221; GlycoMimetics also entered into indemnification agreements with its directors and executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Crescent Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Initial Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2024, Crescent completed a financing of Crescent preferred stock and common stock and issued and sold (i)&#160;an aggregate of 20,000,000 shares of Crescent preferred stock to Fairmount at a purchase price of $0.20 per share per share and (ii)&#160;an aggregate of 5,000,000 shares of Crescent common stock to Paragon for aggregate non-cash upfront consideration of Paragon&#8217;s entry into the Antibody Paragon Option Agreement, valued at $0.20 per share, 2,500,000 of which Paragon subsequently contributed to Parascent. Paragon beneficially owns more than 5% of a class of Crescent&#8217;s voting securities through its holdings of Crescent common stock. Fairmount beneficially owns more than 5% of a class of Crescent voting securities, has two seats on the Crescent Board and beneficially owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Convertible Note&#160;Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October&#160;2024, Crescent completed convertible note financings in which it issued and sold to certain investors an aggregate principal amount of $37.5 million in Convertible Notes&#160;at an interest rate of 12% per annum, and such investors committed to purchase an aggregate additional principal amount of $37.5 million in Convertible Notes&#160;on the same terms when called by Crescent. The principal amount and all accrued interest under each Convertible Note&#160;will convert into a number of shares of Crescent common stock equal to the quotient obtained by dividing the purchase price by the conversion price in connection with the Crescent Pre-Closing Financing, which constitutes a &#8220;Next Equity Financing&#8221; under the Convertible Notes. In a conversion pursuant to a Next Equity Financing such as the Crescent Pre-Closing Financing, the conversion price of the Convertible Notes&#160;is the price per share in the Next Equity Financing. The following table summarizes the purchases of Convertible Notes&#160;by related persons:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Purchaser</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;Commitment</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Principal&#160;Amount</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Purchased</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest&#160;Rate</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">(Per&#160;Annum)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Entities affiliated with Fairmount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.09%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">30,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">279</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:5.75pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="CrescentPreClosingFinancing_958326"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Crescent Pre-Closing Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, on February&#160;14, 2025, Crescent and GlycoMimetics entered into the Subscription Agreement with certain investors to effect the Crescent Pre-Closing Financing. Pursuant to the Subscription Agreement, the investors agreed to purchase an estimated aggregate of 89,833,671 shares of Crescent common stock and 18,363,034 Crescent pre-funded warrants, at an estimated price of $1.8485 per share of common stock and $1.8484 per pre-funded warrant, for aggregate gross proceeds of approximately $200.0 million (which includes $37.5 million of proceeds previously received by Crescent from the issuance of its Convertible Notes&#160;and accrued interest on such notes). The aggregate purchase price of $200.0 million is fixed, while the purchase price per share or warrant and the aggregate number of shares and warrants to be purchased is subject to change pursuant to the terms of the Subscription Agreement. Please see the section titled &#8220;<i style="font-style:italic;">Agreements Related to the Merger&#8212;Subscription Agreement</i>.&#8221; The closing of the Crescent Pre-Closing Financing is conditioned upon the satisfaction or waiver of the conditions to the Merger as well as certain other conditions. Four of the investors or their affiliates are, or are expected to be as of immediately following the Crescent Pre-Closing Financing, beneficial holders of more than 5% of Crescent&#8217;s capital stock, and the table below sets forth the number of shares of Crescent common stock and Crescent pre-funded warrants expected to be purchased by such holders at the closing of the Crescent Pre-Closing Financing (based on the currently estimated purchase price per share or warrant, as applicable).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:60.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Participant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Crescent</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pre-funded</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Warrants&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Crescent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b><br/><b style="font-weight:bold;">Purchase</b><br/><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:60.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Entities affiliated with Fairmount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,110,837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,528,506 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:10.42%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">Entities affiliated with Venrock Healthcare Capital Partners</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,110,836 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,413,752 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">25,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Entities affiliated with BVF</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,110,837 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,413,752 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">25,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Entities affiliated with FMR LLC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,110,838 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,025 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:top;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18,702,718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes $15.0&#160;million of proceeds previously received by Crescent from the issuance of the Convertible Notes&#160;and accrued interest on such notes, with the remainder of the purchase price to be paid in cash.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes $11.25&#160;million of proceeds previously received by Crescent from the issuance of the Convertible Notes&#160;and accrued interest on such notes, with the remainder of the purchase price to be paid in cash.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes $11.25&#160;million of proceeds previously received by Crescent from the issuance of the Convertible Notes&#160;and accrued interest on such notes, with the remainder of the purchase price to be paid in cash.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Crescent&#8217;s Relationships with Paragon, Parascent and Fairmount</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is party to the Paragon Option Agreements with Paragon and Parascent. Paragon and Parascent each beneficially own more than 5% of a class of Crescent&#8217;s voting securities through their respective holdings of Crescent common stock. Fairmount beneficially owns more than 5% of a class of Crescent&#8217;s voting securities, one of Crescent&#8217;s directors is affiliated with Fairmount (Peter Harwin) and Fairmount beneficially owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon. Parascent is an entity formed by Paragon as a vehicle to hold equity in Crescent in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreements other than to receive warrants granted to Parascent under the Paragon Option Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September&#160;19, 2024, Crescent entered into the Antibody Paragon Option Agreement with Paragon and Parascent. On October&#160;28, 2024, Crescent entered into the ADC Paragon Option Agreement with Paragon and Parascent. Under the terms of the Paragon Option Agreements, Paragon agreed to perform certain research activities to discover, generate, identify, and characterize one or more antibody candidates, in the case of the Antibody Paragon Option Agreement, and one or more antibody-drug conjugates, in the case of the ADC Paragon Option Agreement, directed to certain mutually agreed therapeutic targets of interest to Crescent. The Antibody Paragon Option Agreement includes two selected targets for CR-001: PD-1 and VEGF. The ADC Paragon Option Agreement initially includes one undisclosed target for CR-002. From time to time, Crescent can choose to add additional targets to the ADC Paragon Option Agreement by mutual agreement with Paragon and Parascent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Paragon Option Agreements require Crescent, Paragon, and Parascent to develop a research plan for each target that includes design, modeling, synthesis, evaluation, and other mutually agreed activities, which activities primarily include performing preclinical studies. Paragon will perform the activities set forth in each Research Plan on the timelines set forth in such Research Plan and in compliance with a mutually agreed budget. Each Research Program will be overseen and coordinated by a joint development </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">280</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">committee consisting of two employees from Crescent and two employees from Paragon, with Crescent and Paragon each having one vote with respect to decisions of the committee. When Paragon and Parascent have produced an antibody or ADC, as applicable, against a selected target, and upon the completion of each Research Program, Paragon and Parascent will deliver to Crescent a data package that includes sequence information for all then-existing antibodies or ADCs, as applicable, and information directed to such target. Crescent, Paragon, and Parascent have developed a Research Plan for CR-001 and CR-002 consistent with the foregoing, and Paragon and Parascent have delivered an antibody against PD-1 and VEGF in accordance with such Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Paragon Option Agreements, Crescent has an Option, on a Research Program-by-Research Program basis, to enter into a separate agreement with Paragon consistent with a set of pre-negotiated terms. Each License Agreement will include (a)&#160;an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and commercialize the monospecific antibodies or ADCs, as applicable, and products directed to the selected target(s), and (b)&#160;an exclusive (in the case of the Antibody Paragon Option Agreement) or non-exclusive (in the case of the ADC Paragon Option Agreement), worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable Research Program to develop, manufacture, and commercialize multispecific antibodies or ADCs, as applicable, and products directed to the selected target(s). Additionally, each License Agreement under the ADC Paragon Option Agreement will include a non-exclusive, worldwide license to certain patents controlled by Paragon or its affiliates that (i)&#160;include a claim that expressly recites the sequence of the monospecific antibody included in the ADC, or derived from the ADC, applicable to the Research Program, and (ii)&#160;are necessary to develop, manufacture, commercialize or otherwise exploit the ADC or derived ADCs applicable to the Research Program, but exclude any patents owned or otherwise controlled by Paragon or its affiliates that cover the composition of matter of, or any method of specifically making or using, a multispecific ADC or a multispecific product directed to targets other than the undisclosed CR-002 target that is developed, manufactured, commercialized or otherwise exploited by Paragon or its affiliate or sublicensee (other than Crescent and its affiliates and sublicensees). Each License under the ADC Paragon Option Agreement will further include a right of first negotiation for a set period of time after the execution of the License Agreement with regard to any multispecific ADCs or products that are developed by Paragon. The Option with respect to each Research Program is exercisable at Crescent&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following the delivery of the data package from Paragon related to the results of the Research Program. There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements. Activities under a Research Plan may continue past the exercise of an Option or entry into a License Agreement. Crescent&#8217;s Options to acquire the intellectual property rights to the Research Programs under the Paragon Option Agreements, including CR-001 and CR-002, currently remain unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of an Option with respect to a Research Program, the parties are obligated to use reasonable efforts to finalize and execute a License Agreement within 30&#160;days. Under the terms of a License Agreement, Crescent expects that it will have sole authority over and control of the development, regulatory approval, manufacturing and commercialization of such in-licensed intellectual property worldwide. In addition, Crescent expects to have sole authority over and control of the application for and issuance of all regulatory approvals related to such in-licensed intellectual property. Prior to entry into a License Agreement, Paragon is responsible for the prosecution, defense, maintenance and enforcement of patents related to the Research Program. Following entry into a License Agreement, Crescent expects to control prosecution, defense, maintenance and enforcement of patents in-licensed under such License Agreement. However, there is no assurance that Crescent will successfully negotiate future License Agreements with Paragon or that the terms will not differ from those described in this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Paragon Option Agreements shall continue in force on a Research Program- by-Research Program basis until the later of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by Crescent; (ii)&#160;if Crescent exercises its Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 30&#160;days, the expiration of such 30-day period (subject to any mutually agreed extension of such period); and (iii)&#160;the expiration of the applicable Research Term (as defined under the applicable Paragon Option Agreement). Crescent may terminate any Paragon Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon; provided, that Crescent must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Paragon Option Agreements or any Research Program immediately upon written notice to Crescent if, as a result of any action or failure to act by Crescent or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate any Paragon Option Agreement or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30-day period and (ii)&#160;the other party&#8217;s bankruptcy.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">281</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon signing of the Antibody Paragon Option Agreement, Crescent was required to reimburse Paragon $1.5 million for upfront research and development costs related to CR-001 and other general and administrative costs incurred by Paragon prior to September 19, 2024. Contemporaneously, Crescent also issued an aggregate of 5,000,000 shares of Crescent common stock to Paragon for aggregate non-cash upfront consideration of Paragon&#8217;s entry into the Antibody Paragon Option Agreement, valued at $0.20 per share, for a total of $1.0 million. Paragon subsequently contributed 2,500,000 of such shares to Parascent. The $1.5 million of research and development costs related to CR-001 reflects the actual historical direct costs incurred by Paragon as well as a 20% mark-up on the direct costs to approximate the indirect costs incurred by Paragon from the inception of the CR-001 program to the entry into the Paragon Option Agreement. All of the costs reflected in the upfront amount were incurred by Paragon between January 1, 2024 and the parties&#8217; entry into the Paragon Option Agreement. Such direct costs were related to development activities. Of these upfront development costs related to CR-001 incurred by Paragon prior to September 19, 2024, a total of $1.5 million was recognized as research and development expense and less than $0.1 million was recognized as general and administrative expense during the period from September 19, 2024 (inception) to December 31, 2024. Crescent paid $1.5 million to Paragon in November 2024. The non-cash upfront consideration was recorded as research and development expense in Crescent&#8217;s consolidated statement of operations and comprehensive loss during the period from September 19, 2024 (inception) to December 31, 2024 as related IP license fees associated with entering into the Option Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent is also required to pay Paragon for certain development fees and costs on a Research Program-by-Research Program basis. Under the Paragon Option Agreements, Crescent is required to pay Paragon a one-time, non-refundable research initiation fee within 30&#160;days following finalization of a Research Plan in the amount of $1.3 million for CR-001 and $2.5 million for CR-002, which amounts were paid by Crescent in December&#160;2024 for each of CR-001 and CR-002. Under the Paragon Option Agreements, on a Research Program-by- Research Program basis, Crescent is required to make one-time non-refundable milestone payments to Paragon of up to a total of $22.0 million for CR-001 and $46.0 million for CR-002 upon the achievement of certain clinical development and regulatory milestones. Crescent paid a $1.5 million milestone payment to Paragon in connection with the achievement of a development candidate for CR-001, which was expensed as development costs for the fiscal&#160;year ended December&#160;31, 2024 and paid in January&#160;2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of the Option with respect to a Research Program, the parties are obligated to use reasonable efforts to finalize and execute a License Agreement within 30&#160;days. Any License Agreement entered into with respect to a given Research Program shall contain the same milestone payment obligations as the applicable Paragon Option Agreement, provided that any milestone set in such Paragon Option Agreement that has not yet been achieved and is duplicated in such License Agreement shall no longer be achievable and payable under the terms of such Paragon Option Agreement and shall only be achievable under the terms of the License Agreement. For the avoidance of doubt, if a milestone is achieved and paid by Crescent pursuant to a Paragon Option Agreement for a certain Research Program, then there shall be no milestone payment due for the achievement of such milestone under a subsequently executed License Agreement for such Research Program. Further, under a License Agreement, Crescent would also be required to make royalty payments to Paragon in the low single-digit&#160;percentage range based on net sales of products, subject to certain reductions. The royalty term will terminate on a product-by-product and country-by-country basis upon the later of the expiration of the last-to-expire valid claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, as part of the Paragon Option Agreements, on each of December&#160;31, 2025 and December&#160;31, 2026, Crescent will grant Parascent warrants to purchase a number of shares equal to 1.00% of Crescent&#8217;s outstanding capital stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares of Crescent common stock on each respective grant date. Parascent is an entity formed by Paragon as a vehicle to hold equity in Crescent in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreements other than to receive such warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this proxy statement/prospectus, Crescent has paid Paragon (i)&#160;$6.2 million under the Antibody Paragon Option Agreement for development costs related to PD-1 and VEGF incurred by Paragon through the effective date of the agreement, including pre-development costs, and (ii)&#160;$0.8 million under the ADC Paragon Option Agreement for development costs related to the undisclosed CR-002 target incurred by Paragon through the effective date of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Crescent Indemnification Agreements and Insurance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent has entered into an indemnification agreement with each of its directors and officers and purchased directors&#8217; and officers&#8217; liability insurance. The indemnification agreements require Crescent to indemnify its directors and officers to the fullest extent permitted under Delaware law.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">282</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Crescent Restricted Stock Grants to Directors and Executive Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent has entered into restricted stock purchase agreements with certain of its executive officers and directors, as more fully described in the sections titled &#8220;<i style="font-style:italic;">Crescent Executive Compensation</i>&#8221; and &#8220;<i style="font-style:italic;">Crescent Director Compensation</i>&#8221; beginning on pages&#160;171 and 174, respectively, of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Crescent Policies for Approval of Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent does not have a formal policy regarding approval of transactions with related parties. To date, all disclosable transactions with related parties have been approved by the directors not interested in such transaction pursuant to Section&#160;144(a)(1)&#160;of the DGCL. Following the completion of the Merger, Crescent anticipates that the Combined Company will adopt a related party transaction approval policy and the Combined Company&#8217;s audit committee will be responsible for the review, consideration and approval or ratification of related party transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">283</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_bc98c920_30ca_487f_80f2_a08e206a5a3a"></a><a id="UNAUDITEDPROFORMACONDENSEDCOMBINEDFINANC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Defined terms included below shall have the same meaning as terms defined and included elsewhere in this proxy statement/prospectus.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;28, 2024, Crescent entered into the Merger Agreement with GlycoMimetics and the Merger Subs, which agreement was subsequently amended on February&#160;14, 2025, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub I will merge with and into Crescent, with Crescent surviving as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the First Merger, and, immediately following the First Merger and as part of the same overall transaction, Crescent will merge with and into Merger Sub II, with Merger Sub II being the surviving entity of the Second Merger. The closing of the Crescent Pre-Closing Financing is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and is expected to occur immediately prior to the closing of the Merger, the pro forma adjustments reflect the Merger and the Crescent Pre-Closing Financing. The Merger is expected to close in the late second quarter of 2025 following the effectiveness of this registration statement and receipt of approval by the stockholders of each of Crescent and GlycoMimetics, in the latter case pursuant to the GlycoMimetics Special Meeting. In connection with the Merger, Merger Sub II will change its corporate name to &#8220;Crescent Biopharma Operating Company, LLC&#8221; and GlycoMimetics will change its name to &#8220;Crescent Biopharma,&#160;Inc.&#8221; GlycoMimetics following the Merger is referred to herein as the &#8220;Combined Company.&#8221; The Combined Company will be led by Crescent&#8217;s management team and will focus on developing differentiated oncology therapeutics for patients living with solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then-outstanding share of Crescent common stock (including shares of Crescent common stock issued in connection with the Crescent Pre-Closing Financing) will be automatically converted solely into the right to receive a number of shares of GlycoMimetics common stock equal to the Exchange Ratio, (ii)&#160;each then-outstanding share of Crescent preferred stock will be converted into the right to receive a number of shares of GlycoMimetics Series&#160;A Preferred Stock, which are each convertible into 1,000 shares of GlycoMimetics common stock, equal to the Exchange Ratio divided by 1,000, (iii)&#160;each then-outstanding option to purchase Crescent common stock will be assumed by GlycoMimetics and will be converted into an option to purchase shares of GlycoMimetics, subject to adjustment as set forth in the Merger Agreement, (iv)&#160;each then-outstanding pre-funded warrant to purchase shares of Crescent common stock will be converted into a pre-funded warrant to purchase shares of GlycoMimetics common stock, subject to adjustment as set forth in the Merger Agreement and the form of warrant, (v)&#160;<span style="white-space:pre-wrap;">the vesting of each option to acquire shares of GlycoMimetics common stock that is issued and outstanding  will be accelerated, each in-the-money option will be cancelled and converted into the right to receive immediately prior to the First Effective Time a number of shares of GlycoMimetics common stock equal to the number of shares underlying such option, and each out-of-the-money option will be cancelled for no consideration; and (vi)&#160;each GlycoMimetics restricted stock unit will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of unsettled shares of GlycoMimetics common stock underlying such GlycoMimetics restricted stock unit.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Exchange Ratio is currently estimated to be approximately 14.9149 shares of GlycoMimetics common stock for each share of Crescent common stock on the closing date. Each share of Crescent preferred stock will be converted into the right to receive a number of shares of GlycoMimetics Series A Preferred Stock, equal to the Exchange Ratio divided by 1,000. Under the Exchange Ratio formula, the former Crescent stockholders immediately before the effective time, including those purchasing shares and pre-funded warrants in the Crescent Pre-Closing Financing, are estimated to own approximately 96.9% of the outstanding common stock of the Combined Company, and the stockholders of GlycoMimetics immediately before the effective time are estimated to own approximately 3.1% of the outstanding common stock of the Combined Company, which give effect to (a)&#160;GlycoMimetics estimated net cash as of the closing of the Merger being approximately $1.8 million, (b)&#160;Crescent closing the Crescent Pre-Closing Financing for an aggregate gross purchase price of approximately $200.0 million, which reflects the conversion of the previously issued $37.5 million of Convertible Notes&#160;and accrued interest, (c)&#160;a valuation for GlycoMimetics equal to $8.0 million subject to further adjustment for net cash at closing, and (d)&#160;a valuation for Crescent equal to $50.0 million plus $200.0 million of assumed proceeds in the Crescent Pre-Closing Financing, in each case as further described in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following unaudited pro forma condensed combined financial information gives effect to the Merger, which is expected to be accounted for as a reverse recapitalization under U.S. GAAP. For further details related to the accounting for the Merger, please see Notes&#160;1 and 3 below. All share amounts have been adjusted to reflect the estimated Exchange Ratio of 14.9149 shares of GlycoMimetics common stock for each share of Crescent common stock, unless otherwise stated.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">284</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined balance sheet combines the historical balance sheets of GlycoMimetics and Crescent as of December&#160;31, 2024 and depicts the accounting of the transaction prepared pursuant to Article&#160;11 of Regulation S-X (the &#8220;pro forma balance sheet transaction accounting adjustments&#8221;). The unaudited pro forma condensed combined statements of operations for the&#160;year ended December&#160;31, 2024 for GlycoMimetics, the period from September&#160;19, 2024 (inception) to December&#160;31, 2024 for Crescent, combine the historical results of GlycoMimetics and Crescent for those periods and depict the pro forma transaction accounting adjustments assuming that those adjustments were made as of January&#160;1, 2024 (the &#8220;pro forma statements of operations transaction accounting adjustments&#8221;). Collectively, the pro forma balance sheet transaction accounting adjustments and the pro forma statements of operations transaction accounting adjustments are referred to as the &#8220;transaction accounting adjustments&#8221; or &#8220;pro forma adjustments.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These unaudited pro forma condensed combined financial information and related notes have been derived from and should be read in conjunction with:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical audited financial statements of Crescent as of December&#160;31, 2024 and for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024, and the related notes included elsewhere in this proxy statement/prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the historical audited consolidated financial statements of GlycoMimetics as of and for the&#160;year ended December&#160;31, 2024, and the related notes included elsewhere in this proxy statement/prospectus; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sections titled &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">GlycoMimetics&#8217; Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; &#8220;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Crescent&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; and other financial information relating to GlycoMimetics and Crescent included elsewhere in this proxy statement/prospectus.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and pro forma adjustments that are described in the accompanying notes. The pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed including but not limited to additional financing, additional direct and incremental offering costs and a reverse stock split. Adjustments have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final accounting, expected to be completed after the closing of the Merger, may occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro forma condensed combined financial information is not necessarily indicative of the financial position or results of operations in the future periods or the result that actually would have been realized had GlycoMimetics and Crescent been a combined organization during the specified periods. The actual results reported in periods following the Merger may differ significantly from those reflected in the unaudited condensed combined pro forma financial information presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this unaudited pro forma condensed combined financial information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">285</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_0c55f5fc_7311_46c6_b152_6b14055d2b38"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS OF DECEMBER&#160;31, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(In thousands)</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Historical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">5(A)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">5(B)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Glyco</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Mimetics,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Crescent</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Biopharma,</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Accounting</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro&#160;Forma</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">34,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(5,200)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">180,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">161,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(17,365)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(d)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(2,900)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(e)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(912)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(g)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(371)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(f)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">34,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">134,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">180,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(813)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(d)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">35,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">134,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">180,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(4,536)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(870)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(845)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(g)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Related party accounts payable and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Warrant liability, related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(67)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(g)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(6,318)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Notes payable, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">37,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(37,482)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">47,096</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(43,800)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9,074</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Crescent convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(4,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(b)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stockholders&#8217; equity (deficit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">GlycoMimetics Series A convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(b)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">GlycoMimetics common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(64)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(i)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Crescent common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(i)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(i)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">499,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2,387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">38,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">185,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">161,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(18,178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(d)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(h)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(498,699)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(i)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(i)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 5.75pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(494,364)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(17,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(664)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(17,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(2,900)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(e)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(371)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(f)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(h)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">498,699</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">5(i)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;">Total stockholders&#8217; equity (deficit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">5,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(15,479)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">181,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">171,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 11.5pt;"><span style="white-space:pre-wrap;">Total liabilities, convertible preferred stock   and stockholders&#8217; equity (deficit)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.8%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">11,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.08%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">35,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.9%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">134,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.9%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">180,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.09%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to the unaudited pro forma condensed combined financial information.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">286</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8781d8fb_88df_4a55_9e18_3af00cf9efa7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AND COMPREHENSIVE LOSS FOR THE TWELVE&#160;MONTHS ENDED DECEMBER&#160;31, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(In thousands, except share and per share amounts)</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Historical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">6(A)</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Glyco</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Mimetics,&#160;Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">6(B)</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Crescent</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Biopharma</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transaction</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Accounting</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Adjustments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro&#160;Forma</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Combined</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28,294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">18,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6(b)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.05pt;text-indent:-0.05pt;margin:0pt 0pt 0pt 5.75pt;">Restructuring and asset impairment charges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.05pt;text-indent:-0.05pt;margin:0pt 0pt 0pt 11.5pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">40,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">58,666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(40,039)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(17,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1,436)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(58,666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.05pt;text-indent:-0.05pt;margin:0pt 0pt 0pt 5.75pt;">Gain on sale of asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.05pt;text-indent:-0.05pt;margin:0pt 0pt 0pt 5.75pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.05pt;text-indent:-0.05pt;margin:0pt 0pt 0pt 5.75pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(852)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6(d)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.05pt;text-indent:-0.05pt;margin:0pt 0pt 0pt 11.5pt;">Total other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(676)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (37,879)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (17,867)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(584)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (56,330)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">64,477,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:2.25pt double transparent;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:2.25pt double transparent;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:2.25pt double transparent;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:2.25pt double transparent;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,757,888,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6(e)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">298,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6(e)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.59)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (0.03)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:39.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27.40)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to the unaudited pro forma condensed combined financial information.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">287</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3770e174_efbf_4e31_92db_936890e6b61a"></a><a id="NOTESTOUNAUDITEDPROFORMACONDENSEDCOMBINE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES&#160;TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span><b style="font-weight:bold;">Description of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October&#160;28, 2024, Crescent entered into the Merger Agreement with GlycoMimetics and the Merger Subs, which agreement was subsequently amended on February&#160;14, 2025, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub I will merge with and into Crescent, with Crescent surviving as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the First Merger, and, immediately following the First Merger and as part of the same overall transaction, Crescent will merge with and into Merger Sub II, with Merger Sub II being the surviving entity of the Second Merger. The Merger, including the Crescent Pre-Closing Financing, is expected to close in the late second quarter of 2025 following the effectiveness of this registration statement and receipt of approval by the stockholders of each of Crescent and GlycoMimetics, in the latter case pursuant to the GlycoMimetics Special Meeting. In connection with the Merger, Merger Sub II will change its corporate name to &#8220;Crescent Biopharma Operating Company, LLC&#8221; and GlycoMimetics will change its name to &#8220;Crescent Biopharma,&#160;Inc.&#8221; GlycoMimetics following the Merger is referred to herein as the &#8220;Combined Company.&#8221; Subject to the terms and conditions of the Merger Agreement, at closing of the Merger:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each then-outstanding share of Crescent common stock (including shares of Crescent common stock issued in connection with the Crescent Pre-Closing Financing) will be converted into the right to receive a number of shares of GlycoMimetics common stock equal to the Exchange Ratio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each then-outstanding share of Crescent preferred stock will be converted into the right to receive a number of shares of GlycoMimetics Series&#160;A Preferred Stock, which are each convertible into 1,000 shares of GlycoMimetics common stock, equal to the Exchange Ratio divided by 1,000;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each then-outstanding option to purchase Crescent common stock will be assumed by GlycoMimetics and will be converted into an option to purchase shares of GlycoMimetics common stock, subject to adjustment as set forth in the Merger Agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each then-outstanding pre-funded warrant to purchase shares of Crescent common stock will be converted into a pre-funded warrant to purchase shares of GlycoMimetics common stock, subject to adjustment as set forth in the form of pre-funded warrant.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The shares of GlycoMimetics common stock issued in exchange for shares of Crescent restricted stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Merger Agreement, the GlycoMimetics Board will take actions to accelerate the vesting of certain outstanding options to purchase GlycoMimetics common stock held by a current employee, director or consultant of GlycoMimetics as of the closing of the Merger. The acceleration of vesting of GlycoMimetics options occurs upon a modification of the awards as a result of the Merger. The incremental fair value of GlycoMimetics options associated with the modification to accelerate vesting has been included as an adjustment to the unaudited pro forma condensed combined financial information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each option to acquire shares of GlycoMimetics common stock with an exercise price less than or equal to the GlycoMimetics Closing Price will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock underlying such GlycoMimetics option, and each option with an exercise price greater than the GlycoMimetics Closing Price to acquire shares of GlycoMimetics common stock will be cancelled for no consideration. The incremental fair value of GlycoMimetics options associated with the modification to accelerate vesting and the acceleration of grant date fair value associated with the cancelation of certain stock options for no consideration has been included as an adjustment to the unaudited pro forma condensed combined financial information. Each GlycoMimetics restricted stock unit will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of unsettled shares of GlycoMimetics common stock underlying such GlycoMimetics restricted stock unit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Immediately following the Merger, GlycoMimetics securityholders as of immediately prior to the Merger are expected to own approximately 2.9% of the outstanding capital stock of the Combined Company on a fully diluted basis, former Crescent securityholders, excluding shares purchased in the Crescent Pre-Closing Financing, are expected to own approximately 23.5% of the outstanding capital stock of the Combined Company on a fully diluted basis, and shares and pre-funded warrants issued in the </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">288</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:5.75pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Crescent Pre-Closing Financing are expected to own approximately 73.6% of the outstanding capital stock of the Combined Company on a fully diluted basis. Crescent stockholders are expected to receive approximately 2,128,952,453 shares on a fully diluted basis in connection with the Merger, including (i)&#160;142,336,923 shares of GlycoMimetics common stock and stock options subject to vesting terms, based on the number of shares of Crescent common stock outstanding immediately prior to the Merger, including Crescent restricted stock, (ii)&#160;the shares of common stock and pre-funded warrants issued in the Crescent Pre-Closing Financing, and (iii)&#160;Crescent preferred stock outstanding as of December&#160;31, 2024, which will be exchanged into shares of newly created GlycoMimetics Series&#160;A Preferred Stock which are each convertible into 1,000 shares of GlycoMimetics common stock, equal to the Exchange Ratio divided by 1,000. These estimates are subject to certain inputs, which include, but are not limited to, (a)&#160;GlycoMimetics&#8217; net cash as of the closing of the Merger being approximately $1.8 million, (b)&#160;Crescent closing the Crescent Pre-Closing Financing for an aggregate purchase price of approximately $200.0 million, which reflects the contribution and cancellation of the previously issued $37.5 million of Convertible Notes&#160;and accrued interest, (c)&#160;a valuation for GlycoMimetics equal to $8.0 million subject to further adjustment for net cash at closing, and (d)&#160;a valuation for Crescent equal to $50.0 million plus $200 million of assumed proceeds in the Crescent Pre-Closing Financing, in each case as further described in the Merger Agreement. The following table summarizes the pro forma number of shares of common stock of the Combined Company outstanding following the consummation of the transactions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro&#160;Forma</b><br/><b style="font-weight:bold;">(Assuming&#160;GlycoMimetics&#160;Net&#160;Cash</b><br/><b style="font-weight:bold;">at&#160;Closing&#160;of&#160;$1.8&#160;million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Equity Capitalization Summary (fully diluted basis)</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Upon Consummation of the Merger</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares </b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">% Ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.04%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Crescent stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">515,209,423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">23.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">GlycoMimetics stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">64,532,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">2.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Investors participating in the Subscription Agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,613,743,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">73.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total common stock of the combined company</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,193,485,406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 273,882,826 pre-funded warrants issued in the Crescent Pre-Closing Financing after reflecting the estimated Exchange Ratio.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by GlycoMimetics stockholders of the issuance of GlycoMimetics common stock, including shares of GlycoMimetics common stock issuable upon conversion of the GlycoMimetics Series&#160;A Preferred Stock, and the other transactions proposed under the Merger Agreement, (2)&#160;approval by the requisite Crescent stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the listing application to be submitted in connection with the Merger, and (4)&#160;the effectiveness of this registration statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The employment agreements for GlycoMimetics employees include entitlement to change in control payments for certain executives, and severance for certain non-executives, the aggregate of which will be treated as pre-Merger compensation expense of GlycoMimetics and will be reflected as an increase to accrued expenses of GlycoMimetics, which will be assumed by the Combined Company at the closing of the Merger to the extent they are not yet settled in cash beforehand by GlycoMimetics. Prior to the closing of the Merger, GlycoMimetics also has or expects to (i)&#160;discontinue its research and development activities, (ii)&#160;close out of all contracts related to GlycoMimetics&#8217; worldwide clinical trial, and (iii)&#160;terminate its office space leases. Additionally, GlycoMimetics&#8217; current Directors&#160;&amp; Officers (&#8220;D&amp;O&#8221;) policy will be fully utilized at the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Private Financing Transaction&#8212;Subscription Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the Merger, on February&#160;14, 2025, Crescent and GlycoMimetics entered into the Subscription Agreement with certain institutional and accredited investors, pursuant to which such investors have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the Merger, 89,833,671 shares of Crescent common stock and 18,363,034 pre-funded warrants, at an estimated purchase price of $1.8485 per share and $1.8484 per warrant, for an aggregate purchase price of $200.0 million in a private placement, which includes $37.5 million proceeds received as of December&#160;31, 2024 from the issuance of a convertible note and accrued interest. The closing of the Crescent Pre-Closing Financing is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and is expected to occur immediately prior to the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">289</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_95b3c087_c1ed_4361_9b09_e60ea8268a34"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article&#160;11 of Regulation S-X. The adjustments presented in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an understanding of the Combined Company upon consummation of the Merger. The unaudited pro forma condensed combined statement of operations data for the twelve&#160;months ended December&#160;31, 2024 give effect to the Merger as if it had been consummated on January&#160;1, 2024. The unaudited pro forma condensed combined balance sheet as of December&#160;31, 2024 gives effect to the Merger and combines the historical balance sheets of GlycoMimetics and Crescent as if the Merger had been consummated on December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and adjustments that are described in the accompanying notes. Accordingly, the pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary accounting conclusions and estimates and the final accounting conclusions and amounts may occur as a result of, among other reasons: (i)&#160;changes in initial assumptions in the determination of the accounting acquirer and related accounting, (ii)&#160;changes in the amount of GlycoMimetics net cash to be assumed at the closing date, and (iii)&#160;other changes in GlycoMimetics&#8217; assets and liabilities, which are expected to be completed after the closing of the Merger, and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information and the Combined Company&#8217;s future results of operations and financial position.</p><a id="_dcf7e13e_e3df_4807_9f2a_0b68f87137fb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span><b style="font-weight:bold;">Accounting for the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The unaudited pro forma condensed combined financial information gives effect to the Merger, is expected to be accounted for under U.S. GAAP as a reverse recapitalization of GlycoMimetics by Crescent, as the transaction is, in essence, the issuance of equity for GlycoMimetics&#8217; net assets, which will primarily consist of nominal non-operating assets and liabilities. Under this method of accounting, Crescent will be considered the accounting acquirer for financial reporting purposes. This determination is based on the expectations that, immediately following the Merger:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Immediately prior to the Merger, Crescent is not a variable interest entity as it has sufficient equity at risk in order to fund its next development milestones;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent stockholders will own a substantial majority of the voting rights in the Combined Company through existing ownership and additional interest through the Subscription Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s largest stockholder will retain the largest interest in the Combined Company (29.8%);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent will designate the initial members of the Combined Company board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent&#8217;s executive management team will become the management of the Combined Company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Combined Company will be renamed &#8220;Crescent Biopharma,&#160;Inc.&#8221;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of Crescent being the accounting acquirer, Crescent&#8217;s assets and liabilities will be recorded at their pre-combination carrying amounts. GlycoMimetics&#8217; assets and liabilities will be measured and recognized at their fair values as of the effective time of the Merger, which are expected to approximate the carrying value of the acquired other non-operating assets and liabilities, with no goodwill or other intangible assets recorded. Any difference between the consideration transferred and the fair value of the net assets of GlycoMimetics following the determination of the actual consideration transferred for GlycoMimetics will be reflected as an adjustment to additional paid-in capital. For periods prior to closing of the Merger, the historical financial statements of Crescent shall become the historical financial statements of the Combined Company.</p><a id="_e6b268f5_55ad_4675_8fee_b4c9f7658669"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></span><b style="font-weight:bold;">Shares of GlycoMimetics Common Stock, Convertible Preferred Stock, Options, and Warrants Issued to Crescent Stockholders upon Closing of the Merger</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At the closing of the Merger, all outstanding shares of Crescent common stock, on a fully-diluted basis, will be exchanged for shares of GlycoMimetics common stock based on the preliminary estimated Exchange Ratio of 14.9149 shares of GlycoMimetics </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">290</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">common stock for each share of Crescent common stock, determined in accordance with the terms of the Merger Agreement. Each share of Crescent preferred stock will be converted into the right to receive a number of shares of GlycoMimetics Series A Preferred Stock, equal to the Exchange Ratio divided by 1,000 (and each such share of GlycoMimetics Series A Preferred Stock will have the right to convert into 1,000 shares of GlycoMimetics common stock, subject to certain limitations). The estimated number of shares of GlycoMimetics common stock that GlycoMimetics expects to issue to Crescent&#8217;s stockholders assumes GlycoMimetics net cash at the closing of the Merger is $1.8 million and is determined as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Shares of Crescent common stock outstanding as of December 31, 2024<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">7,049,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:86.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Shares of Crescent common stock to be issued upon conversion of Crescent convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Shares of Crescent common stock to be issued upon exercise of Crescent stock options<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">7,494,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated shares of Crescent common stock to be issued in connection with the Purchase Agreements, see Note 5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">89,833,671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated Crescent pre-funded warrants to be issued in connection with the Purchase Agreements, see Note 5(c)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">18,363,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total Crescent fully diluted shares prior to the closing of the merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">142,739,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated Exchange Ratio</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">14.9149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Estimated fully diluted shares to be issued to Crescent stockholders and Investors participating in Purchase Agreements upon closing of the merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">2,128,952,453</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents shares of Crescent common stock outstanding as of December&#160;31, 2024, including 2,049,180 shares of unvested Crescent restricted stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents the outstanding options as of December&#160;31, 2024 to acquire Crescent common stock.</span></td></tr></table><div style="margin-top:12pt;"><a id="_36052705_8ef5_4566_acd5_ac6f0f4e21ba"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></span><b style="font-weight:bold;">Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of December&#160;31, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5(A)&#160;Derived from the audited balance sheet of GlycoMimetics as of December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5(B)&#160;Derived from the audited balance sheet of Crescent as of December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pro forma Balance Sheet Transaction Accounting Adjustments:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5(a)&#160;To reflect preliminary estimated incremental compensation expense of $0.7 million related to severance and retention payments resulting from pre-existing employment agreements or from approval from the GlycoMimetics Board that is expected to be incurred upon the closing of the Merger. This amount is in addition to existing severance and retention payments of $4.5 million owed and unpaid by GlycoMimetics on December&#160;31, 2024. The pro forma adjustment is reflected as a decrease in cash of $5.2 million for the severance payments made subsequent to December&#160;31, 2024, a decrease to accrued expenses of $4.5 million and an increase to accumulated deficit of $0.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5(b)&#160;To reflect the exchange of all outstanding shares of Crescent preferred stock, with a carrying amount of $4.0 million, into newly created GlycoMimetics Series&#160;A Preferred Stock at closing of the Merger, with the terms of GlycoMimetics Series&#160;A Preferred Stock expected to result in classification within stockholders&#8217; equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5(c)&#160;To reflect the issuance of 89,833,671 shares of Crescent common stock and 18,363,034 pre-funded warrants, prior to giving effect to the Exchange Ratio, pursuant to the Subscription Agreement, for an aggregate purchase price of $200.0 million (which includes $37.5 million of gross proceeds previously received by Crescent from the issuance of its Convertible Notes). The aggregate proceeds are net less than $0.1 million of debt issuance costs and include accrued interest of $0.9 million as of December&#160;31, 2024 adjusted through accumulated deficit (see Note&#160;6(d)), for net proceeds prior to transaction costs of $161.6 million. The issuance of shares in connection with the Subscription Agreement are recorded as the issuance of Crescent common stock at par value, with the remaining amount recorded to additional paid-in-capital.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">291</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The net cash proceeds received prior to direct and incremental transaction costs from the Subscription Agreement and corresponding adjustment to additional paid-in-capital upon close of the Merger is determined as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:86.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Aggregate purchase price of Purchase Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:86.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net proceeds previously received from issuance of convertible note as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(37,482)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Debt issuance costs recorded as part of issuance of convertible note as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="white-space:pre-wrap;">Accrued interest payable as part of issuance of convertible note as of December 31, 2024,  see Note 6(d)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(852)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net proceeds received prior to direct and incremental transaction costs from the Purchase Agreement upon close of the Merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">161,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of Crescent common stock and pre-funded warrants at par value upon close of the Merger</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(86)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Additional paid-in capital related to the issuance of Crescent common stock and pre-funded warrants upon close of the Merger (excluding Crescent common stock issued in connection with conversion of convertible note)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">161,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5(d)&#160;To reflect preliminary estimated transaction costs of $17.4 million, not yet reflected in the historical financial statements, that are expected to be incurred by Crescent in connection with the Merger, and $0.8 million reflected in the historical financial statements as deferred offering costs, such as advisory, legal and auditor fees, as a reduction in cash and a reduction in other assets in the unaudited pro forma condensed combined balance sheet. As the Merger will be accounted for as a reverse recapitalization equivalent to the issuance of equity for the net assets, primarily cash, of GlycoMimetics, these direct and incremental costs are treated as a reduction of the net proceeds received within additional paid-in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5(e)&#160;To reflect preliminary estimated transaction costs of $2.9 million, not yet reflected in the historical financial statements, which are expected to be incurred by GlycoMimetics in connection with the Merger, such as advisory, legal and auditor fees and including the estimated $1.6 million cost of a D&amp;O tail policy, as a reduction in cash and a reduction in accumulated deficit of $2.9 million in the unaudited pro forma condensed combined balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5(f)&#160;To derecognize $0.4 million of GlycoMimetics&#8217; prepaid expenses and other current assets consisting of $0.1 million of prepaid expenses related to software that will not be utilized and $0.3 million of prepaid insurance primarily related to the current GlycoMimetics&#8217; D&amp;O insurance policy that will be fully utilized at the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5(g)&#160;To reflect the derecognition of GlycoMimetics&#8217; operating lease liability and other accrued expenses that will be paid prior to the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5(h)&#160;To reflect the one-time stock compensation expense of $0.4 million in general and administrative expense related to the acceleration of stock options pursuant to a modification to accelerate vesting of certain stock options per the terms of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">5(i)&#160;To reflect the recapitalization of Crescent and the derecognition of accumulated other comprehensive income and the accumulated deficit of GlycoMimetics, which is reversed to additional paid-in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The derecognition of accumulated deficit of GlycoMimetics of $498.7 million is determined as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accumulated deficit of GlycoMimetics as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">494,364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Compensation expense related to GlycoMimetics severance and retention payments, see Note 5(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Preliminary estimated transaction costs of GlycoMimetics, see Note 5(e)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">2,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Derecognition of GlycoMimetics prepaid expenses, see Note 5(f)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pre-merger stock-based compensation expense for GlycoMimetics&#8217; accelerated awards, see Note 5(h)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total adjustment to derecognize the accumulated deficit of GlycoMimetics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0pt 0pt;">498,699</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">292</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_ffdfe320_b8e5_454b_b6d6_b3615f83344d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></span><b style="font-weight:bold;">Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations and Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6(A)&#160;Derived from the audited consolidated statements of operations and comprehensive loss of GlycoMimetics for the&#160;year ended December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6(B)&#160;Derived from the audited statement of operations and comprehensive loss of Crescent for the period September&#160;19, 2024 (inception) to December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent and GlycoMimetics did not record any provision or benefit for income taxes during the&#160;year ended December&#160;31, 2024 because each company incurred a pre-tax loss in 2024 and each company maintained a full valuation allowance on its deferred tax assets. Accordingly, no pro forma adjustments have an impact on associated income tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pro forma Statements of Operations Transaction Accounting Adjustments:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6(a)&#160;To reflect preliminary estimated incremental compensation expense related to severance and retention payments recorded in general and administrative expenses of $0.7 million, resulting from pre-existing employment agreements or from approval from the GlycoMimetics Board that will be incurred upon the closing of the Merger, assuming that the adjustment described in Note&#160;5(a)&#160;was made on January&#160;1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6(b)&#160;To reflect the derecognition of GlycoMimetics&#8217; prepaid expenses and other current assets of $0.4 million related to $0.1&#160;million of software that will not be utilized, and prepaid insurance of $0.3 million primarily related to the current GlycoMimetics D&amp;O policy that will be fully utilized at the closing of the Merger, assuming the adjustment made in Note&#160;5(f)&#160;was made on January&#160;1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6(c)&#160;To reflect the one-time stock compensation expense of $0.4 million in general and administrative expense acceleration of stock options pursuant to a modification to accelerate vesting of certain stock options assuming the adjustment made in Note&#160;5(h)&#160;was made on January&#160;1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6(d)&#160;To reflect Crescent&#8217;s interest expense related to its Convertible Notes&#160;that is recorded in its historical financial statements, to be derecognized in the unaudited pro forma condensed combined statement of operations for the twelve&#160;months ended December&#160;31, 2024, assuming the adjustment described in Note&#160;5(c)&#160;was made on January&#160;1, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">6(e)&#160;The pro forma combined basic and diluted net loss per share has been adjusted to reflect the pro forma net loss for the&#160;year ended December&#160;31, 2024. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of shares of common stock of the Combined Company for the respective periods. Pro forma weighted average shares outstanding includes the pre-funded warrants related to the Subscription Agreement as the exercise price is negligible and they are fully vested and exercisable. Shares of GlycoMimetics Series&#160;A Preferred Stock share the same characteristics as common stock and have no substantive preference attributed to them and, accordingly, have been considered a class of common stock in the computation of net loss per share regardless of their legal form. Net loss is allocated to common stock based on its proportional ownership on an as-converted basis. Net loss is not allocated to participating securities as they do not have an obligation to fund losses.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">293</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The pro forma weighted average shares have been calculated as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Basic&#160;and&#160;Diluted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(48,158)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss attributable to Series A non-voting convertible preferred stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8,172)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Historical weighted average number of GlycoMimetics common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">64,477,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Shares of GlycoMimetics common stock issued to Crescent stockholders upon close of Merger, assuming consummation of the Merger as of January 1, 2024 <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,693,411,415</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pro forma combined weighted average number of common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,757,888,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pro forma combined weighted average number of shares of Series A Preferred Stock outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">298,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(27.40)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents the estimated shares of GlycoMimetics common stock and pre-funded warrants issued to Crescent stockholders at the closing of the Merger, excluding (i)&#160;the outstanding and unvested Crescent restricted stock and options to purchase Crescent common stock at the closing of the Merger that were converted to the right to receive 25,469,429 shares of the GlycoMimetics common stock and 111,733,609 options to purchase shares of GlycoMimetics common stock after reflecting the estimated Exchange Ratio and (ii)&#160;the outstanding shares of Crescent preferred stock that were exchanged for 298,298 shares of GlycoMimetics Series&#160;A Preferred Stock. The 25,469,429 shares of GlycoMimetics common stock issued in exchange for shares of Crescent restricted stock and 111,733,609 options to purchase shares of GlycoMimetics common stock issued in exchange for options to purchase shares of Crescent common stock are subject to the same vesting and forfeiture conditions, applicable, as they were prior to the Merger.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">294</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_009241dd_fa0a_434f_a143_37e2a89c5789"></a><a id="DESCRIPTIONOFGLYCOMIMETICSCAPITALSTOCK_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">DESCRIPTION OF GLYCOMIMETICS CAPITAL STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following description of GlycoMimetics capital stock and provisions of the GlycoMimetics Charter and GlycoMimetics Bylaws are summaries and are qualified by reference to such charter and bylaws and applicable provisions of Delaware corporate law. Copies of these documents are filed as exhibits to the registration statement of which this proxy/prospectus forms a part.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Authorized Capital Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Charter authorizes GlycoMimetics to issue up to 150,000,000 shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share. The GlycoMimetics Board may establish the rights and preferences of the preferred stock from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Description of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Voting Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each holder of GlycoMimetics common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under the GlycoMimetics Charter and GlycoMimetics Bylaws, GlycoMimetics&#8217; stockholders do not have cumulative voting rights. Because of this, the holders of a majority of the shares of GlycoMimetics common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to preferences that may be applicable to any then-outstanding shares of preferred stock, holders of GlycoMimetics common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the GlycoMimetics Board out of legally available funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of GlycoMimetics&#8217; liquidation, dissolution or winding up, holders of GlycoMimetics common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of GlycoMimetics&#8217; debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of GlycoMimetics preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Rights and Preferences</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of GlycoMimetics common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the GlycoMimetics common stock. The rights, preferences and privileges of the holders of GlycoMimetics common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of GlycoMimetics preferred stock that GlycoMimetics may designate in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Description of Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Board has the authority, without further action by GlycoMimetics&#8217; stockholders, to issue up to 5,000,000 shares of GlycoMimetics preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The GlycoMimetics Board may authorize the issuance of GlycoMimetics preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of GlycoMimetics common stock. The purpose of authorizing the GlycoMimetics Board to issue GlycoMimetics preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of GlycoMimetics preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of GlycoMimetics and may adversely affect the market price of GlycoMimetics common stock and the voting and other rights of the holders of GlycoMimetics common stock. It is not possible to state the actual effect of the issuance </p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">295</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of any shares of GlycoMimetics preferred stock on the rights of holders of GlycoMimetics common stock until the GlycoMimetics Board determines the specific rights attached to that GlycoMimetics preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the proposed merger between GlycoMimetics and Crescent Biopharma,&#160;Inc., the GlycoMimetics Board is expected to designate shares of GlycoMimetics preferred stock, to be designated as the Series&#160;A Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of the Series&#160;A Preferred Stock will be entitled to receive dividends equal to, on an as-if-converted-to-GlycoMimetics common stock basis, and in the same form as dividends actually paid on shares of GlycoMimetics common stock. Except as otherwise required by law, the Series&#160;A Preferred Stock will not have voting rights. However, as long as any shares of Series&#160;A Preferred Stock are outstanding, GlycoMimetics will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;A Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the s Series&#160;A Preferred Stock, (b)&#160;alter or amend the certificate of designation of the Series&#160;A Preferred Stock, (c)&#160;amend the GlycoMimetics Charter or the GlycoMimetics Bylaws in any manner that adversely affects any rights of the holders of the Series&#160;A Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of GlycoMimetics Preferred Stock (as defined in the certificate of designation for the Series&#160;A Preferred Stock), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;A Preferred Stock, (e)&#160;issue further shares of the Series&#160;A Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series&#160;A Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued Series&#160;A Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the certificate of designation of the Series&#160;A Preferred Stock) or (B)&#160;any merger or consolidation or other business combination in which GlycoMimetics&#8217; stockholders immediately before such transaction do not hold at least a majority of GlycoMimetics&#8217; capital stock immediately after such transaction, (g)&#160;increase the authorized number of directors constituting the GlycoMimetics Board or change the number of votes entitled to be cast by any director or directors on any matter or (h)&#160;enter into any agreement with respect to any of the foregoing. The Series&#160;A Preferred Stock will not have a preference upon GlycoMimetics&#8217; liquidation, dissolution or winding-up.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At all times when at least 30% of the originally issued Series&#160;A Preferred Stock will remain issued and outstanding, (i)&#160;the holders of Series&#160;A Preferred Stock, exclusively and voting together as a separate class on an as-converted to common stock basis, shall be entitled to elect two (2)&#160;directors (the &#8220;Preferred Directors&#8221;); and (ii)&#160;the holders of GlycoMimetics common stock and of any other class or series of voting stock (including the Series&#160;A Preferred Stock), exclusively and voting together as a single class on an as-converted to common stock basis, shall be entitled to elect the balance of the total number of directors. Any Preferred Director may be removed without cause only by the affirmative vote of the holders of a majority of the Series&#160;A Preferred Stock. Each Preferred Director shall be entitled to three (3)&#160;votes on each matter presented to the GlycoMimetics Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to certain limitations and the completion of certain steps in connection with the proposed Merger with Crescent, each share of Series&#160;A Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series&#160;A Preferred Stock, into a number of shares equal to 1,000 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Anti-Takeover Provisions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Charter provides for the GlycoMimetics Board to be divided into three classes with staggered three-year terms. Only one class of directors is elected at each annual meeting of GlycoMimetics&#8217; stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because GlycoMimetics&#8217; stockholders do not have cumulative voting rights, stockholders holding a majority of the shares of common stock outstanding are able to elect all of GlycoMimetics&#8217; directors. The GlycoMimetics Charter and the GlycoMimetics Bylaws also provide that directors may be removed by the stockholders only for cause upon the vote of 66<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2/3</sup>% or more of GlycoMimetics&#8217; outstanding common stock. Furthermore, the authorized number of directors may be changed only by resolution of the board of directors, and vacancies and newly created directorships on the board of directors may, except as otherwise required by law or determined by the GlycoMimetics Board, only be filled by a majority vote of the directors then serving on the board, even though less than a quorum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Charter and the GlycoMimetics Bylaws provide that all stockholder actions must be effected at a duly called meeting of stockholders and eliminate the right of stockholders to act by written consent without a meeting. The GlycoMimetics Bylaws also provide that only GlycoMimetics&#8217; chairman of the board, chief executive officer or the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors may call a special meeting of stockholders.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">296</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Bylaws provide that stockholders seeking to present proposals before a meeting of stockholders to nominate candidates for election as directors at a meeting of stockholders must provide timely advance notice in writing, and specify requirements as to the form and content of a stockholder&#8217;s notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Charter and the GlycoMimetics Bylaws provide that the stockholders cannot amend many of the provisions described above except by a vote of 66<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2/3</sup>% or more of GlycoMimetics&#8217; outstanding common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combination of these provisions makes it more difficult for GlycoMimetics&#8217; existing stockholders to replace the GlycoMimetics Board as well as for another party to obtain control of GlycoMimetics by replacing the GlycoMimetics Board. Since the GlycoMimetics Board has the power to retain and discharge GlycoMimetics&#8217; officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for the GlycoMimetics Board to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change GlycoMimetics&#8217; control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These provisions are intended to enhance the likelihood of continued stability in the composition of the GlycoMimetics Board and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce GlycoMimetics&#8217; vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for GlycoMimetics&#8217; shares and may have the effect of delaying changes in GlycoMimetics&#8217; control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of GlycoMimetics&#8217; stock that could result from actual or rumored takeover attempts. GlycoMimetics believes that the benefits of these provisions, including increased protection of GlycoMimetics&#8217; potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure GlycoMimetics, outweigh the disadvantages of takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Choice of Forum</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Charter provides that the Court of Chancery of the State of Delaware will be the exclusive forum for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any derivative action or proceeding brought on GlycoMimetics&#8217; behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any action asserting a breach of fiduciary duty;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any action asserting a claim against GlycoMimetics arising pursuant to the DGCL, the GlycoMimetics Charter or the GlycoMimetics Bylaws; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any action asserting a claim against GlycoMimetics that is governed by the internal affairs doctrine.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any action, a court could find the choice of forum provisions contained in the GlycoMimetics Charter to be inapplicable or unenforceable in such action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The transfer agent and registrar for the GlycoMimetics common stock is Equiniti (formerly known as the American Stock Transfer&#160;&amp; Trust Company). The transfer agent&#8217;s address is 48 Wall Street, 23rd floor, New York, NY 10043.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Listing on the Nasdaq Capital Market</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics common stock is listed on the Nasdaq Capital Market under the symbol &#8220;GLYC.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">297</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5d049d47_2602_4f63_a424_32b5490ba1a1"></a><a id="COMPARISONOFRIGHTSOFHOLDERSOFGLYCOMIMETI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">COMPARISON OF RIGHTS OF HOLDERS OF GLYCOMIMETICS CAPITAL STOCK AND</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT CAPITAL STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Merger is completed, Crescent stockholders will receive shares of GlycoMimetics common stock and GlycoMimetics Series&#160;A Preferred Stock, pursuant to the terms of the Merger Agreement. Prior to or upon the closing of the Merger, assuming that Proposal Nos.&#160;2 and 3 are approved by GlycoMimetics&#8217; stockholders, the GlycoMimetics Charter will be amended to increase the number of shares of GlycoMimetics common stock that GlycoMimetics is authorized to issue from 150,000,000 to<span style="display:inline-block;width:8.91pt;"></span><span style="display:inline-block;width:18pt;"></span><span style="display:inline-block;width:18pt;"></span>, to effect the proposed reverse stock split, as set forth in the forms of certificates of amendment attached as <i style="font-style:italic;">Annex G</i>, and <i style="font-style:italic;">Annex H</i>,<i style="font-style:italic;">&#160;</i>to this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics and Crescent are both incorporated under the laws of the State of Delaware. The rights of GlycoMimetics stockholders and Crescent stockholders are generally governed by the DGCL. Upon completion of the Merger, Crescent stockholders will become GlycoMimetics stockholders, and their rights will be governed by the DGCL, the GlycoMimetics Bylaws and the GlycoMimetics Charter, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The material differences between the current rights of Crescent stockholders under the Crescent Charter and Crescent Bylaws and their rights as GlycoMimetics stockholders, after the Merger, under the GlycoMimetics Charter and GlycoMimetics Bylaws, both as will be in effect immediately following the completion of the Merger and assuming that that Proposal Nos.&#160;2 and 3 are approved by GlycoMimetics&#8217; stockholders, are summarized below. The summary below does not purport to be complete and is subject to, and qualified in its entirety by reference to, the DGCL and the governing corporate instruments that are subject to amendment in accordance with their terms. You should carefully read this entire document and the other referenced documents, including the governing corporate instruments, for a more complete understanding of the differences between being a stockholder of GlycoMimetics or Crescent before the Merger and being a stockholder of the Combined Company following the completion of the Merger. For more information on how to obtain these documents, see the section titled &#8220;<i style="font-style:italic;">Where You Can Find More Information</i>&#8221; beginning on page&#160;315 of this proxy statement/prospectus.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">GlycoMimetics</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Crescent</b></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Organizational Documents</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The rights of GlycoMimetics stockholders are governed by the GlycoMimetics&#8217; amended and restated certificate of incorporation (as amended, the &#8220;GlycoMimetics Charter&#8221;), GlycoMimetics&#8217; amended and restated bylaws (the &#8220;GlycoMimetics Bylaws&#8221;) and the DGCL.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The rights of Crescent&#8217;s stockholders are governed by Crescent&#8217;s certificate of incorporation (the &#8220;Crescent Charter&#8221;), Crescent&#8217;s bylaws (the &#8220;Crescent Bylaws&#8221;) and the DGCL.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Authorized Capital Stock</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">GlycoMimetics is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that GlycoMimetics is authorized to issue is 155,000,000, of which 150,000,000 shares are common stock, each having a par value $0.001 per share, and 5,000,000 shares are preferred stock, each having a par value $0.001 per share. The preferred stock may be issued from time to time in one or more series. The number of authorized shares of GlycoMimetics preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of GlycoMimetics entitled to vote thereon, without a separate vote of the holders of the preferred stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of preferred stock. </p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Crescent is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that Crescent is authorized to issue is 60,000,000, of which 40,000,000 shares are common stock, par value $0.0001 per share, and 20,000,000 shares are preferred stock, par value $0.0001 per share. The number of authorized shares of Crescent common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Crescent preferred stock that may be required under the Crescent Charter) the affirmative vote of the holders of shares of Crescent capital stock representing a majority of the votes represented by all outstanding shares of Crescent capital stock entitled to vote, irrespective of the provisions of Section&#160;242(b)(2)&#160;of the DGCL.</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">298</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">GlycoMimetics</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Crescent</b></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Common Stock</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The GlycoMimetics authorized common stock consists of 150,000,000 shares of common stock, par value $0.001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Each holder of a share of GlycoMimetics common stock is entitled to one vote for each such share held of record on the applicable record date on each matter properly submitted to the stockholders for their vote.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Crescent&#8217;s authorized common stock consists of 40,000,000 shares of common stock, par value $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Each holder of a share of Crescent common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders (and written actions in lieu of meetings).</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Preferred Stock</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">GlycoMimetics preferred stock consists of 5,000,000 shares of preferred stock, each having a par value $0.001 per share. The voting rights of preferred stockholders can vary depending on the series of preferred stock issued. The GlycoMimetics Board is authorized to determine the voting powers, full or limited, or no voting powers for each series of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">In connection with the Merger, the GlycoMimetics Board intends to designate shares of undesignated preferred stock as GlycoMimetics Series&#160;A Preferred Stock through a certificate of designation in the form attached as <i style="font-style:italic;">Annex F</i> (the &#8220;Certificate of Designation&#8221;). No shares of Series&#160;A Preferred Stock are currently authorized or outstanding. Except as otherwise required by the Certificate of Designation or law, the GlycoMimetics Series&#160;A Preferred Stock will not have voting rights. As long as any shares of GlycoMimetics Series&#160;A Preferred Stock are outstanding, GlycoMimetics will not, without the affirmative vote or written waiver of the holders of a majority of the then outstanding shares of the GlycoMimetics Series&#160;A Preferred Stock: (i)&#160;alter or change adversely the powers, preferences or rights given to the GlycoMimetics Series&#160;A Preferred Stock or alter or amend the Certificate of Designation, amend the GlycoMimetics Charter, the GlycoMimetics Bylaws or other charter documents, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of GlycoMimetics preferred stock, in each case if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the GlycoMimetics Charter or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii)&#160;issue further shares of the GlycoMimetics Series&#160;A Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of the GlycoMimetics Series&#160;A Preferred Stock, (iii)&#160;at any time while at least 30% of the originally issued GlycoMimetics Series&#160;A Preferred Stock remains issued and outstanding, consummate either: (A)&#160;any Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of GlycoMimetics or other business combination in which the stockholders of GlycoMimetics immediately before such transaction do not hold at least a majority on an as-converted-to-GlycoMimetics </p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">All of Crescent&#8217;s 20,000,000 shares of preferred stock are designated as shares of &#8220;Series&#160;Seed Preferred Stock,&#8221; of which 20,000,000 are issued and outstanding. On each matter voted on at a meeting of stockholders (and written actions in lieu of meetings), each holder of a share of Crescent preferred stock is entitled to cast the number of votes equal to the number of whole shares of Crescent common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Holders of Crescent preferred stock vote together with holders of Crescent common stock as a single class and on an as-converted to common stock basis.</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">299</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">GlycoMimetics</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Crescent</b></p></th></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">common stock basis of the capital stock of GlycoMimetics, immediately after such transaction, (iv)&#160;increase the authorized number of directors constituting the GlycoMimetics Board or change the number of votes entitled to be cast by any director or directors on any matter or (v)&#160;enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated to consummate such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"/></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Number and Qualification of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The number of GlycoMimetics directors shall be fixed exclusively by resolutions adopted by a majority of the authorized number of directors constituting the GlycoMimetics Board. No decrease in the authorized number of directors constituting the GlycoMimetics Board will shorten the term of any incumbent director. Following the completion of the Merger, the Combined Company&#8217;s is expected to consist of members. </p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The number of directors of Crescent is established from time to time by the Crescent Board. The Crescent Board currently consists of four members. Any decrease in the authorized number of directors shall not become effective until the expiration of the term of the directors then in office, unless, at the time of such decrease, there are vacancies on the board which are eliminated by the decrease.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Structure of Board of Directors; Term of Directors; Election of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Subject to the rights of the holders of any series of preferred stock to elect additional directors under specified circumstances, the GlycoMimetics directors shall be divided into three classes designated as Class&#160;I, Class&#160;II and Class&#160;III, respectively. At each annual meeting of stockholders, directors shall be elected for a full term of three&#160;years to succeed the directors of the particular class whose terms expire at such annual meeting. Notwithstanding the foregoing provisions of this section, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Except as otherwise provided by statute, the GlycoMimetics Charter or the GlycoMimetics Bylaws, directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, if applicable, or represented by proxy at the meeting and entitled to vote generally on the election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Following the completion of the Merger, at all times when at least 30% of the originally issued GlycoMimetics Series&#160;A Preferred Stock remains issued and outstanding: (i)&#160;the holders of GlycoMimetics Series&#160;A Preferred Stock, exclusively and voting together as a separate class on an as-converted to common stock basis, shall be entitled to elect two (2)&#160;Preferred Directors; and (ii)&#160;the holders of GlycoMimetics common stock and of any other class or series of voting stock (including the GlycoMimetics Series&#160;A Preferred Stock), exclusively and voting together as a single class on an as-converted to common stock basis, shall be entitled to elect the balance of the total number of directors of GlycoMimetics. Each Preferred Director shall be entitled to three votes on each matter presented to the GlycoMimetics Board.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Crescent directors shall be elected at the annual meeting of stockholders by such stockholders as have the right to vote on such election. Election of directors need not be by written ballot. Each director shall hold office for a term of one&#160;year and until his or her successor is elected and qualified, or until such director&#8217;s earlier resignation or removal. All elections shall be determined by a plurality of the votes cast, except as otherwise required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The holders of record of the shares of Crescent preferred stock, voting together exclusively and as a separate class, are entitled to elect one director of Crescent. The holders of record of the shares of common stock and of any other class or series of voting stock (including the Crescent preferred stock), exclusively and voting together as a single class on an as-converted to common stock basis, shall be entitled to elect the balance of the total number of directors.</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">300</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">GlycoMimetics</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Crescent</b></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Removal of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Any director may be removed from office at any time, but only with cause and only by the affirmative vote of the holders of 66<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2/3</sup>% or more of the voting power of the outstanding shares of capital stock of GlycoMimetics entitled to vote at an election of directors, unless otherwise provided under the DGCL or the GlycoMimetics Charter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Following the completion of the Merger, any Preferred Director may be removed without cause only by the affirmative vote of the holders of a majority of the GlycoMimetics Series&#160;A Preferred Stock. </p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Any director may be removed, with or without cause, by the holders of a majority of shares of the class or series of capital stock entitled to elect such director, voting together as a single class on an as-converted to common stock basis, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Vacancies on the Board of Directors</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Subject to the rights of the holders of any series of GlycoMimetics preferred stock, any vacancies on the GlycoMimetics Board resulting from death, resignation, disqualification, removal or other causes, and any newly created directorships resulting from any increase in the number of directors, shall, unless the GlycoMimetics Board determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders, except as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the GlycoMimetics Board, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor shall have been elected and qualified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Any director may resign at any time upon notice given in writing or by electronic transmission to Crescent. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event. A vacancy in any director seat not reserved for holders of Crescent preferred stock can be filled by either (A)&#160;the vote or written consent in lieu of a meeting of the stockholders entitled to elect the director, or (B)&#160;the vote or written consent in lieu of a meeting of a majority of the remaining director(s), although less than a quorum. Vacancies and newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced. If there are no directors in office, then an election of directors may be held in the manner provided by statute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">If the holders of shares of Crescent preferred stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, then any directorship not so filled shall remain vacant until such time as the holders of the Crescent preferred stock elect a person to fill such directorship.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Stockholder Action by Written Consent</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">No action may be taken by the GlycoMimetics stockholders except at an annual or special meeting of the GlycoMimetics stockholders called in accordance with the GlycoMimetics Bylaws, and no action may be taken by the GlycoMimetics stockholders by written consent or electronic transmission in lieu of a meeting.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Any action required or permitted to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within 60&#160;days of the earliest dated consent delivered to Crescent, a written consent signed by a sufficient number of stockholders to take action are delivered to Crescent.</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">301</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">GlycoMimetics</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Crescent</b></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Quorum</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">At all meetings of stockholders, except where otherwise provided by statute or by the GlycoMimetics Charter or the GlycoMimetics Bylaws, the presence, in person, by remote communication, if applicable, or by proxy duly authorized, of the holders of a majority of the outstanding shares of GlycoMimetics common stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. </p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Except as otherwise provided by the DGCL or the Crescent Charter, the holders of a majority of the voting power of all of the shares of stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes. Where a separate vote by a class or series is required, a majority of the voting power of the shares of such class or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. The stockholders present at a duly constituted meeting may continue to transact business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a quorum. If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of stock entitled to vote who are present, in person or by proxy, may adjourn the meeting to another place, if any, date, or time.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Special Meetings of Stockholders</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Special meetings of the GlycoMimetics stockholders may be called, for any purpose as is a proper matter for stockholder action under Delaware law, by (i)&#160;the chairman of the GlycoMimetics Board, (ii)&#160;the chief executive officer of GlycoMimetics, or (iii)&#160;the GlycoMimetics Board pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the GlycoMimetics Board for adoption).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The GlycoMimetics Board shall determine the time and place, if any, of such special meeting. Upon determination of the time and place, if any, of the meeting, the GlycoMimetics secretary shall cause a notice of meeting to be given to the GlycoMimetics stockholders entitled to vote, in accordance with the GlycoMimetics Bylaws. No business may be transacted at such special meeting otherwise than specified in the notice of meeting.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Special meetings of the stockholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by the Crescent Board or the Chief Executive Officer if one is elected, or the President if one is elected, and shall be held at such place, date, and time as they or he or she shall fix.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Notice of Stockholder Meetings</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Except as otherwise provided by law, notice, given in writing or by electronic transmission, of each meeting of GlycoMimetics stockholders shall be given not less than ten (10)&#160;nor more than sixty (60)&#160;days before the date of the meeting to each stockholder entitled to vote at such meeting, such notice to specify the place, if any, date and hour, in the case of special meetings, the purpose or purposes of the meeting, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at any such meeting. </p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Except as otherwise provided by the DGCL or the Crescent Charter, notice of the place, if any, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, shall be given not less than 10&#160;days nor more than 60&#160;days before the date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting.</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">302</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">GlycoMimetics</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Crescent</b></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Advance Notice Requirements for Stockholder Proposals</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Nominations of persons for election to the GlycoMimetics Board may be made at an annual meeting or special meeting of stockholders, and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders, by any GlycoMimetics stockholder who was a stockholder of record at the time of giving the stockholder&#8217;s notice, who is entitled to vote at the meeting and who complied with the notice procedures set forth in the GlycoMimetics Bylaws. Such notice must be received by GlycoMimetics not later than the close of business on the ninetieth day no earlier than the close of business on the one hundred twentieth day prior to the first anniversary of the preceding&#160;year&#8217;s annual meeting, in the case of an annual meeting nomination, and not later than the close of business on the later of the ninetieth day prior to such meeting or the tenth day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the GlycoMimetics Board to be elected at such meeting, in the case of a special meeting nomination. </p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Neither the Crescent Charter nor the Crescent Bylaws contain advance notice requirements for stockholder proposals.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Amendment of Certificate of Incorporation</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The GlycoMimetics Charter may be amended pursuant to Section&#160;<span style="white-space:pre-wrap;">242 of the DGCL, which requires the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote, and the affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose; provided,  however, that pursuant to the GlycoMimetics Charter.the affirmative vote of the holders of 66</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2/3</sup>% of the voting rights is required to amend, repeal or adopt any provision inconsistent with the provisions of the GlycoMimetics Charter relating to: (i)&#160;Article&#160;V of the GlycoMimetics Charter which includes outlines the management structure of GlycoMimetics, including the roles and responsibilities of the GlycoMimetics Board, procedures for amending the GlycoMimetics Bylaws, and requirements for stockholder actions and advance notice provisions, (ii)&#160;Article&#160;VI of the GlycoMimetics Charter which provides for the elimination of directors&#8217; liability for monetary damages to the fullest extent permitted by law, (iii)&#160;Article&#160;VII of the GlycoMimetics Charter which designates the Court of Chancery of the State of Delaware as the exclusive forum for certain legal actions involving GlycoMimetics, unless an alternative forum is consented to in writing and (iv)&#160;Article&#160;VIII of the GlycoMimetics Charter which provides for the&#160;percentage of the shares necessary to amend the GlycoMimetics Charter.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The Crescent Charter may be amended pursuant to Section&#160;242 of the DGCL; provided that, at any time when shares of preferred stock are outstanding, the written consent or affirmative vote of the holders of at least a majority of the outstanding shares of preferred stock, voting together as a single class on an as-converted to common stock basis (the &#8220;Requisite Holders&#8221;), is required to (i)&#160;amend, alter or repeal of any provision of the Crescent Charter in a manner that adversely affects the special rights, powers, and preferences of the preferred stock or any series thereof, (ii)&#160;create or issue any capital stock unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences or (iii)&#160;increase the authorized number of shares of preferred stock or any additional class or series of capital stock of Crescent unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences.</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">303</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">GlycoMimetics</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Crescent</b></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Amendment of Bylaws</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Except as otherwise provided by law, the GlycoMimetics Bylaws may be adopted, amended or repealed by the GlycoMimetics Board. Any adoption, amendment or repeal of the GlycoMimetics Bylaws by the GlycoMimetics Board shall require the approval of a majority of the authorized number of directors. The GlycoMimetics Bylaws may also be adopted, amended or repealed by the stockholders by the affirmative vote of not less than 66<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2/3</sup>% of the outstanding shares of capital stock entitled to vote, voting together as a single class.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The Crescent Bylaws may be amended or repealed by the Crescent Board or by the stockholders; provided that, at any time when shares of preferred stock are outstanding, the written consent or affirmative vote of the Requisite Holders is required to amend, alter or repeal of any provision of the Crescent Bylaws in a manner that adversely affects the special rights, powers, and preferences of the preferred stock or any series thereof.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Limitation on Director and Officer Liability</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of GlycoMimetics shall be eliminated to the fullest extent permitted by the DGCL, as so amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">An officer GlycoMimetics shall not be personally liable to GlycoMimetics or the GlycoMimetics stockholders for monetary damages for breach of his or her fiduciary duty as an officer, except for liability (a)&#160;for any breach of the duty of loyalty to GlycoMimetics or the GlycoMimetics stockholders, (b)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c)&#160;for any transaction from which the officer derived an improper personal benefit, or (d)&#160;arising from any claim brought by or in the right of GlycoMimetics. If the DGCL is amended after the filing of this proxy/prospectus to authorize corporate action further eliminating or limiting the personal liability of officers, then the liability of an officer of GlycoMimetics shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The Crescent Charter provides that, to the fullest extent permitted by law, a director or officer of Crescent shall not be personally liable to Crescent or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL or any other law of the State of Delaware is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of Crescent shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Indemnification</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">GlycoMimetics will indemnify its directors to the fullest extent not prohibited by the DGCL or any other applicable law; <i style="font-style:italic;">provided, however,</i> that the corporation may modify the extent of such indemnification by individual contracts with its directors; and, <i style="font-style:italic;">provided, further,</i> that GlycoMimetics will not be required to indemnify any director in connection with any proceeding (or part thereof) initiated by such person unless (i)&#160;such indemnification is expressly required to be made by law, (ii)&#160;the proceeding was authorized by the GlycoMimetics Board, (iii)&#160;such indemnification is provided by GlycoMimetics, in its sole discretion, pursuant to the powers vested in GlycoMimetics under the DGCL or any other applicable law or (iv)&#160;such indemnification is required to be made under the GlycoMimetics Bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">GlycoMimetics will have power to indemnify its officers, employees and other agents as set forth in the DGCL or any other applicable law. The GlycoMimetics Board shall have the power to delegate the determination of whether indemnification shall </p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The Crescent Charter (i)&#160;requires Crescent to indemnify, to the fullest extent permitted by applicable law, any director or officer of Crescent, and (ii)&#160;authorizes Crescent to indemnify, to the extent permitted by the DGCL, any employee or agent of Crescent, who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (for purposes of this paragraph, a &#8220;proceeding&#8221;) by reason of the fact that he or she is or was a director, officer, employee or agent of Crescent or is or was serving at the request of Crescent as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such proceeding. Crescent is required to indemnify a director or officer in connection with a proceeding initiated by such person only if the proceeding was authorized by the Crescent Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The Crescent Bylaws require Crescent to indemnify, to the fullest extent permitted by Delaware law, except in certain circumstances, each person who was or is made a party to or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (for purpose of this paragraph, a &#8220;proceeding&#8221;), by reason of the fact that he or she is or was a director or an officer of Crescent or is or was serving at the request of Crescent as a director, officer, or trustee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan (for purpose of this paragraph, an &#8220;indemnitee&#8221;), whether the basis of such proceeding is alleged action in an official capacity as a director, officer or trustee, or in any other capacity while serving as a director, officer or trustee. The Crescent Bylaws also provide that an indemnitee will have the right to be paid by Crescent expenses (including attorney&#8217;s fees) incurred in defending any such proceeding in advance of its final disposition, provided, however, that, if the DGCL requires, an advancement of expenses incurred by an indemnitee in his or her capacity as a director or officer shall be made only upon delivery to Crescent of an undertaking, by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled to be indemnified for such expenses. The Crescent Bylaws also provide that the rights to indemnification and advance of expenses shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, the Crescent Charter, the Crescent Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">304</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">GlycoMimetics</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Crescent</b></p></th></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">be given to any such person to such officers or other persons as the GlycoMimetics Board shall determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">GlycoMimetics will advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was a director of GlycoMimetics, or is or was serving at the request of GlycoMimetics as a director or officer of another corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred by any director in connection with such proceeding; <i style="font-style:italic;">provided, however</i>, that, if the DGCL requires, an advancement of expenses incurred by a director in his or her capacity as a director (and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to GlycoMimetics of an undertaking, by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled to be indemnified for such expenses under the GlycoMimetics Bylaws or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The rights conferred on any person by the GlycoMimetics Bylaws will not be exclusive of any other right which such person may have or hereafter acquire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"/></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Conversion Rights</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">When the GlycoMimetics Series&#160;A Preferred Stock is issued in connection with the Merger, the holders of the GlycoMimetics Series&#160;A Preferred Stock will have the right to convert such shares into GlycoMimetics common stock at any time at a ratio of 1 share of GlycoMimetics Series&#160;A Preferred Stock to 1,000 shares of GlycoMimetics common stock, subject to certain limitations, including that a holder of GlycoMimetics Series&#160;A Preferred Stock is prohibited from converting shares of GlycoMimetics Series&#160;A Preferred Stock into shares of GlycoMimetics common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified&#160;percentage of the total number of shares of GlycoMimetics common stock issued and outstanding immediately after giving effect to such conversion.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The Crescent Charter provides that holders of preferred stock have the right to convert such shares into shares of common stock, at the option of the holder, at any time, at a conversion rate in accordance with the terms set forth in the Crescent Charter. In addition, upon the earliest to occur of (i)&#160;immediately prior to the closing of the sale of shares of common stock to the public at a price of at least $1.00 per share (subject to appropriate adjustment for any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act, resulting in at least $50,000,000 of gross proceeds, net of the underwriting discount and commissions, to Crescent and in connection with such offering the shares of Crescent common stock are listed for trading on the Nasdaq Stock Market&#8217;s National Market, the New York Stock Exchange or another exchange or marketplace approved by the Crescent Board; and (ii)&#160;the date and time, or the occurrence of an event, specified by vote or written consent of the Requisite Holders, (A)&#160;all outstanding shares of preferred stock other than the Crescent preferred stock will automatically be converted into shares of common stock and (B)&#160;all outstanding shares of Crescent preferred stock will automatically be converted into shares of non-voting preferred stock with the rights, privileges, duties and </p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">305</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">GlycoMimetics</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Crescent</b></p></th></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">obligations to be determined, at the then effective conversion rate as calculated in accordance with the Crescent Charter.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Preemptive Rights</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">GlycoMimetics stockholders do not have preemptive rights. Thus, if additional shares of GlycoMimetics common stock are issued, the current holders of GlycoMimetics common stock will own a proportionately smaller interest in a larger number of outstanding shares of common stock to the extent that they do not participate in the additional issuance.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Crescent stockholders do not have preemptive rights. Thus, if additional shares of Crescent common stock are issued, the current holders of Crescent common stock will own a proportionately smaller interest in a larger number of outstanding shares of common stock to the extent that they do not participate in the additional issuance.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Distributions to Stockholders</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Subject to preferences that may be applicable to any outstanding shares of GlycoMimetics preferred stock, the holders of GlycoMimetics common stock are entitled to receive ratably such dividends as may be declared by the GlycoMimetics Board out of legally available funds. </p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Crescent shall not declare, pay or set aside any dividends (other than dividends on shares of common stock payable in shares of common stock) unless holders of preferred stock first receive, or simultaneously receive, a dividend on each outstanding share of preferred stock in an amount calculated in accordance with the Crescent Charter.</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Exclusive Forum</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The GlycoMimetics Charter provides that unless GlycoMimetics consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of GlycoMimetics; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of GlycoMimetics to GlycoMimetics or its stockholders; (iii)&#160;any action asserting a claim against GlycoMimetics arising pursuant to any provision of the DGCL, the GlycoMimetics Charter or the GlycoMimetics Bylaws; or (iv)&#160;any action asserting a claim against GlycoMimetics governed by the internal affairs doctrine.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The Crescent Charter provides that, unless Crescent consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&#160;any derivative action or proceeding brought on behalf of Crescent, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of Crescent to Crescent or Crescent&#8217;s stockholders, (iii)&#160;any action asserting a claim against Crescent, its directors, officers or employees arising pursuant to any provision of the DGCL, the Crescent Charter or the Crescent Bylaws or (iv)&#160;any action asserting a claim against Crescent, its directors, officers or employees governed by the internal affairs doctrine or that otherwise relates to the internal affairs of Crescent, except for, as to each of (i)&#160;through (iv)&#160;above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten&#160;days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. These provisions may impose additional costs on Crescent&#8217;s stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or were permitted to select another jurisdiction. Additionally, these provisions may limit Crescent&#8217;s stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with Crescent or its directors, officers or other employees, which may discourage such lawsuits against Crescent and its directors, officers and other employees even though an action, if successful, might benefit its stockholders.</p></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">306</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">GlycoMimetics</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Crescent</b></p></th></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Registration Rights</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other than in connection with the Merger, GlycoMimetics stockholders do not have any registration rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Merger, GlycoMimetics will enter into a registration rights agreement with the investors participating in the Crescent Pre-Closing Financing, pursuant to which, among other things, the Combined Company will agree to prepare and file a resale registration statement covering the resale of certain shares of GlycoMimetics common stock within 30 business&#160;days of the Closing pursuant to Rule&#160;415 and to use its commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act. The registration rights agreement also provides that the Combined Company will pay certain expenses relating to such registrations and indemnify the applicable securityholders against certain liabilities.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Crescent stockholders do not have any registration rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Stock Transfer Restrictions Applicable to Stockholders</i></p></td></tr><tr><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Shares of GlycoMimetics common stock are transferable in the manner prescribed by the DGCL.</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Shares of Crescent are transferable in the manner prescribed by the DGCL.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">307</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:5.75pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6de59e5f_456b_4258_b7df_a2bcdfcc22c6"></a><a id="PRINCIPALSTOCKHOLDERSOFGLYCOMIMETICS_268"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF GLYCOMIMETICS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth certain information regarding the ownership of GlycoMimetics common stock as of February&#160;7, 2025 by: (i)&#160;each director; (ii)&#160;each of the executive officers, also called the named executive officers; (iii)&#160;all executive officers and directors as a group; and (iv)&#160;all those known to be beneficial owners of more than five&#160;percent of GlycoMimetics common stock. Except as otherwise noted below, the address for persons listed in the table is c/o GlycoMimetics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This table is based upon information supplied by GlycoMimetics&#8217; named executive officers, directors and principal stockholders. Unless otherwise indicated in the footnotes to the table and subject to community property laws where applicable, each stockholder named in the table has sole voting and investment power with regard to the shares indicated as being beneficially owned. Applicable&#160;percentages are based on 64,513,862 shares of common stock outstanding on February&#160;7, 2025, adjusted as required by the rules&#160;promulgated by the SEC.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Beneficial Owner</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">5% Stockholders:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Entities affiliated with Biotechnology Value Fund, L.P. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,544,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Entities affiliated with RA Capital Management, L.P. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,383,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Entities affiliated with Adage Capital Management, L.P. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,091,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Entities affiliated with Logos Global Management, L.P. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">Named Executive Officers and Directors:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Harout Semerjian <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,734,919</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Brian Hahn <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">913,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Edwin Rock, M.D. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">972,703</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Patricia Andrews <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">200,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mark Goldberg, M.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(9)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">199,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Scott Jackson <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(10)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">133,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Daniel Junius <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(11)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">226,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Rachel King <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(12)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,122,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Scott Koenig, M.D., Ph.D.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(13)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">157,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Timothy Pearson <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(14)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">177,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">All current directors and executive officers as a group (10 persons)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(14)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,870,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:1.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Represents beneficial ownership of less than one&#160;percent of the outstanding shares of common stock.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As reported on a Schedule 13G/A filed by Biotechnology Value Fund,&#160;L.P., Mark Lampert and affiliated entities (collectively, &#8220;BVF&#8221;) with the SEC on January&#160;29, 2024, which states that BVF had shared voting and dispositive power with respect to these shares. The principal business address of BVF is 44 Montgomery Street, 40th Floor, San Francisco, CA 94104.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As reported on a Schedule 13G filed by RA Capital Management,&#160;L.P. with the SEC on November&#160;6, 2024. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr.&#160;Kolchinsky and Mr.&#160;Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section&#160;13(d)&#160;of the Securities Exchange Act of 1934, as amended (&#8220;Act&#8221;), of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund&#8217;s portfolio, including the shares of common stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61&#160;days&#8217; notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section&#160;13(d)&#160;of the Act and therefore disclaims any obligation to report ownership of the reported securities under Section&#160;13(d)&#160;of the Act. As managers of RA Capital, Dr.&#160;Kolchinsky and Mr.&#160;Shah may be deemed beneficial owners, for purposes of Section&#160;13(d)&#160;of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr.&#160;Kolchinsky, and Mr.&#160;Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section&#160;13(d)&#160;of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">308</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr.&#160;Kolchinsky, or Mr.&#160;Shah is the beneficial owner of such securities for any other purpose. The principal business address of RA Capital Management,&#160;L.P. is 200 Berkeley Street, 18th Floor, Boston MA 02116.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As reported on a Schedule 13D filed on November&#160;4, 2024 by Adage Capital Management, (i)&#160;Adage Capital Management,&#160;L.P., a Delaware limited partnership (&#8220;ACM&#8221;), as the investment manager of Adage Capital Partners,&#160;L.P., a Delaware limited partnership (&#8220;ACP&#8221;), with respect to the shares of common stock directly held by ACP; (ii)&#160;Robert Atchinson (&#8220;Mr.&#160;Atchinson&#8221;), as (i)&#160;managing member of Adage Capital Advisors, L.L.C., a Delaware limited liability company (&#8220;ACA&#8221;), managing member of Adage Capital Partners GP, L.L.C., a Delaware limited liability company (&#8220;ACPGP&#8221;), general partner of ACP and (ii)&#160;managing member of Adage Capital Partners LLC, a Delaware limited liability company (&#8220;ACPLLC&#8221;), general partner of ACM, with respect to the shares of common stock directly held by ACP; and (iii)&#160;Phillip Gross (&#8220;Mr.&#160;Gross&#8221;), as (i)&#160;managing member of ACA, managing member of ACPGP and (ii)&#160;managing member of ACPLLC, general partner of ACM, with respect to the shares of common stock directly held by ACP. The principal business address of Adage Capital Management is 200 Clarendon Street, 52nd floor, Boston, MA 02116.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As reported on a schedule 13G filed on November&#160;27, 2024 by Logos Global Management,&#160;L.P. Logos Global Master Fund LP (&#8220;Global Fund&#8221;), Logos Global Management LP (&#8220;Logos Global&#8221;), Logos GP LLC (&#8220;Logos GP&#8221;), Logos Global Management GP LLC (&#8220;Logos Global GP&#8221;), and Arsani William (collectively, the &#8220;Filers&#8221;). Logos Global is the investment adviser to investment funds, including Global Fund. Logos Global GP is the general partner of Logos Global. Dr.&#160;William is a control person of Logos Global and Logos Global GP.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;25,000 shares of common stock held directly and (b)&#160;1,709,919 shares of common stock underlying options that are vested and exercisable within 60&#160;days of February&#160;7, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;70,643 shares of common stock held directly, (b)&#160;834,175 shares of common stock underlying options that are vested and exercisable within 60&#160;days of February&#160;7, 2025 and (c)&#160;8,625 shares of common stock underlying restricted stock units that will vest and settle within 60&#160;days of February&#160;7, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;680,403 shares of common stock held directly and (b)&#160;292,300 shares of common stock underlying options that are vested and exercisable within 60&#160;days of February&#160;7, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;58,608 shares of common stock held directly and (b)&#160;141,500 shares of common stock underlying options that are vested and exercisable within 60&#160;days of February&#160;7, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(9)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;11,497 shares of common stock held by family trusts for which Dr.&#160;Goldberg serves as trustee, (b)&#160;20,224 shares of common stock held directly and (c)&#160;167,901 shares of common stock underlying options that are vested and exercisable within 60&#160;days of February&#160;7, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(10)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;5,250 shares of common stock held directly and (b)&#160;130,500 shares of common stock underlying options that are vested and exercisable within 60&#160;days of February&#160;7, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(11)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;93,250 shares of common stock held directly and (b)&#160;163,500 shares of common stock underlying options that are vested and exercisable within 60&#160;days of February&#160;7, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(12)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;487,798 shares of common stock held directly, (b)&#160;1,490,490 shares of common stock underlying options that are vested and exercisable within 60&#160;days of February&#160;7, 2025, (c)&#160;45,741 shares of common stock held by Ms.&#160;King&#8217;s spouse, (d)&#160;90,660 shares of common stock held by family trusts for which Ms.&#160;King serves as trustee and (e)&#160;7,500 shares held by a limited liability company for which Ms.&#160;King serves as co-manager.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(13)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;36,750 shares of common stock held directly and (b)&#160;121,000 shares of common stock underlying options that are vested and exercisable within 60&#160;days of February&#160;7, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(14)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;24,650 shares of common stock held directly and (b)&#160;152,500 shares of common stock underlying options that are vested and exercisable within 60&#160;days of February&#160;7, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(15)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;1,657,974 shares of common stock, (b)&#160;5,203,785 shares of common stock underlying options that are vested and exercisable within 60&#160;days of February&#160;7, 2025 and (c)&#160;8,625 shares of common stock underlying restricted stock units that will vest and settle within 60&#160;days of February&#160;7, 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(16)</td><td style="padding:0pt;"/></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">309</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_06e14d5a_bb29_41e7_9de2_b727f3ccb86c"></a><a id="PRINCIPALSTOCKHOLDERSOFCRESCENT_564460"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF CRESCENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth certain information known to Crescent regarding beneficial ownership of Crescent capital stock on an as-converted to Crescent common stock basis as of February&#160;7, 2025 for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person or group of affiliated persons, who is known by Crescent to be the beneficial owner of more than 5% of Crescent capital stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of Crescent&#8217;s directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each Crescent named executive officer; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of Crescent&#8217;s directors and executive officers and directors as a group.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beneficial ownership is determined in accordance with the rules&#160;of the SEC and thus represents voting or investment power with respect to Crescent&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of February&#160;7, 2025. Shares of Crescent common stock that an individual has the right to acquire within 60&#160;days of February&#160;7, 2025 are deemed to be outstanding and beneficially owned by the individual for the purpose of computing the&#160;percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the&#160;percentage ownership of any other person. To Crescent&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned. The&#160;percentage of beneficial ownership shown prior to the Merger and Crescent Pre-Closing Financing in the table below is based on 27,049,180 shares of Crescent common stock deemed to be outstanding as of February&#160;7, 2025, assuming the conversion of all outstanding shares of Crescent preferred stock into shares of Crescent common stock. The following table does not reflect any shares of Crescent common stock or Crescent pre-funded warrants that such holders have agreed to purchase in the Crescent Pre-Closing Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated, the address for each beneficial owner is c/o Crescent Biopharma,&#160;Inc., 221 Crescent Street, Building 23, Suite&#160;105, Waltham, MA 02453.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Shares</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Beneficially </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">of Shares</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Outstanding</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Beneficially</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name of Beneficial Owner</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5% or Greater Stockholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fairmount Healthcare Fund II, L.P.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">73.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Paragon Therapeutics, Inc.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9.2 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Parascent Holding LLC<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">9.2 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Named Executive Officers and Directors:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jonathan Violin<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,935,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">10.8 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Christopher Doughty<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">339,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">1.3 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Ryan Lynch</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Barbara Bispham</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Alexandra Balcom</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Susan Moran</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Peter Harwin<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">73.9 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:78.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">All executive officers and directors as a group (7 persons)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23,298,144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">86.1 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Less than 1%.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 20,000,000 shares of Crescent common stock issuable upon conversion of 20,000,000 shares of Crescent preferred stock held directly by Fairmount Fund II. Fairmount serves as investment manager for Fairmount Fund II. Fairmount Fund II has delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fairmount Fund II&#8217;s portfolio. Because Fairmount Fund II has divested itself of voting and investment power over the securities it holds and may not revoke that delegation on less than 61&#160;days&#8217; notice, Fairmount Fund II disclaims beneficial ownership of the securities it holds. The general partner of Fairmount is Fairmount Funds Management GP LLC (&#8220;Fairmount GP&#8221;). As managing members of Fairmount GP, </span></td></tr></table></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">310</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Peter Harwin and Tomas Kiselak may be deemed to have voting and investment power over the shares held by Fairmount Fund II. Fairmount, Fairmount GP, Peter Harwin and Tomas Kiselak disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of each of the entities and individuals listed is 200 Barr Harbor Drive, Suite&#160;400, West Conshohocken, PA 19428.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 2,500,000&#160;shares of Crescent common stock held by Paragon. Paragon is managed by its board of directors, consisting of Peter Harwin, Tomas Kiselak, and Evan Thompson.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 2,500,000&#160;shares of Crescent common stock held by Parascent. Parascent is managed by its sole manager, Evan Thompson.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;1,366,120 shares of restricted voting common stock, (b)&#160;vested options to acquire 1,404,253 shares of common stock, and (c)&#160;options to acquire 165,206 shares of common stock that will vest within 60&#160;days of the date of this table.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;273,224 shares of restricted voting common stock, (b)&#160;vested options to acquire 22,028 shares of common stock, and (c)&#160;options to acquire 44,055 shares of common stock that will vest within 60&#160;days of the date of this table.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (a)&#160;20,000,000 shares of Crescent common stock issuable upon conversion of 20,000,000 shares of Crescent preferred stock, (b)&#160;1,434,033 shares of restricted voting common stock, (c)&#160;vested options to acquire 1,601,484 shares of common stock, and (d)&#160;options to acquire 224,766 shares of common stock that will vest within 60&#160;days of the date of this table.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">311</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f2b880f0_4f26_4d3e_b019_21ae99e344ad"></a><a id="PRINCIPALSTOCKHOLDERSOFTHECOMBINEDCOMPAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal No.&#160;3 of this proxy statement/prospectus</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth certain information regarding beneficial ownership of the Combined Company&#8217;s common stock immediately after consummation of the Merger, assuming the consummation of the Merger occurred on<span style="display:inline-block;width:16.01pt;"></span><span style="display:inline-block;width:18pt;"></span>, 2025 for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person or group of affiliated persons, who is expected by GlycoMimetics and Crescent to be the beneficial owner of more than 5% of the Combined Company&#8217;s common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person expected to be a director of the Combined Company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person expected to be a named executive officer of the Combined Company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of the Combined Company&#8217;s expected directors and executive officers and directors as a group.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beneficial ownership is determined in accordance with the rules&#160;of the SEC and thus represents voting or investment power with respect to the Combined Company&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual or entity has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025. Shares of the Combined Company&#8217;s common stock that an individual or entity has the right to acquire within 60&#160;days of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 are deemed to be outstanding and beneficially owned by the individual or entity for the purpose of computing the&#160;percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the&#160;percentage ownership of any other person. To GlycoMimetics&#8217; and Crescent&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table lists applicable&#160;percentage ownership based on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of common stock expected to be outstanding upon consummation of the Merger, after giving effect to the Crescent Pre-Closing Financing and prior to giving effect to the anticipated GlycoMimetics reverse stock split and includes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of unvested restricted common stock. The number of shares beneficially owned includes shares of common stock that each person has the right to acquire within 60&#160;days, including upon the exercise of stock options and warrants. These stock options and warrants shall be deemed to be outstanding for the purpose of computing the&#160;percentage of outstanding shares of the Combined Company&#8217;s common stock expected to be owned by such person but shall not be deemed to be outstanding for the purpose of computing the&#160;percentage of outstanding shares of the combined organization&#8217;s common stock expected to be owned by any other person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Immediately after the Merger, GlycoMimetics securityholders as of immediately prior to the Merger are expected to own approximately 3.10% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis, and subject to dilution from any equity issued by Crescent after the date of the Merger Agreement and before the closing), and former holders of Crescent securities are expected to own approximately 96.90% of the outstanding shares of capital stock of the Combined Company (on a fully-diluted basis), subject to certain assumptions, including, but not limited to, GlycoMimetics&#8217; net cash as of closing being equal to $1.8 million. GlycoMimetics&#8217; management currently anticipates GlycoMimetics&#8217; net cash as of closing will be approximately $1.8 million, and the currently estimated ownership&#160;percentages reflect this projection. There can be no assurances any of these assumptions will be accurate at closing when the final Exchange Ratio is determined. The table below assumes that, based on GlycoMimetics&#8217; capitalization as of September&#160;30, 2024 and Crescent&#8217;s capitalization as of October&#160;28, 2024, the date the Merger Agreement was executed, the Exchange Ratio is estimated to be equal to approximately 14.9149&#160;shares of GlycoMimetics common stock for each share of Crescent common stock, prior to giving effect to the anticipated GlycoMimetics reverse stock split. The estimated Exchange Ratio was derived on a fully-diluted basis, using a stipulated value of Crescent of approximately $250.0 million and of GlycoMimetics of approximately $8.0 million, assuming net cash of $1.8 million as of closing. The final Exchange Ratio is subject to adjustment prior to the closing of the Merger based upon GlycoMimetics&#8217; net cash at closing and the aggregate proceeds from the sale of Crescent common stock and Crescent pre-funded warrants in the Crescent Pre-Closing Financing.</p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">312</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated, the address for each beneficial owner is c/o Crescent Biopharma,&#160;Inc., 221 Crescent Street Building 23, Suite&#160;105, Waltham, MA 02453.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b> <b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding Beneficially</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name of Beneficial Owner</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Named Executive Officers and Directors:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">All executive officers and directors as a group ( persons)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">313</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e5121474_426c_4f90_a32a_10237357252f"></a><a id="LEGALMATTERS_200163"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">LEGAL MATTERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sidley Austin LLP will pass upon the validity of GlycoMimetics common stock offered by this proxy statement/prospectus.</p><a id="_bf90bf63_a3d5_43fe_8aa2_f7032886e691"></a><a id="EXPERTS_986908"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">EXPERTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial statements of GlycoMimetics,&#160;Inc. at December&#160;31, 2024 and 2023, and for each of the two&#160;years in the period ended December&#160;31, 2024, included in this proxy statement/prospectus have been audited by Ernst&#160;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about GlycoMimetics,&#160;Inc.&#8217;s ability to continue as a going concern as described in Note&#160;2 to the financial statements) appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial statements of Crescent Biopharma,&#160;Inc. as of December&#160;31, 2024 and for the period from September&#160;19, 2024 (inception) to December&#160;31, 2024 included in this proxy statement/ prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to Crescent Biopharma,&#160;Inc.&#8217;s ability to continue as a going concern as described in Note&#160;1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">314</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_02a4048d_35e9_43c5_95c8_31d5c2dc0167"></a><a id="WHEREYOUCANFINDMOREINFORMATION_403864"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">WHERE YOU CAN FIND MORE INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics is subject to the informational requirements of the Exchange Act and in accordance therewith, files annual, quarterly and current reports, proxy statements and other information with the SEC electronically, and the SEC maintains a website that contains GlycoMimetics&#8217; filings as well as reports, proxy and information statements, and other information issuers file electronically with the SEC at <i style="font-style:italic;">www.sec.gov</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics also makes available free of charge on or through its website at <i style="font-style:italic;">www.glycomimetics.com</i>, its Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange Act as soon as reasonably practicable after GlycoMimetics electronically files such material with or otherwise furnishes it to the SEC. The website addresses for the SEC and GlycoMimetics are inactive textual references and except as specifically incorporated by reference into this proxy statement/prospectus, information on those websites is not part of this proxy statement/prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has filed with the SEC a registration statement on Form&#160;S-4, of which this proxy statement/prospectus is a part, under the Securities Act to register the shares of GlycoMimetics common stock (including the shares of GlycoMimetics common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock) to be issued to Crescent stockholders in the Merger. The registration statement, including the attached annexes, exhibits and schedules, contains additional relevant information about GlycoMimetics and GlycoMimetics common stock. This proxy statement/prospectus does not contain all of the information set forth in the registration statement because certain parts of the registration statement are omitted in accordance with the rules&#160;and regulations of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has supplied all information contained in this proxy statement/prospectus relating to GlycoMimetics and Crescent has supplied all information contained in this proxy statement/prospectus relating to Crescent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you would like to request documents from GlycoMimetics or Crescent, please send a request in writing or by telephone to either GlycoMimetics or Crescent at the following addresses:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:51.72%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">GlycoMimetics,&#160;Inc.<br/>P.O.&#160;Box 65,<br/>Monrovia, MD 21770<br/>Attn:&#160;&#160;Corporate Secretary<br/>Tel:&#160;&#160;(240) 243-1201</p></td><td style="vertical-align:top;width:48.27%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Crescent Biopharma,&#160;Inc.<br/>221 Crescent Street, Building 23, Suite&#160;105<br/>Waltham, MA 02453<br/>Attn:&#160;&#160;Secretary<br/>Tel:&#160;&#160;(617) 430-5595</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you are a GlycoMimetics stockholder and would like additional copies, without charge, of this proxy statement/prospectus or if you have questions about the Merger, including the procedures for voting your shares, you should contact GlycoMimetics&#8217; proxy solicitor,<span style="display:inline-block;width:0.73pt;"></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, at the following telephone number:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Banks and Brokers Call:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Stockholders Call Toll Free:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">315</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_49fb2a0e_3109_428b_a5b7_3105f6f64a14"></a><a id="STOCKHOLDERPROPOSALSORDIRECTORNOMINATION"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">STOCKHOLDER PROPOSALS OR DIRECTOR NOMINATIONS FOR 2025 ANNUAL MEETING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">If a GlycoMimetics stockholder would like GlycoMimetics to consider including a proposal in GlycoMimetics&#8217; proxy statement for its 2025 annual meeting pursuant to Rule&#160;14a-8 of the Exchange Act, then the proposal must be received by GlycoMimetics&#8217; corporate secretary at GlycoMimetics&#8217; principal executive offices on or before&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025. In addition, stockholder proposals must comply with the requirements of Rule&#160;14a-8 regarding the inclusion of stockholder proposals in company-sponsored proxy materials. Proposals should be addressed to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;">GlycoMimetics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;">Attention:&#160;&#160;Corporate Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;">P.O.&#160;Box 65,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;">Monrovia, MD 21770</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The GlycoMimetics Bylaws also establish an advance notice procedure for stockholders who wish to present a proposal or nominate a director at an annual meeting, but do not seek to include the proposal or director nominee in GlycoMimetics&#8217; proxy statement. In order to be properly brought before GlycoMimetics&#8217; 2025 annual meeting, the stockholder must provide timely written notice to GlycoMimetics&#8217; corporate secretary, at GlycoMimetics&#8217; principal executive offices, and any such proposal or nomination must constitute a proper matter for stockholder action. The written notice must contain the information specified in the GlycoMimetics Bylaws. To be timely, a stockholder&#8217;s written notice must be received by GlycoMimetics&#8217; corporate secretary at GlycoMimetics&#8217; principal executive offices:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no earlier than &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no later than &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In the event that GlycoMimetics holds its 2025 annual meeting more than 30&#160;days before, or more than 60&#160;days after, the one-year anniversary of this&#160;year&#8217;s annual meeting, then such written notice must be received by GlycoMimetics&#8217; corporate secretary at GlycoMimetics&#8217; principal executive offices:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no earlier than the 90</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> day prior to the day of GlycoMimetics&#8217; 2025 annual meeting, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no later than close of business on the later of: (i)&#160;the 60</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> day prior to the day of GlycoMimetics&#8217; 2025 annual meeting or (ii)&#160;the 10</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> day following the earlier of the day on which public announcement of the date of GlycoMimetics&#8217; 2025 annual meeting is first made or notice is first given.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Availability of Bylaws</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">A copy of the GlycoMimetics Bylaws may be obtained by accessing GlycoMimetics&#8217; filings on the SEC&#8217;s website at <i style="font-style:italic;">www.sec.gov</i>. You may also contact GlycoMimetics&#8217; corporate secretary at GlycoMimetics&#8217; principal executive offices for a copy of the relevant bylaw provisions regarding the requirements for making stockholder proposals and nominating director candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Householding of Proxy Materials</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The SEC has adopted rules&#160;that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy materials with respect to two or more stockholders sharing the same address by delivering a single set of the proxy materials addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the GlycoMimetics Special Meeting, a number of brokers with account holders who are GlycoMimetics stockholders will be &#8220;householding&#8221; the proxy materials. A single set of the proxy materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be &#8220;householding&#8221; communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate set of the proxy materials, please notify your broker or GlycoMimetics. Direct your written request to Secretary, GlycoMimetics,&#160;Inc., P.O.&#160;Box 65, Monrovia, MD 21770 or contact Investor Relations at (240) 243-1201. GlycoMimetics undertakes to promptly deliver a separate set of the proxy materials upon receiving your written request. Stockholders who currently receive multiple copies of the proxy materials at their addresses and would like to request &#8220;householding&#8221; of their communications should contact their brokers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">316</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d311d7f6_c796_4cac_9f70_3c21ec59a6cf"></a><a id="INDEXTOGLYCOMIMETICSINCSFINANCIALSTATEME"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEX TO GLYCOMIMETICS, INC.&#8217;S FINANCIAL STATEMENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:94.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:5.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:94.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#Report_of_Independent_Registered_Publ_29"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID: 42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#BalanceSheets_656978"><span style="font-style:normal;font-weight:normal;">Balance Sheets as of December&#160;31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-3</p></td></tr><tr><td style="vertical-align:top;width:94.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#StatementsofOperationsandComprehensive_1"><span style="font-style:normal;font-weight:normal;">Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-4</p></td></tr><tr><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#StatementsofStockholdersEquity_712246"><span style="font-style:normal;font-weight:normal;">Statements of Stockholders&#8217; Equity for the years ended December&#160;31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:94.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#StatementsofCashFlows_755635"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows for the years ended December&#160;31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#NotestoFinancialStatements_432888"><span style="font-style:normal;font-weight:normal;">Notes to Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INDEX TO CRESCENT BIOPHARMA, INC.&#8217;S FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:94.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-20</p></td></tr><tr><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#CRESCENTBIOPHARMAINCBALANCESHEET_31643"><span style="font-style:normal;font-weight:normal;">Balance Sheet as of December&#160;31, 2024</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-22</p></td></tr><tr><td style="vertical-align:top;width:94.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#CRESCENTBIOPHARMAINCSTATEMENTOFOPERATION"><span style="font-style:normal;font-weight:normal;">Statement of Operations and Comprehensive Loss for the period from September 19, 2024 (Inception) to December&#160;31, 2024</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-23</p></td></tr><tr><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#CRESCENTBIOPHARMAINCSTATEMENTOFCONVERTIB"><span style="font-style:normal;font-weight:normal;">Statement of Convertible Preferred Stock and Stockholders&#8217; Deficit for the period from September 19, 2024 (Inception) to December&#160;31, 2024</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-24</p></td></tr><tr><td style="vertical-align:top;width:94.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#CRESCENTBIOPHARMAINCSTATEMENTOFCASHFLOWS"><span style="font-style:normal;font-weight:normal;">Statement of Cash Flows for the period from September 19, 2024 (Inception) to December&#160;31, 2024</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:5.84%;background:#cceeff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-25</p></td></tr><tr><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a href="#a1NatureoftheBusinessandBasisofPresentat"><span style="font-style:normal;font-weight:normal;">Notes to Financial Statements</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 1pt 0pt;">F-26</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8bfd16a1_0afc_4c11_a2b5_be283ba713ff"></a><a id="Report_of_Independent_Registered_Publ_29"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:18pt;margin:0pt;">To the Shareholders and the Board of Directors of GlycoMimetics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:18pt;margin:0pt;">We have audited the accompanying balance sheets of GlycoMimetics, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">The Company&#8217;s Ability to Continue as a Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:18pt;margin:0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has incurred recurring losses from operations and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:18pt;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Critical Audit Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:18pt;background:#ffffff;margin:0pt;">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. We determined that there are no critical audit matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2011.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baltimore, Maryland</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 13, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a165de4d_7562_4ba8_9370_35da8caa6f46"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><a id="BalanceSheets_656978"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">BALANCE SHEET</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_43498a5b_8c39_43fe_8e09_01120478f0a2"></a><a id="Tc_db202UNF1k6DEvqALRaTZQ_1_2"></a><a id="Tc_oqCO2boPP060oyGXuesnGg_2_2"></a><a id="Tc_ogDrNQEOaE-wdYO9ZRwMfg_2_5"></a><a id="Tc_521_snoNt02wnuQElccZnQ_3_0"></a><a id="Tc_Go9-Q4KrfkW1He5Y_OHsNQ_4_0"></a><a id="Tc_ErJWBpuY-EWtiGs2yZCJQQ_5_0"></a><a id="Tc_BGd_MjbNvkSnucUkph37Sg_5_2"></a><a id="Tc_Z9aFZSQoQkOCNQxyqzddLQ_5_5"></a><a id="Tc_yolEvEpnnUqmkclJbpH1Vg_6_0"></a><a id="Tc_qUQt7XGf5UW-ngvVHYDdVw_7_0"></a><a id="Tc_4e5jd1FPskOF6IOfUH_LQQ_8_0"></a><a id="Tc_wBpbW1rAfUaKQjSGi9e6Pw_8_3"></a><a id="Tc_OzpZB71BmUqrWLZAm2on4A_9_0"></a><a id="Tc_hsn1zx2kAEaioNan-XOIBw_9_3"></a><a id="Tc_ZfeRZh9gK0qZVS9nqKndhQ_10_0"></a><a id="Tc_rwQyzhiEE0-yHyJhk-Bmew_10_3"></a><a id="Tc_MaNconjSIUOdrHImz_EycA_11_0"></a><a id="Tc_7gocKhGjpk-jY5LvtjEivA_11_2"></a><a id="Tc_gCc-B62wtkabozevG4_FYQ_11_5"></a><a id="Tc_7Zoa_OpbzUqkl1Am5Zvoxg_12_0"></a><a id="Tc_8z29YMAMzk6VJtVrnkjkeA_13_0"></a><a id="Tc_y0d3wZ8XEEOfh9vS9DCaDA_14_0"></a><a id="Tc_2l1eL3ZLaU6L2KSncdO5mw_14_2"></a><a id="Tc_o4ykBkR5AUuIa9oziNiOrg_14_5"></a><a id="Tc_FTHJUapSoUuWa-jzJhNLsA_15_0"></a><a id="Tc_HyppY8Ft4Eu42owxoX34kw_16_0"></a><a id="Tc_biGhLIWPEkSG82D_yr9Cqw_17_0"></a><a id="Tc_5mtokAEvXk2-h5h7j3_a0Q_18_0"></a><a id="Tc_q_kgIq4ARUaqvM8O36Au3Q_18_3"></a><a id="Tc_lX4u0IiRvkiLK8wR5Da4ZQ_19_0"></a><a id="Tc_oZ4SOuCtsEO_jpNgh8eKVA_20_0"></a><a id="Tc_Sh5ye2zCMUiDyjuszYQ4yw_21_0"></a><a id="_e27f3ca8_1164_41a6_9875_f9b39ebb6ea0"></a><a id="_e27f3ca8_1164_41a6_9875_f9b39ebb6ea0_2"></a><a id="_e27f3ca8_1164_41a6_9875_f9b39ebb6ea0_3"></a><a id="Tc_FjyXOsVz-0SFcI9WLBzWhg_22_0"></a><a id="Tc_s7iILxFWbEOAVT6w8GwCmQ_23_0"></a><a id="Tc_x39JPBCAv0qB8DvJwH4k9Q_24_0"></a><a id="Tc_KhxDQBDvNESwkNDMA8-M-Q_25_0"></a><a id="Tc_Jrzk3cBH2kyTOOPpNdWi4g_26_0"></a><a id="Tc_eUsXZcfOpEaZFfRfTwn8Jw_26_2"></a><a id="Tc_1z01TtGN-EqB7yJnzFrp0g_26_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_SPkIRmvvh0a3IHfM6kUusw_5_3">10,720,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_9Fz_vlWSi0-bbUKD9zBHxg_5_6">41,792,830</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_qHd5gnjvTUKm8-4Twn54Ow_6_3">371,276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_KLfXYyp7I0C_9Ec1M8Ek6w_6_6">1,997,904</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_nrUW36OjaU2nm8OjupMHFg_7_3">11,091,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_O2KoUj2FD06TS_m-j8o0Ww_7_6">43,790,734</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" id="Tc_SPijyfs8oEGUufpgrwVSQg_8_6">603,737</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_ayeIpoH2m06cx_bQGsxKvQ_9_6">767,828</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssets" scale="0" id="Tc_OPqhrbkAukCxKbCThYzCqg_10_6">154,176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_oa8WdRJcikakexQCunKeaQ_11_3">11,091,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_7WiAfwCh5EGj7GmQgI-o1A_11_6">45,316,475</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Liabilities&#160;&amp; stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_rlEUEOYcB0GTQjycjNAzig_14_3">329,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_3Ef7xU3XI0uX9TiKbxBXmQ_14_6">868,115</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_iJD_29HcgE2F96fve7p-Xw_15_3">5,381,744</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_UK2mf8ZX6Uq-3T_Z57hFng_15_6">5,225,557</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_CZaQqYT78EW3JcatvycrtA_16_3">66,844</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_O4PfqiXw00e9rVyMz9z51A_16_6">741,558</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_AlUoh1TmXkOA1CvWAhRDlg_17_3">5,777,892</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_bm_aBXBC2kKO59n6XeL9_w_17_6">6,835,230</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_z6khm8IR1EizY5MjKMArWw_18_6">66,844</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_muVA0PSsfUGt1C51TIgUDA_19_3">5,777,892</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_e0pq4y7FYEaVL2YbhJXFlg_19_6">6,902,074</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Preferred stock; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_IO9VJMlr0U-0EQFveRtV9A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_fluDUpV6WUa0RUzjLhdL-Q">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_ZdP2RK25kkuhAhAWEEl5tA"><ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_SANV6k2Y-U6PsIzIGdIM_g">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_PDDVB7an3UOSalP61Hft5g"><ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_8HDOJDuqKEe536HoB0_tJw">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2024 and December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_D7vkSyJr-EqQ_vMdm49tQQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_iYvC6zUDDkeqXWNTByTQFA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Common stock; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_dvcyNbGvRUmqVT_Ps4QTaQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_GslEKzpbzESe6oSc6mBCYA">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_9cET6geSOkuPBEuzDXyYSg">150,000,000</ix:nonFraction> shares authorized at December 31, 2024; <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_OLz91RwF-0msvvlbpZMOUQ">100,000,000</ix:nonFraction> shares authorized at December 31, 2023; <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_e1gCBcPXnUKyC_3zUJuwBw">64,483,958</ix:nonFraction> shares issued and <span style="-sec-ix-hidden:Hidden_i4KFkDItQU-W7JjpHj8jIQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December 31, 2024; <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_-pKn8X6ruEGEuYSBEQ1o9g">64,393,744</ix:nonFraction> shares issued and <span style="-sec-ix-hidden:Hidden_GQx9LJBBZk6tvQkeC5S2pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December&#160;31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_KHC3gzZmykyKliK8CtJr7Q_22_3">64,484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_7mBaYnraY0qvlQyISIKugA_22_6">64,394</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_Cbu5SH0yQ0ec9BP4SqZlAg_23_3">499,613,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_93kmGRz8PE-WhBMOW9S_yg_23_6">494,835,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_QNyMra1B10CjC9EkPL4JLw_24_3">494,364,370</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_hdDjgxvI3kOH5f5beXoNHQ_24_6">456,485,212</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_34h9fJJQAU2wijuwY_JsSw_25_3">5,313,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_7-iH3lquVECKqD4TcV7yUA_25_6">38,414,401</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_7ZAufyOMxkqU7W_z_6BYPA_26_3">11,091,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_cSw76EKY5EiBAkJLHsVODQ_26_6">45,316,475</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">See accompanying notes.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_befb3515_042c_45cb_b092_db94a4668e69"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><a id="StatementsofOperationsandComprehensive_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">STATEMENTS OF OPERATIONS AND COMPREHENSIV</b><b style="font-weight:bold;">E LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_a00db7aa_a7e0_497d_800a_1c0415f93aa9"></a><a id="_d988f326_b5f5_4146_9813_c65d3dd69087"></a><a id="Tc_YPfHhmnY4UGoOD6NFrD8xA_1_2"></a><a id="Tc_FzbQXYBuxkCphaPxrg5NRg_2_2"></a><a id="Tc_2s-vs2JFYk-h3xGqV07T5w_2_5"></a><a id="Tc_oGxhR2J8S0ecyUOMZAQInA_3_0"></a><a id="Tc_QNJZzXtbkkSTZYIE3TgBTw_3_2"></a><a id="Tc_0kd6eWR_KUSAmTSIoIZc5g_3_3"></a><a id="Tc_Y7GWpwt170uihZODNtT5bw_3_5"></a><a id="Tc_i6YTwPC8xkSDf0cbT1_SqQ_5_0"></a><a id="Tc_TpcUePnWo0us6JbUXkd_RA_6_0"></a><a id="Tc_1l8JHcPL5k2ug8rHnzjMug_7_0"></a><a id="Tc_cPppQALgLkeMAyORL2jtOg_8_6"></a><a id="Tc_WNOMAPydakeXmRBybIdPaw_9_0"></a><a id="Tc_MGXLzJgfMEqZDcLEtUlYIQ_10_0"></a><a id="Tc_xMEH_WwYW0aO0h3K-mQRKQ_12_0"></a><a id="Tc_zIw7eMylPk2MhH9NAzkGag_13_0"></a><a id="Tc_YlTeH88rDEmRYe1WwoegjA_13_6"></a><a id="Tc_0OIgz9LMrUSQCZnrNBO5yA_14_0"></a><a id="Tc_hgDioEC5iEyRxL6v8Ff0vw_15_0"></a><a id="Tc_bICwgQF_GUyUy9OUaz3o2w_16_0"></a><a id="Tc_CfgFnAIfI0Sdo-fBSf0nYQ_16_2"></a><a id="Tc_V0f6-C8lY0OeonPXBwLKIQ_16_5"></a><a id="Tc_fxVpvbvHO0u2LNK747pQtA_17_0"></a><a id="Tc_629keVT6K0K3MY0t2VYTVQ_17_2"></a><a id="Tc_ThF0QTngmEuKvHdWXfrgnA_17_5"></a><a id="Tc_OWbznlQIME-YeMyAvOMHNQ_18_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue from collaboration and license agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_F-Cw2CQJpEi7oM0wtu6fPw_3_6">10,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_pCCOb7ElSkSiI-kDqT61PQ_6_3">14,259,756</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_86UKYotXX0iu2HGgA27AjA_6_6">20,071,656</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc__ysYXgIBpE2lhs8lXDLYNA_7_3">18,249,318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_iybAW4zWjUqP0_xTuuwDnQ_7_6">19,213,637</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="-sec-ix-hidden:Hidden__sNpJ6kWbEi0MrQEFcD_Vw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restructuring and asset impairment charges</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" scale="0" id="Tc_qAtIpe4Z1UKwT6HR8iGqlw_8_3">7,530,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_lEB6IiddKUGAiL3goE1dxw_9_3">40,039,378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_7roZKtshcEGavv-06Vr3fw_9_6">39,285,293</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_M1RjkVfIo0SJmWmLx8RXjQ_10_3">40,039,378</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_AEu9wQS9Q06Q2e3wRL7zdQ_10_6">39,275,293</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain on sale of asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="0" id="Tc_c5gETDvMgky2aXbhFN7biQ_13_3">1,224,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_kdRFO4OZIUCwlU6EMGSSfw_14_3">935,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_9fc1_emdiEqIOfWPXNITAg_14_6">2,375,873</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_szUW8OEeWkWFm_DKWAds4Q_15_3">2,160,220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_tg2OtdbSbE6bh5O1W-TuPg_15_6">2,375,873</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_CpeZYxqGa0S284TXQo1vcw_16_3">37,879,158</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_4mtU8YvdI0ynV2447Y7avA_16_6">36,899,420</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_LzAQ6Qkqb0aIj1j2jY-EcQ_17_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_LzAQ6Qkqb0aIj1j2jY-EcQ_17_3_2">0.59</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_8n4rMnqbFkCaJLppmd1H_Q_17_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_8n4rMnqbFkCaJLppmd1H_Q_17_6_2">0.58</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted weighted-average number of common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Uis9b_WaR0KEbQD3GoDeew_18_3"><ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_Uis9b_WaR0KEbQD3GoDeew_18_3_2">64,477,249</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_-1PXRwQBcEmaUjrOUXxoow_18_6"><ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_-1PXRwQBcEmaUjrOUXxoow_18_6_2">63,342,465</ix:nonFraction></ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">See accompanying notes.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4a0f5591_1c2b_4c11_9f72_df6cbd39347d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><a id="StatementsofStockholdersEquity_712246"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENTS OF STOCKHOLDERS&#8217; EQUIT</b><b style="font-weight:bold;">Y</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_cd2eb863_5f63_4bbb_a54b_d5ffa2687b8a"></a><a id="Tc_ZiMPqhdCA0u5d0hEo81-Rw_1_7"></a><a id="Tc_0ho_GI-nskecSism83SjHQ_1_13"></a><a id="Tc_9tdxerD7oUaCFd0R5R5cNg_2_2"></a><a id="Tc_yoDU479tn0mN2ZQm1w5dGA_2_7"></a><a id="Tc_6RNfn0f76EyzDhVbF_oRcA_2_10"></a><a id="Tc_PIzRtqRkdUyW_5yo06pE8g_2_13"></a><a id="Tc_qe9UPbMacUWWWiAFKJMKEw_3_2"></a><a id="Tc_lDrzUPteu0awW7xYX-zNOg_3_4"></a><a id="Tc_yJjDj8rpEUKpg8HTJcxoGQ_3_7"></a><a id="Tc_zmM0iJP3Akqv-27NdGcLpg_3_10"></a><a id="Tc_Yy6OayW--0G-385xeYZTQQ_3_13"></a><a id="Tc_qZQ2A5L3eUSmZIWbI2xzoQ_4_0"></a><a id="Tc_aVaQmcmpck6miK8xZugjVw_4_4"></a><a id="Tc_bAkjI1VXmEeTrJM5yIxc5A_4_7"></a><a id="Tc_mPsDEEiFt064-hWDTYyfyg_4_10"></a><a id="Tc_wSbjAX_3YkWNfIi9x1-vJg_4_13"></a><a id="Tc_N937iI1sOEGNuhFJc451Mw_5_0"></a><a id="Tc_deW5C3lmckWZluQXwnImcQ_5_11"></a><a id="Tc_raNPAQ4Dn02ZQ66dJLBoQw_6_0"></a><a id="Tc_iTO5q9mDLEe7nF8GG-9wSw_6_11"></a><a id="Tc_V8ReWbfKY0av7GX9EPDh2A_7_0"></a><a id="Tc_Cu-P_Pk_S0-Oc0db1MbEIw_7_11"></a><a id="Tc_fjzpD7NEiUOHlIsm4-NJwQ_8_0"></a><a id="Tc_USpNuUJyaEedMHn3hwhhjw_8_2"></a><a id="Tc_o7opePyo1UeDONdlTf1e8A_9_0"></a><a id="Tc_tQepenMYxUWV9RAmO7KoMg_9_2"></a><a id="Tc_4Z1SeSniY0mYkhgqtLgLeQ_9_5"></a><a id="Tc_ah7i-xjoMUSQqHnkS0Ttiw_9_8"></a><a id="Tc_c4AyYNLbSUG_30rIuDUHbg_10_0"></a><a id="Tc_1dgQ4dDFfUa1kziE8ULPzw_11_0"></a><a id="Tc_PvLvD9ItrU-Bd7MXtjz6cA_11_11"></a><a id="Tc_Ew28C1QBQUWF72WP7jNCrw_12_0"></a><a id="Tc_V92YRnLL1k-QoRya5hSRIw_12_11"></a><a id="Tc_2vX6dkFzH06FUtfEDRZ7dw_13_0"></a><a id="Tc_sJ6n80EXJ02AgCp3FRuI_A_13_2"></a><a id="Tc_DsrLaxzOskSsASgNoK4Dew_13_5"></a><a id="Tc_TTvjLkj5DEKjrRVEBZqTAQ_13_11"></a><a id="Tc_-10TH2shUEWF5D3-7OtlEg_14_0"></a><a id="Tc_vZKPYMNa0E2mMu2cLiNoJQ_14_2"></a><a id="Tc_yRW4ByCAeU2z78uPaAOIww_14_5"></a><a id="Tc_jWYLfVeWQ0SmbnBz-eNJvw_14_8"></a><a id="Tc_BrB_eTo5WUa_Zyk0GuSAUQ_15_0"></a><a id="Tc__5OMzmuLTUyjOMbgbnqrmg_15_4"></a><a id="Tc_tETKnhdRTEiU2cB-0B4C2Q_15_7"></a><a id="Tc_pG6ayF9zlU-kCwaNpLtPSQ_15_10"></a><a id="Tc_p6R0N4S3g0C0hzy1_vvatA_15_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b>&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b>&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSdHWh91dUS21LGrb3eG2g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_1MMzetM0IEutsnBor_PYEg_4_2">54,377,798</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSdHWh91dUS21LGrb3eG2g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_-pluQKDEA0mNBLop7cBiug_4_5">54,378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YguH7JjiPk21kMLGoxNsYw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_qelV2FPJEUGd9XDsOR81aA_4_8">462,461,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KsS5cukmYkiHF4C6-dXYBw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_0CDH1MxBV0GhkUK2rb6_zw_4_11">419,585,792</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2022_J_TWX_FgbkyiMy1gXdMchw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_PwIImXdCdkiDgU6WS-TEEg_4_14">42,929,837</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_3kYr6GybxkyWd6dqxOet1A_5_2">9,822,930</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_kKyQiZxCOkGn7q8siPpUlQ_5_5">9,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aWlLHTyMG0CvFZ6zPAULSQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_ACnBp6XXw0y1JfIxp3Xf1w_5_8">28,697,188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_IVzuRDbzpUGuVb8y5jB69Q_5_14">28,707,011</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock for services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_ShCA2FdEfUW5YTCNIpQhYw_6_2">24,001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_NljEnEsIJkmDYYikxjwbNA_6_5">24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aWlLHTyMG0CvFZ6zPAULSQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_YSspGZp_XUmOJo01i9L7UA_6_8">35,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_YUcPMe4dokyh3Y6vqJ7amA_6_14">36,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercise of options and vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw" decimals="INF" format="ixt:num-dot-decimal" name="glyc:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" scale="0" id="Tc_vwfrMFH8B0yVo70hjwgH3A_7_2">169,015</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw" decimals="0" format="ixt:num-dot-decimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" scale="0" id="Tc_Iz68AjSc4UajqpK5HuosBQ_7_5">169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aWlLHTyMG0CvFZ6zPAULSQ" decimals="0" format="ixt:num-dot-decimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" scale="0" id="Tc_L9FCBFJxUEKKWqenrv2wjA_7_8">116,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" scale="0" id="Tc_K3TWkrnwI0aXlYOPYota1Q_7_14">116,497</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aWlLHTyMG0CvFZ6zPAULSQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_QwRhj_jSHUuY2UGy9PTpGQ_8_8">3,524,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_EQmE7TuWEkGGedE4pZaQ0w_8_14">3,524,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_R9ETDiIjiEmYnIZRVb5HJA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_k2zbovJPPUyTPHzf1nGgDg_9_11">36,899,420</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_IAJ7goqt8EiVJ9xikyun1g_9_14">36,899,420</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AwOVplV_P0mDzPrhrPFQXA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_ICkawatOLkOWhb8YWSgXuQ_10_2">64,393,744</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AwOVplV_P0mDzPrhrPFQXA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ONa0iKZ2qEGGVQy1jYDtnQ_10_5">64,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_74z7jNQFhUKDHc5lm0MsVw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_iLiP3IBB0k6tnX5F75rrmA_10_8">494,835,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MVa3Xane0EWGuB31zaHGLw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_x4QJTvEE6ke7oZOpsHOEkw_10_11">456,485,212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_rQdVxJO7vkyznbS3ahYi6w_10_14">38,414,401</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock for services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EjDnsR2epkyuZXXhTKnIHA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_o_4Yw8nU10KzKmFOUwHe0A_11_2">28,383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EjDnsR2epkyuZXXhTKnIHA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_KHEXJNF5LkqT74tq5YrlzQ_11_5">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_R7XVHwnd7U6Sd_9oTQ_uFw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_-Jrbc_FPfkaKjsQ9YXbk3Q_11_8">75,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_2ElXK3YjjU2I3Cmngz9Pqw_11_14">75,375</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercise of options and vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EjDnsR2epkyuZXXhTKnIHA" decimals="INF" format="ixt:num-dot-decimal" name="glyc:StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_Vu75B2l1fUyFikiWQVY9OA_12_2">61,831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EjDnsR2epkyuZXXhTKnIHA" decimals="0" format="ixt:num-dot-decimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_DrfTU35O5kCl25zQbYHqug_12_5">62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_R7XVHwnd7U6Sd_9oTQ_uFw" decimals="0" format="ixt:num-dot-decimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_Btw_Z23oHUmTEJcmZCslsw_12_8">5,336</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" scale="0" id="Tc_BKBjHIWCJEi0P96PTPhqlg_12_14">5,398</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_R7XVHwnd7U6Sd_9oTQ_uFw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_RFzzXQAaM06KqG1XMZGS1Q_13_8">4,697,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_Ga8TJh2lUkWbwN8W4BI71A_13_14">4,697,546</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TMq5bdXLv0uPMiT_XpYChA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_7aRVhtNcqEyQXsLa3HRHeQ_14_11">37,879,158</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_N4-zd0Yd1UCYYh18mxT5ZQ_14_14">37,879,158</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:42.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wERsIdAgWE-wQCQ81ui9CQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_aCykOlh71EaTqYn_-Etndw_15_2">64,483,958</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wERsIdAgWE-wQCQ81ui9CQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_gopNyXiwq0yCuYX1JtPxsQ_15_5">64,484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cIbtCfNf7EazwoGlwZilVQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_9NejIKbjQ0OW40plXOEFLw_15_8">499,613,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tjhcHjf3qUCUEAGiJHVx7g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Uzl020Xc50WmMRdlV2NRtg_15_11">494,364,370</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_KcbeWeRoFEyzPycluPD3dw_15_14">5,313,562</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">See accompanying notes.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a46df56d_c18b_421e_af8b_88f021fe4eca"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><a id="StatementsofCashFlows_755635"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">STATEMENTS OF CASH FLOW</b><b style="font-weight:bold;">S</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_8d93c521_8fc4_40ee_b4c7_7b6e76bccce6"></a><a id="Tc_pKX3HmRSI0uydxIE5RTUQg_1_2"></a><a id="Tc_jVByKQ7ex02LtX7Eeq2S6w_2_2"></a><a id="Tc_lJnCMcWp-kyL6ZjHkuGd4Q_2_5"></a><a id="Tc_kMAfLgA2lECI_2QgqPwxUA_3_0"></a><a id="Tc_1iiNoxfiekObCygUdR0RZA_4_0"></a><a id="Tc_ZX6czHeFg0iaMS5CkbXOGg_4_2"></a><a id="Tc_OyTEvVZxZ0m02e0zAdIn6Q_4_5"></a><a id="Tc_RismIDF5O0C4tbPMOurjtw_5_0"></a><a id="Tc_O6tCIcX8EUGAFH72niOmmg_6_0"></a><a id="Tc_fMxftF6M-0m0kr-qFF_WDg_7_0"></a><a id="Tc_jkW6v09gzUSqg52bhpPapg_8_0"></a><a id="Tc_g4AXgzoYGki2XprOH9DWuQ_8_6"></a><a id="Tc_IiUbRoDO7UCrfvq9Os0OsQ_9_0"></a><a id="Tc_qO8XZ7B9_E2LBimnFp3IuA_10_0"></a><a id="Tc_h5YFEJA5uUeOhRSOAMvyyQ_11_0"></a><a id="Tc_-p7D2oeKk06SAHVD5cWy8w_12_0"></a><a id="Tc_vQ4c4pHxE0KkRBVI_KfEjA_13_0"></a><a id="Tc_r60U8r_liEuKOCO3NSx7VA_14_0"></a><a id="Tc_g2KQRBRiX06GYruiOKZkvg_15_0"></a><a id="Tc_woMUoDzBa0ukzRKzk2hpeA_16_0"></a><a id="Tc_nYb6HYO6PEG4xngjD03hzg_17_0"></a><a id="Tc_HN24XwojpUqKNjv8FSM1qg_18_0"></a><a id="Tc_D3DWY6Ug0EqFG_lay5b7SQ_20_0"></a><a id="Tc_S8MZ1m4cNkycAfyvalCoZA_21_0"></a><a id="Tc_GIHrwLAjBESZO_rkt91Gqg_22_0"></a><a id="Tc_gnbPMlOTIEaRi7uA7i2HzQ_22_6"></a><a id="Tc_-LvxAtwnyE6UsMQFhMHP7g_23_0"></a><a id="Tc_EAh7gA2kCEeEurZ-h5b8_Q_25_0"></a><a id="Tc_FF7BxAeV10GCrfoqDrboFw_26_0"></a><a id="Tc_J6-Xm2hgWUyWh6PDNLumEg_26_3"></a><a id="Tc_R_spadLUfEmWmINDsUXFaA_27_0"></a><a id="Tc_HKJhjwQiO0OeeVGSpWmTlQ_28_0"></a><a id="Tc_l9NM16j2hkmwYSzdip34Lw_29_0"></a><a id="Tc__dI2qOmZtECXrJwJKnJC-g_30_0"></a><a id="Tc_hgm7MK5qkUW5OXGKLa1fdQ_31_0"></a><a id="Tc_xAszCLrib0mTb0zn9cFNeQ_31_2"></a><a id="Tc_q2dJZlHTEUm6AQQQdPtmxQ_31_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_1bmzZqWWUUWEo-ekCklZFg_4_3">37,879,158</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_jnY01y2MaE6Naq8ShIXWlw_4_6">36,899,420</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" id="Tc_-Mf38Kx2sEq28Gfm07w2cg_6_3">35,174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" id="Tc_jRjhOFylgE-D6jNRd6mkhw_6_6">153,301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on disposal of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="0" id="Tc_JOxdljmr8UauVTbmB64zTQ_7_3">46,654</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="0" id="Tc_q4ag3jT450-iKaZEWRv1Ag_7_6">8,627</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Asset impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseImpairmentLoss" scale="0" id="Tc_o0P4nCJqL0itv1vK4Pargw_8_3">365,179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-cash lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_w2bgoOqV6Em3zm1jAKI6Tw_9_3">402,649</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_o7BwnDaZRkeHwDW0IWp-LQ_9_6">856,238</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock for services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" id="Tc_ltZa7CHwE0KS-YKSYV5x4g_10_3">75,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" id="Tc_uqQBuZJe50S9Dj66aTYlbQ_10_6">36,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_P8EkwiuKR0iurzO-IxkOvA_11_3">4,697,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_U5aLZYEuak6e5D4RW6IlWg_11_6">3,524,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Changes in assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_sY3yX021sUqDO2aceJI59A_13_3">1,678,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc__l1OKUKqykKkjeDfdN1JDA_13_6">846,182</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="glyc:IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" sign="-" scale="0" id="Tc_EsdXnVoXjU23bZ0GIP8EkA_14_3">603,737</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="glyc:IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" scale="0" id="Tc__lm7Jb2rUEyLh56nqVVmNA_14_6">553,737</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_AhNCX6HldE2nVycLPtzhLA_15_3">538,811</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_S6ACkXDEPkyl3dxSYr34Zw_15_6">102,076</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_Ktt3ZbKdL0u8ZvYU3_OxhQ_16_3">156,187</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_FeELrMHWH0qw6s2bN5Ov6A_16_6">1,766,449</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="glyc:IncreaseDecreaseInOperatingLeaseLiabilities" sign="-" scale="0" id="Tc_9ddRdh2FcUa3k3J4-u81IQ_17_3">741,558</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="glyc:IncreaseDecreaseInOperatingLeaseLiabilities" sign="-" scale="0" id="Tc_veLaRQ_ST0ODaU0m785rPg_17_6">983,045</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_IAAf5GWsJEqyggHYqFXItg_18_3">31,098,078</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_80nS7thnv0KSTp8vqf6W2A_18_6">34,879,903</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_Mvj3AHHlokaHvA1taUYEqg_21_3">9,972</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_M5dC30ccm06BUrw0aCB2Dw_21_6">21,394</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from sales of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="0" id="Tc_DA-qGczUfUmHXPmFjKdhhQ_22_3">30,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="Tc_tiSioC6IuUGtTiqLn8Y9kg_23_3">20,028</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_yp3k_4mfg0KJI8hTzS2_6w_23_6">21,394</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_Oviwx4C-T0atq6uLkRBu5g_26_6">28,707,011</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="0" id="Tc_1P_J4kbU00qIgI1XfFx0PA_27_3">5,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="0" id="Tc_WKFCoYlmOkaWiCsD41ZgzA_27_6">116,497</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_9-hqzOHbRUGo0byQSCYRIA_28_3">5,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_Bf-hxJFCdUOrG0C4NId6WQ_28_6">28,823,508</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_YNIwL-9wq0SHJPHOA9bMWQ_29_3">31,072,652</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_poRqBeJNcUiXeaJ6e6WiFA_29_6">6,077,789</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_6-gKtrHqUUO6kPKTTiImGg_30_3">41,792,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2022_J_TWX_FgbkyiMy1gXdMchw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_xWQKthPPS0SxXZu6Kra60Q_30_6">47,870,619</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_o9PL3pAUWk2fH6hniXt1DA_31_3">10,720,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_zKxx4g_bYUOJxSCpIwJ29Q_31_6">41,792,830</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">See accompanying notes.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f02740a3_b3d7_456f_8fb9_6bf1996d51b9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><a id="NotestoFinancialStatements_432888"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENT</b><b style="font-weight:bold;">S</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:NatureOfOperations" id="Tb_OrN3nI-x30CsdNsTy0YoeQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Description of the Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">GlycoMimetics, Inc. (the Company), a Delaware corporation, was incorporated in 2003. The Company was previously developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation. In July 2024, following feedback from the U.S. Food and Drug Administration (FDA), the Company determined that the regulatory path forward for its lead product candidate, uproleselan, for the treatment of relapsed and refractory acute myeloid leukemia would require an additional clinical trial. The decision to not conduct an additional clinical trial did not relate to any safety or medical issues or negative regulatory feedback related to the Company&#8217;s programs.  In order to conserve its cash resources, in July 2024 the Company reduced its workforce by approximately </span><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_7_1_2024_To_7_31_2024_kOgWP4JoZ0qcll1HUFWAMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_WsU-vnKEdUSvjMUd7OXYwg">80</ix:nonFraction>%<span style="white-space:pre-wrap;">.  The Company also initiated a strategic review of its business in an effort to maximize shareholder value. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Following the strategic review, on October 28, 2024 the Company entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement) with Crescent Biopharma, Inc., a Delaware corporation (Crescent), pursuant to which Crescent will become a wholly owned subsidiary of the Company (the Merger).  Upon completion of the Merger, the Company plans to operate under the name Crescent Biopharma, Inc. The Merger is expected to close in the late second quarter of 2025, subject to certain closing conditions, including, among other things, approval by the stockholders of each company and the satisfaction of customary closing conditions.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrently with the execution and delivery of the Merger Agreement, certain institutional and accredited investors have entered into a securities purchase agreement (the Purchase Agreement) with the Company, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase, immediately following the consummation of the Merger, shares of the Company&#8217;s common stock and pre-funded warrants (together, the PIPE Securities) for an aggregate purchase price of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_10_28_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8BLdTfohekutDmOuRqt3RQ" decimals="-5" format="ixt:num-dot-decimal" name="glyc:SaleOfStockAggregatePurchasePrice" scale="6" id="Narr_oMXzMEOV5UKLRSAh5yVhFA">200.0</ix:nonFraction> million in a private placement (the Private Placement). The closing of the Private Placement is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement (in addition to other customary closing conditions) and is expected to occur immediately following the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the exchange ratio formula set forth in the Merger Agreement, upon the closing of the Merger (but prior to closing of the Private Placement described below), on a pro forma basis and based upon the number of shares of common stock of the Company expected to be issued in the Merger, pre-Merger Crescent stockholders will own approximately <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="As_Of_10_28_2024_srt_OwnershipAxis_glyc_CrescentBiopharmaIncMember_srt_StatementScenarioAxis_glyc_PriorToClosingOfPrivatePlacementMember_9Nw2kINcWkOS08dTHYx78Q" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_DSlkiuawYkm_a26x-BB17A">86.2</ix:nonFraction>% of the combined company and pre-Merger stockholders of the Company will own approximately <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="As_Of_10_28_2024_srt_OwnershipAxis_glyc_GlycoMimeticsIncMember_srt_StatementScenarioAxis_glyc_PriorToClosingOfPrivatePlacementMember_Tm8848Kss0eZks2g6Tisbg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="Narr_HyEOqVyHZkmzeJr6NZgAdA">13.8</ix:nonFraction>% of the combined company. After giving further effect to the Private Placement, the pre-Merger Crescent stockholders (inclusive of those investors participating in the Private Placement) are expected to own approximately <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="As_Of_10_28_2024_srt_OwnershipAxis_glyc_CrescentBiopharmaIncMember_srt_StatementScenarioAxis_glyc_PostClosingOfPrivatePlacementMember_vPM54hGTmUeMioQHoVKWoA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_7hCm6FOPmEGp5tG6BzRj8Q">96.9</ix:nonFraction>% of the combined company and the pre-Merger stockholders of the Company are expected to own approximately <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="As_Of_10_28_2024_srt_OwnershipAxis_glyc_GlycoMimeticsIncMember_srt_StatementScenarioAxis_glyc_PostClosingOfPrivatePlacementMember_A1VjOonYZ0mFZlFMgXfwHQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="Narr_I3L3-XjH00-6ztbJnO51Iw">3.1</ix:nonFraction>% of the combined company. The exchange ratio will be adjusted to the extent that the Company&#8217;s net cash at closing of the Merger is less than $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_10_28_2024_TP4f-xHx2E2A5iRUPIKLLA" decimals="-5" format="ixt:num-dot-decimal" name="glyc:MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing" scale="6" id="Narr_dfBGOr9GK0-4tOecBEjUDw">1.0</ix:nonFraction> million and will be based on the amount of proceeds actually received by the Company in the Private Placement.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="Tb_mDK2eTsX8Equ19CULvKmVQ" continuedAt="Tb_mDK2eTsX8Equ19CULvKmVQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. During 2024, the Company incurred a net loss of $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="-5" format="ixt:num-dot-decimal" name="glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax" sign="-" scale="6" id="Narr_9IE5Clszwk-_caMrkoB1ag">37.9</ix:nonFraction> million and had net cash flows used in operating activities of $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="6" id="Narr_Xs8_rC9YeEacVi2Ygat7XA">31.1</ix:nonFraction> million. At December 31, 2024, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_1x3JX6FXlEGRZSCfMaL9Kg">10.7</ix:nonFraction> million in cash and cash equivalents and had no committed source of additional funding other than the expected Private Placement. Management believes that given the Company&#8217;s current cash position and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date that these financial statements are issued without the closing of the contemplated Merger and Private Placement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the contemplated Merger and Private Placement does not close by the late second quarter of 2025, the Company may seek other strategic alternatives or liquidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_mDK2eTsX8Equ19CULvKmVQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_3wPu-2rmfk-ao69-4QfZtw" continuedAt="Tb_3wPu-2rmfk-ao69-4QfZtw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Summary of Significant Accounting Policies</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_UkHir6x9xk2vxit3Kp1_2g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Accounting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" id="Tb_J9j-P7GQTEG-THBn7NsIbQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restructuring Charges</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company recognizes restructuring charges related to reorganization plans that have been implemented by management.  In connection with these activities, the Company records restructuring charges, as applicable, at fair value for:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulate when the payment of benefits becomes probable and the amount can be reasonably estimated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-time employee termination benefits to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the detail of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">contract termination costs when the Company cancels a contract in accordance with its terms; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to be incurred over the remaining contract term without economic benefit to the Company at the cease-use date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">For one-time employee terminations benefits, the Company recognizes the liability in full on the communication date when future services are not required or amortizes the liability ratably over the service period, if required. The fair value of termination benefits reflects the Company&#8217;s estimate of expected utilization of certain Company-funded post-employment benefits.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">As described in Note 13, during the year ended December 31, 2024, the Company incurred severance charges of </span><span style="color:#212529;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="6" id="Narr_IFL8Hhu0Q0mB7Yn2fG4g8w">7.0</ix:nonFraction></span><span style="color:#212529;background:#ffffff;"> million in connection with a corporate restructuring, including a reduction in headcount.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_YhMrBQ5I8kGebIlZaJzy2w" continuedAt="Tb_YhMrBQ5I8kGebIlZaJzy2w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company views its operations and manages its business in <ix:nonFraction unitRef="Unit_Standard_segment_hVrhBvSi7EWHtMESRprj8Q" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_j1WNv8TmgE6SQbkBYtO4rQ">one</ix:nonFraction><span style="white-space:pre-wrap;"> segment.  The Company&#8217;s chief operating decision maker is the president and chief executive officer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company has not generated any product revenue since inception.  </span><span style="white-space:pre-wrap;">The Company has no ongoing operations, is not actively performing any research and development, and is preserving cash until the contemplated Merger and Private Placement.  If the contemplated Merger and Placement does not close by the late second quarter of 2025, the Company may seek other strategic alternatives or liquidate. As of December 31, 2024, the Company had no material assets besides cash and cash equivalents and only had </span><ix:nonFraction unitRef="Unit_Standard_employee__mI-PxD8qU-9RiyVThW_0Q" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="INF" format="ixt-sec:numwordsen" name="glyc:NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts" scale="0" id="Narr_uAGZGrqAHUCM-50Tb68h5Q">six</ix:nonFraction> employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies of the Company&#8217;s single reportable segment are the same as those described in Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The chief operating decision maker assesses performance and decides how to allocate resources based on net income (loss) that is reported on the statement of operations and comprehensive loss as net income (loss). The segment-level financial information is the same as the financial information presented in the statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The measure of segment assets is reported on the balance sheet as total assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net income (loss) is used to monitor budget versus actual results. The monitoring of budgeted versus actual results are used in assessing performance of the segment.</p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c54284d5_068a_4c70_8bcd_53a4285c5ef9"></a><a id="_c54284d5_068a_4c70_8bcd_53a4285c5ef9_2"></a><a id="_c54284d5_068a_4c70_8bcd_53a4285c5ef9_3"></a><a id="_25a37f9c_7df4_4cd2_9890_81b3780b2b89"></a><a id="_25a37f9c_7df4_4cd2_9890_81b3780b2b89_2"></a><a id="_25a37f9c_7df4_4cd2_9890_81b3780b2b89_3"></a><a id="_195b2a0e_2eed_4c9e_9650_d9ae95ec990d"></a><a id="_195b2a0e_2eed_4c9e_9650_d9ae95ec990d_2"></a><a id="_195b2a0e_2eed_4c9e_9650_d9ae95ec990d_3"></a><ix:continuation id="Tb_3wPu-2rmfk-ao69-4QfZtw_cont1" continuedAt="Tb_3wPu-2rmfk-ao69-4QfZtw_cont2"><ix:continuation id="Tb_YhMrBQ5I8kGebIlZaJzy2w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company does not have intra-entity sales or transfers. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:UseOfEstimates" id="Tb_pIIAqmyQ10SwnFzr34FAsA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_EnMOcIBjkkm8iEBE5l_O1Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_SaqvaaoLcE2uK6glQyquDg" continuedAt="Tb_SaqvaaoLcE2uK6glQyquDg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December 31, 2024 and 2023, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, <i style="font-style:italic;">Fair Value Measurements</i>. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#8212;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#8212;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#8212;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company had <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_gI4hA-RNTEmj4Ln9TxOBNw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="Narr__d_yhJ-oD0aNRl43OP6h8w"><ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_YUjaMxLsuk-X-7qE4Kk97w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="Narr_trGjuQVoTUemQBjn6dj7kA">no</ix:nonFraction></ix:nonFraction> assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) either on a recurring or non-recurring basis as of December&#160;31, 2024 and 2023. The carrying value of cash held in money market funds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_fba-gQlZbEu4aT4dU-Zdgg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="6" id="Narr_P9TGVhuBPkSVj5n-77jcqg">8.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_DKDfj7hCjUu3mShq3nI3Gg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="6" id="Narr_frTkgxEaW0qentSpjPqRaw">38.8</ix:nonFraction> million as of December&#160;31, 2024 and 2023, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did&#160;not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December 31, 2024 and 2023.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_3wPu-2rmfk-ao69-4QfZtw_cont2" continuedAt="Tb_3wPu-2rmfk-ao69-4QfZtw_cont3"><ix:continuation id="Tb_SaqvaaoLcE2uK6glQyquDg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_X8NOhsbxN0ysmDpXQlh9aQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash balances with financial institutions in federally insured accounts and has cash balances in excess of the insurance limits. Cash equivalents consist of investment in United States government money market funds with major financial institutions. These deposits and funds may be redeemed upon demand and the Company does not anticipate any losses on such balances. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash and cash equivalents. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_FmZKeXPWMkOqxtBVtBGfFQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_aVhmciKEbkqwpxMlc38z4g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i>. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company has elected to account for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A discussion of management&#8217;s methodology for developing some of the assumptions used in the valuation model follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividend Yield</i>&#8212;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility&#8212;</i>Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company bases the expected volatility on the historical volatility of the Company&#8217;s publicly traded common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8212;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8212;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_mfEME_8KIEOUdPf0enFlBA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_wGtAz6_V_UqcRGQXpx0D4g"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_v6lQTXiXUUmyixAKiaaFgA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_fXAYDmx6a0qwHxDWUa3vIw"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_J7qgUFtkl0Wo9KigpKzqfQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_xqnKkQrTeEuaLVNLA3Zb-w">10 years</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>. The Company estimates the expected life of the option term to be <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_wZeRx6oRpUKbM_22ALjCXw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_PdYpxt1wKESkiMzNPuDdqg"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_ZkMbhdMmHkG31o70E1fPFg"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_-qErDbDdcEuyxqBrF_pumg">6.25</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> years. The Company uses a simplified method to calculate the average expected term.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_IEUTIlcm8US-4fGuhBST1Q" continuedAt="Tb_IEUTIlcm8US-4fGuhBST1Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,<i style="font-style:italic;"> Income Taxes</i>. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when necessary to reduce deferred tax assets to the amount expected to be realized.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_3wPu-2rmfk-ao69-4QfZtw_cont3"><ix:continuation id="Tb_IEUTIlcm8US-4fGuhBST1Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_boG8GcvAO02NbFnup6Clvg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&#160;31, 2024 and 2023, the Company&#8217;s net loss was equal to comprehensive loss and, accordingly, no additional disclosure is presented.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="glyc:NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" id="Tb_MAqtkCbiPEmOARemV0tqDA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted this standard for the year ended December 31, 2024 and the primary impact of which was the additional segment disclosures included in Note 3.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_DfB-jJQJ_USJAlsP3rjvCw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company&#8217;s financial statements.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40), which requires disclosure, in the notes to the financial statements, of specified information about certain costs and expenses. This ASU is effective for public entities for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact ASU 2024-03 will have on its consolidated financial statements.</p></ix:nonNumeric></ix:continuation><a id="Tc_MTDOOlyKK0ClNIuZhDooNA_2_2"></a><a id="Tc_eAnYxy_1ok6xFzTW__OVNg_2_4"></a><a id="Tc_mKumip_IRU-Lyf6gDaopHw_3_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:EarningsPerShareTextBlock" id="Tb_eW_efL3eYUWHhcX4K7dgsw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Net Loss Per Share of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#8217;s stock options and restricted stock units (RSUs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average common shares outstanding, as they would be anti-dilutive: </p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_PxHQ_cpYLU-3b3P1AK9-xg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options and RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_goAAe-HQTkGa8mwVYUZwOg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_rfonpt__g0it9Z4w09vv0A_3_2">15,043,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_vGzIZ8H2gUCh6mmnJZxOfg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc__G-dJ6Zy8kCEQe6yXOj_qg_3_4">10,981,357</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_7UI6axxxREqNjdhZjrBGGw_2_2"></a><a id="Tc_UfR2KBryw0SGqFzsBVLUfA_2_5"></a><a id="Tc_1S4D0NIovkq1B09kphWI7g_3_0"></a><a id="Tc_gwXnQ0HwakuTDtpbngTENA_3_2"></a><a id="Tc_Co4270G0p0a7MLOxtZgzEA_3_3"></a><a id="Tc_ge3rbGWFc0C-IcedK_qyXw_3_5"></a><a id="Tc_iFFwq-B9oky6BSJBJfqFQw_4_0"></a><a id="Tc_X8p5JRtGpk6-q9Vl0AiMAw_5_0"></a><a id="Tc_OdAIdSUPkked5kp7XUT-0Q_6_0"></a><a id="Tc_0OkAuczCyEqEGMWUXUbPmA_6_2"></a><a id="Tc_SOh3g2jnNEqZTEvOJ9j6ig_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:OtherCurrentAssetsTextBlock" id="Tb_MaZ3pHOmeEOV9H8gLvdC1w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5. Prepaid Expenses and Other Current Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">The following is a summary of the Company&#8217;s prepaid expenses and other current assets at December 31:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Tb_OevvqNtBpkekpLJGH7WH7A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_eB7wlcTAIUGl6dCkda8jOA_3_6">1,420,642</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc_dPjQFt2cuUGjoUzW6OUaoQ_4_3">234,696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc_qqejFxnx50u32ZFd8_mKHA_4_6">401,442</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_RMfa2FXEVk6uJD7kdFaBqA_5_3">136,580</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" id="Tc_q-a3OD7Az0GUkYh6ErHGKQ_5_6">175,820</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_ZM2dNNCeLUuE7wapOkZthw_6_3">371,276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_ya-6CR10OEOUe2zTyjTDYg_6_6">1,997,904</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_vujzQZgS0ES6iQLJY12CVw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6. Accrued Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the Company&#8217;s accrued expenses at December 31:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_SvBn8Do5Tk2pW9R22EaNrQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51,306</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,824,689</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,561,913</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued consulting and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 790,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 439,192</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,825</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 399,763</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued retention</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,049,105</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,487,258</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,381,744</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,225,557</span></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_rbEYSJWmNkem7Bo8nX1l3w" continuedAt="Tb_rbEYSJWmNkem7Bo8nX1l3w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Operating Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company determines a lease exists if the contract conveys the right to control an identified asset for a period of time in exchange for consideration. Control is considered to exist when the lessee has the right to obtain substantially all of the economic benefits from the use of an identified asset as well as direct the right to use of that asset. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less on the lease commencement date. If a contract is considered to be a lease, the Company recognizes a lease liability based on the present value of the future lease payments over the expected lease term, with an offsetting entry to recognize a right-of-use asset. The Company has also elected to use the practical expedient and account for each lease component and related non-lease component as one </span><span style="-sec-ix-hidden:Hidden_-J90KSXgGUSREtmuyxhLCA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span><span style="font-size:10pt;"> component. The lease component results in a right-of-use asset being recorded on the balance sheet and amortized as lease expense on a straight-line basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a term similar to the term of the lease for which the rate is estimated. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The Company leased office and research space in Rockville, Maryland under an operating lease that was subject to annual rent increases (the Lease). The Company paid a security deposit of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_5_31_2016_srt_StatementGeographicalAxis_glyc_RockvilleMarylandMember_BcWT7OTHpEyojUQYM5l-wA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_ksjXTnAFiEuo-Xd84SmMCw">52,320</ix:nonFraction></span><span style="font-size:10pt;"> to be held until the expiration or termination of the Company&#8217;s obligations under the Lease. In April 2023, the Company and its landlord entered into an amendment to the Lease (the Lease Amendment). Pursuant to the Lease Amendment, the Company and the landlord agreed that the lease term for a portion of the premises, consisting of approximately </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_sqft_c5PYJCWbn0-rXPVafi2irQ" contextRef="As_Of_4_30_2023_srt_StatementGeographicalAxis_glyc_FirstPortionSquareFeetRockvilleMarylandMember_omYj33019EaIg4e-nOCwbQ" decimals="0" format="ixt:num-dot-decimal" name="glyc:SquareFeetLeased" scale="0" id="Narr_NfA-fWBGK0aVRVnYNBebYw">30,000</ix:nonFraction></span><span style="font-size:10pt;"> square feet, would be </span><span style="-sec-ix-hidden:Hidden_QkjKoOCR1UixNvOHv0BEAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extended</span></span><span style="font-size:10pt;"> from November 1, 2023 to January 31, 2025. However, pursuant to the Company&#8217;s strategic review and restructuring plan adopted during the year ended December 31, 2024, the Company abandoned the leased space and determined that its right-of-use-asset was fully impaired. As a result, the Company recognized an impairment charge of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="Narr_NbAW9omDZEWV-Auv8-jjYQ">0.4</ix:nonFraction></span><span style="font-size:10pt;white-space:pre-wrap;"> million, during the year ended December 31, 2024, representing the carrying value of the right-of-use asset.  </span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_TLljw7UI0ECJiqWXdgZcGw_1_2"></a><a id="Tc_VkgX1L48mUW97IoxIxduig_2_2"></a><a id="Tc_5TADi8eOkESqbKCWbePJdg_2_5"></a><a id="Tc_i8vlaDQWsEuVxtK9oNp5IQ_3_0"></a><a id="Tc_IHMj-xJimEC41MfYsCDIpw_3_2"></a><a id="Tc_6G3MqgUjVkKhEUcOI2i3Bg_3_5"></a><a id="Tc_Cs77vB3__kmqxWcf1LDZZQ_4_0"></a><a id="Tc_GX8PfY9UDkqqQhCz8F9gfw_5_0"></a><a id="Tc_9u_GcNeDbkazheNDRVVlzw_5_2"></a><a id="Tc__I59vSrZOkCtyxIFh35f3g_5_5"></a><a id="Tc_wzdN3QGlVUeSzxCqVr4Pfg_7_0"></a><a id="Tc_CvwPMA4m8EqgubBcNpY7vQ_8_0"></a><a id="Tc_WbPf7KaWPkiympBtWdIB6w_8_2"></a><a id="Tc_-AOy05pUPUSxUWEQ1OYf7Q_8_5"></a><a id="Tc_Gl6RINMuEkuEWz0WOOnpEw_1_2"></a><a id="Tc_lcbWcmZAXUyRPlZMnIVe5g_2_2"></a><a id="Tc_Qlv2SykG6k238i1M2KwifQ_3_0"></a><a id="Tc_sjhS2ovbAE-OQGVMaRb6Aw_3_2"></a><a id="Tc_nCOnOX2MpU6RZ3jL4gR-ug_4_0"></a><a id="Tc_v52GarCraE-a3u3cXVhQqg_5_0"></a><a id="Tc_q66fNdeN6EK8ktEdwqSd8A_6_0"></a><a id="Tc__f8KWC3epkWiVL3X48dvBw_7_2"></a><a id="_225084c5_0143_45e5_8f4c_9e9dcd6fbc5b"></a><a id="Tc_9T0-B-b20km7K-cJewIrbA_1_2"></a><a id="Tc_J0Valit9GES5vkNjK8kPEw_1_5"></a><a id="Tc_r6nF8_EkgkCbfEnvcpD5_w_2_0"></a><a id="Tc_DP-gi1KOhkq74mm4OTAaMw_2_2"></a><a id="Tc_ykoHC0w8kkalpAGORw2fCg_2_5"></a><a id="Tc_PeHvkb1-ykSqptWV_2PoMw_3_0"></a><a id="Tc_EBEJtjeJO0mYF3bprIRarA_4_0"></a><ix:continuation id="Tb_rbEYSJWmNkem7Bo8nX1l3w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;white-space:pre-wrap;">The Company&#8217;s lease of the remaining premises, consisting of approximately </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_sqft_c5PYJCWbn0-rXPVafi2irQ" contextRef="As_Of_4_30_2023_srt_StatementGeographicalAxis_glyc_SecondPortionSquareFeetRockvilleMarylandMember_XXtFnEFv6EaiyeUhpgD3cw" decimals="0" format="ixt:num-dot-decimal" name="glyc:SquareFeetLeased" scale="0" id="Narr_4oObz8p5HUipCcdp8i3QZg">12,000</ix:nonFraction></span><span style="font-size:10pt;"> square feet, expired on October 31, 2023. There were </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_lease_a1VBadA-40-Zv384mN5EKA" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="INF" format="ixt-sec:numwordsen" name="glyc:LesseeOperatingLeaseNumberOfNewLeases" scale="0" id="Narr_faj-MIL3J02Oo9-xCeOrgg">no</ix:nonFraction></span><span style="font-size:10pt;"> additional operating leases as of the year ended December 31, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of lease expense and related cash flows were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:LeaseCostTableTextBlock" id="Tb_aYOrq7BwIE-FT8uIPrGGuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating lease cost </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Tc_fG4zE6_Ue0OVYr9TNNKyUA_3_3">450,274</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Tc_G-xFLQjXw0i_x8mSv3jWXA_3_6">944,963</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="0" id="Tc_gMafY8WfbkmP2PFUneZ8Aw_4_3">516,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="0" id="Tc_8xvBDUNaOkKuHigCuQC2FQ_4_6">602,416</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" id="Tc_Fp3lxTtAGECshBv5g52msA_5_3">966,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" id="Tc_IzyJA7m_uU6XQfVigpFSAw_5_6">1,547,379</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating cash outflows for operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_Hh5SPdB0SEewV7hso52A2g_8_3">789,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_q6qKJ4fsC0W8MnGM9VpD8Q_8_6">1,017,770</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Maturities of lease liability due under these lease agreements as of December 31, 2024 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_TDiqXlS5OUO7Sc8FuMGxKQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Lease</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Obligation</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="Tc_yaVAQAdYYUGspUBtdiVKHg_3_3">67,401</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:fixed-zero" name="glyc:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" scale="0" id="Tc_tR5bk1AK_EqnU5TGvSUx-w_4_3">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="Tc_HMo-eyyLpEWyOLMnQTsO2A_5_3">67,401</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="Tc_QGvES4cuOk2-SfZcsp8sdw_6_3">557</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_vgZVo8BJJ0aed1tCmLrUPw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Present value of lease payments</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_ML6C769akk67p_V-Xbv4ZQ_7_3">66,844</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Supplemental information related to leases were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="glyc:LeaseQuantitativeDisclosureTableTextBlock" id="Tb_LxkWj2gfUEy5Ge-ZVRloow" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Operating Leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Tc_G2YvdnKOcEqYqr68ozJFSQ_3_3"> 0.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Tc_Ejrlv50iyE-rbA4d8d9gnQ_3_6"> 1.1</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_y9S6JX9c5ECgLxQMhEoinQ_4_3">10.0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_MJrGJZbFmk6Ii-mwIuUOew_4_6">10.0</ix:nonFraction>%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets obtained in exchange for operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 872,892</span></p></td></tr></table></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_c71QRzLCNU2qd0KWKbXhXA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2024, the Company&#8217;s board of directors adopted, and its stockholders approved, an increase in the total authorized shares of common stock from <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_FNNuyG9GZUqT8sj0pCZUuw">100,000,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_-Z4S6SUXtE-s6f2wC6VomQ">150,000,000</ix:nonFraction> shares with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_YHFyO4_TikCZ66sIKToK4w"><ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr__9hYxjfGXUW8IDK0YL8ETA">0.001</ix:nonFraction></ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">At-The-Market Equity Offerings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In March 2022, the Company filed a shelf registration statement with the SEC, which was declared effective on April 22, 2022. On April 28, 2022, the Company entered into an at-the-market sales agreement (the Sales Agreement) with Cowen and Company, LLC. Under the Sales Agreement, the Company may sell up to $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_3_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_Lgi28lfrs0-59NK1_KFagw" decimals="INF" format="ixt:num-dot-decimal" name="glyc:CommonStockValueAvailableForSaleUnderAgreement" scale="0" id="Narr_F5bxiXMbAEGJMO5BPcbFig">100.0</ix:nonFraction> million worth of shares of common stock. During the year ended December 31, 2023, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_U4gkV-b8YE6xJmFs08VMbg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wL-Eod6UdkiUmvHAIOrk7A">9,822,930</ix:nonFraction> shares of common stock under the Sales Agreement at a weighted average price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_3_31_2022_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_onqX81APG0Ghn54y5zgaMA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_48mDFMm72ku8gh4a_EnqqQ">3.01</ix:nonFraction>, for aggregate net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_U4gkV-b8YE6xJmFs08VMbg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_LlyJUv4BrU6xna_tK0dVgA">28.7</ix:nonFraction> million, after deducting commissions and offering expenses. There were <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_TkPU169fb0a115F1Jhn1kA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wwfiZ-xIIUKdiYS64K5rJA">no</ix:nonFraction><span style="white-space:pre-wrap;"> shares issued under the 2022 Sales Agreement during the year ended December 31, 2024.  As of December 31, 2024, approximately </span>$<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_SmdQHOUz5UqCH4SGTEpEHw" decimals="-5" format="ixt:num-dot-decimal" name="glyc:CommonStockValueAvailableForSaleUnderAgreement" scale="6" id="Narr_LLUWum23VkK2hwSEy4K6WQ">66.0</ix:nonFraction><span style="white-space:pre-wrap;"> million remained available to be sold under the terms of the Sales Agreement.  The shelf registration statement will expire on April 28, 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_WDIULDsCGEa0pkBk0Q6SFw_1_7"></a><a id="Tc_vekhVbgLB0elvgFLSuvvcw_1_9"></a><a id="Tc_gtAtPcRIfkunTvQMzuO1UA_2_4"></a><a id="Tc_tveazdneAk2J7u2VcmVg9w_2_7"></a><a id="Tc_tFswcnxya0SWY1MaVHXAaw_2_9"></a><a id="Tc_j-lhauzwwUGOyvL3Joxxwg_3_4"></a><a id="Tc_hDQxUz45TUanNyl0eJc33w_3_7"></a><a id="Tc_u2pCNr_9ZEi6ughHzYEMlw_3_9"></a><a id="Tc_jhWNAB1Gwky92B7B5vaedA_4_2"></a><a id="Tc_1YvQYswD2UegHYuaNn6IGQ_4_4"></a><a id="Tc_Yyv2eJ1pwUGz96aCzRSudQ_4_7"></a><a id="Tc_LuA55toNZUuzN-QZsgmvRg_4_9"></a><a id="Tc_ezenznBuy0C-TcCFh30cmQ_5_2"></a><a id="Tc_mkfTFubck0awdtC7ijme3Q_5_4"></a><a id="Tc_W2uJgqIVMUOxwL2FRD6A8w_5_7"></a><a id="Tc__9N8JrWSTE6cLexWPLyPlA_5_9"></a><a id="Tc_l40jPm1IW0WrGQvbAMNuJg_6_0"></a><a id="Tc_4BN1lq1330C2ZJF1cIP_LA_6_4"></a><a id="Tc_JlMXCHWoq06m7KE3TqVnxw_7_0"></a><a id="Tc_YNqOnSgPxEafr5irfDI69Q_8_0"></a><a id="Tc_XakwPGgzKkm-_WRtpLbA_A_9_0"></a><a id="Tc_tKzyYPYlj02T3lJfdpGY_g_10_0"></a><a id="Tc_JxvVvIqOLUyWiyMgkt2IBg_10_9"></a><a id="Tc_vw-uwdkmbkSzfwvFGaEauQ_10_10"></a><a id="Tc_I2b2pqCRp0mb1ixON8sLpg_11_0"></a><a id="Tc_lHBtWuSKpUCQY8TSLmjqcw_11_10"></a><a id="Tc_5hkbRuTMbkmUk_okXrGTDg_12_0"></a><a id="Tc_EdQrp66ZCkCvkXgxyAXwbQ_12_10"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_D5cvRzuUMkqaD4ymZTb1Xg" continuedAt="Tb_D5cvRzuUMkqaD4ymZTb1Xg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9. Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2013 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan effective in January 2014, and the 2013 Equity Incentive Plan was amended and restated by approval of the board of directors in April 2022 and by approval of the stockholders in May 2022 (as so amended and restated, the 2013 Plan). The 2013 Plan provides for the grant of incentive stock options within the meaning of Section&#160;422 of the Internal Revenue Code (the Code), to the Company&#8217;s employees and its parent and subsidiary corporations&#8217; employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards (RSUs), stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company&#8217;s employees, consultants and directors. Unless otherwise stated in a stock option agreement, <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_R_eQJnbT5kGlzY8X-rGidQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_HTIiFCDFH02ab3eY1glEHQ">25</ix:nonFraction>% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one <span style="-sec-ix-hidden:Hidden_rkMRBeyC_Ee79e86m5b6WA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">forty</span></span>-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" format="ixt-sec:durwordsen" name="glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" id="Narr_rrP-5GDbkECleMCVE53DBQ">90 days</ix:nonNumeric> after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_z80koursWEOqAaSs515pTQ">10 years</ix:nonNumeric> from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Authorized Shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The maximum number of shares of common stock that may be issued under the 2013 Plan was originally <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HyhkPdyGmU6UnG8nxVmM2Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_gtTjAHtEHUGkXOzkjWIumQ">1,000,000</ix:nonFraction>&#160;shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. Upon the amendment and restatement of the 2013 Plan in May 2022, the existing share reserve was increased by <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JTfAygcVu0yXRQjZySO8fQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_OZXUq2BcQUWMfLtAg7rxLg">2,619,622</ix:nonFraction>. Beginning on January 1, 2023 and ending on (and including) January 1, 2029, the maximum number of shares of common stock that may be issued under the 2013 Plan will cumulatively be increased by <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lEn5z0QjVECg-jhVCra21w" decimals="2" format="ixt:num-dot-decimal" name="glyc:PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee" scale="-2" id="Narr_2YQJ-x7spEqQ9V7r9uuWQg">4</ix:nonFraction>% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares as determined by the board of directors or the compensation committee thereof.<span style="font-size:12pt;"> </span> The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HyhkPdyGmU6UnG8nxVmM2Q" decimals="INF" format="ixt:num-dot-decimal" name="glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" scale="0" id="Narr_qGJWjaASBUCXSxvyJVWJIg">20,000,000</ix:nonFraction>. As of December 31, 2024, the total number of shares reserved for issuance under the 2013 Plan was <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lEn5z0QjVECg-jhVCra21w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_TlVpehOPD0O7_C0V6mEMfA">14,257,627</ix:nonFraction> shares, of which <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lEn5z0QjVECg-jhVCra21w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_PqVor98H30iH1CdjIzyUTA">1,070,346</ix:nonFraction> shares were available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A summary of the Company&#8217;s stock option activity under the 2013 Plan for the year ended December&#160;31, 2024 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_LXioFO29nU-RzGomSQWCgg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NeI1DrJAfU2Pdw5yL4hyCw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_UJS24dE_5E-xrXQy9Nicuw_6_2">8,273,800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NeI1DrJAfU2Pdw5yL4hyCw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_UJq5DCiVS0mI5zVocUmykA_6_5">5.29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_M5J3K2r_hUe_T0x0UXRjpQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_yB-KoSpCOkS_PhV9SZq1MA_6_7"> 6.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_6zcV04TOukSwIM8wqrO9FA_7_2">5,756,875</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_VoTsSi3V-0aqh0QWhZBhPA_7_5">1.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_22S8fj3RuEGDSed0yzN1Eg_8_2">3,250</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_h2GXTZj0UUuJAOwkqUPmrw_8_5">1.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_BYbZQO8PJUSbYPnGuZTa-w_9_2">1,722,543</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_SYj1od5UuEaJjcRZlMPxdw_9_5">6.58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_ndSL-rNaF0eanqVgDW5MMA_10_2">12,304,882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc__EMYfCjSEUu0_-ygulvgTQ_10_5">3.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Of7bJHycmUy5e4FLbIoGnw_10_7">7.4</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_R1CphXnSRUGuR8-ztCpY-Q_11_2">6,561,952</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_opJFFtgYok2RgCoMKqNYzg_11_5">5.06</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_tLXuIIj5pUSSE7-2lQwIKw_11_7">6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_QM7GvykNuUWHCc9v_DNubQ_12_2">6,024,978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_sqQjH8hjXUOakHNW0oPTrA_12_5">5.33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_Lg3oEwGtHkSFu4MeFOZdPQ_12_7">5.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2024, there was $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_LKsC-Z5_-kGkK2RR4zhqKA">915,970</ix:nonFraction> of total unrecognized compensation expense related to unvested options that will be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_i0QJy7CfJkGRIF9cGyr8MQ">0.3</ix:nonNumeric> years. The total fair value of options that vested in the years ended December 31, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_2os2zItJoE6eMcTBB3fAgA">2,919,122</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_M5J3K2r_hUe_T0x0UXRjpQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_0pDAIN-K6kO1an1E4TYWQg">1,710,938</ix:nonFraction>, respectively. During 2024, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_ZlUkZHjUmU24dF7S73v9TQ">3,250</ix:nonFraction> shares of </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6a2cdf49_9716_47f2_b295_eca83bf595b2"></a><a id="Tc_EQv59hXfaE6Zu5de-8WYvg_1_4"></a><a id="Tc_uZURywXux0C0THSYSK0omQ_2_2"></a><a id="Tc_hWUxIPEax0ixA2C05i1xeA_2_4"></a><a id="Tc_0mR1g0C1oU-TJZXpHjJgeQ_3_2"></a><a id="Tc_7etGfWKgDE2OmULbh59tww_3_4"></a><a id="Tc_SRj35vCWtE-weBEX6op4yg_4_0"></a><a id="Tc_GfzUlxSGBU6a17ZrNx1A4Q_4_4"></a><a id="Tc_CxTuw8c2u0aT2SyfDPfX8w_5_0"></a><a id="Tc_s5p2-ioNWkahdBNP0OBXFA_6_0"></a><a id="Tc_lON_tupuvUK3JLCdJmCkyA_7_0"></a><ix:continuation id="Tb_D5cvRzuUMkqaD4ymZTb1Xg_cont1" continuedAt="Tb_D5cvRzuUMkqaD4ymZTb1Xg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">common stock in conjunction with exercises of stock options granted under the 2013 Plan and received $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_HDjaopC0gEGs_FWJqwp3Gg">5,398</ix:nonFraction><span style="white-space:pre-wrap;"> in cash proceeds from the exercise of these stock options.  During 2023, the Company issued </span><ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K4GuybjZVEmN-yz3jNQQZg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_MO9stUoHyEmBnCg4h5hkbQ">100,960</ix:nonFraction> shares of common stock in conjunction with exercises of stock options granted under the 2013 Plan and received $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_M5J3K2r_hUe_T0x0UXRjpQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_0bfYMhAwBk6NAbo8njw-HQ">116,497</ix:nonFraction> in cash proceeds from the exercise of these stock options. Total intrinsic value of the options exercised during the years ended December 31, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_M0-fT3DaYka6e2kUpFYEVw">4,091</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_M5J3K2r_hUe_T0x0UXRjpQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_xrcXdM9iKkq5JtPkWtNV4g">82,300</ix:nonFraction>, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has granted stock options to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_1XsemFUZukWboPPsX0QU9g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_1jpWGL3gHkG0V0RUUPxrAA">2,459,275</ix:nonFraction> shares to certain employees under the 2013 Plan, the vesting of which is subject to performance vesting conditions relating to the achievement of specified regulatory or commercial milestones. The maximum fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_1XsemFUZukWboPPsX0QU9g" decimals="0" format="ixt:num-dot-decimal" name="glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" scale="0" id="Narr_hN2aHHNGOkCtQn5HW8ontA">650,266</ix:nonFraction> associated with performance-based options granted under the 2013 Plan has been excluded from compensation expense as the completion of the performance milestones was not deemed to be probable as of December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock Units (RSUs)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An RSU is a stock award that entitles the holder to receive shares of the Company&#8217;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#8217;s common stock on the date of grant. In January 2021, the Company awarded RSUs under the 2013 Plan to all of its employees. The RSUs granted vest over <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_l6-d0WjB2EWKO9FwgF6G9Q" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_zuYVkcuLdkOlvH3IVdOwBw">four years</ix:nonNumeric> in equal installments on each anniversary of the grant date, provided that the employee remains employed by the Company at the applicable vesting date. Compensation expense is recognized on a straight-line basis. As of December 31, 2024, there was $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8hSvq-SHI0KxvBm4TVYLQw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" id="Narr_odbHe08F9UKGY1q_Jmcrqg">9,541</ix:nonFraction> of total unrecognized compensation expense associated with these RSU grants that will be recognized entirely in the first quarter of 2025.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="Tb_vVGul5J0N0GMy5SeTWoaZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of RSU activity for the 2013 Plan for the year ended December 31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_KEVqEI1mz0alUnOYmZkAMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_asifWdC55k2WRTTiWkoLvA_4_2">117,157</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_KEVqEI1mz0alUnOYmZkAMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_xBfffg0ovkOnCYCDo8tVUw_4_5">3.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_g8Jzg9x9fkCHME1NaPv5rg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_kvJIbLyp3kaRP5KSKmvB8Q_5_2">58,581</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_g8Jzg9x9fkCHME1NaPv5rg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_G3xar4mc906PpfENspJ1Ew_5_5">3.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_g8Jzg9x9fkCHME1NaPv5rg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_nHMMmWJ2E0ygkIszcu4-uA_6_2">10,443</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_g8Jzg9x9fkCHME1NaPv5rg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_Gu_Lx0q7O0WFifwvUb2ZyA_6_5">3.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_V8Yc464DDEuqsw28B2LXXw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_hxqLICvJl0-3PnwXedqDgA_7_2">48,133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_V8Yc464DDEuqsw28B2LXXw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_VOqCZuuy3UOjV8cZtiPX1g_7_5">3.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issuance of Shares to Directors in Lieu of Cash Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2023, the Company&#8217;s board of directors amended the Company&#8217;s Non-Employee Director Compensation Policy to include an election to receive unrestricted shares of common stock in lieu of quarterly board and committee retainer cash payments. The number of shares to be issued to an electing director is determined on the last day of each fiscal quarter by dividing the dollar amount of the compensation to be paid for such quarter that is subject to the election by the closing price of a share of common stock on the last trading day of the fiscal quarter, rounded up to the nearest whole share. Non-employee directors who made such an election received <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_3_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_glyc_OtherAwardsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-V6DN7K7xkqKAShmvSchFQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_87U4pN69okG6IJBmTL6W0g">13,127</ix:nonFraction> shares of common stock in lieu of cash compensation earned for the quarter ended March 31, 2024. All shares of common stock issued pursuant to such an election were fully vested upon issuance and are classified as &#8220;Other Awards&#8221; under the 2013 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In June 2024, the Non-Employee Director Compensation Policy was amended to allow a director to revoke his or her annual election to receive unrestricted shares of common stock in lieu of quarterly board and committee retainer cash payments.  The decision to amend the policy followed a significant decline in the market value of the Company&#8217;s common stock in May 2024. Without the ability of the directors to revoke the prior elections, the Company would have been obligated to issue a significantly greater number of shares than in prior quarters in lieu of the fixed cash retainer payments. Each of the directors who previously elected to receive unrestricted shares of common stock in lieu of quarterly board and committee retainer cash payments for 2024 revoked their elections in June 2024, and as a result there were no additional shares issued subsequent to March 31, 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inducement Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The Company&#8217;s board of directors previously adopted the GlycoMimetics, Inc. Inducement Plan (as amended to date, the Inducement Plan). The Inducement Plan provides for the grant of nonstatutory stock options, restricted stock awards, RSU awards, stock appreciation rights and other forms of stock awards to individuals not previously an employee or director of the Company as an inducement for such individuals to join the Company. Unless otherwise stated in an applicable stock option agreement, </span><span style="-sec-ix-hidden:Hidden_36PO8EraXkq8olRkBZDjHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="font-size:10pt;">-fourth of the shares subject to an option grant under the Inducement Plan will typically vest upon the first anniversary of the vesting start date, </span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_9_DItF4tS0i2shAFXaSs4g_1_7"></a><a id="Tc__yLllTnQS0yGDzm1YaOTXg_1_9"></a><a id="Tc_44uq6M1XTEqQjUO7VitqCA_2_4"></a><a id="Tc_4J_cQNQ35E6nRhoQfwpd0g_2_7"></a><a id="Tc_JbFoPfzhl0qohKA0lRfAHg_2_9"></a><a id="Tc_j0b1fp45cUSKUussHee7jQ_3_4"></a><a id="Tc_2PoLftkClUyzng8TUMng1Q_3_7"></a><a id="Tc_HlMmsJNfE0qoU5Amk72jDQ_3_9"></a><a id="Tc_7X_9hQvUKESS1X93NNfY9g_4_2"></a><a id="Tc_OZDC4BYENEC-ddUxiiW8ZQ_4_4"></a><a id="Tc_ktsLen7HKkCRKcATMCIB8w_4_7"></a><a id="Tc_u_jP16jxFkCSeBWppFIWYg_4_9"></a><a id="Tc_NzTJ1_4_dEmacO-aBekzBQ_5_2"></a><a id="Tc_Ql06slHro0abPvsdpVejWQ_5_4"></a><a id="Tc_RSpI08XsE0K-MX9i7DVN4A_5_7"></a><a id="Tc_VkTJdOUZDUSAabKq5TUWEw_5_9"></a><a id="Tc_w-BXEdAsSEG6Vfl2Mdo4hw_6_0"></a><a id="Tc_RGcvGyYVCEOol3nYPewFlw_6_4"></a><a id="Tc_xz9FVpMMnEaD90AkKs2SJQ_7_0"></a><a id="Tc_rRrbqK0upUCuoVl8UV0miw_8_0"></a><a id="Tc_iXUwLuYgb0Kz9HhS8_-y-A_9_0"></a><a id="Tc_xVumle2GPkicIHkShse3xg_9_9"></a><a id="Tc_xcJwnM2A0k6Ecn25Y_Hwlg_9_10"></a><a id="Tc_dT1I7327jEOAVwEaar3mNw_10_0"></a><a id="Tc_zoE7grJTLUiMdZuCY3maDg_10_10"></a><a id="Tc_6l0mGhuFwkesl8cNn_4Rmg_11_0"></a><a id="Tc_zhC4n3v0GE6IMrQxtuHEQQ_11_10"></a><a id="Tc__E0wPOCh40S9-phoYV4z5w_1_2"></a><a id="Tc_QW8zXFKdOEu2sFTVt1l-rg_1_4"></a><a id="Tc_Mhw8t_YgYkOF29yaWc_xag_2_0"></a><a id="Tc_jay4Tu_JEU-bL9rxTwFeCQ_2_2"></a><a id="Tc_HRlNFY3RqEKF1v9sqoQWaA_2_4"></a><a id="Tc_HvgQmsCc6kaLHxyxjXeaHQ_3_0"></a><a id="Tc_Vs9xne68IEicTFjUdf83Tw_4_0"></a><a id="Tc_Yq2ZEUgg3kSHYJEguz3mmQ_5_0"></a><a id="Tc_DUydAhRor06P00-WLXaRjg_2_2"></a><a id="Tc_u8X1vKQ8DUGiVavqEHuDvQ_2_5"></a><a id="Tc_Azawk2KcI0ODSzhI2BZYRQ_3_0"></a><a id="Tc_XQCDRIuvck2JFIRn6Aj4Sw_3_2"></a><a id="Tc_l29L93sNx0isDLU3BJd2ng_3_5"></a><a id="Tc_snQBcz-bCkSiBQLQLjeNZg_4_0"></a><a id="Tc_vS2yvxuyVUanCrY90X1UqQ_5_0"></a><a id="Tc_fdkkaE6pRkmqfXgY8Gp3pQ_5_2"></a><a id="Tc_imgTxUtSy0GrYlFuR5pIJg_5_5"></a><ix:continuation id="Tb_D5cvRzuUMkqaD4ymZTb1Xg_cont2" continuedAt="Tb_D5cvRzuUMkqaD4ymZTb1Xg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">with the balance of the shares vesting in a series of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_installment_xM6my3fUa0iIeeFWVwoxkA" contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iGa9kvr1_0OCIlThV88zBQ" decimals="INF" format="ixt-sec:numwordsen" name="glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" scale="0" id="Narr__V5J-0qjGE-GXVrczHKv7Q">thirty-six</ix:nonFraction></span><span style="font-size:10pt;"> successive equal monthly installments as of the first day of each month measured from the first anniversary of the vesting start date, subject to the new employee&#8217;s continued service with the Company through the applicable vesting dates. Upon termination of employment by reasons other than death, cause or disability, any vested options will terminate </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_t2wb_CLKRESBcc-YEXDRlw" format="ixt-sec:durwordsen" name="glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" id="Narr_cAXNJGwbWEyta6a__xuhdg"><span style="font-size:10pt;">90 days</span></ix:nonNumeric><span style="font-size:10pt;"> after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_t2wb_CLKRESBcc-YEXDRlw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_mabCi1fPik2FP7S6CMPYQA"><span style="font-size:10pt;">10 years</span></ix:nonNumeric><span style="font-size:10pt;"> from the date of grant. The Inducement Plan was amended by the board of directors on multiple occasions to increase the number of shares reserved for issuance to </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_SGKk_W-IqEa8wgIaEyiQyA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_J4yo16oIQ06B43NUYhZhaw">3,000,000</ix:nonFraction></span><span style="font-size:10pt;"> shares as of December 31, 2024. As of December 31, 2024, there were </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_D4FOp6cmIUiI5UBLS1Pi4Q">299,108</ix:nonFraction></span><span style="font-size:10pt;"> shares available for future grants under the Inducement Plan</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A summary of the Company&#8217;s stock option activity under the Inducement Plan for the year ended December 31, 2024 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_E6PXnE2M2keALVPrnkYpBQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_QC2B5nm5zE6wl4KPu8GzAw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_I1kZTotZxEascCAqI071-A_6_2">2,590,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_QC2B5nm5zE6wl4KPu8GzAw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_tm4uOGoSG0i2dwRos6hHjQ_6_5">1.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K4GuybjZVEmN-yz3jNQQZg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_kx-rMZpea0GrRmpH970yeg_6_7">8.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_2nDRNou_p0i6QhVylaU26g_7_2">130,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_7KNfcZ-ipkaw3Eaj6Q2Yuw_7_5">3.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_Xx4mrRdXPU2Yaz_jhYf2kg_8_2">29,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_2EjGdWcFP0K4ZfFbhAmNmA_8_5">3.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc__kN4BEerwkOzFMuSOJFXeA_9_2">2,690,800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_h1vRShqyFECuceMJ9xG0sw_9_5">2.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_hRiRlzDhsECCwS13bl4Z1Q_9_7">7.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_ThAkgUalCUy0EHPoGDDCyA_10_2">1,610,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_pgCkNPbccECs-gwMlkdQ0Q_10_5">1.96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_4JZM1yaEjUCdDkWwed9xzA_10_7">6.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_TkuV0H9E_UmSiB5etaG4CQ_11_2">1,452,908</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_n5wCAvmhfke30GBMaETpQg_11_5">1.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_GFAuLXUNzkGKdCnBXLSVeg_11_7">7.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, there was $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" id="Narr_DX4XaJ6v0EmWq8DgzGp-IQ">235,087</ix:nonFraction> of total unrecognized compensation expense related to unvested options under the Inducement Plan that will be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_R8WPynz_qkqe1uEql6XdrA">0.3</ix:nonNumeric> years. There were <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K4GuybjZVEmN-yz3jNQQZg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_yY7D-NEe-EqRiELtwgIhWA"><ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_OR9rLjo-Q0OpFu-S2KLZtQ">no</ix:nonFraction></ix:nonFraction> options exercised under the Inducement Plan during the years ended December 31, 2024 or 2023. The total fair value of options that vested in the years ended December 31, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_UUFyaq8Y8U-iraSobymAeg">919,184</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K4GuybjZVEmN-yz3jNQQZg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_pY7NjX7600-bLYVBD3U0Gg">601,586</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has granted stock options to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_GranteeStatusAxis_glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_nWojf5k1XEuW7zoLkHsxkw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_jJVBGAXwbk-ZwYVBpYpiug">584,200</ix:nonFraction> shares to certain newly hired employees under the Inducement Plan which options are subject to performance-based conditions. The maximum fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_GranteeStatusAxis_glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_nWojf5k1XEuW7zoLkHsxkw" decimals="0" format="ixt:num-dot-decimal" name="glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" scale="0" id="Narr_rkK7xif1Q0uxLSDr47My5g">825,353</ix:nonFraction> associated with the performance-based options is excluded from the unrecognized compensation expense under the Inducement Plan as the completion of the performance milestones was not probable as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted-average fair value of the options granted under all equity incentive plans during the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_Ie02c_HdE0epPgIbxTugrQ">1.49</ix:nonFraction><span style="white-space:pre-wrap;"> and  </span>$<ix:nonFraction unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_MqbGu7mIjkOTWq68EXDnPQ">1.96</ix:nonFraction> per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_RrE_KVJO6EyAFWrVwkWsPQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_3VbY8vcxZ0C7W7GxuSgy7w">6.25</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_09bU5Cjj6EeOvPrxzPAbDA">6.25</ix:nonNumeric> years</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_B2uq0B5V6Ey3jCq3DjLcfQ_3_2">101.79</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_u4eS3lMhl0aSMgXLiI7DzQ_3_4">78.36</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_vLokT55USUORdNa8ci8nKQ_4_2">4.17</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_tU01-mKyGk6Br7ZG36LKxg_4_4">3.60</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_oGFLxYlPakCdKoWLohvHTA_5_2">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_MOC0YaJOgkiMz_WGvipHLg_5_4">0</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Total stock-based compensation expense associated with stock options and RSUs was classified as follows on the statement of operations for the years ended December 31:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_Iqy1DRH6Ek2Ua_sGrKkLfA" continuedAt="Tb_Iqy1DRH6Ek2Ua_sGrKkLfA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_8LGYnV6fdkuBJAJjiuhDlw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_nj0DPGFhM0OIvDxB7lEHWQ_3_3">1,271,655</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qaEaEVpgsk2gHQo8gXVEfQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_WnzEqdq__0aV2L0FmPQojA_3_6">909,981</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pj61R-BVG0mAA7jRopE9Lg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_XnI_CkZ5nkqXb-eVzRmHXA_4_3">3,425,891</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_T5bkeU0TREKgcAs7V6M9TA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_DKW4SA31n0i7gPKpz7z0Bg_4_6">2,614,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_NGpqav8bwkShY3rq4b7Law_5_3">4,697,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_usqjmpgtdE6qradX8H6nqQ_5_6">3,524,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_D5cvRzuUMkqaD4ymZTb1Xg_cont3"><ix:continuation id="Tb_Iqy1DRH6Ek2Ua_sGrKkLfA_cont1"></ix:continuation></ix:continuation><a id="Tc_WWL6ItyHSEe_goDoxtSPfg_1_2"></a><a id="Tc_KM97u2HEAEOig3P1hehQXg_1_5"></a><a id="Tc_TJA4U09XE0OCAGWJgr_0Jg_2_0"></a><a id="Tc_wFpTmiVOzEaiVgta-7F7EA_3_0"></a><a id="Tc_0KiNHS7Dt0K5ORBGzoqPWA_3_2"></a><a id="Tc_LaS3dji4r0ulnPhNHGyzlw_3_5"></a><a id="Tc_PeaWKouYKEikJezRbCWdWA_4_0"></a><a id="Tc_ICsbfwfrzU6KVeGpv2mGLg_5_0"></a><a id="Tc_JJWuV66sskS3sKE1RVwUng_6_0"></a><a id="Tc_vsZbs-gz_EGUP1WBLJchLw_7_0"></a><a id="Tc_54Cizas5LkmLwLhv1Awxzw_8_0"></a><a id="Tc_qim3Z31eWkOkrx8TGc3W5A_9_0"></a><a id="Tc_GrrnycFsdU6FsbpjNdlC9A_10_0"></a><a id="Tc_jrfshH-PrEOODqHt17OnRw_11_0"></a><a id="Tc_fLYhuLU3NUGmAB2x8HYQOQ_12_0"></a><a id="Tc_v7oNYDYwZ0uW9E10eV096Q_13_0"></a><a id="Tc_OpL6CvSrPkqj691_DrAoSg_14_0"></a><a id="Tc_s8zIbTsYykW6lqsh4TjG8g_16_0"></a><a id="Tc_pkcRLxyb-0aNlyPgeMMghA_17_0"></a><a id="Tc_7SlugIBVak6K28dNbubKVw_17_3"></a><a id="Tc_PFP6roLHsk-4FjMK07bHbw_18_0"></a><a id="Tc_Y09CrtvCqUGcZA6F37bAdg_19_0"></a><a id="Tc_8elT4l9gHUCRcoLifFKH6A_19_2"></a><a id="Tc_il4f8MWfdEeOcImwC8E2uA_19_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_N7QFPfTgE0OB2MvBjUJIJQ" continuedAt="Tb_N7QFPfTgE0OB2MvBjUJIJQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">10. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">The components of the gross deferred tax asset and related valuation allowance at December 31 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_clWfYZ6iXkeaA_E1kRHvIw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_ZDnokC04KEWEX5uv1VrTkA_3_3">96,811,786</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_baARxDLKS0Wbw_AGTVq3gw_3_6">88,746,869</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Research and orphan drug credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="glyc:DeferredTaxAssetsResearchAndOrphanDrugCredits" scale="0" id="Tc_rWw9GddD0ECpO1GPfhugbg_4_3">54,937,994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="glyc:DeferredTaxAssetsResearchAndOrphanDrugCredits" scale="0" id="Tc_T8jjW0B9iEqUZS9_RvVzHQ_4_6">53,152,849</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Capitalized research costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="glyc:DeferredTaxAssetsCapitalizedResearchCosts" scale="0" id="Tc_AmJudaOL6U-ImZYhs5Z1Pw_5_3">11,861,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="glyc:DeferredTaxAssetsCapitalizedResearchCosts" scale="0" id="Tc_q6QICf0Kw0GzmxyF9B1W_A_5_6">10,748,355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Capitalized start-up costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="glyc:DeferredTaxAssetsCapitalizedStartUpCosts" scale="0" id="Tc_Jxw1pw5FBUmaFBAyDBb7Lg_6_3">339,138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="glyc:DeferredTaxAssetsCapitalizedStartUpCosts" scale="0" id="Tc_5j8aPN5VhkS2q1JsO3-HjA_6_6">532,931</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Patent amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="glyc:DeferredTaxAssetsPatentAmortization" scale="0" id="Tc_Y0JSrPvMhUelJD7IWDN8Tw_7_3">27,071</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="glyc:DeferredTaxAssetsPatentAmortization" scale="0" id="Tc_fC6PHW_pek2J8Fc78wR-Aw_7_6">42,541</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" id="Tc_-uq3BFe3_kOiFoSkPTm_0w_8_3">6,699,628</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" id="Tc_6mJCxkOtFUWT9gYsMlN1qQ_8_6">7,324,617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Accrued bonus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="glyc:DeferredTaxAssetsAccruedBonus" scale="0" id="Tc_Ukqn6RTaF0Oc_yvCekRwZg_9_3">25,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="glyc:DeferredTaxAssetsAccruedBonus" scale="0" id="Tc_kOgbwWjR6kefcLB-TZ20Dg_9_6">704,974</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="glyc:DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" scale="0" id="Tc_M8jZJzuC6kyo8hd2mEif4g_10_3">18,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="glyc:DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" scale="0" id="Tc_-wVz8ScKlE6AdhpHGZFQag_10_6">222,452</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="Tc_ExAPkmET4EOzia5UYoTcLg_11_3">1,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="Tc_zLraCGwcPU-n-78GJrr7Hw_11_6">87,097</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Gross deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc__IN96E77C0u6onPQicHcgQ_12_3">170,722,283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_k-DPVlohAEm9fTNcGFV0pA_12_6">161,562,685</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_VztajSA3IU6hQarm-2vncA_13_3">170,722,283</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_k0t_6uZ--0izypP1N7uM6w_13_6">161,351,398</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Net deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_458vb9MY1EioLUCUnC-NFg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_zuXTqXwRM0-xzdkVZhYvYQ_14_6">211,287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="glyc:DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" scale="0" id="Tc_wrhNKk_5f0un-0p2EbKQ6Q_17_6">211,287</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Gross deferred income tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_eA0MLaJIrUmo4aiKeTHJNw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_U-O52ygDIEe58cVXAUl4eQ_18_6">211,287</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred income tax asset/(liability)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hdWUWzn18kiagf-L_qnDbQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_NTBSQbNInE69YpwADs5_rw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 12pt 0pt;">Based on the Company&#8217;s operating history and management&#8217;s expectation regarding future profitability, management believes the Company&#8217;s deferred tax assets will not be realizable under ASC 740, <i style="font-style:italic;">Income Taxes</i>. Accordingly, a full valuation allowance was recorded as of December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_glyc_FederalAndStateAuthoritiesMember_0VDyvQ7ZGE6FKTRNibG9Aw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_2l35p4RuaEW5wXKFKX9QrA">351.8</ix:nonFraction> million of U.S. Federal and state net operating losses, $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_SHUtEQJ4gEmeTUN1FXH1Jg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_l0IydJu6FEKeXs-hwhFK2g">10.9</ix:nonFraction> million of research and development tax credits and $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_ZY2boBNI1ES9pXTrZe4dfQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_r07-u5CIEEaFn6uJ-mEF6Q">44.1</ix:nonFraction> million of orphan drug tax credits available to carry forward. A portion of the net operating loss carryforwards will begin to expire in 2025, the research and development tax credits in 2025 and the orphan drug tax credit in 2033. Under current federal income tax laws, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s tax attributes, including net operating losses and credits, are subject to any ownership changes as defined under Internal Revenue Code Sections 382 and 383. A change in ownership could affect the Company&#8217;s ability to utilize its net operating losses and credits. As of December 31, 2024, the Company does not believe that an ownership change has occurred. Any future ownership changes, such as the consummation of the Merger, may cause a limitation on the Company&#8217;s ability to utilize existing tax attributes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company files income tax returns in the U.S. federal jurisdiction and the State of Maryland is the only significant state jurisdiction. The Company&#8217;s federal income tax returns for tax years 2005 and after remain subject to examination by the U.S. Internal Revenue Service due to tax attributes available to be carried forward to open or future tax years. The Company&#8217;s Maryland income tax returns for the tax years 2007 and thereafter remain subject to examination by the Comptroller of Maryland. In addition, all of the net operating losses, research and development tax credit and orphan drug credit carryforwards that may be used in future years are still subject to adjustment.  The Company is not currently under examination from any taxing authorities.</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_G1M-LK7SOEGEb7eThik52A_1_2"></a><a id="Tc_KsRWmi4PWUqtbEdqhs5K4w_1_4"></a><a id="Tc_8Z5uLHvelkG71sA3W1Ph_A_2_0"></a><a id="Tc_uQ07pITfLUqVErTeWp_juw_2_3"></a><a id="Tc_oE1AAMbRy0KrOZq4Y1XQ_A_2_5"></a><a id="Tc_79MGU6y3eEyQwluBJs8Ykw_3_0"></a><a id="Tc_uIcm9LgJlUCn8yv-i0gTGQ_4_0"></a><a id="Tc_-GOsiBEdVECEf5aW1Q8WBg_5_0"></a><a id="Tc_nfUOCxqFeEG-36ngcBfRQg_6_0"></a><a id="Tc_xOaSbmMw4EWtE6CNUv5eNg_7_0"></a><a id="Tc_Dlc1GjR400uvg8lTx099tw_8_0"></a><a id="Tc_Syjd9jUSGkWrdIc7L7jzeA_9_0"></a><a id="Tc_0_IGtTQ9r0KLza9cAx1WJg_10_0"></a><a id="Tc_jwSMFb4snk6Y7JacpE1kbQ_10_2"></a><a id="Tc_irwcUMQCbE-yLrPVRXK-Ew_10_3"></a><a id="Tc_N6e-c43IxkKXOvtLzGOu4Q_10_4"></a><a id="Tc_zZ935xwx7k-zPbZVZEwauA_10_5"></a><ix:continuation id="Tb_N7QFPfTgE0OB2MvBjUJIJQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did not have unrecognized tax benefits as of December 31, 2024 and 2023, and does not anticipate this to change significantly over the next 12 months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense is as follows as of December 31:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_7lBQwdP6V0-9MgK94qTekQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">U.S. Federal statutory tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_OlPTayhd2UG0fewcEhOaUA_2_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_Zb9G51HHR0-o-SYUWAKdPQ_2_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_Q1_Cl-cVL0Oi9ssfKoNCsw_3_2">5.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_pTRAna_kOUmknnk2yIF0vw_3_4">6.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_ToFo-UdXT0-PyUnxQnZoYw_4_2">0.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_isHK5a9VBEiFlr9A8pJQfQ_4_4">0.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Orphan drug credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="3" format="ixt:num-dot-decimal" name="glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" scale="-2" id="Tc_1sEM1LWAB0qaOuXBIKYWBg_5_2">4.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="3" format="ixt:num-dot-decimal" name="glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" scale="-2" id="Tc_KUjbCdnTLUaFz0ajNatKdQ_5_4">4.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Tc_uplufujew0io8a3rtPxqAg_6_2">5.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" sign="-" scale="-2" id="Tc_7JgUV2vGBUqoXJoxXouZ9w_6_4">2.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Executive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="3" format="ixt:num-dot-decimal" name="glyc:ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent" sign="-" scale="-2" id="Tc_pwPTEh4iTEqoiAQJT1nnSg_7_2">1.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="3" format="ixt:num-dot-decimal" name="glyc:ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent" sign="-" scale="-2" id="Tc_Ntwt_OvUNEGbRJHCbjW_qg_7_4">0.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc__IdO7ltvnUynhtswjiYPXw_8_2">0.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" sign="-" scale="-2" id="Tc_oiyoy-YOQEKcUfxmFHa-UA_8_4">3.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_1WVDi5Pc10KqtL9o_Nabpg_9_2">24.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_yqKPWFhbVkWZPzKLs96M8Q_9_4">30.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="glyc:ResearchAndLicenseAgreementTextBlock" id="Tb_W2Y32F_P0UWwhDoI1sy-UA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11. &#160;License and Collaboration Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Apollomics</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020, the Company entered into a collaboration and license agreement (the Agreement) with Apollomics (Hong Kong), Limited (Apollomics) for the development, manufacture and commercialization of products derived from two of the Company&#8217;s compounds, GMI-1271 and GMI-1687 (the Products) for therapeutic and prophylactic uses (the Field) in China, Taiwan, Hong Kong and Macau (the Territory). Under the terms of the Agreement, the Company granted Apollomics:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an exclusive license, with the right to sublicense, to develop, manufacture and have manufactured, distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise the Products in the Field in the Territory; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a non-exclusive license to conduct preclinical research with respect to Products in the Field outside of the Territory for the purposes of developing such Products for use in the Territory. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company did not recognize any milestone revenue under the Agreement for the years ended December 31, 2024 or 2023.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company and Apollomics also entered into a clinical supply agreement pursuant to which the Company agreed to manufacture and supply the Products at agreed upon prices. Apollomics has the option to begin manufacture of the Products after appropriate material transfer requirements are met. The Company did not recognize any revenue under the clinical supplies agreement during the years ended December 31, 2024 or 2023.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" id="Tb_mkFmEtqwR0KaVgUNOAqKAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">12. Employee Benefit Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company has a defined contribution plan under the Internal Revenue Code Section&#160;401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. For the years ended December 31, 2024, 2023 and 2022, the Company matched <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2022_To_12_31_2022_wZeRx6oRpUKbM_22ALjCXw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_0LnrwBTv0UeOFXLVZ973ag"><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_5s3fVTehYkWUda3DQTFzTA"><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_s6MxVL5fxkqRw1W9mY5aSA">50</ix:nonFraction></ix:nonFraction></ix:nonFraction>% up to the first <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_mfEME_8KIEOUdPf0enFlBA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_nwbMcFj2NkSlo6uMjHB0cw"><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_v6lQTXiXUUmyixAKiaaFgA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_6UBrG75ZeEyuHXk8-LM5gA"><ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_J7qgUFtkl0Wo9KigpKzqfQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_xwHkhc7i2UWjQEGLoy7WzQ">6</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of employee contributions. All matching contributions have been paid by the Company. The Company&#8217;s matching contributions vest in full immediately. The total Company matching contributions were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_NIOC4Ha9sUCCWSwE1S2IoA">211,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_7BCDiAN7rkWx643UFmEX4g">248,000</ix:nonFraction> for the years ended December 31, 2024 and 2023, respectively. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="Tb_EyiT-XRdGEarCWjUnij6eg" continuedAt="Tb_EyiT-XRdGEarCWjUnij6eg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">13. Restructuring and Asset Impairment Charges</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July 2024, the Company&#8217;s Board of Directors approved a streamlined operating plan that included a reduction in the Company&#8217;s workforce by <ix:nonFraction unitRef="Unit_Standard_employee__mI-PxD8qU-9RiyVThW_0Q" contextRef="Duration_7_1_2024_To_7_31_2024_kOgWP4JoZ0qcll1HUFWAMQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="Narr_UVKsDPquIE2XIYuX2oTk0Q">26</ix:nonFraction> employees, or approximately <ix:nonFraction unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw" contextRef="Duration_7_1_2024_To_7_31_2024_kOgWP4JoZ0qcll1HUFWAMQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_zhG_gkLWe0yajFuaNUyZGg">80</ix:nonFraction>% of its headcount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Employees affected by the reduction in force are entitled to receive severance payments and Company-funded medical insurance for a specific time.  During the year ended December 31, 2024, the Company </span><span style="-sec-ix-hidden:Hidden_gisLThAx_kmBXJrqV8ibaQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recognized</span></span> $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="6" id="Narr_D4AMwF0y3UOxWeUyzvU5rA">7.0</ix:nonFraction><span style="white-space:pre-wrap;"> million of charges for severance and related benefits.  </span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_wYUNGbYzxECaFzKbcrDKow_1_2"></a><a id="Tc_FxcOmpjwx06_vU9ZBwRxVw_2_0"></a><a id="Tc_frYUxILKaU-rm_M1TF0EfA_2_2"></a><a id="Tc_iiWeZnd5bkKhYdg0jhkJsQ_2_3"></a><a id="Tc_ZzXXrlNw606xPcLTatsx_w_3_0"></a><a id="Tc_ZQFqyqjCxk26O-mxnJuNXA_4_0"></a><a id="Tc_1bVaWszuEE2jR4sDgSBXtA_5_0"></a><a id="Tc_L8Mbb_ZFzkeV4wSSN0m3RA_5_2"></a><ix:continuation id="Tb_EyiT-XRdGEarCWjUnij6eg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following is a summary of the activity for accrued severance costs for the year ended December 31, 2024:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="Tb_7A76czkgPUW14mKVnH1i3Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Severance accrual, January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Charges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_VcdbkkEL90CR6p-GileFsw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="0" id="Tc_FVmJgmDdXU6zf0GOhvHbEQ_3_3">7,026,614</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_VcdbkkEL90CR6p-GileFsw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRestructuring" scale="0" id="Tc_M-hqlI4p20a7bXkOriOilQ_4_3">3,539,356</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Severance accrual, December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="As_Of_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ezQHd-wQf0--shnHTiwUGQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserve" scale="0" id="Tc_NgG6PitMoUmXYTuin2Ztsg_5_3">3,487,258</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The accrued severance liability of $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRestructuring" scale="6" id="Narr_EUBYEPiN70ObOPYnojkYZw">3.5</ix:nonFraction> million is payable within the next twelve months and has been included in accrued expenses on the balance sheet as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company also completed an evaluation of the impact of the restructuring on the carrying value of its long-lived assets. Our evaluation determined that indicators of impairment were present within right-of-use assets and property and equipment. Where impairment indicators existed the Company evaluated the identified asset group and separately compared the estimated undiscounted cash flow for each asset group to the net book value of the related long-term asset. The Company calculated the amount of the impairment by developing a fair value estimate of the asset group that was compared to the carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g" contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="Narr_IodTW4eoE0qM6dPD_f_vUg">0.4</ix:nonFraction> million of impairment charges related to its facility operating lease and accelerated depreciation on property and equipment during the year ended December 31, 2024.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_90fe10a5_265c_44a1_8110_01a783c63436"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To the Board of Directors and Stockholders of Crescent Biopharma, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Opinion on the Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying balance sheet of Crescent Biopharma, Inc. (the &#8220;Company&#8221;) as of December&#160;31,&#160;2024, and the related statements of operations and comprehensive loss, of convertible preferred stock and stockholders&#8217; deficit and of cash flows for the period from September&#160;19,&#160;2024 (inception) to December&#160;31,&#160;2024, including the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,&#160;2024, and the results of its operations and its cash flows for the period from September&#160;19,&#160;2024 (inception) to December&#160;31,&#160;2024 in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Substantial Doubt About the Company&#8217;s Ability to Continue as a Going Concern</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred significant operating losses and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We conducted our audit of these financial statements in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Critical Audit Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">External Research and Development Costs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described in Note 2 to the financial statements, research and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities. The Company&#8217;s research and development expense for the period from September 19, 2024 (inception) to December 31, 2024 was $14.0 million, a majority of which relates to external research and development costs.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The principal consideration for our determination that performing procedures relating to external research and development costs is a critical audit matter is a high degree of auditor effort in performing procedures related to the Company&#8217;s external research and development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures included, among others, testing external research and development costs on a sample basis by obtaining and agreeing the contractual terms of the agreement, amounts incurred to date, and estimates of work performed to date to the (i) underlying agreements with vendors engaged to conduct research and development; (ii) purchase orders; (iii) invoices received; (iv) underlying payments made for expenses incurred on the contracts; and (v) external confirmations or communications obtained by management from vendors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ PricewaterhouseCoopers LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Boston, Massachusetts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">February&#160;18,&#160;2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">We have served as the Company&#8217;s auditor since 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_bf41fe3e_d006_4de2_b3f1_87a8f37a6ac8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CRESCENT BIOPHARMA, INC.</b></p><a id="CRESCENTBIOPHARMAINCBALANCESHEET_31643"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BALANCE SHEET</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">34,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 20.15pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">34,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 20.15pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">35,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Accrued expenses and other current liabilities <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Related party accounts payable and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Warrant liability, related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 20.15pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Notes payable, noncurrent<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">37,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 20.15pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">47,096</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Commitments and contingencies (Note 10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Convertible preferred stock:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series Seed convertible preferred stock, $0.0001 par value; 20,000,000 shares authorized as of December 31, 2024; 20,000,000 shares issued and outstanding as of December 31, 2024; liquidation preference of $4,000 as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stockholders&#8217; deficit:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Common stock, $0.0001 par value; 40,000,000 shares authorized, 7,049,180 shares issued and outstanding as of December 31, 2024, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(17,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 20.15pt;">Total stockholders&#8217; deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(15,479)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 20.15pt;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">35,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Includes related party amount of $341 as of December 31, 2024 (see Note 12).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span>Includes related party amount of $14,993 as of December 31, 2024 (see Note 4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_989197e9_2d94_4c3d_b329_35fcb84593df"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT BIOPHARMA, INC.</b></p><a id="CRESCENTBIOPHARMAINCSTATEMENTOFOPERATION"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;19,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 9.75pt;">Research and development<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">14,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 9.75pt;">General and administrative<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 20.25pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(17,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other income/(expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 9.75pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 9.75pt;">Interest expense<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(852)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 20.25pt;">Total other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(676)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(17,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3.36)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.05%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,311,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;border-bottom:2.25pt double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1.5pt;position:relative;top:0.6em;width:30.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Includes related party amount of $13,185 for the period from September 19, 2024 (inception) to December 31, 2024 (see Note 12).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Includes related party amount of $571 for the period from September 19, 2024 (inception) to December 31, 2024 (see Note 12).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Includes related party amount of $341 for the period from September 19, 2024 (inception) to December 31, 2024 (see Note 4).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:center;text-indent:-18pt;margin:0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_bf08109b_0769_42ca_9f31_7629a682b08e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT BIOPHARMA, INC.</b></p><a id="CRESCENTBIOPHARMAINCSTATEMENTOFCONVERTIB"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:17.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible Preferred Stock</b></p></td><td style="vertical-align:top;width:0.99%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:top;width:0.99%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:10%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:10%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Stockholders&#8217;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:top;width:0.99%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.99%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balances as of September 19, 2024 (inception)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;width:0.99%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.99%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of common stock<sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;width:0.99%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.99%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,049,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issuance of Series Seed convertible preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:top;width:0.99%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.99%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;width:0.99%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.99%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;width:0.99%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.99%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(17,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(17,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Balances as of December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:top;width:0.99%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.99%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,049,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(17,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(15,479)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1.5pt;position:relative;top:0.6em;width:30.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes issuance of 2,049,180 restricted stock awards (see Note 7)</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c98e0afb_2560_40dc_b57f_a713874fc604"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT BIOPHARMA, INC.</b></p><a id="CRESCENTBIOPHARMAINCSTATEMENTOFCASHFLOWS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands)</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 19, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Inception) to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(17,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,134</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Non-cash interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Non-cash research and development expense related to Paragon option agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 30.25pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 30.25pt;">Accrued expenses and other current liabilities<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,172</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 30.25pt;">Related party accounts payable and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 30.25pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(38)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 20.15pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(6,269)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Proceeds from issuance of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Proceeds from issuance of Series Seed convertible preferred stock, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Proceeds from the issuance of notes payable, net of issuance costs<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">37,480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Payment of deferred offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(760)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 20.15pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">41,035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net increase in cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">34,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">34,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of non-cash financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred offering costs in accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1.5pt;position:relative;top:0.6em;width:30.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Includes related party amount of $341 for the period from September 19, 2024 (inception) to December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(2)</span></span>Includes related party amount of $14,993 for the period from September 19, 2024 (inception) to December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a7a8f6eb_7822_4d04_921a_0c90f0c5feab"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CRESCENT BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><a id="a1NatureoftheBusinessandBasisofPresentat"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span><b style="font-weight:bold;">Nature of the Business and Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Background and Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent Biopharma, Inc. (&#8220;Crescent&#8221; or the &#8220;Company&#8221;) was established and incorporated under the laws of the state of Delaware on September 19, 2024. Crescent was founded to research and develop cancer therapy candidates licensed from Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;), an antibody discovery engine founded by Fairmount Funds Management LLC (&#8220;Fairmount&#8221;). The Company currently operates as a virtual company, and thus, does not maintain a corporate headquarters or other significant facilities. Crescent was formed to develop therapies for the treatment of solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, the ability to complete preclinical and clinical trials, the ability to obtain regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s potential product candidates will require approval from the U.S. Federal Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company&#8217;s potential product candidates will receive all the required approvals. In addition, there can be no assurance that the Company&#8217;s potential product candidates, if approved, will be accepted in the marketplace, that any future product candidates can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product candidates will be successfully marketed, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics, Inc., a Delaware corporation (&#8220;GlycoMimetics&#8221;), and the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) on October 28, 2024, which agreement was subsequently amended on February 14, 2025, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Gemini Merger Sub Corp., a Delaware corporation, will merge with and into Crescent, with Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Crescent will merge with and into Gemini Merger Sub II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Crescent Biopharma Operating Company, LLC&#8221; and GlycoMimetics will change its name to &#8220;Crescent Biopharma, Inc.&#8221; GlycoMimetics following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Crescent&#8217;s management team and will focus on developing cancer therapies for the treatment of solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the effective time of the First Merger (the &#8220;First Effective Time&#8221;), (i) each then-outstanding share of Crescent common stock (including shares of Crescent common stock issued in the Crescent Pre-Closing Financing described below) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of GlycoMimetics common stock equal to the exchange ratio set forth in the Merger Agreement and (ii) each then-outstanding share of Crescent preferred stock will be converted into the right to receive a number of shares of GlycoMimetics Series A Preferred Stock equal to the exchange ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii) each then-outstanding option to purchase Crescent common stock will be assumed by GlycoMimetics, subject to adjustment as set forth in the Merger Agreement, (iv) each then-outstanding warrant to purchase shares of Crescent common stock will be converted into a warrant to purchase shares of GlycoMimetics common stock, subject to adjustment as set forth in the Merger Agreement and the form of warrant, (v) each in-the-money option to acquire shares of GlycoMimetics common stock that is issued and outstanding (whether vested or unvested) will be cancelled and converted into the right to receive immediately prior to the First Effective Time a number of shares of GlycoMimetics common stock equal to the number of shares underlying such option; and (vi) each GlycoMimetics restricted stock unit will be cancelled and converted into the right to receive a number of shares of GlycoMimetics common stock equal to the number of unsettled shares of GlycoMimetics common stock underlying such GlycoMimetics restricted stock unit.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, on February 14, 2025, Crescent and GlycoMimetics entered into an amended and restated subscription agreement (the &#8220;Subscription Agreement&#8221;) with certain investors, including certain investors of the Company, pursuant to which the Company agreed to issue and sell to such investors in a financing transaction (the &#8220;Crescent Pre-Closing Financing&#8221;) shares of the Company&#8217;s common stock and pre-funded warrants to purchase shares of the Company&#8217;s common stock at an estimated purchase price of $1.8485 per share of common stock and $1.8484 per pre-funded warrant, for gross proceeds of approximately $200.0 million (which includes $37.5 million of gross proceeds previously received by Crescent from the issuance of its convertible notes (the &#8220;Convertible Notes&#8221;) and accrued interest on such notes), which will precede the closing of the Merger. Shares of the Company&#8217;s common stock and pre-funded warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Crescent Pre-Closing Financing will be converted into shares of GlycoMimetics common stock and pre-funded warrants to purchase share of GlycoMimetics common stock in accordance with the exchange ratio at the effective time of the close of the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial statement and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within twelve months of the date that the financial statements are issued. As of December 31, 2024, the Company had $34.8 million in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will devote substantially all of its resources to advancing the development of its programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its potential product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result, the Company will need substantial additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval and prepares for and, if any of its potential product candidates are approved, proceeds to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability to operate as a going concern. The financial statements do not include any adjustments that may result if the Company is not able to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. The Company has incurred a net loss of $17.9 million during the period from September 19, 2024 (inception) to December 31, 2024. As of December 31, 2024, the Company had an accumulated deficit of $17.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October 2024, the Company received $37.5 million in gross proceeds from a Convertible Note Agreement with several investors, of which Fairmount, through an affiliate fund, holds a convertible note with an initial principal amount of $15.0 million, which qualifies as a related party transaction (see Note 12).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, Crescent and GlycoMimetics entered into the Subscription Agreement, as discussed elsewhere in Note 1 of these consolidated financial statements. Shares of Crescent common stock and pre-funded warrants to purchase shares of Crescent common stock issued pursuant to the Subscription Agreement will be converted into shares of GlycoMimetics common stock and pre-funded warrants to purchase shares of GlycoMimetics common stock at Closing pursuant to the Merger Agreement. However, the completion of the transactions is subject to the satisfaction of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic transactions will be available on acceptable terms, or at all.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on its expectations of continuing operating losses and negative cash flows from operations for the foreseeable future, as of February 18, 2025, the date the Company&#8217;s financial statements are available to be issued, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for at least 12 months from the date the financial statements are available to be issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</p><a id="_9b1c584c_28df_4a9a_b5ce_9488193e33fd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span><b style="font-weight:bold;">Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company&#8217;s financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgements that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected within these financial statements include but are not limited to research and development expenses and any applicable prepaid or accrued costs and the valuation of stock-based compensation awards and related expenses. The Company bases its estimates on known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results may differ materially from those estimates or assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s chief executive officer, who is the chief operating decision maker (the &#8220;CODM&#8221;), reviews the Company&#8217;s financial information for purposes of evaluating financial performance and allocating resources (see Note 13).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash. The Company maintains its cash balances at an accredited financial institution in amounts that, at times, may exceed federally insured limits. However, the Company has not experienced any losses on its deposits of cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is dependent on third-party organizations to research, develop, manufacture, and process its potential product candidates for its development programs. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s research and development activities are performed under its agreements with Paragon (see Note 9).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deferred Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company capitalizes certain legal, professional, accounting, and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After the consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholders&#8217; deficit as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss. As of December 31, 2024, deferred offering costs of $0.8 million were recorded as Other assets in the balance sheet.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 &#8212; Quoted prices in active markets that are identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 &#8212; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity periods. The Company accounts for its Convertible Notes at amortized cost, which approximates fair value utilizing Level 2 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Classification of Convertible Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has classified the Series Seed convertible preferred stock (the &#8220;Convertible Preferred Stock&#8221;) outside of stockholders&#8217; deficit on the Company&#8217;s balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Convertible Preferred Stock is not redeemable, except in the event of deemed liquidation (see Note 5). Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the Convertible Preferred Stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values of the Convertible Preferred Stock would be made only when a deemed liquidation event becomes probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Convertible Notes Payable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounted for the Convertible Note (as defined in Note 4) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over the term of the Convertible Note (see Note 4) and were accounted for as interest expense in other income (expense), net within the statements of operations and comprehensive loss using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Contract Costs Accruals</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development activities conducted to date by vendors, including the Company&#8217;s related party Paragon (see Note 9), and contract manufacturing organizations (&#8220;CMOs&#8221;), and in future periods may involve contract research organizations (&#8220;CROs&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company accrues for expenses resulting from obligations under its discovery and option agreements (the &#8220;Option Agreements&#8221;) by and among the Company, Paragon and Parascent Holding LLC (&#8220;Parascent&#8221;), and agreements with CROs, CMOs, and other vendors for which payment flows may not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts, invoices received, and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or other outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. As of December 31, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, which include amounts reimbursed to Paragon under the Paragon Option Agreements (as defined in Note 9).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses on the accompanying balance sheet.  The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period end, the payment is expensed immediately.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and administration costs, and professional fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Commitments and Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company may be subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2024, no liabilities were recorded for loss contingencies (see Note 10).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its statement of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company grants stock options and restricted stock awards that are subject to service-based vesting conditions. Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to non-employees with service- based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. The Company has issued stock options and restricted common stock awards (&#8220;RSAs&#8221;) with service-based vesting conditions only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company measures all stock-based awards granted to employees, directors, and non-employees in the form of stock options to purchase shares of its common stock, based on the fair value of the awards on the date of grant using the Black-Scholes option-pricing model. The Company measures RSAs using the difference, if any, between the purchase price per share of the award and the fair value of the Company&#8217;s common stock at the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s common stock valuations were prepared using a hybrid method, including an option pricing method (&#8220;OPM&#8221;). The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted expected return method (&#8220;PWERM&#8221;), where the equity value in one or more of the scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the company, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if the Company had used significantly different assumptions or estimates, the fair value of incentive shares and stock-based compensation expense could have been materially different.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Net Loss per Share Attributable to Common Stockholders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company applies the two-class method when computing net loss per share attributable to the Company&#8217;s common stockholders as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The two-class method requires loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the undistributed earnings as if all loss for the period had been distributed. The Company considers its Convertible Preferred Stock to be participating securities as, in the event a dividend is paid on common stock, the holders of Convertible Preferred Stock would be entitled to receive dividends on a basis consistent with the Company&#8217;s common stockholders. There is no allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to the Company&#8217;s common stockholders by the weighted average number of common shares outstanding for the period, excluding potentially dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potentially dilutive securities. For purposes of this calculation, the Company&#8217;s outstanding Convertible Preferred Stock, Convertible Notes, stock options to purchase common stock and unvested RSAs are considered potentially dilutive common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company generated a net loss for the period presented. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of December 31, 2024. The Company did not have any uncertain tax positions as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2023-07, Segment Reporting (Topic 280) (&#8220;ASU 2023-07&#8221;), which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss and assets will be required on an interim basis. Entities will also be required to disclose information about the CODM&#8217;s title and position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources. Finally, ASU 2023-07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted and applied the new disclosure requirements in these financial statements (see Note 13).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncement Not Yet Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of this standard on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). The amendments in ASU 2024-03 require public entities to disclose specified information about certain costs and expenses. ASU 2024-03 is effective for the Company&#8217;s annual reporting period beginning after December 15, 2026 and interim reporting periods beginning after December 27, 2027, with early adoption permitted. The Company is currently evaluating the impact of this standard on its financial statements.</p><a id="_a76b23fc_e9f9_46e5_bf16_7f92ace960a2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span><b style="font-weight:bold;">Accrued Expenses and Other Current Liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accrued interest <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accrued research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accrued professional and consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Accrued employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.1%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Includes related party amount of $341 as of December 31, 2024</p><a id="_dcfcbd11_98ec_4f7a_b647_94d13db00455"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></span><b style="font-weight:bold;">Convertible Notes Payable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In October 2024, the Company entered into a Convertible Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;) with a series of investors, pursuant to which the Company issued Convertible Notes with an initial principal amount of $37.5 million (of which $15.0 million is from a related party). The principal amount and all accrued interest of the Convertible Notes will automatically convert into the Company&#8217;s common stock or preferred stock in connection with the closing of a Next Equity Financing or other events (e.g., a sale of substantially all Company assets, a merger, etc.). The Convertible Notes accrue interest at a rate of 12.0% per annum, compounded annually. All unpaid interest and principal are scheduled to mature on December 31, 2026 (the &#8220;Maturity Date&#8221;). Prepayment is not permitted without the prior written consent of the majority of the holders of the Convertible Notes. The principal payment along with the accrued interest on each Convertible Note is due in full on the Maturity Date. Pursuant to the Note Purchase Agreement, the Company has the right to sell and issue additional Convertible Notes up to an aggregate principal amount equal to $37.5 million, in addition to the $37.5 million of initial principal amount of the Convertible Note for a total aggregate principal </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">amount of up to $75.0 million. As of December 31, 2024, the Company had outstanding borrowings of $37.5 million under its Convertible Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Subscription Agreement, the holders of the Convertible Notes have agreed to contribute such notes as consideration in exchange for shares of Crescent common stock and pre-funded warrants to purchase shares of Crescent common stock in the Crescent Pre-Closing Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting. The Company determined that the conversion options of the Convertible Note, including the conversion features related to a defaulting purchaser and highest interest rate, were not clearly and closely associated with a debt host. However, these features did not meet the definition of a derivative under ASC 815, Derivatives and Hedging, and as a result, did not require separate accounting as a derivative liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company paid debt issuance costs of less than $0.1 million in relation to the Convertible Note. The debt issuance costs are reflected as a reduction of the carrying value of Convertible Note on the Company&#8217;s balance sheet and are being amortized as interest expense over the term of the Convertible Note using the effective interest method. As of December 31, 2024, the Company recognized interest expense related to the Convertible Note of $0.9 million, which includes non-cash interest expense related to the amortization of debt issuance costs of less than $0.1 million. As of December 31, 2024, the weighted average effective interest rate of the Convertible Note was approximately 12.0%.</p><a id="_8db9a9cb_04fe_4fab_a59d_4a271e8afa5b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></span><b style="font-weight:bold;">Convertible Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 19, 2024, the Company issued 20,000,000 shares of the Series Seed Convertible Preferred Stock to a related party, Fairmount Healthcare Fund II L.P., an affiliate fund of Fairmount, at a purchase price of $0.20 per share for gross proceeds of $4.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon the issuance of the Convertible Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not require the Company to separately account for these features as embedded derivatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2024, Convertible Preferred Stock consisted of the following (in thousands, except share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:69.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:27.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred</b> <b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liquidation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issuable Upon</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preference</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Conversion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Series Seed Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.99%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of the Convertible Preferred Stock have the following rights and preferences:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Voting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of Convertible Preferred Stock are entitled to vote, together with the holders of the Company&#8217;s common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Convertible Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. A majority vote of the holders of Convertible Preferred Stock is required to liquidate or dissolve the Company, amend the certificate of incorporation or bylaws in a manner that adversely affects the rights of the Convertible Preferred Stock, reclassify common stock or establish another class of capital stock (unless the same ranks junior to the Convertible Preferred Stock with respect to its rights), create shares that would rank senior to or authorize additional shares of Convertible Preferred Stock, declare a dividend or make a distribution.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the holders of shares of Convertible Preferred Stock are entitled to elect one director of the Company. The holders of shares of common stock and any other class or series of voting stock (including Convertible Preferred Stock), exclusively and voting together as a single class, are entitled to elect the balance of the total number of directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conversion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each share of Convertible Preferred Stock is convertible into common shares at the option of the holder, at any time, and without the payment of additional consideration by the holder. Additionally, in the event of a Mandatory Conversion, such as the Merger, each share of Convertible Preferred Stock will be automatically converted into shares of newly created non-voting preferred stock at the applicable conversion ratio then in effect upon (i) the closing of a firm-commitment underwritten public offering of the Company&#8217;s common stock at a price of at least $1.00 per share resulting in at least $50.0 million of gross proceeds to the Company, net of the underwriting discount and commissions, and (ii) the vote or written consent of the holders of a majority of the outstanding shares of preferred stock, voting as a single class. The rights, privileges, duties and obligations relating to the non-voting preferred stock are to be determined at the time of a Mandatory Conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The conversion ratio of Convertible Preferred Stock is determined by dividing the original issue price by the conversion price in effect at the time of conversion. The original issue price is $0.20 per share for Convertible Preferred Stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate of incorporation, as amended and restated). The conversion price is $0.20 per share for Series Seed Convertible Preferred Stock. As of December 31, 2024, each outstanding share of Convertible Preferred Stock was convertible into common stock on a one-for-one basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock payable in shares of common stock) unless the holders of the Convertible Preferred Stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Convertible Preferred Stock in an amount at least equal to (i) in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as-converted basis or (ii) in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Convertible Preferred Stock calculated based on the respective original issue price of Series Seed Convertible Preferred Stock. Dividends are non-cumulative. For the period September 19, 2024 (inception) through December 31, 2024, no cash dividends had been declared or paid by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Convertible Preferred Stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Convertible Preferred Stock are entitled to an amount equal to the greater of (i) the applicable original issue price per share of the Convertible Preferred Stock, plus any declared but unpaid dividends thereon, or (ii) the amount per share that would have been payable had all shares of Convertible Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Convertible Preferred Stock in preference to any distributions to common stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless the holders of a majority in voting power of the then outstanding shares of Convertible Preferred Stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&#8217;s assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Convertible Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_ffd530f9_2802_4813_b17b_0e3afffad6d2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></span><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company has the authority to issue a total of 40,000,000 shares of common stock at a par value of $0.0001 per share. As of December 31, 2024, 5,000,000 shares of common stock were issued and outstanding and 2,049,180 shares of common stock in connection with RSAs were issued and outstanding. Each share of common stock entitles the holder to one vote, together with the holders of Convertible Preferred Stock, on all matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), subject to the preferential dividend rights of the holders of Convertible Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, there are 27,494,090 shares of common stock reserved for issuance for the potential conversion of shares of Convertible Preferred Stock into common stock and the exercise of outstanding stock options for common stock.</p><a id="_77132915_4185_490f_a7a2_c92b06f93f14"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></span><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2024 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 19, 2024, the Board of Directors approved the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), under which the Company may grant stock options, restricted stock awards, restricted stock units, or other stock-based awards to employees, officers, directors, consultants, and advisors. The 2024 Plan is administered by the Board of Directors, or, at the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee, if so delegated. Stock options granted under the 2024 Plan generally vest over four years, subject to the participant&#8217;s continued service, and expire after ten years. Upon adoption, the 2024 Plan authorized 2,049,180 shares of common stock reserved for issuance under the plan. On December 11, 2024, the 2024 Plan was amended to increase the number of shares of common stock reserved for issuance by 6,623,010 shares. On December 27, 2024, the 2024 Plan was amended to increase the number of shares of common stock reserved for issuance by 731,535 shares. As of December 31, 2024, the total number of shares of common stock reserved for issuance under the 2024 Plan was 9,403,725, with 273,224 shares of common stock available for future grants. On December 11, 2024, the Board of Directors approved an award of stock options to an affiliate of a consultant outside of the 2024 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Option Valuation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of each stock option grant is estimated on the grant date using the Black-Scholes option- pricing model. The Company is a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For stock options with service-based vesting conditions, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the period September 19, 2024 (inception) to December 31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:82.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:82.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;19,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:82.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:82.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">96.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:82.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:82.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the stock option activity for the period from September 19, 2024 (inception) to December 31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.060188293%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining&#160;Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;</b>&#160;<b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term&#160;(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic&#160;</b>&#160;<b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Outstanding balance as of September 19, 2024 (inception)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,494,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Outstanding balance as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,494,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Vested and expected to vest, December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,494,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exercisable as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,321,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.94%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted average grant-date fair value of stock options granted for the period September 19, 2024 (inception) to December 31, 2024 was $0.70. For the period from September 19, 2024 (inception) to December 31, 2024, there was no intrinsic value related to outstanding options. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had an exercise price lower than the fair value of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2024 and October 2024, the Company issued a total of 2,049,180 RSAs to certain directors and consultants at a price of $0.20 per share, the fair value of the common stock. Of the 2,049,180 RSAs issued, 136,612 RSAs were issued to a consultant in exchange for regulatory and strategic services provided to the Company and 1,366,120 RSAs were issued to a consultant in exchange for executive services, and such issuances were determined to be related party transactions (see Note 12). The Company&#8217;s RSAs have service-based vesting conditions only and vest over a four-year period or vest upon grant, during which time all unvested shares are subject to forfeiture by the Company in the event the holder&#8217;s service with the Company voluntarily or involuntarily terminates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the RSA activity for the period from September 19, 2024 (inception) to December 31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:5.75pt;"><td style="vertical-align:bottom;width:70.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"/></tr><tr style="height:5.75pt;"><td style="vertical-align:bottom;width:70.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of RSAs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Unvested balance as of September 19, 2024 (inception)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,049,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(341,530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Unvested balance as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,707,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.92%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.51%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Parascent Warrant Obligation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Paragon Option Agreements, Parascent will be entitled to grants of warrants to purchase in the aggregate a number of shares equal to 1.00% of the then outstanding shares of the Company&#8217;s stock, on a fully diluted basis, on December 31, 2025 and December 31, 2026, at the fair market value determined by the Board of Directors (the &#8220;Parascent Warrant Obligation&#8221;). Parascent is an entity formed by Paragon as a vehicle to hold equity in the Company in order to share profits with certain employees of Paragon. The grant dates for the issuance of warrants are expected to be December 31, 2025 and December 31, 2026 as all terms of the award, including number of shares and exercise price, will be known by all parties. Parascent&#8217;s warrant has a service inception period for the grant preceding the grant date, with the full award being vested as of the grant date with no post-grant date service requirement. As of December 31, 2024, the estimated fair value of warrants to be granted on December 31, 2025 was $0.3 million. For the period from September 19, 2024 (inception) to December 31, 2024, $0.1 million was recognized as stock-based compensation expense related to the Parascent Warrant Obligation. The warrants expected to be granted to Parascent are liability-classified and after the initial recognition, the liability is adjusted to fair value using the Black-Scholes option-pricing model at the end of each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the assumptions used in calculating the fair value of the awards for the period September 19, 2024 (inception) to December 31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;19,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">96.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the statement of operations and comprehensive loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;19,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,134</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.44%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, total unrecognized compensation cost related to the unvested stock options was $4.3 million, which is expected to be recognized over a weighted average period of approximately 3.9 years. As of December 31, 2024, total unrecognized compensation cost related to the unvested RSAs was $0.3 million, which is expected to be recognized over a weighted average period of 3.1 years. As of December 31, 2024, the unrecognized compensation cost related to the Parascent Warrant Obligation was $0.2 million, which is expected to be recognized over a weighted average period of 1.0 year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the statement of operations and comprehensive loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;19,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">RSA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Parascent warrant obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,134</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3cb34e0c_7c41_4249_aad6_1e12d79cff0d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></span><b style="font-weight:bold;">Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">A reconciliation of the Company&#8217;s statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;19,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">U.S. federal statutory tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">State income tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(1.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(22.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Effective tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net deferred tax assets consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;19,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Accrued liabilities and reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Capitalized research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,724</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3,940)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Deferred tax assets, net of valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company had a federal net operating loss carryforwards of $2.0 million for the period from September 19, 2024 (inception) to December 31, 2024. The Company had state net operating loss carryforwards of less than $0.5 million for the period from September 19, 2024 (inception) to December 31, 2024. The federal net operating loss carryforwards may be carried forward indefinitely. The state net operating loss carryforwards begin to expire in 2044.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of December 31, 2024, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current year. The Company determined that it is more likely than not that all of the deferred tax assets will not be realized. Accordingly, the Company maintained a full valuation allowance as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For the period from September 19, 2024 (inception) to December 31, 2024, the valuation allowance increased primarily due to the increases in net operating loss carryforwards and research and development tax credit carryforwards. The changes in the valuation allowance were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.45%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period&#160;from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;19,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Inception)&#160;to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Valuation allowance as of September 19, 2024 (inception)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Increases recorded to income tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Valuation allowance as of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Tax Cuts and Jobs Act of 2017 resulted in significant changes to the treatment of research and development expenditures under Section 174. For tax years beginning after the year ended December 31, 2021, taxpayers are required to capitalize and amortize </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">all research and development expenditures that are paid or incurred in connection with its trade or business. Specifically, costs for U.S. based research and development activities must be amortized over five years using a midyear convention. For the period from September 19, 2024 (inception) to December 31, 2024, the Company capitalized $14.0 million of research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company became a loss corporation as defined in Section 382. Future changes in the Company&#8217;s capital ownership, which may be outside of the Company&#8217;s control, may trigger an ownership change. In addition, future equity offerings or acquisitions that have equity as a component of the purchase price could result in an ownership change. If an ownership change has occurred or does occur in the future, utilization of the net operating loss carryforwards or other tax attributes may be limited, which could potentially result in increased future tax liability for the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which the Company operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when the Company&#8217;s judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the Company&#8217;s current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. For the period from September 19, 2024 (inception) to December 31, 2024, the Company has not recorded any uncertain tax positions in the Company&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying statement of operations. For the period from September 19, 2024 (inception) to December 31, 2024, no accrued interest or penalties are included on the related tax liability line in the balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company&#8217;s tax years are still open under statute from inception.</p><a id="_88cd9c17_2df5_4262_bd60_95c1e18fb8cb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></span><b style="font-weight:bold;">Paragon Option Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2024, Crescent entered into the Antibody Paragon Option Agreement with Paragon and Parascent for CR-001, with the selected targets PD-1 and VEGF. In October 2024, Crescent entered into the ADC Paragon Option Agreement with Paragon and Parascent for CR-002, with an undisclosed target (collectively the &#8220;Paragon Option Agreements&#8221;). Parascent is an entity formed by Paragon as a vehicle to hold equity in Crescent in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreements other than to receive such warrants. Under the Paragon Option Agreements, Crescent has the exclusive option (an &#8220;Option&#8221;), on a Research Program-by-Research Program basis, to enter into a separate agreement with Paragon consistent with a set of pre-negotiated terms (a &#8220;License Agreement&#8221;). If the Company exercises its Options and finalizes the related license agreements, it will be required to make non-refundable milestone payments to Paragon of up to $22.0 million for CR-001 and up to $46.0 million for CR-002 upon the achievement of certain clinical development and regulatory milestones, as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale of each developed product. From time to time, the Company can choose to add additional targets by mutual agreement with Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the terms of the Paragon Option Agreements, Paragon agreed to perform certain research activities to discover, generate, identify, and characterize one or more antibody candidates, in the case of the Antibody Paragon Option Agreement, and one or more antibody-drug conjugates, in the case of the ADC Paragon Option Agreement, directed to certain mutually agreed therapeutic targets of interest to Crescent (each, a &#8220;Research Program&#8221;). The Paragon Option Agreements require Crescent, Paragon, and Parascent to develop a research plan for each target that includes design, modeling, synthesis, evaluation, and other mutually agreed activities (each, a &#8220;Research Plan&#8221;), which activities primarily include performing preclinical studies. Paragon will perform the activities set forth in each Research Plan on the timelines set forth in such Research Plan and in compliance with a mutually agreed budget. Each Research Program will be overseen and coordinated by a joint development committee consisting of two employees from Crescent and two employees from Paragon, with Crescent and Paragon each having one vote with respect to decisions of the committee. When Paragon and Parascent have produced an antibody or ADC, as applicable, against a selected target, and upon the completion of each </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research Program, Paragon and Parascent will deliver to Crescent a data package that includes sequence information for all then-existing antibodies or ADCs, as applicable, and information directed to such target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Paragon Option Agreements shall continue in force on a Research Program- by-Research Program basis until the later of: (i) the end of the option period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii) if the Company exercises its Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 30 days, the expiration of such 30-day period (subject to any mutually agreed extension of such period); and (iii) the expiration of the applicable Research Term (as defined under the Paragon Option Agreements).The Company may terminate the Paragon Option Agreements or any Research Program at any time for any or no reason upon 30 days&#8217; prior written notice to Paragon, provided that the Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Paragon Option Agreements or a Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Paragon Option Agreements or any Research Program upon (i) 30 days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30-day period and (ii)the other party&#8217;s bankruptcy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Antibody Paragon Option Agreement, Crescent was required to reimburse Paragon $1.5 million for upfront research and development costs related to CR-001 and other general and administrative costs incurred by Paragon prior to September 19, 2024. Contemporaneously, Crescent also issued an aggregate of 5,000,000 shares of Crescent common stock to Paragon for an aggregate non-cash upfront consideration of Paragon&#8217;s entry into the Antibody Paragon Option Agreement, valued at $0.20 per share for a total of $1.0 million. Paragon subsequently contributed 2,500,000 of such shares to Parascent. Of these upfront development costs related to CR-001 incurred by Paragon prior to September 19, 2024, a total of $1.5 million was recognized as research and development expense and less than $0.1 million was recognized as general and administrative expense during the period from September 19, 2024 (inception) to December 31, 2024. Crescent paid $1.5 million to Paragon in November 2024. The non-cash upfront consideration was recorded as research and development expense in Crescent&#8217;s consolidated statement of operations and comprehensive loss during the period from September 19, 2024 (inception) to December 31, 2024 as related IP license fees associated with entering into the Option Agreement. Crescent is also required to pay Paragon for certain development fees and costs on a Research Program-by-Research Program basis. Under the Antibody Paragon Option Agreement, Crescent is also responsible for certain additional development costs incurred by Paragon, which from September 19, 2024 (inception) to December 31, 2024, totaled $4.7 million, and of which $4.6 million was recognized as research and development expense and $0.1 million was recognized as general and administrative expense in Crescent&#8217;s consolidated statements of operations and comprehensive loss for the period from September 19, 2024 (inception) to December 31, 2024. An amount of $6.2 million is included in related party accounts payable and other current liabilities within Crescent&#8217;s balance sheet as of December 31, 2024. Under the Antibody Paragon Option Agreement, Crescent is obligated to pay Paragon $1.3 million following finalization of the research plan for CR-001, which was paid in December 2024. Crescent also paid a $1.5 million milestone payment to Paragon in January 2025 in connection with the selection of a development candidate for CR-001.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the ADC Paragon Option Agreement, the Company is required to reimburse Paragon $0.8 million for development costs related to CR-002 incurred by Paragon through December 31, 2024, which $0.8 million was recognized as research and development expense and less than $0.1 million was recognized in general and administrative expense in the Company&#8217;s statement of operations and comprehensive loss during the period from September 19, 2024 (inception) to December 31, 2024. An amount of $0.8 million is included in related party accounts payable and other current liabilities as of December 31, 2024 for development costs related to CR-002. In addition, the Company is obligated to pay Paragon $2.5 million following the finalization of the research plan, which was paid in December 2024, and which was recognized as research and development expense in the Company&#8217;s consolidated statement of operations and comprehensive loss during the period September 19, 2024 (inception) to December 31, 2024, as well as for subsequent development costs related to CR-002. No pre-development costs were incurred for CR-002 for periods prior to September 19, 2024 (inception).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Any License Agreement entered into with respect to a given Research Program shall contain the same milestone payment obligations as the Paragon Option Agreements, provided that any milestone set in the Paragon Option Agreements that has not yet been achieved and is duplicated in such License Agreement shall no longer be achievable and payable under the terms of the Paragon Option Agreements and shall only be achievable under the terms of the License Agreement. For the avoidance of doubt, if a milestone is achieved and paid by Crescent pursuant to the Paragon Option Agreements for a certain Research Program, then there shall be no milestone payment due for the achievement of such milestone under a subsequently executed License Agreement for such Research Program. Further, under a License Agreement, Crescent would also be required to make royalty payments to Paragon in the low single-digit percentage range based on net sales of products, subject to certain reductions. The royalty term will terminate on a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">product-by-product and country- by-country basis upon the later of the expiration of the last-to-expire valid claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, as part of the Paragon Option Agreements, on each of December 31, 2025 and December 31, 2026, Crescent will grant Parascent warrants to purchase an aggregate number of shares equal to 1.00% of Crescent&#8217;s outstanding capital stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares of Crescent common stock on each respective grant date. The warrants are liability-classified and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss (see Note 7).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company expenses the fees incurred under the Paragon Option Agreements as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses and general and administrative expenses in the accompanying statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the rights obtained under the Paragon Option Agreements represent an asset acquisition whereby the underlying assets comprise in-process research and development assets with no alternative future use. The Paragon Option Agreements did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The research initiation fees represent a one-time cost on a research program-by research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of on-going development cost, monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of the Paragon Option Agreements that associated with services being rendered under the related Research Programs is recognized as research and development expense when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the period from September 19, 2024 (inception) to December 31, 2024, the Company recognized $13.2 million of research and development expenses in connection with services provided by Paragon under the Paragon Option Agreements.</p><a id="_3ab1fed9_6f3a_418a_8649_865133a0532b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></span><b style="font-weight:bold;">Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">401(k) Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a defined-contribution plan under Section 401(k) of the Internal Revenue Code of 1986 (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the 401(k) Plan may be made at the discretion of management. For the period from September 19, 2024 (inception) to December 31, 2024, the Company has not recorded any expense related to 401(k) Plan match contributions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Indemnification Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with each of its directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or executive officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its financial statements as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time, the Company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">estimated exposure amount. Legal fees and other costs associated with such proceedings are expensed as incurred. As of December 31, 2024, the Company was not a party to any material legal proceedings or claims.</p><a id="_e584bc2b_c9ad_43e1_8530_a6a8d496fa58"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></span><b style="font-weight:bold;">Net Loss per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 19, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Inception) to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(17,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,311,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3.36)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the computation of basic net loss per share attributable to common stockholders, the amount of weighted-average common shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have had an anti-dilutive effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 19, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Inception) to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Convertible preferred stock (as converted to common stock)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Unvested restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,707,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,494,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">29,201,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_4b84b553_c846_4ee4_b3fe_4595161e9b83"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></span><b style="font-weight:bold;">Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fairmount, Paragon, and Parascent have been identified as related parties of Crescent and have engaged in material transactions with the Company. At December 31, 2024, Fairmount, Paragon, and Parascent owned approximately 74%, 9%, and 9%, respectively, of the outstanding shares of stock of Crescent, assuming the conversion of preferred stock into common stock. Fairmount currently has two representatives appointed to Crescent&#8217;s Board of Directors. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon. Parascent is an entity formed by Paragon as a vehicle to hold equity in Crescent in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreements other than to receive warrants granted to Parascent under the Paragon Option Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2024, the Company issued and sold an aggregate of 20,000,000 shares of Series Seed Preferred Stock to Fairmount, at a purchase price of $0.20 per share, for gross proceeds of $4.0 million (see Note 5). Paragon subsequently contributed 2,500,000 of such shares to Parascent. In October 2024, Fairmount entered into the Note Purchase Agreement with the Company and holds a Convertible Note with an initial principal amount of $15.0 million (see Note 4).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 11, 2024, the Board of Directors issued 136,612 RSAs to a consultant in exchange for regulatory and strategic services provided to the Company. The consultant is an employee of Fairmount. On October 11, 2024, the Board of Directors issued the Company&#8217;s Chief Executive Officer 1,366,120 RSAs and options to purchase 5,286,600 shares of Crescent common stock, and the CEO paid $0.2 million for 1,024,590 of such RSAs. The Chief Executive Officer is also a Fairmount employee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with services provided by Paragon and Parascent under the Paragon Option Agreements, the Company recognized $13.2 million of expenses as research and development expense and recognized $0.1 million of expenses as general and administrative expense in the Company&#8217;s statement of operations and comprehensive loss for the period from September 19, 2024 (inception) to December 31, 2024. As of December 31, 2024, the Company had $7.2 million in related party accounts payable pertaining to services provided by Paragon and Parascent under the Paragon Option Agreements and reimbursements of recruiting and start-up fees included in other current liabilities on the consolidated balance sheet. In addition, under the terms of the Paragon Option Agreements, Parascent will be entitled to grants of warrants to purchase an aggregate number of shares equal to 1.00% of outstanding shares of the Company&#8217;s common stock, on a fully diluted basis, as of the date of the grants (see Note 7). If the Company exercises its options under the Paragon Option Agreements, it will be required to make non-refundable milestone payments to Paragon of up to $12.0 million for CR-001 and $26.0 million for CR-002 upon the achievement of certain clinical development milestones, up to $10.0 million for CR-001 and $20.0 million for CR-002 upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale of each product developed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following is a summary of related party accounts payable and other current liabilities (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Paragon reimbursable Option Agreement fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.13%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Paragon reimbursable recruiting and start-up fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.13%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4eb5a192_f23d_47a7_bee1_984f10f77531"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></span><b style="font-weight:bold;">Segment Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has&#160;one&#160;<span style="white-space:pre-wrap;">reportable segment relating to the research and development of its research programs, CR-001 and CR-002.  The Company&#8217;s CODM, its Chief Executive Officer, manages the Company&#8217;s operations on a company wide basis for the allocation of resources and the assessment of performance. The Company&#8217;s measure of segment profit or loss used to assess performance and allocate resources is consolidated net loss and comprehensive loss. Although the Company&#8217;s financial reporting package that is reviewed and approved by the CODM disaggregates significant expenses such as program-level external research and development costs, personnel costs, including stock-based compensation expense, and professional and consulting fees, all decisions made by the CODM are based upon reviewing operating metrics and performance indications at the Company-wide consolidated level. The CODM uses consolidated net loss to evaluate loss generated from the Company&#8217;s business activities in deciding how to allocate company resources and monitoring budget versus actual results. Assets are also managed on a Company-wide consolidated basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The table below is a summary of the segment loss, including significant segment expenses (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Period from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 19, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Inception) to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">CR-001 external research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,510</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">CR-002 external research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">General and administrative personnel costs (including stock-based compensation expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Research and development personnel costs (including stock-based compensation expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Professional and consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.09pt;">Other segment items <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">17,867</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.37%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Other expense including interest expense and miscellaneous other expense offset by interest income</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_427f7a85_6368_4c46_9df7_803554560dfa"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></span><b style="font-weight:bold;">Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has evaluated events and transactions occurring subsequent to December 31, 2024 through February 18, 2025, the date at which the financial statements are available to be issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_07f3b9c0_7530_444a_b183_fba024662487"></a><a id="_Hlk190571844"></a><a id="AnnexA_529116"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Annex A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">among:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">GlycoMimetics,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GEMINI MERGER SUB CORP.</b>;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">GEMINI Merger Sub II, LLC</b>; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Crescent Biopharma,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Dated as of October&#160;28, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_69a6f7a9_781a_4c70_b3ef_ae5789d337c0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Table of Contents</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section1DefinitionsandInterpretativeProv"><span style="font-style:normal;font-weight:normal;">Section&#160;1. Definitions and Interpretative Provisions</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-2</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Definitions_651662"><span style="font-style:normal;font-weight:normal;">1.1</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Definitions_651662"><span style="font-style:normal;font-weight:normal;">Definitions</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-2</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#OtherDefinitionalandInterpretativeProvis"><span style="font-style:normal;font-weight:normal;">1.2</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#OtherDefinitionalandInterpretativeProvis"><span style="font-style:normal;font-weight:normal;">Other Definitional and Interpretative Provisions</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-14</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section2DescriptionofTransaction_963665"><span style="font-style:normal;font-weight:normal;">Section&#160;2. Description of Transaction</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-15</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#TheMerger_243643"><span style="font-style:normal;font-weight:normal;">2.1</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TheMerger_243643"><span style="font-style:normal;font-weight:normal;">The Merger</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-15</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#EffectsoftheMerger_989764"><span style="font-style:normal;font-weight:normal;">2.2</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EffectsoftheMerger_989764"><span style="font-style:normal;font-weight:normal;">Effects of the Merger</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-15</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#ClosingFirstEffectiveTimeSecondEffective"><span style="font-style:normal;font-weight:normal;">2.3</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ClosingFirstEffectiveTimeSecondEffective"><span style="font-style:normal;font-weight:normal;">Closing; First Effective Time; Second Effective Time</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-15</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#OrganizationalDocumentsDirectorsandOffic"><span style="font-style:normal;font-weight:normal;">2.4</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#OrganizationalDocumentsDirectorsandOffic"><span style="font-style:normal;font-weight:normal;">Organizational Documents; Directors and Officers</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-15</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#ConversionofCompanyFirstMergerSubandSeco"><span style="font-style:normal;font-weight:normal;">2.5</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConversionofCompanyFirstMergerSubandSeco"><span style="font-style:normal;font-weight:normal;">Conversion of Company, First Merger Sub and Second Merger Sub Equity Securities</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-16</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#ClosingoftheCompanysTransferBooks_267533"><span style="font-style:normal;font-weight:normal;">2.6</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ClosingoftheCompanysTransferBooks_267533"><span style="font-style:normal;font-weight:normal;">Closing of the Company&#8217;s Transfer Books</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-17</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#SurrenderofCompanyCapitalStock_998909"><span style="font-style:normal;font-weight:normal;">2.7</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SurrenderofCompanyCapitalStock_998909"><span style="font-style:normal;font-weight:normal;">Surrender of Company Capital Stock</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-18</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#CalculationofNetCashandCompanyValuation_"><span style="font-style:normal;font-weight:normal;">2.8</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CalculationofNetCashandCompanyValuation_"><span style="font-style:normal;font-weight:normal;">Calculation of Net Cash and Company Valuation.</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-19</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#FurtherAction_183434"><span style="font-style:normal;font-weight:normal;">2.9</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#FurtherAction_183434"><span style="font-style:normal;font-weight:normal;">Further Action</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-20</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#IntendedTaxTreatmen_389635"><span style="font-style:normal;font-weight:normal;">2.10</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#IntendedTaxTreatmen_389635"><span style="font-style:normal;font-weight:normal;">Intended Tax Treatment</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-21</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Withholding_568379"><span style="font-style:normal;font-weight:normal;">2.11</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Withholding_568379"><span style="font-style:normal;font-weight:normal;">Withholding</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-21</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#AppraisalRights_796032"><span style="font-style:normal;font-weight:normal;">2.12</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AppraisalRights_796032"><span style="font-style:normal;font-weight:normal;">Appraisal Rights</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-21</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section3RepresentationsandWarrantiesofth"><span style="font-style:normal;font-weight:normal;">Section&#160;3. Representations and Warranties of the Company</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-21</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#DueOrganizationSubsidiaries_760779"><span style="font-style:normal;font-weight:normal;">3.1</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#DueOrganizationSubsidiaries_760779"><span style="font-style:normal;font-weight:normal;">Due Organization; Subsidiaries</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-21</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#OrganizationalDocuments_930684"><span style="font-style:normal;font-weight:normal;">3.2</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#OrganizationalDocuments_930684"><span style="font-style:normal;font-weight:normal;">Organizational Documents</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-22</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#AuthorityBindingNatureofAgreement_475032"><span style="font-style:normal;font-weight:normal;">3.3</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AuthorityBindingNatureofAgreement_475032"><span style="font-style:normal;font-weight:normal;">Authority; Binding Nature of Agreement</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-22</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#VoteRequired_589257"><span style="font-style:normal;font-weight:normal;">3.4</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#VoteRequired_589257"><span style="font-style:normal;font-weight:normal;">Vote Required</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-22</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NonContraventionConsents_853150"><span style="font-style:normal;font-weight:normal;">3.5</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NonContraventionConsents_853150"><span style="font-style:normal;font-weight:normal;">Non-Contravention; Consents</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-22</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Capitalization_684060"><span style="font-style:normal;font-weight:normal;">3.6</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Capitalization_684060"><span style="font-style:normal;font-weight:normal;">Capitalization.</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-23</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#FinancialStatements_517714"><span style="font-style:normal;font-weight:normal;">3.7</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#FinancialStatements_517714"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-24</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#AbsenceofChanges_738616"><span style="font-style:normal;font-weight:normal;">3.8</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AbsenceofChanges_738616"><span style="font-style:normal;font-weight:normal;">Absence of Changes</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-24</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#AbsenceofUndisclosedLiabilities_578931"><span style="font-style:normal;font-weight:normal;">3.9</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AbsenceofUndisclosedLiabilities_578931"><span style="font-style:normal;font-weight:normal;">Absence of Undisclosed Liabilities</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-24</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#TitletoAssets_685182"><span style="font-style:normal;font-weight:normal;">3.10</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TitletoAssets_685182"><span style="font-style:normal;font-weight:normal;">Title to Assets</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-25</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#RealPropertyLeasehold_250921"><span style="font-style:normal;font-weight:normal;">3.11</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#RealPropertyLeasehold_250921"><span style="font-style:normal;font-weight:normal;">Real Property; Leasehold</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-25</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#IntellectualProperty_645105"><span style="font-style:normal;font-weight:normal;">3.12</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#IntellectualProperty_645105"><span style="font-style:normal;font-weight:normal;">Intellectual Property</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-25</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#AgreementsContractsandCommitments_169799"><span style="font-style:normal;font-weight:normal;">3.13</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AgreementsContractsandCommitments_169799"><span style="font-style:normal;font-weight:normal;">Agreements, Contracts and Commitments</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-27</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#CompliancePermitsRestrictions_517301"><span style="font-style:normal;font-weight:normal;">3.14</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CompliancePermitsRestrictions_517301"><span style="font-style:normal;font-weight:normal;">Compliance; Permits; Restrictions</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-28</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#LegalProceedingsOrders_508454"><span style="font-style:normal;font-weight:normal;">3.15</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#LegalProceedingsOrders_508454"><span style="font-style:normal;font-weight:normal;">Legal Proceedings; Orders</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-30</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#TaxMatters_73219"><span style="font-style:normal;font-weight:normal;">3.16</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TaxMatters_73219"><span style="font-style:normal;font-weight:normal;">Tax Matters</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-30</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#EmployeeandLaborMattersBenefitPlans_8746"><span style="font-style:normal;font-weight:normal;">3.17</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EmployeeandLaborMattersBenefitPlans_8746"><span style="font-style:normal;font-weight:normal;">Employee and Labor Matters; Benefit Plans.</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-31</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#EnvironmentalMatters_905973"><span style="font-style:normal;font-weight:normal;">3.18</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EnvironmentalMatters_905973"><span style="font-style:normal;font-weight:normal;">Environmental Matters</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-33</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Insurance_724869"><span style="font-style:normal;font-weight:normal;">3.19</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Insurance_724869"><span style="font-style:normal;font-weight:normal;">Insurance</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-33</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NoFinancialAdvisors_3732"><span style="font-style:normal;font-weight:normal;">3.20</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NoFinancialAdvisors_3732"><span style="font-style:normal;font-weight:normal;">No Financial Advisors</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-34</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#TransactionswithAffiliates_279844"><span style="font-style:normal;font-weight:normal;">3.21</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TransactionswithAffiliates_279844"><span style="font-style:normal;font-weight:normal;">Transactions with Affiliates</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-34</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PrivacyandDataSecurity_811068"><span style="font-style:normal;font-weight:normal;">3.22</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PrivacyandDataSecurity_811068"><span style="font-style:normal;font-weight:normal;">Privacy and Data Security</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-34</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#OwnershipofParentCapitalStock_56644"><span style="font-style:normal;font-weight:normal;">3.23</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#OwnershipofParentCapitalStock_56644"><span style="font-style:normal;font-weight:normal;">Ownership of Parent Capital Stock</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-34</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NoOtherRepresentationsorWarranties_50552"><span style="font-style:normal;font-weight:normal;">3.24</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NoOtherRepresentationsorWarranties_50552"><span style="font-style:normal;font-weight:normal;">No Other Representations or Warranties</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-34</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section4RepresentationsandWarrantiesofPa"><span style="font-style:normal;font-weight:normal;">Section&#160;4. Representations and Warranties of Parent, First Merger and Second Merger Sub</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-34</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#DueOrganizationSubsidiaries_66676"><span style="font-style:normal;font-weight:normal;">4.1</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#DueOrganizationSubsidiaries_66676"><span style="font-style:normal;font-weight:normal;">Due Organization; Subsidiaries</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-35</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#OrganizationalDocuments_323878"><span style="font-style:normal;font-weight:normal;">4.2</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#OrganizationalDocuments_323878"><span style="font-style:normal;font-weight:normal;">Organizational Documents</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-35</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#AuthorityBindingNatureofAgreement_64188"><span style="font-style:normal;font-weight:normal;">4.3</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AuthorityBindingNatureofAgreement_64188"><span style="font-style:normal;font-weight:normal;">Authority; Binding Nature of Agreement</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-35</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#VoteRequired_669155"><span style="font-style:normal;font-weight:normal;">4.4</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#VoteRequired_669155"><span style="font-style:normal;font-weight:normal;">Vote Required</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-36</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NonContraventionConsents_177619"><span style="font-style:normal;font-weight:normal;">4.5</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NonContraventionConsents_177619"><span style="font-style:normal;font-weight:normal;">Non-Contravention; Consents</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-36</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Capitalization_434210"><span style="font-style:normal;font-weight:normal;">4.6</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Capitalization_434210"><span style="font-style:normal;font-weight:normal;">Capitalization</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-37</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#SECFilingsFinancialStatements_841347"><span style="font-style:normal;font-weight:normal;">4.7</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SECFilingsFinancialStatements_841347"><span style="font-style:normal;font-weight:normal;">SEC Filings; Financial Statements</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-38</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#AbsenceofChanges_567201"><span style="font-style:normal;font-weight:normal;">4.8</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AbsenceofChanges_567201"><span style="font-style:normal;font-weight:normal;">Absence of Changes</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-39</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#AbsenceofUndisclosedLiabilities_637885"><span style="font-style:normal;font-weight:normal;">4.9</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AbsenceofUndisclosedLiabilities_637885"><span style="font-style:normal;font-weight:normal;">Absence of Undisclosed Liabilities</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-39</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#TitletoAssets_879796"><span style="font-style:normal;font-weight:normal;">4.10</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TitletoAssets_879796"><span style="font-style:normal;font-weight:normal;">Title to Assets</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-39</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#RealPropertyLeasehold_767237"><span style="font-style:normal;font-weight:normal;">4.11</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#RealPropertyLeasehold_767237"><span style="font-style:normal;font-weight:normal;">Real Property; Leasehold</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-40</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#IntellectualProperty_602564"><span style="font-style:normal;font-weight:normal;">4.12</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#IntellectualProperty_602564"><span style="font-style:normal;font-weight:normal;">Intellectual Property</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-40</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#AgreementsContractsandCommitments_284572"><span style="font-style:normal;font-weight:normal;">4.13</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AgreementsContractsandCommitments_284572"><span style="font-style:normal;font-weight:normal;">Agreements, Contracts and Commitments</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-42</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#CompliancePermitsRestrictions_645775"><span style="font-style:normal;font-weight:normal;">4.14</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CompliancePermitsRestrictions_645775"><span style="font-style:normal;font-weight:normal;">Compliance; Permits; Restrictions</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-43</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#LegalProceedingsOrders_709672"><span style="font-style:normal;font-weight:normal;">4.15</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#LegalProceedingsOrders_709672"><span style="font-style:normal;font-weight:normal;">Legal Proceedings; Orders</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-45</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#TaxMatters_199043"><span style="font-style:normal;font-weight:normal;">4.16</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TaxMatters_199043"><span style="font-style:normal;font-weight:normal;">Tax Matters</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-45</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#EmployeeandLaborMattersBenefitPlans_8128"><span style="font-style:normal;font-weight:normal;">4.17</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EmployeeandLaborMattersBenefitPlans_8128"><span style="font-style:normal;font-weight:normal;">Employee and Labor Matters; Benefit Plans</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-46</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#EnvironmentalMatters_611358"><span style="font-style:normal;font-weight:normal;">4.18</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EnvironmentalMatters_611358"><span style="font-style:normal;font-weight:normal;">Environmental Matters</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-48</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Insurance_164897"><span style="font-style:normal;font-weight:normal;">4.19</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Insurance_164897"><span style="font-style:normal;font-weight:normal;">Insurance</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-48</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#TransactionswithAffiliates_830300"><span style="font-style:normal;font-weight:normal;">4.20</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TransactionswithAffiliates_830300"><span style="font-style:normal;font-weight:normal;">Transactions with Affiliates</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-48</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NoFinancialAdvisors_404785"><span style="font-style:normal;font-weight:normal;">4.21</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NoFinancialAdvisors_404785"><span style="font-style:normal;font-weight:normal;">No Financial Advisors</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-49</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#ValidIssuance_191646"><span style="font-style:normal;font-weight:normal;">4.22</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ValidIssuance_191646"><span style="font-style:normal;font-weight:normal;">Valid Issuance</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-49</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PrivacyandDataSecurity_516687"><span style="font-style:normal;font-weight:normal;">4.23</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PrivacyandDataSecurity_516687"><span style="font-style:normal;font-weight:normal;">Privacy and Data Security</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-49</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NoOtherRepresentationsorWarranties_60917"><span style="font-style:normal;font-weight:normal;">4.24</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NoOtherRepresentationsorWarranties_60917"><span style="font-style:normal;font-weight:normal;">No Other Representations or Warranties</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-49</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section5CertainCovenantsoftheParties_497"><span style="font-style:normal;font-weight:normal;">Section&#160;5. Certain Covenants of the Parties</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-49</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#OperationofParentsBusiness_673731"><span style="font-style:normal;font-weight:normal;">5.1</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#OperationofParentsBusiness_673731"><span style="font-style:normal;font-weight:normal;">Operation of Parent&#8217;s Business</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-49</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#OperationoftheCompanysBusiness_408413"><span style="font-style:normal;font-weight:normal;">5.2</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#OperationoftheCompanysBusiness_408413"><span style="font-style:normal;font-weight:normal;">Operation of the Company&#8217;s Business</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-51</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#AccessandInvestigation_256065"><span style="font-style:normal;font-weight:normal;">5.3</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AccessandInvestigation_256065"><span style="font-style:normal;font-weight:normal;">Access and Investigation</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-52</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NoSolicitation_194920"><span style="font-style:normal;font-weight:normal;">5.4</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NoSolicitation_194920"><span style="font-style:normal;font-weight:normal;">No Solicitation</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-53</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NotificationofCertainMatters_886732"><span style="font-style:normal;font-weight:normal;">5.5</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotificationofCertainMatters_886732"><span style="font-style:normal;font-weight:normal;">Notification of Certain Matters</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-53</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section6AdditionalAgreementsoftheParties"><span style="font-style:normal;font-weight:normal;">Section&#160;6. Additional Agreements of the Parties</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-54</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#ProxyStatement_902058"><span style="font-style:normal;font-weight:normal;">6.1</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ProxyStatement_902058"><span style="font-style:normal;font-weight:normal;">Proxy Statement</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-54</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#CompanyStockholderWrittenConsent_664807"><span style="font-style:normal;font-weight:normal;">6.2</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CompanyStockholderWrittenConsent_664807"><span style="font-style:normal;font-weight:normal;">Company Stockholder Written Consent</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-54</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#ParentStockholderMeeting_423253"><span style="font-style:normal;font-weight:normal;">6.3</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ParentStockholderMeeting_423253"><span style="font-style:normal;font-weight:normal;">Parent Stockholder Meeting</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-56</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#EffortsRegulatoryApprovals_566601"><span style="font-style:normal;font-weight:normal;">6.4</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EffortsRegulatoryApprovals_566601"><span style="font-style:normal;font-weight:normal;">Efforts; Regulatory Approvals</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-57</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#CompanyOptionsCompanyWarrants_93450"><span style="font-style:normal;font-weight:normal;">6.5</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CompanyOptionsCompanyWarrants_93450"><span style="font-style:normal;font-weight:normal;">Company Options; Company Warrants</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-58</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#EmployeeBenefits_594628"><span style="font-style:normal;font-weight:normal;">6.6</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EmployeeBenefits_594628"><span style="font-style:normal;font-weight:normal;">Employee Benefits</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-59</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#IndemnificationofOfficersandDirectors_49"><span style="font-style:normal;font-weight:normal;">6.7</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#IndemnificationofOfficersandDirectors_49"><span style="font-style:normal;font-weight:normal;">Indemnification of Officers and Directors</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-60</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Disclosure_615626"><span style="font-style:normal;font-weight:normal;">6.8</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Disclosure_615626"><span style="font-style:normal;font-weight:normal;">Disclosure</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-61</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Listing_625102"><span style="font-style:normal;font-weight:normal;">6.9</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Listing_625102"><span style="font-style:normal;font-weight:normal;">Listing</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-61</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#TaxMatters_508447"><span style="font-style:normal;font-weight:normal;">6.10</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TaxMatters_508447"><span style="font-style:normal;font-weight:normal;">Tax Matters</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-62</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Legend_99197"><span style="font-style:normal;font-weight:normal;">6.11</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Legend_99197"><span style="font-style:normal;font-weight:normal;">Legends</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-62</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#OfficersandDirectors_745923"><span style="font-style:normal;font-weight:normal;">6.12</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#OfficersandDirectors_745923"><span style="font-style:normal;font-weight:normal;">Officers and Directors</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-62</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#TerminationofCertainAgreementsandRights_"><span style="font-style:normal;font-weight:normal;">6.13</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TerminationofCertainAgreementsandRights_"><span style="font-style:normal;font-weight:normal;">Termination of Certain Agreements and Rights</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Section16Matters_721011"><span style="font-style:normal;font-weight:normal;">6.14</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section16Matters_721011"><span style="font-style:normal;font-weight:normal;">Section&#160;16 Matters</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#AllocationInformation_354"><span style="font-style:normal;font-weight:normal;">6.15</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AllocationInformation_354"><span style="font-style:normal;font-weight:normal;">Allocation Information</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#ParentSECDocuments_841417"><span style="font-style:normal;font-weight:normal;">6.16</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ParentSECDocuments_841417"><span style="font-style:normal;font-weight:normal;">Parent SEC Documents</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NoticeofCertainTransactions_195867"><span style="font-style:normal;font-weight:normal;">6.17</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NoticeofCertainTransactions_195867"><span style="font-style:normal;font-weight:normal;">Notice of Certain Transactions</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#ObligationsofMergerSubs_271860"><span style="font-style:normal;font-weight:normal;">6.18</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ObligationsofMergerSubs_271860"><span style="font-style:normal;font-weight:normal;">Obligations of Merger Subs</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#ParentFinancin_54120"><span style="font-style:normal;font-weight:normal;">6.19</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ParentFinancin_54120"><span style="font-style:normal;font-weight:normal;">Parent Financing</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section7ConditionsPrecedenttoObligations"><span style="font-style:normal;font-weight:normal;">Section&#160;7. Conditions Precedent to Obligations of Each Party</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-63</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#RegulatoryApprovals_511720"><span style="font-style:normal;font-weight:normal;">7.1</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#RegulatoryApprovals_511720"><span style="font-style:normal;font-weight:normal;">Regulatory Approvals</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-64</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NoRestraints_770665"><span style="font-style:normal;font-weight:normal;">7.2</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NoRestraints_770665"><span style="font-style:normal;font-weight:normal;">No Restraints</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-64</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#StockholderApproval_844737"><span style="font-style:normal;font-weight:normal;">7.3</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StockholderApproval_844737"><span style="font-style:normal;font-weight:normal;">Stockholder Approval</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-64</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Listing_69572"><span style="font-style:normal;font-weight:normal;">7.4</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Listing_69572"><span style="font-style:normal;font-weight:normal;">Listing</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-64</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#LockUpAgreements_55117"><span style="font-style:normal;font-weight:normal;">7.5</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#LockUpAgreements_55117"><span style="font-style:normal;font-weight:normal;">Lock-Up Agreements</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-64</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#ParentCharterAmendment_85194"><span style="font-style:normal;font-weight:normal;">7.6</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ParentCharterAmendment_85194"><span style="font-style:normal;font-weight:normal;">Parent Charter Amendment</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-64</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#CertificateofDesignation_183912"><span style="font-style:normal;font-weight:normal;">7.7</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CertificateofDesignation_183912"><span style="font-style:normal;font-weight:normal;">Certificate of Designation</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-64</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section8AdditionalConditionsPrecedenttoO"><span style="font-style:normal;font-weight:normal;">Section&#160;8. Additional Conditions Precedent to Obligations of Parent and Merger Subs</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-64</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#AccuracyofRepresentations_127554"><span style="font-style:normal;font-weight:normal;">8.1</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AccuracyofRepresentations_127554"><span style="font-style:normal;font-weight:normal;">Accuracy of Representations</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-64</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PerformanceofCovenants_992301"><span style="font-style:normal;font-weight:normal;">8.2</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PerformanceofCovenants_992301"><span style="font-style:normal;font-weight:normal;">Performance of Covenants</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-65</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Documents_968311"><span style="font-style:normal;font-weight:normal;">8.3</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Documents_968311"><span style="font-style:normal;font-weight:normal;">Documents</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-65</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NoCompanyMaterialAdverseEffect_93901"><span style="font-style:normal;font-weight:normal;">8.4</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NoCompanyMaterialAdverseEffect_93901"><span style="font-style:normal;font-weight:normal;">No Company Material Adverse Effect</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-65</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#CompanyStockholderWrittenConsent_497664"><span style="font-style:normal;font-weight:normal;">8.5</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CompanyStockholderWrittenConsent_497664"><span style="font-style:normal;font-weight:normal;">Company Stockholder Written Consent</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-65</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#ParentFinancing_935500"><span style="font-style:normal;font-weight:normal;">8.6</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ParentFinancing_935500"><span style="font-style:normal;font-weight:normal;">Parent Financing</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-65</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section9AdditionalConditionsPrecedenttoO"><span style="font-style:normal;font-weight:normal;">Section&#160;9. Additional Conditions Precedent to Obligation of the Company</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-65</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#AccuracyofRepresentations_606216"><span style="font-style:normal;font-weight:normal;">9.1</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AccuracyofRepresentations_606216"><span style="font-style:normal;font-weight:normal;">Accuracy of Representations</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-65</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PerformanceofCovenants_593379"><span style="font-style:normal;font-weight:normal;">9.2</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PerformanceofCovenants_593379"><span style="font-style:normal;font-weight:normal;">Performance of Covenants</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-66</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Documents_509958"><span style="font-style:normal;font-weight:normal;">9.3</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Documents_509958"><span style="font-style:normal;font-weight:normal;">Documents</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-66</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NoParentMaterialAdverseEffect_531353"><span style="font-style:normal;font-weight:normal;">9.4</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NoParentMaterialAdverseEffect_531353"><span style="font-style:normal;font-weight:normal;">No Parent Material Adverse Effect</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-66</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section10Termination_386144"><span style="font-style:normal;font-weight:normal;">Section&#160;10. Termination</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-66</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Termination_169795"><span style="font-style:normal;font-weight:normal;">10.1</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Termination_169795"><span style="font-style:normal;font-weight:normal;">Termination</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-66</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#EffectofTermination_94632"><span style="font-style:normal;font-weight:normal;">10.2</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EffectofTermination_94632"><span style="font-style:normal;font-weight:normal;">Effect of Termination</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-67</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#ExpensesTerminationFees_129022"><span style="font-style:normal;font-weight:normal;">10.3</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ExpensesTerminationFees_129022"><span style="font-style:normal;font-weight:normal;">Expenses; Termination Fees</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-67</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Section11MiscellaneousProvisions_266799"><span style="font-style:normal;font-weight:normal;">Section&#160;11. Miscellaneous Provisions</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-69</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NonSurvivalofRepresentationsandWarrantie"><span style="font-style:normal;font-weight:normal;">11.1</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NonSurvivalofRepresentationsandWarrantie"><span style="font-style:normal;font-weight:normal;">Non-Survival of Representations and Warranties</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-69</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Amendment_930923"><span style="font-style:normal;font-weight:normal;">11.2</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Amendment_930923"><span style="font-style:normal;font-weight:normal;">Amendment</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-69</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Waiver_835873"><span style="font-style:normal;font-weight:normal;">11.3</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Waiver_835873"><span style="font-style:normal;font-weight:normal;">Waiver</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-69</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#EntireAgreementCounterpartsExchangesbyEl"><span style="font-style:normal;font-weight:normal;">11.4</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EntireAgreementCounterpartsExchangesbyEl"><span style="font-style:normal;font-weight:normal;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-69</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#ApplicableLawJurisdiction_229457"><span style="font-style:normal;font-weight:normal;">11.5</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ApplicableLawJurisdiction_229457"><span style="font-style:normal;font-weight:normal;">Applicable Law; Jurisdiction</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-69</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Assignability_997322"><span style="font-style:normal;font-weight:normal;">11.6</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Assignability_997322"><span style="font-style:normal;font-weight:normal;">Assignability</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-69</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Notices_135944"><span style="font-style:normal;font-weight:normal;">11.7</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Notices_135944"><span style="font-style:normal;font-weight:normal;">Notices</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-70</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Cooperation_36544"><span style="font-style:normal;font-weight:normal;">11.8</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Cooperation_36544"><span style="font-style:normal;font-weight:normal;">Cooperation</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-70</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Severability_632108"><span style="font-style:normal;font-weight:normal;">11.9</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Severability_632108"><span style="font-style:normal;font-weight:normal;">Severability</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-70</p></td></tr><tr><td style="vertical-align:top;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#OtherRemediesSpecificPerformance_69843"><span style="font-style:normal;font-weight:normal;">11.10</span></a></p></td><td style="vertical-align:top;width:85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#OtherRemediesSpecificPerformance_69843"><span style="font-style:normal;font-weight:normal;">Other Remedies; Specific Performance</span></a></p></td><td style="vertical-align:top;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-71</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#NoThirdPartyBeneficiaries_697387"><span style="font-style:normal;font-weight:normal;">11.11</span></a></p></td><td style="vertical-align:top;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NoThirdPartyBeneficiaries_697387"><span style="font-style:normal;font-weight:normal;">No Third-Party Beneficiaries</span></a></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">A-71</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibits:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exhibit&#160;A-1</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Form&#160;of Parent Stockholder Support Agreement</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exhibit&#160;A-2</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Form&#160;of Company Stockholder Support Agreement</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exhibit&#160;B</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Form&#160;of Lock-Up Agreement</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exhibit&#160;C</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Form&#160;of Subscription Agreement</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exhibit&#160;D-1</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">First Certificate of Merger, including certificate of incorporation of the First Step Surviving Corporation attached as Exhibit&#160;A thereto, incorporated by reference into this Agreement</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exhibit&#160;D-2</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Second Certificate of Merger, incorporated by reference into this Agreement</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit&#160;E</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Form&#160;of Certificate of Designation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d278b486_c7de_4292_a07b_b26c22e6327c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">This Agreement and Plan of Merger and Reorganization </b>(this &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is made and entered into as of October&#160;28, 2024, by and among <b style="font-variant:small-caps;font-weight:bold;">GlycoMimetics,&#160;Inc.</b>, a Delaware corporation (&#8220;<b style="font-weight:bold;">Parent</b>&#8221;), <b style="font-variant:small-caps;font-weight:bold;">Gemini Merger Sub Corp.</b>, a Delaware corporation and wholly owned subsidiary of Parent (&#8220;<b style="font-weight:bold;">First Merger Sub</b>&#8221;), <b style="font-variant:small-caps;font-weight:bold;">Gemini Merger Sub II, LLC</b>, a Delaware limited liability company and wholly owned subsidiary of Parent (&#8220;<b style="font-weight:bold;">Second Merger Sub</b>&#8221; and, together with First Merger Sub, &#8220;<b style="font-weight:bold;">Merger Subs</b>&#8221;), and <b style="font-variant:small-caps;font-weight:bold;">Crescent Biopharma,&#160;Inc.</b>, a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;). Certain capitalized terms used in this Agreement are defined in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Recitals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A.&#160;&#160;&#160;&#160;Parent and the Company intend to effect a merger of First Merger Sub with and into the Company (the &#8220;<b style="font-weight:bold;">First Merger</b>&#8221;) in accordance with this Agreement and the DGCL. Upon consummation of the First Merger, First Merger Sub will cease to exist and the Company will become a wholly owned subsidiary of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">B.&#160;&#160;&#160;&#160;Immediately following the First Merger and as part of the same overall transaction as the First Merger, the Company will merge with and into Second Merger Sub (the &#8220;<b style="font-weight:bold;">Second Merger</b>&#8221; and, together with the First Merger, the &#8220;<b style="font-weight:bold;">Merger</b>&#8221;), with Second Merger Sub being the surviving entity of the Second Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">C.&#160;&#160;&#160;&#160;The Parties intend that, (i)&#160;the First Merger and the Second Merger, taken together, will constitute an integrated transaction described in Rev. Rul. 2001-46, 2001-2 C.B. 321 that qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code, and (ii)&#160;this Agreement will constitute, and is hereby adopted as, a plan of reorganization within the meaning of Treasury Regulations Sections 1.368-2(g)&#160;and 1.368-3(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">D.&#160;&#160;&#160;&#160;The Parent Board has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve this Agreement and thereby approve the Parent Stockholder Matters, including the Contemplated Transactions, and against any competing proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">E.&#160;&#160;&#160;&#160;The First Merger Sub Board has (i)&#160;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of First Merger Sub and its sole stockholder, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">F.&#160;&#160;&#160;&#160;The sole member of the Second Merger Sub has (i)&#160;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger Sub and its sole member, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole member of Second Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">G.&#160;&#160;&#160;&#160;The Company Board has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">H.&#160;&#160;&#160;&#160;Concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company&#8217;s willingness to enter into this Agreement, each of the officers and directors set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;A</span> of the Parent Disclosure Letter (solely in their capacity as stockholders of Parent) are executing support agreements in favor of the Company in substantially the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A-1</span> (the &#8220;<b style="font-weight:bold;">Parent Stockholder Support Agreement</b>&#8221;), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Parent Capital Stock in favor of the approval of this Agreement and thereby approve the Contemplated Transactions, and, if deemed necessary by Parent, an amendment to Parent&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split and any other matters, and against any competing proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">I.&#160;&#160;&#160;&#160;Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s willingness to enter into this Agreement, each of the officers, directors and stockholders of the Company listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;A</span> of the Company Disclosure Letter (solely in their capacity as stockholders of the Company) are executing support agreements in favor of Parent in substantially the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A-2</span> (the &#8220;<b style="font-weight:bold;">Company Stockholder Support Agreement</b>&#8221;), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Company Capital Stock in favor of the adoption of this Agreement and thereby approve the Contemplated Transactions and against any competing proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">J.&#160;&#160;&#160;&#160;Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s and the Company&#8217;s willingness to enter into this Agreement, all of the stockholders of the Company or Parent listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;B</span> of the Company Disclosure Letter are executing lock-up agreements in substantially the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;B</span> (the &#8220;<b style="font-weight:bold;">Lock-Up Agreement</b>,&#8221; and collectively, the &#8220;<b style="font-weight:bold;">Lock-Up Agreements</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">K.&#160;&#160;&#160;&#160;It is expected that within two (2)&#160;Business Days after the date hereof, the holders of shares of Company Capital Stock sufficient to adopt and approve this Agreement and the Merger as required under the DGCL and the Company&#8217;s certificate of incorporation and bylaws will execute and deliver an action by written consent adopting this Agreement, in form and substance reasonably acceptable to Parent, in order to obtain the Required Company Stockholder Vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">L.&#160;&#160;&#160;&#160;Concurrently with the execution and delivery of this Agreement, certain investors have executed a Securities Purchase Agreement in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;C</span> among Parent and the Persons named therein (including as may be amended, restated and/or superseded from time to time, the &#8220;<b style="font-weight:bold;">Subscription Agreement</b>&#8221;), pursuant to which such Persons will have agreed to purchase in the amounts set forth therein shares of Parent Common Stock and pre-funded warrants to purchase Parent Common Stock following the Second Effective Time (the &#8220;<b style="font-weight:bold;">Parent Financing</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Parties, intending to be legally bound, agree as follows:</p><a id="Section1DefinitionsandInterpretativeProv"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;1. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions and Interpretative Provisions.</span></p><a id="Definitions_651662"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">1.1&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;For purposes of this Agreement (including this Section&#160;1):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Acceptable Confidentiality Agreement</b>&#8221; means a confidentiality agreement containing terms not materially less restrictive in the aggregate to the counterparty thereto than the terms of the Confidentiality Agreement, except such confidentiality agreement need not contain any standstill, non-solicitation or no hire provisions. Notwithstanding the foregoing, a Person who has previously entered into a confidentiality agreement with Parent relating to a potential Acquisition Proposal on terms that are not materially less restrictive than the Confidentiality Agreement with respect to the scope of coverage and restrictions on disclosure and use shall not be required to enter into a new or revised confidentiality agreement, and such existing confidentiality agreement shall be deemed to be an Acceptable Confidentiality Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Acquisition Inquiry</b>&#8221; means, with respect to a Party, an inquiry, indication of interest or request for non-public information (other than an inquiry, indication of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to the other Party) that could reasonably be expected to lead to an Acquisition Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Acquisition Proposal</b>&#8221; means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its Affiliates, on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Acquisition Transaction</b>&#8221; means any transaction or series of related transactions (other than any Interim Financing, any Company Acquisition, or the Parent Financing) involving:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">(a)&#160;&#160;&#160;&#160;any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i)&#160;in which a Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules&#160;promulgated thereunder) of Persons directly or indirectly acquires beneficial or record </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries or (ii)&#160;in which a Party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries, or issues securities convertible into more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;&#160;&#160;&#160;any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Affiliate</b>&#8221; shall have the meaning given to such term in Rule&#160;145 under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Affordable Care Act</b>&#8221; means the Patient Protection and Affordable Care Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Anticipated Closing Date</b>&#8221; means the anticipated Closing Date, as agreed upon by Parent and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Business Day</b>&#8221; means any day other than a day on which banks in the State of New York are authorized or obligated to be closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Certificate of Designation</b>&#8221; means the Certificate of Designation of Preferences, Rights and Limitations of Parent Convertible Preferred Stock in the form attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;E</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">COBRA</b>&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as set forth in Section&#160;4980B of the Code and Section&#160;6 of Title I of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Code</b>&#8221; means the Internal Revenue Code of 1986, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Associate</b>&#8221; means any current employee, independent contractor, officer or director of the Company or any of its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Board</b>&#8221; means the board of directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Capital Stock</b>&#8221; means the Company Common Stock and the Company Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Capitalization Representations</b>&#8221; means the representations and warranties of the Company set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections&#160;&#8206;3.6(a)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;3.6(d)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Common Stock</b>&#8221; means the common stock, $0.0001 par value per share, of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Contract</b>&#8221; means any Contract: (a)&#160;to which the Company or any of its Subsidiaries is a Party, (b)&#160;by which the Company or any of its Subsidiaries is or may become bound or under which the Company or any of its Subsidiaries has, or may become subject to, any obligation or (c)&#160;under which the Company or any of its Subsidiaries has or may acquire any right or interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Employee Plan</b>&#8221; means any Employee Plan that the Company or any of its Subsidiaries (i)&#160;sponsors, maintains, administers, or contributes to, (ii)&#160;may reasonably be expected to have any Liability, or (iii)&#160;utilizes to provide benefits to or otherwise cover any current or former employee, officer, director or other service provider of the Company or any of its Subsidiaries (or their spouses, dependents, or beneficiaries), but excluding any Employee Plan in which the Company or any of its Subsidiaries participates that is sponsored by any professional employer organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Fundamental Representations</b>&#8221; means the representations and warranties of the Company set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections&#160;&#8206;3.1(a)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;3.2</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;3.3</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;3.4</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;3.5(a)(i)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;3.20</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company IP Rights</b>&#8221; means all Intellectual Property rights that are owned or purported to be owned by, assigned to, exclusively licensed to, or controlled by the Company or its Subsidiaries that are necessary for, or used or held for use in, the operation of the business of the Company and its Subsidiaries as presently conducted.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company IP Rights Agreement</b>&#8221; means any Contract governing, related to or pertaining to any Company IP Rights other than any confidential information provided under confidentiality agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Key Employee</b>&#8221; means any executive officer of the Company or any of its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Material Adverse Effect</b>&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of the Company or its Subsidiaries, taken as a whole; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Company Material Adverse Effect: (a)&#160;the announcement of this Agreement or the pendency of the Contemplated Transactions, (b)&#160;the taking of any action, or the failure to take any action, by the Company that is required to comply with the terms of this Agreement, (c)&#160;any natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world or any governmental or other response or reaction to any of the foregoing, (d)&#160;any change in GAAP or applicable Law or the interpretation thereof, (e)&#160;general economic or political conditions or conditions generally affecting the industries in which the Company and its Subsidiaries operate or (f)&#160;any change in the cash position of the Company and its Subsidiaries which results from operations in the Ordinary Course of Business; except in each case with respect to clauses (c), (d)&#160;and (e), to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Merger Shares</b>&#8221; means the product determined by <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">multiplying</i> (i)&#160;the Post-Closing Parent Shares <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">by</i> (ii)&#160;the Company Allocation Percentage, in which:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Aggregate Valuation</b>&#8221; means the sum of (i) the Company Valuation, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">plus</i> (ii) the Parent Valuation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Company Acquisition</b>&#8221; means any acquisition or license of, by purchase or otherwise, a portion of, or all or substantially all of, (i) the property or assets, (ii) the equity securities or other evidence of beneficial ownership, or (iii) any division, line of business or other business unit, in each case, of any Person other than Parent and its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Company Allocation Percentage</b>&#8221; means the percentage (rounded to four decimal places) determined by <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subtracting</i> (i) the Parent Allocation Percentage <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">from</i> (ii) 100 percent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Company Outstanding Shares</b>&#8221; means, without duplication, the total number of shares of Company Capital Stock outstanding immediately prior to the First Effective Time (including any shares of Company Common Stock or Company Preferred Stock that are issued in, or issuable upon the exercise or conversion of securities issued in, any Interim Financing or Company Acquisition), expressed on a fully diluted and as-converted-to-Company Common Stock basis assuming, without limitation or duplication, the exercise of all Company Options, Company Warrants or other rights or commitments to receive shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock, including the Company Notes), whether conditional or unconditional or vested or unvested, that are outstanding as of immediately prior to the First Effective Time; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that Company Outstanding Shares shall exclude (i) any Company Options, Company Warrants and any other equity awards issued under the Company Stock Plans (including any shares of Company Common Stock issuable upon the exercise of such Company Options, Company Warrants or other equity awards) issued to directors, employees, consultants or other service providers following the date hereof but prior to the Closing (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service Provider Grants</span>&#8221;) and (ii) any shares of Company Common Stock underlying Company Notes that are to be contributed as consideration in the Parent Financing pursuant to the Subscription Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Company Valuation</b>&#8221; means (i) $50,000,000, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">plus</i> (ii) the Fair Market Value of each Company Acquisition, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">plus</i> (ii) the Fair Market Value of any Interim Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Exchange Ratio</b>&#8221; means the ratio (rounded to four decimal places) equal to the quotient obtained by dividing (i) the Company Merger Shares by (ii) the Company Outstanding Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Fair Market Value</b>&#8221; means (A) for a Company Acquisition, the sum of (i) in the case any Company Capital Stock is issued as consideration for such Company Acquisition, (a) $50,000,000, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">divided</i> by the Company Outstanding Shares (calculated as of the date hereof), <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">multiplied</i> by (b) the aggregate number of shares of Company Capital Stock issued in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">such Company Acquisition, and (ii) in the case any consideration other than cash or shares of Company Capital Stock is issued as consideration for such Company Acquisition, the fair market value for such assets or securities as between a willing buyer and a willing seller in an arm&#8217;s length, non-distressed transaction occurring on the date of valuation, taking into account all relevant factors determinative of value, as reasonably determined by the Company in good faith, and (B) for any Interim Financing, (i) $50,000,000, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">divided</i> by the Company Outstanding Shares (calculated as of the date hereof), <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">multiplied</i> by (ii) the aggregate number of shares of Company Capital Stock issued (or to be issued upon conversion or exercise of any securities convertible into shares of Company Capital Stock) in such Interim Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Parent Allocation Percentage</b>&#8221; means the quotient (expressed as a percentage and rounded to four decimal places) determined by <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">dividing</i> (i) the Parent Valuation <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">by</i> (ii) the Aggregate Valuation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Parent Net Cash Lower Amount</b>&#8221; means, if Parent Net Cash is less than the Parent Net Cash Lower Target, then the amount, if any, that the Parent Net Cash Target exceeds the Parent Net Cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Parent Net Cash Lower Target</b>&#8221; means $1,725,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Parent Net Cash Target</b>&#8221; means $1,800,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Parent Net Cash Upper Amount</b>&#8221; means, if Parent Net Cash is greater than Parent Net Cash Upper Target, then the amount, if any, that the Parent Net Cash exceeds the Parent Net Cash Target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Parent Net Cash Upper Target</b>&#8221; means $1,875,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Parent Outstanding Shares</b>&#8221; means, without duplication, (including, without limitation, the effects of the Nasdaq Reverse Split, if completed) the total number of shares of Parent Common Stock outstanding immediately prior to the First Effective Time expressed on a fully-diluted basis and as converted to Parent Common Stock basis and assuming, without limitation or duplication, (i) the issuance of shares of Parent Common Stock in respect of all Parent Options, warrants or other rights or commitments to receive shares of Parent Common Stock or Parent Preferred Stock (or securities convertible or exercisable into shares of Parent Common Stock or Parent Preferred Stock, but excluding any Parent Common Stock issuable in accordance with the Parent Financing), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time, and (ii) the settlement in shares of Parent Common Stock of Parent Restricted Stock Units outstanding as of immediately prior to the Effective Time on a net settlement basis as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.6(e)</span>. Notwithstanding any of the foregoing, no Out of the Money Parent Options shall be included in the total number of shares of Parent Common Stock outstanding for purposes of determining the Parent Outstanding Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Parent Valuation</b>&#8221; means the greater of (x)(i) $8,000,000, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</i> (ii) the Parent Net Cash Lower Amount (if any) <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">plus</i> (iii) the Parent Net Cash Upper Amount (if any), and (y)(i) the Parent Valuation Floor, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</i> (ii) the Parent Net Cash Lower Amount (if any) <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">plus</i> (iii) the Parent Net Cash Upper Amount (if any).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Parent Valuation Floor</b>&#8221; means an amount equal to (i) 0.03, multiplied by (ii) the sum of (A) the Company Valuation (as of immediately prior to the Closing), (B) the aggregate Aggregate Purchase Amount (as defined in the Subscription Agreement) of the investors thereunder, and (C) $8,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-family:'Symbol';">&#183;</span>&#160;&#160;&#160;&#160;&#8221;<b style="font-weight:bold;">Post-Closing Parent Shares</b>&#8221; mean the quotient determined by <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">dividing</i> (i) the Parent Outstanding Shares <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">by</i> (ii) the Parent Allocation Percentage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Notes</b>&#8221; means the convertible notes issued by the Company on or around October&#160;24, 2024, including the second tranche contemplated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Options</b>&#8221; means options or other rights to purchase shares of Company Capital Stock issued by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Preferred Stock</b>&#8221; means the shares of the Company&#8217;s capital stock designated as preferred stock, including the Company Series&#160;Seed Preferred Stock.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Registered IP</b>&#8221; means all Company IP Rights that are owned or exclusively licensed by the Company that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all applications and registrations for any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Series&#160;Seed Preferred Stock</b>&#8221; means a series of the Company&#8217;s preferred stock designated as Series&#160;Seed Preferred Stock, $0.0001 par value per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Stock Plans</b>&#8221; means the Company&#8217;s 2024 Equity Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Triggering Event</b>&#8221; shall be deemed to have occurred if, at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company Stockholder Vote: (a)&#160;the Company Board shall have made a Company Board Adverse Recommendation Change; (b)&#160;the Company Board or any committee thereof shall have publicly approved, endorsed or recommended any Acquisition Proposal; or (c)&#160;the Company shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Company Warrants</b>&#8221; means warrants to purchase shares of Company Capital Stock issued by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Confidentiality Agreement</b>&#8221; means the letter agreement dated as of September&#160;17, 2024, between the Company and Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Consent</b>&#8221; means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Contemplated Transactions</b>&#8221; means the Merger and the other transactions contemplated by this Agreement (other than the Parent Charter Amendment), the Parent Financing and the Nasdaq Reverse Split (to the extent applicable and deemed necessary by Parent and the Company).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Contract</b>&#8221; means, with respect to any Person, any written agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound or affected under applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">DGCL</b>&#8221; means the General Corporation Law of the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">DLLCA</b>&#8221; means the Delaware Limited Liability Company Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Effect</b>&#8221; means any effect, change, event, circumstance, or development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Employee Plan</b>&#8221; means (A)&#160;an &#8220;employee benefit plan&#8221; within the meaning of Section&#160;3(3)&#160;of ERISA whether or not subject to ERISA; (B)&#160;other plan, program, policy or arrangement providing for stock options, stock purchases, equity-based compensation, bonuses (including any annual bonuses and retention bonuses) or other incentives, severance pay, deferred compensation, employment, compensation, change in control or transaction bonuses, supplemental, vacation, retirement benefits (including post-retirement health and welfare benefits), pension benefits, profit-sharing benefits, fringe benefits, life insurance benefits, perquisites, health benefits, medical benefits, dental benefits, vision benefits, and all other employee benefit plans, agreements, and arrangements, not described in (A)&#160;above; and (C)&#160;all other plans, programs, policies or arrangements providing compensation to employees, consultants and non-employee directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Encumbrance</b>&#8221; means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, exclusive license, option, easement, reservation, servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction or encumbrance of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Enforceability Exceptions</b>&#8221; means the (a)&#160;Laws of general application relating to bankruptcy, insolvency and the relief of debtors and (b)&#160;rules&#160;of law governing specific performance, injunctive relief and other equitable remedies.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Entity</b>&#8221; means any corporation (including any nonprofit corporation), partnership (including any general partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Environmental Law</b>&#8221; means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any law or regulation relating to emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">ERISA Affiliate</b>&#8221; means, with respect to any Entity, any other Person that would be treated as a single employer with such Entity or part of the same &#8220;controlled group&#8221; as such Entity under Sections 414(b), (c), (m)&#160;or (o)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">ERISA</b>&#8221; means the Employee Retirement Income Security Act of 1974, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Exchange Act</b>&#8221; means the Securities Exchange Act of 1934, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">First Merger Sub Board</b>&#8221; means the board of directors of First Merger Sub.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Governmental Authority</b>&#8221; means any: (a)&#160;nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature, (b)&#160;federal, state, local, municipal, foreign, supra-national or other government, (c)&#160;governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority) or (d)&#160;self-regulatory organization (including Nasdaq).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Governmental Authorization</b>&#8221; means any: (a)&#160;permit, license, certificate, franchise, permission, variance, exception, order, approval, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Authority or pursuant to any Law or (b)&#160;right under any Contract with any Governmental Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Hazardous Materials</b>&#8221; means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and petroleum products or by-products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">HSR Act</b>&#8221; means the U.S. Hart Scott-Rodino Antitrust Improvements Act of 1976, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">In the Money Parent Option</b>&#8221; shall mean Parent Options with an exercise price equal to or less than the Parent Closing Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Intellectual Property</b>&#8221; means: (a)&#160;United States, foreign and international patents, patent applications, including all provisionals, nonprovisionals, substitutions, divisionals, continuations, continuations-in-part, reissues, extensions, supplementary protection certificates, reexaminations, term extensions, certificates of invention and the equivalents of any of the foregoing, statutory invention registrations, invention disclosures and inventions (collectively, &#8220;<b style="font-weight:bold;">Patents</b>&#8221;), (b)&#160;trademarks, service marks, trade names, domain names, corporate names, brand names, URLs, trade dress, logos and other source identifiers, including registrations and applications for registration thereof and goodwill associated therewith, (c)&#160;copyrights, including registrations and applications for registration thereof, (d)&#160;software, including all source code, object code and related documentation, (e)&#160;formulae, customer lists, trade secrets, know-how, confidential information and other proprietary rights and intellectual property, whether patentable or not, and (f)&#160;all United States and foreign rights arising under or associated with any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Interim Financing</b>&#8221; means any sale (or series of related sales) by the Company of its Common Stock or Preferred Stock, as applicable, that is completed following the date hereof; <i style="font-style:italic;">provided, however, </i><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">that the issuance of Company Notes and the Parent Financing shall not be an Interim Financing</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">IRS</b>&#8221; means the United States Internal Revenue Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Knowledge</b>&#8221; means, (i)&#160;with respect to an individual, that such individual is actually aware of the relevant fact or such individual would reasonably be expected to know such fact in the ordinary course of the performance of such individual&#8217;s employment </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">responsibilities, and (ii)&#160;with respect to any Person that is an Entity the Knowledge of any executive officer of such Person as of the date such knowledge is imputed. With respect to any matters relating to Intellectual Property, such awareness or reasonable expectation to have knowledge does not require any such individual to conduct or have conducted or obtain or have obtained any freedom to operate opinions of counsel or any Intellectual Property rights clearance searches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Law</b>&#8221; means any federal, state, national, supra-national, foreign, local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority (including under the authority of Nasdaq or the Financial Industry Regulatory Authority).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Legal Proceeding</b>&#8221; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before any court or other Governmental Authority or any arbitrator or arbitration panel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Minimum Concurrent Investment Amount</b>&#8221; means (i)&#160;$100,000,000 <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</i> (ii)&#160;the amount of proceeds actually received by the Company in connection with any Interim Financing prior to the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Multiemployer Plan</b>&#8221; means a &#8220;multiemployer plan,&#8221; as defined in Section&#160;3(37) or 4001(a)(3)&#160;of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Multiple Employer Plan</b>&#8221; means a &#8220;multiple employer plan&#8221; within the meaning of Section&#160;413(c)&#160;of the Code or Section&#160;3(40) of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Multiple Employer Welfare Arrangement</b>&#8221; means a &#8220;multiple employer welfare arrangement&#8221; within the meaning of Section&#160;3(40) of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Nasdaq Reverse Split</b>&#8221; means a reverse stock split of all outstanding shares of Parent Common Stock effected by Parent for the purpose of maintaining compliance with Nasdaq listing standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Nasdaq</b>&#8221; means The Nasdaq Stock Market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Order</b>&#8221; means any judgment, order, writ, injunction, ruling, decision or decree of (that is binding on a Party), or any plea agreement, corporate integrity agreement, resolution agreement or deferred prosecution agreement with, or any settlement under the jurisdiction of, any court or Governmental Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Ordinary Course of Business</b>&#8221; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its business and consistent with its past practice or, with respect to the Company, the customary practices of a recently formed company at a similar stage of development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Organizational Documents</b>&#8221; means, with respect to any Person (other than an individual), (a)&#160;the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (b)&#160;all bylaws, regulations and similar documents or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Out of the Money Parent Options</b>&#8221; shall mean Parent Options with an exercise price greater than the Parent Closing Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Associate</b>&#8221; means any current employee, independent contractor, officer or director of Parent or any of its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Balance Sheet</b>&#8221; means the audited balance sheet of Parent as of December&#160;31, 2023, included in Parent&#8217;s Report on Form&#160;10-K for the year ended December&#160;31, 2023, as filed with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Board</b>&#8221; means the board of directors of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Capital Stock</b>&#8221; means the Parent Common Stock and the Parent Preferred Stock.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Capitalization Representations</b>&#8221; means the representations and warranties of Parent and Merger Subs set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections &#8206;4.6(a)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.6(d)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Closing Price</b>&#8221; means the volume weighted average closing trading price of a share of Parent Common Stock on Nasdaq for the five (5)&#160;consecutive trading days ending three (3)&#160;trading days immediately prior to the Closing Date as reported by Bloomberg L.P.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Common Stock</b>&#8221; means the common stock, $0.001 par value per share, of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Contract</b>&#8221; means any Contract: (a)&#160;to which Parent is a party, (b)&#160;by which Parent or any Parent IP Rights or any other asset of Parent is or may become bound or under which Parent has, or may become subject to, any obligation or (c)&#160;under which Parent has or may acquire any right or interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Convertible Preferred Stock</b>&#8221; means Parent&#8217;s non-voting convertible preferred stock, par value $0.001 per share, with the rights, preferences, powers and privileges specified in the Certificate of Designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Employee Plan</b>&#8221; means any Employee Plan that Parent or any of its Subsidiaries (i)&#160;sponsors, maintains, administers, or contributes to, (ii)&#160;may reasonably be expected to have any Liability, or (iii)&#160;utilizes to provide benefits to or otherwise cover any current or former employee, officer, director or other service provider of Parent or any of its Subsidiaries (or their spouses, dependents, or beneficiaries), but excluding any Employee Plan in which the Parent or any of its Subsidiaries participates that is sponsored by any professional employer organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Fundamental Representations</b>&#8221; means the representations and warranties of Parent and Merger Subs set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections&#160;&#8206;4.1(a)</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.2</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.3</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.4</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.5(a)(i)</span>&#160;and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.21</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent IP Rights Agreement</b>&#8221; means any Contract governing, related or pertaining to any Parent IP Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent IP Rights</b>&#8221; means all Intellectual Property owned, licensed or controlled by Parent that is necessary for, or used or held for use in, the operation of the business of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Key Employee</b>&#8221; means (i)&#160;an executive officer of Parent; and (ii)&#160;any employee of Parent that reports directly to the Parent Board or to an executive officer of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Parent Material Adverse Effect</b>&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of the Parent Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of Parent and its Subsidiaries, taken as a whole; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Parent Material Adverse Effect: (a)&#160;the announcement of this Agreement or the pendency of the Contemplated Transactions, (b)&#160;any change in the stock price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Parent Common Stock may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (c)&#160;the taking of any action, or the failure to take any action, by Parent that is required to comply with the terms of this Agreement, (d)&#160;any natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world, or any governmental or other response or reaction to any of the foregoing, (e)&#160;any change in GAAP or applicable Law or the interpretation thereof, (f)&#160;general economic or political conditions or conditions generally affecting the industries in which Parent or any of its Subsidiaries operates, (g)&#160;failure to achieve or maintain any minimum level of Parent Net Cash, (h)&#160;any determination by the SEC regarding Parent&#8217;s reporting status under the Exchange Act, or (i)&#160;any results, outcomes, data, indications, adverse events, side effects or safety observations arising from preclinical trials, clinical trials and/or testing relating to Parent&#8217;s Uproleselan (GMI-1271) program, including any requirement to conduct further clinical studies or tests or any increased incidence or severity of any previously identified side effects, adverse effects, adverse events or safety observations or reports of any new side effects, adverse events or safety observations (or any public announcements relating to any of the foregoing); except, in each case with respect to clauses (d), (e)&#160;and (f), to the extent materially and disproportionately affecting Parent or any of its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Parent or any of its Subsidiaries operates. Notwithstanding the above, a delisting of Parent Common Stock on Nasdaq shall constitute a Parent Material Adverse Effect, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">provided that the Company has not refused or unreasonably delayed its consent to reasonable actions by Parent to maintain the listing of Parent Common Stock on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Net Cash</b>&#8221; means without duplication, (i)&#160;Parent&#8217;s unrestricted cash and cash equivalents and marketable securities determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">plus</i> (ii)&#160;all prepaid expenses set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1(a)</span>&#160;of the Parent Disclosure Letter, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</i> (iii)&#160;the sum of Parent&#8217;s consolidated short-term and long-term contractual obligations and liabilities accrued at the Closing Date, in each case determined in accordance with GAAP and, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</i> (iv)&#160;the aggregate amount (without duplication) of all fees and expenses incurred by Parent prior to the First Effective Time in connection with the Contemplated Transactions, excluding any Parent Net Cash Excluded Expenses but including (to the extent not a Parent Net Cash Excluded Expense): (a)&#160;any fees and expenses of legal counsel, accountants, financial advisors, investment bankers, brokers, consultants, tax advisors, and other professional advisors of Parent in connection with the Contemplated Transactions; (b)&#160;50% of the fees paid to the SEC in connection with filing the Proxy Statement and any amendments and supplements thereto, with the SEC; (c)&#160;50% of the fees and expenses in connection with the printing, mailing and distribution of the Proxy Statement and any amendments and supplements thereto; (d)&#160;50% of the Nasdaq Fees; (e)&#160;any bonus, retention payments, severance, change-in-control payments or similar payment obligations (including payments with &#8220;single-trigger&#8221; provisions triggered at and as of the consummation of the transactions contemplated hereby) that become due or payable to any director, officer, employee or consultant in connection with the consummation of the Contemplated Transactions, together with any payroll Taxes associated therewith; (f)&#160;the costs associated with obtaining the &#8220;D&amp;O tail policy&#8221; pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;6.7,</span> in each case, to the extent unpaid as of the First Effective Time; and (g)&#160;for the avoidance of doubt, the amount by which the actual amount of any Parent Net Cash Excluded Expense at Closing exceeds the estimate set forth on Schedule 1.1(b)&#160;of the Parent Disclosure Letter, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</i> (v)&#160;all remaining rent payments and any other Liabilities under Parent&#8217;s lease obligations, <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">minus</i> (vi)&#160;any unpaid Taxes of Parent and its Subsidiaries for Tax periods (or portions thereof) ending on or before the Closing Date, and <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">plus</i> (vii)&#160;$300,000 for each month, or portion thereof, after June&#160;30, 2025 by which Closing is delayed (except where such delay is caused primarily by the actions of Parent), which amount shall begin accruing on July&#160;1, 2025 (for example, if the Closing is delayed until (A)&#160;July&#160;31, 2025 as a result of such failure then $300,000 will be added to Parent Net Cash or (B)&#160;August&#160;30, 2025 as a result of such failure then $600,000 will be added to Parent Net Cash); <i style="font-style:italic;">provided, however,</i> that if any portion of the fees and expenses described in subclauses (b), (c), and (d)&#160;of clause (iv)&#160;have been paid by Parent prior to the First Effective Time in an amount greater than Parent&#8217;s share of such fee and expense described in subclauses (b), (c), and (d), then (x)&#160;such portion in excess of Parent&#8217;s shares of such fee and expense described in subclauses (b), (c), and (d)&#160;shall not be deducted by reason of subclauses (b), (c), and (d)&#160;of clause (v)&#160;and (y)&#160;such portion shall be added to the calculation of Parent Net Cash. For avoidance of doubt, (i)&#160;the cash received in the Parent Financing will be excluded from the calculation of Parent Net Cash and (ii)&#160;the calculation of Parent Net Cash may result in a number below $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Net Cash Excluded Expenses</b>&#8221; means those fees and expenses incurred by Parent prior to the First Effective Time in connection with the Contemplated Transactions set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1(b)</span>&#160;of the Parent Disclosure Letter, which schedule shall include a description and good faith estimate of such Parent Net Cash Excluded Expense as of immediately before the Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Options</b>&#8221; means options or other rights to purchase shares of Parent Common Stock granted by Parent, including pursuant to any Parent Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Preferred Stock</b>&#8221; means the shares of Parent&#8217;s capital stock designated as preferred stock, par value $0.001 per share of Parent, including the Parent Convertible Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Registered IP</b>&#8221; means all Parent IP Rights that are owned or exclusively licensed by Parent that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all applications for any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Parent Restricted Stock Units</b>&#8221; means any equity award with respect to Parent Common Stock that represents the right to receive in the future shares of Parent Common Stock pursuant to any Parent Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Parent Triggering Event</b>&#8221; shall be deemed to have occurred if, prior to the approval of this Agreement and the Contemplated Transactions by Parent&#8217;s stockholders and subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;6.3(c)</span>: (a)&#160;Parent shall have failed to include in the Proxy Statement the Parent Board Recommendation, (b)&#160;the Parent Board or any committee thereof shall have made a Parent Board Adverse </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Recommendation Change or subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;6.3(e)</span>, publicly proposed, endorsed or recommended any Acquisition Proposal or (c)&#160;Parent shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement permitted pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;5.4</span>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Party</b>&#8221; or &#8220;<b style="font-weight:bold;">Parties</b>&#8221; means the Company, Merger Subs and Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Permitted Alternative Agreement</b>&#8221; means a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that constitutes a Superior Offer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Permitted Encumbrance</b>&#8221; means (a)&#160;any statutory liens for current Taxes not yet due and payable or for Taxes that are being contested in good faith by the appropriate proceedings and for which adequate reserves will be or have been made on the Company Financial Statements or the Parent Balance Sheet, as applicable, in accordance with GAAP, (b)&#160;minor non-monetary liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the assets subject thereto or materially impair the operations of the Company or Parent, as applicable, (c)&#160;statutory liens to secure obligations to landlords, lessors or renters under leases or rental agreements, (d)&#160;deposits or pledges made in connection with, or to secure payment of, workers&#8217; compensation, unemployment insurance or similar programs mandated by Law, (e)&#160;statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies for amounts that are not yet due and payable and (f)&#160;liens arising under applicable securities Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Person</b>&#8221; means any individual, Entity or Governmental Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Personal Information</b>&#8221; means any data or information that constitutes &#8220;personal information,&#8221; &#8220;personal data,&#8221; &#8220;personally identifiable information,&#8221; &#8220;protected health information,&#8221; or any analogous term under applicable Law, including any such information that identifies, relates to, describes, is linked to, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with any identified or identifiable individual or household.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Privacy Laws</b>&#8221; mean, collectively, (i)&#160;all Laws governing privacy, data protection, data security, trans-border data flow, data loss, data theft, breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of Personal Information, including any such legally binding requirements set forth in regulations and agreements containing consent orders published by regulatory authorities of competent jurisdiction such as the U.S. Federal Trade Commission, U.S. Federal Communications Commission, or state data protection authorities, including HIPAA, Section&#160;5 of the Federal Trade Commission Act, the Controlling the Assault of Non-Solicited Pornography And Marketing Act, the Telephone Consumer Protection Act and U.S. state consumer protection and data breach notification Laws, and (ii)&#160;any legally binding requirements of any self-regulatory organizations governing data privacy, data protection, data security, trans-border data flow, data loss, data theft, breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of Personal Information, including the Payment Card Industry Data Security Standard.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Representatives</b>&#8221; means with respect to a Person, such Person&#8217;s directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and other representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Sarbanes-Oxley Act</b>&#8221; means the Sarbanes-Oxley Act of 2002.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">SEC</b>&#8221; means the United States Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Securities Act</b>&#8221; means the Securities Act of 1933, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Subsequent Transaction</b>&#8221; means any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;<b style="font-weight:bold;">Subsidiary</b>&#8221; means, with respect to an Entity, a Person if such Person directly or indirectly owns or purports to own, beneficially or of record, (a)&#160;an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such entity&#8217;s board of directors or other governing body or (b)&#160;at least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">&#8220;<b style="font-weight:bold;">Superior Offer</b>&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that: (a)&#160;was not obtained or made as a direct or indirect result of a breach of this Agreement, (b)&#160;is on terms and conditions that the Parent Board or the Company Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other Party to this Agreement to amend the terms of this Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to Parent&#8217;s stockholders or the Company&#8217;s stockholders, as applicable, than the terms of the Contemplated Transactions, (c)&#160;is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party) and (d)&#160;is reasonably capable of being completed on the terms proposed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">&#8220;<b style="font-weight:bold;">Tax Return</b>&#8221; means any return (including any information return), report, statement, declaration, claim or refund, estimate, schedule, notice, notification, form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing, filed or required to be filed with any Governmental Authority (or provided to a payee) in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">&#8220;<b style="font-weight:bold;">Tax</b>&#8221; means any U.S. federal, state, local, foreign or other tax, including any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax, estimated tax, employment tax, unemployment tax, national health insurance tax, environmental tax, excise tax, ad valorem tax, transfer tax, conveyance tax, stamp tax, sales tax, use tax, property tax, business tax, withholding tax, payroll tax, social security tax, customs duty, licenses tax, alternative or add-on minimum or other tax or similar charge, duty, levy, fee, tariff, impost, obligation or assessment in the nature of a tax (whether imposed directly or through withholding and whether or not disputed), and including any fine, penalty, addition to tax, interest or additional amount imposed by a Governmental Authority with respect thereto (or attributable to the nonpayment thereof).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">&#8220;<b style="font-weight:bold;">Treasury Regulations</b>&#8221; means the United States Treasury regulations promulgated under the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">(b)&#160;Each of the following terms is defined in the Section&#160;set forth opposite such term:</p><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:48.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Terms</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:49.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Section</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:48.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:49.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AAA</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.8(i)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounting Firm</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.8(i)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agreement</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Allocation Certificate</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.15</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assumed Option</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.5(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assumed Warrant</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.5(b)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capitalization Date</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;4.6(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash Determination Time</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.8(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certificate of Merger</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.3</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certifications</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;4.7(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Closing Date</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.3</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Closing</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.3</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company 409A Plan</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.17(j)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Board Adverse Recommendation Change</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.2(d)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Board Recommendation</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.2(c)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Disclosure Letter</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;3</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Financial Statements</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.1(d)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Intervening Event</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.2(d)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Material Contract</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.13(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Material Contracts</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.13(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Permits</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.14(b)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Product Candidates</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.14(d)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Real Estate Leases</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.11</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Regulatory Permits</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.14(d)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Required S-4 Information</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.1(c)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Stockholder Support Agreement</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recital</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Stockholder Written Consents</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.2(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Termination Fee</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;10.3(b)</p></td></tr></table></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:48.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Terms</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:49.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Section</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:48.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:49.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Valuation Calculation</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.8(b)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Valuation Delivery Date</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.8(b)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Valuation Determination Time</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.8(b)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Valuation Dispute Notice</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.8(d)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Valuation Response Date</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.8(d)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company Valuation Schedule</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.8(b)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Concurrent Investment</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.7(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">D&amp;O Indemnified Parties</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.7(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dispute Notice</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.8(c)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dissenting Shares</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.12(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Drug/Device Regulatory Agency</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.14(b)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employment-Related Laws</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.17(k)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">End Date</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;10.1(b)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exchange Agent</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.7(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDA</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.14(b)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDCA</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.14(c)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">First Certificate of Merger</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.3</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">First Effective Time</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.3</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">First Merger</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recital</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">First Step Surviving Corporation</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;Section&#160;2</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Form&#160;S-4</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.1(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GAAP</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intended Tax Treatment</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.10</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liability</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.9</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lock-Up Agreement</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recital</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lock-Up Agreements</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recital</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Merger Consideration</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.5(a)(ii)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Merger Subs</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Merger</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recital</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nasdaq Fees</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.9</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nasdaq Listing Application</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.9</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notice Period</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.2(d)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ordinary Course Agreement</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.16(g)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent 409A Plan</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;4.17(j)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Board Adverse Recommendation Change</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.3(c)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Board Recommendation</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.3(b)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Charter Amendment</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.4(b)(ii)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Disclosure Letter</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Section&#160;4</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Intervening Event</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.3(c)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Material Contract</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;4.13(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Material Contracts</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;4.13(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Net Cash Calculation</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.8(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Net Cash Schedule</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.8(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Notice Period</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.3(c)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Permits</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;4.14(b)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Product Candidates</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;4.14(d)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Real Estate Leases</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;4.11</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Regulatory Permits</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;4.14(d)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent SEC Documents</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;4.7(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Stock Plans</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;4.6(c)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Stockholder Matters</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.3(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Parent Stockholder Meeting</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.3(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent Stockholder Support Agreement</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recital</p></td></tr></table></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="padding-left:18pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:48.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Terms</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:49.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Section</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:48.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:49.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parent</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PHSA</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.14(c)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Post-Closing Welfare Plan</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.6(b)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-Closing Period</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;5.1(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Privacy Policies</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.22</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proxy Statement</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.1(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Registration Statement</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.1(a)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Required Company Stockholder Vote</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.4</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Required Parent Stockholder Vote</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;4.4</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Response Date</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.8(c)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SEC Documents</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.16</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second Certificate of Merger</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.3</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second Effective Time</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;2.3</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second Merger</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recital</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholder Notice</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.2(b)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subscription Agreement</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recital</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Surviving Entity</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;Section&#160;2</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Certificates</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.10(c)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transaction Litigation</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;6.4(c)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:48.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">WARN Act</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8206;3.17(k)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="OtherDefinitionalandInterpretativeProvis"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;">1.2&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Definitional and Interpretative Provisions</span>. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections, Exhibits and Schedules are to Sections, Exhibits and Schedules of this Agreement unless otherwise specified. Any capitalized terms used in any Exhibit&#160;or Schedule but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract (except for references to any agreements or Contracts listed on the Parent Disclosure Letter or Company Disclosure Letter) are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. The Exhibits to this Agreement, the Parent Disclosure Letter and the Company Disclosure Letter are integral parts of the interpretation of this Agreement, but only Exhibit&#160;D-1 (including Exhibit&#160;A to such Exhibit) and Exhibit&#160;D-2 is incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules&#160;and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule&#160;of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement. The Parties agree that the Company Disclosure Letter or Parent Disclosure Letter shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</span>, respectively. The disclosures in any section or subsection of the Company Disclosure Letter or the Parent Disclosure Letter shall qualify other sections and subsections in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</span>, respectively, to the extent it is readily apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections. The words &#8220;delivered&#8221; or &#8220;made available&#8221; mean, with respect to any documentation, that prior to 5:00 p.m.&#160;(New York City time) on the date that is the day prior to the date of this Agreement, a copy of such material has been (a)&#160;posted to and continuously made available by a Party to the other Party and its Representatives in the electronic data room maintained by such disclosing Party for the purposes of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Contemplated Transactions or (b)&#160;delivered by or on behalf of a Party or its Representatives to the other Party or its Representatives via electronic mail or in hard copy form prior to the execution of this Agreement.</p><a id="Section2DescriptionofTransaction_963665"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;2. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description of Transaction</span>.</p><a id="TheMerger_243643"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">2.1&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Merger</span>. Upon the terms and subject to the conditions set forth in this Agreement, at the First Effective Time, First Merger Sub shall be merged with and into the Company, and the separate existence of First Merger Sub shall cease. The Company will continue as the surviving corporation in the First Merger (the &#8220;<b style="font-weight:bold;">First Step Surviving Corporation</b>&#8221;). Upon the terms and subject to the conditions set forth in this Agreement, at the Second Effective Time, the First Step Surviving Corporation will merge with and into Second Merger Sub, and the separate existence of the First Step Surviving Corporation shall cease. As a result of the Second Merger, Second Merger Sub will continue as the surviving entity in the Second Merger (the &#8220;<b style="font-weight:bold;">Surviving Entity</b>&#8221;).</p><a id="EffectsoftheMerger_989764"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">2.2&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effects of the Merger</span>. The First Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL. As a result of the First Merger, the Company will become a wholly owned subsidiary of Parent. The Second Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL and the DLLCA.</p><a id="ClosingFirstEffectiveTimeSecondEffective"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">2.3&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing; First Effective Time; Second Effective Time</span>. Unless this Agreement is earlier terminated pursuant to the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;Section&#160;10</span>, and subject to the satisfaction or waiver of the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9</span>, the consummation of the Merger (the &#8220;<b style="font-weight:bold;">Closing</b>&#8221;) shall take place remotely, as promptly as practicable (but in no event later than the second Business Day following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;6.19</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9</span>, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions), or at such other time, date and place as Parent and the Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the &#8220;<b style="font-weight:bold;">Closing Date</b>.&#8221; Immediately prior to the Closing on the Closing Date, Parent shall file the Certificate of Designation with the office of the Secretary of State of the State of Delaware. At the Closing, (i)&#160;the Parties shall cause the First Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Merger, satisfying the applicable requirements of the DGCL and in form and substance attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;D-1</span> and incorporated herein by reference (the &#8220;<b style="font-weight:bold;">First Certificate of Merger</b>&#8221;) and (ii)&#160;the Parties shall cause the Second Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Second Merger, satisfying the applicable requirements of the DGCL and the DLLCA and in form and substance attached hereto as <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;D-2</span> and incorporated herein by reference (the &#8220;<b style="font-weight:bold;">Second Certificate of Merger</b>&#8221; and together with the First Certificate of Merger, the &#8220;<b style="font-weight:bold;">Certificate of Merger</b>&#8221;). The First Merger shall become effective at the time of the filing of such Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Certificate of Merger with the consent of Parent and the Company (the time as of which the Merger becomes effective being referred to as the &#8220;<b style="font-weight:bold;">First Effective Time</b>&#8221;). The Second Merger shall become effective at the time of the filing of such Second Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Second Certificate of Merger with the consent of Parent and the Company (the time as of which the Second Merger becomes effective being referred to as the &#8220;<b style="font-weight:bold;">Second Effective Time</b>&#8221;).</p><a id="OrganizationalDocumentsDirectorsandOffic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">2.4&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organizational Documents; Directors and Officers</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 79.2pt;">(a)&#160;&#160;&#160;&#160;At the First Effective Time:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(i)&#160;&#160;&#160;&#160;The certificate of incorporation of the First Step Surviving Corporation shall be amended and restated in the Merger to read as set forth on Exhibit&#160;A to the First Certificate of Merger, until thereafter amended as provided by the DGCL and such certificate of incorporation;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ii)&#160;&#160;&#160;&#160;The bylaws of the First Step Surviving Corporation shall be identical to the bylaws of the Company as in effect immediately prior to the First Effective Time, until thereafter amended as provided by the DGCL and such bylaws; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iii)&#160;&#160;&#160;&#160;The directors and officers of the First Step Surviving Corporation, each to hold office in accordance with the certificate of incorporation and bylaws of the First Step Surviving Corporation, shall be such persons as are designated by the Company prior to the First Effective Time.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 79.2pt;">(b)&#160;&#160;&#160;&#160;At the Second Effective Time:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(i)&#160;&#160;&#160;&#160;The certificate of formation of the Surviving Entity shall be the certificate of formation of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such certificate of formation; provided, however, that at the Second Effective Time (as part of the Second Certificate of Merger), the certificate of formation shall be amended to (A)&#160;change the name of the Surviving Entity to &#8220;Crescent Biopharma Operating Company, LLC,&#8221; and (B)&#160;make such other changes as are mutually agreed to by Parent and the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;The limited liability company agreement of the Surviving Entity shall be amended and restated in its entirety to read identically to the limited liability company agreement of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such limited liability company agreement; provided, however, that following the Second Effective Time (but as soon thereafter as practicable), the limited liability company agreement shall be amended to change the name of the Surviving Entity to &#8220;Crescent Biopharma Operating Company, LLC&#8221;;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iii)&#160;&#160;&#160;&#160;The certificate of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately prior to the Second Effective Time, until thereafter amended as provided by the DGCL and such certificate of incorporation; provided, however, that at the Second Effective Time, Parent shall file an amendment to its certificate of incorporation to (i)&#160;change the name of Parent to &#8220;Crescent Biopharma,&#160;Inc.&#8221;, (ii)&#160;effect the Nasdaq Reverse Split (to the extent applicable and necessary), (iii)&#160;increase the number of shares of Parent Capital Stock that Parent is authorized to issue to a number mutually agreed between Parent and the Company, such amount to be sufficient to allow for consummation of the Contemplated Transactions, (iv)&#160;redomicile Parent from Delaware to such jurisdiction as may be determined by the Company (being either the Cayman Islands or Bermuda), and (v)&#160;make such other changes as are mutually agreeable to Parent and the Company (such amendment, the &#8220;<b style="font-weight:bold;">Parent Charter Amendment</b>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iv)&#160;&#160;&#160;&#160;The directors and officers of Parent, each to hold office in accordance with the certificate of incorporation and bylaws of Parent, shall be as set forth in Section&#160;&#8206;6.12; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(v)&#160;&#160;&#160;&#160;&#160;The directors and officers of Surviving Entity, each to hold office in accordance with the certificate of formation and limited liability company agreement of Second Merger Sub, shall be as set forth in&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.12</span>&#160;after giving effect to the provisions of&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.12</span>, or such other persons as shall be mutually agreed upon by Parent and the Company.</p><a id="ConversionofCompanyFirstMergerSubandSeco"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">2.5&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conversion of Company, First Merger Sub and Second Merger Sub Equity Securities</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;At the First Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Subs, the Company or any stockholder of the Company or Parent:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(i)&#160;&#160;&#160;&#160;any shares of Company Capital Stock held as treasury stock immediately prior to the First Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.5(c)</span>, (A)&#160;each share of Company Common Stock outstanding immediately prior to the First Effective Time (excluding shares of Company Capital Stock to be canceled pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.5(a)(i)</span>&#160;and excluding Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio, and (B)&#160;each share of Company Preferred Stock outstanding immediately prior to the First Effective Time (excluding shares of Company Capital Stock to be canceled pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.5(a)(i)</span>&#160;and excluding Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Convertible Preferred Stock equal to (x)&#160;the Exchange Ratio <i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">divided by</i> (y)&#160;1,000 (collectively, the &#8220;<b style="font-weight:bold;">Merger Consideration</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(b)&#160;&#160;&#160;&#160;If any shares of Company Capital Stock outstanding immediately prior to the First Effective Time are unvested or are subject to a repurchase option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company, then the shares of Parent Capital Stock issued in exchange for such shares of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Company Capital Stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Parent Capital Stock shall accordingly be marked with appropriate legends. The Company shall take all actions that may be necessary to ensure that, from and after the First Effective Time, Parent is entitled to exercise any such repurchase option or other right set forth in any such restricted stock purchase agreement or other agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;No fractional shares of Parent Capital Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. Any holder of Company Common Stock who would otherwise be entitled to receive a fraction of a share of Parent Common Stock (on a per certificate basis) shall receive from Parent, in lieu of such fractional share and upon surrender by such holder of a letter of transmittal in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.7</span> and any accompanying documents as required therein: (i)&#160;one share of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Common Stock would otherwise be entitled to is equal to or exceeds 0.50; or (ii)&#160;no shares of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Common Stock would otherwise be entitled to is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of Parent Preferred Stock that a holder of Company Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Parent Preferred Stock issuable to such and any remaining fractional shares shall be, in lieu of such fractional share and upon surrender by such holder of a letter of transmittal in accordance with Section&#160;&#8206;2.7 and any accompanying documents as required therein, rounded up to the nearest whole share of Parent Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;All Company Options (including any Service Provider Grants) outstanding immediately prior to the First Effective Time shall be treated in accordance with Section&#160;&#8206;6.5(a). All Company Warrants outstanding immediately prior to the First Effective Time shall be treated in accordance with&#160;Section&#160;&#8206;6.5(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;Each share of common stock, $0.001 par value per share, of First Merger Sub issued and outstanding immediately prior to the First Effective Time shall be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.001 par value per share, of the First Step Surviving Corporation. Each book entry share of First Merger Sub evidencing ownership of any such shares shall, as of the First Effective Time, evidence ownership of such shares of common stock of the First Step Surviving Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(f)&#160;&#160;&#160;&#160;If, between the date of this Agreement and the First Effective Time, the outstanding Company Capital Stock or Parent Capital Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split (including the Nasdaq Reverse Split to the extent such split has not previously been taken into account in calculating the Exchange Ratio), combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders of Company Capital Stock, Company Options, Company Warrants and Parent Capital Stock with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares or other like change; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Capital Stock or Parent Capital Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(g)&#160;&#160;&#160;&#160;At the Second Effective Time, by virtue of the Second Merger and without any action on the part of Parent, the First Step Surviving Corporation, Second Merger Sub or their respective stockholders, each share of the First Step Surviving Corporation issued and outstanding immediately prior to the Second Effective Time shall be canceled and extinguished without any conversion thereof and no payment or distribution shall be made with respect thereto.</p><a id="ClosingoftheCompanysTransferBooks_267533"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">2.6&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing of the Company&#8217;s Transfer Books</span>. At the First Effective Time: (a)&#160;all Company Capital Stock outstanding immediately prior to the First Effective Time shall be treated in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;2.5(a)</span>, and all holders of certificates representing Company Capital Stock that were outstanding immediately prior to the First Effective Time shall cease to have any rights as stockholders of the Company and (b)&#160;the stock transfer books of the Company shall be closed with respect to all </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Company Capital Stock outstanding immediately prior to the First Effective Time. No further transfer of any such Company Capital Stock shall be made on such stock transfer books after the First Effective Time.</p><a id="SurrenderofCompanyCapitalStock_998909"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">2.7&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surrender of Company Capital Stock</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;On or prior to the Closing Date, Parent and the Company shall jointly select a reputable bank, transfer agent or trust company to act as exchange agent in the Merger (the &#8220;<b style="font-weight:bold;">Exchange Agent</b>&#8221;). At the First Effective Time, Parent shall deposit with the Exchange Agent evidence of book-entry shares representing the shares of Parent Capital Stock issuable pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.5(a)</span>&#160;in exchange for Company Capital Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;Promptly after the First Effective Time, the Parties shall cause the Exchange Agent to mail to the Persons who were record holders of shares of Company Capital Stock that were converted into the right to receive the Merger Consideration: (i)&#160;a letter of transmittal in customary form and containing such provisions as Parent may reasonably specify (including a provision confirming that delivery of physical stock certificates representing shares of Company Capital Stock, (the &#8220;<b style="font-weight:bold;">Company Stock Certificates</b>&#8221;) shall be effected, and risk of loss and title shall pass, only upon delivery of such Company Stock Certificates to the Exchange Agent) and (ii)&#160;instructions for effecting the surrender of Company Stock Certificates, or uncertificated shares of Company Capital Stock, in exchange for book-entry shares of Parent Capital Stock. Upon surrender of a Company Stock Certificate or other reasonable evidence of the ownership of uncertificated Company Capital Stock to the Exchange Agent for exchange, together with a duly executed letter of transmittal and such other documents as may be reasonably required by the Exchange Agent or Parent: (A)&#160;the holder of such Company Stock Certificate or uncertificated shares of Company Capital Stock shall be entitled to receive in exchange therefor book-entry shares representing the Merger Consideration (in a number of whole shares of Parent Capital Stock) that such holder has the right to receive pursuant to the provisions of Section&#160;&#8206;2.5(a)&#160;and Section&#160;&#8206;2.5(c)&#160;and (B)&#160;the Company Stock Certificate or uncertificated shares of Company Capital Stock so surrendered shall be canceled. Until surrendered as contemplated by this Section&#160;&#8206;2.7(b), each Company Stock Certificate or uncertificated shares of Company Capital Stock shall be deemed, from and after the First Effective Time, to represent only the right to receive book-entry shares of Parent Capital Stock representing the Merger Consideration. If any Company Stock Certificate shall have been lost, stolen or destroyed, Parent may, in its discretion and as a condition precedent to the delivery of any shares of Parent Capital Stock, require the owner of such lost, stolen or destroyed Company Stock Certificate to provide an applicable affidavit with respect to such Company Stock Certificate and post a bond indemnifying Parent against any claim suffered by Parent related to the lost, stolen or destroyed Company Stock Certificate or any Parent Capital Stock issued in exchange therefor as Parent may reasonably request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;No dividends or other distributions declared or made with respect to Parent Capital Stock with a record date after the First Effective Time shall be paid to the holder of any unsurrendered Company Stock Certificate with respect to the shares of Parent Capital Stock that such holder has the right to receive in the Merger until such holder surrenders such Company Stock Certificate or uncertificated shares of Company Capital Stock or provides an affidavit of loss or destruction in lieu thereof in accordance with this Section&#160;&#8206;2.7 (at which time such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar Laws, to receive all such dividends and distributions, without interest).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;Any shares of Parent Capital Stock deposited with the Exchange Agent that remain undistributed to holders of Company Stock Certificates as of the date that is 180 days after the Closing Date shall be delivered to Parent upon demand, and any holders of Company Stock Certificates who have not theretofore surrendered their Company Stock Certificates or uncertificated shares of Company Capital Stock in accordance with this Section&#160;&#8206;2.7 shall thereafter look only to Parent for satisfaction of their claims for Parent Capital Stock and any dividends or distributions with respect to shares of Parent Capital Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;No Person shall be liable to any holder of any Company Stock Certificate or uncertificated shares of Company Capital Stock or to any other Person with respect to any shares of Parent Capital Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to any applicable abandoned property Law, escheat Law or similar Law.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="CalculationofNetCashandCompanyValuation_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">2.8&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Calculation of Net Cash and Company Valuation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;No later than five (5)&#160;Business Days before the Closing, Parent will deliver to the Company a schedule (the &#8220;<b style="font-weight:bold;">Parent Net Cash Schedule</b>&#8221;) setting forth, in reasonable detail, Parent&#8217;s good faith, estimated calculation of the components of Parent Net Cash, including any Parent Net Cash Lower Amount or Parent Net Cash Upper Amount (the &#8220;<b style="font-weight:bold;">Parent Net Cash Calculation</b>&#8221;) as of 11:59 p.m.&#160;on the Business Day prior to the Anticipated Closing Date (the &#8220;<b style="font-weight:bold;">Cash Determination Time</b>&#8221;) prepared and certified by Parent&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for Parent). Parent shall make available to the Company (electronically to the greatest extent possible) as reasonably requested by the Company, the work papers and back-up materials used or useful in preparing the Parent Net Cash Schedule and, if reasonably requested by the Company, Parent&#8217;s internal finance personnel and its accountants and counsel at reasonable times and upon reasonable notice. The Parent Net Cash Calculation shall include Parent&#8217;s determination, as of the Cash Determination Time, of the defined terms in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.1(a)</span>&#160;necessary to calculate the Exchange Ratio. During the period after the delivery of the Parent Net Cash Schedule and prior to the Closing, the Company shall have an opportunity to review the Parent Net Cash Schedule and Parent shall reasonably cooperate with the Company in good faith to respond to any questions regarding the Parent Net Cash Schedule raised by the Company; provided, that this shall in no way limit or otherwise affect the Company&#8217;s remedies under this Agreement or otherwise, or constitute an acknowledgement by the Company of the accuracy of the amounts reflected therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;No later than five (5)&#160;Business Days before the Closing, the Company will deliver to Parent a schedule (the &#8220;<b style="font-weight:bold;">Company Valuation Schedule</b>&#8221;) setting forth, in reasonable detail, the Company&#8217;s good faith, estimated calculations of the components of the Company Valuation (the &#8220;<b style="font-weight:bold;">Company Valuation Calculation</b>&#8221;) and the date of delivery of such schedule being (the &#8220;<b style="font-weight:bold;">Company Valuation Delivery Date</b>&#8221;) as of 11:59 p.m.&#160;on the last Business Day prior to the Anticipated Closing Date (the &#8220;<b style="font-weight:bold;">Company Valuation Determination Time</b>&#8221;) prepared and certified by the Company&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for the Company). The Company shall make available to Parent, as reasonably requested by Parent, the work papers and back-up materials used or useful in preparing the Company Valuation Schedule and, if reasonably requested by Parent, the Company&#8217;s accountants and counsel at reasonable times and upon reasonable notice. During the period after the delivery of the Company Valuation Schedule and prior to the Closing, Parent shall have an opportunity to review the Company Valuation Schedule and the Company shall reasonably cooperate with Parent in good faith to respond to any questions regarding the Company Valuation Schedule raised by Parent; provided, that this shall in no way limit or otherwise affect the Parent&#8217;s remedies under this Agreement or otherwise, or constitute an acknowledgement by Parent of the accuracy of the amounts reflected therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;No later than three (3)&#160;Business Days after the Cash Determination Time (the last day of such period, the &#8220;<b style="font-weight:bold;">Response Date</b>&#8221;), the Company shall have the right to dispute any part of the Parent Net Cash Calculation by delivering a written notice to that effect to Parent (a &#8220;<b style="font-weight:bold;">Dispute Notice</b>&#8221;). Any Dispute Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Parent Net Cash Calculation and will be accompanied by reasonably detailed materials supporting the basis for such revisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;No later than three (3)&#160;Business Days after the Company Valuation Delivery Date (the last day of such period, the &#8220;<b style="font-weight:bold;">Company Valuation Response Date</b>&#8221;), Parent shall have the right to dispute any part of the Company Valuation Calculation by delivering a written notice to that effect to the Company (a &#8220;<b style="font-weight:bold;">Company Valuation Dispute Notice</b>&#8221;). Any Company Valuation Dispute Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Company Valuation Calculation and will be accompanied by reasonably detailed materials supporting the basis for such revisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;If, on or prior to the Response Date, the Company notifies Parent in writing that it has no objections to the Parent Net Cash Calculation or, if on the Response Date, the Company fails to deliver a Dispute Notice as provided in Section&#160;&#8206;2.8(c), then the Parent Net Cash Calculation as set forth in the Parent Net Cash Schedule shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(f)&#160;&#160;&#160;&#160;If, on or prior to the Company Valuation Response Date, Parent notifies the Company in writing that it has no objections to the Company Valuation Calculation or, if on the Company Valuation Response Date, Parent fails to deliver a Company Valuation Dispute Notice as provided in Section&#160;&#8206;2.8(d), then the Company Valuation Calculation as set forth </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">in the Company Valuation Schedule shall be deemed to have been finally determined for purposes of this Agreement and to represent the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(g)&#160;&#160;&#160;&#160;If the Company delivers a Dispute Notice on or prior to the Response Date, then Representatives of Parent and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s)&#160;and negotiate an agreed-upon determination of Parent Net Cash, which agreed upon the Parent Net Cash amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(h)&#160;&#160;&#160;&#160;If Parent delivers a Company Valuation Dispute Notice on or prior to the Company Valuation Response Date, then Representatives of Parent and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s)&#160;and negotiate an agreed-upon determination of the components of the Company Valuation, which agreed upon Company Valuation amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(i)&#160;&#160;&#160;&#160;If Representatives of Parent and the Company are unable to negotiate an agreed-upon determination of Parent Net Cash as of the Cash Determination Time pursuant to Section&#160;&#8206;2.8(g)&#160;or the components of Company Valuation as of the Company Valuation Determination Time pursuant to Section&#160;&#8206;2.8(h)&#160;within three days after delivery of the Dispute Notice or the Company Valuation Dispute Notice, as applicable, (or such other period as Parent and the Company may mutually agree upon), then any remaining disagreements as to the calculation of Parent Net Cash or Company Valuation shall be referred to an independent auditor of recognized national standing jointly selected by Parent and the Company. If the parties are unable to select an independent auditor within five (5)&#160;days, then either Parent or the Company may thereafter request that the Boston, Massachusetts Office of the American Arbitration Association (&#8220;<b style="font-weight:bold;">AAA</b>&#8221;) make such selection (either the independent auditor jointly selected by both parties or such independent auditor selected by the AAA, the &#8220;<b style="font-weight:bold;">Accounting Firm</b>&#8221;). Parent and the Company shall promptly deliver to the Accounting Firm the work papers and back-up materials used in preparing the Parent Net Cash Schedule and the Dispute Notice and the Company Valuation Schedule and the Company Valuation Dispute Notice, and Parent and the Company shall use commercially reasonable efforts to cause the Accounting Firm to make its determination within five&#160;(5)&#160;Business Days of accepting its selection. Parent and the Company shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; provided, however, that no such presentation or discussion shall occur without the presence of a Representative of each of Parent and the Company. The determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. The determination of the amount of Parent Net Cash or the components of the Company Valuation made by the Accounting Firm shall be made in writing delivered to each of Parent and the Company, shall be final and binding on Parent and the Company and shall (absent manifest error) be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time or the components of the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement. The Parties shall delay the Closing until the resolution of the matters described in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.8(i)</span>. The fees and expenses of the Accounting Firm shall be allocated between Parent and the Company in the same proportion that the disputed amount of the Parent Net Cash or the Company Valuation that was unsuccessfully disputed by such Party (as finally determined by the Accounting Firm) bears to the total disputed amount of the Parent Net Cash amount or the components of the Company Valuation. If this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.8(i)</span>&#160;applies as to the determination of the Parent Net Cash at the Cash Determination Time or to the determination of the components of the Company Valuation at the Company Valuation Determination Time, as applicable, upon resolution of the matter in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.8(i)</span>, the Parties shall not be required to determine Parent Net Cash or the Company Valuation again even though the Closing may occur later than the Anticipated Closing Date, except that either Parent and the Company may request a redetermination of Parent Net Cash or the Company Valuation if the Closing Date is more than thirty (30) days after the Anticipated Closing Date.</p><a id="FurtherAction_183434"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">2.9&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Action</span>. If, at any time after the First Effective Time, any further action is determined by the Surviving Entity to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Entity with full right, title and possession of and to all rights and property of the Company, then the officers and directors of the Surviving Entity shall be fully authorized, and shall use their and its commercially reasonable efforts (in the name of the Company, in the name of First Merger Sub, in the name of Second Merger Sub, in the name of the Surviving Entity and otherwise) to take such action.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="IntendedTaxTreatmen_389635"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">2.10&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intended Tax Treatment</span>. The Parties acknowledge and agree that, for U.S. federal (and applicable state and local) income Tax purposes, the Merger is intended to qualify as a reorganization within the meaning of Section&#160;368(a)&#160;of the Code (the &#8220;<b style="font-weight:bold;">Intended Tax Treatment</b>&#8221;). The Parties adopt this Agreement as a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Sections 1.368-2(g)&#160;and 1.368-3.</p><a id="Withholding_568379"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">2.11&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding</span>. Each of the Exchange Agent, Parent and the Surviving Entity shall be entitled to deduct and withhold from any consideration deliverable pursuant to this Agreement to any Person such amounts as are required to be deducted or withheld from such consideration under applicable Law; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that the Exchange Agent, Parent and the Surviving Entity shall use commercially reasonable efforts to promptly notify such Persons of any intention to withhold any portion of such consideration and cooperate with such Persons to reduce or eliminate any such withholding to the extent permitted by applicable Law. To the extent such amounts are so deducted or withheld and remitted to the appropriate Governmental Authority, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. All payments made under this agreement that constitute compensation to employees for services for Tax purposes shall be made through the payroll of the Surviving Entity or Parent, as applicable.</p><a id="AppraisalRights_796032"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">2.12&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appraisal Rights</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Notwithstanding any provision of this Agreement to the contrary, shares of Company Capital Stock that are outstanding immediately prior to the First Effective Time and which are held by stockholders or owned by beneficial owners who have exercised and perfected appraisal rights for such shares of Company Capital Stock in accordance with the DGCL (collectively, the &#8220;<b style="font-weight:bold;">Dissenting Shares</b>&#8221;) shall not be converted into or represent the right to receive the Merger Consideration described in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.5</span> attributable to such Dissenting Shares. Such stockholders or beneficial owners shall be entitled to receive payment of the fair value of such shares of Company Capital Stock held by them in accordance with the DGCL, unless and until such stockholders or beneficial owners fail to perfect or effectively withdraw or otherwise lose their appraisal rights under the DGCL. All Dissenting Shares held by stockholders or owned by beneficial owners who shall have failed to perfect or shall have effectively withdrawn or lost their right to appraisal of such shares of Company Capital Stock under the DGCL (whether occurring before, at or after the First Effective Time) shall thereupon be deemed to be converted into and to have become exchangeable for, as of the First Effective Time, the right to receive the Merger Consideration, without interest, attributable to such Dissenting Shares upon their surrender in the manner provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.5</span> and <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.7</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;The Company shall give Parent prompt written notice of any demands by dissenting stockholders or beneficial owners received by the Company, withdrawals of such demands and any other instruments served on the Company and any material correspondence received by the Company in connection with such demands, and Parent shall have the right to participate in all negotiations and proceedings with respect to such demands. The Company shall not, except with Parent&#8217;s prior written consent, not to be unreasonably withheld, delayed or conditioned, make any payment with respect to, or settle or offer to settle, any such demands, or approve any withdrawal of any such demands or agree to do any of the foregoing.</p><a id="Section3RepresentationsandWarrantiesofth"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;3. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of the Company</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as set forth in the written disclosure document delivered by the Company to Parent (the &#8220;<b style="font-weight:bold;">Company Disclosure Letter</b>&#8221;) concurrently with the execution of this Agreement, the Company represents and warrants to Parent and Merger Subs as follows:</p><a id="DueOrganizationSubsidiaries_760779"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">3.1&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Due Organization; Subsidiaries</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;The Company is a corporation or other legal entity duly incorporated or otherwise organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or organization and has all necessary power and authority: (i)&#160;to conduct its business in the manner in which its business is currently being conducted, (ii)&#160;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii)&#160;to perform its obligations under all Contracts by which it is bound.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(b)&#160;&#160;&#160;&#160;The Company is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Company Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;The Company has no Subsidiaries and the Company does not own any capital stock or membership interests of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other Entity. The Company is not and has never otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. The Company has not agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. The Company has not, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</p><a id="OrganizationalDocuments_930684"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">3.2&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organizational Documents</span>. The Company has delivered to Parent accurate and complete copies of the Organizational Documents of the Company. The Company is not in breach or violation of its Organizational Documents in any material respect.</p><a id="AuthorityBindingNatureofAgreement_475032"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">3.3&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority; Binding Nature of Agreement</span>. The Company has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Company Board has (i)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii)&#160;approved and declared advisable this Agreement and the Contemplated Transactions and (iii)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions. This Agreement has been duly executed and delivered by the Company and assuming the due authorization, execution and delivery by Parent, First Merger Sub and Second Merger Sub, constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions.</p><a id="VoteRequired_589257"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">3.4&#160;&#160;&#160;&#160;Vote Required. The affirmative vote (or written consent) of (i)&#160;the holders of a majority of the shares of Company Capital Stock outstanding on the record date, voting as a single class on an&#160;as-converted&#160;basis, and (ii)&#160;the holders of a majority of the shares of Company Series&#160;Seed Preferred Stock outstanding on the record date and entitled to vote thereon, voting as a separate class, is the only vote of the holders of any class or series of Company Capital Stock necessary to adopt and approve this Agreement and approve the Contemplated Transactions (collectively, the &#8220;<b style="font-weight:bold;">Required Company Stockholder Vote</b>&#8221;).</p><a id="NonContraventionConsents_853150"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">3.5&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Contravention; Consents</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Subject to obtaining the Required Company Stockholder Vote, compliance with any applicable requirements of the HSR Act (if applicable) and the filing of the Certificate of Merger and Certificate of Designation required by the DGCL or DLLCA, neither (x)&#160;the execution, delivery or performance of this Agreement by the Company, nor (y)&#160;the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(i)&#160;&#160;&#160;&#160;contravene, conflict with or result in a violation of any of the provisions of the Company&#8217;s Organizational Documents;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order by which the Company, or any of the assets owned or used by the Company, is subject;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iii)&#160;&#160;&#160;&#160;contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company or that otherwise relates to the business of the Company, or any of the assets owned, leased or used by the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 72pt;">(iv)&#160;&#160;&#160;&#160;contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise any remedy under any Company Material Contract, (B)&#160;any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract, (C)&#160;accelerate the maturity or performance of any Company </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Material Contract or (D)&#160;cancel, terminate or modify any term of any Company Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(v)&#160;&#160;&#160;&#160;&#160;result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for Permitted Encumbrances).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;Except for (i)&#160;the Required Company Stockholder Vote, (ii)&#160;the filing of the Certificate of Merger and Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA, (iii)&#160;compliance with any applicable requirements of the HSR Act (if applicable) and (iv)&#160;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, the Company was not, is not, nor will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x)&#160;the execution, delivery or performance of this Agreement or (y)&#160;the consummation of the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;No state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, the Company Stockholder Support Agreements or any of the Contemplated Transactions.</p><a id="Capitalization_684060"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">3.6&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capitalization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;The authorized capital stock of the Company consists of (i)&#160;40,000,000 shares of Company Common Stock of which 27,049,180 shares have been issued and are outstanding as of the date hereof and (ii)&#160;20,000,000 shares of Company Preferred Stock, of which 20,000,000 shares have been designated Series&#160;Seed Preferred Stock and 20,000,000 have been issued and are outstanding as of the date hereof. The Company does not hold any shares of its capital stock in its treasury. As of the date of this Agreement, the Company&#8217;s capital stock is held by the Persons and in the amounts set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(a)</span>&#160;of the Company Disclosure Letter, which further sets forth for each such Person (i)&#160;the&#160;name of such Person and the number of shares held, (ii)&#160;the class and series of such shares, (iii)&#160;the number of the applicable book-entry positions representing such shares or the number of the certificate representing such shares, (iv)&#160;whether such Person is or has ever been an employee, and (v)&#160;the state of residence of such Person. Each share of Company Preferred Stock is convertible into one share of Company Common Stock. There are no declared or accrued but unpaid dividends with respect to any shares of the Company&#8217;s capital stock and the Company has never declared or paid any dividend or other distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;All of the outstanding Company Capital Stock as set out in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(a)</span>&#160;of the Company Disclosure Letter have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than Encumbrances set forth in the Organizational Documents or under applicable securities Laws. None of the outstanding Company Capital Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding Company Capital Stock is subject to any right of first refusal in favor of the Company. Except as contemplated herein, there is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any Company Capital Stock. The Company is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding Company Capital Stock or other securities. Section&#160;&#8206;3.6(b)&#160;of the Company Disclosure Letter accurately and completely describes all repurchase rights held by the Company with respect to Company Capital Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(c)&#160;&#160;&#160;&#160;Except for the Company Stock Plans and except as set forth on Section&#160;&#8206;3.6(c)&#160;of the Company Disclosure Letter, the Company does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. Section&#160;&#8206;3.6(c)&#160;of the Company Disclosure Letter sets forth the following information with respect to each Company Option outstanding as of the date hereof: (i)&#160;the name of the holder, (ii)&#160;the number of shares of Company Common Stock subject to such Company Option as of the date hereof, (iii)&#160;the exercise price of such Company Option, (iv)&#160;the date on which such Company Option was granted, (v)&#160;the applicable vesting schedule, including any acceleration provisions, (vi)&#160;the date on which such Company Option expires, (vii)&#160;whether such Company Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a nonqualified stock option and (viii)&#160;in the case of a Company Option, the plan pursuant to which such Company Option was granted. The Company has made available to Parent accurate and complete copies of equity incentive plans pursuant </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">to which the Company has equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board and stockholder approval of the Company Stock Plans and any amendments thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;Except for the outstanding Company Options or as set forth on Section&#160;&#8206;3.6(d)&#160;of the Company Disclosure Letter, there is no: (i)&#160;outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any Company Capital Stock or other securities of the Company, (ii)&#160;outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of the Company, (iii)&#160;stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which the Company is or may become obligated to sell or otherwise issue any Company Capital Stock or any other securities or (iv)&#160;condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of the Company. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;All outstanding Company Capital Stock, Company Options and other securities of the Company have been issued and granted in compliance in all material respects with (i)&#160;all applicable securities laws and other applicable Law and (ii)&#160;all requirements set forth in applicable Contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(f)&#160;&#160;&#160;&#160;The Company Capital Stock are uncertificated.</p><a id="FinancialStatements_517714"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">3.7&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;The Company maintains a system of internal accounting controls designed to provide reasonable assurance that: (i)&#160;transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii)&#160;transactions are recorded as necessary to permit preparation of the financial statements of the Company in conformity with GAAP and to maintain accountability of the Company&#8217;s assets, (iii)&#160;access to the Company&#8217;s assets is permitted only in accordance with management&#8217;s general or specific authorization and (iv)&#160;the recorded accountability for the Company&#8217;s assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to any differences. The Company maintains internal controls consistent with the practices of similarly situated private companies over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.7(c)</span>&#160;of the Company Disclosure Letter lists, and the Company has delivered to Parent accurate and complete copies of the documentation creating or governing, all securitization transactions and &#8220;off-balance sheet arrangements&#8221; (as defined in Item 303(c)&#160;of Regulation S-K under the Exchange Act) effected by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of the Company, the Company Board or any committee thereof. Neither the Company nor its independent auditors have identified (i)&#160;any significant deficiency or material weakness in the design or operation of the system of internal accounting controls utilized by the Company, (ii)&#160;any fraud, whether or not material, that involves the Company, the Company&#8217;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company or (iii)&#160;any claim or allegation regarding any of the foregoing.</p><a id="AbsenceofChanges_738616"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">3.8&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Changes</span>. Except as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;</span>3.8 of the Company Disclosure Letter, between the date of its incorporation and the date of this Agreement, the Company has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a)&#160;Company Material Adverse Effect or (b)&#160;action, event or occurrence that would have required consent of Parent pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;5.2(b)</span>&#160;of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.</p><a id="AbsenceofUndisclosedLiabilities_578931"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">3.9&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Undisclosed Liabilities</span>. Since the date of its incorporation, the Company does not have any liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of any kind, whether accrued, absolute, contingent, matured, unmatured or otherwise (each a &#8220;<b style="font-weight:bold;">Liability</b>&#8221;), except for: (a)&#160;Liabilities disclosed, reflected or reserved against (or to be disclosed, reflected or reserved against) in Company Financial Statements, (b)&#160;normal and recurring current Liabilities that have been incurred by the Company since the date hereof in the Ordinary Course of Business (none of which </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c)&#160;Liabilities for performance of obligations of the Company under Company Contracts, (d)&#160;Liabilities incurred in connection with the Contemplated Transactions, and (e)&#160;Liabilities described in Section&#160;&#8206;3.9 of the Company Disclosure Letter.</p><a id="TitletoAssets_685182"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">3.10&#160;&#160;&#160;&#160;Title to Assets. The Company owns and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including all tangible assets reflected in the books and records of the Company as being owned by the Company. All of such assets are owned or, in the case of leased assets, leased by the Company free and clear of any Encumbrances, other than Permitted Encumbrances.</p><a id="RealPropertyLeasehold_250921"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">3.11&#160;&#160;&#160;&#160;Real Property; Leasehold. The Company does not own and has never owned any real property, nor is the Company party to any agreement to purchase or sell any real property. The Company has made available to Parent (a)&#160;an accurate and complete list of&#160;all real properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Company and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;<b style="font-weight:bold;">Company Real Estate Leases</b>&#8221;), each of which is in full force and effect, with no existing material default thereunder by the Company or to the Company&#8217;s Knowledge, the other party thereto.</p><a id="IntellectualProperty_645105"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">3.12&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.12(a)</span>&#160;of the Company Disclosure Letter is an accurate, true and complete listing of all Company Registered IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.12(b)</span>&#160;of the Company Disclosure Letter accurately identifies (i)&#160;all Company Contracts pursuant to which any Company IP Rights are licensed to the Company (other than (A)&#160;any non-customized software that (1)&#160;is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2)&#160;is not incorporated into, or material to the development, manufacturing or distribution of, any of the Company&#8217;s products or services, (B)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C)&#160;any confidential information provided under confidentiality agreements and (D)&#160;agreements between Company and its employees in Company&#8217;s standard form thereof) and (ii)&#160;whether the license or licenses granted to the Company are exclusive or nonexclusive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;Section&#160;&#8206;3.12(c)&#160;of the Company Disclosure Letter accurately identifies each Company Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Company IP Rights (other than (i)&#160;any confidential information provided under confidentiality agreements and (ii)&#160;any Company IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for the Company&#8217;s benefit).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;The Company is not bound by, and no Company IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of the Company to use, exploit, assert or enforce any Company IP Rights anywhere in the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;The Company exclusively owns all right, title and interest to and in Company IP Rights (other than (i)&#160;Company IP Rights licensed to the Company, or co-owned rights each as identified in Section&#160;&#8206;3.12(e)&#160;of the Company Disclosure Letter, (ii)&#160;any non-customized software that (A)&#160;is licensed to the Company solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B)&#160;is not incorporated into, or material to the development, manufacturing or distribution of, any of the Company&#8217;s products or services and (iii)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(i)&#160;&#160;&#160;&#160;All documents and instruments necessary to register or apply for or renew registration of Company Registered IP have been validly executed, delivered and filed in a timely manner with the appropriate Governmental Authority.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;Each Person who is or was an employee or contractor of the Company and who is or was involved in the creation or development of any Intellectual Property for the Company has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to the Company and confidentiality provisions protecting trade secrets and confidential information of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iii)&#160;&#160;&#160;&#160;To the Knowledge of the Company, no current or former stockholder, officer, director or employee of the Company has any claim, right (whether currently exercisable, or exercisable in the future) or interest to or in any Company IP Rights purported to be owned by the Company. To the Knowledge of the Company, no employee of the Company is (a)&#160;bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for the Company or (b)&#160;in breach of any Contract with any former employer or other Person concerning Company IP Rights purported to be owned by the Company or confidentiality provisions protecting trade secrets and confidential information comprising Company IP Rights purported to be owned by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iv)&#160;&#160;&#160;&#160;No funding, facilities or personnel of any Governmental Authority or any university, college, research institute or other educational institution were used, directly or indirectly, to develop or create, in whole or in part, any Company IP Rights in which the Company has an ownership interest, except for any such funding or use of facilities or personnel that does not result in such Governmental Authority or institution owning such Company IP Rights or the right to receive royalties or other remuneration for the practice of such Company IP Rights as of the date of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(v)&#160;&#160;&#160;&#160;&#160;The Company has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary information that the Company holds, or purports to hold, as confidential or a trade secret.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(vi)&#160;&#160;&#160;&#160;The Company has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Company IP Rights to any other Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:86.4pt;margin:0pt 0pt 12pt 0pt;">(f)&#160;&#160;&#160;&#160;The Company has delivered or made available to Parent, a complete and accurate copy of all Company IP Rights Agreements. With respect to each of the Company IP Rights Agreements: (i)&#160;each such agreement is valid and binding on the Company and in full force and effect, (ii)&#160;the Company has not received any written notice of termination or cancellation under such agreement, or received any written notice of breach or default under such agreement, which breach has not been cured or waived and (iii)&#160;the Company, and to the Knowledge of the Company, no other party to any such agreement, is not in breach or default thereof in any material respect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(g)&#160;&#160;&#160;&#160;The manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by the Company does not violate any license or agreement between the Company and any other third party, and, to the Knowledge of the Company, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Company Material Adverse Effect. To the Knowledge of the Company, no third party is infringing upon any Patents owned by Company within the Company IP Rights, or otherwise violating any Company IP Rights Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(h)&#160;&#160;&#160;&#160;As of the date of this Agreement, Company is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, enforceability, claim construction, ownership or right to use, sell, offer for sale, license or dispose of any Company IP Rights. The Company has not received any written notice asserting that any Company IP Rights or the proposed use, sale, offer for sale, license or disposition of products, methods or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that the Company has otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person. None of the Company IP Rights is subject to any outstanding order of, judgment of, decree of or agreement with any Governmental Authority that limits the ability of the Company to exploit any Company IP Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(i)&#160;&#160;&#160;&#160;Each item of Company Registered IP is and at all times has been filed and maintained in compliance in all material respects with all applicable Law and all filings, payments and other actions required to be made or taken to maintain such item of Company Registered IP in full force and effect have been made by the applicable deadline. To the Knowledge of the Company, all Company Registered IP that is issued or granted is valid and enforceable.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(j)&#160;&#160;&#160;&#160;To the Knowledge of the Company, no trademark (whether registered or unregistered) or trade name owned, used or applied for by the Company conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which the Company has or purports to have an ownership interest has been impaired as determined by the Company in accordance with GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(k)&#160;&#160;&#160;&#160;Except as set forth in Sections&#160;&#8206;3.12(b), &#8206;3.12(c)&#160;or &#8206;3.12(k)&#160;of the Company Disclosure Letter or as contained in &#8220;off-the-shelf&#8221; license agreements entered into in the Ordinary Course of Business by the Company, (i)&#160;the Company is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation, or similar claim which is material to the Company, taken as a whole and (ii)&#160;the Company has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation, or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(l)&#160;&#160;&#160;&#160;The Company is not party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the grant of any license or other right to any Company IP Rights, result in breach of, default under or termination of such Contract with respect to any Company IP Rights, or impair the right of the Company or the Surviving Entity and its Subsidiaries to use, sell or license or enforce any Company IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect.</p><a id="AgreementsContractsandCommitments_169799"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">3.13&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreements, Contracts and Commitments</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.13(a)</span>&#160;of the Company Disclosure Letter lists the following Company Contracts in effect as of the date of this Agreement (each, a &#8220;<b style="font-weight:bold;">Company Material Contract</b>&#8221; and collectively, the &#8220;<b style="font-weight:bold;">Company Material Contracts</b>&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(i)&#160;&#160;&#160;&#160;each Company Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;each Company Contract containing (A)&#160;any covenant limiting the freedom of the Company or the Surviving Entity to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Company&#8217;s products or services (B)&#160;any most-favored pricing arrangement, (C)&#160;any exclusivity provision or (D)&#160;any non-solicitation provision;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iii)&#160;&#160;&#160;&#160;each Company Contract (A)&#160;pursuant to which any Person granted the Company an exclusive license under any Intellectual Property, or (B)&#160;pursuant to which the Company granted any Person an exclusive license under any Company IP Rights;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iv)&#160;&#160;&#160;&#160;each Company Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(v)&#160;&#160;&#160;&#160;&#160;each Company Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of the Company, any of its Subsidiaries, or of a product;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(vi)&#160;&#160;&#160;&#160;each Company Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(vii)&#160;&#160;&#160;&#160;each Company Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of the Company or any loans or debt obligations with officers or directors of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 72pt;">(viii)&#160;&#160;&#160;&#160;each Company Contract requiring payment by or to the Company after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A)&#160;any distribution agreement (identifying any that contain exclusivity provisions), (B)&#160;any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of the Company, (C)&#160;any dealer, distributor, joint marketing, alliance, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">joint venture, cooperation, development or other agreement currently in force under which the Company has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which the Company has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by the Company or (D)&#160;any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of the Company or any Contract to sell, distribute or commercialize any products or service of the Company, in each case, except for Company Contracts entered into in the Ordinary Course of Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ix)&#160;&#160;&#160;&#160;each Company Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the Company in connection with the Contemplated Transactions and requiring payments by Company after the date in this Agreement in excess of $100,000 pursuant to its express terms;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(x)&#160;&#160;&#160;&#160;&#160;each Company Contract to which the Company is a party or by which any of its assets and properties is currently bound, which involves annual obligations of payment by, or annual payments to, the Company in excess of $100,000;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xi)&#160;&#160;&#160;&#160;each Company Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which the Company or any of its Subsidiaries has outstanding obligations to pay consideration in excess of $100,000;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xii)&#160;&#160;&#160;&#160;any other Company Contract that is not terminable at will (with no penalty or payment) by the Company, and (A)&#160;which involves payment or receipt by the Company after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate or (B)&#160;that is material to the business or operations of the Company taken as a whole; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xiii)&#160;&#160;&#160;&#160;Company Real Estate Leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;The Company has delivered or made available to Parent accurate and complete copies of all Company Material Contracts, including all amendments thereto. There are no Company Material Contracts that are not in written form. The Company has not, nor to the Company&#8217;s Knowledge, as of the date of this Agreement has any other party to a Company Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Company Material Contract in such a manner, and, if such Company Material Contract provides for a cure period, the Company or such other party fails to have cured such breach, violation or default, so that any other party or the Company, as the case may be, is permitted to modify, cancel or terminate any such Company Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Company Material Adverse Effect. As to the Company, as of the date of this Agreement, each Company Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Company Material Contract to change, any material amount paid or payable to the Company under any Company Material Contract or any other material term or provision of any Company Material Contract.</p><a id="CompliancePermitsRestrictions_517301"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">3.14&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance; Permits; Restrictions</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;The Company is, and has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or other Legal Proceeding or action by any Governmental Authority is pending or, to the Knowledge of the Company, threatened against the Company. There is no agreement or Order binding upon the Company which (i)&#160;has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company, any acquisition of material property by the Company or the conduct of business by the Company as currently conducted, (ii)&#160;is reasonably likely to have an adverse effect on the Company&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii)&#160;is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(b)&#160;&#160;&#160;&#160;Except for matters regarding the U.S. Food and Drug Administration (or any successor agency thereto) (&#8220;<b style="font-weight:bold;">FDA</b>&#8221;) or other comparable Governmental Authority responsible for regulation of the development, testing, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug or medical device products (&#8220;<b style="font-weight:bold;">Drug/Device Regulatory Agency</b>&#8221;), the Company holds all required Governmental Authorizations for the operation of the business of the Company as currently conducted (the &#8220;<b style="font-weight:bold;">Company Permits</b>&#8221;). Section&#160;&#8206;3.14(b)&#160;of the Company Disclosure Letter identifies each Company Permit. The Company is in material compliance with the terms of the Company Permits. No Legal Proceeding is pending or, to the Knowledge of the Company, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Company Permit. The rights and benefits of each Company Permit will be available to the Surviving Entity or its Subsidiaries, as applicable, immediately after the Second Effective Time on terms substantially identical to those enjoyed by the Company as of the date of this Agreement and immediately prior to the First Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;There are no Legal Proceedings pending or, to the Knowledge of the Company, threatened with respect to an alleged violation by the Company of the Federal Food, Drug, and Cosmetic Act (&#8220;<b style="font-weight:bold;">FDCA</b>&#8221;), the Public Health Service Act (&#8220;<b style="font-weight:bold;">PHSA</b>&#8221;), FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;The Company holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the business of the Company as currently conducted, and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its products or product candidates (the &#8220;Company Product Candidates&#8221;) (collectively, the &#8220;<b style="font-weight:bold;">Company Regulatory Permits</b>&#8221;) and no such Company Regulatory Permit has been (i)&#160;revoked, withdrawn, suspended, cancelled or terminated or (ii)&#160;modified in any adverse manner, other than immaterial adverse modifications. Section&#160;&#8206;3.14(d)&#160;of the Company Disclosure Letter identifies each Company Regulatory Permit. The Company has timely maintained and is in compliance in all material respects with the Company Regulatory Permits and has not received any written notice or correspondence or, to the Knowledge of the Company, other communication from any Drug/Device Regulatory Agency regarding (A)&#160;any material violation of or failure to comply materially with any term or requirement of any Company Regulatory Permit or (B)&#160;any revocation, withdrawal, suspension, cancellation, termination or material modification of any Company Regulatory Permit. The Company has made available to Parent all information requested by Parent in the Company&#8217;s possession or control relating to material Company Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Company Product Candidates, including but not limited to complete copies of the following (to the extent there are any): (x)&#160;adverse event reports; preclinical, clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y)&#160;similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information is accurate and complete in all material respects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;All clinical, preclinical and other studies and tests conducted by or on behalf of, or sponsored by, the Company, or in which the Company or its current products or product candidates, including the Company Product Candidates, have participated, were, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific research procedures, in accordance in all material respects with the applicable protocols and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. The Company has not received any written notices, correspondence or other communications from any Drug/Device Regulatory Agency, Governmental Authority, institutional review board, ethics committee or safety monitoring committee requiring, or to the Knowledge of the Company threatening to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by or on behalf of, or sponsored by, the Company or in which the Company or its current products or product candidates, including the Company Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical study conducted by or, to the Knowledge of the Company, on behalf of the Company has been disqualified from participating in studies involving the Company Product Candidates, and to the Knowledge of the Company, no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(f)&#160;&#160;&#160;&#160;The Company is not, and to the Knowledge of the Company, no contract manufacturer with respect to any Company Product Candidate, is the subject of any pending or, to the Knowledge of the Company, threatened investigation in respect of its business or products, including Company Product Candidates, by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">(September&#160;10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable policy. The Company has not, and to the Knowledge of the Company, no contract manufacturer, nor their respective officers, employees or agents, with respect to any Company Product Candidate has committed any acts, made any statement or failed to make any statement, in each case in respect of its business or products that would violate the FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto or a comparable policy of any other Drug/Device Regulatory Agency. None of the Company, and to the Knowledge of the Company, any contract manufacturer with respect to any Company Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in a debarment or exclusion under (i)&#160;21 U.S.C. Section&#160;335a or (ii)&#160;any similar applicable Law. To the Knowledge of the Company, no debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against the Company, and to the Knowledge of the Company, any contract manufacturer with respect to any Company Product Candidate, or any of their respective officers, employees or agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(g)&#160;&#160;&#160;&#160;All manufacturing operations conducted by, or to the Knowledge of the Company, for the benefit of the Company in connection with any Company Product Candidate have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210, 211 and 600-610 and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(h)&#160;&#160;&#160;&#160;Neither the Company nor, to the Knowledge of the Company, any manufacturing site of a contract manufacturer or laboratory, with respect to any Company Product Candidate, (i)&#160;is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii)&#160;has received any Form&#160;FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA or other Drug/Device Regulatory Agency alleging or asserting noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of the Company, neither the FDA nor any other Drug/Device Regulatory Agency is considering such action.</p><a id="LegalProceedingsOrders_508454"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">3.15&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legal Proceedings; Orders</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;There is no pending Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence any Legal Proceeding: (i)&#160;that involves the Company or any of its Subsidiaries or any Company Associate (in his or her capacity as such) or any of the material assets owned or used by the Company or any of its Subsidiaries or (ii)&#160;that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;There is no Order to which the Company or any of its Subsidiaries, or any of the material assets owned or used by the Company or any of its Subsidiaries, is subject. To the Knowledge of the Company, no officer or Company Key Employee is subject to any Order that prohibits such officer or Company Key Employee from engaging in or continuing in any conduct, activity or practice relating to the Company or any of its Subsidiaries or any material assets owned or used by the Company or any of its Subsidiaries.</p><a id="TaxMatters_73219"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">3.16&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;The Company has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed by the Company under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete in all material respects. Subject to exceptions as would not be material, no claim has been made by a Governmental Authority in a jurisdiction where the Company does not file Tax Returns that the Company is subject to taxation by that jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;All material amounts of Taxes due and owing by the Company (whether or not shown on any Tax Return) have been timely paid (taking into account any applicable extensions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;The Company has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;There are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause (a)&#160;of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;No deficiencies for a material amount of Taxes with respect to the Company have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of the Company. The Company has not granted a waiver of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(f)&#160;&#160;&#160;&#160;The Company has not been a United States real property holding corporation within the meaning of Section&#160;897(c)(2)&#160;of the Code in the last five (5)&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(g)&#160;&#160;&#160;&#160;The Company is not a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than customary commercial Contracts entered into in the Ordinary Course of Business the primary purpose of which does not relate to Tax (an &#8220;<b style="font-weight:bold;">Ordinary Course Agreement</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(h)&#160;&#160;&#160;&#160;The Company has not been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is the Company). The Company has no Liability for the Taxes of any Person under Treasury Regulations Section&#160;1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(i)&#160;&#160;&#160;&#160;The Company has not distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(j)&#160;&#160;&#160;&#160;The Company has not entered into any transaction identified as a &#8220;listed transaction&#8221; for purposes of Treasury Regulations Sections&#160;1.6011-4(b)(2)&#160;or 301.6111-2(b)(2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(k)&#160;&#160;&#160;&#160;The Company is not aware of any facts or circumstances and has not taken or agreed to take any action, in each case, that would reasonably be expected to prevent or impede the Intended Tax Treatment.</p><a id="EmployeeandLaborMattersBenefitPlans_8746"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">3.17&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee and Labor Matters; Benefit Plans.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;The Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an employee of the Company or any of its Subsidiaries, whether full- or part-time, such employee&#8217;s annual salary (or if hourly, hourly rate), most recent annual bonus received, and current annual bonus opportunity. No Company Key Employee has indicated to the Company, or any of its Subsidiaries, that he or she intends to resign or retire as a result of the transactions contemplated by this Agreement or otherwise. The Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an individual independent contractor engaged by the Company, such contractor&#8217;s rate of compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;The employment of the Company&#8217;s and each of its Subsidiaries&#8217; employees is terminable by the Company and/or its applicable Subsidiary at will. The Company has made available to Parent accurate and complete copies of all employee manuals and handbooks, to the extent currently effective and material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;Neither the Company nor any of its Subsidiaries is a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing its employees, and there are no labor organizations representing or, to the Knowledge of the Company, purporting to represent or seeking to represent any employees of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;Section&#160;&#8206;3.17(d)&#160;of the Company Disclosure Letter lists all Company Employee Plans (other than employment arrangements which are terminable &#8220;at will&#8221; without any contractual obligation on the part of the Company or any of its Subsidiaries to make any severance, termination, change in control or similar payment and that are substantively identical to the employment arrangements made available to Parent).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;Each Company Employee Plan that is intended to be qualified under Section&#160;401(a)&#160;of the Code has received a favorable determination or opinion letter with respect to such qualified status from the IRS. To the Knowledge of the Company, nothing has occurred that would reasonably be expected to adversely affect the qualified status of any such Company Employee Plan or the exempt status of any related trust.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(f)&#160;&#160;&#160;&#160;Each Company Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of the Company, threatened with respect to any Company Employee Plan. All payments and/or contributions required to have been made with respect to all Company Employee Plans either have been made or have been accrued in accordance with the terms of the applicable Company Employee Plan and applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(g)&#160;&#160;&#160;&#160;Neither the Company nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6)&#160;years, maintained, contributed to or been required to contribute to (i)&#160;any &#8220;employee benefit plan&#8221; that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii)&#160;a Multiemployer Plan, (iii)&#160;any funded welfare benefit plan within the meaning of Section&#160;419 of the Code, (iv)&#160;any Multiple Employer Plan, or (v)&#160;any Multiple Employer Welfare Arrangement. Neither the Company nor any of its ERISA Affiliates has ever incurred any liability under Title IV of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(h)&#160;&#160;&#160;&#160;No Company Employee Plan provides for, and neither the Company nor any of its Subsidiaries has promised to provide any, medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (i)&#160;pursuant to COBRA or an analogous state law requirement or (ii)&#160;continuation coverage through the end of the month in which such termination or retirement occurs. The Company does not sponsor or maintain any self-funded medical or long-term disability benefit plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(i)&#160;&#160;&#160;&#160;No Company Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(j)&#160;&#160;&#160;&#160;Each Company Employee Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section&#160;409A(d)(1)&#160;of the Code and the guidance thereunder) (each, a &#8220;<b style="font-weight:bold;">Company 409A Plan</b>&#8221;) has been operated and maintained in all material respects in operational and documentary compliance with the requirements of Section&#160;409A of the Code and the applicable guidance thereunder. No payment to be made under any Company 409A Plan is or, when made in accordance with the terms of the Company 409A Plan, will be subject to the penalties of Section&#160;409A(a)(1)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(k)&#160;&#160;&#160;&#160;The Company and each of its Subsidiaries is, and has been, in material compliance with all applicable federal, state and local laws, rules&#160;and regulations respecting employment, employment practices, terms and conditions of employment, worker classification, tax withholding, prohibited discrimination, retaliation and harassment, equal employment, fair employment practices, meal and rest periods, immigration status, employee and workplace safety and health, wages (including overtime wages), compensation, hours of work, &#8220;plant closings&#8221; and &#8220;mass layoffs&#8221; within the meaning of the Worker Adjustment and Retraining Act of 1988 or similar state or local law (the &#8220;<b style="font-weight:bold;">WARN Act</b>&#8221;), labor practices or disputes, restrictive covenants, employment agreements, workers&#8217; compensation and long-term disability policies, leaves of absence and worker privacy (collectively, &#8220;<b style="font-weight:bold;">Employment-Related Laws</b>&#8221;), and in each case, with respect to employees of the Company and any of its Subsidiaries: (i)&#160;has withheld and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees, (ii)&#160;is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing and (iii)&#160;is not liable for any material payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of the Company, threatened or reasonably anticipated against or involving the Company or any of its Subsidiaries or any trustee of the Company or any of its Subsidiaries relating to any employee, contingent worker, director, employment agreement or Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of the Company, there are no material pending or threatened or reasonably anticipated claims or actions against the Company, any trustee or any trustee of any Subsidiary of the Company under any workers&#8217; compensation policy or long-term disability policy. The Company is not a party to a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental Authority with respect to employment practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(l)&#160;&#160;&#160;&#160;The Company has no material liability with respect to any misclassification, since its incorporation, of: (i)&#160;any Person as an independent contractor rather than as an employee, (ii)&#160;any employee leased from another employer or (iii)&#160;any employee currently or formerly classified as exempt from overtime wages. Neither the Company nor any of its Subsidiaries has taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has the Company or any of its Subsidiaries been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(m)&#160;&#160;&#160;&#160;To the Company&#8217;s Knowledge, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, by or with respect to any Company Associates. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Company&#8217;s Knowledge, might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(n)&#160;&#160;&#160;&#160;Neither the Company nor any of its Subsidiaries is, nor has the Company nor any of its Subsidiaries been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of the Company, threatened or reasonably anticipated relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers&#8217; compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current or former employee of the Company or any of its Subsidiaries including charges of unfair labor practices or discrimination complaints.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(o)&#160;&#160;&#160;&#160;There is no contract, agreement, plan or arrangement to which the Company or any of its Subsidiaries is a party or by which it is bound to compensate any of its employees or other service providers for any income or excise taxes paid pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(p)&#160;&#160;&#160;&#160;Neither the Company nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other service provider of the Company or any of its Subsidiaries.</p><a id="EnvironmentalMatters_905973"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">3.18&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Matters</span>. The Company has complied with all applicable Environmental Laws, which compliance includes the possession by the Company of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Company Material Adverse Effect. The Company has not received any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that the Company is not in compliance with any Environmental Law and, to the Knowledge of the Company, there are no circumstances that may prevent or interfere with the Company&#8217;s compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Company Material Adverse Effect. To the Knowledge of the Company: (i)&#160;no current or prior owner of any property leased or controlled by the Company has received any written notice or other communication relating to property owned or leased at any time by the Company, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or the Company is not in compliance with or violated any Environmental Law relating to such property and (ii)&#160;the Company has no material liability under any Environmental Law. The Company has made available all environmental site assessments, environmental audits and other material environmental documents in the Company&#8217;s possession or control relating to the Company, including the Company&#8217;s business and current or former facilities.</p><a id="Insurance_724869"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">3.19&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</span>. The Company has delivered to Parent accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of the Company. Each of such insurance policies is in full force and effect and the Company is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, the Company has </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">not received any notice or other communication regarding any actual or possible: (i)&#160;cancellation or invalidation of any insurance policy or (ii)&#160;refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. The Company has provided timely written notice to the appropriate insurance carrier(s)&#160;of each Legal Proceeding pending against the Company, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed the Company of its intent to do so.</p><a id="NoFinancialAdvisors_3732"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">3.20&#160;&#160;&#160;&#160;No Financial Advisors. Except as set forth on Section&#160;&#8206;3.20 of the Company Disclosure Letter, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company.</p><a id="TransactionswithAffiliates_279844"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">3.21&#160;&#160;&#160;&#160;Transactions with Affiliates. Section&#160;&#8206;3.21 of the Company Disclosure Letter describes any material transactions or relationships between, on one hand, the Company and, on the other hand, any (a)&#160;executive officer or director of the Company or any of such executive officer&#8217;s or director&#8217;s immediate family members, (b)&#160;owner of more than 5% of the voting power of the outstanding Company Capital Stock or (c)&#160;to the Knowledge of the Company, any &#8220;related person&#8221; (within the meaning of Item&#160;404 of Regulation S-K under the Securities Act) of any such officer, director or owner (other than the Company) in the case of each of (a), (b)&#160;or (c)&#160;that is of the type that would be required to be disclosed under Item&#160;404 of Regulation&#160;S-K under the Securities Act.</p><a id="PrivacyandDataSecurity_811068"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">3.22&#160;&#160;&#160;&#160;Privacy and Data Security. The Company is and has at all times been in compliance with all applicable Privacy Laws and the applicable terms of any Company Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with the Company in connection with the operation of the Company&#8217;s business), except, in each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, the Company (i)&#160;has implemented and maintains reasonable written policies and procedures that materially comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information (the &#8220;<b style="font-weight:bold;">Privacy Policies</b>&#8221;) and (ii)&#160;has complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, no Legal Proceeding has been asserted or threatened against the Company by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Company Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of the Company, there have been no data security incidents or data breaches or other adverse events or incidents that have resulted in any unauthorized access, use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of the Company or any service provider acting on behalf of the Company, in each case, where such incident, breach or event resulted in a notification obligation to any Person under applicable Law or pursuant to the terms of any Company Contract.</p><a id="OwnershipofParentCapitalStock_56644"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">3.23&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership of Parent Capital Stock</span>. None of the Company, their directors or, to the knowledge of the Company, any of its officers, Affiliates, or employees of the Company or any of its controlled Affiliates (a)&#160;has owned any shares of Parent&#8217;s capital stock; or (b)&#160;has been an &#8220;interested stockholder&#8221; (as defined in Section&#160;203 of the DGCL) of Parent, in each case during the three years prior to the date hereof.</p><a id="NoOtherRepresentationsorWarranties_50552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">3.24&#160;&#160;&#160;&#160;No Other Representations or Warranties. The Company hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither Parent nor any other person on behalf of Parent makes any express or implied representation or warranty with respect to Parent or with respect to any other information provided to the Company, any of its stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of Parent set forth in Section<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;4</span> (in each case as qualified and limited by the Parent Disclosure Letter)) none of the Company, or any of its Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof).</p><a id="Section4RepresentationsandWarrantiesofPa"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">Section&#160;4. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of Parent, First Merger and Second Merger Sub</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Except (i)&#160;as set forth in the written disclosure document delivered by Parent to the Company (the &#8220;<b style="font-weight:bold;">Parent Disclosure Letter</b>&#8221;) concurrently with the execution of this Agreement or (ii)&#160;as disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system (but (A)&#160;without giving effect to any amendment thereof filed with, or furnished to the SEC on or after the date hereof and (B)&#160;excluding any disclosures contained under the heading &#8220;Risk Factors&#8221; and any disclosure of risks included in any &#8220;forward-looking statements&#8221; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), it being understood that any matter disclosed in the Parent SEC Documents shall be deemed to be disclosed in a section of the Parent Disclosure Letter only to the extent that is readily apparent from a reading of such Parent SEC Documents that is applicable to such section or subsection of the Parent Disclosure Letter, Parent, First Merger Sub and Second Merger Sub represent and warrant to the Company as follows:</p><a id="DueOrganizationSubsidiaries_66676"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">4.1&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Due Organization; Subsidiaries</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Each of Parent, First Merger Sub and Second Merger Sub is a corporation duly incorporated or formed, as applicable, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or formation, as applicable, and has all necessary corporate power and authority: (i)&#160;to conduct its business in the manner in which its business is currently being conducted, (ii)&#160;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii)&#160;to perform its obligations under all Contracts by which it is bound. Since the date of its incorporation, Merger Subs have not engaged in any activities other than in connection with or as contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;Each of Parent and its Subsidiaries is licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Parent Material Adverse Effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;Parent has no Subsidiaries other than Merger Subs and except as set forth on Section&#160;4.1(c)&#160;of the Parent Disclosure Letter, Parent does not own any capital stock of, or any equity ownership or profit sharing interest of any nature in, or control directly or indirectly, any other Entity other than Merger Subs. Except as set forth on Section&#160;4.1(c)&#160;of the Parent Disclosure Letter, Parent is not and has not otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. Parent has not agreed and is not obligated to make, nor is Parent bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. Parent has not, at any time, been a general partner of, and has not otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</p><a id="OrganizationalDocuments_323878"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">4.2&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organizational Documents</span>. Parent has delivered to the Company accurate and complete copies of Parent&#8217;s Organizational Documents. Parent is not in breach or violation of its Organizational Documents in any material respect.</p><a id="AuthorityBindingNatureofAgreement_64188"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">4.3&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority; Binding Nature of Agreement</span>. Parent and each Merger Sub has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Parent Board has: (a)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (b)&#160;approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement and (c)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Contemplated Transactions, and, if deemed necessary by Parent and the Company, the amendment to the certificate of incorporation of the Parent to (i)&#160;change the name of Parent to &#8220;Crescent Biopharma,&#160;Inc.&#8221;, (ii)&#160;effect the Nasdaq Reverse Split and (iii)&#160;make such other changes as are mutually agreeable to Parent and the Company pursuant to the terms of this Agreement. The First Merger Sub Board (by unanimous written consent) has: (x)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of First Merger Sub and its sole stockholder, (y)&#160;deemed advisable and approved this Agreement and the Contemplated Transactions and (z)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions. The sole member of Second Merger Sub (by unanimous written consent) has: (A)&#160;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger Sub and the sole member; and (B)&#160;deemed advisable and approved this </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Agreement and the Contemplated Transactions. This Agreement has been duly executed and delivered by Parent and Merger Subs and, assuming the due authorization, execution and delivery by the Company and the accuracy of the representation in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;3.23</span>, constitutes the legal, valid and binding obligation of Parent and Merger Subs, enforceable against each of Parent and Merger Subs in accordance with its terms, subject to the Enforceability Exceptions.</p><a id="VoteRequired_669155"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">4.4&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vote Required</span>. Assuming the accuracy of the representation in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;3.23</span>, the affirmative vote of a majority of the shares of Parent Common Stock properly cast at the Parent Stockholder Meeting is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary to approve this Agreement and thereby approve the Contemplated Transactions and clauses (i), (ii)&#160;and (iii)&#160;of the definition of &#8220;Parent Charter Amendment&#8221; (collectively, the &#8220;<b style="font-weight:bold;">Required Parent Stockholder Vote</b>&#8221;).</p><a id="NonContraventionConsents_177619"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">4.5&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Contravention; Consents</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Subject to obtaining the Required Parent Stockholder Vote, compliance with any applicable requirements of the HSR Act (if applicable) and the filing of the Certificate of Merger and Certificate of Designation required by the DGCL or DLLCA, and assuming the accuracy of the representation in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.23</span>, neither (x)&#160;the execution, delivery or performance of this Agreement by Parent or Merger Subs, nor (y)&#160;the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(i)&#160;&#160;&#160;&#160;contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Parent or its Subsidiaries;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which Parent or its Subsidiaries or any of the assets owned or used by Parent or its Subsidiaries, is subject;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iii)&#160;&#160;&#160;&#160;contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent or its Subsidiaries or that otherwise relates to the business of Parent, or any of the assets owned, leased or used by Parent;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iv)&#160;&#160;&#160;&#160;contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Parent Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise any remedy under any Parent Material Contract, (B)&#160;any material payment, rebate, chargeback, penalty or change in delivery schedule under any such Parent Material Contract, (C)&#160;accelerate the maturity or performance of any Parent Material Contract or (D)&#160;cancel, terminate or modify any term of any Parent Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(v)&#160;&#160;&#160;&#160;&#160;result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Parent or its Subsidiaries (except for Permitted Encumbrances).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;Except for (i)&#160;any Consent set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.5(a)</span>&#160;of the Parent Disclosure Letter under any Parent Contract, (ii)&#160;the Required Parent Stockholder Vote, (iii)&#160;the filing of the Certificate of Merger and Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA, (iv)&#160;compliance with any applicable requirements of the HSR Act (if applicable) and (v)&#160;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, and assuming the accuracy of the representation in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.23</span>, neither Parent nor any of its Subsidiaries was, is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x)&#160;the execution, delivery or performance of this Agreement or (y)&#160;the consummation of the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(c)&#160;&#160;&#160;&#160;Assuming the accuracy of the representation in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.23</span>, the Parent Board and the First Merger Sub Board have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&#160;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Agreement and to the consummation of the Contemplated Transactions. No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement or any of the other Contemplated Transactions.</p><a id="Capitalization_434210"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">4.6&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capitalization</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;The authorized capital stock of Parent consists of (i)&#160;150,000,000 shares of Parent Common Stock of which 64,483,958 shares have been issued and are outstanding as of September&#160;30, 2024 (the &#8220;<b style="font-weight:bold;">Capitalization Date</b>&#8221;) and (ii)&#160;5,000,000 shares of Parent Preferred Stock, par value $0.001 per share, of which none have been designated. No shares of Parent Preferred Stock have been issued and are outstanding as of the Capitalization Date. Parent does not hold any shares of its capital stock in its treasury.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;All of the outstanding shares of Parent Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than Encumbrances set forth in the Organizational Documents or under applicable securities Laws. None of the outstanding shares of Parent Common Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent. Except as contemplated herein, there is no Parent Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Parent Common Stock. Parent is not under any obligation, nor is Parent bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities. Section&#160;&#8206;4.6(b)&#160;of the Parent Disclosure Letter accurately and completely describes all repurchase rights held by Parent with respect to shares of Parent Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;Except for the Parent 2003 Stock Incentive Plan, the Parent 2013 Equity Incentive Plan and the Parent 2020 Inducement Plan (each as may be amended from time to time, collectively, the &#8220;<b style="font-weight:bold;">Parent Stock Plans</b>&#8221;) and except as set forth on Section&#160;&#8206;4.6(c)&#160;of the Parent Disclosure Letter, Parent does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. As of the Capitalization Date, Parent has reserved 14,257,627 shares of Parent Common Stock for issuance under the Parent Stock Plans, of which 13,163,469 shares have been issued and are currently outstanding, 117,157 shares have been reserved for issuance upon exercise or settlement of Parent Options and Parent Restricted Stock Units, as applicable, granted under the Parent Stock Plans, and 977,001 shares remain available for future issuance pursuant to the Parent Stock Plans. As of the Capitalization Date, Parent has reserved 3,554,364 shares of Parent Common Stock for future issuance pursuant to the Parent ESPP (of which 0 shares have been issued and are currently outstanding). <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.6(c)</span>&#160;of the Parent Disclosure Letter sets forth the following information with respect to each Parent Option outstanding as of the Capitalization Date, as applicable: (i)&#160;the name of the holder, (ii)&#160;the number of shares of Parent Common Stock subject to such Parent Option and Parent Restricted Stock Units as of the Capitalization Date, (iii)&#160;the exercise price of such Parent Option, (iv)&#160;the date on which such Parent Option or Parent Restricted Stock Unit was granted, (v)&#160;the applicable vesting schedule, including any acceleration provisions, (vi)&#160;the date on which such Parent Option expires, (vii)&#160;whether such Parent Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a nonqualified stock option and (viii)&#160;in the case of a Parent Option, the plan pursuant to which such Parent Option was granted. Parent has made available to the Company accurate and complete copies of equity incentive plans pursuant to which Parent has equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board and stockholder approval of the Parent Stock Plans and any amendments thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;Except for the outstanding Parent Options and Parent Restricted Stock Units, or as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.6(d)</span>&#160;of the Parent Disclosure Letter, there is no: (i)&#160;outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of Parent, (ii)&#160;outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Parent, (iii)&#160;stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which Parent is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities or (iv)&#160;condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of Parent. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to Parent.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;All outstanding shares of Parent Common Stock, Parent Options and Parent Restricted Stock Units, and other securities of Parent have been issued and granted in compliance in all material respects with (i)&#160;all applicable securities laws and other applicable Law and (ii)&#160;all requirements set forth in applicable Contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(f)&#160;&#160;&#160;&#160;With respect to Parent Options and Parent Restricted Stock Units granted pursuant to the Parent Stock Plans, (i)&#160;each grant of a Parent Option or Parent Restricted Stock Unit was duly authorized no later than the date on which the grant of such Parent Option and Parent Restricted Stock Unit was by its terms to be effective (the &#8220;<b style="font-weight:bold;">Parent Grant Date</b>&#8221;) by all necessary corporate action, including, as applicable, approval by the Parent Board (or a duly constituted and authorized committee thereof) or duly authorized officer and any required stockholder approval by the necessary number of votes or written consents, (ii)&#160;each Parent Option and Parent Restricted Stock Unit grant was made in accordance with the terms of the Parent Stock Plan pursuant to which it was granted and all other applicable Law and regulatory rules&#160;or requirements, and (iii)&#160;the per share exercise price of each Parent Option was not less than the fair market value of a share of Parent Common Stock on the applicable Parent Grant Date.</p><a id="SECFilingsFinancialStatements_841347"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">4.7&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC Filings; Financial Statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Parent has filed or furnished, as applicable, on a timely basis all forms, statements, certifications, reports and documents required to be filed or furnished by it with the SEC under the Exchange Act or the Securities Act (the &#8220;<b style="font-weight:bold;">Parent SEC Documents</b>&#8221;). As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be) and as of the time they were filed, none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The certifications and statements required by (i)&#160;Rule&#160;13a-14 under the Exchange Act and (ii)&#160;18 U.S.C. &#167;1350 (Section&#160;906 of the Sarbanes-Oxley Act) relating to the Parent SEC Documents (collectively, the &#8220;<b style="font-weight:bold;">Certifications</b>&#8221;) are accurate and complete and comply as to form and content with all applicable Laws. As used in this Section&#160;&#8206;4.7, the term &#8220;file&#8221; and variations thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i)&#160;complied as to form in all material respects with the Securities Act and the Exchange Act, as applicable, and the published rules&#160;and regulations of the SEC applicable thereto, (ii)&#160;were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, as permitted by Form&#160;10-Q of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (iii)&#160;fairly present, in all material respects, the financial position of Parent as of the respective dates thereof and the results of operations and cash flows of Parent for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed prior to the date hereof, there has been no material change in Parent&#8217;s accounting methods or principles that would be required to be disclosed in Parent&#8217;s financial statements in accordance with GAAP. The books of account and other financial records of Parent and each of its Subsidiaries are true and complete in all material respects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;Parent&#8217;s auditor has at all times since the date of enactment of the Sarbanes-Oxley Act been: (i)&#160;a registered public accounting firm (as defined in Section&#160;2(a)(12) of the Sarbanes-Oxley Act), (ii)&#160;to the Knowledge of Parent, &#8220;independent&#8221; with respect to Parent within the meaning of Regulation S-X under the Exchange Act and (iii)&#160;to the Knowledge of Parent, in compliance with subsections (g)&#160;through (l)&#160;of Section&#160;10A of the Exchange Act and the rules&#160;and regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;Except as set forth on Section&#160;&#8206;4.7(d)&#160;of the Parent Disclosure Letter, Parent has not received any comment letter from the SEC or the staff thereof or any correspondence from Nasdaq or the staff thereof relating to the delisting or maintenance of listing of the Parent Common Stock on Nasdaq. Parent has not disclosed any unresolved comments in the Parent SEC Documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(e)&#160;&#160;&#160;&#160;There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">general counsel of Parent, the Parent Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(f)&#160;&#160;&#160;&#160;Parent is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act, the Exchange Act and the applicable listing and governance rules&#160;and regulations of Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(g)&#160;&#160;&#160;&#160;Parent maintains a system of internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;of the Exchange Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i)&#160;that Parent maintains records that in reasonable detail accurately and fairly reflect Parent&#8217;s transactions and dispositions of assets, (ii)&#160;that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii)&#160;that receipts and expenditures are made only in accordance with the authorization policy and (iv)&#160;regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Parent&#8217;s assets that could have a material effect on Parent&#8217;s financial statements. Parent has evaluated the effectiveness of Parent&#8217;s internal control over financial reporting and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form&#160;10-K or Form&#160;10-Q (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Parent has disclosed to Parent&#8217;s auditors and the Audit Committee of the Parent Board (and made available to the Company a summary of the significant aspects of such disclosure) (A)&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Parent&#8217;s ability to record, process, summarize and report financial information and (B)&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in Parent&#8217;s or its Subsidiaries&#8217; internal control over financial reporting. Except as disclosed in the Parent SEC Documents filed prior to the date hereof, Parent&#8217;s internal control over financial reporting is effective at the reasonable assurance level and Parent has not identified any material weaknesses in the design or operation of Parent&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(h)&#160;&#160;&#160;&#160;Parent&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;of the Exchange Act) are designed to ensure that all information (both financial and nonfinancial) required to be disclosed by Parent in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules&#160;and forms of the SEC, and that all such information is accumulated and communicated to Parent&#8217;s principal executive officer and principal financial officer as appropriate to allow timely decisions regarding required disclosure and to make the Certifications and such disclosure controls and procedures are effective. Parent has carried out evaluation of the effectiveness of its disclosure controls and procedures as required by Rule&#160;13a-15 of the Exchange Act.</p><a id="AbsenceofChanges_567201"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">4.8&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Changes</span>. Except as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;4.8</span> of the Parent Disclosure Letter, between December&#160;31, 2023 and the date of this Agreement, Parent has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a)&#160;Parent Material Adverse Effect or (b)&#160;action, event or occurrence that would have required consent of the Company pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;Section&#160;5&#8206;(b)</span>&#160;of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.</p><a id="AbsenceofUndisclosedLiabilities_637885"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">4.9&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Absence of Undisclosed Liabilities</span>. Since December&#160;31, 2023, neither Parent nor any of its Subsidiaries has any Liability except for: (a)&#160;Liabilities disclosed, reflected or reserved against in the Parent Balance Sheet, (b)&#160;normal and recurring current Liabilities that have been incurred by Parent or its Subsidiaries since the date of the Parent Balance Sheet in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c)&#160;Liabilities for performance of obligations of Parent or any of its Subsidiaries under Parent Contracts, (d)&#160;Liabilities incurred in connection with the Contemplated Transactions or the Subscription Agreement, and (e)&#160;Liabilities described in Section&#160;&#8206;4.9 of the Parent Disclosure Letter.</p><a id="TitletoAssets_879796"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">4.10&#160;&#160;&#160;&#160;Title to Assets. Each of Parent and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a)&#160;all tangible assets reflected on the Parent Balance Sheet and (b)&#160;all other tangible assets reflected in the books and records of Parent as being owned by Parent. All of such </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">assets are owned or, in the case of leased assets, leased by Parent or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances.</p><a id="RealPropertyLeasehold_767237"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">4.11&#160;&#160;&#160;&#160;Real Property; Leasehold. Neither Parent nor any of its Subsidiaries owns or has ever owned any real property, nor is Parent party to any agreement to purchase or sell any real property. Parent has made available to the Company (a)&#160;an accurate and complete list of&#160;all real properties with respect to which Parent directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by Parent or any of its Subsidiaries and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;<b style="font-weight:bold;">Parent Real Estate Leases</b>&#8221;), each of which is in full force and effect, with no existing material default thereunder by Parent or its Subsidiaries or, to Parent&#8217;s Knowledge, the other party thereto.</p><a id="IntellectualProperty_602564"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">4.12&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.12(a)</span>&#160;of the Parent Disclosure Letter is an accurate, true and complete listing of all Parent Registered IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.12(b)</span>&#160;of the Parent Disclosure Letter accurately identifies (i)&#160;all Parent Contracts pursuant to which any Parent IP Rights are licensed to Parent (other than (A)&#160;any non-customized software that (1)&#160;is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2)&#160;is not incorporated into, or material to the development, manufacturing, or distribution of, any of Parent products or services, (B)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C)&#160;any confidential information provided under confidentiality agreements and (D)&#160;agreements between Parent and its employees in Parent&#8217;s standard form thereof) and (ii)&#160;whether the license or licenses granted to Parent are exclusive or nonexclusive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;Section&#160;&#8206;4.12(c)&#160;of the Parent Disclosure Letter accurately identifies each Parent Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Parent IP Rights (other than (i)&#160;any confidential information provided under confidentiality agreements and (ii)&#160;any Parent IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for Parent&#8217;s benefit).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;Neither Parent nor any of its Subsidiaries is bound by, and no Parent IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of Parent or any of its Subsidiaries to use, exploit, assert, or enforce any Parent IP Rights anywhere in the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;Parent or one of its Subsidiaries exclusively owns all right, title, and interest to and in the Parent IP Rights (other than (i)&#160;Parent IP Rights licensed to Parent, or co-owned rights each as identified in Section&#160;&#8206;4.12(e)&#160;of the Parent Disclosure Letter, (ii)&#160;any non-customized software that (A)&#160;is licensed to Parent solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B)&#160;is not incorporated into, or material to the development, manufacturing or distribution of, any of Parent or its Subsidiaries&#8217; products or services and (iii)&#160;any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(i)&#160;&#160;&#160;&#160;All documents and instruments necessary to register or apply for or renew registration of Parent Registered IP have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;Each Person who is or was an employee or contractor of Parent or any of its Subsidiaries and who is or was involved in the creation or development of any Intellectual Property for Parent or any of its Subsidiaries has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to Parent or such Subsidiary and confidentiality provisions protecting trade secrets and confidential information of Parent and its Subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 72pt;">(iii)&#160;&#160;&#160;&#160;To the Knowledge of Parent, no current or former stockholder, officer, director or employee of Parent or any of its Subsidiaries has any claim, right (whether currently exercisable, or exercisable in the future), or interest to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">or in any Parent IP Rights purported to be owned by Parent. To the Knowledge of Parent, no employee of Parent or any of its Subsidiaries is (a)&#160;bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for Parent or such Subsidiary or (b)&#160;in breach of any Contract with any former employer or other Person concerning Parent IP Rights purported to be owned by Parent or such Subsidiary or confidentiality provisions protecting trade secrets and confidential information comprising Parent IP Rights purported to be owned by Parent or such Subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iv)&#160;&#160;&#160;&#160;No funding, facilities or personnel of any Governmental Authority were used, directly or indirectly, to develop or create, in whole or in part, any Parent IP Rights in which Parent or any of its Subsidiaries has an ownership interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(v)&#160;&#160;&#160;&#160;&#160;Parent and each of its Subsidiaries has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary information that Parent or such Subsidiary holds, or purports to hold, as confidential or a trade secret.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(vi)&#160;&#160;&#160;&#160;Parent or any of its Subsidiaries has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Parent IP Rights to any other Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(f)&#160;&#160;&#160;&#160;Parent has delivered, or made available to the Company, a complete and accurate copy of all material Parent IP Rights Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(g)&#160;&#160;&#160;&#160;The manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by Parent does not violate any license or agreement between Parent or its Subsidiaries and any third party in any material respect, and, to the Knowledge of Parent, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent, no third party is infringing upon any Patents owned by Parent within the Parent IP Rights, or violating any Parent IP Rights Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(h)&#160;&#160;&#160;&#160;As of the date of this Agreement, Parent is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, ownership or right to use, sell, offer for sale, license or dispose of any Parent IP Rights. Parent has not received any written notice asserting that any Parent Registered IP or the proposed use, sale, offer for sale, license or disposition of any products, methods or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that Parent or any of its Subsidiaries have otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(i)&#160;&#160;&#160;&#160;To the Knowledge of Parent, no trademark (whether registered or unregistered) or trade name owned, used or applied for by Parent conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person except as would not have a Parent Material Adverse Effect. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which Parent has or purports to have an ownership interest has been impaired as determined by Parent in accordance with GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(j)&#160;&#160;&#160;&#160;Except as may be set forth in the Contracts listed on Section&#160;&#8206;4.12(b), &#8206;4.12(c)&#160;or &#8206;4.12(k)&#160;of the Parent Disclosure Letter or as contained in &#8220;off-the-shelf&#8221; license agreements entered into in the Ordinary Course of Business by Parent, (i)&#160;Parent is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation or similar claim which is material to Parent taken as a whole and (ii)&#160;Parent has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(k)&#160;&#160;&#160;&#160;Neither Parent nor any of its Subsidiaries is party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the grant of any license or other right to any Parent IP Rights, result in breach of, default under or termination of such Contract with respect to any Parent IP Rights, or impair the right of Parent or the Surviving Entity and its Subsidiaries to use, sell or license or enforce any Parent IP Rights or portion </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">thereof, except for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Parent Material Adverse Effect.</p><a id="AgreementsContractsandCommitments_284572"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">4.13&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreements, Contracts and Commitments</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.13</span> of the Parent Disclosure Letter identifies each Parent Contract that is in effect as of the date of this Agreement other than the Subscription Agreement (each, an &#8220;<b style="font-weight:bold;">Parent Material Contract</b>&#8221; and collectively, the &#8220;<b style="font-weight:bold;">Parent Material Contracts</b>&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(i)&#160;&#160;&#160;&#160;each Parent Contract relating to any material bonus, deferred compensation, severance, incentive compensation, pension, profit-sharing or retirement plans, or any other employee benefit plans or arrangements;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;each Parent Contract requiring payments by Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to the employment of, or the performance of employment-related services by, any Parent Associate providing employment related, consulting or independent contractor services, not terminable by Parent on thirty (30) calendar days&#8217; or less notice without liability;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iii)&#160;&#160;&#160;&#160;each Parent Contract relating to any agreement or plan, including any option plan, stock appreciation right plan or stock purchase plan, any of the benefits of which will be increased or the vesting of benefits of which will be accelerated, by the occurrence of any of the Contemplated Transactions (either alone or in conjunction with any other event, such as termination of employment), or the value of any of the benefits of which will be calculated on the basis of any of the Contemplated Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iv)&#160;&#160;&#160;&#160;each Parent Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(v)&#160;&#160;&#160;&#160;&#160;each Parent Contract containing (A)&#160;any covenant limiting the freedom of Parent or any of its Subsidiaries to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Parent&#8217;s products or services (B)&#160;any most-favored pricing arrangement, (C)&#160;any exclusivity provision or (D)&#160;any non-solicitation provision;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(vi)&#160;&#160;&#160;&#160;each Parent Contract (A)&#160;pursuant to which any Person granted Parent an exclusive license under any Intellectual Property, or (B)&#160;pursuant to which Parent granted any Person an exclusive license under any Parent IP Rights;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(vii)&#160;&#160;&#160;&#160;each Parent Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of Parent, any of its Subsidiaries, or of a product;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(viii)&#160;&#160;&#160;&#160;each Parent Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ix)&#160;&#160;&#160;&#160;each Parent Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(x)&#160;&#160;&#160;&#160;&#160;each Parent Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which Parent or any of its Subsidiaries has outstanding obligations to pay consideration in excess of $100,000;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xi)&#160;&#160;&#160;&#160;each Parent Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of Parent or any loans or debt obligations with officers or directors of Parent;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 72pt;">(xii)&#160;&#160;&#160;&#160;each Parent Contract requiring payment by or to Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A)&#160;any distribution agreement (identifying any that contain exclusivity provisions), (B)&#160;any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of Parent, (C)&#160;any dealer, distributor, joint marketing, alliance, joint </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">venture, cooperation, development or other agreement currently in force under which Parent or any of its Subsidiaries has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Parent or any of its Subsidiaries has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by Parent or such Subsidiary or (D)&#160;any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of Parent or any of its Subsidiaries or any Contract to sell, distribute or commercialize any products or service of Parent or any of its Subsidiaries, in each case, except for Parent Contracts entered into in the Ordinary Course of Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xiii)&#160;&#160;&#160;&#160;each Parent Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to Parent in connection with the Contemplated Transactions and requiring payments by Parent after the date in this Agreement in excess of $100,000 pursuant to its express terms;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xiv)&#160;&#160;&#160;&#160;each Parent Contract to which Parent or any of its Subsidiaries is a party or by which any of their assets and properties is currently bound (other than Parent Real Estate Leases), which involves annual obligations of payment by, or annual payments to, Parent or such Subsidiary in excess of $100,000;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xv)&#160;&#160;&#160;&#160;any Parent Real Estate Lease;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xvi)&#160;&#160;&#160;&#160;a Contract disclosed in or required to be disclosed in Section&#160;&#8206;4.12(b)&#160;or Section&#160;&#8206;4.12(c)&#160;of the Parent Disclosure Letter; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xvii)&#160;&#160;&#160;&#160;any other Parent Contract (other than Parent Real Estate Leases) that is not terminable at will (with no penalty or payment) by Parent or any of its Subsidiaries, and (A)&#160;which involves payment or receipt by Parent or such Subsidiary after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate or (B)&#160;that is material to the business or operations of Parent and its Subsidiaries taken as a whole.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;Parent has delivered or made available to the Company accurate and complete copies of all Parent Material Contracts, including all amendments thereto. There are no Parent Material Contracts that are not in written form. Parent has not nor, to Parent&#8217;s Knowledge as of the date of this Agreement, has any other party to a Parent Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Parent Material Contract in such a manner, and, if such Parent Material Contract provides for a cure period, Parent or such other party fails to have cured such breach, violation or default, so that any other party or Parent, as the case may be, is permitted to modify, cancel or terminate any such Parent Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Parent Material Adverse Effect. As to Parent and its Subsidiaries, as of the date of this Agreement, each Parent Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to Parent under any Parent Material Contract or any other material term or provision of any Parent Material Contract.</p><a id="CompliancePermitsRestrictions_645775"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">4.14&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance; Permits; Restrictions</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Parent and each of its Subsidiaries is, and since January&#160;1, 2023, has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or other action by any Governmental Authority is pending or, to the Knowledge of Parent, threatened against Parent or any of its Subsidiaries. There is no agreement or Order binding upon Parent or any of its Subsidiaries which (i)&#160;has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Parent or any of its Subsidiaries, any acquisition of material property by Parent or any of its Subsidiaries or the conduct of business by Parent or any of its Subsidiaries as currently conducted, (ii)&#160;is reasonably likely to have an adverse effect on Parent&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii)&#160;is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(b)&#160;&#160;&#160;&#160;Except for matters regarding the FDA or other Drug/Device Regulatory Agency, each of Parent and its Subsidiaries holds all required Governmental Authorizations that are material to the operation of the business of Parent and Merger Subs as currently conducted (collectively, the &#8220;<b style="font-weight:bold;">Parent Permits</b>&#8221;). Section&#160;&#8206;4.14(b)&#160;of the Parent Disclosure </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Letter identifies each Parent Permit. Each of Parent and its Subsidiaries is in material compliance with the terms of the Parent Permits. No Legal Proceeding is pending or, to the Knowledge of Parent, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Parent Permit. The rights and benefits of each Parent Permit, if any, will be available to Parent and Surviving Entity immediately after the Second Effective Time on terms substantially identical to those enjoyed by Parent and its Subsidiaries as of the date of this Agreement and immediately prior to the First Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;There are no Legal Proceedings pending or, to the Knowledge of Parent, threatened with respect to an alleged violation by Parent or any of its Subsidiaries of the FDCA, PHSA, FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;Each of Parent and its Subsidiaries holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the business of Parent and Merger Subs as currently conducted, and, as applicable, the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its product candidates (the &#8220;<b style="font-weight:bold;">Parent Product Candidates</b>&#8221;) (the &#8220;<b style="font-weight:bold;">Parent Regulatory Permits</b>&#8221;) and no such Parent Regulatory Permit has been (i)&#160;revoked, withdrawn, suspended, cancelled or terminated or (ii)&#160;modified in any adverse manner other than immaterial adverse modifications. Section&#160;&#8206;4.14(d)&#160;of the Parent Disclosure Letter identifies each Parent Regulatory Permit. Parent has timely maintained and is in compliance in all material respects with the Parent Regulatory Permits and neither Parent nor or any of its Subsidiaries has, since January&#160;1, 2023, received any written notice or correspondence or, to the Knowledge of Parent, other communication from any Drug/Device Regulatory Agency regarding (A)&#160;any material violation of or failure to comply materially with any term or requirement of any Parent Regulatory Permit or (B)&#160;any revocation, withdrawal, suspension, cancellation, termination or material modification of any Parent Regulatory Permit. Parent has made available to the Company all information requested by the Company in Parent&#8217;s or its Subsidiaries&#8217; possession or control relating to material Parent Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Parent Product Candidates, including, but not limited to, complete copies of the following (to the extent there are any): (x)&#160;adverse event reports; pre-clinical, clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y)&#160;similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information are accurate and complete in all material respects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;All clinical, pre-clinical and other studies and tests conducted by or on behalf of, or sponsored by, Parent or its Subsidiaries, in which Parent or its Subsidiaries or their respective product candidates, including the Parent Product Candidates, have participated were, since January&#160;1, 2023, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific research procedures, and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. Since January&#160;1, 2023, neither Parent nor any of its Subsidiaries has received any written notices, correspondence, or other communications from any Drug/Device Regulatory Agency requiring or, to the Knowledge of Parent, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by or on behalf of, or sponsored by, Parent or any of its Subsidiaries or in which Parent or any of its Subsidiaries or its current product candidates, including the Parent Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical study conducted by or, to the Knowledge of Parent, on behalf of Parent or any of its Subsidiaries has been disqualified from participating in studies involving the Parent Product Candidates, and to the Knowledge of Parent, no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(f)&#160;&#160;&#160;&#160;Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate is the subject of any pending or, to the Knowledge of Parent, threatened investigation in respect of its business or products by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September&#160;10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable policy. Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer, nor their respective officers, employees or agents, with respect to any Parent Product Candidate has committed any acts, made any statement or failed to make any statement, in each case in respect of its business or products that would violate FDA&#8217;s &#8220;Fraud, Untrue Statements of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto. None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in a material debarment or exclusion under (i)&#160;21 U.S.C. Section&#160;335a or (ii)&#160;any similar applicable Law. To the Knowledge of Parent, no material debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against Parent, any of its Subsidiaries, and to the Knowledge of the Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of its officers, employees or agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(g)&#160;&#160;&#160;&#160;All manufacturing operations conducted by, or to the Knowledge of Parent, for the benefit of, Parent or its Subsidiaries in connection with any Parent Product Candidate, since January&#160;1, 2023, have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210 and 211, and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(h)&#160;&#160;&#160;&#160;None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any manufacturing site of a contract manufacturer or laboratory, with respect to any Parent Product Candidate, (i)&#160;is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii)&#160;has received any Form&#160;FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA or other Drug/Device Regulatory Agency alleging or asserting noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of Parent, neither the FDA nor any other Drug/Device Regulatory Agency is considering such action.</p><a id="LegalProceedingsOrders_709672"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">4.15&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legal Proceedings; Orders</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;There is no pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened in writing to commence any Legal Proceeding: (i)&#160;that involves Parent or any of its Subsidiaries or any Parent Associate (in his or her capacity as such) or any of the material assets owned or used by Parent or any of its Subsidiaries or (ii)&#160;that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;There is no Order to which Parent or any of its Subsidiaries, or any of the material assets owned or used by Parent or any of its Subsidiaries is subject. To the Knowledge of Parent, no officer or other Parent Key Employee or any of its Subsidiaries is subject to any Order that prohibits such officer or employee from engaging in or continuing in any conduct, activity or practice relating to the business of Parent or any of its Subsidiaries or any material assets owned or used by Parent or any of its Subsidiaries.</p><a id="TaxMatters_199043"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">4.16&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Each of Parent and each of its Subsidiaries has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed by it under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete in all material respects. Subject to exceptions as would not be material, no claim has been made by a Governmental Authority in a jurisdiction where Parent or any of its Subsidiaries does not file Tax Returns that Parent or any of its Subsidiaries is subject to taxation by that jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;All material amounts of Taxes due and owing by Parent or any of its Subsidiaries (whether or not shown on any Tax Return) have been timely paid (taking into account any applicable extensions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;Each of Parent and each of its Subsidiaries has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;There are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause (a)&#160;of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of Parent or any of its Subsidiaries.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;No deficiencies for a material amount of Taxes with respect to Parent or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of Parent or any of its Subsidiaries. Neither Parent nor any of its Subsidiaries has granted a waiver of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(f)&#160;&#160;&#160;&#160;Neither Parent nor any of its Subsidiaries is a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than Ordinary Course Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(g)&#160;&#160;&#160;&#160;Neither Parent nor any of its Subsidiaries has been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is Parent). Neither Parent nor any of its Subsidiaries has any material Liability for the Taxes of any Person (other than Parent or its Subsidiaries) under Treasury Regulations Section&#160;1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(h)&#160;&#160;&#160;&#160;Neither Parent nor any of its Subsidiaries has distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(i)&#160;&#160;&#160;&#160;Neither Parent nor any of its Subsidiaries has entered into any transaction identified as a &#8220;listed transaction&#8221; for purposes of Treasury Regulations Sections&#160;1.6011-4(b)(2)&#160;or 301.6111-2(b)(2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(j)&#160;&#160;&#160;&#160;Neither Parent nor any of its Subsidiaries is aware of any facts or circumstances or has taken or agreed to take any action, in each case, that would reasonably be expected to prevent or impede the Intended Tax Treatment.</p><a id="EmployeeandLaborMattersBenefitPlans_8128"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">4.17&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee and Labor Matters; Benefit Plans</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;The Parent has made available to Company a list setting forth, for each Parent Associate who is an employee of Parent or any of its Subsidiaries, such employee&#8217;s name, employer, title, hire date, location, whether full- or part-time, whether active or on leave (and, if on leave, the expected return), whether exempt from the Fair Labor Standards Act and applicable state law, annual salary (or if hourly, hourly rate), most recent annual bonus received and current annual bonus opportunity. The Parent has made available to Company a list setting forth, for each Parent Associate who is an individual independent contractor engaged by Parent or any of its Subsidiaries, such contractor&#8217;s name, duties and rate of compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;The employment of Parent&#8217;s employees is terminable by Parent at will. Parent has made available to the Company accurate and complete copies of all employee manuals and handbooks, to the extent currently effective and material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;Parent is not a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing any of its employees, and there are no labor organizations representing or, to the Knowledge of Parent, purporting to represent or seeking to represent any employees of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;Section&#160;&#8206;4.17(d)&#160;of the Parent Disclosure Letter lists all Parent Employee Plans (other than employment arrangements which are terminable &#8220;at will&#8221; without any contractual obligation on the part of Parent or any of its Subsidiaries to make any severance, termination, change in control or similar payment and that are substantively identical to the employment arrangements made available to the Company).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;Each Parent Employee Plan that is intended to be qualified under Section&#160;401(a)&#160;of the Code has received a favorable determination or opinion letter with respect to such qualified status from the IRS. To the Knowledge of Parent, nothing has occurred that would reasonably be expected to adversely affect the qualified status of any such Parent Employee Plan or the exempt status of any related trust.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(f)&#160;&#160;&#160;&#160;Each Parent Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of Parent, threatened with respect to any Parent Employee Plan. All payments and/or contributions required to have been made with respect to all Parent Employee Plans either have been made or have been accrued in accordance with the terms of the applicable Parent Employee Plan and applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(g)&#160;&#160;&#160;&#160;Neither Parent nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6)&#160;years, maintained, contributed to or been required to contribute to (i)&#160;any &#8220;employee benefit plan&#8221; that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii)&#160;a Multiemployer Plan, (iii)&#160;any funded welfare benefit plan within the meaning of Section&#160;419 of the Code, (iv)&#160;any Multiple Employer Plan, or (v)&#160;any Multiple Employer Welfare Arrangement. Neither Parent nor any of its ERISA Affiliates has ever incurred any liability under Title IV of ERISA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(h)&#160;&#160;&#160;&#160;No Parent Employee Plan provides for, and neither Parent nor any of its Subsidiaries has promised to provide any, medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (i)&#160;pursuant to COBRA or an analogous state law requirement or (ii)&#160;continuation coverage through the end of the month in which such termination or retirement occurs. Parent does not sponsor or maintain any self-funded medical or long-term disability benefit plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(i)&#160;&#160;&#160;&#160;No Parent Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(j)&#160;&#160;&#160;&#160;Each Parent Employee Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section&#160;409A(d)(1)&#160;of the Code and the guidance thereunder) (each, a &#8220;<b style="font-weight:bold;">Parent 409A Plan</b>&#8221;) has been operated and maintained in all material respects in operational and documentary compliance with the requirements of Section&#160;409A of the Code and the applicable guidance thereunder. No payment to be made under any Parent 409A Plan is or, when made in accordance with the terms of the Parent 409A Plan, will be subject to the penalties of Section&#160;409A(a)(1)&#160;of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(k)&#160;&#160;&#160;&#160;Parent is in material compliance with all Employment-Related Laws and in each case, with respect to the employees of Parent: (i)&#160;has withheld and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees, (ii)&#160;is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing and (iii)&#160;is not liable for any material payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of Parent, threatened or reasonably anticipated against or involving Parent or any trustee of Parent relating to any employee, contingent worker, director, employment agreement or Parent Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of Parent, there are no material pending or threatened or reasonably anticipated claims or actions against Parent, any Parent trustee or any trustee of any Subsidiary of Parent under any workers&#8217; compensation policy or long-term disability policy. Parent is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental Authority with respect to employment practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(l)&#160;&#160;&#160;&#160;Parent has no material liability with respect to any misclassification within the past three (3)&#160;years of: (i)&#160;any Person as an independent contractor rather than as an employee, (ii)&#160;any employee leased from another employer or (iii)&#160;any employee currently or formerly classified as exempt from overtime wages. Parent has not taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has Parent been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(m)&#160;&#160;&#160;&#160;To the Knowledge of Parent, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, with respect to any Parent Associate. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Knowledge of Parent, might directly or indirectly be likely to give rise to or provide a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(n)&#160;&#160;&#160;&#160;Parent is not, nor has Parent been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of Parent, threatened or reasonably anticipated relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers&#8217; compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current or former employee of Parent, including charges of unfair labor practices or discrimination complaints.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(o)&#160;&#160;&#160;&#160;There is no contract, agreement, plan or arrangement to which Parent or any of its Subsidiaries is a party or by which it is bound to compensate any of its employees or other service providers for any income or excise taxes paid pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(p)&#160;&#160;&#160;&#160;Neither Parent nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) (i)&#160;result in the payment of any &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code or (ii)&#160;result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other service provider of Parent or any of its Subsidiaries.</p><a id="EnvironmentalMatters_611358"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">4.18&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Matters</span>. Since January&#160;1, 2023, Parent and each of its Subsidiaries has complied with all applicable Environmental Laws, which compliance includes the possession by Parent of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Parent Material Adverse Effect. Neither Parent nor any of its Subsidiaries has received since January&#160;1, 2023, any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that Parent or any of its Subsidiaries is not in compliance with any Environmental Law, and, to the Knowledge of Parent, there are no circumstances that may prevent or interfere with Parent&#8217;s or any of its Subsidiaries&#8217; compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent: (i)&#160;no current or prior owner of any property leased or controlled by Parent or any of its Subsidiaries has received since January&#160;1, 2023, any written notice or other communication relating to property owned or leased at any time by Parent or any of its Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or Parent or any of its Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (ii)&#160;neither Parent nor any of its Subsidiaries has any material liability under any Environmental Law. Parent has made available all environmental site assessments, environmental audits and other material environmental documents in the Parent&#8217;s possession or control relating to the Parent and its Subsidiaries, including the Parent&#8217;s and its Subsidiaries&#8217; business and current or former facilities.</p><a id="Insurance_164897"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">4.19&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</span>. Parent has delivered to the Company accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Parent and its Subsidiaries (including Merger Subs). Each of such insurance policies is in full force and effect and Parent and its Subsidiaries (including Merger Subs) are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January&#160;1, 2023, neither Parent nor any of its Subsidiaries has received any notice or other communication regarding any actual or possible: (i)&#160;cancellation or invalidation of any insurance policy or (ii)&#160;refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. Each of Parent and its Subsidiaries (including Merger Subs) has provided timely written notice to the appropriate insurance carrier(s)&#160;of each Legal Proceeding pending against Parent or such Subsidiary for which Parent or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Parent or any of its Subsidiaries of its intent to do so.</p><a id="TransactionswithAffiliates_830300"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">4.20&#160;&#160;&#160;&#160;Transactions with Affiliates. Except as set forth in the Parent SEC Documents filed prior to the date of this Agreement, since the date of Parent&#8217;s last proxy statement filed with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item 404 of Regulation S-K promulgated by the SEC. Section&#160;&#8206;4.20 of the Parent </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Disclosure Letter identifies each Person who is (or who may be deemed to be) an Affiliate of Parent as of the date of this Agreement.</p><a id="NoFinancialAdvisors_404785"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">4.21&#160;&#160;&#160;&#160;No Financial Advisors. Except as set forth on Section&#160;&#8206;4.21 of the Parent Disclosure Letter, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent.</p><a id="ValidIssuance_191646"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">4.22&#160;&#160;&#160;&#160;Valid Issuance. The Parent Capital Stock (including any Parent Common Stock issuable upon conversion thereof) to be issued in the Merger will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable. The Parent Common Stock issuable upon conversion of any Parent Capital Stock has been duly reserved for issuance, and upon issuance in accordance with the terms of the Certificate of Designation, will be validly issued, fully paid and nonassessable.</p><a id="PrivacyandDataSecurity_516687"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">4.23&#160;&#160;&#160;&#160;Privacy and Data Security. Parent and its Subsidiaries are and since January&#160;1, 2023, have been in compliance with all applicable Privacy Laws and the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with Parent or any of its Subsidiaries in connection with the operation of Parent&#8217;s and its Subsidiaries&#8217; business), except, in each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, Parent (i)&#160;has implemented and maintains reasonable Privacy Policies that materially comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information and (ii)&#160;has complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, no Legal Proceeding has been asserted or threatened against Parent by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of Parent, there have been no data security incidents or data breaches, or other adverse events or incidents that have resulted in any unauthorized access, use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of Parent or any service provider acting on behalf of Parent, in each case, where such incident, breach, or event has resulted in a notification obligation to any Person under applicable Law or pursuant to the terms of any Parent Contract.</p><a id="NoOtherRepresentationsorWarranties_60917"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">4.24&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Representations or Warranties</span>. Parent hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither the Company nor any of its Subsidiaries nor any other person on behalf of the Company or its Subsidiaries makes any express or implied representation or warranty with respect to the Company or its Subsidiaries or with respect to any other information provided to Parent, Merger Subs or stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of the Company set forth in Section<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;3</span> (in each case as qualified and limited by the Company Disclosure Letter)) none of Parent, Merger Subs nor any of their respective Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof).</p><a id="Section5CertainCovenantsoftheParties_497"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Section&#160;5. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Covenants of the Parties</span>.</p><a id="OperationofParentsBusiness_673731"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">5.1&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operation of Parent&#8217;s Business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(a)&#160;&#160;&#160;&#160;Except (i)&#160;as expressly contemplated or permitted by this Agreement or the Subscription Agreement, (ii)&#160;as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.1(a)</span>&#160;of the Parent Disclosure Letter, (iii)&#160;as required by applicable Law, or (iv)&#160;unless the Company shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the period commencing on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to Section<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;10</span> and the First Effective Time (the &#8220;<b style="font-weight:bold;">Pre-Closing Period</b>&#8221;), Parent shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to (x)&#160;conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Parent Material Contracts and (y)&#160;continue to pay material outstanding accounts payable and other material current Liabilities (including payroll) when due and payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;Except (i)&#160;as expressly contemplated or permitted by this Agreement or the Subscription Agreement, (ii)&#160;as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.1(b)</span>&#160;of the Parent Disclosure Letter, (iii)&#160;as required by applicable Law, or (iv)&#160;with the prior written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent shall not, nor shall it cause or permit any of Subsidiaries to, do any of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(i)&#160;&#160;&#160;&#160;declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities, (except for shares of Parent Common Stock from terminated employees, directors or consultants of Parent);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;except as required to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iii)&#160;&#160;&#160;&#160;sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (A)&#160;any capital stock or other security (except for Parent Common Stock issued upon the valid exercise or settlement of outstanding Parent Options or Parent Restricted Stock Units, as applicable), (B)&#160;any option, warrant or right to acquire any capital stock or any other security or (C)&#160;any instrument convertible into or exchangeable for any capital stock or other security;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iv)&#160;&#160;&#160;&#160;form any Subsidiary or acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(v)&#160;&#160;&#160;&#160;&#160;(A)&#160;lend money to any Person, (B)&#160;incur or guarantee any indebtedness for borrowed money, (C)&#160;guarantee any debt securities of others or (D)&#160;make any capital expenditure or commitment in excess of $25,000;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(vi)&#160;&#160;&#160;&#160;(A)&#160;adopt, establish or enter into any Parent Employee Plan, including, for the avoidance of doubt, any equity awards plans, (B)&#160;cause or permit any Parent Employee Plan to be amended other than as required by law or in order to make amendments for the purposes of compliance with Section&#160;409A of the Code, (C)&#160;pay any bonus or make any profit-sharing or similar payment to (except with respect to obligations in place on the date of this Agreement pursuant to any Parent Employee Plan disclosed to the Company), or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers, employees or consultants, (D)&#160;increase the severance or change of control benefits offered to any current or new employees, directors or consultants, or (E)&#160;hire any officer, employee or consultant;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(vii)&#160;&#160;&#160;&#160;acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(viii)&#160;&#160;&#160;&#160;sell, assign, transfer, license, sublicense or otherwise dispose of any material Parent IP Rights (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ix)&#160;&#160;&#160;&#160;other than in the Ordinary Course of Business: (A)&#160;make, change or revoke any material Tax election; (B)&#160;file any amended income or other material Tax Return; (C)&#160;adopt or change any material accounting method in respect of Taxes; (D)&#160;enter into any material Tax closing agreement, settle any material Tax claim or assessment; (E)&#160;consent to any extension or waiver of the limitation period applicable to or relating to any material Tax claim or assessment; or (F)&#160;surrender any material claim for refund;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(x)&#160;&#160;&#160;&#160;&#160;waive, settle or compromise any pending or threatened Legal Proceeding against Parent or any of its Subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of Parent or its Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Parent or any of its Subsidiaries;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xi)&#160;&#160;&#160;&#160;delay or fail to repay when due any material obligation, including accounts payable and accrued expenses;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xii)&#160;&#160;&#160;&#160;forgive any loans to any Person, including its employees, officers, directors or Affiliate;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xiii)&#160;&#160;&#160;&#160;terminate or modify in any material respect, or fail to exercise renewal rights with respect to, any material insurance policy;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xiv)&#160;&#160;&#160;&#160;(A)&#160;materially change pricing or royalties or other payments set or charged by Parent or any of Subsidiaries to its customers or licensees or (B)&#160;agree to materially change pricing or royalties or other payments set or charged by Persons who have licensed Intellectual Property to Parent or any of Subsidiaries;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xv)&#160;&#160;&#160;&#160;enter into, amend in a manner adverse to Parent or terminate any Parent Material Contract outside of the Ordinary Course of Business; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(xvi)&#160;&#160;&#160;&#160;agree, resolve or commit to do any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nothing contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the First Effective Time. Prior to the First Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</p><a id="OperationoftheCompanysBusiness_408413"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">5.2&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Operation of the Company&#8217;s Business</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Except (i)&#160;as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.2(a)</span>&#160;of the Company Disclosure Letter, (iii)&#160;as required by applicable Law, (iv)&#160;with respect to any Interim Financing or Company Acquisition, which are expressly permitted, or (v)&#160;unless Parent shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the Pre-Closing Period the Company shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute Company Material Contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;Except (i)&#160;as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.2(b)</span>&#160;of the Company Disclosure Letter, (iii)&#160;as required by applicable Law, (iv)&#160;in connection with any Interim Financing or Company Acquisition, which are expressly permitted, or (v)&#160;with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, the Company shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(i)&#160;&#160;&#160;&#160;declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock; or repurchase, redeem or otherwise reacquire any shares of Company Capital Stock or other securities (except for shares of Company Common Stock from terminated employees, directors or consultants of the Company);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;except as required to give effect to anything in contemplation of the Closing, amend any of its or its Subsidiaries&#8217; Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iii)&#160;&#160;&#160;&#160;other than in the Ordinary Course of Business, sell, issue grant, or authorize any of the foregoing actions with respect to more than 25% of the shares of Company Capital Stock outstanding as of the date of this Agreement: (A)&#160;any capital stock or other security of the Company or any of its Subsidiaries (except for shares of outstanding Company Common Stock issued upon the valid exercise of Company Options or Company Warrants), (B)&#160;any option, warrant or right to acquire any capital stock or any other security or (C)&#160;any instrument convertible into or exchangeable for any capital stock or other security of the Company or any of its Subsidiaries;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(iv)&#160;&#160;&#160;&#160;other than in the Ordinary Course of Business, acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(v)&#160;&#160;&#160;&#160;&#160;(A)&#160;lend money to any Person, (B)&#160;incur or guarantee any indebtedness for borrowed money, or (C)&#160;guarantee any debt securities of others;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(vi)&#160;&#160;&#160;&#160;sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties, except in the Ordinary Course of Business;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(vii)&#160;&#160;&#160;&#160;sell, assign, transfer, license, sublicense or otherwise dispose of any material Company IP Rights (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(viii)&#160;&#160;&#160;&#160;waive, settle or compromise any pending or threatened Legal Proceeding against the Company, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of the Company or any equitable relief on, or the admission of wrongdoing by the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(ix)&#160;&#160;&#160;&#160;&#160;enter into, amend in a manner adverse to the Company or terminate any Company Material Contract outside of the Ordinary Course of Business; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 72pt;">(x)&#160;&#160;&#160;&#160;agree, resolve or commit to do any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the First Effective Time. Prior to the First Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</p><a id="AccessandInvestigation_256065"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">5.3&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Access and Investigation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Subject to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement, during the Pre-Closing Period, upon reasonable notice, Parent, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such Party&#8217;s Representatives to: (a)&#160;provide the other Party and such other Party&#8217;s Representatives with reasonable access during normal business hours to such Party&#8217;s Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and its Subsidiaries, (b)&#160;provide the other Party and such other Party&#8217;s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably request, (c)&#160;permit the other Party&#8217;s officers and other employees to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other officers and managers of such Party responsible for such Party&#8217;s financial statements and the internal controls of such Party to discuss such matters as the other Party may deem necessary, and (d)&#160;make available to the other Party copies of any material notice, report or other document filed with or sent to or received from any Governmental Authority in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.3</span> shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.3</span>, no access or examination contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.3</span> shall be permitted to the extent that it would require any Party or its Subsidiaries to waive the attorney-client privilege or attorney work product privilege, or violate any applicable Law; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that such Party or its Subsidiary (i)&#160;shall be entitled to withhold only such information that may not be provided without causing such violation or waiver, (ii)&#160;shall provide to the other Party all related information that may be provided without causing such violation or waiver (including, to the extent permitted, redacted versions of any such information) and (iii)&#160;shall enter into such effective and appropriate joint-defense agreements or other protective arrangements as may be reasonably requested by the other Party in order that all such information may be provided to the other Party without causing such violation or waiver.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="NoSolicitation_194920"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">5.4&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Solicitation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Each of Parent and the Company agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize or permit any of its Representatives to, directly or indirectly,: (i)&#160;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry, (ii)&#160;furnish any non-public information regarding such Party to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry, (iii)&#160;engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry, (iv)&#160;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction or (v)&#160;publicly propose to do any of the foregoing; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that, (x)&#160;any public disclosures made in compliance with Section&#160;6.3(e)&#160;shall not constitute a violation of this Section&#160;5.4 and (y)&#160;notwithstanding anything contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.4</span> and subject to compliance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.4</span>, prior to the approval of this Agreement by a Party&#8217;s stockholders (i.e., the Required Company Stockholder Vote, in the case of the Company and its Subsidiaries, or the Required Parent Stockholder Vote in the case of Parent), such Party may furnish non-public information regarding such Party and its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a bona fide written Acquisition Proposal by such Person which such Party&#8217;s board of directors determines in good faith, after consultation with such Party&#8217;s financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A)&#160;such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of this Agreement, (B)&#160;the board of directors of such Party concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the board of directors&#8217; fiduciary duties under applicable Law, (C)&#160;at least two&#160;(2)&#160;Business Days prior to initially furnishing any such nonpublic information to, or entering into discussions with, such Person, such Party gives the other Party written notice of the identity of such Person and of such Party&#8217;s intention to furnish nonpublic information to, or enter into discussions with, such Person, (D)&#160;such Party receives from such Person an executed Acceptable Confidentiality Agreement and (E)&#160;at least two&#160;(2)&#160;Business Days prior to furnishing any such nonpublic information to such Person, such Party furnishes such nonpublic information to the other Party (to the extent such information has not been previously furnished by such Party to the other Party). Without limiting the generality of the foregoing, each Party acknowledges and agrees that, in the event any Representative of such Party takes any action that, if taken by such Party, would constitute a breach of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.4</span> by such Party, the taking of such action by such Representative shall be deemed to constitute a breach of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.4</span> by such Party for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;If any Party or any Representative of such Party receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then such Party shall promptly (and in no event later than one&#160;(1)&#160;Business Day after such Party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other Party in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the terms thereof). Such Party shall keep the other Party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;Each Party shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any nonpublic information provided to such Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;For the avoidance of doubt and notwithstanding anything to the contrary in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.4</span>, the Company shall be expressly permitted to take any action with respect to an Interim Financing or a Company Acquisition.</p><a id="NotificationofCertainMatters_886732"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">5.5&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notification of Certain Matters</span>. During the Pre-Closing Period, each of the Company, on the one hand, and Parent, on the other hand, shall promptly notify the other (and, if in writing, furnish copies of) if any of the following occurs: (a)&#160;any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions, (b)&#160;any Legal Proceeding against or involving or otherwise affecting such Party or its Subsidiaries is commenced, or, to the Knowledge of such Party, threatened against such Party or, to the Knowledge of such Party, any director or officer of such Party, (c)&#160;such Party becomes aware of any inaccuracy in any representation or warranty made by such Party in this Agreement or (d)&#160;the failure of such Party to comply with any covenant or obligation of such Party; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;6.19</span>, Section<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;8</span> or Section<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;9</span>, as applicable, impossible or materially less likely. No such notice shall be </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">deemed to supplement or amend the Company Disclosure Letter or the Parent Disclosure Letter for the purpose of (x)&#160;determining the accuracy of any of the representations and warranties made by the Company in this Agreement or (y)&#160;determining whether any condition set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;6.19</span>, Section<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;8</span> or Section<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;9</span> has been satisfied. Any failure by either Party to provide notice pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;5.5</span> shall not be deemed to be a breach for purposes of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;8.2</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;9.2</span>, as applicable, unless such failure to provide such notice was knowing and intentional.</p><a id="Section6AdditionalAgreementsoftheParties"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Section&#160;6. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Agreements of the Parties</span>.</p><a id="ProxyStatement_902058"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">6.1&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proxy Statement</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;On or prior to February&#160;14, 2025, Parent shall prepare and file with the SEC a proxy statement relating to the Parent Stockholder Meeting to be held in connection with the Parent Stockholder Matters (together with any amendments thereof or supplements thereto, the &#8220;<b style="font-weight:bold;">Proxy Statement</b>&#8221;). Parent shall use its commercially reasonable efforts to (i)&#160;cause the Proxy Statement to comply with applicable rules&#160;and regulations promulgated by the SEC and (ii)&#160;respond promptly to any comments or requests of the SEC or its staff related to the Proxy Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;Parent covenants and agrees that the Proxy Statement (and the letters to stockholders, notice of meeting and form of proxy included therewith) will (i)&#160;comply as to form in all material respects with the requirements of applicable U.S. federal securities Laws and the DGCL, and (ii)&#160;will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;Parent shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#8217;s stockholders as promptly as practicable after the Proxy Statement has been filed with the SEC and either (i)&#160;the SEC has indicated that it does not intend to review the Proxy Statement or that its review of the Proxy Statement has been completed or (ii)&#160;at least ten (10)&#160;days shall have passed since the Proxy Statement was filed with the SEC without receiving any correspondence from the SEC commenting upon, or indicating that it intends to review, the Proxy Statement, all in compliance with applicable U.S. federal securities laws and the DGCL. If Parent, First Merger Sub, Second Merger Sub or the Surviving Entity (1)&#160;become aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Proxy Statement, (2)&#160;receives notice of any SEC request for an amendment or supplement to the Proxy Statement or for additional information related thereto, or (3)&#160;receives SEC comments on the Proxy Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in Parent filing such amendment or supplement with the SEC and, if appropriate, in mailing such amendment or supplement to the Parent stockholders. The Company and its legal counsel shall be given reasonable opportunity to review and comment on the Proxy Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Proxy Statement, prior to the filing thereof with the SEC. Parent may file the Proxy Statement, or any amendment or supplement thereto, without the prior consent of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;As promptly as reasonably practicable following December&#160;31, 2024, the Company will use commercially reasonable efforts to furnish to Parent audited financial statements for the year ended December&#160;31, 2024 (the &#8220;<b style="font-weight:bold;">Company Financial Statements</b>&#8221;) required to be included in the Proxy Statement.</p><a id="CompanyStockholderWrittenConsent_664807"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">6.2&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Stockholder Written Consent</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Promptly after the date hereof, and in any event no later than two (2)&#160;Business Days thereafter, the Company shall obtain the approval by written consent from Company stockholders sufficient for the Required Company Stockholder Vote in lieu of a meeting pursuant to Section&#160;228 of the DGCL, for purposes of (i)&#160;adopting and approving this Agreement and the Contemplated Transactions, (ii)&#160;acknowledging that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section&#160;262 of the DGCL, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (iii)&#160;acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares in connection with the Merger and thereby waives any rights to receive payment of the fair value of its capital stock under the DGCL (the &#8220;<b style="font-weight:bold;">Company Stockholder Written Consents</b>&#8221;). Under no circumstances shall the Company assert that any other approval or consent is necessary by its stockholders to approve this Agreement and the Contemplated Transactions.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;Reasonably promptly following receipt of the Required Company Stockholder Vote, the Company shall prepare and mail a notice (the &#8220;<b style="font-weight:bold;">Stockholder Notice</b>&#8221;) to every stockholder of the Company that did not execute the Company Stockholder Written Consent. The Stockholder Notice shall (i)&#160;be a statement to the effect that the Company Board determined that the Merger is advisable in accordance with Section&#160;251(b)&#160;of the DGCL and in the best interests of the stockholders of the Company and approved and adopted this Agreement, the Merger and the other Contemplated Transactions, (ii)&#160;provide the stockholders of the Company to whom it is sent with notice of the actions taken in the Company Stockholder Written Consent, including the adoption and approval of this Agreement, the Merger and the other Contemplated Transactions in accordance with Section&#160;228(e)&#160;of the DGCL and the certificate of incorporation and bylaws of the Company and (iii)&#160;include a description of the appraisal rights of the Company&#8217;s stockholders available under the DGCL, along with such other information as is required thereunder and pursuant to applicable Law. All materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.2(b)</span>&#160;shall be subject to Parent&#8217;s advance review and reasonable approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;The Company agrees that, subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.2(d)</span>: (i)&#160;the Company Board shall recommend that the Company&#8217;s stockholders vote to adopt and approve this Agreement and the Contemplated Transactions and shall use commercially reasonable efforts to solicit such approval within the time set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.2(a)</span>&#160;(the recommendation of the Company Board that the Company&#8217;s stockholders vote to adopt and approve this Agreement being referred to as the &#8220;<b style="font-weight:bold;">Company Board Recommendation</b>&#8221;) and (ii)&#160;the Company Board Recommendation shall not be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation in a manner adverse to Parent or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(d)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.2(c)</span>, and subject to compliance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.4</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.2</span>, if at any time prior to approval and adoption of this Agreement by the Required Company Stockholder Vote, (i)&#160;the Company receives a bona fide written Acquisition Proposal that the Company Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii)&#160;as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A)&#160;any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof or (B)&#160;the fact, in and of itself, that the Company meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of the Company that occurs or arises after the date of this Agreement (a &#8220;<b style="font-weight:bold;">Company Intervening Event</b>&#8221;), the Company Board may withhold, amend, withdraw or modify the Company Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Company Board Recommendation) in a manner adverse to Parent (collectively, a &#8220;<b style="font-weight:bold;">Company Board Adverse Recommendation Change</b>&#8221;) if, but only if, (x)&#160;in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i)&#160;the Company Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii)&#160;the Company has, during the Notice Period (as defined below), negotiated with Parent in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and (iii)&#160;if, Parent has delivered to the Company a written offer to alter the terms or conditions of this Agreement during the Notice Period, the Company Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that (1)&#160;Parent receives written notice from the Company confirming that the Company Board has determined to change its recommendation at least four (4)&#160;Business Days in advance of the Company Board Adverse Recommendation Change (the &#8220;<b style="font-weight:bold;">Notice Period</b>&#8221;), which notice shall include a description in reasonable detail of the reasons for such Company Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2)&#160;during any Notice Period, Parent shall be entitled to deliver to the Company one or more counterproposals to such Acquisition Proposal and the Company will, and cause its Representatives to, negotiate with Parent in good faith (to the extent Parent desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3)&#160;in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Company&#8217;s stockholders would receive as a result of such potential Superior Offer), the Company shall be required to provide Parent with notice of such material amendment and the Notice Period shall be extended, if applicable, to ensure </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">that at least three (3)&#160;Business Days remain in the Notice Period following such notification during which the parties shall comply again with the requirements of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.2(d)</span>&#160;and the Company Board shall not make a Company Board Adverse Recommendation Change prior to the end of such Notice Period as so extended (it being understood that there may be multiple extensions) or (y)&#160;in the case of a Company Intervening Event, the Company promptly notifies Parent, in writing, within the Notice Period before making a Company Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Company Intervening Event and that the Company Board intends to make a Company Board Adverse Recommendation Change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;The Company&#8217;s obligation to solicit the consent of its stockholders to sign the Company Stockholder Written Consent in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.2(a)</span>&#160;shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or Acquisition Inquiry, or by any Company Board Adverse Recommendation Change.</p><a id="ParentStockholderMeeting_423253"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">6.3&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Stockholder Meeting</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock to consider and vote to approve (I)&#160;the issuance of shares of Parent Capital Stock (including shares of Parent Capital Stock issuable upon conversion thereof) in connection with the Contemplated Transactions for purposes of the listing rules&#160;of Nasdaq, and (II)&#160;the Parent Charter Amendment (collectively, the &#8220;<b style="font-weight:bold;">Parent Stockholder Matters</b>&#8221; and such meeting, the &#8220;<b style="font-weight:bold;">Parent Stockholder Meeting</b>&#8221;). The Parent Stockholder Meeting shall be held as promptly as practicable after the filing of the Proxy Statements in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.1(a)</span>, and in any event, no later than 60 days after the date thereof. Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholder Meeting are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Stockholder Meeting, or a date preceding the date on which the Parent Stockholder Meeting is scheduled, Parent reasonably believes that (i)&#160;it will not receive proxies sufficient to obtain the Required Parent Stockholder Vote, whether or not a quorum would be present, (ii)&#160;it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Parent Stockholder Meeting or (iii)&#160;that the failure to postpone or adjourn the Parent Stockholder Meeting would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholder Meeting as long as the date of the Parent Stockholder Meeting is not postponed or adjourned more than an aggregate of 30 days in connection with any postponements or adjournments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;Parent agrees that (i)&#160;the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder Matters and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.3(a)</span>&#160;above and (ii)&#160;the Proxy Statement shall include a statement to the effect that the Parent Board recommends that Parent&#8217;s stockholders vote to approve the Parent Stockholder Matters (the recommendation of the Parent Board being referred to as the &#8220;<b style="font-weight:bold;">Parent Board Recommendation</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(c)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.3(b)</span>, and subject to compliance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.4</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.3</span>, the Parent Board may withhold, amend, withdraw or modify the Parent Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation) in a manner adverse to the Company (a &#8220;<b style="font-weight:bold;">Parent Board Adverse Recommendation Change</b>&#8221;) if, at any time prior to approval and adoption of this Agreement by the Required Parent Stockholder Vote, (i)&#160;Parent receives a bona fide written Acquisition Proposal that the Parent Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer or (ii)&#160;as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A)&#160;any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, or (B)&#160;the fact, in and of itself, that Parent meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of Parent that occurs or arises after the date of this Agreement (a &#8220;<b style="font-weight:bold;">Parent Intervening Event</b>&#8221;), if, but only if, (x)&#160;in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i)&#160;the Parent Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii)&#160;Parent has, and has caused its financial advisors and outside legal counsel to, during the Parent Notice Period (as defined below), negotiated with the Company in good faith </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, and (iii)&#160;if, after the Company has delivered to Parent a written offer to alter the terms or conditions of this Agreement during the Parent Notice Period, the Parent Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that (1)&#160;the Company receives written notice from Parent confirming that the Parent Board has determined to change its recommendation at least four (4)&#160;Business Days in advance of the Parent Board Adverse Recommendation Change (the &#8220;<b style="font-weight:bold;">Parent Notice Period</b>&#8221;), which notice shall include a description in reasonable detail of the reasons for such Parent Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2)&#160;during any Parent Notice Period, the Company shall be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and cause its Representatives to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3)&#160;in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Parent&#8217;s stockholders would receive as a result of such potential Superior Offer), Parent shall be required to provide the Company with notice of such material amendment and the Parent Notice Period shall be extended, if applicable, to ensure that at least three (3)&#160;Business Days remain in the Parent Notice Period following such notification during which the parties shall comply again with the requirements of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.3(c)</span>&#160;and the Parent Board shall not make a Parent Board Adverse Recommendation Change prior to the end of such Parent Notice Period as so extended (it being understood that there may be multiple extensions) or (y)&#160;in the case of a Parent Intervening Event, Parent promptly notifies the Company, in writing, within the Parent Notice Period before making a Parent Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Parent Intervening Event and that the Parent Board intends to make a Parent Board Adverse Recommendation Change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;Parent&#8217;s obligation to call, give notice of and hold the Parent Stockholder Meeting in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.3(a)</span>&#160;shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer, Acquisition Proposal or Acquisition Inquiry, or by any Parent Board Adverse Recommendation Change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;Nothing contained in this Agreement shall prohibit Parent or the Parent Board from (i)&#160;complying with Rules&#160;14d-9 and 14e-2(a)&#160;promulgated under the Exchange Act; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that any disclosure made by Parent or the Parent Board pursuant to Rules&#160;14d-9 and 14e-2(a)&#160;shall be limited to a statement that Parent is unable to take a position with respect to the bidder&#8217;s tender offer unless the Parent Board determines in good faith, after consultation with its outside legal counsel, that such statement would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law; (ii)&#160;complying with Item 1012(a)&#160;of Regulation M-A promulgated under the Exchange Act; (iii)&#160;informing any Person of the existence of the provisions contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.4</span>; or (iv)&#160;making any disclosure that the Parent Board (or a committee thereof), after consultation with its outside legal counsel, has determined in good faith is required by applicable Law or by any listing or trading rules&#160;or regulations of Nasdaq; provided that, in the case of (iv), Parent shall provide the Company with a reasonable opportunity to review any such disclosure not less than two (2)&#160;Business Days prior to the making thereof (or, if two Business Days is not reasonably practicable under the circumstances, such shorter period of time as is reasonably practicable under the circumstances) and shall consider in good faith any comments from the Company thereto.</p><a id="EffortsRegulatoryApprovals_566601"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">6.4&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Efforts; Regulatory Approvals</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;The Parties shall use commercially reasonable efforts to obtain all regulatory approvals required by applicable Law to consummate the Contemplated Transactions. Without limiting the generality of the foregoing, each Party (i)&#160;shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions, (ii)&#160;shall use commercially reasonable efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract to remain in full force and effect, (iii)&#160;shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions and (iv)&#160;shall use commercially reasonable efforts to satisfy the conditions precedent to the consummation of this Agreement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;Notwithstanding the generality of the foregoing, each Party shall use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of this Agreement, all applications, notices, reports and other documents reasonably required to be filed by such Party with or otherwise submitted by such Party to any Governmental Authority with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental Authority. Without limiting the generality of the foregoing, the Parties shall prepare and file, if required, (a)&#160;the notification and report forms required to be filed under the Hart&#8211;Scott&#8211;Rodino Antitrust Improvements Act of 1976 and (b)&#160;any notification or other document required to be filed in connection with the Merger under any applicable foreign Law relating to antitrust or competition matters, no later than ten (10)&#160;Business Days after the date the Company and Parent receive notification (in writing or otherwise) from the Federal Trade Commission, the Department of Justice, any state attorney general, foreign antitrust or competition authority or other Governmental Authority that a filing is required in connection with antitrust or competition matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;Without limiting the generality of the foregoing, Parent shall give the Company prompt written notice (email being sufficient) of any litigation against Parent and/or its directors relating to this Agreement or the Contemplated Transactions (&#8220;<b style="font-weight:bold;">Transaction Litigation</b>&#8221;) (including by providing copies of all pleadings with respect thereto) and keep the Company reasonably informed with respect to the status thereof. Parent will (i)&#160;give the Company the opportunity to participate in, but not control, the defense, settlement or prosecution of any Transaction Litigation (to the extent that the attorney-client privilege is not undermined or otherwise adversely affected; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that Parent and the Company will use commercially reasonable efforts to find alternative solutions to not undermine or adversely affect the privilege such as entering into common interest agreements, joint defense agreements or similar agreements), (ii)&#160;consult with the Company with respect to the defense, settlement and prosecution of any Transaction Litigation and (iii)&#160;consider in good faith the Company&#8217;s advice with respect to such Transaction Litigation. Parent will obtain the prior written consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed) prior to settling or satisfying any such claim.</p><a id="CompanyOptionsCompanyWarrants_93450"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">6.5&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Options; Company Warrants</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;At the First Effective Time, Parent shall assume each Company Stock Plan and each Company Option (including any Service Provider Grants), whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Common Stock and shall be converted, at the First Effective Time, into an option to purchase shares of Parent Common Stock (an &#8220;<b style="font-weight:bold;">Assumed Option</b>&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Company Option as of immediately prior to the First Effective Time, except for administrative or ministerial changes as determined by the Company Board (or, following the First Effective Time, the Parent Board or compensation committee). The number of shares of Parent Common Stock subject to each such Assumed Option shall be equal to (i)&#160;the number of shares of Company Common Stock subject to the respective Company Option immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio, rounded down, if necessary, to the nearest whole share of Parent Common Stock, and such Assumed Option shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A)&#160;the exercise price per share of the Company Common Stock otherwise purchasable pursuant to the respective Company Option immediately prior to the First Effective Time divided by (B)&#160;the Exchange Ratio; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that in the case of any Company Option to which Section&#160;421 of the Code applies as of immediately prior to the First Effective Time (taking into account the effect of any accelerated vesting thereof, if applicable) by reason of its qualification under Section&#160;422 of the Code, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section&#160;424(a)&#160;of the Code; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further</span>, that in the case of any Assumed Option to which Section&#160;409A of the Code applies as of the First Effective Time, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section&#160;409A of the Code in order to avoid the imposition of any additional taxes thereunder. The Company Board shall, prior to the First Effective Time, take all actions necessary to effect the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(b)&#160;&#160;&#160;&#160;At the First Effective Time, each Company Warrant, whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Capital Stock and shall be converted, at the First Effective Time, into a warrant to purchase shares of Parent Common Stock (an &#8220;<b style="font-weight:bold;">Assumed Warrant</b>&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Assumed </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Warrant as of immediately prior to the First Effective Time. The number of shares of Parent Common Stock subject to each such Assumed Warrant shall be equal to (i)&#160;the number of shares of the Company Common Stock subject to each Assumed Warrant immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio (rounded up to the next whole share of Parent Common Stock to the extent the aggregate amount of fractional shares of Parent Common Stock such holder of Assumed Warrants would otherwise be entitled to is equal to or exceeds 0.50, and otherwise rounded down), and such Assumed Warrant shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A)&#160;the exercise price per share of the Company Common Stock otherwise purchasable pursuant to such Assumed Warrant immediately prior to the First Effective Time divided by (B)&#160;the Exchange Ratio.</p><a id="EmployeeBenefits_594628"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">6.6&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee Benefits</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Parent shall comply with the terms of any employment, severance, retention, change of control, or similar agreement specified on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.17(d)</span>&#160;or contemplated by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.1(b)</span>&#160;of the Parent Disclosure Letter, subject to the provisions of such agreements. The parties acknowledge and agree that the Merger shall not constitute a &#8220;change in control&#8221; (or term of similar import) under any Company Employee Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;From and after the First Effective Time, with respect to each benefit plan maintained by Parent or the Surviving Entity that is an &#8220;employee welfare benefit plan&#8221; as defined in Section&#160;3(1)&#160;of ERISA (each, a &#8220;<b style="font-weight:bold;">Post-Closing Welfare Plan</b>&#8221;) in which any current or former employee of Parent is or becomes eligible to participate (including under COBRA), Parent and the Surviving Entity shall use commercially reasonable efforts to cause each such Post-Closing Welfare Plan to (i)&#160;waive all limitations as to pre-existing conditions, waiting periods, required physical examinations and exclusions with respect to participation and coverage requirements applicable under such Post-Closing Welfare Plan for such current or former Parent employee and his or her eligible dependents to the same extent that such pre-existing conditions, waiting periods, required physical examinations and exclusions would not have applied or would have been waived under the corresponding Parent Employee Plan in which such current or former Parent employee was a participant immediately prior to his or her commencement of participation in such Post-Closing Welfare Plan, and (ii)&#160;provide each such current or former Parent employee and his or her eligible dependents with credit for any co-payments and deductibles paid in the plan year that includes the First Effective Time, and prior to the date that, such current or former Parent employee commences participation in such Post-Closing Welfare Plan in satisfying any applicable co-payment or deductible requirements under such Post-Closing Welfare Plan for the applicable plan year, to the extent that such expenses were recognized for such purposes under the comparable Parent Employee Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent 401(k)&#160;Plan</span>. Unless directed otherwise by the Company in writing no less than three (3)&#160;Business Days before the Closing Date, Parent shall, at least one (1)&#160;Business Day prior to the Closing Date, (i)&#160;ceased contributions to, and adopted written resolutions (or taken other necessary and appropriate action(s)) to terminate any Parent Employee Plan that is intended to qualify under Section&#160;401(a)&#160;of the Code with a cash or deferred arrangement described in Section&#160;401(k)&#160;of the Code (collectively, the &#8220;<b style="font-weight:bold;">401(k)&#160;Plans</b>&#8221;) in compliance with such 401(k)&#160;Plan&#8217;s terms and the requirements of applicable Law, (ii)&#160;made all employee and employer contributions to the 401(k)&#160;Plans for all periods of service prior to the Closing Date, including such contributions that would have been made on behalf of 401(k)&#160;Plan participants had the Merger not occurred (regardless of any service or end-of-year employment requirements) but prorated for the portion of the plan year that ends on the Closing Date, and (iii)&#160;100% vested all participants under the 401(k)&#160;Plans, with such termination, contributions and vesting effective no later than one (1)&#160;day prior to the Closing Date. Parent shall provide the Company copies of all such corporate actions or documentation related to the same at least three (3)&#160;Business Days before their adoption or approval for the Company&#8217;s reasonable review and comment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(d)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Options</span>. As of immediately prior to the First Effective Time, each Parent Option that is then outstanding but not then vested or exercisable shall become immediately vested and exercisable in full. At the First Effective Time, each In the Money Parent Option that is then outstanding shall be canceled and the holder thereof shall be entitled to receive, immediately prior to the First Effective Time a number of shares of Parent Common Stock equal to the number of shares underlying such Parent Option. Notwithstanding anything herein to the contrary, the tax withholding obligations for each holder receiving shares of Parent Common Stock in accordance with the preceding sentence shall be satisfied by Parent withholding from issuance that number of shares of Parent Common Stock calculated by multiplying the legally-required withholding rate for such holder in connection with such issuance by the number of shares of Parent Common Stock to be issued in accordance with the preceding sentence, and rounding up to the nearest whole share and remitting such withholding in cash to the appropriate taxing authorities. At the First Effective Time, each Out of the Money Parent Option shall be cancelled for no consideration. Prior to the Closing, the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide for the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Restricted Stock Units</span>. As of immediately prior to the First Effective Time, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide that (i)&#160;the vesting of each outstanding and unvested Parent Restricted Stock Unit shall be accelerated in full effective as of immediately prior to the First Effective Time, contingent on the occurrence of the Closing and (ii)&#160;for each outstanding and unsettled Parent Restricted Stock Unit (including any Parent Restricted Stock Units accelerated under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.6(e)(i)</span>&#160;above) the holder thereof shall be entitled to receive, immediately prior to the First Effective Time a number of shares of Parent Common Stock equal to the number of vested and unsettled shares underlying such Parent Restricted Stock Units. Notwithstanding anything herein to the contrary, the tax withholding obligations for each holder receiving shares of Parent Common Stock in accordance with the preceding sentence shall be satisfied by Parent withholding from issuance that number of shares of Parent Common Stock calculated by multiplying the legally-required withholding rate for such holder in connection with such issuance by the number of shares of Parent Common Stock to be issued in accordance with the preceding sentence, and rounding up to the nearest whole share and remitting such withholding in cash to the appropriate taxing authorities. Prior to the Closing, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide for the foregoing.</p><a id="IndemnificationofOfficersandDirectors_49"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">6.7&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification of Officers and Directors</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;From the First Effective Time through the sixth anniversary of the date on which the First Effective Time occurs, each of Parent and the Surviving Entity shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the First Effective Time, a director or officer of Parent or the Company, respectively (the &#8220;<b style="font-weight:bold;">D&amp;O Indemnified Parties</b>&#8221;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements (collectively, &#8220;<b style="font-weight:bold;">Costs</b>&#8221;), incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of Parent or of the Company, whether asserted or claimed prior to, at or after the First Effective Time, in each case, to the fullest extent permitted under the DGCL. Each D&amp;O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Entity, jointly and severally, upon receipt by Parent or the Surviving Entity from the D&amp;O Indemnified Party of a request therefor; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that any such person to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. Without otherwise limiting the D&amp;O Indemnified Parties&#8217; rights with regards to counsel, following the First Effective Time, the D&amp;O Indemnified Parties shall be entitled to continue to retain Sidley Austin LLP or such other counsel selected by the D&amp;O Indemnified Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;The certificate of incorporation and bylaws of the Surviving Entity shall contain, and Parent shall cause the certificate of incorporation and bylaws of the Surviving Entity to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;From and after the First Effective Time, (i)&#160;the Surviving Entity shall fulfill and honor in all respects the obligations of the Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company&#8217;s Organizational Documents and pursuant to any indemnification agreements between the Company and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time and (ii)&#160;Parent shall fulfill and honor in all respects the obligations of Parent to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Parent&#8217;s Organizational Documents and pursuant to any indemnification agreements between Parent and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 54pt;">(d)&#160;&#160;&#160;&#160;From and after the First Effective Time, Parent shall maintain directors&#8217; and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially reasonable terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Parent. In addition, Parent shall purchase at its sole expense, prior to the First Effective Time, a six (6)&#160;year prepaid &#8220;D&amp;O tail policy&#8221; for the non-cancelable extension of the directors&#8217; and officers&#8217; liability coverage of Parent&#8217;s existing directors&#8217; and officers&#8217; insurance policies for a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">claims reporting or discovery period of at least six (6)&#160;years from and after the First Effective Time with respect to any claim related to any period of time at or prior to the First Effective Time with terms, conditions, retentions and limits of liability that are no less favorable than the coverage provided under Parent&#8217;s existing policies as of the date of this Agreement, or otherwise acceptable to Parent, except that Parent will not commit or spend on such &#8220;D&amp;O Tail policy&#8221; annual premiums in excess of 250% of the annual premiums paid by Parent in its last full fiscal year prior to the date hereof for Parent&#8217;s current policies of directors&#8217; and officers&#8217; liability insurance and fiduciary liability insurance (nor, for the avoidance of doubt, shall Parent be obligated to spend any specific amount), and if such premiums for such &#8220;D&amp;O tail policy&#8221; would exceed 250% of such annual premium, then Parent shall purchase policies that provide the maximum coverage available at an annual premium equal to 250% of such annual premium. The Company shall in good faith cooperate with Parent prior to the First Effective Time with respect to the procurement of such &#8220;D&amp;O tail policy.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;From and after the First Effective Time, Parent shall pay all expenses, including reasonable attorneys&#8217; fees, that are incurred by the persons referred to in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.7</span> in connection with their enforcement of the rights provided to such persons in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.7</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(f)&#160;&#160;&#160;&#160;The provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.7</span> are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their Representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(g)&#160;&#160;&#160;&#160;In the event Parent or the Surviving Entity or any of their respective successors or assigns (i)&#160;consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii)&#160;transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Entity, as the case may be, shall succeed to the obligations set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.7</span>. Parent shall cause the Surviving Entity to perform all of the obligations of the Surviving Entity under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.7</span>.</p><a id="Disclosure_615626"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">6.8&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure</span>. The Parties shall use their commercially reasonable efforts to agree to the text of any initial press release and Parent&#8217;s Form&#160;8-K announcing the execution and delivery of this Agreement. Without limiting any Party&#8217;s obligations under the Confidentiality Agreement, no Party shall, and no Party shall permit any of its Subsidiaries or any of its Representative to, issue any press release or make any public disclosure regarding the Contemplated Transactions unless: (a)&#160;the other Party shall have approved such press release or disclosure in writing, such approval not to be unreasonably conditioned, withheld or delayed; or (b)&#160;such Party shall have determined in good faith, upon the advice of outside legal counsel, that such disclosure is required by applicable Law and, to the extent practicable, before such press release or disclosure is issued or made, such Party advises the other Party of, and consults with the other Party regarding, the text of such press release or disclosure; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that each of the Company and Parent may make any public statement in response to specific questions by the press, analysts, investors or those attending industry conferences or financial analyst conference calls, so long as any such statements are consistent with previous press releases, public disclosures or public statements made by the Company or Parent in compliance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;6.8</span>. Notwithstanding the foregoing, a Party need not consult with any other Parties in connection with such portion of any press release, public statement or filing to be issued or made pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;6.2(d)</span>&#160;or pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;6.3(e)</span>.</p><a id="Listing_625102"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">6.9&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Listing</span>. At or prior to the First Effective Time, Parent shall use its commercially reasonable efforts to (a)&#160;maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq, (b)&#160;to the extent required by the rules&#160;and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Parent Common Stock to be issued in connection with the Contemplated Transactions, and to cause such shares to be approved for listing (subject to official notice of issuance); (c)&#160;prepare and timely submit to Nasdaq a notification form for the Nasdaq Reverse Split (if required) and to submit a copy of the amendment to Parent&#8217;s certificate of incorporation effecting the Nasdaq Reverse Split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the Closing Date; and (d)&#160;to the extent required by Nasdaq Marketplace Rule&#160;5110, assist the Company in preparing and filing an initial listing application for the Parent Capital Stock on Nasdaq (including any Parent Common Stock issuable upon conversion thereof) (the &#8220;<b style="font-weight:bold;">Nasdaq Listing Application</b>&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time. Each Party will reasonably promptly inform the other Party of all verbal or written communications between Nasdaq and such Party or its representatives. The Parties will use commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules&#160;and regulations. The Party not filing the Nasdaq Listing Application will cooperate with the other Party as reasonably requested by such filing Party with respect to the Nasdaq </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Listing Application and promptly furnish to such filing Party all information concerning itself and its members that may be required or reasonably requested in connection with any action contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;6.9</span>. All Nasdaq fees associated with any action contemplated by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;6.9</span>, including any fees related to the engagement of a consultant (the &#8220;<b style="font-weight:bold;">Nasdaq Fees</b>&#8221;), shall be paid by the Company.</p><a id="TaxMatters_508447"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">6.10&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Matters</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;The Parties shall use reasonable efforts (and each shall cause its Affiliates) to cause the Merger to qualify for the Intended Tax Treatment. No Party shall take any actions, or fail to take any action, which action or failure to act would reasonably be expected to prevent or impede the Intended Tax Treatment. The Parties shall report the Contemplated Transactions for all applicable Tax purposes in a manner that is consistent with the Intended Tax Treatment. No Party shall take any position that is inconsistent with the Intended Tax Treatment during the course of any audit, litigation or other proceeding with respect to Taxes, in each case, unless otherwise required by a determination within the meaning of Section&#160;1313(a)&#160;of the Code. The Parties shall comply with the recordkeeping and information reporting requirements imposed on them, including, but not limited to, those set forth in Treasury Regulation Section&#160;1.368-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;Parent shall promptly notify the Company if, at any time before the First Effective Time, Parent becomes aware of any fact or circumstance that would reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment. The Company shall promptly notify Parent if, at any time before the First Effective Time, the Company becomes aware of any fact or circumstance that would reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;If the SEC requires that an opinion with respect to the Intended Tax Treatment be prepared and submitted in connection with the Proxy Statement, (i)&#160;the Company shall use its reasonable best efforts to cause Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) to furnish an opinion (as so required and subject to customary assumptions and limitations), (ii)&#160;Parent shall use its reasonable best efforts to cause Sidley Austin LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent) to furnish an opinion (as so required and subject to customary assumptions and limitations), and (iii)&#160;Parent and the Company shall each deliver to each of Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) and Sidley Austin LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent) a Tax certificate, dated as of the date the Proxy Statement shall have been declared effective by the SEC and signed by an officer of Parent or the Company, as applicable, containing customary representations and covenants reasonably acceptable to the Company and Parent, as applicable, in each case, as reasonably necessary and appropriate to enable such advisors to render such opinions (the &#8220;<b style="font-weight:bold;">Tax Certificates</b>&#8221;). Each of Parent and the Company shall use its commercially reasonable efforts not to take or cause to be taken any action that would cause to be untrue (or fail to take or cause not to be taken any action which would cause to be untrue) any of the Tax certifications, covenants or representations included in the Tax Certificates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;Parent and the Company shall reasonably cooperate in the preparation, execution and filing of all Tax Returns, questionnaires, applications or other documents regarding any real property transfer, sales, use, transfer, value added, stock transfer and stamp taxes, and transfer, recording, registration and other fees and similar Taxes which become payable in connection with the Merger that are required or permitted to be filed on or before the First Effective Time. Each of Parent and the Company shall pay, without deduction from any consideration or other amounts payable or otherwise deliverable pursuant to this Agreement and without reimbursement from the other party, any such Taxes or fees imposed on it by any Governmental Authority, which becomes payable in connection with the Merger.</p><a id="Legend_99197"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">6.11&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legends</span>. Parent shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any shares of Parent Capital Stock to be received in the Merger by equityholders of the Company who may be considered &#8220;affiliates&#8221; of Parent for purposes of Rules&#160;144 and 145 under the Securities Act reflecting the restrictions set forth in Rules&#160;144 and 145 and to issue appropriate stop transfer instructions to the transfer agent for any such shares of Parent Capital Stock.</p><a id="OfficersandDirectors_745923"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;">6.12&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Officers and Directors</span>. Until successors are duly elected or appointed and qualified in accordance with applicable Law, the Parties shall use commercially reasonable efforts and take all necessary action so that the Persons listed on </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;6.12</span> of the Parent Disclosure Letter are elected or appointed, as applicable, to the positions of officers or directors of Parent and the Surviving Entity, as set forth therein, to serve in such positions effective as of the Second Effective Time. If any Person listed on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;6.12</span> of the Parent Disclosure Letter is unable or unwilling to serve as officer or director of Parent or the Surviving Entity, as set forth therein, the Party appointing such Person (as set forth on <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;6.12</span> of the Parent Disclosure Letter) shall designate a successor. The Parties shall use reasonable best efforts to have each of the Persons that will serve as directors and officers of the Parent following the Closing to execute and deliver a Lock-Up Agreement prior to Closing.</p><a id="TerminationofCertainAgreementsandRights_"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">6.13&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Certain Agreements and Rights</span>. Each of Parent and the Company shall cause any stockholder agreements, voting agreements, registration rights agreements, co-sale agreements and any other similar Contracts between either Parent or the Company and any holders of Parent Common Stock or Company Capital Stock, respectively, including any such Contract granting any Person investor rights, rights of first refusal, registration rights or director registration rights, to be terminated immediately prior to the First Effective Time, without any liability being imposed on the part of Parent or the Surviving Entity.</p><a id="Section16Matters_721011"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">6.14&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;16 Matters</span>. Prior to the First Effective Time, Parent shall take all such steps as may be required to cause any acquisitions of Parent Common Stock and any options to purchase Parent Common Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting requirements of Section&#160;16(a)&#160;of the Exchange Act with respect to Parent, to be exempt under Rule&#160;16b-3 promulgated under the Exchange Act.</p><a id="AllocationInformation_354"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">6.15&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation Information</span>. The Company will prepare and deliver to Parent prior to the Closing a spreadsheet setting forth (as of immediately prior to the First Effective Time) (a)&#160;each holder of Company Capital Stock, (b)&#160;such holder&#8217;s name and address, (c)&#160;the number or percentage and type of Company Capital Stock held as of the Closing Date for each such holder and (d)&#160;the number of shares of Parent Capital Stock to be issued to such holder pursuant to this Agreement in respect of the Company Capital Stock held by such holder as of immediately prior to the First Effective Time (the &#8220;<b style="font-weight:bold;">Allocation Certificate</b>&#8221;).</p><a id="ParentSECDocuments_841417"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">6.16&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent SEC Documents</span>. From the date of this Agreement to the First Effective Time, Parent shall use commercially reasonable efforts to timely file with the SEC all registration statements, proxy statements, Certifications, reports, schedules, exhibits, forms and other documents required to be filed by Parent with the SEC under the Exchange Act or the Securities Act (&#8220;<b style="font-weight:bold;">SEC Documents</b>&#8221;). As of its filing date, or if amended after the date of this Agreement, as of the date of the last such amendment, each SEC Document filed by Parent with the SEC (a)&#160;shall comply in all material respects with the applicable requirements of the Exchange Act and the Securities Act, and (b)&#160;shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.</p><a id="NoticeofCertainTransactions_195867"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">6.17&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Certain Transactions</span>. As reasonably practicable following the closing of any Interim Financing or Company Acquisition, the Company shall provide notice to Parent (email being sufficient) setting forth in reasonable detail the terms of such Interim Financing or Company Acquisition, including (i)&#160;in the case of any Interim Financing, the amount of proceeds actually received by the Company in connection with such Interim Financing and (ii)&#160;in the case of any Company Acquisition, the Fair Market Value associated therewith.</p><a id="ObligationsofMergerSubs_271860"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">6.18&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligations of Merger Subs</span>. Parent will take all action necessary to cause each Merger Sub to perform its obligations under this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement.</p><a id="ParentFinancin_54120"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">6.19&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Financing</span>. To the extent requested by the Company prior to the Closing, Parent shall use reasonable best efforts to amend, restate and/or supersede the Subscription Agreement, in the manner determined by the Company at the Company&#8217;s cost and expense, to allow for the purchase of additional shares (up to $200,000,000 of such additional shares at a price per share no less than the Nasdaq official closing price (as reflected on Nasdaq.com) immediately preceding the signing of such amendment or restatement of the Subscription Agreement or other or superseding subscription agreement) of Parent Common Stock (whether in a second tranche or otherwise) by new or existing investors.</p><a id="Section7ConditionsPrecedenttoObligations"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Section&#160;7. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions Precedent to Obligations of Each Party</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions:</p><a id="RegulatoryApprovals_511720"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">7.1&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Approvals</span>. Any applicable waiting periods (or any extensions thereof) under the HSR Act (if applicable) shall have expired or otherwise been terminated.</p><a id="NoRestraints_770665"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">7.2&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Restraints</span>. Any material state securities laws applicable to the issuance of the shares of Parent Capital Stock in connection with the Contemplated Transactions (including any Parent Common Stock issuable upon conversion thereof) shall have been complied with and no Order preventing the consummation of the Contemplated Transactions shall have been issued by any Governmental Authority of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal.</p><a id="StockholderApproval_844737"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">7.3&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stockholder Approval</span>. (a)&#160;Parent shall have obtained the Required Parent Stockholder Vote (but solely with respect to such items as are necessary to consummate the transactions contemplated by this Agreement) and (b)&#160;the Company shall have obtained the Required Company Stockholder Vote.</p><a id="Listing_69572"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">7.4&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Listing</span>. The Nasdaq Listing Application shall have been approved by Nasdaq.</p><a id="LockUpAgreements_55117"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">7.5&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lock-Up Agreements</span>. The Lock-Up Agreements shall be in full force and effect.</p><a id="ParentCharterAmendment_85194"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">7.6&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Charter Amendment</span>. The Parent Charter Amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing at least such amendments as are necessary to consummate the transactions contemplated by this Agreement.</p><a id="CertificateofDesignation_183912"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">7.7&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificate of Designation</span>. Parent shall have filed the Certificate of Designation with the Secretary of State of the State of Delaware.</p><a id="Section8AdditionalConditionsPrecedenttoO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Section&#160;8. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Conditions Precedent to Obligations of Parent and Merger Subs</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The obligations of Parent and Merger Subs to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions:</p><a id="AccuracyofRepresentations_127554"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">8.1&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accuracy of Representations</span>. The Company Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Company Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&#160;for such inaccuracies which are de minimis, individually or in the aggregate, (y)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date). The representations and warranties of the Company contained in this Agreement (other than the Company Fundamental Representations and the Company Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a)&#160;in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Company Material Adverse Effect (without giving effect to any references therein to any Company Material Adverse Effect or other materiality qualifications) or (b)&#160;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="PerformanceofCovenants_992301"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">8.2&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance of Covenants</span>. The Company shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the First Effective Time.</p><a id="Documents_968311"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">8.3&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Documents</span>. Parent shall have received the following documents, each of which shall be in full force and effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;a certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company certifying (i)&#160;that the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.1</span>, <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.2</span>, <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.4</span>, <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.5</span> and <b style="font-weight:bold;">&#8206;</b>8.6 have been duly satisfied and (ii)&#160;that the information (other than emails and addresses) set forth in the Allocation Certificate delivered by the company in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.15</span> is true and accurate in all respects as of the Closing Date;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;a certificate pursuant to Treasury Regulations Sections 1.1445-2(c)&#160;and 1.897-2(h), together with a form of notice to the IRS in accordance with the requirements of Treasury Regulations Section&#160;1.897-2(h), in each case, in form and substance reasonably acceptable to Parent;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;the Company Valuation Schedule; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;the Allocation Certificate.</p><a id="NoCompanyMaterialAdverseEffect_93901"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">8.4&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Company Material Adverse Effect</span>. Since the date of this Agreement, there shall not have occurred any Company Material Adverse Effect that is continuing.</p><a id="CompanyStockholderWrittenConsent_497664"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">8.5&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Stockholder Written Consent</span>. The Company Stockholder Written Consent executed by the stockholders of the Company shall be in full force and effect.</p><a id="ParentFinancing_935500"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt 0pt 12pt 0pt;">8.6&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Financing</span>. The Subscription Agreement shall be in full force and effect and proceeds of not less than the Minimum Concurrent Investment Amount shall have been received by Parent or will be received by Parent substantially concurrently with the Closing in connection with the consummation of the transactions contemplated by the Subscription Agreement.</p><a id="Section9AdditionalConditionsPrecedenttoO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Section&#160;9. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Conditions Precedent to Obligation of the Company</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions:</p><a id="AccuracyofRepresentations_606216"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">9.1&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accuracy of Representations</span>. The Parent Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Parent Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&#160;for such inaccuracies which are de minimis, individually or in the aggregate, (y)&#160;for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date). The representations and warranties of Parent and Merger Subs contained in this Agreement (other than the Parent Fundamental Representations and the Parent Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a)&#160;in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications) or (b)&#160;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="PerformanceofCovenants_593379"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">9.2&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance of Covenants</span>. Parent and Merger Subs shall have performed or complied with in all material respects all of their agreements and covenants required to be performed or complied with by each of them under this Agreement at or prior to the First Effective Time.</p><a id="Documents_509958"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">9.3&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Documents</span>. The Company shall have received the following documents, each of which shall be in full force and effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;a certificate executed by an executive officer of Parent certifying that the conditions set forth in Sections&#160;<b style="font-weight:bold;">&#8206;</b>9.1, <b style="font-weight:bold;">&#8206;</b>9.2 and <b style="font-weight:bold;">&#8206;</b>9.4 have been duly satisfied;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;written resignations in forms satisfactory to the Company, dated as of the Closing Date and effective as of the Closing executed by the officers and directors of Parent who are not to continue as officers or directors of Parent pursuant to Section&#160;<b style="font-weight:bold;">&#8206;</b>6.12 hereof; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;the Parent Net Cash Schedule.</p><a id="NoParentMaterialAdverseEffect_531353"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">9.4&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Parent Material Adverse Effect</span>. Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect that is continuing.</p><a id="Section10Termination_386144"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Section&#160;10. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</span>.</p><a id="Termination_169795"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">10.1&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</span>. This Agreement may be terminated prior to the First Effective Time (whether before or after adoption of this Agreement by the Company&#8217;s stockholders and whether before or after approval of the Parent Stockholder Matters by Parent&#8217;s stockholders, unless otherwise specified below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;by mutual written consent of Parent and the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;by either Parent or the Company if the Merger shall not have been consummated by September&#160;30, 2025 (subject to possible extension as provided in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(b)</span>, the &#8220;<b style="font-weight:bold;">End Date</b>&#8221;); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the right to terminate this Agreement under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(b)</span>&#160;shall not be available to the Company or Parent if such Party&#8217;s (or in the case of Parent, Merger Subs&#8217;) action or failure to act has been a principal cause of the failure of the Merger to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(c)&#160;&#160;&#160;&#160;by either Parent or the Company if a court of competent jurisdiction or other Governmental Authority shall have issued a final and nonappealable Order having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(d)&#160;&#160;&#160;&#160;by Parent if the Required Company Stockholder Vote shall not have been obtained within two (2)&#160;Business Days of the date hereof; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that once the Required Company Stockholder Vote has been obtained (whether timely or not), Parent may not terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(d)</span>;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(e)&#160;&#160;&#160;&#160;by either Parent or the Company if (i)&#160;the Parent Stockholder Meeting (including any adjournments and postponements thereof) shall have been held and completed and Parent&#8217;s stockholders shall have taken a final vote on the Parent Stockholder Matters and (ii)&#160;the Parent Stockholder Matters shall not have been approved at the Parent Stockholder Meeting (or at any adjournment or postponement thereof) by the Required Parent Stockholder Vote; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the right to terminate this Agreement under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(e)</span>&#160;shall not be available to Parent where the failure to obtain the Required Parent Stockholder Vote shall have been caused by the action or failure to act of Parent and such action or failure to act constitutes a material breach by Parent of this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(f)&#160;&#160;&#160;&#160;by the Company (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) if a Parent Triggering Event shall have occurred;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(g)&#160;&#160;&#160;&#160;by Parent (at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company Stockholder Vote) if a Company Triggering Event shall have occurred;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(h)&#160;&#160;&#160;&#160;by the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Subs or if any representation or warranty of Parent or Merger Subs shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.1</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.2</span> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further</span>, that if such inaccuracy in Parent&#8217;s or Merger Subs&#8217; representations and warranties or breach by Parent or Merger Subs is curable by Parent or Merger Subs, then the Company shall not be permitted to terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(h)</span>&#160;as a result of such particular breach or inaccuracy until the earlier of (i)&#160;the expiration of a thirty (30) day period commencing upon delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(h)</span>&#160;and (ii)&#160;Parent or Merger Subs (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(h)</span>&#160;(it being understood that the Company shall not be permitted to terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(h)</span>&#160;as a result of such particular breach or inaccuracy if such breach by Parent or Merger Subs is cured prior to such termination becoming effective);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(i)&#160;&#160;&#160;&#160;by Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty of the Company shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.1</span> or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.2</span> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that Parent is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</span>, that if such inaccuracy in the Company&#8217;s representations and warranties or breach by the Company is curable by the Company then Parent shall not be permitted to terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(i)</span>&#160;as a result of such particular breach or inaccuracy until the earlier of (i)&#160;the expiration of a thirty (30) day period commencing upon delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(i)</span>&#160;and (ii)&#160;the Company ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(i)</span>&#160;(it being understood that Parent shall not be permitted to terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(i)</span>&#160;as a result of such particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective); or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(j)&#160;&#160;&#160;&#160;by Parent (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) and following compliance with all of the requirements set forth in the proviso to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(j)</span>, upon the Parent Board authorizing Parent to enter into a Permitted Alternative Agreement; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that Parent shall not enter into any Permitted Alternative Agreement unless: (i)&#160;Parent shall have complied in all material respects with its obligations under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.4</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.3</span>, (ii)&#160;the Parent Board shall have determined in good faith, after consultation with its outside legal counsel, that the failure to enter into such Permitted Alternative Agreement would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law and (iii)&#160;Parent shall concurrently pay to the Company the Company Termination Fee in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3(d)</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Party desiring to terminate this Agreement pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;Section&#160;10</span> (other than pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;10.1(a)</span>) shall give a notice of such termination to the other Party specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable detail.</p><a id="EffectofTermination_94632"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">10.2&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Termination</span>. In the event of the termination of this Agreement as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;Section&#160;10</span>, this Agreement shall be of no further force or effect; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that (a)&#160;this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;10.2</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;10.3</span> and <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Error! Reference source not found.</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11</span> (other than <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;11.8)</span> and the related definitions of the defined terms in such sections shall survive the termination of this Agreement and shall remain in full force and effect and (b)&#160;the termination of this Agreement and the provisions of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;10.3</span> shall not relieve any Party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement.</p><a id="ExpensesTerminationFees_129022"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">10.3&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses; Termination Fees</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(a)&#160;&#160;&#160;&#160;Except as set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3</span> and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.9</span>, all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the Party incurring such expenses, whether or not the Merger is consummated.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(b)&#160;&#160;&#160;&#160;If (i)&#160;this Agreement is terminated by Parent or the Company pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(e)</span>&#160;or by the Company pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(f)</span>, (ii)&#160;at any time after the date of this Agreement and prior to the Parent Stockholder Meeting, a bona fide third party Acquisition Proposal for a change of control transaction with respect to Parent shall have been publicly announced, disclosed or otherwise communicated to the Parent Board (and shall not have been withdrawn) and (iii)&#160;within twelve (12) months after the date of such termination, Parent enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction (excluding in each case any transactions occurring in connection with the liquidation, dissolution and winding up of Parent), then Parent shall pay to the Company, within ten (10)&#160;Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $320,000 (the &#8220;<b style="font-weight:bold;">Company Termination Fee</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(c)&#160;&#160;&#160;&#160;If this Agreement is terminated by the Company (other than pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10.1(e)</span>&#160;or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10.1(f)</span>), the Company shall pay to Parent, within ten (10)&#160;Business Days of such termination, a non-refundable fee in an amount equal to $500,000 for each month (or portion thereof) that has elapsed after May&#160;30, 2025 at the time of such payment; <i style="font-style:italic;">provided</i> that in no event shall the amount of the fee payable by the Company pursuant to this Section&#160;10.3(c)&#160;exceed $2,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(d)&#160;&#160;&#160;&#160;If this Agreement is terminated by Parent pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(d),</span> the Company shall pay to Parent, within ten (10)&#160;Business Days of such termination, a nonrefundable fee in an amount equal to $2,000,000. If (i)&#160;this Agreement is terminated by Parent pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(g)</span>, (ii)&#160;at any time after the date of this Agreement and before obtaining the Required Company Stockholder Vote, a, Acquisition Proposal with respect to the Company shall have been announced, disclosed or otherwise communicated to the Company Board (and shall not have been withdrawn) and (iii)&#160;within twelve (12) months after the date of such termination, the Company enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then the Company shall pay to Parent, within ten (10)&#160;Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $2,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(e)&#160;&#160;&#160;&#160;If either Party fails to pay when due any amount payable by it under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3</span>, then (i)&#160;such Party shall reimburse the other Party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by the other Party of its rights under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3</span> and (ii)&#160;such Party shall pay to the other Party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the other Party in full) at a rate per annum equal to the &#8220;prime rate&#8221; (as announced by Bank of America or any successor thereto) in effect on the date such overdue amount was originally required to be paid plus three percent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">(f)&#160;&#160;&#160;&#160;The Parties agree that, subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.2</span>, the payment of the fees and expenses set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3</span> shall be the sole and exclusive remedy of each Party following a termination of this Agreement under the circumstances described in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3</span>, it being understood that in no event shall either Parent or the Company be required to pay the individual fees or damages payable pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3</span> on more than one occasion. Subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.2</span>, following the payment of the fees and expenses set forth in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3</span> by a Party, (i)&#160;such Party shall have no further liability to the other Party in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the other Party giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (ii)&#160;no other Party or their respective Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against such Party or seek to obtain any recovery, judgment or damages of any kind against such Party (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such Party) in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (iii)&#160;all other Parties and their respective Affiliates shall be precluded from any other remedy against such Party and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated. Each of the Parties acknowledges that (x)&#160;the agreements contained in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3</span> are an integral part of the Contemplated Transactions, (y)&#160;without these agreements, the Parties would not enter into this Agreement and (z)&#160;any amount payable pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3</span> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the Parties in the circumstances in which such amount is payable; provided, however, that nothing in this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3(f)</span>&#160;shall limit the rights of the Parties under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;</span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.10</span>.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Section11MiscellaneousProvisions_266799"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Section&#160;11. <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous Provisions</span>.</p><a id="NonSurvivalofRepresentationsandWarrantie"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">11.1&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Survival of Representations and Warranties</span>. The representations and warranties of the Company, Parent and Merger Subs contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the First Effective Time, and only the covenants that by their terms survive the First Effective Time and this Section<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;11</span> shall survive the First Effective Time.</p><a id="Amendment_930923"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">11.2&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</span>. This Agreement may be amended with the approval of the respective boards of directors of the Company, Merger Subs and Parent at any time (whether before or after the adoption and approval of this Agreement by the Company&#8217;s stockholders or before or after obtaining the Required Parent Stockholder Vote); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that after any such approval of this Agreement by a Party&#8217;s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Company, Merger Subs and Parent.</p><a id="Waiver_835873"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">11.3&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(a)&#160;&#160;&#160;&#160;Any provision hereof may be waived by the waiving Party solely on such Party&#8217;s own behalf, without the consent of any other Party. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 54pt;">(b)&#160;&#160;&#160;&#160;No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.</p><a id="EntireAgreementCounterpartsExchangesbyEl"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">11.4&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission</span>. This Agreement and the other schedules, exhibits, certificates, instruments and agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">further</span>, that only Exhibit&#160;D (including Exhibit&#160;A to such Exhibit) is incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement.</p><a id="ApplicableLawJurisdiction_229457"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">11.5&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Law; Jurisdiction</span>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: (a)&#160;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (b)&#160;agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&#160;of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;11.5</span>, (c)&#160;waives any objection to laying venue in any such action or proceeding in such courts, (d)&#160;waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (e)&#160;agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;11.7</span> of this Agreement and (f)&#160;irrevocably and unconditionally waives the right to trial by jury.</p><a id="Assignability_997322"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">11.6&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignability</span>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#8217;s prior written consent shall be void and of no effect.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Notices_135944"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">11.7&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a)&#160;one&#160;(1)&#160;Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery by hand or (c)&#160;on the date delivered in the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 6:00 p.m.&#160;(New York City time), otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">if to Parent or Merger Subs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">GlycoMimetics Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">9708 Medical Center Drive</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Rockville, Maryland 20850</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Attention: Christian Dinneen-Long</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Email: cdinneen-long@glycomimetics.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">with a copy to (which shall not constitute notice):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Sidley Austin LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">787 Seventh Avenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">New York, NY 10019</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Attention: Asher M. Rubin; John Butler</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Email: arubin@sidley.com; john.butler@sidley.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">if to the Company:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Crescent Biopharma,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">221 Crescent Street, Building 23, Suite&#160;105</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Waltham, Massachusetts 02453</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Attention: Jonathan Violin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Email: jviolin@crescentbiopharma.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">with a copy to (which shall not constitute notice):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Gibson, Dunn&#160;&amp; Crutcher LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">One Embarcadero Center, Suite&#160;2600<br/>San Francisco, CA 94111<br/>Attention: Ryan Murr, Branden Berns, Chris Trester<br/>Email: rmurr@gibsondunn.com, bberns@gibsondunn.com, ctrester@gibsondunn.com</p><a id="Cooperation_36544"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">11.8&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation</span>. Each Party agrees to cooperate fully with the other Party and to execute and deliver such further documents, certificates, agreements and instruments and to take such other actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated Transactions and to carry out the intent and purposes of this Agreement.</p><a id="Severability_632108"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">11.9&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="OtherRemediesSpecificPerformance_69843"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">11.10&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Remedies; Specific Performance</span>. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</p><a id="NoThirdPartyBeneficiaries_697387"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">11.11&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third-Party Beneficiaries</span>. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties and the D&amp;O Indemnified Parties to the extent of their respective rights pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;6.7</span>) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of page&#160;intentionally left blank</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3e7645f0_bfb9_4210_9868_d195675d8200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">IN WITNESS WHEREOF</b><b style="font-weight:bold;">,</b> the Parties have caused this Agreement to be executed as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;text-transform:uppercase;">GlycoMimetics Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;text-transform:uppercase;">Gemini MERGER SUB CORP.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;text-transform:uppercase;">Gemini MERGER SUB II, LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">IN WITNESS WHEREOF</b><b style="font-weight:bold;">,</b> the Parties have caused this Agreement to be executed as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Crescent Biopharma,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jonathan Violin</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jonathan Violin</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.1pt 0pt;"><b style="font-size:11pt;font-weight:bold;">AMENDMENT NO. 1 TO THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:11pt;">This </span><b style="font-size:11pt;font-weight:bold;">AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION </b><span style="font-size:11pt;">(this &#8220;</span><span style="font-size:11pt;font-style:italic;font-weight:bold;">Amendment</span><span style="font-size:11pt;">&#8221;) is made as of February 14, 2025, with respect to that certain Agreement and Plan of Merger and Reorganization (the &#8220;</span><span style="font-size:11pt;font-style:italic;font-weight:bold;">Merger Agreement</span><span style="font-size:11pt;">&#8221;), dated as of October 28, 2024 (the &#8220;</span><span style="font-size:11pt;font-style:italic;font-weight:bold;">Agreement Date</span><span style="font-size:11pt;">&#8221;), by and among GlycoMimetics, Inc., a Delaware corporation (&#8220;</span><span style="font-size:11pt;font-style:italic;font-weight:bold;">Parent</span><span style="font-size:11pt;">&#8221;), Gemini Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of Parent (&#8220;</span><span style="font-size:11pt;font-style:italic;font-weight:bold;">First Merger Sub</span><span style="font-size:11pt;">&#8221;), Gemini Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (&#8220;</span><span style="font-size:11pt;font-style:italic;font-weight:bold;">Second Merger Sub</span><span style="font-size:11pt;">&#8221; and, together with First Merger Sub, &#8220;</span><span style="font-size:11pt;font-style:italic;font-weight:bold;">Merger Subs</span><span style="font-size:11pt;">&#8221;), and Crescent Biopharma, Inc. (the &#8220;</span><span style="font-size:11pt;font-style:italic;font-weight:bold;">Company</span><span style="font-size:11pt;white-space:pre-wrap;">&#8221;),  a  Delaware  corporation. All  capitalized  terms  used  but  not  otherwise defined herein shall have the respective meanings ascribed to them in the Merger Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">W I T N E S S E T H:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS</b><span style="font-size:11pt;">, pursuant to Section 11.2 of the Merger Agreement, the Merger Agreement may be amended by any instrument in writing signed on behalf of the Company, Parent and Merger Subs, with the approval of the respective boards of directors of the Company, Parent and Merger Subs;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS</b><span style="font-size:11pt;">, the Parent Board has (i) determined that the Contemplated Transactions (including as adjusted pursuant to this Amendment) are fair to, advisable and in the best interests of Parent and its stockholders, (ii) approved and declared advisable the Merger Agreement (including as amended hereby) and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of the Merger Agreement (including as amended hereby) and (iii) determined to recommend, upon the terms and subject to the conditions set forth in the Merger Agreement (including as amended hereby), that the stockholders of Parent vote to approve the Merger Agreement (including as amended hereby) and thereby approve the Parent Stockholder Matters, including the Contemplated Transactions, and against any competing proposals;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS</b><span style="font-size:11pt;">, the First Merger Sub Board has (i) determined that the Contemplated Transactions (including as adjusted pursuant to this Amendment) are fair to, advisable, and in the best interests of First Merger Sub and its sole stockholder, (ii) approved and declared advisable the Merger Agreement (including as amended hereby) and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in the Merger Agreement (including as amended hereby), that the stockholder of First Merger Sub votes to adopt the Merger Agreement (including as amended hereby) and thereby approve the Contemplated Transactions;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS</b><span style="font-size:11pt;">, the sole member of the Second Merger Sub has (i) determined that the Contemplated Transactions (including as adjusted pursuant to this Amendment) are fair to, advisable, and in the best interests of Second Merger Sub and its sole member, (ii) approved and declared advisable the Merger Agreement (including as amended hereby) and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in the Merger Agreement (including as amended hereby), that the sole member of Second Merger Sub votes to adopt the Merger Agreement (including as amended hereby) and thereby approve the Contemplated Transactions; and</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS</b><span style="font-size:11pt;">, the Company Board has (i) determined that the Contemplated Transactions (including as adjusted pursuant to this Amendment) are fair to, advisable and in the best interests of the Company and its stockholders, and (ii) approved and declared advisable the Merger Agreement (including as amended hereby) and the Contemplated Transactions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOW, THEREFORE</b><span style="font-size:11pt;">, in consideration of the foregoing recitals, the mutual covenants and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, intending to be legally bound, the Company, Parent and Merger Subs hereby agree as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">ARTICLE 1</b></span><b style="font-size:11pt;font-weight:bold;">AMENDMENTS TO THE MERGER AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">1.1.</span></span><span style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pre-Closin</span><span style="font-size:11pt;">g </span><span style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financing</span><span style="font-size:11pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.1.1</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">Recital L of the Merger Agreement shall be, and hereby is, amended and replaced in its entirety with the following:</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">L.</span></span><span style="font-size:11pt;">Certain investors have executed a Securities Purchase Agreement in the form attached hereto as </span><span style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</span><span style="font-size:11pt;"> among Parent, the Company and the Persons named therein (including as may be amended, restated and/or superseded from time to time, the &#8220;</span><b style="font-size:11pt;font-weight:bold;">Subscription Agreement</b><span style="font-size:11pt;">&#8221;), pursuant to which such Persons will have agreed to purchase in the amounts set forth therein (including by contribution of Company Notes) (i) shares of Company Common Stock and (ii) pre- funded Company Warrants, in each case, immediately prior to the First Effective Time (the &#8220;</span><b style="font-size:11pt;font-weight:bold;">Company Pre-Closing Financing</b><span style="font-size:11pt;">&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.1.2</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</span><span style="font-size:11pt;"> of the Merger Agreement shall be, and hereby is, amended and replaced in its entirety with the form of Subscription Agreement set forth on </span><span style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex A</span><span style="font-size:11pt;"> hereto.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.1.3</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">The definition of &#8220;Company Outstanding Shares&#8221; shall be, and hereby is, amended and replaced in its entirety with the following:</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="font-size:11pt;">&#8220;</span><b style="font-size:11pt;font-weight:bold;">Company Outstanding Shares</b><span style="font-size:11pt;">&#8221; means, without duplication, the total number of shares of Company Capital Stock outstanding immediately prior to the First Effective Time (including any shares of Company Common Stock or Company Preferred Stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Company Pre-Closing Financing, any Interim Financing or any Company Acquisition), expressed on a fully diluted and as-converted-to-Company Common Stock basis assuming, without limitation or duplication, the exercise of all Company Options, Company Warrants or other rights or commitments to receive shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock, including the Company Notes), whether conditional or unconditional or vested or unvested, that are outstanding as of immediately prior to the First Effective Time; </span><span style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span><span style="font-size:11pt;">, that Company Outstanding Shares shall exclude (i) any Company Options, Company Warrants and any other equity awards issued under the Company Stock Plans (including any shares of Company Common Stock issuable upon the exercise of such Company Options, Company Warrants or other equity awards) issued to directors, employees, consultants or other service providers following the Agreement &#160;Date &#160;but &#160;prior &#160;to &#160;the &#160;Closing &#160;(collectively, &#160;the &#8220;</span><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Service </b><span style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </span><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Provider Grants</b><span style="font-size:11pt;">&#8221;) and (ii) any shares of Company Common Stock underlying Company Notes that are to be contributed as consideration in the Company Pre-Closing Financing pursuant to the Subscription Agreement (to avoid double counting).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 170.4pt;"><span style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.1.4</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">The definition of &#8220;Company Valuation&#8221; shall be, and hereby is, amended and replaced in its entirety with the following:</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="font-size:11pt;">&#8220;</span><b style="font-size:11pt;font-weight:bold;">Company Valuation</b><span style="font-size:11pt;">&#8221; means (i) $50,000,000, </span><i style="font-size:11pt;font-style:italic;">plus </i><span style="font-size:11pt;">(ii) the amount of proceeds actually received by the Company from the Company Pre- Closing Financing (including the Company Notes and any interest thereon contributed as consideration in the Company Pre-Closing Financing), </span><i style="font-size:11pt;font-style:italic;">plus </i><span style="font-size:11pt;">(iii) the Fair Market Value of each Company Acquisition, </span><i style="font-size:11pt;font-style:italic;">plus </i><span style="font-size:11pt;">(iv) the Fair Market Value of any Interim Financing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.1.5</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">The definition of &#8220;Parent Valuation Floor&#8221; shall be, and hereby is, amended and replaced in its entirety with the following:</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="font-size:11pt;">&#8220;</span><b style="font-size:11pt;font-weight:bold;">Parent Valuation Floor</b><span style="font-size:11pt;">&#8221; means an amount equal to (i) 0.03, multiplied by (ii) the sum of (A) the Company Valuation (as of immediately prior to the Closing), and (B) $8,000,000.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.1.6</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">The Parties hereby acknowledge and agree that (i) references to shares of Company Common Stock in Section 2.5(a)(ii) of the Merger Agreement shall include any shares issued pursuant to the Company Pre-</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:11pt;">Closing Financing and (ii) references to Company Warrants in Section 6.5(b) of the Merger Agreement shall include any pre-funded Company Warrants issued pursuant to the Company Pre-Closing Financing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.1.7</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">Section 5.1(a)(i) and Section 5.1(b)(i) of the Merger Agreement shall be, and hereby are, amended by deleting any reference to the Subscription Agreement in such provisions.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.1.8</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">References to &#8220;this Agreement&#8221; in Section 5.2(a)(i) and Section 5.2(b)(i) of the Merger Agreement shall be, and hereby are, deemed to include &#8220;or the Subscription Agreement.&#8221;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.1.9</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">References to &#8220;Parent&#8221; in Section 8.6 of the Merger Agreement shall be deemed deleted and replaced with a reference to &#8220;the Company.&#8221;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.1.10</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">All references to the Parent Financing in the Merger Agreement shall be (to the extent not otherwise deleted pursuant to Section 1.1 of this Amendment) deemed deleted and replaced with a reference to the Company Pre-Closing Financing.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.2.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Re</span><span style="font-size:11pt;">g</span><span style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">istration Statement on Form S-4</span><span style="font-size:11pt;">.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.2.1</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">Section 6.1 of the Merger Agreement shall be, and hereby is, amended and replaced in its entirety with the following:</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">6.1.</span></span><span style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Re</span><span style="font-size:11pt;">g</span><span style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">istration Statement, Proxy Statement</span><span style="font-size:11pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:10.5pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="font-size:11pt;">As promptly as practicable after the date of this Agreement, Parent, in cooperation with the Company, shall prepare and file with the SEC a registration statement on Form S-4 (the &#8220;</span><b style="font-size:11pt;font-weight:bold;">Form S-4</b><span style="font-size:11pt;">&#8221;), in which a proxy statement relating to the Parent Stockholder Meeting to be held in connection with the Merger (together with any amendments thereof or supplements thereto, the &#8220;</span><b style="font-size:11pt;font-weight:bold;">Proxy Statement</b><span style="font-size:11pt;">&#8221;) shall be included as a part (the Proxy Statement and the Form S-4, collectively, the &#8220;</span><b style="font-size:11pt;font-weight:bold;">Registration Statement</b><span style="font-size:11pt;">&#8221;), in connection with the registration under the Securities Act of the shares of Parent Common Stock (including any Parent Common Stock issuable upon (I) conversion of the Parent Convertible Preferred Stock or (II) exercise of any Assumed Warrant) to be issued by virtue of the Contemplated Transactions, other than any shares of Parent Capital Stock which are not permitted to be registered on Form S-4 pursuant to applicable Law. Parent shall use commercially reasonable efforts to (i) cause the Registration Statement to comply with applicable rules and regulations promulgated by the SEC, (ii) cause the Registration Statement to become effective as promptly as practicable, and (iii) respond promptly to any comments or requests of the SEC or its staff related to the Registration Statement. Parent shall use commercially reasonable efforts to take all actions required under any applicable federal, state, securities and other Laws in connection with the issuance of shares of Parent Capital Stock pursuant to the Contemplated Transactions (including any Parent Common Stock issuable upon (I) conversion of the Parent Convertible Preferred Stock or (II) exercise of any Assumed Warrant). Each of the Parties shall reasonably cooperate with the other Party and furnish all information concerning itself and its Affiliates, as applicable, to the other Parties that is required by law to be included in the Registration Statement as the other Parties may reasonably request in connection with such actions and the preparation of the Registration Statement and Proxy Statement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</span></span><span style="font-size:11pt;white-space:pre-wrap;">Parent covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith) will (i) comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL and DLLCA, and (ii) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company covenants and agrees that the information supplied by or on behalf of the Company to Parent for inclusion in the Registration Statement will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make such information, in light of the circumstances  under which they were made, not misleading. Notwithstanding the foregoing, neither Party makes any covenant, representation or warranty with respect to statements made in </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:11pt;white-space:pre-wrap;">the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), if any, based on information provided by the other Party or any of its Representatives regarding such other Party or its Affiliates for inclusion therein.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</span></span><span style="font-size:11pt;">Parent shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#8217;s stockholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act. If at any time before the First Effective Time, (i) Parent, Merger Subs or the Company (A) become aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement or Proxy Statement, (B) receives notice of any SEC request for an amendment or supplement to the Registration Statement or for additional information related thereto, or (C) receives SEC comments on the Registration Statement, or (ii) the information provided in the Registration Statement has become &#8220;stale&#8221; and new information should be disclosed in an amendment or supplement to the Registration Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in Parent filing such amendment or supplement with the SEC (and, if appropriate, in mailing such amendment or supplement to the Parent stockholders) or otherwise addressing such SEC request or comments and each Party and shall use their commercially reasonable efforts to cause any such amendment to become effective, if required. Parent shall promptly notify the Company if it becomes aware (1) that the Registration Statement has become effective, (2) of the issuance of any stop order or suspension of the qualification or registration of the Parent Capital Stock issuable in connection with the Contemplated Transactions (including any Parent Common Stock issuable upon (I) conversion of the Parent Convertible Preferred Stock and (II) exercise of any Assumed Warrant) for offering or sale in any jurisdiction, or (3) any order of the SEC related to the Registration Statement, and shall promptly provide to the Company copies of all written correspondence between it or any of its Representatives, on the one hand, and the SEC or staff of the SEC, on the other hand, with respect to the Registration Statement and all orders of the SEC relating to the Registration Statement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="font-size:11pt;white-space:pre-wrap;">The Company shall reasonably cooperate with Parent and provide, and cause its Representatives to provide, Parent and its Representatives, with all true, correct and complete information regarding the Company that is required by Law to be included in the Registration Statement or reasonably requested by Parent to be included in the Registration Statement (collectively, the &#8220;Company Required S-4 Information&#8221;). Without limiting the foregoing, the Company will use commercially reasonable efforts to cause to be delivered to Parent a consent letter of the Company&#8217;s independent accounting firm, dated no later than the date on which the Registration Statement is filed with the SEC (and reasonably satisfactory in form and substance to Parent), that is customary in scope and substance for consent letters delivered by independent public accountants in connection with registration statements similar to the Registration Statement. The Company and its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Registration Statement, prior to the filing thereof with the SEC. Parent may file the Registration Statement, or any amendment or supplement thereto, without the prior consent of the Company, provided  that Parent has included the Company Required S-4 Information in the Registration Statement in substantially the same form as it was provided to Parent by the Company pursuant to this Section 6.1; provided, further, that if the prior consent of the Company is not obtained then, notwithstanding anything else herein, the Company makes no covenant or representation regarding the portion of such information supplied by or on behalf of the Company to Parent for inclusion in such Registration Statement that the Company reasonably identifies prior to such filing of the Registration Statement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</span></span><span style="font-size:11pt;">As promptly as reasonably practicable following February 14, 2025, the Company will use commercially reasonable efforts to furnish to Parent audited financial statements for the year ended December 31, 2024 (the &#8220;Company Financial Statements&#8221;) required to be included in the Proxy Statement. As promptly as reasonably practicable following any request therefore, the Company will use commercially reasonable efforts to furnish to Parent any unaudited interim financial statements for each interim period completed prior to Closing that would be required to be included in the Registration Statement or any periodic report due prior to the Closing </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:11pt;">if the Company were subject to the periodic reporting requirements under the Securities Act or the Exchange Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.2.2</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">The parties acknowledge and agree that, as a result of this Amendment, the further approval of the Merger Agreement (including as amended hereby) by the stockholders of the Company is required. As a result, Section 6.2(a) of the Merger Agreement shall be, and hereby is, amended and replaced in its entirety with the following:</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:11pt;">Promptly after the Registration Statement has been declared effective under the Securities Act, and in any event no later than two (2) Business Days thereafter, the Company shall obtain the approval by written consent from Company stockholders sufficient for the Required Company Stockholder Vote in lieu of a meeting pursuant to Section 228 of the DGCL, for purposes of (i) adopting and approving this Agreement and the Contemplated Transactions, (ii) acknowledging that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section 262 of the DGCL, and that such stockholder has received and read a copy of Section 262 of the DGCL and (iii) acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares in connection with the Merger and thereby waives any rights to receive payment of the fair value of its capital stock under the DGCL (the &#8220;Company Stockholder Written Consents&#8221;). Under no circumstances shall the Company assert that any other approval or consent is necessary by its stockholders to approve this Agreement and the Contemplated Transactions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.2.3</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">The second sentence of Section 6.3(a) shall be, and hereby is, amended and replaced in its entirety with the following:</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="font-size:11pt;">The Parent Stockholder Meeting shall be held as promptly as practicable after the date that the Registration Statement is declared effective under the Securities Act, and in any event, no later than 45 days after the effective date of the Registration Statement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.2.4</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">A new Section 7.8 is hereby inserted into the Merger Agreement as follows:</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">7.8.</span></span><span style="font-size:11pt;">Effectiveness of Registration Statement. The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject to any stop order or Legal Proceeding seeking a stop order with respect to the Registration Statement that has not been withdrawn.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.2.5</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">A new proviso is hereby inserted at the end of Section 10.1(b) the Merger Agreement as follows: &#8220;; provided further, however, that, in the event that the SEC has not declared effective under the Securities Act the Registration Statement by the date which is sixty (60) days prior to the End Date, then either the Company or Parent shall be entitled to extend the End Date for an additional sixty (60) days.&#8221;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.2.6</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">Section 10.1(d) of the Merger Agreement shall be, and hereby is, amended and replaced in its entirety with the following:</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</span></span><span style="font-size:11pt;">by Parent if the Required Company Stockholder Vote shall not have been obtained within two (2) Business Days of the Registration Statement becoming effective in accordance with the provisions of the Securities Act; provided, however, that once the Required Company Stockholder Vote has been obtained (whether timely or not), Parent may not terminate this Agreement pursuant to this Section 10.1(d);</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">1.2.7</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:11pt;">All references to the Proxy Statement in the Merger Agreement shall be (to the extent not otherwise deleted pursuant to Section 1.2 of this Amendment) deemed deleted and replaced with a reference to the Registration Statement.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">ARTICLE 2</b></span><b style="font-size:11pt;font-weight:bold;">ADDITIONAL SUPPORT AGREEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:11pt;">2.1. Subject to applicable law, the Company hereby agrees to obtain additional Support Agreements from the investors in an Interim Financing such that the Company Common Stock subject to Support Agreements continues to exceed a majority of the Company Outstanding Shares (measured as of immediately following the closing of such Interim Financing).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">ARTICLE 3</b></span><b style="font-size:11pt;font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:10.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">3.1.</span></span><span style="font-size:11pt;">Except as specifically modified herein, the Merger Agreement remains in full force and effect, and the Parties hereto reserve all of their respective rights and remedies with respect to all other matters and claims, whether known or unknown, arising under the Merger Agreement. The Merger Agreement (including as amended hereby) and the other schedules, exhibits, certificates, instruments and agreements referred to in the Merger Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; provided, however, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">3.2.</span></span><span style="font-size:11pt;">This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument, with the same effect as if the signatures thereto were in the same instrument. The exchange of a fully executed Amendment (in counterparts or otherwise) by all Parties by electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Amendment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">3.3.</span></span><span style="font-size:11pt;">Article 11 of the Merger Agreement is hereby incorporated by reference into this Amendment, </span><i style="font-size:11pt;font-style:italic;">mutatis mutandis</i><span style="font-size:11pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 80.4pt;"><span style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">[</span><i style="font-size:11pt;font-style:italic;">Signature Pages Follow</i><span style="font-size:11pt;">]</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF, </b>the Parties have caused this Amendment to be executed as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 313.4pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">GLYCOMIMETICS INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">GEMINI MERGER SUB CORP.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">GEMINI MERGER SUB II, LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">[</span><i style="font-size:11pt;font-style:italic;">Signature Page to Amendment No. 1</i><span style="font-size:11pt;">]</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed as of the date first above written.<br/><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CRESCENT BIOPHARMA, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jonathan Violin</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Jonathan violin</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Signature Page to Amendment No. 1]<br/><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:54pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8b187920_d6b0_441b_913b_579532e70019"></a><a id="AnnexB_979236"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="glyc-20241231xs4054.jpg" alt="Graphic" style="display:inline-block;height:53.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:144pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Strictly Confidential</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">October&#160;28, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GlycoMimetics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9708 Medical Center Drive</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rockville, MD 20850</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attention: Timothy R. Pearson</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Chairman of the Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Members of the Board of Directors:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have been advised that GlycoMimetics,&#160;Inc., a Delaware corporation (&#8220;GlycoMimetics&#8221; or &#8220;Parent&#8221;), proposes to enter into an Agreement and Plan of Merger and Reorganization (the &#8220;Agreement&#8221;), by and among GlycoMimetics, Gemini Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (&#8220;First Merger Sub&#8221;), Gemini Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (&#8220;Second Merger Sub&#8221; and, together with First Merger Sub, &#8220;Merger Subs&#8221;), and Crescent Biopharma&#160;Inc., a Delaware corporation (&#8220;Crescent&#8221; or the &#8220;Company&#8221;). Upon the terms and subject to the conditions set forth in the Agreement, at the First Effective Time, First Merger Sub will be merged with and into the Company (the &#8220;First Merger&#8221;), and the separate existence of First Merger Sub will cease. The Company will continue as the surviving corporation in the First Merger (the &#8220;First Step Surviving Corporation&#8221;). Upon the terms and subject to the conditions set forth in the Agreement, at the Second Effective Time, the First Step Surviving Corporation will merge with and into Second Merger Sub (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;), and the separate existence of the First Step Surviving Corporation shall cease. As a result of the Second Merger, Second Merger Sub will continue as the surviving entity in the Second Merger (the &#8220;Surviving Entity&#8221;). Pursuant to the terms and subject to the conditions set forth in the Agreement, upon consummation of the Merger, (i)&#160;each outstanding share of Company Common Stock (excluding shares of Company Capital Stock held as treasury stock immediately prior to the First Effective Time which shall be canceled and excluding Dissenting Shares) will be converted solely into the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio, and (ii)&#160;each outstanding share of Company Preferred Stock (excluding shares of Company Capital Stock held as treasury stock immediately prior to the First Effective Time which shall be canceled and excluding Dissenting Shares) will be converted solely into the right to receive a number of shares of Parent Convertible Preferred Stock equal to (x)&#160;the Exchange Ratio divided by (y)&#160;1,000 (collectively, the &#8220;Merger Consideration&#8221;). The terms and conditions of the Merger are more fully set forth in the Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Agreement also contemplates that concurrently with the execution and delivery of the Agreement, certain investors will execute a Subscription Agreement pursuant to which such Persons will agree to purchase shares of Parent Common Stock following the First Effective Time (the &#8220;Parent Financing&#8221;). It is a condition precedent to the obligations of Parent and Merger Subs to effect the Merger that proceeds of not less than $100 million (minus the amount of proceeds actually received by the Company in connection with any Interim Financing) be received (the &#8220;Minimum Concurrent Investment Amount&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;"><img src="glyc-20241231xs4053.jpg" alt="Graphic" style="display:inline-block;height:34.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:216.75pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">B-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c0fce1ca_1846_47d2_9a08_c87162b616ba"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of rendering our Opinion we have, with your consent, assumed that (i)&#160;Parent will receive $200 million in proceeds from the Parent Financing and that no Interim Financing will have occurred, (ii)&#160;the Exchange Ratio will be 14.7507, (iii)&#160;upon closing of the Merger, the holders of Company Common Stock, Company Preferred Stock, Company Options and Company Warrants will in the aggregate hold approximately 86.2% of the fully-diluted shares of Parent Common Stock (excluding certain Parent Options) immediately following the Merger (19.4% after giving effect to the Parent Financing), the holders of Parent Common Stock will in the aggregate hold approximately 13.8% of the fully-diluted shares of Parent Common Stock (excluding certain Parent Options) immediately following the Merger (3.1% after giving effect to the Parent Financing) and (iv)&#160;the investors in the Parent Financing will in the aggregate hold approximately 77.5% of the fully-diluted shares of Parent Common Stock (excluding certain Parent Options).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have, with your consent, relied upon the assumption that all information provided to us by GlycoMimetics and Crescent is accurate and complete in all material respects. We expressly disclaim any undertaking or obligation to advise any person of any change in any fact or matter affecting our Opinion of which we become aware after the date hereof. We have assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of GlycoMimetics or Crescent since the date of the last financial statements made available to us. We have not obtained any independent evaluations, valuations or appraisals of the assets or liabilities of GlycoMimetics or Crescent, nor have we been furnished with such materials. In addition, we have not evaluated the solvency or fair value of GlycoMimetics or Crescent under any state or federal laws relating to bankruptcy, insolvency or similar matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Opinion does not address any legal, regulatory, tax or accounting matters related to the Merger, as to which we have assumed that GlycoMimetics and the Board of Directors have received such advice from legal, tax and accounting advisors as each has determined appropriate. Our Opinion addresses only the fairness from a financial point of view of the Exchange Ratio as set forth in the Agreement to the holders of Parent Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We express no view as to any other aspect or implication of the Merger or any other agreement or arrangement entered into in connection with the Merger. Our Opinion is necessarily based upon economic and market conditions and other circumstances as they exist and can be evaluated by us on the date hereof. It should be understood that although subsequent developments may affect our Opinion, we do not have any obligation to update, revise or reaffirm our Opinion and we expressly disclaim any responsibility to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not considered any potential legislative or regulatory changes currently being considered or recently enacted by the United States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the Securities and Exchange Commission (the &#8220;SEC&#8221;), the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In your capacity as members of the Board of Directors of GlycoMimetics (the &#8220;Board of Directors&#8221;), you have requested our opinion (our &#8220;Opinion&#8221;) as to the fairness, from a financial point of view and as of the date hereof, of the Exchange Ratio as set forth in the Agreement to the holders of Parent Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with our Opinion, we took into account an assessment of general economic, market and financial conditions as well as our experience in connection with similar transactions and securities valuations generally and, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed a draft of the Merger Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain publicly available financial and other information for each of GlycoMimetics and Crescent, respectively, including equity research on comparable companies, and certain relevant financial and operating data furnished to Lucid by the management of each of GlycoMimetics and Crescent, respectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain relevant historical financial and operating data concerning Crescent furnished to Lucid by the management of Crescent and its financial advisors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Discussed with certain members of the management of GlycoMimetics the historical and current business operations, financial condition and prospects of GlycoMimetics and Crescent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain operating results of Crescent as compared to operating results and the reported price and trading histories of certain publicly traded companies that Lucid deemed relevant;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">B-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain financial terms of the Merger Agreement as compared to the publicly available financial terms of certain selected business combinations that Lucid deemed relevant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain financial terms of completed initial public offerings for certain companies that Lucid deemed relevant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed certain pro forma financial effects of the Merger;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed certain internal financial analyses, including the cash burn model over the next</span><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">year and whether the concurrent capital raised would sufficiently cover select programs, reports and other information concerning Crescent prepared by Crescent; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as Lucid deemed relevant for purposes of this Opinion.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of rendering our Opinion we have assumed, with your consent, that except as would not be in any way meaningful to our analysis: (i)&#160;the final form of the Agreement will not differ from the Draft Agreement that we have reviewed; (ii)&#160;the representations and warranties of each party contained in the Agreement are true and correct in all respects; (iii)&#160;each party will perform all of the covenants and agreements required to be performed by such party under the Agreement; and (iv)&#160;the transactions contemplated by the Agreement will be consummated in accordance with the terms of the Agreement, without any waiver or amendment of any term or condition thereof. We have also assumed that all governmental, regulatory and other consents and approvals contemplated by the Agreement or otherwise required for the transactions contemplated by the Agreement will be obtained and that in the course of obtaining any of those consents no restrictions will be imposed, or waivers made that would have an adverse effect on GlycoMimetics, Crescent, or the contemplated benefits of the Merger. We have assumed that the Merger will be consummated in a manner that complies with the applicable provisions of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and all other applicable federal and state statutes and the rules&#160;and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is understood that this letter is intended for the benefit and use of the Board of Directors (in its capacity as such) in its consideration of the financial terms of the Merger and, except as set forth in our engagement letter with GlycoMimetics, dated as of July&#160;24, 2024 (the &#8220;Engagement Letter&#8221;), may not be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose without our prior written consent, except that this Opinion may be included in its entirety in any filing related to the Merger required to be filed with the SEC and any proxy statement to be mailed to holders of Parent Common Stock. This letter does not constitute a recommendation to the Board of Directors of whether to approve the Merger or to any stockholder of GlycoMimetics or any other person as to how to vote or act with respect to the transactions contemplated by the Agreement (including the Merger) or any other matter. Our Opinion does not address GlycoMimetics&#8217; underlying business decision to proceed with the Merger or the relative merits of the Merger compared to other alternatives available to GlycoMimetics. We express no opinion as to the prices or ranges of prices at which shares or the securities of any person, including GlycoMimetics, will trade at any time, including following the announcement or consummation of the Merger, or as to the potential effects of volatility in the credit, financial, and stock markets on GlycoMimetics, Crescent or the transactions contemplated by the Agreement. We have not been requested to opine as to, and our Opinion does not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the Merger, or any class of such persons, relative to the compensation to be paid to the holders of Parent Common Stock in connection with the Merger or with respect to the fairness of any such compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Lucid is an investment bank providing investment banking, brokerage, equity research, institutional sales and trading services. As part of our investment banking services, we are regularly engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. We have acted as GlycoMimetics&#8217; financial advisor in connection with the Merger and will receive a fee for our services pursuant to the terms of our Engagement Letter, a significant portion of which is contingent upon consummation of the Merger. In addition, GlycoMimetics has agreed to reimburse our expenses and indemnify us for certain liabilities that may arise out of our engagement. We will also receive an additional fee for rendering our Opinion set forth below pursuant to the Engagement Letter, which is not contingent upon consummation of the Merger. In the two&#160;years preceding the date hereof, Lucid has not had a relationship with GlycoMimetics or its affiliates and has not received any fees from GlycoMimetics or any of its affiliates. In the two&#160;years preceding the date hereof, Lucid has not had a relationship with Crescent or any of its affiliates and has not received any fees from Crescent or any of its affiliates. Lucid and its affiliates may in the future seek to provide investment banking or financial </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">B-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:24pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">advisory services to GlycoMimetics and Crescent and/or their respective affiliates and expect to receive fees for the rendering of these services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, Lucid or certain of our affiliates, as well as investment funds in which we or our affiliates may have financial interests, may acquire, hold or sell long or short positions, or trade or otherwise effect transactions in debt, equity, and other securities and financial instruments (including bank loans and other obligations) of, or investments in, GlycoMimetics, Crescent or any other party that may be involved in the Merger and/or their respective affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consistent with applicable legal and regulatory requirements, Lucid has adopted policies and procedures to establish and maintain the independence of our research department and personnel. As a result, our research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to GlycoMimetics and the proposed Merger that may differ from the views of Lucid&#8217;s investment banking personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Opinion set forth below was reviewed and approved by a fairness opinion committee of Lucid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based upon and subject to the foregoing, including the various assumptions and limitations set forth herein and such other factors that we deem relevant, it is our opinion that, as of the date hereof, the Exchange Ratio is fair, from a financial point of view, to the holders of Parent Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Very truly yours,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><img src="glyc-20241231xs4055.jpg" alt="Graphic" style="display:inline-block;height:23.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:108pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lucid Capital Markets, LLC</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">B-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f7651d35_6614_45e7_9fef_70815272c761"></a><a id="AnnexC_190262"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SUPPORT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Support Agreement (this &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221;) is made and entered into as of October 28, 2024, by and among Crescent Biopharma, Inc., a Delaware corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span>&#8221;), GlycoMimetics, Inc., a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</span>&#8221;), and the undersigned stockholder (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stockholder</span>&#8221; and each of the Stockholder, Company, and Parent a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</span>&#8221; and, collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</span>&#8221;) of the Company. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company and Gemini Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Merger Sub</span>&#8221;), and Gemini Merger Sub II, LLC a Delaware limited liability company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Merger Sub</span>&#8221;) have entered into an Agreement and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Agreement</span>&#8221;), pursuant to which (i) the First Merger Sub will merge with and into the Company, with the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii) the Company will merge with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and subject to the conditions set forth in the Merger Agreement (together, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of such number of shares of Company Capital Stock as indicated in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, as an inducement to the willingness of Parent to enter into the Merger Agreement, Parent has required that Stockholder enter into this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, intending to be legally bound, the Parties hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">1.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Definitions</span>. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(a)&#160;&#160;&#160;&#160;&#8221;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Constructive Sale</span>&#8221; means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic benefits or risks of ownership of such security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(b)&#160;&#160;&#160;&#160;&#8221;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares</span>&#8221; means (i) all shares of Company Capital Stock beneficially owned by the Stockholder as of the date hereof, (ii) all additional shares of Company Capital Stock acquired and beneficially owned by the Stockholder during the period commencing with the execution and delivery of this Agreement and expiring on the Closing Date, and (iii) all convertible notes, promissory notes, warrants, options, rights or other securities or instruments directly or indirectly held by the Stockholder as of the date hereof that are convertible into or exercisable or exchangeable for shares of Company Capital Stock, whether or not currently convertible, exercisable or exchangeable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(c)&#160;&#160;&#160;&#160;&#8221;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer</span>&#8221; or &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transferred</span>&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">2.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer and Voting Restrictions</span>. The Stockholder covenants to Parent and the Company as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(a)&#160;&#160;&#160;&#160;Except as otherwise permitted by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2&#8206;(c)</span>, during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below), the Stockholder shall not Transfer any of the Stockholder&#8217;s Shares, or publicly announce its intention to Transfer any of its Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(b)&#160;&#160;&#160;&#160;Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Authority, the Stockholder will not commit any act that would restrict the Stockholder&#8217;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity in each case which has the effect of limiting or affecting the Stockholder&#8217;s legal power, authority or right to execute and deliver the Company Stockholder Written Consents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(c)&#160;&#160;&#160;&#160;Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i) by will or other testamentary document or by intestacy, (ii) to such Stockholder&#8217;s Affiliates (in each case, directly or indirectly) (iii) to any member of the Stockholder&#8217;s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Stockholder), (iv) to any trust or other entity for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise for estate tax or estate planning purposes, (v) in the case of a Stockholder who is not a natural person, by pro rata distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder&#8217;s organizational documents, (vi) purchased from Parent pursuant to the Parent Financing on or about the Closing Date (including any shares of Parent issued upon conversion of any pre-funded warrants of Parent), and (vii) to the extent required by applicable Law; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that in the cases of clauses (i)-(v), (x) such Transferred Shares shall continue to be bound by this Agreement and (y) the applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer if not already a party thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 18pt;">(d)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to acquire any shares of Company Capital Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">3.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement to Vote Shares</span>. The Stockholder covenants to the Company as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(a)&#160;&#160;&#160;&#160;Until the Expiration Date (as defined below), at any meeting of the stockholders of the Company, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of the Company, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (A) in favor of the adoption and approval of the Merger Agreement, (B) in favor of approval of the Contemplated Transactions, and (C) against any Acquisition Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(b)&#160;&#160;&#160;&#160;If the Stockholder is not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#8217;s Shares in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(c)&#160;&#160;&#160;&#160;In the event of a stock split, stock dividend or distribution, or any change in the capital stock of the Company by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">4.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Action in Stockholder Capacity Only</span>. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as the beneficial owner of its Shares and not in the Stockholder&#8217;s capacity as a director or officer of the Company. Nothing herein shall limit or affect the Stockholder&#8217;s ability to act as an officer or director of the Company.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">5.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Irrevocable Proxy</span>. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3</span> at any applicable meeting of the stockholders of the Company or pursuant to any applicable written consent of the stockholders of the Company, the Stockholder shall be deemed to have irrevocably granted to, and appointed, the Company, and any individual designated in writing by it, and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and in its name, place and stead, to vote his, her or its Shares in any action by written consent of Company stockholders or at any meeting of the Company stockholders called with respect to any of the matters specified in, and in accordance and consistent with, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3</span> of this Agreement. The Company agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided for herein (including the next sentence), the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate on the Expiration Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">6.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Solicitation</span>. The Stockholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take any action that the Company is prohibited from taking pursuant to Section 5.4 of the Merger Agreement and Section 5.4 of the Merger Agreement is hereby incorporated by reference <i style="font-style:italic;">mutatis mutandis</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">7.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Documentation and Information</span>. The Stockholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Stockholder&#8217;s identity and ownership of the Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement; provided, that, Parent and the Company provide such documents, schedules, press release or other disclosure document to the Stockholder in advance for its review and comment. Each of Parent and the Company is an intended third-party beneficiary of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;7</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">8.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Exercise of Appraisal Rights; Waivers</span>. The Stockholder hereby irrevocably and unconditionally (a) waives, and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters&#8217; rights and any similar rights (including any notice requirements related thereto) relating to the Merger that Stockholder may have by virtue of, or with respect to, any Shares (including all rights under Section 262 of the DGCL) and (b) agrees that the Stockholder will not bring, commence, institute, maintain, prosecute or voluntarily aid or participate in any action, claim, suit or cause of action, in law or in equity, in any court or before any Governmental Authority, which (i) challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii) alleges that the execution and delivery of this Agreement by the Stockholder breaches any duty that such Stockholder has (or may be alleged to have) to the Company or to the other Company stockholders; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that (x) the Stockholder may defend against, contest or settle any such action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of the Company and (y) the foregoing shall not limit or restrict in any manner the Stockholder from enforcing the Stockholder&#8217;s rights under this Agreement and the other agreements entered into by the Stockholder in connection herewith, or otherwise in connection with the Merger, including the Stockholder&#8217;s right to receive the Merger Consideration pursuant to the terms of the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">9.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of the Stockholder</span>. The Stockholder hereby represents and warrants to Parent and the Company as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(a)&#160;&#160;&#160;&#160;(i) The Stockholder is the beneficial owner of the shares of Company Capital Stock indicated in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span> (each of which shall be deemed to be &#8220;held&#8221; by the Stockholder for purposes of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3</span> unless otherwise expressly stated with respect to any shares in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span>), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed pursuant to this Agreement, any lock-up agreement entered into by and between the Stockholder, the Company and Parent, and Encumbrances arising under applicable securities or community property laws); and (ii) the Stockholder does not beneficially own any securities of the Company other than the shares of Company Capital Stock and rights to purchase shares of Company Capital Stock set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">(b)&#160;&#160;&#160;&#160;Except as otherwise provided in this Agreement, the Stockholder has full power and authority to (i) make, enter into and carry out the terms of this Agreement and (ii) vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality of the foregoing, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#8217;s Shares, deposited any of the Stockholder&#8217;s Shares in a voting trust or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares on any matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(c)&#160;&#160;&#160;&#160;This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by the other Parties) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, or any applicable law to which the Stockholder (or any of the Stockholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Stockholder&#8217;s ability to perform its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(d)&#160;&#160;&#160;&#160;The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Authority, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#8217;s ability to perform its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(e)&#160;&#160;&#160;&#160;The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Entity) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(f)&#160;&#160;&#160;&#160;With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">10.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Agreements</span>. Each Stockholder, by this Agreement, and with respect to such Stockholder&#8217;s Shares, severally and not jointly, hereby agrees to terminate, subject to the occurrence of, and effective immediately prior to, the First Effective Time any rights under any letter agreement providing for redemption rights, put rights, purchase rights, information rights, rights to consult with and advise management, inspection rights, preemptive rights, board of directors observer rights or rights to receive information delivered to the board of directors or other similar rights not generally available to stockholders of the Company between the Stockholder and the Company, but excluding, for the avoidance of doubt, any rights the Stockholder may have that relate to any indemnification, commercial, development or employment agreements or arrangements between such Stockholder and the Company or any subsidiary of the Company, which shall survive in accordance with their terms. Each Stockholder hereby terminates and waives all rights of first refusal, redemption rights and rights of notice of the Merger and the other transactions contemplated by the Merger Agreement, effective as of immediately prior to, and contingent upon, the First Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">11.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</span>. This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a) such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof as in effect on the date of this Agreement (and without giving effect to any amendments thereto unless consented to by the Stockholder), (b) the First Effective Time and (c) the time this Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expiration Date</span>&#8221;); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span><i style="font-style:italic;">, </i><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span><i style="font-style:italic;">,</i> that (i) <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;12</span> shall survive the termination of this Agreement and (ii) the termination of this Agreement shall not relieve any Party from any liability for any material and willful breach of this Agreement prior to the First Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">12.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous Provisions</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(a)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments</span>. No amendment of this Agreement shall be effective against any Party unless it shall be in writing and signed by each of the Parties.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(b)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span>. This Agreement constitutes the entire agreement between the Parties and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the Parties with respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(c)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Law; Jurisdiction.</span> This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement, each of the Parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i) of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;12&#8206;12&#8206;(c)</span>, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (v) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;12&#8206;(h)</span> of this Agreement and (vi) irrevocably and unconditionally waives the right to trial by jury.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(d)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</span>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated (except pursuant to the Merger) by such Party without the prior written consent of the other Parties, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Parties&#8217; prior written consent shall be void and of no effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(e)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third-Party Rights</span>. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(f)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(g)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</span>. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;">(h)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii) upon delivery in the case of delivery by hand or (iii) on the date delivered in the place of delivery if sent by email or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, (A) if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section 11.7 of the Merger Agreement, including to the persons designated therein to receive copies; and/or (B) if to the Stockholder, to the Stockholder&#8217;s address, electronic mail address or facsimile shown below Stockholder&#8217;s signature to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(i)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</span>. Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding the Company, this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until the Company and Parent have publicly disclosed their entry into the Merger Agreement and this Agreement; provided, however, that the Stockholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that such Persons are subject to confidentiality obligations at least as restrictive as those contained herein). Neither the Stockholder nor any of its Affiliates (other than the Company, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to the Company, this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing Party shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">(j)&#160;&#160;&#160;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</span>. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Remainder of Page Left Intentionally Blank</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">C-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5041c142_7f9a_49f9_bb39_12a8cd16329f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">COMPANY:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Crescent Biopharma, Inc.</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page to Company Stockholder Support Agreement]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PARENT:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page to Company Stockholder Support Agreement]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[STOCKHOLDER],</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in his/her capacity as the Stockholder:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature:</p></td><td style="vertical-align:bottom;width:41.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page to Company Stockholder Support Agreement]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5be44e9e_4a11_49e2_958e_f834512ee114"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6be93bb9_3d25_4cf2_8406_8dc5f7dd3b87"></a><a id="AnnexD_955409"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SUPPORT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Support Agreement (this &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</span>&#8221;) is made and entered into as of October 28, 2024, by and among Crescent Biopharma, Inc., a Delaware corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span>&#8221;), GlycoMimetics, Inc., a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</span>&#8221;), and the undersigned stockholder (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stockholder</span>&#8221; and each of the Stockholder, Company, and Parent a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</span>&#8221; and, collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</span>&#8221;) of the Parent. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company and <span style="text-transform:uppercase;">Gemini Merger Sub Corp</span>., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Merger Sub</span>&#8221;), and <span style="text-transform:uppercase;">Gemini Merger Sub II, LLC</span>, a Delaware limited liability company (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Merger Sub</span>&#8221;) have entered into an Agreement and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Agreement</span>&#8221;), pursuant to which (i) the First Merger Sub will merge with and into the Company, with the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii) the Company will merge with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and subject to the conditions set forth in the Merger Agreement (together, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger</span>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of such number of shares of Parent Common Stock as indicated in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, as an inducement to the willingness of the Company to enter into the Merger Agreement, the Company has required that Stockholder enter into this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, intending to be legally bound, the Parties hereby agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">1.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Definitions</span>. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(a)&#160;&#160;&#160;&#160;</span>&#8221;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Constructive Sale</span>&#8221; means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic benefits or risks of ownership of such security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(b)&#160;&#160;&#160;&#160;</span>&#8221;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent Stockholder Matters</span>&#8221; means the approval of (i) the issuance of Parent Capital Stock (including shares of Parent Common Stock issuable upon conversion thereof) in connection with the Contemplated Transactions for purposes of the listing rules of Nasdaq and (ii) the Parent Charter Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(c)&#160;&#160;&#160;&#160;</span>&#8221;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares</span>&#8221; means (i) all shares of Parent Common Stock owned, beneficially or of record, by the Stockholder as of the date hereof, (ii) all additional shares of Parent Common Stock acquired by the Stockholder, beneficially owned or of record, during the period commencing with the execution and delivery of this Agreement and expiring on the Closing Date, and (iii) all convertible notes, promissory notes, warrants, options, rights or other securities or instruments directly or indirectly held by the Stockholder as of the date hereof that are convertible into or exercisable or exchangeable for shares of Parent Common Stock, whether or not currently convertible, exercisable or exchangeable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(d)&#160;&#160;&#160;&#160;</span>&#8221;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer</span>&#8221; or &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transferred</span>&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the record or beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">2.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer and Voting Restrictions</span>. The Stockholder covenants to Parent and the Company as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(a)&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2&#8206;(c)</span>, during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below), the Stockholder shall not Transfer any of the Stockholder&#8217;s Shares, or publicly announce its intention to Transfer any of its Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(b)&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Authority, the Stockholder will not commit any act that would restrict the Stockholder&#8217;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement, and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity in each case which has the effect of limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares in favor of the Parent Stockholder Matters and against any competing proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(c)&#160;&#160;&#160;&#160;</span>Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i) by will or other testamentary document or by intestacy, (ii) to such Stockholder&#8217;s Affiliates (in each case, directly or indirectly) (iii) to any member of the Stockholder&#8217;s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Stockholder), (iv) to any trust or other entity for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise for estate tax or estate planning purposes, (v) in the case of a Stockholder who is not a natural person, by pro rata distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder&#8217;s organizational documents, (vi) purchased from Parent on or about the Closing Date (including any shares of Parent issued upon conversion of any pre-funded warrants of Parent), (vii) to the extent required by applicable Law and (viii) pursuant to the exercise of any option to purchase any Parent Common Stock, including in order to pay the exercise price of such option or satisfy taxes applicable thereto; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, that in the cases of clauses (i)-(v), (x) such Transferred Shares shall continue to be bound by this Agreement and (y) the applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer if not already a party thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(d)&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to acquire any shares of Parent Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">3.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement to Vote Shares</span>. The Stockholder covenants to the Company as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(a)&#160;&#160;&#160;&#160;</span>Until the Expiration Date (as defined below), at any meeting of the stockholders of Parent called to vote upon the Parent Stockholder Matters, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of Parent, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (A) in favor of the Parent Stockholder Matters, and (B) against any Acquisition Proposal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(b)&#160;&#160;&#160;&#160;</span>If the Stockholder is the beneficial owner, but not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#8217;s Shares in accordance with this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(c)&#160;&#160;&#160;&#160;</span>In the event of a stock split, stock dividend or distribution, or any change in the capital stock of Parent by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">4.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Action in Stockholder Capacity Only</span>. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as a record holder and beneficial owner, as applicable, of its Shares and not in the Stockholder&#8217;s capacity as a director or officer of Parent. Nothing herein shall limit or affect the Stockholder&#8217;s ability to act as an officer or director of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">5.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Irrevocable Proxy</span>. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3</span> at any applicable meeting of the stockholders of Parent or pursuant to any applicable written consent of the stockholders of Parent, the Stockholder shall be deemed to have irrevocably granted to, and appointed, Parent, and any individual designated in writing by it, and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and in its name, place and stead, to vote his, her or its Shares in any action by written consent of Parent stockholders or at any meeting of Parent stockholders called with respect to any of the matters specified in, and in accordance and consistent with, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3</span> of this Agreement. Parent agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided for herein, the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate on the Expiration Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">6.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Solicitation</span>. The Stockholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take any action that Parent is prohibited from taking pursuant to Section 5.4 of the Merger Agreement and Section 5.4 of the Merger Agreement is hereby incorporated by reference <i style="font-style:italic;">mutatis mutandis</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">7.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Documentation and Information</span>. The Stockholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Stockholder&#8217;s identity and ownership of the Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement. Each of Parent and the Company is an intended third-party beneficiary of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;7</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">8.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of the Stockholder</span>. The Stockholder hereby represents and warrants to Parent and the Company as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(a)&#160;&#160;&#160;&#160;</span>(i) The Stockholder is the beneficial or record owner of the shares of Parent Common Stock indicated in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span> (each of which shall be deemed to be &#8220;held&#8221; by the Stockholder for purposes of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3</span> unless otherwise expressly stated with respect to any shares in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span>), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed pursuant to this Agreement and Encumbrances arising under applicable securities or community property laws); and (ii) the Stockholder does not beneficially own any securities of Parent other than the shares of Parent Common Stock and rights to purchase shares of Parent Common Stock set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(b)&#160;&#160;&#160;&#160;</span>Except as otherwise provided in this Agreement, the Stockholder has full power and authority to (i) make, enter into and carry out the terms of this Agreement and (ii) vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality of the foregoing, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#8217;s Shares, deposited any of the Stockholder&#8217;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares on any matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(c)&#160;&#160;&#160;&#160;</span>This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by the other Parties) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, or any applicable law to which the Stockholder (or any of the Stockholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Stockholder&#8217;s ability to perform its obligations under this Agreement.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(d)&#160;&#160;&#160;&#160;</span>The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Authority, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#8217;s ability to perform its obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(e)&#160;&#160;&#160;&#160;</span>The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Entity) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(f)&#160;&#160;&#160;&#160;</span>With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">9.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</span>. This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a) such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof as in effect on the date of this Agreement (and without giving effect to any amendments thereto unless consented to by the Stockholder), (b) the First Effective Time and (c) the time this Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expiration Date</span>&#8221;); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span><i style="font-style:italic;">, </i><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span><i style="font-style:italic;">,</i> that (i) <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;10</span> shall survive the termination of this Agreement, and (ii) the termination of this Agreement shall not relieve any Party from any liability for any material and willful breach of this Agreement prior to the First Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">10.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous Provisions</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(a)&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments</span>. No amendment of this Agreement shall be effective against any Party unless it shall be in writing and signed by each of the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(b)&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span>. This Agreement constitutes the entire agreement between the Parties and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the Parties with respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(c)&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Law; Jurisdiction.</span> This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement, each of the Parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i) of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;10&#8206;(c)</span>, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (v) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;10&#8206;(h)</span> of this Agreement and (vi) irrevocably and unconditionally waives the right to trial by jury.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:11pt;">(d)&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</span>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated (except pursuant to the Merger) by such Party without the prior </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">written consent of the other Parties, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Parties&#8217; prior written consent shall be void and of no effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">(e)&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third-Party Rights</span>. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="font-size:11pt;">(f)&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="font-size:11pt;">(g)&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</span>. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="font-size:11pt;">(h)&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii) upon delivery in the case of delivery by hand or (iii) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, (A) if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section 11.7 of the Merger Agreement, including to the persons designated therein to receive copies; and/or (B) if to the Stockholder, to the Stockholder&#8217;s address, electronic mail address or facsimile shown below Stockholder&#8217;s signature to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 18pt;"><span style="font-size:11pt;">(i)&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</span>. Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding the Company, this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until the Company and Parent have publicly disclosed their entry into the Merger Agreement and this Agreement; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the Stockholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that such Persons are subject to confidentiality obligations at least as restrictive as those contained herein). Neither the Stockholder nor any of its Affiliates (other than Parent, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to Parent, this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing Party shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:11pt;">(j)&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</span>. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[<i style="font-style:italic;">Remainder of Page Left Intentionally Blank</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">D-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1f2a1b9f_1ce3_40b2_914b_8b69febf5d73"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">COMPANY:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Crescent Biopharma, Inc.</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[Signature Page to Company Stockholder Support Agreement]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-transform:uppercase;">Parent</span>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Glycomimetics, INC.</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.24%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page to Company Stockholder Support Agreement]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[STOCKHOLDER],</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in his/her capacity as the Stockholder:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature:</p></td><td style="vertical-align:bottom;width:41.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page to Company Stockholder Support Agreement]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_7197161a_72e1_4024_bf24_3006b99c9d50"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8a3b0cb2_f172_4544_8d44_675fcc8ffd40"></a><a id="AnnexE_977427"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex E</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LOCK-UP AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;">October 28, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GlycoMimetics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9708 Medical Center Drive</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rockville, Maryland 20850</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attention: Christian Dinneen-Long</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: cdinneen-long@glycomimetics.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Ladies and Gentlemen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The undersigned signatory of this lock-up agreement (this &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lock-Up Agreement</span>&#8221;) understands that GlycoMimetics, Inc., a Delaware corporation (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parent</span>&#8221;), has entered into an Agreement and Plan of Merger and Reorganization, dated as of October 28, 2024 (as the same may be amended from time to time, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Merger Agreement</span>&#8221;) with <span style="text-transform:uppercase;">Gemini Merger Sub Corp</span>., a Delaware corporation and a wholly owned subsidiary of Parent, <span style="text-transform:uppercase;">Gemini Merger Sub II, LLC</span>, a Delaware limited liability company and a wholly owned subsidiary of Parent, and Crescent Biopharma, Inc., a Delaware corporation (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</span>&#8221;). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">1.&#160;&#160;&#160;&#160;As a condition and inducement to each of the parties to enter into the Merger Agreement and to consummate the transactions contemplated thereby, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Parent, the undersigned will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Period</span>&#8221;); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided,</span> that if a registration statement covering the shares of Parent Common Stock and pre-funded warrants of Parent issued and sold in connection with the Parent Financing (other than any shares or pre-funded warrants of Parent held by affiliates of Parent) has not been declared effective by the SEC prior to the end of such 180-day period, then the Restricted Period shall end on such later date upon which such registration statement is first declared effective:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">a.&#160;&#160;&#160;&#160;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for shares of Parent Common Stock (including without limitation, shares of Parent Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the SEC and securities of Parent which may be issued upon exercise of an option to purchase shares of Parent Common Stock or a warrant to purchase shares of Parent Common Stock) that are currently or hereafter owned by the undersigned, except as set forth below (collectively, the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Undersigned&#8217;s Shares</span>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">b.&#160;&#160;&#160;&#160;enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Undersigned&#8217;s Shares regardless of whether any such transaction described in clause (a) above or this clause (b) is to be settled by delivery of shares of Parent Common Stock or other securities, in cash or otherwise;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">c.&#160;&#160;&#160;&#160;make any demand for, or exercise any right with respect to, the registration of any shares of Parent Common Stock or any security convertible into or exercisable or exchangeable for shares of Parent Common Stock (other than such rights set forth in the Merger Agreement); or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">d.&#160;&#160;&#160;&#160;publicly disclose the intention to do any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">2.&#160;&#160;&#160;&#160;The restrictions and obligations contemplated by this Lock-Up Agreement shall not apply to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">a.&#160;&#160;&#160;&#160;transfers of the Undersigned&#8217;s Shares:</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">E-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9.35pt;text-indent:-9.35pt;margin:0pt 0pt 12pt 54pt;">i.&#160;&#160;&#160;&#160;(A) to any person related to the undersigned (or to an ultimate beneficial owner of the undersigned) by blood or adoption who is an immediate family member of the undersigned, or by marriage or domestic partnership (each, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Family Member</span>&#8221;), or to a trust formed for the benefit of the undersigned or any of the undersigned&#8217;s Family Members, (B) to the undersigned&#8217;s estate, following the death of the undersigned, by will, intestacy or other operation of Law, (C) as a bona fide gift or a charitable contribution, (D) by operation of Law pursuant to a qualified domestic order or in connection with a divorce settlement or (E) to any partnership, corporation or limited liability company which is controlled by or under common control with the undersigned and/or by any such Family Member(s);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9.35pt;text-indent:-9.35pt;margin:0pt 0pt 12pt 54pt;">ii.&#160;&#160;&#160;&#160;if the undersigned is a corporation, partnership, limited liability company or other entity, (A) to another corporation, partnership, limited liability company or other entity that is a direct or indirect affiliate (as defined under Rule 12b-2 of the Exchange Act) of the undersigned, including investment funds or other entities that controls or manages, is under common control or management with, or is controlled or managed by, the undersigned, (B) as a distribution or dividend to equity holders, current or former general or limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#8217;s equity holders), (C) as a bona fide gift or a charitable contribution or otherwise to a trust or other entity for the direct or indirect benefit of an immediate family member of a beneficial owner (as defined in Rule 13d-3 of the Exchange Act) of the Undersigned&#8217;s Shares or (D) transfers or dispositions not involving a change in beneficial ownership; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:9.35pt;text-indent:-9.35pt;margin:0pt 0pt 12pt 54pt;">iii.&#160;&#160;&#160;&#160;if the undersigned is a trust, to any grantors or beneficiaries of the trust;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value (other than transfers pursuant to 1(A), 1(E) or 2(A)) and each donee, heir, beneficiary or other transferee or distributee shall sign and deliver to Parent a lock-up agreement in the form of this Lock-Up Agreement with respect to the shares of Parent Common Stock or such other securities that have been so transferred or distributed;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;">b.&#160;&#160;&#160;&#160;the exercise of an option to purchase shares of Parent Common Stock (including a net or cashless exercise of an option to purchase shares of Parent Common Stock ), and any related transfer of shares of Parent Common Stock to Parent for the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;">c.&#160;&#160;&#160;&#160;transfers to Parent in connection with the net settlement of any other equity award that represents the right to receive in the future shares of Parent Common Stock, settled in shares of Parent Common Stock, to pay any tax withholding obligations; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;">d.&#160;&#160;&#160;&#160;the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Parent Common Stock; <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that such plan does not provide for any transfers of shares of Parent Common Stock during the Restricted Period;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;">e.&#160;&#160;&#160;&#160;transfers by the undersigned of shares of Parent Common Stock purchased by the undersigned on the open market or in a public or private offering by Parent, in each case at or following the Effective Time (including for avoidance of doubt, the Parent Financing);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;">f.&#160;&#160;&#160;&#160;pursuant to a bona-fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Parent&#8217;s capital stock involving a change of control of Parent, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Undersigned&#8217;s Shares shall remain subject to the restrictions contained in this Lock-Up Agreement; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 54pt;">g.&#160;&#160;&#160;&#160;pursuant to an order of a court or regulatory agency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">and <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, further, that, with respect to each of (b), (c), and (d) above, no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee) under Section 16 of the Exchange Act or other public announcement shall be made voluntarily reporting a reduction in beneficial ownership of shares of Parent Common </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">E-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock in connection with such transfer or disposition during the Restricted Period (other than any exit filings) and if any filings under Section 16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Parent Common Stock in connection with such transfer or distribution, shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes therein, in reasonable detail, a description of the circumstances of the transfer and that the shares remain subject to the lock-up agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">3.&#160;&#160;&#160;&#160;For purposes of this Lock-Up Agreement, &#8220;change of control&#8221; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of the Company&#8217;s voting securities if, after such transfer, the Company&#8217;s stockholders as of immediately prior to such transfer do not hold a majority of the outstanding voting securities of the Company (or the surviving entity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">4.&#160;&#160;&#160;&#160;Any attempted transfer in violation of this Lock-Up Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be recorded on the share register of Parent. In furtherance of the foregoing, the undersigned agrees that Parent and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Lock-Up Agreement. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the undersigned&#8217;s ownership of Parent Common Stock:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">5.&#160;&#160;&#160;&#160;The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">6.&#160;&#160;&#160;&#160;The undersigned understands that if the Merger Agreement is terminated for any reason, the undersigned shall be released from all obligations under this Lock-Up Agreement. The undersigned understands that Parent is proceeding with the transactions contemplated by the Merger Agreement in reliance upon this Lock-Up Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">7.&#160;&#160;&#160;&#160;Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Lock-Up Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Lock-Up Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;">8.&#160;&#160;&#160;&#160;In the event that any holder of Parent&#8217;s securities that are subject to a substantially similar agreement entered into by such holder, other than the undersigned, is permitted by Parent to sell or otherwise transfer or dispose of shares of Parent Common Stock for value other than as permitted by this or a substantially similar agreement entered into by such holder (whether in one or multiple releases or waivers), the same percentage of shares of Parent Common Stock held by the undersigned on the date of such release or waiver as the percentage of the total number of outstanding shares of Parent Common Stock held by such holder on the date of such release or waiver that are the subject of such release or waiver shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pro-Rata Release</span>&#8221;); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that such Pro-Rata Release shall not be applied unless and until permission has been </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">E-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">granted by Parent to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holders shares of Parent Common Stock in an aggregate amount in excess of 1% of the number of shares of Parent Common Stock subject to a substantially similar agreement. In the event of any Pro-Rata Release, Parent shall promptly (and in any event within two (2) Business Days of such release) inform each relevant holder of Parent Common Stock or warrants of the terms of such Pro-Rata Release.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">9.&#160;&#160;&#160;&#160;Upon the release of any of the Undersigned&#8217;s Shares from this Lock-Up Agreement, Parent will reasonably cooperate with the undersigned to facilitate the timely preparation and delivery of certificates representing the Undersigned Shares without the restrictive legend above or the withdrawal of any stop transfer instructions by virtue of this Lock-Up Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;">10.&#160;&#160;&#160;&#160;This Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the parties arising out of or relating to this Lock-Up Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with foregoing clause (i) of this paragraph, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party and (v) irrevocably and unconditionally waives the right to trial by jury. This Lock-Up Agreement constitutes the entire agreement between the parties to this Lock-Up Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Lock-Up Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Lock-Up Agreement (in counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">[SIGNATURE PAGE FOLLOWS]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-style:italic;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">E-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_72e08819_8c22_420e_8ab6_4002966da442"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:30.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:30.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Very truly yours,</p></td></tr><tr><td style="vertical-align:middle;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:33.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Print Name of Stockholder:</p></td><td colspan="2" style="vertical-align:middle;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:33.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:35.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:35.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature (for individuals):</p></td></tr><tr><td style="vertical-align:middle;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:33.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:35.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:35.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:35.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature (for entities):</p></td></tr><tr><td style="vertical-align:top;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:30.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:top;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[Signature Page to Lock-Up Agreement]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_643aa58f_b5fd_4af9_a820_b1137329c28a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:37.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accepted and Agreed</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">by GlycoMimetics, Inc.:</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page to Lock-Up Agreement]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_18fe3752_d28d_4d25_85bd_fa2f8082d3fb"></a><a id="AnnexF_238963"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">A</b><b style="font-weight:bold;">nnex</b><b style="font-weight:bold;text-transform:uppercase;"> f</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Glycomimetics, inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATE OF DESIGNATION OF PREFERENCES,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RIGHTS AND LIMITATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pursuant to Section 151 of the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">General Corporation Law of the State of Delaware</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of GlycoMimetics, Inc., a Delaware corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Corporation</span>&#8221;), that the following resolution was duly adopted by the Board of Directors of the Corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Board of Directors</span>&#8221;), in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware (the &#8220;<span style="font-style:italic;font-weight:bold;">DGCL</span>&#8221;), at a meeting duly called and held on [<span style="font-family:'Symbol';">&#183;</span>], which resolution provides for the creation of a series of the Corporation&#8217;s Preferred Stock, par value $0.001 per share, which is designated as &#8220;Series A Non-Voting Convertible Preferred Stock,&#8221; with the preferences, rights and limitations set forth therein relating to dividends, conversion, redemption, dissolution and distribution of assets of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Amended and Restated Certificate of Incorporation of the Corporation (as amended from time to time, the &#8220;<span style="font-style:italic;font-weight:bold;">Certificate of Incorporation</span>&#8221;), provides for a class of its authorized stock known as Preferred Stock, consisting of 5,000,000 shares, $0.001 par value per share (the &#8220;<span style="font-style:italic;font-weight:bold;">Preferred Stock</span>&#8221;), issuable from time to time in one or more series.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RESOLVED</b>:&#160;&#160;&#160;&#160;that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, (i) a series of Preferred Stock of the Corporation be, and hereby is, authorized by the Board of Directors, (ii)&#160;the Board of Directors hereby authorizes the issuance of [<span style="font-family:'Symbol';">&#183;</span>] shares of &#8220;Series A Non-Voting Convertible Preferred Stock&#8221; pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated October 28, 2024, by and among the Corporation, Gemini Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Corporation, Gemini Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Corporation, and Crescent Biopharma, Inc. (the &#8220;<span style="font-style:italic;font-weight:bold;">Merger Agreement</span>&#8221;), and (iii) the Board of Directors hereby fixes the designations, powers, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, of such shares of Preferred Stock, in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred Stock of all classes and series, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TERMS OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">1.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</span>. For the purposes hereof, the following terms shall have the following meanings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Buy-In</span>&#8221; shall have the meaning set forth in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.4.3</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Closing Sale Price</span>&#8221; means, for any security as of any date, the last closing trade price for such security immediately prior to 4:00 p.m., New York City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg, L.P. (or an equivalent, reliable reporting service), or if the foregoing do not apply, the last trade price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, L.P., or, if no last trade price is reported for such security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the OTC Pink Market by OTC Markets Group, Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of Directors of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Commission</span>&#8221; means the United States Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Common Stock</span>&#8221; means the Corporation&#8217;s common stock, par value $0.001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Conversion Shares</span>&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series A Non-Voting Preferred Stock in accordance with the terms hereof.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Exchange Act</span>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Holder</span>&#8221; means a holder of shares of Series A Non-Voting Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Person</span>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Trading Day</span>&#8221; means a day on which the principal Trading Market is open for business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<span style="font-style:italic;font-weight:bold;">Trading Market</span>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">2.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Designation, Amount and Par Value</span>. The series of Preferred Stock shall be designated as the Corporation&#8217;s Series A Non-Voting Convertible Preferred Stock (the &#8220;<span style="font-style:italic;font-weight:bold;">Series A Non-Voting Preferred Stock</span>&#8221;) and the number of shares so designated shall be [<span style="font-family:'Symbol';">&#183;</span>]. Each share of Series A Non-Voting Preferred Stock shall have a par value of $0.001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">3.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividends</span>. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series A Non-<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting</span> Preferred Stock (on an as-if-converted-to-Common-Stock basis, without regard to the Beneficial Ownership <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation</span> (as defined below)) equal to and in the same form, and in the same manner, as dividends (other than <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">dividends</span> on shares of the Common Stock payable in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Series A Non-Voting Preferred Stock, and the Corporation shall pay no dividends (other than dividends payable in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">4.&#160;&#160;&#160;&#160;</span>Voting<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </span>Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">4.1&#160;&#160;&#160;&#160;</span>Except as otherwise provided herein or as otherwise required by the DGCL, the Series A Non-Voting Preferred Stock shall have no voting rights. However, as long as any shares of Series A Non-Voting Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Non-Voting Preferred Stock: (i) alter or change adversely the powers, preferences or rights given to the Series A Non-Voting Preferred Stock or alter or amend this Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock (the &#8220;<span style="font-style:italic;font-weight:bold;">Certificate of Designation</span>&#8221;), amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Amended and Restated Bylaws of the Corporation, as amended, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series A Non-Voting Preferred Stock, regardless of whether any of the foregoing actions shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii) issue further shares of Series A Non-Voting Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series A Non-Voting Preferred Stock, (iii) at any time while at least 30% of the originally issued Series A Non-Voting Preferred Stock remains issued and outstanding, consummate either: (A) any Fundamental Transaction (as defined below) or (B) any merger or consolidation of the Corporation with or into another entity or any stock sale to, or other business combination in which the stockholders of the Corporation immediately before such transaction do not hold at least a majority of the capital stock of the Corporation immediately after such transaction, (iv) increase the authorized number of directors constituting the Board of Directors or change the number of votes entitled to be cast by any director or directors on any matter or (v) enter into any agreement with respect to any of the foregoing. Holders of shares of Common Stock acquired upon the conversion of shares of Series A Non-Voting Preferred Stock shall be entitled to the same voting rights as each other holder of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">4.2&#160;&#160;&#160;&#160;</span>Any vote required or permitted under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4.1</span> may be taken at a meeting of the Holders or through the execution of an action by written consent in lieu of such meeting, provided that the consent is executed by Holders representing a majority of the outstanding shares of Series A Non-Voting Preferred Stock.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><span style="font-size:11pt;">4.3&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Election of Directors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 39.6pt;"><span style="font-size:11pt;">4.3.1&#160;&#160;&#160;&#160;</span>At all times when at least 30% of the originally issued Series A Non-Voting Preferred Stock remains issued and outstanding, (i) the holders of record of the shares of Series A Non-Voting Preferred Stock, exclusively and voting together as a separate class on an as-converted to Common Stock basis, shall be entitled to elect 2 directors of the Corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Preferred Directors</span>&#8221;); and (iii) the holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Series A Non-Voting Preferred Stock), exclusively and voting together as a single class on an as-converted to Common Stock basis, shall be entitled to elect the balance of the total number of directors of the Corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">At-Large Directors</span>&#8221;); <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>, <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, for administrative convenience, the initial Preferred Directors may also be appointed by the Board of Directors in connection with the approval of the initial issuance of Series A Non-Voting Preferred Stock without a separate action by the holders of Series A Non-Voting Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 39.6pt;"><span style="font-size:11pt;">4.3.2&#160;&#160;&#160;&#160;</span>Any Preferred Director elected as provided in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.3.1</span> may be removed without cause by, and only by, the affirmative vote of the holders of a majority of the shares of the Series A Non-Voting Preferred Stock, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 39.6pt;"><span style="font-size:11pt;">4.3.3&#160;&#160;&#160;&#160;</span>If the holders of shares of the Series A Non-Voting Preferred Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.3.1</span> (and to the extent any of such directorships is not otherwise filled by a director appointed in accordance with the proviso in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.3.1</span>), then any directorship not so filled shall remain vacant until such time as the holders of the Series A Non-Voting Preferred Stock fill such directorship in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.3.1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 39.6pt;"><span style="font-size:11pt;">4.3.4&#160;&#160;&#160;&#160;</span>At any meeting held for the purpose of electing a Preferred Director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the Series A Non-Voting Preferred Stock shall constitute a quorum for the purpose of electing such Preferred Director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 39.6pt;"><span style="font-size:11pt;">4.3.5&#160;&#160;&#160;&#160;</span>Each Preferred Director shall be entitled to three votes on each matter presented to the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">5.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rank; Liquidation</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">5.1&#160;&#160;&#160;&#160;</span>The Series A Non-Voting Preferred Stock shall rank on parity with the Common Stock as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">5.2&#160;&#160;&#160;&#160;</span>Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a &#8220;<span style="font-style:italic;font-weight:bold;">Liquidation</span>&#8221;), each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Series A Non-Voting Preferred Stock were fully converted (disregarding for such purpose any Beneficial Ownership Limitations) to Common Stock which amounts shall be paid <i style="font-style:italic;">pari passu</i> with all holders of Common Stock, plus an additional amount equal to any dividends declared on but unpaid to such shares. If, upon any such Liquidation, the assets of the Corporation shall be insufficient to pay the Holders of shares of the Series A Non-Voting Preferred Stock the amount required under the preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to the Holders and the holders of Common Stock in accordance with the respective amounts that would be payable on all such securities if all amounts payable thereon were paid in full. For the avoidance of any doubt, a Fundamental Transaction shall not be deemed a Liquidation unless the Corporation expressly declares that such Fundamental Transaction shall be treated as if it were a Liquidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">6.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conversion</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:11pt;">6.1&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conversion at Option of Holder</span>. Subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.3</span>, each share of Series A Non-Voting Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the Holder thereof, into a number of shares of Common Stock equal to the Conversion Ratio, subject to the Beneficial Ownership Limitation (as defined below) (each, an &#8220;<span style="font-style:italic;font-weight:bold;">Optional Conversion</span>&#8221;). Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annex A</b> (a &#8220;<span style="font-style:italic;font-weight:bold;">Notice of Conversion</span>&#8221;), duly completed and executed. Provided the Corporation&#8217;s transfer agent is participating in the Depository Trust Company (&#8220;<span style="font-style:italic;font-weight:bold;">DTC</span>&#8221;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder&#8217;s election, whether the applicable Conversion Shares shall be credited to the account of the Holder&#8217;s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a &#8220;<span style="font-style:italic;font-weight:bold;">DWAC Delivery</span>&#8221;). The date on which an Optional Conversion shall be deemed effective (the &#8220;<span style="font-style:italic;font-weight:bold;">Conversion Date</span>&#8221;) shall be the Trading Day that the Notice of Conversion, completed and executed, is sent via </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">email to, and received during regular business hours by, the Corporation; provided, that the original certificate(s) (if any) representing such shares of Series A Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2) Trading Days thereafter. In all other cases, the Conversion Date shall be defined as the Trading Day on which the original certificate(s) (if any) representing such shares of Series A Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">6.2&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conversion Ratio</span>. The &#8220;<span style="font-style:italic;font-weight:bold;">Conversion Ratio</span>&#8221; for each share of Series A Non-Voting Preferred Stock shall be 1,000 shares of Common Stock issuable upon the conversion (the &#8220;<span style="font-style:italic;font-weight:bold;">Conversion</span>&#8221;) of each share of Series A Non-Voting Preferred Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:11pt;">6.3&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Beneficial Ownership Limitation</span>. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion of any share of Series A Non-Voting Preferred Stock, and a Holder shall not have the right to convert any portion of the Series A Non-Voting Preferred Stock pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.1</span>, to the extent that, after giving effect to such attempted conversion set forth on an applicable Notice of Conversion (as defined in the Certificate of Designation) with respect to the Series A Non-Voting Preferred Stock, such Holder (or any of such Holder&#8217;s affiliates or any other Person who would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable rules and regulations of the Commission, including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;<span style="font-style:italic;font-weight:bold;">Attribution Parties</span>&#8221;)) would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Series A Non-Voting Preferred Stock subject to the Notice of Conversion with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series A Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to and would exceed a limitation on conversion or exercise similar to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.3</span>, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission, and the terms &#8220;beneficial ownership&#8221; and &#8220;beneficially own&#8221; have the meanings ascribed to such terms therein. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission. For purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.3</span>, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (A) the Corporation&#8217;s most recent periodic or annual filing with the Commission, as the case may be, (B) a more recent public announcement by the Corporation that is filed with the Commission, or (C) a more recent notice by the Corporation or the Corporation&#8217;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email), the Corporation shall, within two (2) Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to any actual conversion or exercise of securities of the Corporation, including shares of Series A Non-Voting Preferred Stock, by such Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was last publicly reported or confirmed to the Holder. The &#8220;<span style="font-style:italic;font-weight:bold;">Beneficial Ownership Limitation</span>&#8221; shall initially be 19.99% of the number of shares of Common Stock outstanding or deemed to be outstanding as of the applicable measurement date. The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation. Notwithstanding the foregoing, by written notice to the Corporation, (i) the Holder may reset the Beneficial Ownership Limitation percentage to a higher percentage, not to exceed 19.99%, which increase will not be effective until the sixty-first (61st) day after such written notice is delivered to the Corporation, and (ii) the Holder may reset the Beneficial Ownership Limitation percentage to a lower percentage effective immediately after the delivery of such notice to the Corporation. Upon such an increase by a Holder of the Beneficial Ownership Limitation pursuant to clause (i), not to exceed 19.99%, the Beneficial Ownership Limitation may not be further amended by such Holder without first providing the minimum notice required by this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.3</span>. Notwithstanding the foregoing, (x) at any time following notice of a Fundamental Transaction, the Holder may waive and/or change the Beneficial Ownership Limitation effective immediately upon written notice to the Corporation and may reinstitute a Beneficial Ownership Limitation at any time thereafter effective immediately upon written notice to the Corporation (y) at any time that the beneficial ownership of shares of Common Stock of a Holder (together with any of such Holder&#8217;s Attribution Parties) is equal to or less than 9.00% of the number of shares of Common Stock outstanding as of any given date, then such Holder&#8217;s Beneficial Ownership Limitation shall automatically be set to 9.99%. The provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.3</span> shall be construed, corrected and implemented in a manner so as to effectuate the intended Beneficial Ownership Limitation herein contained and the shares of Common Stock underlying the Series A Non-Voting Preferred Stock in excess of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="font-size:11pt;">6.4&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mechanics of Conversion</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 46.8pt;"><span style="font-size:11pt;">6.4.1&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delivery of Certificate or Electronic Issuance</span>. Upon Conversion not later than two (2)&#160;Trading Days after the applicable Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&#160;Trading Days after receipt by the Corporation of the original certificate(s) representing such shares of Series A Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#8220;<span style="font-style:italic;font-weight:bold;">Share Delivery Date</span>&#8221;), the Corporation shall either: (a)&#160;deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series A Non-Voting Preferred Stock, or (b)&#160;in the case of a DWAC Delivery (if so requested by the Holder), electronically transfer such Conversion Shares by crediting the account of the Holder&#8217;s prime broker with DTC through its DWAC system. If in the case of any Notice of Conversion such certificate or certificates for the Conversion Shares are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series A Non-Voting Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series A Non-Voting Preferred Stock unsuccessfully tendered for conversion to the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 46.8pt;"><span style="font-size:11pt;">6.4.2&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligation Absolute</span>. Subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.3</span> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to Section<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> &#8206;6.4.1</span>, the Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon conversion of Series A Non-Voting Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.3</span> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.4.1</span>, in the event a Holder shall elect to convert any or all of its Series A Non-Voting Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Series A Non-Voting Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the value of the Conversion Shares into which would be converted the Series A Non-Voting Preferred Stock which is subject to such injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.3</span> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.4.1</span>, issue Conversion Shares upon a properly noticed conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 46.8pt;"><span style="font-size:11pt;">6.4.3&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Buy-In on Failure to Timely Deliver Certificates</span>. If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.4.1</span> (other than a failure caused by materially incorrect or incomplete information provided by Holder to the Corporation or the application of the Beneficial Ownership Limitation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;<span style="font-style:italic;font-weight:bold;">Buy-In</span>&#8221;), then the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount by which (x) such Holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) at the option of such </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 46.8pt;">Holder, either reissue (if surrendered) the shares of Series A Non-Voting Preferred Stock equal to the number of shares of Series A Non-Voting Preferred Stock submitted for conversion or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.4.1</span>. For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of Series A Non-Voting Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3) Trading Days after the occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In together with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series A Non-Voting Preferred Stock as required pursuant to the terms hereof; provided, however, that the Holder shall not be entitled to both (i) require the reissuance of the shares of Series A Non-Voting Preferred Stock submitted for conversion for which such conversion was not timely honored and (ii) receive the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.4.1</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 46.8pt;"><span style="font-size:11pt;">6.4.4&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reservation of Shares Issuable Upon Conversion</span>. The Corporation covenants that at all times it will reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series A Non-Voting Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series A Non-Voting Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;7</span>) upon the conversion of all outstanding shares of Series A Non-Voting Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and non-assessable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 46.8pt;"><span style="font-size:11pt;">6.4.5&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fractional Shares</span>. No fractional shares of Common Stock shall be issued upon conversion of the Series A Non-Voting Preferred Stock, no certificates or scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares. Any fractional shares of Common Stock that a Holder of Series A Non-Voting Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Common Stock issuable to such Holder and any remaining fractional shares shall be rounded up to the nearest whole share. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Series A Non-Voting Preferred Stock the Holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 46.8pt;"><span style="font-size:11pt;">6.4.6&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer Taxes</span>. The issuance of certificates for shares of the Common Stock upon conversion of the Series A Non-Voting Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of such shares of Series A Non-Voting Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 46.8pt;"><span style="font-size:11pt;">6.5&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Status as Stockholder</span>. Upon each Conversion Date, (i) the shares of Series A Non-Voting Preferred Stock being converted shall be deemed converted into shares of Common Stock and (ii) the Holder&#8217;s rights as a holder of such converted shares of Series A Non-Voting Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&#8217;s failure to convert Series A Non-Voting Preferred Stock.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="font-size:11pt;">7.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Adjustments</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-size:11pt;">7.1&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Dividends and Stock Splits</span>. If the Corporation, at any time while this Series A Non-Voting Preferred Stock is outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of this Series A Non-Voting Preferred Stock) with respect to the then outstanding shares of Common Stock; (B) subdivides outstanding shares of Common Stock into a larger number of shares; or (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Ratio shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;7.1</span> shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-size:11pt;">7.2&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fundamental Transaction</span>. If, at any time while this Series A Non-Voting Preferred Stock is outstanding, (A) the Corporation effects any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another Person (other than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not exchanged for or converted into other securities, cash or property), (B) the Corporation effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one transaction or a series of related transactions, (C) any tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged for or converted into other securities, cash or property, or (D) the Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;7.1</span>) to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#8220;<span style="font-style:italic;font-weight:bold;">Fundamental Transaction</span>&#8221;), then, upon any subsequent conversion of this Series A Non-Voting Preferred Stock the Holders shall have the right to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of one share of Common Stock (the &#8220;<span style="font-style:italic;font-weight:bold;">Alternate Consideration</span>&#8221;). For purposes of any such subsequent conversion, the determination of the Conversion Ratio shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall adjust the Conversion Ratio in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series A Non-Voting Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new certificate of designations with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&#8217; right to convert such preferred stock into Alternate Consideration. The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;7.2</span> and insuring that this Series A Non-Voting Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the stock books of the Corporation, written notice of any Fundamental Transaction at least 20 calendar days prior to the date on which such Fundamental Transaction is expected to become effective or close.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;"><span style="font-size:11pt;">7.3&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Calculations</span>. All calculations under this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;7</span> shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;7</span>, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">8.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Redemption</span>. The shares of Series A Non-Voting Preferred Stock shall not be redeemable; provided, however, that the foregoing shall not limit the ability of the Corporation to purchase or otherwise deal in such shares to the extent otherwise permitted hereby and by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">9.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer</span>. A Holder may transfer any shares of Series A Non-Voting Preferred Stock together with the accompanying rights set forth herein, held by such holder without the consent of the Corporation; provided that such transfer is in compliance with applicable securities laws. The Corporation shall in good faith (i) do and perform, or cause to be done and performed, all such further acts and things, and (ii) execute and deliver all such other agreements, certificates, instruments and documents, in each case, as any holder of Series A Non-Voting Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;9</span>. The transferee of any shares of Series A Non-Voting Preferred Stock shall be subject to the Beneficial Ownership Limitation applicable to the transferor as of the time of such transfer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">10.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Series A Non-Voting Preferred Stock Register</span>. The Corporation shall maintain at its principal executive offices (or such other office or agency of the Corporation as it may designate by notice to the Holders in accordance with <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;11</span>), a register for the Series A Non-Voting Preferred Stock, in which the Corporation shall record (i) the name, address, and electronic mail address of each holder in whose name the shares of Series A Non-Voting Preferred Stock have been issued and (ii) the name, address, and electronic mail address of each transferee of any shares of Series A Non-Voting Preferred Stock. The Corporation may deem and treat the registered Holder of shares of Series A Non-Voting Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all other purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by any holder of Series A Non-Voting Preferred Stock or his, her or its legal representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">11.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</span>. Any notice required or permitted by the provisions of this Certificate of Designation to be given to a Holder of shares of Series A Non-Voting Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the Delaware General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">12.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Book-Entry; Certificates</span>. The Series A Non-Voting Preferred Stock will be issued in book-entry form; provided that, if a Holder requests that such Holder&#8217;s shares of Series A Non-Voting Preferred Stock be issued in certificated form, the Corporation will instead issue a stock certificate to such Holder representing such Holder&#8217;s shares of Series A Non-Voting Preferred Stock. To the extent that any shares of Series A Non-Voting Preferred Stock are issued in book-entry form, references herein to &#8220;certificates&#8221; shall instead refer to the book-entry notation relating to such shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">13.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lost or Mutilated Series A Non-Voting Preferred Stock Certificate</span>. If a Holder&#8217;s Series A Non-Voting Convertible Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series A Non-Voting Convertible Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">14.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</span>. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Series A Non-Voting Preferred Stock granted hereunder may be waived as to all shares of Series A Non-Voting Preferred Stock (and the Holders thereof) upon the written consent of the Holders of not less than a majority of the shares of Series A Non-Voting Preferred Stock then outstanding, provided, however, that the Beneficial Ownership Limitation applicable to a Holder, and any provisions contained herein that are related to such Beneficial Ownership Limitation, cannot be modified, waived or terminated without the consent of such Holder, provided further, that any proposed waiver that would, by its terms, have a disproportionate and materially adverse effect on any Holder shall require the consent of such Holder(s).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">15.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</span>. Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;">16.&#160;&#160;&#160;&#160;</span><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Status of Converted Series A Non-Voting Preferred Stock</span>. If any shares of Series A Non-Voting Preferred Stock shall be converted or redeemed by the Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such acquisition, and shall not be reissued as a share of Series A Non-Voting Preferred Stock. Any share of Series A Non-Voting Preferred Stock so acquired shall, upon its retirement and cancellation, and upon the taking of any action required by applicable law, resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series A Non-Voting Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[<i style="font-style:italic;">Remainder of Page Intentionally Left Blank</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_adbe9497_dc3e_473f_af41_d82291354a3b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, GlycoMimetics, Inc. has caused this Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock to be duly executed by its [<span style="font-family:'Symbol';">&#183;</span>] on [<span style="font-family:'Symbol';">&#183;</span>], 202[5].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;width:29.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">GLYLCOMIMETICS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:50.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="3" style="vertical-align:bottom;width:46.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td colspan="2" style="vertical-align:bottom;width:44.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td colspan="2" style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e774af94_8700_4272_b3a2_007068471ad9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTICE OF CONVERSION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series A Non-Voting Preferred Stock indicated below, represented in book-entry form, into shares of common stock, par value $0.001 per share (the &#8220;<span style="font-style:italic;font-weight:bold;">Common Stock</span>&#8221;), of GlycoMimetics, Inc., a Delaware corporation (the &#8220;<span style="font-style:italic;font-weight:bold;">Corporation</span>&#8221;), as of the date written below. If securities are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock (the &#8220;<span style="font-style:italic;font-weight:bold;">Certificate of Designation</span>&#8221;) filed by the Corporation with the Secretary of State of the State of Delaware on [<span style="font-family:'Symbol';">&#183;</span>], 202[5].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder&#8217;s Attribution Parties), including the number of shares of Common Stock issuable upon conversion of the Series A Non-Voting Preferred Stock subject to this Notice of Conversion, but excluding the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series A Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained in <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6.3</span> of the Certificate of Designation, is _____. For purposes hereof, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations of the Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CONVERSION CALCULATIONS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date to Effect Conversion:</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of shares of Series A Non-Voting Preferred Stock owned prior to Conversion:</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of shares of Series A Non-Voting Preferred Stock to be Converted:</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of shares of Common Stock to be Issued:</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address for delivery of physical certificates:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For DWAC Delivery, please provide the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:19.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="3" style="vertical-align:bottom;width:50.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Broker No.:</p></td><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:19.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Account No.:</p></td><td style="vertical-align:bottom;width:30.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-transform:uppercase;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-transform:uppercase;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-transform:uppercase;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-transform:uppercase;">[HOLDER]</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:46.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f8f8a371_3136_4bc2_92e2_ff356329fb39"></a><a id="ANNEXG_146265"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX G</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATE OF AMENDMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GlycoMimetics, Inc.</b>, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#8220;<span style="font-style:italic;font-weight:bold;">Company</span>&#8221;), hereby certifies that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">FIRST:</b><span style="color:#231f20;">&#160;The name of this Company is GlycoMimetics, Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">SECOND:&#160;</b><span style="color:#231f20;">The Company&#8217;s original Certificate of Incorporation was filed on April 4, 2003. The Company&#8217;s Amended and Restated Certificate of Incorporation was filed on January 15, 2014. The Company&#8217;s Amended and Restated Certificate of Incorporation was amended by two Certificates of Amendment filed on May 1, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">THIRD:&#160;</b>The Board of Directors of the Company, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending the Amended and Restated Certificate of Incorporation (as amended) to amend and restate Paragraph A of Article IV of the Certificate of Incorporation in its entirety:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<b style="font-weight:bold;">A. </b>The Company is authorized to issue two classes of stock to be designated, respectively, &#8220;Common Stock&#8221; and &#8220;Preferred Stock.&#8221; The total number of shares of all classes of capital stock which the Company shall have authority to issue is [<span style="font-family:'Symbol';">&#183;</span>] shares, of which [<span style="font-family:'Symbol';">&#183;</span>] shares shall be Common Stock (the &#8220;<span style="font-style:italic;font-weight:bold;">Common Stock</span>&#8221;), each having a par value of one-tenth of one cent ($0.001), and Five Million (5,000,000) shares shall be Preferred Stock (the &#8220;<span style="font-style:italic;font-weight:bold;">Preferred Stock</span>&#8221;), each having a par value of one-tenth of one cent ($0.001).&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">FOURTH:&#160;</b><span style="color:#231f20;">This Certificate of Amendment to the Amended and Restated Certificate of Incorporation (as amended) was submitted to the stockholders of the Company and was duly adopted and approved in accordance with the provisions of Sections&#160;228 and 242 of the General Corporate Law of the State of Delaware.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">FIFTH: </b><span style="color:#231f20;">This Certificate of Amendment shall be effective at [</span><span style="color:#231f20;font-family:'Symbol';">&#183;</span><span style="color:#231f20;">] (Eastern Time) as of [</span><span style="color:#231f20;font-family:'Symbol';">&#183;</span><span style="color:#231f20;">], 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Company has caused this Certificate of Amendment to be signed by its President and Chief Executive Officer this&#160;[<span style="font-family:'Symbol';">&#183;</span>]&#160;day of [<span style="font-family:'Symbol';">&#183;</span>], 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">G-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c5903b47_f2de_4c80_943b_ceafab901cc7"></a><a id="ANNEXH_824276"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANNEX H</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATE OF AMENDMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GlycoMimetics, Inc.</b>, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#8220;<span style="font-style:italic;font-weight:bold;">Company</span>&#8221;), hereby certifies that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">FIRST:</b><span style="color:#231f20;">&#160;The name of this Company is GlycoMimetics, Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">SECOND:&#160;</b><span style="color:#231f20;">The Company&#8217;s original Certificate of Incorporation was filed on April 4, 2003. The Company&#8217;s Amended and Restated Certificate of Incorporation was filed on January 15, 2014. The Company&#8217;s Amended and Restated Certificate of Incorporation was amended by two Certificates of Amendment filed on May 1, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">THIRD:&#160;</b><span style="color:#231f20;">The Board of Directors of the Company, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending the Amended and Restated Certificate of Incorporation (as amended) to add the following new Paragraph D and Paragraph E immediately following the existing Paragraph C of Article IV:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">&#8220;<b style="font-weight:bold;">D.</b> Effective as of [<span style="font-family:'Symbol';">&#183;</span>] p.m. (Eastern Time) on [<span style="font-family:'Symbol';">&#183;</span>], 2025 (such time, the &#8220;Effective Time&#8221;), a one-for-[<span style="font-family:'Symbol';">&#183;</span>] reverse stock split of the shares of Common Stock, pursuant to which every [<span style="font-family:'Symbol';">&#183;</span>] shares of the Common Stock issued and held of record by each stockholder of the Company (including treasury shares) immediately prior to the Effective Time shall be reclassified and combined into one validly issued, fully paid and non-assessable share of Common Stock from and after the Effective Time, without any action on the part of the Company or the respective stockholders thereof (such reclassification and combination of shares, the &#8220;Reverse Stock Split&#8221;). The par value of the Common Stock following the Reverse Stock Split shall remain at $0.001 per share. No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split. In lieu of any fractional shares, if upon aggregating all of the shares of Common Stock held by a record holder immediately following the Reverse Stock Split such holder would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, the Company shall pay in cash (without interest) to each such holder an amount equal to the product of such resulting fractional interest in one share of Common Stock multiplied by the closing trading price on The Nasdaq Stock Market LLC of a share of Common Stock on the last trading day immediately prior to the date on which the Effective Time occurs (with such price proportionately adjusted to give effect to the Reverse Stock Split).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">E.</b> Each stock certificate or book entry share that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares formerly represented by such certificate or book entry share have been combined (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time); provided, however, that each stockholder of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been combined.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">FOURTH:&#160;</b><span style="color:#231f20;">This Certificate of Amendment to the Amended and Restated Certificate of Incorporation (as amended) was submitted to the stockholders of the Company and was duly adopted and approved in accordance with the provisions of Sections&#160;228 and 242 of the General Corporate Law of the State of Delaware.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;">FIFTH</b><span style="color:#231f20;">. This Certificate of Amendment shall be effective at [</span><span style="color:#231f20;font-family:'Symbol';">&#183;</span><span style="color:#231f20;">] (Eastern Time) as of [</span><span style="color:#231f20;font-family:'Symbol';">&#183;</span><span style="color:#231f20;">], 2025.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">H-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Company has caused this Certificate of Amendment to be signed by its President and Chief Executive Officer this&#160;[<span style="font-family:'Symbol';">&#183;</span>]&#160;day of [<span style="font-family:'Symbol';">&#183;</span>], 2025.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">H-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_edc8f09e_626e_4678_bfb6_0f09bdfe0f84"></a><a id="AnnexI_679679"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Annex I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Section 262 of the Delaware General Corporation Law</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#167; 262. Appraisal rights</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d) of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, who has otherwise complied with subsection (d) of this section and who has neither voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b) and (c) of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &#8220;beneficial owner&#8221; mean a person who is the beneficial owner of shares of stock held either in voting trust or by a nominee on behalf of such person; and the word &#8220;person&#8221; means any individual, corporation, partnership, unincorporated association or other entity.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Appraisal rights shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation in a merger, consolidation, conversion, transfer, domestication or continuance to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g) of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264, &#167; 266 or &#167; 390 of this title (other than, in each case and solely with respect to a converted or domesticated corporation, a merger, consolidation, conversion, transfer, domestication or continuance authorized pursuant to and in accordance with the provisions of &#167; 265 or &#167; 388 of this title):</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Provided, however</i><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders, or at the record date fixed to determine the stockholders entitled to consent pursuant to &#167; 228 of this title, to act upon the agreement of merger or consolidation or the resolution providing for the conversion, transfer, domestication or continuance (or, in the case of a merger pursuant to &#167; 251(h) of this title, as of immediately prior to the execution of the agreement of merger), were either: (i) listed on a national securities exchange or (ii) held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167; 251(f) of this title.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Notwithstanding paragraph (b)(1) of this section, appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation if the holders thereof are required by the terms of an agreement of merger or consolidation, or by the terms of a resolution providing for conversion, transfer, domestication or continuance, pursuant to &#167; 251, &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264, &#167; 266 or &#167; 390 of this title to accept for such stock anything except:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shares of stock of the corporation surviving or resulting from such merger or consolidation, or of the converted entity or the entity resulting from a transfer, domestication or continuance if such entity is a corporation as a result of the conversion, transfer, domestication or continuance, or depository receipts in respect thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger, consolidation, conversion, transfer, domestication or continuance will be either listed on a national securities exchange or held of record by more than 2,000 holders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">I-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(4)</span></span><span style="color:#231f20;">[Repealed.]</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant to &#167; 266 of this title or a transfer, domestication or continuance effected pursuant to &#167; 390 of this title. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g) of this section, shall apply as nearly as is practicable.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Appraisal rights shall be perfected as follows:</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If a proposed merger, consolidation, conversion, transfer, domestication or continuance for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20 days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167; 255(c) of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b) or (c) of this section that appraisal rights are available for any or all of the shares of the constituent corporations or the converting, transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and, &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger, consolidation, conversion, transfer, domestication or continuance, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger, consolidation, conversion, transfer, domestication or continuance shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10 days after the effective date of such merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or converted entity shall notify each stockholder of each constituent or converting, transferring, domesticating or continuing corporation who has complied with this subsection and has not voted in favor of or consented to the merger, consolidation, conversion, transfer, domestication or continuance, and any beneficial owner who has demanded appraisal under paragraph (d)(3) of this section, of the date that the merger, consolidation or conversion has become effective; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the merger, consolidation, conversion, transfer, domestication or continuance was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167; 267 of this title, then either a constituent, converting, transferring, domesticating or continuing corporation before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, or the surviving, resulting or converted entity within 10 days after such effective date, shall notify each stockholder of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation who is entitled to appraisal rights of the approval of the merger, consolidation, conversion, transfer, domestication or continuance and that appraisal rights are available for any or all shares of such class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting, transferring, domesticating or continuing corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Such notice may, and, if given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, shall, also notify such stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance. Any stockholder entitled to appraisal rights may, within 20 days after the date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h) of this title, within the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days after the date of giving such notice, demand in writing from the surviving, </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">I-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">resulting or converted entity the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs such entity of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s shares. If such notice did not notify stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, either (i) each such constituent corporation or the converting, transferring, domesticating or continuing corporation shall send a second notice before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance notifying each of the holders of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation that are entitled to appraisal rights of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance or (ii) the surviving, resulting or converted entity shall send such a second notice to all such holders on or within 10 days after such effective date; provided, however, that if such second notice is sent more than 20 days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h) of this title, later than the later of the consummation of the offer contemplated by &#167; 251(h) of this title and 20 days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection and any beneficial owner who has demanded appraisal under paragraph (d)(3) of this section. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation or the converting, transferring, domesticating or continuing corporation may fix, in advance, a record date that shall be not more than 10 days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the day next preceding the day on which the notice is given.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Notwithstanding subsection (a) of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&#8217;s name, demand in writing an appraisal of such beneficial owner&#8217;s shares in accordance with either paragraph (d)(1) or (2) of this section, as applicable; provided that (i) such beneficial owner continuously owns such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a) of this section and (ii) the demand made by such beneficial owner reasonably identifies the holder of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of stock and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provides an address at which such beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified list required by subsection (f) of this section.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Within 120 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or converted entity, or any person who has complied with subsections (a) and (d) of this section and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance. Within 120 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person who has complied with the requirements of subsections (a) and (d) of this section, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity a statement setting forth the aggregate number of shares not voted in favor of the merger, consolidation, conversion, transfer, domestication or continuance (or, in the case of a merger approved pursuant to &#167; 251(h) of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167; 251(h)(2) of this title)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3) of this section, the record holder of such shares shall not be considered a separate stockholder holding such shares for purposes of such aggregate number). Such statement shall be given to the person within </p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">I-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">10 days after such person&#8217;s request for such a statement is received by the surviving, resulting or converted entity or within 10 days after expiration of the period for delivery of demands for appraisal under subsection (d) of this section, whichever is later.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Upon the filing of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon such entity, which shall within 20 days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all persons who have demanded appraisal for their shares and with whom agreements as to the value of their shares have not been reached by such entity. If the petition shall be filed by the surviving, resulting or converted entity, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving, resulting or converted entity and to the persons shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(g)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">At the hearing on such petition, the Court shall determine the persons who have complied with this section and who have become entitled to appraisal rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If immediately before the merger, consolidation, conversion, transfer, domestication or continuance the shares of the class or series of stock of the constituent, converting, transferring, domesticating or continuing corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1) the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2) the value of the consideration provided in the merger, consolidation, conversion, transfer, domestication or continuance for such total number of shares exceeds $1 million, or (3) the merger was approved pursuant to &#167; 253 or &#167; 267 of this title.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(h)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">After the Court determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger, consolidation, conversion, transfer, domestication or continuance, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation, conversion, transfer, domestication or continuance through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger, consolidation or conversion and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1) the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2) interest theretofore accrued, unless paid at that time. Upon application by the surviving, resulting or converted entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f) of this section may participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under this section.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall be so made to each such person upon such terms and conditions as the Court may order. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or of any state.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(j)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f) of this section who participated in the proceeding and incurred expenses in connection therewith, the Court may order all or a portion of such expenses, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal not </p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">I-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">dismissed pursuant to subsection (k) of this section or subject to such an award pursuant to a reservation of jurisdiction under subsection (k) of this section.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(k)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Subject to the remainder of this subsection, from and after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, no person who has demanded appraisal rights with respect to some or all of such person&#8217;s shares as provided in subsection (d) of this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger, consolidation, conversion, transfer, domestication or continuance). If a person who has made a demand for an appraisal in accordance with this section shall deliver to the surviving, resulting or converted entity a written withdrawal of such person&#8217;s demand for an appraisal in respect of some or all of such person&#8217;s shares in accordance with subsection (e) of this section, either within 60 days after such effective date or thereafter with the written approval of the corporation, then the right of such person to an appraisal of the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, an appraisal proceeding in the Court of Chancery shall not be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just, including without limitation, a reservation of jurisdiction for any application to the Court made under subsection (j) of this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance within 60 days after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, as set forth in subsection (e) of this section. If a petition for an appraisal is not filed within the time provided in subsection (e) of this section, the right to appraisal with respect to all shares shall cease.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(l)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The shares or other equity interests of the surviving, resulting or converted entity to which the shares of stock subject to appraisal under this section would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or other equity interests of the surviving, resulting or converted entity, unless and until the person that has demanded appraisal is no longer entitled to appraisal pursuant to this section.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">I-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2e5b86fb_6ba6_438f_a471_80948b275200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INFORMATION NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;20.</b></span><b style="font-weight:bold;">Indemnification of Directors and Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Delaware</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics and Crescent are corporations under the DGCL. Section&#160;145(a)&#160;of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;145(b)&#160;of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery of the State of Delaware or such other court shall deem proper.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;145 of the DGCL further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a)&#160;and (b)&#160;of Section&#160;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&#160;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section&#160;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs, executors and administrators. Section&#160;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&#160;145.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;102(b)(7)&#160;of the DGCL provides that a corporation&#8217;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the DGCL, or (iv)&#160;for any transaction from which the director derived an improper personal benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">GlycoMimetics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The GlycoMimetics Charter contains provisions that eliminate, to the maximum extent permitted by the DGCL, the personal liability of directors for monetary damages for breach of fiduciary duty as a director. The GlycoMimetics Charter and GlycoMimetics Bylaws provide that GlycoMimetics shall indemnify its directors and executive officers and may indemnify its employees and other agents to the fullest extent permitted by the DGCL.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has entered into indemnification agreements with its directors and executive officers, in addition to the indemnification provided for in the GlycoMimetics Charter and GlycoMimetics Bylaws, and it intends to enter into indemnification agreements with any new directors and executive officers in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics has purchased and intends to maintain insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her incurred by him or her in any such capacity, subject to certain exclusions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Crescent</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Crescent Charter contains provisions that limit or eliminate the personal liability of Crescent&#8217;s directors or officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. These limitations of liability do not alter director or officer liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission. In addition, the Crescent Bylaws provide that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent will indemnify its directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Crescent will advance expenses, including attorneys&#8217; fees, to its directors and officers in connection with legal proceedings relating to their service for or on behalf of Crescent, subject to limited exceptions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Crescent has entered into indemnification agreements with its directors and executive officers. These agreements provide that Crescent will indemnify each of its directors and executive officers to the fullest extent permitted by Delaware law. Crescent will advance expenses, including attorneys&#8217; fees (but excluding judgments, fines and settlement amounts), to each indemnified director or executive officer in connection with any proceeding in which indemnification is available and Crescent will indemnify its directors and officers for any action or proceeding arising out of that person&#8217;s services as a director or officer brought on behalf of Crescent or in furtherance of Crescent&#8217;s rights. Additionally, certain of Crescent&#8217;s directors may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#8217;s services as a director referenced herein. Nonetheless, Crescent has agreed in the indemnification agreements that Crescent&#8217;s obligations to those same directors are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Crescent also intends to maintain general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act.</p><a id="_6843b1e4_2f56_496d_b979_d36c56a1cc0a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;21.</b></span><b style="font-weight:bold;">Exhibits and Financial Statement Schedules</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(a)</span>Exhibit&#160;Index</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A list of exhibits filed with this registration statement on Form&#160;S-4 is set forth on the Exhibit&#160;Index and is incorporated herein by reference.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(b)</span>Financial Statements</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The financial statements filed with this registration statement on Form&#160;S-4 are set forth on the Financial Statement Index and are incorporated herein by reference.</p><a id="_c5b9eaf6_d3f3_48ac_a184_ad5af2e88681"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;22.</b></span><b style="font-weight:bold;">Undertakings</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The undersigned registrant hereby undertakes:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To include any prospectus required by Section&#160;10(a)(3)&#160;of the Securities Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b)&#160;if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221; table in the effective registration statement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><i style="font-style:italic;">Provided, however</i>, that paragraphs (a)(1)(i)&#160;and (a)(1)(ii)&#160;herein do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">The undersigned registrant hereby undertakes as follows:  that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule&#160;145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">The registrant undertakes that every prospectus:  (i)&#160;that is filed pursuant to paragraph (a)(5)&#160;immediately preceding, or (ii)&#160;that purports to meet the requirements of Section&#160;10(a)(3)&#160;of the Act and is used in connection with an offering of securities subject to Rule&#160;415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the prospectus pursuant to Item&#160;4, 10(b),&#160;11, or 13 of this form, within one business day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The undersigned registrant hereby undertakes to supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:2.85pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><div style="height:2.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><div style="height:2.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><div style="height:2.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;</b><br/><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.1(a)&#8224;*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexA_529116"><span style="font-style:normal;font-weight:normal;">Agreement and Plan of Merger and Reorganization, dated as of October&#160;28, 2024, by and among GlycoMimetics,&#160;Inc., Gemini Merger Sub Corp., Gemini Merger Sub II, LLC, and Crescent Biopharma,&#160;Inc. (included in Annex A to the proxy statement/prospectus and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.1(b)&#8224;*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexA_529116"><span style="font-style:normal;font-weight:normal;">Amendment No.&#160;1 to Agreement and Plan of Merger and Reorganization, dated as of February&#160;14, 2025, by and among GlycoMimetics,&#160;Inc., Gemini Merger Sub Corp., Gemini Merger Sub II, LLC, and Crescent Biopharma,&#160;Inc. (included in Annex A to the proxy statement/prospectus and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000119312514012028/d657730dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit&#160;3.1 to GlycoMimetics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-36177), filed with the Commission on January&#160;15, 2014).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/glyc-20240501xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Certificate of Incorporation of GlycoMimetics,&#160;Inc. (incorporated herein by reference to Exhibit&#160;3.1 to GlycoMimetics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-36177), filed with the Commission on May&#160;1, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/glyc-20240501xex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Certificate of Incorporation of GlycoMimetics,&#160;Inc. (incorporated herein by reference to Exhibit&#160;3.2 to GlycoMimetics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-36177), filed with the Commission on May&#160;1, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000119312514012028/d657730dex32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws (incorporated herein by reference to Exhibit&#160;3.2 to GlycoMimetics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-36177), filed with the Commission on January&#160;15, 2014).</span></a></p></td></tr><tr style="height:29.7pt;"><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000110465924112054/tm2427013d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit&#160;3.1 of GlycoMimetics,&#160;Inc.&#8217;s Form&#160;8-K filed on October&#160;29, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.6*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex3d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of Crescent Biopharma,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.7*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex3d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of Crescent Biopharma,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000119312513421071/d572031dex42.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen stock certificate evidencing shares of Common Stock (incorporated herein by reference to Exhibit&#160;4.2 to Amendment No.&#160;2 to GlycoMimetics,&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1 (File&#160;No.&#160;333-191567), filed with the Commission on October&#160;31, 2013).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837025000948/glyc-20241231xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Certain of Registrant&#8217;s Securities (incorporated herein by reference to Exhibit&#160;4.2 to GlycoMimetics,&#160;Inc.&#8217;s Annual Report on Form&#160;10-K (File No.&#160;001-36177), filed with the Commission on February 13, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.1**</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Opinion of Sidley Austin LLP</p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexC_190262"><span style="font-style:normal;font-weight:normal;">Form&#160;of Crescent Support Agreement (included in Annex C to the proxy statement/prospectus and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexD_955409"><span style="font-style:normal;font-weight:normal;">Form&#160;of GlycoMimetics Support Agreement (included in Annex D to the proxy statement/prospectus and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3&#8224;</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837025001016/glyc-20250214xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Amended and Restated Securities Purchase Agreement (incorporated herein by reference to Exhibit&#160;10.2 to GlycoMimetics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-36177), filed with the Commission on February&#160;14, 2025).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Registration Rights Agreement.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#AnnexE_977427"><span style="font-style:normal;font-weight:normal;">Form&#160;of Lock-Up Agreement (included in Annex E to the proxy statement/prospectus and incorporated herein by reference).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000110465922063262/tm2216126d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">GlycoMimetics,&#160;Inc. Amended and Restated 2013 Equity Incentive Plan (incorporated herein by reference to Exhibit&#160;10.1 to GlycoMimetics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-36177), filed with the Commission on May&#160;20, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000119312513412381/d572031dex1012.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Stock Option Grant Notice and Stock Option Agreement under 2013 Equity Incentive Plan (incorporated herein by reference to Exhibit&#160;10.12 to Amendment No.&#160;1 to GlycoMimetics,&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1 (File&#160;No.&#160;333-191567), filed with the Commission on October&#160;28, 2013).</span></a></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:2.85pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><div style="height:2.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><div style="height:2.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><div style="height:2.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;</b><br/><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000119312513412381/d572031dex1013.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under 2013 Equity Incentive Plan (incorporated herein by reference to Exhibit&#160;10.13 to Amendment No.&#160;1 to GlycoMimetics,&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1 (File&#160;No.&#160;333-191567), filed with the Commission on October&#160;28, 2013).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000119312513412381/d572031dex1014.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2013 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit&#160;10.14 to Amendment No.&#160;1 to GlycoMimetics,&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1 (File&#160;No.&#160;333-191567), filed with the Commission on October&#160;28, 2013).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837022002737/glyc-20211231xex10d19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">GlycoMimetics,&#160;Inc. Amended and Restated Inducement Plan (incorporated herein by reference to Exhibit&#160;10.19 to GlycoMimetics,&#160;Inc.&#8217;s Annual Report on Form&#160;10-K (File No.&#160;001-36177), filed with the Commission on March&#160;3, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837020001723/glyc-20191231ex10222a5bd.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Stock Option Grant Notice and Stock Option Agreement under the GlycoMimetics,&#160;Inc. Inducement Plan (incorporated herein by reference to Exhibit&#160;10.22 to GlycoMimetics,&#160;Inc.&#8217;s Annual Report on Form&#160;10-K (File No.&#160;001-36177), filed with the Commission on February&#160;28, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000119312513412381/d572031dex1015.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Indemnification Agreement (incorporated herein by reference to Exhibit&#160;10.15 to Amendment No.&#160;1 to GlycoMimetics,&#160;Inc.&#8217;s Registration Statement on Form&#160;S-1 (File&#160;No.&#160;333-191567), filed with the Commission on October&#160;28, 2013).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.13#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837021014003/glyc-20210930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Executive Employment Agreement, dated as of August&#160;3, 2021, by and between GlycoMimetics,&#160;Inc. and Harout Semerjian (incorporated herein by reference to Exhibit&#160;10.1 to GlycoMimetics,&#160;Inc.&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36177), filed with the Commission on November&#160;2, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837019006741/glyc-20190630ex103863aa0.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Executive Employment Agreement, dated as of July&#160;30, 2019, by and between GlycoMimetics,&#160;Inc. and Brian Hahn (incorporated herein by reference to Exhibit&#160;10.3 to GlycoMimetics,&#160;Inc.&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36177), filed with the Commission on August&#160;1, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837023007744/glyc-20230331xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Executive Employment Agreement, dated as of February&#160;16, 2022, by and between GlycoMimetics,&#160;Inc. and Bruce Johnson (incorporated herein by reference to Exhibit&#160;10.4 to GlycoMimetics,&#160;Inc.&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36177), filed with the Commission on May&#160;3, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837022017036/glyc-20220930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Executive Employment Agreement, dated as of August&#160;31, 2022, by and between GlycoMimetics,&#160;Inc. and Edwin Rock, M.D. (incorporated herein by reference to Exhibit&#160;10.1 to GlycoMimetics,&#160;Inc.&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36177), filed with the Commission on November&#160;9, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.17#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837023007744/glyc-20230331xex10d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Executive Employment Agreement, dated as of February&#160;10, 2023, by and between GlycoMimetics,&#160;Inc. and Chinmaya Rath (incorporated herein by reference to Exhibit&#160;10.5 to GlycoMimetics,&#160;Inc.&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36177), filed with the Commission on May&#160;3, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.18#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837024004013/glyc-20231231xex10d13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Amended and Restated Non-Employee Director Compensation Policy, as currently in effect  (incorporated herein by reference to Exhibit&#160;10.13 to GlycoMimetics,&#160;Inc.&#8217;s Annual Report on Form&#160;10-K (File No.&#160;001-36177), filed with the Commission on March&#160;27, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.19</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000119312514281651/d762605dex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement, dated July&#160;23, 2014, by and between GlycoMimetics,&#160;Inc. and BMR-Medical Center Drive, LLC (incorporated herein by reference to Exhibit&#160;10.1 to GlycoMimetics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-36177), filed with the Commission on July&#160;28, 2014).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.20</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837016004451/glyc-20160324ex101357c41.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Lease, dated March&#160;24, 2016, by and between GlycoMimetics,&#160;Inc. and BMR-Medical Center Drive LLC (incorporated herein by reference to Exhibit&#160;10.1 to GlycoMimetics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-36177), filed with the Commission on March&#160;29, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837024004013/glyc-20231231xex10d16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Lease, dated April&#160;20, 2018, by and between GlycoMimetics,&#160;Inc. and BMR-Medical Center Drive LLC (incorporated herein by reference to Exhibit&#160;10.16 to GlycoMimetics,&#160;Inc.&#8217;s Annual Report on Form&#160;10-K (File No.&#160;001-36177), filed with the Commission on March&#160;27, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837023006434/glyc-20230419xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Lease, dated April&#160;19, 2023, by and between GlycoMimetics,&#160;Inc. and ARE-Maryland No.&#160;45, LLC (incorporated herein by reference to Exhibit&#160;10.1 to GlycoMimetics,&#160;Inc.&#8217;s Current Report on Form&#160;8-K (File No.&#160;001-36177), filed with the commission on April&#160;21, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.23&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837020001723/glyc-20191231ex1020d5bed.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration and License Agreement, dated January&#160;2, 2020, by and between GlycoMimetics,&#160;Inc. and Apollomics (Hong Kong) Limited (incorporated herein by reference to Exhibit&#160;10.20 to GlycoMimetics,&#160;Inc.&#8217;s Annual Report on Form&#160;10-K (File No.&#160;001-36177), filed with the Commission on February&#160;28, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837022006260/glyc-20220331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sales Agreement, dated April&#160;28, 2022, by and between GlycoMimetics,&#160;Inc. and Cowen and Company, LLC (incorporated herein by reference to Exhibit&#160;10.1 to GlycoMimetics,&#160;Inc.&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36177), filed with the Commission on April&#160;28, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.25&#8224;&#8224;</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837024004013/glyc-20231231xex10d20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Project Agreement dated January&#160;2, 2024, with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific (incorporated herein by reference to Exhibit&#160;10.20 to GlycoMimetics,&#160;Inc.&#8217;s Annual Report on Form&#160;10-K (File No.&#160;001-36177), filed with the Commission on March&#160;27, 2024).</span></a></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:2.85pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><div style="height:2.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><div style="height:2.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><div style="height:2.85pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;</b><br/><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.26#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837024015537/glyc-20240930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Retention Agreement, dated as of August&#160;7, 2024, by and between GlycoMimetics,&#160;Inc. and Harout Semerjian (incorporated herein by reference to Exhibit&#160;10.1 to GlycoMimetics,&#160;Inc.&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36177), filed with the Commission on November&#160;13, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.27#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837024015537/glyc-20240930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Retention Agreement, dated as of August&#160;7, 2024, by and between GlycoMimetics,&#160;Inc. and Brian Hahn (incorporated herein by reference to Exhibit&#160;10.2 to GlycoMimetics,&#160;Inc.&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36177), filed with the Commission on November&#160;13, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.28#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837024015537/glyc-20240930xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Separation Agreement, dated as of July&#160;30, 2024, by and between GlycoMimetics,&#160;Inc. and Edwin Rock (incorporated herein by reference to Exhibit&#160;10.3 to GlycoMimetics,&#160;Inc.&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36177), filed with the Commission on November&#160;13, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.29#</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1253689/000155837024015537/glyc-20240930xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement, dated as of July&#160;31, 2024, by and between GlycoMimetics,&#160;Inc. and Edwin Rock (incorporated herein by reference to Exhibit&#160;10.4 to GlycoMimetics,&#160;Inc.&#8217;s Quarterly Report on Form&#160;10-Q (File No.&#160;001-36177), filed with the Commission on November&#160;13, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.30#**</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Crescent Biopharma,&#160;Inc. 2025 Stock Incentive Plan (included as Annex J to the proxy statement/prospectus and incorporated herein by reference).</p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.31#**</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Crescent Biopharma,&#160;Inc. 2025 Employee Stock Purchase Plan (included as Annex K to the proxy statement/prospectus and incorporated herein by reference).</p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.32#*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex10d32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Crescent Biopharma,&#160;Inc. 2024 Equity Incentive Plan, as amended by the First Amendment dated May&#160;7, 2024, the Second Amendment dated December&#160;27, 2024, and the Thi</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">r</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">d Amendment dated January&#160;13, 2024.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.33(a)#*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex10d33a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Notice and Restricted Stock Purchase Agreement (With Purchase Price) of Crescent Biopharma,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.33(b)#*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex10d33b.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Notice and Restricted Stock Purchase Agreement (No Purchase Price) of Crescent Biopharma,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.34#*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex10d34.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Stock Option Agreement under Crescent Biopharma,&#160;Inc. 2024 Equity Incentive Plan</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.35#*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex10d35.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement, dated September&#160;28, 2024, by and between Crescent Biopharma,&#160;Inc. and Jonathan Violin.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.36#*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex10d36.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Indemnification Agreement between Crescent Biopharma,&#160;Inc. and its directors and officers</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.37#*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex10d37.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement, dated September&#160;28, 2024, by and between Crescent Biopharma,&#160;Inc. and Christopher Doughty.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.38&#8224;&#8224;#*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex10d38.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Offer Letter, dated November&#160;27, 2024, by and between Crescent Biopharma,&#160;Inc. and Christopher Doughty.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.39&#8224;&#8224;#*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex10d39.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Offer Letter, dated November&#160;15, 2024, by and between Crescent Biopharma,&#160;Inc. and Ryan Lynch.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.40&#8224;&#8224;#*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex10d40.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Offer Letter, dated December&#160;20, 2024, by and between Crescent Biopharma,&#160;Inc. and Barbara Bispham.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.41&#8224;&#8224;&#8224;*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex10d41.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Antibody Discovery and Option Agreement, dated September&#160;19, 2024, by and among Paragon Therapeutics,&#160;Inc., Parascent Holding LLC and Crescent Biopharma,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.42&#8224;&#8224;&#8224;*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex10d42.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">ADC Discovery and Option Agreement, dated October&#160;28, 2024, by and among Paragon Therapeutics,&#160;Inc., Parascent Holding LLC and Crescent Biopharma,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.1*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst&#160;&amp; Young LLP, independent registered public accounting firm of GlycoMimetics,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.2*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex23d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of Crescent Biopharma,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.3**</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consent of Sidley Austin LLP (included in Exhibit&#160;5.1).</p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.4*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex23d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Lucid Capital Markets,&#160;LLC.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24.1*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_203914"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included in the signature page&#160;hereto).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Alexandra Balcom to serve as a director of GlycoMimetics,&#160;Inc., to be renamed Crescent Biopharma,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.2*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Peter Harwin to serve as a director of GlycoMimetics,&#160;Inc., to be renamed Crescent Biopharma,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.3*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex99d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Susan Moran to serve as a director of GlycoMimetics,&#160;Inc., to be renamed Crescent Biopharma,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.4*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xex99d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Jonathan Violin to serve as a director of GlycoMimetics,&#160;Inc., to be renamed Crescent Biopharma,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document.</p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema.</p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase.</p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase.</p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Label Linkbase.</p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase.</p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page&#160;Interactive Data File. Formatted in Inline XBRL and contained in exhibit 101.</p></td></tr><tr><td style="vertical-align:top;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">107*</p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20241231xexfees.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Filing Fee Table.</span></a></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;">Filed herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;">To be filed by amendment.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;">Indicates management contract or compensatory plan or arrangement.</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;">Exhibits and/or schedules have been omitted pursuant to Item&#160;601(a)(5)&#160;of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule&#160;24b-2 under the Exchange Act for any exhibits or schedules so furnished.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;">&#8224;&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;">Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because they are both (i)&#160;not material and (ii)&#160;customarily and actually treated as private or confidential.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c4b1398f_3b48_446d_8c35_20cb5be3f33a"></a><a id="SIGNATURES_203914"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in Monrovia, State of Maryland, on February&#160;18, 2025.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">GlycoMimetics,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Harout Semerjian</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Act this registration statement has been signed by the following persons in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:27.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:42.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:26.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Harout Semerjian</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">President, Chief Executive Officer and Director</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February&#160;18, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Harout Semerjian</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:17.2pt;"><td style="vertical-align:bottom;width:27.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Brian Hahn</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February&#160;18, 2025</p></td></tr><tr><td style="vertical-align:top;width:27.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian Hahn</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<i style="font-style:italic;">Principal Financial Officer and Principal Accounting Officer</i>)</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Timothy R. Pearson</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chairman of the Board of Directors</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February&#160;18, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Timothy R. Pearson</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Patricia S. Andrews</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February&#160;18, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patricia S. Andrews</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Mark A. Goldberg, M.D.</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February&#160;18, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mark A. Goldberg, M.D.</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Scott Jackson</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February&#160;18, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Scott Jackson</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Daniel M. Junius</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February&#160;18, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Daniel M. Junius</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Rachel K. King</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February&#160;18, 2025</p></td></tr><tr><td style="vertical-align:top;width:27.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rachel K. King</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Scott Koenig M.D., Ph.D.</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:1.84%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February&#160;18, 2025</p></td></tr><tr><td style="vertical-align:top;width:27.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Scott Koenig M.D., Ph.D.</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:26.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6
<SEQUENCE>2
<FILENAME>glyc-20241231xex3d6.htm
<DESCRIPTION>EXHIBIT-3.6
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:21:22 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 3.6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATE OF INCORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CRESCENT BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NAME OF CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The name of this corporation (the &#8220;<b style="font-weight:bold;">Corporation</b>&#8221;) is Crescent Biopharma, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REGISTERED OFFICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The address of the registered office of the Corporation in the State of Delaware is Corporation Trust Company, 1209 Orange Street, in the city of Wilmington, New Castle County, Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PURPOSE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the &#8220;<b style="font-weight:bold;">DGCL</b>&#8221;), as the same exists or as may hereafter be amended from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AUTHORIZED CAPITAL STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The total number of shares of all classes of stock which the Corporation shall have the authority to issue is 60,000,000. The Corporation has two classes of stock, referred to as Common Stock and Preferred Stock. There are 40,000,000 shares of authorized Common Stock, $0.0001 par value per share (&#8220;<b style="font-weight:bold;">Common Stock</b>&#8221;), and 20,000,000 shares of authorized Preferred Stock, $0.0001 par value per share (&#8220;<b style="font-weight:bold;">Preferred Stock</b>&#8221;), all of which are hereby designated as &#8220;<b style="font-weight:bold;">Series Seed Preferred Stock</b>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a statement of the designations and the powers, preferences and special rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A.</font></font>COMMON STOCK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated, references to &#8220;Sections&#8221; in this Part A of this Article IV refer to sections of Part A of this Article IV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights, powers, preferences and special rights of the holders of the Preferred Stock set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting</u>. Except as otherwise provided herein or by applicable law, the holders of the Common Stock are entitled to one (1) vote for each share of Common Stock held as of the applicable record date for each meeting of stockholders (and written actions in lieu of meetings). The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one (1) or more series of Preferred Stock that may be required by the terms of this Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dilution Events</u>. Upon each Dilution Event, the Corporation shall, for no additional consideration, grant shares of Common Stock to each of Paragon Therapeutics, Inc. and Parascent Holding LLC (collectively, the &#8220;<b style="font-weight:bold;">Paragon Entities</b>&#8221;) pursuant to a Subscription Agreement with the same terms and conditions as set forth in such Paragon Entity&#8217;s initial Subscription Agreement or Contribution Agreement, as applicable, such that the aggregate Common Stock owned by each such Paragon Entity after such Dilution Event is equal to 10.00% of the sum of (A) the Preferred Stock issued and outstanding (on an as-converted to Common Stock basis) and (B) the Common Stock issued and outstanding; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that such sum shall exclude (X) any shares of Common Stock underlying any options issued pursuant to any of the Corporation&#8217;s equity incentive plans, as may be adopted or amended from time to time (each, an &#8220;<b style="font-weight:bold;">EIP</b>&#8221;), (Y) any shares of Common Stock reserved by the Corporation for issuance under an EIP and (Z) any shares of Common Stock issued to individuals (or entities designated by such individuals) in contemplation of employment, advisory, consulting or director services to be provided by such individuals. For purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3</u>, &#8220;<b style="font-weight:bold;">Dilution Event</b>&#8221; means any sale of the Corporation&#8217;s equity securities made after the date hereof solely to Fairmount Healthcare Fund II, L.P. and/or its affiliates, up to an aggregate sale amount of $20,000,000. For the avoidance of doubt, the issuance of equity securities pursuant to an EIP shall not be considered a Dilution Event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">B.</font></font>PREFERRED STOCK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The shares of the Preferred Stock shall have the powers, preferences and special rights set forth in this Part B of this Article IV. Unless otherwise indicated, references to &#8220;Sections&#8221; in this Part B of this Article IV refer to sections of Part B of this Article IV. References to &#8220;Preferred Stock&#8221; mean the Series Seed Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividends</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in this Certificate of Incorporation) the holders of the Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Preferred Stock in an amount at least equal to (i) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Preferred Stock as would equal the product of (A) the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (B) the number of shares of Common Stock issuable upon conversion of a share of such Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (ii) in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Preferred Stock determined by (A) dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (B) multiplying such fraction by an amount equal to the applicable Original Issue Price (as defined below); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one (1) class or series of capital stock of the Corporation, the dividend payable to the holders of a series of Preferred Stock pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;1</u> shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest dividend for such series of Preferred Stock. The &#8220;<b style="font-weight:bold;">Original Issue Price</b>&#8221; shall mean, with respect to the Series Seed Preferred Stock, $0.0001 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the applicable Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preferential Payments to Holders of Preferred Stock</u>. In the event of (a) any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders or (b) a Deemed Liquidation Event (as defined below), out of the consideration payable to stockholders in such Deemed Liquidation Event or the Available Proceeds (as defined below), before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i) one (1) times the Original Issue Price, plus any dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Preferred Stock been converted into Common Stock pursuant to Section &#8206;4 immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as the &#8220;<b style="font-weight:bold;">Liquidation Amount</b>&#8221;). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Preferred Stock the full amount to which they shall be entitled under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2.1</u>, the holders of shares of Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments to Holders of Common Stock</u>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, after the payment in full of all Liquidation Amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Corporation available for distribution to its stockholders or, in the case of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Preferred Stock pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2.1</u> or the remaining Available Proceeds, as the case may be, shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares held by each such holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deemed Liquidation Events</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">2.3.1<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definition</u>. Each of the following events shall be considered a &#8220;<b style="font-weight:bold;">Deemed Liquidation Event</b>&#8221; unless the holders of at least a majority of the outstanding shares of Preferred Stock, voting together as a single class on an as-converted to Common Stock basis (the &#8220;<b style="font-weight:bold;">Requisite Holders</b>&#8221;), elect otherwise by affirmative vote or written notice:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:148.5pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:20.4pt;"></font>a merger, consolidation, statutory conversion, transfer, domestication or continuance, in each case with a person or persons other than those that, directly or indirectly, control, are controlled by or under common control with the Corporation (each an &#8220;<b style="font-weight:bold;">Affiliate</b>&#8221;), and in which</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the Corporation is a constituent party or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger, consolidation, statutory conversion, transfer, domestication or continuance,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">except any such merger, consolidation, statutory conversion, transfer, domestication or continuance involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger, consolidation, statutory conversion, transfer, domestication, or continuance continue to represent, or are converted into or exchanged for shares of capital stock or other equity interests that represent, immediately following such merger, consolidation, statutory conversion, transfer, domestication or continuance, at least a majority, by voting power, of the capital stock of (1) the surviving or resulting corporation or entity; or (2) if the surviving or resulting corporation or entity is a wholly owned subsidiary of another corporation immediately following such merger, consolidation, statutory conversion, transfer, domestication or continuance, the parent corporation or entity of such surviving or resulting corporation or entity; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>(1) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets or intellectual property (other than a license in a field of use not central to the Corporation&#8217;s business) of the Corporation and its subsidiaries taken as a whole to persons that are not directly or indirectly Affiliates of the Corporation or (2) the sale, lease, transfer, exclusive license or other disposition (whether by merger, consolidation, statutory conversion, transfer, domestication or continuance or otherwise,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and whether in a single transaction or a series of related transactions) of one (1) or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries to persons that are not directly or indirectly Affiliates of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">2.3.2<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effecting a Deemed Liquidation Event</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2.3.1(a)(i)</u> unless the agreement or plan with respect to such transaction, or terms of such transaction (any such agreement, plan or terms, the &#8220;<b style="font-weight:bold;">Transaction Document</b>&#8221;), provides that the consideration payable to the stockholders of the Corporation in such Deemed Liquidation Event shall be allocated to the holders of capital stock of the Corporation in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections &#8206;2.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2.2.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>In the event of a Deemed Liquidation Event referred to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2.3.1(a)(ii)</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2.3.1(b)</u>, if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within ninety (90) days after such Deemed Liquidation Event, then (i) the Corporation shall send a written notice to each holder of Preferred Stock no later than the ninetieth (90<sup style="font-size:7.5pt;vertical-align:top;">th</sup>) day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following clause (ii) to require the redemption of such shares of Preferred Stock, and (ii) if the Requisite Holders so request in a written instrument delivered to the Corporation not later than one hundred twenty (120) days after such Deemed Liquidation Event, the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, any other expenses reasonably related to such Deemed Liquidation Event or any other expenses incident to the dissolution of the Corporation as provided herein, in each case as determined in good faith by the Board of Directors of the Corporation (the &#8220;<b style="font-weight:bold;">Board of Directors</b>&#8221;))<b style="font-weight:bold;">, </b>together with any other assets of the Corporation available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to stockholders (the &#8220;<b style="font-weight:bold;">Available Proceeds</b>&#8221;), on the one hundred fiftieth (150<sup style="font-size:7.5pt;vertical-align:top;">th</sup>) day after such Deemed Liquidation Event (the &#8220;<b style="font-weight:bold;">DLE Redemption Date</b>&#8221;), to redeem all outstanding shares of Preferred Stock at a price per share equal to the applicable Liquidation Amount; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, that if the definitive agreements governing such Deemed Liquidation Event contain contingent indemnification obligations on the part of the Corporation and prohibit the Corporation from distributing all or a portion of the Available Proceeds while such indemnification obligations remain outstanding, then the DLE Redemption Date shall automatically be extended to the date that is ten (10) business days following the date on which such prohibition expires. Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, the Corporation shall redeem a pro rata portion of each holder&#8217;s shares of Preferred Stock to the fullest extent of such Available Proceeds, based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the Available Proceeds were sufficient to redeem all such shares, and shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders. Prior to the distribution or redemption provided for in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;2.3.2&#8206;(b)</u>, the Corporation shall not expend or dissipate the Available Proceeds for any purpose, except to discharge expenses incurred in connection with such Deemed Liquidation Event. In connection with a distribution or redemption provided for in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2.3.2</u>,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Corporation shall send written notice of the redemption (the &#8220;<b style="font-weight:bold;">Redemption Notice</b>&#8221;) to each holder of record of Preferred Stock. Each Redemption Notice shall state:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the number of shares of Preferred Stock held by the holder that the Corporation shall redeem on the date specified in the Redemption Notice;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the redemption date and the price per share at which the shares of Preferred Stock are being redeemed; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner and at the place designated, his, her or its certificate or certificates representing the shares of Preferred Stock to be redeemed.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the Redemption Notice shall have been duly given, and if payment is tendered or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding that any certificates evidencing any of the shares of Preferred Stock so called for redemption shall not have been surrendered, all rights with respect to such shares shall forthwith after the date terminate, except only the right of the holders to receive the payment without interest upon surrender of any such certificate or certificates therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">2.3.3<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amount Deemed Paid or Distributed</u>. The amount deemed paid or distributed to the holders of capital stock of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities to be paid or distributed to such holders pursuant to such Deemed Liquidation Event. The value of such property, rights or securities shall be determined in good faith by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">2.3.4<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation of Escrow and Contingent Consideration</u>. In the event of a Deemed Liquidation Event pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2.3.1&#8206;(a)&#8206;(i)</u>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the &#8220;<b style="font-weight:bold;">Additional Consideration</b>&#8221;), the Transaction Document shall provide that (a) the portion of such consideration that is not Additional Consideration (such portion, the &#8220;<b style="font-weight:bold;">Initial Consideration</b>&#8221;) shall be allocated among the holders of capital stock of the Corporation in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections &#8206;2.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2.2</u> as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b) any Additional Consideration which becomes payable to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections &#8206;2.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2.2</u> after taking into account the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2.3.4</u>, consideration placed into escrow or retained as a holdback to be available for satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible (as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4</u> below) as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of this Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class and on an as-converted to Common Stock basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Election of Directors</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.2.1<font style="display:inline-block;width:16pt;"></font>The holders of record of the shares of Preferred Stock, voting together exclusively and as a separate class on an as-converted to Common Stock basis, shall be entitled to elect one (1) director of the Corporation (the &#8220;<b style="font-weight:bold;">Preferred Director</b>&#8221;) and the holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting together as a single class on an as-converted to Common Stock basis, shall be entitled to elect the balance of the total number of directors of the Corporation (the &#8220;<b style="font-weight:bold;">At-Large Directors</b>&#8221;); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, for administrative convenience, the initial Preferred Director may also be appointed by the Board of Directors in connection with the approval of the initial issuance of Preferred Stock without a separate action by the holders of Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.2.2<font style="display:inline-block;width:16pt;"></font>Any director elected as provided in the <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3.2.1</u> may be removed without cause by, and only by, the affirmative vote of the holders of a majority of the shares of the class or series of capital stock entitled to elect such director or directors, voting together as a single class on an as-converted to Common Stock basis, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.2.3</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>If the holders of shares of Preferred Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3.2.1</u> (and to the extent any of such directorships is not otherwise filled by a director appointed in accordance with the proviso in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3.2.1)</u>, then any directorship not so filled shall remain vacant until such time as the holders of the Preferred Stock fill such directorship in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3.2.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>A vacancy in any At-Large Director seat can be filled by either (A) the vote or written consent in lieu of a meeting of the stockholders entitled elect the At-Large Directors, or (B) the vote or written consent in lieu of a meeting of a majority of the remaining director(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.2.4<font style="display:inline-block;width:16pt;"></font>At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Common Stock and of any other class or series of capital stock entitled to elect such director shall constitute a quorum for the purpose of electing such director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preferred Stock Protective Provisions</u>. At any time when shares of Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Preferred Stock) are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation, domestication, transfer, continuance, recapitalization, reclassification, waiver, statutory conversion, or otherwise, effect any of the following acts or transactions without (in addition to any other vote required by law or this Certificate of Incorporation) the written consent or affirmative vote of the Requisite Holders and any such&#160;act or transaction that has not been approved by such consent or vote prior to such act or transaction being effected shall be null and void <i style="font-style:italic;">ab initio</i>, and of no force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.1<font style="display:inline-block;width:16pt;"></font>liquidate, dissolve or wind-up the business and affairs of the Corporation or effect any Deemed Liquidation Event or any other merger, consolidation, statutory conversion, transfer, domestication or continuance or consent to any of the foregoing;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.2<font style="display:inline-block;width:16pt;"></font>amend, alter or repeal any provision of this Certificate of Incorporation or Bylaws of the Corporation (the &#8220;<b style="font-weight:bold;">Bylaws</b>&#8221;) in a manner that adversely affects the special rights, powers and preferences of the Preferred Stock (or any series thereof);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.3<font style="display:inline-block;width:16pt;"></font>create, or authorize the creation of, or issue or obligate itself to issue shares of, or reclassify, any capital stock unless the same ranks junior to the Preferred Stock with respect to its special rights, powers and preferences;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.4<font style="display:inline-block;width:16pt;"></font>increase the authorized number of shares of Preferred Stock or any additional class or series of capital stock of the Corporation unless the same ranks junior to the Preferred Stock with respect to its rights, preferences and privileges;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.5<font style="display:inline-block;width:16pt;"></font>purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of the Corporation other than (i) redemptions of or dividends or distributions on the Preferred Stock as expressly authorized herein, (ii) dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock and (iii)&#160;repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Corporation or any subsidiary in connection with the cessation of such employment or service at no greater than the original purchase price thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.6<font style="display:inline-block;width:16pt;"></font>create, or hold capital stock in, any subsidiary that is not wholly owned (either directly or through one (1) or more other subsidiaries) by the Corporation, or permit any subsidiary to create, or authorize the creation of, or issue or obligate itself to issue, any shares of any class or series of capital stock, or sell, transfer or otherwise dispose of any capital stock of any direct or indirect subsidiary of the Corporation, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the assets of such subsidiary, in each case without the approval of the Board of Directors; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">3.3.7<font style="display:inline-block;width:16pt;"></font>enter into any agreement or otherwise obligate the Corporation or any subsidiary to do any of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Optional Conversion</u>. The holders of the Preferred Stock shall have conversion rights as follows (the &#8220;<b style="font-weight:bold;">Conversion Rights</b>&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Convert</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.1.1<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conversion Ratio</u>. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time, and without the payment of additional consideration by the holder thereof, into such whole number of fully paid and non-assessable shares of Common Stock (calculated as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2</u> below) as is determined by dividing the applicable Original Issue Price by the applicable Conversion Price (as defined below) in effect at the time of conversion. The &#8220;<b style="font-weight:bold;">Conversion Price</b>&#8221; applicable to the Series Seed Preferred Stock as of the Original Issue Date shall be equal to $0.0001 per share. Such initial Conversion Price for a series of Preferred Stock, and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.1.2<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Conversion Rights</u>. In the event of a liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred Stock; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that the foregoing termination of Conversion Rights shall not affect the amount(s) otherwise paid or payable in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2.1</u> to the holders of Preferred Stock pursuant to such liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Number of Shares Issuable Upon Conversion</u>. The number of shares of Common Stock issuable to a holder of Preferred Stock upon conversion of such Preferred Stock shall be rounded to the nearest whole share. For the avoidance of doubt, no fractional interests in shares of Common Stock shall be created or issuable as a result of the conversion of the Preferred Stock pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.1.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mechanics of Conversion</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.3.1<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Conversion</u>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of Common Stock, such holder shall (a) provide written notice to the Corporation&#8217;s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent) that such holder elects to convert all or any number of such holder&#8217;s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (b), if such holder&#8217;s shares are certificated, surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">own transfer agent). Such notice shall state such holder&#8217;s name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued. If required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) shall be the time of conversion (the &#8220;<b style="font-weight:bold;">Conversion Time</b>&#8221;), and the shares of Common Stock issuable upon conversion of the specified shares shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as practicable after the Conversion Time (i) issue and deliver to such holder of Series Seed Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Series Seed Preferred Stock represented by any surrendered certificate that were not converted into Common Stock, and (ii) pay all declared but unpaid dividends on the shares of Preferred Stock converted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.3.2<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reservation of Shares</u>. The Corporation shall at all times when the Preferred Stock shall be outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to this Certificate of Incorporation. Before taking any action that would cause an adjustment reducing the Conversion Price for any series of Preferred Stock below the then par value of the shares of Common Stock issuable upon conversion of such series of Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and non-assessable shares of Common Stock at such adjusted Conversion Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.3.3<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Conversion</u>. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor and to receive payment of any dividends declared but unpaid thereon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.3.4<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Further Adjustment</u>. Upon any such conversion, no adjustment to the Conversion Price shall be made for any declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.3.5<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u>. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;4</u>. The Corporation shall not,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustments to Preferred Stock Conversion Price for Diluting Issues</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.4.1<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Definitions</u>. For purposes of this Article IV, the following definitions shall apply:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>&#8220;<b style="font-weight:bold;">Additional Shares of Common Stock</b>&#8221; means all shares of Common Stock issued (or, pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;4.4.3</u> below, deemed to be issued) by the Corporation after the Original Issue Date (as defined below), other than (1) the following shares of Common Stock and (2) shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1) and (2), collectively, &#8220;<b style="font-weight:bold;">Exempted Securities</b>&#8221;):</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">as to any series of Preferred Stock shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on such series of Preferred Stock (including dividends payable in connection with dividends on other classes or series of stock);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock that is covered by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4.5</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.6</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.7</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.8</u><b style="font-weight:bold;">;</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved (i) prior to the Original Issue Date or (ii) by the Board of Directors;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(v)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 216pt;">real property leasing transaction approved by the Board of Directors;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(vi)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock, Options or Convertible Securities issued to suppliers or third-party service providers in connection with the provision of goods or services pursuant to transactions approved by the Board of Directors;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(vii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock, Options or Convertible Securities issued as acquisition consideration pursuant to the acquisition of another corporation by the Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that such issuances are approved by the Board of Directors; or</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(viii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board of Directors.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>&#8220;<b style="font-weight:bold;">Convertible Securities</b>&#8221; means any evidences of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(c)<font style="display:inline-block;width:24.9pt;"></font>&#8220;<b style="font-weight:bold;">Option</b>&#8221; means rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(d)<font style="display:inline-block;width:24.34pt;"></font>&#8220;<b style="font-weight:bold;">Original Issue Date</b>&#8221; means the date the first share of Series Seed Preferred Stock is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.4.2<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Adjustment of Preferred Stock Conversion Price</u>. No adjustment in the Conversion Price of any series of Preferred Stock shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Requisite Holders agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.4.3<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deemed Issue of Additional Shares of Common Stock</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>If the Corporation at any time or from time to time after the Original Issue Date shall issue any Options or Convertible Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">convertibility or exchangeability but without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Conversion Price of any series of Preferred Stock pursuant to the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4.4.4</u>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1) any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or (2) any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the Conversion Price of such series of Preferred Stock computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such Conversion Price of such series of Preferred Stock as would have obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4.3(b)</u> shall have the effect of increasing the Conversion Price applicable to a series of Preferred Stock to an amount which exceeds the lower of (i) the Conversion Price for such series of Preferred Stock in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii) the Conversion Price for such series of Preferred Stock that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(c)<font style="display:inline-block;width:24.9pt;"></font>If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to the Conversion Price of a series of Preferred Stock pursuant to the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4.4.4</u> (either because the consideration per share (determined pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4.4.5</u>) of the Additional Shares of Common Stock subject thereto was equal to or greater than the applicable Conversion Price then in effect, or because such Option or Convertible Security was issued before the Original Issue Date), are revised after the Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1) any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (2) any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4.4.3&#8206;(a))</u> shall be deemed to have been issued effective upon such increase or decrease becoming effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(d)<font style="display:inline-block;width:24.34pt;"></font>Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Conversion Price of any series of Preferred Stock pursuant to the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;4.4.4</u>, the Conversion Price of such series of Preferred Stock shall be readjusted to such Conversion Price for such series of Preferred Stock as would have obtained had such Option or Convertible Security (or portion thereof) never been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(e)<font style="display:inline-block;width:24.9pt;"></font>If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is potentially subject to adjustment based upon subsequent events, any adjustment to the Conversion Price of a series of Preferred Stock provided for in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;4.4.3</u> shall be effected at the time of such issuance or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clauses &#8206;(b)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(c)</u> of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;4.4.3</u>). If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to the Conversion Price of a series of Preferred Stock that would result under the terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;4.4.3</u> at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the Conversion Price for such series of Preferred Stock that such issuance or amendment took place at the time such calculation can first be made. In the event an Option or Convertible Security contains alternative conversion terms, such as a cap on the valuation of the Corporation at which such conversion will be effected, or circumstances where the Option or Convertible Security may be repaid in lieu of conversion, then the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of such Option or Convertible Security shall be deemed not calculable until such time as the applicable conversion terms are determined.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.4.4<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment of Conversion Price Upon Issuance of Additional Shares of Common Stock</u>. In the event the Corporation shall at any time after the Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;4.4.3</u>), without consideration or for a consideration per share less than the Conversion Price of a series of Preferred Stock in effect immediately prior to such issuance or deemed issuance, then the Conversion Price for such series of Preferred Stock shall be reduced, concurrently with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CP<sub style="font-size:7.5pt;vertical-align:sub;">2</sub> = CP<sub style="font-size:7.5pt;vertical-align:sub;">1</sub>* (A + B) &#247; (A + C).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For purposes of the foregoing formula, the following definitions shall apply:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>&#8220;CP<sub style="font-size:7.5pt;vertical-align:sub;">2</sub>&#8221; shall mean the Conversion Price of such series of Preferred Stock in effect immediately after such issuance or deemed issuance of Additional Shares of Common Stock;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>&#8220;CP<sub style="font-size:7.5pt;vertical-align:sub;">1</sub>&#8221; shall mean the Conversion Price of such series of Preferred Stock in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(c)<font style="display:inline-block;width:24.9pt;"></font>&#8220;A&#8221; shall mean the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(d)<font style="display:inline-block;width:24.34pt;"></font>&#8220;B&#8221; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued or deemed issued at a price per share equal to CP<sub style="font-size:7.5pt;vertical-align:sub;">1</sub> (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP<sub style="font-size:7.5pt;vertical-align:sub;">1</sub>); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(e)<font style="display:inline-block;width:24.9pt;"></font>&#8220;C&#8221; shall mean the number of such Additional Shares of Common Stock issued in such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.4.5<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Determination of Consideration</u>. For purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4.4</u>, the consideration received by the Corporation for the issuance or deemed issuance of any Additional Shares of Common Stock shall be computed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash and Property</u>. Such consideration shall:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation, excluding amounts paid or payable for accrued interest;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of such issue, as determined in good faith by the Board of Directors; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clauses &#8206;(i)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(ii</u>) above, as determined in good faith by the Board of Directors.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Options and Convertible Securities</u>. The consideration per share received by the Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;4.4.3</u>, relating to Options and Convertible Securities, shall be determined by dividing:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The total amount, if any, received or receivable by the Corporation as consideration for the issue of such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities, by</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:180pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">4.4.6<font style="display:inline-block;width:16pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Multiple Closing Dates</u>. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to the Conversion Price of a series of Preferred Stock pursuant to the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4.4.4</u>, then, upon the final such issuance, the Conversion Price for such series of Preferred Stock shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances within such period).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment for Stock Splits and Combinations</u>. If the Corporation shall at any time or from time to time after the Original Issue Date effect a subdivision of the outstanding Common Stock, the Conversion Price of each series of Preferred Stock in effect immediately before that subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time after the Original Issue Date combine the outstanding shares of Common Stock, the Conversion Price of each series of Preferred Stock in effect immediately before the combination shall be proportionately increased so that the number of shares of Common</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4.5</u> shall become effective at the close of business on the date the subdivision or combination becomes effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.6</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment for Certain Dividends and Distributions</u>. In the event the Corporation at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event the Conversion Price of each series of Preferred Stock in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the Conversion Price of each such series of Preferred Stock then in effect by a fraction:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(1)<font style="display:inline-block;width:24.34pt;"></font>the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(2)<font style="display:inline-block;width:24.34pt;"></font>the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, (a) if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the Conversion Price of each series of Preferred Stock shall be recomputed accordingly as of the close of business on such record date and thereafter the Conversion Price of each series of Preferred Stock shall be adjusted pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4.6</u> as of the time of actual payment of such dividends or distributions; and (b) that no such adjustment shall be made if the holders of such series of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of such series of Preferred Stock had been converted into Common Stock on the date of such event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.7</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustments for Other Dividends and Distributions</u>. In the event the Corporation at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;1</u> do not apply to such dividend or distribution, then and in each such event the holders of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.8</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment for Merger or Reorganization, etc</u>. Subject to the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2.3</u>, if there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections &#8206;4.4</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.6</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.7</u>), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of Preferred Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one (1) share of such Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board of Directors) shall be made in the application of the provisions in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4</u> with respect to the rights and interests thereafter of the holders of the Preferred Stock, to the end that the provisions set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4 </u>(including provisions with respect to changes in and other adjustments of the Conversion Price of each series of Preferred Stock) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of the Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.9</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificate as to Adjustments</u>. Upon the occurrence of each adjustment or readjustment of the Conversion Price of a series of Preferred Stock pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;4</u>, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than ten (10) days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of each series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which such series of Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock (but in any event not later than ten (10) days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i) the Conversion Price then in effect for each series of Preferred Stock held by such holder, and (ii) the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of each such series of Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.10</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Record Date</u>. In the event:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or series or any other securities, or to receive any other security; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>of any capital reorganization of the Corporation, any reclassification of the Common Stock of the Corporation, or any Deemed Liquidation Event; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;">(c)<font style="display:inline-block;width:24.9pt;"></font>of the voluntary or involuntary dissolution, liquidation or winding-up of the Corporation,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">then, and in each such case, the Corporation will send or cause to be sent to the holders of the Preferred Stock a notice specifying, as the case may be, (i) the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii) the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up is proposed to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up, and the amount per share and character of such exchange applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least ten (10) days prior to the record date or effective date for the event specified in such notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mandatory Conversion</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trigger Events</u>. Upon the earliest to occur of any of the following events (the time of such conversion is referred to herein as the &#8220;<b style="font-weight:bold;">Mandatory Conversion Time</b>&#8221;), (A) all outstanding shares of Preferred Stock other than the Series Seed Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections&#160;4.1.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.2</u> and (B) all outstanding shares of Series Seed Preferred Stock shall be automatically converted into shares of non-voting Preferred Stock with the rights, privileges, duties and obligations to be determined, at the then effective conversion rate as calculated pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections&#160;4.1.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;4.2</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">5.1.1<font style="display:inline-block;width:16pt;"></font>Immediately prior to the closing of the sale of shares of Common Stock to the public at a price of at least $1.00 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $50,000,000 of gross proceeds, net of the underwriting discount and commissions, to the Corporation and in connection with such offering the shares of Common Stock are listed for trading on the Nasdaq Stock Market&#8217;s National Market, the New York Stock Exchange or another exchange or marketplace approved by the Board of Directors; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">5.1.2<font style="display:inline-block;width:16pt;"></font> The date and time, or the occurrence of an event, specified by vote or written consent of the Requisite Holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Procedural Requirements</u>. All holders of record of shares of Preferred Stock (or the applicable series thereof) shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;5</u>. Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock being converted that holds such shares of Preferred Stock in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Preferred Stock converted pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;5.1</u>, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;5.2</u>. As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a) issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock or Preferred Stock, as applicable, issuable upon such conversion in accordance with the provisions hereof, and (b) pay any declared but unpaid dividends on the shares of Preferred Stock converted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Redeemed or Otherwise Acquired Shares</u>. Unless approved by the Board of Directors and the Requisite Holders, any shares of Preferred Stock that are redeemed, converted or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption, conversion or acquisition. The Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u>. Except as otherwise set forth herein, (a) any of the rights, powers, preferences and other terms of the Preferred Stock set forth herein may be waived on behalf of all holders of Preferred Stock by the affirmative written consent or vote of the holders that would otherwise be required to amend such right, powers, preferences and other terms and (b) at any time more than one (1) series of Preferred Stock is issued and outstanding, any of the rights, powers, preferences and other terms of any series of Preferred Stock set forth herein may be waived on behalf of all holders of such series of Preferred Stock by the affirmative written consent or vote of the holders of such series of Preferred Stock that would otherwise be required to amend such right, power, preference, or other term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. Any notice required or permitted by the provisions of this Article IV to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic transmission in compliance with the provisions of the DGCL, and shall be deemed sent upon such mailing or electronic transmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BOARD POWER REGARDING BYLAWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:22.5pt;margin:0pt 0pt 12pt 0pt;">Subject to any additional vote required by this Certificate of Incorporation or the Bylaws, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE VI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BOARD OF DIRECTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to any additional vote required by this Certificate of Incorporation, the number of directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. Each director shall be entitled to one (1) vote on each matter presented to the Board of Directors; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that, so long as the holders of Preferred Stock are entitled to elect one or more Preferred Directors, the affirmative vote of such Preferred Directors shall be required for the authorization by the Board of Directors of any of the matters set forth in the Investors&#8217; Rights Agreement, dated on or about the Original Issue Date, by and among the Corporation and the other parties thereto, as such agreement may be amended from time to time, to the extent required by such provision and if such Preferred Directors are then serving.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ELECTION OF DIRECTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Elections of directors need not be by written ballot unless the Bylaws shall so provide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE VIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MEETINGS OF STOCKHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Meetings of stockholders may be held within or outside of the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept (subject to any provision of applicable law) outside of the State of Delaware at such place or places or in such manner or manners as may be designated from time to time by the Board of Directors or in the Bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE IX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">LIABILITY OF DIRECTORS AND OFFICERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the fullest extent permitted by law, a director or officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL or any other law of the State of Delaware is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">amended after approval by the stockholders of this Article IX to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation shall indemnify, to the fullest extent permitted by applicable law, any director or officer of the Corporation who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative ( a &#8220;<b style="font-weight:bold;">Proceeding</b>&#8221;) by reason of the fact that he or she is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding. The Corporation shall be required to indemnify a person in connection with a Proceeding initiated by such person only if the Proceeding was authorized by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation shall have the power to indemnify, to the extent permitted by the DGCL, as it presently exists or may hereafter be amended from time to time, any employee or agent of the Corporation who was or is a party or is threatened to be made a party to any Proceeding by reason of the fact that he or she is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Neither any amendment nor repeal of this Article, nor the adoption of any provision of this Certificate of Incorporation inconsistent with this Article, shall eliminate or reduce the effect of this Article in respect of any matter occurring, or any cause of action, suit or claim accruing or arising or that, but for this Article, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE X</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CORPORATE POWER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Except as provided in Article IX above, the Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred on stockholders herein are granted subject to this reservation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE XI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXCLUDED OPPORTUNITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity. An &#8220;<b style="font-weight:bold;">Excluded Opportunity</b>&#8221; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of (i) any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii) any holder of Preferred Stock or any partner, member, director, stockholder, employee, affiliate or agent of any such holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, the persons referred to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">clauses (</u>i) and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(ii)</u> are &#8220;<b style="font-weight:bold;">Covered Persons</b>&#8221;), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#8217;s capacity as a director of the Corporation while such Covered Person is performing services in such capacity. Any repeal or modification of this Article XI will only be prospective and will not affect the rights under this Article XI in effect at the time of the occurrence of any actions or omissions to act giving rise to liability. Notwithstanding anything to the contrary contained elsewhere in this Certificate of Incorporation, in addition to any other vote required by law or this Certificate of Incorporation, the affirmative vote of the Requisite Holders, will be required to amend or repeal, or to adopt any provisions inconsistent with this Article XI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE XII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXCLUSIVE FORUM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&#160;any derivative action or proceeding brought on behalf of the Corporation, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&#8217;s stockholders, (iii)&#160;any action asserting a claim against the Corporation, its directors, officers or employees arising pursuant to any provision of the DGCL or the Corporation&#8217;s Certificate of Incorporation or Bylaws or (iv)&#160;any action asserting a claim against the Corporation, its directors, officers or employees governed by the internal affairs doctrine or that otherwise relates to the internal affairs of the Corporation, except for, as to each of (i) through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten (10) days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE XIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SEVERABILITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any provision or provisions of this Certificate of Incorporation shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Certificate of Incorporation (including, without limitation, each portion of any sentence of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLE XIV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INCORPORATOR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The name and mailing address of the incorporator of the Corporation is:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Luke Magsino</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">Gibson, Dunn &amp; Crutcher LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;">200 Park Avenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">New York, NY 10166</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">THE UNDERSIGNED, being the incorporator hereinbefore named, for the purpose of incorporating and organizing a corporation under the DGCL, does make and file this Certificate of Incorporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">Dated:  September 19, 2024</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Luke Magsino</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Luke Magsino, Incorporator</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">* * *</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.7
<SEQUENCE>3
<FILENAME>glyc-20241231xex3d7.htm
<DESCRIPTION>EXHIBIT-3.7
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:21:22 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 3.7</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CRESCENT BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BYLAWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Adopted September 19, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">STOCKHOLDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Annual Meeting</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors shall each year fix, which date shall be within 13 months of the last annual meeting of stockholders or, if no such meeting has been held, the date of incorporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Meetings</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Special meetings of the stockholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by the Board of Directors or the Chief Executive Officer, if one is elected, or the President, if one is elected, and shall be held at such place, on such date, and at such time as they or he or she shall fix.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Meetings</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notice of the place, if any, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, shall be given, not less than 10 nor more than 60 days before the date on which the meeting is to be held, to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting, except as otherwise provided herein or required by law (meaning, here and hereinafter, as required from time to time by the Delaware General Corporation Law or the Certificate of Incorporation of the Corporation).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that if the date of any adjourned meeting is more than 30 days after the date for which the meeting was originally noticed, notice of the place, if any, date, and time of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting, shall be given to each stockholder in conformity herewith. If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new record date for notice of such adjourned meeting,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and, except as otherwise required by law, shall not be more than 60 nor less than 10 days before the date of such adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting. At any adjourned meeting, any business may be transacted which might have been transacted at the original meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quorum</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At any meeting of the stockholders, the holders of a majority of the voting power of all of the shares of stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence of a larger number may be required by law. Where a separate vote by a class or classes or series is required, a majority of the voting power of the shares of such class or classes or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. The stockholders present at a duly constituted meeting may continue to transact business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a quorum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of stock entitled to vote who are present, in person or by proxy, may adjourn the meeting to another place, if any, date, or time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Such person as the Board of Directors may have designated or, in the absence of such a person, the President of the Corporation, if one is elected, or, in his or her absence, such person as may be chosen by the holders of a majority of the voting power of the shares entitled to vote who are present, in person or by proxy, shall call to order any meeting of the stockholders and act as chairman of the meeting. In the absence of the Secretary of the Corporation, the secretary of the meeting shall be such person as the chairman of the meeting appoints.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conduct of Business</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The chairman of any meeting of stockholders shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seem to him or her in order. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proxies and Voting</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At any meeting of the stockholders, every stockholder entitled to vote may vote in person or by proxy authorized by an instrument in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission created pursuant to this paragraph may be substituted or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used; <i style="font-style:italic;">provided</i>, that such</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation may, and to the extent required by law, shall, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The Corporation may designate one or more alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting may, and to the extent required by law, shall, appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. Every vote taken by ballots shall be counted by an inspector or inspectors appointed by the chairman of the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All elections shall be determined by a plurality of the votes cast, and except as otherwise required by law, all other matters shall be determined by a majority of the votes cast affirmatively or negatively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock List</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The officer who has charge of the stock ledger of the Corporation shall, at least 10 days before every meeting of stockholders, prepare and make a complete list of stockholders entitled to vote at any meeting of stockholders; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that if the record date for determining the stockholders entitled to vote is less than 10 days before the meeting date, the list shall reflect the stockholders entitled to vote as of the 10th day before the meeting date, arranged in alphabetical order and showing the address of each such stockholder and the number of shares registered in his or her name. Such list shall be open to the examination of any stockholder for a period of at least 10 days prior to the meeting in the manner provided by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A stock list shall also be open to the examination of any stockholder during the whole time of the meeting as provided by law. This list shall presumptively determine (a)&#160;the identity of the stockholders entitled to examine such stock list and to vote at the meeting and (b)&#160;the number of shares held by each of them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consent of Stockholders in Lieu of Meeting</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any action required to be taken at any annual or special meeting of stockholders of the Corporation, or any action which may be taken at any annual or special meeting of the stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation by delivery to its registered office in Delaware, its principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation&#8217;s registered office shall be made by hand or by certified or registered mail, return receipt requested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within 60 days of the earliest dated consent delivered to the Corporation, a written consent or consents signed by a sufficient number of holders to take action are delivered to the Corporation in the manner prescribed in the first paragraph of this Section. A telegram, cablegram or other electronic transmission consenting to an action to be taken and transmitted by a stockholder or proxyholder, or by a person or persons authorized to act for a stockholder or proxyholder, shall be deemed to be written, signed and dated for the purposes of this Section to the extent permitted by law. Any such consent shall be delivered in accordance with Section&#160;228(d)(1) of the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any copy, facsimile or other reliable reproduction of a consent in writing may be substituted or used in lieu of the original writing for any and all purposes for which the original writing could be used; <i style="font-style:italic;">provided</i>, that such copy, facsimile or other reproduction shall be a complete reproduction of the entire original writing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BOARD OF DIRECTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Number and Term of Office</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The number of directors who shall constitute the whole Board of Directors shall be such number as the Board of Directors shall from time to time have designated. Each director shall be elected for a term of one year and until his or her successor is elected and qualified, except as otherwise provided herein or required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Whenever the authorized number of directors is increased between annual meetings of the stockholders, a majority of the directors then in office shall have the power to elect such new directors for the balance of a term and until their successors are elected and qualified. Any decrease in the authorized number of directors shall not become effective until the expiration of the term of the directors then in office unless, at the time of such decrease, there shall be vacancies on the board which are being eliminated by the decrease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal of Directors; Resignation</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise provided by the Certificate of Incorporation or these bylaws, any director or the entire Board of Directors may be removed, with or without cause, by the holders of a majority of shares entitled to vote at an election of directors. Any director may resign at any time upon notice given in writing or by electronic transmission to the Corporation. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vacancies</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise provided in the Corporation&#8217;s Certificate of Incorporation, as it may be amended, if the office of any director becomes vacant by reason of death, resignation, disqualification, removal or other cause, a majority of the directors remaining in office, although less than a quorum, may elect a successor for the unexpired term and until his or her successor is</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">elected and qualified. Unless otherwise provided in the Corporation&#8217;s Certificate of Incorporation, as it may be amended, vacancies and newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced. If there are no directors in office, then an election of directors may be held in the manner provided by statute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regular Meetings</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Regular meetings of the Board of Directors shall be held at such place or places, on such date or dates, and at such time or times as shall have been established by the Board of Directors and publicized among all directors. A notice of each regular meeting shall not be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Meetings</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Special meetings of the Board of Directors may be called by one-third of the directors then in office (rounded up to the nearest whole number) or by the Chief Executive Officer, if one is elected, or, if there is no Chief Executive Officer, the President, if one is elected, and shall be held at such place, on such date, and at such time as they or he or she shall fix. Notice of the place, date, and time of each such special meeting shall be given to each director by whom it is not waived by mailing written notice not less than five days before the meeting or by telegraphing or telexing or by facsimile or electronic transmission of the same not less than 24 hours before the meeting. Unless otherwise indicated in the notice thereof, any and all business may be transacted at a special meeting. A meeting may be held at any time without notice if all the directors are present (except as otherwise provided by law) or if those not present waive notice of the meeting in writing, either before or after such meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quorum</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At any meeting of the Board of Directors, the greater of (a) a majority of the directors then in office at the time quorum is to be determined and (b) one-third of the total number of directors fixed pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#160;1</u> of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#160;II</u> of these Bylaws shall constitute a quorum for the transaction of business. Less than a quorum may adjourn any meeting from time to time, and the meeting may be held as adjourned without further notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Participation in Meetings By Conference Telephone</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Members of the Board of Directors, or of any committee thereof, may participate in a meeting of such Board of Directors or committee by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation shall constitute presence in person at such meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conduct of Business</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At any meeting of the Board of Directors, business shall be transacted in such order and manner as the Board of Directors may from time to time determine, and all matters shall be determined by the vote of a majority of the directors present, except as otherwise provided herein</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or required by law. Action may be taken by the Board of Directors without a meeting if all members thereof consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation of Directors</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Directors, as such, may receive, pursuant to resolution of the Board of Directors, fixed fees and other compensation for their services as directors, including, without limitation, their services as members of committees of the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COMMITTEES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committees of the Board of Directors</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors may from time to time designate committees of the Board of Directors, with such lawfully delegable powers and duties as it thereby confers, to serve at the pleasure of the Board of Directors and shall, for those committees and any others provided for herein, elect a director or directors to serve as the member or members, designating, if it desires, other directors as alternate members who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of any member of any committee and any alternate member in his or her place, the member or members of the committee present at the meeting and not disqualified from voting, whether or not he or she or they constitute a quorum, may by unanimous vote appoint another member of the Board of Directors to act at the meeting in the place of the absent or disqualified member.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conduct of Business</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each committee may determine the procedural rules for meeting and conducting its business and shall act in accordance therewith, except as otherwise provided herein or required by law. Adequate provision shall be made for notice to members of all meetings; one-third of the members shall constitute a quorum unless the committee shall consist of one or two members, in which event one member shall constitute a quorum; and all matters shall be determined by a majority vote of the members present. Action may be taken by any committee without a meeting if all members thereof consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of the proceedings of such committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">OFFICERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Generally</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The officers of the Corporation will be chosen by the Board of Directors and will consist of a Secretary, a Treasurer and such other officers, including, without limitation, a Chief Executive Officer, a President, and one or more Vice Presidents, as may from time to time be appointed by the Board of Directors. Officers shall be elected by the Board of Directors, which shall consider that subject at its first meeting after every annual meeting of stockholders. Each officer shall hold office until his or her successor is elected and qualified or until his or her earlier resignation or removal. Any number of offices may be held by the same person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to any limitations which may be set forth in a resolution of the Board of Directors, all deeds, leases, transfers, contracts, bonds, notes and other obligations to be entered into by the Corporation in the ordinary course of its business without director action may be executed on behalf of the Corporation by a President or by any other officer, employee or agent of the Corporation as the Board of Directors may authorize.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chief Executive Officer.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Chief Executive Officer, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">President</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the provisions of these Bylaws and to the direction of the Board of Directors, the President, if one is elected, shall have the responsibility for the general management and control of the business and affairs of the Corporation and shall perform all duties and have all powers which are commonly incident to the office of President or which are delegated to him or her by the Board of Directors. He or she shall have power to sign all stock certificates, contracts and other instruments of the Corporation which are authorized and shall have general supervision and direction of all of the other officers, employees and agents of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vice President</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each Vice President shall have such powers and duties as may be delegated to him or her by the Board of Directors. One Vice President may be designated by the Board of Directors to perform the duties and exercise the powers of the President in the event of the President&#8217;s absence or disability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treasurer</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Treasurer shall have the responsibility for maintaining the financial records of the Corporation. He or she shall make such disbursements of the funds of the Corporation as are authorized and shall render from time to time an account of all such transactions and of the financial condition of the Corporation. The Treasurer shall also perform such other duties as the Board of Directors may from time to time prescribe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Secretary</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Secretary shall issue all authorized notices for, and shall keep minutes of, all meetings of the stockholders and the Board of Directors. He or she shall have charge of the corporate books and shall perform such other duties as the Board of Directors may from time to time prescribe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chairman of the Board</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise provided by the Board of Directors, the Chairman of the Board of Directors, if one is elected, shall preside, when present, at all meetings of the stockholders and the Board of Directors. The Chairman of the Board shall have such other powers and shall perform such duties as the Board of Directors may from time to time designate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delegation of Authority</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors may from time to time delegate the powers or duties of any officer to any other officers or agents, notwithstanding any provision hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any officer of the Corporation may be removed at any time, with or without cause, by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Action with Respect to Securities of Other Corporations</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise directed by the Board of Directors, the President, if one is elected, or any officer of the Corporation authorized by the President, if one is elected, shall have power to vote and otherwise act on behalf of the Corporation, in person or by proxy, at any meeting of stockholders of or with respect to any action of stockholders of any other corporation in which this Corporation may hold securities and otherwise to exercise any and all rights and powers which this Corporation may possess by reason of its ownership of securities in such other corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificates of Stock</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The shares of the Corporation shall be represented by certificates; <i style="font-style:italic;">provided</i>, that the Board may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation. Each holder of stock represented by certificates shall be entitled to a certificate signed by, or in the name of the Corporation, by any two of the President, a Vice President, the Secretary, an Assistant Secretary, the Treasurer, an Assistant Treasurer or any other authorized officers of the Corporation, certifying the number of shares owned by him or her. Any or all of the signatures on the certificate may be by facsimile or electronic means.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfers of Stock</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Transfers of stock shall be made only upon the transfer books of the Corporation kept at an office of the Corporation or by transfer agents designated to transfer shares of the stock of the Corporation. Except where a certificate is issued in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#160;4</u> of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#160;V</u> of these Bylaws, an outstanding certificate, if one has been issued, for the number of shares involved shall be surrendered for cancellation before a new certificate, if any, is issued therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Record Date</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the Board of Directors may, except as otherwise required by law, fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor less than 10 days before the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that the Board of Directors may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance with the foregoing provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#160;3</u> at the adjourned meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order that the Corporation may determine the stockholders entitled to consent to corporate action without a meeting, (including by telegram, cablegram or other electronic transmission as permitted by law), the Board of Directors may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall be not more than ten days after the date upon which the resolution fixing the record date is adopted. If no record date has been fixed by the Board of Directors and no prior action by the Board of Directors is required by the Delaware General Corporation Law, the record date shall be the first date on which a consent setting forth the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">action taken or proposed to be taken is delivered to the Corporation in the manner prescribed by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#160;9</u> of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article I</u> hereof. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by the Delaware General Corporation Law with respect to the proposed action by consent of the stockholders without a meeting, the record date for determining stockholders entitled to consent to corporate action without a meeting shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lost, Stolen or Destroyed Certificates</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of the loss, theft or destruction of any certificate of stock, another may be issued in its place pursuant to such regulations as the Board of Directors may establish concerning proof of such loss, theft or destruction and concerning the giving of a satisfactory bond or bonds of indemnity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulations</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The issue, transfer, conversion and registration of certificates of stock shall be governed by such other regulations as the Board of Directors may establish.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;VI</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If mailed, notice to stockholders shall be deemed given when deposited in the mail, postage prepaid, directed to the stockholder at such stockholder&#8217;s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section&#160;232 of the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waivers</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A written waiver of any notice, signed by a stockholder or director, or waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such person. Neither the business nor the purpose of any meeting need be specified in such a waiver. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;VII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Facsimile or Electronic Signatures</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the provisions for use of facsimile or electronic signatures elsewhere specifically authorized in these Bylaws, facsimile or electronic signatures of any officer or officers of the Corporation may be used whenever and as authorized by the Board of Directors or a committee thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporate Seal</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors may provide a suitable seal, containing the name of the Corporation, which seal shall be in the charge of the Secretary. If and when so directed by the Board of Directors or a committee thereof, duplicates of the seal may be kept and used by the Treasurer or by an Assistant Secretary or Assistant Treasurer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reliance upon Books, Reports and Records</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each director, each member of any committee designated by the Board of Directors, and each officer of the Corporation shall, in the performance of his or her duties, be fully protected in relying in good faith upon the books of account or other records of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of its officers or employees, or committees of the Board of Directors so designated, or by any other person as to matters which such director or committee member reasonably believes are within such other person&#8217;s professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fiscal Year</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fiscal year of the Corporation shall be as fixed by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Offices</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the Corporation may require.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Records and Reports</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The application and requirements of Section&#160;1501 of the California General Corporation Law are hereby expressly waived to the fullest extent permitted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time Periods</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In applying any provision of these Bylaws which requires that an act be done or not be done a specified number of days prior to an event or that an act be done during a period of a</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">specified number of days prior to an event, calendar days shall be used, the day of the doing of the act shall be excluded, and the day of the event shall be included.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;VIII</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INDEMNIFICATION OF DIRECTORS AND OFFICERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Indemnification</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each person who was or is made a party to or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a &#8220;<b style="font-weight:bold;">proceeding</b>&#8221;), by reason of the fact that he or she is or was a director or an officer of the Corporation or is or was serving at the request of the Corporation as a director, officer, or trustee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan (hereinafter an &#8220;<b style="font-weight:bold;">indemnitee</b>&#8221;), whether the basis of such proceeding is alleged action in an official capacity as a director, officer or trustee, or in any other capacity while serving as a director, officer or trustee, shall be indemnified and held harmless by the Corporation to the fullest extent permitted by Delaware law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment) against all expense, liability and loss (including attorneys&#8217; fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such indemnitee in connection therewith; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that, except as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#160;3</u> of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#160;VIII</u> with respect to proceedings to enforce rights to indemnification, the Corporation shall indemnify any such indemnitee in connection with a proceeding (or part thereof) initiated by such indemnitee only if such proceeding (or part thereof) was authorized by the Board of Directors of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Advancement of Expenses</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the right to indemnification conferred in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#160;1</u> of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#160;VIII</u>, an indemnitee shall also have the right to be paid by the Corporation the expenses (including attorney&#8217;s fees) incurred in defending any such proceeding in advance of its final disposition (hereinafter an &#8220;<b style="font-weight:bold;">advancement of expenses</b>&#8221;); <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that, if the Delaware General Corporation Law requires, an advancement of expenses incurred by an indemnitee in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the Corporation of an undertaking (hereinafter an &#8220;<b style="font-weight:bold;">undertaking</b>&#8221;), by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal (hereinafter a &#8220;<b style="font-weight:bold;">final adjudication</b>&#8221;) that such indemnitee is not entitled to be indemnified for such expenses under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#160;2</u> or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of Indemnitee to Bring Suit</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a claim under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section&#160;1</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2</u> of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#160;VIII</u> is not paid in full by the Corporation within 60 days after a written claim has been received by the Corporation, except in the case of a</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">claim for an advancement of expenses, in which case the applicable period shall be 20 days, the indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. To the fullest extent permitted by law, if successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the indemnitee shall be entitled to be paid also the expense of prosecuting or defending such suit. In (i) any suit brought by the indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the indemnitee to enforce a right to an advancement of expenses) it shall be a defense that, and (ii)&#160;in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that, the indemnitee has not met any applicable standard for indemnification set forth in the Delaware General Corporation Law. Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the indemnitee is proper in the circumstances because the indemnitee has met the applicable standard of conduct set forth in the Delaware General Corporation Law, nor an actual determination by the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its stockholders) that the indemnitee has not met such applicable standard of conduct, shall create a presumption that the indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the indemnitee, be a defense to such suit. In any suit brought by the indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#160;VIII</u> or otherwise, shall be on the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Exclusivity of Rights</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The rights to indemnification and to the advancement of expenses conferred in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#160;VIII</u> shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, the Corporation&#8217;s Certificate of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification of Employees and Agents of the Corporation</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Corporation may, to the extent authorized from time to time by the Board of Directors, grant rights to indemnification and to the advancement of expenses to any employee or agent of the Corporation to the fullest extent of the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#160;VIII</u> with respect to the indemnification and advancement of expenses of directors and officers of the Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#010000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nature of Rights</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The rights conferred upon indemnitees in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#160;VIII</u> shall be contract rights and such rights shall continue as to an indemnitee who has ceased to be a director, officer or trustee and shall inure to the benefit of the indemnitee&#8217;s heirs, executors and administrators. Any amendment, alteration or repeal of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article&#160;VIII</u> that adversely affects any right of an indemnitee or its successors shall be prospective only and shall not limit, eliminate, or impair any such right with respect to any proceeding involving any occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment, alteration or repeal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#010000;font-weight:bold;text-transform:uppercase;">Article&#160;IX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These Bylaws may be amended or repealed by the Board of Directors at any meeting or by the stockholders at any meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATE OF SECRETARY OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT BIOPHARMA, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The undersigned, K. Evan Thompson, hereby certifies that he is the duly elected and acting Secretary of Crescent Biopharma, Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Corporation</b>&#8221;), and that the Bylaws attached hereto constitute the Bylaws of said Corporation as duly adopted by Action by Written Consent of the Sole Director in Lieu of the Organizational Meeting of the Board of Directors on September 19, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the undersigned has hereunto subscribed his or her name on September 19, 2024.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ K. Evan Thompson</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">K. Evan Thompson, Secretary</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><b style="font-weight:bold;">SIGNATURE PAGE TO CRESCENT BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BYLAWS</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>glyc-20241231xex10d4.htm
<DESCRIPTION>EXHIBIT-10.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:21:23 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">REGISTRATION RIGHTS AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">THIS REGISTRATION RIGHTS AGREEMENT</b><font style="font-size:11pt;"> (this &#8220;</font><b style="font-size:11pt;font-weight:bold;">Agreement</b><font style="font-size:11pt;">&#8221;), dated as of [</font><font style="font-family:'Symbol';">&#183;</font><font style="font-size:11pt;">]</font><font style="font-size:11pt;">, 2025</font><font style="font-size:11pt;">, is entered into by and among Crescent Biopharma, Inc., a Delaware corporation (&#8220;</font><b style="font-size:11pt;font-weight:bold;">Crescent</b><font style="font-size:11pt;">&#8221;), GlycoMimetics, Inc., a Delaware corporation (&#8220;</font><b style="font-size:11pt;font-weight:bold;">Parent</b><font style="font-size:11pt;">&#8221;), and </font><font style="font-size:11pt;">the several investors signatory hereto</font><font style="font-size:11pt;"> (individually as an &#8220;</font><b style="font-size:11pt;font-weight:bold;">Investor</b><font style="font-size:11pt;">&#8221; and collectively together with their respective permitted assigns, the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Investors</b><font style="font-size:11pt;">&#8221;).&#160;Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among Crescent, Parent and the Investors party thereto, dated as of October 28, 2024 (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Purchase Agreement</b><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">WHEREAS:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">A.</font></font><font style="font-size:11pt;">Crescent is party to that certain Agreement and Plan of Merger and Reorganization by and among the Crescent, Parent, Gemini Merger Sub Corp., a Delaware corporation and wholly-owned subsidiary of Parent (&#8220;</font><b style="font-size:11pt;font-weight:bold;">First Merger Sub</b><font style="font-size:11pt;">&#8221;) and Gemini Merger Sub II, LLC, a Delaware limited liability company and wholly-owned subsidiary of Parent (&#8220;</font><b style="font-size:11pt;font-weight:bold;">Second Merger Sub</b><font style="font-size:11pt;">&#8221;), dated October 28, 2024 (as amended from time to time, the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Merger Agreement</b><font style="font-size:11pt;">&#8221;), pursuant to which (i) First Merger Sub will merge with and into Crescent, with Crescent surviving and becoming a wholly-owned subsidiary of Parent, (ii) Crescent will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly-owned subsidiary of Parent ((i) and (ii) together, the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Merger</b><font style="font-size:11pt;">&#8221;), and (iii) Parent will change its name to Crescent Biopharma, Inc. (&#8220;</font><b style="font-size:11pt;font-weight:bold;">TopCo</b><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">B.</font></font><font style="font-size:11pt;">Upon the terms and subject to the conditions of the Purchase Agreement, Crescent has agreed to issue to certain Investors, and such Investors have agreed to purchase, severally and not jointly, an aggregate of&#160;up to $[</font><font style="font-family:'Symbol';">&#183;</font><font style="font-size:11pt;">] of (x) shares (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Initial Shares</b><font style="font-size:11pt;">&#8221;) of Crescent&#8217;s common stock, par value $0.001 per share (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Common Stock</b><font style="font-size:11pt;">&#8221;) and/or (y) pre-funded warrants (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Pre-Funded Warrants</b><font style="font-size:11pt;">&#8221;) to purchase shares of Common Stock, in each case, pursuant to the Purchase Agreement. The Initial Shares and the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants are collectively referred to herein as the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Shares</b><font style="font-size:11pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">C.</font></font><font style="font-size:11pt;">To induce the Investors to enter into the Purchase Agreement, the Company has agreed to provide certain registration rights under the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Securities Act</b><font style="font-size:11pt;">&#8221;), and applicable state securities laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">NOW, THEREFORE,</b><font style="font-size:11pt;"> in consideration of the promises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Crescent, Parent and the Investors hereby agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-size:11pt;font-weight:bold;">DEFINITIONS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">For purposes of this Agreement,</font><font style="font-size:11pt;"> the following terms shall have the following meanings:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Company</b><font style="font-size:11pt;">&#8221; means Crescent for all periods prior to the Effective Time and TopCo for all periods following the Effective Time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Filing Deadline</b><font style="font-size:11pt;">&#8221; means, with respect to the Initial Registration Statement required hereunder, the 30th calendar day following the Closing Date and, with respect to any New Registration Statements or other Registration Statement filed hereunder, the 30th calendar day following the later of (i) date on which the Company is permitted by SEC Guidance to file such New Registration</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><font style="font-size:11pt;">Statement related to the Registrable Securities and (ii) the date on which the Company becomes aware of the necessity of filing such New Registration Statement related to the Registrable Securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Person</b><font style="font-size:11pt;">&#8221; means any individual or entity including but not limited to any corporation, limited liability company, association, </font><font style="font-size:11pt;">partnership</font><font style="font-size:11pt;">, organization, business, individual, governmental or political subdivision thereof or a governmental agency.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Register</b><font style="font-size:11pt;">,&#8221; &#8220;</font><b style="font-size:11pt;font-weight:bold;">Registered</b><font style="font-size:11pt;">,&#8221; and &#8220;</font><b style="font-size:11pt;font-weight:bold;">Registration</b><font style="font-size:11pt;">&#8221; refer to a registration effected by preparing and filing one or more registration statements of the Company in compliance with the Securities Act and providing for offering securities on a continuous basis, and the declaration or ordering of effectiveness of such registration statement(s) by the U.S. Securities and Exchange Commission (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">SEC</b><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Registrable Securities</b><font style="font-size:11pt;">&#8221; means (i) the Shares, (ii) any Shares of Common Stock issued to an Investor on or around the date hereof pursuant to that certain Agreement and Plan of Merger and Reorganization, dated on or around the date hereof, by and among the Company, Crescent Biopharma, Inc., Gemini Merger Sub Corp. and Gemini Merger Sub II, LLC, and (iii) any Common Stock issued or issuable with respect to the foregoing as a result of any stock split or subdivision, stock dividend, recapitalization, exchange or similar event. Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) upon the earliest to occur of (A) the date on which such Investor shall have resold such Registrable Securities covered by the Registration Statement, (B) such Registrable Securities have been previously sold by such Investor in accordance with Rule 144, (C) such securities become eligible for resale by such Investor without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144 and (D) five (5) years after the date of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(f)</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Registration Expenses</b><font style="font-size:11pt;">&#8221; means all registration and filing fee expenses incurred by the Company in effecting any registration pursuant to this Agreement, including (i) all registration, qualification, and filing fees, printing expenses, and any other fees and expenses associated with filings required to be made with the SEC, FINRA or any other regulatory authority, (ii) all fees and expenses in connection with compliance with or clearing the Registrable Securities for sale under any securities or &#8220;Blue Sky&#8221; laws, (iii) all printing, duplicating, word processing, messenger, telephone, facsimile and delivery expenses, and (iv) all fees and disbursements of counsel for the Company and of all independent certified public accountants of the Company (including the expenses of any special audit and cold comfort letters required by or incident to such performance); provided that in no event shall the Company be responsible for any underwriting, broker or similar fees or commissions of any Investor or, except to the extent provided for in the Purchase Agreement, any legal fees or other costs of the Investors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(g)</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Registration Statement</b><font style="font-size:11pt;">&#8221; means any registration statement of the Company filed with, or to be filed with, the SEC under the Securities Act, that Registers Registrable Securities, including the related preliminary or final prospectus, amendments and supplements to such registration statement, including pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement as may be necessary to comply with applicable securities laws. &#8220;Registration Statement&#8221; shall also include a New Registration Statement, as amended when each became effective, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a prospectus subsequently filed with the SEC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(h)</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">SEC Guidance</b><font style="font-size:11pt;">&#8221; means (i) any publicly-available written or oral guidance of the SEC staff, or any comments, requirements or requests of the SEC staff (whether or not publicly-available); provided, that any such oral guidance, comments, requirements or requests are reduced to writing by the SEC (and shared with the Investors upon request if not publicly-available) and (ii) the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Selling Expenses</b><font style="font-size:11pt;">&#8221; means all underwriting discounts and selling commissions applicable to the sale of Registrable Securities and all similar fees and commissions relating to an Investor&#8217;s disposition of its Registrable Securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-size:11pt;font-weight:bold;">REGISTRATION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mandatory Registration</u><font style="font-size:11pt;">. </font><font style="font-size:11pt;">The Company shall, as promptly as reasonably practicable and in any event no later than the Filing Deadline, prepare and file with the SEC an initial Registration Statement (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Initial Registration Statement</b><font style="font-size:11pt;">&#8221;) covering the resale of all Registrable Securities. Before filing the Registration Statement, the Company shall furnish to the Investors a copy of the Registration Statement. The Investors and their respective counsel shall have at least three (3) Business Days prior to the anticipated filing date of a Registration Statement to review and comment upon such Registration Statement and any amendment or supplement to such Registration Statement and any related prospectus (including any documents incorporated by reference therein), prior to its filing with the SEC. The Company shall (a) consider in good faith any comments as the Investor or its counsel reasonably proposed by the Investor to such document prior to being so filed with the SEC, and (b) not file any Registration Statement or related prospectus or any amendment or supplement thereto containing information regarding the Investor to which Investor reasonably believes contains untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, unless such information is required (in the opinion of the Company) to comply with any applicable law or regulation or SEC Guidance. Each Investor shall furnish all information reasonably requested by the Company with respect to such Investor as shall be reasonably required in connection with any registration referred to in this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effectiveness</u><font style="font-size:11pt;">. The Company shall use its commercially reasonable efforts to have the Initial Registration Statement and any amendment declared effective by the SEC at the earliest possible date but no later than the earlier of the sixtieth (60th) calendar day following the initial filing date of the Initial Registration Statement if the SEC notifies the Company that it will &#8220;review&#8221; the Initial Registration Statement and (b) the fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the Initial Registration Statement will not be &#8220;reviewed&#8221; or will not be subject to further review (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Effectiveness Deadline</b><font style="font-size:11pt;">&#8221;). The Company shall notify the Investor by e-mail as promptly as practicable, and in any event, within twenty-four (24) hours, after the Initial Registration Statement is declared effective or is supplemented and shall provide the Investor with copies of any related prospectus to be used in connection with the sale or other disposition of the securities covered thereby. The Company shall use commercially reasonable efforts to keep the Initial Registration Statement continuously effective pursuant to Rule 415 promulgated under the Securities Act and available for the resale by the Investors of all of the Registrable Securities covered thereby at all times until the earlier to occur of the following events: (i) the date on which the Investors shall have resold all the Registrable Securities covered thereby; (ii) the date on which the Registrable Securities may be resold by the Investors without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144 under the Securities Act or any other rule of similar effect and (iii) five (5) years after the date of this Agreement (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Registration Period</b><font style="font-size:11pt;">&#8221;). The Initial Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sufficient Number of Shares Registered</u><font style="font-size:11pt;">. In the event the number of shares available under the Initial Registration Statement at any time is insufficient to cover the Registrable</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Securities, the Company shall, to the extent necessary and permissible, amend the Initial Registration Statement or file a new registration statement (together with any prospectuses or prospectus supplements thereunder, a &#8220;</font><b style="font-size:11pt;font-weight:bold;">New Registration Statement</b><font style="font-size:11pt;">&#8221;), so as to cover all of such Registrable Securities as soon as reasonably practicable, but in any event not later than the Filing Deadline.&#160;The Company shall use its commercially reasonable efforts to have such amendment and/or New Registration Statement become effective as soon as reasonably practicable following the filing thereof but no later than the earlier of (a) the seventy-fifth (75th) calendar day following the initial filing date of the New Registration Statement if the SEC notifies the Company that it will &#8220;review&#8221; the New Registration Statement and (b) the fifth (5th) Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the New Registration Statement will not be &#8220;reviewed&#8221; or will not be subject to further review. The provisions of </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections &#8206;2(a)</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;2(b)</u><font style="font-size:11pt;"> shall apply to the New Registration Statement, except as modified hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allowable Delays</u><font style="font-size:11pt;">. On no more than two (2) occasions in any twelve (12)-month period for not more than thirty (30) consecutive days or for a total of not more than sixty (60) days, the Company may delay the effectiveness of the Initial Registration Statement or any other Registration Statement, or suspend the use of any prospectus included in any Registration Statement, in the event that the Board of Directors reasonably determines, in good faith and upon advice of legal counsel, that such delay or suspension is necessary to (A) delay the disclosure of material non-public information concerning the Company, including in connection with the negotiation or consummation of a material transaction by the Company that is pending, that would require additional disclosure by the Company in the Registration Statement of material non-public information that the Company has a bona fide business purpose for preserving as confidential and the non-disclosure of which would be expected, in the reasonable determination of the Board of Directors, upon advice of legal counsel, to cause the Registration Statement to fail to comply with applicable disclosure requirements, or (B) amend or supplement the affected Registration Statement or the related prospectus so that such Registration Statement or prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the case of the prospectus in light of the circumstances under which they were made, not misleading (an &#8220;</font><b style="font-size:11pt;font-weight:bold;">Allowed Delay</b><font style="font-size:11pt;">&#8221;); </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, that the Company shall promptly (a) notify each Investor in writing of the commencement of an Allowed Delay, but shall not (without the prior written consent of an Investor) disclose to such Investor any material non-public information giving rise to an Allowed Delay, (b) advise the Investors in writing to cease all sales under the applicable Registration Statement until the end of the Allowed Delay and (c) use commercially reasonable efforts to terminate an Allowed Delay as promptly as practicable. Each Investor may deliver written notice (an &#8220;</font><b style="font-size:11pt;font-weight:bold;">Opt-Out Notice</b><font style="font-size:11pt;">&#8221;) to the Company requesting that such Investor not receive notices from the Company otherwise required by this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2</u><font style="font-size:11pt;">; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that such Investor may later revoke any such Opt-Out Notice in writing, which shall be effective five (5) Business Days after the receipt thereof. Following receipt of an Opt-Out Notice from an Investor (unless subsequently revoked), the Company shall not deliver any notices pursuant to this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2(d)</u><font style="font-size:11pt;"> to such Investor and such Investor shall no longer be entitled to the rights associated with any such notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rule&#160;415; Cutback</u><font style="font-size:11pt;">. If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in any Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule&#160;415 under the Securities Act (</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, the Company shall be obligated to use commercially reasonable efforts to advocate with the SEC for the registration of all of the Registrable Securities) or requires any Investor to be named as an &#8220;underwriter,&#8221; the Company shall (i) promptly notify each holder of Registrable Securities thereof and (ii) make commercially reasonable efforts to persuade the SEC that the offering contemplated by such Registration Statement is a valid secondary offering and not an offering &#8220;by or on behalf of the issuer&#8221; as defined in Rule&#160;415 and that none of the Investors is an &#8220;underwriter.&#8221; Each Investor shall have the right to have its legal counsel, at such Investor&#8217;s expense, to review and oversee any registration or matters pursuant to this</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;2(e)</u><font style="font-size:11pt;">, including to comment on any written submission made to the SEC with respect thereto. In the event that, despite the Company&#8217;s commercially reasonable efforts and compliance with the terms of this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;&#8206;2(e)</u><font style="font-size:11pt;">, the SEC refuses to alter its position, the Company shall (i)&#160;remove from such Registration Statement such portion of the Registrable Securities and/or (ii)&#160;agree to such restrictions and limitations on the registration and resale of the Registrable Securities as the SEC may require to assure the Company&#8217;s compliance with the requirements of Rule&#160;415 (collectively, the &#8220;</font><b style="font-size:11pt;font-weight:bold;">SEC Restrictions</b><font style="font-size:11pt;">&#8221;); </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that the Company shall not name any Investor as an &#8220;underwriter&#8221; in such Registration Statement without the prior written consent of such Investor (</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;"> that, in the event an Investor withholds such consent, the Company shall have no obligation hereunder to include any Registrable Securities of such Investor in any Registration Statement covering the resale thereof until such time as the SEC no longer requires such Investor to be named as an &#8220;underwriter&#8221; in such Registration Statement or such Investor otherwise consents in writing to being so named). Any cut-back imposed on the Investors pursuant to this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2(e)</u><font style="font-size:11pt;"> shall be allocated among the Investors on a pro rata basis and shall be applied first to any of the Registrable Securities of an Investor that the SEC has indicated cannot be included or must be limited in the number of Registrable Securities that can be included, and thereafter to all other Investors, unless the SEC Restrictions otherwise require or provides otherwise, or an Investor otherwise agrees.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(f)</font></font><font style="font-size:11pt;">Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another form in accordance with the </font><font style="font-size:11pt;">provisions</font><font style="font-size:11pt;"> of this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2(f)</u><font style="font-size:11pt;">). If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form S-3 as soon as such form is available, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;"> that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the SEC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-size:11pt;font-weight:bold;">RELATED COMPANY OBLIGATIONS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">With respect to the Registration Statement and whenever any Registrable Securities are to be Registered pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2</u><font style="font-size:11pt;">, including on the Initial Registration Statement or on any New Registration Statement, the Company shall use its </font><font style="font-size:11pt;">commercially reasonable </font><font style="font-size:11pt;">efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition thereof and, pursuant thereto, the Company shall have the following obligations:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notifications</u><font style="font-size:11pt;">. The Company will promptly notify the Investors of the time when any subsequent amendment to the Initial Registration Statement or any New Registration Statement, other than documents incorporated by reference, has been filed with the SEC and/or has become effective or where a receipt has been issued therefor or any subsequent supplement to a prospectus has been filed and of any request by the SEC for any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus or for additional information regarding the Investor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments</u><font style="font-size:11pt;">. The Company will prepare and file with the SEC any amendments, post-effective amendments or supplements to the Initial Registration Statement, any New Registration Statement or any related prospectus, as applicable, that, (a) as may be necessary to keep such Registration Statement effective for the Registration Period and to comply with the provisions of the Securities Act and the Exchange Act with respect to the distribution of all of the Registrable Securities covered thereby, or (b) in the reasonable opinion of the Investors and the Company, as may be necessary or advisable in connection with any acquisition or sale of Registrable Securities by the Investors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investor Review</u><font style="font-size:11pt;">. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus, other than documents incorporated by reference, relating to any Investor, the Registrable Securities or the transactions</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">contemplated hereby unless (A) such Investor and its counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from such Investor or its counsel.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Copies Available</u><font style="font-size:11pt;">. The Company will furnish to any Investor whose Registrable Securities are included in any Registration Statement and its counsel copies of the Initial Registration Statement, any prospectus thereunder (including all documents incorporated by reference therein), any prospectus supplement thereunder, any New Registration Statement and all amendments to the Initial Registration Statement or any New Registration Statement that are filed with the SEC during the Registration Period (including all documents filed with or furnished to the SEC during such period that are deemed to be incorporated by reference therein), each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment) and such other documents as such Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Investor that are covered by such Registration Statement, in each case as soon as reasonably practicable upon such Investor&#8217;s request and in such quantities as such Investor may from time to time reasonably request; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that the Company shall not be required to furnish any document to such Investor to the extent such document is available on EDGAR.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notification of Stop Orders; Material Changes</u><font style="font-size:11pt;">. The Company shall use commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if such order is issued, obtain the withdrawal of any such order as soon as practicable. The Company shall advise the Investors promptly (but in no event later than 24 hours) and shall confirm such advice in writing, in each case: (i) of the Company&#8217;s receipt of notice of any request by the SEC or any other federal or state governmental authority for amendment of or a supplement to the Registration Statement or any prospectus or for any additional information; (ii) of the Company&#8217;s receipt of notice of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness of the Initial Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, or any New Registration Statement, or of the Company&#8217;s receipt of any notification of the suspension of qualification of the Registrable Securities for offering or sale in any jurisdiction or the initiation or contemplated initiation of any proceeding for such purpose; and (iii) of the Company becoming aware of the happening of any event, which makes any statement of a material fact made in any Registration Statement or any prospectus untrue or which requires the making of any additions to or changes to the statements then made in any Registration Statement or any prospectus in order to state a material fact required by the Securities Act to be stated therein or necessary in order to make the statements then made therein (in the case of any prospectus, in light of the circumstances under which they were made) not misleading, or of the necessity to amend any Registration Statement or any prospectus to comply with the Securities Act or any other law. The Company shall not be required to disclose to the Investors the substance of specific reasons of any of the events set forth in clauses (i) through (iii) of the immediately preceding sentence (each, a &#8220;</font><b style="font-size:11pt;font-weight:bold;">Suspension Event</b><font style="font-size:11pt;">&#8221;), but rather, shall only be required to disclose that the event has occurred; provided that the Company shall not provide any material non-public information to the Investors in such notice. If at any time the SEC, or any other federal or state governmental authority shall issue any stop order suspending the effectiveness of any Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, the Company shall use its commercially reasonable efforts to obtain the withdrawal of such order at the earliest practicable time. The Company shall furnish to any Investor upon request, without charge, a copy of any correspondence from the SEC or the staff of the SEC, or any other federal or state governmental authority to the Company or its representatives relating to the Initial Registration Statement, any New Registration Statement or any prospectus, or prospectus supplement as the case may be. In the event of a Suspension Event set forth in clause (iii) of the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">second sentence of this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3(e)</u><font style="font-size:11pt;">, the Company will use its commercially reasonable efforts to publicly disclose such event as soon as reasonably practicable, or otherwise resolve the matter such that sales under Registration Statements may resume.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confirmation of Effectiveness</u><font style="font-size:11pt;">. If requested by an Investor at any time in respect of any Registration Statement, the Company shall deliver to such Investor a written confirmation (email being sufficient) from Company&#8217;s counsel of whether or not the effectiveness of such Registration Statement has lapsed at any time for any reason (including, without limitation, the issuance of a stop order) and whether or not such Registration Statement is currently effective and available to the Company for sale of Registrable Securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Listing</u><font style="font-size:11pt;">. The Company shall use commercially reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be listed on the Nasdaq Global Market and/or any other National Exchange upon which the Registrable Securities are listed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance</u><font style="font-size:11pt;">. The Company shall otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final prospectus, including any supplement or amendment thereof, with the SEC pursuant to Rule 424 under the Securities Act, promptly inform the Investor in writing if, at any time during the Registration Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Investor is required to deliver a prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder, and make available to its security holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement covering a period of at least twelve (12) months, beginning after the effective date of each Registration Statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act, including Rule 158 promulgated thereunder (for the purpose of this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3(h)</u><font style="font-size:11pt;">, &#8220;</font><b style="font-size:11pt;font-weight:bold;">Availability Date</b><font style="font-size:11pt;">&#8221; means the forty-fifth (45</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;">) day following the end of the fourth (4</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;">) fiscal quarter that includes the effective date of such Registration Statement, except that, if such fourth (4</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;">) fiscal quarter is the last quarter of the Company&#8217;s fiscal year, &#8220;Availability Date&#8221; means the ninetieth (90</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;">) day after the end of such fourth (4</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;">) fiscal quarter).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Blue-Sky</u><font style="font-size:11pt;">. The Company shall use commercially reasonable efforts to register or qualify or cooperate with any Investor and its counsel in connection with the registration or qualification of such Registrable Securities for the offer and sale under the securities or blue sky laws of such jurisdictions reasonably requested by such Investor; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3(i)</u><font style="font-size:11pt;">, (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;3(i)</u><font style="font-size:11pt;">, or (iii) file a general consent to service of process in any such jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(j)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rule 144</u><font style="font-size:11pt;">. With a view to making available to the Investors the benefits of Rule 144 (or its successor rule) and any other rule or regulation of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, the Company covenants and agrees to use commercially reasonable efforts to make and keep adequate current public information available, as those terms are understood and defined in Rule 144, until the date as all of the Initial Shares may be sold without restriction by the holders thereof pursuant to Rule 144 or any other rule of similar effect (without the requirement for the Company to be in compliance with any current public information requirements). &#160;In addition for so long as any Registrable Securities are outstanding, the Company covenants and agrees to use commercially reasonable efforts to (i) file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act; (ii) furnish electronically to each Investor upon request, as long as such Investor owns any Registrable Securities, (A) a written</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">statement by the Company that it has complied with the reporting requirements of the Exchange Act, (B) a copy of or electronic access to the Company&#8217;s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be reasonably requested in order to avail such Investor of any rule or regulation of the SEC that permits the selling of any such Registrable Securities without registration, and (iii) provide any legal opinions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(k)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation.</u><font style="font-size:11pt;">&#160;The Company shall cooperate with the holders of the Registrable Securities to facilitate the timely preparation and delivery of certificates or uncertificated shares representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule 144 free of any restrictive legends and representing such number of shares of Common Stock and registered in such names as the holders of the Registrable Securities may reasonably request in accordance with the provisions of the Purchase Agreement, and the Company may satisfy its obligations hereunder without issuing physical stock certificates through the use of The Depository Trust Company&#8217;s Direct Registration System.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(l)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal of Restrictive Legends</u><font style="font-size:11pt;">.&#160;Without limiting Section 5.5 of the Purchase Agreement, the Company shall use commercially reasonable efforts to cause the Company&#8217;s transfer agent to remove any restrictive legend from any Registrable Securities, as promptly as practicable following effectiveness of the applicable Registration Statement, without any request for removal being required from any holder of Registrable Securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-size:11pt;font-weight:bold;">OBLIGATIONS OF THE INVESTORS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investor Information</u><font style="font-size:11pt;">. Each Investor shall provide a completed Investor Questionnaire in the form attached hereto as </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u><font style="font-size:11pt;"> or such other form of questionnaire or information required by the Company in connection with the registration of the Registrable Securities within three (3) Business Days of request by the Company and no later than the end of the third (3rd) Business Day following the date on which such Investor receives draft materials in accordance with </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;2(a)</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Suspension of Sales</u><font style="font-size:11pt;">. Each Investor, severally and not jointly with any other Investor, agrees that, upon receipt of any notice from the Company of the existence of an Allowed Delay or Suspension Event, the Investor will promptly discontinue disposition of Registrable Securities pursuant to any Registration Statement covering such Registrable Securities until the Investor&#8217;s receipt of a notice from the Company confirming the resolution of such Allowed Delay or Suspension Event and that such dispositions may again be made.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investor Cooperation</u><font style="font-size:11pt;">. Each Investor, severally and not jointly with any other Investor, agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of any amendments and supplements to any Registration Statement or New Registration Statement hereunder, unless such Investor has notified the Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-size:11pt;font-weight:bold;">EXPENSES OF REGISTRATION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">All Registration Expenses incurred in connection with registrations pursuant to this Agreement shall be borne by the Company. All Selling Expenses relating to securities registered on behalf of an Investor shall be borne by such Investor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-size:11pt;font-weight:bold;">INDEMNIFICATION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend each Investor, each Person, if any, who controls each Investor, the shareholders, directors, officers, partners, employees, members, managers, agents, representatives and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">advisors of each Investor and each Person, if any, who controls any of the foregoing within the meaning of the Securities Act or the Exchange Act (each, an &#8220;</font><b style="font-size:11pt;font-weight:bold;">Indemnified Person</b><font style="font-size:11pt;">&#8221;), against any losses, obligation, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges and costs (including, without limitation, court costs and costs of preparation), reasonable and documented attorneys&#8217; fees, amounts paid in settlement or reasonable and documented expenses (collectively, &#8220;</font><b style="font-size:11pt;font-weight:bold;">Indemnified Damages</b><font style="font-size:11pt;">&#8221;) reasonably incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency or body or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a party thereto (&#8220;</font><b style="font-size:11pt;font-weight:bold;">Claims</b><font style="font-size:11pt;">&#8221;), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration Statement, or (ii) any violation or alleged violation by the Company or any of its Subsidiaries of the Securities Act, Exchange Act or any other state securities or other &#8220;blue sky&#8221; laws of any jurisdiction in which Registrable Securities are offered or any rule or regulation promulgated thereunder applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration of the Registrable Securities (the matters in the foregoing clauses (i) and (ii) being, collectively, &#8220;</font><b style="font-size:11pt;font-weight:bold;">Violations</b><font style="font-size:11pt;">&#8221;).&#160;The Company shall reimburse each Indemnified Person promptly as such Indemnified Damages are incurred and are due and payable, for any reasonable out-of-pocket legal fees or other reasonable and documented expenses incurred by them in connection with investigating or defending any such Claim.&#160;Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6(a)</u><font style="font-size:11pt;">: (A) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company by the Investors or such Indemnified Person specifically for use in such Registration Statement and was reviewed and approved in writing by such Investor or such Indemnified Person expressly for use in connection with the preparation of any Registration Statement; (B) with respect to any superseded prospectus, shall not inure to the benefit of any such Person from whom the Person asserting any such Claim purchased the Registrable Securities that are the subject thereof (or to the benefit of any other Indemnified Person) if the untrue statement or omission of material fact contained in the superseded prospectus was corrected in the revised prospectus, as then amended or supplemented, and the Indemnified Person was promptly advised in writing not to use the outdated, defective or incorrect prospectus prior to the use giving rise to a Violation; (C) shall not be available to the extent such Claim is based on a failure of the Indemnified Person to deliver, or cause to be delivered, if required the prospectus to the Persons asserting an untrue statement or omission or alleged untrue statement or omission at or prior to the written confirmation of the sale of Registrable Securities; and (D) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed.&#160;Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Investor pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;8</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:11pt;">In connection with the Initial Registration Statement, any New Registration Statement or any prospectus, each Investor, severally and not jointly, agrees to indemnify, hold harmless and defend, the Company, each of its directors, and officers who signed the Initial Registration Statement or signs any New Registration Statement, and each Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act (each, an &#8220;</font><b style="font-size:11pt;font-weight:bold;">Indemnified Party</b><font style="font-size:11pt;">&#8221;), against any losses, claims, damages, liabilities and expense (including reasonable attorney fees) resulting from any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration Statement or (ii) any violation or alleged violation by Investor of its obligations under this Agreement, in each case to the extent, and only to the extent, that such violation occurs in reliance upon and in conformity with information about such Investor furnished in writing by such Investor to the Company expressly for use in connection with the preparation of the Registration Statement, any New</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Registration Statement. In no event shall the liability of an Investor be greater in amount than the dollar amount of the proceeds (net of all expense paid by such Investor in connection with any claim relating to this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6</u><font style="font-size:11pt;"> and the amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission) received by such Investor upon the sale of the Registrable Securities included in such Registration Statement giving rise to such indemnification obligation. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6(b)</u><font style="font-size:11pt;">, shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the such Investor, which consent shall not be unreasonably withheld, conditioned or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the Registrable Securities by an Investor pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;8</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:11pt;">Promptly after receipt by an Indemnified Person or Indemnified Party under this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6</u><font style="font-size:11pt;"> of notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect thereof is to be made against any indemnifying party under this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6</u><font style="font-size:11pt;">, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be, and upon such notice, the indemnifying party shall not be liable to the Indemnified Person or the Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified Person or the Indemnified Party in connection with the defense thereof; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that an Indemnified Person or Indemnified Party (together with all other Indemnified Persons and Indemnified Parties that may be represented without conflict by one counsel) shall have the right to retain its own counsel with the reasonable fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such proceeding. The Indemnified Party or Indemnified Person shall cooperate with the indemnifying party in connection with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim.&#160;The indemnifying party shall keep the Indemnified Party or Indemnified Person fully apprised as to the status of the defense or any settlement negotiations with respect thereto.&#160;No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its written consent, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that the indemnifying party shall not unreasonably withhold, delay or condition its consent.&#160;No indemnifying party shall, without the consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise unless such judgment or settlement (i) imposes no liability or obligation on, (ii) includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the Indemnified Party or Indemnified Person in respect to or arising out of such claim or litigation in favor of, and (iii) does not include any admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on behalf of, the Indemnified Party or Indemnified Person.&#160;Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made.&#160;The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6</u><font style="font-size:11pt;">, except to the extent that the indemnifying party is prejudiced in its ability to defend such action.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:11pt;">The indemnification required by this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6</u><font style="font-size:11pt;"> shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred.&#160;Any Person receiving a payment pursuant to this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6</u><font style="font-size:11pt;"> which person is later determined to not be entitled to such payment shall return such payment (including reimbursement of expenses) to the person making it.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:11pt;">The indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-size:11pt;font-weight:bold;">CONTRIBUTION.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6</u><font style="font-size:11pt;"> to the fullest extent permitted by law; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that: (i) no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds (net of all expenses paid by such holder in connection with any claim relating to this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;7</u><font style="font-size:11pt;"> and the amount of any damages such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by such seller from the sale of such Registrable Securities giving rise to such contribution obligation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-size:11pt;font-weight:bold;">ASSIGNMENT OF REGISTRATION RIGHTS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The Company shall not assign this Agreement or any rights or obligations hereunder (whether by operation of law or otherwise) without the prior written consent of the Investors holding a majority of the Registrable Securities then outstanding (determined as if all of the Pre-Funded Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) (voting together as a single class); </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that in any transaction, whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company is a party and in which the Registrable Securities are converted into the equity securities of another Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term &#8220;Company&#8221; shall be deemed to refer to such Person and the term &#8220;Registrable Securities&#8221; shall be deemed to include the securities received by the Investor in connection with such transaction unless such securities are otherwise freely tradable by the Investor after giving effect to such transaction, and the prior written consent of the Investors holding a majority of the Registrable Securities then outstanding (determined as if all of the Pre-Funded Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) shall not be required for such transaction.&#160;No Investor may assign its rights under this Agreement, other than to an affiliate of such Investor or to any other investment funds or accounts managed or advised by the investment manager who acts on behalf of the Investor, without the prior written consent of the Company. The provisions of this Agreement shall be binding upon and inure to the benefit of the Investor and its successors and permitted assigns.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-size:11pt;font-weight:bold;">AMENDMENTS AND WAIVERS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The provisions of this Agreement, including the provisions of this sentence, may be amended, modified or supplemented, or waived only by a written instrument executed by (a) the Company and (b) the holders of a majority of the then outstanding Registrable Securities (determined as if all of the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Pre-Funded Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) (voting together as a single class), </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;"> that (i) any party may give a waiver as to itself, (ii) any amendment, modification, supplement or waiver that disproportionately and adversely affects the rights and obligations of any Investor relative to the comparable rights and obligations of the other Investors shall require the prior written consent of such adversely affected Investor or each Investor, as applicable, and (iii) any amendments to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;6</u><font style="font-size:11pt;"> or to the definitions of &#8220;Filing Deadline,&#8221; &#8220;Effectiveness Deadline,&#8221; or &#8220;Registration Period&#8221; shall require the written consent of each Investor. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of one or more Investors and that does not adversely directly or indirectly affect the rights of other Investors may be given by Investors holding a majority of the Registrable Securities (determined as if all of the Pre-Funded Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) to which such waiver or consent relates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-size:11pt;font-weight:bold;">MISCELLANEOUS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="font-size:11pt;">. Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a) when delivered if personally delivered to the party for whom it is intended, (b) when delivered, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient&#8217;s next business day, provided no rejection or undeliverable notice is received, (c) three (3) days after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">i.</font></font><font style="font-size:11pt;">If to Parent (prior to the Closing), addressed as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;"><font style="font-size:11pt;">GlycoMimetics, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;"><font style="font-size:11pt;">9708 Medical Center Drive</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;"><font style="font-size:11pt;">Rockville, Maryland 20850</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;"><font style="font-size:11pt;">Attention: Christian Dinneen-Long</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Email: cdinneen-long@glycomimetics.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:90pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">with a copy (which shall not constitute notice), prior to the Closing:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;"><font style="font-size:11pt;">Sidley Austin, LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;"><font style="font-size:11pt;">2850 Quarry Lake Drive, Suite 301</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;"><font style="font-size:11pt;">Baltimore, MD 21209</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;"><font style="font-size:11pt;">Attention: Asher Rubin</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Email: arubin@sidley.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">ii.</font></font><font style="font-size:11pt;">If to the Company, addressed as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;"><font style="font-size:11pt;">Crescent Biopharma, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;"><font style="font-size:11pt;">221 Crescent Street, Building 23, Suite 105</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;"><font style="font-size:11pt;">Waltham, Massachusetts 02453</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt;"><font style="font-size:11pt;">Attention: General Counsel</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Email: barbara.bispham@crescentbiopharma.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:90pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">with a copy (which shall not constitute notice):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt;"><font style="font-size:11pt;">Gibson, Dunn &amp; Crutcher LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt;"><font style="font-size:11pt;">One Embarcadero Center, Suite 2600</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt;"><font style="font-size:11pt;">San Francisco, CA 94111</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Attention:  Ryan Murr, Branden Berns; Chris Trester</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:90pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Email: rmurr@gibsondunn.com, bberns@gibsondunn.com; ctrester@gibsondunn.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">iii.</font></font><font style="font-size:11pt;">If to any Investor, at its e-mail address or address set forth on </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u><font style="font-size:11pt;"> to the Purchase Agreement or to such e-mail address, or address as subsequently modified by written notice given in accordance with this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;10</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Any Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Waiver</u><font style="font-size:11pt;">. No failure or delay on the part of either party hereto in the exercise of any power, right or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude any other or further exercise thereof or of any other right, power or privilege.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury</u><font style="font-size:11pt;">. The provisions of Section 8.5 of the Purchase Agreement are incorporated by reference herein </font><i style="font-size:11pt;font-style:italic;">mutatis mutandis</i><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Integration</u><font style="font-size:11pt;">. This Agreement and the other Transaction Agreements (including all schedules and exhibits hereto and thereto) constitute the entire agreement between the parties hereto respecting the subject matter hereof and thereof and supersedes all prior agreements, negotiations, understandings, representations and statements respecting the subject matter hereof and thereof, whether written or oral.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u><font style="font-size:11pt;">. The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="font-size:11pt;">. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction of a) signature.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</u><font style="font-size:11pt;">. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contract Interpretation</u><font style="font-size:11pt;">. This Agreement is the joint product of each Investor and the Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third-Party Beneficiaries</u><font style="font-size:11pt;">. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as expressly provided in this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:54pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(j)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u><font style="font-size:11pt;">. If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(k)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Recourse</u><font style="font-size:11pt;">. Notwithstanding anything that may be expressed or implied in this Agreement, the Company covenants, agrees and acknowledges that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or future director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise be incurred by any current or future director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof, as such for any obligation of the Investors under this Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(l)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</u><font style="font-size:11pt;">. In addition to any and all other remedies that may be available at law in the event of any breach of this Agreement, each Investor shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunction or equitable relief as may be granted by a court of competent jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:54pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(m)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cumulative Remedies</u><font style="font-size:11pt;">. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:11pt;font-style:italic;">[Signature Page Follows]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF,</b><font style="font-size:11pt;"> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PARENT:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">GLYCOMIMETICS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 10pt 0pt;"><i style="font-size:11pt;font-style:italic;">[Signature Page to Registration Rights Agreement]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF,</b><font style="font-size:11pt;"> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CRESCENT:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CRESCENT BIOPHARMA, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 10pt 0pt;"><i style="font-size:11pt;font-style:italic;">[Signature Page to Registration Rights Agreement]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF,</b><font style="font-size:11pt;"> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:46.48%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.2%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">INVESTOR:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">[NAME]</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:bottom;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-style:italic;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 10pt 0pt;"><i style="font-size:11pt;font-style:italic;">[Signature Page to Registration Rights Agreement]</i></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Investor Questionnaire</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">QUESTIONNAIRE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-size:11pt;font-weight:bold;">Name.</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">Full Legal Name of Investor</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:24pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by this Questionnaire):</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">2. Address for Notices to Investor:</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:94.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Telephone:</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:4pt 0pt 0pt 0pt;">E-Mail:</p></td><td style="vertical-align:top;width:94.15%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:11pt;">Contact </font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">Person:</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">3. Broker-Dealer Status:</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">Are you a broker-dealer?</font></p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:20%;" align="center"><tr><td style="vertical-align:top;width:23.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Yes&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:24.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</font></p></td><td style="vertical-align:top;width:20.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">No&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:31.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">If &#8220;yes&#8221; to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?</font></p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:20%;" align="center"><tr><td style="vertical-align:top;width:23.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Yes&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:24.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</font></p></td><td style="vertical-align:top;width:20.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">No&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:31.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">Note:</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">If &#8220;no&#8221; to Section 3(b), the SEC&#8217;s staff has indicated that you should be identified as an underwriter in the Registration Statement.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">Are you an affiliate of a broker-dealer?</font></p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:20%;" align="center"><tr><td style="vertical-align:top;width:23.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Yes&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:24.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</font></p></td><td style="vertical-align:top;width:20.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">No&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:31.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-align:justify;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?</font></p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:20%;" align="center"><tr><td style="vertical-align:top;width:23.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Yes&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:24.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</font></p></td><td style="vertical-align:top;width:20.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">No&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:31.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-align:justify;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">Note:</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">If &#8220;no&#8221; to Section 3(d), the SEC&#8217;s staff has indicated that you should be identified as an underwriter in the Registration Statement.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">4. Beneficial Ownership of Securities of the Company Owned by the Investor.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-size:11pt;font-style:italic;">Except as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable pursuant to the Purchase Agreement.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">Type and Amount of other securities beneficially owned by the Investor:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-align:justify;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">5. Relationships with the Company:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-size:11pt;font-style:italic;">Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">State any exceptions here:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:14.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:45.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:14.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beneficial Owner:</p></td><td style="vertical-align:bottom;width:33.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">PLEASE EMAIL A .PDF COPY OF THE COMPLETED AND EXECUTED QUESTIONNAIRE TO:</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>5
<FILENAME>glyc-20241231xex10d32.htm
<DESCRIPTION>EXHIBIT-10.32
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:21:22 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.32</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-transform:uppercase;">CRESCENT BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">2024 Equity INCENTIVE PLAN</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purpose</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The purpose of this 2024 Equity Incentive Plan (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Plan</b><font style="font-size:11pt;">&#8221;) of Crescent Biopharma, Inc., a Delaware corporation (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Company</b><font style="font-size:11pt;">&#8221;), is to advance the interests of the Company&#8217;s stockholders by enhancing the Company&#8217;s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company&#8217;s stockholders. Except where the context otherwise requires, the term &#8220;Company&#8221; shall include any of the Company&#8217;s present or future parent or subsidiary corporations as defined in Sections&#160;424(e) or (f) of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Code</b><font style="font-size:11pt;">&#8221;) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the Company (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Board</b><font style="font-size:11pt;">&#8221;).</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Eligibility</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">All of the Company&#8217;s employees, officers, directors, consultants and advisors are eligible to be granted options, restricted stock, restricted stock units, and other stock-based awards (each, an &#8220;</font><b style="font-size:11pt;font-weight:bold;">Award</b><font style="font-size:11pt;">&#8221;) under the Plan. Each person who receives an Award under the Plan is deemed a &#8220;</font><b style="font-size:11pt;font-weight:bold;">Participant</b><font style="font-size:11pt;">&#8221;.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration and Delegation</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administration by Board of Directors</u><font style="font-size:11pt;">. The Plan will be administered by the Board. The Board shall have authority to grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may construe and interpret the terms of the Plan and any Award agreements entered into under the Plan. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board&#8217;s sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. No director or person acting pursuant to the authority delegated by the Board shall be liable for any action or determination relating to or under the Plan made in good faith.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appointment of Committees</u><font style="font-size:11pt;">. To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (a &#8220;</font><b style="font-size:11pt;font-weight:bold;">Committee</b><font style="font-size:11pt;">&#8221;). All references in the Plan to the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Board</b><font style="font-size:11pt;">&#8221; shall mean the Board or a Committee of the Board or the officers referred to in Section &#8206;3(c) to the extent that the Board&#8217;s powers or authority under the Plan have been delegated to such Committee or officers. The Board may abolish any Committee at any time, and notwithstanding any delegation of authority, the Board will always retain full authority to take any action permitted under the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delegation to Officers</u><font style="font-size:11pt;">. To the extent permitted by applicable law, the Board may delegate to one or more officers of the Company the power to grant Awards (subject to any limitations under the Plan) to employees or officers of the Company and to exercise such other powers under the Plan as the Board may determine, </font><i style="font-size:11pt;font-style:italic;">provided that</i><font style="font-size:11pt;"> the Board shall fix the terms of the Awards to be granted by such officers (including the exercise price of such Awards, which may include a formula by which the exercise price will be determined) and the maximum number of shares subject to Awards that the officers may grant;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">provided further, however</i><font style="font-size:11pt;">, that no officer shall be authorized to grant Awards to any &#8220;executive officer&#8221; of the Company (as defined by Rule 3b-7 under the Securities Exchange Act of 1934, as amended (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Exchange Act</b><font style="font-size:11pt;">&#8221;)) or to any &#8220;officer&#8221; of the Company (as defined by Rule 16a-1 under the Exchange Act). The Board may rescind any such delegation at any time.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Available for Awards</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Number of Shares</u><font style="font-size:11pt;">. Subject to adjustment under Section &#8206;8 hereof, Awards may be made under the Plan covering up to 2,049,180 shares of common stock of the Company (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Common Stock</b><font style="font-size:11pt;">&#8221;), all of which may be granted as Incentive Stock Options (as defined below). If any Award expires, lapses, or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at or below the original issuance price), in any case in a manner that results in any shares of Common Stock covered by such Award not being issued or being so reacquired by the Company, the unused Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock delivered (whether by actual delivery or attestation) or tendered to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award and/or to satisfy any applicable tax withholding obligation (including shares retained by the Company from the Award being exercised or purchased and/or creating the tax obligation) shall again be available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options, the foregoing provisions shall be subject to any limitations under the Code. Shares of Common Stock issued under the Plan may consist in whole or in part of authorized but unissued shares, shares purchased on the open market, or treasury shares. At no time while there is any Option (as defined below) outstanding and held by a Participant who was a resident of the State of California on the date of grant of such Option, shall the total number of shares of Common Stock issuable upon exercise of all outstanding options and the total number of shares provided for under any stock bonus or similar plan or agreement of the Company exceed the applicable percentage as calculated in accordance with the conditions and exclusions of Section 260.140.45 of the California Code of Regulations (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">California Regulations</b><font style="font-size:11pt;">&#8221;), to the extent applicable, based on the shares of the Company which are outstanding at the time the calculation is made.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Substitute Awards</u><font style="font-size:11pt;">. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted prior to such merger or consolidation by such entity or an affiliate thereof. Substitute Awards may be granted on such terms as the Board deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit set forth in Section &#8206;4(a) hereof, except as may be required by reason of Section 422 and related provisions of the Code.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Options</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u><font style="font-size:11pt;">. The Board may grant options to purchase Common Stock (each, an &#8220;</font><b style="font-size:11pt;font-weight:bold;">Option</b><font style="font-size:11pt;">&#8221;) and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable. An Option that is not intended to be an Incentive Stock Option shall be designated a &#8220;</font><b style="font-size:11pt;font-weight:bold;">Nonstatutory Stock Option</b><font style="font-size:11pt;">&#8221;.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incentive Stock Options</u><font style="font-size:11pt;">. An Option that the Board intends to be an &#8220;incentive stock option&#8221; as defined in Section 422 of the Code (an &#8220;</font><b style="font-size:11pt;font-weight:bold;">Incentive Stock Option</b><font style="font-size:11pt;">&#8221;) shall only be granted to employees of the Company (including any of the Company&#8217;s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Code but excluding any other business venture (including, without</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">limitation, joint venture or limited liability company) in which the Company has a controlling interest). All Options intended to qualify as Incentive Stock Options shall be subject to and shall be construed consistently with the requirements of Section 422 of the Code, and without limiting generality of the foregoing, such Options shall be deemed to include terms that comply with the eligibility standards described Section 422(b) of the Code. Subject to the remaining provisions of this Section &#8206;5(b), if an Option intended to qualify as an Incentive Stock Option does not so qualify, the Board may, at its discretion, amend the Plan and Award with respect to such Option so that such Option qualifies as an Incentive Stock Option. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Participant during any calendar year (under all plans of the Company and any affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with the rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Award. Neither the Company nor the Board shall have any liability to a Participant, or any other party, (i) if an Option (or any part thereof) which is intended to qualify as an Incentive Stock Option fails to qualify as such or (ii) for any action or omission by the Company or Board that causes an Option not to qualify as an Incentive Stock Option, including without limitation the conversion of an Incentive Stock Option to a Nonstatutory Stock Option or the grant of an Option intended as an Incentive Stock Option that fails to satisfy the requirements under the Code applicable to an Incentive Stock Option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Price</u><font style="font-size:11pt;">. The Board shall establish the exercise price of each Option and specify the exercise price in the applicable option agreement. The exercise price shall be not less than 100% of the Fair Market Value on the date the Option is granted. In the case of an Incentive Stock Option granted to an employee who, at the time of grant of the Option, owns (or is treated as owning under Section 424 of the Code) stock representing more than 10% of the voting power of all classes of stock of the Company (or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof within the meaning of Sections 424(e) or 424(f) of the Code, respectively) (such employee, a &#8220;</font><b style="font-size:11pt;font-weight:bold;">10% Holder</b><font style="font-size:11pt;">&#8221;), the per share exercise price shall be no less than 110% of the Fair Market Value on the date the Option is granted.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Duration of Options</u><font style="font-size:11pt;">. Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable option agreement, </font><i style="font-size:11pt;font-style:italic;">provided that</i><font style="font-size:11pt;"> the term of any Option shall not exceed 10 years. In the case of an Incentive Stock Option granted to a 10% Holder, the term of the Option shall not exceed five years.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Option; Notification of Disposition</u><font style="font-size:11pt;">. Options may be exercised by delivery to the Company of a written notice of exercise signed by the proper person or by any other form of notice (including electronic notice) approved by the Board together with payment in full as specified in Section&#160;&#8206;5(f) for the number of shares for which the Option is exercised. Unless otherwise determined by the Board, an Option may not be exercised for a fraction of a share of Common Stock. Shares of Common Stock subject to the Option will be delivered by the Company as soon as practicable following exercise. If an Option is designated as an Incentive Stock Option, the Participant shall give prompt notice to the Company of any disposition or other transfer of any shares of Common Stock acquired from the Option if such disposition or transfer is made (i) within two years from the grant date with respect to such Option or (ii) within one year after the transfer of such shares to the Participant (other than any such disposition made in connection with a Reorganization Event). Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by the Participant in such disposition or other transfer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment Upon Exercise</u><font style="font-size:11pt;">. Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:11pt;">in cash or by check, payable to the order of the Company;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font></font><font style="font-size:11pt;">when the Common Stock is registered under the Exchange Act, except as may otherwise be provided in the applicable option agreement, by (A) delivery of an irrevocable and unconditional undertaking by a creditworthy broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (B) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(iii)</font></font><font style="font-size:11pt;">when the Common Stock is registered under the Exchange Act and to the extent provided for in the applicable option agreement or approved by the Board, in its sole discretion, by delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their fair market value as determined by (or in a manner approved by) the Board (&#8220;</font><b style="font-size:11pt;font-weight:bold;">Fair Market Value</b><font style="font-size:11pt;">&#8221;), </font><i style="font-size:11pt;font-style:italic;">provided</i><font style="font-size:11pt;"> (A) such method of payment is then permitted under applicable law, (B) such Common Stock, if acquired directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (C) such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(iv)</font></font><font style="font-size:11pt;">to the extent permitted by applicable law and provided for in the applicable option agreement or approved by the Board, in its sole discretion, by (A) delivery of a promissory note of the Participant to the Company on terms determined by the Board, or (B)&#160;payment of such other lawful consideration as the Board may determine;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(v)</font></font><font style="font-size:11pt;">to the extent provided for in the applicable option agreement or approved by the Board, in its sole discretion, by having the Company retain from the shares of Common Stock otherwise issuable upon the exercise of such Option a number of shares valued at their Fair Market Value; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(vi)</font></font><font style="font-size:11pt;">by any combination of the above permitted forms of payment or any other lawful consideration as approved by the Board in its sole discretion.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Early Exercise of Options</u><font style="font-size:11pt;">. The Board may provide in the terms of an option agreement that the Participant may exercise an Option in whole or in part prior to the full vesting of the Option in exchange for unvested shares of Restricted Stock (as defined below) with respect to any unvested portion of the Option so exercised. Shares of Restricted Stock acquired upon the exercise of any unvested portion of an Option shall be subject to such terms and conditions as the Board shall determine.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock; Restricted Stock Units</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u><font style="font-size:11pt;">. The Board may grant Awards entitling recipients to acquire shares of Common Stock (&#8220;</font><b style="font-size:11pt;font-weight:bold;">Restricted Stock</b><font style="font-size:11pt;">&#8221;), subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the recipient in the event that conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. The Board may also grant Awards entitling the recipient to receive shares of Common Stock or cash to be delivered at or following the time such Award vests (&#8220;</font><b style="font-size:11pt;font-weight:bold;">Restricted Stock Units</b><font style="font-size:11pt;">&#8221; or &#8220;</font><b style="font-size:11pt;font-weight:bold;">RSUs</b><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Terms and Conditions</u><font style="font-size:11pt;">. The Board shall determine and set forth in the applicable award agreement the terms and conditions of Restricted Stock or RSUs, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Provisions Relating to Restricted Stock</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividends</u><font style="font-size:11pt;">. Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such shares to the extent such dividends have a record date that is on or after the date on which the Participant to whom such Restricted Stock is granted becomes the record holder of such Restricted Stock, unless otherwise provided by the Board. Unless otherwise provided by the Board, if any dividends or distributions are paid in shares, or consist of a dividend or distribution to holders of Common Stock other than an ordinary cash dividend, the shares or other property will be subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid. Each dividend payment will be made as provided in the applicable award agreement, but no later than the end of the calendar year in which the dividends are paid to shareholders of that class of stock or, if later, the 15th day of the third month following the later of (A) the date the dividends are paid to shareholders of that class of stock and (B) the date the dividends are no longer subject to forfeiture.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Certificates</u><font style="font-size:11pt;">. The Company may require that any stock certificates issued in respect of shares of Restricted Stock shall be deposited in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). At the expiration of the applicable restriction periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to the beneficiary designated, in a manner determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant&#8217;s death (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Designated Beneficiary</b><font style="font-size:11pt;">&#8221;). In the absence of an effective designation by a Participant, &#8220;Designated Beneficiary&#8221; shall mean the Participant&#8217;s estate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Provisions Relating to Restricted Stock Units</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Settlement</u><font style="font-size:11pt;">. Upon or following the vesting of a Restricted Stock Unit, the Participant shall be entitled to receive from the Company one share of Common Stock or an amount of cash or other property equal to the Fair Market Value of one share of Common Stock on the settlement date (or such other date), as the Board shall determine and as provided in the applicable award agreement. The Board may provide that settlement of Restricted Stock Units shall occur upon or as soon as reasonably practicable after the vesting of the Restricted Stock Units or shall instead be deferred, on a mandatory basis or at the election of the Participant, in a manner that complies with Section 409A of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voting Rights</u><font style="font-size:11pt;">. A Participant shall have no voting rights with respect to any Restricted Stock Units unless and until shares are delivered in settlement thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(iii)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dividend Equivalents</u><font style="font-size:11pt;">. To the extent provided by the Board, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, may be settled in cash and/or shares of Common Stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are paid, as determined by the Board, subject, in each case, to such terms and conditions as the Board shall establish and set forth in the applicable award agreement. &#8220;</font><b style="font-size:11pt;font-weight:bold;">Dividend Equivalents</b><font style="font-size:11pt;">&#8221; means a right granted to a Participant to receive the equivalent value (in cash or shares of Common Stock) of dividends paid on shares of Common Stock.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Stock-Based Awards</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, shares of Common Stock or other property, may be granted hereunder to Participants (&#8220;</font><b style="font-size:11pt;font-weight:bold;">Other Stock-Based Awards</b><font style="font-size:11pt;">&#8221;), including without limitation stock appreciation rights (which shall be subject to the same limitations applicable to awards of Nonstatutory Stock Options)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">and Awards entitling recipients to receive shares of Common Stock to be delivered in the future. Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall determine. Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other Stock-Based Award, including any purchase price, transfer restrictions, vesting conditions and other terms and conditions applicable thereto.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustments for Changes in Common Stock and Certain Other Events</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off, merger, consolidation, liquidation, reorganization, or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i) the number and class of securities available under this Plan, (ii) the number and class of securities and exercise price per share of each outstanding Option, (iii) the number of shares subject to and the repurchase price per share subject to each other outstanding Award, and (iv) the terms of each other outstanding Award shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner determined by the Board; </font><i style="font-size:11pt;font-style:italic;">provided that</i><font style="font-size:11pt;">, unless otherwise determined by the Board, such changes to the Options shall comply with Section 1.424-1 of the Treasury Regulations and Section 409A of the Code. Without limiting the generality of the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then a Participant who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reorganization Events and Change in Control</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(A)</font><font style="display:inline-block;width:20.73pt;"></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Beneficial Owner</b><font style="font-size:11pt;">&#8221; shall have the meaning set forth in Rule 13d-3 under the Exchange Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(B)</font><font style="display:inline-block;width:21.34pt;"></font><font style="font-size:11pt;">A &#8220;</font><b style="font-size:11pt;font-weight:bold;">Change in Control</b><font style="font-size:11pt;">&#8221; means, except as otherwise provided in an Award agreement, the occurrence of any one of the following events:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(I)</font><font style="display:inline-block;width:25.01pt;"></font><font style="font-size:11pt;">any Person (as defined below) (other than any Designated Affiliate (as defined below)) is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including the securities beneficially owned by such Person or any securities acquired directly from the Company or any entity in which the Company has a substantial direct or indirect equity interest, as determined by the Board from time to time (an &#8220;</font><b style="font-size:11pt;font-weight:bold;">Affiliate</b><font style="font-size:11pt;">&#8221;)) representing 50% or more of the combined voting power of the Company&#8217;s then outstanding securities, excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in clause (III)(1) or (2) below;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(II)</font><font style="display:inline-block;width:21.35pt;"></font><font style="font-size:11pt;">the following individuals cease for any reason to constitute a majority of the number of directors then serving: (1) individuals who, on the Effective Date (as defined below), constitute the Board and (2) any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board or nomination for</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">election by the Company&#8217;s stockholders was approved or recommended by a vote of at least a majority of the directors then still in office who were either directors on the Effective Date or whose appointment, election or nomination for election was previously so approved or recommended;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(III)</font><font style="display:inline-block;width:17.68pt;"></font><font style="font-size:11pt;">there is consummated a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other entity (other than with any Designated Affiliate), other than (1) a merger or consolidation which would result in the holders of the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) at least 50% of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, or (2) a reverse merger or similar transaction;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(IV)</font><font style="display:inline-block;width:17.07pt;"></font><font style="font-size:11pt;">the implementation of a plan of complete liquidation or dissolution of the Company; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(V)</font><font style="display:inline-block;width:20.73pt;"></font><font style="font-size:11pt;">there is consummated a sale or disposition by the Company of all or substantially all of the Company&#8217;s assets, other than a sale or disposition by the Company of all or substantially all of the Company&#8217;s assets to (1) an entity, at least 50% of the combined voting power of the voting securities of which is owned by stockholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale or (2) any Designated Affiliate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(C)</font><font style="display:inline-block;width:21.34pt;"></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Designated Affiliates</b><font style="font-size:11pt;">&#8221; means Fairmount Healthcare Fund II, L.P., its respective Controlled Affiliates, and any entity in which any such entity has a substantial direct or indirect equity interest, as determined by the Board from time to time; provided, however, that Fairmount Healthcare Fund II, L.P., its Controlled Affiliates, and any entity in which any such entity has a substantial direct or indirect equity interest, as determined by the Board from time to time, will cease to be Designated Affiliates at the time they no longer are the Beneficial Owner of securities of the Company represents at least 10% of the combined voting power of the Company&#8217;s then outstanding securities. For purposes of this definition, &#8220;</font><b style="font-size:11pt;font-weight:bold;">Controlled Affiliates</b><font style="font-size:11pt;">&#8221; means any Person referred to in the preceding sentence that, directly or indirectly, through one or more intermediaries, is controlling, controlled by, or under common control with, such other Person.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(D)</font><font style="display:inline-block;width:20.73pt;"></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Person</b><font style="font-size:11pt;">&#8221; shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 14(d) and 15(d) thereof, except that such term shall not include (I) the Company or any of its Affiliates, (II) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its subsidiaries, (III) an underwriter temporarily holding securities pursuant to an offering of such securities or (IV) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(E)</font><font style="display:inline-block;width:21.95pt;"></font><font style="font-size:11pt;">A &#8220;</font><b style="font-size:11pt;font-weight:bold;">Reorganization Event</b><font style="font-size:11pt;">&#8221; means the consummation of: (I) the dissolution or liquidation of the Company, (II) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated Person, (III) a merger, reorganization or consolidation pursuant to which all or substantially all of the Persons who were Beneficial Owners of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own, directly or indirectly, a majority (determined on an as-converted basis) of the outstanding voting power of the surviving or resulting entity (or its ultimate parent, if applicable), (IV) the acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of a related transactions by a Person or group of Persons, or (V)&#160;any other acquisition of the business of the Company, as determined by the Board; </font><i style="font-size:11pt;font-style:italic;">provided, however</i><font style="font-size:11pt;">, that the first firm commitment underwritten public offering pursuant to an effective registration</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">statement under the Securities Act of 1933, as amended, covering the offer and sale by the Company of its equity securities, as a result of or following which the Common Stock shall be public, any subsequent public offering or another capital raising event, or a merger effected solely to change the Company&#8217;s domicile shall not constitute a &#8220;Reorganization Event.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consequences of a Reorganization Event or Change in Control on Awards</u><font style="font-size:11pt;">. In connection with a Reorganization Event and/or a Change in Control, the Board may take any one or more of the following actions as to all or any (or any portion of) outstanding Awards on such terms as the Board determines: (A)&#160;provide that Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof); </font><i style="font-size:11pt;font-style:italic;">provided that</i><font style="font-size:11pt;">, unless otherwise determined by the Board, such assumption or substitution of the Options shall comply with Section 1.424-1 of the Treasury Regulations and Section 409A of the Code, (B)&#160;upon written notice to a Participant, provide that the Participant&#8217;s unexercised Awards will terminate immediately prior to the consummation of such Reorganization Event unless exercised by the Participant within a specified period following the date of such notice, (C)&#160;provide that outstanding Awards shall become vested, exercisable, realizable, or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (D)&#160;in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share surrendered in the Reorganization Event (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Acquisition Price</b><font style="font-size:11pt;">&#8221;), make or provide for a cash payment to a Participant equal to the excess, if any, of (I)&#160;the Acquisition Price times the number of shares of Common Stock subject to the Participant&#8217;s Awards (to the extent the exercise price does not equal or exceed the Acquisition Price) over (II) the aggregate exercise price of all such outstanding Awards and any applicable tax withholdings, in exchange for the termination of such Awards (and the Board may cancel and terminate without payment or consideration any Award with an exercise price equal to or in excess of the Acquisition Price), (E)&#160;provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise price thereof and any applicable tax withholdings) and (F) any combination of the foregoing. In taking any of the actions permitted under this Section &#8206;8(b), the Board shall not be obligated by the Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type, identically.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">For purposes of clause (A) above, an Option shall be considered assumed if, following consummation of the Reorganization Event or Change in Control, the Option confers the right to purchase, for each share of Common Stock subject to the Option immediately prior to the consummation of the Reorganization Event or Change in Control, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event or Change in Control by holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the Reorganization Event or Change in Control (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); </font><i style="font-size:11pt;font-style:italic;">provided, however</i><font style="font-size:11pt;">, that if the consideration received as a result of the Reorganization Event or Change in Control is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise of Options to consist solely of common stock of the acquiring or succeeding corporation (or an affiliate thereof) equivalent in value (as determined by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event or Change in Control.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Provisions Applicable to Awards</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transferability of Awards</u><font style="font-size:11pt;">. Except as the Board may otherwise determine or provide in an Award, Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">distribution or, other than in the case of an Incentive Stock Option, pursuant to a qualified domestic relations order, and during the life of the Participant, shall be exercisable only by the Participant. Notwithstanding the foregoing, as permitted by the Committee, a Participant may transfer or assign an Award as a gift to any &#8220;family member&#8221; (as such term is defined in Rule 701 promulgated under the Securities Act) (an &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Assignee Entity</font><font style="font-size:11pt;">&#8221;), provided that such Assignee Entity shall be entitled to exercise assigned Options and Stock Appreciation Rights only during the lifetime of the assigning Participant (or following the assigning Participant&#8217;s death, by the Participant&#8217;s beneficiaries or as otherwise permitted by the Committee) and provided further that such Assignee Entity shall not further sell, pledge, transfer, assign, or otherwise alienate or hypothecate such Award. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Documentation</u><font style="font-size:11pt;">. Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each Award may contain terms and conditions in addition to those set forth in the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board Discretion</u><font style="font-size:11pt;">. Except as otherwise provided by the Plan, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Status</u><font style="font-size:11pt;">. The Board shall determine the effect on an Award of the disability, death, retirement, termination or other cessation of employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant&#8217;s legal representative, conservator, guardian or Designated Beneficiary, may exercise rights under the Award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font> <font style="font-size:11pt;">For purposes of the Plan, &#8220;</font><b style="font-size:11pt;font-weight:bold;">Cause</b><font style="font-size:11pt;">&#8221; has the meaning set forth in the written employment, offer, services or severance agreement or letter between the Participant and the Company or its subsidiary, or in any severance plan in which the Participant participates, or if there is no such agreement or plan or no such term is defined in such agreement or plan, means (A) the Participant&#8217;s dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (B) the Participant&#8217;s conviction or plea of no contest to (1) a felony or (2) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (C) the Participant&#8217;s failure to perform in all material respects the Participant&#8217;s assigned duties and responsibilities; (D) the Participant&#8217;s gross negligence, willful misconduct that results in or is reasonably anticipated to result in harm to the Company; or (E) the Participant&#8217;s violation of any material provision of any agreement(s) between the Participant and the Company or its subsidiary or any Company policies including, without limitation, agreements relating to non-competition, non-solicitation, non-disparagement, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font></font><font style="font-size:11pt;">For purposes of the Plan, &#8220;</font><b style="font-size:11pt;font-weight:bold;">Disability</b><font style="font-size:11pt;">&#8221; shall mean a permanent and total disability within the meaning of Section 22(e)(3) of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding</u><font style="font-size:11pt;">. The Company shall not be obligated to deliver certificates, release from forfeiture, otherwise recognize a Participant&#8217;s unrestricted ownership in an Award or the cash or property proceeds therefrom, until the Company satisfies all applicable federal, state, and local or other income and employment tax withholding obligations. In its sole discretion, the Company may satisfy such withholding obligations by any of the following means or by a combination of such means: (i) causing the Participant to tender to the Company cash payment; (ii) withholding cash from an Award settled in cash; (iii)&#160;withholding from amounts otherwise payable by the Company to the Participant, including but not</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">limited to additional withholding on the Participant&#8217;s salary or wages, or from proceeds from the sale of Common Stock issued pursuant to an Award; (iv) delivery of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value; </font><i style="font-size:11pt;font-style:italic;">provided, however</i><font style="font-size:11pt;">, except as otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company&#8217;s maximum statutory withholding obligations (based on maximum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income), and </font><i style="font-size:11pt;font-style:italic;">provided, further</i><font style="font-size:11pt;">, shares surrendered to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements; or (v) by such other method as determined by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment of Award</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:11pt;">The Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or settlement, and converting an Incentive Stock Option to a Nonstatutory Stock Option. The Participant&#8217;s consent to such action shall be required unless (A) the Board determines that the action, taking into account any related action, would not materially and adversely affect the Participant&#8217;s rights under the Plan, (B) the change is permitted under Section &#8206;8 hereof, or (C) the change is to ensure that an Option intended to qualify as an Incentive Stock Option qualifies as such.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font></font><font style="font-size:11pt;">The Board may, without stockholder approval, amend any outstanding Award granted under the Plan to provide an exercise price per share that is lower than the then-current exercise price per share of such outstanding Award. The Board may also, without stockholder approval, cancel any outstanding award (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan covering the same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions on Delivery of Stock</u><font style="font-size:11pt;">. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove restrictions from shares previously delivered under the Plan until (i) all conditions of the Award have been met or removed to the satisfaction of the Company, (ii)&#160;in the opinion of the Company&#8217;s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and any applicable stock exchange or stock market rules and regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is determined by the Board to be necessary to the lawful issuance and sale of any securities hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such shares as to which such requisite authority was not obtained.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acceleration</u><font style="font-size:11pt;">. The Board may at any time provide that any Award shall become immediately exercisable in full or in part, free of some or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Right To Employment or Other Status</u><font style="font-size:11pt;">. No person shall have any claim or right to be granted an Award, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan, except as expressly provided in the applicable Award.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Rights As Stockholder</u><font style="font-size:11pt;">. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder of such shares. Notwithstanding any other provision of the Plan, unless otherwise determined by the Board or required by any applicable laws, the Company shall not be required to deliver to any Participant certificates evidencing shares of Common Stock issued in connection with any Award and instead such shares of Common Stock may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on any stock certificates issued under the Plan deemed necessary or appropriate by the Board in order to comply with applicable laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date and Term of Plan</u><font style="font-size:11pt;">. The Plan shall become effective on the date on which it is adopted by the Board (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Effective Date</b><font style="font-size:11pt;">&#8221;). No Awards shall be granted under the Plan after the expiration of 10 years from the earlier of (i) the Effective Date or (ii) the date the Plan was approved by the Company&#8217;s stockholders, but Awards previously granted may extend beyond that date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment of Plan</u><font style="font-size:11pt;">. The Board may amend, suspend or terminate the Plan or any portion thereof at any time; </font><i style="font-size:11pt;font-style:italic;">provided that</i><font style="font-size:11pt;"> if at any time the approval of a Company stockholder is required as to any modification or amendment under Section 422 of the Code or any successor provision with respect to Incentive Stock Options or pursuant to any other applicable law or regulation, the Board may not effect such modification or amendment without stockholder approval. Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance with this Section &#8206;10(d) shall apply to, and be binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, </font><i style="font-size:11pt;font-style:italic;">provided</i><font style="font-size:11pt;"> the Board determines that such amendment does not materially and adversely affect the rights of Participants under the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization of Sub-Plans</u><font style="font-size:11pt;">. The Board may from time to time establish one or more sub-plans under the Plan for purposes of satisfying applicable blue sky, securities or tax laws of various jurisdictions. The Board shall establish such sub-plans by adopting supplements to this Plan containing (i)&#160;such limitations on the Board&#8217;s discretion under the Plan as the Board deems necessary or desirable or (ii)&#160;such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not the subject of such supplement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Code Section 409A</u><font style="font-size:11pt;">. Unless otherwise expressly provided for in an Award, the Plan and Award will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&#160;409A of the Code, and, to the extent not so exempt, in compliance with Section&#160;409A of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&#160;409A of the Code, the Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section&#160;409A(a)(1) of the Code, and to the extent an Award is silent on terms necessary for compliance, such terms as deemed necessary by the Board in its sole discretion are hereby incorporated by reference into the Award. Without limiting the generality of the foregoing, if shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section 409A of the Code is a &#8220;specified employee&#8221; for purposes of Section 409A of the Code, no distribution or payment of any amount that is due because of a &#8220;separation from service&#8221; (as defined in Section 409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months following the date of such Participant&#8217;s &#8220;separation from service&#8221; or, if earlier, the date of the Participant&#8217;s death, unless such distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">balance paid thereafter on the original schedule. The Company shall have no liability to a Participant, or any other party, if an Award that is intended to be exempt from, or compliant with, Section 409A of the Code is not so exempt or compliant or for any other action taken by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="font-size:11pt;">. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than such state.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Privacy</u><font style="font-size:11pt;">. As a condition of receipt of any Award, each Participant explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this paragraph by and among, as applicable, the Company and its subsidiaries and affiliates for the exclusive purpose of implementing, administering and managing the Participant&#8217;s participation in the Plan. The Company and its subsidiaries and affiliates may hold certain personal information about a Participant, including but not limited to, the Participant&#8217;s name, home address and telephone number, date of birth, social security or insurance number or other identification number, salary, nationality, job title(s), any shares of stock held in the Company or any of its subsidiaries and affiliates, details of all Awards, in each case, for the purpose of implementing, managing and administering the Plan and Awards (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Data</b><font style="font-size:11pt;">&#8221;). The Company and its subsidiaries and affiliates may transfer the Data amongst themselves as necessary for the purpose of implementation, administration and management of a Participant&#8217;s participation in the Plan, and the Company and its subsidiaries and affiliates may each further transfer the Data to any third parties assisting the Company in the implementation, administration and management of the Plan. These recipients may be located in the Participant&#8217;s country, or elsewhere, and the Participant&#8217;s country may have different data privacy laws and protections than the recipients&#8217; country. Through acceptance of an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing the Participant&#8217;s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Company or the Participant may elect to deposit any shares of Common Stock. The Data related to a Participant will be held only as long as is necessary to implement, administer, and manage the Participant&#8217;s participation in the Plan. A Participant may, at any time, view the Data held by the Company with respect to such Participant, request additional information about the storage and processing of the Data with respect to such Participant, recommend any necessary corrections to the Data with respect to the Participant or refuse or withdraw the consents herein in writing, in any case without cost, by contacting his or her local human resources representative. The Company may cancel Participant&#8217;s ability to participate in the Plan and, in the Board&#8217;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws his or her consents as described herein. For more information on the consequences of refusal to consent or withdrawal of consent, Participants may contact their local human resources representative.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictions on Shares; Clawback Provisions</u><font style="font-size:11pt;">. Shares of Common Stock acquired in respect of Awards shall be subject to such terms and conditions as the Board shall determine, including, without limitation, restrictions on the transferability of shares of Common Stock, the right of the Company to repurchase shares of Common Stock, the right of the Company to require that shares of Common Stock be transferred in the event of certain transactions, tag-along rights, bring-along rights, redemption and co-sale rights and voting requirements. Such terms and conditions may be additional to those contained in the Plan and may, as determined by the Board, be contained in the applicable Award agreement or in an exercise notice, stockholders&#8217; agreement or in such other agreement as the Board shall determine, in each case in a form determined by the Board. The issuance of such shares of Common Stock shall be conditioned on the Participant&#8217;s consent to such terms and conditions and the Participant&#8217;s entering into such agreement or agreements. All Awards (including any proceeds, gains or other economic benefit actually or constructively received by Participant upon any receipt or exercise of any Award or upon the receipt or resale of any shares</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">of Common Stock underlying the Award) shall be subject to the provisions of any clawback policy implemented by the Company, including, without limitation, any clawback policy adopted to comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder, to the extent set forth in such clawback policy and/or in the applicable Award agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-transform:uppercase;">CRESCENT BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">2024 Equity INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-transform:uppercase;">CALIFORNIA SUPPLEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Pursuant to Section &#8206;10(e) of the Plan, the Board has adopted this supplement for purposes of satisfying the requirements of Section 25102(o) of the California Corporations Code:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Any Awards granted under the Plan to a Participant who is a resident of the State of California on the date of grant (a &#8220;</font><b style="font-size:11pt;font-weight:bold;">California Participant</b><font style="font-size:11pt;">&#8221;) shall be subject to the following additional limitations, terms and conditions:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Limitations on Options</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maximum Duration of Options</u><font style="font-size:11pt;">. No Options granted to California Participants shall have a term in excess of 10 years measured from the Option grant date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Minimum Exercise Period Following Termination</u><font style="font-size:11pt;">. Unless a California Participant&#8217;s employment is terminated for cause (as defined by applicable law, the terms of any contract of employment between the Company and such Participant, or in the instrument evidencing the grant of such Participant&#8217;s Option), in the event of termination of employment of such Participant, such Participant shall have the right to exercise an Option, to the extent that he or she was otherwise entitled to exercise such Option on the date employment terminated, as follows: (i) at least six months from the date of termination, if termination was caused by such Participant&#8217;s death or &#8220;permanent and total disability&#8221; (within the meaning of Section&#160;22(e)(3) of the Code) and (ii) at least 30 days from the date of termination, if termination was caused other than by such Participant&#8217;s death or &#8220;permanent and total disability&#8221; (within the meaning of Section 22(e)(3) of the Code).</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Limitations for Other Stock-Based Awards</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The terms of all Awards granted to a California Participant under Section &#8206;7 of the Plan shall comply, to the extent applicable, with Section 260.140.41 or Section 260.140.42 of the California Regulations.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Requirement to Provide Information to California Participants</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">To the extent required by Section 260.140.46 of the California Regulations, the Company shall provide to each California Participant and to each California Participant who acquires Common Stock pursuant to the Plan, not less frequently than annually, copies of annual financial statements (which need not be audited). The Company shall not be required to provide such statements to key employees whose duties in connection with the Company assure their access to equivalent information.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Limitations on Timing of Awards</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">No Award granted to a California Participant shall become exercisable, vested or realizable, as applicable to such Award, unless the Plan has been approved by the holders of a majority of the Company&#8217;s outstanding voting securities within 12 months before or after the date the Plan was adopted by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Restriction Regarding Recapitalizations, Stock Splits, Etc</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">For purposes of Section &#8206;8 of the Plan, in the event of a stock split, reverse stock split, stock dividend, recapitalization, combination, reclassification or other distribution of the Company&#8217;s securities, the number of securities allocated to each California Participant must be adjusted proportionately and without the receipt by the Company of any consideration from any California Participant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">A-2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">First </b><b style="font-weight:bold;">AMENDMENT TO THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">2024 EQUITY INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Crescent Biopharma, Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), maintains the Crescent Biopharma, Inc. 2024 Equity Incentive Plan (the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, pursuant to Section 10(d) of the Plan, the Board may amend the Plan at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, pursuant to its authority under Section 10(d) of the Plan, the Board hereby amends the Plan as follows, effective as of December 11, 2024 (the &#8220;<b style="font-weight:bold;">Amendment Effective Date</b>&#8221;):</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The first sentence of Section 4(a) of the Plan is hereby amended and restated in its entirety to read as follows:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 36pt 12pt 36pt;">&#8220;Subject to adjustment under Section &#8206;8 hereof, Awards may be made under the Plan covering up to 8,672,190 shares of common stock of the Company (the &#8220;<b style="font-weight:bold;">Common Stock</b>&#8221;), all of which may be granted as Incentive Stock Options (as defined below).&#8221;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This amendment shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than such state.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">All capitalized terms used but not otherwise defined herein shall have the meaning assigned to them in the Plan. Except as expressly amended hereby, the Plan shall remain in full force and effect in accordance with its terms.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Signature Page Follows]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the undersigned has executed this First Amendment to the Crescent Biopharma, Inc. 2024 Equity Incentive Plan, effective as of the Amendment Effective Date.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CRESCENT BIOPHARMA, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jonathan Violin</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jonathan Violin</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and President</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">SIGNATURE PAGE TO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">FIRST AMENDMENT TO THE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CRESCENT BIOPHARMA, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024 EQUITY INCENTIVE PLAN</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Second </b><b style="font-weight:bold;">AMENDMENT TO THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">2024 EQUITY INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Crescent Biopharma, Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), maintains the Crescent Biopharma, Inc. 2024 Equity Incentive Plan (as amended, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, pursuant to Section 10(d) of the Plan, the Board may amend the Plan at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, pursuant to its authority under Section 10(d) of the Plan, the Board hereby amends the Plan as follows, effective as of December 27, 2024 (the &#8220;<b style="font-weight:bold;">Amendment Effective Date</b>&#8221;):</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The first sentence of Section 4(a) of the Plan is hereby amended and restated in its entirety to read as follows:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 36pt 12pt 36pt;">&#8220;Subject to adjustment under Section 8 hereof, Awards may be made under the Plan covering up to 9,403,725 shares of common stock of the Company (the &#8220;<b style="font-weight:bold;">Common Stock</b>&#8221;), all of which may be granted as Incentive Stock Options (as defined below).&#8221;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This amendment shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than such state.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">All capitalized terms used but not otherwise defined herein shall have the meaning assigned to them in the Plan. Except as expressly amended hereby, the Plan shall remain in full force and effect in accordance with its terms.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Signature Page Follows]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the undersigned has executed this Second Amendment to the Crescent Biopharma, Inc. 2024 Equity Incentive Plan, effective as of the Amendment Effective Date.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CRESCENT BIOPHARMA, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jonathan Violin</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jonathan Violin</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and President</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">SIGNATURE PAGE TO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">SECOND AMENDMENT TO THE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CRESCENT BIOPHARMA, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024 EQUITY INCENTIVE PLAN</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">THIRD </b><b style="font-weight:bold;">AMENDMENT TO THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">2024 EQUITY INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Crescent Biopharma, Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), maintains the Crescent Biopharma, Inc. 2024 Equity Incentive Plan (as amended, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, pursuant to Section 10(d) of the Plan, the Board may amend the Plan at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, pursuant to its authority under Section 10(d) of the Plan, the Board hereby amends the Plan as follows, effective as of January 13, 2025 (the &#8220;<b style="font-weight:bold;">Amendment Effective Date</b>&#8221;):</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The first sentence of Section 4(a) of the Plan is hereby amended and restated in its entirety to read as follows:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 36pt 12pt 36pt;">&#8220;Subject to adjustment under Section 8 hereof, Awards may be made under the Plan covering up to 11,094,669 shares of common stock of the Company (the &#8220;<b style="font-weight:bold;">Common Stock</b>&#8221;), all of which may be granted as Incentive Stock Options (as defined below).&#8221;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This amendment shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than such state.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">All capitalized terms used but not otherwise defined herein shall have the meaning assigned to them in the Plan. Except as expressly amended hereby, the Plan shall remain in full force and effect in accordance with its terms.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[Signature Page Follows]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the undersigned has executed this Third Amendment to the Crescent Biopharma, Inc. 2024 Equity Incentive Plan, effective as of the Amendment Effective Date.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CRESCENT BIOPHARMA, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jonathan Violin</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jonathan Violin</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and President</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">SIGNATURE PAGE TO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">THIRD AMENDMENT TO THE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CRESCENT BIOPHARMA, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024 EQUITY INCENTIVE PLAN</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33(A)
<SEQUENCE>6
<FILENAME>glyc-20241231xex10d33a.htm
<DESCRIPTION>EXHIBIT10.33(A)
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:21:36 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.33(a)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">2024 EQUITY INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Restricted Stock Agreement</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant of Award</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award</u>. This Restricted Stock Agreement (this &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) evidences the following grant by Crescent Biopharma, Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), of an award (this &#8220;<b style="font-weight:bold;">Award</b>&#8221;) a number of shares of Restricted Stock on the terms provided herein and in the Crescent Biopharma, Inc. 2024 Equity Incentive Plan (as amended from time to time, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;) set forth below.</p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:91.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:31.21%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:68.78%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:31.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;">Participant:</b></p></td><td style="vertical-align:top;width:68.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[&#8226;]</p></td></tr><tr><td style="vertical-align:top;width:31.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;">Date of Grant:</b></p></td><td style="vertical-align:top;width:68.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[&#8226;]</p></td></tr><tr><td style="vertical-align:top;width:31.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;">Shares of Restricted Stock:</b></p></td><td style="vertical-align:top;width:68.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[&#8226;] (the &#8220;<b style="font-weight:bold;">Shares</b>&#8221;)</p></td></tr><tr><td style="vertical-align:top;width:31.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;">Per Share Purchase Price:</b></p></td><td style="vertical-align:top;width:68.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">$[&#8226;]</p></td></tr><tr><td style="vertical-align:top;width:31.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;">Vesting Commencement Date:</b></p></td><td style="vertical-align:top;width:68.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[&#8226;]</p></td></tr><tr><td style="vertical-align:top;width:31.21%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:68.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[&#8226;]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Plan and Defined Terms</u>. This Award is granted pursuant to the Plan, a copy of which the Participant acknowledges having received. The provisions of the Plan are incorporated into this Agreement by this reference. Capitalized terms used but not defined herein shall have the meanings set forth in the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment for Shares</u>. The Purchaser shall pay the Company the Per Share Purchase Price for each Share, in cash, as consideration for the Company&#8217;s agreement to issue and sell the Shares to Purchaser.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Spousal Consent</u>. If the Participant has a spouse or registered domestic partner, as a condition of accepting this Award, the Participant shall also deliver a signed and completed Consent of Spouse or Domestic Partner in the form attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> to the Company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting of Restricted Stock; Termination of Service</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting</u>. Shares of Restricted Stock that have not yet become vested shall be referred to herein as &#8220;<b style="font-weight:bold;">Unvested Shares</b>&#8221; and Shares of Restricted Stock that have vested hereunder shall be referred to herein as &#8220;<b style="font-weight:bold;">Vested Shares</b>.&#8221; Shares of Restricted Stock shall become Vested Shares in accordance with the Vesting Schedule set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1(a)</u> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Termination of Service</u>. If the Participant&#8217;s continuous Services to the Company terminates for any reason other than a termination by the Company for Cause, all Unvested Shares as of the date of such termination shall be subject to repurchase by the Company under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4(d)</u> below upon the Participant&#8217;s termination of Services to the Company. If the Participant&#8217;s continuous Services to the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Company is terminated by the Company for Cause, all Unvested Shares shall be automatically forfeited for no consideration.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of Shares</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On the Date of Grant, the Company shall cause to be issued one or more certificates evidencing, or electronic notation representing, the Shares of Restricted Stock subject to this Award. Such Shares shall be registered in the name of the Participant, or in the names of such person and his or her spouse as community property or as joint tenants with the right of survivorship. Until the issuance of the Shares has been entered into the books and records of the Company or a duly authorized transfer agent of the Company, no right to vote, receive dividends or any other right as a stockholder will exist with respect to such Shares. In the case of Unvested Shares, the Company shall cause any certificates evidencing such Shares to be deposited in escrow under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4(c)</u>. In the case of Vested Shares, the Company shall cause any certificates evidencing such Shares to be recorded with appropriate notations regarding the restrictions set forth herein.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right Of Repurchase</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Scope of Repurchase Right</u>. Until they become Vested Shares, the Shares granted hereunder shall be subject to the Company&#8217;s right of repurchase at a repurchase price equal to the lower of the Per Share Purchase Price and the Fair Market Value (the &#8220;<b style="font-weight:bold;">Right of Repurchase</b>&#8221;). The Right of Repurchase may be exercised in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4(d)</u> below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lapse of Repurchase Right</u>. The Right of Repurchase shall lapse with respect to the Shares as and when such Shares become Vested Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Escrow</u>. Upon issuance, any certificate(s) for Unvested Shares shall be deposited in escrow with the Company to be held in accordance with the provisions of this Agreement. All ordinary cash dividends on Unvested Shares (or on other securities held in escrow) shall be subject to the restrictions and the risk of forfeiture applicable to the related Unvested Share and shall only be paid to the Participant if the underlying Shares become Vested Shares. If the Unvested Shares to which such dividends relate become Vested Shares, then such dividends shall be paid as soon as administratively feasible after such Unvested Shares become Vested Shares, but in no event later than 60 days after the date such Unvested Shares become Vested Shares. Unvested Shares, together with any other assets held in escrow under this Agreement, shall be surrendered to the Company upon forfeiture under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2(b)</u>. All Shares, together with any other assets held in escrow under this Agreement, shall be (i) surrendered to the Company for repurchase upon exercise of the Right of Repurchase or the Right of First Refusal or (ii) if held in escrow, released to the Participant upon his or her request to the extent that the Shares are Vested Shares. In any event, all Vested Shares, together with any other vested assets held in escrow under this Agreement, shall be released within 90 days after the earlier of (i) the termination of the Participant&#8217;s Service to the Company or (ii) the lapse of the Right of First Refusal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Repurchase Right</u>. The Company may exercise its Right of Repurchase for all Unvested Shares at any time on or after the date of the termination of the Participant&#8217;s Services to the Company by delivery of written notice to the Participant (email being sufficient). If the Shares being repurchased are represented by certificate(s), any such certificate(s) shall be delivered to the Company. If the Shares being repurchased are not represented by certificate, the repurchase shall be effected by an appropriate book entry on the stock ledger for the Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Rights as Stockholder</u>. Upon the exercise of the Right of Repurchase in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4</u>, the person from whom the Shares are repurchased shall no longer have any</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="text-transform:uppercase;">2</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">rights as a holder of the Shares. Such Shares shall be deemed to have been repurchased pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4</u>, subject to payment by the Company of the repurchase price, whether or not any certificate(s) for such Restricted Stock have been delivered to the Company.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right Of First Refusal</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of First Refusal</u>. Before any Vested Shares held by the Participant or any transferee of the Participant (either being sometimes referred to herein as the &#8220;<b style="font-weight:bold;">Holder</b>&#8221;) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company shall first, to the extent the Company&#8217;s approval is required by any applicable provisions of the Company&#8217;s Bylaws, have the right to approve such sale or transfer, in full or in part, and shall then have the right to purchase all or any part of the Shares proposed to be sold or transferred, in each case, in its sole and absolute discretion (the &#8220;<b style="font-weight:bold;">Right of First Refusal</b>&#8221;). If the Holder would like to sell or transfer any Shares, the Holder must provide the Company or its assignee(s) with a Transfer Notice (as defined below) requesting approval to sell or transfer the Shares and offering the Company or its assignee(s) a Right of First Refusal on the same terms and conditions set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;5</u>. The Company may either (i) exercise its Right of First Refusal in full or in part and purchase such Shares pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;5</u>, (ii) decline to exercise its Right of First Refusal in full or in part and permit the transfer of such Shares to the Proposed Transferee (as defined below) in full or in part or (iii) decline to exercise its Right of First Refusal in full or in part and, to the extent the Company&#8217;s approval is required by any applicable provisions in the Company&#8217;s Bylaws, decline the request to sell or transfer the Shares in full or in part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Proposed Transfer</u>. The Holder of the Shares shall deliver to the Company a written notice (the &#8220;<b style="font-weight:bold;">Transfer Notice</b>&#8221;) stating: (i) the Holder&#8217;s intention to sell or otherwise transfer such Shares; (ii) the name of each proposed purchaser or other transferee (&#8220;<b style="font-weight:bold;">Proposed Transferee</b>&#8221;); (iii) the number of Shares to be sold or transferred to each Proposed Transferee; (iv) the terms and conditions of each proposed sale or transfer, including the purchase price for such Shares (the &#8220;<b style="font-weight:bold;">Transfer Purchase Price</b>&#8221;); and (v) the Holder&#8217;s offer to the Company or its assignee(s) to purchase the Shares at the Transfer Purchase Price and upon the same terms (or terms that are no less favorable to the Company).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Right of First Refusal</u>. At any time within 30 days after receipt of the Transfer Notice, the Company or its assignee(s) shall deliver a written notice to the Holder indicating whether the Company or its assignee(s) elect to permit or reject the proposed sale or transfer, in full or in part, or elect to accept or decline the offer to purchase any or all of the Shares proposed to be sold or transferred to any one or more of the Proposed Transferees, at the Transfer Purchase Price, provided that if the Transfer Purchase Price consists of no legal consideration (as, for example, in the case of a transfer by gift), the purchase price will be the fair market value of the Shares as determined in good faith by the Company. If the Transfer Purchase Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the Company in good faith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment</u>. Payment of the Transfer Purchase Price shall be made, at the election of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness, or by any combination thereof within 60 days after receipt of the Transfer Notice or in the manner and at the times set forth in the Transfer Notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Holder&#8217;s Right to Transfer</u>. If any of the Shares proposed in the Transfer Notice to be sold or transferred to a given Proposed Transferee are both (i) not purchased by the Company or its assignee(s) as provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;5</u> and (ii) approved by the Company to be sold or transferred, then the Holder may sell or otherwise transfer any such Shares to the applicable Proposed Transferee at the Transfer Purchase Price or at a higher price, provided that such sale or other transfer is consummated within 120 days after the date of the Transfer Notice; provided that any such sale or other transfer is also effected in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="text-transform:uppercase;">3</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">accordance with the Company&#8217;s Bylaws and any applicable laws and the Proposed Transferee agrees in writing that the Company&#8217;s Bylaws and the provisions of this Agreement, including <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9</u>, shall continue to apply to the Shares in the hands of such Proposed Transferee. The Company, in consultation with its legal counsel, may require the Holder to provide an opinion of counsel evidencing compliance with applicable laws. If the Shares described in the Transfer Notice are not transferred to the Proposed Transferee within such period, or if the Holder proposes to change the price or other terms to make them more favorable to the Proposed Transferee, a new Transfer Notice shall be given to the Company, and the Company or its assignees shall again have the right to approve such transfer and be offered the Right of First Refusal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exception for Certain Family Transfers</u>. Anything to the contrary contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5</u> notwithstanding, the transfer of any or all of the Shares during Holder&#8217;s lifetime or on Holder&#8217;s death by will or intestacy to Holder&#8217;s Approved Relatives or a trust for the benefit of Holder or Holder&#8217;s Approved Relatives shall be exempt from the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5</u>. In such case, the transferee or other recipient shall receive and hold the Shares so transferred subject to the Company&#8217;s Bylaws and the provisions of this Agreement, including <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9</u>, and there shall be no further transfer of such Shares except in accordance with the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9</u> and the Company&#8217;s Bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u>. The right of the Company to purchase any part of the Shares may be assigned in whole or in part to any holder or holders of capital stock of the Company or other persons or organizations.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Participant shall be solely responsible for all federal, state, local and foreign tax (including any social insurance) resulting from the grant or vesting of the Shares of Restricted Stock granted hereunder. The Participant hereby releases and holds harmless the Company, its directors, officers and stockholders from any and all claims that may arise from or relate to any tax liability, penalties, interest, costs, fees or other liability incurred by the Participant in connection with the Award. The Participant hereby acknowledges that he or she has been advised to seek the advice of his or her own independent tax advisor prior to entering into this Agreement and is not relying upon any representations of the Company or any of its agents as to the effect of or the advisability of entering into this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legality Of Initial Issuance</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No Shares shall be issued upon the grant of this Award unless and until the Company has determined that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>It and the Participant have taken any actions required to register the Shares under the Securities Act of 1933, as amended (the &#8220;<b style="font-weight:bold;">Securities Act</b>&#8221;) or to perfect an exemption from the registration requirements thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Any applicable listing requirement of any stock exchange or other securities market on which Common Stock is listed has been satisfied; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Any other applicable provision of federal, State or foreign law and any applicable requirements of the Company&#8217;s shareholders&#8217; agreement have been satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="text-transform:uppercase;">4</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Registration Rights</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may, but shall not be obligated to, register or qualify the sale of Shares under the Securities Act or any other applicable law. The Company shall not be obligated to take any affirmative action in order to cause the sale of Shares under this Agreement to comply with any law.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictions on Transfer of Shares</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Restrictions</u>. In addition to any other limitation on transfer pursuant to applicable securities laws, except as otherwise provided in Section 9(a) of the Plan, any Unvested Shares shall not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law (any of the foregoing, a &#8220;<b style="font-weight:bold;">Transfer</b>&#8221;), except by will or the laws of descent and distribution. After any Unvested Shares have vested pursuant to the Vesting Schedule, the Participant shall not Transfer any interest in such Shares except in compliance with the provisions herein, in the Company&#8217;s Bylaws and applicable securities laws. Furthermore, the Shares shall be subject to the Right of Repurchase and the Right of First Refusal. Notwithstanding the foregoing, the Participant may, subject to compliance with the transfer restrictions set forth in the Company&#8217;s Bylaws, transfer Unvested Shares, subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;10</u> below, as part of the sale of all or substantially all of the shares of capital stock of the Company (including pursuant to a merger or consolidation). The Company shall not be required (a) to transfer on its books any of the Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or the provisions of the Company&#8217;s Bylaws or (b) to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom any such Shares shall have been so sold or transferred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Law Restrictions</u>. Regardless of whether the offer and sale of Shares under the Plan have been registered under the Securities Act or have been registered or qualified under the securities laws of any State or other relevant jurisdiction, the Company at its discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends on the stock certificates (or electronic equivalent) or the imposition of stop-transfer instructions) and may refuse (or may be required to refuse) to transfer Shares acquired hereunder (or Shares proposed to be transferred in a subsequent transfer) if, in the judgment of the Company, such restrictions, legends or refusal are necessary or appropriate to achieve compliance with the Securities Act or other relevant securities or other laws, including under Regulation S of the Securities Act or pursuant to another available exemption from registration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Market Stand-Off</u>. The Participant shall not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Shares (or other securities of the Company) or enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Shares (or other securities of the Company) held by the Participant (other than those included in the applicable Registration Statement (as defined below)) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed 180 days following the effective date of any registration statement of the Company filed under the Securities Act (each a &#8220;<b style="font-weight:bold;">Registration Statement</b>&#8221;) (or such other period as may be requested by the Company or the underwriters to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including the restrictions contained in FINRA Rule 2241, or any successor provisions or amendments thereto) (the &#8220;<b style="font-weight:bold;">Lock-Up Period</b>&#8221;); provided, however, that nothing contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;9(c)</u> shall prevent a forfeiture of Unvested Shares during the Lock-Up Period. The Participant agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter that are consistent with the foregoing or that are necessary to give further effect thereto. In addition, if requested by</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="text-transform:uppercase;">5</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, the Participant shall provide, within ten days of such request, such information as may be required by the Company or such representative in connection with the completion of any public offering of the Company&#8217;s securities pursuant to a registration statement filed under the Securities Act. The obligations described in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;9(c)</u> shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a SEC Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of the Lock-Up Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Intent</u>. The Participant represents and agrees that the Shares granted hereunder will be acquired for investment only, and not with a view to, or for sale in connection with, any distribution of the Shares in violation of the Securities Act, or any rule or regulation under the Securities Act. In the event that the sale of Shares under the Plan is not registered under the Securities Act but an exemption is available that requires an investment representation or other representation, the Participant shall represent and agree, as of the Date of Grant, that the Shares granted hereunder are being acquired for investment, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legends</u>. Any certificates (or electronic equivalent) evidencing Shares purchased under this Agreement shall bear the following legends:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 36pt 12pt 36pt;">&#8220;THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 36pt 12pt 36pt;">&#8220;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF REPURCHASE AND RIGHT OF FIRST REFUSAL IN FAVOR OF THE COMPANY AND/OR ITS ASSIGNEE(S) AND TRANSFER RESTRICTIONS AS PROVIDED IN THE RESTRICTED STOCK AGREEMENT BETWEEN THE <font style="text-transform:uppercase;">Participant </font>AND THE COMPANY. SUCH RIGHT OF REPURCHASE AND RIGHT OF FIRST REFUSAL AND TRANSFER RESTRICTIONS ARE BINDING UPON TRANSFEREES OF THESE SECURITIES. A COPY OF THE RESTRICTED STOCK AGREEMENT OF THE COMPANY MAY BE OBTAINED UPON WRITTEN REQUEST TO THE COMPANY.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certificates may bear any other notations required by any applicable federal or state securities laws. The Company may be authorized from time to time pursuant to its certificate of incorporation to issue more than one class or series of stock. In such case and at any time or from time to time thereafter the Company will furnish without charge to the Participant upon request the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences or rights. To the extent the Shares are issued in uncertificated form, (i) this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;9(e)</u> provides the Participant with notice that the Shares are subject to the aforementioned restrictions in satisfaction of the notice requirement set forth in Section 151(f) of the General Corporation Law of the State of Delaware (the &#8220;<b style="font-weight:bold;">DGCL</b>&#8221;) and (ii) the recording of the Shares in the books and records of the Company shall be accompanied by the legends included in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;9(e)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="text-transform:uppercase;">6</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal of Legends</u>. If, in the opinion of the Company and its counsel, any legend placed on a stock certificate representing Shares sold under this Agreement is no longer required, the holder of such certificate shall be entitled to exchange such certificate for a certificate representing the same number of Shares but without such legend.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment Of Shares</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of any transaction described in Section&#160;8 of the Plan, the terms of this Award (including the number and kind of Shares subject to this Award) shall be adjusted as set forth in Section&#160;8 of the Plan. In the event of any transaction described in Section&#160;8 of the Plan, any new, substituted or additional securities that by reason of such transaction are distributed with respect to any Unvested Shares or into which such Unvested Shares thereby become convertible shall immediately be subject to the Vesting Schedule, Right of Repurchase, Right of First Refusal and forfeiture provisions (and shall be released at the same rate as such Unvested Shares are, or would have been, released under this Agreement).</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous Provisions</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Retention Rights</u>. Nothing in this Award or in the Plan shall confer upon the Participant any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any parent or subsidiary employing or retaining the Participant) or of the Participant, which rights are hereby expressly reserved by each, to terminate his or her Service at any time and for any reason, with or without cause.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice</u>. Any notice required by the terms of this Agreement shall be given in writing. It shall be deemed effective upon (i)&#160;personal delivery, (ii)&#160;deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid, (iii)&#160;deposit with Federal Express Corporation, with shipping charges prepaid or (iv) deposit with any internationally recognized express mail courier service, with shipping charges prepaid. Notice shall be addressed to the Company at its principal executive office and to the Participant at the address that he or she most recently provided to the Company in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;11(b)</u>. In addition, to the extent required or permitted pursuant to rules established by the Company from time to time, notices may be delivered electronically.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Modifications and Waivers</u>. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by the Participant and by an authorized officer of the Company (other than the Participant); provided, however, that a modification that is otherwise favorable to the Participant (for example, providing the Participant with additional time to exercise this Award after termination of employment or providing for additional forms of payment) but causes this Award to lose its tax-favored status shall not require the consent of the Participant. No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. This Agreement and the Plan constitute the entire contract between the parties hereto with regard to the subject matter hereof. They supersede any other agreements, representations or understandings (whether oral or written and whether express or implied) that relate to the subject matter hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than such state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="text-transform:uppercase;">7</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect on Transferees, Heirs, Successors and Assigns</u>. This Agreement shall be binding upon Participant&#8217;s permitted transferees, heirs, successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</u>. Headings are given to the Sections and subsections of this Agreement solely as a convenience to facilitate reference and shall not be deemed in any way material or relevant to the construction or interpretation of this Agreement or any provision thereof. Words in the masculine gender shall include the feminine gender, and where appropriate, the plural shall include the singular and the singular shall include the plural. The use herein of the word &#8220;including&#8221; following any general statement, term or matter shall not be construed to limit such statement, term or matter to the specific items or matters set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as &#8220;without limitation&#8221;, &#8220;but not limited to&#8221;, or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that could reasonably fall within the broadest possible scope of such general statement, term or matter. The word &#8220;or&#8221; as used herein is not exclusive and is deemed to have the meaning &#8220;and/or.&#8221; Unless the context requires otherwise, all references herein to a law, agreement, instrument or other document shall be deemed to refer to such law, agreement, instrument or other document as amended, supplemented, modified and restated from time to time to the extent permitted by the provisions thereof.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgements of the Participant</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the other terms, conditions and restrictions imposed on this Award and the Shares issuable under this Award pursuant to this Agreement and the Plan, the Participant expressly acknowledges being subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 4</u> (Right of Repurchase), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5</u> (Right of First Refusal), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7</u> (Legality of Initial Issuance) and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9</u> (Restrictions on Transfer of Shares, including the Market Stand-Off), as well as the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Consequences</u>. The Participant agrees that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes the Participant&#8217;s tax liabilities. The Participant shall not make any claim against the Company, the Board, the Committee or the Company&#8217;s officers or employees related to tax liabilities arising from this Award or the Participant&#8217;s other compensation. The Participant hereby acknowledges that he has been informed that, with respect to the grant of Unvested Shares, that unless an election is filed by the Participant with the Internal Revenue Service and, if necessary, the proper state taxing authorities, within 30 days after the Date of Grant, electing pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended (and similar state tax provisions if applicable) to be taxed currently on any difference between the purchase price of the Shares (if any) and the fair market value of the Shares on the date of grant (the &#8220;<b style="font-weight:bold;">Election</b>&#8221;), there will be a recognition of taxable income to the Participant, measured by the excess, if any, of the fair market value of the Shares, at the time the Unvested Shares vest over the purchase price for the Shares (if any). The Participant represents that the Participant has consulted any tax consultant(s) or advisor(s) the Participant deems advisable in connection with the grant of the Shares or the filing of the Election under Section 83(b) and similar tax provisions. The Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. The Participant understands that the Participant (and not the Company) shall be responsible for the Participant&#8217;s own income tax liability that may arise as a result of the grant or vesting of the Shares contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="text-transform:uppercase;">8</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">The Participant</b><b style="font-weight:bold;"> ACKNOWLEDGES THAT IT IS </b><b style="font-weight:bold;text-transform:uppercase;">The Participant</b><b style="font-weight:bold;">&#8217;S SOLE RESPONSIBILITY AND NOT THE COMPANY&#8217;S TO FILE TIMELY THE ELECTION UNDER SECTION 83(b), EVEN IF </b><b style="font-weight:bold;text-transform:uppercase;">The Participant</b><b style="font-weight:bold;"> REQUESTS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON </b><b style="font-weight:bold;text-transform:uppercase;">The Participant&#8217;S</b><b style="font-weight:bold;"> BEHALF.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Electronic Delivery of Documents</u>. The Participant acknowledges and agrees that the Company may, in its sole discretion, deliver all documents relating to the Company, the Plan or this Award and all other documents that the Company is required to deliver to its security holders (including disclosures that may be required by the Securities and Exchange Commission) by email or other means of electronic transmission (including by posting them on a website maintained by the Company or a third party under contract with the Company). The Participant acknowledges that he or she may incur costs in connection with any such delivery by means of electronic transmission, including the cost of accessing the internet and printing fees, and that an interruption of internet access may interfere with his or her ability to access the documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Statutory Information Rights</u>. The Participant acknowledges and agrees that, upon the Date of Grant and until the first sale of the Common Stock to the general public pursuant to a registration statement filed under the Securities Act, he or she shall waive, and shall be deemed to have waived, any rights the Participant would otherwise have under Section 220 of the DGCL (or under similar rights pursuant to any other applicable law) to inspect for any purpose and to make copies and extracts from the Company&#8217;s stock ledger, a list of its stockholders and its other books and records or the books and records of any subsidiary of the Company (the &#8220;<b style="font-weight:bold;">Inspection Rights</b>&#8221;). The Participant acknowledges and understands that, but for the waiver made herein, the Participant would be entitled, upon compliance with the procedures set forth in Section 220 of the DGCL, to Inspection Rights pursuant thereto, and further acknowledges and agrees that the waiver set forth herein is a knowing and voluntary waiver of such rights, that the Participant has received sufficient consideration for such waiver and that the Company would not be willing to provide the benefits to the Participant hereunder without the benefit of such waiver from the Participant. This waiver applies only in the Participant&#8217;s capacity as a stockholder and does not affect any other inspection rights the Participant may have pursuant to any written agreement with the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan Discretionary</u>. The Participant understands and acknowledges that (i)&#160;the Plan is entirely discretionary, (ii)&#160;the Company and the Participant&#8217;s engaging entity have reserved the right to amend, suspend or terminate the Plan at any time, (iii)&#160;the grant of this Award does not in any way create any contractual or other right to receive additional Awards (or benefits in lieu of Award) at any time or in any amount and (iv)&#160;all determinations with respect to any additional Awards, including the times when Awards will be granted, the number of Shares offered, and the vesting schedule, will be at the sole discretion of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Service</u>. The Participant understands and acknowledges that participation in the Plan ceases upon termination of the Participant&#8217;s Service for any reason, except as may explicitly be provided otherwise in the Plan or this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Extraordinary Compensation</u>. The value of this Award shall be an extraordinary item of compensation and shall not be considered a part of the Participant&#8217;s normal or expected compensation for purposes of calculating severance, resignation, redundancy or end-of-service payments, bonuses, long-service awards, pension or retirement benefits or similar payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization to Disclose</u>. The Participant hereby authorizes and directs the Participant&#8217;s engaging entity to disclose to the Company or any subsidiary any information regarding the Participant&#8217;s Service, the nature and amount of the Participant&#8217;s compensation and the fact and conditions of the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="text-transform:uppercase;">9</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Participant&#8217;s participation in the Plan, as the Participant&#8217;s engaging entity deems necessary or appropriate to facilitate the administration of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Personal Data Authorization</u>. As a condition to the receipt of this Award, the Participant explicitly and unambiguously consents to Section 10(h) of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page Follows]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="text-transform:uppercase;">10</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Company has caused this Agreement to be executed by its duly authorized officer.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CRESENT BIOPHARMA, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[Signature Page &#8211; Restricted Stock Agreement]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PARTICIPANT&#8217;S ACCEPTANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The undersigned hereby accepts the foregoing Award and agrees to the terms and conditions thereof. The undersigned hereby acknowledges receipt of a copy of the Plan.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PARTICIPANT:</b></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">[&#8226;]</b></p></td><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:40.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Email:</p></td><td style="vertical-align:top;width:40.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[Signature Page &#8211; Restricted Stock Agreement]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33(B)
<SEQUENCE>7
<FILENAME>glyc-20241231xex10d33b.htm
<DESCRIPTION>EXHIBIT-10.33(B)
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:21:39 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">E</b><b style="font-weight:bold;">xhibit</b><b style="font-weight:bold;text-transform:uppercase;"> 10.33(</b><b style="font-weight:bold;">b</b><b style="font-weight:bold;text-transform:uppercase;">)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">CRESCENT BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">2024 EQUITY INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Restricted Stock Agreement</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant of Award</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Award</u>. This Restricted Stock Agreement (this &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) evidences the following grant by Crescent Biopharma, Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), of an award (this &#8220;<b style="font-weight:bold;">Award</b>&#8221;) a number of shares of Restricted Stock on the terms provided herein and in the Crescent Biopharma, Inc. 2024 Equity Incentive Plan (as amended from time to time, the &#8220;<b style="font-weight:bold;">Plan</b>&#8221;) set forth below.</p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:93%;"><tr style="height:1pt;"><td style="vertical-align:top;width:44.4%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:55.59%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:44.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;">Participant:</b></p></td><td style="vertical-align:top;width:55.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[&#9679;]</p></td></tr><tr><td style="vertical-align:top;width:44.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;">Date of Grant:</b></p></td><td style="vertical-align:top;width:55.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[&#9679;]</p></td></tr><tr><td style="vertical-align:top;width:44.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;">Shares of Restricted Stock:</b></p></td><td style="vertical-align:top;width:55.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[&#9679;] (the &#8220;<b style="font-weight:bold;">Shares</b>&#8221;)</p></td></tr><tr><td style="vertical-align:top;width:44.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 3.6pt;"><b style="font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:55.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;">[&#9679;]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Plan and Defined Terms</u>. This Award is granted pursuant to the Plan, a copy of which the Participant acknowledges having received. The provisions of the Plan are incorporated into this Agreement by this reference. Capitalized terms used but not defined herein shall have the meanings set forth in the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting of Restricted Stock</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Shares of Restricted Stock shall be referred to herein as &#8220;<b style="font-weight:bold;">Vested Shares</b>.&#8221;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of Shares</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On the Date of Grant, the Company shall cause to be issued one or more certificates evidencing, or electronic notation representing, the Shares of Restricted Stock subject to this Award. Such Shares shall be registered in the name of the Participant, or in the names of such person and his or her spouse as community property or as joint tenants with the right of survivorship. Until the issuance of the Shares has been entered into the books and records of the Company or a duly authorized transfer agent of the Company, no right to vote, receive dividends or any other right as a stockholder will exist with respect to such Shares. The Company shall cause any certificates evidencing such Shares to be deposited in escrow under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4</u>. In the case of Vested Shares, the Company shall cause any certificates evidencing such Shares to be recorded with appropriate notations regarding the restrictions set forth herein.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Escrow</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon issuance, any certificate(s) for Shares shall be deposited in escrow with the Company to be held in accordance with the provisions of this Agreement. All Shares, together with any other assets held in escrow under this Agreement, shall be (i)&#160;surrendered to the Company for repurchase upon exercise (or deemed exercise) of the Right of First Refusal or (ii)&#160;if held in escrow, released to the Participant upon his or her request. In any event, all Shares, together with any other vested assets held in escrow under this</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Agreement, shall be released within 90 days after the earlier of (i)&#160;the termination of the Participant&#8217;s Service to the Company or (ii)&#160;the lapse of the Right of First Refusal.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right Of First Refusal</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of First Refusal</u>. Before any Vested Shares held by the Participant or any transferee of the Participant (either being sometimes referred to herein as the &#8220;<b style="font-weight:bold;">Holder</b>&#8221;) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company shall first, to the extent the Company&#8217;s approval is required by any applicable provisions of the Company&#8217;s Bylaws, have the right to approve such sale or transfer, in full or in part, and shall then have the right to purchase all or any part of the Shares proposed to be sold or transferred, in each case, in its sole and absolute discretion (the &#8220;<b style="font-weight:bold;">Right of First Refusal</b>&#8221;). If the Holder would like to sell or transfer any Shares, the Holder must provide the Company or its assignee(s) with a Transfer Notice (as defined below) requesting approval to sell or transfer the Shares and offering the Company or its assignee(s) a Right of First Refusal on the same terms and conditions set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;5</u>. The Company may either (i) exercise its Right of First Refusal in full or in part and purchase such Shares pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;5</u>, (ii) decline to exercise its Right of First Refusal in full or in part and permit the transfer of such Shares to the Proposed Transferee (as defined below) in full or in part or (iii) decline to exercise its Right of First Refusal in full or in part and, to the extent the Company&#8217;s approval is required by any applicable provisions in the Company&#8217;s Bylaws, decline the request to sell or transfer the Shares in full or in part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Proposed Transfer</u>. The Holder of the Shares shall deliver to the Company a written notice (the &#8220;<b style="font-weight:bold;">Transfer Notice</b>&#8221;) stating: (i) the Holder&#8217;s intention to sell or otherwise transfer such Shares; (ii) the name of each proposed purchaser or other transferee (&#8220;<b style="font-weight:bold;">Proposed Transferee</b>&#8221;); (iii) the number of Shares to be sold or transferred to each Proposed Transferee; (iv) the terms and conditions of each proposed sale or transfer, including the purchase price for such Shares (the &#8220;<b style="font-weight:bold;">Transfer Purchase Price</b>&#8221;); and (v) the Holder&#8217;s offer to the Company or its assignee(s) to purchase the Shares at the Transfer Purchase Price and upon the same terms (or terms that are no less favorable to the Company).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Right of First Refusal</u>. At any time within 30 days after receipt of the Transfer Notice, the Company or its assignee(s) shall deliver a written notice to the Holder indicating whether the Company or its assignee(s) elect to permit or reject the proposed sale or transfer, in full or in part, or elect to accept or decline the offer to purchase any or all of the Shares proposed to be sold or transferred to any one or more of the Proposed Transferees, at the Transfer Purchase Price, provided that if the Transfer Purchase Price consists of no legal consideration (as, for example, in the case of a transfer by gift), the purchase price will be the fair market value of the Shares as determined in good faith by the Company. If the Transfer Purchase Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the Company in good faith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment</u>. Payment of the Transfer Purchase Price shall be made, at the election of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness, or by any combination thereof within 60 days after receipt of the Transfer Notice or in the manner and at the times set forth in the Transfer Notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Holder&#8217;s Right to Transfer</u>. If any of the Shares proposed in the Transfer Notice to be sold or transferred to a given Proposed Transferee are both (i) not purchased by the Company or its assignee(s) as provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;5</u> and (ii) approved by the Company to be sold or transferred, then the Holder may sell or otherwise transfer any such Shares to the applicable Proposed Transferee at the Transfer Purchase Price or at a higher price, provided that such sale or other transfer is consummated within 120 days after the date of the Transfer Notice; provided that any such sale or other transfer is also effected in accordance with the Company&#8217;s Bylaws and any applicable laws and the Proposed Transferee agrees in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">writing that the Company&#8217;s Bylaws and the provisions of this Agreement, including <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9</u>, shall continue to apply to the Shares in the hands of such Proposed Transferee. The Company, in consultation with its legal counsel, may require the Holder to provide an opinion of counsel evidencing compliance with applicable laws. If the Shares described in the Transfer Notice are not transferred to the Proposed Transferee within such period, or if the Holder proposes to change the price or other terms to make them more favorable to the Proposed Transferee, a new Transfer Notice shall be given to the Company, and the Company or its assignees shall again have the right to approve such transfer and be offered the Right of First Refusal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exception for Certain Family Transfers</u>. Anything to the contrary contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5</u> notwithstanding, the transfer of any or all of the Shares during Holder&#8217;s lifetime or on Holder&#8217;s death by will or intestacy to Holder&#8217;s Approved Relatives or a trust for the benefit of Holder or Holder&#8217;s Approved Relatives shall be exempt from the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5</u>. In such case, the transferee or other recipient shall receive and hold the Shares so transferred subject to the Company&#8217;s Bylaws and the provisions of this Agreement, including <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9</u>, and there shall be no further transfer of such Shares except in accordance with the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;9</u> and the Company&#8217;s Bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u>. The right of the Company to purchase any part of the Shares may be assigned in whole or in part to any holder or holders of capital stock of the Company or other persons or organizations.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Participant shall be solely responsible for all federal, state, local and foreign tax (including any social insurance) resulting from the grant or vesting of the Shares of Restricted Stock granted hereunder. The Participant hereby releases and holds harmless the Company, its directors, officers and stockholders from any and all claims that may arise from or relate to any tax liability, penalties, interest, costs, fees or other liability incurred by the Participant in connection with the Award. The Participant hereby acknowledges that he or she has been advised to seek the advice of his or her own independent tax advisor prior to entering into this Agreement and is not relying upon any representations of the Company or any of its agents as to the effect of or the advisability of entering into this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legality Of Initial Issuance</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No Shares shall be issued upon the grant of this Award unless and until the Company has determined that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>It and the Participant have taken any actions required to register the Shares under the Securities Act of 1933, as amended (the &#8220;<b style="font-weight:bold;">Securities Act</b>&#8221;) or to perfect an exemption from the registration requirements thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Any applicable listing requirement of any stock exchange or other securities market on which Common Stock is listed has been satisfied; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Any other applicable provision of federal, State or foreign law and any applicable requirements of the Company&#8217;s shareholders&#8217; agreement have been satisfied.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Registration Rights</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may, but shall not be obligated to, register or qualify the sale of Shares under the Securities Act or any other applicable law. The Company shall not be obligated to take any affirmative action in order to cause the sale of Shares under this Agreement to comply with any law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictions on Transfer of Shares</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Restrictions</u>. The Participant shall not sell, assign, transfer, pledge or otherwise encumber, either voluntarily or by operation of law, any interest in such Shares except in compliance with the provisions herein, in the Company&#8217;s Bylaws and applicable securities laws. Furthermore, the Shares shall be subject to the Right of First Refusal. The Company shall not be required (a) to transfer on its books any of the Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or the provisions of the Company&#8217;s Bylaws or (b) to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom any such Shares shall have been so sold or transferred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Law Restrictions</u>. Regardless of whether the offer and sale of Shares under the Plan have been registered under the Securities Act or have been registered or qualified under the securities laws of any State or other relevant jurisdiction, the Company at its discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends on the stock certificates (or electronic equivalent) or the imposition of stop-transfer instructions) and may refuse (or may be required to refuse) to transfer Shares acquired hereunder (or Shares proposed to be transferred in a subsequent transfer) if, in the judgment of the Company, such restrictions, legends or refusal are necessary or appropriate to achieve compliance with the Securities Act or other relevant securities or other laws, including under Regulation S of the Securities Act or pursuant to another available exemption from registration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Market Stand-Off</u>. The Participant shall not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Shares (or other securities of the Company) or enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Shares (or other securities of the Company) held by the Participant (other than those included in the applicable Registration Statement (as defined below)) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed 180 days following the effective date of any registration statement of the Company filed under the Securities Act (each a &#8220;<b style="font-weight:bold;">Registration Statement</b>&#8221;) (or such other period as may be requested by the Company or the underwriters to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including the restrictions contained in FINRA Rule 2241, or any successor provisions or amendments thereto) (the &#8220;<b style="font-weight:bold;">Lock-Up Period</b>&#8221;). The Participant agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter that are consistent with the foregoing or that are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, the Participant shall provide, within ten days of such request, such information as may be required by the Company or such representative in connection with the completion of any public offering of the Company&#8217;s securities pursuant to a registration statement filed under the Securities Act. The obligations described in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;9(c)</u> shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a SEC Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of the Lock-Up Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investment Intent</u>. The Participant represents and agrees that the Shares granted hereunder will be acquired for investment only, and not with a view to, or for sale in connection with, any distribution of the Shares in violation of the Securities Act, or any rule or regulation under the Securities Act. In the event that the sale of Shares under the Plan is not registered under the Securities Act but an exemption is</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">available that requires an investment representation or other representation, the Participant shall represent and agree, as of the Date of Grant, that the Shares granted hereunder are being acquired for investment, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legends</u>. Any certificates (or electronic equivalent) evidencing Shares purchased under this Agreement shall bear the following legends:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 36pt 12pt 36pt;">&#8220;THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 36pt 12pt 36pt;">&#8220;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL IN FAVOR OF THE COMPANY AND/OR ITS ASSIGNEE(S) AND TRANSFER RESTRICTIONS AS PROVIDED IN THE RESTRICTED STOCK AGREEMENT BETWEEN THE <font style="text-transform:uppercase;">Participant </font>AND THE COMPANY. SUCH RIGHT OF FIRST REFUSAL AND TRANSFER RESTRICTIONS ARE BINDING UPON TRANSFEREES OF THESE SECURITIES. A COPY OF THE RESTRICTED STOCK AGREEMENT OF THE COMPANY MAY BE OBTAINED UPON WRITTEN REQUEST TO THE COMPANY.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certificates may bear any other notations required by any applicable federal or state securities laws. The Company may be authorized from time to time pursuant to its certificate of incorporation to issue more than one class or series of stock. In such case and at any time or from time to time thereafter the Company will furnish without charge to the Participant upon request the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences or rights. To the extent the Shares are issued in uncertificated form, (i) this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;9(e)</u> provides the Participant with notice that the Shares are subject to the aforementioned restrictions in satisfaction of the notice requirement set forth in Section 151(f) of the General Corporation Law of the State of Delaware (the &#8220;<b style="font-weight:bold;">DGCL</b>&#8221;) and (ii) the recording of the Shares in the books and records of the Company shall be accompanied by the legends included in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#8206;9(e)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal of Legends</u>. If, in the opinion of the Company and its counsel, any legend placed on a stock certificate representing Shares sold under this Agreement is no longer required, the holder of such certificate shall be entitled to exchange such certificate for a certificate representing the same number of Shares but without such legend.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Adjustment Of Shares</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of any transaction described in Section&#160;8 of the Plan, the terms of this Award (including the number and kind of Shares subject to this Award) shall be adjusted as set forth in Section&#160;8 of the Plan.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous Provisions</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Retention Rights</u>. Nothing in this Award or in the Plan shall confer upon the Participant any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any parent or subsidiary employing or retaining the Participant) or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of the Participant, which rights are hereby expressly reserved by each, to terminate his or her Service at any time and for any reason, with or without cause.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice</u>. Any notice required by the terms of this Agreement shall be given in writing. It shall be deemed effective upon (i)&#160;personal delivery, (ii)&#160;deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid, (iii)&#160;deposit with Federal Express Corporation, with shipping charges prepaid or (iv) deposit with any internationally recognized express mail courier service, with shipping charges prepaid. Notice shall be addressed to the Company at its principal executive office and to the Participant at the address that he or she most recently provided to the Company in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;11(b)</u>. In addition, to the extent required or permitted pursuant to rules established by the Company from time to time, notices may be delivered electronically.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Modifications and Waivers</u>. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by the Participant and by an authorized officer of the Company (other than the Participant); provided, however, that a modification that is otherwise favorable to the Participant (for example, providing the Participant with additional time to exercise this Award after termination of employment or providing for additional forms of payment) but causes this Award to lose its tax-favored status shall not require the consent of the Participant. No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. This Agreement and the Plan constitute the entire contract between the parties hereto with regard to the subject matter hereof. They supersede any other agreements, representations or understandings (whether oral or written and whether express or implied) that relate to the subject matter hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than such state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect on Transferees, Heirs, Successors and Assigns</u>. This Agreement shall be binding upon Participant&#8217;s permitted transferees, heirs, successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</u>. Headings are given to the Sections and subsections of this Agreement solely as a convenience to facilitate reference and shall not be deemed in any way material or relevant to the construction or interpretation of this Agreement or any provision thereof. Words in the masculine gender shall include the feminine gender, and where appropriate, the plural shall include the singular and the singular shall include the plural. The use herein of the word &#8220;including&#8221; following any general statement, term or matter shall not be construed to limit such statement, term or matter to the specific items or matters set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as &#8220;without limitation&#8221;, &#8220;but not limited to&#8221;, or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that could reasonably fall within the broadest possible scope of such general statement, term or matter. The word &#8220;or&#8221; as used herein is not exclusive and is deemed to have the meaning &#8220;and/or.&#8221; Unless the context requires otherwise, all</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">references herein to a law, agreement, instrument or other document shall be deemed to refer to such law, agreement, instrument or other document as amended, supplemented, modified and restated from time to time to the extent permitted by the provisions thereof.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgements of the Participant</b><b style="font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the other terms, conditions and restrictions imposed on this Award and the Shares issuable under this Award pursuant to this Agreement and the Plan, the Participant expressly acknowledges being subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 5</u> (Right of First Refusal), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7</u> (Legality of Initial Issuance) and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9</u> (Restrictions on Transfer of Shares, including the Market Stand-Off), as well as the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Consequences</u>. The Participant agrees that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes the Participant&#8217;s tax liabilities. The Participant shall not make any claim against the Company, the Board, the Committee or the Company&#8217;s officers or employees related to tax liabilities arising from this Award or the Participant&#8217;s other compensation. The Participant represents that the Participant has consulted any tax consultant(s) or advisor(s) the Participant deems advisable in connection with the grant of the Shares. The Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. The Participant understands that the Participant (and not the Company) shall be responsible for the Participant&#8217;s own income tax liability that may arise as a result of the grant or vesting of the Shares contemplated by this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Electronic Delivery of Documents</u>. The Participant acknowledges and agrees that the Company may, in its sole discretion, deliver all documents relating to the Company, the Plan or this Award and all other documents that the Company is required to deliver to its security holders (including disclosures that may be required by the Securities and Exchange Commission) by email or other means of electronic transmission (including by posting them on a website maintained by the Company or a third party under contract with the Company). The Participant acknowledges that he or she may incur costs in connection with any such delivery by means of electronic transmission, including the cost of accessing the internet and printing fees, and that an interruption of internet access may interfere with his or her ability to access the documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Statutory Information Rights</u>. The Participant acknowledges and agrees that, upon the Date of Grant and until the first sale of the Common Stock to the general public pursuant to a registration statement filed under the Securities Act, he or she shall waive, and shall be deemed to have waived, any rights the Participant would otherwise have under Section 220 of the DGCL (or under similar rights pursuant to any other applicable law) to inspect for any purpose and to make copies and extracts from the Company&#8217;s stock ledger, a list of its stockholders and its other books and records or the books and records of any subsidiary of the Company (the &#8220;<b style="font-weight:bold;">Inspection Rights</b>&#8221;). The Participant acknowledges and understands that, but for the waiver made herein, the Participant would be entitled, upon compliance with the procedures set forth in Section 220 of the DGCL, to Inspection Rights pursuant thereto, and further acknowledges and agrees that the waiver set forth herein is a knowing and voluntary waiver of such rights, that the Participant has received sufficient consideration for such waiver and that the Company would not be willing to provide the benefits to the Participant hereunder without the benefit of such waiver from the Participant. This waiver applies only in the Participant&#8217;s capacity as a stockholder and does not affect any other inspection rights the Participant may have pursuant to any written agreement with the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan Discretionary</u>. The Participant understands and acknowledges that (i)&#160;the Plan is entirely discretionary, (ii)&#160;the Company and the Participant&#8217;s engaging entity have reserved the right to amend, suspend or terminate the Plan at any time, (iii)&#160;the grant of this Award does not in any way create any contractual or other right to receive additional Awards (or benefits in lieu of Award) at any time or in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">any amount and (iv)&#160;all determinations with respect to any additional Awards, including the times when Awards will be granted, the number of Shares offered, and the vesting schedule, will be at the sole discretion of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Service</u>. The Participant understands and acknowledges that participation in the Plan ceases upon termination of the Participant&#8217;s Service for any reason, except as may explicitly be provided otherwise in the Plan or this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Extraordinary Compensation</u>. The value of this Award shall be an extraordinary item of compensation and shall not be considered a part of the Participant&#8217;s normal or expected compensation for purposes of calculating severance, resignation, redundancy or end-of-service payments, bonuses, long-service awards, pension or retirement benefits or similar payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization to Disclose</u>. The Participant hereby authorizes and directs the Participant&#8217;s engaging entity to disclose to the Company or any subsidiary any information regarding the Participant&#8217;s Service, the nature and amount of the Participant&#8217;s compensation and the fact and conditions of the Participant&#8217;s participation in the Plan, as the Participant&#8217;s engaging entity deems necessary or appropriate to facilitate the administration of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Personal Data Authorization</u>. As a condition to the receipt of this Award, the Participant explicitly and unambiguously consents to Section 10(h) of the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page Follows]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Company has caused this Agreement to be executed by its duly authorized officer.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CRESENT BIOPHARMA, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[Signature Page &#8211; Restricted Stock Agreement]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">PARTICIPANT&#8217;S ACCEPTANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The undersigned hereby accepts the foregoing Award and agrees to the terms and conditions thereof. The undersigned hereby acknowledges receipt of a copy of the Plan.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PARTICIPANT:</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[&#9679;]</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email:</p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[Signature Page &#8211; Restricted Stock Agreement]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>8
<FILENAME>glyc-20241231xex10d34.htm
<DESCRIPTION>EXHIBIT-10.34
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:21:39 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-transform:uppercase;">E</b><b style="font-size:11pt;font-weight:bold;">xhibit</b><b style="font-size:11pt;font-weight:bold;text-transform:uppercase;"> 10.34</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-style:italic;font-weight:bold;">Pre-IPO Form &#8211; U.S. Employees &amp; Directors</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-transform:uppercase;">CRESCENT BIOPHARMA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-transform:uppercase;">2024 EQUITY INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Stock Option Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-transform:uppercase;">[Incentive stock option // nonstatutory stock option]</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Grant of Option</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">This Stock Option Agreement (this &#8220;</font><b style="font-size:11pt;font-weight:bold;">Agreement</b><font style="font-size:11pt;">&#8221;) evidences the following grant by Crescent Biopharma, Inc., a Delaware corporation (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Company</b><font style="font-size:11pt;">&#8221;), of an option (this &#8220;</font><b style="font-size:11pt;font-weight:bold;">Option</b><font style="font-size:11pt;">&#8221;) to purchase, in whole or in part, on the terms provided herein and in the Crescent Biopharma, Inc. 2024 Equity Incentive Plan (as amended from time to time, the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Plan</b><font style="font-size:11pt;">&#8221;), the shares of Common Stock set forth below:</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:93%;"><tr style="height:1pt;"><td style="vertical-align:top;width:31.23%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0.7pt 0pt 0pt;"><font style="font-size:1pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:68.76%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0.7pt 0pt 0pt;"><font style="font-size:1pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0.7pt 12pt 7.2pt;"><b style="font-size:11pt;font-weight:bold;">Participant:</b></p></td><td style="vertical-align:top;width:68.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.6pt 12pt 7.2pt;"><font style="font-size:11pt;">[&#9679;]</font></p></td></tr><tr><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0.7pt 12pt 7.2pt;"><b style="font-size:11pt;font-weight:bold;">Grant Date:</b></p></td><td style="vertical-align:top;width:68.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.6pt 12pt 7.2pt;"><font style="font-size:11pt;">[&#9679;]</font></p></td></tr><tr><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0.7pt 12pt 7.2pt;"><b style="font-size:11pt;font-weight:bold;">Shares of Common Stock Subject to the Option:</b></p></td><td style="vertical-align:top;width:68.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.6pt 12pt 7.2pt;"><font style="font-size:11pt;">[&#9679;] (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Shares</b><font style="font-size:11pt;">&#8221;)</font></p></td></tr><tr><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0.7pt 12pt 7.2pt;"><b style="font-size:11pt;font-weight:bold;">Exercise Price per Share:</b></p></td><td style="vertical-align:top;width:68.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.6pt 12pt 7.2pt;"><font style="font-size:11pt;">$[&#9679;]</font></p></td></tr><tr><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0.7pt 12pt 7.2pt;"><b style="font-size:11pt;font-weight:bold;">Expiration Date:</b></p></td><td style="vertical-align:top;width:68.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.6pt 12pt 7.2pt;"><font style="font-size:11pt;">11:59 p.m. ET on [&#9679;]</font><sup style="font-size:8.25pt;vertical-align:top;">1</sup></p></td></tr><tr><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0.7pt 12pt 7.2pt;"><b style="font-size:11pt;font-weight:bold;">Vesting Commencement Date:</b></p></td><td style="vertical-align:top;width:68.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.6pt 12pt 7.2pt;"><font style="font-size:11pt;">[&#9679;]</font></p></td></tr><tr><td style="vertical-align:top;width:31.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0.7pt 12pt 7.2pt;"><b style="font-size:11pt;font-weight:bold;">Vesting Schedule:</b></p></td><td style="vertical-align:top;width:68.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 3.6pt 12pt 7.2pt;"><font style="font-size:11pt;">This Option, and any Shares received upon exercise of this Option, will vest (&#8220;</font><b style="font-size:11pt;font-weight:bold;">vest</b><font style="font-size:11pt;">&#8221;) in accordance with the following schedule, subject to the Participant&#8217;s continued employment with or service to the Company through each vesting date: [(i) 25% of the Shares subject to this Option shall vest on the first anniversary of the Vesting Commencement Date and (ii) thereafter, this Option shall vest with respect to an additional 1/48th of the Shares at the end of each successive month following the first anniversary of the Vesting Commencement Date].</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:11pt;">This Option is subject to the terms of the Plan, which are incorporated into this Agreement by reference. &#160;A copy of the Plan has been furnished to the Participant with the Option. &#160;Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Plan. &#160;Except as otherwise indicated by the context, Participant shall be deemed to include any person who acquires the right to exercise this Option validly under its terms.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:11pt;">[</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Include if granted to employee and is an ISO: </font><font style="font-size:11pt;">This Option is intended to qualify as an &#8220;incentive stock option&#8221; under Section 422 of the Code. &#160;However, the Company does not represent or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.5" width="30.0%" style="background-color:#000000;color:#000000;height:1.5pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><sup style="font-size:8.25pt;vertical-align:top;">1</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><font style="font-size:11pt;">NTD: Enter date that is 10 years from the Grant Date.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">warrant that this Option qualifies as such. &#160;The Participant should consult with his or her own tax advisors regarding the tax effects of this Option and the requirements necessary to obtain favorable income tax treatment under Section 422 of the Code, including the holding period requirements. &#160;If the Participant disposes (whether by sale, gift, transfer or otherwise) any Shares acquired upon exercise of this Option within the one-year period beginning on the exercise date or within the two-year period beginning on the Grant Date, the Participant shall notify the Company within 30 days after such disposition. &#160;To the extent that the aggregate Fair Market Value (determined as of the Grant Date) of the Shares with respect to which the Option (plus all other incentive stock options held by the Participant) are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and its affiliates) exceeds $100,000, the Option or portions thereof that exceed such limit (according to the order in which they were granted) will be treated as Nonstatutory Stock Options. &#160;In addition, to the extent any portion of this Option does not qualify as an &#8220;incentive stock option,&#8221; such portion shall be deemed to be a Nonstatutory Stock Option.][</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Include if granted to non-employee or to employee and is an NSO: &#160;</font><font style="font-size:11pt;">This Option is not intended to be an incentive stock option under Section 422 of the Code and will be interpreted accordingly.]</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting Schedule</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">This Option will be fully exercisable as of the Grant Date until the earlier of the Expiration Date or the termination of this Option under Section 3 hereof or the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:11pt;">This Option, and any Shares received upon exercise of this Option, will vest in accordance with the Vesting Schedule set forth in Section 1 above. In determining the number of vested Shares, the number of Shares shall be rounded down to the nearest whole Share.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:11pt;">[In the event of a </font><font style="font-size:11pt;">Change in Control, all of the Participant&#8217;s then unvested Shares shall automatically accelerate and become fully vested, subject to the Participant&#8217;s continued employment with or service to the Company through such Change in Control.</font><font style="font-size:11pt;">]</font><sup style="font-size:8.25pt;vertical-align:top;">2</sup></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Option</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Form of Exercise</u><font style="font-size:11pt;">. &#160;Each election to exercise this Option shall be accompanied by a completed Notice of Stock Option Exercise in the form attached hereto as </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</u><font style="font-size:11pt;"> (if such Options have vested) or </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-size:11pt;"> (if such Options have not vested) and signed by the Participant, and where applicable, a signed and completed Consent of Spouse or Domestic Partner in the form attached hereto as </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;C</u><font style="font-size:11pt;">, and received by the Company at its principal office, accompanied by this Agreement, and payment of the Exercise Price in full in the manner provided in the Plan. &#160;The Participant may purchase less than the number of Shares covered hereby; </font><i style="font-size:11pt;font-style:italic;">provided that</i><font style="font-size:11pt;"> no partial exercise of this Option may be for any fractional Share or for fewer than 100 whole Shares. &#160;Subject to applicable law and as a condition to the exercise of this Option and the issuance of any Common Stock hereunder, the Participant agrees to become party to any stockholders&#8217; agreement, voting agreement, drag along agreement, right of first refusal and co-sale agreement, or any other agreement approved by the Board and creating obligations of or among any stockholder of the Company, as the Company may request.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuous Relationship with the Company Required</u><font style="font-size:11pt;">. &#160;Except as otherwise provided in this Section&#160;&#8206;3, this Option may not be exercised unless the Participant, at the time this Option is exercised, is, and has been at all times since the Grant Date, in continued employment with or providing service to the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.5" width="30.0%" style="background-color:#000000;color:#000000;height:1.5pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><sup style="font-size:8.25pt;vertical-align:top;">2</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><font style="font-size:11pt;">To be included for non-employee director awards only.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Company or any of its subsidiaries (an &#8220;</font><b style="font-size:11pt;font-weight:bold;">Eligible Participant</b><font style="font-size:11pt;">&#8221;). &#160;The date on which the Participant ceases to be an Eligible Participant shall be referred to as the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Termination Date</b><font style="font-size:11pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Relationship with the Company</u><font style="font-size:11pt;">. &#160;If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in Sections 3(d) and 3(e) below, the right to exercise this Option shall terminate three months after the Termination Date (but in no event after the Expiration Date); provided that this Option shall be exercisable only to the extent that the Option was vested on the Termination Date. &#160;Notwithstanding the foregoing, if the Participant, prior to the Expiration Date, violates any non-competition, non-solicitation, non-disparagement or confidentiality provisions of any agreement between the Participant and the Company or its subsidiary, the right to exercise this Option shall terminate immediately upon such violation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise Period Upon Death or Disability</u><font style="font-size:11pt;">. &#160;If the Participant dies or becomes disabled (within the meaning of Section&#160;22(e)(3) of the Code) prior to the Expiration Date while he or she is an Eligible Participant and the Company has not terminated such relationship for Cause (as defined below), this Option shall be exercisable by the Participant (or, in the case of death, by the Participant&#8217;s Designated Beneficiary) within the period of one year following the Termination Date (but in no event after the Expiration Date); provided that this Option shall be exercisable only to the extent that this Option was vested on the Termination Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Cause</u><font style="font-size:11pt;">. &#160;If, prior to the Expiration Date, the Participant&#8217;s employment or service is terminated by the Company for Cause, the right to exercise this Option shall terminate immediately upon the Termination Date. &#160;If prior to the Expiration Date, the Participant is given notice by the Company of the termination of the Participant&#8217;s employment or service by the Company for Cause, and the Termination Date is subsequent to the date of delivery of such notice, the right to exercise this Option shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&#8217;s employment or service shall not be terminated for Cause as provided in such notice or (ii) the Termination Date (in which case the right to exercise this Option shall, pursuant to the preceding sentence, terminate upon the Termination Date). &#160;If the Participant is party to an employment or severance contract or agreement or offer letter (excluding any non-competition agreement) with the Company that contains a definition of &#8220;cause&#8221; for termination, &#8220;</font><b style="font-size:11pt;font-weight:bold;">Cause</b><font style="font-size:11pt;">&#8221; shall have the meaning ascribed to such term in such agreement or offer letter. &#160;Otherwise, &#8220;</font><b style="font-size:11pt;font-weight:bold;">Cause</b><font style="font-size:11pt;">&#8221; shall mean (A) the Participant&#8217;s dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (B) the Participant&#8217;s conviction or plea of no contest to (1) a felony or (2) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (C) the Participant&#8217;s failure to perform in all material respects the Participant&#8217;s assigned duties and responsibilities; (D) the Participant&#8217;s gross negligence, willful misconduct that results in or is reasonably anticipated to result in harm to the Company; or (E) the Participant&#8217;s violation of any material provision of any agreement(s) between the Participant and the Company or its subsidiary or any Company policies including, without limitation, agreements relating to non-competition, non-solicitation, non-disparagement, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Right of First Refusal</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Proposed Transfer</u><font style="font-size:11pt;">. &#160;If the Participant proposes to sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation of law or otherwise (collectively, &#8220;</font><b style="font-size:11pt;font-weight:bold;">transfer</b><font style="font-size:11pt;">&#8221;) any vested Shares acquired upon exercise of this Option, then the Participant shall first give written notice of the proposed transfer (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Transfer Notice</b><font style="font-size:11pt;">&#8221;) to the Company. &#160;The Transfer Notice shall name the proposed transferee and state the number of such Shares the Participant proposes to transfer (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Offered Shares</b><font style="font-size:11pt;">&#8221;),</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">the price per Offered Share and all other material terms and conditions of the transfer. &#160;For the avoidance of doubt, unvested Shares purchased upon exercise of this Option are not transferrable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Right to Purchase</u><font style="font-size:11pt;">. &#160;For 30 days following its receipt of such Transfer Notice, the Company shall have the option to purchase all or part of the Offered Shares at the price and upon the terms set forth in the Transfer Notice (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Right of First Refusal</b><font style="font-size:11pt;">&#8221;). &#160;In the event the Company elects to purchase all or part of the Offered Shares, it shall give written notice of such election to the Participant within such 30-day period. &#160;Within 10&#160;days after the Participant&#8217;s receipt of such notice, the Participant shall tender to the Company at its principal offices the certificate or certificates, if any, representing the Offered Shares to be purchased by the Company, duly endorsed in blank by the Participant or with duly endorsed stock powers attached thereto, all in a form suitable for transfer of the Offered Shares to the Company. &#160;Promptly following receipt of such certificate or certificates, the Company shall deliver or mail to the Participant a check in payment of the purchase price for such Offered Shares; </font><i style="font-size:11pt;font-style:italic;">provided that</i><font style="font-size:11pt;"> if the terms of payment set forth in the Transfer Notice were other than cash against delivery, the Company may pay for the Offered Shares on the same terms and conditions as were set forth in the Transfer Notice; and </font><i style="font-size:11pt;font-style:italic;">provided further</i><font style="font-size:11pt;"> that any delay in making such payment shall not invalidate the Company&#8217;s exercise of its option to purchase the Offered Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares Not Purchased By Company</u><font style="font-size:11pt;">. &#160;If the Company does not elect to acquire all of the Offered Shares, the Participant may, within the 30-day period following the expiration of the option granted to the Company under Section 4(b) above, transfer the Offered Shares which the Company has not elected to acquire to the proposed transferee; </font><i style="font-size:11pt;font-style:italic;">provided that</i><font style="font-size:11pt;"> such transfer shall not be on terms and conditions more favorable to the transferee than those contained in the Transfer Notice. &#160;Notwithstanding any of the above, all Offered Shares transferred pursuant to this Section &#8206;4 shall remain subject to the right of first refusal set forth in this Section &#8206;4 and such transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Section &#8206;4.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consequences of Non-Delivery</u><font style="font-size:11pt;">. &#160;After the time at which the Offered Shares are required to be delivered to the Company for transfer to the Company pursuant to Section 4(b) above, the Company shall not pay any dividend to the Participant on account of such Offered Shares or permit the Participant to exercise any of the privileges or rights of a stockholder with respect to such Offered Shares, but shall, insofar as permitted by law, treat the Company as the owner of such Offered Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exempt Transactions</u><font style="font-size:11pt;">. &#160;The following transactions shall be exempt from the provisions of this Section &#8206;4:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:11pt;">any transfer of Shares to or for the benefit of any spouse, child or grandchild of the Participant, or to a trust for their benefit;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font></font><font style="font-size:11pt;">any transfer pursuant to an effective registration statement filed by the Company under the Securities Act of 1933, as amended (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Securities Act</b><font style="font-size:11pt;">&#8221;); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(iii)</font></font><font style="font-size:11pt;">the sale of all or substantially all of the outstanding shares of capital stock of the Company (including pursuant to a merger or consolidation);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-size:11pt;font-style:italic;">provided, however</i><font style="font-size:11pt;">, that in the case of a transfer pursuant to clause (i) above, such Shares shall remain subject to the right of first refusal set forth in this Section &#8206;4 and such transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Section &#8206;4.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment of Company Right</u><font style="font-size:11pt;">. &#160;The Company may assign its rights to purchase Offered Shares in any particular transaction under this Section &#8206;4 to one or more persons or entities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u><font style="font-size:11pt;">. &#160;The provisions of this Section &#8206;4 shall terminate upon the earlier of the following events:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><font style="font-size:11pt;">the closing of the sale of shares of Common Stock in an underwritten public offering pursuant to an effective registration statement filed by the Company under the Securities Act or any other transaction that results in the shares of Common Stock (or any equity securities substituted therefore) being listed on an established stock exchange; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(ii)</font></font><font style="font-size:11pt;">a Change in Control.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(h)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Obligation to Recognize Invalid Transfer</u><font style="font-size:11pt;">. &#160;The Company shall not be required (i) to transfer on its books any of the Shares which shall have been sold or transferred in violation of any of the provisions set forth in this Section &#8206;4, or (ii) to treat as owner of such Shares or to pay dividends to any transferee to whom any such Shares shall have been so sold or transferred.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(i)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legends</u><font style="font-size:11pt;">. &#160;In addition to any legends set forth in the Notice of Stock Option Exercise, any certificate representing Shares or notice of issuance of uncertificated stock evidencing the issuance of Shares shall bear a legend substantially in the following form (in addition to, or in combination with, any legend required by applicable federal and state securities laws and agreements relating to the transfer of the Company securities) until the Company&#8217;s right of first refusal has terminated in accordance with Section 4(g):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 36pt 12pt 36pt;"><font style="font-size:11pt;">&#8220;The shares [represented by this certificate][referenced herein] are subject to a right of first refusal in favor of the Company, as provided in a certain stock option agreement with the Company.&#8221;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement in Connection with Initial Public Offering</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The Participant agrees, in connection with the initial underwritten public offering of the Common Stock pursuant to a registration statement under the Securities Act, (a) not to (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any other securities of the Company or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of shares of Common Stock or other securities of the Company, whether any transaction described in clause (i) or (ii) is to be settled by delivery of securities, in cash or otherwise, for a period specified by the representative of the underwriters of Common Stock or other securities of the Company not to exceed 180 days following the effective date of any registration statement of the Company filed under the Securities Act (or such other period as may be requested by the Company or the underwriters to accommodate regulatory restrictions on (A) the publication or other distribution of research reports and (B) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2241 or any successor provisions or amendments thereto), and (b) to execute any agreement reflecting clause (a) above as may be requested by the Company or the managing underwriters at the time of such offering. &#160;The Company may impose stop-transfer instructions with respect to the shares of Common Stock or other securities subject to the foregoing restriction until the end of the &#8220;lock-up&#8221; period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Matters</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding</u><font style="font-size:11pt;">. &#160;No Shares will be issued pursuant to the exercise of this Option unless and until the Company satisfies all applicable federal, state, and local or other income and employment tax withholding obligations as described in the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disqualifying Disposition</u><font style="font-size:11pt;">. &#160;If this Option is intended to qualify </font><font style="font-size:11pt;">as an &#8220;incentive stock option&#8221; under Section 422 of the Code and if</font><font style="font-size:11pt;"> the Participant disposes of Shares acquired upon exercise of this Option within two years from the Grant Date or one year after such Shares were acquired pursuant to exercise of this Option, the Participant shall notify the Company in writing of such disposition.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nontransferability</b><b style="font-size:11pt;font-weight:bold;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">This Option and any Shares purchased hereunder that remain unvested may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this Option shall be exercisable only by the Participant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:11pt;">The Participant agrees that the Participant will not transfer any Shares issued pursuant to the exercise of this Option unless the transferee, as a condition to such transfer, delivers to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of Section &#8206;4 and Section &#8206;5; </font><i style="font-size:11pt;font-style:italic;">provided</i><font style="font-size:11pt;">,</font><i style="font-size:11pt;font-style:italic;"> that</i><font style="font-size:11pt;"> such a written confirmation shall not be required with respect to (i)&#160;Section &#8206;4 after such provision has terminated in accordance with Section &#8206;4(g) or (ii) Section &#8206;5 after the completion of the lock-up period in connection with the Company&#8217;s initial underwritten public offering.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">[</font><i style="font-size:11pt;font-style:italic;">Signature Page Follows</i><font style="font-size:11pt;">]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF</b><font style="font-size:11pt;">, the Company has caused this Option to be executed by its duly authorized officer.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Crescent Biopharma, Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:41.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:41.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 270pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[Signature Page &#8211; Stock Option Agreement]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-transform:uppercase;">PARTICIPANT&#8217;S ACCEPTANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The undersigned hereby accepts the foregoing Option and agrees to the terms and conditions thereof. &#160;The undersigned hereby acknowledges receipt of a copy of the Plan.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PARTICIPANT:</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td style="vertical-align:bottom;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email:</p></td><td style="vertical-align:bottom;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[Signature Page &#8211; Stock Option Agreement]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Exhibit A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-transform:uppercase;">NOTICE OF STOCK OPTION EXERCISE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Date:</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><sup style="font-size:8.25pt;vertical-align:top;">3</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Crescent Biopharma, Inc.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:51.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:15.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:15.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Attention: Treasurer</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Dear Sir or Madam:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">I am the holder of an Option granted to me under the Crescent Biopharma, Inc. 2024 Equity Incentive Plan (as the same may be amended and restated from time to time, the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Plan</b><font style="font-size:11pt;">&#8221;) on [</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="font-size:11pt;">]</font><sup style="font-size:8.25pt;vertical-align:top;">4</sup><font style="font-size:11pt;"> for the purchase of [</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="font-size:11pt;">]</font><sup style="font-size:8.25pt;vertical-align:top;">5</sup><font style="font-size:11pt;"> shares of Common Stock of the Company at an exercise price of $[</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="font-size:11pt;">]</font><sup style="font-size:8.25pt;vertical-align:top;">6</sup><font style="font-size:11pt;"> per share. &#160;Capitalized terms used but not defined herein shall have the meanings set forth under the Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">I hereby exercise my option to purchase [</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="font-size:11pt;">]</font><sup style="font-size:8.25pt;vertical-align:top;">7</sup><font style="font-size:11pt;"> shares of Common Stock (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Shares</b><font style="font-size:11pt;">&#8221;), for which I have enclosed [</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="font-size:11pt;">]</font><sup style="font-size:8.25pt;vertical-align:top;">8</sup><font style="font-size:11pt;"> in the amount of [</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="font-size:11pt;">]</font><sup style="font-size:8.25pt;vertical-align:top;">9</sup><font style="font-size:11pt;">. &#160;Please register the Shares as follows:</font></p><div style="padding-left:54pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:58.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name(s):</p></td><td style="vertical-align:bottom;width:58.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">10</sup><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:58.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="vertical-align:top;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td style="vertical-align:bottom;width:58.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:58.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:68.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:68.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email:</p></td><td style="vertical-align:bottom;width:58.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.5" width="30.0%" style="background-color:#000000;color:#000000;height:1.5pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">3</sup><font style="display:inline-block;width:14.5pt;"></font><font style="font-size:11pt;">Enter the date of exercise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">4</sup><font style="display:inline-block;width:14.5pt;"></font><font style="font-size:11pt;">Enter the date of grant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">5</sup><font style="display:inline-block;width:14.5pt;"></font><font style="font-size:11pt;">Enter the total number of shares of Common Stock for which the option was </font><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">granted</b><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">6</sup><font style="display:inline-block;width:14.5pt;"></font><font style="font-size:11pt;">Enter the option exercise price per share of Common Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">7</sup><font style="display:inline-block;width:14.5pt;"></font><font style="font-size:11pt;">Enter the number of shares of Common Stock </font><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">to be purchased upon exercise</b><font style="font-size:11pt;"> of all or part of the option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">8</sup><font style="display:inline-block;width:14.5pt;"></font><font style="font-size:11pt;">Enter &#8220;cash&#8221;, &#8220;personal check&#8221; or if permitted by the Option or Plan, &#8220;stock certificates No. XXXX and XXXX&#8221; or &#8220;notice of issuance of uncertificated stock No. XXXX and XXXX&#8221;.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">9</sup><font style="display:inline-block;width:14.5pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">Enter the dollar amount (price per share of Common Stock times the number of shares of Common Stock to be purchased), or the number of shares tendered.  Fair market value of shares tendered, together with cash or check, must cover the purchase price of the shares issued upon exercise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">10</sup><font style="display:inline-block;width:11pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">Enter name(s) to appear on stock certificate or notice of issuance of uncertified stock: (a) Your name only; (b) Your name and other name (i.e., John Doe and Jane Doe, Joint Tenants With Right of Survivorship); or (c) a Child&#8217;s name, with you as custodian (i.e., Jane Doe, Custodian for Tommy Doe).  Note: There may be income and/or gift tax consequences of registering shares in a Child&#8217;s name.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[Signature Page &#8211; Notice of Stock Option Exercise]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">Tax I.D. #:</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><sup style="font-size:8.25pt;vertical-align:top;">11</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">I represent, warrant and covenant as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">1.</font></font><font style="font-size:11pt;">I am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in connection with, any distribution of the Shares in violation of the Securities Act of 1933, as amended (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Securities Act</b><font style="font-size:11pt;">&#8221;), or any rule or regulation under the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">2.</font></font><font style="font-size:11pt;">I have had such opportunity as I have deemed adequate to obtain from representatives of the Company such information as is necessary to permit me to evaluate the merits and risks of my investment in the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">3.</font></font><font style="font-size:11pt;">I have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">4.</font></font><font style="font-size:11pt;">I can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">5.</font></font><font style="font-size:11pt;">I understand that (a) the Shares have not been registered under the Securities Act and are &#8220;restricted securities&#8221; within the meaning of Rule 144 under the Securities Act, (b) the Shares cannot be sold, transferred or otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption from registration is then available; (c) in any event, the exemption from registration under Rule&#160;144 will not be available for at least one year and even then will not be available unless a public market then exists for the Common Stock, adequate information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and (d) there is now no registration statement on file with the Securities and Exchange Commission with respect to any stock of the Company and the Company has no obligation, and has not made any representations regarding any current intention, to register the Shares under the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">6.</font></font><font style="font-size:11pt;">I acknowledge and agree that, until the first sale of the Common Stock to the general public pursuant to a registration statement filed under the Securities Act, I have waived and will be deemed to have waived, any rights I would otherwise have under Section 220 of the General Corporation Law of the State of Delaware (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">DGCL</b><font style="font-size:11pt;">&#8221;) (or under similar rights pursuant to any other applicable law) to inspect for any purpose and to make copies and extracts from the Company&#8217;s stock ledger, a list of its stockholders and its other books and records or the books and records of any subsidiary of the Company (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Inspection Rights</b><font style="font-size:11pt;">&#8221;). &#160;I acknowledge and understand that, but for the waiver made herein, I would be entitled, upon compliance with the procedures set forth in Section 220 of the DGCL, to Inspection Rights pursuant thereto, and further acknowledge and agree that the waiver set forth herein is a knowing and voluntary waiver of such rights, that I have received sufficient consideration for such waiver and that the Company would not be willing to provide the benefits to me hereunder without the benefit of such waiver from me. &#160;This waiver</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.5" width="30.0%" style="background-color:#000000;color:#000000;height:1.5pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><sup style="font-size:8.25pt;vertical-align:top;">11</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><font style="font-size:11pt;">Social Security Number of Holder(s).</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[Signature Page &#8211; Notice of Stock Option Exercise]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 18pt 0pt;"><font style="font-size:11pt;">applies only in my capacity as a stockholder and does not affect any other inspection rights I may have pursuant to any written agreement with the Company.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Very truly yours,</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Signature)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[Signature Page &#8211; Notice of Stock Option Exercise]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Exhibit B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-transform:uppercase;">NOTICE OF STOCK OPTION EARLY EXERCISE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-transform:uppercase;">AND RESTRICTED STOCK PURCHASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Date:</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><sup style="font-size:8.25pt;vertical-align:top;">12</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Crescent Biopharma, Inc.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:15.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:51.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:15.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:15.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:15.01%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Attention: </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Dear Sir or Madam:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><sup style="font-size:8.25pt;vertical-align:top;">13</sup><font style="font-size:11pt;"> (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Participant</b><font style="font-size:11pt;">&#8221;) is the holder of an Option granted to the Participant under the Crescent Biopharma, Inc. (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Company</b><font style="font-size:11pt;">&#8221;) 2024 Equity Incentive Plan (as the same may be amended and restated from time to time, the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Plan</b><font style="font-size:11pt;">&#8221;) on </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><sup style="font-size:8.25pt;vertical-align:top;">14</sup><font style="font-size:11pt;"> for the purchase of </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><sup style="font-size:8.25pt;vertical-align:top;">15</sup><font style="font-size:11pt;"> shares of Common Stock of the Company at an exercise price of $</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><sup style="font-size:8.25pt;vertical-align:top;">16</sup><font style="font-size:11pt;"> per share pursuant to the terms of that certain Stock Option Agreement (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Option Agreement</b><font style="font-size:11pt;">&#8221;). Capitalized terms used but not defined herein shall have the meanings set forth under the Option Agreement or the Plan, as applicable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Pursuant to the terms of this Notice of Stock Option Early Exercise and Restricted Stock Purchase Agreement (this &#8220;</font><b style="font-size:11pt;font-weight:bold;">Agreement</b><font style="font-size:11pt;">&#8221;), the Participant hereby exercises the Participant&#8217;s option to purchase </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><sup style="font-size:8.25pt;vertical-align:top;">17</sup><font style="font-size:11pt;"> shares of Common Stock (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Shares</b><font style="font-size:11pt;">&#8221;), for which the Participant has enclosed a personal check in the amount of $</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><sup style="font-size:8.25pt;vertical-align:top;">18</sup><font style="font-size:11pt;">. Please register the Shares as follows:</font></p><div style="padding-left:54pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:58.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name(s):</p></td><td style="vertical-align:bottom;width:58.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">19</sup><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:58.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="vertical-align:top;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Address:</p></td><td style="vertical-align:bottom;width:58.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:58.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:68.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:68.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email:</p></td><td style="vertical-align:bottom;width:58.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.5" width="30.0%" style="background-color:#000000;color:#000000;height:1.5pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">12</sup><font style="display:inline-block;width:11pt;"></font><font style="font-size:11pt;">Enter the date of exercise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">13</sup><font style="display:inline-block;width:11pt;"></font><font style="font-size:11pt;">Enter the Participant&#8217;s name.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">14</sup><font style="display:inline-block;width:11pt;"></font><font style="font-size:11pt;">Enter the date of grant.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">15</sup><font style="display:inline-block;width:11pt;"></font><font style="font-size:11pt;">Enter the total number of shares of Common Stock for which the option was </font><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">granted</b><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">16</sup><font style="display:inline-block;width:11pt;"></font><font style="font-size:11pt;">Enter the option exercise price per share of Common Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">17</sup><font style="display:inline-block;width:11pt;"></font><font style="font-size:11pt;">Enter the number of shares of Common Stock to be purchased upon exercise of all or part of the option.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">18</sup><font style="display:inline-block;width:11pt;"></font><font style="font-size:11pt;">Enter the dollar amount (price per share of Common Stock times the number of shares of Common Stock to be purchased).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">19</sup><font style="display:inline-block;width:11pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">Enter name(s) to appear on stock certificate or notice of issuance of uncertified stock: (a) Your name only; (b) Your name and other name (i.e., John Doe and Jane Doe, Joint Tenants With Right of Survivorship); or (c) a Child&#8217;s name, with you as custodian (i.e., Jane Doe, Custodian for Tommy Doe).  Note: There may be income and/or gift tax consequences of registering shares in a Child&#8217;s name.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">Tax I.D. #:</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><sup style="font-size:8.25pt;vertical-align:top;">20</sup></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">Limitations on Transfer</b><font style="font-size:11pt;">.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The Participant acknowledges and agrees that the Shares purchased under this Agreement are subject to (i) the transfer restrictions set forth in the Plan and Sections 4, 5 and 7 of the Option Agreement and (ii) any other limitation or transfer created by applicable laws. In addition to the foregoing, the Participant will not assign, encumber or dispose of any interest in the Shares while the Shares are subject to the Company&#8217;s Right of Repurchase (as defined below). After any Shares have been released from such Right of Repurchase, the Participant will not assign, encumber or dispose of any interest in such Shares except to the extent permitted by, and in compliance with, Sections 4 and 5 of the Option Agreement, applicable laws, and the provisions below.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">Right of Repurchase</b><font style="font-size:11pt;">.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Scope of Repurchase Right</u><font style="font-size:11pt;">. &#160;In the event Participant cease to be an Eligible Participant for any reason, all Unvested Shares (as defined below) shall be subject to the Company&#8217;s right of repurchase at a repurchase price equal to the lower of the original Exercise Price (adjusted in accordance with Section 8(a) of the Plan) and the Fair Market Value (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Right of Repurchase</b><font style="font-size:11pt;">&#8221;). The Right of Repurchase may be exercised in accordance with Section 2(d) below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lapse of Repurchase Right</u><font style="font-size:11pt;">. As used herein, &#8220;</font><b style="font-size:11pt;font-weight:bold;">Unvested Shares</b><font style="font-size:11pt;">&#8221; means Shares that have not yet vested in accordance with the vesting schedule set forth in Section 1 and Section 2 of the Option Agreement and Shares that have vested in accordance with such vesting schedule shall be referred to herein as &#8220;</font><b style="font-size:11pt;font-weight:bold;">Vested Shares</b><font style="font-size:11pt;">.&#8221; Fractional shares shall be rounded down to the nearest whole share.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Escrow</u><font style="font-size:11pt;">. Upon issuance, any certificate(s) for Unvested Shares shall be deposited in escrow with the Company to be held in accordance with the provisions of this Agreement. All ordinary cash dividends on Unvested Shares (or on other securities held in escrow) shall be subject to the restrictions and the risk of forfeiture applicable to the related Unvested Share and shall only be paid to the Participant if the underlying Shares become Vested Shares. If the Unvested Shares to which such dividends relate become Vested Shares, then such dividends shall be paid as soon as administratively feasible after such Unvested Shares become Vested Shares, but in no event later than 60 days after the date such Unvested Shares become Vested Shares. Unvested Shares, together with any other assets held in escrow under this Agreement, shall be surrendered to the Company upon exercise of the Right of Repurchase. All Shares, together with any other assets held in escrow under this Agreement, shall be (i) surrendered to the Company for repurchase upon exercise of the Right of Repurchase or the Right of First Refusal or (ii) if held in escrow, released to the Participant upon his or her request to the extent that the Shares are Vested Shares. In any event, all Vested Shares, together with any other vested assets held in escrow under this Agreement, shall be released within 90 days after the earlier of (i) the termination of the Participant&#8217;s service to the Company or (ii) the lapse of the Right of First Refusal.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exercise of Repurchase Right</u><font style="font-size:11pt;">. The Company may exercise its Right of Repurchase for all Unvested Shares at any time on or after the Termination Date by delivery of written notice to the Participant (email being sufficient). If the Shares being repurchased are represented by certificate(s), any such certificate(s) shall be delivered to the Company. If the Shares being repurchased are not represented by certificate, the repurchase shall be effected by an appropriate book entry on the stock ledger for the Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.5" width="30.0%" style="background-color:#000000;color:#000000;height:1.5pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><sup style="font-size:8.25pt;vertical-align:top;">20</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><font style="font-size:11pt;">Social Security Number of Holder(s).</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Rights as Stockholder</u><font style="font-size:11pt;">. Upon the exercise of the Right of Repurchase in accordance with this Section 2, the person from whom the Shares are repurchased shall no longer have any rights as a holder of the Shares. Such Shares shall be deemed to have been repurchased pursuant to this Section 2, subject to payment by the Company of the repurchase price, whether or not any certificate(s) for such Shares have been delivered to the Company.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">Legends</b><font style="font-size:11pt;">.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Any stock certificate or, in the case of uncertificated securities, any notice of issuance, for the Shares shall bear the following legends (as well as any legends required by the Company or applicable state and federal corporate and securities laws):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 36pt 12pt 36pt;"><font style="font-size:11pt;">&#8220;THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 36pt 12pt 36pt;"><font style="font-size:11pt;">&#8220;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF REPURCHASE AND RIGHT OF FIRST REFUSAL IN FAVOR OF THE COMPANY AND/OR ITS ASSIGNEE(S) AND TRANSFER RESTRICTIONS AS PROVIDED IN THE STOCK OPTION AGREEMENT AND THE NOTICE OF STOCK OPTION EARLY EXERCISE AND RESTRICTED STOCK PURCHASE AGREEMENT BETWEEN THE </font><font style="font-size:11pt;text-transform:uppercase;">Participant </font><font style="font-size:11pt;">AND THE COMPANY. SUCH RIGHT OF REPURCHASE AND RIGHT OF FIRST REFUSAL AND TRANSFER RESTRICTIONS ARE BINDING UPON TRANSFEREES OF THESE SECURITIES. COPIES OF THE AGREEMENTS MAY BE OBTAINED UPON WRITTEN REQUEST TO THE COMPANY.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Certificates may bear any other notations required by any applicable federal or state securities laws. The Company may be authorized from time to time pursuant to its certificate of incorporation to issue more than one class or series of stock. In such case and at any time or from time to time thereafter the Company will furnish without charge to the Participant upon request the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences or rights. To the extent the Shares are issued in uncertificated form, (i) this Section 3 provides the Participant with notice that the Shares are subject to the aforementioned restrictions in satisfaction of the notice requirement set forth in Section 151(f) of the General Corporation Law of the State of Delaware (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">DGCL</b><font style="font-size:11pt;">&#8221;) and (ii) the recording of the Shares in the books and records of the Company shall be accompanied by the legends included in this Section &#8206;3.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">Section 83(b) Election</b><font style="font-size:11pt;">.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The Participant understands that Section 83(a) of the Code taxes as ordinary income for a Nonstatutory Stock Option the difference between the amount paid for the Shares and the Fair Market Value of the Shares as of the date any restrictions on the Shares lapse. In this context, &#8220;restriction&#8221; means the right of the Company to buy back the Shares pursuant to the Right of Repurchase set forth in Section 2 of this Agreement. The Participant understands that the Participant may elect to be taxed at the time the Shares are purchased, rather than when and as the Right of Repurchase expires, by filing an election under Section 83(b) of the Code (an &#8220;</font><b style="font-size:11pt;font-weight:bold;">83(b) Election</b><font style="font-size:11pt;">&#8221;) with the Internal Revenue Service within 30 days from the date of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">purchase. Even if the Fair Market Value of the Shares at the time of the execution of this Agreement equals the amount paid for the Shares, the election must be made to avoid income tax under Section 83(a) of the Code. The Participant understands that failure to file such an election in a timely manner may result in adverse tax consequences. The Participant acknowledges that the foregoing is only a summary of the effect of United States federal income taxation with respect to purchase of the Shares hereunder, and does not purport to be complete. The Participant further acknowledges that the Company has directed the Participant to seek independent advice regarding the applicable provisions of the Code, the income tax laws of any municipality, state or foreign country in which the Participant resides, and the tax consequences of the Participant&#8217;s death. The Participant understands that the Participant (and not the Company) shall be responsible for the Participant&#8217;s own income tax liability that may arise as a result of the grant or vesting of the Shares contemplated by this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">THE PARTICIPANT ACKNOWLEDGES THAT IT IS THE PARTICIPANT&#8217;S SOLE RESPONSIBILITY AND NOT THE COMPANY&#8217;S TO FILE TIMELY THE ELECTION UNDER SECTION 83(b), EVEN IF THE PARTICIPANT REQUESTS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON THE PARTICIPANT&#8217;S BEHALF.</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">Representations</b><font style="font-size:11pt;">. &#160;The Participant represents, warrants and covenants as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The Participant is purchasing the Shares for the Participant&#8217;s own account for investment only, and not with a view to, or for sale in connection with, any distribution of the Shares in violation of the Securities Act of 1933, as amended (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Securities Act</b><font style="font-size:11pt;">&#8221;), or any rule or regulation under the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The Participant has had such opportunity as the Participant deemed adequate to obtain from representatives of the Company such information as is necessary to permit the Participant to evaluate the merits and risks of the Participant&#8217;s investment in the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The Participant has sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The Participant can afford a complete loss of the value of the Shares and is able to bear the economic risk of holding such Shares for an indefinite period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The Participant understands that (a) the Shares have not been registered under the Securities Act and are &#8220;restricted securities&#8221; within the meaning of Rule 144 under the Securities Act, (b) the Shares cannot be sold, transferred or otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption from registration is then available; (c) in any event, the exemption from registration under Rule&#160;144 will not be available for at least one year and even then will not be available unless a public market then exists for the Common Stock, adequate information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and (d) there is now no registration statement on file with the Securities and Exchange Commission with respect to any stock of the Company and the Company has no obligation or current intention to register the Shares under the Securities Act.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">Waiver of Statutory Information Rights.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The Participant acknowledges and agrees that until the first sale of the Common Stock to the general public pursuant to a registration statement filed under the Securities Act, he or she shall waive, and shall be deemed to have waived, any rights the Participant would otherwise have under Section 220 of the DGCL (or under similar rights pursuant to any other applicable law) to inspect for any purpose and to make copies</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">and extracts from the Company&#8217;s stock ledger, a list of its stockholders and its other books and records or the books and records of any subsidiary of the Company (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Inspection Rights</b><font style="font-size:11pt;">&#8221;). &#160;The Participant acknowledges and understands that, but for the waiver made herein, the Participant would be entitled, upon compliance with the procedures set forth in Section 220 of the DGCL, to Inspection Rights pursuant thereto, and further acknowledges and agrees that the waiver set forth herein is a knowing and voluntary waiver of such rights, that the Participant has received sufficient consideration for such waiver and that the Company would not be willing to provide the benefits to the Participant hereunder without the benefit of such waiver from the Participant. &#160;This waiver applies only in the Participant&#8217;s capacity as a stockholder and does not affect any other inspection rights the Participant may have pursuant to any written agreement with the Company.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Very truly yours,</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">(Signature)</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Exhibit C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-transform:uppercase;">CONSENT OF SPOUSE OR DOMESTIC PARTNER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">I, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="font-size:11pt;">, spouse or registered domestic partner of </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="font-size:11pt;">, have read and approve the Stock Option Agreement dated </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="font-size:11pt;"> (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Stock Option Agreement</b><font style="font-size:11pt;">&#8221;), between my spouse or registered domestic partner and Crescent Biopharma, Inc. In consideration of granting of the right to my spouse or registered domestic partner to purchase shares of common stock of Crescent Biopharma, Inc. set forth in the Stock Option Agreement, I hereby appoint my spouse or registered domestic partner as my attorney-in-fact in respect to the exercise of any rights under the Stock Option Agreement and agree to be bound by the provisions of the Stock Option Agreement insofar as I may have any rights in said Stock Option Agreement or any options or shares issued pursuant thereto under the community property laws or similar laws relating to marital property in effect in the state of our residence as of the date of the signing of the foregoing Stock Option Agreement.</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Dated:</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="font-size:11pt;">,</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Signature of Spouse or Registered Domestic Partner</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>9
<FILENAME>glyc-20241231xex10d35.htm
<DESCRIPTION>EXHIBIT-10.35
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:21:39 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.35</b><b style="font-size:11pt;font-weight:bold;"><br></b><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Consulting Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">This Consulting Agreement (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u><font style="font-size:11pt;">&#8221;) is effective as of September 28, 2024 (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-size:11pt;">&#8221;), </font><b style="font-size:11pt;font-weight:bold;">Crescent Biopharma, Inc.</b><font style="font-size:11pt;">, a Delaware corporation, with a primary place of business at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Crescent</u><font style="font-size:11pt;">&#8221;), and </font><b style="font-size:11pt;font-weight:bold;">Jonathan Violin</b><font style="font-size:11pt;"> (&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consultant</u><font style="font-size:11pt;">&#8221;). Crescent and the Consultant may be referred to herein individually as </font><i style="font-size:11pt;font-style:italic;">&#8220;</i><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</u><i style="font-size:11pt;font-style:italic;">&#8221; </i><font style="font-size:11pt;">or collectively, as </font><i style="font-size:11pt;font-style:italic;">&#8220;</i><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</u><font style="font-size:11pt;">&#8221;.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Recitals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Whereas, </b><font style="font-size:11pt;">Consultant has certain special expertise and knowledge regarding biotechnology companies;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Whereas, </b><font style="font-size:11pt;">Crescent has need of Consultant&#8217;s expertise; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Whereas, </b><font style="font-size:11pt;">Crescent and Consultant desire to enter into this Agreement in order to set out the terms for Consultant to the services to Crescent as further described herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Therefore, </b><font style="font-size:11pt;">in consideration of the promises and undertakings set forth herein, the Parties agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Agreement</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">1.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Services and Payment</u><font style="font-size:11pt;">. Consultant agrees to provide the services described in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule A</u><font style="font-size:11pt;"> attached hereto (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Services</u><font style="font-size:11pt;">&#8221;).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">2.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance.</u><font style="font-size:11pt;"> For the Term of this Agreement, Consultant will provide all time, resources and attention required for the performance of the Services and will always act in the best interest of Crescent. Consultant represents that it has the requisite expertise, ability and legal right to provide the Services. The manner and means used by the Consultant to perform the Services desired by Crescent are in the sole discretion and control of the Consultant. Consultant agrees to perform the Services in a prompt, efficient, skillful and professional manner.</font></div><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The Services will be provided solely by Consultant. Consultant may not subcontract any of the Services under this Agreement to any third party.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Consultant represents that it has the requisite expertise, ability, and legal right to provide the Services and will perform the Services diligently and with due care. Consultant will abide by all applicable laws, rules, and regulations applicable to it in the performance of the Services. Crescent acknowledges and agrees that Consultant will perform the Services on a best efforts basis.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Consultant shall keep Crescent reasonably informed about the status of the Services. Consultant agrees to participate in activities including meetings and/or conference calls if required that may be held on a regular basis between Consultant and Crescent to evaluate, review or discuss the progress made on the performance of the Services.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">D.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Consultant shall not disclose to Crescent any confidential or proprietary information that belongs to any third party unless Consultant first obtains the consent of such third party and enters into a separate confidentiality agreement with Crescent covering that disclosure. Consultant shall not represent to Crescent as being unrestricted any designs, plans, models, samples, or other writings or products that Consultant knows are covered by valid patent, copyright, or other form of intellectual property protection belong to a third party.</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. As the only consideration due Consultant for such Services, Crescent will provide Consultant with the consideration described in the Scope of Services, attached hereto as </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule A</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reimbursement for Expenses</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Certain expenses may be identified on </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule A</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> as reimbursable by Crescent. If and only if </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule A</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> provides for the reimbursement of such expenses, Consultant may obtain reimbursement of such expenses by submitting expense reports with receipts or such other documentation as may be required under Crescent&#8217;s policies or under the terms of this Agreement. All other expenses incurred by Consultant in connection with providing the Services under this Agreement will be the sole responsibility of Consultant.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Invoicing</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Consultant shall invoice Crescent in accordance with the invoice schedule in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule A</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">D.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Consultant hereby acknowledges that Crescent will report as compensation all payments to Consultant hereunder. Consultant will pay all required taxes on Consultant&#39;s income from Crescent under this Agreement. Consultant will provide Crescent with Consultant&#8217;s taxpayer identification number or social security number, as applicable.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">E.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Benefits</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. During the Term, Crescent shall not be obligated, under any circumstances, to pay for, or keep in effect, any hospitalization, health, life or other insurance for the benefit of Consultant, to pay any employment or similar taxes, to make any tax withholdings or to provide any benefits that Crescent provides to its employees. All payroll and employment taxes, insurance and benefits shall be the sole responsibility of Consultant. If Consultant (or any individual service provider of Consultant) is reclassified by a state or federal agency or court as Crescent&#8217;s employee, Consultant and its individual service providers will receive no benefits from Crescent, except those mandated by state or federal law, even if by the terms of Crescent&#8217;s benefit plans or programs of Crescent in effect at the time of such reclassification, Consultant or any individual service provider would otherwise be eligible for such benefits.</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definition</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. For purposes of this Agreement, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means information not generally known or available outside Crescent and information entrusted to Crescent in confidence by third parties. Confidential Information includes, but is not limited to, all information and data in whatever form disclosed to Consultant by or on behalf of Crescent or its Affiliates, including, without limitation, information concerning Crescent&#8217;s business, financial condition, operations, inventions, know-how, procedures, products, marketing plans, developmental or experimental work, clinical or other programs, and plans for research and development. Confidential Information also includes (i) any written work product or deliverables provided by Consultant to Crescent pursuant to this Agreement, and (ii) the existence and terms of this Agreement. Consultant acknowledges the confidential and secret character of the Confidential Information and agrees that the Confidential Information is the sole, exclusive and extremely valuable property of Crescent.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Confidential Information does not include information that Consultant can demonstrate by competent evidence (i) was in the public domain at the time of its receipt from or on behalf of Crescent or thereafter enters into the public domain through no fault of the Consultant; (ii) was already in Consultant&#8217;s possession prior to receipt from or on behalf of Crescent, as evidenced by Consultant&#8217;s written records, and under no obligation of confidentiality to</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">Crescent; or (iii) was or is furnished to Consultant by a third party not bound by any obligation of confidentiality.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">At all times during and following the Term of this Agreement, Consultant shall not, directly or indirectly: (i) reproduce any of the Confidential Information except as necessary to perform the Services without the applicable prior written consent of Crescent, (ii) use the Confidential Information except in the performance of the Services, (iii) disclose, divulge, reveal, report, publish, or transfer to any third party for any purpose whatsoever, any Confidential Information, and (iv) keep in confidence all Confidential Information. Consultant will exercise all reasonable precautions to physically protect the confidentiality of the Confidential Information. Consultant shall, promptly upon request, whether during or after Term, return to Crescent or destroy any and all Confidential Information (whether in hard copy or electronic format, and including any copies thereof) in Consultant&#8217;s possession or under Consultant&#8217;s control, and upon request shall certify to Crescent the return or destruction of all such Confidential Information.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">D.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Consultant agrees and acknowledges that, in the event of any breach of this Agreement by Consultant, Crescent may be irreparably and immediately harmed and may not be made whole by monetary damages. Accordingly, it is agreed that, in addition to any other remedy to which it may be entitled in law or in equity Crescent, shall be entitled to seek an injunction or injunctions in a court of competent jurisdiction to prevent breaches or threatened breaches of this Agreement and/or to seek to compel specific performance of this Agreement. Nothing herein shall be construed as prohibiting Crescent from pursuing any other remedies available to it for such breach or threatened breach, including the recovery of damages.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">E.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Consultant shall, promptly upon request, whether during or after the Term, return to Crescent or destroy any and all Confidential Information (whether in hard copy or electronic format, and including any copies thereof) in Consultant&#8217;s possession or under Consultant&#8217;s control, and upon request shall certify to Crescent the return or destruction of all such Confidential Information.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">F.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">If Consultant is required by a governmental authority or by order of a court of competent jurisdiction to disclose any of Crescent&#8217;s Confidential Information, Consultant will give Crescent prompt advance written notice thereof (if legally permitted) and Consultant will take all reasonable and lawful actions to avoid or minimize the degree of such disclosure. Consultant will cooperate reasonably with Crescent in any efforts to seek a protective order.</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Nothing in this Agreement will affect a Party&#8217;s rights to its Background Intellectual Property nor imply a grant of any license to a Party&#8217;s Background Intellectual Property unless expressly set forth herein. Except as expressly provided in this Agreement, no right, title or interest in or to any Crescent product or any trademark or any other intellectual property right of Crescent is granted, whether express or implied, by Crescent to Consultant. &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background Intellectual Property</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means all intellectual property owned or licensed by the respective Parties as of the Effective Date (and during the term of this Agreement) and/or any intellectual property conceived, reduced to practice, used or developed by either Party outside the scope of this Agreement, and any improvements or enhancements thereof, and that is under the control of either Party and that is reasonably necessary, relevant or otherwise useful for performing the Services under this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Consultant hereby agrees that any know-how, invention, discovery, improvement, drawing or design or other intellectual property which Consultant develops as a result of performing</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">the Services (collectively, &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Crescent Intellectual Property</u><font style="font-size:11pt;">&#8221;) are &#8220;works for hire,&#8221; and furthermore, Consultant hereby assigns to Crescent any right, title, and interest Consultant may have in any Crescent Intellectual Property. Upon the request of Crescent, Consultant shall provide Crescent with all documentation relating to any Crescent Intellectual Property, and execute and deliver to Crescent such further assignments, documents, and other instruments, as may be necessary to assign Crescent Intellectual Property to Crescent and to assist Crescent in applying for, obtaining and enforcing patents or other rights in the United States and in any foreign country with respect to any Crescent Intellectual Property. Crescent will bear the cost of preparation of all patent or other applications and assignments, and the cost of obtaining and enforcing all patents and other rights to Crescent Intellectual Property.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Upon the written request of Crescent, Consultant shall make any assignment provided for in this Section 5 directly to, or for the benefit of, Crescent or Crescent&#39;s designee, including Consultant&#39;s performance of any related obligations hereunder. If Crescent is unable, for any reason, to secure Consultant&#8217;s signature on any document needed in connection with the actions described in Section 5(B) Consultant hereby irrevocably designates and appoints Crescent and its duly authorized officers and agents as Consultant&#8217;s agent and attorney-in-fact to act for and in Consultant&#8217;s behalf to execute, deliver and file any and all documents with the same legal force and effect as if executed by Consultant. Consultant acknowledges that this appointment is coupled with an interest.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">D.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Consultant agrees not to publish any Crescent Intellectual Property without the prior written consent of Crescent.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">E.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Crescent acknowledges that Consultant may possess intellectual property relevant to Consultant&#8217;s business generally, and not developed specifically for Crescent or as a direct result of performing the Services. Any intellectual property described by the preceding sentence is hereinafter referred to as &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consultant Intellectual Property</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.&#8221; Consultant hereby grants Crescent a perpetual, fully paid-up, non-exclusive license to Consultant Intellectual Property for the purposes of receiving or enjoying the benefits of the Services, or of using the end products of the Services.</font></td></tr></table><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">6.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term; Termination</u><font style="font-size:11pt;">. This Agreement is effective as of the Effective Date and will continue in full force until the end of the period specified in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule A</u><font style="font-size:11pt;">, unless terminated as provided in this Section 6.</font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of the Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Either Party may terminate this Agreement at any time without cause upon thirty (30) days&#8217; prior written notice to the other Party. Crescent may also delay or suspend the Services under a Scope of Service at any time for any reason by giving Consultant written notice.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Breach</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Either Party may terminate this Agreement by written notice to the other Party, if the other Party is in breach of its material obligations, representations or warranties set forth in this Agreement, which breach is not cured within ten (10) business days after receipt of written notice of such breach.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Cause</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Either Party may terminate this Agreement upon written notice if the other Party: (a) becomes insolvent; (b) becomes the subject of a petition in bankruptcy which is not withdrawn or dismissed within sixty (60) days thereafter; or (c) makes an assignment for the benefit of creditors.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">D.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligations following Termination</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Upon Consultant&#39;s receipt of Crescent&#39;s notice of termination of this Agreement, Consultant shall use all reasonable efforts to conclude or</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">transfer the Services in accordance with all applicable laws and Crescent&#39;s instructions. If necessary, the Parties shall negotiate in good faith a wind-down plan, including the tasks to be undertaken and the costs associated with the winding down and closing out of the Services. Upon termination of this Agreement, Consultant shall: (a) be entitled only to the fees due and documented expenses, including reasonable and necessary non-cancelable expenses, incurred prior to notice of termination; (b) return the prorated share of any fees Crescent paid in advance under any Scope of Service, and (c) the fees agreed upon for any wind down Services.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">E.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Any termination of this Agreement or a Scope of Service shall not relieve either party of its obligations or liability for breaches or defaults of this Agreement or the Scope of Service incurred prior to or in connection with termination. All rights and obligations of the Parties arising prior to the termination of this Agreement or a Scope of Service, all provisions of this Agreement either allocating responsibility or liability between the Parties, and all rights and obligations of the Parties which by their terms are to be performed or complied with subsequent to or survive the termination of this Agreement, including but not limited to, the Parties&#8217; rights and obligations under Sections 3.E, 4, 5, 6.D, 6.E, 9, 11, 12, and 13 shall survive the termination of this Agreement and any Scopes of Service and continue in effect.</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Debarment or Exclusion Clause</u><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">.</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Consultant hereby certifies that Consultant (i) has never been debarred under the Generic Drug Enforcement Act of 1992, 21 U.S.C. &#167;&#167; 335a(a) or (b), or debarred or sanctioned by any state or federal agency and (ii) is not currently excluded or otherwise ineligible from participating in any federal or state health care program. In the event that during the term of this Agreement Consultant (i) becomes debarred, (ii) becomes excluded or otherwise ineligible from participating in any federal or state health care program, or (iii) receives notice of an action or threat of an action with respect to any such debarment, sanction, or exclusion, Consultant agrees to immediately notify Crescent. Consultant also agrees that in the event that Consultant becomes debarred or excluded Consultant shall immediately cease all activities relating to this Agreement and Crescent shall have the right to terminate this Agreement immediately.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Consultant hereby certifies that it has not and will not use in any capacity the services of any individual, corporation, partnership or association which (i) has been debarred under the Generic Drug Enforcement Act of 1992, 21 U.S.C. &#167;&#167; 335a(a) or (b), (ii) has been debarred or sanctioned by any state or federal agency, or (iii) is excluded or otherwise ineligible from participating in any federal or state health care program. In the event that Consultant becomes aware of the debarment, sanction, or exclusion, or threatened debarment, sanction, or exclusion of any individual, corporation, partnership or association providing services to Consultant which directly or indirectly relate to the Services, Consultant shall notify Crescent immediately. Upon the receipt of such notice by Crescent, or if Crescent otherwise becomes aware of such debarment, sanction, exclusion or threatened debarment, sanction, or exclusion, Crescent shall have the right to terminate this Agreement immediately.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">It is the intent of the Parties that this Agreement and the performance of the Parties&#8217; duties hereunder shall not violate the anti-kickback and related provisions of the Social Security Act, 42 U.S.C. &#167; 1320a-7b(b) (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Anti-Kickback Statute</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;). The Parties represent that they have no intention to violate the prohibitions set forth in the Anti-Kickback Statute in connection with this Agreement. Consultant represents and warrants that Consultant will not attempt to and will not improperly or illegally influence, directly or indirectly individuals licensed to prescribe, and governmental agencies and their employees, by</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">means including, but not limited to, offering inducements through monetary payments or other gifts of value designed to influence decisions relating to the marketing, approval, sale or purchase of Crescent&#8217;s products. Consultant shall receive, for Services contracted hereunder, a fair market value compensation rate.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">D.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">In performing Services, Consultant will perform all obligations in compliance with all relevant anti-corruption laws of the United States including the Foreign Corrupt Practice Act (FCPA), and of other countries, states, provinces or municipalities where Services are to be performed and Studies conducted. Neither Consultant, nor any of Consultant&#8217;s Affiliates shall make any payment or provide any other thing of any value to any government official, political party, official of a political party, candidate for political office, an employee of a state-owned or state-controlled entity, or any other person in order to either influence or induce such person to perform or forbear to perform acts, wherein such performance or forbearance would constitute a violation of anti-corruption laws.</font></td></tr></table><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">8.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Contractor; No Employee Benefits</u><font style="font-size:11pt;">. Nothing in this Agreement shall be construed to create an employment relationship between Consultant and Crescent. Except as specifically set forth herein, neither Party shall have nor exercise any control or direction over the methods by which the other Party performs work or obligations under this Agreement. Consultant shall be an independent contractor and shall have no authority to enter into contracts on behalf of Crescent, bind Crescent to any third parties or act as an agent on behalf of Crescent in any way. Consultant shall not be entitled to receive any compensation, or medical or other benefits as a Crescent employee.</font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publicity, Use of Name, and Disclosures.</u></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Consultant shall not use the name of Crescent, Crescent&#8217;s Affiliates, or any of Crescent&#8217;s or Crescent&#8217;s Affiliate&#8217;s trademarks, whether registered or not, in any oral or written marketing-related communications to third parties, including any websites owned by Consultant, and advertising or customer lists, without Crescent&#8217;s prior written consent.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Consultant&#8217;s relationship with Crescent is confidential information subject to the terms of Section 5, with the exception that Consultant hereby grants to Crescent an option at no additional expense to disclose confidentially, to display in Crescent website, or to issue a public announcement regarding the existence of this Agreement including the appointment of Consultant as &#8220;Chief Executive Officer&#8221; of Crescent and/or the collaboration hereunder during the Term at a time decided by Crescent.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Consultant agrees to the disclosure by Crescent of Consultant&#8217;s name, all funds payable to Consultant or an entity by or in which any Consultant receiving payments is employed, has tenure, or has an ownership interest, and such other information as may be required or appropriate, as follows: (i) as and if required by any laws or regulations applicable to the Services rendered to Crescent, and/or (ii) as may be required by other applicable government authority.</font></td></tr></table><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicts</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicting Obligations</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Consultant represents and warrants that Consultant does not have any relationship with third parties, including competitors of Crescent, which would place them in conflict of interest in the performance of the Services, or which would prevent them from carrying out the terms of this Agreement. Consultant agrees to advise Crescent of any such relationships that arise during the Term of this Agreement. Crescent will then have the option to terminate this Agreement immediately without further liability to Consultant other than the payment of Services performed to the date of termination. Consultant further</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">represents and warrants that Consultant&#8217;s performance of the Services and all other obligations under this Agreement does not and will not breach any written or oral agreement Consultant has entered into, or will enter into, with any other party.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicting Activities</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Consultant agrees that, during the term of the Relationship, other than its activities engaged, assistance provided or actions taken in performing services for the Other Entities, Consultant will not (i) engage in any activity (whether or not during business hours) that is in any way competitive, or prepare to compete, with the business or demonstrably anticipated business of Crescent, (ii) assist any other person or entity in competing, or in preparing to compete, with any business or demonstrably anticipated business of Crescent, and (iii) act as an employee, consultant, director or advisor to any other business, or take any action that would constitute a conflict of interest, without the prior written consent of Crescent. To the extent Consultant serves, has served or will serve as a director or officer of third-party entities, Consultant agrees to use reasonable efforts to avoid or minimize any conflict between the terms of the Agreement, Consultant&#8217;s obligations to such third-party entities and applicable law.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">If so required, Consultant shall notify Consultant&#8217;s institution and/or other applicable authorities or organizations of the financial relationship being established by this Agreement by providing same with a copy of this Agreement prior to providing the Services. If required by local laws or institution policy, Consultant shall obtain authorization from its employer in the signature block at the end of this Agreement.</font></td></tr></table><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">11.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u><font style="font-size:11pt;">. Consultant agrees to indemnify, defend and hold Crescent, its affiliates and their respective directors, officers, agents and employees harmless from and against all claims, demands, damages, losses, judgments and other costs, including court costs and attorneys&#8217; fees, arising out of or based upon (i) any claim that the Services provided hereunder or any related intellectual property rights or the exercise of any rights to any Work Product infringe on, constitute a misappropriation of the subject matter of, or otherwise violate any patent, copyright, trade secret or trademark of any person or breaches any person&#8217;s contractual rights, (ii) any breach or alleged breach by Consultant of any representation, warranty, certification, covenant, obligation or other agreement set forth in this Agreement or (iii) Consultant&#8217;s negligence or willful misconduct under this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;white-space:nowrap;">12.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation of Liability</u><font style="font-size:11pt;">. In no event shall either Party be liable to the other Party under this Agreement for any special, incidental, indirect, exemplary, or consequential damages, whether based on breach of contract, warranty, tort (excluding gross negligence or willful misconduct), lost profits or saving, loss of income, loss of production, punitive damages, injury to reputation, loss of customers or business, or otherwise, and whether or not such Party has been advised of the possibility of such damage.</font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">13.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Provisions</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">A.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliates</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a Party, any entity, that controls, is controlled by, or is under common control with, such Party. For purposes of this definition, &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">control</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; will refer to: (a) the possession, directly or indirectly, of the power to direct the management of an entity, whether through ownership of voting securities, by contract or otherwise, or (b) the ownership, directly or indirectly, of at least fifty percent (50%) of the voting securities or other ownership interest of an entity</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">B.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-exclusivity</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Crescent does not grant exclusivity to Consultant for any of the Services. Crescent is free to obtain the services of any third party to perform any or all of the Services. Consultant shall be free to provide consulting services to any third party and/or be employed by any third party, so long as such provision of consulting services or employment does not impede Consultant&#8217;s provision of the Services.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">C.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; Venue</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. This Agreement will be governed by the laws of the State of Delaware, without giving effect to the principles of conflict of laws. With respect to any disputes arising out of or related to this Agreement, the Parties consent to the exclusive jurisdiction of, and venue in, the state courts in New Castle County in the State of Delaware (or in the event of exclusive federal jurisdiction, the courts of the District of Delaware).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">D.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defend Trade Secrets Act of 2016</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Consultant understands that pursuant to the federal Defend Trade Secrets Act of 2016, an individual may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret the individual&#8217;s attorney and may use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">E.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prevailing Party</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. If it is necessary for a Party to initiate legal proceedings to enforce the terms of this Agreement, the prevailing Party shall be entitled to recover from the non-prevailing Party, in addition to all other remedies, all costs of such enforcement, including reasonable attorneys&#8217; fees.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">F.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. No failure or delay of a Party in exercising any right herein shall act as a waiver thereof, nor shall any single or partial waiver thereof preclude any other or further exercise of any right hereunder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">G.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Amendments and Waivers</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. This Agreement sets forth the entire agreement and understanding between the parties relating to its subject matter and supersedes all prior discussions and agreements (whether oral or written) between the parties with respect thereto. No amendments or waivers to this Agreement will be effective unless in writing and signed by the party against whom such amendment or waiver is to be enforced. The failure of either party to enforce its rights under this Agreement at any time for any period will not be construed as a waiver of such rights; nor shall any single or partial waiver thereof preclude any other or further exercise of any right hereunder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">H.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. If any provision of this Agreement is held invalid by any law, rule, order or regulation of any government or by the final determination of any court of competent jurisdiction, such invalidity shall not affect the enforceability of the enforceability and validity of the remainder of this Agreement and such provisions shall be interpreted so as to best accomplish the objectives of such invalid provisions within the limits of applicable law or court decision.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">I.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Consultant may not assign, transfer or subcontract any obligations under this Agreement without the written consent of Crescent. Any attempt to do so will be void. Crescent may assign its rights and obligations under this Agreement in whole or part. This Agreement will be binding upon Consultant&#8217;s heirs, executors, administrators and other legal representatives, and Consultant&#8217;s successors and permitted assigns, and will be binding on and for the benefit of Crescent and its successors and assigns.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">J.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Consultant acknowledges and agrees that violation of this Agreement may cause Crescent irreparable harm and that Crescent will therefore be entitled to seek extraordinary relief in court, including, but not limited to, temporary restraining orders, preliminary</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">injunctions and permanent injunctions without the necessity of posting a bond or other security (or, if such bond or security is required, Consultant agrees that a $1,000 bond will be adequate), in addition to any other rights or remedies that Crescent may have for a breach of this Agreement. If any party brings any suit, action, counterclaim or other proceeding to enforce or interpret the provisions of this Agreement, the prevailing Party will be entitled to recover a reasonable allowance for attorneys&#8217; fees and litigation expenses in addition to court costs.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">K.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. All notices under this Agreement must be in writing and shall be deemed given when delivered personally and confirmed by signature, or when received after being sent by nationally recognized courier service, or when received when sent by prepaid certified mail, to the address of the Party to be noticed as set forth herein or such other address as such Party last provided to the other Party by written notice.</font></td></tr></table><div style="margin-top:12pt;"></div><div style="padding-left:72pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:25.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:20.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><font style="font-size:11pt;">If to Consultant:</font></p></td><td style="vertical-align:top;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:48.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">If to Crescent:</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Jonathan Violin</font></p></td><td style="vertical-align:top;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;"><font style="font-size:11pt;">Crescent Biopharma, Inc.</font></p></td></tr><tr><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;"><font style="font-size:11pt;">221 Crescent Street</font></p></td></tr><tr><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;"><font style="font-size:11pt;">Building 23, Suite 105</font></p></td></tr><tr><td style="vertical-align:top;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;"><font style="font-size:11pt;">Waltham, MA 02453</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">L.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Not Construed Against Drafter</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. The Parties acknowledge that they have read this Agreement, have had the opportunity to review it with an attorney of their respective choice, and have agreed to all its terms. Under these circumstances, the Parties agree that the rule of construction that a contract be construed against the drafter shall not be applied in interpreting this Agreement and that in the event of any ambiguity in any of the terms or conditions of this Amendment, such ambiguity shall not be construed for or against any Party hereto on the basis that such Party did or did not author same.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">M.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts.</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, and all of which together shall be deemed to be one and the same agreement. A facsimile, PDF or other electronic signature of a Party shall be binding as an original.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">N.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. By signing this Agreement, each Party represents that it is duly authorized to execute, enter into delivery and perform its obligations under this Agreement and that this Agreement is enforceable against it in accordance with its terms.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF</b><font style="font-size:11pt;">, the parties have entered into this Agreement as of the Effective Date.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:40.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CRESCENT BIOPHARMA, INC.</b></p></td><td style="vertical-align:top;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">JONATHAN VIOLIN</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By: </font></p></td><td style="vertical-align:top;width:40.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ K. Evan Thompson</font></p></td><td style="vertical-align:top;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Jonathan Violin</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name: </font></p></td><td style="vertical-align:top;width:40.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">K. Evan Thompson</font></p></td><td style="vertical-align:top;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Title: </font></p></td><td style="vertical-align:top;width:40.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Secretary and Vice President of</font></p></td><td style="vertical-align:top;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Corporate Development</font></p></td><td style="vertical-align:top;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SCHEDULE A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 17.54pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SCOPE OF SERVICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6.15pt 0pt;"><font style="font-size:11pt;">Principal contacts will be:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">Crescent: Peter Harwin / pharwin@fairmountfunds.com</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Services</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Consultation and advice on establishment of operations for Crescent.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Compensation</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 46.1pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consulting Fees</u><font style="font-size:11pt;">. Crescent shall pay to the Consultant fees at a rate of $50,000 per month (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees</u><font style="font-size:11pt;">&#8221;), which Fees shall be payable in arrears on a monthly basis and pro-rated for any partial months of service.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 46.1pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Grant</u><font style="font-size:11pt;">. </font><font style="font-size:11pt;">Subject to approval by the Board of Directors of Crescent (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u><font style="font-size:11pt;">&#8221;), Crescent will grant Consultant shares of Crescent&#8217;s common stock representing 1.25% of Crescent&#8217;s fully-diluted equity (reflecting all outstanding shares of common stock on an as-converted basis) as soon as practicable following the Effective Date (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shares</u><font style="font-size:11pt;">&#8221;). The Shares will be 100% vested on the date of grant. The Shares will be governed by the terms of the related award agreement, the Equity Plan and the terms and conditions approved by the Board.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 46.1pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Stock Purchase</u><font style="font-size:11pt;">. Subject to approval by the Board, Consultant will be provided with the ability to purchase a number of shares of Crescent&#8217;s common stock representing 3.75% of Crescent&#8217;s fully-diluted equity (reflecting all outstanding shares of common stock on an as-converted basis) with a purchase price determined by the Board on the date of grant (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Shares</u><font style="font-size:11pt;">&#8221;). The Restricted Shares will vest as follows: </font><font style="font-size:11pt;">(a) 25% of the Restricted Shares will vest on the one-year anniversary of the Effective Date and (b) 1/48th of the Restricted Shares will vest at the end of each successive month thereafter, provided that Consultant continues to provide services to Crescent from the Effective Date through each such vesting date; provided, however, that in the event Consultant&#8217;s services to Crescent terminate (other than for cause) prior to such vesting date, Crescent will repurchase the unvested Restricted Shares at the lower of cost or fair market value. The Restricted Shares will be governed by the terms of the related award agreement, the Equity Plan and the terms and conditions approved by the Board. Crescent shall permit Consultant to make, and Consultant shall make, a timely election under Section 83(b) of the Internal Revenue Code of 1986, as amended, in accordance with Treasury Regulation 1.83-2 with respect to the Restricted Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 46.1pt;"><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Replenishment Options</u><font style="font-size:11pt;">. </font><font style="font-size:11pt;">Subject to approval by the Board or a committee thereof, following the Effective Date, Crescent (or any successor entity following a reverse merger transaction) will periodically grant to Consultant additional stock options to purchase shares of Crescent&#8217;s common stock, at an exercise price as determined by the Board or a committee thereof (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Replenishment Options</u><font style="font-size:11pt;">&#8221;), in order to maintain your ownership at approximately 5% of Crescent&#8217;s fully-diluted equity (reflecting all outstanding convertible preferred stock, warrants, options and other equity interests that are convertible into or exercisable for common stock on an as-converted and as-exercised basis) until Crescent has raised an aggregate of $200,000,000; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that the Board shall have no obligation to grant you additional stock options thereafter. The Replenishment Options will vest as follows: (i) 25% will be immediately as of the applicable date of grant and (ii) 75% will vest in 48 approximately equal monthly installments commencing on the applicable date(s) of grant; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, that Consultant continues providing services to Crescent through each vesting date. The Replenishment Options will be governed by the terms of the related award agreements, the Equity Plan and the terms and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 46.1pt;"><font style="font-size:11pt;">conditions approved by the Board or a committee thereof; </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-size:11pt;">, that the Replenishment Options will fully vest upon the consummation of a Change in Control (as defined in the Equity Plan), subject to Consultant&#8217;s continued services to Crescent through such Change in Control.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Payments and Invoices</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. Consultant will invoice Crescent quarterly for any expenses. Invoices shall be submitted to AccountsPayable@CrescentBiopharma.com. Each invoice shall describe in reasonable detail the Services related thereto and the expenses incurred in accordance with the terms of this Agreement. Crescent shall pay each undisputed invoice within thirty (30) days after receipt by Crescent of an invoice and all required supporting documentation.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Expenses. </b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">If Crescent requests that Consultant travel in connection with performance of the Services, Crescent will also reimburse Consultant for all out-of-pocket expenses actually incurred by Consultant in rendering services under this Agreement so long as such expenses, in Crescent&#8217;s opinion, are reasonable and necessary and have been pre-approved in writing by Crescent. Such expenses will include reasonable and necessary travel, lodging and meals. Consultant shall provide Crescent with a written expense report, complete with receipts or other reasonable documentation, for all such expenses requested for reimbursement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:27.35pt;padding:0pt;">5.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Term</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. This Agreement will be for a term beginning on the Effective Date and automatically expire upon the date Consultant commences employment with Crescent as its Chief Executive Officer (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Officer Commencement Date</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;).</font></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>10
<FILENAME>glyc-20241231xex10d36.htm
<DESCRIPTION>EXHIBIT-10.36
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:21:47 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Exhibit 10.36</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">INDEMNIFICATION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">THIS INDEMNIFICATION AGREEMENT (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) is made and entered into as of [<font style="font-family:'Symbol';">&#183;</font>], 2024 between Crescent Biopharma, Inc., a Delaware corporation (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;), and [<font style="font-family:'Symbol';">&#183;</font>] (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnitee</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WITNESSETH THAT:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, highly competent persons have become more reluctant to serve companies as directors or officers, or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Board of Directors of the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u>&#8221;) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. Indemnitee may also be entitled to indemnification pursuant to the Delaware General Corporation Law (as amended from time to time, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Act</u>&#8221;). The Act, the Company&#8217;s Certificate of Incorporation (as amended, restated and/or otherwise modified from time to time, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificate of Incorporation</u>&#8221;) and the Company&#8217;s Bylaws (as amended, restated and/or otherwise modified from time to time, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bylaws</u>&#8221;) expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the Board, officers and other persons with respect to indemnification;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company&#8217;s stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, this Agreement is a supplement to and in furtherance of the Bylaws and Certificate of Incorporation of the Company and any resolutions adopted pursuant thereto, and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, Indemnitee does not regard the protection available under the Company&#8217;s Bylaws and insurance as adequate in the present circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he or she be so indemnified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, in consideration of Indemnitee&#8217;s agreement to serve or continue to serve, as applicable, as an officer or director of the Company from and after the date hereof, the parties hereto agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnity of Indemnitee</u>. The Company hereby agrees to hold harmless and indemnify Indemnitee to the fullest extent permitted by law, as such may be amended from time to time. In furtherance of the foregoing indemnification, and without limiting the generality thereof:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proceedings Other Than Proceedings by or in the Right of the Company</u>. Indemnitee shall be entitled to the rights of indemnification provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section l(a)</u> if, by reason of such person&#8217;s Official Status (as hereinafter defined), the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding (as hereinafter defined) other than a Proceeding by or in the right of the Company. Pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1(a)</u>, Indemnitee shall be indemnified against all Expenses (as hereinafter defined), judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by such person, or on such person&#8217;s behalf, in connection with such Proceeding or any claim, issue or matter therein, if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and with respect to any criminal Proceeding, had no reasonable cause to believe the Indemnitee&#8217;s conduct was unlawful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proceedings by or in the Right of the Company</u>. Indemnitee shall be entitled to the rights of indemnification provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1(b)</u> if, by reason of such person&#8217;s Official Status, the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding brought by or in the right of the Company. Pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1(b)</u>, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by the Indemnitee, or on the Indemnitee&#8217;s behalf, in connection with such Proceeding if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company; <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, if applicable law so provides, no indemnification against such Expenses shall be made in respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been adjudged to be liable to the Company unless and to the extent that the Court of Chancery of the State of Delaware shall determine that such indemnification may be made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification for Expenses of a Party Who is Wholly or Partly Successful</u>. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his or her Official Status, a party to (or participant in) and is successful, on the merits or otherwise, in any Proceeding, he or she shall be indemnified to the maximum extent permitted by law, as such may be amended from time to time, against all Expenses actually and reasonably incurred by him or her, or on his or her behalf, in connection </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her, or on his or her behalf, in connection with each successfully resolved claim, issue or matter. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Indemnity</u>. In addition to, and without regard to any limitations on, the indemnification provided for in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1</u> of this Agreement, the Company shall and hereby does indemnify and hold harmless Indemnitee against all Expenses, judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by him or her, or on his or her behalf if, by reason of his or her Official Status, he or she is, or is threatened to be made, a party to or participant in any Proceeding (including a Proceeding by or in the right of the Company), including, without limitation, all liability arising out of the negligence or active or passive wrongdoing of Indemnitee. The only limitation that shall exist upon the Company&#8217;s obligations pursuant to this Agreement shall be that the Company shall not be obligated to make any payment to Indemnitee that is finally determined (under the procedures, and subject to the presumptions, set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 6</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7</u> hereof) to be unlawful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contribution</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Whether or not the indemnification provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2</u> hereof is available, in respect of any threatened, pending or completed action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such action, suit or proceeding without requiring Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have against Indemnitee. The Company shall not enter into any settlement of any action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Without diminishing or impairing the obligations of the Company set forth in the preceding subparagraph, if, for any reason, Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any threatened, pending or completed action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall contribute to the amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received by the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, from the transaction or events from which such action, suit or proceeding arose; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the relative fault of the Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, in connection with the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">transactions or events that resulted in such expenses, judgments, fines or settlement amounts, as well as any other equitable considerations which the applicable law may require to be considered. The relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, shall be determined by reference to, among other things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the degree to which their conduct is active or passive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>The Company hereby agrees to fully indemnify and hold Indemnitee harmless from any claims of contribution which may be brought by officers, directors or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>To the fullest extent permissible under applicable law and without diminishing or impairing the obligations of the Company set forth in the preceding subparagraphs of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</u>, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification for Expenses of a Witness</u>. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his or her Official Status, a witness, or is made (or asked) to respond to discovery requests, in any Proceeding to which Indemnitee is not a party, he or she shall be indemnified against all Expenses actually and reasonably incurred by him or her, or on his or her behalf, in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Advancement of Expenses</u>. Notwithstanding any other provision of this Agreement, the Company shall advance all Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding by reason of Indemnitee&#8217;s Official Status within thirty (30) days after the receipt by the Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by a written undertaking by or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not entitled to be indemnified against such Expenses. Any advances and undertakings to repay pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u> shall be unsecured and interest free and not conditioned on Indemnitee&#8217;s ability to repay such advances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Procedures and Presumptions for Determination of Entitlement to Indemnification</u>. It is the intent of this Agreement to secure for Indemnitee rights of indemnity that are as favorable as may be permitted under the Act and public policy of the State of Delaware. Accordingly, the parties agree that the following procedures and presumptions shall </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">apply in the event of any question as to whether Indemnitee is entitled to indemnification under this Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. Notwithstanding the foregoing, any failure of Indemnitee to provide such a request to the Company, or to provide such a request in a timely fashion, shall not relieve the Company of any liability that it may have to Indemnitee unless, and to the extent that, such failure actually and materially prejudices the interests of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Upon written request by Indemnitee for indemnification pursuant to the first sentence of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(a)</u> hereof, a determination with respect to Indemnitee&#8217;s entitlement thereto shall be made in the specific case by one of the following four methods, which shall be at the election of the Board: (i) by a majority vote of the Disinterested Directors, even though less than a quorum, (ii) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum, (iii) if there are no Disinterested Directors or if the Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to the Indemnitee, or (iv) if so directed by the Board, by the stockholders of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(b)</u> hereof, notwithstanding <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(b)</u> above, the Independent Counsel shall be selected as provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(c)</u>. The Independent Counsel shall be selected by a majority of the votes held by the Board. Indemnitee may, within 10 days after such written notice of selection shall have been given, deliver to the Company a written objection to such selection; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Counsel</u>&#8221; as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13</u> of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If a written objection is made and substantiated, the Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within 20 days after submission by Indemnitee of a written request for indemnification pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(a)</u> hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Court of Chancery of the State of Delaware or other court of competent jurisdiction for resolution of any objection which shall have been made by the Indemnitee to the Company&#8217;s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(b)</u> hereof. The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(b)</u> hereof, and the Company shall pay all reasonable fees and expenses incident to the procedures of this </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(c)</u>, regardless of the manner in which such Independent Counsel was selected or appointed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence. Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>Indemnitee shall be deemed to have acted in good faith if Indemnitee&#8217;s action is based on the records or books of account of the Enterprise (as hereinafter defined), including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise. In addition, the knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(e)</u> are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>If the person, persons or entity empowered or selected under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6</u> to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making such determination with respect to entitlement to indemnification in good faith requires such additional time to obtain or evaluate documentation and/or information relating thereto; and provided further, that the foregoing provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(f)</u> shall not apply if the determination of entitlement to indemnification is to be made by the stockholders pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(b)</u> of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination, the Board or the Disinterested Directors, if appropriate, resolve to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for such purpose within sixty (60) days after having been so called and such determination is made thereat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(g)</font></font>Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any Independent Counsel, member of the Board or stockholder of the Company shall act reasonably and in good faith in making a determination regarding the Indemnitee&#8217;s entitlement to indemnification under this Agreement. Any costs or expenses (including attorneys&#8217; fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee&#8217;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h)</font></font>The Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a party to avoid expense, delay, distraction, disruption and uncertainty. In the event that any action, claim or proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including, without limitation, settlement of such action, claim or proceeding with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise in such action, suit or proceeding. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(i)</font></font>The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies of Indemnitee</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>In the event that (i) a determination is made pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6</u> of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u> of this Agreement, (iii) no determination of entitlement to indemnification is made pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(b)</u> of this Agreement within 90 days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to this Agreement within ten (10) days after receipt by the Company of a written request therefor or (v) payment of indemnification is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6</u> of this Agreement, Indemnitee shall be entitled to an adjudication in an appropriate court of the State of Delaware, or in any other court of competent jurisdiction, of Indemnitee&#8217;s entitlement to such indemnification. Indemnitee shall commence such proceeding seeking an adjudication within </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7(a)</u>. The Company shall not oppose Indemnitee&#8217;s right to seek any such adjudication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>In the event that a determination shall have been made pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(b)</u> of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding commenced pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7</u> shall be conducted in all respects as a de novo trial on the merits, and Indemnitee shall not be prejudiced by reason of the adverse determination under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(b)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>If a determination shall have been made pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6(b)</u> of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding commenced pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7</u>, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s misstatement not materially misleading in connection with the application for indemnification, or (ii) a prohibition of such indemnification under applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>In the event that Indemnitee, pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7</u>, seeks a judicial adjudication of his or her rights under, or to recover damages for breach of, this Agreement, or to recover under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company, the Company shall pay on Indemnitee&#8217;s behalf, in advance, any and all expenses (of the types described in the definition of Expenses in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13</u> of this Agreement) actually and reasonably incurred by him or her in such judicial adjudication, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of expenses or insurance recovery. The Company irrevocably authorizes the Indemnitee from time to time to retain counsel of Indemnitee&#8217;s choice, at the expense of the Company to the extent provided hereunder or under applicable law, to advise and represent Indemnitee in connection with any such judicial adjudication or recovery, including, without limitation, the initiation or defense of any litigation or other legal action, whether by or against the Company or any director, officer, stockholder or other person affiliated with the Company. Notwithstanding any existing or prior attorney-client relationship between the Company and such counsel, the Company irrevocably consents to Indemnitee&#8217;s entering into an attorney-client relationship with such counsel, and in that connection the Company and Indemnitee agree that a confidential relationship shall exist between Indemnitee and such counsel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>The Company shall be precluded from asserting in any judicial proceeding commenced pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7</u> that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court that the Company is bound by all the provisions of this Agreement. The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Exclusivity; Survival of Rights; Insurance; Primacy of Indemnification; Subrogation</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The rights of indemnification as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders, a resolution of directors, of the Company or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Official Status prior to such amendment, alteration or repeal. To the extent that a change in the Act, whether by statute or judicial decision, permits greater indemnification than would be afforded currently under the Certificate of Incorporation, Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any director, officer, employee, agent or fiduciary under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>The Company&#8217;s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exception to Right of Indemnification</u>. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any claim made against Indemnitee:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 16(b)</u> of the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common law; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation, (ii) the Proceeding is initiated by Indemnitee pursuant to Indemnitee&#8217;s rights under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7</u> of this Agreement, or (iii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Duration of Agreement</u>. All agreements and obligations of the Company contained herein shall continue during the period ending three years after Indemnitee ceases to serve in an Official Status (or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise) and shall continue thereafter so long as Indemnitee shall be subject to any Proceeding (or any proceeding commenced under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7</u> hereof) by reason of his or her Official Status, whether or not he or she is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), assigns, spouses, heirs, executors and personal and legal representatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security</u>. To the extent requested by Indemnitee and approved by the Board, the Company may at any time and from time to time provide security to Indemnitee for the Company&#8217;s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral. Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of the Indemnitee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enforcement</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The Company expressly confirms and agrees that it has entered into this Agreement and assumes the obligations imposed on it hereby in order to induce Indemnitee to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">serve as an officer or director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as an officer or director of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>The Company shall not seek from a court, or agree to, a &#8220;bar order&#8221; which would have the effect of prohibiting or limiting the Indemnitee&#8217;s rights to receive advancement of expenses under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. For purposes of this Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disinterested Director</u>&#8221; means a director of the Company who is not and was not a party to the action, claim or proceeding in respect of which indemnification is sought by Indemnitee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enterprise</u>&#8221; shall mean the Company and any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that Indemnitee is or was serving at the express written request of the Company as a director, officer, employee, agent or fiduciary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</u>&#8221; shall include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, participating, or being or preparing to be a witness in a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding. Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding and any federal, state, local or foreign taxes imposed on the Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, including, without limitation, the premium, security for, and other costs relating to any cost bond, supersede as bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Counsel</u>&#8221; means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &#8220;Independent Counsel&#8221; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement. The Company agrees to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Official Status</u>&#8221; describes the status of a person who is or was a director, officer, employee, agent or fiduciary of the Company or of any other limited liability company, corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person is or was serving at the express written request of the Company. For purposes of this Agreement, a director, officer, employee, agent or fiduciary of the Company who is serving or has served as a director, officer, employee, agent or fiduciary of a subsidiary of the Company shall be deemed to be serving in such capacity at the request of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(f)</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proceeding</u>&#8221; includes any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and whether civil, criminal, administrative or investigative, in which Indemnitee was, is or will be involved as a party or otherwise, by reason of his or her Official Status, by reason of any action taken by him or her, or of any inaction on his or her part, while acting in his or her Official Status, or by reason of the fact that he or she is or was serving at the request of the Company as a director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust or other Enterprise; in each case whether or not he or she is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement; including one pending on or before the date of this Agreement, but excluding one initiated by an Indemnitee pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7</u> of this Agreement to enforce his or her rights under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. Further, the invalidity or unenforceability of any provision hereof as to Indemnitee shall in no way affect the validity or enforceability of any provision hereof as to the other. Without limiting the generality of the foregoing, this Agreement is intended to confer upon Indemnitee indemnification rights to the fullest extent permitted by applicable laws. In the event any provision hereof conflicts with any applicable law, such provision shall be deemed modified, consistent with the aforementioned intent, to the extent necessary to resolve such conflict.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Modification and Waiver</u>. No supplement, modification, termination or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice By Indemnitee</u>. Indemnitee agrees promptly to notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification covered hereunder. The failure to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise unless and only to the extent that such failure or delay materially prejudices the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">17.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>To Indemnitee at the address set forth below Indemnitee signature hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>To the Company at:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">221 Crescent Street, Building 23, Suite 105</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Waltham, MA 02453</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Attention: President</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">With a copy to (which shall not constitute notice):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Gibson, Dunn &amp; Crutcher LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">One Embarcadero Center, Suite #2600</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">San Francisco, CA 94111</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Attention: Ryan Murr and Branden Berns</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Email: rmurr@gibsondunn.com; bberns@gibsondunn.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or to such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">18.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u>. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law and Consent to Jurisdiction</u>. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware Court</u>&#8221;), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[Signature page follows]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement on and as of the day and year first above written.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:45.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CRESCENT BIOPHARMA, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:45.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:45.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">K. Evan Thompson</p></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Secretary and Vice President of</p></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate Development</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">INDEMNITEE</b></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">SIGNATURE PAGE TO INDEMNIFICATION AGREEMENT (CRESCENT BIOPHARMA, INC.)</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>11
<FILENAME>glyc-20241231xex10d37.htm
<DESCRIPTION>EXHIBIT-10.37
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:21:52 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.37</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consulting Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Consulting Agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) is effective as of September 28, 2024 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221;), <b style="font-weight:bold;">Crescent Biopharma, Inc.</b>, a Delaware corporation, with a primary place of business at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Crescent</u>&#8221;), and <b style="font-weight:bold;">Christopher Doughty </b>(&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consultant</u>&#8221;). Crescent and the Consultant may be referred to herein individually as <i style="font-style:italic;">&#8220;</i><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</u><i style="font-style:italic;">&#8221; </i>or collectively, as <i style="font-style:italic;">&#8220;</i><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</u>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recitals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Whereas, </b>Consultant has certain special expertise and knowledge regarding biotechnology companies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Whereas, </b>Crescent has need of Consultant&#8217;s expertise; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Whereas, </b>Crescent and Consultant desire to enter into this Agreement in order to set out the terms for Consultant to the services to Crescent as further described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Therefore, </b>in consideration of the promises and undertakings set forth herein, the Parties agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.</u></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Services and Payment</u>. Consultant agrees to provide the services described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule A</u> attached hereto (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Services</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.</u></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance.</u> For the Term of this Agreement, Consultant will provide all time, resources and attention required for the performance of the Services and will always act in the best interest of Crescent. Consultant represents that it has the requisite expertise, ability and legal right to provide the Services. The manner and means used by the Consultant to perform the Services desired by Crescent are in the sole discretion and control of the Consultant. Consultant agrees to perform the Services in a prompt, efficient, skillful and professional manner.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Services will be provided solely by Consultant. Consultant may not subcontract any of the Services under this Agreement to any third party.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Consultant represents that it has the requisite expertise, ability, and legal right to provide the Services and will perform the Services diligently and with due care. Consultant will abide by all applicable laws, rules, and regulations applicable to it in the performance of the Services. Crescent acknowledges and agrees that Consultant will perform the Services on a best efforts basis.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Consultant shall keep Crescent reasonably informed about the status of the Services. Consultant agrees to participate in activities including meetings and/or conference calls if required that may be held on a regular basis between Consultant and Crescent to evaluate, review or discuss the progress made on the performance of the Services.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Consultant shall not disclose to Crescent any confidential or proprietary information that belongs to any third party unless Consultant first obtains the consent of such third party and enters into a separate confidentiality agreement with Crescent covering that disclosure. Consultant shall not represent to Crescent as being unrestricted any designs, plans, models,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">samples, or other writings or products that Consultant knows are covered by valid patent, copyright, or other form of intellectual property protection belong to a third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation</u>.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation</u>. As the only consideration due Consultant for such Services, Crescent will provide Consultant with the consideration described in the Scope of Services, attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule A</u>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reimbursement for Expenses</u>. Certain expenses may be identified on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule A</u> as reimbursable by Crescent. If and only if <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule A</u> provides for the reimbursement of such expenses, Consultant may obtain reimbursement of such expenses by submitting expense reports with receipts or such other documentation as may be required under Crescent&#8217;s policies or under the terms of this Agreement. All other expenses incurred by Consultant in connection with providing the Services under this Agreement will be the sole responsibility of Consultant.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Invoicing</u>. Consultant shall invoice Crescent in accordance with the invoice schedule in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule A</u>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u>. Consultant hereby acknowledges that Crescent will report as compensation all payments to Consultant hereunder. Consultant will pay all required taxes on Consultant&#39;s income from Crescent under this Agreement. Consultant will provide Crescent with Consultant&#8217;s taxpayer identification number or social security number, as applicable.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">E.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Benefits</u>. During the Term, Crescent shall not be obligated, under any circumstances, to pay for, or keep in effect, any hospitalization, health, life or other insurance for the benefit of Consultant, to pay any employment or similar taxes, to make any tax withholdings or to provide any benefits that Crescent provides to its employees. All payroll and employment taxes, insurance and benefits shall be the sole responsibility of Consultant. If Consultant (or any individual service provider of Consultant) is reclassified by a state or federal agency or court as Crescent&#8217;s employee, Consultant and its individual service providers will receive no benefits from Crescent, except those mandated by state or federal law, even if by the terms of Crescent&#8217;s benefit plans or programs of Crescent in effect at the time of such reclassification, Consultant or any individual service provider would otherwise be eligible for such benefits.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u>.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definition</u>. For purposes of this Agreement, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u>&#8221; means information not generally known or available outside Crescent and information entrusted to Crescent in confidence by third parties. Confidential Information includes, but is not limited to, all information and data in whatever form disclosed to Consultant by or on behalf of Crescent or its Affiliates, including, without limitation, information concerning Crescent&#8217;s business, financial condition, operations, inventions, know-how, procedures, products, marketing plans, developmental or experimental work, clinical or other programs, and plans for research and development. Confidential Information also includes (i) any written work product or deliverables provided by Consultant to Crescent pursuant to this Agreement, and (ii) the existence and terms of this Agreement. Consultant acknowledges the confidential and secret character of the Confidential Information and agrees that the</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Confidential Information is the sole, exclusive and extremely valuable property of Crescent.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Confidential Information does not include information that Consultant can demonstrate by competent evidence (i) was in the public domain at the time of its receipt from or on behalf of Crescent or thereafter enters into the public domain through no fault of the Consultant; (ii) was already in Consultant&#8217;s possession prior to receipt from or on behalf of Crescent, as evidenced by Consultant&#8217;s written records, and under no obligation of confidentiality to Crescent; or (iii) was or is furnished to Consultant by a third party not bound by any obligation of confidentiality.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">At all times during and following the Term of this Agreement, Consultant shall not, directly or indirectly: (i) reproduce any of the Confidential Information except as necessary to perform the Services without the applicable prior written consent of Crescent, (ii) use the Confidential Information except in the performance of the Services, (iii) disclose, divulge, reveal, report, publish, or transfer to any third party for any purpose whatsoever, any Confidential Information, and (iv) keep in confidence all Confidential Information. Consultant will exercise all reasonable precautions to physically protect the confidentiality of the Confidential Information. Consultant shall, promptly upon request, whether during or after Term, return to Crescent or destroy any and all Confidential Information (whether in hard copy or electronic format, and including any copies thereof) in Consultant&#8217;s possession or under Consultant&#8217;s control, and upon request shall certify to Crescent the return or destruction of all such Confidential Information.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Consultant agrees and acknowledges that, in the event of any breach of this Agreement by Consultant, Crescent may be irreparably and immediately harmed and may not be made whole by monetary damages. Accordingly, it is agreed that, in addition to any other remedy to which it may be entitled in law or in equity Crescent, shall be entitled to seek an injunction or injunctions in a court of competent jurisdiction to prevent breaches or threatened breaches of this Agreement and/or to seek to compel specific performance of this Agreement. Nothing herein shall be construed as prohibiting Crescent from pursuing any other remedies available to it for such breach or threatened breach, including the recovery of damages.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">E.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Consultant shall, promptly upon request, whether during or after the Term, return to Crescent or destroy any and all Confidential Information (whether in hard copy or electronic format, and including any copies thereof) in Consultant&#8217;s possession or under Consultant&#8217;s control, and upon request shall certify to Crescent the return or destruction of all such Confidential Information.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">F.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If Consultant is required by a governmental authority or by order of a court of competent jurisdiction to disclose any of Crescent&#8217;s Confidential Information, Consultant will give Crescent prompt advance written notice thereof (if legally permitted) and Consultant will take all reasonable and lawful actions to avoid or minimize the degree of such disclosure at Crescent&#8217;s cost. Consultant will cooperate reasonably with Crescent in any efforts to seek a protective order.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</u>.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Nothing in this Agreement will affect a Party&#8217;s rights to its Background Intellectual Property nor imply a grant of any license to a Party&#8217;s Background Intellectual Property</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">unless expressly set forth herein. Except as expressly provided in this Agreement, no right, title or interest in or to any Crescent product or any trademark or any other intellectual property right of Crescent is granted, whether express or implied, by Crescent to Consultant. &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background Intellectual Property</u>&#8221; means all intellectual property owned or licensed by the respective Parties as of the Effective Date (and during the term of this Agreement) and/or any intellectual property conceived, reduced to practice, used or developed by either Party outside the scope of this Agreement, and any improvements or enhancements thereof, and that is under the control of either Party and that is reasonably necessary, relevant or otherwise useful for performing the Services under this Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Consultant hereby agrees that any know-how, invention, discovery, improvement, drawing or design or other intellectual property which Consultant develops as a result of performing the Services (collectively, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Crescent Intellectual Property</u>&#8221;) are &#8220;works for hire,&#8221; and furthermore, Consultant hereby assigns to Crescent any right, title, and interest Consultant may have in any Crescent Intellectual Property. Upon the request of Crescent, Consultant shall provide Crescent with all documentation relating to any Crescent Intellectual Property, and execute and deliver to Crescent such further assignments, documents, and other instruments, as may be necessary to assign Crescent Intellectual Property to Crescent and to assist Crescent in applying for, obtaining and enforcing patents or other rights in the United States and in any foreign country with respect to any Crescent Intellectual Property. Crescent will bear the cost of preparation of all patent or other applications and assignments, and the cost of obtaining and enforcing all patents and other rights to Crescent Intellectual Property.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Upon the written request of Crescent, Consultant shall make any assignment provided for in this Section 5 directly to, or for the benefit of, Crescent or Crescent&#39;s designee, including Consultant&#39;s performance of any related obligations hereunder. If Crescent is unable, for any reason, to secure Consultant&#8217;s signature on any document needed in connection with the actions described in Section 5(B) Consultant hereby irrevocably designates and appoints Crescent and its duly authorized officers and agents as Consultant&#8217;s agent and attorney-in-fact to act for and in Consultant&#8217;s behalf to execute, deliver and file any and all documents with the same legal force and effect as if executed by Consultant. Consultant acknowledges that this appointment is coupled with an interest.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Consultant agrees not to publish any Crescent Intellectual Property without the prior written consent of Crescent.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">E.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Crescent acknowledges that Consultant may possess intellectual property relevant to Consultant&#8217;s business generally, and not developed specifically for Crescent or as a direct result of performing the Services. Any intellectual property described by the preceding sentence is hereinafter referred to as &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consultant Intellectual Property</u>.&#8221; Consultant hereby grants Crescent a perpetual, fully paid-up, non-exclusive license to Consultant Intellectual Property for the purposes of receiving or enjoying the benefits of the Services, or of using the end products of the Services.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term; Termination</u>. This Agreement is effective as of the Effective Date and will continue in full force until the end of the period specified in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule A</u>, unless terminated as provided in this Section 6.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of the Agreement</u>. Either Party may terminate this Agreement at any time without cause upon thirty (30) days&#8217; prior written notice to the other Party. Crescent may</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">also delay or suspend the Services under a Scope of Service at any time for any reason by giving Consultant written notice.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Breach</u>. Either Party may terminate this Agreement by written notice to the other Party, if the other Party is in breach of its material obligations, representations or warranties set forth in this Agreement, which breach is not cured within ten (10) business days after receipt of written notice of such breach.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Cause</u>. Either Party may terminate this Agreement upon written notice if the other Party: (a) becomes insolvent; (b) becomes the subject of a petition in bankruptcy which is not withdrawn or dismissed within sixty (60) days thereafter; or (c) makes an assignment for the benefit of creditors.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligations following Termination</u>. Upon Consultant&#39;s receipt of Crescent&#39;s notice of termination of this Agreement, Consultant shall use all reasonable efforts to conclude or transfer the Services in accordance with all applicable laws and Crescent&#39;s instructions. If necessary, the Parties shall negotiate in good faith a wind-down plan, including the tasks to be undertaken and the costs associated with the winding down and closing out of the Services. Upon termination of this Agreement, Consultant shall: (a) be entitled only to the fees due and documented expenses, including reasonable and necessary non-cancelable expenses, incurred prior to notice of termination; (b) return the prorated share of any fees Crescent paid in advance under any Scope of Service, and (c) the fees agreed upon for any wind down Services.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">E.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u>. Any termination of this Agreement or a Scope of Service shall not relieve either party of its obligations or liability for breaches or defaults of this Agreement or the Scope of Service incurred prior to or in connection with termination. All rights and obligations of the Parties arising prior to the termination of this Agreement or a Scope of Service, all provisions of this Agreement either allocating responsibility or liability between the Parties, and all rights and obligations of the Parties which by their terms are to be performed or complied with subsequent to or survive the termination of this Agreement, including but not limited to, the Parties&#8217; rights and obligations under Sections 3.E, 4, 5, 6.D, 6.E, 9, 11, 12, and 13 shall survive the termination of this Agreement and any Scopes of Service and continue in effect.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Debarment or Exclusion Clause</u><b style="font-weight:bold;">.</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Consultant hereby certifies that Consultant (i) has never been debarred under the Generic Drug Enforcement Act of 1992, 21 U.S.C. &#167;&#167; 335a(a) or (b), or debarred or sanctioned by any state or federal agency and (ii) is not currently excluded or otherwise ineligible from participating in any federal or state health care program. In the event that during the term of this Agreement Consultant (i) becomes debarred, (ii) becomes excluded or otherwise ineligible from participating in any federal or state health care program, or (iii) receives notice of an action or threat of an action with respect to any such debarment, sanction, or exclusion, Consultant agrees to immediately notify Crescent. Consultant also agrees that in the event that Consultant becomes debarred or excluded Consultant shall immediately cease all activities relating to this Agreement and Crescent shall have the right to terminate this Agreement immediately.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Consultant hereby certifies that it has not and will not use in any capacity the services of any individual, corporation, partnership or association which (i) has been debarred under</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">the Generic Drug Enforcement Act of 1992, 21 U.S.C. &#167;&#167; 335a(a) or (b), (ii) has been debarred or sanctioned by any state or federal agency, or (iii) is excluded or otherwise ineligible from participating in any federal or state health care program. In the event that Consultant becomes aware of the debarment, sanction, or exclusion, or threatened debarment, sanction, or exclusion of any individual, corporation, partnership or association providing services to Consultant which directly or indirectly relate to the Services, Consultant shall notify Crescent immediately. Upon the receipt of such notice by Crescent, or if Crescent otherwise becomes aware of such debarment, sanction, exclusion or threatened debarment, sanction, or exclusion, Crescent shall have the right to terminate this Agreement immediately.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">It is the intent of the Parties that this Agreement and the performance of the Parties&#8217; duties hereunder shall not violate the anti-kickback and related provisions of the Social Security Act, 42 U.S.C. &#167; 1320a-7b(b) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Anti-Kickback Statute</u>&#8221;). The Parties represent that they have no intention to violate the prohibitions set forth in the Anti-Kickback Statute in connection with this Agreement. Consultant represents and warrants that Consultant will not attempt to and will not improperly or illegally influence, directly or indirectly individuals licensed to prescribe, and governmental agencies and their employees, by means including, but not limited to, offering inducements through monetary payments or other gifts of value designed to influence decisions relating to the marketing, approval, sale or purchase of Crescent&#8217;s products. Consultant shall receive, for Services contracted hereunder, a fair market value compensation rate.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In performing Services, Consultant will perform all obligations in compliance with all relevant anti-corruption laws of the United States including the Foreign Corrupt Practice Act (FCPA), and of other countries, states, provinces or municipalities where Services are to be performed and Studies conducted. Neither Consultant, nor any of Consultant&#8217;s Affiliates shall make any payment or provide any other thing of any value to any government official, political party, official of a political party, candidate for political office, an employee of a state-owned or state-controlled entity, or any other person in order to either influence or induce such person to perform or forbear to perform acts, wherein such performance or forbearance would constitute a violation of anti-corruption laws.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Contractor; No Employee Benefits</u>. Nothing in this Agreement shall be construed to create an employment relationship between Consultant and Crescent. Except as specifically set forth herein, neither Party shall have nor exercise any control or direction over the methods by which the other Party performs work or obligations under this Agreement. Consultant shall be an independent contractor and shall have no authority to enter into contracts on behalf of Crescent, bind Crescent to any third parties or act as an agent on behalf of Crescent in any way. Consultant shall not be entitled to receive any compensation, or medical or other benefits as a Crescent employee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publicity, Use of Name, and Disclosures.</u></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Consultant shall not use the name of Crescent, Crescent&#8217;s Affiliates, or any of Crescent&#8217;s or Crescent&#8217;s Affiliate&#8217;s trademarks, whether registered or not, in any oral or written marketing-related communications to third parties, including any websites owned by Consultant, and advertising or customer lists, without Crescent&#8217;s prior written consent.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Consultant&#8217;s relationship with Crescent is confidential information subject to the terms of Section 5, with the exception that Consultant hereby grants to Crescent an option at no additional expense to disclose confidentially, to display in Crescent website, or to issue a</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">public announcement regarding the existence of this Agreement including the appointment of Consultant as &#8220;Chief Business Officer&#8221; of Crescent and/or the collaboration hereunder during the Term at a time decided by Crescent.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Consultant agrees to the disclosure by Crescent of Consultant&#8217;s name, all funds payable to Consultant or an entity by or in which any Consultant receiving payments is employed, has tenure, or has an ownership interest, and such other information as may be required or appropriate, as follows: (i) as and if required by any laws or regulations applicable to the Services rendered to Crescent, and/or (ii) as may be required by other applicable government authority.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicts</u>.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicting Obligations</u>. Consultant represents and warrants that Consultant does not have any relationship with third parties, including competitors of Crescent, which would place them in conflict of interest in the performance of the Services, or which would prevent them from carrying out the terms of this Agreement. Consultant agrees to advise Crescent of any such relationships that arise during the Term of this Agreement. Crescent will then have the option to terminate this Agreement immediately without further liability to Consultant other than the payment of Services performed to the date of termination. Consultant further represents and warrants that Consultant&#8217;s performance of the Services and all other obligations under this Agreement does not and will not breach any written or oral agreement Consultant has entered into, or will enter into, with any other party.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicting Activities</u>. Consultant agrees that, during the term of the Relationship, other than its activities engaged, assistance provided or actions taken in performing services for the Other Entities, Consultant will not (i) engage in any activity (whether or not during business hours) that is in any way competitive, or prepare to compete, with the business or demonstrably anticipated business of Crescent, (ii) assist any other person or entity in competing, or in preparing to compete, with any business or demonstrably anticipated business of Crescent, and (iii) act as an employee, consultant, director or advisor to any other business, or take any action that would constitute a conflict of interest, without the prior written consent of Crescent. To the extent Consultant serves, has served or will serve as a director or officer of third-party entities, Consultant agrees to use reasonable efforts to avoid or minimize any conflict between the terms of the Agreement, Consultant&#8217;s obligations to such third-party entities and applicable law.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">If so required, notwithstanding anything in this Agreement to the contrary, Consultant shall notify Consultant&#8217;s institution and/or other applicable authorities or organizations of the financial relationship being established by this Agreement by providing same with a copy of this Agreement prior to providing the Services. If required by local laws or institution policy, Consultant shall obtain authorization from its employer in the signature block at the end of this Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u>. Consultant agrees to indemnify, defend and hold Crescent, its affiliates and their respective directors, officers, agents and employees harmless from and against all claims, demands, damages, losses, judgments and other costs, including court costs and attorneys&#8217; fees, arising out of or based upon (i) any claim that the Services provided hereunder or any related intellectual property rights or the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">exercise of any rights to any Work Product infringe on, constitute a misappropriation of the subject matter of, or otherwise violate any patent, copyright, trade secret or trademark of any person or breaches any person&#8217;s contractual rights, (ii) any breach or alleged breach by Consultant of any representation, warranty, certification, covenant, obligation or other agreement set forth in this Agreement or (iii) Consultant&#8217;s negligence or willful misconduct under this Agreement. Crescent agrees to indemnify, defend and hold Consultant harmless from and against all claims demands, damages, losses, judgments and other costs, including court costs and attorneys&#8217; fees, arising out of or based upon any breach or alleged breach by Crescent of any representation, warranty, certification, covenant, obligation or other agreement set forth in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation of Liability</u>. In no event shall either Party be liable to the other Party under this Agreement for any special, incidental, indirect, exemplary, or consequential damages, whether based on breach of contract, warranty, tort (excluding gross negligence or willful misconduct), lost profits or saving, loss of income, loss of production, punitive damages, injury to reputation, loss of customers or business, or otherwise, and whether or not such Party has been advised of the possibility of such damage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Provisions</u>.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">A.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliates</u>. &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</u>&#8221; means, with respect to a Party, any entity, that controls, is controlled by, or is under common control with, such Party. For purposes of this definition, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">control</u>&#8221; will refer to: (a) the possession, directly or indirectly, of the power to direct the management of an entity, whether through ownership of voting securities, by contract or otherwise, or (b) the ownership, directly or indirectly, of at least fifty percent (50%) of the voting securities or other ownership interest of an entity</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">B.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-exclusivity</u>. Crescent does not grant exclusivity to Consultant for any of the Services. Crescent is free to obtain the services of any third party to perform any or all of the Services. Consultant shall be free to provide consulting services to any third party and/or be employed by any third party, so long as such provision of consulting services or employment does not impede Consultant&#8217;s provision of the Services.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">C.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; Venue</u>. This Agreement will be governed by the laws of the State of Delaware, without giving effect to the principles of conflict of laws. With respect to any disputes arising out of or related to this Agreement, the Parties consent to the exclusive jurisdiction of, and venue in, the state courts in New Castle County in the State of Delaware (or in the event of exclusive federal jurisdiction, the courts of the District of Delaware).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">D.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defend Trade Secrets Act of 2016</u>. Crescent acknowledges and agrees and Consultant understands that pursuant to the federal Defend Trade Secrets Act of 2016, an individual may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret the individual&#8217;s attorney and may use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">E.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prevailing Party</u>. If it is necessary for a Party to initiate legal proceedings to enforce the terms of this Agreement, the prevailing Party shall be entitled to recover from the non-prevailing Party, in addition to all other remedies, all costs of such enforcement, including reasonable attorneys&#8217; fees.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">F.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u>. No failure or delay of a Party in exercising any right herein shall act as a waiver thereof, nor shall any single or partial waiver thereof preclude any other or further exercise of any right hereunder.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">G.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement; Amendments and Waivers</u>. This Agreement sets forth the entire agreement and understanding between the parties relating to its subject matter and supersedes all prior discussions and agreements (whether oral or written) between the parties with respect thereto. No amendments or waivers to this Agreement will be effective unless in writing and signed by the party against whom such amendment or waiver is to be enforced. The failure of either party to enforce its rights under this Agreement at any time for any period will not be construed as a waiver of such rights; nor shall any single or partial waiver thereof preclude any other or further exercise of any right hereunder.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">H.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. If any provision of this Agreement is held invalid by any law, rule, order or regulation of any government or by the final determination of any court of competent jurisdiction, such invalidity shall not affect the enforceability of the enforceability and validity of the remainder of this Agreement and such provisions shall be interpreted so as to best accomplish the objectives of such invalid provisions within the limits of applicable law or court decision.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">I.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u>. Consultant may not assign, transfer or subcontract any obligations under this Agreement without the written consent of Crescent. Any attempt to do so will be void. Crescent may assign its rights and obligations under this Agreement in whole or part. This Agreement will be binding upon Consultant&#8217;s heirs, executors, administrators and other legal representatives, and Consultant&#8217;s successors and permitted assigns, and will be binding on and for the benefit of Crescent and its successors and assigns.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">J.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies</u>. Consultant acknowledges and agrees that violation of this Agreement may cause Crescent irreparable harm and that Crescent will therefore be entitled to seek extraordinary relief in court, including, but not limited to, temporary restraining orders, preliminary injunctions and permanent injunctions without the necessity of posting a bond or other security (or, if such bond or security is required, Consultant agrees that a $1,000 bond will be adequate), in addition to any other rights or remedies that Crescent may have for a breach of this Agreement. If any party brings any suit, action, counterclaim or other proceeding to enforce or interpret the provisions of this Agreement, the prevailing Party will be entitled to recover a reasonable allowance for attorneys&#8217; fees and litigation expenses in addition to court costs.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">K.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. All notices under this Agreement must be in writing and shall be deemed given when delivered personally and confirmed by signature, or when received after being sent by nationally recognized courier service, or when received when sent by prepaid certified mail, to the address of the Party to be noticed as set forth herein or such other address as such Party last provided to the other Party by written notice.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:72pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:86.65%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">If to Consultant:</p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If to Crescent:</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 10.8pt;">Christopher Doughty</p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 10.8pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 10.8pt;">Crescent Biopharma, Inc.</p></td></tr><tr><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 10.8pt;"><font style="color:#242424;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 10.8pt;"><font style="color:#242424;">221 Crescent Street</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 10.8pt;"><font style="color:#242424;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 10.8pt;"><font style="color:#242424;">Building 23, Suite 105</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 10.8pt;"><font style="color:#242424;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 10.8pt;"><font style="color:#242424;">Waltham, MA 02453</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">L.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Not Construed Against Drafter</u>. The Parties acknowledge that they have read this Agreement, have had the opportunity to review it with an attorney of their respective choice, and have agreed to all its terms. Under these circumstances, the Parties agree that the rule of construction that a contract be construed against the drafter shall not be applied in interpreting this Agreement and that in the event of any ambiguity in any of the terms or conditions of this Amendment, such ambiguity shall not be construed for or against any Party hereto on the basis that such Party did or did not author same.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">M.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts.</u> This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, and all of which together shall be deemed to be one and the same agreement. A facsimile, PDF or other electronic signature of a Party shall be binding as an original.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">N.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority</u>. By signing this Agreement, each Party represents that it is duly authorized to execute, enter into delivery and perform its obligations under this Agreement and that this Agreement is enforceable against it in accordance with its terms.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the parties have entered into this Agreement as of the Effective Date.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:50.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Crescent Biopharma, Inc.</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Christopher Doughty</b></p></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:50.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ K. Evan Thompson</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Christopher Doughty</p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:45.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">K. Evan Thompson</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:45.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Secretary and Vice President of Corporate Development</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SCHEDULE A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 17.54pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SCOPE OF SERVICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Principal contacts will be:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Crescent: Jonathan Violin / jviolin@crescentbiopharma.com</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Services</b>. Consultation and advice on establishment of operations for Crescent.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Compensation</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consulting Fees</u>. Crescent shall pay to the Consultant fees at a rate of $35,416 per month (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees</u>&#8221;), which Fees shall be payable in arrears on a monthly basis and pro-rated for any partial months of service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity</u>. Subject to approval by the Board of Directors of Crescent (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u>&#8221;), Consultant will be provided with the ability to purchase a number of shares of Crescent&#8217;s common stock representing 1% of Crescent&#8217;s fully-diluted equity (reflecting all outstanding shares of common stock on an as-converted basis) with a purchase price determined by the Board on the date of grant (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Shares</u>&#8221;) as soon as practicable following the Effective Date. The Restricted Shares will vest as follows: (a) 25% of the Restricted Shares will vest on the one-year anniversary of the Effective Date and (b) 1/48th of the Restricted Shares will vest at the end of each successive month thereafter, provided that Consultant continues to provide services to Crescent from the Effective Date through each such vesting date. Crescent shall permit Consultant to make, and Consultant shall make, a timely election under Section 83(b) of the Internal Revenue Code of 1986, as amended, in accordance with Treasury Regulation 1.83-2 with respect to the Restricted Shares.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Payments and Invoices</b>. Consultant will invoice Crescent quarterly for any expenses. &#160;Invoices shall be submitted to AccountsPayable@CrescentBiopharma.com. &#160;Each invoice shall describe in reasonable detail the Services related thereto and the expenses incurred in accordance with the terms of this Agreement. Crescent shall pay each undisputed invoice within 30 days after receipt by Crescent of an invoice and all required supporting documentation.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Expenses</b>. If Crescent requests that Consultant travel in connection with performance of the Services, Crescent will also reimburse Consultant for all out-of-pocket expenses actually incurred by Consultant in rendering services under this Agreement so long as such expenses, in Crescent&#8217;s opinion, are reasonable and necessary and have been pre-approved in writing by Crescent. Such expenses will include reasonable and necessary travel, lodging and meals. Consultant shall provide Crescent with a written expense report, complete with receipts or other reasonable documentation, for all such expenses requested for reimbursement.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Term</b>. This Agreement will be for a term beginning on the Effective Date and automatically expire upon the date Consultant commences employment with Crescent as its Chief Business Officer (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Officer Commencement Date</u>&#8221;) pursuant to that certain form of offer letter attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule B</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Offer Letter</u>&#8221;) or otherwise.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SCHEDULE B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Offer Letter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[See Attached]</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>12
<FILENAME>glyc-20241231xex10d38.htm
<DESCRIPTION>EXHIBIT-10.38
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:21:53 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.38</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">November 27, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Christopher Doughty</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Email &#8211; [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Re: Offer of Employment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dear Christopher:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On behalf of Crescent Biopharma, Inc. (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;), I am very pleased to offer you a position as Chief Business Officer of the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Role</u>&#8221;) pursuant to this letter agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;), provided you accept such offer as indicated by your signature below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Your employment with the Company in the Role will commence as of December 31, 2024 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221;). Should you not commence services by the Effective Date or if this Agreement is otherwise terminated on or prior to the Effective Date, you hereby agree that this Agreement shall be void <i style="font-style:italic;">ab initio</i> and of no force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;">Position</b>. While serving in the Role, you will initially report to the Company&#8217;s Chief Executive Officer or such other person as the Board of Directors of the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u>&#8221;) may designate, and have such duties, authorities, and responsibilities as are customarily associated with the Role. This is a full-time employment position. It is understood and agreed that, commencing as of the Effective Date you will not engage in any other employment, consulting or other business activities (whether full-time or part-time), except as otherwise expressly authorized in writing by the Company. Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">Base Salary</b>. Following the Effective Date, the Company will pay you an initial base salary of $425,000 per year, payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be subject to periodic review and potential adjustment in the Company&#8217;s discretion. Your base salary in effect at any given time is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">Annual Bonus</b>. Commencing as of the Effective Date, you will be eligible to receive an annual performance bonus targeted at 40% of your Base Salary. The target annual bonus in effect at any given time is referred to herein as &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Target Bonus</u>.&#8221; Your annual bonus for the calendar year in which the Effective Date occurs will be prorated based on your period of employment following the Effective Date. The actual bonus amount is discretionary and may be subject to achievement of performance targets established by the Company for such year. To earn an annual bonus, you must be employed by the Company as of the payment date of such bonus. Any annual bonus will be paid no later than March 15th of the calendar year following the calendar year to which such bonus relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">Equity</b>. Subject to approval by the Board or a committee thereof, following the Effective Date, the Company (or any successor entity following a reverse merger transaction) will periodically grant you additional stock options to purchase shares of the Company&#8217;s common stock, at an exercise price as </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">determined by the Board or a committee thereof (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Replenishment Options</u>&#8221;), in order to maintain your ownership at approximately 1% of the Company&#8217;s fully-diluted equity (reflecting all outstanding convertible preferred stock, warrants, options and other equity interests that are convertible into or exercisable for common stock on an as-converted and as-exercised basis) until the Company has raised an aggregate of $200,000,000; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that the Board shall have no obligation to grant you additional stock options thereafter. The Replenishment Options will vest in 48 approximately equal monthly installments commencing on the applicable date(s) of grant; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, that you continue providing services to the Company through each vesting date. The Replenishment Options will be governed by the terms of the related award agreements, the Equity Plan and the terms and conditions approved by the Board or a committee thereof; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that the Replenishment Options will fully vest upon the consummation of a Change in Control, subject to your continued services to the Company through such Change in Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-weight:bold;">Benefits/Paid Time Off</b>. Commencing as of the Effective Date, you will be eligible, subject to the terms of the applicable plans and programs, to participate in the employee benefits and insurance programs generally made available to the Company&#8217;s full-time employees. Details of such benefits programs, including applicable employee contributions and waiting periods, if applicable, will be made available to you when such benefit(s) become available. You will be entitled to paid time off consistent with the terms of the Company&#8217;s paid time off policy, as in effect from time to time. The Company reserves the right to modify, limit, amend or cancel any of its benefits plans or programs at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-weight:bold;">Expense Reimbursement. The</b> Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing your duties as an employee of the Company and that are pre-approved by the Company, provided that you comply with any Company policy or practice on submitting, accounting for and documenting such expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-weight:bold;">Location</b>. Your primary work location will be remotely in California, provided that you may be required to engage in reasonable travel for business, consistent with the Company&#8217;s business needs. You may change your remote work location with prior written notice to and approval from the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-weight:bold;">At-Will Employment; Date of Termination</b>. At all times, your employment with the Company is &#8220;at will,&#8221; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title, reporting structure, compensation and benefits, as well as the Company&#8217;s benefit plans and personnel policies and procedures, may change from time to time (subject to the terms of this Agreement), the &#8220;at will&#8221; nature of your employment may only be changed in an express written agreement signed by you and an authorized officer of the Company. Your last day of employment for any reason is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Termination</u>.&#8221; In the event that you elect to end your employment with the Company, the Company requires you to provide at least 30 days&#8217; advance written notice to the Company; and in the event that the Company terminates you without Cause, you shall be given at least 30 days advance written notice by the Company. Notwithstanding the foregoing, the Company may unilaterally accelerate the Date of Termination, and such acceleration shall not result in a termination by the Company without Cause for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">your employment for any reason. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-weight:bold;">Accrued Obligations</b>. In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary and, if applicable, any accrued but unused vacation, through the Date of Termination, and (ii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-weight:bold;">Severance Pay and Benefits Outside of the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) outside of the Change in Control Period (as such capitalized terms are defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u>), then, in addition to the Accrued Obligations, and subject to (i) your execution and non-revocation of a separation agreement and release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide that if you breach the Continuing Obligations, all payments of the following severance pay and benefits shall immediately cease (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and Release</u>&#8221;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The Company shall pay you an amount equal to 12 months of your Base Salary, payable in substantially equal installments over the 12-month period following the Date of Termination in accordance with the Company&#8217;s regular payroll practices beginning on the Company&#8217;s first regularly scheduled payroll date following the date that is 60 days after the Date of Termination; provided, however, that the first installment shall include any amounts that would have been paid following the Date of Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>The Company shall pay you any bonus earned but unpaid for the year immediately preceding the year in which the Date of Termination occurs, payable at the time such bonuses are paid to other Company employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Subject to your copayment of premium amounts at the applicable active employees&#8217; rate and your proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA</u>&#8221;), the Company shall pay to the group health plan provider(s), the COBRA provider, or you a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the 12-month anniversary of the Date of Termination; (B) your eligibility for group health plan benefits under any other employer&#8217;s group health plan; or (C) the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to tax-related deductions and withholdings and paid on the Company&#8217;s regular payroll dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-weight:bold;">Severance Pay and Benefits Within the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) or you resign for Good Reason, in each case within the Change in Control Period, then, in addition to you being entitled to the Accrued Obligations, and subject to your execution and non-revocation of the Separation Agreement and Release and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>You will receive the severance pay and benefits set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, the unvested portion of your then outstanding equity-based awards subject to time-based vesting shall immediately accelerate and become vested or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the avoidance of doubt, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant to both <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-weight:bold;">Continuing Obligations</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Restrictive Covenant Agreement</b>. As a condition of your employment, you are required to enter into an Invention Assignment, Non-Disclosure, and Business Protection Agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covenant Agreement</u>&#8221;), which must be signed prior to the Effective Date. For purposes of this Agreement, the obligations in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12</u> and those that arise in the Covenant Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuing Obligations</u>.&#8221; You are advised to discuss the Covenant Agreement with an attorney of your choice, and you have had an adequate opportunity to do so prior to executing this Agreement or the Covenant Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Third Party Agreements and Rights</b>. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or other party which would prevent you from performing your obligations hereunder. You represent to the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Litigation and Regulatory Cooperation</b>. You shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were engaged or employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">in connection with such claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your engagement and employment, you also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses, including fees and costs for an independent attorney of your choice hired by you, incurred in connection with your performance of obligations pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12(c).</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Relief</b>. You agree that it would be difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-weight:bold;">Golden Parachute Taxes</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Best After-Tax Result</b>. In the event that any payment or benefit received or to be received by you pursuant to this Agreement or otherwise (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments</u>&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code and (ii) but for this subsection (a), be subject to the excise tax imposed by Section 4999 of the Code, any successor provisions, or any comparable federal, state, local or foreign excise tax (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u>&#8221;), then, subject to the provisions of Section 14, such Payments shall be either (A) provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B) provided as to such lesser extent which would result in the Payments being $1.00 less than the amount at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without limitation, any interest or penalties on such taxes), results in the receipt, on an after-tax basis, of the greatest amount of payments and benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise Tax. Unless the Company and you otherwise agree in writing, any determination required under this Section shall be made by independent tax counsel designated by the Company and reasonably acceptable to you (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Tax Counsel</u>&#8221;), whose determination shall be conclusive and binding upon you and the Company for all purposes. For purposes of making the calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. The Company and you shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make a determination under this Section. The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations contemplated by this Section. In the event that <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(a)(ii)(B)</u> above applies, then based on the information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section 409A of the Code prior </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to compensation subject to Section 409A of the Code and will otherwise apply on a reverse chronological basis from payments latest in time. If the Internal Revenue Service (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IRS</u>&#8221;) determines that any Payment is subject to the Excise Tax, then <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u> hereof shall apply, and the enforcement of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u> shall be the exclusive remedy to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Adjustments</b>. If, notwithstanding any reduction described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(a)</u> hereof (or in the absence of any such reduction), the IRS determines that you are liable for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or pay back to the Company within one-hundred 120 days after a final IRS determination, an amount of such payments or benefits equal to the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Repayment Amount</u>.&#8221; The Repayment Amount with respect to such Payments shall be the smallest such amount, if any, as shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into account the payment of the Excise Tax imposed on such Payments) shall be maximized. Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received from the Payments. If the Excise Tax is not eliminated pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u>, you shall pay the Excise Tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></font><b style="font-weight:bold;">Section 409A</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision (without interest), and the balance of the installments shall be payable in accordance with their original schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">benefit is payable upon the termination of your employment, then such payments or benefits shall be payable only upon your &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-l(h).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">15.</b></font><b style="font-weight:bold;">Withholding; Tax Effect</b>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">16.</b></font><b style="font-weight:bold;">Recoupment</b>. Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable under this Agreement, subject to applicable state law. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason under this Agreement or any other agreement between you and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">17.</b></font><b style="font-weight:bold;">Interpretation and Enforcement</b>. This Agreement, together with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u>, the Covenant Agreement, and any award agreement between you and the Company, constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disputes</u>&#8221;) will be governed by federal law to the extent applicable and otherwise by California law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of California in connection with any Dispute or any claim related to any Dispute, except for Disputes arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">18.</b></font><b style="font-weight:bold;">Assignment</b>. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> or pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">19.</b></font><b style="font-weight:bold;">Waiver; Amendment</b>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">20.</b></font><b style="font-weight:bold;">Enforceability</b>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">21.</b></font><b style="font-weight:bold;">Conditions</b>. You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly authorize by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States on or prior to the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">22.</b></font><b style="font-weight:bold;">Employee Representations</b>. It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies or third parties. If you have or have had access to trade secrets or other confidential, proprietary information from your former employer or another third party, the use of such information in performing your duties at the Company is prohibited. This may include, but is not limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans or strategies. In making this employment offer, the Company has relied on your representation that: (a) you are not currently a party to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b) you are not subject to any noncompetition or non-solicitation agreement or other restrictive covenants that might restrict your employment by the Company as contemplated by this offer; (c) you have the full right, power and authority to execute and deliver the Agreement and to perform all of your obligations thereunder; and (d) you will not bring with you to the Company or use in the performance of your responsibilities at the Company any materials, documents or work product of a former employer or other third party that are not generally</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">available to the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have provided the Company with a copy of same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">23.</b></font><b style="font-weight:bold;">Other Terms</b>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I look forward to working with you to make the Company a great success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Sincerely,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jonathan Violin</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Jonathan Violin</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer and President</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accepted and acknowledged:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:44.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Christopher Doughty</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Christopher Doughty</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: </p></td><td style="vertical-align:bottom;width:44.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12/02/2024</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</b><sup style="font-size:7.5pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;vertical-align:top;">1</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u>&#8221; shall mean (i) your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii) your conviction or plea of no contest to: (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) your failure to perform in all material respects your assigned duties and responsibilities, which failure continues for 30 days after written notice given to you describing such failure; (iv) your gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; or (v) your violation of any material provision of any agreement(s) between you and the Company or any written Company policies including, without limitation, agreements relating to non-solicitation, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u>&#8221; shall have the meaning set forth in the Equity Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control Period</u>&#8221; shall mean the period beginning three months before and ending 12 months after the consummation of the first event constituting a Change in Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u>&#8221; means the Internal Revenue Code of 1986, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability</u>&#8221; shall mean a permanent and total disability as defined in Section 22(e)(3) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Plan</u>&#8221; shall mean the Company&#8217;s 2024 Equity Incentive Plan or any successor plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u>&#8221; shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without your written consent, of any of the following events: (i) a material diminution in your base salary or Target Bonus except for across-the-board salary and target bonus reductions of no more than 10% based on the Company&#8217;s financial performance similarly affecting all or substantially all senior management employees of the Company; (ii) a material change in the geographic location at which you are required to provide services to the Company or a requirement that you change your remote location to a location other than your then-current residence; (iii) the failure of the Company to obtain the assumption of this Agreement by a successor; or (iv) the material breach of this Agreement (or any other agreements with you) by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason Process</u>&#8221; shall mean that (i) you reasonably determine in good faith that a &#8220;Good Reason&#8221; condition has occurred; (ii) you notify the Company in writing of the first occurrence of the Good Reason condition within 30 days of the first occurrence of such condition; (iii) you cooperate in good faith with the Company&#8217;s efforts, for a period not less than 30 days following such notice (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cure Period</u>&#8221;), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate your employment within 60 days after the end of the Cure Period. If the Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">1 </sup>NTD: Language may be updated based on the Company&#8217;s finalization of its equity incentive plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>13
<FILENAME>glyc-20241231xex10d39.htm
<DESCRIPTION>EXHIBIT-10.39
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:21:53 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.39</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">November 15, 2024</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ryan Lynch</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">[residence address line 1]</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[residence address line 2]</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Email: [***]</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Re: Offer of Employment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Dear Ryan:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On behalf of Crescent Biopharma, Inc. (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u>&#8221;), I am very pleased to offer you a position as Senior Vice President of Finance and Chief Accounting Officer of the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Role</u>&#8221;) pursuant to this letter agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;), provided you accept such offer as indicated by your signature below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Your employment with the Company in the Role will commence as of December 10, 2024 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221;). &#160;Should you not commence services by the Effective Date or if this Agreement is otherwise terminated on or prior to the Effective Date, you hereby agree that this Agreement shall be void <i style="font-style:italic;">ab initio </i>and of no force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;">Position</b>. While serving in the Role, you will initially report to the Company&#8217;s Chief Executive Officer (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CEO</u>&#8221;) or such other person as the CEO may designate, and have such duties, authorities, and responsibilities as are customarily associated with the Role. &#160;This is a full-time employment position. &#160;It is understood and agreed that, commencing as of the Effective Date you will not engage in any other employment, consulting or other business activities (whether full-time or part-time). &#160;Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">Base Salary</b>. The Company will pay you an initial base salary of $340,000 per year, payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings. &#160;Your base salary will be subject to periodic review and potential adjustment in the Company&#8217;s discretion. &#160;Your base salary in effect at any given time is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">Annual Bonus</b>. Commencing as of the Effective Date, you will be eligible to receive an annual performance bonus targeted at 35% of your Base Salary. &#160;The target annual bonus in effect at any given time is referred to herein as &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Target Bonus</u>.&#8221; You will not be eligible for a 2024 annual bonus. &#160;The actual bonus amount is discretionary and may be subject to achievement of performance targets established by the Company for such year. &#160;To earn an annual bonus, you must be employed by the Company as of the payment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-transform:uppercase;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">date of such bonus. Any annual bonus will be paid no later than March 15th of the calendar year following the calendar year to which such bonus relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">Equity. </b>Subject to approval by the Board of Directors of the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u>&#8221;) or the Compensation Committee of the Board (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committee</u>&#8221;), it is anticipated that the Company will grant you stock options to purchase a number of shares of the Company&#8217;s common stock representing 0.5% of the Company&#8217;s fully diluted equity (reflecting all outstanding shares of common stock on an as-converted basis) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Options</u>&#8221;) as soon as practicable following the Effective Date, with an exercise price per share equal to the fair market value of a share of the Company&#8217;s common stock on the date of grant (as determined by the Board or the Committee in its sole discretion). &#160;The Options will vest over a four-year period following the Effective Date, with 25% of the Options vesting on the first anniversary of the Effective Date, and the remainder vesting in 36 equal monthly installments on each monthly anniversary thereafter, in each case, subject to your continued service with the Company through the applicable vesting dates. &#160;The Options will be governed by the terms of the related award agreement, the Company&#8217;s 2024 Equity Incentive Plan (as amended from time to time and including any successor plan, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Plan</u>&#8221;) and the terms and conditions approved by the Board or the Committee. &#160;In addition to the Options, you may be eligible to receive such future equity grants as the Board or the Committee may deem appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-weight:bold;">Benefits/Paid Time Off. </b>Commencing as of the Effective Date, you will be eligible, subject to the terms of the applicable plans and programs, to participate in the employee benefits and insurance programs generally made available to the Company&#8217;s full-time employees. &#160;Details of such benefits programs, including applicable employee contributions and waiting periods, if applicable, will be made available to you when such benefit(s) become available. &#160;You will be entitled to paid time off consistent with the terms of the Company&#8217;s paid time off policy, as in effect from time to time. &#160;The Company reserves the right to modify, limit, amend or cancel any of its benefits plans or programs at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-weight:bold;">Expense Reimbursement. </b>The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing your duties as an employee of the Company and that are pre-approved by the Company, provided that you comply with any Company policy or practice on submitting, accounting for and documenting such expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-weight:bold;">Location</b>. Your primary work location will be remotely in Massachusetts, provided that you may be required to engage in reasonable travel for business, consistent with the Company&#8217;s business needs. &#160;You may change your remote work location with prior written notice to and approval from the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-weight:bold;">At-Will Employment; Date of Termination</b>. At all times, your employment with the Company is &#8220;at will,&#8221; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. &#160;Although your job duties, title, reporting structure, compensation and benefits, as well as the Company&#8217;s benefit plans and personnel policies and procedures, may change from time to time (subject to the terms of this Agreement), the &#8220;at will&#8221; nature of your employment may only be changed in an express written agreement signed by you and an authorized officer of the Company. &#160;Your last day of employment for any reason is referred to herein as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Termination</u>.&#8221; In the event that you elect to end your employment with the Company, the Company requires you to provide at least 30 days&#8217; advance written notice to the Company. &#160;Notwithstanding the foregoing, the Company may unilaterally accelerate </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-transform:uppercase;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Date of Termination, and such acceleration shall not result in a termination by the Company without Cause for purposes of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. &#160;You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-weight:bold;">Accrued Obligations</b>. In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary and, if applicable, any accrued but unused vacation, through the Date of Termination, and (ii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. &#160;(the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-weight:bold;">Severance Pay and Benefits Outside of the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) outside of the Change in Control Period (as such capitalized terms are defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u>), then, in addition to the Accrued Obligations, and subject to (i) your execution and non-revocation of a separation agreement and release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide that if you breach the Continuing Obligations, all payments of the following severance pay and benefits shall immediately cease (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and Release</u>&#8221;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>The Company shall pay you an amount equal to nine months of your Base Salary, payable in substantially equal installments over the nine-month period following the Date of Termination in accordance with the Company&#8217;s regular payroll practices beginning on the Company&#8217;s first regularly scheduled payroll date following the date that is 60 days after the Date of Termination; provided, however, that the first installment shall include any amounts that would have been paid following the Date of Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>The Company shall pay you any bonus earned but unpaid for the year immediately preceding the year in which the Date of Termination occurs, payable at the time such bonuses are paid to other Company employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>Subject to your copayment of premium amounts at the applicable active employees&#8217; rate and your proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA</u>&#8221;), the Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the nine-month anniversary of the Date of Termination; (B) your eligibility for group health plan benefits under any other employer&#8217;s group health plan; or (C) the cessation of your continuation rights </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-transform:uppercase;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. &#160;Such payments, if to you, shall be subject to tax-related deductions and withholdings and paid on the Company&#8217;s regular payroll dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-weight:bold;">Severance Pay and Benefits Within the Change in Control Period</b>. In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) or you resign for Good Reason, in each case within the Change in Control Period, then, in addition to you being entitled to the Accrued Obligations, and subject to your execution and non-revocation of the Separation Agreement and Release and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>You will receive the severance pay and benefits set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, the unvested portion of your then outstanding equity-based awards subject to time-based vesting shall immediately accelerate and become vested or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the avoidance of doubt, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant to both <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-weight:bold;">Continuing Obligations.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Restrictive Covenant Agreement</b>. As a condition of your employment, you are required to enter into an Invention Assignment, Non-Disclosure, and Business Protection Agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covenant Agreement</u>&#8221;), which must be signed prior to the Effective Date. &#160;For purposes of this Agreement, the obligations in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12</u> and those that arise in the Covenant Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuing Obligations</u>.&#8221; You are advised to discuss the Covenant Agreement with an attorney of your choice, and you have had an adequate opportunity to do so prior to executing this Agreement or the Covenant Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Third Party Agreements and Rights</b>. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or other party which would prevent you from performing your obligations hereunder. &#160;You represent to the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. &#160;In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-transform:uppercase;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-weight:bold;">Litigation and Regulatory Cooperation</b>. You shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were engaged or employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information. &#160;Your full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. &#160;During and after your engagement and employment, you also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. &#160;The Company shall reimburse you for any reasonable out-of-pocket expenses, including fees and costs for an independent attorney of your choice hired by you, incurred in connection with your performance of obligations pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12(c).</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-weight:bold;">Relief</b>. You agree that it would be difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. &#160;Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-weight:bold;">Golden Parachute Taxes</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-weight:bold;">Best After-Tax Result</b>. In the event that any payment or benefit received or to be received by you pursuant to this Agreement or otherwise (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments</u>&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code and (ii) but for this subsection (a), be subject to the excise tax imposed by Section 4999 of the Code, any successor provisions, or any comparable federal, state, local or foreign excise tax (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u>&#8221;), then, subject to the provisions of Section 14, such Payments shall be either (A) provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B) provided as to such lesser extent which would result in the Payments being $1.00 less than the amount at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without limitation, any interest or penalties on such taxes), results in the receipt, on an after-tax basis, of the greatest amount of payments and benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise Tax. &#160;Unless the Company and you otherwise agree in writing, any determination required under this Section shall be made by independent tax counsel designated by the Company and reasonably acceptable to you (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Tax Counsel</u>&#8221;), whose determination shall be conclusive and binding upon you and the Company for all purposes. &#160;For purposes of making the calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning applicable </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-transform:uppercase;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. &#160;The Company and you shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make a determination under this Section. &#160;The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations contemplated by this Section. &#160;In the event that <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(a)(ii)(B)</u> above applies, then based on the information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section 409A of the Code prior to compensation subject to Section 409A of the Code and will otherwise apply on a reverse chronological basis from payments latest in time. &#160;If the Internal Revenue Service (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IRS</u>&#8221;) determines that any Payment is subject to the Excise Tax, then <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u> hereof shall apply, and the enforcement of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u> shall be the exclusive remedy to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-weight:bold;">Adjustments</b>. If, notwithstanding any reduction described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(a)</u> hereof (or in the absence of any such reduction), the IRS determines that you are liable for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or pay back to the Company within one-hundred 120 days after a final IRS determination, an amount of such payments or benefits equal to the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Repayment Amount</u>.&#8221; The Repayment Amount with respect to such Payments shall be the smallest such amount, if any, as shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into account the payment of the Excise Tax imposed on such Payments) shall be maximized. &#160;Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received from the Payments. &#160;If the Excise Tax is not eliminated pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b),</u> you shall pay the Excise Tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></font><b style="font-weight:bold;">Section 409A.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font>Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) nine months and one day after your separation from service, or (B) your death. &#160;If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the nine-month period but for the application of this provision (without interest), and the balance of the installments shall be payable in accordance with their original schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font>All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. &#160;All reimbursements shall be paid as soon as administratively practicable, but in no event shall </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-transform:uppercase;">6</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. &#160;The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). &#160;Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(c)</font></font>To the extent that any payment or benefit described in this Agreement constitutes &#8220;non- qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such payments or benefits shall be payable only upon your &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-l(h).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(d)</font></font>The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. &#160;To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. &#160;Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). &#160;The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(e)</font></font>The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">15.</b></font><b style="font-weight:bold;">Withholding; Tax Effect</b>. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. &#160;You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">16.</b></font><b style="font-weight:bold;">Recoupment</b>. Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable under this Agreement, subject to applicable Massachusetts law. &#160;No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason under this Agreement or any other agreement between you and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">17.</b></font><b style="font-weight:bold;">Interpretation and Enforcement</b>. This Agreement, together with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u>, the Covenant Agreement, and any award agreement between you and the Company, constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-transform:uppercase;">7</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">between you and the Company. &#160;The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disputes</u>&#8221;) will be governed by federal law to the extent applicable and otherwise by Massachusetts law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan. &#160;You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the Commonwealth of Massachusetts in connection with any Dispute or any claim related to any Dispute, except for Disputes arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">18.</b></font><b style="font-weight:bold;">Assignment</b>. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u> or pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of this Agreement solely as a result of such transaction. &#160;This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">19.</b></font><b style="font-weight:bold;">Waiver; Amendment</b>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. &#160;The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. &#160;This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">20.</b></font><b style="font-weight:bold;">Enforceability</b>. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">21.</b></font><b style="font-weight:bold;">Conditions</b>. You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly authorize by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States on or prior to the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">22.</b></font><b style="font-weight:bold;">Employee Representations</b>. It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies or third parties. &#160;If you have or have had access to trade secrets or other confidential, proprietary information from your former employer or another third party, the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-transform:uppercase;">8</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">use of such information in performing your duties at the Company is prohibited. &#160;This may include, but is not limited to, confidential or proprietary information in the form of documents, magnetic media, software, customer lists, and business plans or strategies. &#160;In making this employment offer, the Company has relied on your representation that: (a) you are not currently a party to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b) you are not subject to any noncompetition or non-solicitation agreement or other restrictive covenants that might restrict your employment by the Company as contemplated by this offer; (c) you have the full right, power and authority to execute and deliver the Agreement and to perform all of your obligations thereunder; and (d) you will not bring with you to the Company or use in the performance of your responsibilities at the Company any materials, documents or work product of a former employer or other third party that are not generally available to the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have provided the Company with a copy of same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">23.</b></font><b style="font-weight:bold;">Other Terms</b>. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment to the extent necessary to effectuate the terms contained herein. &#160;The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. &#160;This Agreement may be executed in separate counterparts. &#160;When both counterparts are signed, they shall be treated together as one and the same document. &#160;PDF copies of signed counterparts shall be equally effective as originals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I look forward to working with you to make the Company a great success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Sincerely,</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jonathan Violin</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Jonathan Violin</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Interim CEO</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accepted and acknowledged:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ryan Lynch</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ryan Lynch</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: </p></td><td style="vertical-align:top;width:43.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11/15/2024</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-transform:uppercase;">9</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u>&#8221; shall mean (i) your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii) your conviction or plea of no contest to: (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) your failure to perform in all material respects your assigned duties and responsibilities, which failure continues for 30 days after written notice given to you describing such failure; (iv) your gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; or (v) your violation of any material provision of any agreement(s) between you and the Company or any written Company policies including, without limitation, agreements relating to non-solicitation, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u>&#8221; shall have the meaning set forth in the Equity Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control Period</u>&#8221; shall mean the 12-month period beginning on the consummation of the first event constituting a Change in Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u>&#8221; means the Internal Revenue Code of 1986, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability</u>&#8221; shall mean a permanent and total disability as defined in Section 22(e)(3) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u>&#8221; shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without your written consent, of any of the following events: (i) a material diminution in your base salary or Target Bonus except for across-the-board salary and target bonus reductions of no more than 10% based on the Company&#8217;s financial performance similarly affecting all or substantially all senior management employees of the Company; (ii) a material change in the geographic location at which you are required to provide services to the Company or a requirement that you change your remote location to a location other than your then-current residence; (iii) the failure of the Company to obtain the assumption of this Agreement by a successor; or (iv) the material breach of this Agreement (or any other agreements with you) by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason Process</u>&#8221; shall mean that (i) you reasonably determine in good faith that a &#8220;Good Reason&#8221; condition has occurred; (ii) you notify the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) you cooperate in good faith with the Company&#8217;s efforts, for a period not less than 30 days following such notice (the &#8220;Cure Period&#8221;), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate your employment within 60 days after the end of the Cure Period. &#160;If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-transform:uppercase;">10</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>14
<FILENAME>glyc-20241231xex10d40.htm
<DESCRIPTION>EXHIBIT-10.40
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:21:58 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.40</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">December 20, 2024</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Barbara Bispham</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Address: [***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Email: [***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Re: Offer of Employment</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Dear Barbara:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">On behalf of Crescent Biopharma, Inc. (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-size:11pt;">&#8221;), I am very pleased to offer you a position as General Counsel of the Company (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Role</u><font style="font-size:11pt;">&#8221;) pursuant to this letter agreement (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u><font style="font-size:11pt;">&#8221;), provided you accept such offer as indicated by your signature below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Your employment with the Company in the Role will commence as of January 13, 2025 (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u><font style="font-size:11pt;">&#8221;). &#160;Should you not commence services by the Effective Date or if this Agreement is otherwise terminated on or prior to the Effective Date, you hereby agree that this Agreement shall be void </font><i style="font-size:11pt;font-style:italic;">ab initio</i><font style="font-size:11pt;"> and of no force or effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-size:11pt;font-weight:bold;">Position</b><font style="font-size:11pt;">. &#160;While serving in the Role, you will initially report to the Company&#8217;s Chief Executive Officer (&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CEO</u><font style="font-size:11pt;">&#8221;) or such other person as the CEO may designate, and you will have such duties, authorities, and responsibilities as are customarily associated with the Role. &#160;This is a full-time employment position. &#160;It is understood and agreed that, commencing as of the Effective Date you will not engage in any other employment, consulting or other business activities (whether full-time or part-time). &#160;Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such activities do not unreasonably interfere or conflict with your obligations to the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-size:11pt;font-weight:bold;">Base Salary</b><font style="font-size:11pt;">. &#160;The Company will pay you an initial base salary of $450,000 per year, payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings. &#160;Your base salary will be subject to periodic review and potential adjustment in the Company&#8217;s discretion. &#160;Your base salary in effect at any given time is referred to herein as the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u><font style="font-size:11pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-size:11pt;font-weight:bold;">Bonus Compensation.</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">Annual Bonus.</b><font style="font-size:11pt;"> Commencing as of the Effective Date, you will be eligible to receive an annual performance bonus targeted at 35% of your Base Salary. &#160;Your 2024 annual bonus will be prorated based on your period of employment following the Effective Date. &#160;The actual bonus amount is discretionary and may be subject to achievement of performance targets established by the Company for such year. &#160;To earn an annual bonus, you must be employed by the Company as of the payment date of such bonus. &#160;Any annual bonus will be paid no later than March 15th of the calendar year following the calendar year to which such bonus relates.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">Signing Bonus</b><font style="font-size:11pt;">. Within 30 days following the Effective Date, you will receive a one-time lump sum signing bonus of $70,000 (the &#8220;Signing Bonus&#8221;). In the event of your termination for Cause (as defined below) or resignation within twelve (12) months of the Effective Date, you will be required to repay the full Signing Bonus within 30 days following the date of such termination of employment.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-size:11pt;font-weight:bold;">Equity. &#160;</b><font style="font-size:11pt;">Subject to approval by the Board of Directors of the Company (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u><font style="font-size:11pt;">&#8221;) or the Compensation Committee of the Board (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Committee</u><font style="font-size:11pt;">&#8221;), it is anticipated that the Company will grant you stock options to purchase a number of shares of the Company&#8217;s common stock representing .5% of the company&#8217;s fully diluted equity (reflecting all outstanding shares of common stock on an as-converted basis) (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Options</u><font style="font-size:11pt;">&#8221;) as soon as practicable following the Effective Date, with an exercise price per share equal to the fair market value of a share of the Company&#8217;s common stock on the date of grant (as determined by the Board or the Committee in its sole discretion). &#160;The Options will vest over a four-year period following the Effective Date, with 25% of the Options vesting on the first anniversary of the Effective Date, and the remainder vesting in 36 equal monthly installments on each monthly anniversary thereafter, in each case, subject to your continued service with the Company through the applicable vesting dates. &#160;The Options will be governed by the terms of the related award agreement, the Company&#8217;s 2024 Equity Incentive Plan (as amended from time to time and including any successor plan, the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Plan</u><font style="font-size:11pt;">&#8221;) and the terms and conditions approved by the Board or the Committee. &#160;In addition to the Options, you may be eligible to receive such future equity grants as the Board or the Committee may deem appropriate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-size:11pt;font-weight:bold;">Benefits/Paid Time Off. &#160;</b><font style="font-size:11pt;">Commencing as of the Effective Date, you will be eligible, subject to the terms of the applicable plans and programs, to participate in the employee benefits and insurance programs generally made available to the Company&#8217;s full-time employees. &#160;Details of such benefits programs, including applicable employee contributions and waiting periods, if applicable, will be made available to you when such benefit(s) become available. &#160;You will be entitled to paid time off consistent with the terms of the Company&#8217;s paid time off policy, as in effect from time to time. &#160;The Company reserves the right to modify, limit, amend or cancel any of its benefits plans or programs at any time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-size:11pt;font-weight:bold;">Expense Reimbursement. &#160;</b><font style="font-size:11pt;">The Company will reimburse you for all reasonable and necessary expenses incurred by you in connection with performing your duties as an employee of the Company and that are pre-approved by the Company, provided that you comply with any Company policy or practice on submitting, accounting for and documenting such expenses.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-size:11pt;font-weight:bold;">Location</b><font style="font-size:11pt;">. &#160;Your primary work location will be remotely in New York, provided that you may be required to engage in reasonable travel for business, consistent with the Company&#8217;s business needs. &#160;You may change your remote work location with prior written notice to and approval from the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-size:11pt;font-weight:bold;">At-Will Employment; Date of Termination</b><font style="font-size:11pt;">. &#160;At all times, your employment with the Company is &#8220;at will,&#8221; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. &#160;Although your job duties, title, reporting structure, compensation and benefits, as well as the Company&#8217;s benefit plans and personnel policies and procedures, may change from time to time (subject to the terms of this Agreement), the &#8220;at will&#8221; nature of your employment may only be changed in an express written agreement signed by you and an authorized officer of the Company. &#160;Your last day of employment for any reason is referred to herein as the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date of Termination</u><font style="font-size:11pt;">.&#8221; In the event that you elect to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">end your employment with the Company, the Company requires you to provide at least 30 days&#8217; advance written notice to the Company. &#160;Notwithstanding the foregoing, the Company may unilaterally accelerate the Date of Termination, and such acceleration shall not result in a termination by the Company without Cause for purposes of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. &#160;You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-size:11pt;font-weight:bold;">Accrued Obligations</b><font style="font-size:11pt;">. &#160;In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary and, if applicable, any accrued but unused vacation, through the Date of Termination, and (ii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. &#160;(the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accrued Obligations</u><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-size:11pt;font-weight:bold;">Severance Pay and Benefits Outside of the Change in Control Period</b><font style="font-size:11pt;">. &#160;In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) outside of the Change in Control Period (as such capitalized terms are defined in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u><font style="font-size:11pt;">), then, in addition to the Accrued Obligations, and subject to (i) your execution and non-revocation of a separation agreement and release in a form acceptable to the Company, which shall include a general release of claims against the Company and all related persons and entities and a reaffirmation of the Continuing Obligations (as defined below) and shall provide that if you breach the Continuing Obligations, all payments of the following severance pay and benefits shall immediately cease (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and Release</u><font style="font-size:11pt;">&#8221;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">The Company shall pay you an amount equal to nine months of your Base Salary, payable in substantially equal installments over the nine-month period following the Date of Termination in accordance with the Company&#8217;s regular payroll practices beginning on the Company&#8217;s first regularly scheduled payroll date following the date that is 60 days after the Date of Termination; provided, however, that the first installment shall include any amounts that would have been paid following the Date of Termination had such installments commenced on the first regularly scheduled payroll date following the Date of Termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:11pt;">The Company shall pay you any bonus earned but unpaid for the year immediately preceding the year in which the Date of Termination occurs, payable at the time such bonuses are paid to other Company employees.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:11pt;">Subject to your copayment of premium amounts at the applicable active employees&#8217; rate and your proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA</u><font style="font-size:11pt;">&#8221;), the Company shall pay to the group health plan provider(s), the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the nine-month anniversary of the Date of Termination; (B) your eligibility for group health</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">plan benefits under any other employer&#8217;s group health plan; or (C) the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. &#160;Such payments, if to you, shall be subject to tax-related deductions and withholdings and paid on the Company&#8217;s regular payroll dates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-size:11pt;font-weight:bold;">Severance Pay and Benefits Within the Change in Control Period</b><font style="font-size:11pt;">. &#160;In the event that the Company terminates your employment without Cause (and not as a result of your death or Disability) or you resign for Good Reason, in each case within the Change in Control Period, then, in addition to you being entitled to the Accrued Obligations, and subject to your execution and non-revocation of the Separation Agreement and Release and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven-day revocation period:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">You will receive the severance pay and benefits set forth in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u><font style="font-size:11pt;"> above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:11pt;">Notwithstanding anything to the contrary in any applicable equity-based award agreement or plan, the unvested portion of your then outstanding equity-based awards subject to time-based vesting shall immediately accelerate and become vested or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">For the avoidance of doubt, </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u><font style="font-size:11pt;"> of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant to both </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u><font style="font-size:11pt;"> and </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u><font style="font-size:11pt;"> of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-size:11pt;font-weight:bold;">Continuing Obligations</b><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-size:11pt;font-weight:bold;">Restrictive Covenant Agreement</b><font style="font-size:11pt;">. &#160;As a condition of your employment, you are required to enter into an Invention Assignment, Non-Disclosure, and Business Protection Agreement (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covenant Agreement</u><font style="font-size:11pt;">&#8221;), which must be signed prior to the Effective Date. &#160;For purposes of this Agreement, the obligations in this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12</u><font style="font-size:11pt;"> and those that arise in the Covenant Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuing Obligations</u><font style="font-size:11pt;">.&#8221; &#160;You are advised to discuss the Covenant Agreement with an attorney of your choice, and you have had an adequate opportunity to do so prior to executing this Agreement or the Covenant Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-size:11pt;font-weight:bold;">Third Party Agreements and Rights</b><font style="font-size:11pt;">. &#160;You hereby confirm that you are not bound by the terms of any agreement with any previous employer or other party which would prevent you from performing your obligations hereunder. &#160;You represent to the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. &#160;In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><b style="font-size:11pt;font-weight:bold;">Litigation and Regulatory Cooperation</b><font style="font-size:11pt;">. &#160;You shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were engaged or employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information. &#160;Your full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being reasonably available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. &#160;During and after your engagement and employment, you also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. &#160;The Company shall reimburse you for any reasonable out-of-pocket expenses, including fees and costs for an independent attorney of your choice hired by you, incurred in connection with your performance of obligations pursuant to this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12(c).</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><b style="font-size:11pt;font-weight:bold;">Relief</b><font style="font-size:11pt;">. &#160;You agree that it would be difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. &#160;Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to seek an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-size:11pt;font-weight:bold;">Golden Parachute Taxes</b><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><b style="font-size:11pt;font-weight:bold;">Best After-Tax Result</b><font style="font-size:11pt;">. &#160;In the event that any payment or benefit received or to be received by you pursuant to this Agreement or otherwise (&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments</u><font style="font-size:11pt;">&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code and (ii) but for this subsection (a), be subject to the excise tax imposed by Section 4999 of the Code, any successor provisions, or any comparable federal, state, local or foreign excise tax (&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u><font style="font-size:11pt;">&#8221;), then, subject to the provisions of Section 14, such Payments shall be either (A) provided in full pursuant to the terms of this Agreement or any other applicable agreement, or (B) provided as to such lesser extent which would result in the Payments being $1.00 less than the amount at which any portion of the Payments would be subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state, local and foreign income, employment and other taxes and the Excise Tax (including, without limitation, any interest or penalties on such taxes), results in the receipt, on an after-tax basis, of the greatest amount of payments and benefits provided for hereunder or otherwise, notwithstanding that all or some portion of such Payments may be subject to the Excise Tax. Unless the Company and you otherwise agree in writing, any determination required under this Section shall be made by independent tax counsel designated by the Company and reasonably acceptable to you (&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Tax Counsel</u><font style="font-size:11pt;">&#8221;), whose determination shall be conclusive and binding upon you and the Company for all purposes. &#160;For purposes of making the calculations required under this Section, Independent Tax Counsel may make reasonable assumptions and approximations concerning applicable</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that Independent Tax Counsel shall assume that you pay all taxes at the highest marginal rate. &#160;The Company and you shall furnish to Independent Tax Counsel such information and documents as Independent Tax Counsel may reasonably request in order to make a determination under this Section. &#160;The Company shall bear all costs that Independent Tax Counsel may reasonably incur in connection with any calculations contemplated by this Section. &#160;In the event that </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(a)(ii)(B)</u><font style="font-size:11pt;"> above applies, then based on the information provided to you and the Company by Independent Tax Counsel, the cutback described hereunder will apply as to compensation not subject to Section 409A of the Code prior to compensation subject to Section 409A of the Code and will otherwise apply on a reverse chronological basis from payments latest in time. &#160;If the Internal Revenue Service (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IRS</u><font style="font-size:11pt;">&#8221;) determines that any Payment is subject to the Excise Tax, then </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u><font style="font-size:11pt;"> hereof shall apply, and the enforcement of </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u><font style="font-size:11pt;"> shall be the exclusive remedy to the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><b style="font-size:11pt;font-weight:bold;">Adjustments</b><font style="font-size:11pt;">. &#160;If, notwithstanding any reduction described in </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(a)</u><font style="font-size:11pt;"> hereof (or in the absence of any such reduction), the IRS determines that you are liable for the Excise Tax as a result of the receipt of one or more Payments, then you shall be obligated to surrender or pay back to the Company within one-hundred 120 days after a final IRS determination, an amount of such payments or benefits equal to the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Repayment Amount</u><font style="font-size:11pt;">.&#8221; The Repayment Amount with respect to such Payments shall be the smallest such amount, if any, as shall be required to be surrendered or paid to the Company so that your net proceeds with respect to such Payments (after taking into account the payment of the Excise Tax imposed on such Payments) shall be maximized. &#160;Notwithstanding the foregoing, the Repayment Amount with respect to such Payments shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on such Payments or if a Repayment Amount of more than zero would not maximize the net amount received from the Payments. &#160;If the Excise Tax is not eliminated pursuant to this </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13(b)</u><font style="font-size:11pt;">, you shall pay the Excise Tax.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">14.</b></font><b style="font-size:11pt;font-weight:bold;">Section 409A</b><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:11pt;">Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) nine months and one day after your separation from service, or (B) your death. &#160;If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the nine-month period but for the application of this provision (without interest), and the balance of the installments shall be payable in accordance with their original schedule.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:11pt;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. &#160;All reimbursements shall be paid as soon as administratively practicable, but in no event shall</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. &#160;The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). &#160;Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:11pt;">To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such payments or benefits shall be payable only upon your &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-l(h).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:11pt;">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. &#160;To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. &#160;Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). &#160;The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:11pt;">The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">15.</b></font><b style="font-size:11pt;font-weight:bold;">Withholding; Tax Effect</b><font style="font-size:11pt;">. &#160;All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. &#160;You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">16.</b></font><b style="font-size:11pt;font-weight:bold;">Recoupment</b><font style="font-size:11pt;">. &#160;Amounts paid or payable under this Agreement shall be subject to the provisions of any applicable clawback or recoupment policies or procedures adopted by the Company, which clawback or recoupment policies may provide for forfeiture and/or recoupment of amounts paid or payable under this Agreement, subject to applicable Massachusetts law. No forfeiture or recoupment under such policies or procedures will give rise to a right to resign for Good Reason under this Agreement or any other agreement between you and the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">17.</b></font><b style="font-size:11pt;font-weight:bold;">Interpretation and Enforcement</b><font style="font-size:11pt;">. &#160;This Agreement, together with </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u><font style="font-size:11pt;">, the Covenant Agreement, and any award agreement between you and the Company, constitute the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. &#160;The terms of this Agreement and the resolution of any disputes as to the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disputes</u><font style="font-size:11pt;">&#8221;) will be governed by federal law to the extent applicable and otherwise by Massachusetts law, excluding laws relating to conflicts or choice of law and excluding Disputes arising in connection with any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan. &#160;You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the Commonwealth of Massachusetts in connection with any Dispute or any claim related to any Dispute, except for Disputes arising under any equity incentive plan, which shall be governed by the terms of the applicable equity incentive plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">18.</b></font><b style="font-size:11pt;font-weight:bold;">Assignment</b><font style="font-size:11pt;">. &#160;Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further, that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u><font style="font-size:11pt;"> or pursuant to </font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u><font style="font-size:11pt;"> of this Agreement solely as a result of such transaction. &#160;This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">19.</b></font><b style="font-size:11pt;font-weight:bold;">Waiver; Amendment</b><font style="font-size:11pt;">. &#160;No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. &#160;The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. &#160;This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">20.</b></font><b style="font-size:11pt;font-weight:bold;">Enforceability</b><font style="font-size:11pt;">. &#160;If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">21.</b></font><b style="font-size:11pt;font-weight:bold;">Conditions</b><font style="font-size:11pt;">. &#160;You must submit satisfactory proof of your identity, successfully complete a criminal background check, which you hereby expressly authorize by your execution of this Agreement, and provide documentation of your legal authorization to work in the United States on or prior to the Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">22.</b></font><b style="font-size:11pt;font-weight:bold;">Employee Representations</b><font style="font-size:11pt;">. &#160;It is the policy of the Company not to solicit or accept proprietary information and/or trade secrets of other companies or third parties. &#160;If you have or have had access to trade secrets or other confidential, proprietary information from your former employer or another third party, the use of such information in performing your duties at the Company is prohibited. &#160;This may include, but is not limited to, confidential or proprietary information in the form of documents, magnetic media, software,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">customer lists, and business plans or strategies. &#160;In making this employment offer, the Company has relied on your representation that: (a) you are not currently a party to any agreement that would restrict your ability to accept this offer or to perform services for the Company; (b) you are not subject to any noncompetition or non-solicitation agreement or other restrictive covenants that might restrict your employment by the Company as contemplated by this offer; (c) you have the full right, power and authority to execute and deliver the Agreement and to perform all of your obligations thereunder; and (d) you will not bring with you to the Company or use in the performance of your responsibilities at the Company any materials, documents or work product of a former employer or other third party that are not generally available to the public, unless you have obtained written authorization from such former employer or third party for their possession and use and have provided the Company with a copy of same.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">23.</b></font><b style="font-size:11pt;font-weight:bold;">Other Terms</b><font style="font-size:11pt;">. &#160;The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment to the extent necessary to effectuate the terms contained herein. &#160;The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. &#160;This Agreement may be executed in separate counterparts. &#160;When both counterparts are signed, they shall be treated together as one and the same document. &#160;PDF copies of signed counterparts shall be equally effective as originals.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">I look forward to working with you to make the Company a great success.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Sincerely,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jonathan Violin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Jonathan Violin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Interim CEO</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Accepted and acknowledged:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Barbara Bispham</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Barbara Bispham</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: </p></td><td style="vertical-align:bottom;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12/23/2024</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">1.</font></font><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cause</u><font style="font-size:11pt;white-space:pre-wrap;">&#8221; shall mean (i) your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii) your conviction or plea of no contest to:  (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) your failure to perform in all material respects your assigned duties and responsibilities, which failure continues for 30 days after written notice given to you describing such failure; (iv) your gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; or (v) your violation of any material provision of any agreement(s) between you and the Company or any written Company policies including, without limitation, agreements relating to non-solicitation, non-disclosure and/or assignment of inventions or policies related to ethics or workplace conduct.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">2.</font></font><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control</u><font style="font-size:11pt;">&#8221; shall have the meaning set forth in the Equity Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">3.</font></font><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change in Control Period</u><font style="font-size:11pt;">&#8221; shall mean the 12-month period beginning on the consummation of the first event constituting a Change in Control.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">4.</font></font><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u><font style="font-size:11pt;">&#8221; means the Internal Revenue Code of 1986, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">5.</font></font><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disability</u><font style="font-size:11pt;">&#8221; shall mean a permanent and total disability as defined in Section 22(e)(3) of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">6.</font></font><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u><font style="font-size:11pt;">&#8221; shall mean that you have complied with the Good Reason Process (hereinafter defined) following the occurrence, without your written consent, of any of the following events: (i) a material diminution in your base salary or Target Bonus except for across-the-board salary and target bonus reductions of no more than 10% based on the Company&#8217;s financial performance similarly affecting all or substantially all senior management employees of the Company; (ii) a material change in the geographic location at which you are required to provide services to the Company or a requirement that you change your remote location to a location other than your then-current residence; (iii) the failure of the Company to obtain the assumption of this Agreement by a successor; or (iv) the material breach of this Agreement (or any other agreements with you) by the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">7.</font></font><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason Process</u><font style="font-size:11pt;">&#8221; shall mean that (i) you reasonably determine in good faith that a &#8220;Good Reason&#8221; condition has occurred; (ii) you notify the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) you cooperate in good faith with the Company&#8217;s efforts, for a period not less than 30 days following such notice (the &#8220;</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cure Period</u><font style="font-size:11pt;white-space:pre-wrap;">&#8221;), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate your employment within 60 days after the end of the Cure Period.  If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>15
<FILENAME>glyc-20241231xex10d41.htm
<DESCRIPTION>EXHIBIT-10.41
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:22:04 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:30pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.41</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ANTIBODY DISCOVERY AND OPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">This Antibody Discovery and Option Agreement</b> (&#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is entered into and effective as of September 19, 2024 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;), by and among Paragon Therapeutics, Inc., a Delaware corporation (&#8220;<b style="font-weight:bold;">Paragon</b>&#8221;), Parascent Holding LLC, a Delaware limited liability company (&#8220;<b style="font-weight:bold;">Parascent</b>&#8221;) and Crescent Biopharma, Inc., a Delaware corporation (&#8220;<b style="font-weight:bold;">Crescent</b>&#8221;). Paragon, Parascent and Crescent are also referred to herein individually as a &#8220;<b style="font-weight:bold;">Party</b>&#8221;, or collectively as the &#8220;<b style="font-weight:bold;">Parties</b>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Recitals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Whereas, </b>Paragon has developed a proprietary platform technology for the discovery and development of antibodies against therapeutically relevant targets;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Whereas, </b>Crescent desires to engage Paragon to perform, and Paragon is willing to perform, certain research activities to discover, generate, identify, and characterize one or more bispecific antibody candidates directed to certain mutually agreed therapeutic targets of interest to Crescent; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Whereas, </b>Crescent will have an exclusive option to enter into a separate license agreement with Paragon to develop, manufacture and commercialize the resulting antibodies, all on the terms and subject to the conditions set forth in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Now Therefore, </b>in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">DEFINED TERMS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.1</b></font>&#8220;<b style="font-weight:bold;">Achievement of Development Candidate</b>&#8221; means the first to occur of: (a)&#160;nomination by Crescent&#8217;s Board of Directors of a Crescent Product as a &#8220;Development Candidate&#8221;; and (b)&#160;the&#160;initiation by or on behalf of Crescent or its Affiliate or sublicensee of a toxicology study with respect to a Crescent Product that employs applicable then-current good laboratory practice standards, the results of which are intended to be submitted as part of an IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.2</b></font>&#8220;<b style="font-weight:bold;">Actual Annual Costs</b>&#8221; shall have the meaning set forth in Section&#160;5.2(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.3</b></font>&#8220;<b style="font-weight:bold;">Affiliate</b>&#8221; shall mean any entity controlled by, controlling, or under common control with a Party hereto. For the purpose of this definition, &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control&#8221;) means the direct or indirect ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) in the equity of, or the right to appoint more than fifty percent (50%) of the directors or management of, such corporation or other business entity. Notwithstanding the foregoing,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(a)&#160;with respect to either Party, Affiliates of such Party do not include [***] or its Affiliates other than such Party and its subsidiaries, (b) [***], and (c) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.4</b></font>&#8220;<b style="font-weight:bold;">Agreement</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.5</b></font>&#8220;<b style="font-weight:bold;">Antibody</b>&#8221; shall mean any molecule, including [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.6</b></font>&#8220;<b style="font-weight:bold;">Antibody Production Activities</b>&#8221; shall have the meaning provided in Section&#160;2.1(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.7</b></font>&#8220;<b style="font-weight:bold;">Applicable Law</b>&#8221; shall mean any national, supra-national, federal, state or local laws, rules, guidances and regulations, in each case, as applicable to the subject matter and the party at issue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.8</b></font>&#8220;<b style="font-weight:bold;">Background IP</b>&#8221; shall mean all Patents and Know-How Controlled by a Party (a) as of the Effective Date, or (b) that otherwise arise outside of and independently of this Agreement. Paragon&#8217;s Background IP includes the Paragon Platform Technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.9</b></font>&#8220;<b style="font-weight:bold;">Bankruptcy Code</b>&#8221; shall have the meaning set forth in Section 9.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.10</b></font>&#8220;<b style="font-weight:bold;">Bankruptcy Event</b>&#8221; shall have the meaning set forth in Section 9.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.11</b></font>&#8220;<b style="font-weight:bold;">Bispecific Antibody</b>&#8221; shall mean an Antibody that is Directed To two (2) separate Targets (and for clarity, no additional Targets).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.12</b></font>&#8220;<b style="font-weight:bold;">Budget</b>&#8221; shall mean the agreed budget for the activities set forth in the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.13</b></font>&#8220;<b style="font-weight:bold;">Business Day</b>&#8221; shall mean any day other than Saturday, Sunday, or other national holidays in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.14</b></font>&#8220;<b style="font-weight:bold;">Calendar Quarter</b>&#8221; shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30, and December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.15</b></font>&#8220;<b style="font-weight:bold;">Calendar Year</b>&#8221; shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.16</b></font>&#8220;<b style="font-weight:bold;">Change of Control</b>&#8221; means, with respect to any entity, any of the following: (a) the sale or disposition of all or substantially all of the assets of such entity or its direct or indirect controlling Affiliate to a Third Party; or (b) (i) the acquisition by a Third Party, alone or together with any of its Affiliates, other than an employee benefit plan (or related trust) sponsored or maintained by such entity or any of its Affiliates, of more than fifty percent (50%) of the then-outstanding shares of voting capital stock of such entity or its direct or indirect parent entity that holds, directly or indirectly, beneficial ownership of more than fifty percent (50%) of the then-outstanding shares of voting capital stock of such entity (a &#8220;<b style="font-weight:bold;">Parent Entity</b>&#8221;), or (ii) the acquisition,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">merger or consolidation of such entity or its Parent Entity with or into another entity, other than, in the case of clause (i) or (ii), an acquisition or a merger or consolidation of such entity or its Parent Entity in which the holders of shares of voting capital stock of such entity or its Parent Entity, as the case may be, immediately prior to such acquisition, merger or consolidation will beneficially own, directly or indirectly, at least fifty percent (50%) of the shares of voting capital stock of the acquiring Third Party or the surviving corporation in such acquisition, merger or consolidation, as the case may be, immediately after such acquisition, merger or consolidation, and in each case of (a) or (b), whether through a single transaction or a series of related transactions, but excluding any and all bona fide financing transactions or internal reorganizations for tax purposes (including the change of place of incorporation or domicile of such entity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.17</b></font>&#8220;<b style="font-weight:bold;">CMC Activities</b>&#8221; shall have the meaning provided in Section 5.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.18</b></font>&#8220;<b style="font-weight:bold;">CMC Rate</b>&#8221; shall have the meaning provided in Section 5.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.19</b></font>&#8220;<b style="font-weight:bold;">Commercialize</b>&#8221; or &#8220;<b style="font-weight:bold;">Commercializing</b>&#8221; shall mean to market, promote, distribute, offer for sale, sell, have sold, import, have imported, export, have exported or otherwise commercialize an Antibody or product, including a Project Antibody, Derived Antibody, Product, Multispecific Antibody, or Multispecific Product, as applicable. When used as a noun, &#8220;Commercialization&#8221; means any and all activities involved in Commercializing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.20</b></font>&#8220;<b style="font-weight:bold;">Confidential Information</b>&#8221; of a Party shall mean any and all non-public scientific, business, regulatory, or technical information that is disclosed or made available by or on behalf of one Party (the &#8220;<b style="font-weight:bold;">Disclosing Party</b>&#8221;) to any other Party (a &#8220;<b style="font-weight:bold;">Receiving Party</b>&#8221;) in connection with this Agreement, whether in writing, orally, visually or otherwise. Notwithstanding any provision of this Agreement to the contrary, all Project Antibody Inventions and Project Antibody Technology shall be the Confidential Information of all Parties, and each Party shall be deemed as both the &#8220;Disclosing Party&#8221; and the &#8220;Receiving Party&#8221; with respect thereto; <i style="font-style:italic;">provided, that</i> if Crescent does not exercise the Option or the Parties do not enter into the License Agreement in accordance with this Agreement, then the Project Antibody Inventions and Project Antibody Technology shall thereafter be the Confidential Information of Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.21</b></font>&#8220;<b style="font-weight:bold;">Control</b>&#8221; (including any variations such as &#8220;<b style="font-weight:bold;">Controlled</b>&#8221; and &#8220;<b style="font-weight:bold;">Controlling</b>&#8221;) shall mean, with respect to any technology or Intellectual Property Rights, possession by a Party and the ability (whether by ownership, license or otherwise) to grant a license or a sublicense of or under such technology or Intellectual Property Rights without violating the terms of any agreement or other arrangement with any Third Party or requiring a payment. Notwithstanding the foregoing, a Party and its Affiliates shall not be deemed to &#8220;Control&#8221; any technology or Intellectual Property Rights that (a) prior to the consummation of a Change of Control of such Party, is owned or in-licensed, or (b)&#160;after the consummation of a Change of Control of such Party, becomes owned or in-licensed (to the extent such technology or Intellectual Property Rights are developed outside of the scope of the activities conducted hereunder and without use of or reference to any technology or Intellectual Property Rights Controlled by such Party or any Affiliate of such Party immediately before such Change of Control, or any Confidential Information of the other Party), in each case ((a) or (b)), by a Third Party that becomes an Affiliate</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of such Party after the Effective Date as a result of such Change of Control or an assignee of such Party after the Effective Date as the result of an assignment of this Agreement in connection with a Change of Control unless prior to the consummation of such Change of Control or assignment, such Party or any of its Affiliates also Controlled such technology or Intellectual Property Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.22</b></font>&#8220;<b style="font-weight:bold;">Cost Advance</b>&#8221; shall have the meaning set forth in Section 5.2(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.23</b></font>&#8220;<b style="font-weight:bold;">Cover</b>&#8221; or &#8220;<b style="font-weight:bold;">Covering</b>&#8221; shall mean, with respect to a Patent, that, in the absence of a license granted under, or ownership of, such Patent, the making, using, selling, importation, or exportation of such product would infringe a valid and unexpired claim of such Patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.24</b></font>&#8220;<b style="font-weight:bold;">Crescent</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.25</b></font>&#8220;<b style="font-weight:bold;">Crescent Indemnitee</b>&#8221; shall have the meaning provided in Section 10.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.26</b></font>&#8220;<b style="font-weight:bold;">Crescent Multispecific Antibody</b>&#8221; means any Multispecific Antibody that is Developed, Manufactured, Commercialized, or otherwise exploited by Crescent, its Affiliates, or sublicensees (other than Paragon and its Affiliates and other licensees).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.27</b></font>&#8220;<b style="font-weight:bold;">Crescent Multispecific Product</b>&#8221; means any product that comprises or contains any Crescent Multispecific Antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.28</b></font>&#8220;<b style="font-weight:bold;">Crescent Product</b>&#8221; means, individually or collectively, as applicable, Project Antibodies, Derived Antibodies, Products, Crescent Multispecific Antibodies, and Crescent Multispecific Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.29</b></font>&#8220;<b style="font-weight:bold;">Deliverables</b>&#8221; shall have the meaning set forth in Section 2.1(c)(i).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.30</b></font>&#8220;<b style="font-weight:bold;">Derived Antibody</b>&#8221; shall mean any Bispecific Antibody that (a)&#160;is derived from or constitutes a modification of a Project Antibody, including [***], and (b)&#160;[***]. For avoidance of doubt, any Bispecific Antibody that [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.31</b></font>&#8220;<b style="font-weight:bold;">Derived Antibody Patent</b>&#8221; shall mean any Patent that Covers the composition of matter of, or any method of specifically making or using, any Derived Antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.32</b></font>&#8220;<b style="font-weight:bold;">Develop</b>&#8221; or &#8220;<b style="font-weight:bold;">Developing</b>&#8221; shall mean to discover, evaluate, test, research or otherwise develop an Antibody or product, including a Project Antibody, Derived Antibody, Product, Multispecific Antibody, or Multispecific Product, as applicable. When used as a noun, &#8220;<b style="font-weight:bold;">Development</b>&#8221; means any and all activities involved in Developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.33</b></font>&#8220;<b style="font-weight:bold;">Development Costs</b>&#8221; shall mean (a) [***] (such amounts, the &#8220;<b style="font-weight:bold;">Third Party Costs</b>&#8221;), and (b) [***] (such development fees, the &#8220;<b style="font-weight:bold;">Development Fees</b>&#8221;, and the development fees to be paid in any given Calendar Year during the Research Program, the &#8220;<b style="font-weight:bold;">Annual Development Fees</b>&#8221;); in each case ((a) and (b)) to the extent consistent with the Research Plan (including [***]).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.34</b></font>&#8220;<b style="font-weight:bold;">Directed To</b>&#8221; shall mean, with regard to an Antibody or product, that such Antibody or product is developed or designed to (a) [***], and (b) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.35</b></font>&#8220;<b style="font-weight:bold;">Dispute</b>&#8221; shall have the meaning provided in Section 11.7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.36</b></font>&#8220;<b style="font-weight:bold;">Effective Date</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.37</b></font>&#8220;<b style="font-weight:bold;">Election Notice</b>&#8221; shall have the meaning provided in Section 4.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.38</b></font>&#8220;<b style="font-weight:bold;">Equity Grant</b>&#8221; shall have the meaning provided in Section&#160;5.8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.39</b></font>&#8220;<b style="font-weight:bold;">FDA</b>&#8221; means the United States Food and Drug Administration, or a successor federal agency thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.40</b></font>&#8220;<b style="font-weight:bold;">Field</b>&#8221; shall mean the prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.41</b></font>&#8220;<b style="font-weight:bold;">Final Deliverable</b>&#8221; shall have the meaning provided in the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.42</b></font>&#8220;<b style="font-weight:bold;">Indemnified Party</b>&#8221; shall have the meaning provided in Section 10.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.43</b></font>&#8220;<b style="font-weight:bold;">Indemnifying Party</b>&#8221; shall have the meaning provided in Section 10.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.44</b></font>&#8220;<b style="font-weight:bold;">Intellectual Property Rights</b>&#8221; shall mean any and all proprietary rights provided under (a) patent law, including any Patents; (b) copyright law; or (c) any other applicable statutory provision or common law principle, including trade secret law, that may provide a right in Know-How, or the expression or use thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.45</b></font>&#8220;<b style="font-weight:bold;">JDC</b>&#8221; shall have the meaning provided in Section 3.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.46</b></font>&#8220;<b style="font-weight:bold;">Know-How</b>&#8221; shall mean all technical information and know-how in any tangible or intangible form, including (a) inventions, discoveries, trade secrets, data, specifications, instructions, processes, formulae, materials (including cell lines, vectors, plasmids, nucleic acids and the like), methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b) all data, instructions, processes, formulae, strategies, and expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines. Notwithstanding the foregoing, Know-How excludes Patent claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.47</b></font>&#8220;<b style="font-weight:bold;">License Agreement</b>&#8221; shall have the meaning set forth in Section 4.4(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.48</b></font>&#8220;<b style="font-weight:bold;">License Template</b>&#8221; shall have the meaning set forth in Section 4.4(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.49</b></font>&#8220;<b style="font-weight:bold;">Losses</b>&#8221; shall have the meaning provided in Section 10.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.50</b></font>&#8220;<b style="font-weight:bold;">MAA</b>&#8221; means (a) a New Drug Application in the United States, as defined in the United States Federal Food, Drug and Cosmetics Act, and applicable regulations promulgated thereunder by the FDA, (b) a Biologics License Application in the United States, as defined in the United States Public Health Service Act, or (c) any application filed with any Regulatory Authority in a country other than the United States that is equivalent to either of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.51</b></font>&#8220;<b style="font-weight:bold;">Manufacture</b>&#8221; or &#8220;<b style="font-weight:bold;">Manufacturing</b>&#8221; shall mean to make, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, ship or store an Antibody or product, including a Project Antibody, Derived Antibody, Product, Multispecific Antibody, or Multispecific Product or any component thereof, as applicable. When used as a noun, &#8220;Manufacture&#8221; or &#8220;Manufacturing&#8221; means any and all activities involved in Manufacturing an Antibody or product, including a Project Antibody, Derived Antibody, Product, Multispecific Antibody, or Multispecific Product or any component thereof, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.52</b></font>&#8220;<b style="font-weight:bold;">Milestone</b>&#8221; shall have the meaning provided in Section 5.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.53</b></font>&#8220;<b style="font-weight:bold;">Milestone Payment</b>&#8221; shall have the meaning provided in Section 5.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.54</b></font>&#8220;<b style="font-weight:bold;">Multispecific Antibody</b>&#8221; means any Antibody that is comprised of (a) [***], and (b) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.55</b></font>&#8220;<b style="font-weight:bold;">Multispecific Product</b>&#8221; means any product that comprises or contains any Multispecific Antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.56</b></font>&#8220;<b style="font-weight:bold;">Notice of Dispute</b>&#8221; shall have the meaning provided in Section 11.7(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.57</b></font>&#8220;<b style="font-weight:bold;">Option</b>&#8221; shall have the meaning provided in Section&#160;4.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.58</b></font>&#8220;<b style="font-weight:bold;">Option Period</b>&#8221; shall have the meaning provided in Section&#160;4.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.59</b></font>&#8220;<b style="font-weight:bold;">Paragon</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.60</b></font>&#8220;<b style="font-weight:bold;">Paragon </b><b style="font-weight:bold;">Indemnitee</b>&#8221; shall have the meaning provided in Section 10.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.61</b></font>&#8220;<b style="font-weight:bold;">Paragon Platform Know-How</b>&#8221; shall mean (a) Know-How Controlled by Paragon or its Affiliates prior to or during the Term relating to antibody discovery and development, (b) all methods, materials and other Know-How used in the foregoing Controlled by Paragon or its Affiliates, and (c) platforms embodying, components, component steps and other portions of any of the foregoing in (a) or (b) Controlled by Paragon or its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.62</b></font>&#8220;<b style="font-weight:bold;">Paragon Platform Know-How Improvement</b>&#8221; shall mean all Know-How developed or discovered through or as a result of the activities performed by or on behalf of Paragon under the Research Program that constitutes an improvement, enhancement, modification,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">substitution, or alteration to the Paragon Platform Technology; <i style="font-style:italic;">provided, however</i>, to the extent any of the Know-How developed or discovered under the Research Program specifically and solely relates to a Project Antibody, such Know-How will be considered Project Antibody Technology and not Paragon Platform Know-How Improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.63</b></font>&#8220;<b style="font-weight:bold;">Paragon Platform Patents</b>&#8221; shall mean all Patents that Paragon or its Affiliates Control prior to or during the Term that Cover Paragon Platform Know-How or Paragon Platform Know-How Improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.64</b></font>&#8220;<b style="font-weight:bold;">Paragon Platform Technology</b>&#8221; shall mean Paragon Platform Know-How, Paragon Platform Know-How Improvements, and Paragon Platform Patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.65</b></font>&#8220;<b style="font-weight:bold;">Parascent</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.66</b></font>&#8220;<b style="font-weight:bold;">Party</b>&#8221; or &#8220;<b style="font-weight:bold;">Parties</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.67</b></font>&#8220;<b style="font-weight:bold;">Patents</b>&#8221; shall mean (a) unexpired patents and patent applications, (b) any and all divisionals, continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates and the like of any such patents and patent applications, and (c) any and all foreign equivalents of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.68</b></font>&#8220;<b style="font-weight:bold;">PD-1</b>&#8221; shall mean Programmed cell death protein 1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.69</b></font>&#8220;<b style="font-weight:bold;">Phase I Trial</b>&#8221; means a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(a), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.70</b></font>&#8220;<b style="font-weight:bold;">Phase II Trial</b>&#8221; means a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(b), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.71</b></font>&#8220;<b style="font-weight:bold;">Phase III Trial</b>&#8221; means a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(c), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.72</b></font>&#8220;<b style="font-weight:bold;">Pre-Effective Date Development Costs</b>&#8221; shall have the meaning provided in Section 5.2(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.73</b></font>&#8220;<b style="font-weight:bold;">Product</b>&#8221; shall mean any product that comprises or contains any Project Antibody or any Derived Antibody thereof, other than as part of a Multispecific Antibody or a Multispecific Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.74</b></font>&#8220;<b style="font-weight:bold;">Project Antibody</b>&#8221; shall mean any and all Bispecific Antibodies that are Directed To both of the Selected Targets and that are discovered, generated, identified or characterized by Paragon in the course of performing the Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.75</b></font>&#8220;<b style="font-weight:bold;">Project Antibody Invention</b>&#8221; shall mean (a) any invention or discovery, whether or not patentable, that was discovered or reduced to practice by or on behalf of Paragon under the Research Program that constitutes the composition of matter of, or any method of specifically making or using, any Project Antibody, and (b) all Intellectual Property Rights therein that are Controlled by Paragon or its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.76</b></font>&#8220;<b style="font-weight:bold;">Project Antibody Patents</b>&#8221; shall mean all Patents that Cover the composition of matter of, or any method of specifically making or using, any Project Antibody, that are in each case Controlled by Paragon or its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.77</b></font>&#8220;<b style="font-weight:bold;">Project Antibody Samples</b>&#8221; shall have the meaning provided in Section&#160;2.1(c)(i).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.78</b></font>&#8220;<b style="font-weight:bold;">Project Antibody Selection Criteria</b>&#8221; shall mean those criteria agreed to by the Parties in the Research Plan that establish that a Project Antibody is suitable for clinical testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.79</b></font>&#8220;<b style="font-weight:bold;">Project Antibody Technology</b>&#8221; shall mean (a) the Project Antibody Inventions, (b) the Project Antibody Patents, (c) the Sequence Information and Results, and (d) all Intellectual Property Rights therein that are Controlled by Paragon and its Affiliates. For clarity, if the Parties execute the License Agreement and the Research Term for the Research Program continues following execution of the License Agreement, any Project Antibody Technology first conceived, reduced to practice or otherwise generated following the execution of the License Agreement shall be licensed to Crescent under the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.80</b></font>&#8220;<b style="font-weight:bold;">Regulatory Approval</b>&#8221; means all clearances, approvals (including approval of an MAA as well as any applicable pricing and/or reimbursement approvals), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell and market a pharmaceutical or biologic product in a country or territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.81</b></font>&#8220;<b style="font-weight:bold;">Regulatory Authority</b>&#8221; means any supranational, multinational, federal, national, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the clinical development, manufacture, marketing or sale of a pharmaceutical or biologic product in a country or region, including the FDA in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.82</b></font>&#8220;<b style="font-weight:bold;">Representatives</b>&#8221; of a Party shall mean such Party&#8217;s and its Affiliates&#8217; officers, directors, employees, contractors, subcontractors, agents and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.83</b></font>&#8220;<b style="font-weight:bold;">Research Plan</b>&#8221; shall have the meaning set forth in Section 2.1(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.84</b></font>&#8220;<b style="font-weight:bold;">Research Program</b>&#8221; shall mean the research program agreed to by the Parties to identify Bispecific Antibodies with activity against both of the Selected Targets and to perform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">such additional activities with respect to such Bispecific Antibodies as set forth in the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.85</b></font>&#8220;<b style="font-weight:bold;">Research Term</b>&#8221; shall mean the period of time beginning on the agreement by the Parties on the Research Plan and continuing until completion of the activities under the Research Plan or such other date mutually agreed upon by the Parties; <i style="font-style:italic;">provided, that</i> (a) if Crescent does not exercise the Option in accordance with Section 4.3 prior to expiration of the Option Period, then upon such expiration the Research Term shall automatically terminate and Paragon shall have no obligation to perform any activities under the Research Plan thereafter, or (b) if Crescent exercises the Option during the Option Period in accordance with Section 4.3 but the Parties are unable to finalize and execute the License Agreement during the thirty (30) day period referenced in Section 4.4(b), then upon the expiration of such period the Research Term shall automatically terminate and Paragon shall have no obligation to perform any activities under the Research Plan thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.86</b></font>&#8220;<b style="font-weight:bold;">Results</b>&#8221; shall mean the data, results, analysis, conclusions, outcomes, information, documentation, and reports that are generated by or on behalf of Paragon in performance of the Research Program, excluding Project Antibodies, Project Antibody Inventions, Project Antibody Patents, and the Sequence Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.87</b></font>&#8220;<b style="font-weight:bold;">Selected Target</b>&#8221; shall have the meaning set forth in Section 2.1(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.88</b></font>&#8220;<b style="font-weight:bold;">Sequence Information</b>&#8221; shall mean electronic files containing all Project Antibody sequences generated under the Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.89</b></font>&#8220;<b style="font-weight:bold;">Shares</b>&#8221; shall mean shares of common stock, par value $0.0001, of Crescent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.90</b></font>&#8220;<b style="font-weight:bold;">Target</b>&#8221; shall mean a protein molecule that (a) [***], and (b) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.91</b></font>&#8220;<b style="font-weight:bold;">Term</b>&#8221; shall have the meaning provided in Section 9.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.92</b></font>&#8220;<b style="font-weight:bold;">Territory</b>&#8221; shall mean worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.93</b></font>&#8220;<b style="font-weight:bold;">Third Party</b>&#8221; shall mean any person or entity other than Paragon, Parascent or Crescent or an Affiliate of any of Paragon, Parascent or Crescent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.94</b></font>&#8220;<b style="font-weight:bold;">Third Party Claim</b>&#8221; shall have the meaning provided in Section 10.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.95</b></font>&#8220;<b style="font-weight:bold;">Valid Claim</b>&#8221; means, with respect to particular Patent in a particular country, (a) a claim of an issued and unexpired patent (including the term of any patent term extension, supplemental protection certificate, renewal or other similar extension) in such country within such Patent that has not been abandoned or revoked, or held unpatentable, invalid or unenforceable in a final decision of a court or other governmental authority of competent jurisdiction from which no appeal may be taken, or has been taken before the expiry of the permitted time period, and that has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise, or (b) a claim within a patent application in such country</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">within such Patent that has not been pending more than seven (7) years from the earliest priority date of such claim and which claim has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.96</b></font>&#8220;<b style="font-weight:bold;">VEGF</b>&#8221; shall mean Vascular endothelial growth factor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONDUCT OF RESEARCH PROGRAM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.1</b></font><b style="font-weight:bold;">Research Program.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Target Selection</b>. The Parties intend to initiate the Research Program to discover, generate, identify, and characterize one or more Bispecific Antibody candidates Directed To both PD-1 and VEGF (each of PD-1 and VEGF, a &#8220;<b style="font-weight:bold;">Selected Target</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Research Plan. </b>No later than [***] after the Effective Date, the Parties will agree on a research plan, to the extent a research plan has not been previously agreed upon, for the Research Program that will include design, modeling, synthesis, evaluation, and other mutually agreed activities (&#8220;<b style="font-weight:bold;">Research Plan</b>&#8221;). For clarity, if at the end of such [***] period (or any extension thereof mutually agreed in writing) (i) the Parties have not agreed on the Research Plan, or (ii) Crescent has not paid Paragon the Research Initiation Fee, Paragon shall have no obligations to Crescent with respect to the Research Program or the Selected Targets. Once the Parties agree on the Research Plan and Crescent pays the Research Initiation Fee for the Research Program, Paragon and Parascent shall conduct research under the Research Program during the applicable Research Term in an effort to (1)&#160;produce Project Antibodies for further Development, Manufacture and Commercialization (&#8220;<b style="font-weight:bold;">Antibody Production Activities</b>&#8221;), and (2) perform such other Development and Manufacturing activities with respect to the Project Antibodies as set forth in the Research Plan (which other activities, for clarity, may be performed following Crescent&#8217;s exercise of the Option or execution of a License Agreement). The Parties may amend the Research Plan upon mutual written agreement. Paragon and Parascent will use [***] to conduct and complete the activities set forth in the Research Plan on the timelines set forth in the Research Plan and in compliance with the Budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Deliverables; Project Antibody Samples.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>Following completion of the Antibody Production Activities set forth in the Research Plan, Paragon and Parascent will deliver to Crescent a data package that includes Sequence Information for all then-existing Project Antibodies and Results (the &#8220;<b style="font-weight:bold;">Deliverables</b>&#8221;). Additionally, upon request by Crescent, and at [***] cost and expense, Paragon and Parascent shall provide to Crescent samples of proteins corresponding to such Project Antibodies that have been expressed in accordance with the Research Plan (&#8220;<b style="font-weight:bold;">Project Antibody Samples</b>&#8221;) to enable Crescent to evaluate the Option. Following completion of the Research Program, Paragon shall deliver to Crescent the Final Deliverable for the Research Program, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>During the Option Period with respect to the Research Program, Crescent will review the Deliverables and Project Antibody Samples for the Research Program to determine whether [***] Project Antibody meets the Project Antibody Selection Criteria. If Crescent determines that [***] Project Antibody meets the Project Antibody Selection Criteria, then Crescent shall so notify Paragon in writing prior to the end of the Option Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">Conduct of Research Program. </b>During the Research Term, Paragon and Parascent shall (i) perform the activities assigned to it under the Research Plan in a professional, diligent and good scientific manner, in compliance with all Applicable Law, and in compliance with the Research Plan; (ii) ensure that its Representatives and subcontractors diligently perform the Research Program in a manner in accordance with generally accepted industry practices by appropriately trained personnel who are experienced in the relevant fields and in compliance with Applicable Law; (iii) keep Crescent fully informed regarding the progress and results of the Research Program; (iv) [***] provide Crescent with any additional information regarding the Research Program that Crescent reasonably requests; (v)&#160;participate in teleconference(s) at a time(s) agreed upon by the Parties to provide an update to Crescent on the performance of the Research Program; and (vi) give Crescent [***] notice with respect to information known or believed by Paragon and Parascent to be likely to materially impede or otherwise adversely affect the performance of the Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.2</b></font><b style="font-weight:bold;">Subcontractors. </b>Paragon and Parascent may perform the activities under the Research Program through one or more subcontractors; <i style="font-style:italic;">provided, that </i>Paragon and Parascent shall at all times be fully responsible for the compliance of such subcontractors with this Agreement and for the performance of their obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.3</b></font><b style="font-weight:bold;">Research Books and Records; Audit</b>. Paragon shall maintain complete and accurate records related to the activities performed by Paragon under the Research Program. All such books and records shall be retained by Paragon and Parascent until the later of: (a) [***] after the end of the applicable stage of research; and (b) such longer period as may be required by Applicable Law. Upon Crescent&#8217;s request and at [***] expense, Paragon shall provide copies of such records or such records shall be made available for Crescent&#8217;s reasonable review, audit and inspection upon reasonable notice and with reasonable frequency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">GOVERNANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.1</b></font><b style="font-weight:bold;">Joint Development Committee</b>. The Parties will establish a single Joint Development Committee (the &#8220;<b style="font-weight:bold;">JDC</b>&#8221;) to oversee and coordinate the activities under the Research Program in accordance with the remainder of this Article 3. The JDC shall be comprised of two (2) employees from Crescent and two (2) employees from Paragon, with each Party designating one (1) such employee as its JDC co-chairperson. Subject to the foregoing, each Party shall appoint its respective Representatives to the JDC from time to time, and may change its Representatives, in its sole discretion, effective upon notice to the other Parties designating such change. Representatives from each Party shall have appropriate technical credentials, experience and knowledge pertaining to and ongoing familiarity with the activities to be performed under the Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.2</b></font><b style="font-weight:bold;">JDC Meetings</b>. The JDC shall meet in accordance with a schedule established by mutual written agreement of the Parties no less frequently than once every three (3) months until the end of the period specified in Section 3.5. The JDC may meet by means of teleconference, videoconference or other similar means, as jointly determined by the Parties. As appropriate, additional employees or consultants may from time to time attend the JDC meetings as nonvoting observers; <i style="font-style:italic;">provided, that</i> any such consultant shall agree in writing to comply with the confidentiality obligations under this Agreement; and <i style="font-style:italic;">provided, further that</i> no Third Party personnel may attend unless otherwise agreed by all Parties. Each Party shall bear its own expenses related to the attendance of the JDC meetings by its representatives. Each Party may also call for special meetings to resolve particular matters requested by such Party. Paragon shall be responsible for keeping minutes of each JDC meeting that record in writing all decisions made, action items assigned or completed and other appropriate matters. Paragon shall send meeting minutes to all members of the JDC within [***] after a meeting for review. Each member shall have [***] from receipt in which to comment on and to approve/provide comments to the minutes (such approval not to be unreasonably withheld, conditioned or delayed). If a member, within such time period, does not notify the drafting Party that s/he does not approve of the minutes, the minutes shall be deemed to have been approved by such member.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.3</b></font><b style="font-weight:bold;">JDC Functions</b>. The JDC&#8217;s responsibilities are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Developing, reviewing, overseeing and coordinating the activities under the Research Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Periodically reviewing the progress of activities under the Research Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>Updating or modifying the Research Plan; <i style="font-style:italic;">provided, that</i> such update or modification does not obligate any Party to perform any task or expend any resources outside of or beyond its obligations under the Budget;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>Reviewing performance against the Budget and timeline for the Research Program periodically (at least [***]), and periodically meeting to review and (subject to mutual</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">approval of the Parties), approving any discovery project Budget deviation where such deviation is greater than [***] percent ([***]%);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>Reviewing the reconciliation of Actual Annual Costs against the Cost Advance at the end of each Calendar Year for the Research Program; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font>Determining whether the Project Antibody Selection Criteria for the Research Program are not achievable for any reason and therefore the Research Program no longer warrants further research.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.4</b></font><b style="font-weight:bold;">JDC Decision Making and Disputes</b>. The JDC will endeavor to make decisions by consensus, with each of Crescent and Paragon having one vote. If consensus is not reached by the Parties&#8217; Representatives pursuant to such vote, then disputes relating to: (a) the reconciliation of Actual Annual Costs against the Cost Advance, as set forth in Section&#160;5.2(c), will be resolved in accordance with Section 11.7; (b) technical or scientific decisions in the course of operationalizing the Research Program, including the nature of activities to be performed by Paragon and Parascent thereunder, shall be finally decided by [***]; and (c) the Budget for the Research Program, and all other matters not covered by clauses (a) or (b), shall be finally decided by [***]. For clarity, and notwithstanding the creation of the JDC, each Party shall retain the rights, powers and discretion granted to it hereunder, and the JDC shall not be delegated or vested with such rights, powers or discretion unless such delegation or vesting is expressly provided herein, or the Parties expressly so agree in writing. The JDC shall not have the power to amend, waive or modify any term of this Agreement, and no decision of the JDC shall be in contravention of any terms and conditions of this Agreement. It is understood and agreed that issues to be formally decided by the JDC are limited to those specific issues that are expressly provided in this Agreement to be decided by the JDC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.5</b></font><b style="font-weight:bold;">Disbandment</b>. The JDC shall remain in effect from the date on which it is established in accordance with Section 3.1 until the expiration of the Research Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">OPTION; LICENSE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.1</b></font><b style="font-weight:bold;">Grant of Option. </b>Subject to the terms and conditions of this Agreement, Paragon hereby grants to Crescent, during the Term and subject to delivery of the Election Notice in accordance with Section 4.3, an exclusive option (&#8220;<b style="font-weight:bold;">Option</b>&#8221;) to be granted an exclusive license under the Project Antibody Technology to Develop, Manufacture and Commercialize Project Antibodies, Derived Antibodies and Products in the Field in the Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.2</b></font><b style="font-weight:bold;">Limited License Grant During Option Period. </b>Subject to the terms and conditions of this Agreement, and effective only during the Term, Paragon hereby grants to Crescent a limited, exclusive, royalty-free license, without the right to sublicense, under the Project Antibody Technology solely to evaluate the Option and for the purpose of allowing Crescent to determine whether to exercise the Option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.3</b></font><b style="font-weight:bold;">Option Exercise. </b>Crescent may, in its sole discretion, exercise the Option by delivering written notice of such exercise to Paragon (&#8220;<b style="font-weight:bold;">Election Notice</b>&#8221;) at any time during the period beginning on the initiation of activities under the Research Program and ending [***] following Crescent&#8217;s receipt of the Deliverables for the Research Program, or such longer period as agreed upon by the Parties (&#8220;<b style="font-weight:bold;">Option Period</b>&#8221;). If Crescent fails to exercise the Option in accordance with this Section 4.3 prior to expiration of the Option Period, then, upon such expiration, the Option shall terminate and be of no further force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.4</b></font><b style="font-weight:bold;">License Template; Execution After Option Exercise.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Within [***] of the Effective Date, the Parties shall negotiate [***] and use [***] to agree upon a form of agreement template (&#8220;<b style="font-weight:bold;">License Template</b>&#8221;) to be used in connection with Crescent&#8217;s exercise of the Option, which will be consistent with the economic and other terms set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>, and upon mutual agreement by the Parties on the form of such License Template, will be attached to this Agreement and replace the terms on the existing <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>. If the Parties are unable to reach agreement on the definitive terms of the License Template within such [***] period, the matter will be resolved in accordance with Section 11.7 unless the Parties mutually agree to resolve the matter otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Within [***] of Crescent&#8217;s exercise of the Option as set forth in Section 4.3, subject to any extension as mutually agreed by the Parties, the Parties shall use [***] to finalize and execute a definitive written agreement consistent with the License Template (the &#8220;<b style="font-weight:bold;">License Agreement</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">PAYMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.1</b></font><b style="font-weight:bold;">Research Initiation Fee</b>. Crescent shall pay to Paragon a one-time nonrefundable, non-creditable fee of One Million Two Hundred Fifty Thousand Dollars ($1,250,000) (the &#8220;<b style="font-weight:bold;">Research Initiation Fee</b>&#8221;) no later than thirty (30) days following finalization of the Research Plan. For clarity, the Research Initiation Fee is nonrefundable, non-creditable, and separate from any Development Costs (including the Pre-Effective Date Development Costs) or Cost Advance paid or owing with respect to the Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.2</b></font><b style="font-weight:bold;">Development Costs</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>The monthly rate for the Development Fees (the &#8220;<b style="font-weight:bold;">Monthly Rate</b>&#8221;) shall be determined and charged on a calendar month-by-calendar month basis. For the period beginning on the Effective Date and continuing through December 31, 2024, the Monthly Rate shall be [***]. If the Research Plan requires Paragon to perform certain chemistry, manufacturing, and control activities (&#8220;<b style="font-weight:bold;">CMC Activities</b>&#8221;) in furtherance of the Research Program, then the Monthly Rate that would otherwise apply shall be [***]. Paragon shall have the right to adjust the Monthly Rate and the CMC Rate on an annual basis to account for inflation and other increases in costs by providing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">written notice thereof to Crescent at least [***] prior to the commencement of each [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>On a quarterly basis, Crescent will advance to Paragon any Development Costs contemplated in the Budget, including [***], and any [***] reasonably expected to be incurred by Paragon in the performance of the Research Program during the upcoming [***] in accordance with the Research Plan and Budget (less any pre-payments for Third Party Costs from earlier [***] that Paragon reasonably anticipates will be carried over to such upcoming [***]) (the &#8220;<b style="font-weight:bold;">Cost Advance</b>&#8221;). On a quarterly basis, Paragon will deliver an invoice to Crescent for the Cost Advance, and Crescent will pay the Cost Advance within [***] after receipt of Paragon&#8217;s invoice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>Within [***] after the end of each Calendar Year, Paragon will calculate and provide to Crescent a written reconciliation of its actually-incurred Third Party Costs (incurred in a manner consistent with the Budget) for the prior Calendar Year (&#8220;<b style="font-weight:bold;">Actual Annual Costs</b>&#8221;) against that portion of the Cost Advance for such Third Party Costs for that Calendar Year, including reasonable documentation of such Actual Annual Costs. The form of such reconciliation shall be subject to JDC review and approval. If the amounts paid for anticipated Third Party Costs in the Cost Advance exceeds the Actual Annual Costs, then Paragon will credit such excess payment against Development Costs contemplated in the Budget and reasonably expected to be incurred by Paragon in the performance of the Research Program during any upcoming Calendar Year and Crescent will deduct such amount from its next quarterly Cost Advance. If the Cost Advance is less than the Actual Annual Costs, then Paragon will invoice Crescent for the difference and Crescent will pay such amount together with its next quarterly Cost Advance. If no further amounts will be owed to Paragon hereunder, Paragon will refund such amount. For clarity, the above reconciliation will not apply to Annual Development Fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>Notwithstanding Sections 5.2(a), 5.2(b) and 5.2(c) to the contrary, the Parties acknowledge that Paragon has incurred approximately $1.5 million in Development Costs as a result of work performed by Paragon at risk on the Research Program (the &#8220;<b style="font-weight:bold;">Pre-Effective Date Development Costs</b>&#8221;). Crescent shall reimburse Paragon for the Pre-Effective Date Development Costs within [***] after Crescent&#8217;s receipt of a written invoice that details the Pre-Effective Date Development Costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.3</b></font><b style="font-weight:bold;">Milestones</b>. Crescent shall make the following one-time non-refundable and non-creditable milestone payments to Paragon (or to such other designee(s), as designated by Paragon) as set forth below (each payment, a &#8220;<b style="font-weight:bold;">Milestone Payment</b>&#8221;), based on the achievement of the corresponding milestone set forth below (each, a &#8220;<b style="font-weight:bold;">Milestone</b>&#8221;) by Crescent, its Affiliates, or its sublicensees with respect to the first Crescent Product to achieve such Milestone. Crescent shall, within [***] after it or its Affiliates achieve a Milestone, or within [***] after it learns that its or its Affiliate&#8217;s sublicensee has achieved a Milestone, notify Paragon of the achievement of such Milestone [***]. Following receipt of such notice, Paragon shall invoice Crescent for such Milestone Payment, which invoice shall specify the bank account information into which such Milestone Payment should be paid. Crescent shall make such Milestone Payment to Paragon or Paragon&#8217;s designee within [***] after receipt of Paragon&#8217;s invoice. Each Milestone Payment shall be paid no more than once, and Crescent&#8217;s total Milestone Payments hereunder (together with any such Milestone Payments achieved and payable pursuant to a subsequently executed License</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Agreement) shall not exceed Twenty-Two Million Dollars ($22,000,000). For avoidance of doubt, upon achievement of any Milestone, all prior unachieved Milestones shall be deemed thereby achieved and, if the Milestone Payment for any such prior Milestone has not previously been paid, it shall thereupon also be paid at the same time that the Milestone Payment for such subsequent achieved Milestone is paid. The Parties acknowledge and agree that once the License Agreement has been executed and is effective, any Milestone set forth in this Agreement that (a) has not yet been achieved, and (b) is duplicated in the License Agreement, together with the corresponding Milestone Payment, shall no longer be achievable and payable under the terms of this Agreement and shall only be achievable and payable under the terms of the License Agreement. Additionally, for the avoidance of doubt, if a Milestone is achieved and paid by Crescent pursuant to this Agreement, then there shall be no Milestone Payment due for the achievement of such Milestone under the subsequently executed License Agreement, notwithstanding the inclusion of the same Milestone in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> hereto or in the License Agreement.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:79.92%;" align="center"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:75.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Regulatory/Development Milestones</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:24.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></th></tr><tr><td style="vertical-align:top;width:75.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:24.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:75.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:24.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:75.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:24.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:75.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:24.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:75.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td><td style="vertical-align:top;width:24.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.4</b></font><b style="font-weight:bold;">Financial Records. </b>Paragon shall keep complete and accurate books of account and records in sufficient detail to enable the Development Costs and Milestones payable under this Agreement to be determined. Such books and records shall be kept at the principal place of business of Paragon, for at least [***] following the end of the [***] to which such books and records pertain, and Crescent shall be entitled to inspect such books and records at Paragon&#8217;s offices upon Crescent&#8217;s reasonable request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.5</b></font><b style="font-weight:bold;">Manner and Method of Payment</b>. All cash payment amounts hereunder are expressed in U.S. dollars (USD) unless otherwise specified. Each payment shall be made by electronic funds transfer in immediately available funds to a bank and account designated in writing by Paragon, unless otherwise specified in writing by Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.6</b></font><b style="font-weight:bold;">Tax</b>. Each Party shall be responsible for paying its own respective taxes in connection with any activities that it performs and any payments that it receives under this Agreement. The Parties will commit [***] to provide each other with any tax forms that may be reasonably necessary in order for any Party to not pay or withhold tax or to pay or withhold tax at a reduced rate under an applicable income tax treaty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.7</b></font><b style="font-weight:bold;">Late Payments</b>. In the event that any cash payment due for any undisputed amount under this Agreement is not made when due, then the cash payment shall accrue interest from the date due at a per annum rate equal to [***] above the then-current per annum prime rate reported by the <i style="font-style:italic;">Wall Street Journal</i> (U.S., Western Edition) or, if lower, the maximum legal annual interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.8</b></font><b style="font-weight:bold;">Equity Grants</b>. Except as expressly agreed otherwise by the Parties in writing, upon completion of each of the Calendar Years ending December 31, 2025 and December 31, 2026, Crescent will grant to Parascent a warrant to purchase a number of Shares equal to 1.00% of the outstanding Shares as of the date of the grant, on a fully-diluted basis (assuming the exercise or conversion of any convertible non-voting preferred stock, stock options, pre-funded warrants or similar instruments), with an exercise price equal to the fair market value of the underlying Shares on the date of the grant as determined by the board of directors of Crescent (each grant, an &#8220;<b style="font-weight:bold;">Equity Grant</b>&#8221;); <i style="font-style:italic;">provided, that</i> if Crescent undergoes an initial public offering or a reverse merger transaction the rights and obligations of this Section 5.8 shall continue and Parascent shall be entitled to warrants from the ultimate public company parent to purchase a number of shares of such parent equal to 1.00% of the outstanding shares of the parent as of the date of the grant, on a fully-diluted basis (assuming the exercise or conversion of any convertible non-voting preferred stock, stock options, pre-funded warrants or similar instruments), as applicable. Such warrants will be exercisable for a period of ten (10) years following the date of the grant. Each Equity Grant shall be effected on the last Business Day of each applicable Calendar Year and the corresponding grant date shall be such date. If the Term ends prior to the end of a Calendar Year, the Equity Grant for such Calendar Year shall be pro-rated for such Calendar Year and such Equity Grant shall be effected within five (5) Business Days of the end of the Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INTELLECTUAL</b><b style="font-variant:small-caps;font-weight:bold;"> PROPERTY RIGHTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.1</b></font><b style="font-weight:bold;">Ownership.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Background IP</b>. As between the Parties, each Party will retain all right, title and interest in and to all of its Background IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Project Antibody Technology. </b>Subject to the rights and licenses granted to Crescent in this Agreement, as between the Parties, Paragon or its Affiliates shall own all right, title and interest in and to all Project Antibody Technology, irrespective of inventorship. Crescent agrees to assign and hereby assigns to Paragon all of Crescent&#8217;s right, title and interest in and to the Project Antibody Technology, including any and all Intellectual Property Rights therein. Crescent shall execute and deliver, and shall cause its Affiliates to execute and deliver, such additional documents, instruments, conveyances and assurances and take any such further actions as may be reasonably required to ensure that all right, title and interest in the Project Antibody Technology is effectively assigned to and held by Paragon. Crescent and its Affiliates shall cause all of its and their employees who, in each case, generated, conceived of or created any Project Antibody Technology to assign without additional consideration all ownership rights in such Project Antibody Technology to Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.2</b></font><b style="font-weight:bold;">Patent Prosecution, Maintenance and Enforcement &#8211; Project Antibody Patents.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Prior to execution of the License Agreement, Paragon shall have the sole right, but not the obligation, to prepare, file, prosecute, maintain or enforce any Project Antibody Patents at Paragon&#8217;s sole expense, and Crescent shall reasonably cooperate and assist Paragon in such preparation, filing, prosecution, maintenance and enforcement, at Paragon&#8217;s request. Following execution of the License Agreement, (i) with respect to Project Antibody Patents that have been filed prior to the execution of the License Agreement, the Parties&#8217; respective rights relating to the preparation, filing, prosecution, maintenance and enforcement of such Project Antibody Patents shall be as set forth therein and Crescent shall reimburse Paragon for any costs and expenses actually incurred by Paragon in the prosecution and maintenance of any such Project Antibody Patents in accordance with the terms of the License Agreement, and (ii) with respect to Project Antibody Patents that have not been filed prior to the execution of the License Agreement, (1) Paragon, at its sole expense, shall have the sole right, but not the obligation, to prepare, file, prosecute, maintain and enforce such Product Antibody Patents until the date on which the Final Deliverable for such Research Program is delivered to Crescent, and during such period Paragon shall provide Crescent with drafts of all proposed filings to any patent office with respect to such Project Antibody Patents in reasonably adequate time before submission of such filings for Crescent&#8217;s review and comment, and (2) following the date on which the Final Deliverable for such Research Program is delivered to Crescent, the Parties&#8217; respective rights relating to the preparation, filing, prosecution, maintenance and enforcement of such Project Antibody Patents shall be as set forth therein and Crescent shall reimburse Paragon for any costs and expenses actually incurred by Paragon in the prosecution and maintenance of any such Project Antibody Patents in accordance with the terms of the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Crescent covenants and agrees that it will not file or prosecute any Patents Covering any Project Antibody or Derived Antibody (including without limitation any Project Antibody Inventions) during the Term of this Agreement except as permitted under the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.3</b></font><b style="font-weight:bold;">Defense of Claims Brought by Third Parties. </b>If a Party becomes aware of any actual or potential claim that the Development, Manufacture or Commercialization of any Project Antibody, Derived Antibody, Product, Multispecific Antibody or Multispecific Product infringes or in the future will infringe the Intellectual Property Rights of any Third Party, such Party will [***] notify the other Parties. In any such instance, the Parties will [***] thereafter meet (which may be through the JDC) to discuss [***] regarding the best response to such notice. Certain additional rights and obligations of the Parties with respect to any such claim will be set forth in the License Agreement (to the extent applicable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.4</b></font><b style="font-weight:bold;">No Implied Licenses. </b>Except as expressly set forth herein, no right or license under any Patents, Know-How or Intellectual Property Right of any Party is granted or shall be granted by implication hereunder. All such rights or licenses are or shall be granted only as expressly provided in this Agreement or the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 7</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">PROTECTION OF CONFIDENTIAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.1</b></font><b style="font-weight:bold;">Confidentiality.</b> Except to the extent expressly authorized by this Agreement, the Receiving Party agrees that, during the Term and for [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than as expressly provided for in this Agreement, any Confidential Information of the Disclosing Party. The Receiving Party may disclose Confidential Information of the Disclosing Party to those of the Receiving Party&#8217;s Representatives who have a need for such information; <i style="font-style:italic;">provided, that</i> the Receiving Party shall advise such Representatives of the confidential nature thereof, shall ensure that each such Representative is bound in writing by obligations of confidentiality and non-use at least as stringent as those contained in this Agreement, and shall be responsible for the compliance of its Representatives with the terms of this Agreement. The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to ensure that its Representatives do not disclose or make any unauthorized use of the Confidential Information of the Disclosing Party. The Receiving Party shall [***] notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential Information of the Disclosing Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.2</b></font><b style="font-weight:bold;">Exceptions.</b> The Receiving Party&#8217;s obligations under Section 7.1 shall not apply to any Confidential Information of the Disclosing Party that the Receiving Party can prove by competent evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement, generally known or available; (b) is known by the Receiving Party at the time of receiving such information from the Disclosing Party; (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and without restriction on disclosure; or (d) is independently discovered or developed by the Receiving Party, without the aid, use or application of any Confidential Information of the Disclosing Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.3</b></font><b style="font-weight:bold;">Authorized Disclosure.</b> Notwithstanding the provisions of this Article 7, the Receiving Party may disclose Confidential Information, without violating its obligations under this Agreement, to the extent the disclosure is:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>required by a valid order of a court or other governmental body of competent jurisdiction or as otherwise required by Applicable Law, rule, regulation (including securities laws and regulations), government requirement, or as may be required in connection with any filings made with, or by the disclosure policies of, a stock exchange; <i style="font-style:italic;">provided, that</i> the Receiving Party shall give reasonable prior written notice to the Disclosing Party of such required disclosure and, at [***] request and expense, shall cooperate with the Disclosing Party&#8217;s efforts to contest such requirement, to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or the law, rule or regulation required, or to obtain other confidential treatment of such Confidential Information; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>reasonably necessary to file or prosecute patent applications, prosecute or defend litigation or otherwise establish rights or enforce obligations under this Agreement, in each case, in accordance with this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.4</b></font><b style="font-weight:bold;">No Requirement to Disclose Paragon Platform Technology. </b>Notwithstanding anything to the contrary in this Agreement, Paragon will not be required to disclose any of the Paragon Platform Technology to Crescent other than as required to be included in the Deliverables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.5</b></font><b style="font-weight:bold;">Use of Names. </b>No Party shall use any other Party&#8217;s name or trademarks in any advertising, sales, or promotional material or in any publication without the prior written consent of such other Party or Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.6</b></font><b style="font-weight:bold;">Confidentiality of this Agreement.</b> This Agreement and its terms are considered Confidential Information of all Parties, and each Party shall keep confidential and shall not publish or otherwise disclose the terms of this Agreement without the prior written consent of the applicable other Party, except as expressly permitted by Section 7.3 or Section 7.7, and except that each Party may disclose this Agreement and its terms to actual or potential investors, lenders, and strategic partners in connection with due diligence or similar investigations by such Third Parties or in confidential financing documents; <i style="font-style:italic;">provided</i>, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and non-use at least as restrictive as those set forth in this Article 7 (<i style="font-style:italic;">provided, that</i> the confidentiality term applicable to such Third Party may be shorter so long as it is commercially reasonable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.7</b></font><b style="font-weight:bold;">Publicity. </b>Except to the extent required by Applicable Law or the rules of any stock exchange or listing agency, no Party shall issue a press release announcing that they have entered into an Antibody discovery partnership, without the other Parties&#8217; prior written consent, which shall not be unreasonably withheld.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPRESENTATIONS</b><b style="font-variant:small-caps;font-weight:bold;">, WARRANTIES AND COVENANTS; DISCLAIMER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.1</b></font><b style="font-weight:bold;">Mutual Representations and Warranties.</b> Each Party represents and warrants to each other that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not and will not conflict with any agreement, instrument, or understanding, oral or written, to which it is or may become a party or by which it may be or become bound.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.2</b></font><b style="font-weight:bold;">Paragon Representations, Warrants and Covenants</b>. Paragon hereby represents, warrants and covenants to Crescent that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>it will perform its activities under the Research Program with due care and in accordance with (i) Applicable Law, (ii) the terms and conditions contained herein and the Research Plan, and (iii) generally prevailing industry standards;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>neither it nor any of its Affiliates have entered or will enter, directly or indirectly, into any contract or any other transaction with any Third Party or Affiliate that conflicts or derogates from its undertakings under this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>it has the unencumbered right to the Paragon Platform Technology and the right, power and authority to use the Paragon Platform Technology in performance of the Research Plan and the performance of its obligations under this Agreement, in each case in accordance with the terms hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>each Representative employed or engaged by Paragon or its Affiliate to conduct the activities under the Research Program has assigned and has executed an agreement assigning its entire right, title and interest in and to Project Antibody Technology to Paragon;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>there are no claims, actions, or proceedings pending or threatened, nor are there any formal inquiries initiated or written notices received that may lead to the institution of any such legal proceedings, in each case (or in aggregate) against Paragon or its properties, assets or business, which would, individually or in the aggregate, have a material adverse effect on, or materially prevent, Paragon&#8217;s ability to perform under this Agreement or to grant the Option or other rights granted to Crescent under this Agreement; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font>none of Paragon, its Representatives, or any other person used by Paragon in the performance of this Agreement has been or is (i) debarred, convicted, or is subject to a pending debarment or conviction, pursuant to section 306 of the United States Federal Food Drug and Cosmetic Act, 21 U.S.C. &#167; 335a, (ii) listed by any government or regulatory agencies as ineligible to participate in any Federal healthcare programs (as that term is defined in 42 U.S.C. 1320a-7b(f)) or government procurement or non-procurement programs, or excluded, debarred, suspended or otherwise made ineligible to participate in any such program, or (iii) convicted of a criminal offense related to the provision of healthcare items or services, or is subject to any such pending action. Paragon agrees to inform Crescent [***] if Paragon or any person who is performing activities on its behalf under the Agreement is subject to the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending or threatened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.3</b></font><b style="font-weight:bold;">Disclaimer. </b>EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 9</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">TERM AND TERMINATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.1</b></font><b style="font-weight:bold;">Term. </b>The term of this Agreement (&#8220;<b style="font-weight:bold;">Term</b>&#8221;) shall commence on the Effective Date and, subject to earlier termination in accordance with this Article 9, shall continue until the later of: (a)&#160;the expiration of the Option Period if Crescent does not exercise the Option in accordance with Section 4.3; (b) if Crescent exercises the Option during the Option Period in accordance with Section 4.3 but the Parties are unable to finalize and execute the License Agreement during the thirty (30) day period referenced in Section&#160;4.4(b), the expiration of such thirty (30) day period; or (c) the expiration of the Research Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.2</b></font><b style="font-weight:bold;">Termination of Agreement for Material Breach.</b> Each Party shall have the right to terminate this Agreement upon thirty (30) days&#8217; prior written notice to the other Parties upon or after the material breach of any provision of this Agreement by any other Party if the breaching Party has not cured such breach by the end of such thirty (30) day period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.3</b></font><b style="font-weight:bold;">Termination for Convenience. </b>Crescent shall have the right to terminate this Agreement for any reason or no reason upon thirty (30) days&#8217; prior written notice to Paragon; <i style="font-style:italic;">provided, that </i>Crescent will pay Paragon any unpaid fees due for Development Costs accrued prior to such effective termination date, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under the Research Plan, as evidenced by Paragon&#8217;s records.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.4</b></font><b style="font-weight:bold;">Termination for Delay</b>. Paragon shall have the right to terminate this Agreement immediately upon written notice to Crescent if, as a result any action or failure to act by Crescent or its Affiliates, the Research Program or all material activities under the Research Plan are suspended, discontinued or otherwise delayed for a period of four (4) consecutive months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.5</b></font><b style="font-weight:bold;">Termination for a Bankruptcy Event. </b>Each Party will have the right to terminate this Agreement in the event of a Bankruptcy Event with respect to any other Party. &#8220;<b style="font-weight:bold;">Bankruptcy Event&#8221; </b>means the occurrence of any of the following: (a) the institution of any bankruptcy, receivership, insolvency, reorganization or other similar proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section or chapter of the United States Bankruptcy Code, as amended, or under any similar laws or statutes of the United States or any state thereof (the &#8220;<b style="font-weight:bold;">Bankruptcy Code</b>&#8221;), where in the case of involuntary proceedings, such proceedings have not been dismissed or discharged within [***] after they are instituted, (b) the insolvency or making of an assignment for the benefit of creditors or the admittance by a Party of any involuntary debts as they mature, (c) the institution of any reorganization, arrangement or other readjustment of debt plan of a Party not involving the Bankruptcy Code, (d) the appointment of a receiver for all or substantially all of a Party&#8217;s assets, or (e) any corporate action taken by the board of directors of a Party in furtherance of any of the foregoing actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.6</b></font><b style="font-weight:bold;">Disposal of Confidential Information.</b> In the event this Agreement expires or is terminated and the Parties have not entered into the License Agreement, each Party shall return to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the applicable other Party all Confidential Information of such other Party (including all copies thereof) in such Party&#8217;s possession related to the Research Program; <i style="font-style:italic;">provided, however</i>, that each Party may retain one copy of such other Party&#8217;s Confidential Information in such Party&#8217;s secure archives for the sole purpose of monitoring compliance with its obligations hereunder or Applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.7</b></font><b style="font-weight:bold;">Accrued Rights; Survival.</b> The expiration or termination of this Agreement for any reason shall not release any Party from any liability or obligation that, at the time of such expiration or termination, has already accrued to any other Party or that is attributable to a period prior to such expiration or termination, nor will expiration or any termination of this Agreement preclude any Party from pursuing all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement. In the event of expiration or any termination of this Agreement, the following provisions of this Agreement shall survive such expiration or termination in accordance with their respective terms and conditions: Article 5, Article 7, Article 10 and Article 11, as well as Sections 2.3, 6.1(a), 6.2(a), 6.4, 9.3, 9.6 and 9.7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 10</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">INDEMNIFICATION; LIMITATION OF LIABILITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.1</b></font><b style="font-weight:bold;">By Crescent. </b>Crescent hereby agrees to defend, indemnify, and hold harmless Paragon, Parascent, their Affiliates and their Representatives (each, a &#8220;<b style="font-weight:bold;">Paragon Indemnitee</b>&#8221;) from and against any and all losses, damages, liabilities, expenses, and costs, including reasonable legal expense and attorneys&#8217; fees (collectively, &#8220;<b style="font-weight:bold;">Losses</b>&#8221;), to which any Paragon Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party (&#8220;<b style="font-weight:bold;">Third Party Claim</b>&#8221;) to the extent such Losses result from: (a)&#160;the negligence or willful misconduct of any Crescent Indemnitee in the performance of this Agreement; or (b) the material breach by any Crescent Indemnitee of this Agreement; except, in each case, to the extent such Losses result from the negligence or willful misconduct of any Paragon Indemnitee or the material breach by Paragon of this Agreement, or where such Losses are subject to indemnification pursuant to Section 10.2 below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.2</b></font><b style="font-weight:bold;">By Paragon. </b>Paragon hereby agrees to defend, indemnify, and hold harmless Crescent, its Affiliates and its and their Representatives (each, an &#8220;<b style="font-weight:bold;">Crescent Indemnitee</b>&#8221;) from and against any and all Losses to which any Crescent Indemnitee may become subject as a result of any Third Party Claim to the extent such Losses result from: (a) the negligence or willful misconduct of any Paragon Indemnitee in the performance of this Agreement; or (b) the material breach by any Paragon Indemnitee of this Agreement; except, in each case, to the extent such Losses result from the negligence or willful misconduct of any Crescent Indemnitee, the material breach by Crescent of this Agreement, or where such Losses are subject to indemnification pursuant to Section 10.1 above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.3</b></font><b style="font-weight:bold;">Indemnification Procedure. </b>In connection with any Third Party Claim for which a Party (the &#8220;<b style="font-weight:bold;">Indemnified Party</b>&#8221;) seeks indemnification from another Party (the &#8220;<b style="font-weight:bold;">Indemnifying Party</b>&#8221;) pursuant to this Agreement, the Indemnified Party will: (a) give the Indemnifying Party [***] notice of the Third Party Claim; <i style="font-style:italic;">provided, however, </i>that failure to provide such notice will</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">not relieve the Indemnifying Party from its liability or obligation hereunder, except to the extent of any material prejudice as a direct result of such failure; (b) cooperate with the Indemnifying Party, at the Indemnifying Party&#8217;s expense, in connection with the defense and settlement of the Third Party Claim; and (c) permit the Indemnifying Party to control the defense and settlement of the Third Party Claim; <i style="font-style:italic;">provided, however, </i>that the Indemnifying Party may not settle the Third Party Claim without the Indemnified Party&#8217;s prior written consent, which will not be unreasonably withheld or delayed, in the event that such settlement materially adversely impacts the Indemnified Party&#8217;s rights or obligations. Further, the Indemnified Party will have the right to participate (but not control) and be represented in any suit or action by advisory counsel of its selection and at its own expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.4</b></font><b style="font-weight:bold;">Limitation of Liability.</b> EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 7 OR FOR INDEMNIFICATION CLAIMS UNDER ARTICLE 10, IN NO EVENT SHALL ANY PARTY BE ENTITLED TO RECOVER FROM ANY OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, EVEN IF SUCH OTHER PARTY HAD NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 11</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.1</b></font><b style="font-weight:bold;">Independent Contractor Relationship. </b>Each of Paragon&#8217;s and Parascent&#8217;s relationship with Crescent is that of an independent contractor, and nothing in this Agreement should be construed to create a partnership, joint venture or employer-employee relationship. No Party is an agent of any other Party or authorized to make any representation, contract or commitment on behalf of any other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.2</b></font><b style="font-weight:bold;">Force Majeure. </b>No Party will be charged with any liability for delay or failure in performance of an obligation under this Agreement (other than any obligation to pay monies when due) to the extent such delay or failure is due to a cause beyond the reasonable control of the affected Party, such as war, riots, labor disturbances, epidemic, pandemic, fire, explosion, and compliance in good faith with any Applicable Law. The Party affected will give [***] notice to the other Parties of the nature of the cause of any material delay or failure to perform, its anticipated duration and any action being taken to avoid or minimize the effect. The Party affected will use its diligent efforts to avoid or remove such causes of delay or failure to perform and to mitigate the effect of such occurrence, and will continue performance in accordance with the terms of this Agreement whenever such causes are removed. The Party affected will give [***] notice to the other Parties of such resumed performance. If any such failure or delay in a Party&#8217;s performance hereunder continues for more than [***], any of the other Parties may terminate this Agreement upon written notice to the affected Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.3</b></font><b style="font-weight:bold;">Entire Agreement; Amendment.</b> This Agreement, together with all Exhibits attached hereto, constitutes the final, complete, and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous understandings and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">agreements, relating to its subject matter. This Agreement (including its Exhibits) may not be changed, modified, amended, or supplemented except by a written instrument signed by all Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.4</b></font><b style="font-weight:bold;">Non-Waiver.</b> The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.5</b></font><b style="font-weight:bold;">Severability. </b>Should one or more of the provisions of this Agreement become void or unenforceable as a matter of Applicable Law, then this Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and the Parties will use their best efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.6</b></font><b style="font-weight:bold;">Assignment.</b> Neither this Agreement nor any rights or obligations hereunder may be assigned by any Party without the prior written consent of the other Parties (which consent shall not be unreasonably withheld); <i style="font-style:italic;">provided, however</i>, that any Party may assign this Agreement and its rights and obligations hereunder without the other Parties&#8217; consent to its successor to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this section. Any assignment not in accordance with this Agreement shall be void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.7</b></font><b style="font-weight:bold;">Dispute Resolution. </b>The Parties recognize that a <i style="font-style:italic;">bona fide </i>dispute as to certain matters may arise from time to time during the Term relating to any Party&#8217;s rights or obligations hereunder or otherwise relating to the validity, enforceability or performance of this Agreement, including disputes relating to alleged breach or termination of this Agreement but excluding any disputes relating to Article 7 (Confidentiality) hereof or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&#8217; respective Intellectual Property Rights (hereinafter, a &#8220;<b style="font-weight:bold;">Dispute</b>&#8221;). In the event of the occurrence of any Dispute, the Parties will follow the following procedures in an attempt to resolve the dispute or disagreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>The Party claiming that such a Dispute exists will give notice in writing (a &#8220;<b style="font-weight:bold;">Notice of Dispute</b>&#8221;) to the other Parties of the nature of the Dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>The Dispute will be referred to the then Chief Executive Officer or Chief Operating Officer of Paragon and the then Chief Executive Officer or President of Crescent who will meet no later than [***] following the initial receipt of the Notice of Dispute and use reasonable efforts to resolve the Dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>If, within [***] of initial receipt of the Notice of Dispute, the Dispute has not been resolved, or if, for any reason, the meeting described in Section 11.7(b) hereof has not been held within [***] of initial receipt of the Notice of Dispute, then the Parties agree that such Dispute will be finally resolved through binding arbitration to be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited Procedures in those Rules, as specifically modified by the provisions of this Section&#160;11.7(c). The arbitration will be conducted by a panel of three arbitrators. Within [***] after the initiation of the arbitration, each Party will nominate one person to act as arbitrator, and the two arbitrators so named will then jointly appoint the third arbitrator within [***] of their appointment, who will serve as chairman of the panel. All three arbitrators must be independent Third Parties having at least [***] of dispute resolution experience (which may include judicial experience) or legal or business experience in the biotech or pharmaceutical industry. If any Party fails to nominate its arbitrator, or if the arbitrators selected by the Parties cannot agree on a person to be named as chairman within such [***]-day period, JAMS will make the necessary appointments for such arbitrator(s) or the chairman. Once appointed by a Party, such Party will have no <i style="font-style:italic;">ex parte </i>communication with its appointed arbitrator. The place of arbitration will be in Boston, Massachusetts or such other venue as the Parties may mutually agree. The arbitration proceedings and all communications with respect thereto will be in English. Any written evidence originally in another language will be submitted in English translation accompanied by the original or a true copy thereof. The arbitrators have the power to decide all matters in Dispute, including any questions of whether or not such matters are subject to arbitration hereunder. The arbitration will be governed by the Federal Arbitration Act, 9 U.S.C. &#167;&#167;1 <i style="font-style:italic;">et seq., </i>and judgment upon the award rendered by the arbitrators may be entered in any court having competent jurisdiction thereof. The existence, content and results of any arbitration proceedings pursuant to this Section 11.7 will be deemed the Confidential Information of all Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>Notwithstanding any provision of this Agreement to the contrary, any Party may immediately initiate litigation in any court of competent jurisdiction seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>The Parties agree that any disputes relating to Article 7 (Confidentiality) hereof or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&#8217; respective Intellectual Property Rights shall be subject to the exclusive jurisdiction of the state and federal courts in Boston, Massachusetts and each Party hereby submits to such jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.8</b></font><b style="font-weight:bold;">Governing Law.</b> This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without reference to conflicts of laws principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.9</b></font><b style="font-weight:bold;">Notices.</b> Any notice to be given under this Agreement must be in writing and delivered either in person, by internationally recognized express courier, by email, or by facsimile, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">purposes upon the earliest of: (a) the date of actual receipt; (b) if delivered by express courier, the next Business Day the express courier regularly makes deliveries; or (c) if delivered by email, upon the date upon which the receipt of such email is confirmed by return email. &#160;Together with any notice provided by a Party to any other Party in accordance with this Section 11.9, the Party shall send a copy of such notice by email to such other Party.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:80%;" align="center"><tr><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">If to Paragon or Parascent:</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Paragon Therapeutics, Inc.</p></td></tr><tr><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">221 Crescent Street</p></td></tr><tr><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Building 23, Suite 105</p></td></tr><tr><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Waltham, MA 02453</p></td></tr><tr><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Attn: [***]</p></td></tr><tr><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">If to Crescent:</p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Crescent Biopharma, Inc.</p></td></tr><tr><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">221 Crescent Street</p></td></tr><tr><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Building 23, Suite 105</p></td></tr><tr><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Waltham MA 02453</p></td></tr><tr><td style="vertical-align:top;width:48.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Attn: [***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="border-bottom-style:solid;border-bottom-width:0.5pt;text-decoration-line:underline;text-decoration-style:double;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.10</b></font><b style="font-weight:bold;">Interpretation. </b>Except where the context expressly requires otherwise, (a)&#160;the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&#160;the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;, (c)&#160;the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;, (d)&#160;any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person or entity shall be construed to include such person&#8217;s or entity&#8217;s successors and assigns, (f) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement include all Exhibits hereto, (h) the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (k) the term &#8220;or&#8221; shall be interpreted in the inclusive sense commonly associated with the term &#8220;or&#8221;. The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement or have any effect on its interpretation or construction. Ambiguities and uncertainties in this Agreement,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">if any, shall not be interpreted against any Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language. To the extent there is any inconsistency or conflict between the terms and conditions of this Agreement and any Research Plan, the terms and conditions of this Agreement will prevail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.11</b></font><b style="font-weight:bold;">No Third Party Rights.</b> The provisions of this Agreement are for the exclusive benefit of the Parties and their successors and permitted assigns, and no other person shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.12</b></font><b style="font-weight:bold;">Counterparts.</b> This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.13</b></font><b style="font-weight:bold;">Expenses</b>. Each Party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation, and completion of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.14</b></font><b style="font-weight:bold;">Binding Effect</b>. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.15</b></font><b style="font-weight:bold;">Construction</b>. The Parties hereto acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c)&#160;the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.16</b></font><b style="font-weight:bold;">Cumulative Remedies</b>. No remedy referred to in this Agreement is intended to be exclusive unless explicitly stated to be so, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;font-weight:bold;">[Remainder of page left intentionally blank; signature page follows.]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:30pt 0pt 12pt 0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,<br>MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS<br>NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT<br>BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">In Witness Whereof,</b> the Parties hereto have executed this Antibody Discovery and Option Agreement on the Effective Date.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:40.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:40.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">PARAGON THERAPEUTICS, INC.</b></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CRESCENT BIOPHARMA, INC.</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ K. Evan Thompson</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:40.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ K. Evan Thompson</p></td></tr><tr><td style="vertical-align:top;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">K. Evan Thompson</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">K. Evan Thompson</p></td></tr><tr><td style="vertical-align:top;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Operating Officer</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Secretary and Vice President of Corporate</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Development</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PARASCENT HOLDING LLC</b></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:48.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:40.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ K. Evan Thompson</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:40.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">K. Evan Thompson</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">President</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:48.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[Exhibit A to Antibody Discovery and Option Agreement]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>16
<FILENAME>glyc-20241231xex10d42.htm
<DESCRIPTION>EXHIBIT-10.42
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:22:06 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.42</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ADC DISCOVERY AND OPTION AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">This ADC Discovery and Option Agreement</b> (&#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is entered into and effective as of October 28, 2024 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;), by and among Paragon Therapeutics, Inc., a Delaware corporation (&#8220;<b style="font-weight:bold;">Paragon</b>&#8221;), Parascent Holding LLC, a Delaware limited liability company (&#8220;<b style="font-weight:bold;">Parascent</b>&#8221;) and Crescent Biopharma, Inc., a Delaware corporation (&#8220;<b style="font-weight:bold;">Crescent</b>&#8221;). &#160;Paragon, Parascent and Crescent are also referred to herein individually as a &#8220;<b style="font-weight:bold;">Party</b>&#8221;, or collectively as the &#8220;<b style="font-weight:bold;">Parties</b>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Recitals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Whereas, </b>Paragon has developed a proprietary platform technology for the discovery and development of antibodies against therapeutically relevant targets;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Whereas, </b>Crescent desires to engage Paragon to perform, and Paragon is willing to perform, certain research activities to generate, conjugate and develop one or more antibody-drug conjugates directed to a certain mutually agreed therapeutic target of interest to Crescent; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Whereas, </b>Crescent will have an exclusive option to enter into a separate license agreement with Paragon to further develop, manufacture and commercialize the resulting antibody-drug conjugates, all on the terms and subject to the conditions set forth in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Now Therefore, </b>in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">DEFINED TERMS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.1</b></font>&#8220;<b style="font-weight:bold;">Achievement of Development Candidate</b>&#8221; means the first to occur of: (a)&#160;nomination by Crescent&#8217;s Board of Directors of a Crescent Product as a &#8220;Development Candidate&#8221;; and (b)&#160;the&#160;initiation by or on behalf of Crescent or its Affiliate or sublicensee of a toxicology study with respect to a Crescent Product that employs applicable then-current good laboratory practice standards, the results of which are intended to be submitted as part of an IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.2</b></font>&#8220;<b style="font-weight:bold;">Actual Annual Costs</b>&#8221; shall have the meaning set forth in Section&#160;5.2(c).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.3</b></font>&#8220;<b style="font-weight:bold;">ADC</b>&#8221; shall mean a compound that comprises or contains an Antibody chemically conjugated or otherwise attached to a payload with a linker.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.4</b></font>&#8220;<b style="font-weight:bold;">ADC Conjugation Activities</b>&#8221; shall have the meaning set forth in Section&#160;2.1(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.5</b></font>&#8220;<b style="font-weight:bold;">Affiliate</b>&#8221; shall mean any entity controlled by, controlling, or under common control with a Party hereto. &#160;For the purpose of this definition, &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control&#8221;) means the direct or indirect ownership of more than fifty percent (50%) of the voting interest in, or more than fifty </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">percent (50%) in the equity of, or the right to appoint more than fifty percent (50%) of the directors or management of, such corporation or other business entity. &#160;Notwithstanding the foregoing, (a)&#160;with respect to either Party, Affiliates of such Party do not include [***] or its Affiliates other than such Party and its subsidiaries, (b) [***], and (c) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.6</b></font>&#8220;<b style="font-weight:bold;">Agreement</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.7</b></font>&#8220;<b style="font-weight:bold;">Antibody</b>&#8221; shall mean any molecule, including [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.8</b></font>&#8220;<b style="font-weight:bold;">Applicable Law</b>&#8221; shall mean any national, supra-national, federal, state or local laws, rules, guidances and regulations, in each case, as applicable to the subject matter and the party at issue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.9</b></font>&#8220;<b style="font-weight:bold;">Background IP</b>&#8221; shall mean all Patents and Know-How Controlled by a Party (a) as of the Effective Date, or (b) that otherwise arise outside of and independently of this Agreement. &#160;Paragon&#8217;s Background IP includes the Paragon Platform Technology and any Paragon In-Licensed IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.10</b></font>&#8220;<b style="font-weight:bold;">Bankruptcy Code</b>&#8221; shall have the meaning set forth in Section 9.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.11</b></font>&#8220;<b style="font-weight:bold;">Bankruptcy Event</b>&#8221; shall have the meaning set forth in Section 9.5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.12</b></font>&#8220;<b style="font-weight:bold;">Budget</b>&#8221; shall mean the agreed budget for the activities set forth in the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.13</b></font>&#8220;<b style="font-weight:bold;">Business Day</b>&#8221; shall mean any day other than Saturday, Sunday, or other national holidays in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.14</b></font>&#8220;<b style="font-weight:bold;">Calendar Quarter</b>&#8221; shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30, and December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.15</b></font>&#8220;<b style="font-weight:bold;">Calendar Year</b>&#8221; shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.16</b></font>&#8220;<b style="font-weight:bold;">Change of Control</b>&#8221; means, with respect to any entity, any of the following: (a) the sale or disposition of all or substantially all of the assets of such entity or its direct or indirect controlling Affiliate to a Third Party; or (b) (i) the acquisition by a Third Party, alone or together with any of its Affiliates, other than an employee benefit plan (or related trust) sponsored or maintained by such entity or any of its Affiliates, of more than fifty percent (50%) of the then-outstanding shares of voting capital stock of such entity or its direct or indirect parent entity that holds, directly or indirectly, beneficial ownership of more than fifty percent (50%) of the then-outstanding shares of voting capital stock of such entity (a &#8220;<b style="font-weight:bold;">Parent Entity</b>&#8221;), or (ii) the acquisition, merger or consolidation of such entity or its Parent Entity with or into another entity, other than, in the case of clause (i) or (ii), an acquisition or a merger or consolidation of such entity or its Parent Entity in which the holders of shares of voting capital stock of such entity or its Parent</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Entity, as the case may be, immediately prior to such acquisition, merger or consolidation will beneficially own, directly or indirectly, at least fifty percent (50%) of the shares of voting capital stock of the acquiring Third Party or the surviving corporation in such acquisition, merger or consolidation, as the case may be, immediately after such acquisition, merger or consolidation, and in each case of (a) or (b), whether through a single transaction or a series of related transactions, but excluding any and all bona fide financing transactions or internal reorganizations for tax purposes (including the change of place of incorporation or domicile of such entity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.17</b></font>&#8220;<b style="font-weight:bold;">CMC Activities</b>&#8221; shall have the meaning provided in Section 5.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.18</b></font>&#8220;<b style="font-weight:bold;">CMC Rate</b>&#8221; shall have the meaning provided in Section 5.2(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.19</b></font>&#8220;<b style="font-weight:bold;">Commercialize</b>&#8221; or &#8220;<b style="font-weight:bold;">Commercializing</b>&#8221; shall mean to market, promote, distribute, offer for sale, sell, have sold, import, have imported, export, have exported or otherwise commercialize an ADC or product, including a Project ADC, Derived ADC, Product, Multispecific ADC or Multispecific Product, as applicable. &#160;When used as a noun, &#8220;<b style="font-weight:bold;">Commercialization</b>&#8221; means any and all activities involved in Commercializing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.20</b></font>&#8220;<b style="font-weight:bold;">Confidential Information</b>&#8221; of a Party shall mean any and all non-public scientific, business, regulatory, or technical information that is disclosed or made available by or on behalf of one Party (the &#8220;<b style="font-weight:bold;">Disclosing Party</b>&#8221;) to any other Party (a &#8220;<b style="font-weight:bold;">Receiving Party</b>&#8221;) in connection with this Agreement, whether in writing, orally, visually or otherwise. &#160;Notwithstanding any provision of this Agreement to the contrary, all Project ADC Inventions and Project ADC Technology shall be the Confidential Information of all Parties, and each Party shall be deemed as both the &#8220;Disclosing Party&#8221; and the &#8220;Receiving Party&#8221; with respect thereto; <i style="font-style:italic;">provided, that</i> if Crescent does not exercise the Option or the Parties do not enter into the License Agreement in accordance with this Agreement, then the Project ADC Inventions and Project ADC Technology shall thereafter be the Confidential Information of Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.21</b></font>&#8220;<b style="font-weight:bold;">Control</b>&#8221; (including any variations such as &#8220;<b style="font-weight:bold;">Controlled</b>&#8221; and &#8220;<b style="font-weight:bold;">Controlling</b>&#8221;) shall mean, with respect to any technology or Intellectual Property Rights, possession by a Party and the ability (whether by ownership, license or otherwise) to grant a license or a sublicense of or under such technology or Intellectual Property Rights without violating the terms of any agreement or other arrangement with any Third Party or requiring a payment. &#160;Notwithstanding the foregoing, a Party and its Affiliates shall not be deemed to &#8220;Control&#8221; any technology or Intellectual Property Rights that (a) prior to the consummation of a Change of Control of such Party, is owned or in-licensed, or (b)&#160;after the consummation of a Change of Control of such Party, becomes owned or in-licensed (to the extent such technology or Intellectual Property Rights are developed outside of the scope of the activities conducted hereunder and without use of or reference to any technology or Intellectual Property Rights Controlled by such Party or any Affiliate of such Party immediately before such Change of Control, or any Confidential Information of the other Party), in each case ((a) or (b)), by a Third Party that becomes an Affiliate of such Party after the Effective Date as a result of such Change of Control or an assignee of such Party after the Effective Date as the result of an assignment of this Agreement in connection with</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">a Change of Control unless prior to the consummation of such Change of Control or assignment, such Party or any of its Affiliates also Controlled such technology or Intellectual Property Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.22</b></font>&#8220;<b style="font-weight:bold;">Cost Advance</b>&#8221; shall have the meaning set forth in Section 5.2(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.23</b></font>&#8220;<b style="font-weight:bold;">Cover</b>&#8221; or &#8220;<b style="font-weight:bold;">Covering</b>&#8221; shall mean, with respect to a Patent, that, in the absence of a license granted under, or ownership of, such Patent, the making, using, selling, importation, or exportation of such product would infringe a valid and unexpired claim of such Patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.24</b></font>&#8220;<b style="font-weight:bold;">Crescent</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.25</b></font>&#8220;<b style="font-weight:bold;">Crescent Indemnitee</b>&#8221; shall have the meaning provided in Section 10.2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.26</b></font>&#8220;<b style="font-weight:bold;">Crescent IP</b>&#8221; shall have the meaning provided in Section 2.1(c)(ii).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.27</b></font>&#8220;<b style="font-weight:bold;">Crescent Multispecific ADC</b>&#8221; shall mean any Multispecific ADC that is Developed, Manufactured, Commercialized or otherwise exploited by Crescent, its Affiliates, or sublicensees (other than Paragon and its Affiliates and other licensees).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.28</b></font>&#8220;<b style="font-weight:bold;">Crescent Multispecific Product</b>&#8221; shall mean any product that comprises or contains any Crescent Multispecific Antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.29</b></font>&#8220;<b style="font-weight:bold;">Crescent Product</b>&#8221; shall mean, individually or collectively, as applicable, Project ADCs, Derived ADCs, Products, Crescent Multispecific ADCs and Crescent Multispecific Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.30</b></font>&#8220;<b style="font-weight:bold;">Deliverables</b>&#8221; shall have the meaning set forth in Section 2.1(d)(i).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.31</b></font>&#8220;<b style="font-weight:bold;">Derived ADC</b>&#8221; shall mean any ADC that (a)&#160;includes a monospecific Antibody that is derived from or constitutes a modification of the monospecific Antibody included in a Project ADC, including [***], and (b)&#160;[***]. &#160;For avoidance of doubt, any ADC that contains an Antibody that [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.32</b></font>&#8220;<b style="font-weight:bold;">Derived ADC Patent</b>&#8221; shall mean any Patent that Covers the composition of matter of, or any method of specifically making or using, any Derived ADC or any component thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.33</b></font>&#8220;<b style="font-weight:bold;">Develop</b>&#8221; or &#8220;<b style="font-weight:bold;">Developing</b>&#8221; shall mean to discover, evaluate, test, research or otherwise develop an ADC or product, including a Project ADC, Derived ADC, Product, Multispecific ADC or Multispecific Product, as applicable. &#160;When used as a noun, &#8220;<b style="font-weight:bold;">Development</b>&#8221; means any and all activities involved in Developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.34</b></font>&#8220;<b style="font-weight:bold;">Development Costs</b>&#8221; shall mean (a) [***] (such amounts, the &#8220;<b style="font-weight:bold;">Third Party Costs</b>&#8221;), and (b) [***] (such development fees, the &#8220;<b style="font-weight:bold;">Development Fees</b>&#8221;, and the development fees to be paid in any given Calendar Year during the Research Program, the &#8220;<b style="font-weight:bold;">Annual</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Development Fees</b>&#8221;); in each case ((a) and (b)) to the extent consistent with the Research Plan (including [***]).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.35</b></font>&#8220;<b style="font-weight:bold;">Directed To</b>&#8221; shall mean, with regard to an Antibody, ADC or product, that such Antibody, ADC or product is developed or designed to (a) [***], and (b) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.36</b></font>&#8220;<b style="font-weight:bold;">Dispute</b>&#8221; shall have the meaning provided in Section 11.7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.37</b></font>&#8220;<b style="font-weight:bold;">Effective Date</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.38</b></font>&#8220;<b style="font-weight:bold;">Election Notice</b>&#8221; shall have the meaning provided in Section 4.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.39</b></font>&#8220;<b style="font-weight:bold;">Equity Grant</b>&#8221; shall have the meaning provided in Section&#160;5.8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.40</b></font>&#8220;<b style="font-weight:bold;">FDA</b>&#8221; means the United States Food and Drug Administration, or a successor federal agency thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.41</b></font>&#8220;<b style="font-weight:bold;">Field</b>&#8221; shall mean the prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.42</b></font>&#8220;<b style="font-weight:bold;">Final Deliverable</b>&#8221; shall have the meaning provided in the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.43</b></font>&#8220;<b style="font-weight:bold;">Indemnified Party</b>&#8221; shall have the meaning provided in Section 10.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.44</b></font>&#8220;<b style="font-weight:bold;">Indemnifying Party</b>&#8221; shall have the meaning provided in Section 10.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.45</b></font>&#8220;<b style="font-weight:bold;">Intellectual Property Rights</b>&#8221; shall mean any and all proprietary rights provided under (a) patent law, including any Patents; (b) copyright law; or (c) any other applicable statutory provision or common law principle, including trade secret law, that may provide a right in Know-How, or the expression or use thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.46</b></font>&#8220;<b style="font-weight:bold;">JDC</b>&#8221; shall have the meaning provided in Section 3.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.47</b></font>&#8220;<b style="font-weight:bold;">Know-How</b>&#8221; shall mean all technical information and know-how in any tangible or intangible form, including (a) inventions, discoveries, trade secrets, data, specifications, instructions, processes, formulae, materials (including cell lines, vectors, plasmids, nucleic acids and the like), methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b) all data, instructions, processes, formulae, strategies, and expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines. &#160;Notwithstanding the foregoing, Know-How excludes Patent claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.48</b></font>&#8220;<b style="font-weight:bold;">License Agreement</b>&#8221; shall have the meaning set forth in Section 4.4(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.49</b></font>&#8220;<b style="font-weight:bold;">License Template</b>&#8221; shall have the meaning set forth in Section 4.4(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.50</b></font>&#8220;<b style="font-weight:bold;">Losses</b>&#8221; shall have the meaning provided in Section 10.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.51</b></font>&#8220;<b style="font-weight:bold;">MAA</b>&#8221; means (a) a New Drug Application in the United States, as defined in the United States Federal Food, Drug and Cosmetics Act, and applicable regulations promulgated thereunder by the FDA, (b) a Biologics License Application in the United States, as defined in the United States Public Health Service Act, or (c) any application filed with any Regulatory Authority in a country other than the United States that is equivalent to either of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.52</b></font>&#8220;<b style="font-weight:bold;">Manufacture</b>&#8221; or &#8220;<b style="font-weight:bold;">Manufacturing</b>&#8221; shall mean to make, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, ship or store an ADC or product, including a Project ADC, Derived ADC, Product, Multispecific ADC or Multispecific Product, or any component thereof, as applicable. &#160;When used as a noun, &#8220;Manufacture&#8221; or &#8220;Manufacturing&#8221; means any and all activities involved in Manufacturing an ADC or product, including a Project ADC, Derived ADC, Product, Multispecific ADC or Multispecific Product, or any component thereof, as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.53</b></font>&#8220;<b style="font-weight:bold;">Milestone</b>&#8221; shall have the meaning provided in Section 5.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.54</b></font>&#8220;<b style="font-weight:bold;">Milestone Payment</b>&#8221; shall have the meaning provided in Section 5.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.55</b></font>&#8220;<b style="font-weight:bold;">Multispecific ADC</b>&#8221; shall mean any ADC that is comprised of (a) [***], and (b) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.56</b></font>&#8220;<b style="font-weight:bold;">Multispecific Product</b>&#8221; shall mean any product that comprises or contains any Multispecific ADC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.57</b></font>&#8220;<b style="font-weight:bold;">Notice of Dispute</b>&#8221; shall have the meaning provided in Section 11.7(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.58</b></font>&#8220;<b style="font-weight:bold;">Option</b>&#8221; shall have the meaning provided in Section&#160;4.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.59</b></font>&#8220;<b style="font-weight:bold;">Option Period</b>&#8221; shall have the meaning provided in Section&#160;4.3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.60</b></font>&#8220;<b style="font-weight:bold;">Paragon</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.61</b></font>&#8220;<b style="font-weight:bold;">Paragon In-Licensed IP</b>&#8221; shall have the meaning provided in Section 2.1(c)(i).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.62</b></font>&#8220;<b style="font-weight:bold;">Paragon </b><b style="font-weight:bold;">Indemnitee</b>&#8221; shall have the meaning provided in Section 10.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.63</b></font>&#8220;<b style="font-weight:bold;">Paragon Platform Know-How</b>&#8221; shall mean (a) Know-How Controlled by Paragon or its Affiliates prior to or during the Term relating to ADC and/or antibody discovery and development, including conjugation technology, and methods of making or manufacturing an</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ADC or its components, (b) all methods, materials and other Know-How used in the foregoing Controlled by Paragon or its Affiliates, and (c) platforms embodying, components, component steps and other portions of any of the foregoing in (a) or (b) Controlled by Paragon or its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.64</b></font>&#8220;<b style="font-weight:bold;">Paragon Platform Know-How Improvement</b>&#8221; shall mean all Know-How developed or discovered through or as a result of the activities performed by or on behalf of Paragon under the Research Program that constitutes an improvement, enhancement, modification, substitution, or alteration to the Paragon Platform Technology; <i style="font-style:italic;">provided, however</i>, to the extent any of the Know-How developed or discovered under the Research Program specifically and solely relates to a Project ADC, such Know-How will be considered Project ADC Technology and not Paragon Platform Know-How Improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.65</b></font>&#8220;<b style="font-weight:bold;">Paragon Platform Patents</b>&#8221; shall mean all Patents that Paragon or its Affiliates Control prior to or during the Term that Cover Paragon Platform Know-How or Paragon Platform Know-How Improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.66</b></font>&#8220;<b style="font-weight:bold;">Paragon Platform Technology</b>&#8221; shall mean Paragon Platform Know-How, Paragon Platform Know-How Improvements, and Paragon Platform Patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.67</b></font>&#8220;<b style="font-weight:bold;">Parascent</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.68</b></font>&#8220;<b style="font-weight:bold;">Party</b>&#8221; or &#8220;<b style="font-weight:bold;">Parties</b>&#8221; shall have the meaning provided in the first paragraph of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.69</b></font>&#8220;<b style="font-weight:bold;">Patents</b>&#8221; shall mean (a) unexpired patents and patent applications, (b) any and all divisionals, continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection certificates and the like of any such patents and patent applications, and (c) any and all foreign equivalents of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.70</b></font>[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.71</b></font>&#8220;<b style="font-weight:bold;">Phase I Trial</b>&#8221; shall mean a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(a), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.72</b></font>&#8220;<b style="font-weight:bold;">Phase II Trial</b>&#8221; shall mean a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(b), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.73</b></font>&#8220;<b style="font-weight:bold;">Phase III Trial</b>&#8221; shall mean a human clinical trial in any country of the type described in 21 C.F.R. &#167;312.21(c), or the foreign equivalent thereof, regardless of where such clinical trial is conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.74</b></font>&#8220;<b style="font-weight:bold;">Pre-Effective Date Development Costs</b>&#8221; shall have the meaning provided in Section 5.2(d).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.75</b></font>&#8220;<b style="font-weight:bold;">Product</b>&#8221; shall mean any product that comprises or contains any Project ADC or any Derived ADC, other than as part of a Multispecific ADC or a Multispecific Product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.76</b></font>&#8220;<b style="font-weight:bold;">Project ADC</b>&#8221; shall mean any and all ADCs that are Directed To the Selected Target and that are generated or conjugated by Paragon in the course of performing the Research Program. &#160;For clarity, Project ADCs (a) are limited to ADCs that contain a monospecific Antibody, and (b) do not include the components of an ADC (i.e., a monospecific Antibody, a linker, a payload or any conjugation technology) other than as part of a complete ADC generated or conjugated by Paragon in the course of performing the Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.77</b></font>&#8220;<b style="font-weight:bold;">Project ADC Information</b>&#8221; shall mean electronic files containing a description of the Project ADCs generated or conjugated under the Research Program, including the sequences of all monospecific Antibodies included in the Project ADCs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.78</b></font>&#8220;<b style="font-weight:bold;">Project ADC Invention</b>&#8221; shall mean (a) any invention or discovery, whether or not patentable, that was discovered or reduced to practice by or on behalf of Paragon under the Research Program that constitutes the composition of matter of any Project ADC, and (b) all Intellectual Property Rights therein that are Controlled by Paragon or its Affiliates. &#160;Project ADC Inventions expressly exclude any invention or discovery, whether or not patentable, that was discovered or reduced to practice by or on behalf of Paragon under the Research Program that (i)&#160;relates to a component of a Project ADC (other than a monospecific Antibody included in a Project ADC) except as part of a Project ADC, or (ii) does not specifically and solely relate to a Project ADC (including, without limitation, payloads, linkers or conjugation technology with broader applicability to ADCs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.79</b></font>&#8220;<b style="font-weight:bold;">Project ADC Patents</b>&#8221; shall mean all Patents that Cover the composition of matter of any Project ADC, including Patents with the following claims: (a) claims to the monoclonal Antibody portion of a Project ADC; (b)&#160;claims to the monoclonal Antibody portion of a Project ADC with any payload; and (c)&#160;specific picture claims to the Project ADCs, that are in each case Controlled by Paragon or its Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.80</b></font>&#8220;<b style="font-weight:bold;">Project ADC Samples</b>&#8221; shall have the meaning provided in Section&#160;2.1(d)(i).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.81</b></font>&#8220;<b style="font-weight:bold;">Project ADC Selection Criteria</b>&#8221; shall mean those criteria agreed to by the Parties in the Research Plan that establish that a Project ADC is suitable for clinical testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.82</b></font>&#8220;<b style="font-weight:bold;">Project ADC Technology</b>&#8221; shall mean (a) the Project ADC Inventions, (b) the Project ADC Patents, (c) the Project ADC Information and Results, and (d) all Intellectual Property Rights therein that are Controlled by Paragon and its Affiliates, but excluding in each case any Paragon In-Licensed IP. &#160;For clarity, if the Parties execute the License Agreement and the Research Term for the Research Program continues following execution of the License Agreement, any Project ADC Technology first conceived, reduced to practice or otherwise generated following the execution of the License Agreement shall be licensed to Crescent under the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.83</b></font>&#8220;<b style="font-weight:bold;">Regulatory Approval</b>&#8221; means all clearances, approvals (including approval of an MAA as well as any applicable pricing and/or reimbursement approvals), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell and market a pharmaceutical or biologic product in a country or territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.84</b></font>&#8220;<b style="font-weight:bold;">Regulatory Authority</b>&#8221; means any supranational, multinational, federal, national, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the clinical development, manufacture, marketing or sale of a pharmaceutical or biologic product in a country or region, including the FDA in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.85</b></font>&#8220;<b style="font-weight:bold;">Representatives</b>&#8221; of a Party shall mean such Party&#8217;s and its Affiliates&#8217; officers, directors, employees, contractors, subcontractors, agents and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.86</b></font>&#8220;<b style="font-weight:bold;">Research Plan</b>&#8221; shall have the meaning set forth in Section 2.1(b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.87</b></font>&#8220;<b style="font-weight:bold;">Research Program</b>&#8221; shall mean the research program agreed to by the Parties to generate and conjugate ADCs using monospecific Antibodies with activity against the Selected Target and to perform such additional activities with respect to such ADCs as set forth in the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.88</b></font>&#8220;<b style="font-weight:bold;">Research Term</b>&#8221; shall mean the period of time beginning on the agreement by the Parties on the Research Plan and continuing until completion of the activities under the Research Plan or such other date mutually agreed upon by the Parties; <i style="font-style:italic;">provided, that</i> (a) if Crescent does not exercise the Option in accordance with Section 4.3 prior to expiration of the Option Period, then upon such expiration the Research Term shall automatically terminate and Paragon shall have no obligation to perform any activities under the Research Plan thereafter, or (b) if Crescent exercises the Option during the Option Period in accordance with Section 4.3 but the Parties are unable to finalize and execute the License Agreement during the thirty (30) day period referenced in Section 4.4(b), then upon the expiration of such period the Research Term shall automatically terminate and Paragon shall have no obligation to perform any activities under the Research Plan thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.89</b></font>&#8220;<b style="font-weight:bold;">Results</b>&#8221; shall mean the data, results, analysis, conclusions, outcomes, information, documentation, and reports that are generated by or on behalf of Paragon in performance of the Research Program, excluding Project ADCs, Project ADC Inventions, Project ADC Patents, and the Project ADC Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.90</b></font>&#8220;<b style="font-weight:bold;">Selected Target</b>&#8221; shall have the meaning set forth in Section 2.1(a).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.91</b></font>&#8220;<b style="font-weight:bold;">Shares</b>&#8221; shall mean shares of common stock, par value $0.0001, of Crescent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.92</b></font>&#8220;<b style="font-weight:bold;">Target</b>&#8221; shall mean a protein molecule that (a) [***], and (b) [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.93</b></font>&#8220;<b style="font-weight:bold;">Term</b>&#8221; shall have the meaning provided in Section 9.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.94</b></font>&#8220;<b style="font-weight:bold;">Territory</b>&#8221; shall mean worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.95</b></font>&#8220;<b style="font-weight:bold;">Third Party</b>&#8221; shall mean any person or entity other than Paragon, Parascent or Crescent or an Affiliate of any of Paragon, Parascent or Crescent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.96</b></font>&#8220;<b style="font-weight:bold;">Third Party Claim</b>&#8221; shall have the meaning provided in Section 10.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.97</b></font>&#8220;<b style="font-weight:bold;">Valid Claim</b>&#8221; means, with respect to particular Patent in a particular country, (a) a claim of an issued and unexpired patent (including the term of any patent term extension, supplemental protection certificate, renewal or other similar extension) in such country within such Patent that has not been abandoned or revoked, or held unpatentable, invalid or unenforceable in a final decision of a court or other governmental authority of competent jurisdiction from which no appeal may be taken, or has been taken before the expiry of the permitted time period, and that has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise, or (b) a claim within a patent application in such country within such Patent that has not been pending more than seven (7) years from the earliest priority date of such claim and which claim has not been cancelled, withdrawn or abandoned or finally rejected by an administrative agency action from which no appeal can be taken.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CONDUCT OF RESEARCH PROGRAM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.1</b></font><b style="font-weight:bold;">Research Program.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Overview</b>. &#160;The Parties intend to initiate the Research Program to discover, generate, identify, and characterize one or more ADC candidates Directed To [***] (the &#8220;<b style="font-weight:bold;">Selected Target</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Research Plan. &#160;</b>No later than [***] after the Effective Date, the Parties will agree on a research plan, to the extent a research plan has not been previously agreed upon, for the Research Program that will include design, modeling, synthesis, evaluation, and other mutually agreed activities (&#8220;<b style="font-weight:bold;">Research Plan</b>&#8221;). &#160;The Research Plan shall also provide for the use of any Paragon In-Licensed IP or Crescent IP that has been agreed by the Parties. &#160;For clarity, if at the end of such [***] period (or any extension thereof mutually agreed in writing) (i) the Parties have not agreed on the Research Plan, or (ii) Crescent has not paid Paragon the Research Initiation Fee, Paragon shall have no obligations to Crescent with respect to the Research Program or the Selected Target. &#160;Once the Parties agree on the Research Plan and Crescent pays the Research Initiation Fee for the Research Program, Paragon and Parascent shall conduct research under the Research Program during the Research Term in an effort to (1)&#160;generate or conjugate Project ADCs for further Development, Manufacture and Commercialization (&#8220;<b style="font-weight:bold;">ADC Conjugation Activities</b>&#8221;), and (2) perform such other Development and Manufacturing activities with respect to the Project ADCs as set forth in the Research Plan (which other activities, for clarity, may be performed following Crescent&#8217;s exercise of the Option or execution of a License Agreement). &#160;The Parties may amend the Research Plan upon mutual written agreement. &#160;Paragon and Parascent will use [***] to conduct and complete the activities set forth in the Research Plan on the timelines set forth in the Research Plan and in compliance with the Budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-weight:bold;">Use of Other Technology.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>If the Parties desire for Paragon to use Third Party Intellectual Property Rights Controlled by Paragon (e.g., huMab murine models, linkers, conjugation technology or payloads) (&#8220;<b style="font-weight:bold;">Paragon In-Licensed IP</b>&#8221;) in the conduct of the Research Program, then (x) such use shall be set forth in the Research Plan, and (y) Crescent shall be responsible for paying to Paragon as part of the Development Fees the out-of-pocket costs incurred by Paragon to access and use such Paragon In-Licensed IP in the conduct of the Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>If the Parties desire for Paragon to use (x) Intellectual Property Rights owned by Crescent or its Affiliates, or (y) Intellectual Property Rights in-licensed by Crescent or its Affiliates (e.g., linkers, conjugation technology or payloads) ((x) and (y) collectively, &#8220;<b style="font-weight:bold;">Crescent IP</b>&#8221;) in the conduct of the Research Program, then (1) such use shall be set forth in the Research Plan, (2) Crescent shall be responsible for obtaining any necessary licenses and rights with respect to any in-licensed Crescent IP to enable Paragon and Parascent to access and use such in-licensed Crescent IP to conduct the Research Program in accordance with the Research Plan, and (3) Crescent shall be responsible for all costs to provide Paragon with the right to access and use such Crescent IP in the conduct of the Research Program. &#160;During the Research Term, Crescent hereby grants to Paragon and Parascent a non-exclusive, sublicensable (to Paragon&#8217;s and Parascent&#8217;s Third Party service providers, subcontractors, consultants and other agents performing activities on behalf of Paragon or Parascent under the Research Program), royalty-free and fully paid-up license under the Crescent IP to access and use the Crescent IP to conduct the Research Program in accordance with the Research Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-weight:bold;">Deliverables; Project ADC Samples.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>Following completion of the ADC Conjugation Activities set forth in the Research Plan, Paragon and Parascent will deliver to Crescent a data package that includes the Project ADC Information and the Results for the then existing Project ADCs (the &#8220;<b style="font-weight:bold;">Deliverables</b>&#8221;). &#160;Additionally, upon request by Crescent, and at [***] cost and expense, Paragon and Parascent shall provide to Crescent samples of the Project ADCs that have been expressed in accordance with the Research Plan (&#8220;<b style="font-weight:bold;">Project ADC Samples</b>&#8221;) to enable Crescent to evaluate the Option. &#160;Following completion of the Research Program, Paragon shall deliver to Crescent the Final Deliverable for the Research Program, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>During the Option Period with respect to the Research Program, Crescent will review the Deliverables and Project ADC Samples for the Research Program to determine whether [***] Project ADC meets the Project ADC Selection Criteria. &#160;If Crescent determines that [***] Project ADC meets the Project ADC Selection Criteria, then Crescent shall so notify Paragon in writing prior to the end of the Option Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font><b style="font-weight:bold;">Conduct of Research Program. &#160;</b>During the Research Term, Paragon and Parascent shall (i) perform the activities assigned to it under the Research Plan in a professional, diligent and good scientific manner, in compliance with all Applicable Law, and in compliance with the Research Plan; (ii) ensure that its Representatives and subcontractors diligently perform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Research Program in a manner in accordance with generally accepted industry practices by appropriately trained personnel who are experienced in the relevant fields and in compliance with Applicable Law; (iii) keep Crescent fully informed regarding the progress and results of the Research Program; (iv) [***] provide Crescent with any additional information regarding the Research Program that Crescent reasonably requests; (v)&#160;participate in teleconference(s) at a time(s) agreed upon by the Parties to provide an update to Crescent on the performance of the Research Program; and (vi) give Crescent [***] with respect to information known or believed by Paragon and Parascent to be likely to materially impede or otherwise adversely affect the performance of the Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.2</b></font><b style="font-weight:bold;">Subcontractors. &#160;</b>Paragon and Parascent may perform the activities under the Research Program through one or more subcontractors; <i style="font-style:italic;">provided, that </i>Paragon and Parascent shall at all times be fully responsible for the compliance of such subcontractors with this Agreement and for the performance of their obligations under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.3</b></font><b style="font-weight:bold;">Research Books and Records; Audit</b>. &#160;Paragon shall maintain complete and accurate records related to the activities performed by Paragon under the Research Program. &#160;All such books and records shall be retained by Paragon and Parascent until the later of: (a) [***] after the end of the applicable stage of research; and (b) such longer period as may be required by Applicable Law. &#160;Upon Crescent&#8217;s request and at [***] expense, Paragon shall provide copies of such records or such records shall be made available for Crescent&#8217;s reasonable review, audit and inspection upon reasonable notice and with reasonable frequency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">GOVERNANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.1</b></font><b style="font-weight:bold;">Joint Development Committee</b>. &#160;The Parties will establish a single Joint Development Committee (the &#8220;<b style="font-weight:bold;">JDC</b>&#8221;) to oversee and coordinate the activities under the Research Program in accordance with the remainder of this Article 3. &#160;The JDC shall be comprised of two (2) employees from Crescent and two (2) employees from Paragon, with each Party designating one (1) such employee as its JDC co-chairperson. &#160;Subject to the foregoing, each Party shall appoint its respective Representatives to the JDC from time to time, and may change its Representatives, in its sole discretion, effective upon notice to the other Parties designating such change. &#160;Representatives from each Party shall have appropriate technical credentials, experience and knowledge pertaining to and ongoing familiarity with the activities to be performed under the Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.2</b></font><b style="font-weight:bold;">JDC Meetings</b>. &#160;The JDC shall meet in accordance with a schedule established by mutual written agreement of the Parties no less frequently than once every three (3) months until the end of the period specified in Section 3.5. &#160;The JDC may meet by means of teleconference, videoconference or other similar means, as jointly determined by the Parties. &#160;As appropriate, additional employees or consultants may from time to time attend the JDC meetings as nonvoting observers; <i style="font-style:italic;">provided, that</i> any such consultant shall agree in writing to comply with the confidentiality obligations under this Agreement; and <i style="font-style:italic;">provided, further that</i> no Third Party personnel may attend unless otherwise agreed by all Parties. &#160;Each Party shall bear its own</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">expenses related to the attendance of the JDC meetings by its representatives. &#160;Each Party may also call for special meetings to resolve particular matters requested by such Party. &#160;Paragon shall be responsible for keeping minutes of each JDC meeting that record in writing all decisions made, action items assigned or completed and other appropriate matters. &#160;Paragon shall send meeting minutes to all members of the JDC within [***] after a meeting for review. &#160;Each member shall have [***] from receipt in which to comment on and to approve/provide comments to the minutes (such approval not to be unreasonably withheld, conditioned or delayed). &#160;If a member, within such time period, does not notify the drafting Party that s/he does not approve of the minutes, the minutes shall be deemed to have been approved by such member.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.3</b></font><b style="font-weight:bold;">JDC Functions</b>. &#160;The JDC&#8217;s responsibilities are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Developing, reviewing, overseeing and coordinating the activities under the Research Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Periodically reviewing the progress of activities under the Research Plan;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>Updating or modifying the Research Plan; <i style="font-style:italic;">provided, that</i> such update or modification does not obligate any Party to perform any task or expend any resources outside of or beyond its obligations under the Budget;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>Reviewing performance against the Budget and timeline for the Research Program periodically (at least [***]), and periodically meeting to review and (subject to mutual approval of the Parties), approving any discovery project Budget deviation where such deviation is greater than [***] percent ([***]%);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>Reviewing the reconciliation of Actual Annual Costs against the Cost Advance at the end of each Calendar Year for the Research Program; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font>Determining whether the Project ADC Selection Criteria for the Research Program are not achievable for any reason and therefore the Research Program no longer warrants further research.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.4</b></font><b style="font-weight:bold;">JDC Decision Making and Disputes</b>. &#160;The JDC will endeavor to make decisions by consensus, with each of Crescent and Paragon having one vote. &#160;If consensus is not reached by the Parties&#8217; Representatives pursuant to such vote, then disputes relating to: (a) the reconciliation of Actual Annual Costs against the Cost Advance, as set forth in Section&#160;5.2(c), will be resolved in accordance with Section 11.7; (b) technical or scientific decisions in the course of operationalizing the Research Program, including the nature of activities to be performed by Paragon and Parascent thereunder, shall be finally decided by [***]; and (c) the Budget for the Research Program, and all other matters not covered by clauses (a) or (b), shall be finally decided by [***]. &#160;For clarity, and notwithstanding the creation of the JDC, each Party shall retain the rights, powers and discretion granted to it hereunder, and the JDC shall not be delegated or vested with such rights, powers or discretion unless such delegation or vesting is expressly provided herein, or the Parties expressly so agree in writing. &#160;The JDC shall not have the power to amend,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;"> </font>waive or modify any term of this Agreement, and no decision of the JDC shall be in contravention of any terms and conditions of this Agreement.  It is understood and agreed that issues to be formally decided by the JDC are limited to those specific issues that are expressly provided in this Agreement to be decided by the JDC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.5</b></font><b style="font-weight:bold;">Disbandment</b>. &#160;The JDC shall remain in effect from the date on which it is established in accordance with Section 3.1 until the expiration of the Research Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">OPTION; LICENSE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.1</b></font><b style="font-weight:bold;">Grant of Option. &#160;</b>Subject to the terms and conditions of this Agreement, Paragon hereby grants to Crescent, during the Term and subject to delivery of the Election Notice in accordance with Section 4.3, an exclusive option (&#8220;<b style="font-weight:bold;">Option</b>&#8221;) to be granted an exclusive license under the Project ADC Technology to Develop, Manufacture and Commercialize Project ADCs, Derived ADCs and Products in the Field in the Territory. &#160;Notwithstanding anything to the contrary, Crescent shall have no rights under the Option to obtain a license to Develop, Manufacture or Commercialize any component of a Project ADC or a Derived ADC (i.e., an Antibody, linker, payload or conjugation technology) other than as part of a Project ADC or a Derived ADC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.2</b></font><b style="font-weight:bold;">Limited License Grant During Option Period. &#160;</b>Subject to the terms and conditions of this Agreement, and effective only during the Term, Paragon hereby grants to Crescent a limited, exclusive, royalty-free license, without the right to sublicense, under the Project ADC Technology and, to the extent Controlled by Paragon for this purpose, the Paragon In-Licensed IP, solely to evaluate the Option and for the purpose of allowing Crescent to determine whether to exercise the Option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.3</b></font><b style="font-weight:bold;">Option Exercise. &#160;</b>Crescent may, in its sole discretion, exercise the Option by delivering written notice of such exercise to Paragon (&#8220;<b style="font-weight:bold;">Election Notice</b>&#8221;) at any time during the period beginning on the initiation of activities under the Research Program and ending [***] following Crescent&#8217;s receipt of the Deliverables for the Research Program, or such longer period as agreed upon by the Parties (&#8220;<b style="font-weight:bold;">Option Period</b>&#8221;). &#160;If Crescent fails to exercise the Option in accordance with this Section 4.3 prior to expiration of the Option Period, then, upon such expiration, the Option shall terminate and be of no further force or effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.4</b></font><b style="font-weight:bold;">License Template; Execution After Option Exercise.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Within [***] of the Effective Date, the Parties shall negotiate [***] and use [***] to agree upon a form of agreement template (&#8220;<b style="font-weight:bold;">License Template</b>&#8221;) to be used in connection with Crescent&#8217;s exercise of the Option, which will be consistent with the economic and other terms set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>, and upon mutual agreement by the Parties on the form of such License Template, will be attached to this Agreement and replace the terms on the existing <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>. &#160;If the Parties are unable to reach agreement on the definitive terms of the License Template within</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">such [***] period, the matter will be resolved in accordance with Section 11.7 unless the Parties mutually agree to resolve the matter otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Within [***] of Crescent&#8217;s exercise of the Option as set forth in Section 4.3, subject to any extension as mutually agreed by the Parties, the Parties shall use [***] to finalize and execute a definitive written agreement consistent with the License Template (the &#8220;<b style="font-weight:bold;">License Agreement</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">PAYMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.1</b></font><b style="font-weight:bold;">Research Initiation Fee</b>. &#160;Crescent shall pay to Paragon a one-time nonrefundable, non-creditable fee of Two Million Five Hundred Thousand Dollars ($2,500,000) (the &#8220;<b style="font-weight:bold;">Research Initiation Fee</b>&#8221;) no later than thirty (30) days following finalization of the Research Plan. &#160;For clarity, the Research Initiation Fee is nonrefundable, non-creditable, and separate from any Development Costs (including the Pre-Effective Date Development Costs) or Cost Advance paid or owing with respect to the Research Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.2</b></font><b style="font-weight:bold;">Development Costs</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>The monthly rate for the Development Fees (the &#8220;<b style="font-weight:bold;">Monthly Rate</b>&#8221;) shall be determined and charged on a calendar month-by-calendar month basis. &#160;For the period beginning on the Effective Date and continuing through December 31, 2024, the Monthly Rate shall be [***]. &#160;If the Research Plan requires Paragon to perform certain chemistry, manufacturing, and control activities (&#8220;<b style="font-weight:bold;">CMC Activities</b>&#8221;) in furtherance of the Research Program, then the Monthly Rate that would otherwise apply shall be [***]. &#160;Paragon shall have the right to adjust the Monthly Rate and the CMC Rate on an annual basis to account for inflation and other increases in costs by providing written notice thereof to Crescent at least [***] prior to the commencement of each [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>On a quarterly basis, Crescent will advance to Paragon any Development Costs contemplated in the Budget, including [***], and any [***] reasonably expected to be incurred by Paragon in the performance of the Research Program during the upcoming [***] in accordance with the Research Plan and Budget (less any pre-payments for Third Party Costs from earlier [***] that Paragon reasonably anticipates will be carried over to such upcoming [***]) (the &#8220;<b style="font-weight:bold;">Cost Advance</b>&#8221;). &#160;On a quarterly basis, Paragon will deliver an invoice to Crescent for the Cost Advance, and Crescent will pay the Cost Advance within [***] after receipt of Paragon&#8217;s invoice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>Within [***] after the end of each Calendar Year, Paragon will calculate and provide to Crescent a written reconciliation of its actually-incurred Third Party Costs (incurred in a manner consistent with the Budget) for the prior Calendar Year (&#8220;<b style="font-weight:bold;">Actual Annual Costs</b>&#8221;) against that portion of the Cost Advance for such Third Party Costs for that Calendar Year, including reasonable documentation of such Actual Annual Costs. &#160;The form of such reconciliation shall be subject to JDC review and approval. &#160;If the amounts paid for anticipated Third Party Costs in the Cost Advance exceeds the Actual Annual Costs, then Paragon will credit such excess payment against Development Costs contemplated in the Budget and reasonably expected to be</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">incurred by Paragon in the performance of the Research Program during any upcoming Calendar Year and Crescent will deduct such amount from its next quarterly Cost Advance. &#160;If the Cost Advance is less than the Actual Annual Costs, then Paragon will invoice Crescent for the difference and Crescent will pay such amount together with its next quarterly Cost Advance. &#160;If no further amounts will be owed to Paragon hereunder, Paragon will refund such amount. &#160;For clarity, the above reconciliation will not apply to Annual Development Fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>Notwithstanding Sections 5.2(a), 5.2(b) and 5.2(c) to the contrary, the Parties acknowledge that Paragon has incurred certain Development Costs between October 1, 2024 &#160;and the Effective Date, as a result of work performed by Paragon at risk on the Research Program (the costs described in (i) and (ii), the &#8220;<b style="font-weight:bold;">Pre-Effective Date Development Costs</b>&#8221;). &#160;Crescent shall reimburse Paragon for the Pre-Effective Date Development Costs within [***] after Crescent&#8217;s receipt of a written invoice that details the Pre-Effective Date Development Costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.3</b></font><b style="font-weight:bold;">Milestones</b>. &#160;On a Crescent Product-by-Crescent Product basis, Crescent shall make the following one-time non-refundable and non-creditable milestone payments to Paragon (or to such other designee(s), as designated by Paragon) as set forth below (each payment, a &#8220;<b style="font-weight:bold;">Milestone Payment</b>&#8221;), based on the achievement of the corresponding milestone set forth below (each, a &#8220;<b style="font-weight:bold;">Milestone</b>&#8221;) by Crescent, its Affiliates, or its sublicensees with respect to each such Crescent Product. &#160;Crescent shall, within [***] after it or its Affiliates achieve a Milestone, or within [***] after it learns that its or its Affiliate&#8217;s sublicensee has achieved a Milestone, notify Paragon of the achievement of such Milestone [***]. &#160;Following receipt of such notice, Paragon shall invoice Crescent for such Milestone Payment, which invoice shall specify the bank account information into which such Milestone Payment should be paid. &#160;Crescent shall make such Milestone Payment to Paragon or Paragon&#8217;s designee within [***] after receipt of Paragon&#8217;s invoice. &#160;Each Milestone Payment shall be paid no more than once per Crescent Product, and Crescent&#8217;s total Milestone Payments hereunder per Crescent Product (together with any such Milestone Payments per each such Crescent Product achieved and payable pursuant to a subsequently executed License Agreement) shall not exceed Forty-Six Million Dollars ($46,000,000). &#160;For avoidance of doubt, upon achievement of any Milestone for a Crescent Product, all prior unachieved Milestones for such Crescent Product shall be deemed thereby achieved and, if the Milestone Payment for any such prior Milestone has not previously been paid, it shall thereupon also be paid at the same time that the Milestone Payment for such subsequent achieved Milestone is paid. &#160;The Parties acknowledge and agree that once the License Agreement has been executed and is effective, any Milestone for a Crescent Product set forth in this Agreement that (a) has not yet been achieved, and (b) is duplicated in the License Agreement, together with the corresponding Milestone Payment, shall no longer be achievable and payable under the terms of this Agreement and shall only be achievable and payable under the terms of the License Agreement. &#160;Additionally, for the avoidance of doubt, if a Milestone with respect to a Crescent Product is achieved and paid by Crescent pursuant to this Agreement, then there shall be no Milestone Payment due for the achievement of such Milestone for such Crescent Product under the subsequently executed License Agreement, notwithstanding the inclusion of the same Milestone in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> hereto or in the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:73%;" align="center"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:74.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:25%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:74.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 2.9pt;"><b style="font-weight:bold;">Regulatory/Development Milestones per Crescent Product</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 2.9pt;"><b style="font-weight:bold;">Amount</b></p></th></tr><tr><td style="vertical-align:top;width:74.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 2.9pt;">[***]</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 2.9pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:74.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 2.9pt;">[***]</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 2.9pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:74.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 2.9pt;">[***]</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 2.9pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:74.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 2.9pt;">[***]</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 2.9pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:74.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 2.9pt;">[***]</p></td><td style="vertical-align:top;width:25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 2.9pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.4</b></font><b style="font-weight:bold;">Financial Records. &#160;</b>Paragon shall keep complete and accurate books of account and records in sufficient detail to enable the Development Costs and Milestones payable under this Agreement to be determined. &#160;Such books and records shall be kept at the principal place of business of Paragon, for at least [***] following the end of the [***] to which such books and records pertain, and Crescent shall be entitled to inspect such books and records at Paragon&#8217;s offices upon Crescent&#8217;s reasonable request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.5</b></font><b style="font-weight:bold;">Manner and Method of Payment</b>. &#160;All cash payment amounts hereunder are expressed in U.S. dollars (USD) unless otherwise specified. &#160;Each payment shall be made by electronic funds transfer in immediately available funds to a bank and account designated in writing by Paragon, unless otherwise specified in writing by Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.6</b></font><b style="font-weight:bold;">Tax</b>. Each Party shall be responsible for paying its own respective taxes in connection with any activities that it performs and any payments that it receives under this Agreement. &#160;The Parties will commit [***] to provide each other with any tax forms that may be reasonably necessary in order for any Party to not pay or withhold tax or to pay or withhold tax at a reduced rate under an applicable income tax treaty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.7</b></font><b style="font-weight:bold;">Late Payments</b>. &#160;In the event that any cash payment due for any undisputed amount under this Agreement is not made when due, then the cash payment shall accrue interest from the date due at a per annum rate equal to [***] above the then-current per annum prime rate reported by the <i style="font-style:italic;">Wall Street Journal</i> (U.S., Western Edition) or, if lower, the maximum legal annual interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.8</b></font><b style="font-weight:bold;">Equity Grants</b>. &#160;Except as expressly agreed otherwise by the Parties in writing, upon completion of each of the Calendar Years ending December 31, 2025 and December 31, 2026, Crescent will grant to Parascent a warrant to purchase a number of Shares equal to 1.00% of the outstanding Shares as of the date of the grant, on a fully-diluted basis (assuming the exercise or conversion of any convertible non-voting preferred stock, stock options, pre-funded warrants or similar instruments), with an exercise price equal to the fair market value of the underlying Shares on the date of the grant as determined by the board of directors of Crescent (each grant, an &#8220;<b style="font-weight:bold;">Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Grant</b>&#8221;); <i style="font-style:italic;">provided, that</i> if Crescent undergoes an initial public offering or a reverse merger transaction the rights and obligations of this Section 5.8 shall continue and Parascent shall be entitled to warrants from the ultimate public company parent to purchase a number of shares of such parent equal to 1.00% of the outstanding shares of the parent as of the date of the grant, on a fully-diluted basis (assuming the exercise or conversion of any convertible non-voting preferred stock, stock options, pre-funded warrants or similar instruments), as applicable. &#160;Such warrants will be exercisable for a period of ten (10) years following the date of the grant. &#160;Each Equity Grant shall be effected on the last Business Day of each applicable Calendar Year and the corresponding grant date shall be such date. &#160;If the Term ends prior to the end of a Calendar Year, the Equity Grant for such Calendar Year shall be pro-rated for such Calendar Year and such Equity Grant shall be effected within five (5) Business Days of the end of the Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INTELLECTUAL</b><b style="font-variant:small-caps;font-weight:bold;"> PROPERTY RIGHTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.1</b></font><b style="font-weight:bold;">Ownership.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-weight:bold;">Background IP</b>. &#160;As between the Parties, each Party will retain all right, title and interest in and to all of its Background IP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-weight:bold;">Project ADC Technology and Paragon Platform Technology. &#160;</b>Subject to the rights and licenses granted to Crescent in this Agreement, as between the Parties, Paragon or its Affiliates shall own all right, title and interest in and to all Project ADC Technology and all Paragon Platform Technology, irrespective of inventorship. &#160;Crescent agrees to assign and hereby assigns to Paragon all of Crescent&#8217;s right, title and interest in and to the Project ADC Technology and the Paragon Platform Technology, including any and all Intellectual Property Rights therein. &#160;Crescent shall execute and deliver, and shall cause its Affiliates to execute and deliver, such additional documents, instruments, conveyances and assurances and take any such further actions as may be reasonably required to ensure that all right, title and interest in the Project ADC Technology and Paragon Platform Technology is effectively assigned to and held by Paragon. &#160;Crescent and its Affiliates shall cause all of its and their employees who, in each case, generated, conceived of or created any Project ADC Technology and Paragon Platform Technology to assign without additional consideration all ownership rights in such Project ADC Technology and Paragon Platform Technology to Paragon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.2</b></font><b style="font-weight:bold;">Patent Prosecution, Maintenance and Enforcement &#8211; Project ADC Patents.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>Prior to execution of the License Agreement, Paragon shall have the sole right, but not the obligation, to prepare, file, prosecute, maintain or enforce any Project ADC Patents at Paragon&#8217;s sole expense, and Crescent shall reasonably cooperate and assist Paragon in such preparation, filing, prosecution, maintenance and enforcement, at Paragon&#8217;s request. &#160;Following execution of the License Agreement, (i) with respect to Project ADC Patents that have been filed prior to the execution of the License Agreement, the Parties&#8217; respective rights relating to the preparation, filing, prosecution, maintenance and enforcement of such Project ADC Patents shall be as set forth therein and Crescent shall reimburse Paragon for any costs and expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">actually incurred by Paragon in the prosecution and maintenance of any such Project ADC Patents in accordance with the terms of the License Agreement, and (ii) with respect to Project ADC Patents that have not been filed prior to the execution of the License Agreement, (1) Paragon, at its sole expense, shall have the sole right, but not the obligation, to prepare, file, prosecute, maintain and enforce such Product ADC Patents until the date on which the Final Deliverable for such Research Program is delivered to Crescent, and during such period Paragon shall provide Crescent with drafts of all proposed filings to any patent office with respect to such Project ADC Patents in reasonably adequate time before submission of such filings for Crescent&#8217;s review and comment, and (2) following the date on which the Final Deliverable for such Research Program is delivered to Crescent, the Parties&#8217; respective rights relating to the preparation, filing, prosecution, maintenance and enforcement of such Project ADC Patents shall be as set forth therein and Crescent shall reimburse Paragon for any costs and expenses actually incurred by Paragon in the prosecution and maintenance of any such Project ADC Patents in accordance with the terms of the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>Crescent covenants and agrees that it will not file or prosecute any Patents Covering any Project ADC or Derived ADC (including without limitation any Project ADC Inventions) or any component thereof during the Term of this Agreement except as permitted under the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.3</b></font><b style="font-weight:bold;">Defense of Claims Brought by Third Parties. &#160;</b>If a Party becomes aware of any actual or potential claim that the Development, Manufacture or Commercialization of any Project ADC, Derived ADC, Product, Multispecific ADC, Multispecific Product or any component thereof infringes or in the future will infringe the Intellectual Property Rights of any Third Party, such Party will [***] notify the other Parties. &#160;In any such instance, the Parties will [***] thereafter meet (which may be through the JDC) to discuss [***] regarding the best response to such notice. &#160;Certain additional rights and obligations of the Parties with respect to any such claim will be set forth in the License Agreement (to the extent applicable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.4</b></font><b style="font-weight:bold;">No Implied Licenses. &#160;</b>Except as expressly set forth herein, no right or license under any Patents, Know-How or Intellectual Property Right of any Party is granted or shall be granted by implication hereunder. &#160;All such rights or licenses are or shall be granted only as expressly provided in this Agreement or the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 7</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">PROTECTION OF CONFIDENTIAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.1</b></font><b style="font-weight:bold;">Confidentiality.</b> &#160;Except to the extent expressly authorized by this Agreement, the Receiving Party agrees that, during the Term and for [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than as expressly provided for in this Agreement, any Confidential Information of the Disclosing Party. &#160;The Receiving Party may disclose Confidential Information of the Disclosing Party to those of the Receiving Party&#8217;s Representatives who have a need for such information; <i style="font-style:italic;">provided, that</i> the Receiving Party shall advise such Representatives of the confidential nature thereof, shall ensure that each such Representative is bound in writing by obligations of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">confidentiality and non-use at least as stringent as those contained in this Agreement, and shall be responsible for the compliance of its Representatives with the terms of this Agreement. &#160;The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to ensure that its Representatives do not disclose or make any unauthorized use of the Confidential Information of the Disclosing Party. &#160;The Receiving Party shall [***] notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential Information of the Disclosing Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.2</b></font><b style="font-weight:bold;">Exceptions.</b> &#160;The Receiving Party&#8217;s obligations under Section 7.1 shall not apply to any Confidential Information of the Disclosing Party that the Receiving Party can prove by competent evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement, generally known or available; (b) is known by the Receiving Party at the time of receiving such information from the Disclosing Party; (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and without restriction on disclosure; or (d) is independently discovered or developed by the Receiving Party, without the aid, use or application of any Confidential Information of the Disclosing Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.3</b></font><b style="font-weight:bold;">Authorized Disclosure.</b> &#160;Notwithstanding the provisions of this Article 7, the Receiving Party may disclose Confidential Information, without violating its obligations under this Agreement, to the extent the disclosure is:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>required by a valid order of a court or other governmental body of competent jurisdiction or as otherwise required by Applicable Law, rule, regulation (including securities laws and regulations), government requirement, or as may be required in connection with any filings made with, or by the disclosure policies of, a stock exchange; <i style="font-style:italic;">provided, that</i> the Receiving Party shall give reasonable prior written notice to the Disclosing Party of such required disclosure and, at [***] request and expense, shall cooperate with the Disclosing Party&#8217;s efforts to contest such requirement, to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or the law, rule or regulation required, or to obtain other confidential treatment of such Confidential Information; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>reasonably necessary to file or prosecute patent applications, prosecute or defend litigation or otherwise establish rights or enforce obligations under this Agreement, in each case, in accordance with this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.4</b></font><b style="font-weight:bold;">No Requirement to Disclose Paragon Platform Technology. &#160;</b>Notwithstanding anything to the contrary in this Agreement, Paragon will not be required to disclose any of the Paragon Platform Technology to Crescent other than as required to be included in the Deliverables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.5</b></font><b style="font-weight:bold;">Use of Names. &#160;</b>No Party shall use any other Party&#8217;s name or trademarks in any advertising, sales, or promotional material or in any publication without the prior written consent of such other Party or Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.6</b></font><b style="font-weight:bold;">Confidentiality of this Agreement.</b> &#160;This Agreement and its terms are considered Confidential Information of all Parties, and each Party shall keep confidential and shall not publish</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or otherwise disclose the terms of this Agreement without the prior written consent of the applicable other Party, except as expressly permitted by Section 7.3 or Section 7.7, and except that each Party may disclose this Agreement and its terms to actual or potential investors, lenders, and strategic partners in connection with due diligence or similar investigations by such Third Parties or in confidential financing documents; <i style="font-style:italic;">provided</i>, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and non-use at least as restrictive as those set forth in this Article 7 (<i style="font-style:italic;">provided, that</i> the confidentiality term applicable to such Third Party may be shorter so long as it is commercially reasonable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.7</b></font><b style="font-weight:bold;">Publicity. &#160;</b>Except to the extent required by Applicable Law or the rules of any stock exchange or listing agency, no Party shall issue a press release announcing that they have entered into an ADC discovery partnership, without the other Parties&#8217; prior written consent, which shall not be unreasonably withheld.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPRESENTATIONS</b><b style="font-variant:small-caps;font-weight:bold;">, WARRANTIES AND COVENANTS; DISCLAIMER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.1</b></font><b style="font-weight:bold;">Mutual Representations and Warranties.</b> &#160;Each Party represents and warrants to each other that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not and will not conflict with any agreement, instrument, or understanding, oral or written, to which it is or may become a party or by which it may be or become bound.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.2</b></font><b style="font-weight:bold;">Paragon Representations, Warrants and Covenants</b>. &#160;Paragon hereby represents, warrants and covenants to Crescent that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>it will perform its activities under the Research Program with due care and in accordance with (i) Applicable Law, (ii) the terms and conditions contained herein and the Research Plan, and (iii) generally prevailing industry standards;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>neither it nor any of its Affiliates have entered or will enter, directly or indirectly, into any contract or any other transaction with any Third Party or Affiliate that conflicts or derogates from its undertakings under this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>it has the unencumbered right to the Paragon Platform Technology and the right, power and authority to use the Paragon Platform Technology in performance of the Research</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Plan and the performance of its obligations under this Agreement, in each case in accordance with the terms hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>each Representative employed or engaged by Paragon or its Affiliate to conduct the activities under the Research Program has assigned and has executed an agreement assigning its entire right, title and interest in and to Project ADC Technology to Paragon;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>there are no claims, actions, or proceedings pending or threatened, nor are there any formal inquiries initiated or written notices received that may lead to the institution of any such legal proceedings, in each case (or in aggregate) against Paragon or its properties, assets or business, which would, individually or in the aggregate, have a material adverse effect on, or materially prevent, Paragon&#8217;s ability to perform under this Agreement or to grant the Option or other rights granted to Crescent under this Agreement; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(f)</b></font>none of Paragon, its Representatives, or any other person used by Paragon in the performance of this Agreement has been or is (i) debarred, convicted, or is subject to a pending debarment or conviction, pursuant to section 306 of the United States Federal Food Drug and Cosmetic Act, 21 U.S.C. &#167; 335a, (ii) listed by any government or regulatory agencies as ineligible to participate in any Federal healthcare programs (as that term is defined in 42 U.S.C. 1320a-7b(f)) or government procurement or non-procurement programs, or excluded, debarred, suspended or otherwise made ineligible to participate in any such program, or (iii) convicted of a criminal offense related to the provision of healthcare items or services, or is subject to any such pending action. &#160;Paragon agrees to inform Crescent [***] if Paragon or any person who is performing activities on its behalf under the Agreement is subject to the foregoing, or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending or threatened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.3</b></font><b style="font-weight:bold;">Disclaimer. &#160;</b>EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, DURABILITY, MERCHANTABLE QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 9</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">TERM AND TERMINATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.1</b></font><b style="font-weight:bold;">Term. &#160;</b>The term of this Agreement (&#8220;<b style="font-weight:bold;">Term</b>&#8221;) shall commence on the Effective Date and, subject to earlier termination in accordance with this Article 9, shall continue until the later of: (a)&#160;the expiration of the Option Period if Crescent does not exercise the Option in accordance with Section 4.3; (b) if Crescent exercises the Option during the Option Period in accordance with Section 4.3 but the Parties are unable to finalize and execute the License Agreement during the thirty (30) day period referenced in Section&#160;4.4(b), the expiration of such thirty (30) day period; or (c) the expiration of the Research Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.2</b></font><b style="font-weight:bold;">Termination of Agreement for Material Breach.</b> &#160;Each Party shall have the right to terminate this Agreement upon thirty (30) days&#8217; prior written notice to the other Parties upon or after the material breach of any provision of this Agreement by any other Party if the breaching Party has not cured such breach by the end of such thirty (30) day period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.3</b></font><b style="font-weight:bold;">Termination for Convenience. &#160;</b>Crescent shall have the right to terminate this Agreement for any reason or no reason upon thirty (30) days&#8217; prior written notice to Paragon; <i style="font-style:italic;">provided, that </i>Crescent will pay Paragon any unpaid fees due for Development Costs accrued prior to such effective termination date, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities under the Research Plan, as evidenced by Paragon&#8217;s records.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.4</b></font><b style="font-weight:bold;">Termination for Delay</b>. &#160;Paragon shall have the right to terminate this Agreement immediately upon written notice to Crescent if, as a result any action or failure to act by Crescent or its Affiliates, the Research Program or all material activities under the Research Plan are suspended, discontinued or otherwise delayed for a period of four (4) consecutive months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.5</b></font><b style="font-weight:bold;">Termination for a Bankruptcy Event. &#160;</b>Each Party will have the right to terminate this Agreement in the event of a Bankruptcy Event with respect to any other Party. &#160;&#8220;<b style="font-weight:bold;">Bankruptcy Event&#8221; </b>means the occurrence of any of the following: (a) the institution of any bankruptcy, receivership, insolvency, reorganization or other similar proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section or chapter of the United States Bankruptcy Code, as amended, or under any similar laws or statutes of the United States or any state thereof (the &#8220;<b style="font-weight:bold;">Bankruptcy Code</b>&#8221;), where in the case of involuntary proceedings, such proceedings have not been dismissed or discharged within [***] after they are instituted, (b) the insolvency or making of an assignment for the benefit of creditors or the admittance by a Party of any involuntary debts as they mature, (c) the institution of any reorganization, arrangement or other readjustment of debt plan of a Party not involving the Bankruptcy Code, (d) the appointment of a receiver for all or substantially all of a Party&#8217;s assets, or (e) any corporate action taken by the board of directors of a Party in furtherance of any of the foregoing actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.6</b></font><b style="font-weight:bold;">Disposal of Confidential Information.</b> &#160;In the event this Agreement expires or is terminated and the Parties have not entered into the License Agreement, each Party shall return to the applicable other Party all Confidential Information of such other Party (including all copies thereof) in such Party&#8217;s possession related to the Research Program; <i style="font-style:italic;">provided, however</i>, that each Party may retain one copy of such other Party&#8217;s Confidential Information in such Party&#8217;s secure archives for the sole purpose of monitoring compliance with its obligations hereunder or Applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.7</b></font><b style="font-weight:bold;">Accrued Rights; Survival.</b> &#160;The expiration or termination of this Agreement for any reason shall not release any Party from any liability or obligation that, at the time of such expiration or termination, has already accrued to any other Party or that is attributable to a period prior to such expiration or termination, nor will expiration or any termination of this Agreement preclude any Party from pursuing all rights and remedies it may have under this Agreement, or at</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">law or in equity, with respect to breach of this Agreement. &#160;In the event of expiration or any termination of this Agreement, the following provisions of this Agreement shall survive such expiration or termination in accordance with their respective terms and conditions: Article 5, Article 7, Article 10 and Article 11, as well as Sections 2.3, 6.1(a), 6.2(a), 6.4, 9.3, 9.6 and 9.7.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 10</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">INDEMNIFICATION; LIMITATION OF LIABILITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.1</b></font><b style="font-weight:bold;">By Crescent. &#160;</b>Crescent hereby agrees to defend, indemnify, and hold harmless Paragon, Parascent, their Affiliates and their Representatives (each, a &#8220;<b style="font-weight:bold;">Paragon Indemnitee</b>&#8221;) from and against any and all losses, damages, liabilities, expenses, and costs, including reasonable legal expense and attorneys&#8217; fees (collectively, &#8220;<b style="font-weight:bold;">Losses</b>&#8221;), to which any Paragon Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party (&#8220;<b style="font-weight:bold;">Third Party Claim</b>&#8221;) to the extent such Losses result from: (a)&#160;the negligence or willful misconduct of any Crescent Indemnitee in the performance of this Agreement; or (b) the material breach by any Crescent Indemnitee of this Agreement; except, in each case, to the extent such Losses result from the negligence or willful misconduct of any Paragon Indemnitee or the material breach by Paragon of this Agreement, or where such Losses are subject to indemnification pursuant to Section 10.2 below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.2</b></font><b style="font-weight:bold;">By Paragon. &#160;</b>Paragon hereby agrees to defend, indemnify, and hold harmless Crescent, its Affiliates and its and their Representatives (each, an &#8220;<b style="font-weight:bold;">Crescent Indemnitee</b>&#8221;) from and against any and all Losses to which any Crescent Indemnitee may become subject as a result of any Third Party Claim to the extent such Losses result from: (a) the negligence or willful misconduct of any Paragon Indemnitee in the performance of this Agreement; or (b) the material breach by any Paragon Indemnitee of this Agreement; except, in each case, to the extent such Losses result from the negligence or willful misconduct of any Crescent Indemnitee, the material breach by Crescent of this Agreement, or where such Losses are subject to indemnification pursuant to Section 10.1 above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.3</b></font><b style="font-weight:bold;">Indemnification Procedure. &#160;</b>In connection with any Third Party Claim for which a Party (the &#8220;<b style="font-weight:bold;">Indemnified Party</b>&#8221;) seeks indemnification from another Party (the &#8220;<b style="font-weight:bold;">Indemnifying Party</b>&#8221;) pursuant to this Agreement, the Indemnified Party will: (a) give the Indemnifying Party [***] notice of the Third Party Claim; <i style="font-style:italic;">provided, however, </i>that failure to provide such notice will not relieve the Indemnifying Party from its liability or obligation hereunder, except to the extent of any material prejudice as a direct result of such failure; (b) cooperate with the Indemnifying Party, at the Indemnifying Party&#8217;s expense, in connection with the defense and settlement of the Third Party Claim; and (c) permit the Indemnifying Party to control the defense and settlement of the Third Party Claim; <i style="font-style:italic;">provided, however, </i>that the Indemnifying Party may not settle the Third Party Claim without the Indemnified Party&#8217;s prior written consent, which will not be unreasonably withheld or delayed, in the event that such settlement materially adversely impacts the Indemnified Party&#8217;s rights or obligations. &#160;Further, the Indemnified Party will have the right to participate (but not control) and be represented in any suit or action by advisory counsel of its selection and at its own expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.4</b></font><b style="font-weight:bold;">Limitation of Liability.</b> &#160;EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 7 OR FOR INDEMNIFICATION CLAIMS UNDER ARTICLE 10, IN NO EVENT SHALL ANY PARTY BE ENTITLED TO RECOVER FROM ANY OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, EVEN IF SUCH OTHER PARTY HAD NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Article 11</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.1</b></font><b style="font-weight:bold;">Independent Contractor Relationship. &#160;</b>Each of Paragon&#8217;s and Parascent&#8217;s relationship with Crescent is that of an independent contractor, and nothing in this Agreement should be construed to create a partnership, joint venture or employer-employee relationship. &#160;No Party is an agent of any other Party or authorized to make any representation, contract or commitment on behalf of any other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.2</b></font><b style="font-weight:bold;">Force Majeure. &#160;</b>No Party will be charged with any liability for delay or failure in performance of an obligation under this Agreement (other than any obligation to pay monies when due) to the extent such delay or failure is due to a cause beyond the reasonable control of the affected Party, such as war, riots, labor disturbances, epidemic, pandemic, fire, explosion, and compliance in good faith with any Applicable Law. &#160;The Party affected will give [***] notice to the other Parties of the nature of the cause of any material delay or failure to perform, its anticipated duration and any action being taken to avoid or minimize the effect. &#160;The Party affected will use its diligent efforts to avoid or remove such causes of delay or failure to perform and to mitigate the effect of such occurrence, and will continue performance in accordance with the terms of this Agreement whenever such causes are removed. &#160;The Party affected will give [***] notice to the other Parties of such resumed performance. &#160;If any such failure or delay in a Party&#8217;s performance hereunder continues for more than [***], any of the other Parties may terminate this Agreement upon written notice to the affected Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.3</b></font><b style="font-weight:bold;">Entire Agreement; Amendment.</b> &#160;This Agreement, together with all Exhibits attached hereto, constitutes the final, complete, and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous understandings and agreements, relating to its subject matter. &#160;This Agreement (including its Exhibits) may not be changed, modified, amended, or supplemented except by a written instrument signed by all Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.4</b></font><b style="font-weight:bold;">Non-Waiver.</b> &#160;The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. &#160;Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.5</b></font><b style="font-weight:bold;">Severability. &#160;</b>Should one or more of the provisions of this Agreement become void or unenforceable as a matter of Applicable Law, then this Agreement shall be construed as if</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and the Parties will use their best efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.6</b></font><b style="font-weight:bold;">Assignment.</b> &#160;Neither this Agreement nor any rights or obligations hereunder may be assigned by any Party without the prior written consent of the other Parties (which consent shall not be unreasonably withheld); <i style="font-style:italic;">provided, however</i>, that any Party may assign this Agreement and its rights and obligations hereunder without the other Parties&#8217; consent to its successor to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. &#160;The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this section. &#160;Any assignment not in accordance with this Agreement shall be void.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.7</b></font><b style="font-weight:bold;">Dispute Resolution. &#160;</b>The Parties recognize that a <i style="font-style:italic;">bona fide </i>dispute as to certain matters may arise from time to time during the Term relating to any Party&#8217;s rights or obligations hereunder or otherwise relating to the validity, enforceability or performance of this Agreement, including disputes relating to alleged breach or termination of this Agreement but excluding any disputes relating to Article 7 (Confidentiality) hereof or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&#8217; respective Intellectual Property Rights (hereinafter, a &#8220;<b style="font-weight:bold;">Dispute</b>&#8221;). &#160;In the event of the occurrence of any Dispute, the Parties will follow the following procedures in an attempt to resolve the dispute or disagreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></font>The Party claiming that such a Dispute exists will give notice in writing (a &#8220;<b style="font-weight:bold;">Notice of Dispute</b>&#8221;) to the other Parties of the nature of the Dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></font>The Dispute will be referred to the then Chief Executive Officer or Chief Operating Officer of Paragon and the then Chief Executive Officer or President of Crescent who will meet no later than [***] following the initial receipt of the Notice of Dispute and use [***] to resolve the Dispute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(c)</b></font>If, within [***] of initial receipt of the Notice of Dispute, the Dispute has not been resolved, or if, for any reason, the meeting described in Section 11.7(b) hereof has not been held within [***] of initial receipt of the Notice of Dispute, then the Parties agree that such Dispute will be finally resolved through binding arbitration to be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures and in accordance with the Expedited Procedures in those Rules, as specifically modified by the provisions of this Section&#160;11.7(c). &#160;The arbitration will be conducted by a panel of three arbitrators. &#160;Within [***] after the initiation of the arbitration, each Party will nominate one person to act as arbitrator, and the two arbitrators so named will then jointly appoint the third arbitrator within [***] of their appointment, who will serve as chairman of the panel. &#160;All three arbitrators must be independent Third Parties having at least [***] of dispute resolution experience (which may include judicial experience) or legal or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">business experience in the biotech or pharmaceutical industry. &#160;If any Party fails to nominate its arbitrator, or if the arbitrators selected by the Parties cannot agree on a person to be named as chairman within such [***]-day period, JAMS will make the necessary appointments for such arbitrator(s) or the chairman. &#160;Once appointed by a Party, such Party will have no <i style="font-style:italic;">ex parte </i>communication with its appointed arbitrator. &#160;The place of arbitration will be in Boston, Massachusetts or such other venue as the Parties may mutually agree. &#160;The arbitration proceedings and all communications with respect thereto will be in English. &#160;Any written evidence originally in another language will be submitted in English translation accompanied by the original or a true copy thereof. &#160;The arbitrators have the power to decide all matters in Dispute, including any questions of whether or not such matters are subject to arbitration hereunder. &#160;The arbitration will be governed by the Federal Arbitration Act, 9 U.S.C. &#167;&#167;1 <i style="font-style:italic;">et seq., </i>and judgment upon the award rendered by the arbitrators may be entered in any court having competent jurisdiction thereof. &#160;The existence, content and results of any arbitration proceedings pursuant to this Section 11.7 will be deemed the Confidential Information of all Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(d)</b></font>Notwithstanding any provision of this Agreement to the contrary, any Party may immediately initiate litigation in any court of competent jurisdiction seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></font>The Parties agree that any disputes relating to Article 7 (Confidentiality) hereof or disputes relating to the determination of the validity, scope, infringement, enforceability, inventorship or ownership of the Parties&#8217; respective Intellectual Property Rights shall be subject to the exclusive jurisdiction of the state and federal courts in Boston, Massachusetts and each Party hereby submits to such jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.8</b></font><b style="font-weight:bold;">Governing Law.</b> &#160;This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without reference to conflicts of laws principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.9</b></font><b style="font-weight:bold;">Notices.</b> &#160;Any notice to be given under this Agreement must be in writing and delivered either in person, by internationally recognized express courier, by email, or by facsimile, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other. &#160;Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt; (b) if delivered by express courier, the next Business Day the express courier regularly makes deliveries; or (c) if delivered by email, upon the date upon which the receipt of such email is confirmed by return email. &#160;Together with any notice provided by a Party to any other Party in accordance with this Section 11.9, the Party shall send a copy of such notice by email to such other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:85.84%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:64.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If to Paragon or Parascent:</p></td><td style="vertical-align:bottom;width:64.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paragon Therapeutics, Inc. </p></td></tr><tr><td style="vertical-align:bottom;width:35.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:64.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">221 Crescent Street</p></td></tr><tr><td style="vertical-align:bottom;width:35.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:64.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building 23, Suite 105</p></td></tr><tr><td style="vertical-align:bottom;width:35.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:64.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waltham, MA 02453</p></td></tr><tr><td style="vertical-align:bottom;width:35.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:64.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: [***]</p></td></tr><tr><td style="vertical-align:bottom;width:35.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:64.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">If to Crescent:</p></td><td style="vertical-align:bottom;width:64.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Crescent Biopharma, Inc.</p></td></tr><tr><td style="vertical-align:bottom;width:35.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:64.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">221 Crescent Street</p></td></tr><tr><td style="vertical-align:bottom;width:35.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:64.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building 23, Suite 105</p></td></tr><tr><td style="vertical-align:bottom;width:35.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:64.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waltham MA 02453</p></td></tr><tr><td style="vertical-align:bottom;width:35.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:64.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attn: [***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.10</b></font><b style="font-weight:bold;">Interpretation. &#160;</b>Except where the context expressly requires otherwise, (a)&#160;the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&#160;the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;, (c)&#160;the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;, (d)&#160;any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person or entity shall be construed to include such person&#8217;s or entity&#8217;s successors and assigns, (f) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement include all Exhibits hereto, (h) the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (k) the term &#8220;or&#8221; shall be interpreted in the inclusive sense commonly associated with the term &#8220;or&#8221;. &#160;The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement or have any effect on its interpretation or construction. &#160;Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against any Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. &#160;This Agreement has been prepared in the English language, and the English language shall control its interpretation. &#160;In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;"> </font>To the extent there is any inconsistency or conflict between the terms and conditions of this Agreement and any Research Plan, the terms and conditions of this Agreement will prevail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.11</b></font><b style="font-weight:bold;">No Third Party Rights.</b> &#160;The provisions of this Agreement are for the exclusive benefit of the Parties and their successors and permitted assigns, and no other person shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.12</b></font><b style="font-weight:bold;">Counterparts.</b> &#160;This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. &#160;This Agreement may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.13</b></font><b style="font-weight:bold;">Expenses</b>. &#160;Each Party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation, and completion of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.14</b></font><b style="font-weight:bold;">Binding Effect</b>. &#160;This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.15</b></font><b style="font-weight:bold;">Construction</b>. &#160;The Parties hereto acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c)&#160;the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.16</b></font><b style="font-weight:bold;">Cumulative Remedies</b>. &#160;No remedy referred to in this Agreement is intended to be exclusive unless explicitly stated to be so, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;font-weight:bold;">[Remainder of page left intentionally blank; signature page follows.]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">In Witness Whereof,</b> the Parties hereto have executed this ADC Discovery and Option Agreement on the Effective Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:47.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Paragon Therapeutics, Inc.</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Crescent Biopharma, Inc.</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:top;width:42.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ K. Evan Thompson</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u></p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jonathan Violin</p></td></tr><tr><td style="vertical-align:top;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">K. Evan Thompson</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:44.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jonathan Violin</p></td></tr><tr><td style="vertical-align:top;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Operating Officer</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and President</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Parascent Holding LLC</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:47.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-variant:small-caps;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u></p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ K. Evan Thompson</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:42.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">K. Evan Thompson</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:&#160; </p></td><td style="vertical-align:top;width:42.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">[Exhibit A to ADC Discovery and Option Agreement]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>17
<FILENAME>glyc-20241231xex23d1.htm
<DESCRIPTION>EXHIBIT-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:22:05 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We consent to the reference to our firm under the caption &quot;Experts&quot; and to the use of our report dated February 13, 2025, included in the Proxy Statement of GlycoMimetics, Inc. that is made a part of the Registration Statement (Form S-4) and Prospectus of GlycoMimetics, Inc. for the registration of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">/s/ Ernst &amp; Young LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baltimore, Maryland</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2025</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>18
<FILENAME>glyc-20241231xex23d2.htm
<DESCRIPTION>EXHIBIT-23.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:22:09 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:24pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.2</b></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:center;margin:0pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><font style="white-space:pre-wrap;">We hereby consent to the use in this Registration Statement on Form S-4 of Glycomimetics, Inc. of our report dated February 18, 2025  relating to the financial statements of Crescent Biopharma, Inc., which appears in this Registration Statement.  We also consent to the reference to us under the heading </font><font style="font-family:'Georgia';">&#8220;</font>Experts<font style="font-family:'Georgia';">&#8221;</font> in such Registration Statement.</p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:0pt;margin:0pt;">/s/ PricewaterhouseCoopers LLP <br>Boston, Massachusetts <br>February 18, 2025</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.4
<SEQUENCE>19
<FILENAME>glyc-20241231xex23d4.htm
<DESCRIPTION>EXHIBIT-23.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:22:15 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;23.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent of Lucid Capital Markets, LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">February 18, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GlycoMimetics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9708 Medical Center Drive</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Rockville, MD 20850</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Re: Registration Statement on&#160;Form&#160;S-4&#160;of&#160;GlycoMimetics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Members of the Board:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We hereby consent to the inclusion of our opinion letter, dated October 28, 2024, to the Board of Directors of GlycoMimetics, Inc. (&#8220;GLYC&#8221;) as Annex B to, and to the reference thereto under the headings &#8220;Prospectus Summary &#8212; Opinion of Lucid Capital Markets to the GlycoMimetics Board,&#8221; &#8220;The Merger &#8212; Background of the Merger,&#8221; &#8220;The Merger &#8212; GlycoMimetics&#8217; Reasons for the Merger,&#8221; and &#8220;The Merger &#8212; Opinion of Lucid, GlycoMimetics&#8217; Financial Advisor, to the GlycoMimetics Board of Directors&#8221; in the proxy statement/prospectus relating to the proposed merger involving GLYC and Crescent Biopharma, Inc. (&#8220;Crescent&#8221;), which such proxy statement/prospectus forms a part of GLYC&#8217;s and Crescent&#8217;s Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) to be filed on the date hereof, which this consent is filed as an exhibit thereto. In giving the foregoing consent, we do not admit (1) that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the rules and regulations of the Securities and Exchange Commission (the &#8220;Commission&#8221;) promulgated thereunder, or (2) that we are experts with respect to any part of the Registration Statement within the meaning of the term &#8220;experts&#8221; as used in the Securities Act and the rules and regulations of the Commission promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.47%;"><tr><td style="vertical-align:bottom;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Very truly yours, </p></td><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td rowspan="3" style="vertical-align:bottom;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="glyc-20241231xex23d4001.jpg" alt="Graphic" style="display:inline-block;height:33.3pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:151.45pt;"></p></td><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="display:none;vertical-align:bottom;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="display:none;vertical-align:bottom;width:50.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.76%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LUCID CAPITAL MARKETS, LLC</p></td><td style="vertical-align:bottom;width:49.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LUCID CAPITAL MARKETS, LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">570 Lexington Ave, 40th Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">New York NY 10022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>20
<FILENAME>glyc-20241231xex99d1.htm
<DESCRIPTION>EXHIBIT-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:22:15 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.</b><b style="font-weight:bold;">1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics, Inc. is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sincerely,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Alexandra Balcom</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Alexandra Balcom</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2025</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>21
<FILENAME>glyc-20241231xex99d2.htm
<DESCRIPTION>EXHIBIT-99.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:22:18 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.</b><b style="font-weight:bold;">2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics, Inc. is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Sincerely,</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:53.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Peter Harwin</p></td><td colspan="2" style="vertical-align:top;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:53.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:&#160;Peter Harwin</p></td><td style="vertical-align:top;width:43.41%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:53.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:43.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:53.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2025</p></td><td colspan="2" style="vertical-align:top;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:53.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:top;width:43.41%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>22
<FILENAME>glyc-20241231xex99d3.htm
<DESCRIPTION>EXHIBIT-99.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:22:18 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.</b><b style="font-weight:bold;">3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics, Inc. is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Sincerely,</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:53.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Susan Moran</p></td><td colspan="2" style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:53.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:&#160;Susan Moran</p></td><td style="vertical-align:top;width:43.41%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:53.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:43.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:53.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2025</p></td><td colspan="2" style="vertical-align:top;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:53.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:top;width:43.41%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>23
<FILENAME>glyc-20241231xex99d4.htm
<DESCRIPTION>EXHIBIT-99.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:22:24 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 99.</b><b style="font-weight:bold;">4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Consent to be Named as a Director</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">GlycoMimetics, Inc. is filing a Registration Statement on Form S-4 (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the board of directors of the combined company following the consummation of the merger. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sincerely,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jonathan Violin</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Jonathan Violin</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2025</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>24
<FILENAME>glyc-20241231xexfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/18/2025 09:22:25 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 107</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Calculation of Filing Fee Tables</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Form S-4</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Form Type)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">GLYCOMIMETICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Exact Name of Registrant as Specified in its Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Table 1 - Newly Registered and Carry Forward Securities</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:-0.4pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:91.65pt;"><td style="vertical-align:bottom;width:8.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:5.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Security<br>Type</p></td><td style="vertical-align:bottom;width:17.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Security<br>Class Title</p></td><td style="vertical-align:bottom;width:6.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fee<br>Calculation<br>or Carry<br>Forward<br>Rule</p></td><td style="vertical-align:bottom;width:9.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Amount<br>Registered</p></td><td style="vertical-align:bottom;width:6.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Proposed<br>Maximum<br>Offering<br>Price Per<br>Unit</p></td><td style="vertical-align:bottom;width:7.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Maximum<br>Aggregate<br>Offering Price</p></td><td style="vertical-align:bottom;width:8.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Fee Rate</p></td><td style="vertical-align:bottom;width:7.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Amount of<br>Registration Fee</p></td><td style="vertical-align:bottom;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Carry<br>Forward<br>Form<br>Type</p></td><td style="vertical-align:bottom;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Carry<br>Forward<br>File<br>Number</p></td><td style="vertical-align:bottom;width:5.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Carry<br>Forward<br>Initial<br>effective<br>date</p></td><td style="vertical-align:bottom;width:6.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Filing Fee<br>Previously<br>Paid In<br>Connection<br>with Unsold<br>Securities to<br>be Carried<br>Forward</p></td></tr><tr style="height:13pt;"><td colspan="13" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Newly Registered Securities</p></td></tr><tr style="height:57.35pt;"><td style="vertical-align:middle;width:8.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Fees to Be Paid</p></td><td style="vertical-align:middle;width:5.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Equity</p></td><td style="vertical-align:middle;width:17.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Common Stock, $0.001 par value per share</p></td><td style="vertical-align:middle;width:6.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Other</p></td><td style="vertical-align:middle;width:9.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">2,128,952,453 (1)</p></td><td style="vertical-align:middle;width:6.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(2)</p></td><td style="vertical-align:middle;width:7.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$70,965.08 (2)</p></td><td style="vertical-align:middle;width:8.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$0.00015310</p></td><td style="vertical-align:middle;width:7.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$10.87</p></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr style="height:35.5pt;"><td style="vertical-align:middle;width:8.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Fees Previously Paid</p></td><td style="vertical-align:middle;width:5.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:17.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:6.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:9.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:6.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:7.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:8.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:7.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr style="height:13pt;"><td colspan="13" style="vertical-align:middle;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Carry Forward Securities</p></td></tr><tr style="height:35.5pt;"><td style="vertical-align:middle;width:8.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Carry Forward Securities</p></td><td style="vertical-align:middle;width:5.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:17.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:6.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:9.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:6.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:7.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:8.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:7.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:5.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:6.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td></tr><tr style="height:13pt;"><td style="vertical-align:middle;width:8.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:middle;width:39.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 7.2pt 0pt 0pt;">Total Offering Amounts</p></td><td style="vertical-align:middle;width:6.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:7.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$70,965.08 (2)</p></td><td style="vertical-align:middle;width:8.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:7.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$10.87</p></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr style="height:13pt;"><td style="vertical-align:middle;width:8.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:middle;width:39.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 7.2pt 0pt 0pt;">Total Fees Previously Paid</p></td><td style="vertical-align:middle;width:6.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:7.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:8.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:7.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr style="height:13pt;"><td style="vertical-align:middle;width:8.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:middle;width:39.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 7.2pt 0pt 0pt;">Total Fee Offsets</p></td><td style="vertical-align:middle;width:6.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:7.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:8.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:7.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">-</p></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr style="height:13pt;"><td style="vertical-align:middle;width:8.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="4" style="vertical-align:middle;width:39.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 7.2pt 0pt 0pt;">Net Fee Due</p></td><td style="vertical-align:middle;width:6.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:7.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:8.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:7.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$10.87</p></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:6.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:27.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Relates to common stock, $0.001 par value per share, of GlycoMimetics, Inc., a Delaware corporation (&#8220;GlycoMimetics&#8221;), issuable to holders of common stock, $0.0001 par value per share, of Crescent Biopharma, Inc., a Delaware corporation (&#8220;Crescent&#8221;), in the proposed merger of Gemini Merger Sub Corp., a Delaware corporation and a direct, wholly owned subsidiary of GlycoMimetics, with and into Crescent, with Crescent surviving the merger, and as part of the same overall transaction, Crescent will merge with and into Gemini Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Crescent, with Gemini Merger Sub II, LLC continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the merger. The amount of common stock of GlycoMimetics to be registered includes the estimated maximum number of shares of common stock of GlycoMimetics that are expected to be issued (or become issuable) pursuant to the merger, without taking into account the effect of a reverse stock split of common stock of GlycoMimetics, assuming an estimated pre-split exchange ratio (which is subject to adjustment prior to the closing of the merger) of approximately 14.9149 shares of common stock of GlycoMimetics for each outstanding share of common stock of Crescent.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:27.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) of the U.S. Securities Act of 1933, as amended. Crescent is a private company, no market exists for its securities, and it has an accumulated capital deficit. Therefore, the proposed maximum aggregate offering price for the shares expected to be issued pursuant to the merger is one-third of the aggregate par value of the Crescent securities expected to be exchanged in the proposed merger.</p></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>25
<FILENAME>glyc-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/18/2025 9:22:04 PM-->
<!--Modified on: 2/18/2025 9:22:04 PM-->
<xsd:schema targetNamespace="http://glyc.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt="http://fasb.org/srt/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:attributeFormDefault="unqualified" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:glyc="http://glyc.com/20241231">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://glyc.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>40501 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetailsCalc2" id="DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetailsCalc2">
        <link:definition>40603 - Disclosure - Operating leases - Maturities of lease liability (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" id="DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails">
        <link:definition>40702 - Disclosure - Operating Leases - Components of lease expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" id="DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails">
        <link:definition>40703 - Disclosure - Operating Leases - Maturities of lease liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" id="DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail">
        <link:definition>41001 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" id="DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail">
        <link:definition>41003 - Disclosure - Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30903 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureDescriptionOfBusinessDetails" id="DisclosureDescriptionOfBusinessDetails">
        <link:definition>40101 - Disclosure - Description of the Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails">
        <link:definition>40302 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails">
        <link:definition>40304 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails">
        <link:definition>40305 - Disclosure - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureNetLossPerCommonShareDetails" id="DisclosureNetLossPerCommonShareDetails">
        <link:definition>40401 - Disclosure - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeasesDetails" id="DisclosureOperatingLeasesDetails">
        <link:definition>40701 - Disclosure - Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails" id="DisclosureStockholdersEquityEquityOfferingsDetails">
        <link:definition>40801 - Disclosure - Stockholders' Equity - Equity Offerings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails" id="DisclosureStockBasedCompensationIncentivePlansDetails">
        <link:definition>40901 - Disclosure - Stock-based Compensation - Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails" id="DisclosureStockBasedCompensationCompanySStockOptionActivityDetails">
        <link:definition>40902 - Disclosure - Stock-based Compensation - Company's Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails" id="DisclosureStockBasedCompensationSummaryOfRsuActivityDetails">
        <link:definition>40903 - Disclosure - Stock-based Compensation - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails" id="DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails">
        <link:definition>40904 - Disclosure - Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails" id="DisclosureStockBasedCompensationInducementPlanDetails">
        <link:definition>40905 - Disclosure - Stock-based Compensation - Inducement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails" id="DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails">
        <link:definition>40906 - Disclosure - Stock-based Compensation - Inducement Plan - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" id="DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails">
        <link:definition>40907 - Disclosure - Stock-based Compensation - Weighted-Average assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>40908 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail" id="DisclosureIncomeTaxesNolsAndCarryforwardsDetail">
        <link:definition>41002 - Disclosure - Income Taxes - NOLs and carryforwards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail" id="DisclosureEmployeeBenefitPlanDetail">
        <link:definition>41201 - Disclosure - Employee Benefit Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails" id="DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails">
        <link:definition>41302 - Disclosure - Restructuring and Asset Impairment Charges - Severance cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureDescriptionOfBusiness" id="DisclosureDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureGoingConcern" id="DisclosureGoingConcern">
        <link:definition>10201 - Disclosure - Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock" id="DisclosureNetLossPerShareOfCommonStock">
        <link:definition>10401 - Disclosure - Net Loss Per Share of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>10501 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10601 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeases" id="DisclosureOperatingLeases">
        <link:definition>10701 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10801 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10901 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11001 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureResearchAndLicenseAgreements" id="DisclosureResearchAndLicenseAgreements">
        <link:definition>11101 - Disclosure - Research and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
        <link:definition>11201 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentCharges" id="DisclosureRestructuringAndAssetImpairmentCharges">
        <link:definition>11301 - Disclosure - Restructuring and Asset Impairment Charges</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables" id="DisclosureNetLossPerShareOfCommonStockTables">
        <link:definition>30403 - Disclosure - Net Loss Per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30603 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeasesTables" id="DisclosureOperatingLeasesTables">
        <link:definition>30703 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31003 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesTables" id="DisclosureRestructuringAndAssetImpairmentChargesTables">
        <link:definition>31303 - Disclosure - Restructuring and Asset Impairment Charges (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureGoingConcernDetails" id="DisclosureGoingConcernDetails">
        <link:definition>40201 - Disclosure - Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestructuringAndSegmentInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRestructuringAndSegmentInformationDetails">
        <link:definition>40301 - Disclosure - Summary of Significant Accounting Policies - Restructuring and Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" id="DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails">
        <link:definition>40601 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeasesSupplementalInformationDetails" id="DisclosureOperatingLeasesSupplementalInformationDetails">
        <link:definition>40704 - Disclosure - Operating Leases - Supplemental Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesDetails" id="DisclosureRestructuringAndAssetImpairmentChargesDetails">
        <link:definition>41301 - Disclosure - Restructuring and Asset Impairment Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20241231_pre.xml" xlink:title="Presentation Links, all" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20241231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20241231_def.xml" xlink:title="Definition Links, all" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20241231_lab.xml" xlink:title="Label Links, all" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://glyc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:element name="DeferredTaxAssetsCapitalizedStartUpCosts" id="glyc_DeferredTaxAssetsCapitalizedStartUpCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetsPatentAmortization" id="glyc_DeferredTaxAssetsPatentAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" id="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" id="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="EmployeeStockOptionsAndRestrictedStockUnitsMember" id="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquityIncentivePlan2013Member" id="glyc_EquityIncentivePlan2013Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" id="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" id="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchAndLicenseAgreementTextBlock" id="glyc_ResearchAndLicenseAgreementTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FederalAndStateAuthoritiesMember" id="glyc_FederalAndStateAuthoritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockValueAvailableForSaleUnderAgreement" id="glyc_CommonStockValueAvailableForSaleUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetsResearchAndOrphanDrugCredits" id="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ResearchAndLicenseAgreementsAbstract" id="glyc_ResearchAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" id="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingLeaseNumberOfNewLeases" id="glyc_LesseeOperatingLeaseNumberOfNewLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInOperatingLeaseLiabilities" id="glyc_IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RockvilleMarylandMember" id="glyc_RockvilleMarylandMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetsAccruedBonus" id="glyc_DeferredTaxAssetsAccruedBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" id="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" id="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="EquityInducementPlanMember" id="glyc_EquityInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" id="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" id="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" id="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NetIncomeLossAndComprehensiveIncomeNetOfTax" id="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" id="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" id="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockOptionsVestingBasedOnPerformanceMember" id="glyc_StockOptionsVestingBasedOnPerformanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" id="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="GoingConcernAbstract" id="glyc_GoingConcernAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" id="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AtMarketOffering2022Member" id="glyc_AtMarketOffering2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee" id="glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedPaymentArrangementNewlyHiredEmployeeMember" id="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetsCapitalizedResearchCosts" id="glyc_DeferredTaxAssetsCapitalizedResearchCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SquareFeetLeased" id="glyc_SquareFeetLeased" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="FirstPortionSquareFeetRockvilleMarylandMember" id="glyc_FirstPortionSquareFeetRockvilleMarylandMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SecondPortionSquareFeetRockvilleMarylandMember" id="glyc_SecondPortionSquareFeetRockvilleMarylandMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LeaseQuantitativeDisclosureTableTextBlock" id="glyc_LeaseQuantitativeDisclosureTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OtherAwardsMember" id="glyc_OtherAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" id="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PriorToClosingOfPrivatePlacementMember" id="glyc_PriorToClosingOfPrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CrescentBiopharmaIncMember" id="glyc_CrescentBiopharmaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PostClosingOfPrivatePlacementMember" id="glyc_PostClosingOfPrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing" id="glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SaleOfStockAggregatePurchasePrice" id="glyc_SaleOfStockAggregatePurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GlycoMimeticsIncMember" id="glyc_GlycoMimeticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts" id="glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent" id="glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>26
<FILENAME>glyc-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/18/2025 9:22:04 PM-->
<!--Modified on: 2/18/2025 9:22:04 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#StatementBalanceSheets" roleURI="http://glyc.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#StatementStatementsOfCashFlows" roleURI="http://glyc.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetailsCalc2" roleURI="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails" xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationCompanySStockOptionActivityDetails" />
  <link:roleRef roleURI="http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" />
  <link:roleRef roleURI="http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails" xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationSummaryOfRsuActivityDetails" />
  <link:roleRef roleURI="http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <calculationLink xlink:role="http://glyc.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638755105221140170" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638755105221140170" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638755105221140170" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638755105221140170" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638755105221140170" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638755105221140170" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638755105221140170" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638755105221140170" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_638755105221140170" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent_638755105221140170" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_638755105221140170" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssets_638755105221140170" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638755105221140170" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638755105221140170" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638755105221150143" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638755105221150143" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638755105221150143" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638755105221150143" xlink:to="us-gaap_LiabilitiesCurrent_638755105221150143" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638755105221150143" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638755105221150143" xlink:to="us-gaap_AccountsPayableCurrent_638755105221150143" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638755105221150143" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638755105221150143" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638755105221150143" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638755105221150143" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638755105221150143" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638755105221150143" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638755105221150143" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638755105221150143" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638755105221150143" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638755105221160145" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638755105221160145" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638755105221160145" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638755105221160145" xlink:to="us-gaap_PreferredStockValue_638755105221160145" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638755105221160145" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638755105221160145" xlink:to="us-gaap_CommonStockValue_638755105221160145" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638755105221160145" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638755105221160145" xlink:to="us-gaap_AdditionalPaidInCapital_638755105221160145" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638755105221160145" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638755105221160145" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638755105221160145" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:label="NetIncomeLossAndComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638755105221170137" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NonoperatingIncomeExpense_638755105221170137" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638755105221170137" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638755105221170137" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638755105221170137" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_638755105221170137" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638755105221170137" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_638755105221170137" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638755105221170137" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OperatingIncomeLoss_638755105221170137" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638755105221170137" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638755105221170137" xlink:to="us-gaap_OperatingExpenses_638755105221170137" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentCharges_638755105221180301" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638755105221170137" xlink:to="us-gaap_RestructuringCostsAndAssetImpairmentCharges_638755105221180301" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638755105221180301" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638755105221170137" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638755105221180301" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638755105221180301" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638755105221170137" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638755105221180301" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638755105221180301" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638755105221170137" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638755105221180301" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638755105221190148" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" xlink:to="us-gaap_ProfitLoss_638755105221190148" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638755105221190148" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" xlink:to="us-gaap_Depreciation_638755105221190148" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638755105221190148" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638755105221190148" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_638755105221190148" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_638755105221190148" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638755105221190148" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638755105221190148" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_638755105221190148" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_638755105221190148" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638755105221200140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" xlink:to="us-gaap_ShareBasedCompensation_638755105221200140" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638755105221200140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638755105221200140" order="8" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" xlink:label="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_638755105221200140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" xlink:to="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_638755105221200140" order="9" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638755105221200140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638755105221200140" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638755105221200140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638755105221200140" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_638755105221210138" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105221190148" xlink:to="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_638755105221210138" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638755105221210138" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638755105221210138" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638755105221210138" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638755105221210138" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638755105221210138" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638755105221210138" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638755105221210138" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638755105221210138" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638755105221210138" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638755105221210138" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638755105221210138" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638755105221210138" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638755105221210138" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638755105221220136" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638755105221210138" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638755105221220136" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638755105221220136" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_638755105221220136" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638755105221220136" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_638755105221220136" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638755105221230155" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638755105221230155" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetailsCalc2" xlink:type="extended" xlink:title="40603 - Disclosure - Operating leases - Maturities of lease liability (Details) Calc 2" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638755105221230155" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638755105221230155" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638755105221230155" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638755105221230155" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Operating Leases - Components of lease expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638755105221230155" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638755105221230155" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638755105221240144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_VariableLeaseCost_638755105221240144" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Operating Leases - Maturities of lease liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638755105221240144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638755105221240144" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" xlink:type="extended" xlink:title="41001 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638755105221240144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638755105221240144" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638755105221240144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638755105221240144" xlink:to="us-gaap_DeferredTaxAssetsGross_638755105221240144" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638755105221250144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638755105221240144" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638755105221250144" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_638755105221250144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638755105221240144" xlink:to="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_638755105221250144" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsCapitalizedResearchCosts" xlink:label="glyc_DeferredTaxAssetsCapitalizedResearchCosts_638755105221250144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638755105221240144" xlink:to="glyc_DeferredTaxAssetsCapitalizedResearchCosts_638755105221250144" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsPatentAmortization" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_638755105221250144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638755105221240144" xlink:to="glyc_DeferredTaxAssetsPatentAmortization_638755105221250144" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits" xlink:label="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_638755105221250144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638755105221240144" xlink:to="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_638755105221250144" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" xlink:label="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_638755105221250144" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638755105221240144" xlink:to="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_638755105221250144" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_638755105221260219" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638755105221240144" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_638755105221260219" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsAccruedBonus" xlink:label="glyc_DeferredTaxAssetsAccruedBonus_638755105221260219" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638755105221240144" xlink:to="glyc_DeferredTaxAssetsAccruedBonus_638755105221260219" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638755105221260219" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638755105221240144" xlink:to="us-gaap_DeferredTaxAssetsOther_638755105221260219" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638755105221260219" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638755105221240144" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638755105221260219" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638755105221510140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638755105221510140" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" xlink:label="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_638755105221510140" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638755105221510140" xlink:to="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_638755105221510140" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638755105221520154" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638755105221520154" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638755105221520154" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638755105221520154" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638755105221520154" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638755105221520154" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_638755105221520154" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_638755105221520154" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent" xlink:label="glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent_638755105221520154" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent_638755105221520154" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638755105221530150" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638755105221530150" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638755105221530150" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638755105221530150" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638755105221530150" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638755105221530150" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>27
<FILENAME>glyc-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/18/2025 9:22:04 PM-->
<!--Modified on: 2/18/2025 9:22:04 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://glyc.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureDescriptionOfBusinessDetails" roleURI="http://glyc.com/role/DisclosureDescriptionOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureNetLossPerCommonShareDetails" roleURI="http://glyc.com/role/DisclosureNetLossPerCommonShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureOperatingLeasesDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockholdersEquityEquityOfferingsDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationIncentivePlansDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationCompanySStockOptionActivityDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationSummaryOfRsuActivityDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationInducementPlanDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureIncomeTaxesNolsAndCarryforwardsDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureEmployeeBenefitPlanDetail" roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails" roleURI="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://glyc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract" xlink:label="LiabilitiesAbstract" xlink:title="LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="definition: LiabilitiesAbstract to OperatingLeaseLiabilityCurrent" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="definition: LiabilitiesAbstract to OperatingLeaseLiabilityNoncurrent" use="optional" priority="0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:title="us-gaap_RestructuringCostsAndAssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RestructuringCostsAndAssetImpairmentCharges" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_RestructuringCostsAndAssetImpairmentCharges" order="70" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://glyc.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="CumulativeEffectPeriodOfAdoptionAxis" xlink:title="CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CumulativeEffectPeriodOfAdoptionAxis" xlink:to="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="definition: CumulativeEffectPeriodOfAdoptionAxis to CumulativeEffectPeriodOfAdoptionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="definition: VestingAxis to VestingDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="GranteeStatusAxis" xlink:title="GranteeStatusAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="GranteeStatusDomain" xlink:title="GranteeStatusDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GranteeStatusAxis" xlink:to="GranteeStatusDomain" xlink:title="definition: GranteeStatusAxis to GranteeStatusDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:title="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" xlink:title="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_1 To us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_1" xlink:title="us-gaap_RestructuringCostAndReserveAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_1" xlink:title="us-gaap_TypeOfRestructuringDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestructuringCostAndReserveAxis_1" xlink:to="us-gaap_TypeOfRestructuringDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestructuringCostAndReserveAxis_1 To us-gaap_TypeOfRestructuringDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" xlink:to="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" xlink:to="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stock-based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityIncentivePlan2013Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityInducementPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureDescriptionOfBusinessDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of the Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_PriorToClosingOfPrivatePlacementMember" xlink:label="glyc_PriorToClosingOfPrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="glyc_PriorToClosingOfPrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_PostClosingOfPrivatePlacementMember" xlink:label="glyc_PostClosingOfPrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="glyc_PostClosingOfPrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_CrescentBiopharmaIncMember" xlink:label="glyc_CrescentBiopharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="glyc_CrescentBiopharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_GlycoMimeticsIncMember" xlink:label="glyc_GlycoMimeticsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_OwnershipDomain" xlink:to="glyc_GlycoMimeticsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing" xlink:label="glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_SaleOfStockAggregatePurchasePrice" xlink:label="glyc_SaleOfStockAggregatePurchasePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="glyc_SaleOfStockAggregatePurchasePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureNetLossPerCommonShareDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Net Loss Per Common Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Operating Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_RockvilleMarylandMember" xlink:label="glyc_RockvilleMarylandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="glyc_RockvilleMarylandMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_FirstPortionSquareFeetRockvilleMarylandMember" xlink:label="glyc_FirstPortionSquareFeetRockvilleMarylandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="glyc_FirstPortionSquareFeetRockvilleMarylandMember" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_SecondPortionSquareFeetRockvilleMarylandMember" xlink:label="glyc_SecondPortionSquareFeetRockvilleMarylandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="glyc_SecondPortionSquareFeetRockvilleMarylandMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" xlink:label="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_SquareFeetLeased" xlink:label="glyc_SquareFeetLeased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="glyc_SquareFeetLeased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_LesseeOperatingLeaseNumberOfNewLeases" xlink:label="glyc_LesseeOperatingLeaseNumberOfNewLeases" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="glyc_LesseeOperatingLeaseNumberOfNewLeases" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stockholders' Equity - Equity Offerings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_AtMarketOffering2022Member" xlink:label="glyc_AtMarketOffering2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="glyc_AtMarketOffering2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_CommonStockValueAvailableForSaleUnderAgreement" xlink:label="glyc_CommonStockValueAvailableForSaleUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="glyc_CommonStockValueAvailableForSaleUnderAgreement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock-based Compensation - Incentive Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityIncentivePlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockOptionsVestingBasedOnPerformanceMember" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="glyc_StockOptionsVestingBasedOnPerformanceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" xlink:label="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stock-based Compensation - Company's Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityIncentivePlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" xlink:label="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockOptionsVestingBasedOnPerformanceMember" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="glyc_StockOptionsVestingBasedOnPerformanceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stock-based Compensation - Summary of RSU Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityIncentivePlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_OtherAwardsMember" xlink:label="glyc_OtherAwardsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="glyc_OtherAwardsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Stock-based Compensation - Inducement Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityInducementPlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockOptionsVestingBasedOnPerformanceMember" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="glyc_StockOptionsVestingBasedOnPerformanceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" xlink:label="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Stock-based Compensation - Inducement Plan - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityInducementPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40908 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail" xlink:type="extended" xlink:title="41002 - Disclosure - Income Taxes - NOLs and carryforwards (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_FederalAndStateAuthoritiesMember" xlink:label="glyc_FederalAndStateAuthoritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="glyc_FederalAndStateAuthoritiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_GeneralBusinessMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail" xlink:type="extended" xlink:title="41201 - Disclosure - Employee Benefit Plan (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Restructuring and Asset Impairment Charges - Severance cost (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>28
<FILENAME>glyc-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/18/2025 9:22:04 PM-->
<!--Modified on: 2/18/2025 9:22:04 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities &amp; stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities, net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at September 30, 2024 and December 31, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock; $0.001 par value; 150,000,000 shares authorized at September 30, 2024; 100,000,000 shares authorized at December 31, 2023; 64,483,958 shares issued and outstanding at September 30, 2024; 64,393,744 shares issued and outstanding at December 31, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Including Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from collaboration and license agreements.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:to="us-gaap_RestructuringCostsAndAssetImpairmentCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Costs and Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and asset impairment charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total costs and expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on sale of asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Nonoperating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:to="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The portion of profit or loss and comprehensive income for the period, net of income taxes, which is attributable to the parent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Loss And Comprehensive Income Net Of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss and comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per common share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per common share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic weighted-average number of common shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted weighted-average number of common shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for services, shares</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" xlink:to="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of share options and warrants and vesting of stock units exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Stock Options And Warrants And Restricted Stock Units Vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options and vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" xlink:to="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options and warrants and vesting of stock units exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Stock Options And Warrants And Restricted Stock Units Vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options and vesting of restricted stock units, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of issuance costs, shares</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" xlink:to="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of share options and vesting of stock units exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Stock Options And Restricted Stock Units Vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options and vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" xlink:to="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options and vesting of stock units exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Stock Options And Restricted Stock Units Vesting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options and vesting of restricted stock units, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Stock and Warrants for Services or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" xlink:label="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" xlink:to="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in prepaid research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Prepaid Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="glyc_IncreaseDecreaseInOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flows used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of the Business</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_GoingConcernAbstract" xlink:label="glyc_GoingConcernAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_GoingConcernAbstract" xlink:to="glyc_GoingConcernAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_GoingConcernAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_GoingConcernAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Going Concern</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Substantial Doubt about Going Concern [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Going Concern</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share of Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share of Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Assets [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ResearchAndLicenseAgreementsAbstract" xlink:label="glyc_ResearchAndLicenseAgreementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ResearchAndLicenseAgreementsAbstract" xlink:to="glyc_ResearchAndLicenseAgreementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ResearchAndLicenseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ResearchAndLicenseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and License Agreements</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ResearchAndLicenseAgreementTextBlock" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ResearchAndLicenseAgreementTextBlock" xlink:to="glyc_ResearchAndLicenseAgreementTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for research services and license agreements, including contracts and arrangements to be performed by or for others. Includes contingent payment receivables or liabilities for achievement of specific milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And License Agreement Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and License Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" xlink:to="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Asset Impairment Charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring, Impairment, and Other Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Asset Impairment Charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" xlink:label="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" xlink:to="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy pertaining to new accounting pronouncements that have been adopted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements Adopted Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Adopted Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive securities outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of lease expense and related cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturities of lease liabilities due</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_LeaseQuantitativeDisclosureTableTextBlock" xlink:label="glyc_LeaseQuantitativeDisclosureTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_LeaseQuantitativeDisclosureTableTextBlock" xlink:to="glyc_LeaseQuantitativeDisclosureTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_LeaseQuantitativeDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of supplemental information related to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_LeaseQuantitativeDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Quantitative Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_LeaseQuantitativeDisclosureTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of supplemental information related to leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_EquityIncentivePlan2013Member" xlink:to="glyc_EquityIncentivePlan2013Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_EquityIncentivePlan2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertaining to the 2013 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_EquityIncentivePlan2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2013 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_EquityIncentivePlan2013Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2013 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_EquityInducementPlanMember" xlink:to="glyc_EquityInducementPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_EquityInducementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to inducement plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_EquityInducementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Inducement Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_EquityInducementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of the Company's stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of RSU activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted-average fair value of options granted under all equity incentive plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of the gross deferred tax asset and related valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of activity for accrued severance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Cost [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_PriorToClosingOfPrivatePlacementMember" xlink:label="glyc_PriorToClosingOfPrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_PriorToClosingOfPrivatePlacementMember" xlink:to="glyc_PriorToClosingOfPrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_PriorToClosingOfPrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the scenario prior to the closing of the private placement as per the terms of the merger agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_PriorToClosingOfPrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior to Closing of Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_PriorToClosingOfPrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior to closing of private placement</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_PostClosingOfPrivatePlacementMember" xlink:label="glyc_PostClosingOfPrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_PostClosingOfPrivatePlacementMember" xlink:to="glyc_PostClosingOfPrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_PostClosingOfPrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the scenario post the closing of the private placement as per the terms of the merger agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_PostClosingOfPrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Post the Closing of Private Placement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_CrescentBiopharmaIncMember" xlink:label="glyc_CrescentBiopharmaIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_CrescentBiopharmaIncMember" xlink:to="glyc_CrescentBiopharmaIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_CrescentBiopharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Crescent Biopharma Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_CrescentBiopharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Crescent Biopharma Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_CrescentBiopharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Crescent Biopharma, Inc.</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_GlycoMimeticsIncMember" xlink:label="glyc_GlycoMimeticsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_GlycoMimeticsIncMember" xlink:to="glyc_GlycoMimeticsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_GlycoMimeticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to GlycoMimetics, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_GlycoMimeticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GlycoMimetics, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_GlycoMimeticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GlycoMimetics, Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Cost and Reserve [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of reduction in workforce under corporate restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Ownership Percentage, Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Parent ownership (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Ownership Percentage, Noncontrolling Owner</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling ownership (as percentage)</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing" xlink:label="glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing" xlink:to="glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum net cash of the company at the closing of the merger for the determination of the exchange ratio of shares as per the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger Agreement, Exchange Ratio Determination, Maximum Net Cash at Closing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash at closing of the merger</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_SaleOfStockAggregatePurchasePrice" xlink:label="glyc_SaleOfStockAggregatePurchasePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_SaleOfStockAggregatePurchasePrice" xlink:to="glyc_SaleOfStockAggregatePurchasePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_SaleOfStockAggregatePurchasePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate value of shares and warrants to be issued by the entity as per the stock transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_SaleOfStockAggregatePurchasePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock, Aggregate Purchase Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_SaleOfStockAggregatePurchasePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate purchase price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts" xlink:label="glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts" xlink:to="glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of positions remaining after restructuring and related activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Positions Remaining After Restructuring and Related Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of positions remaining after restructuring and related activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets measured at fair value levels 2 or 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities measured at fair value levels 2 or 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value of cash held in money market fund</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Disclosure</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:to="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information related to stock options and restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Options And Restricted Stock Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options and restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive securities excluded from computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_RockvilleMarylandMember" xlink:label="glyc_RockvilleMarylandMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_RockvilleMarylandMember" xlink:to="glyc_RockvilleMarylandMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_RockvilleMarylandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertaining to Rockville, Maryland.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_RockvilleMarylandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rockville Maryland [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_RockvilleMarylandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rockville, Maryland</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_FirstPortionSquareFeetRockvilleMarylandMember" xlink:label="glyc_FirstPortionSquareFeetRockvilleMarylandMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_FirstPortionSquareFeetRockvilleMarylandMember" xlink:to="glyc_FirstPortionSquareFeetRockvilleMarylandMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_FirstPortionSquareFeetRockvilleMarylandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertaining to first portion of the Rockville, Maryland lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_FirstPortionSquareFeetRockvilleMarylandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Portion Square Feet Rockville, Maryland [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_FirstPortionSquareFeetRockvilleMarylandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First portion of Rockville, Maryland lease</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_SecondPortionSquareFeetRockvilleMarylandMember" xlink:label="glyc_SecondPortionSquareFeetRockvilleMarylandMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_SecondPortionSquareFeetRockvilleMarylandMember" xlink:to="glyc_SecondPortionSquareFeetRockvilleMarylandMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_SecondPortionSquareFeetRockvilleMarylandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertaining to second portion of the Rockville, Maryland lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_SecondPortionSquareFeetRockvilleMarylandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Portion Square Feet Rockville, Maryland [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_SecondPortionSquareFeetRockvilleMarylandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second portion of Rockville, Maryland lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Description [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" xlink:label="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" xlink:to="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Practical Expedient, Lessor Single Lease Component [true false]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_SquareFeetLeased" xlink:label="glyc_SquareFeetLeased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_SquareFeetLeased" xlink:to="glyc_SquareFeetLeased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_SquareFeetLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Square feet leased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_SquareFeetLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Square Feet Leased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_SquareFeetLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Square feet leased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_LesseeOperatingLeaseNumberOfNewLeases" xlink:label="glyc_LesseeOperatingLeaseNumberOfNewLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_LesseeOperatingLeaseNumberOfNewLeases" xlink:to="glyc_LesseeOperatingLeaseNumberOfNewLeases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_LesseeOperatingLeaseNumberOfNewLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of additional operating leases entered into during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_LesseeOperatingLeaseNumberOfNewLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Number Of New Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_LesseeOperatingLeaseNumberOfNewLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional operating leases entered during the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Operating Activities, Lessee [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash outflows for operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of lease liability due</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:to="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due After Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average incremental borrowing rate</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_AtMarketOffering2022Member" xlink:label="glyc_AtMarketOffering2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AtMarketOffering2022Member" xlink:to="glyc_AtMarketOffering2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AtMarketOffering2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertains to the sale of common stock under an at-the-market sales agreement under a shelf registration statement filed in March 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AtMarketOffering2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Market Offering 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AtMarketOffering2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022 Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate net proceeds from stock sale</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_CommonStockValueAvailableForSaleUnderAgreement" xlink:label="glyc_CommonStockValueAvailableForSaleUnderAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_CommonStockValueAvailableForSaleUnderAgreement" xlink:to="glyc_CommonStockValueAvailableForSaleUnderAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_CommonStockValueAvailableForSaleUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of common stock remaining available to be sold under the terms of the agreement at the end of the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_CommonStockValueAvailableForSaleUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Value Available For Sale Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_CommonStockValueAvailableForSaleUnderAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock available for sale under agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upon first anniversary of start date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Each month after the first anniversary</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Award Types</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockOptionsVestingBasedOnPerformanceMember" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_StockOptionsVestingBasedOnPerformanceMember" xlink:to="glyc_StockOptionsVestingBasedOnPerformanceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents a stock option award with vesting based on achievement of performance conditions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options Vesting Based On Performance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options vesting based on performance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" xlink:label="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" xlink:to="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Newly hired recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Newly Hired Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Newly hired employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of shares subject to option grant that will vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of monthly installments for Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition. Includes, but is not limited to, combination of market, performance or service condition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Number of Monthly Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of monthly installments</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Expiration Period After Termination Of Employment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period from date of termination that any vested options shall expire</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense related to unvested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for unrecognized compensation expense related to unvested options yet has not been recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intrinsic value of options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued from exercise of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of shares vested</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum fair value of option excluded from the unrecognized compensation expense under the share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Fair Value Of Option Excluded From Unrecognized Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum fair value of option excluded from the unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Authorized Shares Disclosure Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future grants</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation arrangement by share based payment award number of maximum shares issued upon exercise of incentive stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number Of Maximum Shares Issued Upon Exercise Of Incentive Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of shares that may be issued pursuant to exercise of incentive stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in number of shares of common stock</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee" xlink:to="glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of shares of common stock issued and outstanding on the immediately preceding fiscal year, or such lesser number of shares as determined by the board of directors or the compensation committee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Total Number Of Common Stock Stock Issued Or Outstanding Immediately Preceding Fiscal Year Or Lesser Number As Determined By Board Of Directors Or Compensation Committee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of shares of common stock issued and outstanding on the immediately preceding fiscal year, or such lesser number of shares as determined by the board of directors or the compensation committee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OUTSTANDING OPTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WEIGHTED-AVERAGE EXERCISE PRICE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">VESTED AND EXPECTED TO VEST</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADDITIONAL DISCLOSURES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding options exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average exercise price exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average contractual term outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average contractual term (years) exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense related to unvested service RSUs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense related to unvested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NUMBER OF SHARES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WEIGHTED-AVERAGE GRANT DATE FAIR VALUE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonemployee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-employee</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_OtherAwardsMember" xlink:label="glyc_OtherAwardsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_OtherAwardsMember" xlink:to="glyc_OtherAwardsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_OtherAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to other awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_OtherAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Awards [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_OtherAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title and Position [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title and Position [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average fair value of the options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforward</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits" xlink:label="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits" xlink:to="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from research and orphan drug credits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Research And Orphan Drug Credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and orphan drug credits</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsCapitalizedResearchCosts" xlink:label="glyc_DeferredTaxAssetsCapitalizedResearchCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetsCapitalizedResearchCosts" xlink:to="glyc_DeferredTaxAssetsCapitalizedResearchCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetsCapitalizedResearchCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences capitalized research costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetsCapitalizedResearchCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Capitalized Research Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetsCapitalizedResearchCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research costs</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:to="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences capitalized start up costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Capitalized Start Up Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized start-up costs</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsPatentAmortization" xlink:label="glyc_DeferredTaxAssetsPatentAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetsPatentAmortization" xlink:to="glyc_DeferredTaxAssetsPatentAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences patent amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Patent Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsAccruedBonus" xlink:label="glyc_DeferredTaxAssetsAccruedBonus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetsAccruedBonus" xlink:to="glyc_DeferredTaxAssetsAccruedBonus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetsAccruedBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Accrued bonus.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetsAccruedBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Accrued Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetsAccruedBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued bonus</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" xlink:label="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" xlink:to="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Deferred Expense Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred income tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred income tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" xlink:label="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" xlink:to="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from operating lease right-of-use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities Tax Deferred Expense Operating Lease Liabilities Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred income tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred income tax asset/(liability)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_FederalAndStateAuthoritiesMember" xlink:label="glyc_FederalAndStateAuthoritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_FederalAndStateAuthoritiesMember" xlink:to="glyc_FederalAndStateAuthoritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_FederalAndStateAuthoritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Designated tax department of the U. S. government and the designated tax department of the state government entitled to levy and collect income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_FederalAndStateAuthoritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal And State Authorities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_FederalAndStateAuthoritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Federal And State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralBusinessMember" xlink:to="us-gaap_GeneralBusinessMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralBusinessMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General Business Tax Credit Carryforward [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralBusinessMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General Business Tax Credit Carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credits available to carry forward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Federal statutory tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research credit</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:to="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Orphan drug credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent" xlink:label="glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent" xlink:to="glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to executive compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive Compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company matching contribution percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of employee contributions the company contributes a matching contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer match contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Number of Positions Eliminated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in workforce under corporate restructuring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total charges in headcount reduction under corporate restructuring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="us-gaap_RestructuringReserveAcceleratedDepreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="us-gaap_RestructuringReserveAcceleratedDepreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveAcceleratedDepreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Cost, Accelerated Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveAcceleratedDepreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment charges related to our facility operating lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Restructuring [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Severance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeSeveranceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee severance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance accrual, December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance accrual, January 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Restructuring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payments</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>29
<FILENAME>glyc-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/18/2025 9:22:04 PM-->
<!--Modified on: 2/18/2025 9:22:04 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://glyc.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#StatementBalanceSheets" roleURI="http://glyc.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://glyc.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://glyc.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#StatementStatementsOfCashFlows" roleURI="http://glyc.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureDescriptionOfBusiness" roleURI="http://glyc.com/role/DisclosureDescriptionOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureGoingConcern" roleURI="http://glyc.com/role/DisclosureGoingConcern" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureNetLossPerShareOfCommonStock" roleURI="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureAccruedExpenses" roleURI="http://glyc.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureOperatingLeases" roleURI="http://glyc.com/role/DisclosureOperatingLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockholdersEquity" roleURI="http://glyc.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensation" roleURI="http://glyc.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureIncomeTaxes" roleURI="http://glyc.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureResearchAndLicenseAgreements" roleURI="http://glyc.com/role/DisclosureResearchAndLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureEmployeeBenefitPlan" roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureRestructuringAndAssetImpairmentCharges" roleURI="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureNetLossPerShareOfCommonStockTables" roleURI="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureAccruedExpensesTables" roleURI="http://glyc.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureOperatingLeasesTables" roleURI="http://glyc.com/role/DisclosureOperatingLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureIncomeTaxesTables" roleURI="http://glyc.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureRestructuringAndAssetImpairmentChargesTables" roleURI="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureDescriptionOfBusinessDetails" roleURI="http://glyc.com/role/DisclosureDescriptionOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureGoingConcernDetails" roleURI="http://glyc.com/role/DisclosureGoingConcernDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRestructuringAndSegmentInformationDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestructuringAndSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureNetLossPerCommonShareDetails" roleURI="http://glyc.com/role/DisclosureNetLossPerCommonShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" roleURI="http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureOperatingLeasesDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureOperatingLeasesSupplementalInformationDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesSupplementalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockholdersEquityEquityOfferingsDetails" roleURI="http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationIncentivePlansDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationCompanySStockOptionActivityDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationSummaryOfRsuActivityDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationInducementPlanDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureIncomeTaxesNolsAndCarryforwardsDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureEmployeeBenefitPlanDetail" roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureRestructuringAndAssetImpairmentChargesDetails" roleURI="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="glyc-20241231.xsd#DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails" roleURI="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://glyc.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638755105222370157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638755105222370157" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638755105222370157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638755105222370157" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638755105222370157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638755105222370157" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638755105222370157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638755105222370157" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638755105222370157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638755105222370157" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638755105222380150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638755105222380150" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638755105222380150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638755105222380150" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638755105222380150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638755105222380150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638755105222380150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638755105222380150" xlink:to="us-gaap_AssetsCurrentAbstract_638755105222380150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638755105222380150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638755105222380150" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638755105222380150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638755105222380150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638755105222380150" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638755105222380150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638755105222380150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638755105222380150" xlink:to="us-gaap_AssetsCurrent_638755105222380150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_638755105222390148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638755105222380150" xlink:to="us-gaap_PrepaidExpenseNoncurrent_638755105222390148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638755105222390148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638755105222380150" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638755105222390148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_638755105222390148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638755105222380150" xlink:to="us-gaap_OtherAssets_638755105222390148" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638755105222390148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638755105222380150" xlink:to="us-gaap_Assets_638755105222390148" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638755105222390148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638755105222390148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638755105222390148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638755105222390148" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638755105222390148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638755105222390148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638755105222390148" xlink:to="us-gaap_AccountsPayableCurrent_638755105222390148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638755105222390148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638755105222390148" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638755105222390148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638755105222400146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638755105222390148" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638755105222400146" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638755105222400146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638755105222390148" xlink:to="us-gaap_LiabilitiesCurrent_638755105222400146" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638755105222400146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638755105222390148" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638755105222400146" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638755105222400146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638755105222390148" xlink:to="us-gaap_Liabilities_638755105222400146" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638755105222400146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638755105222390148" xlink:to="us-gaap_StockholdersEquityAbstract_638755105222400146" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638755105222400146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638755105222400146" xlink:to="us-gaap_PreferredStockValue_638755105222400146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638755105222400146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638755105222400146" xlink:to="us-gaap_CommonStockValue_638755105222400146" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638755105222410138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638755105222400146" xlink:to="us-gaap_AdditionalPaidInCapital_638755105222410138" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638755105222410138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638755105222400146" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638755105222410138" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638755105222410138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638755105222400146" xlink:to="us-gaap_StockholdersEquity_638755105222410138" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638755105222410138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638755105222390148" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638755105222410138" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638755105222410138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638755105222410138" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638755105222420148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638755105222420148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638755105222420148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638755105222420148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638755105222420148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638755105222420148" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638755105222420148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638755105222420148" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638755105222420148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638755105222420148" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638755105222420148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638755105222420148" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638755105222420148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638755105222420148" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638755105222420148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638755105222420148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_638755105222430148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_638755105222430148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638755105222430148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract_638755105222430148" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638755105222430148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638755105222430148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract_638755105222430148" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638755105222430148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentCharges_638755105222430148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract_638755105222430148" xlink:to="us-gaap_RestructuringCostsAndAssetImpairmentCharges_638755105222430148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638755105222430148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAndAssetImpairmentCharges_638755105222430148" xlink:to="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638755105222430148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638755105222430148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract_638755105222430148" xlink:to="us-gaap_OperatingExpenses_638755105222430148" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638755105222430148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638755105222430148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_638755105222430148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_638755105222430148" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638755105222440146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638755105222440146" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638755105222440146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense_638755105222440146" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_638755105222440146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_638755105222440146" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638755105222440146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638755105222440146" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638755105222440146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638755105222440146" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638755105222440146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638755105222440146" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638755105222440146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638755105222440146" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638755105222450139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638755105222450139" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638755105222450139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222450139" xlink:to="us-gaap_StatementEquityComponentsAxis_638755105222450139" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638755105222450139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638755105222450139" xlink:to="us-gaap_CommonStockMember_638755105222450139" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638755105222450139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638755105222450139" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638755105222450139" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638755105222450139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638755105222450139" xlink:to="us-gaap_RetainedEarningsMember_638755105222450139" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638755105222450139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638755105222450139" xlink:to="us-gaap_EquityComponentDomain_638755105222450139" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638755105222460144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222450139" xlink:to="us-gaap_StatementLineItems_638755105222460144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638755105222460144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222460144" xlink:to="us-gaap_StockholdersEquity_638755105222460144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638755105222460144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222460144" xlink:to="us-gaap_SharesOutstanding_638755105222460144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_638755105222460144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222460144" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_638755105222460144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638755105222460144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_638755105222460144" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638755105222460144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting_638755105222460144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222460144" xlink:to="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting_638755105222460144" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting_638755105222460144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting_638755105222460144" xlink:to="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting_638755105222460144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638755105222460144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222460144" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638755105222460144" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638755105222460144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638755105222460144" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638755105222460144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_638755105222470140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222460144" xlink:to="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_638755105222470140" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting_638755105222470140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting_638755105222470140" xlink:to="glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting_638755105222470140" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638755105222470140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222460144" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638755105222470140" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638755105222470140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222460144" xlink:to="us-gaap_NetIncomeLoss_638755105222470140" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638755105222470140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222460144" xlink:to="us-gaap_StockholdersEquity_638755105222470140" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638755105222470140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222460144" xlink:to="us-gaap_SharesOutstanding_638755105222470140" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638755105222480139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" xlink:to="us-gaap_ProfitLoss_638755105222480139" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638755105222480139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" xlink:to="us-gaap_Depreciation_638755105222480139" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638755105222480139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638755105222480139" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_638755105222660137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_638755105222660137" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638755105222660137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638755105222660137" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_638755105222660137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_638755105222660137" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638755105222660137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" xlink:to="us-gaap_ShareBasedCompensation_638755105222660137" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638755105222660137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638755105222660137" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638755105222660137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638755105222660137" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638755105222660137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" xlink:label="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_638755105222660137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638755105222660137" xlink:to="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_638755105222660137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638755105222660137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638755105222660137" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638755105222660137" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638755105222670146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638755105222660137" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638755105222670146" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_638755105222670146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638755105222660137" xlink:to="glyc_IncreaseDecreaseInOperatingLeaseLiabilities_638755105222670146" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638755105222670146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638755105222670146" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105222670146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638755105222480139" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105222670146" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638755105222670146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638755105222670146" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638755105222670146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638755105222670146" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638755105222670146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638755105222680140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638755105222670146" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638755105222680140" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638755105222680140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638755105222670146" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638755105222680140" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638755105222680140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638755105222680140" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638755105222680140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638755105222680140" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638755105222680140" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638755105222680140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638755105222680140" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638755105222680140" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638755105222680140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638755105222680140" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638755105222680140" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638755105222680140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638755105222680140" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638755105222690136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638755105222690136" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6387551052226901361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6387551052226901361" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Description of the Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638755105222690136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638755105222690136" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureGoingConcern" xlink:type="extended" xlink:title="10201 - Disclosure - Going Concern" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_GoingConcernAbstract" xlink:label="GoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_638755105222700149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_638755105222700149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638755105222700149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638755105222700149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock" xlink:type="extended" xlink:title="10401 - Disclosure - Net Loss Per Share of Common Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="EarningsPerShareBasicAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638755105222700149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638755105222700149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="10501 - Disclosure - Prepaid Expenses and Other Current Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_638755105222710158" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_638755105222710158" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10601 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638755105222710158" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638755105222710158" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeases" xlink:type="extended" xlink:title="10701 - Disclosure - Operating Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638755105222720168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638755105222720168" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10801 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638755105222720168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638755105222720168" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10901 - Disclosure - Stock-based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638755105222720168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638755105222720168" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11001 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638755105222730133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638755105222730133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureResearchAndLicenseAgreements" xlink:type="extended" xlink:title="11101 - Disclosure - Research and License Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ResearchAndLicenseAgreementsAbstract" xlink:label="ResearchAndLicenseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ResearchAndLicenseAgreementTextBlock" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock_638755105222730133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndLicenseAgreementsAbstract" xlink:to="glyc_ResearchAndLicenseAgreementTextBlock_638755105222730133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureEmployeeBenefitPlan" xlink:type="extended" xlink:title="11201 - Disclosure - Employee Benefit Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_638755105222730133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_638755105222730133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentCharges" xlink:type="extended" xlink:title="11301 - Disclosure - Restructuring and Asset Impairment Charges" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_638755105222740160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" xlink:to="us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_638755105222740160" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638755105222740160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638755105222740160" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_638755105222740160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_638755105222740160" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638755105222740160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638755105222740160" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638755105222740160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638755105222740160" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638755105222750264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638755105222750264" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638755105222750264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638755105222750264" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638755105222750264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638755105222750264" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638755105222750264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638755105222750264" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638755105222750264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638755105222750264" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638755105222750264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638755105222750264" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638755105222750264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638755105222750264" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock" xlink:label="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_638755105222750264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock_638755105222750264" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638755105222750264" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638755105222750264" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables" xlink:type="extended" xlink:title="30403 - Disclosure - Net Loss Per Share of Common Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="EarningsPerShareBasicAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638755105222760131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638755105222760131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638755105222760131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638755105222760131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638755105222770131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638755105222770131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Operating Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638755105222770131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638755105222770131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638755105222770131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638755105222770131" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_LeaseQuantitativeDisclosureTableTextBlock" xlink:label="glyc_LeaseQuantitativeDisclosureTableTextBlock_638755105222770131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="glyc_LeaseQuantitativeDisclosureTableTextBlock_638755105222770131" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stock-based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638755105222780231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_StatementTable_638755105222780231" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638755105222780231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222780231" xlink:to="us-gaap_PlanNameAxis_638755105222780231" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638755105222780231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638755105222780231" xlink:to="us-gaap_PlanNameDomain_638755105222780231" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member_638755105222780231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638755105222780231" xlink:to="glyc_EquityIncentivePlan2013Member_638755105222780231" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember_638755105222780231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638755105222780231" xlink:to="glyc_EquityInducementPlanMember_638755105222780231" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638755105222780231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222780231" xlink:to="us-gaap_StatementLineItems_638755105222780231" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638755105222780231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222780231" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638755105222780231" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_638755105222780231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222780231" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_638755105222780231" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638755105222780231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222780231" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638755105222780231" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638755105222790134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222780231" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638755105222790134" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638755105222790134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638755105222790134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638755105222790134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638755105222790134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesTables" xlink:type="extended" xlink:title="31303 - Disclosure - Restructuring and Asset Impairment Charges (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_638755105222800133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_2" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_638755105222800133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureDescriptionOfBusinessDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of the Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638755105222800133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638755105222800133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638755105222800133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638755105222800133" xlink:to="srt_StatementScenarioAxis_638755105222800133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638755105222800133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638755105222800133" xlink:to="srt_ScenarioUnspecifiedDomain_638755105222800133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_PriorToClosingOfPrivatePlacementMember" xlink:label="glyc_PriorToClosingOfPrivatePlacementMember_638755105222800133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638755105222800133" xlink:to="glyc_PriorToClosingOfPrivatePlacementMember_638755105222800133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_PostClosingOfPrivatePlacementMember" xlink:label="glyc_PostClosingOfPrivatePlacementMember_638755105222800133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638755105222800133" xlink:to="glyc_PostClosingOfPrivatePlacementMember_638755105222800133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638755105222800133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638755105222800133" xlink:to="srt_OwnershipAxis_638755105222800133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638755105222800133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638755105222800133" xlink:to="srt_OwnershipDomain_638755105222800133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_CrescentBiopharmaIncMember" xlink:label="glyc_CrescentBiopharmaIncMember_638755105222810135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638755105222800133" xlink:to="glyc_CrescentBiopharmaIncMember_638755105222810135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_GlycoMimeticsIncMember" xlink:label="glyc_GlycoMimeticsIncMember_638755105222810135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638755105222800133" xlink:to="glyc_GlycoMimeticsIncMember_638755105222810135" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638755105222810135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638755105222800133" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638755105222810135" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638755105222810135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638755105222810135" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638755105222810135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638755105222810135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638755105222810135" xlink:to="us-gaap_PrivatePlacementMember_638755105222810135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_638755105222810135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638755105222800133" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_638755105222810135" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638755105222810135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638755105222810135" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638755105222810135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_638755105222810135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638755105222810135" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_638755105222810135" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_638755105222820141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638755105222810135" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_638755105222820141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing" xlink:label="glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing_638755105222820141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638755105222810135" xlink:to="glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing_638755105222820141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_SaleOfStockAggregatePurchasePrice" xlink:label="glyc_SaleOfStockAggregatePurchasePrice_638755105222820141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638755105222810135" xlink:to="glyc_SaleOfStockAggregatePurchasePrice_638755105222820141" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureGoingConcernDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Going Concern (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_GoingConcernAbstract" xlink:label="GoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax" xlink:label="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_638755105222820141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax_638755105222820141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105222820141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638755105222820141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638755105222820141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638755105222820141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestructuringAndSegmentInformationDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Summary of Significant Accounting Policies - Restructuring and Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1_638755105222830177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SeveranceCosts1_638755105222830177" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638755105222830177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments_638755105222830177" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts" xlink:label="glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts_638755105222830177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts_638755105222830177" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638755105222840183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638755105222840183" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638755105222840183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638755105222840183" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638755105222840183" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638755105222840183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638755105222840183" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638755105222840183" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638755105222840183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638755105222840183" xlink:to="us-gaap_FairValueInputsLevel1Member_638755105222840183" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638755105222840183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638755105222840183" xlink:to="us-gaap_FairValueInputsLevel2Member_638755105222840183" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638755105222840183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638755105222840183" xlink:to="us-gaap_FairValueInputsLevel3Member_638755105222840183" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638755105222840183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638755105222840183" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638755105222840183" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638755105222840183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638755105222840183" xlink:to="us-gaap_AssetsFairValueDisclosure_638755105222840183" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_638755105222840183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638755105222840183" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_638755105222840183" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_638755105222840183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638755105222840183" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_638755105222840183" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_638755105222850154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_DefinedContributionPlanTable_638755105222850154" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638755105222850154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638755105222850154" xlink:to="srt_RangeAxis_638755105222850154" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638755105222850154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638755105222850154" xlink:to="srt_RangeMember_638755105222850154" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638755105222850154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638755105222850154" xlink:to="srt_MaximumMember_638755105222850154" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_638755105222850154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638755105222850154" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_638755105222850154" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638755105222850154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638755105222850154" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638755105222850154" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638755105222850154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638755105222850154" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638755105222850154" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638755105222860134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638755105222860134" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638755105222860134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222860134" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638755105222860134" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638755105222860134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638755105222860134" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638755105222860134" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_638755105222860134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638755105222860134" xlink:to="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_638755105222860134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638755105222860134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222860134" xlink:to="us-gaap_StatementLineItems_638755105222860134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638755105222860134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222860134" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638755105222860134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureNetLossPerCommonShareDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Net Loss Per Common Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638755105222870130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638755105222870130" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638755105222870130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638755105222870130" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638755105222870130" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638755105222870130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638755105222870130" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638755105222870130" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_638755105222870130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638755105222870130" xlink:to="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_638755105222870130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638755105222870130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638755105222870130" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638755105222870130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638755105222870130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638755105222870130" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638755105222870130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638755105222870130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent_638755105222870130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638755105222870130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638755105222870130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_638755105222880163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent_638755105222880163" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638755105222880163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638755105222880163" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638755105222880163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638755105222880163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Operating Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638755105222880163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638755105222880163" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638755105222890137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638755105222880163" xlink:to="srt_StatementGeographicalAxis_638755105222890137" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638755105222890137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638755105222890137" xlink:to="srt_SegmentGeographicalDomain_638755105222890137" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_RockvilleMarylandMember" xlink:label="glyc_RockvilleMarylandMember_638755105222890137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638755105222890137" xlink:to="glyc_RockvilleMarylandMember_638755105222890137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_FirstPortionSquareFeetRockvilleMarylandMember" xlink:label="glyc_FirstPortionSquareFeetRockvilleMarylandMember_638755105222890137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638755105222890137" xlink:to="glyc_FirstPortionSquareFeetRockvilleMarylandMember_638755105222890137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_SecondPortionSquareFeetRockvilleMarylandMember" xlink:label="glyc_SecondPortionSquareFeetRockvilleMarylandMember_638755105222890137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638755105222890137" xlink:to="glyc_SecondPortionSquareFeetRockvilleMarylandMember_638755105222890137" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638755105222890137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638755105222880163" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638755105222890137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638755105222890137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638755105222890137" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638755105222890137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent" xlink:label="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent_638755105222890137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638755105222890137" xlink:to="us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent_638755105222890137" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638755105222890137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638755105222890137" xlink:to="us-gaap_SecurityDeposit_638755105222890137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_SquareFeetLeased" xlink:label="glyc_SquareFeetLeased_638755105222890137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638755105222890137" xlink:to="glyc_SquareFeetLeased_638755105222890137" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638755105222900130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638755105222890137" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638755105222900130" order="4" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_LesseeOperatingLeaseNumberOfNewLeases" xlink:label="glyc_LesseeOperatingLeaseNumberOfNewLeases_638755105222900130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638755105222890137" xlink:to="glyc_LesseeOperatingLeaseNumberOfNewLeases_638755105222900130" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_638755105222900130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_638755105222890137" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_638755105222900130" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Operating Leases - Components of lease expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638755105222900130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract_638755105222900130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638755105222900130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638755105222900130" xlink:to="us-gaap_OperatingLeaseCost_638755105222900130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638755105222910141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638755105222900130" xlink:to="us-gaap_VariableLeaseCost_638755105222910141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638755105222910141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638755105222900130" xlink:to="us-gaap_LeaseCost_638755105222910141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_638755105222910141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_638755105222910141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638755105222910141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_638755105222910141" xlink:to="us-gaap_OperatingLeasePayments_638755105222910141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Operating Leases - Maturities of lease liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638755105222910141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638755105222910141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638755105222910141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638755105222910141" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638755105222910141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_638755105222910141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638755105222910141" xlink:to="glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_638755105222910141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638755105222920153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638755105222910141" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638755105222920153" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638755105222920153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638755105222910141" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638755105222920153" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638755105222920153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638755105222910141" xlink:to="us-gaap_OperatingLeaseLiability_638755105222920153" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_638755105222920153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638755105222910141" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_638755105222920153" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesSupplementalInformationDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Operating Leases - Supplemental Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_638755105222920153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_638755105222920153" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638755105222920153" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638755105222920153" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stockholders' Equity - Equity Offerings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638755105222930149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StatementTable_638755105222930149" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638755105222930149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222930149" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638755105222930149" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638755105222930149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638755105222930149" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638755105222930149" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_AtMarketOffering2022Member" xlink:label="glyc_AtMarketOffering2022Member_638755105222930149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638755105222930149" xlink:to="glyc_AtMarketOffering2022Member_638755105222930149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638755105222930149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222930149" xlink:to="srt_RangeAxis_638755105222930149" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638755105222930149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638755105222930149" xlink:to="srt_RangeMember_638755105222930149" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638755105222930149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638755105222930149" xlink:to="srt_MaximumMember_638755105222930149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638755105222930149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222930149" xlink:to="us-gaap_StatementLineItems_638755105222930149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_638755105222940147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638755105222930149" xlink:to="us-gaap_StockholdersEquityNoteAbstract_638755105222940147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638755105222940147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_638755105222940147" xlink:to="us-gaap_CommonStockSharesAuthorized_638755105222940147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638755105222940147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_638755105222940147" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638755105222940147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638755105222940147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_638755105222940147" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638755105222940147" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638755105222940147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_638755105222940147" xlink:to="us-gaap_SharesIssuedPricePerShare_638755105222940147" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638755105222940147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_638755105222940147" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638755105222940147" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_CommonStockValueAvailableForSaleUnderAgreement" xlink:label="glyc_CommonStockValueAvailableForSaleUnderAgreement_638755105222940147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_638755105222940147" xlink:to="glyc_CommonStockValueAvailableForSaleUnderAgreement_638755105222940147" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock-based Compensation - Incentive Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638755105222950146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9" xlink:to="us-gaap_StatementTable_638755105222950146" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638755105222950146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222950146" xlink:to="us-gaap_StatementEquityComponentsAxis_638755105222950146" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638755105222950146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638755105222950146" xlink:to="us-gaap_EquityComponentDomain_638755105222950146" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638755105222950146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638755105222950146" xlink:to="us-gaap_CommonStockMember_638755105222950146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638755105222950146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222950146" xlink:to="us-gaap_PlanNameAxis_638755105222950146" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638755105222950146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638755105222950146" xlink:to="us-gaap_PlanNameDomain_638755105222950146" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member_638755105222950146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638755105222950146" xlink:to="glyc_EquityIncentivePlan2013Member_638755105222950146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638755105222960149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222950146" xlink:to="us-gaap_VestingAxis_638755105222960149" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638755105222960149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638755105222960149" xlink:to="us-gaap_VestingDomain_638755105222960149" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638755105222960149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638755105222960149" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638755105222960149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638755105222960149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638755105222960149" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638755105222960149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638755105222970171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222950146" xlink:to="us-gaap_AwardTypeAxis_638755105222970171" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105222970171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638755105222970171" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105222970171" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockOptionsVestingBasedOnPerformanceMember" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember_638755105222970171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105222970171" xlink:to="glyc_StockOptionsVestingBasedOnPerformanceMember_638755105222970171" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638755105222970171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222950146" xlink:to="us-gaap_GranteeStatusAxis_638755105222970171" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638755105222970171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638755105222970171" xlink:to="us-gaap_GranteeStatusDomain_638755105222970171" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638755105222970171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638755105222970171" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638755105222970171" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" xlink:label="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_638755105222970171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638755105222970171" xlink:to="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_638755105222970171" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105222980134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638755105222950146" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105222980134" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105222980134" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638755105222980134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638755105222980134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_638755105222980134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_638755105222980134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_638755105222980134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_638755105222980134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638755105222980134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638755105222980134" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638755105222990133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638755105222990133" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638755105222990133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638755105222990133" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638755105222990133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638755105222990133" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638755105222990133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638755105222990133" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638755105222990133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638755105222990133" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638755105222990133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638755105222990133" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_638755105223000129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_638755105223000129" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_638755105223000129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_638755105222980134" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_638755105223000129" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638755105223000129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_638755105223000129" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638755105223000129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638755105223000129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_638755105223000129" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638755105223000129" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_638755105223000129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_638755105223000129" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_638755105223000129" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638755105223000129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_638755105223000129" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638755105223000129" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee_638755105223010146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_638755105223000129" xlink:to="glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee_638755105223010146" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stock-based Compensation - Company's Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223010146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223010146" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638755105223010146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223010146" xlink:to="us-gaap_PlanNameAxis_638755105223010146" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638755105223020147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638755105223010146" xlink:to="us-gaap_PlanNameDomain_638755105223020147" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member_638755105223020147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638755105223020147" xlink:to="glyc_EquityIncentivePlan2013Member_638755105223020147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638755105223020147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223010146" xlink:to="us-gaap_GranteeStatusAxis_638755105223020147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638755105223020147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638755105223020147" xlink:to="us-gaap_GranteeStatusDomain_638755105223020147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638755105223020147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638755105223020147" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638755105223020147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" xlink:label="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_638755105223020147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638755105223020147" xlink:to="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_638755105223020147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638755105223020147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223010146" xlink:to="us-gaap_AwardTypeAxis_638755105223020147" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105223020147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638755105223020147" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105223020147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockOptionsVestingBasedOnPerformanceMember" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember_638755105223020147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105223020147" xlink:to="glyc_StockOptionsVestingBasedOnPerformanceMember_638755105223020147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223020147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223010146" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223020147" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638755105223030135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223020147" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638755105223030135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638755105223030135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638755105223030135" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638755105223030135" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638755105223030135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638755105223030135" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638755105223030135" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638755105223030135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638755105223030135" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638755105223030135" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638755105223030135" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638755105223030135" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638755105223030135" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6387551052230301351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638755105223030135" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6387551052230301351" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223040159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223020147" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223040159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638755105223040159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223040159" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638755105223040159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638755105223040159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223040159" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638755105223040159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638755105223040159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223040159" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638755105223040159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638755105223040159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223040159" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638755105223040159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6387551052230401591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223040159" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6387551052230401591" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_638755105223050351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223020147" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_638755105223050351" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638755105223050351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_638755105223050351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638755105223050351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638755105223050351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_638755105223050351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638755105223050351" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638755105223050351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_638755105223050351" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638755105223050351" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638755105223050351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223020147" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638755105223050351" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638755105223050351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638755105223050351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638755105223050351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638755105223060136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638755105223050351" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638755105223060136" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638755105223060136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638755105223050351" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638755105223060136" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638755105223060136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638755105223050351" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638755105223060136" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stock-based Compensation - Summary of RSU Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223070143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223070143" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638755105223070143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223070143" xlink:to="us-gaap_AwardTypeAxis_638755105223070143" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105223070143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638755105223070143" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105223070143" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638755105223070143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105223070143" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638755105223070143" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638755105223070143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223070143" xlink:to="us-gaap_PlanNameAxis_638755105223070143" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638755105223070143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638755105223070143" xlink:to="us-gaap_PlanNameDomain_638755105223070143" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member_638755105223070143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638755105223070143" xlink:to="glyc_EquityIncentivePlan2013Member_638755105223070143" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638755105223070143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223070143" xlink:to="us-gaap_GranteeStatusAxis_638755105223070143" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638755105223080139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638755105223070143" xlink:to="us-gaap_GranteeStatusDomain_638755105223080139" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638755105223080139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638755105223080139" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638755105223080139" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223080139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223070143" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223080139" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_638755105223080139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223080139" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_638755105223080139" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638755105223080139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_638755105223080139" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638755105223080139" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638755105223080139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_638755105223080139" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638755105223080139" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638755105223080139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_638755105223080139" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638755105223080139" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638755105223080139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223080139" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638755105223080139" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638755105223090130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638755105223080139" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638755105223090130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638755105223090130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638755105223080139" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638755105223090130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638755105223090130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638755105223080139" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638755105223090130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6387551052230901301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638755105223080139" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6387551052230901301" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638755105223090130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223080139" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638755105223090130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638755105223090130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638755105223090130" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638755105223090130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638755105223090130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638755105223090130" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638755105223090130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638755105223100127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638755105223090130" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638755105223100127" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638755105223100127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638755105223090130" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638755105223100127" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223270515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223270515" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638755105223270515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223270515" xlink:to="us-gaap_GranteeStatusAxis_638755105223270515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638755105223270515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638755105223270515" xlink:to="us-gaap_GranteeStatusDomain_638755105223270515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638755105223270515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638755105223270515" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638755105223270515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638755105223270515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223270515" xlink:to="us-gaap_AwardTypeAxis_638755105223270515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105223270515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638755105223270515" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105223270515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_OtherAwardsMember" xlink:label="glyc_OtherAwardsMember_638755105223270515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105223270515" xlink:to="glyc_OtherAwardsMember_638755105223270515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638755105223280377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223270515" xlink:to="srt_TitleOfIndividualAxis_638755105223280377" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638755105223280377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638755105223280377" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638755105223280377" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638755105223280377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638755105223280377" xlink:to="srt_DirectorMember_638755105223280377" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223280377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223270515" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223280377" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638755105223280377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223280377" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638755105223280377" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Stock-based Compensation - Inducement Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223280377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223280377" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638755105223290499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223280377" xlink:to="us-gaap_StatementEquityComponentsAxis_638755105223290499" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638755105223290499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638755105223290499" xlink:to="us-gaap_EquityComponentDomain_638755105223290499" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638755105223290499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638755105223290499" xlink:to="us-gaap_CommonStockMember_638755105223290499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638755105223290499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223280377" xlink:to="us-gaap_PlanNameAxis_638755105223290499" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638755105223290499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638755105223290499" xlink:to="us-gaap_PlanNameDomain_638755105223290499" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember_638755105223290499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638755105223290499" xlink:to="glyc_EquityInducementPlanMember_638755105223290499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638755105223290499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223280377" xlink:to="us-gaap_VestingAxis_638755105223290499" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638755105223290499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638755105223290499" xlink:to="us-gaap_VestingDomain_638755105223290499" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638755105223290499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638755105223290499" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638755105223290499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638755105223290499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638755105223290499" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638755105223290499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638755105223300197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223280377" xlink:to="us-gaap_AwardTypeAxis_638755105223300197" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105223300197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638755105223300197" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105223300197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_StockOptionsVestingBasedOnPerformanceMember" xlink:label="glyc_StockOptionsVestingBasedOnPerformanceMember_638755105223300197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638755105223300197" xlink:to="glyc_StockOptionsVestingBasedOnPerformanceMember_638755105223300197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638755105223300197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223280377" xlink:to="us-gaap_GranteeStatusAxis_638755105223300197" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638755105223300197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638755105223300197" xlink:to="us-gaap_GranteeStatusDomain_638755105223300197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638755105223300197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638755105223300197" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638755105223300197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember" xlink:label="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_638755105223300197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638755105223300197" xlink:to="glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_638755105223300197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223280377" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638755105223310537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638755105223310537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_638755105223310537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments_638755105223310537" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_638755105223310537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_638755105223310537" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638755105223310537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638755105223310537" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638755105223310537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638755105223310537" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638755105223310537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638755105223310537" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638755105223310537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638755105223310537" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638755105223320502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638755105223320502" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638755105223320502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638755105223320502" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638755105223320502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638755105223320502" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638755105223320502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638755105223320502" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638755105223320502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638755105223320502" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638755105223320502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638755105223320502" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_638755105223320502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense_638755105223320502" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638755105223330509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638755105223330509" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638755105223330509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223300197" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638755105223330509" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Stock-based Compensation - Inducement Plan - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223330509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223330509" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638755105223330509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223330509" xlink:to="us-gaap_PlanNameAxis_638755105223330509" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638755105223340490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638755105223330509" xlink:to="us-gaap_PlanNameDomain_638755105223340490" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EquityInducementPlanMember" xlink:label="glyc_EquityInducementPlanMember_638755105223340490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638755105223340490" xlink:to="glyc_EquityInducementPlanMember_638755105223340490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223340490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638755105223330509" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223340490" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638755105223340490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223340490" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638755105223340490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638755105223340490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638755105223340490" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638755105223340490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638755105223340490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638755105223340490" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638755105223340490" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638755105223340490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638755105223340490" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638755105223340490" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6387551052233404901" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638755105223340490" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6387551052233404901" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223340490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223340490" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223340490" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638755105223350492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223340490" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638755105223350492" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638755105223350492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223340490" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638755105223350492" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638755105223350492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223340490" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638755105223350492" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638755105223350492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223340490" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638755105223350492" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6387551052233504921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638755105223340490" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6387551052233504921" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_638755105223350492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223340490" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_638755105223350492" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638755105223350492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_638755105223350492" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638755105223350492" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638755105223350492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_638755105223350492" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638755105223350492" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638755105223360199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_638755105223350492" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638755105223360199" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638755105223360199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638755105223340490" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638755105223360199" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638755105223360199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638755105223360199" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638755105223360199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638755105223360199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638755105223360199" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638755105223360199" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638755105223360199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638755105223360199" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638755105223360199" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638755105223360199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638755105223360199" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638755105223360199" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="40907 - Disclosure - Stock-based Compensation - Weighted-Average assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638755105223370216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638755105223370216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638755105223370216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638755105223370216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638755105223370216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638755105223370216" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638755105223370216" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638755105223370216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638755105223370216" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638755105223370216" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638755105223370216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638755105223370216" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638755105223370216" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638755105223370216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638755105223370216" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638755105223370216" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40908 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638755105223380509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638755105223380509" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638755105223380509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638755105223380509" xlink:to="us-gaap_IncomeStatementLocationAxis_638755105223380509" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638755105223380509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638755105223380509" xlink:to="us-gaap_IncomeStatementLocationDomain_638755105223380509" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638755105223380509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638755105223380509" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638755105223380509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638755105223380509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638755105223380509" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638755105223380509" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638755105223380509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638755105223380509" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638755105223380509" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638755105223380509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638755105223380509" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638755105223380509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" xlink:type="extended" xlink:title="41001 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638755105223390509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638755105223390509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638755105223390509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638755105223390509" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638755105223390509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits" xlink:label="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_638755105223390509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638755105223390509" xlink:to="glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits_638755105223390509" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsCapitalizedResearchCosts" xlink:label="glyc_DeferredTaxAssetsCapitalizedResearchCosts_638755105223390509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638755105223390509" xlink:to="glyc_DeferredTaxAssetsCapitalizedResearchCosts_638755105223390509" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_638755105223390509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638755105223390509" xlink:to="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_638755105223390509" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsPatentAmortization" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_638755105223390509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638755105223390509" xlink:to="glyc_DeferredTaxAssetsPatentAmortization_638755105223390509" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_638755105223390509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638755105223390509" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_638755105223390509" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsAccruedBonus" xlink:label="glyc_DeferredTaxAssetsAccruedBonus_638755105223390509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638755105223390509" xlink:to="glyc_DeferredTaxAssetsAccruedBonus_638755105223390509" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities" xlink:label="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_638755105223390509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638755105223390509" xlink:to="glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities_638755105223390509" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638755105223400507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638755105223390509" xlink:to="us-gaap_DeferredTaxAssetsOther_638755105223400507" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638755105223400507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638755105223390509" xlink:to="us-gaap_DeferredTaxAssetsGross_638755105223400507" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638755105223400507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638755105223390509" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638755105223400507" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638755105223400507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet_638755105223400507" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638755105223400507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638755105223400507" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets" xlink:label="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_638755105223400507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638755105223400507" xlink:to="glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets_638755105223400507" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638755105223400507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638755105223400507" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638755105223400507" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638755105223400507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638755105223400507" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail" xlink:type="extended" xlink:title="41002 - Disclosure - Income Taxes - NOLs and carryforwards (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable_638755105223410217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable_638755105223410217" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638755105223410217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_638755105223410217" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638755105223410217" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638755105223410217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638755105223410217" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638755105223410217" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_FederalAndStateAuthoritiesMember" xlink:label="glyc_FederalAndStateAuthoritiesMember_638755105223410217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638755105223410217" xlink:to="glyc_FederalAndStateAuthoritiesMember_638755105223410217" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638755105223410217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_638755105223410217" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638755105223410217" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638755105223410217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638755105223410217" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638755105223410217" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638755105223410217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638755105223410217" xlink:to="us-gaap_ResearchMember_638755105223410217" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember_638755105223410217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638755105223410217" xlink:to="us-gaap_GeneralBusinessMember_638755105223410217" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_638755105223410217" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable_638755105223410217" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_638755105223410217" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638755105223420541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638755105223410217" xlink:to="us-gaap_OperatingLossCarryforwards_638755105223420541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638755105223420541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems_638755105223410217" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638755105223420541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" xlink:type="extended" xlink:title="41003 - Disclosure - Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638755105223420541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638755105223420541" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638755105223420541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638755105223420541" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638755105223420541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638755105223420541" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_638755105223420541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_638755105223420541" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638755105223420541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638755105223420541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="glyc-20241231.xsd#glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent" xlink:label="glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent_638755105223430524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent_638755105223430524" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638755105223430524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_638755105223430524" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638755105223430524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638755105223430524" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638755105223430524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638755105223430524" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail" xlink:type="extended" xlink:title="41201 - Disclosure - Employee Benefit Plan (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_638755105223430524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable_638755105223430524" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638755105223430524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638755105223430524" xlink:to="srt_RangeAxis_638755105223430524" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638755105223430524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638755105223430524" xlink:to="srt_RangeMember_638755105223430524" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638755105223440267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638755105223430524" xlink:to="srt_MaximumMember_638755105223440267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_638755105223440267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638755105223430524" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_638755105223440267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638755105223440267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638755105223440267" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638755105223440267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638755105223440267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638755105223440267" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638755105223440267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638755105223440267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638755105223440267" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638755105223440267" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Restructuring and Asset Impairment Charges (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638755105223450602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_1" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_638755105223450602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638755105223450602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_1" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638755105223450602" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638755105223450602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_1" xlink:to="us-gaap_RestructuringCharges_638755105223450602" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638755105223450602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_1" xlink:to="us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_638755105223450602" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="us-gaap_RestructuringReserveAcceleratedDepreciation_638755105223450602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_1" xlink:to="us-gaap_RestructuringReserveAcceleratedDepreciation_638755105223450602" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Restructuring and Asset Impairment Charges - Severance cost (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract" xlink:label="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638755105223450602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract_3" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638755105223450602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_638755105223450602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638755105223450602" xlink:to="us-gaap_RestructuringCostAndReserveAxis_638755105223450602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_638755105223460721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis_638755105223450602" xlink:to="us-gaap_TypeOfRestructuringDomain_638755105223460721" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember_638755105223460721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain_638755105223460721" xlink:to="us-gaap_EmployeeSeveranceMember_638755105223460721" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_638755105223460721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638755105223450602" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_638755105223460721" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve_638755105223460721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638755105223460721" xlink:to="us-gaap_RestructuringReserve_638755105223460721" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges_638755105223460721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638755105223460721" xlink:to="us-gaap_RestructuringCharges_638755105223460721" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring_638755105223460721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638755105223460721" xlink:to="us-gaap_PaymentsForRestructuring_638755105223460721" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve_6387551052234607211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638755105223460721" xlink:to="us-gaap_RestructuringReserve_6387551052234607211" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>glyc-20241231xex23d4001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xex23d4001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !# 2\# 2(  A$! Q$!_\0
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M&20: /NVBO-?V=-*^(&C_!SP[!\4=9CUWQPT1EU"ZBA2(*SL66/" *2BD*2
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MY9_:2_X*$_#+X)>!+R_T+Q%HWC#Q2SK!9:+9WRMN=CC?*5SLC7DD^V!UKO\
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M]*^9?VHOA-\#=1^(4'PJ^%?PST/Q'\7];)$\D#.;30H?X[BXVMA2H.0GTSU
M-[]FO]G/]HRV\!Q_#S4WL_A/X7^USW>NZ]IUP+C6=<FE<LY63_EED87=UP.#
MVKG_ -GKX0?&[X/>,OB!X1\!_#FW\/:OJ^JNLWQ'UZ3SH8-/!_=B%?O2OR6Y
M)RQR0: .RU;X,_LW_L(?#G2--\1>&;3XA?$2^"I::>T(N-0U.X;@!(^?+CW<
M9(_,URW@3XC?%6?]H+P_H/A;P]X \,:F/](UCPSI>C1R_P!@6/\ >O+Y<;9M
MO_+-<X/4CI4'PK_8'^,D7[47B+Q5XD\0C^RU)A3Q9?2_:-4ND(&Y[?G$+L,K
MNQ\@.%P>:Z7]E_\ X)^>.=!/BVS\>ZRNA^#]3U:>[DT72K@M=ZPNX^4+RZR7
M,('/E@_,6.[.: ,O]J[]HC7/VI/BWI_P)^$]GJ'B?PS!*'\5:AH4FQ)P/^6/
MV@_+'#D ,_?) SC!]J^&?PI\-? WQ+I%O=6UMXM^*/V41:5X=TL!;30[7H2N
M<^4G]Z9_F<] >E>2_ 'X"_M(?"N;Q5\/_"^E>'O F@:CK4]Y/XZD"3W;6['"
M+!".-RJ %+9 ]!7NOB^>S_9"\ 2Z3\/_  YJOQ ^)NOL6\Z8-<W=_<G@W%W,
M?NH">F0 . * .L_:7_:<M?@=INF:)I5E_P )'\2O$)\C0_#=JVZ260\>8_\
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M*** "BBB@ HHHH R/%OBC3_!/A?5?$&JR-#INF6TEU<.BEF"(I)P!R3QTKY
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40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>glyc-20241231xs4007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !? ;4# 2(  A$! Q$!_\0
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ME_Z\Q_Z11UM_\$7O^3>/$O\ V'&_]%K6(/\ DT7]J3_KS'_I%'6W_P $7O\
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' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>glyc-20241231xs4008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X 3,# 2(  A$! Q$!_\0
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M+^)"<?6+/KF-LKDC ^E<_P",?!6D>.M-DT_6+&.\@8':6^\A]5;JIKQGPO\
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M>RTXS?VAH&I $; #S S'@LG0^H(K]*_V7?VAM._:'^'EIJ]NRQ:Q:XM]5LN
M89@/O#U5NH(KT'XA?##PM\5-*ATWQ9H=EX@L(91-'!>Q[U1P,;A[X)K!\!_
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B#* /SHHI 1_9DSG))^M/6(!]V23[FBBA@/S1114<S __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>glyc-20241231xs4027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4027.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &; ZD# 2(  A$! Q$!_\0
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M]S2>:_\ ?;\Z)?\ 6O\ 4TROTL_ KNX_S7_OM^='FO\ WV_.F44!J/\ -?\
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MW?AD'VKGJ5Z=%VF_/9O\CLH82OB4Y4HW2=MTM>VK5WY(\&\U_P"^WYT>:_\
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MC_-?^^WYT>:_]]OSIE% :C_-?^^WYT>:_P#?;\Z910&H_P U_P"^WYT>:_\
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MSMX/)7&#7D?P8\+:'X1\"^.OB)JNF0Z_+H-S/::?:W.&0",@;CD$;F9AEL9
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M]?C'_P"2/G.BOHS_ (8PO/\ H>--_P# 0_\ QRC_ (8PO/\ H>--_P# 0_\
MQRC^T,-_/^#_ ,@_L7,/^?7XQ_\ DCYSHKZ,_P"&,+S_ *'C3?\ P$/_ ,<I
MT?[%=_,VU/&VGNQZ*MH3_P"U*7]H87^?\'_D']BYC_SY_&/_ ,D?.-%?1K?L
M77J$J?'&G C@@VAS_P"C*3_AC"\_Z'C3?_ 0_P#QRG_:&&_G_!_Y!_8N8_\
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M&H>#/V1?"D_AR[ETV.[F3[??6;;)!NW%LL.1E@ 30\343]DTN>Z76VJO?O\
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MU_Y-T^&'UA_]$&N#$?Q:7K^C/7P7^[8K_"O_ $I'SM111TKO/(#&?:HYIXH
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M:M;6@W74>F7!DFMP!DY4J,XZG!Z5[)\-)(6^.OQ?MXF4:S+&?LG.&(P?N_\
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M$.GF)9KZ(P^80=S$*P!P .ON*\U\*_M"^/?!/A^TT71M1LK?3+52L,<EBLC
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ML_N%E]=.5>O75Z:?-J_M)WBO5WL>#>-/$LOC+QAK&NS?>OKEI%!&,)G"C\%
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MMGYJS]E6FX2J-73OZ*VR[FOUC#4XUJ=&+2G!15]VT[MO72_9'T!\9_\ DO\
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M9[^'?_0K6?YO_P#%4?VQ1_E?X?YA_JOBOYX_C_D?GK17Z%?\,]_#O_H5K/\
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M%:S_ #?_ .*H_MBC_*_P_P P_P!5\5_/'\?\C\]:*_0K_AGOX=_]"M9_F_\
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MF<7^J^*_GC^/^1^>M%?H5_PSW\._^A6L_P W_P#BJ/\ AGOX=_\ 0K6?YO\
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M9[^'?_0K6?YO_P#%4?VQ1_E?X?YA_JOBOYX_C_D?GK17Z%?\,]_#O_H5K/\
M-_\ XJC_ (9[^'?_ $*UG^;_ /Q5']L4?Y7^'^8?ZKXK^>/X_P"1^>M%?H5_
MPSW\._\ H5K/\W_^*H_X9[^'?_0K6?YO_P#%4?VQ1_E?X?YA_JOBOYX_C_D?
MGK17Z%?\,]_#O_H5K/\ -_\ XJC_ (9[^'?_ $*UG^;_ /Q5']L4?Y7^'^8?
MZKXK^>/X_P"1^>M%?H5_PSW\._\ H5K/\W_^*H_X9[^'?_0K6?YO_P#%4?VQ
M1_E?X?YA_JOBOYX_C_D?GE+_ *I_H:^C/CK_ ,FZ?##ZP_\ H@U] ']GKX=$
M$'PK9X/N_P#\56WJ_P ,?"^OZ'I^C:AH\%UIEAC[-;.3MBP-HQ@YZ<5SU<SI
M5)PDHOW7?IV.[#\/XBC2K4Y35YI);]'?L?FW17Z%?\,]_#O_ *%:S_-__BJ/
M^&>_AW_T*UG^;_\ Q5=']L4?Y7^'^9P_ZKXK^>/X_P"1^>M%?H5_PSW\._\
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M (9[^'?_ $*UG^;_ /Q5']L4?Y7^'^8?ZKXK^>/X_P"1^>M%?H5_PSW\._\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M43S:/S$^,%]X5TWX7^)[GQN(#X32QE_M);@ JT17!4#NQ) 7'.XC'.*_)_\
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MQJ__  4.VC_D0\_]Q;_[343?\%%]H_Y$+_RK?_::?]F8O^3\5_F/^T,-_/\
M@_\ (^SZ*^*G_P""CVP9_P"$ S_W%_\ [343?\%)MH_Y)]_Y6/\ [13_ +,Q
M?\GXK_,?]H8;^;\'_D?;5%?#[_\ !2W9_P T]S_W&?\ [143_P#!378/^2=_
M^5G_ .T4?V7B_P"3\5_F/Z]A_P";\'_D?<M%?";?\%.L?\TZ/_@Y_P#M%1-_
MP5!VG_DG)/\ W&O_ +13_LO&?R?BO\Q_7:'\WX/_ "/=OVZ/^37/&OTM/_2N
M&OD7]C3]LF7X97-IX*\9W3S>$IFV6=](<MIK$_=/<PD]?[AY'&:?\=?V]O\
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M#/GC_@J_\4/MF?._L\^7O_N_9[?;C_@-,_92M!J/_!0CX_6R!CITUG-%.$.
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MVKG( ;H/O5\<S_LSZA::-\4_B#X4^/%VVH27MWK##PQ<B.U$ZAIO*NMDC;B
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M_AMKOQ-_9.T.3X?ZE\,=>^)'AG3YI/[ \0^%6AEDDMV8LD5Q"[J8F3.W<,C
M[XR>Z^#5M\6;K5?'?Q*\=6EYIW]HVRIH'PYAOUE6TBB0D%V^X)Y6QG&-O?LJ
M_0U5=2L(-4L+BSNHEGM;B-HIHFZ.C A@?J#BBWF-ROT.,^!_Q/7XS?"OP_XS
M&ER:*-6A:3[!+*)6@*R,A7>  W*GD#O7COC+2_&'P,_:'\0?$C1_!NI^/O"?
MBO3;>TU*ST QOJ-C=09$<BQ2,@DC9"1@'(/)[ _2.B:-8>'-'LM*TNS@T[3;
M*%+>VM+:,1Q0QJ-JHJC@    "KU%KH2=F?(.F?"?QY\5)?C#\0-;\//X5U+Q
M5X?&@:#X?O9T:Y6W4,P>X*$JCLYX4'CG/J>>L/!WCOQIX9_9NBF\ :UH%UX*
M\10QZM#?F(^7#%;E#<*RL<H3T[U]OT4N4KG9\]_%/X=:YXG_ &G_ (?ZS#IE
MQ-X<M="U*ROK]-NR%I0 JGG.2,XXQ7SEH7P*MOA-I>J>$=?_ &8X_B5XD2XG
M.C^*+&TM9;&]1V)B-W)(ZM#MR V0<XXQ7Z(T4.*8E-H^2/\ A37BS3/%O[-L
MH\):/I<7A^ZU*XURW\+0^3IVFM-;8 568D@MQD9R>PKZV7@4M%4E8ENX4444
MQ!1110 5\J_M2?L4R_&7QAI?Q"\"^)Y/ ?Q(TP*L>I1AC%.JYV[]O*L,GY@#
MP<$&OJJBDTGHQIN+NCX&TG]@7XI?%7XA:'K_ ,?_ (H6WC#3-&D$EOI.F1L$
ME(((!S'&J X&2%)/3->H_M!?LBZS\7/CU\,O'.CZSINE:5X26..2QN(WWR*L
MI?";1@#' S7U114\J+YY7N>!?MA?LLZ=^U/\-ET8SPZ7XBL)?/TO4Y4+"%C@
M.C@<E&'7'< _7K_V??!7C'P#\*]'\-^/-7L/$>L:8GV9-2LPY\Z%>(R^\9+A
M>">^,]Z].HIVUN3S.UCP_P#:T_9DTO\ :C^%;^%[B].C:E:W OM-U%8]XAG
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M,:5=ZK:BRU.>VCDN;9>D<A4%E_ YK7K4Q"BBB@ HHHH **** "BBB@ HHHH
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MI3H/#PT3=W^&GX'.Z,95/:2 =!2T45Q'0%%%% !1110 4444 %%%% !1110
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M/_P&7^1V=%<9_P )/XM_Z$EO_!K#_A1_PD_BW_H26_\ !K#_ (4>SEY?>O\
M,/K$.S_\!E_D=G17&?\ "3^+?^A);_P:P_X4?\)/XM_Z$EO_  :P_P"%'LY>
M7WK_ ##ZQ#L__ 9?Y'9T5QG_  D_BW_H26_\&L/^%'_"3^+?^A);_P &L/\
MA1[.7E]Z_P P^L0[/_P&7^1V=%<9_P )/XM_Z$EO_!K#_A1_PD_BW_H26_\
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MO_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\
MA)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHK
MC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R
M.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^
M R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB
M'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_
MF'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O
M+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"
MCV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#
M6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM
M_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O
M_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A
M)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\
M"C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-
M8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0D
MM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%
MO_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\
MA)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHK
MC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R
M.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^
M R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB
M'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_
MF'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O
M+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"
MCV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM_P"#
M6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O_0DM
M_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A)_%O
M_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\ "C_A
M)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-8?\
M"C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0DM_X-
M8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%O_0D
MM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\ A)_%
MO_0DM_X-8?\ "C_A)_%O_0DM_P"#6'_"CV<O+[U_F'UB'9_^ R_R.SHKC/\
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M/>'_ !39?#63]J#QO\([:/2?AKINDI!I[V* :;-K<<3++/9H/D$:90-L 5B
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M]3_&OH%B\.OMK[SYV.#Q"_Y=O[F?/UWU-8MWWKZ*N/V-?B;)TTZR_P# Z/\
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MC4M>N]!G?9J6I37,A:W\B%OGF5XS$JL@*YSSPQK(\.R>)O@UX)^!_P ,M?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 457^V0?\]H_P#OH4?;(/\ GM'_ -]"F*Z+
M%%5_MD'_ #VC_P"^A1]L@_Y[1_\ ?0H"Z+%%5_MD'_/:/_OH4?;(/^>T?_?0
MH"Z+%%5_MD'_ #VC_P"^A1]L@_Y[1_\ ?0H"Z+%%5_MD'_/:/_OH4?;(/^>T
M?_?0H"Z+%%5_MD'_ #VC_P"^A1]L@_Y[1_\ ?0H"Z+%%5_MD'_/:/_OH4?;(
M/^>T?_?0H"Z+%%5_MD'_ #VC_P"^A1]L@_Y[1_\ ?0H"Z+%<9\9O"NL>.OA-
MXO\ #>@7=M8:QK&EW&GV]U=EA'"TL9C+DJ"> Q(P.H%=7]L@_P">T?\ WT*/
MMD'_ #VC_P"^A2L',CA/AW\&O#W@KPEX(T^YTC3=0U?POI%MI=KJTMHCSQB*
M)4)CD9=R@D$X!'6NK\2>$]$\8Z=_9^OZ/I^MV)8/]EU*U2XB+#H=K@C(]:T/
MMD'_ #VC_P"^A1]L@_Y[1_\ ?0HL',GU.3\8>']5TSPU?7'@#3/#MMXMCM!;
M:>^K0LEJJC[L<AA&\1CLJURGP ^#6I?#>VU[7O%FHVNN>/O$UT+S6=0LXV2W
M4@;8X( W(C0<#(!/4\UZO]L@_P">T?\ WT*/MD'_ #VC_P"^A2Y=;CYM+7(K
M32K/3YKF:UM(+>6Z?S)Y(HPIE;&,L1]XX[FLO3_ 'AC2=>N-<LO#NDV>M7'$
MVHV]C$EQ)_O2 ;C^)K9^V0?\]H_^^A1]L@_Y[1_]]"G87,NYE>(_!'AWQ@;8
MZ]H.F:V;5_,M_P"T;..X\EO[R;U.T^XK0M]*LK.ZGN(+2"">?;YLL<2J\FT8
M7<1UP.!FI?MD'_/:/_OH4?;(/^>T?_?0HL',NYBZ?\/_  OH[2M8>&](L6FN
M5O9#;6$49>X7.V4D*,N,G#=1D\UQ/PG^%.IZ1XW\4_$+QE-:7OC772+.%;,L
M\&E:7&Y,%G$[@,Q))DE;"AI&X7"J3ZA]L@_Y[1_]]"C[9!_SVC_[Z%%@YO,L
M457^V0?\]H_^^A1]L@_Y[1_]]"F%T6**K_;(/^>T?_?0H^V0?\]H_P#OH4!=
M%BBJ_P!L@_Y[1_\ ?0H^V0?\]H_^^A0%T6**K_;(/^>T?_?0H^V0?\]H_P#O
MH4!=%BBJ_P!L@_Y[1_\ ?0H^V0?\]H_^^A0%T6**K_;(/^>T?_?0H^V0?\]H
M_P#OH4!=%BBJ_P!L@_Y[1_\ ?0H^V0?\]H_^^A0%T6**K_;(/^>T?_?0H^V0
M?\]H_P#OH4!=%BBJ_P!L@_Y[1_\ ?0H^V0?\]H_^^A0%T6**K_;(/^>T?_?0
MH^V0?\]H_P#OH4!=%BBJ_P!L@_Y[1_\ ?0H^V0?\]H_^^A0%T6**K_;(/^>T
M?_?0H^V0?\]H_P#OH4!=%BBJ_P!L@_Y[1_\ ?0H^V0?\]H_^^A0%T6**K_;(
M/^>T?_?0H^V0?\]H_P#OH4!=%BBJ_P!L@_Y[1_\ ?0H^V0?\]H_^^A0%T6**
MK_;(/^>T?_?0H^V0?\]H_P#OH4!=%BBJ_P!L@_Y[1_\ ?0H^V0?\]H_^^A0%
MT6**K_;(/^>T?_?0H^V0?\]H_P#OH4!=%BBJ_P!L@_Y[1_\ ?0H^V0?\]H_^
M^A0%T6**K_;(/^>T?_?0H^V0?\]H_P#OH4!=%BBJ_P!L@_Y[1_\ ?0H^V0?\
M]H_^^A0%T6**K_;(/^>T?_?0H^V0?\]H_P#OH4!=%BBJ_P!L@_Y[1_\ ?0H^
MV0?\]H_^^A0%T6**K_;(/^>T?_?0H^V0?\]H_P#OH4!=%BBJ_P!L@_Y[1_\
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M , 8O_B:/^%<>$O^A8TG_P  8O\ XFNFHH]I/^9_>'L*7\B^Y',_\*X\)?\
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M_$UTU%'M)_S/[P]A2_D7W(YG_A7'A+_H6-)_\ 8O_B:/^%<>$O\ H6-)_P#
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MFC_A7'A+_H6-)_\  &+_ .)KIJ*/:3_F?WA["E_(ON1S/_"N/"7_ $+&D_\
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MO2]374[S6(;26%=-M\H6WLZJ1C 8X_N@=2*Y'XM77@;PS\<OB/?^#?BYXM^
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M"&\M8X]9\3ZK-"9DL+#=B.W09"_:+AA@9/R(&?:?EKC_ -KS]I#Q#\(+?3=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXTSZC((/!S[ U;^!7PKN/@M\.-.\(2>([SQ-;::/*M+J^B5)8X?X(CM."%'
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MMBCQ)$"6/08VM^1KW_\ :'_8PT;XY>+]-\9Z7XFU?P#XWL8OLXUK1F^:2+G
M8 J<C<P#*P.#@Y&,;_[/7[*'A3]G_P (ZSI%M/<^([[76+ZOJFIX,EYD$;2!
M]U?F;C)))))/& =SQK]KWX>:'^T_\);OXB^%OB2USH?ARVEECTZWD\S2KN6-
M@S"9<C+=!G' /O7KW[%?Q7D^,7[/?AS7)=*M-%FAWV#6MA'Y=O\ NL#,:?PJ
M?3ZUXWJG_!,319+S4;#1/B9XJ\/^!]1N/M%UX5MGW0/SG;G<%('0;D8CU-?6
MGPX^'NA?"OP;IGA;PW9BQTC3HQ%#'G+'U9F_B8GDF@1T]%%% @I&Z4M(W -
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M?<\%_P#8SV/\VKY<UC_DG7Q-_P"PY:_^C)J^H_C&0$\%9_Z&>Q_FU?+FL?\
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M%%% !1110 4444 %%%(>E "T5\2?!_X6W7[3.D?$OQOXL\>>*U\.W_B;4O\
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MEF'M/W%)Z=7W_P" >7@,'R+VM1:] 7I2T45\Z>V%%%% !1110 4444 %%%%
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MH?,RX@QQG(]:=115D!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>glyc-20241231xs4028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4028.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (D X\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]B#FOA+]I*S_ &F-7^%VHI\1M-\(WGPZA9+KQ':> IIH]2EL8W620*USN55
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MP?"7_GX\5_\ @^FI?^"D?_)LMS_V&M-_]*%KZEH&?+/_  [@^$O_ #\>*_\
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M]H_<_P#,^_O#_P"T?X%\3ZU9:5IVI3S7MY((HD:TD0%CTR2 !7J5?G7\"/\
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M6F_^E"U]2U\M?\%(_P#DV6Y_[#6F_P#I0M?4M PHHHH$%%%% !1110 4444
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MW8[5K?M$67B+4_@3X]M?"1G_ .$DFT:Z2Q%J2)FD,;?+&1R'(R%QSNQ7Y,_
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M@D(/5=RJ"%/H#B@5RUX@LYM/^%>I6UW-]HN8-%ECEF))WL("&;/7DC-?'_\
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M^)?CAXST^V\2>)=>UFZ@TQM1C6=-,T^%RD,,"L"$(PV6')'N6+,_:\\#Z/\
M 75/!WQP\%:?;>'->TK7+:QUE-.C6"+5=/G;9)',B@!V&%PQ&1UZJNT\!:]K
M/[$FL>)O"7B+PIK>M?"V^U.?5?#_ (C\/V+7OV!9CN>TNHT^9-K#Y7 ^8M[X
M5/&VMZU^VUXJ\)>'-!\*:WH/PLT?58=9USQ!X@LVLCJ1AYCM;:)_F=6+?,Q
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M7GSQP&9Q%'YKA=[GHJY/+'' %6J "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBB@ HHHH **** "BBB@#P;QM^Q9\+/'GBC5-?N](O=,O\ 5_\
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MI**MH>T?\+IT'_GG>_\ ?@_XT?\ "Z=!_P">=[_WX/\ C7B]%=/]EX?S^_\
MX!C]=J^7W'M'_"Z=!_YYWO\ WX/^-'_"Z=!_YYWO_?@_XUXO11_9>'\_O_X
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M7!(8Y.X@8^7UH Z>BO&?^&G]#_Z >L?]\1?_ !RC_AI_0_\ H!ZQ_P!\1?\
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MT31K*+3M*T^!;:UM8%VI%&HPJ@>P%>6_\-/Z'_T ]8_[XB_^.4?\-/Z'_P!
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M)2T=[V#[-.EY")D:/.2NW(Z]_6LZG/RODWZ%1Y>9<VQZEI?C/3]6\+?$/0M
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MP)KGA7Q5\3_%OBNSU*>SN(Y=4>!I+-K>;S08ML8'SD -D'@<5]"T4#N%%%%
M@HHHH **** "BBB@ HHHH **** "BBB@#YVTS_E(!KW_ &3BT_\ 3C+7T37S
MMIG_ "D U[_LG%I_Z<9:^B:!A1110(**** "BBB@ HHHH **** "BBB@#Y:_
MX*1_\FRW/_8:TW_TH6OJ6O,_V@O@E9_M _#N7PC?ZK<Z/;O=P7?VJTC1W#1.
M' PP(Y(KTR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP^NTO/[CO?\ A )?^?\ B_[]G_&C_A )?^?^+_OV?\:X+_A=&N_\^UA^3_\
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M_GPE_-?\:/\ A$M7_P"?"7\U_P :].HH]O+L'L5W/,?^$2U?_GPE_-?\:/\
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M;N+$+G"[N *Y7XF_L,_!CXM^+9O$OB#PF/[8N'\RZGL+N:U%RW=I%C8 L>[
M!CW- 'QG\ OCE\4-*_8"^+6I:?J.H7O_  C]W!8:)JLQ+SVMN[1).$8Y.(D<
M,O/R;^.% '-Z]\,_@IH/[#.D_$71_$ A^+8:WO(M4AU9QJ!U(S+YL/E!_E"+
MO8$*" @?///ZD^&?AWX9\(>#(?"6CZ'96/AJ*%K<:7'"#"8WSO5E.0V[<=V<
M[LG.<UXC!_P3P^ MMXH&N)X'1Y!)YHL9+R=[/=G/^I+E2O\ LGY?:@=SY,_;
M=\5:_P"-_P!A7X&:]XG+/KM_=0S7,T@VM-FUEVS$# RZ;7/;YZZ[5OV>OV+F
M^&[7LWBW1M*U+^S1))/I_BDW-U'*8P25@,K;W#?P;.3QBOM7XM? 7P+\<= T
M_1?&FA+JVEZ?,+BVMUN)K=8G"E 08G4X"DC&<5Y?#_P3I_9\AE1Q\/U8J<X?
M5;XK^(,V#0%SSC_@E?\ $3Q?XY^#.O6?B*\N=3TO1-0CLM(O;LEF$?DJ6@#'
MDK&-A .=HDQT  ^VJP?!O@K0OAYX=L]!\-Z5::)H]H"L-G91A(UR<DX'4DG)
M)Y)Y-;U!(4444 %%%% !1110 4444 %%%% !1110 4444 %>%_M??\DRLO\
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M_P _^%>R>/KN+3O!&O74\?FPPV,TCH #N 0DC!KX\_X6OX;_ .@)+_X#I_\
M%5TT</5K)NG&]C&I6A3=I.QZ_P#\-.:C_P! :S_[_/\ X4?\-.:C_P! :S_[
M_/\ X5Y!_P +7\-_] 27_P !T_\ BJ/^%K^&_P#H"2_^ Z?_ !5='U'$?\^V
M9?6J/\R/7_\ AIS4?^@-9_\ ?Y_\*/\ AIS4?^@-9_\ ?Y_\*\@_X6OX;_Z
MDO\ X#I_\51_PM?PW_T!)?\ P'3_ .*H^HXC_GVP^M4?YD>O_P##3FH_] :S
M_P"_S_X4?\-.:C_T!K/_ +_/_A7D'_"U_#?_ $!)?_ =/_BJ/^%K^&_^@)+_
M . Z?_%4?4<1_P ^V'UJC_,CU_\ X:<U'_H#6?\ W^?_  H_X:<U'_H#6?\
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M_P R/<?#7[0E_KWB+3--?2+6-+NX2 NDS$J&8 D<=LU[G7Q[\/OB5H&H>.=
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MZX4444 %%%% !1110 4444 %%%% 'EOQ3_Y#MK_U[C_T-JXZNQ^*?_(=M?\
MKW'_ *&U<=7KT?X://G\3"BBBMB HHHH ***^:OCK^UO!X4UJT\->!HEUW5D
MU:VL=7U)(6DLM*#3!&C=QA3,Q# +GY<$GD8I-J.K&DV?2M%<WX_^(7A[X7>&
M+GQ!XFU./2]+M^&EDR2S8)5%4 LSG'"@9KS#]G#XY:U\:_$7Q!;4=(ET+3M)
MN[6'3M.NX#'=)')$S[I\G[S_ "L%Q\H..>M%U>P6TN>YT444Q!1110 4444
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M?^OA?_06KLJXWXH?\B]#_P!?"_\ H+5K2_B(B?PL\NHHHKV#SPHHHH ****
M"BOE3]K;XS>/K/PIXOTOP)HU[H]AHD*G5O%UT3;HH;9B*S(^:1SY@!<<+R.N
M"/9/%'Q$/PW^ EQXPN4-[-IVAI=A)7.9Y?*7:&;K\SD GWJ>97?D5;8]'HKY
M4;X7?$EOA4/B2OQ1\0CX@_V<-9.F&9?[&QM\W[)]D"[<;?DW9SGFO?/A+X^C
M^)_PT\-^*XXEM_[5LH[AX0<B*0C#H">H#A@*:=Q-6.OHHHIB"BBB@ KLOA7_
M ,ANY_Z]S_Z$M<;79?"O_D-W/_7N?_0EK&M_#9</B1ZC1117D'H!1110 444
M4 %%%% !1110 4444 >6_%/_ )#MK_U[C_T-JXZNQ^*?_(=M?^O<?^AM7'5Z
M]'^&CSY_$PHHHK8@**** "BBB@ HHHH **** "BBB@ HHHH ]/\ A;_R +C_
M *^&_P#05KM*XOX6_P#( N/^OAO_ $%:[2O'J_Q&=]/X4%%%%9&@4444 4=7
MT>SU[3Y;'4($N;27&^)\X."".GN :YS_ (5%X/\ ^@%;?FW^-:_BWQ19>"_#
M]UK.H"0VEMM\P0KN?YF"C SZM7G'_#4O@S_GGJG_ (#+_P#%T =?_P *@\';
M]W]A6^<8ZM_C2_\ "HO!_P#T K;\V_QKCO\ AJ;P;OQY6IXQG=]G7_XNE_X:
ME\&?\\]4_P# 9?\ XNGJ+0[C3_AGX7TJ]@O+31K>&YA8/'(I;*L.A&374UY=
MX?\ VA_"WB?6[+2K./4/M5W*(HS) H7/N0QXKU&D,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "F/(L2,['"J"2?04^B@#P_Q]X%\*_M?_#ZSFT;X@:[
M;>&Y/M$0N?"6IB"&[8G8RS#:?,52I^4\<GVKXV\>Z[K%_P#L+?%OX>WMI87#
M?"_Q+;Z+]KTJU%M#>VT=V@$C1IPK[B2Y'U;YMQ/T_-^QYJWA75]</PP^*^N_
M#;P_KER]Y>Z!:64%W;I*_P#K&MC)\UOG'\/3MP !Z)\/_P!FWP3\//A%?_#J
MVLI=1T/5$F&JRZA)YEQJ4DR[999G&"788^88Q@8QB@=QG[1>MV _9?\ B+J1
MDC>QG\*7S1MGY'$EJX0 ^Y8 ?6H_V2=/GTS]F/X86]TI24>'[-RK#! :(, 1
M]&%>:1_L17]_I%EX.\0?%SQ/X@^%=E)&8?",\,,;/%&P:*":[4"22)=J@)@8
M"C;MP,?4-O;Q6=O'!!&D4,:A$C0 *H P !T  H GKSOXM_"*;XK1:9'#X[\7
M>"18M(Q;PGJ*VC7.\*,2EHWW!=O&,8W&O1**!'R-\&OA[+\,OVV?$>D3>+/$
M7C)I/ 5M<?VAXHNUN;J,&_D'EJRHH"#;D#'5C7US7SMIG_*0#7O^R<6G_IQE
MKZ)H&PHHHH$%%%% &9XC_P"1?U+_ *]W_P#037AFU?[B_D*]S\1_\B_J7_7N
M_P#Z":\/KT,+\+.2MNAFU?[B_D*R]?T5]8A@2*2.$QL6)8=1C':M>BN]-Q=T
M<S2>C./_ .$(NO\ G[M_R:C_ (0BZ_Y^[?\ )J["BM/:R(]G$IZ79&PTZWMG
MV2/&,%@.#R3WJSM7^XOY"GT5DW=W-$K#-J_W%_(4;5_N+^0I]%(!FU?[B_D*
M-J_W%_(4^B@!FU?[B_D*-J_W%_(4^B@!FU?[B_D*-J_W%_(4^B@#1\,*/^$B
MTWY1_P ?"=A_>%>Y5X=X8_Y&+3/^OB/_ -"%>XUYV)^)'50V84445QG2%%%%
M !1110 4444 %%%% !7&_%#_ )%Z'_KX7_T%J[*N-^*'_(O0_P#7PO\ Z"U:
MTOXB(G\+/+J***]@\\**** "BBB@#Q;]LS_DV/Q]_P!><?\ Z.CK)_:'T^;5
M/V,_$$, 9W7P_;SD+UVQB-V/T"H37J_Q-^'NG?%;P)J_A35I;F'3M318II+1
MU24 ,KC:2"!RO<5KV>B6MIH,&CM']IL8[5;1DG ?S(PNS##&#D=>*EJ[92=D
MCB1XDT\?L]C7?/A.F#PS]K\[(V>7]EW9SZ8K#_8_T^;2_P!F?X?PSJP=M/\
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MP[,]/HHHIB"BBB@ HHHH TO#'_(Q:9_U\1_^A"O<:\.\,?\ (Q:9_P!?$?\
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M/_ J3_XJC^SW_-^ ?ZR+_GS_ .3?\ ^S?(E_YYG\J/(E_P">9_*OC+[5=?\
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M6G_IQEKZ)H&%%%% @HHHH S/$?\ R+^I?]>[_P#H)KP^O</$?_(OZE_U[O\
M^@FO#Z]#"_"SDK;H****[3G"BBB@ HHHH **** "BBB@ HHHH **** -+PQ_
MR,6F?]?$?_H0KW&O#O#'_(Q:9_U\1_\ H0KW&O.Q/Q(ZJ&S"BBBN,Z0HHHH
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M?0-?/W[%W_),]4_["K_^B8J^@:^"QW^\U/4_9<H_W"EZ?JPHHHKA/8"BBB@
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M''_31:_2.O!S*A["<5>]T?69-F#S"G*;CRV?>_3T04445Y!] %%%% !1110
M4444 %%%% !7@G[9?_)*[/\ ["L7_HN6O>Z\$_;+_P"25V?_ &%8O_1<M=F#
M_P!YI^IY&;_[A6]#XJHHHK[\_&0HHHH **** "BBB@ HHHH **** "BBB@ K
MZ#_8K_Y*-K/_ &"V_P#1T=?/E?0?[%?_ "4;6?\ L%M_Z.CK@Q_^ZS]#V<F_
MW^EZ_H?9M%%%?!G[(%%%% !1110 4444 %%%% !1110!\8_MI?\ )1]'_P"P
M4G_HZ2OGVOH+]M+_ )*/H_\ V"D_]'25\^U]Y@/]UAZ'XUG'^_UO7]$%%%%=
MYXX4444 %%%% !1110 4444 %%%% !1110!]G_L7?\DSU3_L*O\ ^B8J^@:^
M?OV+O^29ZI_V%7_]$Q5] U\%CO\ >:GJ?LN4?[A2]/U84445PGL!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5KZ^@TZSN
M+NZE6"VMXVEEE<X5$4$LQ/H ,U9J-T65&1U#*PP5/((]#0!^:>H?M1_##]IW
MX@7.I?%GQT/#?PPT2^(T;P,EI<NVK,F"MW?M'&P*G/RQ \=.S&3WWXXZUX3_
M &Q_V3?'NC?"74T\03:9' ;>"SM)H,2P,DRP(CHI)9$*J ,9(%?3P\*:(O T
M>PQ_UZI_A5FRTVSTQ'2SM8;57.YEAC" GU.!0.Y\=?%7]LSP/\2/V9=1T?PY
MJ#ZI\0O%FEOH-OX3MHG;4(KV>,PR1M'MRH0LYW'Y6V_*3D5],_!+P-+\,?@_
MX,\)W#K)=:-I%K93NIRK2I&H<CV+9Q710^&='MM6DU6'2K*+4Y<B2]2W19W'
M?+@;CT]:UJ!!1110!\[:8Q;]O_7 22%^'%J%SV']HRGC\37T37SMIG_*0#7O
M^R<6G_IQEKZ)H&%%%% @HHHH Y#XM?\ )+/%W_8*NO\ T4U?F]7Z0_%K_DEG
MB[_L%77_ **:OS>KZK)_X<_4_-^*/X]/T_4****^A/B@HHHH **** "BBB@
MHHHH **** "BBB@#L?@Y_P E7\(?]A2V_P#1BU^C]?G!\'/^2K^$/^PI;?\
MHQ:_1^OE,X_BP]#]'X6_@5/5?D%%%%?/GVP4444 %%%% !1110 4444 %>"?
MME_\DKL_^PK%_P"BY:][KP3]LO\ Y)79_P#85B_]%RUV8/\ WFGZGD9O_N%;
MT/BJBBBOOS\9"BBB@ HHHH **** "BBB@ HHHH **** "OH/]BO_ )*-K/\
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M_;2_Y*/H_P#V"D_]'25\^U]!?MI?\E'T?_L%)_Z.DKY]K[S ?[K#T/QK./\
M?ZWK^B"BBBN\\<**** "BBB@ HHHH **** "BBB@ HHHH ^S_P!B[_DF>J?]
MA5__ $3%7T#7S]^Q=_R3/5/^PJ__ *)BKZ!KX+'?[S4]3]ERC_<*7I^K"BBB
MN$]@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ^=M,_P"4@&O?]DXM/_3C+7T37SMIG_*0#7O^
MR<6G_IQEKZ)H&%%%% @HHHH Y#XM?\DL\7?]@JZ_]%-7YO5^D/Q:_P"26>+O
M^P5=?^BFK\WJ^JR?^'/U/S?BC^/3]/U"BBBOH3XH**** "BBB@ HHHH ****
M "BBB@ HHHH ['X.?\E7\(?]A2V_]&+7Z/U^<'P<_P"2K^$/^PI;?^C%K]'Z
M^4SC^+#T/T?A;^!4]5^04445\^?;!1110 4444 %%%% !1110 5X)^V7_P D
MKL_^PK%_Z+EKWNO!/VR_^25V?_85B_\ 1<M=F#_WFGZGD9O_ +A6]#XJHHHK
M[\_&0HHHH **** "BK-AI=_JOFFPTZ^U 0@F1K2U>58_7)4$ ^U5L]00R%3A
ME<%64CJ"#@@CT-"LP"BI_L%]VTS43Z?Z#-_\34+*R,5='C<<,D@*L#Z$'!!^
MM A****!A1110 5]!_L5_P#)1M9_[!;?^CHZ^?*^@_V*_P#DHVL_]@MO_1T=
M<&/_ -UGZ'LY-_O]+U_0^S:***^#/V0**** "BBB@ HHHH **** "BBB@#XQ
M_;2_Y*/H_P#V"D_]'25\^U]!?MI?\E'T?_L%)_Z.DKY]K[S ?[K#T/QK./\
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MJ^IZ-"K-9A1LFK.,?>7O-7MS6>S>W=+2_4\XN?\ C]O?^OF;_P!&-4=27/\
MR$+[_KZF_P#1C5'7I]#P0HHHH&%%%% '8_!S_DJ_A#_L*6W_ *,6OT?K\X/@
MY_R5?PA_V%+;_P!&+7Z/U\IG'\6'H?H_"W\"IZK\@HHHKY\^V"BBB@ HHHH
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M:^?OV+O^29ZI_P!A5_\ T3%7T#7P6._WFIZG[+E'^X4O3]6%%%%<)[ 4444
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MS4]3]ERC_<*7I^K"BBBN$]@**** "BBB@ HHHH **** "BBB@ HHHH ****
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MH/\ 8K_Y*-K/_8+;_P!'1U\^5]!_L5_\E&UG_L%M_P"CHZX,?_NL_0]G)O\
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MZGYOQ1_'I^GZA1117T)\4%%%% !1110 4444 %%%% !1110 4444 =C\'/\
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M_P#PDFF?\_T'_?Q?\:/^$DTS_G^@_P"_B_XU^C'_  S-\(?^B6^#?_!!:?\
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M+,Q("J!R2:^_?^%]?#+_ **+X4_\'EK_ /%UGG]F7X0,,'X6^#"#V_L"U_\
MC=-_X9>^#G_1*?!7_A/VG_QNO+Q>+>+DI-6L?0Y9EL<MA*$9\UW<TO\ A?7P
MR_Z*+X4_\'EM_P#'*/\ A?7PR_Z*+X4_\'EM_P#'*S?^&7O@Y_T2GP5_X3]I
M_P#&Z/\ AE[X.?\ 1*?!7_A/VG_QNN ]G0TO^%]?#+_HHOA3_P 'EM_\<H_X
M7U\,O^BB^%/_  >6W_QRLW_AE[X.?]$I\%?^$_:?_&Z/^&7O@Y_T2GP5_P"$
M_:?_ !N@-#2_X7U\,O\ HHOA3_P>6W_QRC_A?7PR_P"BB^%/_!Y;?_'*S?\
MAE[X.?\ 1*?!7_A/VG_QNC_AE[X.?]$I\%?^$_:?_&Z T-+_ (7U\,O^BB^%
M/_!Y;?\ QRC_ (7U\,O^BB^%/_!Y;?\ QRLW_AE[X.?]$I\%?^$_:?\ QNC_
M (9>^#G_ $2GP5_X3]I_\;H#0TO^%]?#+_HHOA3_ ,'EM_\ '*/^%]?#+_HH
MOA3_ ,'EM_\ '*S?^&7O@Y_T2GP5_P"$_:?_ !NC_AE[X.?]$I\%?^$_:?\
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MX*_\)^T_^-T!H:7_  OKX9?]%%\*?^#RV_\ CE'_  OKX9?]%%\*?^#RV_\
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MG?8_.?\ X233/^?Z#_OXO^-'_"2:9_S_ $'_ '\7_&OT8_X9F^$/_1+?!O\
MX(+3_P"-T?\ #,WPA_Z);X-_\$%I_P#&ZW_MJ?\ (OO.3_56E_S^?W(_.?\
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M?:O9: 84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_%WAOP9\.8?B5X)U;4[C6-$GM]9AL)=-DG(+VTZ2]4#<AU[<GEL+H>%OA/\
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>glyc-20241231xs4029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4029.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'Q ZD# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<\=:XB/3[Z6-773KUU8 ADMG93]"!S]:F,XSV_J^I<Z52G\2[_@[/\1GFO\
MWV_.CS7_ +[?G3C976YT^QW6]!ET\A@R#U(QP/K3%AE>%I4AD>%?O3!"8U]B
MP&!5F-V+YK_WV_.CS7_OM^=21Z?>S2B..PO'E9=XCCMG9BO]X #./?I4<=M<
M30R31VMQ)#$=LDJ0N4C/<,PX%,+L/-?^^WYT>:_]]OSHMK>>]E\JUMY[N7&?
M+MHFD;'K@ \5M>#O"Y\3>-=*\/W;7&FM>3"&1FCVRQY!.=K?2I<E%-OH7!2G
M)1CNW9>K,7S7_OM^='FO_?;\ZWO'?@Z7P;XLUO2H$N[VQTVX,!OFMV"MCNQ
MV@USHYHC)22DMF$XRIS<);H[OX'NS?%WPH"S$?;X^_O7Z*<^A_.OSC^"TK1_
M&#P8J]'U.-6^F&/]*_1S=7RV<+]['T_4_1>%I?[/4_Q?HAU%%%?/GVP4444
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MGY:+S.\U/XH?$;QIIWC;2;W2$\1::KR+<1W%N!_9B!B 5Q@YP >>:[/4R?\
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MU:+B]Y6Z]$E8]1^$_C#7?BMX/^)>D^-&6^TJSL3<1&6W$8L9@''EH !C:%!
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M?\\M+_\  O\ ^M7W711_:^([+[@_U9P7>7W_ / /A3_AD3XC?\\M+_\  O\
M^M1_PR)\1O\ GEI?_@7_ /6K[KHH_M?$=E]P?ZLX+O+[_P#@'PI_PR)\1O\
MGEI?_@7_ /6H_P"&1/B-_P \M+_\"_\ ZU?==%']KXCLON#_ %9P7>7W_P#
M/A3_ (9$^(W_ #RTO_P+_P#K4?\ #(GQ&_YY:7_X%_\ UJ^ZZ2C^U\1V7W!_
MJS@N\OO_ . ?"O\ PR)\1O\ GEI?_@7_ /6H_P"&1/B-_P \M+_\"_\ ZU?=
M=%']KXCLON#_ %9P7>7W_P# /A3_ (9$^(W_ #RTO_P+_P#K4?\ #(GQ&_YY
M:7_X%_\ UJ^ZZ*/[7Q'9?<'^K."[R^__ (!\*?\ #(GQ&_YY:7_X%_\ UJ/^
M&1/B-_SRTO\ \"__ *U?==%']KXCLON#_5G!=Y??_P  ^%/^&1/B-_SRTO\
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MXCLON#_5G!=Y??\ \ ^%/^&1/B-_SRTO_P "_P#ZU'_#(GQ&_P">6E_^!?\
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MK^G>(89)M,OK>_ABE:%WMY X5U.&4D=".XK2KY7_ .">7_)+?&W_ &/.M?\
MH^OJB@ HHIKLJJ2Q  ZDT .HIJLI P0:=0 44E&10 M%)FC- "T444 %%%%
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MDL0F(+1$A2>28]H^IKS/X]?#;2OB-_P4+\#Z5XAT+^U_#LNBE)HI8F,)(5R
M2.!CZU]0:3\#_#WP8\*^)[GX5>%M,T3Q#=V;&)%#;+B5%8Q*^2>,DC_@5# _
M/CX:^)W^-/AO5]2\0_'[6/"7Q=,]PUKHUY*;6SB=7/EQX.!M( SQ\N?:OT=^
M _\ PF8^%>AQ^/KFSO?%"1LES>Z?*)(K@!CLD!'&2NW..,YKX"\2_%_X3?$G
MP%JUO\9/A7?:=\6(!-#(NDZ6\33RY81LCJ,9QMSD'G)KV+]F_P")>K?LI_L7
M^'=9^)FG:O*)-4DBM;54+SVUO*2T>\'E5RKGGH&6@9]LN^Q'8YP 37RS?_\
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MEXB>V,BZI%C!0N%.&!XVT =W^SY#HX\ 176A>,K[QSIMU*TD>I7\PED![ID
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M9?OE4 W_ %]:\N_X59X[_P"BG:A_X"1?X4?\*L\=_P#13M0_\!(O\*OV4/\
MGXOQ_P C/ZS6_P"?$OOC_P#)'IYTRS,(A^R0&$'(C\M=H/KC%6EPJ@#  XP*
M\F_X5;X[_P"BG:A_X"1?X4?\*M\=_P#13]0_\!(O\*/90_Y^+\?\@^LUO^?$
MOOC_ /)'J;V=N]RLYAC:=1@2% 6 ^O6IQTZUY+_PJWQW_P!%/U#_ ,!(O\*/
M^%6^._\ HI^H?^ D7^%'LH?\_%^/^0?6:W_/B7WQ_P#DCTR?1--NKG[1-86L
MTX/^M>%6;\R,US7Q3^&.G?%OPVF@:Q/<1Z2US'/=00$#[5&ASY+G^Z3C..>*
MYC_A5OCO_HIVH?\ @)%_A1_PJWQW_P!%.U#_ ,!(O\*/90_Y^+\?\@^LUO\
MGQ+[X_\ R1ZPJA550 % P .PJ&.QMH4D2.WB1)#EU5  Q]3ZUY;_ ,*M\=_]
M%.U#_P !(O\ "C_A5OCO_HI^H?\ @)%_A1[*'_/Q?C_D'UFM_P ^)??'_P"2
M/4#I]JUL+<VL/D*>(C&-H_#I3Y[.WNX#!/!%/"1CRY$#*?P/%>6?\*M\=_\
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M_13]0_\  2+_  H_X59X[_Z*=J'_ ("1?X4>RA_S\7X_Y!]9K?\ /B7WQ_\
MDCUK-&:\E_X59X[_ .BG:A_X"1?X4?\ "K/'?_13M0_\!(O\*/90_P"?B_'_
M "#ZS6_Y\2^^/_R1ZUFC->2_\*L\=_\ 13M0_P# 2+_"C_A5GCO_ **=J'_@
M)%_A1[*'_/Q?C_D'UFM_SXE]\?\ Y(]:)JI?:79ZDJ"\M(+L*<J)XP^T^HR*
M\P_X59X[_P"BG:A_X"1?X4?\*L\=_P#13M0_\!(O\*/90_Y^+\?\@^LUO^?$
MOOC_ /)'JDEM#+!Y+Q(\.,>6R@K^5,N=/MKZ V]S!%<0'_EE*@9?R/%>7?\
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MN)C%151V7F3RKL?(OQ0_9&LK"XTH>&K;5;^-V?[29;UF*#Y<8R>_-=-XK_9
M\,6GA;4I](DUN;58[9VMH#J#_-+C@=<=:^D\<YIKQANM;/,L5:*YWI^/J+DC
MV/B[P+XK^)G@6_\ "NE2^ ;F[O\ 3M/GC2*2[ -PI8$N><#%>[_ OXT:C\4K
M_P 06.J:"-!O=(D6*6'S=YW'UKT.[T'3GURVUJ:/%[:Q-#'(6("HW4>G:OG+
MX<?;O /[4GB?29]5M&TW68#J)&5&2?NKD]QZ5T.I3QT*C]FE-*^E^^O4+.-M
M3ZFI:CB</D@@CUI]>&G<L6BDR/6EI@%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%9.K>+M"T"Y6WU/6M.TZ=EWK%=W4<3%<XR Q!QD8S
M5+_A9/A'_H:=%_\ !A#_ /%5:A)ZI&3JTT[.2^\Z.BN<_P"%D^$?^AIT7_P8
MP_\ Q5'_  LGPC_T-.B_^#&'_P"*I^SG_*Q>VI?S+[SR#]M7X%>(OV@OA7:>
M'/#,UC#?Q:E#=LU_(R)L0Y(!52<U[9X8TC^QO#^F6<D<8N+>UBAD:,<%E0 \
M_452_P"%D^$?^AIT7_P8P_\ Q5'_  LGPC_T-.B_^#&'_P"*H]G/^5A[:E_,
MOO/#O'7[/7B?Q'^V1X)^*5I+8+X<T;3WM;F*25A<%BL@^5=N"/F'4U[]XH\/
M6_BOPWJFB7AE6TU&UEM)6A<HX1T*L5(Z'!X-4O\ A9/A'_H:=%_\&,/_ ,51
M_P +)\(_]#3HO_@QA_\ BJ/9S_E8>VI?S+[SXX\-?!+]J3X*>'[_ ,!^"?$'
MAK7?"LDLIL-5UAG%U9I(Q)X*L.I)Q\W)XKWS]D7]G;_AF?X11^%I;]=4U.YN
MY-1OKJ-=J-.ZJI"@_P (6- /7&<"O2_^%D^$?^AIT7_P8P__ !5'_"R?"/\
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MQQ[4^LSP[H=IX<TFUTZQ1DM+=-D:O(SD#_>8DFM.MCYUV3=M@HHHIB"BBB@
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M_F?WA]7H_P B^Y&A_P *H\%'_F4M%_\  "+_ .)I?^%3^"O^A2T7_P  (O\
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M (O_ (FNLHH]K4_F?WA]7H_R+[D<G_PJ?P7_ -"EHO\ X 1?_$T?\*G\%_\
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M!?\ T*6B_P#@!%_\37644>UJ?S/[P^KT?Y%]R.3_ .%3^"_^A2T7_P  (O\
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M)4DIT:^T;5&O$\Z--[V\RM&A5PG.X94\T>UJ?S/[P^KT?Y%]R/4O^%4>"O\
MH4M%_P# "+_XFC_A4_@K_H4M%_\  "+_ .)K=UK5(="T:^U*Y(%M9P/<2'T5
M%+'] :^=OAW\>OC;\1]"T+7]/^#6D1^'M66*XBNI?%:B46[D?O/+,(/W3NQF
MCVM3^9_>'U>C_(ON1[9_PJ?P5_T*6B_^ $7_ ,32_P#"I_!?_0I:+_X 1?\
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M<4P/>Z***0!1110 4444 %%%% !1110 4AZ4M)0!P/QY@TB[^#7C&TU_7O\
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M*]BO0PF)C+$4Y\KOUV_!&:<EHT?8>?7-(3DUX%_PJ'XQ?]%4C_\  $?X4?\
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M4D%O';IMCC2,=2$4 9J2B@ IK4ZB@"I/80W"2I)!'(DPVR*RCYQC&#ZUA_\
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MZ$'(- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP!X'U_Q-=1-/;Z18SW\D2,%+B-"Y4$\ G&.:^3O$GPJ^(O[8FEV=_K>A^%O
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MJ'4]0PR#6M*I[*HI]O.P-75CY=^&O@/2?%OQ4?5/"DNJKH&F:/<V;>)+LO\
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MQ]RXQU3\L_C7@?Q(\=Z'\8? 6D^$/"^DW)\375U;$61LGB_LDHZL\CL5 4*
M0,'G-?41&14"6D44A=(8T=NK*H!/U-10KQHV;C=IW6OYC:N?.MF=(^"OQP\6
MZIXJM)(]/\06]M+9:S]F::-71-LL+%02I+ $<<UT?[..D2SQ^.M=^PRV'A_Q
M#K4EWIMC<Q>6?)VJID*'[N\@G!KVB>UCN1MEC25<YPX!%/6,*H4+@#C Z5=3
M%NI3<;:M)-W[;:?(2C9GA&JVMSXW\7^(K[0+5$T[P3:7-MI44<86.XUAXLO(
M!QGRE*H/]IVQTKF?@/=6A\=>$!X:OK^\-QH<LGBM;EY&"7F(]ID#_=D\PRC
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MS0XM4T:Y:ZLG)42-$T9R.HPP!KH%Z5TGR$HRA)QFK-=!:***"0HHHH ****
M"BBB@!",UCZ-X4TS0-0U6]L;5;>YU.?[3=N"3YL@7:&]N*V:*+M: 9VNZ%9^
M(])NM,U" 7-E<H8YHFZ,IZCBO,A^RI\+<;1X2M<#_;?_ !KUZDK2%6K25J<V
MO1BLGNCR/_AE/X7_ /0IVW_?Q_\ &C_AE/X7_P#0IVW_ '\?_&O7:*U^M8G_
M )^R^]BY8]CR+_AE/X7_ /0I6W_?Q_\ &O-_%_[/6M^ _B;HGB7X5^'=+BCM
M+=TEBNIV57=LC.,YZ&OJ6BM:>-Q$'>4G);6;;0<JZ'SX?$'[0Q'_ "+'A?\
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MIG^S8.G3[-^<8W;,8SWSBM7QE\3]"\"3VT.K272O<*S1_9[2688'7)13C\:
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MHH C:,-D%00>U.V]*=10 S;GCM2A O0 "G44 ," '( S1MSU%/HH 9L'I33
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH'XD?]%>U'_P'%?0(C [8IVRLGCZ][^[_P" Q_R'R(^?/^% ?$C_ **_J/\
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MQ7T*T088*@CT-*$QV H_M"ORI67_ ("O+R#DB?/O_"@/B1_T5_4?_ <4?\*
M^)'_ $5_4?\ P'%?0>WV%&WV%3]?Q':/_@,?\A<J/GS_ (4!\2/^BOZC_P"
MXI#\ ?B/Q_Q=[4?_  '%?0FWV%(4S1]?K_W?_ 8_Y#Y$?*&B?!3QY/\ $'Q!
M:1_$O48+J*&$R7PMAF<'.%].*]B^%GPS\5^"M4NKG7O'%UXH@EC")!/&$$9S
MU%>F&(9R  3QFG*,4JN,JUERR2M9=%^=AJ*6J%48%+117"AA1113 XCXT^,;
M[X??"+QGXFTVW%U?Z1I%U?6\+ D/)'$S*"!VR.:^<_"W[+-CXT^&^G>-]2^+
M/C"?Q3J%A'JCZY::T8K.*5D$GRP#Y!&"?NGJ!S7T%XN\>W^E^(-6T,>"-6UV
MP@T"75?MUNB-;74H9E^PJ">9F R >,-7PU-X!T>>\E,'P!^-%CI4CF1M!M-7
M$>GX/)3R=^-I],UE(UAL?9O[+GCO5_B3\$?#VMZY,EWJ3^=;2WL:[4N_*F>(
M3J/1P@;\:]8/2N,^$%W%>?#;0'@\*W/@F!;?RXM!O$5);-%)548+D= #^(KM
M*T6QF]V?#_Q(T_XOV/B_XG^+]4^'$6N02:9=:;I%Z-7B1-/T_P IM[+&>2[<
ML3WQBN'L;WQ#J'[#'PGU;5M!_LS2?#&MZ/>+<"X65;BQ5R'N6"_<VENA]*_0
M_4-/@U6PN;*\B6>UN8VAEB?HZ,,,I]B":R=/\#:%I7A*+PO:Z3:Q^'HK?[*F
MF[,PB+^YM/:H<;E\_D?-_P"U5KVF_$'QM\"/#N@7T&J:C<>*(=8"6L@D*6L,
M;,\AP>%^8#)KKM0^'W[0DNH74EK\3?#4-HTK-#$^B.S(F?E!._D@=Z[[X??L
M_?#[X5ZI<:CX5\*V.D7TZ['N(@S.%S]U2Q.U?9<"O0CTJUYDMKH?*/\ P3EC
MN(OA!XM2[F2XND\::NLTT:[5D?SOF8+V!/:OJ^OEC_@GE_R2SQM_V/&M?^CZ
M^IZ8@HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UJ
M=4;]_P!: .3^$GC&X\?_  \TC7[N&."XO%D+QQ'*KME=!C\%%=A6!X%FT.X\
M*V,GAH0C1&#_ &;R!A,;V#8_X%NK?H **** "BBB@ HHHH **** "BBB@ HH
MHH **** &LN00>17G?C/X467BCQ%X6U.*VL8$TF]:YN$-NN;E3&5"].>3GFO
M13TJ)K<,>_'3FDTGN:TJLZ,N:#L_\U8^</#_ .S'KOA&U\1S:=J&C7&HZG(_
MD_;+,O'%$TK,0!V;:0 17E7PP^&WQ!\"^)O'/A[P]J^EV]S9VT3:@TJ%ED5U
M+*%], FONG!YYK-BT"Q@O;J\CLX4NKL*MQ,J@-*!T#'OBL71CI8]^EGN(C&I
M&JE+GMNENK6_"Y\S_#/P_P#&JX\"Z+)HOB#1;;2VMQ]GCF@)=5R>#[URGA;1
MOBE)\;O%$%CK6E1>)8[=/MER\)\ITXQM%?9MI80V-ND%M$D$*#"1QJ JCV%0
MQ:)8V^H37T5I#'=RC;)<*@#N/0GO1[)62NQQSJ474?LH>\G]E=7?7N?/'B;P
M]\>8O#NI//X@T.X@6WD+QI9F5F 4Y 0_>SZ=ZJ^!] ^.MSX.T>6SUS1;.V:V
M0QP2Z?\ 9W08Z&,<*?:O?O'0">#-;.5VBSESYDQA'W#UD'*?4=*H_"=@_P -
M_#C*R,ALX^8[HW2].TIY?ZGK6O(N6QP_VG/FO[*&W\J/+?\ A&?C_P#]#-H'
M_?@T?\(S\?\ _H9M _[\&OH':/2D*C'2H]FN[+_M2?\ SZI_^ (^4M7T'XS)
M\2?#\=QK^BOK+6=R;:58"$2/Y=X/N>/RKB_BGXX^)_P?\?Z7J>M:OIESJ%Q8
M^1YEO;DHMN9<D$=<Y&:^UYK"WDN5N7A1IT4JDA4;E!Z@'WQ7R_\ M2_!W5-0
MT5=9DU^_U;9= 16+6ZE85(8G!49P*RJ4W&#<6[GMY7F-+$XJG2Q-."BU9^ZN
MM^R/<?A]X_A\56&G0-.EQJ4NG1:A(T<91"CD@$ ].G2NWC<GK7P%ING>+/!?
MC'X=VT7B;4[5->M;5&?8%,"%C^Y&>NW'3WK[TTJU>TL8(9)WNI(U"M.XPSGU
M.*UISYE9K8\;-<!#!2A*G-.,[M;][?F7:***U/#"BBB@ HHHH *0]*6D/2@#
MA_B%X@U'1-<\'064GEPW^J+;W(V9W1E&./;D"NW48-8/B3Q+I^A:AHMO>QF2
M74;L6UL=N[;(5)S[=#S6\N>* '4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!PGQN\5:EX%^#OC7Q#H\7GZKI>D75Y:
M1[=P,B1,R\=^0.*^/DU.\^+6N>!/ $GQ2U*Z\/Z-X6D\5^)O$MC>+"\T\Q_<
M1M*O"!&8G8?X<9K[6^(_BW3O 7@'Q#XCU9#-IFEV$UY<Q 9+QHA9E /4D#%?
M'%QJ7V;PYX7\">$/@UX7T_Q-\0+*YUW6M$NI6%M#91G='YS+SN<%1CH&R*SE
MN:PV/HS]D[Q=J_CCX#^&]4UF\?4KLF>W349%VM>11SR1QS$>K(JG]:]AKSC]
MG_QO8_$'X2Z!JUAI,>@QK&UI)I46-MI+"[121C'8,AQ[8KT>K6QF]V%%1O/'
M%C>ZIDX&XXR:>&!IB%I#TID<\<N=CJV#@X.<&GGI0!\L_P#!/+_DEGC;_L>-
M:_\ 1]?4]?+'_!/+_DEGC;_L>-:_]'U]3T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6_M/5M*66]*^6\T<C1F51T5]I&X?6NNTS2;;1;"WLK&WCM;2! D<,0VJBCH
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M'H/2KBI?:./$3PTK?5X./>[3_1$U%%%4<84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% &)XO\1Z;X/\ "NL:YK,HATG3;26[NY67<%B12SG'?@'B
MOSV;X*S^,9Q\2])_9BTEO#EP/[0M])NO$DT%U<PGYA)]E4^0I9?FV,.^#FON
MOXVZ=H.L?"#QG9>*;_\ LOPY<:1=1:A?8YMX#$P>08!.57)X!Z5\^^#=;_:6
MA^'VC:)H.D^!/$FFRZ?#'IGC9[^>&.>U:,>3<26Q7<'*%20#C-9R5V:P=EH>
MQ_!RS\ _$:PT3XJ>'M!AM-0O=,2PBFFAV3VD,;,K6VW^#8P92!CIZ5ZQ7 ?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-S$#N:V-)UO3]>TZ'4--O;?4+&8;H[FUE62-QZA@<&@"Z3BC->*_&[]HS3_
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M5C<Q;0MHY)1MI' ;[P':OHK]H:TN[W]LOX:6^G,8K^Y\*ZO;PRKP0[#"C/\
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MQ:A\;K3XBW;^(["?^QM!TV*&PL$W#YF=26 YPH8CZ5^G!\,:0SW[-I=D6U
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M6!*_4=J\._;EO[K1_P!E/X@7MG<2VMW!;0/%- Y1T(N8L$$'(KQKXH_ C3O
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M_ E?\:X?_AE#X9?] !?^_P W^-'_  RA\,O^@ O_ '^;_&B\^R#DRS_GY/\
M\!C_ /)'<?\ "QO#/_0<T[_P)7_&C_A8OAG_ *#NG?\ @2O^-</_ ,,H?#+_
M * "_P#?YO\ &D/[)_PR(Q_8"\_]-F_QHO/L@Y,L_P"?D_\ P&/_ ,D>KV.H
M6^HVD=S:S)<V\@W)+&VY6'J#7P5X%^'VC_&?]H?X]Q>-/B!XET:#1-<MK?3K
M6Q\1O8QI&\&YP%SC&0.E?<WAOPW8>$="L](TJ#[-I]FGEPQ D[5],FOBKX/?
MLV>"/C%^T7^T3>^//"0U8P:_:K8377FQC8UN=^TJ0&&0/6J9Y:Y4Y<KTZ&O\
M!/&X^$O[0_Q"\$VOCN\\9?#/1] 36IM1U2[^U/I5QOPT1G_BR@SBNXT_]NC3
MY38ZSJ'P^\4Z1\/K^X6WMO&%W;J+1MS;4D9<[UC8XPQ&*W?BG^S)X?T;]FWX
M@>"_AGX?L_#]UJ^F31I'9KAIY-O 9CDG/3D]Z^+8;7P!KGPRTCPQ=:K\4_$'
MC":.#3+KP"+B2/9*H5'!)3:L2D9!ST J=5H-)2U/M3XC_M>6'@[XDW7@'1?!
MVO>,_%*6$.I06NCQJRSPR9.[>2 H '4]<\5QD7_!072]7\.76KZ'\./%VMP:
M1N_X2$6]NH_L=E/SI(2?F8#DA<\5-\*- GT?]M?Q5&;"XM[2#P)I-M&\RE@I
M0D%/,Q@L,<XKE/@AIEY:_ 3]H]7LIX9Y]3UHQJ8F5I087 *C&3GMBB[%9$'Q
MX_:'72_CW\!O%6@-K6MZ#KFD7=Q;:-I.XOJ#R*/*4QYP3SU;I@U[5X$_:KTO
MQ3#XQLM9\-:OX1\6>%M/?5+WP[JJJ+B2V5"XDB()5E.TC(/!QFOE#1_$Z_"W
M5_V3?$>LZ/J<FDZ=X0FCOI;:R>4V09%&]U R #@'N :[Z]UL?'WXR_$7XD>%
M+&[/@S1OAQ?^'(]2F@:(:E=R%IOW0(RZH!C/J>*$V#2V/2? 7[>'AKQGH>I>
M*KKPKX@\/?#^QTG^TV\5ZE $M)'#*K0)@Y:3>^T #YB#BIM#_;6MCKOAZ#Q=
M\/?$_@/0O$<\=KI.NZS"HMYI9!F-'VDF,N,$;L5X_J/PO\1>//\ @EOX4T;1
M-,ENM:L-/T_4O[),962Z$$Z2R1;3_$55B >I JY^T5\;]"_:V^'&A_#;X>:?
MJ>H>+-=U6PFN(KBQDA.BQ0SI++).S !"H0KCJ<G%%W85EV)_$'C7[!J/[8+^
M)-8UX:!I%QI8B32KHI<6B-8JS"W).$)/)QC->NW_ .T1JO@/1-%BTWX7>,?%
M6BKHUI=+K<'E%"C1 _O&9@2P&"Q]37SY\7-+U"ZTW]ML1Z?=,;N321;A86/G
M8L%4[./FY':J_P :OCU::Y:^"/@]J5SK'ACPC9Z)I\WBC5;6QF>:[7R(R+*
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M$=Y'I^E^+KJW"6=Q/)_JQC.X!CP"1@UY3\(M(O8/V*_CE!)8SQW4VI:X4B:
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MO>K3,I*PZBBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "FL.<TZF/TZ9H
MP/A]X2L_ O@_3M"L)VN;2T#B.5R"6W.SGI[L:Z*N%^!^B:IX=^%NA:=K4<D6
MIPK*)EE?<P)F=AD_0BNZH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ,+QL"WA#60I(/V27!$_D?PG_EI_!_O=JH_"T,OP\\/AF+
M,+1,DW?VH]/^>O\ '_O=ZO\ C-BOA+6#Z6DO2#SOX3_RS_B_W>]4?ABV_P"'
MV@'UM$_Y=?LW;_GE_!]*%L!U5%%% !1110 4444 %%%% !1110 4444 %(>E
M+2'I0!A>(M.T>^OM'DU,Q_:+>[$MEO?:3-@XQZG&:W .:X[QWX3N_$FM>$[N
MV:,1Z5J2W<P<\E C#CWYKL5Z^U #J*** "BBB@ HHHH :Z"12K#*G@@]Z^?;
MW]D2*&;5[+P]X\\0^&/"FKW#W-[X>L60PLSG,@C<C=&&[@>IKZ$HH \\/P7T
MZPL?!6G:%J-]X=TGPO*KPV%@^V.Y0 CRY?4$DD^]<YX\_9PC\1>-+KQ9X:\6
MZMX&UV^@6VU";2PCI>(O0NCC 8=-PYKV:B@#SGPI\#="\&?"W4/ ^ES74=KJ
M$,\=U?N^ZYFDF!$DK-W8Y)KH?AMX$L?ACX$T/PKIKR26.DVJ6D,DOWV51@%O
M>NEHH XOXQ_"[3_C1\-=;\%ZK<SVFGZK&D<TUMCS%"R*_&?= /QJ'QC\)--\
M::QX'U&[NKB*;PG?_P!H6BQXQ*_E-%A_;#&NZHH \_N?@SH][\7[SX@W$LL]
M]=^'1X:FLI # ]OYYF)(]<DCZ&O,8_V+]/CTT>&1XY\1_P#"NA*9!X2,JF':
M6W>5YN-_E9)^3TXZ5]'44 >.^.?V<;77O$MAXC\+>)-2\!:_:6*Z7]JTD(R2
MVJ_<B:-QM(7L>U=/\)?A%IOPETN_BMKR[U;5-3N/M>I:M?L&GO)L8W-@ # &
M !TKNZ* "BBB@ HHHH **** "BBB@ HHHH 0U\HZ'X,T;X[_ +4_Q+/C*QBU
MW2?#%M:Z9ING7@W0P,Z[I9 O3<V>M?5QZ5\Q^)=/\7? OX]>*/&FB>$+[QKX
M9\66D'VBUTET%Q:7<0*Y*L1E7&.>U3+H7'K8G_8^FF\/:U\6O 2322:+X5\2
MR6^DQ.Q;R+9XUD$0)YP"S8]L5WMW^U;\)K*[FM9_&^GQ7$+M%)&5DRK X(^[
MV-8G[+WPZU_PI9^,?%7BJT73O$'C36I-8GTU7#_8HRH2.$L.I"J,^Y->NMX0
MT-W9VT;3R[')8VJ$D^O2B.PI;GR'^P/\6/!>A_"_Q>FH^*=)L9)_&6KW$<=U
M=I&S1M/E6VL0<$5],_\ "\_AV/\ F=] _P#!A%_\57,7_P"R!\&-4O[B]N_A
MOH$UU<2&660VV"[GJ3@U!_PQC\#_ /HF6@?^ _\ ]>J).N_X7I\.Q_S.^@?^
M#"+_ .*H_P"%Y_#L_P#,[:#CU_M"+_&N0/[&/P/P?^+9:!_X#?\ UZ\8^*W[
M(7P[MOCG\(H-&^&NG#P_/<7HUA;>U/DE1 QC\WG^]C'O0!]+?\+T^'7_ $.^
M@?\ @PB_QH_X7G\.O^AWT#_P81?XUR _8S^"!/\ R3+0/_ ;_P"O2_\ #&/P
M/_Z)EH'_ (#_ /UZ .N_X7G\.O\ H=] _P#!A%_C1_PO/X=?]#OH'_@PB_QK
MD?\ AC'X'_\ 1,M _P# ?_Z]'_#&/P/_ .B9:!_X#_\ UZ .N_X7G\.O^AWT
M#_P81?XT'XY_#K_H=]!_\&$7^-<C_P ,8_ __HF6@?\ @/\ _7H_X8Q^!_\
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M#4EQ%_JY7O(6=/H<Y%2+\9OAHI./&/AT?/YG_']%][^]UZ^]<NO[&?P0.?\
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M (3FPP/Q:IEL5'<TOV@_'GB67Q[X&^%_@_5?[!U?Q09[BYU=8P\EK9P+F0Q
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M3]4LX-1LIEVR6]S&'1Q[@U!X9\(:+X,TY=/T+2[32+%22+>SA6-,^N *V**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/6L?X.?!/X;>/_V,O^$O\3V%CJ7B'5]/NM4U3Q1<@&^6[#R$OYQ^:,H0  "
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 SU^M.'2BBDA"T444QA1110 4444 %-'2
MBBD^@AU%%%,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>glyc-20241231xs4030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4030.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "+ JH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "N>^(O_)/O$_\ V"[K_P!%-70USWQ$_P"2?^)O^P7=?^BF
MK2G\<?4QK_PI>C_(_-(RN#]]NOJ:7S7_ +[?G3#U-%?HY^$:C_-?^^WYT>:_
M]]OSIE% :C_-?^^WYT>:_P#?;\Z910&H_P U_P"^WYT>:_\ ?;\Z910&H_S7
M_OM^='FO_?;\Z910&H_S7_OM^='FO_?;\Z910&H_S7_OM^='FO\ WV_.F;MU
M% :C_-?^^WYT>:_]]OSIE% :C_-?^^WYTGF/_?;\Z;2>E 79]7_L2L6LO$N6
M)_>Q]3[5YW^UL[+\7KD!B!]EAZ?[HKT3]B3_ )!_B;_KK'_*O.OVM_\ DKUS
M_P!>T/\ Z"*^?I?\C*?I^B/M,1_R(J7K^K/&?-?^^WYT>:_]]OSIE%?0'Q>H
M_P U_P"^WYT>:_\ ?;\Z910&H_S7_OM^='FO_?;\Z910&H_S7_OM^='FO_?;
M\Z910&H_S7_OM^='FO\ WV_.F44!J/\ -?\ OM^='FO_ 'V_.F9 ZT;@* U'
M^:_]]OSH\U_[[?G3/<4;LT!J/\U_[[?G1YK_ -]OSIE% :CO-?\ OM^=?>G[
M,))^#FD9.3F3J?>O@@]*^^/V8O\ DCFD?63^=>'F_P#NZ]?\SZ[AE_[9+_#^
MJ/BKX@2./'&NC>W_ !^2]_\ :-8'FO\ WV_.MSX@?\CQKO\ U^2_^A&L"O8I
M_!'T1\O6_BR]6/\ -?\ OM^='FO_ 'V_.F45H8ZC_-?^^WYT>:_]]OSIE=%\
M.-"M/%'Q$\,Z-J"N]AJ%\MO.L;%&*%6)PPY'(%3*2C%R?0J$95)QA'=M+[W8
MP/-?^^WYT>:_]]OSKUW]H[X(0_"6_P!/U#11.WAR\'DD2N9&@N!DX+'J''3/
M<>]9WC_X=Z+X:^#_ (%\26$4T>JZRH-VSSLZ'Y&)PIX7D=JYX8FG4C"4=I:+
M_@G;4P->C.I3FDG35WZ:;=]_(\S\U_[[?G1YK_WV_.KND>&M8\0I*VDZ-J&J
M)%_K'LK5Y53ZD#&:HB*0W!M_)F^TA_+-NR$2!O[I7&<^U=*:?4X;223[[>8O
MFO\ WV_.CS7_ +[?G6A:^%-?OK^6QM]!U.>^B7?);1V4ADC7L2,<5G2Q20RO
M%+%)!,A*O'*A1E/H0>11=/1,&I+5H7S7_OM^='FO_?;\Z913%J/\U_[[?G1Y
MK_WV_.F44!J/\U_[[?G3X)'\^+YVY8=_<5#3[?\ X^(O]\?S% TW<_1#QAQ\
M%M1YY_L?K_VRK\[_ #7_ +[?G7Z(>,?^2+ZC_P!@;_VD*_.ROG\H^&IZGV7$
MOQT?\(_S7_OM^='FO_?;\Z917T!\9J/\U_[[?G1YK_WV_.F44!J/\U_[[?G1
MYK_WV_.F44!J/\U_[[?G1YK_ -]OSIE% :C_ #7_ +[?G1YK_P!]OSIE% :C
M_-?^^WYT>:_]]OSIE% :C_-?^^WYT>:_]]OSIE% :C_-?^^WYT>:_P#?;\Z9
M10&H_P U_P"^WYU<C+&-?F?H.YJA5Z/_ %:_04%)GZA4445^:'[V%%%% !11
M10 4444 %<]\1/\ DG_B;_L%W7_HIJZ&N>^(G_)/_$W_ &"[K_T4U:4_CCZF
M-?\ A2]'^1^:!ZFB@]317Z.?A 5]"^#? GPUTOX&:?XT\7Z+>W\K2M'+)92R
M%V/F%5PH=1CI7SR>E?57A2X\*6_[*&G/XRMKRZT/[0=\=CN\W=YQVG@@]:\[
M'2<8PLWK);;GMY3"$ZE5R47:$FN97BG=6;.>/PJ^&GQ5\#:UJ_P^&I:3JNE(
M6:WNV?#$ D*R.6&" <$&JOPS\"?#M?@5_P )OXQT>[O7BG>.9K2:3>0&  "A
MU'%1ZE\<_ _@_P #ZEH'PT\/7ME/J2E;B^U %2N1C<=S,SG&0!P*LZ6HA_8G
MU!<X NF')Y_UB]:XY>V4$I.23FDKOWK==CTHO"NJYPC"4HTY.5E[G,K6LGY;
MV)-)^&GPH^-%GJ-KX#?4M!\1VD7F1VU\SA9!VRK,P()XR#D5\^75M-97=Q:W
M*"*X@D:*52>C*<$5[+^Q_%)<_%YY(#NB@L)/-*\@ D8!JOH_PZT'XJ_$CQRU
M]XKB\+V]M?OY,D@CQ<9)SC>1TQVKJA4>'J3A.3<4D]=6KGGU*/UVA1K4H1C.
M4I1M&T4[:WU=EY]RC^S?\/-%^)GCK4-+U^"2XM(;+ST2.9HR'W8SD<GBO--4
MA2UU;4+>,$10W,D2#.2%5R!R>O KZ?\ V?\ P/IWP_\ COJNF:9KR>([8Z,D
MOVQ/+QDR'*_(2.*^8=<FC'B#5P9%!^W3]6_Z:-6E&I[2O.SO&T6C#%8?ZO@Z
M7.DI\TT]NC5M?(Z+X>?"_7?BGJ<UGHPBM[>VPUYJ-PP$5JIS\Q&<LV 2!^?%
M=W^TY\,O#GPPM?"T7ARW,37=M,;BY,S2?:&4)M?YB0,Y)^7 Z5X[)K>H6.@Z
MI8V=_<VMC?1_Z5;P2%%N N=N_'W@,GBOH']KR,-H_P .4&%4Z=*H"CI\D72B
MHZBQ5).7NN^GRZ]_T*HQHSR_$-0_>1Y-7YRM[O;3=[N_8P?&/PPT[5O$VD1V
MTUIX9T.S\)VFKZO?K 6";MVYP@(W2,?Y5A?\*:CO(H[S2/$2:KIE[IT]_ID_
MV0QR7$D/^LMY$))C<#)!YZ'BH3\;+V36H;N?1+&[T]M%BT"]TR:1MEY;IG#%
ML91^>HJ+_A<=Y9>(O#%[H^CVFBZ1X;+FPT:&9G1P^?,\R5AN8L#C/UJ8QQ,4
MDGT\O^'O?Y6\RYU,!.;DUHWTYD[76R^&W+=[<W-Y&I>? &_TU=.GO-3$-C/H
MTFK7-PL&XVQ55;R2-W7YU&>._%>51N'16QC(S@]A].U>BZW\<=<\0>&?$FAW
M%O"+?7+S[6\HD8M N%!B0$<KA!R<?2O/.W3'M731]K9^UW_K^OD<&*>&<E]6
MO;K?OMU]+_/R"D]*6D]*Z#B/J_\ 8D_Y!_B;_KK'_*O.OVM_^2O7/_7M#_Z"
M*]%_8D_Y!_B;_KK'_*O.OVM_^2O7/_7M#_Z"*^?I?\C*?I^B/M<1_P B&EZ_
MJSQ:N_\ @'X1TKQW\5M-T/6K<W>F36MQ(\(D9/F105.5(/>N ]:]8_94_P"2
M[Z/_ ->5W_Z M>QB&XT)R3LTG^1\O@8QGBZ49*Z<HII]=4=M?V'P"M?&MSX3
MNM%U>QOXKW^SWNS)+Y*RDA0=XD. 20,D5@W'P,TOPM^T1HG@Z^>35/#VI1M<
MPK+(1+Y>UOD=EP258#GN#ZUU/BGQ;\$O#'Q0UJ_O_#VM:AXEM-1>6?*,\!N5
M(.X R!2,X(R/PKG_  7\2[KXK_M/>'=<N;;[% H>WM+0L&,481R=Q'5B3D^G
M KR8>V47./,H\COS/K;2Q]'5CA958TYJFY^U22@OL\VJGT^7<TO%EG\ ?"GB
MF^\.:GH>M6EU:R"&6[B:5HDR =P82$X /7;7G_QP^$$7PMU33KG2KR34/#FJ
MQ^99S2G<\9QG:3_$".0>OK6=^T3/&GQE\6AG4'ST'7N8UP,5ZM\>T^P_ OX9
M:1>2>3J+/!D/]Y5\OYCSZ UO3YJ3HOF;Y]TW?I>Z.2M[/$1Q473C'V7PN*L_
MBM9VWO\ F?-SL0IY Z=#7L/Q\^&F@?#_ $/P=<Z);26\VIP>9<M).TFX[ >A
M/')[5;\7_L]^%_#GA"_UBT^(\&I7=O!YR:>OD9E/'R\-G],UN?M8NJ^%_AP2
M57-I_$?^F:UH\1&K6I>S;M=WW70Q^HRPV%Q#KQ2DE"VJ=KRL]5>Q\\JC2.B(
MA>1V"*HZLQ. ![Y-?2GPY_9AMK+PAKFJ^.((9M4^QO/::;%.<VJA"0[%" 6)
M'3D#%?-,4X25)(I!YL;!U93RI!R"/H17T?\ LNZE>ZQI7Q0O-1O)M0O)+(;[
MBXD+NW[I^Y[>PXJ\>ZD*+E"5K6]=U]QGD\:%3%*%:',W>W9:-W:ZO33IUWL>
M7_![0M*\1Z+X[.LRP6J6NDI-'?SP&7[(?,.751R6P,<'FM[1OA=!I7B)1::A
M8>(-*U'PO<ZQ9W.I:>V515 /[K<"D@/W6R0,GBO.O"?BN7PYH?B*PCM8YUUR
MQ6RED=R#"H8MN4=">>A]*Z>P^,-[8_V7C2+:4:?H$WA]5:=AYD<F,RGCAN/N
MXQSVJZL*W/+D>C].W^9SX2MAE2I^U7O+6]G_ #-^C]WROTN:?AGX&6NJ3^$]
M*U+Q;%I/B3Q#:+?V^FFS:9!;E21F4,!YA"L0,8PI'UV;'X:^'/$O@#X=P7&K
M1>']9U.^OK!+B*P:>74)5G*1[R" JKMZGID8[FMSX=>/_#FG6_@O7-;UGPS=
MWN@:>;1[JZ\^/5H(@K!8$@!,<C9(42$_=)('S5Y9:_%.[MH/!B+ID./"VHW&
MHP;I"#<&68R[7X^7&0,C/2N=?6*LFDVK/R_O;::KX=]3N_V+#P3:34E:UY-V
MO3=W9NS^/:R>W=',:UI4V@ZWJ.EW+H]Q8W,EK(T?W69&*DCV.*IU>U_5W\0Z
M_JFK21+;R7]U)=/$IR$9VW$ ]QSUJC7IJ]E?<\&7+S/EVZ>@AZ5]\?LQ?\D<
MTCZR?SKX'/2OOC]F+_DCFD?63^=>+F_^[KU_S/J^&/\ ?)?X?U1\3_$#_D>-
M=_Z_)?\ T(U@5O\ Q _Y'C7?^OR7_P!"-8%>Q3^!>B/F*W\67JPHHHK0Q"NQ
M^"X_XO)X()_Z"B=O]EJXZMGP3XB7P?XST/7FMWNUTRZ%R;=&"M)@$;03P.M9
MU$Y4Y);M/\C6A)0K4YRV4HM^B:;/JFY\3V7CSXB_$'X3>)I"]K?%9M)E?K&_
ME*S(I[%2 Z_\"KBOCOX2N_#WPE^%_AO4F6*YAO$L9I(SD=&7<#].:\=\<>/[
MCQ3\2+OQCIT,NC7CSQ7-NC.&:!T50#N&,_=[=LUU?QG^//\ PN/0M'L7T672
M[JQE\Z2X\]621MI4[0!E>>1GIC%>3#"U*=2DXZ1TNNSM:_\ PQ])6S&AB*.(
MC4UF[J+U]Z+ES6?IY]'W/1?V@?B7KWP3U#P]X3\%2PZ)IEK8^>2MNCF8@XP<
MC&/7')S4?Q@LK;Q+9_"CQY);16>M:E=VT=TL8V^:#AL_@1Q[&N2B_:%T/Q'H
M>EV7Q"\"Q^+;W30!;7T4BHS #C>K$$$XYY(/I7+^/_C/J'Q"\7:)JEQ91V&D
MZ-*CV6DV[9VJI&<MC!8@8Z8%*EAJD7!.%FKW>GO7_'7SV'B<=1J*H_:<T9\O
M+"S7)9J^^BMK\.Y[1\>OBUXE\'_&;1=(T.]33K%O(EN4CA0FZ+MMQ(2"2 .F
M"*YW]H'P;:^+/V@]&TM[V+14U/3P\]\Z@JI7.&() /IR:\T^)_Q4C^)'Q#L_
M%*:7)IR6ZQ*;.657=MC9^\!@9J'XS?$N'XO^)+?51I3Z:D5J+8VT\BR[L'.[
M(JZ&%E3=-I<KY6F]-^GJ98S,*==5TY<Z<XN*=]EO;M?;N;/Q<^"]A\,-'LKZ
MS\76_B-[B?R&AAC1#&,$[OE=O3TKR_\ #%116D-NQ:*&.)CP2B@5+7J4XRA'
MEE+F?>UCP*TX5)N5.'(NUV_Q84445H8A3[?_ (^(O]\?S%,I]O\ \?$7^^/Y
MB@%NC]$/&/\ R1?4?^P-_P"TA7YV5^B?C'_DB^H_]@;_ -I"OSLKY_*/AJ>I
M]GQ+\='_  ABC.:]K^!/PV\.ZQX0\1>,_$FES^)+?2F,<.CVX+%R!DL5!&X^
M@/'6M+3M4^#/Q9T76+1]"M?AQKEI%NMKB2=(RQQQT(!YZJ17IRQ2C*45%M1W
M:Z?K^!X%/+Y3A"3J1BYIN*;:;2\[67E=G@5%7]"\.ZMXFU4:9H^GS:K?\GRK
M-=WR@XWD] ON36Y=?"7QO9WES;3>$M36:VB\^8!$*I'S\^[=@C@]#GBNJ4X1
M=G)7]3SXTJLX\T8-KR3?RT6YRE%:5IX6UJ_\/SZ_;:5<W&A6Y*S:C&%,49!P
M0?FSG) Z=Z=9^%M;U'0;K7+;2;BXT6S)6YU",*8H",$ALD'C(/3O3<HKKY"4
M)O:+UUV>W?T\]C+HKH/"OP[\4^.HY9?#^@7>IV\3&-[B)56(,!DKN8@$X["J
MFM^$=>\,ZS#I.KZ/=:;J4Y40VUP@!F+-M780<-EN.":7/#FY;Z]@=.HH*HXO
ME?6SM\GL95%==:_!_P >7M_/91>$-4^U0H'EC=$ 0'.W+%L$G!P,DU7T;X7>
M,_$%Q>PZ?X6U.XFLF*7*&(1^6XYV$L0"V/2I]K3_ )E]Z+]A6NE[.6O]U_Y'
M,T5)<VEQ:7CV<]O/#>I)Y+VKQD2J_3;MQG/TKJ;WX0>/-/TDZG=>$=4BL0-S
M2>6K,J_WB@)8#\*ISC&W,TKD1IU*EW"+=M[)NWKIH<E16CX>\,ZSXNEEBT/2
MKG5Y84\R5;7!*+ZD,1Q3M \,:SXKOY;'1-+N=6O8U+R6]L%+J <$G)'>GS15
M[O82C.5N6+=]M'KZ=_D9E%:_A_P?K_BS4IM/T71[O5+V$XFB@0?NN<?,Q.T=
M/7-3^*? 'B7P.8_^$@T*\TE)3MCFE4&.1L9P&4D9QVSFESQYN6ZN5[.IR>TY
M7R][.WW[&#5Z/_5K]!5&KT?^K7Z"K(1^H5%%%?FA^^!1110 4444 %%%% !7
M/?$3_DG_ (F_[!=U_P"BFKH:Y[XB?\D_\3?]@NZ_]%-6E/XX^IC7_A2]'^1^
M:!ZFB@]317Z.?@XE>AW7Q>-Q\&H/ ']D86*02?VC]HZ_O-^-F/PZUSP\$W,7
M@:/Q/>W45C;7=Q]FTVUD0F34&!P[K@X6-<'YCQ_7TC3?V6=0UBTEN+3Q]X6N
M(X$$EP8G:00C_;*M@ >]<E:I05G5>S\]U_PYZ6&HXQN2P\&^:-G\/POU?6WK
M;79GBV>*]B^'7[0-EX)^'Z>$]2\'0^([,3/*YN;A1&^X@X,;(W2LRW^ 5YJ/
MC&P\.:;XOT'5KF[MY+IKNR+2PP(F/OD$\G/&*T5_9DU2^@O?[&\:>%O$%Y:(
MSM86$Q\TXZC.YL'MSBLZU7"U4HU)>?5&^&H9AAY.="FT]G\+[-JS;3^5RWKO
M[3]S_85SI?A#PCIG@V.Z0I-<6^UG /!VA449QW.:\0>WCE4>:B2XYS( 3GOU
M[UWO@3X1:CXXTO4M6N-4T_PQHFGR>1/J&K'"^:."@4$=/4_K2^/OA!J7@31[
M'6XM4T_Q)X>O&\N/5-*)**_96&3CH>035TG0HR]E3=F_7?U_X)AB%C,935>N
MG**6FUDK_P JZ7ZVMYC?@M\3$^#GB6\U:/21JBW%M]G\A)A#M^;=NSM/Y8%>
M@R_M(>#Y9&=_@]HS.Y+,[/"223R2?)]:\&ZX4!F8_*%12S,?0 =3[5VVM?!_
MQ'X9^'Z>+=;C32H)KA+>WTZX5OM,N[HQ'1!@$X//':BM0H2FIU=WIN]?N96%
MQ>,I4G2P_P $;OX8M+N[M?\ #]#EO%E_!XDUO5[ZULH](M;V5GBL8L%;92
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MP /3USV )[5[LXQG%QEL]SXZG.5*<:D-T[KKKTT-#Q=KW_"6>+M<UWR/LO\
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M(X[5M+V&,M=WMZK_ ".:#Q>5)V7(I;Z1:=NCW5UVW/0?B;\4] \>:-;V6D^
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M+_DCFD?63^=>-F_^[KU_S/JN&/\ ?)?X?U1\3_$#_D>-=_Z_)?\ T(U@5O\
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M%DTV[NL7,@!Z[5! ![9/-<%X;\%:[XO\2?V!I&G/<ZLK,LD#D*L.TX8R-T4
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M_:(U74KWP5\,- U*\EOM8OD%[<SSX7,CA4!8#  !=OH!7@"X$D9*[PKJQ0G
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MN,+RW;;^]W.#&3A.K:&JBE&_?E25_P#+R/J_]B3_ )!_B;_KK'_*O.OVM_\
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MA!+L!TYP.>]6/ GCR+PM-XCCUC3)/$NF^(;?R=2A:Z,$\K;BX<2@$Y)8Y_\
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MJF@:B^GW@78Q"ATD7^ZZG@C]:]*=/VM#D23NEO\ \ \&G5]AB_:MM6;VM?\
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MM*_O*VB3Z>NI['^S;IMW;_!OXI7DMK/!;7%K(L4D\102%;9@V 0,X)Y]ZJ^
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M^;__ !5/^V*/\K_#_,/]5\5_/'\?\C\] ,#'ITH]*_0O_AGOX=_]"M9_F_\
M\51_PSY\.QT\+6?YO_\ %4?VS1_E?X?YA_JOBOYX_C_D>1_L2?\ (/\ $W_7
M6/\ E7G7[6__ "5ZY_Z]H?\ T$5]A^$OA]X>\#"X&A:7#IHGP9?*)^;'3.2:
MH^(_A)X0\8:H^HZSH5M?WK*%,TA;) X'0^E>7#'4XXN6(L[-?/H?05<HK5,M
MA@E)<R=[ZVZ^7F?G#2$9Q[<U^A?_  SW\._^A6L_S?\ ^*H_X9[^'?\ T*UG
M^;__ !5>I_;%'^5_A_F?/_ZKXK^>/X_Y'YZGWZT5^A7_  SW\._^A6L_S?\
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ML_S?_P"*H_MBC_*_P_S#_5?%?SQ_'_(_/6BOT*_X9[^'?_0K6?YO_P#%4?\
M#/?P[_Z%:S_-_P#XJC^V*/\ *_P_S#_5?%?SQ_'_ "/SUQ\P)RQ[$G.*/SK]
M"O\ AGOX=_\ 0K6?YO\ _%4?\,]_#O\ Z%:S_-__ (JG_;-'^5_A_F'^J^*_
MGC^/^1^>AZ5]\?LQ?\D<TCZR?SK3_P"&?/AV#_R*UG^;_P#Q5=AX?\-Z;X4T
MI-.TFTCL;*,DI#']T$]>M>=CL?3Q5)0BFM3W,HR:ME]=U:DDTU;2_EY'YR?$
M#_D>-=_Z_)?_ $(U@5^A]W\!_ .H74US<>&;26>9B[N2^68\D_>J+_AGOX=_
M]"M9_F__ ,57='-Z,8I.+_#_ #/'J<,XF<W)3CJ_/_(_/6BOT*_X9[^'?_0K
M6?YO_P#%4?\ #/?P[_Z%:S_-_P#XJJ_MBC_*_P /\S/_ %7Q7\\?Q_R/SS\I
M&?>44N.A(IU?H5_PSW\._P#H5K/\W_\ BJ/^&>_AW_T*UG^;_P#Q5/\ MFC_
M "O\/\P_U7Q/\\?Q_P C\]:*_0K_ (9[^'?_ $*UG^;_ /Q5'_#/?P[_ .A6
ML_S?_P"*I?VQ1_E?X?YA_JOBOYX_C_D?GK17Z%?\,]_#O_H5K/\ -_\ XJC_
M (9[^'?_ $*UG^;_ /Q5']L4?Y7^'^8?ZKXK^>/X_P"1^>M%?H5_PSW\._\
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MJC_AGOX=_P#0K6?YO_\ %4?VQ1_E?X?YA_JOBOYX_C_D?GK17Z%?\,]_#O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\0?%#3=;OM"\ 7-QI?AG1-+@CFC6[BE,;W<WF.@!+(7&.<K$,_N^0>Y]%_\
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M]@'XD_#2PMM177](M6U*><PK]GDB>[5L(P8MN !SE0.*!V/3/#'C#]KCXS>
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MVG++CZUF?'+]DR'XU:QX OI/%$VD_P#")M&RK'9"7[3L*GDEQMSM]^M?0%%
M'!?&OX-:'\=/ASJ/A'75*07*AH;I4#/;2C[LB@]Q]>0<5C?LX?!;4_@'X C\
M)77BJ3Q786LA-E+/9B![>,]8^';< <XYXZ=J]6HH *?#_KH_]X4RGP_ZZ/\
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L0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>glyc-20241231xs4031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4031.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $9 ZD# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\4?M,Z\\WQK
MN%<EXK"VBA1#_#D%B1_WU7VO7Q5^U=H<FE_%=[X@^3J5I&ZL1QN3*L/T!KYS
M/^;ZDW'HU_7WV/MN#W#^U4I]8RMZ_P##7/*]3U0WVU54I$O.#U/UJA117YI*
M3D[L_<TK*P4R4;HG^E/J*[?9 WJ>!4C>A#IQS$1Z&K=5=/39"6/\1JU20H[(
M*]._90U:32_C5#;(W[J^M9H7'^Z-X_45YB2$!)Z#DUZE^R5I(O?BE=:U.X@L
M](LI)I)W("*7^4;B>!@;C^%>KE:D\=2Y>_X=3Y[B%P65U^?^7\;JWXV/N:BN
M6\%?$GPQ\18;N7PUK=IK4=I+Y,YM7W>6W;/L<<'H>U=37ZX?SN%%%% !1110
M 4444 %(>E+3)I4@B>21UCC12S,QP !U)- 'SC^V5JTL.A^'M.1B(I[EI7'9
MMB\#]:^;KW7/.M?*BCV,1AB>F/05[M^TEXK\.?$_PE9:QX7UFTUR/1KUH+PV
M;[C$'&,D=<9 YZ>]?.>>*_-,]E4CC97V:7]?>?NG"'LY97'EW4G?U_X:P8%%
M%%?-'VX=*HVYV7L@'0YJZS!5)/0#-4;+,MP[_C29#W1?HHH')XY-,L72M1DT
M7Q5H^H0,4F@N8I05Z\.*_3*&02(C#HP!K\U?">B2^+O'FB:3;#>]Q=QITSA0
MP9B?8 $U^@7AOXG^$O%'B"\T#1_$%CJ.KV"_O[6"4,Z <$^AP>#C..]?>\,J
M7LJC>UU^1^.<;N#Q-%+XK._I?3]3K:***^S/S<**** "BBB@ HHHH *\_P#C
MSK$NA_"CQ!<PDK(8#&".OS<?UKOG.%S7D/Q*\8>&/B5X9\6>$-&UZRO]?M+=
MFEL() TBLO.,=\8YQT[UA7YG2GR[V9U81P6(INIMS*_I<^.;#6%LM/6!8RTB
M]&/3ZFL^1VD=F8Y8G)/K3$.8U]>A^O>EK\8<I223Z']/I*]T% HHZ\5)12N_
MDNXV^E736?,?/OE Z#BM _\ UJ74B/4*J:DH:V)/K5L<52U.3"*@!+9S@=_:
MACEL?H!^SWJ\NM?!_P -W$S;I%M_*+>NTD#]!7HM<+\#_#\GACX5>'+"9=LR
MVJNX/8M\W]17=5^U8=25&"EO9?D?S!BG!XBHZ?P\SMZ7T"BBBMSE"BBB@ HH
MHH *9+((HG=ONJ"3]*\P^,GQ_P##OP=M(XKMGU/7[E2;31;0@S2]@S?W$SU8
M_AFOEJS_ &IOB%I_C.W\2:MJ$4^BAPMWX=M(4\A+<GG8Y&\R*.=Q/.,8QQ71
M3P]2JG*"T1QUL91H2C"I+5_U\D3?&?\ :,U[XJW=WI&BW$V@>$(Y'@<PMMNM
M0VDAMSCF./(^Z.3W/.*\P\/ZM>> M<TS7_#X6VO],?>B1C:)8_XXV]0P]>]>
M@_'[P-9^#O%MIXET)DE\'>+ +JVEB'[N&Y8;BOL''S >N[I7GU?0X2G1J8>T
M5ON?'YA6Q-+%WF_A=UVM_6Y^C?@#QGI_Q#\(Z9X@TUP]M>1!]N<E&_B4^X.1
M72U\/?LK?%-O 'C?_A%K^;;X?UV3=:EVPMM=]QST#_SK[AKYRM2E1FX2/LL-
MB(XFE&K'K^#"BBBL3J"BBB@ I&Z&EJAK^M6?AS1;[5-0F6WLK.%III7. JJ,
MDT >/_M2_%Q_ASX)_LW2Y@OB36]UO9CJ8D_Y:2_@.GN17Q!;::E@;>2TEEM+
MVV;S(;ZW<K.C]=V\=R>N:Z+QKXXO?BAXUU#Q5?[E6Y/E6%N3Q;VH/R #U;J:
MR)IDMXGED;;&@+,WH*^IP>&5.E>:UEOZ'P>98V5>NE3>D=K=^Y]6?LR_M$:O
MXRUH>#O%<:W.K+ T]KJT("BYC7 82+_"XR.1P:^EZ^(?ALR_ GX5W_Q+U2W1
MO%?B!19Z!8S=4C/W21U&?OM[ "J/P[_:H\<>"M4,GBBZ;QCHT[[KE%B2.YM<
M]3#MP&4?W6YXX->+.@ZLIRH+W4?3T\6J$*<,7*TY?UJ?=E%<WX%\>Z#\1]"A
MUGP]J$6I6,A*EXS\T;=T=>JL.X.*Z2N ]4**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "O,?CM\*A\4/"C16VR/6;)C-92OP"
MV.4/LPX^O->G45E5I0K0=.:NF;X>O4PM6->D[2B[IGYFWEE<Z9>3V-Y;O:WD
M#E);>52&1AV.>WO4-??'Q'^"WACXG(7U2T,.H*,)J%HWESKZ9/\ $/8@UX?J
MO[%FIB<_V7XNC:'/ O;7YA^*GFOSO$Y!B:4OW'O1];/\3]FP/&.!KTU]:O"7
M71M?*UW]Y\ZR.L2Y8[:H,YOIPHX0<<^O^-?4_AW]B>T29)?$'B2>]53DP6<8
MC##TW')Q7LDGP2\%2>%%\._V!:C35.X!%Q('_O[Q\V[WS3H\/8FHFZK4>W7\
MB,7QE@:4E&C%S75[:?/5O[O4^!%0(H4=!TI3P,G@>M?2WB+]C#=,S^'_ !/+
M;Q'D07\(DV^VX8/Z5X-\4? UC\-[Y](G\30^(O$@&#INFQ'9;_[4\A/R?[H&
M?I7.LAS!S5.%.[]4=SXNR>%)U9U;)=&G?_+\3D;Z[WQR")'D6-&E?RT+-M4$
ML<#L ,FHM.U/5=2\.'39[AK/0[B47,FG6YVFY./E,[#EP!T3H/K7<? 3Q\OP
MK\;1'Q#]EU+P_K0^PW\LULG^A[^%97QGRB3M8$^]0_%7X<2_"'X@WGA_#'1K
MD->Z-.>=]N3S%GN8S\O^[@]Z_1.'\AAEE>^,LZC6G9?YO_AC\7XMXKJ9YA4L
MO;C13][I)_Y+_.[\JGPW\>S_  >\=:?XHLT/V! +75;2/@36A(RVT=63[P^F
M*_1S3=2M=8T^UO[*=+JSNHEFAGC.5D1@"K ^A!S7YCX!X^\OI7T?^QM\4I+*
M>;X<:I+NAB5[K1)7//E9S);^^W)9?]G(["OJLQP__+Z/S/A,FQG_ ##3?I_D
M?6E%%%>"?5A1110 444AZ4 !Z&OF#]L?XK/8V%O\/]'NO*O]4C\[5)(VPT-E
MDC;GL9"-OT#>M>[?$SQ]IWPP\$:IXDU)AY-G$3'%NP9Y3Q'$ONS$ ?6OSIN]
M5U+Q%K&I:_K<WVC6]6F-S=2 Y"G&%C7_ &44!0/8UZ."P_MZEWLCQ\SQGU6C
M:+]Z6B\N[,ZXTE @:QE?3KE4$:36_P IV_W6'1E]C5O3M1\_-O.52]C \Q!T
M/^T/8TR]NTL;5YGY"@ (HY9NBJ!ZDUZ[XJ\/6'P4^"=KI.J:=:7_ ,1O%[BX
MD%RFYM/C X([CRU./=FYS7+Q)E-',804-*O1^79^1W\%<0XG)*E24_>P]O>7
M9]X^??H_6QYG2$@#). .YK(TLS6-]%#K&IRKI3$*VI);[W@/]YT7JOJ5YKZ/
M\(?LC1>+;&UU,^.;?4M)N%#Q3Z7$&61?9B<5^65^'<RH5/9SI_.ZL?O6&XUR
M7%4?;4ZK].5W7KI;\3YYN[OS3Y<9R.Y'^>E6[>#R(@.I/)-?>O@CX$>#O VE
MSV=II4=XURFRXN;U1++*.X)(X'L*\[\8_L>:)J<\EQX<U6XT(L<_967SH ?;
M/S#\ZUJ<.XJ,%*#3EU7_  >OX'-0XSP,ZTHU8N,>CW^]+5?*Y\I8SVS5:ZO%
MC&U&'F>I[5WOQ8^$\'PBB6+6?%UM?ZI.,VNC:;;EKJ;_ &F!.$3U8_AS7 >
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M"7,63\MM>$8S[!\8/N!7W&M>/7I.A4<&?2X;$1Q5)58]?P8ZBBBL#J"BBB@
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M0N/^$BD=II-45R9&D/)R"<%>V.F*]'!4)59\]KI'C9EBX4*?L[VE+\/,W?8
M =AVKKO@_P##IOBGXZCM+@B+PYI.+W5[ECA=J_,L1^N,GV%>:^&KCQ)JNKIX
M=&@W.IZ[*/\ 13IZ;XK@=V./N8ZG/ KZ ^(\H^!?POL/AGI-P&\4ZZOVO7KV
M(C=&A^\/;/W1[ UZV*Q#DE1I?%+3T/ P&$Y)/$U_@CKWN_Z_'0XKXP?$C_A;
M'CR34+;*>'=+!L])A PNP<-+C_:QQ[ 5R). 23@#J34<4:PQI'&NU$ "J!C
MK8\$>![KXH^-M.\*6;.B7)\V^N(U_P"/>V4_,?JWW1]:ZXJ&$H^2/.G*IF&)
MTWD]/)?\ ^@?V'_"-]'!XC\7,7MM*U1TMK2 <+/Y>=TY'N3M!_V3[5]65FZ!
MHEGX;T>RTO3X$MK&TB6&&%!@(JC  K2KY&I-U9N;ZGZ'1I*A3C3CL@HHHK,V
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** (9X_.AD0.8RX*[EZCWK\U/%WA"^^'OCC7?#VI_/?17#7(N#G_2HG
M)*R9/)X.#Z5^F->!?M8_"%_'/A2/Q)I,0;Q#H*-*J#K<V_62+Z]6'O\ 6NW"
M5_855)[/1GF9AA?K=!P6ZU1\:W%O%=V\L,R"2&12CH>A'>O;/!9?]H3X-W?@
M&ZF0>/O"*K=Z+=S?>N(!Q&2Q]1^Z?WVL:\2M;F.\MXYXR6CD7<OK]*T=#\3:
MCX$\3:9XIT9?,U/2I#((2<+<0D8EA..S+T]#@U]!BZ/MJ:E#XEJCY#+\2L/5
M<*GP2T?]?F9EG<FZA+/"]O.C-%-!(,/#*IPR,#T((Q4C7%WIUQ;:EIUP;34]
M/E%U:W XV2*<\^QZ$=Q7KOQ^\'0:S':?%[P39W&J^%O$%N+C58[&/>]M,J\S
ML@Y PI5_1DR>M?.L=MJ?CE1)=^9H^A-S';*<3W*^KD?=4^@YJ:6(CB:5K7;W
M7];(NO@YX.NW>T5JG_6[_K1'ZC?"OQLOQ%^'F@^(Q"+=]0MEDDB4Y"/T8 ^F
M0<>V*ZVOSY_9T^)2_!?QQ:6K2>1X2U9TM;N%G/EVLG2.8#G SP?8U^@8(8 @
MY!YXYS7S=>C*A/DD?:87$PQ5)5(#Z***P.L*0]#0>E>'_M3_ !?F^''@Z/2M
M'G\KQ-KA:"U=3\UO$!^\G]B!P#ZD>E5&+G)16[(G.-.+G)Z(\+_:R\>7/C'X
MJ'PSO,>B^&1'(80^1<7<B!O,8#LBG:H_O%J\CKF+_P &A9A?:5=R:?JRCYIV
M)=;COB8$\Y/<5M^!-/\ %/Q+UD>&M,T"YCU[<B33(A:UMXF./M!DZ!.._.:^
MJH\N#I<M32W7O_P3X+$<^8UN>EK?2W5+_+K?[['JO[/O@VQUC7;_ ,>>(BL'
M@WPB&F,DP_=W%XJYQSU$8.>G+$5P_BSQI??$OQCJ7BS45>*2^.RUMG.?LUL#
M^[3V)^\?<UZ+\>]>T[P]IFC_  <\,R!M$T...;69Q_R\SGYUC8^I;]XPYZJ.
M*\H)_"LL)!UIO%5.NWH=&83CAZ<<#2>VLO-_U^@V>=+:&265ML:*68^U?9'[
M'/@;4?"7PTDOM0WVPUJY-];V#=+>(C"X'8M]XCWKYQ^!OPP_X6_\1(K&Y4MX
M?TDK=:BV/EE;/[N'/N>2/05^@D$*6\:1QJ$C0!55>@ Z 5Q9E7YY*DNGYGI9
M-A'"#Q$OM;>G_!)J1NAI:0UXI],?G]^T3X-OO!7QHUBYOW-Q;^(&-[8W;\DJ
M  T.>VP]!Z'-< >E?>WQ[^$L'Q=\!7&FHP@UBU/VK3+KO'.HX!/]UONGV.>U
M? <#S8EBNH6M+ZVD:"YMY!AX95.'1OH17TV75^>G[)[Q_(^(SC"NE5]NMI?G
M_P $]?\ @+J>F>,?#NM_!?Q+)C3M422[T"XD.3!*/F:)">A1AYB\\C=7D]UI
MFH^'M7U#0M:B\C6=+E^SW4?9CC*R+ZJRX(^M0R_:(Y;>ZLIFM-1LY5N+2Y0X
M:*9""K?3U]J]O^)6G/\ '_X>Z-\4/"VF-<>*-.7^S]?T:T7=,R@_, O4LA.]
M<=5<\U,K8*OS?8E^#+C_ ,*6$Y/^7E/;S7]?C;N>(7=J+RW:(LR$\JZ'#(PY
M# ^H-?=?[,GQ)NOB7\,;6YU'#:I82-8W,H;(E9, /^(Q^.:_.N6ZU?Q;/+;6
MB3:-I2,8Y;F9=EQ*1P553]T=LGFN]^%7BJ7X&>)K'7-$61;%"(M2LPYQ<P$_
M,QSU9>N:,92>)CSTUMU[^@9;76"G[.K+XNG9^?\ EKYV/TRHJAHFKVNO:7::
MC8S+<6=U$LT,BG(96&0:OU\V?:!112&@!&Z5\G_MK^/+J2ZT7P!:LT-G>Q'4
MM2='PTL2/M2''H6!9O917N/QP^*EK\(?A]?:W($GU%L6VG6;'FYN7X1<>@Y9
MO15:OSAUOPS)XBG;4[_4KI_$LLC3RZQYF97E;EL@\%<\ >@'I7HX/#RJSY[7
M2/'S+%PH4_9\UI2_#S-STZ#OP./RKJ_A'\.'^+/CR'3)2T7A_3 +W6+@' $8
MY2+)[N1S[ UYQX<N_$FI:Q'X>_L&XU779@?LATV,NER!W/\ <QU.>, FOH+X
MB2?\*%^%.G_#;2[A6\8>(U-[KU]%C=!$>'&1_P!^U^A->MBL0Y15&E\4OP/G
ML!@U"3Q%?X(Z^3[6_KR.*^,GQ*7XK>/&O+(*GAK2%-EI,2C:C </*!Z'&![#
MWKCA]1C%-AA6WB2*-1'&@"JH'0=JV/!7@FZ^)_C73?"EF71;H^9>SQCFWMA]
M]L]B>@^M=45#"4;=%^)P3E4S#$^<G]R_X"/??V(/"-[GQ%XN.ZVTG4"MK;1C
M@7!0G=,1]>!WXKZO7\JS?#FA67AC1+'2-.@6VL;*%8(8E'"J!@5IU\E4J.K-
MS?4_0J-)4*<:<=D@HHHK,V"BBB@ HHHH **** "BBB@ HHHH *^,_P!KKX4C
MPIX@3Q]IL.S2]19;?5T486*7I'/@>O"L?H:^S*S/$?A[3O%>BWFD:M:1WVG7
M<9BFMY1E74]JVI5'1FIQZ'/B*,<12=*6S_JY^7FN^)+/P^B"X9I+B4[8;6$;
MI)#V"BO1OV:_C)??"S7KJ/Q)IEM%H'B"=([IHY&,MGQM5FQP1SSWKE_&WPTM
M/AE\5?$>E_8C;SI)YMF\CM(3:-]S8S9.!@@^]49H$N87BD >-P5(/0BOIG36
M-I<TG9/;_@GQ$:KRVORP5VMV^ODNWKN==\6?A]/\+OB!=:83YVCZB6OM*NAR
M'B8Y9,\\J3^(KEF4.I5@&4C!!Z$5['X*<_'SX1WG@.]D5?&?A=?M6C7<G6>(
M?='OQ\A_"O%;69YT82QM!<1,8IH6X:.0'#*?Q%+!U6TZ,_BB/,L/&,EB:7P3
MU^9](_L<?%-K&ZF^'FJ3%D4-<Z/*YZQYR\/U4\CV^E?6]?EUYUY87=IJ.ESF
MVU6PE6YM)Q_#(O8^QZ$>]?H9\&_B/;_%7X?Z7XAA3R9IDV7,!ZQ3*=LB_@P-
M>-CL/[&?-'9_F?1Y5C/K-+DD_>C^7?\ S.YILCB.-F8@*H))/I2GIS7SA^V-
M\49_#_AVT\%Z3,8-6U]&-U.APUM9#B1@?[SGY!]6K@A!U)*$=V>M5J1HP=2>
MR/ OC;\3O^%Q?$2;4K>;S?#FE%[32ASB4])9\?[1& ?[H]ZXL\ ],>]1Q0I;
M11PQ(L<2*$1!V [5K^#?!5_\3O&6F>%=/W(;L[[RX7_EWM@?G<GU(X'J37U\
M5#"4;=$?GDY5<PQ-^LGIY+_@=3T?X :?:>#M*UGXP^(C)#HVEQ/:Z1%GYKF5
MOE9@.^3\H_&O%OB'\0]=U_QOJ/BW5](CCM-1VF5+%F=[51P,@\D8ZXKU?X_^
M.++Q!KUCX(\.@0^#O"86W"QGY;BY48(/J$_]")KS8$-D$9R.0.GTKBPU&55O
M$3=I/;T/3QN(A02P5-7A'?S?KW_4HIK5I+IG]H6\PN;8C*F(;BQ/10/4GBON
M+]EKX1-\./!AU+4XPOB/6]MS=D]8DQ^[A'LH_4FOGS]D'X+:'XK\>:QXBN]'
M6?2M->,P%W81?; <E@@.&(&.3WK[O QCTKS\=B95)>RZ+\SULKP<*,?;K>6U
M]TAU%%%>4>^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !12$XH!S0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4AYX[4M% 'P-^T9\+/^%4_$1KFTCV^&
MO$,CSVH'"VUSUDB]@?O+]2.U>-ZYXI@TB=+2WB?4=6D&8[*#EOJQZ*ON:_3;
MQ]\/]$^)?AV;1?$%BE_8N0ZH6*E''W75@0589ZBOS3T_PFO@O5M9TJYM/LVL
MVEW)!>^9EG+ G!W'DJ5P5/0BOH,#B)5(^QZKKY'R&:82G1G]9M=/IY][]OS9
M[+^R]\2/[,TJ7X6^,K2VATGQ*URL5[;2L!'/,,&W;/ W#A2._P!:\W\1>$M2
M^'/BG4?"6KAC>:<P\F<C NK8D^5,/J!@CL0169>6HO+=H]YB;(=)5X:-P<JX
M/J",U[AXB>;]H[X,V_B>UA5_B/X-!M]3MHU >\AQEB .2'4;U]&# "JFOJ59
M5%\,M_\ ,BG/^U,,Z4OXD-5YKM^GW'B-Q;QW4$D,JAHY!AA[5]@_LD?%R3Q;
MX8?PGK%R)->T-%1'<Y:YM>B/]1]T_A7Q];7$5[;1W$)WQ2J&4]_Q]^U:'A_Q
M/J/@+Q/IOBC2/^/W3GW/%_SW@/\ K(C[$9Q[BNK&T/;T[QW6J.'+<7]4K<L_
MAEH_+S^1^F](>E8_A/Q)9^,O#>F:W8-NM+^!9XR>H!'0^X/'X5L'I7R9^@&;
MX@UZQ\+:)>ZMJ5PMK86<333RN?NJ!D_C[5^<GC3QI??$[QKJ?BO4 5:[;R[.
M GBWME/R(/<]3CN:]M_;%^)TFM:Q;_#ZPE*V5N$O-7=3CS#UCA^G\1_"OGT<
M=,8':O?R[#_\OI?+_,^2SG&?\PT'Z_HOU&32I!$\DC;(T4LS'L!U->X?"J]_
MX9[^%=_\3-:M#+XC\4>7::'HSG8Q@Y:(-Z;N9&/90HZUP/P;^&W_  MKX@)I
M]T?+\,:,%OM:N&.U7 .Z*WS_ +94EC_=4^M)\7_B@_QB\?3:O =GAS30UGHL
M'9H\X>XQV+D<?[(6ML0WBJJP\=EJSGP<5@L.\9/XGI%?K_73U/,=7\7ZC8^)
M=6U+Q#9QQ6VJWLEXUY9$O'"\C9*L#SC/0\BMM9)+PVL.G 7MU>R+!:1Q'=YK
ML<+BI98TFC9)%5XV!#*_0CWKZ"_8?^#&D0V-YXUGT@<W;)HLTSL0B %9'1"<
M %L@'D\&M:]1X.G:.VR[K_,PPM".8UKST>[ML_\ )O[CW[X'?"RV^$?@.ST=
M=LNH2?Z1?W..9IV^\<^@Z#V%>AT45\LVV[L^[225D%%%%(8UAE2#TKXV_; ^
M%?\ PBVOQ?$'2X0NEZBZ6VLQHO\ JICQ%<X_VN$8^NT]S7V76=XAT'3_ !1H
ME[I.JVD=]IUY$89[>895U/4'_/%:TJCHS4X]#GQ%".(INE/9GY=:[XCL?#T:
M&XD+SRG;#;0#?)*>P4?UKT/]FSXRZA\)_$-X_B+3+>'P_P"(IX8[S8Y:6Q !
M5';'RD?-\V.V.>*YWQY\,+7X7_%WQ-I7V$P,L@FTYY9&D)L6_P!7L9CGC!5A
MZBJ$\*7$+Q2*'1QM93W!KZ=P6-I<S>CV7^9\.JCRRORP5Y+=OJO+MZ[G7?%_
MX>2_"OXAW>FJ#)H>J,]_I-P.5*,<O%GU4GCV(KDB P((!!&"#7LW@!D^/'PB
MOOAUJ4H_X3#PR@N]"NY6RTL*\)SWQ]PCT(KQ.WDD=9$N(FM[N%VAN('&&BD4
MX92/J*G!56TZ-3XH_D7F6'BFL31^">OS/H[]CGXJ-I-Y-\/=5F)@;=<Z-*YX
M"]7@Y]#R/8U]<KR<U^7GG7=E=6M_I\WV;4[*47%K,#@I(O3/L>A^M?H3\%?B
M7#\5_ &G:ZB>3=.IBNX"/]7,O#CZ9Z5Y&/P_L:G-'9GT658SZS2Y)OWH_EW.
M\J.=UBB9W8*BC)8] /6G-TKYT_;"^*<OASPW;^#-*F:+5M?1OM$R=8+,<2$>
M['Y1[9KSX0<Y*,=V>M4J1I0<Y[(\ ^.?Q./Q?^(\VH6TQE\.Z1NM-*3/RNV<
M2W'ON(P#_= KB<<^WH:CA@CMXHX8P$C10JKV %:WA'P9?_$OQCIGA/3-T<U^
M2]S< <6MJI'FRG_:P0![L*^OC&&$HVZ(_/)RJ9AB;K>3T\E_P#TC]GW3;3PE
MIVL?&/Q$9(M#T6&2UTF(<-=3-\KN!W!)\M?4DGM7C'Q&^(VO>)/'&H>,-5T:
M**TU)$$L-BS/):*HPN0>6XZXXS7J_P"T#XWLM9UNP\ ^' L/@WP@%@*QGY;B
M[48P3_$(QU]6)KS4<\<'U!KAPM&55O$S=F]O0]/'8B&'2P5-7C'?S?J4(]9L
M[C3?M]O,MS;D95HN=Q[*.^>V*^X?V5/A*WP]\%MJVIPA?$.MXN+C(^:&+_EG
M%Z\#D^YKY\_9&^"VA^,/'^LZ[>:.+G2M-,9C+2,(?MF<Y"@X8@=>PK[PCP ,
M5P8[$NH_9=OS/6RO!PHQ]NOM;7Z(?1117E'OA1110 4444 %%%% !1110 44
M44 %%%% !1110!X)^U9\()/B!X2CU[1X@?$FA!IH0/\ EXA_Y:1''7(&1[@5
M\96MS%?6\<\63'(,C/;\.U?J.RAE((!!&"#7P3^T=\+!\+/'YO;*/9X=U]VF
MA 'RV]SU>,=@&^\/QKV,OQ')+V4MGMZ_\$^;SC!^TA[>"UCOZ?\  //=#\1Z
MAX(\2:9XET@$ZCILF_RQG$T1_P!9$?7(_7%;7QS\<>#/$?Q"AU_P?<2W<&I6
M:7&N);V[F+3YSPK2OC"L>A'J,URUS>16:*TA(+$*D:+N=S_=5>I)]*^O?V1?
MA9JW@_P3K<GB+28=.BUR[^U1Z=/&C.(RH&91CJ>NT]*ZL<U1J1K1?O=NZ.'*
MXRQ-&>&J+W-[]F?%OC,>*-.^'=SXOTC19GT"*98'U:;Y4R?^>:GE^GWAP*_1
M#]G2R\/6OP=\,2>%T9-*NK1+D-(^^1G<;G+MCEMQ.:T?C'X'L/&/PB\3>'IH
MDAM)M/E"+&@ C*J63 Z#! KY=_82_:!\*^$O@S)X=\7>*--T>YTK49H;6.]G
M$;/ 2&! /N6'X5XU?$3Q$KR^X^EPN#I82-J:UZOJS[=/0U\=_P#!12[TKPQX
M4\,Z]!$Q\7/>_8K(J?ED@.6E61?XE^[CT+"O=/\ AI_X3G_FH.@_^!BU\H?%
M?Q3HO[1G[:WPWT"PU.VUKPIIB)<;[20212R#=*XSZG:BGZ5A&3@U*+U.N4(U
M(N,U=,\^\1Z;K/@.>"R\6Z1/HFHS0K-%&?WD<^1G$3CACV(^\":[?X<_%C0O
MAY\)-?71YYO^%JZW<&RNK&[MVBFTN/D#(8?=5<MD<%B.F*^_;W3;/4!%]KM(
M+DQ-OC\V,/L8=UR."/:OBS]K7P%K.A_$FY\:W&G_ &G0+NVCM_[0MHAFT*G[
MLV.<'/WS]*]-8B6+E"G6=EU\SPW@XY?"I7PZ;ET78\7M+9;2W6)2S8&6=_O.
MQY+'W)YS5JPTB_\ $VM:=H.DHTNIZG*((@!_JQ_'(?0*,FJYFB6#SBX,(7?O
M[8KZJ_8[^%!L-.E\>ZM 5U#4T,=A&XP8;;^]CU<\_2O8Q==8>G[N[V/F\NPK
MQE;W_A6K_P OF>Z?#;P'IWPT\':;X?TU,0VL>&DQS*Y^\[>Y.374445\D?H*
MT"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1136H 9<2I
M!$TLCK'&@+,S'  [DU\M_%;]JN[>\GTOP5Y<5O&2CZM(NXN1U\M?3KR?PKH?
MVN?B)+HFB6/A6RE,5QJH:2Z=3@K;KQC_ ($?T!KY."A0 !MQQBOC,ZS:="?U
M;#NSZO\ 0_3>%^'J.+I_7L6KQO[L>CMU??LD;6J^-/$.M3&>_P!=U&[E/)+7
M+ ?D",5T/ACQCXR\-+%=:9XFNXVX;R)Y3+&WL58D5PO:KUCJ\MDGEA5DCZ@-
MVKX^EBJL9\TIROWNS]-J8#"RI^S5&-NW*O\ (^MO@U^T=#XUO5T+Q#!'INO=
M(Y$.(;C_ '<]&]J]S7I7YH3WTTMX+J-C#.K!T9.J,.00:^[/@1X^;XA?#ZSO
M9SF_@)M[KW=>_P"/6ONLFS26,O1J_$MGW7^9^1\39##+G'$X96IRT:[/_)GH
ME%%%?4GP(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 QN.
M<?C7FO@[]HGP-\0/'%SX4\/:G-JFK6WFF4PVLGDJ(R%9O-(VD;N <X)Z5YS^
MVU\;7^''@-?#>E77V?7O$"/&TR'YK6S Q+*/0G.Q?]XG^&I?V)O@ZOP[^&,6
MO7UJ(-;\1JERR,F&@M0/W$7MP=Y]W]J /HT=*6D'2EH **** "BBB@ KY3_;
M)^%6R*+XCZ5!^]LU6WUJ.,<RVV<)-@=3&3R?[I_V:^K*K7EG!J-G/:7423VT
MZ-%+%(,JZD8*D=P0<5I3G*E-3CNC&M2C7ING/9GYBJP=0RE2I&01T(KH?AK\
M0[CX2>/++Q+$C3:>Z_9-6@7DRVI(Y XRR'YA],=Z?\4/AO+\'?']WX8)>72I
M%-YI%Q)R7MB>8R?[T;?+[K@]ZY>21WN(+2"VFO[ZZ;R[>RMXS)+,Q[*HKZV4
MJ>)H<S^%_@?G\8UL#BE&*O)/[_\ AT7?B-KOA&W^).OOX1OGU#PC--YJ:@D#
MK:07+_,\"/@!O48Z9([5SOCF+7_"VE>&];U;1+O3?!NKWJ6SW\A$<TL><L40
M\J"N<,1SVK[\_9U^&5WX(^#NEZ!XEL+/[0)'N39>6CK &;<J-QAF'<_X5A_M
MM>!K7QK^SKXF\T!)=+B%_ ^.59.<#ZCBOGOKE6-/V2>BZ];'V"RVA*M]8DM]
M;=+_ -?(]A\&:;I>D>%=)L]%B$6DQ6T?V503_JRH*GZX.?QK:/0U\M?LO_M.
M^"5^!_ABW\4>+](TO6+6W^SRP75T%DPIPI(/M7JI_:>^$YX_X6#H/_@8M>>>
MO8^8?VX4MM-^,7@RS\+V/VCQCX@_<W4'FA8IX\A8RW96SGYCVKR7Q+_:GA6^
MNM(U'1KRV\20C:ND&(M+*V,CR]N=ZGKE>U>J_"?4K#XY_M[^(?$/VR+4]*T"
MU8Z9+ P:)U&$5@>A'+'ZU]TSZ;:37<5V]K#)=0@K%.T8,B ]0&(R,UW4,95H
M1Y5JCRL5EM#%24Y:/K;KZ_YGP'-\4/#NC_ +1O!'@'5'OM6\0;[CQ+J7E&*>
MW&<2Q.I&5=C^["]D4^H)X&.-(XU1%"1H-JA>@':NU^._@35?AQ\3O$6H:Q8>
M3IFO7S75GJT$8$$N<;8G('R.HXP<9QGG-<->W<=A;2SRYV(,X'.3T 'J37N8
M&,(T>=.[>K/ELUG4GB/9N-DM(K]3H/ G@.\^*OC;3_"ED7BCN/WU_<Q\BVM5
M/SD^[?=7W:OT8T/1;+P[I-GI>G6Z6MC:1+###&,*B*, 8KR3]EWX/M\-O!?]
MI:G$1XFUS;=7I8?- F/W< ] H/(]2?05[97@XO$/$5&ULMCZO 8182BHOXGJ
M_P#+Y!1117&>D%%%% !2-TI:* /"?VJ_@])\1/!T>M:/"&\3Z"&GM548-S"1
M^]@/KD#(]& ]:^+;.\BO[:.XA.8Y!E?;U'X=/PK]1G&4(KX,_:2^%0^%GQ _
MM*PC,?AGQ%*TD8 PMK>=7C'HK@%A[Y]J]C+L1R2]E)Z/;U/G,XP?M8>WAO'?
MT_X!YUH^O7_@WQ!IGB/23MU/3)?-102!*G\<9]0PS6[\=/'7@SQ/X\M?$/A"
M:6X&I623Z[#! QCL)>BM*X& QY4CV!KE+F[BLD#S,020JHH)9V[*H'4U]=_L
M@_"W5O"/@_7;GQ!I,>GPZ[<+<16$Z*9-FW!,HQQNZ[3TKJQS5"I&M!^]V[HX
M,KB\32GAJB]SOV?]?UJ?&7B\>)['X=WOB[1]%FE\/VTBPR:M-A8\DX_=J>7_
M -X<"OT'_9HL_#UM\&O#4_AE&73[RV6Y=I9/,D>5N7+MW.[-;7Q;\%V'BSX3
M^(_#TL$<-G-I\J*D: *F%)&!VY%?*W["/Q\\*^"_A)>>'?%OBG3='GTW4)([
M:.]G$;M&><C/49S7C5\1/$2O+[CZ7"X.EA(6IK7J^K/N%NE?(/\ P4.N='\.
M>#_#OB".(GQ>UX+*P*L<2PGF1'7^(<KCOEJ]N/[3WPG/_-0-!_\  Q:^4/BY
MXKT7]H;]M#X;:'IFJVNM>&=.59_,M9!)%*Z[I6!QW^4 _2L(R<7=;G9*$9IQ
MFKIGGWB'3]9\"36]IXOTF;0+^>%9HD)WQS @']TXX8\XV]<G!KMOA?\ %G1/
MAO\ "3Q)+I<TR?%_6[LZ?<:7>6[13:1&,A#AA]Q$^?(ZNP':OOV\TRSOUA%U
M:P7(A8/'YT8<(PZ,,]#[U\8?M=^ =8T;XF3^.)M/:Z\/75C#:&_M8ANLF7.1
M-CDJQ((<\#IZ5Z2Q,L7*%*J[+KYGA/!PP$:E?#Q;E;1;V/%+.U6SMTA1FD*\
MM(_+.QY+$]R3DYJS9Z;?^(-6T_0](B-QJVIRBWMT7W^\Y] HR2?:H3-&(/.W
MKY.W?Y@.5QZ@U]2?L<_"C[)83?$#5H&2^U%##ID4HYAM<\R#T:0C\@/6O:Q=
M=8>EIN]$?-Y?A7C*_O;+5_UYGNWPQ^'^G_#'P9IWA[35'E6L?[R4CYII#R\C
M'N2?Z>E=735.:=7R)^A;!1110 4444 %%%% #6JA-KNFVMZMG-J%K#=MC; \
MRASZ?+G-7VZBOES]MKX/G7?#UMX\TB/R]:T3'GO"G[R2#.<DC^X?FH ^I!2U
MXQ^R]\:%^+WP^B:\E#:]IN+>]4GE\#Y9/Q'7WKV9: %HHHH **** "BBB@!#
M7(_$OX<:7\5?"-WH&KJRP3 -'/'_ *R"0?==#Z@UU]%&VJ$TFK,\7^$/[+OA
MKX67PU6XGF\3:^.$U'447]R/2)!PA]3U/K7M%%(>AJI2<GS2=V3"$:<>6*LC
M*\6C/A761_TY3?\ HLU^<'[(OB/P[HOA3Q'#J_PAU;XC3MJKLM]I^B1WRP+@
M#RRS<J<@G'O7T=\=/VH-;\->,=8\'Z#H=A=0VT'DW-WJ$S@EI$Z(J]@#U-?/
M7P!^*GBG]G'0-7LK'3M)UNVO;QM0F,TDD;C*@%$[=!U-=$,+6G'GC'0Y)X_#
M4ING.=FCW#_A._ __1KOB4?]RE#7D?@74M.U?]O_ ,-7&E^#[SP+:&S(&CWU
MBME)&PMWRQC7@;OUKZB^*7[2C>#OA=X4\3:-I"WU_P")A&;.VNI"D<0:/>Q<
M@9.!Q@=37R'?>/\ Q3?_ +0UG\6WL]'&IVUN+==.#2^2P\MH]V[.<X;-13H5
M:RYH1NBZV,H8>7+5E9GZ95#=VT-Y;2P7$2302*4>.10RL#U!!ZBO(/V=/CE>
M_&6PUF/5-+@TS5-)FCCE%HY:&174E67=R.AR#7LM92BXMQENCHA.-2*E%W3/
MG;7?V*?!^J>*X]2L[Z^TK1WE$]UH-OM-O,P.<*3S&I[J.#VQ7T%:6T=G!%!#
M&(H8U"(BC 50, "IZ*'*4K<SO8(PC"[BK7W"BBBI+"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "FOVIU-<#()[4 ?$'[55U)-\;+B%R2D
M.G0)&#V!R3^IKRCK7NW[9OA>73?%NB>)8T/V>Z@-G*P&0)$)9<_4$_E7A"L'
M4,OW3TQ7Y+FT)0QU52ZN_P F?T-PW5A5RJCR=%9^J8M%%%>2?2BBOIW]C.]E
M-IXCM<YA65)%]B1S7S"6"@D]!U-?7G[('AJ73O =WJ\\91M3N2\6[KY8X!_&
MOHL@A*6-36R3N?$\7U(0RMPEO)JWYGO8I:04M?IQ^%!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %,=@@+,< #)/H*?7G'[1'BJ3P;\$_&.J0,%
MN(]/>*$D_P <G[M3^;9_"@#X5U>]D_:A_:KMX7WS:3>ZD+:- >%TZW)9L>SA
M6)_ZZ5^ET4:PQI&BA$4!551@ #H!7Y^?\$^O#D=]\5M9U1X]RZ7I(CB8_P +
MRR8_]!C/YU^@U-@%%%%( HHHH **** "BBB@#S?XU?!C2_C/X?M["\N)=-OK
M.83V6I6R*TEN^,'@\,I'!'?\*K_!_P" 'AKX/V[362/J6NS#_2-8O0&G?U5>
MT:_[*_CFO4**KFER\M]".2/-SVU[]0KR[]I]<_L^^/1_U"IOY5Z@>E?$7QR_
M:7U_QO:>,O!6EZ+IUOHLOG:4UY=RN9R1\K.%'R]>@JZ=*=67+!79%6O3P\>>
MJ[(XW]F/Q7X6TSX.:1;ZG\"M:\;7:L^[6++P[%=QR\\ 2GDX_2O55\=^!PP_
MXQ>\2CG_ *%&&O,?@1\?_$/P%\%Z/X6GTC3=6T.TGQ-<QS2)<E789(!RO'I7
MT7\??VC]0^%]UH-AH.CVVH7NIVQO#)J$C)%'%T_AY+$U<L/5C-0<=7L9QQE"
M<)58RO%;L^?OV-;FUOOVN_B-<V.B2^&[1[9S%I$\ @DM%\P?NVC'"D>E??QZ
M&OS.\!?$#Q7X!^,7BKXAVMGH]W?Z_N$EG,\HCARV>"#DU]U_ GXL'XP^!(=<
MEL/[-O$F>UN;=6W*LB'!VGNII5*%6DKSC8*.+H8AM4I7L=MK>AV'B32KG3M4
MLH-0L+A2DMM<H'1P>Q!_R*\,\._L9^%?#GCZTUV+4M0N=&LI?M-IH%R1)#%,
M/NDN?F95/*H>GJ>E?0E%9*4HW2>YO*$9M.2O;88!C I]%%26%%%% !1110 4
M444 (3@5RGQ*^'.D_%+PA>^'M8C8VMPH*RQ\20N.5D0]F!YKK**:=M1-7T9X
MK\(OV7/#7POO?[4NYYO%&O@_NM1U"-<6X[>5&/E0^K=37M"\&G4C=*<I.3O)
MW9,(1IQ48*R1E^*_^18U?'_/I-_Z :_.+]DSQ)X>T7PYXEAUCX0:M\19VU1V
M2]T_18[Y8%_N%FY4]\5]&_';]J#6O#'C'5O"&@:)8W4=O;^7=76H2NN6D4\(
MJ^@/4U\]? 7XK>*OV=-!UFSL=.TG6K:]NVOY?.DD1UXY5<''3IFNB&%K3CSQ
MCH<D\?AJ4W3G.S/;O^$[\#_]&N^)3_W*,%>1>$-2T[6/V]_"D^E^#;SP):?9
M6 TB^L%LY%(@;+^6O !ZY[U]1_$S]I%O"/PK\,^)]*T@7FH>(MGV2VNI"D<6
M5W,7(&< >G6OD34_B#XKU;]H"P^*[V>C)J=I;BW73U:4PL/+*9)SGH:FGAZM
M57A&Z+JXW#T'RU9V>Y^F J.ZMXKN!X9HUEAD!1XW7<K \$$=Q7C_ .SC\=+S
MXRV.M1:KI<&F:KI,J)*+1V>&1'!*LN[D'@Y!KV6L91<&XRW1T0G&I%3B[IGS
MIXC_ &*?"&J^+(]2LKV\T?1GE$UYH5L%-O,0<X0GF-2>JC@^U?0=G;16<$<$
M$:Q01((XXT& J@   >@%6**)2E*W,[V",(P;<5:^X4445)84444 %%%% !11
M10 55U/3X-5L+BRN4$EO<1M'(C#.5(P:M4TT ?G5\-=9N/V<?VF;K1YV,>E2
M79L9TS\IA=OW;>^,C]:_12,AD!4@@\@BO@7]O;PU_8_Q.TK6H5V'4+,9<<8>
M,XZ^O-?8'P*\6_\ ";?"?PUJS-NFDM$27V=1M/\ *FP.]HHHI %%%% !1110
M 4444 %(>E+2'I0!^>GQ]_Y+UXR_ZZ0_^BQ7 ZA_R#KK_KD_\C7??'W_ )+U
MXR_ZZ0_^BQ7 ZA_R#KK_ *Y/_(U]?@_]WAZ'YUF/^^3]?\CV3XT_\D"^!7_7
M-?\ TF%>1KVKUSXT_P#) O@5_P!<U_\ 285Y&O:N;*_X+]?T1W9W_O4?\*_-
MGT?^PS_R$_'_ /UUL_\ T"2OK.ODS]AG_D)^/_\ KK9_^@25]9UX>*_CS]3Z
MG ?[K3]$%%%%<IW!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 444AH \M_:6N-%A^$NK+K</VA)0([:-2%?[03\A4]B#S],U\$*T
MU@=K89>OH#_A7T]^VCK3R:QX4T56(B5)KQP.C'A%S].?SKYS*JR\@$>XX-?F
M?$%95<7R)?"K??J?M_!^%=++O;.7QMOR26GXVU*\=_$R\G;[8S0]]"!]XD^P
MI6LHF.0NW_=-*MG$ASMW'_:-?-'W/O$.Y[T\KB('.UNC>Q]J_0/X%^,K#QI\
M.].N+&WCL_LRBVEM8^D3J,$#V[U\$@ #[H^@KZ#_ &.]:D@\1ZYI6XF":%9P
MN> P.#7TN08ET<5[)[3_ $V/B.+\"L1@/K'VJ;O\GH_T/K2BFH>*=7Z8?AP4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SW^W5=/;_ +/U^L;8
M\Z_M(V^GF9_I7T)7A7[:VCMJW[/6OLG_ "YRV]V?HLJ@_P Z /)/^"<T"-%X
M^N,?-YUG%GV"2'^M?9XKXB_X)U:NB:OX[TO=^\DBM+M1[#S$/]*^WJ;$%%%%
M(84444 %%%% !1110 4444 (>AK\Q]<_Y&_Q5_V%[G_T,U^G!Z&OS'US_D;_
M !5_V%[G_P!#->OEG\5^G^1\]G?^[+U_1F3K/_'@?^NB?^ABO<OVL_\ D<O
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M@GA4_?J6T\D[M_H>A+TI:**_2C\0"BBB@ HHHH **** "BBB@ HHHH ****
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MYR*<#RE[;:[J\IO%4WR_D>7A84U@*R4]+[V?D>+*#N''>OKG]AW_ )))>_\
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M3Q'J(_%<?RKFR^4E2=HWU\O(Z\WA3E7BY3MIV?=]CZU_88_Y"_Q"_P!^R_\
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MI.4[;L]:A2]C2C3O>RL?3%K=0WL"3V\T<\#C*21L&5AZ@C@U/7QKX5^(5O\
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M6&I'4;;1=/MM0)8FZBM468EOO?.!GG/K6C^Y](ORJQ10 444AH YCXD^+(?
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M;KO3@$_48->E5]M&2DDT?:Q:DDT%%%%44%%%% !1110 4444 %%%% !1110
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M)W13()%X[$9_J:V(O%L^A6GPV^)L[[Y_#5ZW@_Q.1GY["=E6*5P.H1C&_/\
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M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KX3BFDBUW7;743Y>NC4+B2]BEX?>SD[L'JI!&".,
M5]V5RGB[X9>%O'P1M>T2UU"5!A)W7;*@] ZD,![9K@QF&^M4^5.UCAQF&^M4
M^2]CY(L]!D\9^)=&\,0/A]2N!YY'5+9/FE;\ACZFNAOO&+7WB3XE?$:U*I#9
M8\$>%T4#:9%/[^5.WWSCCJ$(KTSXCZ!X>_9V^$OB[Q+X;TORM9-G]FCNY)&D
ME,DC!(P78DA0[J<#CBN*^(?PHO?AQ\(_AUIEG:W&HV/A]2=3^S(9F\]T)DN"
M ,D;VD)/8-6-&A+!8>7+K+<RHX=X+#RY=9' :;8KIMC;VJG<L2!<]R>Y/N3S
M75_"7PR/&?Q4TZ&6/?8:.O\ :$^>07Z1KSUYY_"N,C\1Z3+9/>)J5K);IG=(
MDH('L>>OM7T?^S3X2GT/P5-J]]#)!?ZW-]J,<H(9(AQ&,'D9'/XUXF6T75K\
M\E\/YGAY;1=2OSR^SK\SV*D/2EHK[ ^O/)_VCO![^)?AU-?6J%]1T9QJ$&T9
M8JO^L7\5S^5?.5K<I=VT<T9+)(H88]"*^XIXDGADBD4/&ZE65AD$$<@U\0ZW
MI!\!^+]7\-7S^0UO.TMFTIV^=;,<HR]CC.#CIBOGLVHWC&JNFC/G\VH7C&JN
MFC+_ (+L;75]?UWP9J 1=)\<Z9)8EW^[%>1QL8I/J5Z8[HM07>KWOBGX1>$_
M$^I(R>(O"=U+X4\2;A\ZLA""1CZ9"-_VU-9V@V]QXY\3Z-IWAD-?ZA;ZC;W#
MW=I\T5@(Y%9GD<<*=H("YR2>E>S0:+:>$OVH=<T*6WCNM ^(6BG4)[)T#(+R
MV/ERL5]'C9<GNPK; Q=?".G46FWR-L#%U\&Z516Z?(\@FFCMXVEDD6.->2[-
MA?KFO<?V3_M3>#=5D"E=&FU%Y;!F'WP0/,*Y_AW X_&NDTW]G/X>Z;>K<)X=
MBN#&VZ.*[E>:*/V5&)7'L17I,$$=M$D44:QQ(-JH@ "CT '2M,%@'A9.;E<O
M!8!X63FY7N2T445ZYZX4444 %-?[IIU(: /C?XI2S6WQH\3IJQ$-W<M"UGO.
MT26HC 0IGK\V_..^:YO5GF>&*SM SW]_*EI;1@99Y'.T8'MG-?9_BKP3H/C:
MR%KKNDVNJ0C[@N8PQ3W5NJGZ&N+C^%G@CX36NH^*['1C]LTVUEGCEEE>9HE"
MDD1AB=OX<^]>%5RWVM?VO-HWJCPZN6^UK^UYM&]3QV[2QL/B5:VN[S?#'PGT
M43R$=)=3E7Y/^! 9;ZM7#:2L\D$EW='-[>R/=3MWWN<X_#('X5VOA[P-J^M_
MLS2^(K2)[_6O$^H?\)'J-M;KN>>-GRL2_P!X*@7 ^HKAK7Q!IMYY@CO(5DB_
MUL4CA'B/HZG!4CT(K#-W+W8I:&.;RE:,$O=-?1O#\OC7Q=HOAZ( I=3B6YR,
M@0H=S?GP*^U+:%+>*.*-0D:*%51T ' %?/?[+7AHZE>ZOXRFB;R9<66G2,O#
MQ#EW3O@MQGOBOHJO2R^A[&@KK5ZGH9?0]C05]WJ%<I\4_!R^// .L:)P)[B$
MFW<_P3+\T;9[?,!75TU^!7HM7T9Z+U5CX4T>\>]TZ.25/+N%S'*I_@D4[6!^
MA&*UO#.O1^$?'>C:M< '3+AFTK48V&5:WG(7+#N%?:<>F:UOC#H:>!/BGJ*2
M(+73-<(OK.5OEC:8\3Q[NF[(#8ZX:N)U&YC\0>?H>E(=9UBX4QQV5D/-D!/1
MG SL ZDFOBE">%Q:C!;/\#XOV<\+B^6"O9_@SIK70[BR^'?C#P',K2:S\.=5
M.H:8&(W2:;+ET ]@C.I]P*R[>[ANK6.YCD#02('5STP>:]9\8Z/=_#CXM_"C
MQ-+(+B?5X$\(ZT-V?M):/?$_^UB16.?>N\?]G+X>RZC)=OX=B*NQD:V\UQ!N
M)R3Y8;;U]L5[^-P/UJ2E%V:/H,;@?K4HSB[-'G?[*DLUUXJ\5W%FS2:.T42O
M*O\ JVN >Q[G;UQ7TI5+2M+L]&LX[.PM8;*UC&$AMXPB+] .*NUZ-&E[&FJ=
M[V.^C2]C3C3O>P4445L;!1110 4444 %%%% !1110 4444 %%%% !1110 57
MN[2&_M9K:XC$L$JF.2-^0RD8(JQ10!\\Z/\ "CXM> +>[\,^"_%/AZV\)-.\
MMC=:K:2SWVG1L<F)$!V. 3QN/%=?X%_9S\*>%]':+6;2#Q?K=S<M>WVLZQ;I
M)/<SM]YCD' [!1P!7J]% $-O;Q6L*0PQK#"@"I'&H55 Z  =!4U%% !2'I2T
M4 9>N^&]*\46+66L:?:ZI:DY\BZA61<^H!'!]Z\J\7_ &XL_$5IXG^&>JVG@
M;7[>W-K-"+!9+&^ASD)-&NTY!Z..17M-% 'B?A+X5^,O$/Q$T[QA\2]0T>YG
MT:)HM)TK0DD%M%(W#W#F3DN1P .F:]LHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>%7ZD5Y)/IVL?"2_\'^$]9OK#XA_#O7;Z#3+&RU"W4WMET,3#&1+&F 2Q&0
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M."2:]$7@4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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;K[TM% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>glyc-20241231xs4032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4032.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %X ZD# 2(  A$! Q$!_\0
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ML^>#O@M=_#JXTVXBOH[J7Q \B&UA@%P92S8.X2<D%<9Q^5??MG%Y$$<62VQ
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MF6SE1H9U'][8P!Q[T >LT4B]*6@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^A#\.?^"N#_ .(H'P+^'/\ T(7AL_72H#_[+4_[+VE]Z#WSF_\ AKGX.?\
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MQE\,OB=\++FUT2]\3:9I_AR70KR\L"";:608+D,?NC/7T%>;:)^SOXRTEI?
MVJ>%O%FLP/K;7BW5OJ\=OHK0F7>)3\C,)!UQW-4L/AI)._3NN[N_RT%SU%T/
MJ7QM^UC\/O 7B+5M"U"[OI=8TM5>XM+2PEF8(1G>-H(V@=3GBN*^*?[9VC>$
M=6^&PT)'U?1?%!:YGOH[.:5DM@, 1(H!:0L,$=5 Z<T_PS\*]?TSXN_&34Y-
M'D%AJNA0V6FW+D'[0ZQ.NT'ZD5Y99_"KQ_X*^'WP*U"+P??ZI>^$]4OKC4-*
MM2OGA90%0@$X]:FG1PUUU^:UO%O\QN53^O4]\T;XWV6E>+_B?+XA\56DF@>&
MTM9C:KITD,E@L@. \A_UI8[0 HR#QWJYX,_:<\(?$F\U/1]$GO[+7K?3I-1@
MM-5L)+9IH0,"5 X&Y<X]Z\@\1^ /BCI>O?'W7/">CF#4]<739-)DN$1_-" ^
M<$5LJ64'C(Z^IK#^%WPN\9S_ !XL/%UUX:\56VDS^&;S3WN_%%ZEQ="Y.XX*
MJ<1(2<*H ]>]+ZO0E&4VULNJ[)[>;#GFFD>__LH_$K6OBW\ O#?BSQ%)#+J]
M]]J\][>/RT.RYEC7"]OE1:\@^'O[3NL?$3]I7Q1I#^(FT#P9H1(CTZ;0R?M*
M)$S2O/<,<P$,I*YP&&!BO5/V-_!6L_#O]G/PGX>\0V$FFZQ9F[\^VEQN3?=S
M.O\ XZRFO-4^!/BKQ/XD_:3LY[:33+7QA#;Q:5>RGY)BL#J>G;) /L:F*H*K
M63M;IY>];3Y#?-RQ_KH>E>#OVO/AMXX\3V>AZ?JMS%<7\C16%S=V4L-O>N#@
MB*1E 8YZ<\]JLZ7^U/X"USQZO@ZPN[V[UX7SV$MO%8RD0NO5G;;A5]#FO!(_
M _Q%^*'A[X9_#R_^'T_A*'PE=V\M]KT\B>0RPKMS;E>69^I]R:]@_9C^'^N>
M"_$WQ4N]9TI].75M>-S:2/C]_%AL,/;G]:56AAZ<92OKVNGUT=_36P1G-M([
MSXL?'#PG\%(-*G\5WDME%J<S06[10/+EU7=@[0<<=*Y+5_VNO &BZ1I%[/)J
MC2ZK"UU;V,6FS-<B!3@RO&%RJ^YQGM6;^TY\/=<\<^+?A1<:3I;ZE:Z3KWVJ
M^( *Q1[,!CGWKSO]H+X3>++3X\2^/-,T[Q1K.D7^F)9-%X2NT@NX94X ;>#F
M,]R*FC1H34>=ZM-[]MD.4IINQ[?XC_:6^'_AOP/I'BN;6?M>F:RPCTY+*)II
M[I^Z)&HW9'<$<'K7F7@#]K*#7OB%\5[V]OB_@/PQ865W!BQ>.YA+J?.5U(#E
M@PQ@CC'%<-)\$?%O@#P[\)?%6B^#;J]F\,:A>7M_X8^VK<W.VXSEE<JH9_F)
M(QP<<]Z?;?"?X@^/]6^/^JWOA!_#<GB_1[6/2[6>529'16^5B"0'(QGT)K>-
M##1C+6]^MU_,NGIK<ASFVM/ZL?2E_P#'/PKIT_@.&:XN%?QK_P @?;;L=_R*
M_P W'R<.O6N7U_\ :^^&GASQ;=Z!=:M<-)97(LKV_@LY9+.TG)QY<DP&T,#P
M>>.^*\1TCP[\2/&WB;]G_P"V?#S4= TWP/-]GU"ZO)$R["&-&=4!SY?[O@GJ
M35CP/X?^*'P6TSQ7\/-/^'">+#JOB&74['7;K8VG/#*\9+7&>0RA<CW^E0L+
M12U=W_B2ZM;^2MH/VDM_T\CW3X@_M1^ /AOXB.B:IJ%U/?0PK<W8T^TDN5LX
M6^[),R A 00>><<U9\<_M*>!/ -IH,M[J<M_)KD8GT^#3+=[J6>+ /F!4!.T
M ]37S3\2?@GXS\.?%OQYJ<>A>*O$6E^+(;9K<>%-0CMX!*L/EM%=!U)$8.<$
M#A2/PZ(?"GQ=\%/&?PU\8Z)X-NO$-EINA/H]YHUG=+/<V3NS,"LC;0Z@N03Q
M@"G]6P]HVE=M=UJ[?AKH'//L>I?LP_&K4OC+>^/[BYO;>^TK3=5%OIDD%N8C
MY)4GY@>2?J >*Q/VM?CGXP^'<^A>'OAU;V]YXJO4FOYHKB,.$M(5R[8)'^/I
M5K]DKP9XJ\+7GQ'OO%.@?\(]-K.M?;H+8.KJ492>"#@GD9]\UP]U^S]X_P#C
M!\<?&'C2^\0:C\/;>!1I6E&&VCF>XM<?.<,< -S]:2C06)E*5N5+Y/1=M_,;
M<W326YT/Q=_:2U>U_99T#XC>$+RTL]0U&>TBDDNX1+'$7R) 5SQ@C\*?\*O&
MGCK7_%^CQWWQF\"^(;.3,EQI&F6J"YE3:254A\@@XY]C7B>N_ #XE^'?A#XQ
M^&,.AWGB?3+77[;4])O0%474!9C*N,\'/)'O7KOPNBETOQ5HXA_9V/ABXQY+
MZT(X%\C*X+$KS@]\>M;2ITH4I*%GJ^VUE;?7[M2$Y-J_ZG?Z?^UQ\/=1\06V
MG6]WJ+VMW>?V?;ZN-.F^P2W&XKY:S[=N<@C.<5[6C;AGI7P'%\+?B5X>\900
M> _"GBCP-J;:KYMQ"NHK>>&_(,A+NH?D$CD@#/)P:^^8%94 <Y; SCIFN#%4
M:=+E]F]_.YO3E*5^8EHHHKA-0HHHH **** "BBB@ HHHH **KV^H6MW--%!<
MPS2P-ME2.0,T9]& Z'ZU8H$FGL%)D4M>6?'3XI:U\-K;PU!X>TFTUC6-?U2/
M2[:*^G,,*.P)#,R@G'% SU+(]:,UXCX8^.>MZ/XX;PG\2M'TSPUJ$FG2:K;W
MUC?F:T>"-L2;V=5*$9[\&MW_ (:!\(>(/#?B"]\)>(](U6^TFV,[QW<[6\2#
MLSDKD(?[P!% 'J5)7!2?&[P5I^KVVAZEXGTNUUYX//DLO/R441>8S$XX7;SD
MX!%7? OQ:\(?$M[R/PSKUIJTMICSXHB5>,'[K%6 .T]FQ@XX- '8TAZ&N%\:
M?'#P)\.M6BTSQ'XGL=*OY$$GV>5B61"<!GP#L4GH6P*B\5?'CX?^";\66N>*
M].L+O$;^2\NYE1QE'(4'"$<[SQSUH T/B!\*_"WQ3L(++Q3HUOJ\$#^;"900
MT3^JL""*?\/OA?X8^%NGS6/AC1[?2+>=_,E$0):5O[S,223^-<)XE_:5T/3/
M'WB#P982V;:QIOA_^W(KJ]N#'9R9#$(SA3M4(N\MR,$8KM?&GC#4_#_PROO$
MFEZ=%K%_;6'VU;.&0E9L*&8(W?C.#5\\^7DOIV)Y5>]M3LLT9KRGQ3\=;73/
MAMX6\3:-:+K%UXFEM(-,L1* 97GQQG_8!)./[IKCM%^,GQ7\?ZEX@?PAX1\-
M7&D:7J4VF"74M3EBFD>/ 8E50@#FH*/H?(]:,UXWXL^+GBBU\0:=X,\,^'K'
M6/'$EBM_J(FNC'8Z?&3M&]P-S%B#M  SC-8NO_M >+? OP^\:ZCXH\$K9:_X
M;BMY4^SSL^GWZS2*BF*4@$$%CN4C(Q[T#L>_9HKRKX>^(?BOJVLVQ\5>&_#>
MG:'+$9#/INHRS3J2,KA60 CUYK0O?BLUA\<T\!S6D4-C_P (S)XADU.27;LV
M7*PE"#P!@[MV>U CT7-&:\YT/]H3X=>*)+F+2O%NFWLUO%+</&DA#&*-=SR
M$#* ?QCY3C@UY_8_&_XG>(O#R>-]"^'EI=^"98OM=K:S7S+JUY:]5E2,+L!=
M?F5"<D,.10!]#9I:QX->6?PPFM):7*))9B\%K+'MG *;]C+V?L1ZUXY^SY^T
MA?\ QD\07FGWFC6EG$;(:A!+87#3&W0R%/(N00/+FXSM]CQ0![W17.^-?B#X
M=^'>EIJ'B/5[;2;21_+C:=OFD;^ZBC)8^P!K!;X]?#Y/#5GK[>+=,71[QGCM
M[HRX$CI]] .NX?W<9]J /0*3->0^(OVGO NBV?A"]M=7M]4LO$NI_P!F6US;
MLVU&"DL6&TG@A5VG!RP]Z[?P)XDG\5:-<7EPU@TD=Y<6V=.N#/'B.5D&6('S
M8 W#L<B@#I\CUHKYOT_X[_$_Q5?>-[SPSX)T*^T#PQK5]I$AO-5>"YN#:L0S
M*-A4$CIDXSUID/[3'BOX@^*_#^D?#CPOIFH1ZGX1M/%AEUR\>V*13S21"(;5
M.6!0<]#F@=CZ4I,UYQ\(OBQ+\0Y?$.DZMI+>'_%?AVY2UU33/-$R)O7?%+'(
M -T;KD@X!&"#R*ROC1\?;?X4ZCHVF0Z/=ZMJ&H7=O"[K&RVUK')*(_,DEQ@<
MG 49)/:@1ZYFEK/UG6[#PYI5UJ>J7D-AI]LADFN)W"HBCJ2:Y70_C9X%\2:!
MJ6MZ=XHT^;3--&;R=Y/+%N/5PP! /;CGM0!W-%>&_$+]IO2+/P#;Z[X"GT_Q
M=>7&KVVCI \S1+'+,2%,G&Y1QGIS6UX9\>^-]$NQ)\2]/\,^&]+GDCM;2XT_
M4))FEN9&PD9#* ,]N>M 'K-%<EXD^*7A/P>^H)K.OV6GR6$<4MS'+)\\:REE
MBRHY)8JP ')P:T/!OCC0?B!HXU7P[JMMJ]AO:(RV[9V.OWD8'E6'=2 : -VB
MBB@ HHHH **** "BBDSB@#Y?_:Y_Y++^SG_V-3?RBKZ@'2OE_P#:X_Y++^SG
M_P!C4W\HJ^H >*ZZW\*EZ/\ ,2W9%=7,5I#)-.ZQ0QJ7>1VPJ@<DD]J^-_CA
M^WJCZG<>$/@S8)XQ\1AC%<:T<_V=IQ]6?^-AZ"M'_@IOXHU30/@5H]C8:A-I
M>GZWK]KIFJW<#;62T?<7&[L"0H_&O&_"GA72?!NBP:=HMG#962*,+$H^;CJ3
MW/O7RV:YD\!%1@KREMV/K^'\C6;SE*I.T(VOW=SDM$^%,NIZ\_BKQ]JLWC7Q
M;/\ ,]S?_-!;G^[#&>%%5_B'X4U'PGJ6F_$+P'&NG^+O#\@N%2U4(+V$??A<
M#J",UZ=VI,9S7P$<PQ"KK$.5Y+^K>A^OSR?!/"/!QII1?W^M^Y]A_ +XT:/\
M>?ACI/BS2) %N8]MS;$_/;3CAXV'8@YKT45^8WPJ^),G[(_QL6ZGD9/ACXQN
M%BOXE&4TZ]/W9O96Z&OTUMIX[BWCEB</$ZAU<'(8'D&OU/"XF&*I1JPV9^!8
M_!5,OQ$L/56J_%=&2T445U'GA1110 4444 %%%% !1110 4444 %%%% !7S]
M^V+^T5'\!/APR::!=^,]<8V.BV*<LTK<&0C^ZN<YKV?Q?XKTSP/X:U/7M8NH
M[+3-/@:XGGE. JJ,FOS$TC7M4_:+^*NH_%SQ%&T>FJ6M?#.GRJ<6]L#CS2#_
M !-US7!C<7#!475E\O-GKY5EU3-,5&A#;J^R+7PS^%5IX8T)I-;2+6?$6H,;
MG4K^[C$CS2MRPR<\#.,57B\!^)?A1XC?Q9\(M:;P[J18/<:([$Z??<Y(:/HI
M/J*]+HK\QIYAB:=9UXS]Y[]G\C]WJY/@JV&6$G37*EIW7S[GL7[/7[<_AWXG
MZA%X6\:6O_"!>/P=G]F7S8ANB/XH)#PV?3K7U+D'O7Y=_&;P5H7BCP3J5SJZ
M)!+86\ES;Z@IV2VSJNX,K]N17VM^Q;XRU[Q_^S!\/=<\3-))K%SIRB:65<-*
M%9E20Y[LJJV>^:_1<LS!9A3<N6S6_8_%L]R9Y/74%+FC+5=_F<=_P45_Y-LN
MO^PK8_\ HX5],VG_ !Z0?[B_R%?,W_!14C_AFRZY_P"8K8?^CA7TS:?\>D'^
MXO\ (5])/_=J?K+\HGRZ^)_UW)Z***XRPHHHH **** "BBH+N^MM/MVGNKB*
MV@7[TDSA%'U)XHW$VEJR>BFHZR*&5@RD9!!R"*=0,*3-##(->(ZQ\8/&?B;Q
MAKNB_#CPUIVKP^'Y1;ZCJ&L7CP1M/MW&&(*IW$#JW09H ]NHKS'3OCKHFG>
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ML(D^8N!DH&^Z6']T'/M63\6/C7I_PC\1>$+75_(MM+UJ6XBGOIY"HM_+16&
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M"?QK9Z+)8?\ ")7UW/JWPCM?#R21&-A!J,$3%X9B6RI.X*&&03QGO7T3X/\
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M=3.<ZC8?P$$]608!]L5QM>;_ !=\,:S')I7CKP;*;3QQX7E^V6,J-CSXQS)
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MTU=L^@Q.(IX2E*O5=HQ5V16_@V^_:D^,MI\+=-,T7A'2F2^\7:E#C;Y8.4M
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MI-WU9:2BK+81ONFOG32;GQ/\ /&7C2%?!&M^,O#_ (@U!M5TZ[\/B&22&5U
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M^K6MY=6\+2^7OP" #\WNON*HZ;\5-)MO"NE:IKVH6-C+?Y"+!+YB-@\[3C)
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M7NW/%=1>_$[QEXKT#P=ITNMZM<Z]_9=Q>7MOX5N[>))8UE,:7,MTWRA0!RJ
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M9-*O2Q(U"P/^K<$]2 0"*V?AI\19?V2OC>NKR22#X:>,)U@U6 -^ZTZ\/"W
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M6>[BL33P=&5>J[1BKD-AX0OOVIOCA8_#33-P\(Z%+%J/B>_'*,%8-';J>Y)
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M0"NP#&W'IBN1O/@GX$U#0(-$N?"6E2Z3!,]Q#:-;+LCD<Y=E'\.3UQUKN**
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^%6***YCN2MH%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M."<^6O7Y5_'->YJ,#GK0.*6OHTK*R/BFVW=A36IU(W2F(_G?_:B5(_VD?BD
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M*]*M?VU/M7PJGU:+1(+OQ<FKKH2:=;7&^VEN6^ZZR=XR.?6MCQ5^R7<WVE^
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MMW[.]_G83]INBY\6?C1J6KZG\8_ 7V2.UMM$\+-J$-_#(PE=W &/;&>U>?\
MPQU6^E^+?[.T3WUR\<_A.[>5&E8K(P P6&>3[FO2-)_94\0/K/C_ %KQ!XV3
M6-6\7:%_9,THL!$D#Y'S*H;[H P%Z]>:W/"?[,\WAKQC\--<;74G_P"$0T>;
M2WB%N0;DOCYP=WRX].:M5*%.#A%]//?EM^8N6;=W_6ID_MX:E>:3\%+.YL'F
M6Y77M/VI!*8VD_>_<R/7I4?A#]H3QC9_$2^\%^,?#6GZ;>C09-:T][&Z:8,D
M:Y*2$C[W3I7I'Q]^$#_&OP5:Z"FIC2C!J5MJ'GM%YF?*?=MQD=?6LC5O@!_:
M_P :8/',NK[;9- ET-[!8?F82  N'SQC'3%84ZE'V*A/?7OY6+DI<]UY'!WW
M[5VLVGP"\)>/QH=FU[K6MPZ5):&1MD:/(Z[P>I/RUF^*_P!J;Q_%XD^)6G^'
M/".DWEGX(C6[N[R\NWCW0;"Q  '+_*WY527]BOQ;<>%-,\)77Q&C?PMH^KIJ
MFGV2Z:H?Y9"^)'W98\D#&,9KT2#]F>:*^^,-P=>4CQ]:+;(GV?\ X\\1.F3\
MWS_?SVZ5T?['!NUG]^UU^ER%[5^7_#'(>$?VK?%FK>+OAHVL>$;+2_"7C_?'
MIDL=T9+N)U16W2#&W!+# '8UC_%']L?Q5\,/$=S)J.A^'ET6WU(6?]FC4_,U
M22+=M\[8N57J.&QUKOK7]EJ:UMO@G"/$",/ATSE\VW_'Z&1%X^;Y/N>_6O-]
M4_81U[4/#_B3PW%XZM4T+4M4.JQR3:4LEZ\A<,%FF+9=1CH,<X]*<'@W-.5D
MOGW?Z6$U5M_7;_,[3Q?^T)\0?^%J^./!?@_PGI>IMX<LH+\WM_=M$I1HPS*0
M/XCG QZ'->G_  $^*J_&WX4Z'XO%I_9\E^C^9;!MP1U8J<'N#C/XUD:/\#+C
M3_BGX\\82ZPDO_"4:;!8_95@QY#(@4MNSSG&<5K?L_\ PD?X(_"S2?"#ZDNJ
MM8F3_2EB\L/N<M]W)QC/K7'5=!TK07O*W?MK^)K#GYKL^8OA[\;)?A!I_P <
M]?GCGUF[3Q5%8V%E+,2IED+*BY/W5R1G%>D6'[1?Q"T+XC:/X/\ &7A'2].N
M;_2+K5%N;&Z:566)-P4 ]#G@Y_"L#XF_LW0>#/AG\3+B_EU7Q(FOZU#K,4>A
M6P^UV+(Q(=5)/F;2<D<9 KB?@M9:_P#$7]H_PGK]UJVN>+;+2]&GM[[4=4T@
MV%O;[@ D**1\S$?>.3DUZ+C0JQE523M?OTBK6^=]S!.46HO^M2MX*\)>&OB9
M\(]4^+/Q3UOQ!?7NIZA-;6XTN:4BP <K&L<:=QC)-?2/[)_B#3M<^$]O#IOB
MF]\76]A/):C4-0A,4PP>$8'DX&!DUQ#?LK^-O!5]JUM\-/B/_P (SX:U2X:Y
METJ^T];L6[L<L86)&WO7JOP$^"EI\#/!3Z%;ZE<ZM-/</=W-Y<@ R2N<L0!T
M'M7-BJM.I3?+*^NB[+[M/DS2G&49*Z/C?XC7.BWG[6/Q,M?%&D^+?$5E!':&
MUMO#<TO[AC&-Q8*> >,?0U[B?BD?A/X7^&W@CX<^'+N[\0>+?/N+&Q\27+AK
M6-0996G8Y;(^; _V37I?@GX(2>$?CAXY^(#:LMS'XEAMXA8B':8/*7&2V><_
M055^./P*O/B3K?A;Q5X<U[_A&/&?AF65[#4&@$\3)(NV2.2,D;@1GOW/K3GB
M*524(2^%)=[7Y>WKN)0DDVM_^"=!\'?%7C'Q+IFJ1>-_"Z^&]7L+HVX:WF$M
MO>)C(EB/7:?>O0:\X^"WPWU_P!8:Q/XH\67/BS7=7NS=W$[KY=O!Q@1PQ9(1
M1Z?X5Z/7F5>7G?+MY;?B=$;V5PHHHK(H**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH \,_;@&?V3?BCGI_8D_\ (5\B_#3CX=>&/^P;;_\ HM:^NOVX
M/^33/BC_ -@2?^0KY&^&O_).O"__ &#;;_T6M?&\2?PZ7J_T/TS@C^-7]%^;
M.DI.^:6D-?!GZX;7_!.(?\7(^-IX_P"0E#V_V*Y#]K<8_;R\.?\ 8LM_Z'78
M?\$XO^2D?&W_ +"4/_H-<A^UQ_R?GX;_ .Q9;_T.OU.M_P BQ_X/T/Y_PO\
MR/5_U\_]N-0=*6D'2BORT_H \:_:X_Y(EJ?_ %]6O_HY:_5CPC_R*FB_]>4/
M_HM:_*?]KCCX):I_U]6O_HY:_5CPEQX4T7_KRA_]%K7Z-P]_NC_Q/\D?B?&?
M_(QC_@7YLUJ***^G/@PHHHH **** "BBB@ HHHH **** "BBB@ I#TI:0]*
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M-W'HVGIJ5]/JE[]F,T;'[MN,?.P]*]\\)>)5\6>&-*UF.WDMH[^V2X6&88=
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MH%WX@TZWUJ7 6QDN%$I)Z#&>OM2=*:2=M_T#F1U%%0S7"V\3RR,L<: LSN<
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M' /H<=#]:VJEIIV8PHHHI %%%% !1110 44UFQBE#9H 6BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \,_;@_P"33/BC_P!@2?\ D*^1OAK_ ,DZ
M\+_]@VV_]%K7US^W!_R:9\4?^P)/_(5\C?#7_DG7A?\ [!MM_P"BUKXWB3^'
M2]7^A^F<$?QJ_HOS9TE(:6D-?!GZX;?_  3B_P"2D?&W_L)0_P#H-<A^UQ_R
M?GX;_P"Q9;_T.NO_ ."<7_)2/C;_ -A*'_T&N0_:X_Y/S\-_]BRW_H=?J=;_
M )%C_P 'Z'\_X7_D>+_KY^I;U*Z>QTV[N4B,[PP/(L0ZN0"0!]37S[X'_:$\
M3:MK]U!=:*VK0E69;;3XL20X/J>HKZ+':JEEHUAIL\LUI906TTW,DD484O\
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MWB__ *(3XS_[])_C1_PV-XO_ .B$^,_^_2?XU]28HQ1[:C_SZ7WL+/N?+?\
MPV-XO_Z(3XS_ ._2?XT?\-C>+_\ HA/C/_OTG^-?4F*,4>VH_P#/I?>PL^Y\
MM_\ #8WB_P#Z(3XS_P"_2?XT?\-C>+_^B$^,_P#OTG^-?4F*,4>VH_\ /I?>
MPL^Y\M_\-C>+_P#HA/C/_OTG^-'_  V-XO\ ^B$^,_\ OTG^-?4F*,4>VH_\
M^E]["S[GRW_PV-XO_P"B$^,_^_2?XU)#^V'XNED"_P#"BO&IR<?+$G^-?4&*
M-HI>VH_\^E][%9]SYI_X:X\5_P#1"O''_?F/_P"*H_X:X\5_]$*\<?\ ?F/_
M .*KZ6Q[T8]Z/;4O^?2^]_YD\LOYCYI_X:X\5_\ 1"O''_?F/_XJC_AKCQ7_
M -$*\<?]^8__ (JOI;'O2%<CK1[:E_SZ7WO_ ##EG_,?/?[$GA_7/#WPJU5=
M?T6\T&\O==O+U+2^39((Y&4@D5[UJ.D6>KVKVU];0WENY!:&>,.A],@U;"XI
M:PJU'5J.IM<I02CRO8BBMT@1$C4)&@"JJC  '0 5+11618C?=->3R?#/Q7I/
MBW7]7T#Q#96<6KS+,\-Q:&0J0H'7->L-]TTSMZBM85)4[VZG/6H0KVYKZ;6=
MOR/+]4^&GB2?6-.U^SU^VM]?BM39W<QMBT4R$YW!<\,.U<5X!^%VLZMX"\.7
M$5S_ &5KVBZI>3PM>PDI()'()9?<<BOH4C.: !6RQ511Y?T]?\SCEEU&4^=W
MZ]7OH[^NB/'(/@3>BPN(KC6DN+FX\11:]),8-H8J.4 SQDUMWWP;M[WXK6OB
M\W9%M&%FET_'RR7*(424]LA3^8KTC(]: .,9J7B:K=[_ -,M8##I)<NS3^:V
M_-GA?B/]GK4M<U/6Y/[8LWAO[\:A'<75J9;N+Y@WDB0GY8Q@X"UL^(_@2OB%
MO%#S:@GF:I?6]_;AHMRQ21)MPPS\P.2/I7K8 /0T[8*KZW6TUV_X'^1']FX;
M6\=_-^?^;/&9/@3=7WA'4M,NKS3;6\O;FWFW:=9"&*-8G#;0.ISCO6]X@^%$
MGB#Q!KNH-?B./4]'72_+"<H0<[\_TKTC9[TA7 J7B:K=[_UI_DBU@,.E;E_'
MU_S9R?A#PMJ&D^!X]"U2[ANIT@:V6>VC*C9C X)Z@5PEA\#]9L-!T>&+7+>/
M5-#NGFTRY6 E=C#!209YSZBO9E&<TX)Q4QKSBVUU\BYX.C445)/166K\O\D<
M3\/_  %<^%;G5=3U2_74M;U6427,T:;(U &%1%]![UF?\*ABN=/\=6=Y=+-!
MXDN'N% 3_4,5&T^Y5@#^%>D[/<T$8&:7MJEW)/?]"OJE'E4&M%?\=_ON>26W
MP'CA^&T?A]M4D.L1Z@-6&K;<L;L-E9"#UXPOX4RZ^#6K>((O$5_KNMPW.O:K
MIG]DQRVT!2"W@W;R I)));G->N< XHZ=JM8FK>]]=S)Y?AVDN71*V[\TOGJ]
M3S;4/A$-4U+P]+<WH>UTW2)=*FB5,&8/$$+#TZ9K&\#_  +N_"^H0M+>Z8;>
MSA>*VEM=.5;AR1@/(YSR/;K7L1Z4J\G':CZQ5Y>6^G]?YC> P[FI\NJ\_3_)
M'C'AKX#7>G^*H]5U'4+(+%%)$QTRU-N]T&!&90#M[]A6GX3^%OB+PS+8Z>OB
M53X:T]G:WM(X,2R*V<)(V<%1GM7JFSGK2E<"AXFK+=_@3#+Z%.W*FOF_+?OL
MCR7P]\%)]"O?#,QU-)1I%U<W#*L9'F"4DX'/&,T#X)3GP_;Z:VIH3%KZ:UYG
MEG!"N6V=??K7K(7WS2$XH>)JO6_]?TQK+\.E;ET]7V2_1'A^K_L^ZCJFK7]P
MVKV4D<VI)J,=Q/:E[H;6SY1D)X0#L!5S5?@MX@N)_%45CXBM[73O$EP6O('M
M2S1QD8/EG/WB,@Y]J]DZ^U*!GO5?6ZO?\%_70C^S<-KH]?-^?^;*>AZ5!H6C
MV6G6P(M[2".WC!ZA44*/T J_3<;?>D#\'VXKE;OJSTTE%60^BD!R*6D,****
M "BBB@ HHHH ^&?A7^S[H_Q6^-'QWO/$/]N6(MO$;?96L[N:T296:7)^7 ?E
M1SSUKS?P_P"&+W3?V6KK3DTZ_)A^)6Z..2"1I#$#%AR,9(P.M?I4L"(6*J%+
M<D@=3[TW[)"%V^6FW.[&T8SZUZRS"=]5I[NE^RM^)S>Q7Y_B?#/C.ST[PK\:
M_C'_ ,+ \&ZGXDDUZTC/AZY@L6N$:)8L-&CCB,AN><8VD]ZX_P"'GA6#Q9X$
M_9DL;_37U'36U6X%U$8B\>W<W#XXQGUKZO\ B#^RYI_C;Q3J6N67C+Q5X6FU
M2,1W]OHU^$AN  %R596P=H ^7%>D> OA[HOPW\(:5X:T6V\G3--B\J!9#N;K
MDDD]R23^-:/&QC37+K+3Y>ZU^I/LFWY?\$^(_&GA1]'A_:DTS2=(FM-.DM(#
M;6MM;L(W;*9**!@_A6C\:KC5/@?IO@'XH:18S2SZEX<_X1R_A3Y7\YX@+=SG
MN#P![5]U&UB.[**=WWOE'/UKRWQ]^SQI'Q,\=Z1X@UW6]9NK#2Y8YX/#PN%&
MG^<GW9#'MR6S@]:BGC4Y+VBTZ^>B5OPN-TG;3^M2Q^SA\.!\+_@YX=T60 7W
MD"YO' Y>>3YY#^9-?$%OJW@*PG_:,LO%'ARZU/7M0UB^MM(GBL7N-\YW".*-
ME!".K[7[<$=:_2P1@# X Z#TK@OAS\%=#^&FI^*;[3YKJ[E\0ZF^JW*WA5UC
ME;&1'A1@<=\_6LJ&*]FYSGN[;:=;[E3IN5DNA\@W&CW'@'Q5\$]9^+ND7NH^
M#['P:ME*TT#W45CJ6YCF9 #@^647<>X]JY/Q-X)NM3_9O^-6L:9X;O+;P==^
M);6_\,6$]LWF6\0G47$T<9Y1&4CIV!^M?I)+:Q3Q[)465/[K@$4OV:(Q>644
MQXQMP,8^E7''N+3Y==.NFCOMW\Q.C?J?GC\49K";XK>'/%-M-;:/\-KWPR;;
M1[J^\/R7=I!,)7\V+R  8Y&.<-CG(QQS5JZ^'0G^&7P*T>X@U76-&F\9&7RM
M2L&MVBM65OD,8+;8\Y(R>AK] 386[1+$88S&O1"H('X4\VT1VY0$+]W(Z?2G
M]?:44H[>?KY;ZA['?4^$O%GP]@@^(O[0ND:;X=8:;)X;AGM;2"U/DM.I&&08
MP6'M7T-^R+J&@ZC\"O#ZZ%;?91;PB&[3[,T)^T 8<D$#)SWKV?[-'N9MB[F&
M"<<D416T4"[8HUC7^Z@ %<U7$NK3Y&NW7LK%QI\KN?FG\:(9=?\ 'WB_5?&<
MFL0?$G2=5C/A;3ET]Y[.YM58%8E &&#'J37UK^R+\3?$_P 1_ FHR>,X+FS\
M1V5_)!/:36!M4MUZI&G'S #'/X5[J]E!)(LCQ([KT9E!(_&GK"B,2JA2QR2!
MC)JZV+5:DJ;AML^WDO(4:;C+FN?GO^T!%8^%?BE\0+JRO)$U'4662?P]XH\/
M->P:N57Y5LYD#$ X]L9'TKJ]:_L_3_V@O@5XF\6^$$T&+4?#ZPW$,=FTL=O?
M$*L,;$ D%/D SR *^V9;"WG96DA21EZ,R@D4Y[2*5E,B+(5.5W*#@^U7]=]U
M)QZ-;]U;M_F+V6NY^7GQKU.;Q?H?CR.#0XO#FOP^(R[^'=.T&6:]?;.N;R:\
M(.U6&<;#@G'&#FO5]?U/P=H'[4'Q*UOQWX=N]3T6?1;.&UU!].DN(%E:!/EX
M4@,PX!]<CO7W6;&W,C.88][C#-M&6^II7LX) 0T2,#C(*@YQTK1X]./+R=+;
M^GEY"]C;6Y^?'@;PKXATKPE^SU'J.FWT"#QK)=VL$\3%[6S;/EAQ_".IY]:X
MW5O#-W!KGCGP_P"*KZ?3_$E]XB>>VAA\//>:C<(9,PRP7&0 JC'?BOTZ:VC;
M;E =O(XZ?2FM90/*LC1(9%X#E1D?C0LQ:;?+_5[]@]CYG ^.M(%S\$-2TS4A
MJ=Z#I @G-@H^V2?NP&*+G[_?&:^.O@-JD^G?%7P7I&@I9>,[58Y;<W,_AY['
M4M!CV'!GDP%8YP#R<U^@_E@U''900LS1PHC-U95 )KDI8CV4)0:O?^NWZHTE
M3YFF?GKX NO!WAC0=0\*^._ &J^)/B>WB22800VSBYN"928YEGQ@(JXYSC^=
M=?I/P/M_BQ^UK\51JT^N:):PVUB\$NG3O;AR8@&4N.&Q@=_7UK[;^Q0>=YIB
M0R]-Y4;OSIRV\:.7"@.PP6 Y-=#Q\KN459M=_-;?<0J2T3/EO]I3X>77PI\(
M_#SQ_P"%8+W6M5^'=W&DBN[2W-YI\O[J9&8 EC\PY[ N:\GO_AG_ &;^SOX:
M\3^+9M8TGQ/XC\2GQ9=ZE9Z=]MALYY<F$7</WO*5"#C!VDD=\'[_ )(UE4JX
M#*>H(R#3&M8WC\MD#1]-K $?E44\;*$5%K9[^7;[VV-TDVV?+G[%6O:AJNL>
M.8WTK2KG3/-@D3Q9I&FOI\6JR%<G]TP'*@XR!P<YZBOJBHH+>*V3;%&L:_W5
M  J6N6M456;FE8TA'E5@HHHK L**** "BBB@"KJ3M'87#H=K+&Q!]#BO&?V,
M?'.N?$?X :%KWB*_?4M5N9;A9+B0#+!9651QZ "O9=6_Y!EW_P!<G_D:^?/^
M"?7_ ":WX9_Z[77_ */>NN"7U>;MK>/Y2,G\:]'^A]'4445R&H4444 %%%%
M!1110 4444 %%%% !1110 4444 >&?MP'_C$WXH_]@2?^5?(WPU_Y)SX7_[!
MEM_Z+6ON?]H7X?W'Q6^"?C?PC:,%O-6TFXMK<DX'FE#L!/INQFOS.\!_'?PY
MX/\ #%AX:\<7#^#_ !5HL*V%]IFJPO&ZO&-N5XY4X!!'K7RG$%"K6I4W3BW9
MO97/T'@[%T,-7JJO-1NE:[ML_,]NI#7F?_#2_P ,/^ART_\ -O\ "HKK]IWX
M8V\$DB^++2X91D10*SNY[!0!R37Q'U/$O_EU+[F?JKS/ I7=>'_@2_S/:_\
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M:[B'@&ODK]HSXY:KX>^)S#1?%,&CZ?X(M8=3U33I+F-/[5,K[3!M+ MMCR^
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MUK6+J,7HN%NK:*T651,H4;)(P"^,D?,<'@U:/QJ\:^*OBQ\&7N]"N_"?AKQ
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M ..*7;[XI:* $V^YI-HIU% #2@/^-*!BEHH **** "BBB@ HHHH ;L%.HHH
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M6C6]YK^O7$#$$QO>\'!R.U<GX(\3ZC!\2O#&E)XQE\265]ILEW<QNZ,4DP,
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M/VX/^33/BC_V!)_Y"OD;X:_\DZ\+_P#8-MO_ $6M?7/[<'_)IGQ1_P"P)/\
MR%?(WPU_Y)UX7_[!MM_Z+6OC>)/X=+U?Z'Z9P1_&K^B_-G24AI:0U\&?KAM_
M\$XO^2D?&W_L)0_^@UR'[7'_ "?GX;_[%EO_ $.NO_X)Q?\ )2/C;_V$H?\
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M_P"B7>/O_!/)_A7T/U.O_+^1\9SQ[GU#17R]_P -TV?_ $2[Q]_X)Y/\*/\
MANFS_P"B7>/O_!/)_A1]3K_R_D'/'N?4-%?+W_#=-G_T2[Q]_P"">3_"C_AN
MFS_Z)=X^_P#!/)_A1]3K_P OY!SQ[GU#17R]_P -TV?_ $2[Q]_X)Y/\*/\
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M8>TBU<]Z+8HS7QWX_P#CWKL_QV^%^I^%+/5=<TK6] GNX] MY5B$\A(VERW
MV\Y->Z_ _P".%K\8[+6(I-*N?#^OZ+=&SU+2KI@SP2=1AAP01WJ:F&J4X*;V
M_+6PU4BW8].+'-&XCK7Q1^T;XR6V_:FL?#^O_$75/ ?A1]"-RTUC.4!G#?*,
M8/4$]NU<58?%SQ@?V<_CC-IWB[5==T+0[JU3P]XIN 8[B8-<(L@#8&0!C_OH
MUTQP$IPC)2WMWZNVYFZR3:/T,W'-+O']X5\->#/C!JO[5/Q&\.^!]$\67?AS
MPQH>FPWM_=Q,8;[7) H601D]$#9!(YZGTQ]F?\(W9_WIO^_IKFJX?V#4:CL^
MQ<9\^L=C;HHHKE-0K,U?PSI6OS6$NI:?;WLEA.+JU:>,,891T=<]"/6M.J][
M>PZ?:375S*L-O C222/P%4#))]@!0!#K6AZ?XCTFZTS5+.&_T^ZC,4]M<('C
MD4]0P/45R/A+X$?#WP)JJ:EX?\':/I.H(I5+FVM$610>H!QQ6_X/\:Z+X_\
M#]KKGA[4K?5])N03%=6S[D?!P:U+V_M]-LY[N[GCMK6!#)+/*P5(U R2Q/
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M^&O!/A_PFD8T72+3356$6Z_98@N(P20G'\(+$X]S6@?#^FG7!K)L8/[6%O\
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M3Q"Q47[Z?-\[W/R:/[5'@)#M>ZOT<<%6L)<@^A^6@?M5> #_ ,OE[_X 3?\
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M1K>9,< A3\P]17<_"WP!XH;XD^(/B#XQ@L=,U74;&'3(=+T^7SDBAC8MO:3
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MME^)O&'B2\CTF^O1=3:;;7W[MYFD;:J+GN(STKGK'3;;3;=(;:!((D&%5%P
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M<&CVA2<XY!I?#'CC1[/0U>]?3- B\^:&*&&9!$0AY(Q@ ^HKS/P_X!UG3X_
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M<\%ZS-;>"-!3PG-H^I:%JB7FH:TY01O$C,7VN#ES)D9%$L/2=[2M]W=[_P#
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M*7L*G,H6U?Z%+&T'!U.;16_';YG?XI:\;/Q]^U:-H-SI^CM>7FI7\FFFV6<
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M(**** "BBB@ HHHH **** "BBB@ KXH_X*+:W+/J7PU\-9_T2ZO9;Z5?4Q*
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M?=]/I[5/10!&;>(R%_+3>R[2VT9(],^E5Y-'L)IK>62RMGEM_P#4NT2EHO\
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MOO>^]C3^(WP+@^(?CFVUR?5)(+*329]$U'3?*5TNK:0EN&/*,&.<CTK+\(?
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M5T"72)Q;RF0JY(VL..1QDT[0/AMXMNM0\+6^O/ID&E>&B6ADLBQENVV[5)!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>glyc-20241231xs4033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4033.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %% ZD# 2(  A$! Q$!_\0
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MS[5M;#;/^MNO;<YKX]W<5;[O[UM+V3^&_J6O$/QGT[3[F.RT_3M3UFXDT_\
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M>"_&_C'6M5LAJEAX=M]+EC:262TU(RS(NPD87'/.,_B:R;3XL>-?%.GW.O\
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MO[<-=PDC-P&+85>2=K8;Y>G(KL$.5!(P?2N(]@=1110 4444 %%%% !1110
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M["?]-?YA]<H]_P '_D>C45YS_P +;O?^B>^+_P#P$@_^/4?\+;O?^B>^+_\
MP$@_^/4>PG_37^8?7*/?\'_D>C45YS_PMN]_Z)[XO_\  2#_ ./4?\+;O?\
MHGOB_P#\!(/_ (]1["?]-?YA]<H]_P '_D>C45YS_P +;O?^B>^+_P#P$@_^
M/4?\+;O?^B>^+_\ P$@_^/4>PG_37^8?7*/?\'_D>C4AZ5YU_P +;O?^B>^+
M_P#P$@_^/4?\+;O?^B>^+_\ P$@_^/4>PG_37^8?7*/?\'_D=Q)I-A<ZI!J,
MME;R:A;(\<-T\2F6)6QN56(R =HR!P<#TJ]7G/\ PMN]_P"B>^+_ /P$@_\
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M)_TU_F'URCW_  ?^1Z-17G/_  MN]_Z)[XO_ / 2#_X]1_PMN]_Z)[XO_P#
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M/4?\+;O?^B>^+_\ P$@_^/4>PG_37^8?7*/?\'_D>C45YS_PMN]_Z)[XO_\
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M_A;=[_T3WQ?_ . D'_QZG["?]-?YD_7*/?\ !_Y'HU%><_\ "V[W_HGOB_\
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M'L)_TU_F'URCW_!_Y'HU%><_\+;O?^B>^+__  $@_P#CU'_"V[W_ *)[XO\
M_ 2#_P"/4>PG_37^8?7*/?\ !_Y'HU%><_\ "V[W_HGOB_\ \!(/_CU'_"V[
MW_HGOB__ ,!(/_CU'L)_TU_F'URCW_!_Y'HU%><_\+;O?^B>^+__  $@_P#C
MU'_"V[W_ *)[XO\ _ 2#_P"/4>PG_37^8?7*/?\ !_Y'HU%><_\ "V[W_HGO
MB_\ \!(/_CU'_"V[W_HGOB__ ,!(/_CU'L)_TU_F'URCW_!_Y'HU%><_\+;O
M?^B>^+__  $@_P#CU'_"V[W_ *)[XO\ _ 2#_P"/4>PG_37^8?7*/?\ !_Y'
MHU%><_\ "V[W_HGOB_\ \!(/_CU'_"V[W_HGOB__ ,!(/_CU'L)_TU_F'URC
MW_!_Y'HU%><_\+;O?^B>^+__  $@_P#CU'_"V[W_ *)[XO\ _ 2#_P"/4>PG
M_37^8?7*/?\ !_Y'HU%><_\ "V[W_HGOB_\ \!(/_CU'_"V[W_HGOB__ ,!(
M/_CU'L)_TU_F'URCW_!_Y'H%Y;Q7=K+!/&DT,BE7CD4,K*>H(/4&F6-G!86T
M5O;0QV]O$H2.*)0J(!V ' %<%_PMN]_Z)[XO_P# 2#_X]1_PMN]_Z)[XO_\
M 2#_ ./4_8U/Z:_S%];H7O?\'_D>C45YS_PMN]_Z)[XO_P# 2#_X]1_PMN]_
MZ)[XO_\  2#_ ./4O83_ *:_S']<H]_P?^1Z-17G/_"V[W_HGOB__P !(/\
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M)_TU_F'URCW_  ?^1Z-17G/_  MN]_Z)[XO_ / 2#_X]1_PMN]_Z)[XO_P#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7^53T""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***0]* /%_V@/VK?!7[.-QHUIXD@UC4M3U?>;33="L3=W#HOWG*
MY "CIUJU\ OVE?#W[1-OJLV@Z'XDT9=.=4E'B'3#9ERPR"GS-NKQ7]NZSU;P
M9XC\$?$W2?BAX7^%ESHJ7%C_ &CKMG)=2W(EQF)(E1]ZX&2 N1US7>?L9^-O
M&7Q%\):EKWB/XH^&/B?IL\P2QN_#=@;3[/@?.DJ,BL&SV(S0,^C:**0]#0(6
MBN43XH^#V\<'P8GBC1V\7"(S'0A?1_;0FW<3Y.=WW>>G3FJM_P#&;X?Z9XG'
MAN]\=>&[/Q$94@&D7&KVZ7?F-]Q!$7W;CD8&,G- ':T5RT7Q.\(3>-W\&Q^)
M]'?Q:D7G/H:WT9O53&[=Y6=V,<].G-$'Q.\(7?C:;P=#XHTB7Q7#'YTFB1WL
M1O$3&=QBSN QSTZ<]* .II#TKEK/XG^$-0\:7/A"U\4:1<>*K:/S9]$BOHFO
M(EZY:('<!WZ=Z73OB?X1U;QE>>$[+Q/I%WXHLT\RXT>&]C:[A7U:('</RH ^
M-OVH?!NHZ1^W)\!-?N/%.I:EI^IZI+';Z#.!]FL"D!W/'@]6[\5]XBOCC]L#
M_DZW]F/_ +#%W_Z)-?8XH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%% !1110 4444 %?(O_  5+_P"3/]=_["NF?^E4=?75?#7_  5B^).E:'\
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MOCC]L#_DZW]F/_L,7?\ Z)-?8XH$+1110 4444 %%%% !1110 4444 %%%%
M!2-2TU^G;\: /$/VJO'WBGP'X0LIO#9>U%Q/Y=S?QQ>8T"XXQV&?4U'\(_C5
M+#\(H/$7Q"OXM/;S6CAN9D\N2[4="L8Y)/L.:W?BC\7#I$UUX<\-Z>OB/Q1Y
M)DDMB-T%HG9YST'LO4U2^&_PPL8ROB[Q>T^K>)MN[[7JRHD-JN/NV\8)6-/?
MKZUZ"E35!0J1L[WOU?\ P//\#PG"O+&2JT:C<;6L_A3[[ZOR7S:T&KX^^(/Q
M'0'P;X=B\/:/)]W6O$@(D<?WH[8?-]-Q%<Y\2/V>=?\ $?@[49K[QWJ^N:Z
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M+C0CRIN[]1:***YSM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-1:Y,L"N["5V!8!B0,<'%>@?M!?'WQO\+F\*:7X7NHO$][HVD?\ "5^+KO[
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MQQ1,MXTL!A5ACA&SCS'W8.[G'//-=\*6D:"+TZTM%% @HHHH **** "BBB@
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MN?$LGAV+7],E\0Q1^:^DK>1F[1/[QB!W@>^*_/BTT2QM?@!HWC=+:V?XK?\
M"U7!U15!OI+O^U6A:$M]XKY V^7TV]JV(/#^BV'P6\+^-[.RM$^*,OQ(D87\
M87[9+=MJ$D<D#-]XJ(1CRSP%'2@+'W=;>./#EYXDG\/0:_I<WB"!/,ETF.]C
M:[C3^\T0.\#W(I;+QOX<U#Q'<^'[77M,N=>M5\R?2XKR-KJ)?[S1 [E'N17P
M#:Z)I^C_  2^&?C30K"T/Q-NO'<QDU!$'VRXN'N94FB=OO,-@ V'@ #BK/AC
M0M&T7X9? _Q;HMK;+X]O_&T@N]0B13=W#R2RBYCD;[S#:!E3P,#@4!8]*_;
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MPI\5?B18Z'X6^(MWX^U769+_ ,7WN@2>&I8;<6,EJK2^6@"('\T%  ^XD]*
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MGDT#L>Y^%?A+\,;7Q=J7C/P]X;\/?\)!=EXKO5["")I&;HX+#."?XL<GO3/
M7P;^%_AU-8U+PCX6\.V\6NAX[^?3;:)X[I22'C;:"I0DL"@XY/%?&_QA\'Z+
M\*/%3^%?!5HOASPKXE\,Z/\ \)#;:7*T,05]12%[A@I^1GC)1GX+ \YZUZYX
M%^&MEHWQK^+/P[\"W]SX&\.76B:1>.?#NR(V%P[2+(\"$%(Y)8HQEMN<_-U%
M 6/</!_P*^&GA'2(+'PYX/T.QL+;4AJ<<=K:H1'>QY59@<'$B990<_*.!BM;
M1/A]X+M(M%72M#TB./P]+.NF_984Q822;EG$>!\A;<P;'7)S7D_[!%I'8?LP
M>';:-Y9$AO\ 58UDGD,DCA=1N!N=CRS'&2?6D_8Z<V_A'XG2X) ^(7B%P#W_
M -*/^% CT37/V?/AIXF?2O[5\#:%?_V7-)<68FL4*PO(Q>3 QC#,22IR">U0
M:S^S?\+/$,-A#J/P^\/7<=CM%JLFGQ_N%5RX5<#A-S,=OW>>E?+/PQ_:V^*O
MB_Q#X<\3SZ/JC^$-?U&6WN+2\\/QVNE:79AY$2XCU'SM\[IY:EP4^;+A57;F
MJOAG]KWXC:-XJL[[5;V?Q5X>U32M3U"/S/"[:3I[M! \T1T^=W\Z>,[0"TB<
M@Y&.*!V/N^.:ULG@LE>*!RG[J ,%.T<?*OH/TK+\7:!X;URULV\2V.G7MO:7
M*7%L=2C1EBG!^1U+<!\],<U\@:)>_$V'XX?#+Q/KNJZ7X]UK5/"-_J>G:19P
M+I:1/(D;_9UE)8-'A@ [C((YSFF^ KSXF?M*^$?BUX*\:^$FM-/DOKM+74SX
M@@N7TN[C57@MXT6,$@.!^\![F@+'U#\2_A!\./B1/8WGCOPMH6NRVP\BUGUB
MVCD:/<<[$9NF3V%8WA[PE\&/#OAJ]\%:-8^#K30]2D*W.A0-;^3<R-@$-%G#
M$X';KBOG71O&]Q^T?J7P]TZXP%\$Z#<:UX@2%BRQ:FB/;Q0N#P2-KR=^HKD?
MV2?A#J&I^%/ &MR?L^> M0LVG6Z/C"XU-/[1($C,+GRC 3YF<'&_KW% 6/K;
M0/A)\&?@S:7.AZ;X>\*>$X_$*M;36A2&!]05AM,9W<R*0<;>1SC%=-XMT_P+
M#X63PMXD70[?P_- D"Z3J+Q1V[Q(050(V 54JN !V'I7R7X%\ :#\4O!/Q"\
M8>)?AG!\9_B/<^)[W2=1T74+BW2XTF*.9DC@@DN& MU2(1N-A#'>"#TKRW28
M;3XR>//A'-X=^'$?Q3LHO 6HPQ:)\1-7A,UN(-3$)E:<1NDKJ5V#Y?NMDG-
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MJ?\ "4>)/ 6A:#=>!_!MG;7FKC59)C>7YDB6::.W*$+&8XVZN&#$= *P[_\
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M6WC7_A&=(M)[WP;X>\4+JVJZ-J$LUM?7YNIK.41JUE8P S,CD@L[MMCQC))
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M^$'B'2+?Q=HA^+>F:1&;C3()D>>"X;RT>3RL]%+EO3@=J!V-[P_^Q[X$\/\
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M\,_\%8_B9H^@_ 2'P5=17YUCQ!>VL]E)%;%K<""YB+B23.$)!X'>ON:OD?\
MX*EN5_8]U\ X#:GIH/N/M<9_I0!]8V?_ !ZP?[B_RJ>H+/\ X]8/]Q?Y5/0
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M!)RY;PW_ *]2/2?&]AJ5ZMK)'<Z=<2Q^; M]'Y7GIG&4Y.>HR.O(XKE_C_\
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M$X5@/G/F J-N=S8"YR*Q/V:3\*AX!N_^%0/ ?#;ZG<2W,4#S[DO'(:42)/\
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M>51\KHPRI'X&K[QH<DJ.1@Y'44 ?E]KG_!8'QWX:U">RU+X$BWN;>=[:2/\
MMIVQ(N"RY6W(/#+TX]*]!^#_ /P4)^.'QZT6_P!5\"?LZ6^N65A<"UN9!XHC
M@,<N,[2LD:GI7VY;>//#5[XXU'PE;ZK:S>)-.M8[^\T^-MTEO#(2J._&%)(/
M!.<<]#7EWP)\;? H^./&&C?#+5M/?Q'JU_/JNK0V\MPPO+@,5EEB:7Y) &R#
MY)*CGI0!X7KW[;G[0WAGQ?X?\+ZE^S3#;:[K_F?V=;?\)5"_G>6 7RRQE5P#
M_$16/J__  4(^..AZOXJTR^_9SABO?"]BNI:O'_PD\;?9[=NC9$6'^BY/M7V
MAX*^+7AGXA>*/$VAZ%=O?7OAN9+?4)/)*QQRON^16(^8C:<[> :[+RU)8E02
M>O'6@+GYLZ]_P5,^*?AE-^H_L^K;K]FMKO(U_?\ NI\^2WRPG[V#QV[XK)\(
M?\%B/$?B'QEH6AW?P>BTZ+4M0AL6N'U>0^7YD@7(!@ )&<]>:_2?Q5XCT;P7
MH%]KFO7UMI6D6,1FN;VZ8)'$@[DFO)OC[XE^"=]X$\,ZK\3KRRD\/37T.HZ,
M[BXW2W"#S(Y$CA_>-M'S'@@#K0![="_F1JW]X U)7F7B7X]>%O#WA/0=>L!?
M^++'6E+::OANU-XUQ&J;V<$$*%"\G<1Z#)XKM?"'BC3O&OAG3=>TB8W&F:C
MMS;RE2I9&&02#R#0(V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /ST^)^CZ+KWA7]L;6/$UO:S^)--O56PNK
ML#[1:0QVT+6)B8_,@W\J1C+$]:YO_@H-XK^-=U^SQ<Z?JG@S1S\.S%HLK>(I
M;_;J#7)\AF5K?/'[\LAX^[S7US\>_!/P.T75+#X@_$[2M)CU*.XM[6VO+K?O
MNI@X\A#$AQ<,K'*AE;;UX X/VD_B+\&[/1XO!OQ31=6L+V!=5FTI;&XNO)M8
MG'^ES"%28X4< %FP,^N#0.YYBGQ0_;-15"_!7P*% '_,P_\ VRN,\(_M6_M.
M^.-$\0ZI+\*/#>B^']"O[G3=6U'[?()[<P >=)#$S9E"@Y4J"&QQFOMN\\3V
MEIX0EU^QCFUFQ6R^VVZ:4GVA[J/9N40A?OEAC;CKD5@?"CXJ6WQ4TG4KA-+O
M-%OM,O6T^^T^],;O!,%5RN^-F1CM=<@'*G((!%-:">JL?$WAG]H3XE> SJ%S
MI\.K>+;N>VEO?[.NUQO2-=\CJS@ $+T7OT&:J>(_^"DGC+0;"VD?P1XAEOIH
MXI6M%T4[(UD&X'S!G.!STK]'%15)P ">3CO7#:+\;?!'B+6?%FF:?XAM;JX\
M*@?VRR,3%9DJ6PS_ '<@ Y /%;UZJK3YU%1\D<6#PSPE%4I3<VKZMW9\4_#K
MXI?$KQ;XNN=:\&&\\1Z[<Q&=M,FF6%,$959/,XB_X$!TKN?BS\>?V@/A;9^'
M&F\&27]_KE\FGQ6L4]LR12-C[SH&P/\ :( KV'X(^/O@WXY^(7B35O L20^+
M=6A2ZOKF>RGM9=1MP=J3Q^: )(\C 9.*Z7XC?'6S^&NO6]G?>'=;NM-WPI>Z
MU! HM+0S.$B!9F!D8L1D(&*@@FG7K>VDFHI65M PF$>%A*+FY7;>O2_3T/C_
M ,977Q M?BC-=:OIFJ)XI@A_M'R8(S*P2-=Q$;H-AQ@\ X-<CX^_;1^,>FV6
M@ZAHGACQ+=:=?:<=8G-U&$E6T%P(/E6,?ZW=N.QN<8/3-?IZD@DC#@Y4C(XK
ME/B5\5/"WP>\+S^(?%^L0:-I43+%YLV2TCLP"HB@%G8D]%!]> ":*M>55132
M5E8,/A8X:4Y1DWSN^KV\EY'Y7^-?VFY_$4SZ]>>$?&%P$_T;4+N_M8X_)PQ"
M+*\F%6,@G#9QV(S7T'_P@WQLB-G_ &/\&M)U_19(T*WFJ^*$641D?*88UE"8
MVD'#@\^U?1O[1_Q'^$EEX;_X0[XGK_:^F:U;?;9M&BLI[MC:0NCM<RI""R0Q
ML$8N<#([]*]3T76]'G\(V&K:5=03>'VLDN;6YMCOB:WV!D92.J[<8Q[5,JU2
M<8PD]%L73PM*E4G5A'66^_\ 7W'YP2^//BAXATCQ)-I/P+L!9>&=0FTO4_,N
MQ!=+,@)9X=I*2 ;<*QRIW<=16H?VF/V@_#/A_P *>'O#WPQLVTK7]-N-4T^\
M_M';<110C?-&SA=J$=%#+N;G&:^\OA7\4](^+N@W>LZ+!?065O?SV&-0MS!*
M[Q$!FV'Y@ISD;@#C&0*[1NA[UES/8Z.57N?D=K/[<7Q@\2Z#::+XC\ &PA79
M?6NJ7 NIL.V3&LQ1>!P>BDCC-;WPT^.?Q?\ CB=2\&^"/A[H.N:GIBQW^L3-
MJEQIP+L2JX,K(7R.IVX]*_26^^*GA?3OB'IO@6?6+<>*]2MI+RWTM,M+Y*#+
M.V!A1Z9QGM7EVA?%?X(Z5\>=6ATR:*W\>:Q*ND7FK):S^1=3QC<MK]HQY1D4
M<[0<T<S6P<BO<^6OB_X^_:.\'>"_#>G>)_@?X;ELFOH=-T]['7I;F9)I"%!;
M:YPI[LPP.M6O''Q,^/D'Q!T+P;?? 7PY=R1:))>65I?:P9[>**,XD;S(VV[S
MCA223VK[%LOVA=#N_B;_ ,(@NFZF$:[?3H]:,:FTDO47>\ .[?D+_%MVD@C/
M%>K4KNUA\JO<_+74_P!O'XUIH>BZC>_ #PQ=6<^GSW5F'CN)72"*7R77:<E?
MF'"GJ.>E< /^"E7Q&\!WSZA)\#+.U_LX-"DU[)J#PVB$@$)YA*H"<?GCVK]?
MM6U2ST33+K4-1NX;&PM8S-/<W$@CCB11DLS$@  =R<5X_P#$#XJ?"/X@_ '^
MW?$]S%KGPZ\2,EE! UK,SZG(TN(HH85'F.[.F5"C)QGH":11XYH_QG_;#U[2
M;#5+/X,^!I;.]MX[F"0^(,%D=0RG!?(X(KS#P[\;/VA?%/B+QCK%A\ O"']I
M^%;UX]2DFU:XB3[0JDEXT9PDIP/OJ#GUYK[)\*_&WP%-\(9_%F@7<LGA70T>
MREMK>SE^TVCP81K9H"OF+(IVKM(SR#T.:Z_X=>-[3XD^"=#\4Z?#/;V&KVD=
MY!%=*%E1'&0& )P<=1F@&?"&G?MQ_M-ZK9^#[F#X+>'/*\507%QIV^\G5MD.
M=_F@M^[/RG ;&>U>4>)?^"B7Q9O;FPUG5_V?-%O+I(4N+>:2WO'=59B%!'KE
M3P>G6OUJ/2N0UGXK>%=!\>:-X+O-8@C\4ZPDDMGIBDM,\:#+.0/NJ/4XH%H]
MSX(^"G_!0;]HGX^^)=3T#PG\'_#']K:;;K=7-KJ>H36;)&QPI E89Y]*W/CE
M\8/VD=!T+3M3\=_L^>"-5LFOX;&W\G5'NI$FE;"Y$;DA,CDG@=Z^C(OBM\$]
M&^/FH"*2&'Q_?&/1+S6%M)S"T@&Z.T>XV^4'P<A<@UUU_P#'.STKXE6?A2Z\
M.ZU;6UY=?V?!KDL"I:RW6POY: L'8;0?G"E<\9H6FP-=SY:U']IK]JGPEXP\
M.^"W^"?@^'4-6M9)K&.VU20VZ1QCD-(K;4]@37"7'_!17]HJTT33M5D^"NBB
MTOH+NXA DNC)LMI#'+N4<K\P. >HY'%?I<O6H=1O[;2[&>\O+B*TM($,LT\[
MA(XT R69CP !SDT#/REU7_@KA\:M&2Y>]^#&GVT, )EFEBO51!ZECP!7Z>_#
M'Q3/XY^''A3Q)<PI;7&L:3::A+#$24C>6%9"H)YP"V!]*\]\8_%[X2?$#X 7
MOB?7]1M]8^&NL[K L\,I&H$S&$111J!([/(I"A1D]1QS5WP7\8?"%U\)I]3\
M"Z=J.KZ=X>*:./#VGV3QWUI-$$C6T>"3:T;(&3._ "_-G;S0!ZW17(?"SXBV
M/Q2\)Q:Y803VJ^=-:S6]P58Q31.8Y%#H2DBAE.'0E6&"#77T""BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH 0G -?*GQP^'/AOP[^U#\&/%EI8*GB76=:N(+K4)97>62)+8E8EW$A%'7
M:N/4YKZK/2J%YH^GZC=VES=V5O<W-FYDMI9HE=X&(P60D94D<9% 'P%X@UO1
M+/X,?$WPO?WMHOQ'G^("^58O(OVV2Y:[C:WD4?>;$8R&'  /-?3GQ$_9IC^)
MEC=27GC3Q997L\:R):1ZF'L8)UB**1 Z,N,L2<<YY!!YKTZ;X>^%KSQ7!XGG
M\-://XD@79%K,MA$UY&N,868KO QQC-='0.YQOP@\#W'PT^&OASPO=ZI-K-S
MI5E':R7TV 92HP3P!QZ=\5I>/? ^C?$GPCJ/AKQ!:M>Z+J"K'=6RS/%YJ!@V
MTLA#8)4 @'D9!R"1704C=*!'YV>'UT_1OV9_A3=,MM8>$]&^,)>_*[8[.RM$
MU2Y1#)GY4B5VBZ\#C/2O9?ACI5M\4OCM^T(VB^(+R#PS??V/;'6/#=]Y;_;(
MX&,GE3ID;E0QJV.1D ]J^E&\'Z$VA76B'1M.;1;KS//T\VJ?9Y=Y)?='C:=Q
M))R#G-/\+^$]#\%:3%I7AW1M/T'2XR62RTRUCMH5)ZD(@ &?I0.YX[8? ;Q.
M_P 8M%\4ZIK]A=66A*\=EJ,5NZZO=6[)M^R7,A.QXP?G+XW,V,XZU[MVP!4E
M(W2@1\I_M&_#_P .Z5^T-\%O&$=@@\3ZAXC6RDU&:5G?R5@<B- 3A%SR0H&>
M^:\G^(>NZ-IWPW_:5\-ZI?V47C*_\4QM9:?-(JW=R[R0_9FAC)W/P/E*CL?2
MOO6^T;3]4GM9[RRM[N:TD\VWDGA5V@?&-R$CY3CC(K+U'X=>%=8\26GB*_\
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MI,<+ORJ=A7MND^'-*T%[EM,TRSTUKJ0S7!M+=(O.?^\VT#<WN>:TZ N,7*J
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M[C47CM8/L]K;-,VXPV\63Y<2GH,GJ3WQ7H5%% @HHHH **** "BBB@ HHHH
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MV.E?3E8O@OPEIG@/PII7AW1K<6FE:9;):VT(_A11@?X_C6U0(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"<"OBO\
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MJ^MOV[_%NH>$_P!EG5(]-GDM;G6);/1O/B.&C2X<(Q![<9'XUY?\>OV2-?\
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M1W%W&PE2[5EF$N(QNX=L8Q[YH&?!>@?$#_A?'[?7PS^*-E+.=!NM530; /\
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>glyc-20241231xs4034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4034.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &2 ZD# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M= P25 X#@@@$9Y!Z'VH I?\ ".:5_P! ^V_[]"C_ (1S2O\ H'VW_?H5IT4
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M(BA5!)Y/ ')JY10 444A..M "T4@.:6@".X_U$G^Z?Y5X17N]Q_J)/\ =/\
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M*8'SBEW4 .HIF^EW>U #J*;N]J-WT_.@!U%-WT!@3Q0 ZBBB@ HHHH ****
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M@G@%<C=D\XH\-_L]^'O#'PIC\&VD=O'.-&&CRZS#9QQW$H\KRS(0.YZD9Y-
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M/? /[/WPZ^%NLRZMX4\):=H6HRQ&%[BT0ABA()7D^H%>@@DT"%HHHH ****
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M"3CI74>!+J9? =LR*9I8(Y%1?[^TD*/T JA>:YXFM--GL+G17NKZ1#%#>V;
MPN3P&8$@IZ]ZZCPWI(T+0[*P#;C#&%9O4]2?SH ^/OAI?V?BOPSI7Q(\6?%C
M5O#GBF?Q"UF]LMYBW5Q,46Q^RX(Y  SC/?-<1XQ^+WQ2T[X:_M#C2],N;_2K
M'Q)=Q)XD;74AETE5>/$<<!4LP QT8?>-?:K?!'P"WC4>+CX0T@^)0V\:G]E7
MS=W][/\ >_VNM7I?A;X2FTC7-*?P_8MIVN3M<ZE;&(;+N5L9>0=R=HY]A0!\
M9>(9?%_B[X[_ !#M+;3]6\2V&G'3T@BM_&PT1;;?91,V$*G?EF)S4GQ[G\06
MGQ"\9ZK9>)+WQ!X>\,Z79-+I^@^)ET_4_# 2#?).\4H$=X)!F0$DEBI4#/7Z
MH\4_LV_##QMK,VK:[X)TC5-2F55DNKB %W"J%4$^P4 ?2I_$W[//PV\97VG7
MNM^"](U.ZT^%+>VEGM@62-.$3_:48X!S2'<^</B7HEOXI^)'P3U'3?%GBF+2
MO'Y\V\6/49+;S8A9+)&PB4XB)P&8+W)J]XMT"Y\;Z5\7M<3Q'KMKI?@Z"/2-
M%DL=4DBWRVUMOF>3!^=BTJ@D]2AKZIU#P7H>JZCI%_=Z7;3WFD,6T^9HQFU)
M7:=GIQQ45GX!\/:?HNHZ1;:1:PZ9J,LT]Y:K'A)WE.9&8=RW>@+GQ3J-]XF^
M'?P]_9^UOPWJ>M^(M=\3:S;37FG:AK)5+]C;L3%YCY$:$\],<"J_B+XP?$!;
MKXD+K=U<^!7G\2Z5I=TD6I)>#2;69?G:.0* -W W #&:^VG^''AB2VT&W;1+
M-H=!D672T,8Q9NHP&C]"!Q1/\-_"]TVMF?0;"?\ ML :D)8%878 P/,!X; H
M ^1?'5_<_!WQEK_A7PCXSU;5='O/!5_JUU'>:@;R2QN(Q^ZF60Y*;\],\]JY
MC]GKQ/XJMOBK\/8=2U#6/"$#Z+)J^JMXD\0?;K?7K<Q\&U4 JA1AO8%@0.U?
M9/A?X$_#[P7I&IZ7H?A'2M,L-30QWL,%N!]H0]58]2.>F<5<UWX/^"O$NDZ7
MIFI^&M/O+#2XVBL89(1BV1DV,J8Y *\$=Q0%SXP^#?[4M[JG[1%CKFH:[JDG
MAKQQ?7>E0Z1>V,T-GI@0C^SGCG9/+=IPK@A&/+C-=%\(=3MO&/P_T/XJ>-?B
MIJ_A;QI=^(WL[BR2\/V>"07;Q)IOV,@XW(J\%=P#;LXKZYOOAQX8U+PUI_AZ
MYT.RET33VA:TL3$/*MS%CRB@_A*XXQTK*_X4;X _X3D>,O\ A$=)_P"$H#>8
M-4^RKYN_^_GIO_VNOO0%SX[M/B%XD\0:W=>%-4\5:CI/AS6OB[K>CWNK1W/E
MRPVT42/!9)*?]6KMD#&#V'6OIWX"6>A^'M3\8^'-$\?7OC*+3+N(/97\QN'T
MHM&3Y7G$9?=C/).,$<5U]]\'O!.IZ#J^B7?AC3+G2=6O)-0OK26W5DN+E\;Y
MF']\X'S=>*T?!7@#P[\.=%32?#&C6>B::K%Q;V<012QZL>Y/ Y/- '04444"
M"BBB@ HHHH **** ,OP[_P >4W_7Q+_Z&:U*R_#O_'E-_P!?$O\ Z&:TF) X
MH =17#W/QF\(6GBD>'I=;MUU3<$,9SM#=E+8QFNT$A([5<H2A;F5KF4*M.K=
M0DG;>Q)17#Z;\8?#VJ?$K5/!$,TO]L:?;BYD=H\0..-ZJ_0LFY-P[;U]:9XC
M^.'@;POH&J:Q=^)M-EL],:%;LVERDS0F618X]RJ20"S#KZ'T-0:G=T5S!\=0
M'P]K^K165U.FCO<(]O $DEG,2[CY:JQR6'0'!Z9 KGM;^/GA30O#OAS6I+F6
MYL]>LI-1L_L\>YC;1VYN'D89X 0 ?[S*.IH ](HKS71_C7;WOAR7Q%J>@:KX
M>\.I8#4O[2U$1;#"5##A'9LD$<8J#2_CM;W0$NH^%O$&AV<UG+?6MU>V@V31
M(F\@[6/EMM&0KXS]>* /4:*X?P#\2Y_'L5K=1^&-7TK3KJW6Y@O+]8E216 *
M\*Y()!SR*VO^$[\.C69M(.O:9_:L*EY+'[7'YR*!DEDSD8')R* -ZBN:M_B1
MX5N[*_NX/$VCSVMAC[7-'?1,EMGIYA#87/O6/IWQG\.ZOX0\4^)[.=[G1_#K
M7:W5Q$ ZR"W4M(8R"0XP#@@\T =[28YKQB]_:BT/1-,>^US0M;T2-]'GURS%
MU A-[;PJC2"/:Y^<+(AVMC@^U=7X:^+EGK?BP>&=0TC4_#>NR6S7EM;:I$JB
MZA0J)&C=&96*EUW+G(W XQ0.QW94$TH&*XSQ%\6M!\,^-M \)7,LTFN:RY6"
M&&%F5%"L=SO]U0=I R<D]!P:P-8^/^EV/BM?#EAH^J:YJS2S1)%81QD-Y*(T
MI#,X&!O4?6@1ZG17CMA^TOH^O2V\.A:!KFN7;V\MS/:VMN@DM1%)Y;HX9Q\P
M;C SFNPTSXJ:%K/P[G\:64TD^C06\MS)B,B5!&#O0IU# J01ZT#L=E17*:]\
M2=%\,>!CXMU*>2WT@6RW((B9Y&#+N50BY)8^E:GA'Q-:>,_#&EZ[8K(MGJ-N
MES")EVN%89&1V/- C3N/]1)_NG^5>$5[O<?ZB3_=/\J\(H ][HHHH *^9OVD
M/C1XU\">+[/3=#;^S[ PK()_LZR>>Q/*Y8'IQTYYKZ9JM=:;:7NW[1;13[#E
M?,0-@^V:Z</4A2J<TX\R['!C:%7$T?9TJC@^Z/*_$GQ=U#PQ\!/^$NU&T,&O
M3VBQVUDJ_-+=R';&JJ>I)(./0&O'/#/Q9\86^E:?X5O]7U%?%5CXAMQ'/JT?
MV>74+6:"9U$BX^X)%V$C^Y7U=JUAIMU;Q-J4%M)!:R+/&;E5*Q.OW7&> 1GK
M6=J%AX8OKZTU>\BTR:Z4!;>]FV%N"2 C'T)/0]ZPDTVVE8[*<7""C)W:Z]SP
M>^_:RU6YT2*]TO08,FYL]'G:=V*VVIR[VEB8  D1(@'J6<#BB/\ :5\6ZC"]
ME#IN@Z7JFGV%]J-[<:K=-';74=O*8PL&,E2V"6W?ZO@$'->Z7GA_PG-9:CIU
MU9:4UK=R&ZO;:1$VR.3DR./7./F-9UWX$\ 76DZ78W&C:')IT#,;&&2*,Q@L
M<MY8/J<9QUJ30\*TK]HC7RNJS6%Q;O>ZQJ_GV.GZNKO):6HTFPN&C2., X5[
MC+,Q& V><@5W_P &_C3XC^+NNV$D5AI=AH2Z#IVK7H\YY+@RW<<I$<> %VHT
M1RQZYX'%=_J_A3P5J4[+J6FZ//-'*UVPG2/<LFQ8RYSSG8J*3Z*!V%7]+LO#
MOASR1I\>G:<+B*.*,0[(Q)&F=BKC&0-[8Q_>- 'BOB']I?6/"OC77+/4=,L?
M[)M&N8K*.!VDFNWCA\P 2+E Y((,;8( SD]*X_QU\;O'&N:/%H*7^C:;J%X=
M-O1J.AW<A5+>>95,!?[ROR,,.HR1BOIE/ 7AL:Y+K0T.P&JS B2\^SKYCY&T
MY.,]./I4>F?#7PIHUM+;V/AW3;2&659W2*V10SJ<JQXZ@]/2@#QOP+\7?%&D
M? /Q;XIUBYT_7-5T:_NH(4WF--B2A$61N2, \L1D]35.X_:3\1V$D^BW$>@2
M:^;FV2VN;-Y9[:5)8O-**JC<TB#J,@8YR.E>T>)/A=X>\1>%M=T%K)+"SUH[
MKUK)5C>5L@EB<8). "2*99?";P=9:+#I,?AO33812"81&V7'F 8W]/O8[T ?
M/-]^TSX\\:> +Z]\-VFB:1<VOAFXUB\O+F1YFC=9)XL1(!C(,.[+\#."#7T[
MX/O;C4?"NCW5W/!<W4UI%)+-;?ZIV*@DKGL33++P/X>TZVEM[71;&W@E@:V>
M..W55:(EB4(QRI+,<>YK2TO2K/1-/M["PMHK.RMT$4,$*A4C4# 4 = * +5%
M%% @HHHH **** "BBB@ IKG:,TZFMTH \)3]H^?_ (3@Z6=*7^S_ +4;;?N/
MF\-MSCIU[5Z#\7_B$WPQ^'VK>(DMEO9[9%6"!CM5I&8*NX]ER1D^E:"_#SP[
M_;_]L_V5;C4MV_SMO\7]['3/O6EXA\/:=XKT6]TC5;2.]TZ\B,,\$HRKJ>HK
MS\)3Q-/F^L3YKO3R1Z^85\%6]G]3I.%E[UW>[^_^NQX?XG^*?C?X<O>V^K:]
MX:UG5%TJ:[^PQ6,]L\4Z)N C)9A+'@'/*L.OM6AH7[1SW4"VW]D76OZX[2,;
M'3(!%Y4<<:-(Q9WPPRV >">F*WH?V<_#&'6_O==UJ-;>2TMH]3U6:=;2)UV,
ML63P2O&XY..]27/[.GA*6!1:G4]+N!)(_P!LL+Z2*;;(BI)'N!^XRJ,C\1@U
MZ!Y)RNB?M-F_US5+B30;RX\)1RV*1:Q;Q "V^T(HQ,&;)(D8*=HXR,U4M/VK
M8M \&Z?JOBC2F:2;<\\M@Z(B)]H:)=J.^YR  2!GBNRC_9N\%PZC#/;17]M:
MHUNTFFQ7T@M)V@ $)DCSABN ?<C)S5#4_P!E3P'JJ2Q2Q:BEO/;"TN88KYU6
MXC#LZ!^^59B1@CT.10!F>)OVH8;+3O'*:/H-S<ZGX=L+ZZCCNI$B$S6X[H6W
MA&ZAL8*@D=JV8OVA[2.^\FZT'4DLK6_M-'U/5$"&WLK^=8ML#?-N;#31(64$
M N!GK5F\_9N\&ZGK%_?WT>H7WVJVN[1;>XO7>*W2YC*7'E#JNY21UPN?E J2
M+]GGPPNJ6M[)/JMRB3VUY<6DVH2-;WMW;HBQ74Z='E'EQDL>I12<E0: .7C_
M &LK&?36OH?!VOO;'3Y]6B8K$#):02^5-)@MQM8K@'E@1BMR;]I'0X?&^D>'
M6L;K&J7$-K;7@>/#/+&)$)CW;PN& W$=:V+;X#^$K32H=/CM+C[-'I-QH@!N
M7)^RSR"20$YZEE!W=1VK-M/V:O!EAXBMM8BBO_,M[^+5(;<WC^3'=(JJ)0O<
ME44$$D>PH ]61MV:=34Z&G4""BBB@ HHHH **** "BBB@ HHHH **** "D/6
MEKCOB?XGOO"NA0W5@8UF>=8RTJ[@ 02>/PH \?\ &L7V;Q?JT; (?.+8!]0#
M6)N'K4^N:U/X@U274+F-$GEQO$0P"0,9JANH'<L;QZT;U]15?=1NH'<L;QZT
M;QZU7W4;J N6-X]:W_ ,1N/&FD*I.5FW\#L!FN8W5H:!K]QX<U1+^T6-IT5E
M7S<D#(P3CO0*Y]1BEKCOACXGU#Q5H$EUJ"H94F,8>--H<8';\:[&@04444 %
M%%% !2;1Z4M% "8%&.*6D/2@#@?B)\7-*^'<UK;W<,]U<S@N(H ,A1W.:W_#
M7BZS\5^'(]9T_<]LZ%@K## CJ#[UC>/_ (2Z-\1);::_:XMKF %5FMG 8J>Q
MR"#6WX=\*6/A?P_'H]@K1VD:% 6.6)/4D]S7'#V_MI<UN3IW.&'UGV\N>WL^
MG<\H^&_[2;>.YK>>>VT33=-=)II=VL*]S#'&&+%H@O;;SSQ77P?'SP;<:*^J
M)J4OV7S8X(@UK('G:093REQF3< 2-O8'TKEO _P#U_P3%!IT7C:UN-#A26(0
M#P];I<['#?\ +?<<D%LY*G..0:IZ+^S!-HC+>V_BY[?6+6[AO-/EMM,CCM+>
M1$>-F:VW%6:1)7#%2G\)&W%=NAW'7WO[17@:PL[:ZEU9S#+;R73;+:1C!'&_
MERM* ,IL;(;.,8-5-!_:*\.:EXVU;PS?%]-O;;6!I-I*REX;LM;0W$;"0#:I
M<2G:I.3MSWKBI_V=_$T6MW=E8^+9+2QU?2[V/6-6-A#))=7%U<&2?9&6 A.U
ML(1N [AL5U5M^SKI]A9?9+75[J"W3Q):>(8D$2DQ_9[6"V2 $]1M@5MQYR?2
MD,V+?]H;P--_:1?5VM5L+9KR0W-O)%YD(D$9DCW ;QO95XZEE]:8/VB_ YLI
M;@:E,9(K@6CV?V63[2LI3S-OEXW<)\QXX%>6:E^R?>Z-HMW>P:W<>)M6ATW[
M%;QQPQ6EQ.XGAG2>29RXDG#0*?FPC<C"@DU#X?\ V;O$WC2[U;Q+XHU/^S=?
MFU07=DU_86]Q^Y^S"%UFMXY#&,_,5"R$C ))SB@-#U^_^/\ X*L(].F;5C):
MWT<<L=U# [PHKMM4NX&%RV1R>H-;/PW\>?\ "P=(OKX63V/V:_GL3&[!BWEM
MC=QZ^E>3:S^R6FK0VUL/%DJ6,5M!#Y,NFQ-Y3QR%V>  JD6]C\P"'M@COZW\
M// L?@#2KRQCO9+X7-]-?-)(@4@R')4 =A0!UE%%% @HHHH **** "BBB@ H
MHHH **** "BBB@#+\._\>4W_ %\2_P#H9K1D&16=X=_X\IO^OB7_ -#-:E '
MS9J7[)'V_P"(;ZTNN!=+DNOM30%"9@=V[:#TQGO7T24:&T*PJ&9$P@=L D#C
M)JS@>E,EPJY)"J.3FMZM>I6LIN]CAPV"H81R=&-N9W9\WZ=^R]K6DSZ#XH3Q
M7=7OC.UU2;4K^&>X8:;,+G(NXT0*&&5*E22<&-:H:M^RCJK^#M'T[3I=%@N]
M/\+0Z/)^Z*QW%U%>6]QN8A<E6\EADY(+DXY-3S?M:ZK9W.LR2:!I=_8QZ7>Z
MEI[Z??3%9/L[QH8WF>%8VW>:#NC+!=ISGK6S<?M ^+;365\+/X=T-_%,^I6M
MI!/'JK?V>L-Q;7$Z2LQCW[T^SLICQELJ0<'C []3H/ 'P0O=!U74M1O_ !!?
MV;3^(KW6EL-(N?+M;A+AD81W*E?WA7:1P1QBN:TO]F>_TZQ\<V/]I6ALKC3;
MS1_"T05@--M;IVFE1P<Y_>E5&WI'$@J@W[5FM1IJ$LOA2R6UT#2+[4]>DBU!
MI&+VUU/:F*T'E@2!Y(-PD<H K<\BM=_VBM=\(ZM-IWC#0](B:U-C=WUYI&IM
M-;VME=221+(2\:DM'(B[N@9'W@C!  U,'P?^S+=6?@J_\+W7AGP]X<^VZ0NF
MRZWI&H3W$SNBKM<Q2(HP60$C-;U_\+OB+XRUV&]UF]L-(>"QFM+I],U2[>#5
M"T+(NZU;$4:[FW$X9N, ]ZQ/$G[5NLZ-IUKJ</A_3C:^2M_/8S74[7GV629D
MA8A(62'>BAPTC '=M&<$BG:_M$>*?"AO1>06NI:?'K-XDVJZG))'%!"DJ(D&
MZ&)_*P&)$D@"\8SDT#/7_@]\&]"^$?ARP@L-/@M]46QAMKVX@DD99F11D@.Q
MP"<GH*^8O%>@Z[KWC6XN[R'4GM(=0OYD\G1I4A9)HGB7;"D8'F L-TC,Q;%?
M;UG,EW;1S(5>.10ZLIR"",@@U-@>E CXDO?#=M!!H3Z;H>H)+H]CIL*V3>'Y
MTM[R:UEE<B3"_=(ERK'.UE!Q7JWPP\'ZAXG^#WQ.T=;9-'OO$MQJC1026DD$
M%LUU&0HPZ@L 7^9@,$YXKZ%VCTHP/2@+GS[KW[*.C-\(-8T31+:&W\8WWA_^
MQAJU[=W%RJ A2Z*9&8QHS(,A ,X&0<"MBX^%GBOXA^-;+Q#XQN[3PZ-*TZZL
M=-B\-74CW*27!C\V<SNB[<+&%50I^\Q)Z5[5@44"/-/$OPPOKS_A!%LM4EO6
M\.:@;R6ZU64RW%PODRH-S #+;G';H*X=?V9#K'B'P??Z_-%<VVGV^H/J<=I=
M3V\DUS<ONW*\;*VT#Y<$] .*^@\#.<<T8% 'A]Q\)->\ >.K/5/AUI>A1Z/%
MHS:6+"_N981"QF\SS,JCE\GKDY)[U!I/[-USI7P^NM+7Q1J)U:YM;T7$$$_E
M:;<7-P&+.\.TD@%@!SG KW?%&!Z4#/-/"FA^-+GP/>^'O$5AHUCMTS[%:W&G
MWDDV]O+*;G#1KM'0\$UTOPQ\+W'@GX>^'= NY8Y[K3;**UDEBSL=E4 D9YQ]
M:Z; /:EH$1W'^HD_W3_*O"*]WN/]1)_NG^5>$4 >]T444 %%%<AXM^)V@>";
MJ*VU6[\J>4;A&B[B!ZGTK.I4A2CSU'9&U&A5Q$_9T8N4NRU,GX[>";WQ]\.[
MO2;"U%[<M-%,L)NS;%MK9X?!&?9@5/0UX%K_ .S[\1=8\(V>D-IFC%?L=[#"
MT4T<<MI)(Q,9D.PIC&W)B4'/3CFOI/Q;\2=%\'^"I/%%Y,\VF )L:W&XREV"
MHH[9+$#G ]:SO#OQ=T_4;?4I-=L+WP?)IRHTXUL+%%M?[C),"4?/3 .0>,5:
M::NC-IQ=FM3Q^Y_9T\0R:7JU_/9:??ZS-K5E?O;/=-B]LX845[5I"/E!<%@#
ME25&>IK/\0_ ?Q7J4&J/#X,T,QZMI,^G:?IHU-UC\.3O+*XN%;:=Q82(SF,
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M=&L4TQ+6RL-3757AB_Y>IE@DA4R,3NX$F1@\;1CBN_\ [6G_ .@9=?\ CO\
MC1_:T_\ T#+K_P =_P : ,K3/AOX6T:#R;+0+&WA^P?V846$;6M=S-Y)!ZJ6
M=B0>I8YZU4TOX0>#=&T/4](L_#UE'IVIQB*\@*;A.@7:JMG)*@< 9P.U=!_:
MT_\ T#+K_P =_P :/[6G_P"@9=?^._XT 8.L?"7P?K]PL^H:!9W,BPQV^&3
M:-/N*P!P0O;/3M3+_P"#O@S5)UEN?#ME+('=RVPC>6(9MV#\P) )!R,BNA_M
M:?\ Z!EU_P"._P"-']K3_P#0,NO_ !W_ !H T(8UBC5$4(BC"JHP /04^LS^
MUI_^@9=?^._XT?VM/_T#+K_QW_&@#3HK,_M:?_H&77_CO^-']K3_ /0,NO\
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M.<W=O5GS?;_LTZW=66L?;+G2+:XU72M<MG@MHV,-K-?N'18\C)C3!R< DDD
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M=BX<$<$&O:Z* N?*>K?LU_$76=/MK&]U[2KM#:0Q/-$HLPK),),3+#"#<<
M$E!G)*\UU<O[/^KZ9#I>J6"Z3?:UIWB"ZUDVMP&CAO%F!4*[A20Z@\$J>_K7
MT#10%SYJE_9Y\5R1ZI9^5X6CM_$$]C<WMS:020/I9MV1O+M4P=R_N\J2RX9F
M8@]*O6/[,UW#;:*+AM(GGLH]?$LC0;M[W[@QMRO51D-GUXKZ'HH"Y\JC]F3Q
MK]I\.VS:IIKZ?I%QH5S&4E:&/%B+?S$>)8MTTC&%]LLDA 5E7:-N3]4*",4Z
MB@04444 %%%% "&O)=1_=_M(:8UYCRWT9Q9;N@;>-^/?%>M&N(^*'@.X\6V%
MG?:5.MEXCTJ7[187##Y2W>-O]ENE '; \]:4_G7%?#3X@/XSM+VVO[%]*U[3
M'$-_9/R%8C(=3W5AR#7F^DW7BKXNW6OZPGBR3PEHNF7DEI%!:H"<1\L[L2*
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M>7<^K'O7S=\,(#>_$'0XV&Y1.9"/]U"?Z"OJH=!0)@.E+110(**** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTK2\*^.M$\:S:U%HU\MZ^CW\FF7P52/)N4"EXSD<D!EZ<<T ;]%%% !1110
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M(V(BB4C[1:LI+/,_! P,%CD]Z^BX_'F@3Z#=ZS%J,4VFVLCPS3P@OM='V.N
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M"GQJ\.>)PD;7/]FWC?\ +O=G;D^S=#0*QWU%1QS+*@=&#*>A4Y!J2@04444
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M!7X5MXPWT]:D2YB>8Q"1#(!DH&&X#Z4"):*** "BBB@ HHHH **** "BBB@
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MBSXE_#;4H]''BK6[V]LM4@U=]0DDD@G_ 'RBU$ )V;E(8KL PH.[)Q7W*TJ
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M?449/J*;NHW4 .R?44A)'3FDW4;J &M(XZ1EOH14;7$P_P"75S_P):FW4;J
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ML9-D;LJ28XG7:&8G:2IYK!\:^*]*N_A]\4/"W@ZWCT6Q6[TZ2+5/#_B*34[
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M!;K':6L%E;-&61X(87#PJC Y78X# @Y![UL^$?!&B^!;2YM=#L$L(;JX:[N
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MJ-M&V@ W4;J-M&V@ W4;J-M&V@ W4;L4;::PX- 'V+\%[;[+\,M 3&,V^_\
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M'BO7?'7A.Y\&2^'$DDN%>Z2YM[E57<&@F7&X$_+R <\8KC](_;#T^^^!.O\
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M@#='(.30!T5C86^FVR6]K"D$"#"QQJ  *\TT>WBOOC+JIN(UG\L.R[QD B*
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M32(@YZ\T ?)R#"BG4?6B@U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD=8S<"+'3<KU]/Z)\)/!?AN".+2_"NCV"1W$=VODV4:D3)N\N3.,[E#L%/4
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M]8O8K&T4A?,D/4GH !R3["LWPS\3/#7B^4PZ7JT$URJ[C;/F.4#UV, <>XH
MZBBJQU&U$WD_:8?._P">?F#=^6:PO$GQ'\.>$75-6U>"UF896'EY"/78H)Q[
MXH Z:BLCP[XITOQ;8"]T>^BO[7=M+QG[I]"#R#[&M>@ HHHH **** "BBB@
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MJO/D<DO4X,=BW@Z+JJ#EY(^H9H8KB)HY422-AAE< @CW%5D73M0*JHM;DP<
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MFW@'P_?_ /"Q_&7B*ZAFM[6Y^SV-MYPVM.(4PTV/0MG'M7I ^F*6B@ HHHH
M*CGE6&)Y'.$12Q/I4E<G\4M4;2/ >L7"'#^24!]"W']: /F'QQKS>*?%>I:B
MS9220I$/1%X'^/XUA;*F6,  8'%+MQV%*YJ0;*-E3[?84;?:E<#MO@?IWVSX
MC6+XW+;QR2GVXP/YU?\ V@HQ_P +!W#JUK'G\S70_LWZ06U'5]192 B+ IQW
M/)_I7-_'B7SOB-<@<^7!$OZ9_K5"ZGFVS-&RI]N.U&WV%*XR$)2^6*EV^PHV
M^PI7 B\L4>6*EV^PHV^PHN!%Y8H\L5+M'H:-H]#3N!%Y8H\L5+M'H:-H]#1<
M"+RQ1Y8J7;[4;?:BX'>? F)?^%AVQ/40N1^5+\=],%G\0+B3^&YB23\<8-1_
M!>8VWQ#T_/'F*Z?F*[/]I#23YNDZB%^7#0LP_,4R>IX=Y8H\L5+M]J79["E<
MHA\L5K>$]=D\+^)=/U2(_P#'O*"X]4/##\036?L]A2;<]J+@?;5O<1W5O%/$
M^^*50ZL.X(R#5?4]+M=:TZXL;R%+BUN$,<L3C(93U!KF/@]JAU7X?:6['<\*
M&!B3GE3@?IBNUIK35&+2:LSSGP#\"O"'PVU6?4=$L'BO)04$DTS2%%/\*YZ"
MM#QU\.-)\<W^G7$]Y=Z5K=B'-IJ&FW'DW,:-PZCKN4]P017;5X)\=/%&M^'_
M !U:?V(9//CT=KG%M;>=/L6Y3S"H +$!-V0*TG4G5ES3=V8T:%+#P]G2BHKL
MM#<'[,WAE1;S"_U=M3CNI+N34FN0TT[N@1MX*[<;54#"\8XQ26W[,OA6T@T.
MUBN]5_L[21 (K)KK=&QADWQL<C<#N R5(W8 .:X&#QGXS^(/C6*WTO4M>TWP
MO=ZM<K'>Q::T!-LEM&R;3(F0ID+88CDC%0:+XZ\8RW6AIXGU3Q)ID\UA8C3X
M=.TEI#J%P9"+GS1LP& QN#%0J_,*@W/4](^!GA?2UU&RAN[R6/4;&_LC!)=;
MC';W,N^58^X"LS8],T_1_@)H>@ZY:WUCJ6L6UK%-;W<NF1WK"VN;F&%(8YI%
M R6V1QY (5B@)!(KP#0-0\8>%_"BV]C_ &VMW9"YM]1O6TZ26[LHFU9!<O%E
M,R%("74*&R"64-C%=/X?UWQQXQ\4Z;I6GZ_XCC\&W&J:D+37)+ PW%S:I90.
MF]G0;56Y>9$8@%PN.0,E#1]$:+X7L/#=YKNH([F?5;G[7=S3L#@B-8PH/90J
M# ]SZUYCK/P(\%->R6,OB'4-/T749VNY/#<>IA+.=W;<Y5#\P#-R55@"2>*P
M=?U[7M:_9P\#7/B8SVMQJ5UI4&OR31FWD6%[B-)BZ\%<C@\?Q&N'\406/AR7
MQ[8^+?#3:GXOU+57DTN6[T:[O8[ZRV+Y$-K+ I\LK@J5!4ACD\'- 6/4KC]G
MWP#8^(_MMSK-W!<I>2W\-L^H!/)FE7:Y4\/R#P"3CMBK5O\ LV^$].MRTFJZ
MFU[+=17G]H272K*3$I4#A0I&UB"<9/4GO7@L$;:;\3]=NO$0C\/2W4&ER"UU
M7PO<ZJQ(@&]4G5& VM\IR<YY->LZ[XBM_B7\6?!NF6VD:K;)H3WK:H+VPE@@
M6V> *D@D(V%7R=H#9X.0,4 =C?\ [/GAR_TW2;6RO]5TK[#8-IJW.GW922>T
M<EFB=L'())YZC/!%):?LW^%=-U^#4=.DO]-@C>&633[6?9!/)$H5&<8W=%7(
M! ..<U/^SA>7]]\*=,>_+N$FGCM9).KVZR,(V]_E YKU&@1XT?V7?"DUU>7E
MQ>:Q=7\BQBUO);O]]9&.7SHVC< $L'YW/N...F16=J7[,V?%?A[4]-\3ZM9&
MV?4KG4]2%V?[0O+BYCMXU;?M*[52 +MP  $VXQ7NU% 'E=K^SEX0L=!O]&M8
M;JWTV]73U:%;AOD%EM\D+G..5!;NQ)S7/:C^RCX;,-W/:2W%Y>K%?+9P:I.S
MVL9N=YD#A-KL-SD@EBPXP>,5[K10!\[^$_V8KN_DU74?&NJRS:M/):/9366H
M27<EF8%=0PFFC7=NWM\I3&/[Q.:Z#5OV6/"FM6T4-Q>ZQC[&UC<$7>6N8R^\
M[B1P=W=-OITKVBB@9S'@;P#I?@"TO+;2Q,([J?[1)YTA<[MH7C/0845T]%%
M@HHHH **Q_%FM/X?\/W=_'&LLD0&U&. 22 ,_G7 QZKX@BU!YO[25[L7EQ;N
MC(?LYCCA#C"]0<]\^M,#U:BL/PGXIMO%%@D\(>*81H\L,L;(R[AD$ CE3S@]
M\5MY'K2 6BD)Q1F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ J&2:*(+YCJF3@;B!DU*:^7OVF/AQXZ\5^+[*[T:&YO\
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M/I1Y)]*0%/RJ/*JYY)]*/)/I0!3\JCRJN>2?2CR3Z4 4_*H\JKGDGTH\D^E
M%:)3%-$XXVN#^M?76FRB;3[9P<AHE.?P%?)QA)!&*^F? 5^-1\):9*#N(B"'
MZCBJ1,C@OCSX;\ZVM-9C3+1'R9<#^$_=/YUXOY?;FOK/Q%I":]HEY828Q/&5
M!]#V/YU\MW-B]G<RP2J5EB8HP]"*&$2CY7UH\JK?DTOD4BCT7X!7(@UW4;<G
M'FP!A]0>?YU[I7S;\-=1_L?QGI\C$+'*QA8GT88KZ1+8JB&-VFEV_G2[AZBD
MWB@D-O-)LI?,'J/SHWB@!"F15+4="L-8ELI+ZS@NWLIA<6QF0,8I " ZYZ,
M3S[U>WC('<TI;% %:\TZVU#R?M-O%/Y,JS1>8H;8ZG*L/0CUJ?9GK2[Q1NH
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MYNOM<4TLTLD/E!+<1DX09W[F(.0HQUKJ@W**<E9]C@J1C&<HP=TGH^Z[GO\
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M: RF:V^14!\T#B3[P(P3SFJ7ACX'Z_JL^E66H:;J]KX0.HRRS://>-;QHGD
M?<25CL:3G:6/(SQ4WC#]I7Q9X:\6>)]'N]6T+2+K14M(X;1]#NKQ;^XEC+,G
MG),HBR_RKD$\Y.:[G3OB!\1/B+K&M6?AT:%X9?P_;6XO(-7M9;I[B\DB$C1
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M]J5C2YFI8QPO'((DW(0P..XKZ.T/3-)UG1[2\^Q1-YT08G'?'/ZUX'Y%>O\
MP@U3S]&FL6/SVSY4?[)IDLZ@^$-&;KI\/Y&HSX)T-NNFP?\ ?-;E%!!@'P'H
M#==*MS_P&HS\._#C=='MC_P&NCHH YK_ (5MX8R#_8MIGW2@_#7PNW70K+_O
MW72T4 <L?A?X4;KH-D?^V5,/PI\(GKX?L3_VRKK** .1/PE\'-U\.6!_[94T
M_!_P6W7PUI__ 'ZKL** .-/P<\$D<^&=._[\TG_"F? __0L:=_WY%=G10!Q9
M^#'@8_\ ,KZ;_P!^12?\*6\"_P#0K:;_ -^17:T4 <2?@IX$(Y\*Z;_WY%-/
MP1\!G_F5--_[\BNXHH X8_ [P">OA/3#_P!L!2'X&> "/^12TS_OP*[JB@#@
MS\"?A\>OA+2S_P!L11_PH?X>_P#0HZ7_ -^!7>44 <$?@-\/3U\(:6?K *LZ
M7\%_ VBZE;:A8>%]-M+VV<20SQ0@,C#N#7:44 (!BLKQ3XCMO">A7>JW88P6
MZ[F5>I] /J:UJHZSHUGX@TRXT^_A$]I.I22,\9%3+FY7R[D3YN5\FYQ/PX^,
MMA\0KZXLH[26RN8U\P+(00RY]1WJ+XC?$?5='\7^'O!WARSM;C7]8CFN1-?N
MRV]O!$/F<[02QR0 !6UX*^%F@^ IYY],BF:>8;3+<2;V"_W1P,"H/'_POM?&
MU]I.JP:I?>'_ !#I3.;+5M/\LR('&'1DD5D=&'56'N,&L<.JJII5G>7D8895
ME32KM.7D9^B_$V\TF2/2O&ME#IFO-'<SQBQ8S03P0#<TJD@%<@_=/-<]I7[3
M6D:IJNO)'I.H2Z5I]M:7$%[#"6-SYZD@!?X<8Y+$"I+S]G.SDLX)%\6^((M9
M5KEKK66EA>>Y6=-LRLK1F-!@#;L5=O:LV7]E?PY<60MK#Q#JL4*P6:>6S07$
M;/;J5CD=6C(?*L05/RG . 1FN@Z]#6?]J#PA_8\%_##JEV9(+NY:WMK0R211
MVS[+AFP<80^A.>V:M/\ M+>"$\16FDB^D87$UO;?;0@$$<TZ*\,;$G(+!T[8
M!8 GFJ>@?LS^'-!LKJWCU/59Q<66H6+O(\2_)>/OF*A8PH(;[N!@#C!J'3_V
M8-!T?7K6^L]7U**T22WGN;(QVSBZE@B2)&:0Q>8H98TW(C ,1VRP(&A<C_:<
M\&FSEO9_[1M-/:SEU"SNY[-ECO[>)U222#NP!=3V)4AAQ5_Q7^T'X4\(ZM>:
M7<O=3ZC:WL5@]O%%@M-) 9U4,Q"G]VI/7D\#)KF6_9=\.-IBZ3JGB+6[[1[;
M3;C1-$L[BXB4Z5!/MW+"X0,[@1HB-(7*HN.<DF>__9GM=3MM9DNO%FLW6JZS
M=PW>H7MS!:21W!C@\E4: P^7L"<@!<AQN!S0!VGB[XO:%X*\(:=XBU+[3%::
M@\,=M$8BLK/+C8K!L!#SSN(Q6'J'[1GAG38XGEM=6;%JMY=".R9C9Q,Y16E_
MNY8'&,Y STJYJ/P5TZ?X::7X+L=6U.PLM-CCC@N3(ES)(J?PS"56253W5EQZ
M8XK@O$'[*L>G>";S3_!WB#4]-U">S^RW"RRQ^3?@2F11(#&?+ +,!Y07"G;0
M&AZ2_P :?#"BV/VB=OM%_+ID82!B6GC3>R\>W?O7.1_M/^#R+\3IJ-M/9M #
M;26V97$SE(\*">K#&#@CO54_LU:;?:BMU=^(=:6T%Q+?+I=M+$D$-S+%Y<KH
M_E^9C'(!; /2JNA_LG>'=*E\^76-4NIQ]E *);P(%MY3)'\L<2Y8DG<QR6]J
M T-:W_:<\(-<O%>1ZEI21BZ66:]M&2..6W7=-$6_OJ!G Z]JN6'[0_A>YNK>
MTNHM3TN]N+FTMX;:^LVCDD%R7$$@']QC&XSV(P<57UK]G'PQX@ADAOKG49;>
M6]O[Z2(3* [7:E9%R%R ,Y7!!! Y-9]S^S3:ZC%+<:EXNU_4M=1[)K'5YV@$
MEFMH[O JHL01AN=R^Y26W'IQ@#0U-:_:1\(Z-JT&F?Z=>7\L]Y!]GMK<LX^R
MS"&=@"1NPY PN21SC%>I*VX9KPW6OV4='UO1!I5QXFUR6WGGO)[YIQ;2M<O<
MR&260;H?W,H9F"21;653CL"/;[6W6UMXX4W;(U"+N8L< 8Y)Y/UH EHHHH$%
M%%% !1110 4444 %%%% "&N:\2>/M \)3PPZMJ,5G--]Q"K,3[D ' ]S72GI
M7DGQ1^"<GCW7HM3MK];20QK%(DJE@0.A%<V(E5A"]&-V<F)G6A3O0C>1WVM^
M)X]*\//J]K8WNNQ;0Z0:5&LTLH/=06 /YUQWP_\ CYH/C_3KC45T[5O#NEQ,
M4%_X@@2TAD<,59%)<DD$>E=MX5\/Q^%_#]EI4<C2I:QA-[=3[UXYH_[/M\FB
M>!].U;^SM0AT77[G5KF*5-\<B.)-@"D8)!<'GTK>+;BN;<ZH7<4Y;GJ=E\1-
M$N+2UGN[R+2&NI6@@@U&:.&25@Q4;1N.[<0<8ZU5TOXK^%]2BU6634XM.ATW
M59-'FEU%A;HURA *H6(W<G@CKBOFJY_9]\4P^(]0T"/0M$U2.^\/7-F=6OXW
M\NS^T7MPX,1P<R(KABHP<A.:W-<_9?\ $S7IO(9M/UE/-U2+[%=2^6DD=UY.
MV5F*-\X\HJP R0W!'>BCZ=U+5['2+)KN_O(+*T R9[B140<9ZDXZ?RJA-XT\
M/VUA8WTVN:=%97Q"VEP]T@CN">@C8G#9]J\Z\3_!2?7/!'PN\.,;6[M_"VIZ
M==WB7FZ5)X[>%T(&[)8EBI&[TYKS3Q#^RWX@EE62S&F7EEMUBT32GE\F""*[
MO6N8W3Y&P0I"L% /3!% 'TK)XGT2VU@:9+JEA#JLB!Q:-.@F9<X!VYR1FL?7
M?BIX/\.:9JVI7GB'35@TL+]N,5PLCP9. &522.37S%J/PTUC2_&^G>&;'0%U
M:9?$6G:@VOW>FS&:&**.(-MN2"C1*(B!E]WS,"N3DZP_9<\8W@O7NCH:S2Z5
M<V)1$"PRRO.)4<(J#:OR\@[CDYS0!],Z-XML-8:Z$4AB6W9ANE90)$ !\U,$
MY0Y^\<5/!XIT:YU-=.AU:QEU%H_.6UCN$,I3^\$SG'O7@NK?LZ>(=7CEO8;O
M3M*U.\U69[I;<,5.GSI&)H 1CGY#CZTFC_LVZIHOQ-34(S9R:-%K']JPW?GE
M)XHQ'M6 (%R<#C[^W':@-#V!?BMX;7QU?>$9]06SUJU2%_+NB(EF\T$HL1)^
M<_*<@=*U;OQMX>L5OGN-<TVW6P"_:S+=1J+?<2%WY/RY(.,^AKQ3XI_ 37O&
MGCSQ-J%G!HTEEKUK86HOKO=]JT[R)-YDBX^]_=P1@\U0UK]F/4_[/TV\T\V#
M:K:>);_6KJ$$1#48YVF$?F2%&R\:R@C<I YQB@#WN?Q=H.EG3XY]8TZU_M @
M6227,:?:,XQY>3\W4=,]:JZ]\2O#/AJVUB;4-=L8!H]LUY?Q"96EMX5&2S("
M6 Q[<YKYE\3?LI>,-2\&CP]9-HL,+Z*MG$[,2;.<W,T[J79"\D0,BA%4IMP>
MQ '2:W^S;XAU7Q;XJFMET>PTO6(]4\UY!Y[3-<P[%*AEWQ-OPSX<JP7A1G@
M^@1XST4>&[;Q!)JEK;Z-<0I/'>3S+'$48 J=S''.:63QEH<%U96TFM:>EQ?
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M_M0!F>1]*/(^E:?V?VH^S^U &;]GH^SBM+[/[4?9_:@#-^SBE\@5I?9Z/L]
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M\J G:P&[DA<98C ZU[8#N]ZJW6JV5I=6]K<7<$%S<$B&&215>4CDA03DX]J
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MB@ Q1@>E8?BCQAI_@ZUBN=2-P(I&V+]GMI)CGZ(I(KFQ\<_"Q_BU3_P4W/\
M\;H ] Q2UP'_  O#PL?XM3_\%5S_ /$4X?&SPP>C:G_X*KG_ .(H [VBN#_X
M73X9/1M2_P#!7<?_ !%.'QF\-?WM2_\ !9<?_$4 =U17#CXQ^'#T;4?_  67
M'_Q%.'QA\.$_>U'_ ,%EQ_\ $4 =M17%_P#"W?#QZ-J'_@MN/_B*7_A;7A\]
M&U#_ ,%T_P#\10!V=%<=_P +6T _Q7__ (+Y_P#XBG#XJ:#ZW_\ X+Y__B*
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M30&^WR&8+&W,ZM&$8O@')#<?9:]/2EHH ****!!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 A&1@TWRU QM%/HH 9Y:_W1^5
M'EK_ '1^5/HH :$4=A2@8&*6B@ HHHH *;L7TIU% ";1Z"C:/04M% ";1Z"C
M:/04M% ";1Z"DV#T%.HH 9L'H*-@]!3Z* &;!Z"G;1Z"EHH ;L'H*-B^@IU%
M #=B^@HV+Z"G44 (% [48^E+10 F*6BB@ HHHH *3%+10 F*,4M% "8HI:*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>glyc-20241231xs4035.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4035.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #^ ZD# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#Y]_:T^!?@+XJZ1IFK^/O%EYX3TS2
M"4%U!<Q0QDR$##F16_"O"K_]@/X'Z8='%Y\4-8M&UC!TY9M1M$-WGIY>8OG[
M=*]@_P""A_\ R;#KO_7U:_\ HRO%?C:!_;7[+F?2W_DM?081UO914:C2O+33
MHKG%4Y>9W78[ ?\ !+CX=_\ 0V>+/^_]M_\ &:P= _X)Y_!CQ5JFIZ9HWQ)U
MO5-0TM_*OK6SU"SEDM6R1MD58LJ<JW!]#7W;WKXR_8H _P"&B_VBCW_MB/\
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M*35EK[MM?Q"DH.6B7XGT-1117S)WA1110 4444 %%%% !1110 4444 %%%%
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M2ZJTL$ZW MU")+*RL"$;.X2?I73?:/VU_P#GU\,?]]6O^-'VC]M?_GU\,?\
M?5K_ (UM&$8<R7L[-6:YGWN0VW;?[CN-4D\?_M5_!+XA^%/$WP^G^&VH26\*
MZ8VH7?G1W<NXR $A 5 :*,$X/$G'(Q7CUCX^^/NC?!0_"-_@GJ,^J1V3:1'K
MJ2DVPB(*ACA=A(7C=YF#P?:NI^T?MK_\^OAC_OJU_P :/M'[:_\ SZ^&/^^K
M7_&G"*BN6]-QO=+F>C&W?76_H;9_9[^)W@/]E'P]X;\%>()M+\<Z3+]ON+>Q
MN?+CNBQ):#?D9P,=\$CKBO/?BSXC^,_[2/@*S\ WOP)GTK6)&C2X\0:FX\B(
MK]Z2,LBA,]>';T -=/\ :/VU_P#GU\,?]]6O^-'VC]M?_GU\,?\ ?5K_ (TX
M<T7SRE3<KW3N]WZ"=GHD['T)/X O?#G[-]YX.M]^J:C;^')M/C\OEII?(90!
MGU)P*Y+]ASP3KWP]_9[TC1/$FEW&C:K#=73O:W2X=0TS,I_$'->4?:/VU_\
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M!_Z%O6?_ "'_ /%5]"[%_NC\J-B_W1^5'M<-_P ^G_X$_P#(/JV/_P"@E?\
M@"_S/GK_ (;-T'_H6]9_\A__ !5'_#9N@_\ 0MZS_P"0_P#XJOH78O\ ='Y4
M;%_NC\J/:X;_ )]/_P "?^0?5L?_ -!*_P# %_F?/7_#9N@_]"WK/_D/_P"*
MH_X;-T'_ *%O6?\ R'_\57T+L7^Z/RHV+_='Y4>UPW_/I_\ @3_R#ZMC_P#H
M)7_@"_S/GK_ALW0?^A;UG_R'_P#%4?\ #9N@_P#0MZS_ .0__BJ^A=B_W1^5
M&Q?[H_*CVN&_Y]/_ ,"?^0?5L?\ ]!*_\ 7^9\\/^V?X?526\.:P!ZGR_P#X
MJO;/!'BN#QMX8T[6[:"2W@O8O-2.7&Y1DC!Q]*Y7]H90/@[XEP /]']/<5-\
M /\ DC_A?_KT_P#9C3JQHRH*K3CRN]M[]",//$T\8\/6J<RY;[6ZV/0J**1N
ME>>>Z+29Q7'_ !-^)FC_  J\,RZQJ\O?9;VL9_>W,O:-!W/J>@&2>!7R%X;_
M &I?%VF_$&?Q!JLKWNCWA"7&B1-F.WBSQY/^VH/)/WN?;'H8? U<3%SALOQ\
MD>'CLXPV7U8TJKNWO;HN[_JY]VY'J*,CU%<EHFMZ;XNT.UUO1+I;W3;I-Z.A
MZ>H(Z@CN#T-6.W?'O7"XM.S/:C*,XJ47=,Z7(]11D>HKFJ*5BCI<CU%&1ZBN
M:HHL!TN1ZBC(]17-446 Z7(]11D>HKFJ*+ =+D>HHR/45S5%%@.ER/449'J*
MYJBBP'2Y'J*,CU%<U118#I<CU%&1ZBN:HHL!TN1ZBC(]17-446 Z7(]11D>H
MKFJ*+ =+D>HHR/45S5%%@.ER/449'J*YJBBP'2Y'J*,CU%<U118#I<CU%&1Z
MBN:HHL!TN1ZBC(]17-446 Z7(]11D>HKFJ*+ =+D>HHR/45S5%%@.ER/6C(]
M:YM068 #)/85P?QG^,EA\'=#"H4O?$MVI%I9;L[?^FC]PH_7H*TITIU9J$%=
MLY\1B*6%I.M5=HH]@-&X>M?$_P &?VG-6\/^()K3QIJ$NJZ-J4Q=[N;EK.1O
M3_IE[?PU];L(Y88KFWE6>UE4/'(A!!!Z=/YUT8G"5,+)1GL]GT.'+\RHYC3<
MZ>C6Z>Z.AR/449'J*YJBN.QZQTN1ZBC(]17-446 Z7(]11D>HKFJ*+ =+D>M
M(SJHRS!1ZDUSE27$-KK-C)I^HH)(''#="I[$'L1ZT6 W?.C_ .>B_F*/.C_Y
MZ+^8KP;Q/X7NO"]_Y$[/)"Y/DW SB0>_HWJ/QK((/J1^)IVN*Y](>='_ ,]%
M_,4>='_ST7\Q7S?CW/YFC'N?S-/E"Y](>='_ ,]%_,4>='_ST7\Q7S?CW/YF
MC'N?S-'*%SZ0\Z/_ )Z+^8H\Z/\ YZ+^8KYOQ[G\S6?X@\1:3X2TF;5=<U.#
M2=,@(\V[NW*QIDX&3]:7*%SZ@\Z/_GHOYBCSH_\ GHOYBOC?1_CI\-?$6I0:
M=I?C[0K^_N&V16\=V0TC=@-P )-=&/%FB/XFD\-KJ]L?$447GOI8D/VA(_[Y
M'I18+GU+YT?_ #T7\Q1YT?\ ST7\Q7S>.G4_F:,>Y_,T^4+GTAYT?_/1?S%'
MG1_\]%_,5\WX]S^9HQ[G\S1RA<^D/.C_ .>B_F*/.C_YZ+^8KYN(]S^)-<YX
MO^)?A'X?-;+XG\3Z=H#W/^ICO;C:[CN0HR<>_2ERA<^M/.C_ .>B_F*/.C_Y
MZ+^8KYILKRWU*R@O+.YCN[2=!)#<V\N])%/0@C@BI@/<_F:?*%SZ0\Z/_GHO
MYBCSH_\ GHOYBOF\ YP"<GW-*R%#AMP/IDT<H7/H_P Z/_GHOYBCSH_^>B_F
M*^;\>Y_,TZ.-Y6VH'=O1<DC\*.4+GT=YT?\ ST7\Q1YT?_/1?S%?./DNJ+(5
M8(>C'."?2A8G9&91(RI]YADA?K1RA<^CO.C_ .>B_F*/.C_YZ+^8KYOQ[G\S
M1M/JWYFCE"Y](>='_P ]%_,4>='_ ,]%_,5\WX]S^9IT<3RDJ@=R!G"Y/'K1
MRA<^CO.C_P">B_F*/.C_ .>B_F*^<4B>1PJ!Y&/15R3^E-((."2#]31RA<^D
M/.C_ .>B_F*/.C_YZ+^8KYOQ[G\S4@MY6$9"2L)#A2,_-CL/6CE"Y]&>='_S
MT7\Q1YT?_/1?S%?.!!0D'((X().0:3'N?S-'*%SZ0\Z/_GHOYBCSH_\ GHOY
MBOF_:3W;\S3C"ZQK(0XC;@,<@'\:.4+GT=YT?_/1?S%'G1_\]%_,5\WX]S^9
MHQ[G\S1RA<^D/.C_ .>B_F*/.C_YZ+^8KYO_ !/YFE\M@N[D*>,Y-'*%SZ/\
MZ/\ YZ+^8H\Z/_GHOYBOF_'N?S-&/<_F:.4+GTAYT?\ ST7\Q1YT?_/1?S%?
M-^/<_F:,>Y_,T<H7/I#SH_\ GHOYBCSH_P#GHOYBOF_'N?S-&/<_F:.4+GTA
MYJ'I(I_&G]Z^;,'U;\":]-^'_CTS>7IFIRGSONP7#?\ +3_9/O\ SI-6"YZ/
M12#FEJ1GS=\!;4?$3XN>,_'MZ/-6VN#::>'Y"*<J"/0B-0/^VAKZ1KY]_8Q
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M[3=->W16*A1)EB<M@<D_A0&AI_M'>(K;1/!VEZ7)8W>I?V]J]OI<<-A?-9S
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MPZT>]\06U^GAO7I_$.HS+ ZOJ4[GY0,GY<#@ENN30&AI7?Q>\3+J^N:#\/?
M8\6Z?X06.QU&ZN]1,4DLRJ 8;88+2R  Y9NI!J;XJ?'/6/A_#;36WA[1;:$Z
M?]NG;Q5KT6GR!\9-M'"I,CRCD=,547X%^,-(U[Q!%X9\?Q>'O">O:L-8O((;
M(G4HI,Y>.*?. K<\G'%8OCS]E[6O$_B/QK?:9XITBVM?$\2(\^KZ1]MU"UVJ
M!Y<4Q(V(<9)7GDT!H5/'WQH\:^+1\(K7P5HWV)/&++>RI-?"&=E0Y>W8[3LC
MXY<8+=*F?XZ:-X9UKXD>+O['U*]U&+5X/#%C8IJ+O%J%WC[L4;+MA4'&6&2<
MBNOF^#&N6?CKX>>(]&\06%K'X6TO^RYK.ZM7E65<8:2+!^5C_M=*P?\ AF"X
M?X90:$WB6&+Q1:>(G\2VNMI:DQ"Y+ JLD9.2N O0]1Z4!H=)X<^,&OV_CR[\
M'^/O"UCX9U8:)-K]I/I6H?:[>:"$%ID<G!610K>W'TSQ&A_M3^*=1\/^!O$>
MH?#NTTSP[XIU5=)AE_M<O=,Q9@)8HM@_=@*>6ZD$  8)WKKX!^)?$TWC37_%
M/BVPO_'&NZ&_A^QNK"Q>"QTJU? DV)G<S,-X)/\ >;UK9_X4<QD^$%K_ &G
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M6MUS%$HR6G^?Y!QVSU%<#J?[=_PXTGS[J?2O%CZ+:ZJ='O==BTG-C:3@\;I
MYW X)PH+8!R!D9 /:=7^'?A;7[71;;4?#VGWUOH<J3Z7%/ &6Q=  CQ#^$J
MN#_LUDZO\#_AYXA\7MXJU3P/H.H^(W7:^HW5BLDC_+MRP/RL=O&2,UR?A/\
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M5FA-CJ.S)'?8_=HV[CMU'->G@,5'#5'SK1]>J_X!\UGF75,?13I/WHZVZ/\
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MVE>W6VNWX[E/%4)+DUCK%N48I-N-^B:2WT:;U5VCE?%:ZF/$>JC7N=8^T/\
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MVIWFGMJL-H;::*0VJN4,C"1!M^=6&#@G&0",&NV*G/3- %__ (1_P;_<O/\
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M*%Z5YI^T1\*?BMX[^*&I'3])N/%?@JYTCR-,LXO%$FD6FGWG.Z6XCC(:<GC
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M\17FN:IX?E-[?,)+Z*UOIK>VO6'1IX48)(?7(H%<\N^-/B+Q[+8^#[K0=?\
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M_&GQ3\2?%#Q#I-JL5^^D:1IQCCC9&D\M/-D()8$G:%& %Z<FOH?P;^S?\./
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M_AK!6]O%YZQQMV]S2 N^#]/NK*S9IV*QR?,D)YV^_MGTKH:04M2!\^_L8_\
M)/=9_P"PL_\ Z*CKZ"KY]_8Q_P"2>ZS_ -A9_P#T5'7T%7=CO]YGZGC9/_N%
M+T_5B&OB[]LSX.7.A3?\)GX<UJY\/VVL7<5OK9@MTD6,MP)U)Y1FX4MAAG!Z
MXK[2K)\3>&]/\8>']0T75K9;O3KZ%H)H7'#*PQQZ'N#V->37HQKTW3EU_JY]
M)A,3/"5HUJ;>F]FU==5==S\X/#7A"V^%AL]8\'V:_P!K6+-)+]H;S&U6)O\
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M;;OK=Y8:;J'V=9[F!KI-L6<9.2?NY.,]*E?QGH$4=G(^MZ<L5YQ;,;J/$_\
MN'/S?A2Y9=A^UA;5FWL7T%&Q?04B>N:?4FHW8OH*-B^@IU% #=B^@H9%<890
M1[C-.HH C\B/_GFO_?(H\B/_ )YK_P!\BI** (_(C_YYK_WR*/(C_P">:_\
M?(J2B@"/R(_^>:_]\BCR(_\ GFO_ 'R*DHH C\B/_GFO_?(H\B/_ )YK_P!\
MBI** (_(C_YYK_WR*/(C_P">:_\ ?(J2B@"/R(_^>:_]\BCR(_\ GFO_ 'R*
MDHH C\B/_GFO_?(H\B/_ )YK_P!\BI** (_(C_YYK_WR*/(C_P">:_\ ?(J2
MB@"/R(_^>:_]\BCR(_\ GFO_ 'R*DHH C\B/_GFO_?(H\B/_ )YK_P!\BI**
M (_(C_YYK_WR*/(C_P">:_\ ?(J2B@"/R(_^>:_]\BCR(_\ GFO_ 'R*DHH
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MTUOMZ6_$_4:U>7]@8>'LY6O#7W;/7_%?\"'XB_\ (DZM_P!<O_9A7Z)>#?\
MD4]$_P"O&#_T6M?EUK6B^.+#33<>(O$VF:QHD3(U]8V>E&VEGBW#<J2>8VPG
MUVFOU)\,O!)X?TI[9&BMFM8C'&YRRKL& 3WP,5U\/P4*,[23UZ7[>:1YO&%6
M57$TG*#C[KWMW\FS6HHHKZH^ "BBB@#SC]H?_DCOB7_KW_J*E^ '_)'_  O_
M ->G_LQJ+]H?_DCOB7_KW_J*E^ '_)'_  O_ ->G_LQKO?\ N?\ V]^AXO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1&G&3]G:WKY'M8&=:<8^WO>SW5NN^RUM_G8UJ***XSU0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *:_ IU,D[#UH X#PM\:O#OB
M_P ;:EX7L&N#J-D&+-)%B.0*0&VG/8D=0*[]3GW/>L33?!6A:-K5YJUEI5K:
MZE=_Z^YCC >3ZGWK;'OVK2HX-_NTTO,YJ"K1C:LTW=[=NA\K_'3XL:/\(_VM
M/ 6I^(KS4+?1I/#6H1M'8VD]UND,L6"8H59NQYQBN?U+]H+PS\7_ -JSX0P>
M%-0U:2WMK?5#=PW5A=V*/F#Y>)40/T/3./:O:-?^'^NWW[4?A+QE!:HWAZP\
M/WNGW-QYRAEFDDC9%V9W'(4\BJWQ1^&WB'Q+^T#\+/%.GV:2Z)H4.HI?SF=4
M,;2Q!8P$)!;)STZ=ZS.I'"^"OCW8^&_ FF6'@GP??:KXCUW7M1M-/T*ZU<N&
M>.5O.GDN'#&.(8)Q@XS@"L3XL_'[7O&?PS^,G@S6_"5QX(\2>'O#\=Y--'JB
M7$<GF/A3#(BJ=N!G<0IYQM%96F?#'Q9\)I/ ^LP0:5/X[L=:U<VOAB^U2.W.
MK6=S(S,L$IRHE"X8!O<'%8=SHOCSXS>//V@=/N_#MIIGB6_\+V%A;:3;ZBDZ
M6YWEECEGP$\S') R!QS0,]@^'O[0GBJPU/X?:)XP^'D_AS1?%$"VNDZFVJQW
M-QYR0[\7,(4>7N5200S=@?9=6_:F\0W%IX@\4^%_AT_B3X<^'Y9X[S6QK$5O
M=7*0$BYEM;9E(D6/8_WI$+;2%&>NU\1/AAXD\0:C\$IK"RCE3PSJ"W&J%IT4
MPH+4QDC)^;YCCY<U\^R?LFZAX)37?#\'P)\/_$74[B]N)M'\::CJ<<5LL<LC
M.IOH6<2EHMV"L:D.% !')H#0]V\5_M/ZI)X\T?PG\// TOCV\U?PY;>*;2\&
MJ165O]BEE9"SF125. A7 .XOC VDUZ+\7?BK:?"+P0^O7FGW&HW<DL5I9Z79
ML#+=7,K!(XD)XY8CYNPR>U<#X$^$6O>$_P!H?3->:QL(?#=G\.[3PYYVG8A@
M%Y%=LYCB@+,Z1A/NY)P,#)(KHOVC_AKK'Q&\&:>WALV[>(M#U.VUG3X+M]D-
MQ)"X;RF;^'<,@'L2":!'/0_M%^(?!T>M2?%#X>W7A""QTU]4BO\ 2[[^U+29
M%(!@,BQILF!(&TC#?PDU6T/]I+Q3I^H>&[CQU\.'\(>%O$LR6^FZJFKQW<D$
ML@S$EU$$7RBXZ%68 \5C^,/#WQ<_:*T/7M%U?P];_#/P])I;Q0V>H7<%_<75
M_D,DFZ$D)$A7'7+9^Z*IZGX;^*GQK@\%>$_%/@.'P9I&@ZA:ZAJFM-J\%TEV
M]M]Q;5(SOP[<DR*N!QC- %O4OVM/%TMGXPU;0?A1/JGASPA>W%KJU]-K<4#R
M)$?G>VC*'S"J_,0Q4=@2:XWXEW]]\;_VGOAAITWA@Z]X%DT,ZY9QMX@>R5LR
MV^Z\>) "S1;]HB)._DY KT#0?@_XLLO@W\8] N;")=5\17FJRZ;$+A"LRSJP
MB).<+DD<'&.].^'GP@\5:!\3/A9K%]810V&A>!I-$OY%N8V,=V9(6$8 .6&(
MV^89''O0,Y_X9_M"6FD_![X::=X!\&:AJNO>+;O5$TG0M3UHMY,=O=S?:KBY
MO)%8A%/S ;2WSJB@XK)^'OQNNO"/Q,^._BGQYHU[X<?1[/25GTC[2MTAEV2@
M"V<85UD)3:<*<GY@""*J?#WX&?$KX2^!OA!XCL?#MOK'BGPB=;L]7\-+J$4<
MEU9WUW)*K03D^7YB8C?:2 P9@2"*GU?X!?$3XW6WQEF\6:)9>$#XLM--&CVC
MWR76TVQD81W+1]"6(W;<@!P 21F@#T_PW^T'XGL_%GAS2?B#\/U\&V?B:3[/
MI%Y;ZQ'??O\ ;N6"X0(ICD*@XV[UR,$UQ\G[8WB:X\,ZWXPLOA7+)X(T#4)K
M+5=3EUN))@L4OEO)!#Y9,@7@D$J><#/6L#X5_ :[@^(OAB_@_9_\+_#=-*E^
MT:GK5U>QW\DLBC@6*Q2$ID\^9)@@<;2:W+#X%^-(/V2OB+X'?3(AXEUB^U&:
MRM1=Q[9$FN-\9,F=JY7G!Z4"T.[\5_M :U=>,8_"GPX\&KXSUJ+3H=5OVO=3
M33K>SAF&859RCLTCCD*%P!U-4+S]IG5;W3_"VFZ%\/\ 4)_'^NQW$S>&M7NE
ML!I\4#^7--/,58^7OP$*H=^> *PU\'?$/X._$6?QAX>\'_\ "=6VNZ'8:??Z
M9:ZE!9W%E<VT6Q65I2$>-AP2&R,9P:Y#XD?L^^-?&]_X-\?>.O!6C?$[6K:T
MNK'5_"<5VENL$$D_FP-;2.51Y81E&WL-X/!ST!GO?P=^,4_Q)O?$N@ZUH3>%
MO&7AB>*#5M(-TMTB+-'YD$T4R@!XY$R02%8%6!4$5Y:?B[XK\._M7^.+?7;,
M6W@31_#$-[)(VKAH[6$/*QNA $Y=RNPKG("@Y(.*Z;]EWX577@$>*=3N/AYX
M>^&EMJD\2V.B:4_GWJ01AOFO+A6*2.S.Q54X0'&YB>.?^)_P=\5^*?C=XM\K
M1/M?@WQKX1'AZZUF&]B1],E5IFW-"Q#2*V]1E,XYR*!%BU_:I\2V-AHGBOQ)
M\,Y]!^&^M3Q16VM_VK'-=P)*0(9KBU"#:CY7[KL0""17H_[0^O:YX<^"OBW4
M?#EH+S4XM/E*$7GV4Q+L.9%?!Y4<@#&?45XCJ/@[XO\ Q"^'/ASX3:OX(M?#
M]AI[VEOJ7BT:M#-;3VUL5PUO "92\@0?*ZJ%)/-?0_Q7\.7?B7X5>)M#TJ$3
MWUYILUK;Q,X3<[(0H+$X'U- '@?[*7B&U^'NF>!/!S>$9=(U7Q=IL^MW5XVM
M/?\ F-'L7S6+C[T@;.U2 O3FNP\<?M76W@G1?B3J4GA>[OU\%:I::;)!;W*^
M;>><8AN0%>"/-X4]<=1GCE]3^'7Q!\ WGPD\6:)X43Q;?>'-$DT?5-#AU"&V
MG3S G[R.20A'PRX(R..>:YG4?@C\4O%W@?XM/JOANQTW6_%/B/3=5L=/MM2C
MF5((I+=F5I3M&Y5C8'@9(.."*!GK'A?]H'Q''\3=(\(>/_ 0\%'7[&ZU#1;R
M+6([Y95MPK313A4412*CJQP77G 8XS7A_P"T+^T+XO\ B+^SWJ_B#2_ 5[IG
M@#5+B"/3?$<>K*+PH+E56XDM0H:.%R,##E@#DK@Y'N'Q8^%&L^-_CI\)=;AL
MUE\.Z-8:[::M/YZHT/VJUCBBVJ3ELE6'RCCO7B^O_#GXWM^STOP3M? UC>?V
M8L=G%XL_M>".UO;**8,A2 GS$F* *5;"@@MN/ H ^R-:U@:!H%UJ3VUS?"U@
M:;[/9Q&6:7 SM11RS'L*\'A_:7\::'JWA>;QI\+O^$6\->)+Q+*TN6UR.:^M
M7?\ U?VBU\M2N>X5V*YYKU[XI:-XAUWX:>(=-\*ZB-)\2W-A)%87I.!#,5PK
M9[?7M7QC:?LT^*;Q_!=SIWP5AT#7-)U2TN];\1ZSXCBOM0OBI_>M YD?Y2<N
M=[+P<!<T"1[/K/[4WBZ;4O'J>%_A;)K>F>"+R6WU:_N=;CM1(D:AV-NIC)=M
MF6*G:.,;B36YJO[3-WKEQX0TOX<^%&\7:]XBT<:^L-]?K86UG9$@!Y9=CG<S
M95452>I/ JOX4^%'B?2O#_QWM+FQ19O%-_J$^D*+A")TEMRB$G/R9;CYL5P_
M@OX6?$CX)CX<^*=*\*1^*KRT\(V_AO7_  ];ZC#!<Q21G>DT,LA$;@$LK+N'
M&""<8H&=3^Q_XDU/Q5K'QEO=6T^]T>]'C*6.33+Z82M:$6MN&C5E)4J&S@KP
M0<]Z^D:\-_9G\'^-_#U[\1]7\<Z19Z)J'B3Q$VJV]I97BW*1P&WA1%+@#++L
M*DX&2I(&,5[E0)A1110(**** "BBB@ HHHH **** "BBB@#Y]_8Q_P"2>ZS_
M -A9_P#T5'7T%7S[^QC_ ,D]UG_L+/\ ^BHZ^@J[L=_O,_4\;)_]PI>GZL*:
MY"HQ)P ,DFG5Q7QD\0/X5^%GBG5(D:22"PEVA3SDC:#^&<_A7 W9'M(_/3XG
M:]_PLCX@>)-?U%6G66YDAMQ*^[RH$)"JOH./UKT;1?B)J.@Z9\.-:UF&35'\
M$^&;S68(YY0#/->7'V2QC9NW[H.V>3@$C->*I;2W&E6]G; O=WC);Q 'YGDD
M8 #/N37??$80PQZK!;6_E6=[X@32[;<^1]CTBV6W1EYY#32S'\*]S,*$>;"X
M**L^OX:_>FSX+)L9/DQ^9R=UT72^K2W[-)'=_!SXYZ[JW[1^F^(/%=K:7=QK
MUE'X=B^P*8EL%,IE78I)W*SD!BQ)P%YXP?NIONFOSU_9F\.#Q3\>_#J2*TD.
ME13:I(1_L (F?H\BFOT*/2N/'4:5#$2IT59:>>N_7Y'OY)B,3B\%&MBI<S;=
MG9+1:=+=;GSK^VKXRCT;X8#PZEFES>>()/L\4LGW;;;\QE'JPQQ[UX5/\>-<
M\9>%[6#Q EG'JG@^ZL]9M-3ME8//;1NL<ZLG/S[7SD8'M7NW[;7AX:E\+;;6
M$#&72+Z.8;!GY6^1L^V#FODCPF8W\6:?;3%5M=42;2IBXXVSQE!Q_O%#^%.G
MA*5?!5:B7OQZ^6^VW<Y\3F.(PF;8>BY?NI]++=MK>U[WY>MK#_BLLGB;XF^+
M9]7E&H7;WC!)').R+ ,83/W0 1@"OMK]D_QK<>-?@UI$E]=_;-2T\OI]Q(22
MV8SA=Q/5BFTDGUKXD\43RW[^&]6GDWW%_I2V]T2N#]IMF,$G/<G9G\:^A/V$
M];ECU3QMH7)ME:WU!<#A7<,C9^HC6NFM&%;+J->"M;3]/S2^\X<%.IAL\Q.%
MFVU+5?@U^#:^270^NZ***\8^S/./VA_^2.^)?^O?^HJ7X ?\D?\ "_\ UZ?^
MS&HOVA_^2.^)?^O?^HJ7X ?\D?\ "_\ UZ?^S&N]_P"Y_P#;WZ'B_P#,T_[<
M_P#;CT*BBBN ]H**** "BBB@ HHHH **** &L*YB7X<>&YO% \12:1;RZV,8
MO'!+ CH1DX!]ZZFFMU%4I..SL9SIPJ6YU>VHWKCG\:XZUO?"/A[Q[/I5DMO'
MXJU:,W=S#;1EY3&N<2S%0=BDD@%L9.0,X./(/C%^UI>?#OQMJO@"+PC=#Q??
M0Q+X5>1S+!J\LC%2QV+^[2(@LV3R!7J'P9^%:_#3P](]_=OK/BO4W^UZWK4P
M'F7=P1S_ +J+]U$'"J *5W:Q3BFTVMB[X_\ C-X&^%$ME%XP\5Z5X;EO59K=
M=1N%B,H7&XKGKC(_.G>!_C+X$^)B7;^%/%VC>(?LB;[A=.O8YGA7^\Z@Y4>Y
M&*^?/VG/$,/A;]JGX.:A/X4U3QI&FDZRITG1[*.[N),K%A@DC*N!U))XINBZ
M!JGQ0^/F@>/-(^&FJ_#+0?#NC:C:ZC<Z[:065SJS3Q;8H1#$[$K&VZ3<QQR<
M8/5%V/IO0_'&@>)/"T7B;2]8LK[P]-$TR:G#,I@9%)#-OZ8!4@GVJ7PAXQT3
MQYH4&L^'M2M]7TJ<D17EJ^^*3!P=K=QGN*_.3X/>*=1\5_";X0^#/&>FZEX:
M^"LEU-IM[JJNJ+K-Z9Y)(X)"#NCM"Q"%\ .P*Y !S^E6E:=;:1IUO965M%9V
M=N@BAMX$")&@& JJ.  .PH MT444""BBB@ IC<FGT4 <OI7PY\-Z%KUUK5AI
M%O;ZK<DF6[4$N<]<$GC/M73K]T4M%4Y.6LG<B%.%-6@K>@4445)84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1137[4 .HKR3XR^,-9\.7MA'9^*-%\*Z<\;/+<WD9N+N1\X"Q0 '<
M.F3COU'?B]-_:#UP_">YU.2*TO=<&J?V5:S^6T44I.,2,G4<$G'':NR&%J3@
MIQZGE5,RH4:LJ4[II7Z=/G?[U;S/8_B/\+O"OQ8T5=(\6Z);:W8*_F)'."&C
M?^\CJ0R'W4@TOPY^%OA3X3:&VD^$M$MM$L6?S)$@!+2O_>=V)9S[L2:Y'2[_
M .(7@J2^NO%-WINNZ)%9/<M=6\0MY(90,^6%'W@3QG'^%87@SQ!\5/%NGZ5X
MJMKC1Y]*OYLG16B\LQP$XW"7J6QV_2E]7;3?,K=[E?7XW473E=]+:I=]]M>E
MSW:LO4?$>F:9JECIUU?007U]N%M;R. \Q7D[1WQ7SUXO^/>LR>*/$-OIWB'2
M/#EOHSF*"ROK9II-0D7J,X^4'&!CO^=6K[Q;_P )W\0/@OKGD?9GNUNVDAZ[
M'$>& ]@0<'Z5LL%-6<]K?I<Y99M2DW&EJTTODY*+V?2_6Q]&ITIU?*-W^TCK
MMZ^J:U9:_I%E:V=TT=KX:FMF>>[A4CYC( 2K$9QCCBNU\0?$?QEXB\?:'H?A
M*YL=/MM7T:/4!+?P;S 6RQ.1U.   1BE+!58VYK(J&;X>:?(F]EI;6^BZ^76
MQ[S5>[NX+-5:>:.$,P13(P7+'H.>]>"?$SX@^*?"=\UO)XTT'2'MK5"EM':F
M[NKR;;\Q>,+^Z4G.*Y/QIXE\2>/H?A9K,=[9V$U[,?+C,!9(YP.7()Y7';L:
M=/!2FE)M6?KVN*MFL*;E&,6Y*VFG=+OY];7/JU>E.KYK\:?&_6X?%^KZ/:>)
MM*\-IHT80M>VC2M?S@?,!C.U<CMSS7L7PJ\;GXB>!=-UN2%;>>8,DT2_=#JQ
M5L9YP2,CV-85,-4I0526S.JAF%'$571ANK]NCL^O?O;R+_BGQ_X<\%O&NN:U
M9Z8\HRD<\H#N/4+U(]\5.OC'0VT%M;75;1]'5=QODF5H@/=A7B?P9\.Z7\0_
M&OQ"U[Q'80:KJ,6JO9Q1WT8E6WB7("A6XZ8&?]GZU;\=^ - \!_"/Q_%X?N9
M6ANE,L]H+@21VS_W54?<Z]#S@#TK9X>FIJDV^;3TU_KYG''&XB5*6(45R6E;
M5WTO:_K;;H>DV?Q@\#W]PL$'BK27F<A5072@D]@,FNR1@R @Y!Z$5\8:MJ%C
MK'@_0_"B_#BUT?6=3MXH[/6[SRX1(<#]ZL@4$D]<$]Z^A)?B1X<^$>E:'H'B
M;6_*U)+1%W>1(^_'&<A2.O'-57PG)94[MN^FCT[Z"PF9.JY.LTHI+75*[Z:]
M3KM:\<^'O#NH0V.J:U8Z?>3D>7!<7"HS9Z<$U8UWQ+I/AC3_ +;JVHVVG6>0
MHFN90BDGH 2>37S5'IFG^-IOC)JNIVL5[<0@BUFF4,T**NY=A/*]NE-T"0^-
M/%'P9TW6T&H6/]DR7#0W #I)($< L#U/R*?PJ_J<4KM[;_\ @-]/R,O[4J-V
M45J_=_\  N77\]#Z>TC6+'7]/AOM.NX;VTE&8YX'#(WT(J'3_$6FZIJ%]86E
M[!<WEBRK<PQ2!FA)&0& Z9KPWX1Z->SGXK^%]"U(Z%%;ZT5LYX8PPM0S,'"+
MZ[$ 'IUJ;]G+0X?#7C[XD:9#-/<);7,">=<OOD<X<EF;N22364\-&*J>]K&U
MOG;_ #.BECZE1T5R64VTW?JKZ+[CVS7/$6E^'(H9-4OH+&.:011M<.%WN>BC
MU-:HZ"O*?C[KCZ#H^AR1VEC>&75(8RM];+,%!/50W1O<=*P;_P 9^//$'Q(\
M5>&="U'3M.MM-A6=+BXM?,D3CA0,X.3W/2LH8=U(*:=M]_5+]3>KCHT:KIM-
M[)6WNTWW\CVRYNH;*%YKB9((4Y:21@H'U)JPI#*"""",@BODSQ[XR\2?$'X-
M:-J%U=6MO-#K2VETJ1$":17(1QSP!@DBO0]6\8^-KKQ1H_@+1-0T^#68].%[
MJ6L36V44< "./..Z]?7MCG5X.45K)7UOY6ZF$,UA.3M!VM&W=N72W];,]QKF
M_$?Q \-^$+B.#6M:LM,FE4NB7,H0LN>HS7(?"7Q]K6MZWXC\+>)%MWUW0I$#
MW=J-L=S&^2KA>QXY^HXZUP'QVOK/3?C?X.N-0T*?Q':K8S;M-M[9;AY<[@,(
M>#@D'\*FEAN:M[.?:^GI<TQ&/4<,J]+NEKTUL[V['N_A[QAH?BN&271]7L]3
M2/\ UAM9UDV?7!./QJ#3O'GAS5M8DTNRUVPN]2C)#VL5PK2#'48![5XE\+/!
MUQKOQ.UC7K3PI>>"O#%Q8&T-I,OV=[ACU(08Q^' V]>:H^-?!6F>!/'7@RVB
MT-/#OAVRO 5\0QE9+BYE;I&Y'S 9/WFK3ZM2]HX*3O:_3[O/Y'-_:&(]C&LX
M*U[/==;75UHNMWH?3M%?-/BWXR^)+3QQK&FR^(K'P8UI,$L+/4],>6"]3CYW
MG&=@/J!BOH'P_>RZCHEE<3RVTTTT*NTMC)OA8D=48]5]*YJM"=%)RZ_U_5CT
ML/C:>*G*$/L^G^=_O2-0G -<AXQ^+?@[X?ZQI&D^(O$=AI&J:O)Y6GV=S+B6
MY;(&$09)Y8#/K7R#\6OVH/%_@,>(]8D^+_A:'Q+I$TLL?PYT?1_[4@,"2;1%
M<7J?O$D*X+-\BJ21@=1KZYX?\7^,/VQKK4=,\9P:0;KX=C4;7SM$BN3;6S7"
MC[."SC)WDOYF <';C%<QZ%C[-L;ZVU& 3VD\5S"69?,A<.N02",CT((_"K5?
MGC\,?C1K_P "_P!E3X:6;>+K"Q?Q1?W,%MJ]]I+21:);)-,97\J,EKARRDJ&
MP!OP>!SV_A']K'6VTGX@Z79^-+/XAMI6AOJVF>*8]$DL"LJG#03PE0AQU#+C
M(X([T!8^UCTKS;Q=^T?\+_ &O7&A^(_'FAZ)JUN%,MG>WBQR(& *Y!]00:SO
MV?5^(>H^%XO$'CSQ/IVLOK%M#=VVFZ;I@MH[ ,H)02;RTN<]6Q@UX"OCJU\&
M?M;_ !E^U?#;Q'X_$\6E[3H&E0WOV;$'\?F2+MSGC&<XH ^NO"/CCP[\0='7
M5O#.N:?X@TMF,8O--N4GBW#JI920"/3K5G3?%&D:MKFJZ/9ZE;76JZ5Y7V^T
MBD#26WF*6C\Q1RNY02,]0*^<_@3\-?$FJ>)?B_XLAT:_^$>F>,DM8-)TPQPB
M\M9(HG22]:%=T<<CLX(4Y.5RV>I9^R;X)M/AQ\<OCWX;L+J_OK>TN]&D:[U2
MZ:YN[B66Q,DLLLC<L[.[,3TYX  H"Q]2T444""BBB@ HHHH ^??V,?\ DGNL
M_P#86?\ ]%1U]!5\^_L8_P#)/=9_["S_ /HJ.OH*N['?[S/U/&R?_<*7I^K"
MJU]90:E93VEU"MQ;3HT<D4@RKJ1@@CT(JS17">R>#Z?^R?X&\#ZI<>)=$TR[
MO=4LTEN--T^[NFEMH)]I*;$/.<X W$X[8P*^3_$&@Z9=?"7X3:GX>UJ#6?$M
MP9-'NO#BR*;Z6]FG>679%P04E:3S"V %P?K^DYZ5RVF_#'PCI/BZ[\4V7AC2
M;3Q'=@BXU:&SC6YDSUS(!NY[\\]Z%.K"K&M"6L>^O]>AA/#8>KAYX:</=ENE
MIK\O/7\SQ_\ 91^!FM_#0ZUKWBF&"TUK4MEO#8PRB4VT"<_,Z_*6=N<#(&T<
MY) ^BJ**N<Y5).<W=L*%"GAJ4:-)6C'1'-_$/PC'X\\$:UX?EE:!-0MG@\T=
M4)'!_/%? <7P<\1^#/B9X5\-^-9;'PU9W5V)(=>GN5^RW(A8-L1N,2L ,*V.
MYK]'STK%\5>#]#\<Z/+I/B'2+/6M,EP7M+Z%98V(Z':PQGWJX5ZM&,HTG;F5
MF8XC X?%SISKQNX.ZU:_X?5+?L?-/PR^%/A/XT1?$>PO$:^\.6?BFXET75+"
M?88RRJ9O)D7(*[]P/4$BO=OA7\'_  S\']+EL?#MK)$;F3S+FZN9#+/<-C +
MN?3L!@#L*ZC0?#VF>&-,M=-T?3[;2].MEV0VEG$(HHU] JX K3KF@G&"A?3\
M#LG&$JCJ\JOM>RO;M?\ 0****L9YQ^T/_P D=\2_]>_]14OP _Y(_P"%_P#K
MT_\ 9C47[0__ "1WQ+_U[_U%2_ #_DC_ (7_ .O3_P!F-=[_ -S_ .WOT/%_
MYFG_ &Y_[<>A4445P'M!1110 4444 %%%% !1110 4444 8>I>"]"U;Q)IWB
M"\TJUNM:TZ-X[2^EC#2P*WW@A/3-;2]*&'.>_P#.N&TCXJ6GBGQ]?^&O#]G+
MJT&D$Q:QJZ.%M;.?&1;*V#YLW=E7A 1N(/RT 9_BSX0R^)/CEX&^("ZHL$7A
MNQO[1M/\C<;C[0JJ"'S\NW;G&#FO0;VW-Y97%ONV&5&3=C.,C&<5P?Q:^-VD
M?":31;&;3-7\1^(=;D>+3-!T&V%Q>76P!I' +*JQH""SLP !K/\ AE^T%I/Q
M&\5WWA2\T'7O!GBRSMA>MHOB2U2&::V+;?.B9'=)$#?*2K<'([4 9?@[]FK2
M](_9LL?A%XANUU^QAM9;:2^6'R6+-*\BR(N3L92PP0<Y7.:[?X1>$]>\"^ M
M-T'Q'X@7Q1?6"F!-4^S^2\T0XC\Q=QRX7 )'7%=@"/6O-;KXWVO_  MX?#_3
MO#>NZQ>P11RZAJEI%&++3UDSL\UWD5LG!X52: /3:*9DXZG-<WX0^(>A^.K[
MQ!::-=-<RZ#?OIE^#$R".X5060$CG&X<B@#IZ*1>E+0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !36&>*=2'J* /+?&_PIU76/B!9>+M!UZ'2=0CM/L4@N;,7
M*^7N8AD!(PWS&L>S_9U4^#-:\/W^NRWCWE__ &C;Z@(0LL,W7<PSAN>O3O7H
M[>+V7QXGAK^Q-6,;:<VH?VR+;-@") GD&7/^N.=P3'W0370\UU+$U8Q44]O)
M=-CSI9?AY3E-QWO?5VUWTO;4\K\-?"?7#JTM_P"+_%D_B _9&LH[6&'R(=C#
M#,Z@D,WOCKS6-I7P%U[3?L6D_P#"<7/_  B=E<BXALK>W$=P<'(1I0<[:]*\
M+_$/0_%^O>)-&TNZ:XO_  ]<)::BAB95BE=-X4$C#?+@\9ZUTU'UFKKK^"%_
M9V'TT>GF[OU=]5ILSQ[5?@UKMCXAUB_\(^*SX?M]98->PO:B9E?H7C8D%3BM
M>^^%$]YXE\$ZJ^MS7#^'4D5VNDWRW9==N2P(P?PKL?&&OMX5\,ZCJZ:9?ZRU
MG"TPT_2X?-NKC'\$:9&YCZ9J_IEX=1TZVNC!-:F:-9/(N$V21Y&=K#L1W%+Z
MQ4TU_!=K?D4L#05]'J[[NV]]%>RU/'H/@?X@\/W&H6'AKQI+HOAN^NS>/:I:
MJUQ Q(++%+D8!V@?3]>M3X;./B98>+!J32):Z;_9YMY4W.YR?G+YZ\],5WU%
M$L14EN_+8(8&A#2*V:>[TMM;70\:U;X):P_B[Q#J6C>*5TRSUY=MXCV2S3)Q
M@B-R1@$55O/@'J7_  B'A;3;#Q$EKJ?AZX:6VO6M0RL#V9">HKO?'_Q/TSX>
M:GX6L=0M[J>;Q%J2:7:_9D4A)6!(+Y887CMD^U=@ARM4L555M=O)>GY&;RW#
M/FT>OF^KOIKIKKH>0:K\'?$%MX@O]9\->+%T:[U:%8]25[(2I)(!@RQ\_(QR
M37I'AC1IM!T*TL)]1N=5FA3#WEVV9)3W)_P]*HWWQ"T.R^(&G^"Y;IO^$BOK
M&34H;58VP8(W",Y?&T?,P&,YKI4&%%93K3J)1D=-+"TZ,G.%]?-V[[7L>0>)
M/@KJMOXMU'Q!X*\42>%KG5,&_MVMUG@F?GYPI/#<D]#R2<CD%=/^ $.F_#WQ
M#H2ZO)<ZOKI+WNK7,>XR.3G.W/09/&>I/->P45I]9JV2OM;HNFU^YA_9^&YG
M+EWOU=M=[*]E?R/,_%/P<M?%?PUT_P +7-WMNK"*,6VI)'\T<B# <+GOZ9_&
MNCT3P?&NB:?;^($LM=U*UB$1O9;5<OCH<'.#^-7/&?B5O"'AR^U==*U'6VM5
MWBPTJ#SKF7G&$3(R?QK7LKC[79P3^5)!YJ*_E3+M=,C.&'8CN*S=6;7*WUN=
M$<+2C+G4=;)?);'COB_X"ZAJNNZS<Z#XD.AZ=KP5=4LS;"3>!U,;9^4G_/I6
MEXI^"BW5GX8D\-:H=!U?PXGE65V\(F5H]NTHZGKGGGW/KQZM16GUFKIKM_E;
M7OIIJ<_]GX?WO=^+S?>^FNFNNG4X3X5_#5?AUI5\L^H/JVK:E=->WU\Z!/-D
M;KA1T'4_4TG@?X;MX0\8^+=<:_%TNNSI,L'E;?)V@\9R<]?:N\HK-UIR<FW\
M6YO'"TH*"BO@V^YK]3AOBA\/'^(NGZ;;+?+8&SO8[LL8M^_:?N]1CZU!HGPS
MDTCXA^)?$S:@)4UB!(1;"+!BQWW9Y_2O0**%6FH<B>G]?Y!+"TI5/:M>]H_N
MNOU9XG+^SY,WPUE\,IKH6Z&I'4H;P6V%5MQ8*4).1S^E7M8^#NO7=[H_B*Q\
M4K8>,;.U^R7%^MFI@NTST:+.!^O0=,5Z]7GX^+NG2KXK%OIVIW4OAV40W$,$
M >2=B<8B4-\W/KCBMXUZ\W=:_)==/N.*I@\'124M-++5_9UTUW6NNXOPR^&)
M\!MJM_?:G)K>OZM*)K[4)$$>XC.U50<*HR?_ -6 ':Y\-WUCXH>'_%JZ@L2:
M7!+"UIY.3+O!&=V>,9]#77:1J*ZQI=I>B&6W6XB640SIMD0,,[67L1G!%7ZQ
M=:ISN3>KT_0[(X6C[*-.*]U-->M[W^_4HZKIL.KZ=<V<Y<0SHT;&-BK $8R#
MVKQRS^ &L37.EV&L^+YM6\,:5<?:+6P:V596(.5$DF<L!_G%>W2R+#$\CL%1
M068GL!7%2_%+29/"4_B+3;:_UJRBF, 2PMR\KL#@E5.,@>M51G5@FJ?]/]&9
MXJEAZC3K;I=WLK7NENMCD_%_P<\2:]<:C;6_B\2Z)J!RUIJMBMT]KG@B%V/R
M\=/3]:]%\(>%K;P?X7L-#M7DDM[.$0K)(?G8 8R<5JV=P+NU@G"O&)4#A)!A
MER,X([&K51.M.<>23T1I2PM&E-U8+5^;>F_4^28_V/?&]K\)];^$]C\1]/TW
MP#=K=>1+;Z%C59?-=I!'<3>;L9 Q 9E17=1MRN<UZQH/P.N--^*UGXSN-9CF
M\KP:GA62RCMMFYUF60SABQP#@C;C\:]>HK$[;GS#X?\ V2_$7AWP#HNA6OCB
M"#5?">IR7WA75XM,^:VC=G9X;I/,Q.K>80<%?\.D?X%>.?%V@>,8_&WQ"&HZ
MGK^FG3(+/2[22VTJP4_\M%@:1F>0]V9NG KWA^%-<%IOQ<L=8\=W/AFPTG5+
MR2T<17.H0P VT#XSAFSD?7%7&$IW<5L8U*T*32F[7=D='X.T ^%?"6C:,9Q<
MMI]I%:F8+M#E%"[L<XSCI7'^"?A#)X2^,7CWQNVJ"Z3Q0EFJV0@V&W\B,IR^
MX[MV?08KTRBH-1&X4UYUX#^$\G@WXK_$KQBVJ"[3QA+I\J68AVFT^S6WD$%\
MG?N^]T&/>O1J* "BBB@ HHHH **** /GW]C'_DGNL_\ 86?_ -%1U]!5\^_L
M8_\ )/=9_P"PL_\ Z*CKZ"KNQW^\S]3QLG_W"EZ?JPHHHKA/9"BBB@ HHHH
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M0 .#N( !Z=NO&><5[U\2/$K^%O FNZI;,IN;2TDDC&0?F .*SJX=TYQ@GO\
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M@!_R1_PO_P!>G_LQJ+]H?_DCOB7_ *]_ZBI?@!_R1_PO_P!>G_LQKO?^Y_\
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M\:3B';C'GBWA$_X[^M?0%!(4444 %%%% !1110 4444 %%%% !1110 4444
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M?3?_  LGPG_9AU(>)-*^P"3R3<_;(]F_^[G/7VK1O?$^CZ5I*ZK=ZI9VVF,
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MVLV&J-%]];2X20K]0#7$_'C1=&G^'6H1:A>'0X)YXY)+VWLS,#(",&55'(X
M)/:O-?A/K L/BGI>GSVOA;7[B:S;RM;\,C:\48QQ,JX49]",UR1H0JTG4CHU
M^B/1GC*F&Q$:$[--[]=6[*R[=-->Z/I*_P!0MM+LY;J\N(K2UB7=)-,X1%'J
M2>E4=!\5:-XIA>71M5M-4CB.UWLYUE"GT.T\5Y3^TV"-*\+RWRNWAU-6C.IJ
M 2GEY&-X]/O5D75[X+OY_&4?PXLW/B+^PWWW>DH1:%<#"*$.WS2.GRYSG!SF
MHAAU.FIZZ_<M4M36MCY4J\J5E9=&]7=7T/9;3QWX<U#6&TBWU[3IM34D&SCN
MD:3/<;<YR*EU[Q=H7A41'5]7LM+\TXC%W<+&7/MN/-?)NI2>!I_@CX:@\/1V
MQ\>FXMQ&+1/]/%UN'F%B/FV_>QGC[N*[B=O#5M\=/$[?$H69#:?!_9QU10UN
M4\M?,V;N,[M^/?=BNAX*,;N[TOI;5V:V\M3CCFLY))J-WRZW]U73=GYJWXH^
M@;CQ%I5G8PWL^I6D-G.5$5P\ZB-R>FULX.:BTKQ?H>OW=Q::;J]E?W5N<30V
MUPLCQGW /%?(>I#;\$-3<K+_ ,(PWB,-IJR;@1;[SG;GG&,?KWS79RR>&+SX
MK>!S\.5M!.MI(;LZ: -J;#@28_BSC.>?6F\#%)ZOKTTT5]11S><I1]U:\NE]
M7S-K3OW]#Z%D\;>'XM:&COKE@FJDX^QFY02Y]-N<Y]J75O&V@:%+-'J.M6%A
M)"JO)'<72(R*QPI()R :^.].MK6Z\)ZA::IJ_AK1]3;4W\R:YLIY-9CF\S*E
M=AR1TZ+C\:]6B\(Z9XK_ &C'M=?MK?5U@T"*0I/%E'D^0;MI]B>O3-*>"ITW
MK)V2?3M;85+-:U9+E@KMI+7O??KI;YGLVJ_$+POH<T$.H^(=,LIIE#QI<7:(
M74]& )Z'UK \:_&+1_!?B3P]H\\UM))JKY:=KI$2VBXQ(WLV>.@.#SQ7A?Q(
MUS1]4U?XCQQV7AG0I;56MI9M71KC4;UU0JAMD9@(P=N 5''RMVIES%H2V7P1
MU'6DLY+1X'ANKF[564HA&U'8CE5); / YJX8."492OK?3_MVZ,ZN:56Y0ARJ
MS6OESJ+O?^O7<^@+?QU+!XIUN#5+K1;/0K**-XKD7Z^<"V/]:I/R#G@GVKI[
MWQ!I>G06\]WJ-K;PW3!8))9E592>@4D_-GVKP_2M L?&/Q;^)>DGRWM;S2X8
MUV8Q@JNTC'X5S/PQ-_\ $#QEX:\.ZI$_D^"DE-T9@"LLP;;&0/3']*Q>&BUS
M7M9)O[O\]#ICCZD6H6OS2:7JI6?R2U^1]&7OC;P_I>K1:7=ZW86NI2D!+26Y
M196STPI.:W@00/>OB62&&5/&UMXBU'PSIM\]^_GS:S:2S:DHW?*T&T@D=/N@
M^]?7'@6&>W\(:+%<79OIEM8U:YV,GFG:/FVMR,^]9XC#*@DT[W_RN=. Q\L7
M.2<4DO/7>UFCHZ***X#V@HHHH **** "BBB@ HHHH **** "BBB@#Y]_8Q_Y
M)[K/_86?_P!%1U]!5\^_L8_\D]UG_L+/_P"BHZ^@J[L=_O,_4\;)_P#<*7I^
MK$/2O/\ XS_#R7XC^"I].M)A!J$4BW-J[' \Q>@/L:]!HKDA-TY*<=T>G6I1
MKTY4Y[/0^>KOQ%\7_$FD6/AJU\+/X;U!'1+G7OM*M$J+_$@]_3)].]:_BOP!
MJVJ_'+P1J-QIYU71[+3I(+V\F2,H7VR_>7ORRGICFO;J*ZOK+3]V*6_XGG_V
M>I*U2HY:Q>MOLNZT2MZ]3PG3O ^N?"CXM&Y\-:;)>^"-=.;VRMRH%C+TWJI(
MPH)SQ_"6&!M6K]_^S+X;C.NWVG2WJ:IJ-O<1[IYPT8:4')VA1Z^IKV>BD\55
MNFG9[/SMW*66X=)QDKJ[:3^S?>W8^8-%\%>-O%3>"?#.L>')-)T[PU/YUSJ4
MDZE)PN=NP#KD'_\ 55WQ%X3\9>#?$/C:UT3PY)KMCXH'[FZBF55MV(PV_/MG
MTKZ2HK3ZY*]^56[?.]_O.=93!1MSOF[Z7M;EMM;8\]\+>";GPG\'U\.@>??1
MZ;)$RH?ORLAX!^IQ5?\ 9\\.ZEX5^&&EZ;JUF]C?123EX9""P!E<KT]B/SKT
MJBN:5:4HRB^KO_7WG?#"0ISA./V8\J]-/\@I&Z4M,E94C9F(50,DGL*P.T\M
M_:8U2+3/@]K8D8*;@+ H]2Q'2M_X+Z:^D_"[PU;2*5=+-20??G^M>*^.M9;]
MH3XH:;X5T1S-X:TB7S[Z\3[CL#S@]Q_"/7-?3-K!';01PPJ$BC4(JCH !@"O
M0K+V5"%*6[=WY=CP\++ZSC*F(C\*2BGWUN_\B>BBBO//<"BBB@ HHHH ****
M "BBB@ HHHH **** ,'Q/X%\-^,_(/B#P_I6N_9P1%_:=E'<>6#UV[U.,X&<
M>E4M#^%G@OPQJ O]&\(:#I-\JL@N;#3(8)0I&& 94!P1VSS75T4 8L7A'0X+
M:QMX]'L$M[&7S[6)+9 EO+DG>@Q\C9)Y'J:GBT#2HA?[-.M$%^=UWM@0?:3C
M!,G'SG''-:=% '-^'/AUX3\'6-W9:#X8T;0[.[)-S;Z;I\5O',3U+JB@-GWS
M571?A/X)\,PF'1_!^@Z3";A;LQV.EP0KYRYVRX51\XR<-U&:ZZB@#FM2^'/A
M/6?$MKXBU#PQHU]X@L\?9M6N=/BDNH,=-DK+N7'L:X7Q#\*/$OC;XV:+XA\1
M:OI<G@CPU,;[1=%M+1Q<27C0^7YMS(S$'R]TI0(%^\-V=O/K]% #!T%>=?#7
MX6S?#G7?%]O;W%O-X4UJ].I6^G^7A[6>08N%SC#(Y ;D\$GUKTBB@#FO"WPX
M\)>!Y[N?PYX7T70)KMMUQ)I6GPVS3'U<HHW'ZUS?Q+^&NJ:OX2:R\":CI_A+
M45NOM;)+IZ36-]G=YD-S$,;DDW?,00W<&O2:* /!?@S\ ]9\*^.IO&GBR;PW
M#JB:4=$L-&\'Z<]GIEE:M-YTA".Q+R.X4EL#&W%>A^(OA-H'B&Q\,6"VT>F:
M9X?U2#5;2QL((HXQ+"2T8 V_(H<[CLVDX(SAB#V]% "#I7*7?PG\$W_B5/$5
MSX.T"X\0(0RZK+I<#W0(Z$2E-X_.NLHH H:AH]AJDEO)>V5O=O:R"6!IX@YB
M?^\I(X/N*-7T73_$.GRV&JV-MJ5C-Q):W<2RQ/WY5@0?RJ_10!G6>B:?IUY<
MW=K86MO=7(03SPPJDDH080.P +!1P,]!Q5#7O#\=VUQJNG6&F'Q5%9RV]AJ-
M[;@M&2"0ID WB/=@E5/ZUT%% '#?!KX:Q_"CX?:=H!NVU*_5I+K4=2D0*][>
M2N9)YF Z;G9B!V&!VKN:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ IKTZFMVH \Q\6>%/'NI>*I=1T76-!M+6,!;4WFG>9<0
M@J P$GH3FLH^"OBJU^+T^(O##7JKL%R=+/F!?[N[&<5U/C;XPZ!X"UJUTG4_
MMC7UU"9K>*UMC,93G 10.2Q/08_$5RGB3XSV?B?X6>*M1\.W%YIFKZ9"PE@N
MHA%<VS]LKD@=#Z^]>E3]LU&T%;:]CP*WU2,IWJ/F5VTI/HKC-6^'OQ,UZ)8M
M4USPIJ<2G*I>:/YJJ?4!@:=+X$^)\]@MC)KWA:2R3&VV?2=T8QTPN,<4WP)\
M?]&N;/PUINI'4VO+Z)(UU2>S9+:>;'*ASC)SW Q6[XI^/&@>%M:O---CK&JS
M6(!O9=-LC-%:#UD;(Q^&:I_6%+DY%]R,H_490]JZKL]'[S];/4QI?!'Q3GG@
MFD\1>%Y)[?B&1]*W-%_NG'R_A56Y^&7Q&OM3CU&YU7P?<ZC'C9>2Z,'F3'3#
MD9KI_$/QX\*^'+/1[J>:ZFAU>#S[-K6V:0R#LN.N3_DU7O/C_P"';!["VFLM
M8&H7]D+VVT^.Q9[B122 @12<-\I.#QCO23Q%KJFON^\J4<#JI5GI9_$_E_P#
M#UCX<?$GQ&BQZMK'A'5$C.46]T83!3ZC<#4__"$?%06'V'_A(O"XLMNS[,-*
M_=;?[NW&,>U/_P"&G_![:;'>QPZQ/"#MN_+L2?L'S;1YYSM7)'&"<XKH?%?Q
MGT+PO+IT"0ZCKEYJ$ NK>UT>U,\C0D9\S&1@8]3FFWB$U%TU_P" H$L"U*:K
M/I?WGUVZG)Z=\-_B3H]M);:?J_A&PMI?]9!:Z.(T?ZJ!@_C3U^'GQ+1;8+K7
MA,"U.;<+HX A_P!SCY?PKJ[7XU>%KKP3-XI-U-!IT,AAD2:(K.LHX\O9_>Y%
M1^#?C7H'C/4YM.2+4-'U"*$W'V;5[?[.[Q#_ ):+R<KCFIYZ]FW!:;Z%*E@K
MQ@JKUV]Y_P"9SJ^!OBDD]Q,OB#PP)KE=L\@TK#2CT<X^855NOAG\1;[2UTVY
MU3P?<:<IW+9RZ,&A!ZY"$8[UJK^TIX0.I"#.I+8--]G76'LV%D9,XQYF>/KC
M%*GBO4G_ &B#HHOW.BMH?VH6W'E[]ZC=]<&K3KK>*6E]NQFU@Y)<E24KOETD
M^OSV,Q?AO\255U&L>$@)(Q;N!HPP\0Z(>.5'ITI+?X;?$BTOQ?P:OX2BOU01
MK=1Z,%E" 8"[@,@8'2M)_P!I?P<E^\8_M*33DG^SOK*6;&R63/"E\Y_2MWQG
M\8]"\&:A86$D5]JVHWT?G0V>DVYN)3'_ '\ ]/UJ7+$)J+AOY%*&!<7-5G9?
MWG_F8$_A;XN74313>*?#LL3C#))II92/0@]:S](^&OQ&\/F0Z3JWA#2S(<R&
MST81%S[[1S6[#^T)X3N-(U'4XGO9;+3IXK:XD^S%2C2=#M;!P#D'CC%='JGQ
M'TC3/$&AZ,YGGO=87S+98(]P"8SN8YX%2YUX^ZX+[ET-%3P<[355O;[3ZNR^
M]G&77A/XMWT#P7/BCPW<02#:\4NF%E8>A!ZU6TGX>_$W0(&BTK6O">FPL<F*
MSTCRE)]2%%>TCH*6L?K,K6Y5]R.OZA3;YN:5_P#$_P#,\/@^&GQ&MM4?4H-5
M\(0ZF^=U['HH69L^KXS4FK_#OXF:]&B:IK/A+4DC.46\TCS0I]1N!Q7ME%/Z
MU.][+[D+^SJ5N7FE;_$_\SP'Q7\(?B3XRT>#3+_Q-H(LH)4ECC@L#&%*G*XP
M.GM6EIWP[^)>CSS3V.M>$[.XFYFFM](V/*?5R!S^->V44/%3:Y;*WHA++:*E
MS\TK_P")GB$GPT^(\^J+J<FJ^$)-37[M\^B@S#Z/C/ZU;'@OXJ+?->KXC\,"
M]9=C7(TO]X5_NEL9(]J]DHI?69]E]R&LOI+:4O\ P)_YGB$_PV^)%SJ?]I3:
MOX1EU(+L%Y)HP:;;C&W>1G&..M)<?#+XBWEA#8W&J>#Y[&$[HK6710T<9]54
MC /)[5[A11]:GV7W(/[.I:^]+7^\SQJ#P1\4[2YDN(?$7AB&YD4(\T>E;791
MT!(Y('I2V_@OXJ6<\T]OXC\,P3SG,LL>E;6D/JQ')KV2BE]9EV7W(KZA37VI
M?^!/_,\/O?AI\1=2OXK^\U7PA=WT1!CNI]%#RICIAB,BO5/"=KK-GHMO%K]Y
M;7^J*3YD]I$8XVY.,+VXK<HJ*E:516:7R1M1PL*$G*+>O=M_F%%%%8'8%%%%
M !1110 4444 %%%% !1110 4444 ?'/P;^('B[X1^'[W2A\-]:U7[1>-=>;Y
M4T6W*JNW'E-G[N<YKO\ _AICQA_T2/6O^^IO_C%?0]%>E4Q5*K)SG25WYL\"
MCEV)P]-4J>):BMO=C_D?/'_#3'C#_HD>M?\ ?4W_ ,8H_P"&F/&'_1(]:_[Z
MF_\ C%?0]%1[:A_SY7WLV^J8S_H*?_@,?\CYX_X:8\8?]$CUK_OJ;_XQ1_PT
MQXP_Z)'K7_?4W_QBOH>BCVU#_GROO8?5,9_T%/\ \!C_ )'SQ_PTQXP_Z)'K
M7_?4W_QBC_AICQA_T2/6O^^IO_C%?0]%'MJ'_/E?>P^J8S_H*?\ X#'_ "/G
MC_AICQA_T2/6O^^IO_C%'_#3'C#_ *)'K7_?4W_QBOH>BCVU#_GROO8?5,9_
MT%/_ ,!C_D?/'_#3'C#_ *)'K7_?4W_QBC_AICQA_P!$CUK\&F_^,5]#T4>V
MH?\ /E?>P^J8S_H*?_@,?\CYV?\ :4\;3 )!\)=8$K< N9B ?^_ _G6?>>'_
M (P_&H_9=;\GP5X<D.)88_EDD7N"N2S?1BJU],T4UBH0UI4TGWU?YDO+JE7W
M<17E*/96C?ULKG)_#GX<Z+\--#33-'@V@_--</S),W]YC_3H*ZRBBN&4I3;E
M)W;/7ITX4H*%-62Z!1114F@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C=*6HY3C:#WX
MH$> ?%K6I_#W[0G@O4+?2KC67@TZ<M:6:AIRN'#%%)&X@$G'?%8%YX<U_P 7
M6OQ1\4)X>U*PAU>S6UL=/N("+F<J%&[R^N?E]._4XKU#Q7\!M$\9>+)O$5SK
M&OV>I854:RO1&L(V!<1_*2H(ZX/4GUJM_P ,\:>[;_\ A,?&9;U.L'/_ *!7
ML0Q%&,(6>J26S[W[GRM7!8FI4J7C>+;:U76/+?;\#F/%OA;5KCP+\+K>#2+R
M2>RNX&N88[=B\ "\EP!\N/?%8OQ"/B[7M=\5Z9JEEXMEAPR:3:Z%'Y=C,A'W
MI9 /F^A/MBO01^SMIX)/_"8^,LGJ?[8/_P 12C]GC3P-H\9>,]O]W^V#C_T"
MG&O2B[WOOT[N_<53!XB::4;7M]I=%;M\_4X'PQX3U==9^#K3Z+?Q1:=;RK=F
M6W<"W?8P&_(^7)QBNUNM"U)_VFK/5A87)TQ=%:$WHA;R0^X_*7Q@'VJP?V=M
M/.<^,O&9SU_XG!_^(H_X9UT[;C_A,?&6/3^V#_\ $5,JU.3;YMTUMW=^Y=/"
M5Z<5%4]I1E\2^RDNWD<!I'A#6U^#7Q2M)-%OEO[[5[B6VMFMF$LZ$H5*+C+#
MKR/>K&NW/BNQ;PGI5S:^*;;PRNA6ZNOANWQ<M=A &CE?&Y!P!CCOSZ=O_P ,
M[:<<$^,O&>1T/]L?_84H_9XT]2=OC+QF,]<:P>?_ !RK^L4F[MWZ[>27?R,_
MJ.(45&,;627Q+6S;UT\SR+3?AUXEE^%MVD>@Z@E_I^O_ -H_8+Q"9KB+.?E)
M^^<=QG)KT^W\3:Y\5I]3T^V\'WOA_3WTV2%M2UB P3B9A@1H.<KGJ:N_\,[:
M<2/^*Q\9<=/^)Q_]A2O^SOI[_?\ &7C-C[ZP?_B*4Z]*IK)Z]-'IMY^15'!8
MBBK0CI9)ZK6U_+3<\ND/B.Z^$4?PR'@/5H]:W+;F]>VQ8JH<'SA+T.<?S^E=
M=#X"U=?BV]NT%U]B/A(Z;_:AB;RO-.U?O]-W?UXKHS^SQ8;-G_"9^,]OI_;!
MQ_Z!2?\ #.NG8Q_PF/C+'I_;'_V%-XBGKRNU[]'N_F3' XA<O-"]K6]Y+2-[
M+;SW/+[5_$FF_!^?X7OX#U:37&=[9+Q+?-BZM*7\[SLX&,_F%R>:Z";0=>^%
MGQ"\/:Q'H=WXHM(M @TJX73%$D\,B#&0G!"DCJ??FNQ_X9WL!'M_X3+QGL/\
M/]L''_H%4C^R_P"'SJ2ZB?$?BDZ@B;%NSJ0\U5YX#[,@<G\Z?UBBV[O1WOH]
M6]^N@E@<3%1M&[CRI/F6BCM]G4X[X5^'Y?'2?%K3]2T_[!+?W"AK8D,8G*L0
M-PXSTSCOFI?V;K'4_%'B6\UW6D7=H5L-&MB"2-RD[V_0#BNLM/V7_#]B)OLW
MB/Q5;?:#NF\K4POFGU;"<GGO5_PA^S]H?@75K6\TW6O$ 6"4RBTDO@;=V(_C
M0* :53$4G":C+>UM-M+/KU'0P.)A4I2G!>[>_O;W=UTZ7/5QT%+35^Z*=7BG
MUH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>glyc-20241231xs4036.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4036.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ** Z$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <WX6B\.QW^N?V']F%RUZ[:CY'4W'\6__:KHQT%>=?"_PMJ7AW7?
M'4]_;B"+4M:EN[9@P.^(@8/'2O11TK6JDIM)W.7#2<J2;CR[Z?-_GN+28'I2
MT5D=1R?C[X;Z!\3-&;3M=L4NHNL<G22)O56Z@UX[!X%^*GP68Q^$M2C\7^&T
MY33-28B>,9^ZK9KZ.HK>%:<%R[KL]O\ @?(XJV$IUI>TUC/NM'_D_1IH\"LO
MVK]-TUQ;>+O#NL>&;P<-YMN9(\^S"NED^/'PN\4V;V5WKNG7,$JX>"[7@CT(
M(KTV]TNSU%-EU:0W*^DL88?K7,W_ ,(_!>IH%N?"^EN <_+;*IS]0!6G/0>\
M6O1_YF7L\9'15(R7G%I_@[?@CY[\2^'/A#I=ZVH^%_'[^$;]CN']G7+-'G_=
M[5S/_#1'CCPW?+9Z/XEMO'$8; )T]PY'U'7ZU]2V/P:\#Z:Y:W\*Z6K$8^:W
M#_SS71Z=X;TG2% L=-M+0#@""%4Q^0K98BE'>+EZV_RN>=_9M:_[J2I_X5+\
MN;E^],\?^&OQ"^+7BJ9'U/PAI^GV+$9GGE>%@.Y"G)/TXKW!<D#=U[XZ4^BN
M.I-3=U%+T/<HTY4H<LIN3[NWZ)"$<5\6W7P9\7/\;=;U*#0=7,\WB2#4K.\D
MN%.D^0H4.TD)/+XS@XR#7VG13IU73O;J;6N>3_$_PIJNN?%/X:ZG8V;3V&F7
M<\EY*" (E,9 )_&N<^(6F>(/!'QUMO'NG^'+WQ1I=SHYTV6#32IGAE#[E.UB
M!M/KZU[W12C4:LNEK >!^#/A?K_A_P#9<UWPS<VHDU_4+#4'%BKY"R3^8RQ
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M\+G5(<YI],C&,^_-/K,Z HHHH **** "BBB@ HHHH **** "D;[I^E+2-T-
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M2%%%% !112;A0 M%)N HW 4 +12;A1F@!:*3-+0 44A.*3>/6@!U%)N'K06
MH 6BF[@*7<* %HI-P]: P- "T444 %%%% #6KR_QW<WD?QE^'T4,LZ6D@N_/
M2,GRVQ$=N[''7UKU!JYK6_&FGZ-XMT+0;B"9[_5O-^S2(@*)L7<VXDY''IFM
MJ3:DVE?1_E^AR8F*E!*4N76/YK3Y['2)W-/IB=33ZQ.L**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \Q^$FA:AI'B#X@2WME+:1WNO33V[RK@2QD#
M#+Z@UZ:.@KC? OCI_%^J^*;5[46PT;4Y+ ,K;O,"X.X^G7I79#I6U9R=1N:U
MT_(X\(H1HI4W=:_F_P!1-XY[8IU> ?%OXYWWPG^*]E;3HU[H-Q9HTUNN T9W
MD;U/K[5[/X7\6:7XQT6WU32+I+RSF'RNAY![J1V(]*J="=.$:C6C)HXRC7JS
MHQ?O1=FOU]#8HHHKG.X:7 S[#->(Z]\>-5USQ-<^'?AYH'_"0W=J2EQ?ROLM
MHF!P><C('3.1G'&:[CXT:S<>'OA;XEO[5S'<1V;K&Z]59OER/<;LURW[+GAZ
MVT?X0:7<PHHGU%I+B=P.6(=D7GV"C\S7=2C"%)UYJ^MDO\SQL35JU<3'"4I<
MNCDWUM>UD8>J?$7XN>!K9M2U_P *Z=J6E)\TYTZ;,D2]SC.?T->I^#/'^F>/
M?"B:YI,A>%D):-^&C<#E6%=)<6R7,,D4@#QNI5E(X(/45S'AWP#HG@+2=0M]
M$LQ:17&Z610Q.YL'UZ?A42J4ZD/AM+RV^9K3H5Z%32HY0:Z[I]+:?F>-^$OC
M7\4/'XU&7P_X7TB\M[.X-N[R7'EG<.<89QVK;O\ X@?&;0[26]O? FG7-K"I
M:1;.Z#R;1R<*')/'H#7E_P !?C3X?^&%IXCM-8BOY)KC4&E0VL D 7 '))&#
MP:].N/VM/#NH1O;^']'UG6=592(K2.V&6..^TDXZ=!7J5J$XU&H4$X]]?SN?
M.87%TJE!3JXN2GV5N_;EN=[\)/BG8?%?PV-2LXGM9XG\FZM7.3%)@'KW!!X-
M=T>!7BO[,_P\UCP7H>L:CKL(LK_6;D3_ &(<&%!N(R!T)WGCL .]>TEA7D8F
M,(59*F]#ZC 5*U7#0G75I-:]#B_BG\3['X8Z E[<0O>7EP_DVEE']^:0]OI7
MGE_\5?B?X:TQ=?UKP39_V(,/-%:W!-S GJPR?\]<53^+2G6OVA?A]IDPS:Q;
MIBAZ$YS_ $KW76+!+[1[VVD :.:!XV4CJ"I!_G73:G1A#FBFY:O[^AP7K8NK
M6Y*CBH.RM;>UVW=>91\.>+M-\3^%[;7[.=3IT\/G^:Y "+C)W>F.<_2O)['X
MR^-?B+<7]QX"\,6ESH=I*8EO]3F,?VAAU"#(]OSY(KS[X?:U<6/[,7CZ)'(%
MG=2VT8ST20H"/_'S^=>X?L_Z='IWP=\+I$ N^T$S8[LY+$_F:UJ48893DU?W
MK*_WG/1Q57'NE!2<+PYG:U[WM;7SN0?"OXP-XXU+4=!UG2WT'Q/IH!N+%SN5
MEZ;D/<<C\P>:J?$'XS7FC>+(/"7A713X@\22IYCQL^R*!?5C^O48KD_&:G1/
MVK/"5S;_ "-?6)AFQ_$/G'/X$?D*]@TWP)HNE>*+_P 16UH$U:^79/<;B=PX
M[=N@K*<:-.4:CCI*-TNE_P#(WHSQ->$J*GK"5G+KRVO==+ZI'ENJ_&+QY\.F
MM[OQMX4M%T2601O?:5,9/(S_ 'AD_P!,^M>V:9J%OJMC;WEK()K>>,21R+T*
MD9%>'?M'>-XM7L%^'VB1C4_$.IR(K0Q?,(%SG+8Z'^0KU[P-H#>%_">D:2[^
M8]G:I"S^I YJ*\8^RC4Y>63Z+MW-,)4G]9J45-SA%+5VT?575NGW&]1117">
MV%%%% #6[5QWB3P+)KOCSPOXA2[2%-&\_=;LA)E\Q-O7/&*[(]*\R\;^(-0L
M/B[X"TV"\>*QOA=?:(%^[+MCRN?H:VI*3D^5VT?Y''BG3C33J*ZYH_?=6_$]
M,48S3J8AR.:?6)V!1110 4444 %%%% !1110 4444 (>17/>,_!T?C'2TMCJ
M-]IDT4@EANK"8Q2(W3MU&#T-=%2,,J1[4U)Q=T1.$:D7&2NF?/NC>!O&'PU&
MI+%X\TJQ%YJ,MS%!JJ(?M&['SL<@[SCD#CBNMT2S^)=_XMTB35YM+MM'M2SS
MR:?(3]IR.%V$<?4&O*_%&FZ)J.G_ !(N->BBF\:VU](;<WC9>.TW#R#""<!=
MI[=^M>AQ2R^$/BEX=_L_4))HO$40%]I;R;Q&5B&V9!_ .,'M7M5$VKZ7L_L^
M2>GR>[/E*#C"2BKJ*:T4F]Y-:I^:U2Z,]GHHHKQ#ZX*^?/V=/^2L?%W_ +"I
M_P#1T]?0=?/G[.G_ "5CXN_]A4_^CIZ[Z'\"MZ+\T>-C/][PWK+_ -)9]!T4
M45P'LA1110 4444 %%%% !2,<4M8/CKQ3;^"O"6J:W=$>590-(%/\;=%7\6(
M'XTTG)J*W9$YQIQ<Y;(W%?<306Q7SG\%_C!XLN?&FFZ1XSN8Y8?$&G"_TQUB
M5 N2VU> ,Y"GK_L^M?11Y4Y]*VK494)<LCEPF+IXRG[2G==+/?\ JVHX,3VH
MW<]*^8O"'BGXK?$CQ#XFM]%\365C;:9>O $N;5"=NY@N#M/8=ZZ+48/CEX5M
MVU#^T])\1QPC<]HMN$9P.N, <UT2P;C+E<XI]KO_ ".&&:*I'GC2FXZZV733
MO<]\S03BN!^$7Q8L_BGX?>[BA^QW]L_E7=HQR8G]O4'M7,?$OXRZM!XPB\$^
M";"+4_$CKNGFF_U-HN <MZD @\],CZ5@L/4=1T[:K?R.R6.H1HJO>\9;6W;?
M1+N>Q[^.E.4Y%>&/X&^,BP_:U\?6;76-WV3[&@B]=N=GZUH_"+XQZEK_ (@O
MO"'BRSCT[Q199.8QB.X4=2OOCFK>'?*Y0DI6WM?3\#*&/3J1IU82AS;7M9^6
MC>OJ>QT4BDD<TM<AZ@445YM\>/B7?_"OP;%K&GVT%U,UTD!CGSC!5CGCZ5I3
MIRJS4([LPKUH8>G*K4V6YZ317QK_ ,-J>*/^@-IOYO\ XT?\-J^*/^@+IOYO
M_C7I_P!EXGLOO/ _UCR_^9_<S[*HKXU_X;5\4?\ 0%TW\W_QH_X;5\4?] 73
M?S?_ !H_LO$]E]XO]8\O_F?W,^RJ*^-?^&U?%'_0%TW\W_QH_P"&U?%'_0%T
MW\W_ ,:/[+Q/9?>'^L>7_P S^YGV517QK_PVKXH_Z NF_F_^-'_#:OBC_H"Z
M;^;_ .-']EXGLOO#_6/+_P"9_<S[*HKXU_X;5\4?] 73?S?_ !H_X;5\4?\
M0%TW\W_QH_LO$]E]X?ZQY?\ S/[F?95%?&O_  VKXH_Z NF_F_\ C1_PVKXH
M_P"@+IOYO_C1_9>)[+[P_P!8\O\ YG]S/LJBOC7_ (;5\4?] 73?S?\ QH_X
M;5\4?] 73?S?_&C^R\3V7WA_K'E_\S^YGV517QK_ ,-J^*/^@+IOYO\ XT?\
M-J^*/^@+IOYO_C1_9>)[+[P_UCR_^9_<S[*HKXU_X;5\4?\ 0%TW\W_QH_X;
M5\4?] 73?S?_ !H_LO$]E]X?ZQY?_,_N9]E45\:_\-J^*/\ H"Z;^;_XT?\
M#:OBC_H"Z;^;_P"-']EXGLOO#_6/+_YG]S/LJBOC7_AM7Q1_T!=-_-_\:/\
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MC_H"Z;^;_P"-'_#:OBC_ * NF_F_^-']EXGLOO#_ %CR_P#F?W,^RJ*^-?\
MAM7Q1_T!=-_-_P#&C_AM7Q1_T!=-_-_\:/[+Q/9?>'^L>7_S/[F?95%?&O\
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M^V:O\J_$/]5L/_S\E^!^='_"C?'W_0K:A_W[_P#KT?\ "C?'W_0K:A_W[_\
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M _.C_A1OC[_H5M0_[]__ %Z/^%&^/O\ H5M0_P"_?_UZ_1>BC^V:O\J_$/\
M5;#_ //R7X'YT?\ "C?'W_0K:A_W[_\ KT?\*-\??]"MJ'_?O_Z]?HO11_;-
M7^5?B'^JV'_Y^2_ _.C_ (4;X^_Z%;4/^_?_ ->C_A1OC[_H5M0_[]__ %Z_
M1>BC^V:O\J_$/]5L/_S\E^!^='_"C?'W_0K:A_W[_P#KT?\ "C?'W_0K:A_W
M[_\ KU^B]%']LU?Y5^(?ZK8?_GY+\#\Z/^%&^/O^A6U#_OW_ /7H_P"%&^/O
M^A6U#_OW_P#7K]%Z*/[9J_RK\0_U6P__ #\E^!^='_"C?'W_ $*VH?\ ?O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M48 PHQ7I0Z"MZRDJCY]]/R./".#I)TU9:_F[BT445@=@4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-/X(^@4445)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!SGACPWHVA7^N3Z4ZM/?WK7-[B7?B8
MXR"/X>,<5T0Z5YE\(]$OM(\0?$&6[LY+6.\UZ:>W:1<>:A ^8>QKTT5K55IM
M7O\ \,<F%ES4D^7EWT^8M%%%9'6%%%% 'D7[6=S=6O[-GQ%DLRRS?V/.I*]0
MA7#_ /CI:N0_8!M;2V_98\(O;!0\S74D^.\GVB0<_P# 0M>\^)/#]IXIT#4M
M&U"/SK#4+>2UGC/\2.I5A^1KX8^%7Q"U[]A+5-5\!^/]'U"_\"2WCW6D^(;*
M$R)&K8!#=AD $KP0<]<UZ=!.MAI4(?%=.W=6M^!A+W9J3V/ODD8JI/#'#I]P
MD:JB[&.U1@9P:^5O&?\ P4)\$R:1):> K74_%OB>Y0I:6=M9L '/ +'KP>P%
M=%^R!\(O%GP[\!ZUK7C:^NI?$/B"5[R2QEG9TM%;)VA22%))R<?2L986=*FY
MU?=?1=65[12=HZGRU^R#XJ^+GAZ/QVGPX\(:9XDLY-9D:ZEO;L0M')V &1D8
MQ^M=[XR_:R^.^E^++3P-K?AWP]\.M8U92EIJ^JS-]F&>-RR?,A.?7@$C-='_
M ,$U87BTSXF"1&3.NM@,,9XKZ!_:1^ NE_M!?#6]\/WH2+4H@;C3+XKS;7 '
M!SUVM]UAZ'U QZN(KT8XMQJP36FO79:^9SPC)T[Q9S?[,G[/UI^S+X%UJ?5M
M7&IZWJ4GV_5]38$)\H) &>2%W.<GDEC6C_PV1\%]H/\ PL'2^>1Q)_\ $UY/
M^Q5\8]1UK3]5^"_Q&@=/%7AX26<27R[OM=JORF,D\,4'&?XDP><$U[;_ ,,L
M?"+'/PX\.?7^SX_\*X*T8QK2^M7<NZM9HVC=Q7LSYZ^.^I6?B?\ ;.^ ]Q'<
M"YTJXA-Q:R#[D@8Y!'UXK[1OHXYK&XCD(\MHV5OH1S7RK^V-\+M5T=O 'Q"\
M%Z0;N?P1<+OTVSC^;[)QD(H],=*;XP_;Z\":C\/[F+PO_:&J^,+^W:WM=$CM
M'\Z.=UVC=Q_"3VSTK2=*6(ITG15TE9^6O42DH2ES'@OP7NY[?]BCX_QPLQAC
MU25(\?W3Y(;'X9K[&_8WAB@_9C^'JQ$;#IBL<?WBS%OU)KAOV?\ ]FRYT3]E
M;6/!GB%5M-9\40W-Q>@C/V>69<(#[H F1_LUP7[.7[2VD?L]>"/^%8?%E+KP
MMKGAV66&WGG@=XKR N64HP!SC=C/0C%=&)?UF-2-+5J5].JM:_WF</<Y7+L:
M/QZ A_;T^#<\!_?R6IC?'4IO?_XIJ^K-3\">'];\16&N:CH]I?:M8(T=I=W$
M0=X Q!.S/0\#D<U\H?")+W]IO]JO_A;4>FW5CX%\.61L=(FO(RAO9"&^=0>V
M79L_[*CK7V>>#DFN'%MP]G3OK&-G\[NWXFU/6[[L^-O@K_R?Y\5_^O-/Z5]E
MU\;?!:-U_;[^*[E&"&S3#%3@]*^R:,=\<?\ #'\@I;/U"BBBO.-@HHHH :QQ
M7.:UXRT_1_%6AZ'<1RM?:IYOV=U0%5V+N;)[<5T;5QGB7P++KGC[PMXB2Y2*
M/1O/WPE23)YB;>#VQ6E/E;:GM9_EI^)SUW445[)7=U]UU?\  [-:=35ZFG5F
M= 4444 %%%% !1110!XK^T%\+-?^(VH^&;K0+VWLKK2WFD$DTFU@S&/:5X/(
M*5YQK/P"^+7B&\L;O4O%$%W<V+;[>26<DQMQR/E]A76_M(3RP_$3X6*DCHKZ
MA(&"L0#^\@ZU)\6]<U*Q^/?P^L;:_N;>SN)!YL$4K!)/G'#*#@U[M"=6-.G&
M+6TGJNUSXS&4<+4K5IU%*ZE!.TK)MI6=O(S]#\ _%_3?$.FR:KXXCDLQ.K2P
M/=<R(#R ,<U](5\Z_M%R.GQ.^'0#, ;CD \'YQ7T57#B6YPA4=M4]E;J>QE\
M8TJM:C%M\K6\F]U?KL%>:?%%/%5AXB\,:YH-O<:II^GM<"_TNVG\MK@.@"''
M1MI!.#7I1Z4UEX/I7'"?)+FM<]2M2]M#ENUMJO)W/EBZ\7>$_B8-3?X@:!J-
MA?6U_-;P7]C:NCP0@C;%)(F067)SG([UZ'\(].^&=IK8NO#VM'6-;D3REEU"
M[::X1 .54-C ^@K'U[XH>*K.'Q+K'A[0=$_X1K3-2>SF6Z#BXN9E95DD^4@8
MR>I[5J^%?%5U>_$:PTO6?AW::1JQC:9=22>-QM'4QG:">O0&O8J*3IM*Z792
M7ST>I\M0=.%>+E:4KK5P=W=V3NM.]KI'M5%%%>(?8!7SY^SI_P E8^+O_85/
M_HZ>OH.OGS]G3_DK'Q=_["I_]'3UWT/X%;T7YH\;&?[WAO67_I+/H.BBBN ]
MD**** "BBB@ HHHH **** "BBB@#RO\ :1_Y)RG_ &$K3_T8*N?'7_DB7B/_
M *\U_P#0EJG^TC_R3E/^PE:?^C!5SXZ_\D2\1_\ 7FO_ *$M>A2VI?XG_P"V
MGA8GXL3_ (%_[<=IX7_Y%S3/^O:/_P!!%:E9?A?_ )%S3/\ KVC_ /016I7#
M/XF>S3^"/H%%%%2:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 <=X'\='Q=JGBBU-G]F&C:E)8;
M@^[S=N/FZ<?2NP'05S/A3P78^$]1\075G<33R:O?/?3K,P(21@,JN ,#ZUTP
MZ"M*G)S/DV.>A[3V:]KOK^>GX"T445F= 4444 %07%G%=Q&.:))HV^\LBA@?
MJ#4]% &;8^'=,TN1I++3;.T=NK00(A/X@"KY7L!Q3Z*+M[@0PVT=OGRXTC!.
M3L4"I32T4 5Q9Q"82^3'Y@.0^T;NF.M3FEK#\8^-M%\ >'KO7-?OXM-TNU7=
M+<3'  _J?:FDY-)"T1M$;ATK/B\/:;;WC7<6G6D5VW6=(%#GZL!FET#Q#IWB
MG1K/5=*NX[[3[N,2PW$+95U/0UHT:IV#<9M.*IZAH>GZJ%^W6-M>[>5^T0K)
M@^V0:OT4EIJAD4$"6\:I&BQQKP$0  #Z5(1FEHH B2VCCE:01H)&ZN%&3]34
MM%% !1110 4444 -;I7FOC?Q%J.G_%SP%I=M>/#8WPNC<VZXVR[8\KGZ'FO2
MR:YS6=9T*R\4:)87RQ?VS=>9]A+1[F&U<OM;''%:TG:3TOH_R_0Y<3'F@ES<
MNL?S6GSV.AC.<T^FI3JR.H**** "BBB@ HHHH \0_:(^&7BCQ[J7A6^\+F!+
MG27FE,DTH0HQ,90C(Y^X:\TUCX,?&C7M?T[6KZ_LY]2T\YMIS<(#&<YX&W%>
MT_&7X?>*O'3Z2?#7B,>'UM1+YX+./-W;-OW?3#?G7@'BOPG\1/"?C;P]X:G\
M<S3W&LOLCFCEDV1_,!\W'O7T&#FW3C",XW2>Z;=NI\1F=&,:\ZDZ<[-QU4DD
MWHEH=,GP?^+7B'Q?H&I^)KNTOX=.N%D!-PF57.3@ "OJJOG;P]\"_B3I>NV%
MW>>/1=VD,RO+ 'E^=0>1R*^B:X,94Y^5*2=NRL>UE5%TE-N$HMM?$TV_N"D/
M0TM(WW3]*\X]T\<U'X;"34?&.A:?X@MEM-=MY+S^R9 #+;7;%<S#!SL)'(/>
MJOAFP\:^+?%OAM]=TRPTFV\.Y,MU;7JS/=OLV@*J_=4]2#_]:N0N]7NO"VH>
M,-+M=+O'^(FLZI-%:78@9A]DD(\MUD^Z%5>V>"*W=$\-Z5\//B+X/TO0-0>Z
MUJ;S$UB,3M)YB;,M)(,\'=TS7MVDHM-ZVTT\M7H]NEW<^04H2J)I-)-)I/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2\1_]>:_^A+5/]I'_DG*?]A*T_\ 1@JY\=?^2)>(_P#KS7_T):]"EM2_Q/\
M]M/"Q/Q8G_ O_;CM/"__ "+FF?\ 7M'_ .@BM2LOPO\ \BYIG_7M'_Z"*U*X
M9_$SV:?P1] HHHJ30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M )*Q\7?^PJ?_ $=/7?0_@5O1?FCQL9_O>&]9?^DL^@Z***X#V0HHHH ****
M"BBB@ HHHH **** /*_VD?\ DG*?]A*T_P#1@JY\=?\ DB7B/_KS7_T):I?M
M)''PY3) ']HVG7_KH*7XX:K:3?!?Q#$EW;O(;-0$2522=R^]>C23:I?XO\CP
M<2TI8E/^1?\ MQZ!X7_Y%S3/^O:/_P!!%:E97A8Y\.:;_P!>T?\ Z"*U:X)?
M$SVJ?P1] HHHJ30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M )*Q\7?^PJ?_ $=/7?0_@5O1?FCQL9_O>&]9?^DL^@Z***X#V0HHHH ****
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M+K48QY;M).]VD[-WO9>ECTD'-+38P5103D@<GUIU>>>X%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 AZ&OR#_X*)?\ )SFM?]>EM_Z!7Z^'H:_(/_@HE_R<
MYK7_ %Z6W_H%>_DO^\OT?YHY,3\!UW_!+_\ Y+EJG_8+?_T(5^I]?EA_P2__
M .2Y:I_V"W_]"%?J?6><?[T_1#PW\,****\0Z@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "D;[I^E+2-]TT ?-7BR75/%F
MA>-O$D_B+4K&YT34I;.TTRQN#!'$L; *S@<MO!)YX]*]"M?$FN>&?'NCVNHW
M2ZCH?B! +7*@26LPC!VY_B5L$\UROB;PKX?^*_CK7+#1)=7TB_1/LVJ:K8C%
MI,Z8_=2*>'8<#VK3^&_A_2G\?3+JOBR^\2^)M&0Q16]_&(5@4CEXT'#<8&ZO
M9FX.G[W1;6VNE;\3Y.DJBK7B]VES<VC:;OH]=G:RNNS/:Z***\8^L"OGS]G3
M_DK'Q=_["I_]'3U]!U\^?LZ?\E8^+O\ V%3_ .CIZ[Z'\"MZ+\T>-C/][PWK
M+_TEGT'1117 >R%%%% %'6]*@US2+S3KI=]M=PO!*OJK*5(_(U\Y^%&\??L]
M&YT5O#L_BSPSYS26UQ8#,B ]05&<>N,8SFOIDC-)M]ZZ:5;V<7!J\7T.#$X3
MV\XU82<9QV:[/HUU1\_>(?BYXS\?:;/HOAKP'JFGS7:&%[S4T,<<2G@GD"O2
MOA%X _X5KX%L=$:43SINEFD7[ID;DX]J[?8#]*Q_%_\ ;*^'[L^'Q;MJX7,"
MW7^K8YZ'GTS52K<\52A%15_ZNS*GA72F\15FYR2LM%HNR2[GRY\8O"NI:3\5
M;SPYHI"6/C8PM*B]4VOER!]03^%?26J>'+NS\!2:-X<NAI-Y!:""RG501&R@
M;>".G&/QKAOAO\-/$MUXWF\:>.9[635EA^SV=I:<QVZ]S]?\37L03'>M\37O
MR033Y=^S?_#:')E^$M[6K)./.W9/1J/Z7;;/!/#OQ>\4>&M$31?&7@G6M2U2
M$&%KJSMO.BNAV)(&.1UI_P #O .JP_$#Q%XSO-&'ABQU!/+M=*P P&1EF4=/
MNYQZFO=S$#WI0F*REB%RR4(I<V^_Y=#>& ESPE5J.2AM=+TU>[/FWPS+XB^%
MOQB\3R3>%=2U73];N%,5Y9QED121\Q(&,#O]*TO$'ACQ+\*?BC?^+_#^E2:]
MHNK@?;[&V/[Y&Z[@.IY_G7T!L% 3'>J>+;ES.*U5GYDK+%&'(IO27-%Z>ZW>
M_KOU/ O$WQ0\;^/[:+2/!GA?5M"N)9%$VJ:E!Y2P*#SC<,']:T/V@_"VMZI\
M%[+2X%N->U:*XMC-)#%EY" =S[5''->V", YH,8(J%B%"490@ERN_P#3+E@)
M585(UJCDYJW9)>2V^9E64<B>%[>%HV646:H4/7.P#'UKRW]EGP]JGAKP1J%M
MJMA<:?.]_(ZQW"%&*D#!P>U>T;.* F,\UBJK4)0MO9_<=<L,I5J=:_P)K[[?
MY'A\_AK53^U,FL_V?<?V4-,\O[9Y9\K=MZ;O6I?#?A[5+?\ :4\1:M+I]PFF
M36"I'=LA$;-\O ;H:]K*Y-)Y?.:V>)DU:WV>4YEE\$^;F?Q\_P ]K>A\_7VA
M>(_@U\3];\2:/HL_B'PWKK![NWLANF@DR3D+U(!9NGK3O$7BKQI\8[W3=+\.
M:/J_A+3(YUFO-5O%:W?:,_*HX)]Q]*^@-G/6D$8%5]:NU)P3DM+_ / (>7-)
MTXU&H-W:TZN[2>Z3&VT?DV\<>XOL4+N8Y)QZ^]2T@&!2UPGKK0****!A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 AZ&OR#_ ."B7_)SFM?]>EM_Z!7Z^'H:_(/_
M (*)?\G.:U_UZ6W_ *!7OY+_ +R_1_FCDQ/P'7?\$O\ _DN6J?\ 8+?_ -"%
M?J?7Y8?\$O\ _DN6J?\ 8+?_ -"%?J?6><?[T_1#PW\,****\0Z@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D;[II:1ON
MGZ4 >,P-X@^#NLZVL&@3^(?#>IWTFHI-IY!N+:23'F*R'&5R.,=OT98WMY\2
M?B-X>U:Q\.7NB6VE,[7&H7\8B>52I'E 9R03SS6=H?A+6/&_B?Q3)?\ C37-
M%UNSU*2.WLK.X40QVO\ RR;RR/F# ]<]O6NU\*^&/'^@ZY;C4?%EGX@T4$B1
M;BQ$-P!CC#+P?QKUIN,;NZY[>?;[F?-4HU*C45&7L[Z+W7:S];I7]7YGHU%%
M%>2?2A7SY^SI_P E8^+O_85/_HZ>OH.OGS]G3_DK'Q=_["I_]'3UWT/X%;T7
MYH\;&?[WAO67_I+/H.BBBN ]D**** "BBB@ I",TCD@<5YU\0/C9I7@758='
MCM;O6]=F&Y-.L$#.!V+'H*TA"51\L%=F%:O3P\>>J[(]$(V]!6+<^-='L_$]
MKX>EOHTUFYC,L5H<[G0 G(_[Y/Y5Y]I/[0=N-?M-(\2^'M2\)W-XP6VDO@#%
M(3T&X=#7$?%+Q/8>$/VFO#>KZC*R6=OI#D[%+,Q(F554#J22 !753PDW)QFN
MC:\['FU\RI0IJI2::YDG>ZLF^NQ])J<YIU>'WG[3 T22&?6?!FNZ1H\[A8[^
M>-<8/0E>WYFO66\4::GAY=<>\B32C"+C[2QPOED9!_*L*E"I3MS+<[:.,H5^
M90EMOT^>O0UZ*\6C_:/?5O.N- \%ZWK>E1$@W\2!%;'4J#U'Y5W'P^^)^C_$
MG3Y;C3))(IX&V7%I<+MEA;T9:<\/5IQYI1T_K?L32QV'KRY*<[M[;Z^G?Y'8
MT5X[/^TIHR:GJFE6^E:E>ZQ9W36L=C;QJ\DY'5EP>%]S4>D_M+Z2-5NM-\3:
M5?>$KV&$W"QWZAA(H[+CDL>PQS5_5:UK\IG_ &EA+V]HOQM]^Q[-17B%_P#M
M-+HTD-SJG@W7-.T29PJ:E<1@#GH2G8?CFO4[[Q?I>G^&CK\]['%I7DBX^T'H
M4(R"/KZ5G.A5IVYH[FM+&X>MS<DOAWZ?/7H;E%>*1?M'SZI%)>:-X(US5M(C
M)S?(@4,!W5>_YBN[^'OQ0T;XEZ;)=:3*ZR0MLGM9UV2PMZ,/ZTYX>K37-):"
MI8[#UY<E.=W\]?2^_P CL**13D4M<YW!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% "'H:_(/\ X*)?\G.:U_UZ6W_H%?KX>AK\@_\ @HE_R<YK7_7I
M;?\ H%>_DO\ O+]'^:.3$_ ==_P2_P#^2Y:I_P!@M_\ T(5^I]?EA_P2_P#^
M2Y:I_P!@M_\ T(5^I]9YQ_O3]$/#?PPHHHKQ#J"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *1ONGZ4M(WW3]* /G3Q[:_"
MK3O'%[-/K^JZ'X@WDW-WILLQ6-R<X9MK(IYZ5T7P\U#/B*Q73_BM'XDL')4Z
M;>1QO.XQV<$$$?2N<U71+[3M!^)/AFZT>XDNI[F?7K2^2+='<Q,ZL$#?WU/&
MW_)LZ'K7A'5/B=X/U'PE%9W&IWL3+J4-M$!Y*;,EG 'R,&X_.O<:YJ=KMV6^
MC6U^VA\=&7)74FHQNUHN:+UE9];2:TOIUN?0E%%%>&?8A7SY^SI_R5CXN_\
M85/_ *.GKZ#KY\_9T_Y*Q\7?^PJ?_1T]=]#^!6]%^:/&QG^]X;UE_P"DL^@Z
M***X#V0HHHH **** &M7SW\#(DU7XU?$34+Y1)J,,PCC+\E$SCCTKZ#D. *\
M<\8?";Q!IGCB;QEX$O[:TU*Y7;>:?>@B&Y]\@'!_SFNW#RBE.$G;F6_S/)QU
M.;G2K1CS*#NTM]5:Z]#O?'WA[PUKVG6P\316KVD,P>)KI]@$F.,'(_R*\=\9
MZ;:ZE^UCX*BE1)8$TPRJI&5)43E3^! /X5IZE\-/'GQ7U'3U\=SZ9IN@V<PG
M.FZ:S.T[#^\3P!^)[UT.J_#+4[KXY^'O%UN]JNCZ?8-:O&7(EW%9 ,#&,?..
M]=%)QHW3G=\LO17_ %9PXB-3%M2C2LN>&^[2>K:[+S+O[0T,<OP;\3[T5MMM
MN&1G!##!KQWXBWEQ%^REX4CB9MEP88Y3GJNYL GTR!7OGQ5\+7OC7X?ZUHM@
M8DN[R'RXS.Q5 <CJ0#_*L33_ (31ZG\'+'P7K^PR1VPC>6W.0CAB0RD@=#CM
M4X>M"E"',]I7^5BL;A:N(KU%!;T[7\[[')>&-3^+6E^'M.M=-\'^'/L,<""'
M%Z1E=HPW#=^M5OACX,\::?\ &/4O$6LZ;IVE6M_;%;FVL;M7&_C:VW)/K5K1
M?#GQC\"Z<NB:9-H>NZ?"-EM>7CNDL:=@1[?C70_"GX3:EX5U?4?$?B35?[5\
M1:A_K#"6\F)?[J@XS^5:3G&,9M..O:[;_'0YZ-&=2=)24_==WS625NUEKVT>
MQQW[/6FV[_%3XF7S1J9TO?+1R.5!=R<?7C\JC^.%A;WW[0/PQCGB61)'&X,N
M=P67(!]1UKM_A/\ #75O!'BWQGJ6H26SV^KW8GMQ Y+!<L?F! P>14?Q"^&>
MK^*?BMX+\26<EJNGZ,Q-RLKL)#\V?E !!_.G[:"Q+GS:<MK_ /;O^8?5:GU"
M-+D][GO;RY[W^XL?M(Q(_P &?$&Y0V(U(R.A#BO(OBK<R_\ #._P^MMS?9;J
M:".XYX*@$C->\?%WPE>^.?A[JVB:<T*7=T@6,SL53(8'D@$]JQY?A%%K_P '
M]/\ !^MNBW%O;JGGVY+".5>C*2!FL\/6A2A#FZ2O^&YMCL)5KU:J@MX63\[W
ML=SH5C;:?H=C;6D:);1P(L:H,#&T8KPGPE%'I'[67B&STX!+.YL/.N(TX7S/
MD/..^2:U=+T3XS^%-.CT2RGT'5[6(".#4KIW61$Z LN.<#V-=)\)OA%-X'O=
M2US6M0&L>)=3.;BZ52$09SM3/.,U*Y:$:C<T^965OS+G[3%SHQC3<>1W;:M:
MRM9=[^1Z@O2EI%X44M>:?0A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% "'H:_(/_@HE_R<YK7_ %Z6W_H%?KX>AK\@_P#@HE_R<YK7_7I;?^@5[^2_
M[R_1_FCDQ/P'7?\ !+__ )+EJG_8+?\ ]"%?J?7Y8?\ !+__ )+EJG_8+?\
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M?7+31[W3'^_?64K*Z\<'8>.?K7I5.51?)RVMYI_I<^?H>TYU[7GYD_[LEO\
M-K3T/1****\L^D"OGS]G3_DK'Q=_["I_]'3U]!U\^?LZ?\E8^+O_ &%3_P"C
MIZ[Z'\"MZ+\T>-C/][PWK+_TEGT'1117 >R%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)))]J[#]EW0--\2_&/\ :<TW5;&#4-/G\1Q"6VN(P\;@2W3#(/7!&:ROV&?
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M5%:8L2H.5^^O7'6OH/:/2C:!VJ9XJ<TTTM4D_E;_ "!4TCY#_:U_9L\<>/\
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MQG;M&!Q[8QR:^G=HQTHVCTH^M3Y=4KVM?K;;TV\K@J:3\CY]_9U^$_B?X?\
MQ7^-NMZW8Q6NG>)M:2\TN2.X20S1!IR254Y7B1.#SR?2HOV4_A'XI^%__"S?
M^$BL8[/^V]?GO['9<)+YD3%B&.TG;U'!P:^A\48Q4RQ,YJ2?VK?AL-02L?,/
M[/\ ^SUK6B_#[XH>&/&U@EG:^)M5NI8A%.DI:"0MAOE)P>0<'FL7P):_'_\
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M<G&*^P=<^"G@CQ3HFAZ3K?ARPU>RT:'[/8Q7<>X0)M52%],A%_(5W2@*, 8
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M^&,?#?\ T.WQ _\ "EGH_P"&,?#?_0[?$#_PI9Z^@J*T^MU_YV+V<.Q\^_\
M#&/AO_H=OB!_X4L]'_#&/AO_ *';X@?^%+/7T%11];K_ ,[#V<.Q\^_\,8^&
M_P#H=OB!_P"%+/1_PQCX;_Z';X@?^%+/7T%11];K_P [#V<.Q\^_\,8^&_\
MH=OB!_X4L]'_  QCX;_Z';X@?^%+/7T%11];K_SL/9P['S[_ ,,8^&_^AV^(
M'_A2ST?\,8^&_P#H=OB!_P"%+/7T%11];K_SL/9P['S[_P ,8^&_^AV^('_A
M2ST?\,8^&_\ H=OB!_X4L]?05%'UNO\ SL/9P['S[_PQCX;_ .AV^('_ (4L
M]'_#&/AO_H=OB!_X4L]?05%'UNO_ #L/9P['S[_PQCX;_P"AV^('_A2ST?\
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M=_U9K"S>C?\ 7R-RBBBO/-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1KHGBL%V"@G19<<_A7T;]@@_YX1?]\"C[#!_SPB_[X%;5:]"M-U)4W=_WO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)IW_ ("1_P"%'/A/^?<O_ E_\B%JG=?=_P $^=/^'C_P<_Y^-<_\%;_XT?\
M#Q_X.?\ /QKG_@K?_&OHO_A#]!_Z FG?^ D?^%'_  A^@_\ 0$T[_P !(_\
M"CGPG_/N7_@2_P#D0M4[K[O^"?.G_#Q_X.?\_&N?^"M_\:/^'C_P<_Y^-<_\
M%;_XU]%_\(?H/_0$T[_P$C_PH_X0_0?^@)IW_@)'_A1SX3_GW+_P)?\ R(6J
M=U]W_!/G3_AX_P#!S_GXUS_P5O\ XT?\/'_@Y_S\:Y_X*W_QKZ+_ .$/T'_H
M":=_X"1_X4?\(?H/_0$T[_P$C_PHY\)_S[E_X$O_ )$+5.Z^[_@GSI_P\?\
M@Y_S\:Y_X*W_ ,:/^'C_ ,'/^?C7/_!6_P#C7T7_ ,(?H/\ T!-._P# 2/\
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MP\?^#G_/QKG_ (*W_P :^B_^$/T'_H":=_X"1_X4?\(?H/\ T!-._P# 2/\
MPHY\)_S[E_X$O_D0M4[K[O\ @GSI_P /'_@Y_P _&N?^"M_\:/\ AX_\'/\
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M^%'/A/\ GW+_ ,"7_P B%JG=?=_P3YT_X>/_  <_Y^-<_P#!6_\ C1_P\?\
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M^@_] 33O_ 2/_"C_ (0_0?\ H":=_P" D?\ A1SX3_GW+_P)?_(A:IW7W?\
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M?^!+_P"1"U3NON_X)\Z?\/'_ (.?\_&N?^"M_P#&C_AX_P#!S_GXUS_P5O\
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M.?\ /QKG_@K?_&C_ (>/_!S_ )^-<_\ !6_^-?1?_"'Z#_T!-._\!(_\*/\
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M_P '/^?C7/\ P5O_ (T?\/'_ (.?\_&N?^"M_P#&OHO_ (0_0?\ H":=_P"
MD?\ A1_PA^@_] 33O_ 2/_"CGPG_ #[E_P"!+_Y$+5.Z^[_@GSI_P\?^#G_/
MQKG_ (*W_P :/^'C_P '/^?C7/\ P5O_ (U]%_\ "'Z#_P! 33O_  $C_P *
M/^$/T'_H":=_X"1_X4<^$_Y]R_\  E_\B%JG=?=_P3YT_P"'C_P<_P"?C7/_
M  5O_C1_P\?^#G_/QKG_ (*W_P :^B_^$/T'_H":=_X"1_X4?\(?H/\ T!-.
M_P# 2/\ PHY\)_S[E_X$O_D0M4[K[O\ @GSI_P /'_@Y_P _&N?^"M_\:/\
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M FG?^ D?^%'/A/\ GW+_ ,"7_P B%JG=?=_P3YT_X>/_  <_Y^-<_P#!6_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&ZE>@['L/3?#WP\^)WC_ %CQ/KWC?5O^$2AU#2)M'TOPUH]X;B*Q\Q2#<S.
MHEE!/&!@#\,<7\-?A[\9? OPYM_AYIO@SPEHUQ9PO;IXV>_\Y) 2?WPM5C#F
M4@YRS ;N3QP(C*-W*<DY*W9?BU9VVT0VGT1C_#K]I[Q!X?\ V</&'BC4[U_%
M=QIFN2Z+H&H7D(ADU#+*L+2JH'(+@D]<?2NMN/@C\7X?#%MXFL_BQK=UX_PE
MS)I%RT2:,V<%H/("< #C=G/%9ND_LJ^(+G]DS2? EU-;:=XSL+PZH)VD\Z&6
MY6X:12[ =&7:"<<?A732Z3\;/BQJFAV?B"RL_AEH&GW"7&HS:1JYNKK4RO\
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M %# 9 KT,>&OCMXC\.V/@^7PYX9\'^2D=M=^,K2]6YDEC4 %X+<("DA ZL<
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MEH5&WB-6(7'UYIGQ0\;)K_Q,UC3?$7QGE\%Z#8XCL]'\%S8OY#W>>7RW*G/
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***YNT^)'A2_\
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M+;NP6?7=)AE@LKIF/[E9 0^!G&2"1FNF'04=:6AMO=A8****0PHHHH ****
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MRH?7:"'4GD$_GW_[.?[=_A+P3\.M.\'_ !#CO]!\0:#$+)]ULS"54X&0.5;
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M7X@ZM\*/BG\1OA+K6H2ZCHWA^*ZN[3><^4;=]L@3T#!@<>H/K7-?LP?#&/\
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MZ18:;-<?ZZ2TMDB:3O\ ,5 )[]?6M:BB[[BLC(TSPCH>BV]S;Z?H]A807/\
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MNDP0^HW XK4HI7=[W"Q'%;QP1)%&@2-%"JBC 4#H .U<GJ/P=\!:QJ1U&_\
M!/AV]U G=]KN-*@DESZ[RA/ZUV%%"DX[,&D]R&VLX;."."")(88U"I'&H55
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>glyc-20241231xs4037.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4037.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $_ ZD# 2(  A$! Q$!_\0
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M*-G?3NM=%]P>TGKH>B?LI?%[5?C%H?BO4]1U*+5+2VUF6WL)8;80C[..4!
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MYE_NIZGFOG3]GWQ%\4/BS\3_ !IJ.I^/5@\*>%/%>H:2FC0:7#NO8E)"J\P
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MN@*S/CA0'P, '@Y)R",H8*<K:I7]>K:[=T-U4NG];GWC<0I<0O'*JO&X*NC
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M'-8OA;]L^^2W\9C5X_#7BN71=-BU"VN/!EU,UO*TDHA6!VG4#.\K^\1F7!Z
M\5Z-J/[/.L^*?#>K:'XO^*&O^*+&\6,P"XL+" VDR.'25?*@7?@@95]RD=JK
MC]ENVUR[U6Z\8>,-9\57&JZ2-'N%>."TBCB5]\;0)"B^4RMAL@\D9.:"CA/B
M_P"+OB[:?#663Q)HNB6=P=1TBZTN[\.ZG-''/*]Y&#93;P'4XQF0 H0QXXQ7
MJGPG^)'BW5_'7B;P7XUTS2+36=(M;74(KK0YI'MYK>X\P*I$@#!U:)@3T/!
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MKA[1D4G9*X78S?[AX[XKI[#X*6446@+>:M?Z@VCV=Q8Q/($0R0RJ$VL0/X5
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MSKH5A#)XL\<W VVWA_3CN96/0S.,^6.^.6]N]:4Z<ZTE""NQ-I*[.9\.#?\
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M5K;]D2UM[:WTH>-]:'AFPU==;T_1X[:U1(K@2&0^;((M\PR2!N((SU-;%O\
MLT0V&O8L_%^N6/@XZI_;;>%;1HXH#=[]Y_?*HE\DN=YBW8)QGCB@9Y-^S]\7
MO'_A;P3\-I==T_3=0\&^(-3DT2*[>^GEU=9F,S1SR;E*%&\HC;G*Y!R>0.Z_
M;#\>:9IFE>$/ FI>*8_!UOXQU,Q7^KO=?93;:=;IYUP4ES\CN1#"OJ9378:9
M^SOH^F>"_!/AM-4U![?PKJR:Q;3N4\R:11* DF%QM_?'I@\#FNDC^%NG2_%B
MY\?W5Q/>:B=(31K:UF"^3:0"4RR%!CEG?9N)[1J.U CY8OOB2_QH_9N^%MK?
MZT=0O!X\TSPGXAN])OY46^,5SY,K+-&RL5FCV2Y4CB6O0]8\(VW[./Q1\$'P
M5>ZK%HOB)[RQU'0K[4[F_AD9+62:*XC\^1S&RM$ 2I (8Y]:ZKQS^ROI'BW7
M/$&KV'B'5?#E]JNIZ9K8-B(GCM;^Q!6.XCCD5DW.NP.&!#>4IK6\'_ 1=(\8
MP>+/%?B[6OB#XAL[>2UL9]82VBAL8Y!B7RH8(HT#N/E9SDD<9Q0!Y5\+?@=I
M_P 9OA'I'Q$UWQ'K47Q#UNV.I1^)K75;B,:8S,2D<$(E\I8XQ@;",-@[LYKW
M+QYX^_X51\);CQ%>RGQ%<V%I& \>R+[=,0%4C&53>QSQP,\5Y_-^RF([*]\/
M:5\0O$FC_#R^EDEN/"5LEL8E61BTD,,[1&6&)B2=BMQDX(S7J7B/X::#XG^'
MD_@JXM6@T&2T6RCAM7*-#&H 0HW4%<#!]J /-9/B3\6_"/AC7-2\5^%O"@$5
MFEU9:A:ZW]ELHV9@&BN6G&Y=@.XNO#8P #7G>A_ME:_-H?C4?8_"_BS5] BL
MKBWN_#MU<1Z?>"XF$0CW2J6#*3]X;E/Z5W6L?LH?\)=I%S!XJ^('B+Q%J"+
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MD/8.^T&-0?[N<U'J/QR\2_V3?^(-.\/Z?<>'(;X6$;S7;)<%@^PR%0I&W/&
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M>VD/\,C#D=>3C%8=E\:U_P"$\\8Z3?:;=P:5H5J)Q<BV;)V@ERS$X ;C9_>
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MMVN)8TGA< >6TB ,C8'49QCKSFI?^%-ZF_@NZM9-!\.37=W?"XGT^>>YD#Q
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MT@&8XD*[9 V% 8'Y0<UZ!#X$\9^'-3N=6\.V^FW?]MZ7:VUU#J4C1-:2QQ!
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MJ0BA<_I7B9KBYTHQA!V;O?O;^KG=AX*7O21KT445\@>@%%%% !1110 4444
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M<7Z8K*IB74CRM6_KL;X? QHU/:1E?Y+\]UOL+1117&>L%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >;?M!?!K3?CK\--2\,WP$=PZ^=8W>,M:W*@^7(/QZ^H)'>OAOX=>
M(-1N(]1\,^(XS;^+?#DOV+48F/\ K O"2@]P1@_D>]?I6QP:^/?VVOA!>:/>
MV7QD\*6V_5='3RM;M(UYO;+NQ ZLGKZ?05[F68OV4_8S?NO\'_P3FKT^>-UN
MCA:*J:-K%GXBTBSU/3Y1/97<8DCDS^A]".E7#U_PKZ\\LHZYHEGXET6\TK4(
MA+9W<9CD4C./1A[@\UZA^Q+\7KNW>]^$'BJX\W7- 3S-+NY6/^FV6?EQZE 0
M/H1[UY[CC-<?\0-&U1)=,\7>&)/LWB[PY+]LLW3@SQCEX6]01GCZCO7%B\-'
M%4G![]/4UI5/9ROT._\ VM?AM)\$OB4GQ5T>W?\ X1+7I%MO$UM'R()R<)<@
M>A)YQWR/XJSHY$FBCDB=9(I%#I(IR'4C(8?4<U]2?#OQIX7_ &JO@@MS-;QW
M.F:Q:M::E82$%X)<8DC/HRGD'V!]*^'-2DN/V8?$=]X"\>O<PZ3;2-)X?U]H
M&DANK,D[48J#AE].QXZ 5P9=B')/#U/BC_7X'17I_;B>@C.>.M<KXN^(MEX6
MOK;2+2TG\0>*;ME2TT+3T,DTC-]W=C.T?K6"VK?$3XR:#KDOPA\.75SI>G6D
MDTVOW:F$SE5)\FU#=9#V[_[M?&7P*_:0\1?!OXVZ'\0=TEQ]EF:._L'.?-@?
MY9E.>=X!/)Z$5T8O'TL,N7>7;_/^KF=.A*>LM$?L1^QS\$==^%?AC7=:\7+'
M#XK\47@O;NTB.Y;5 "(XL]"P!.<>U>]/K>GQ:K'ICWD*ZA(AE2U+CS&4=2%]
M*\NUW]IWP1%X&A\0Z#XCT+7))X([B&P&KP13,C@'E2Q(8 \KC.1BOG7XD_%V
MZ\=>,K#Q%I]M)H5U90A(F6;<X.<YR !CVKXRM5E6FZDMV>I&-E9'V^-3LVU
MV'VJ'[:$\PVXD'F;?[VWKCWJV.!7PU\,/BW_ ,(7XWOO$NNQ76M7-U"8WE#K
MY@)/OV^E?8_@KQ2/&/ARTU=;"ZTU+E=RV]VH60#UX]:S&U8H?%CP#;_%#X=>
M(?"MS(8(]5M'MQ,!_JW/*-] P!_"OSRL]8UGX.:G9^ _B9IS^']3MU$-CJ^=
MUEJ$0.$(D' .,#T]<&OTW]Z_('_@J+^U#+\0OBC;_#SPY>JNA>%)2]W<P'/G
MWQ&&4G^[&#MQ_>)]J]/!8UX1M-7BS"K251'T,04QG'(R#GJ/8T@'3CCT%?./
M[,K?&*?X-2^.HO#,WB/P#:73V[6\<A-UL3&^>V7J8U)((&1E6[ D>@W/QZT7
M6K5;'P;'>Z_XJO?W%AI4=DXE$S?*#(.@"GG )SCWK["E7IUH\]-W7Y>IYDJ4
MXNS1O_\ "*WWQ_\ BE8?"_297BTJWVWWB:^0\16X((AS_>;CCZ=LU]C_ !T^
M*>C?LR?!HW-C:1QO;Q)IVBZ7'QYDNW;&@'H,9/L#5#]F+X)6_P"SS\*Y&UN:
M)_$U_NU+7]2D<',N"2N_^Z@)'UW$=:^4?$_CF;]I3XOW'C:=6_X0WP_(UEX>
MMF^[<N/OW# ]<GI_P'WKP7?,L39?PX_U^)VJU"G?J5OAUX8O-%LKS5=<D-WX
MIUR8WNIW+==[<B,>@7/3_"NLI>3UY-)7TJ5MCSMW=A6=XF\167A'P]?:SJ#;
M;6SC+L"<%V_A0>Y/%:0!8@#J>E8_PF^'Q_::^,T<$H+_  ^\'3K-=/M^2_O1
MRL?/!48Y]O\ >K*M5C1@ZD]D5"'/)(]F_8D^"M[I=C?_ !4\6P;?%?BA0]M"
MXYL;(X*1@?PE@%)'H%'4&OJ^F(BQ(J(H55& HX %/KX"M6E7J.I/J>S&*BK(
M****Q*"BBB@ HHHH **** "BBB@ HHHH YWXB:M>Z%X&US4--3S+ZVM7DA4#
M/S >E?/%I>^3XB\"ZC!XMN_$^H36L]Z]M=SK-Y<WED_* ,J,\;?:OJ:5%DC9
M& 96&"#T(KGM-\!^&M'N!<6.@:9:7 <RK-!:1HP<]2"!G/O790KQI1::U?\
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MSWS6/-\"M!DT>ST^*ZU.T^QWTFH07-M<A)HY7.6PVTC!^E.%;#Q?P_AZ_P#
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M /Q5?2]%'M,/_P ^W_X%_P  %&??\#Y;/_!1'X; G_B1>-/_  1G_P"+I/\
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M%%% !1110!D>+?%.F^"/#.IZ]K%P+73-.@:XN)2,[44>G<]J\"\<_M):[<>
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M.>F* -KPI^TC;>+-4LI+?P;XFA\*:D\T6G>)WM4:VNFB#,Q\I',T:,$;8SH
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MAQ^SIJ?@CQ7X5UZZUJSU"^M5U^[UJ6*W>(75]J=Q!.[0ID[(T,14 G.,'N:
M#PW^UEI?BL^'Y(O"_B'1]'\1-+8Z;K6I1PI"=0C20O;,@D,@*F*1=^TH60@'
MO7._!+]J'4M6\$^#QXTT?689-;::QM_%C06ZVEY>K)(%C6.-RR A0JLR!688
MXSSKV?[->LV_@7X::&^L6+7'A7Q+=:W<RA'"3QRO=L$0=0P^TKUX^4UC>#/V
M=/B'::)X+\*>(=?\/MX4\*WAU*WGTR&;[;=RJ[O#'('^145G!+*26V@8')H
MVM#_ &EUM=!\*6&FZ%XJ^(.O:W9WE];[;:SM96C@N&C?S?WB11XZ* ?F '\1
MKHT_:,36_#VA7_A3P1XD\57FK0RSFSMHHK=;,1L4D6>>618D<," NXEL<#'-
M9WPL^ 6K^ M8\(7UWJMG=#1M'OM.G6!'7S7GNC.K+GH #@YYS7"ZC^REXH-M
MX:MS+X8\4:=IIO#+HWB$W7V$2S3M(ER(T.V5U5MI61<'LPH#0VV_:?O?%7B_
MP/#X;T?4!X:UO3=1N+ZX9(!/9RP !@0SX/EG.=N0V5P2,UK:#^T>LGAOPU:Z
M%H7B;XE:[=:0FKW(MX+2VGBMF)59)\R)$LCE6VQ(26P<#%<UX-_9;\5^"--\
M&06FKZ%/+HZZG9W:>3+#$;:[YW0J,[70@ (?EQWJ_P"&/V?_ ![\)AH^I>!]
M5\.76M?V%!HFJ0ZY'.MO(868Q3Q-'ELC>04(&[CYA0&AO/\ M8:1K-SHMEX0
M\+Z]XSU+5](.M6]KIP@BV0+*8I%E::5 CJRD;>23P.]0M^USHFL)H$?A+PQK
MGC"_U31?^$A;3K V\5S!9!VC;Y)95\V4/&Z^7%N.4/(RN4^#O[-UW\)_&FCZ
MLFM1:C96GAU]+N=T3)+/>27;W$LP&2%0F0X7)(]:X&^_9)\6#X<^%_"TL?@;
MQ=:Z9I\MMY.OV=Q UE=-.\@N[6ZA_?*2KJK1Y4?NE(9<F@#ZMT/4TUK1['48
MX+FVCNX([A8+V!H)X@ZA@LD; ,C#."I&0<@\U>KFOAOX8O/!7@/0-!U'6;GQ
M%?:;8PVD^JWF?-NG1 ID;))R2,\DGU)/-=+0(**** "BBB@ HHHH **** .4
M\&>.?^$QO?$-M_8.M:-_8]_)8>;J]GY$=YM_Y;6YR?,B/9N,UT=]=)86<]S(
M"8X8S(P7K@#-?G+\4=?U2/X5_'YX]7OHI;?XE"*"9+IPT">=]U#G*J/0<5ZG
M8^!['X-?M8:;H/AV^U3^SM=\*WESJD=_J$MT;V=%<^<YD8_.2H)(P/0#FO5E
M@HI-\W?2W9)O7YG,JS['TO\ !_XKZ3\:O MGXLT2VO+73KMG5([^-4E!5L'(
M5F'4>M9'BWXYZ?X*@\:76I^'?$,6G^%[1;R>_-D%M[M3CY;=V8!V&>1Q7P/X
M=\#V?A?]D[P=\2].U#5H?%T&O1PVMVNI3".VB:X"M''$&V!3R3@9)/7M7K'Q
M4U.ZO-5_:<BFNYI;>/P[ Z6\LQ,<9(7.U2<#\JV>!IJHTG=7M]S2_4E59<NN
M_P#P#[7\+>(H/%OAS3=:M8Y8K6_MTN8DG4!U5AD!@"0#SZFN'NOCYH>C^&-6
MU[7]+USPS8:?J TY?[5L&BDNY"V%:!03O5CT;BOC[PM!X8\$ZO\  C6OAWXI
MO-4\7:Y-':ZQ!_:TETUS $^82Q,Y"!3P!@#@<5C>/--MO%/P)\:7FM75W=-I
MWC[RH));V15BC=\./O8Q@=^G48I1P$'/5Z-KUW:_0/;.VFY^D=M.MU!%,F0D
MBAQNX.".]3U\*^)-%\'>*?C?X>^'_B[7Y+#X86/AB*ZT2V.LR0V]]*0-TC3^
M9F1E.[!W?P^QKSW4]=UKQ#\$--T6V\4:O<Z);?$^'0]!UR*Z9;B;3RK*"DO5
M@I)PV>,8_AQ64<!S6][>W3H]OGIL5[:W0_2RBN/^&7PUT7X3^$H/#V@1W"6$
M;O*!=7#SR%W;<Q+L2>I-?GK:Z;X/UWP#\=]>\1>,M1M?&OAWQ%J,OA^V.MRQ
M&U8,3"T,.\ F60&,G!.$&-O4X4,-&NY6EHFEMW=MKESJ<MM#].J0]#7YZ_$C
M7;+XIMX9L/$]E/K?BJR\$VNJ7_\ ;OBAM&TBQ9T#?:5CC7S)+@DC< 0H!QVX
M=X5\3ZSX:^!7P3^,5]JE]=Q>'[V2PUF3SGD:73Y)63YESEBN% ST!K?Z@^5/
MFU>GX.W7K8GVROL?9WQ7^+ND?!_2-.U#6;:\N8;Z^BL(ELD5F$DC84D%A\OT
MS]*[=#Z\9K\[_$RZAKOP>3Q]J-S/,WB_QW;7=JL['"V<<VR':I^[D#D>U;OB
MBT\+_$GXI_&.;XK>*KK1M0\,G'AZU;5GLUM8A'N6:%05#L6P.ASFJ^HQLO>V
MO?2_9;>K%[5WV/O9NAJLMC;QW#W*P1K<. K3!!O8>A/6OS]NO&"_$GX=_"CP
M_P".+74_$FNW]I/=0V=_XA_L73+NU1BJ7%W* 9'8 9"IR:Y+1?&.L+^SM;:-
M>>(+BT\)2>.UTG4+NRU"25+>P)!,2SL=WEGYCD]A0LODU\76WY[:^79 ZZ['
MWZ/B]I'_  N-?AO]FO1K;:2=8%QY:_9C"'"$;MV[=EAQMQ[UWE?G]X>T7PCX
M,_:9\::=X%\7/9:/:_#N[6+4GU&2]CT9RT?S)(69@J$B0@$X+'&.E97[/\EK
M\+_BQ\.AJNE+<W6ORR6L'BSPCXLDNX-:<KC?>6<C%MHW;B<1A2<[?EPI+!1Y
M;Q>R3VWT;[_YL2JN]FC]%3TJ.&".#=Y<:1ACD[5 R?4X[TY>N:?7D'4%%%%
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MB"L[2-"T_P /V\D&G64-E#)(TKI"@4%V.2Q]S6C10 R-%C&U5"CT P*?110
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M3[CQKC"L.Q'(KIZSKO7=.L-3L-.N;^UMK^^W_9+2:94EN-@!?RU)R^T$$XZ
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M?!\Q:***\ ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYSFO2D[C&* 'T444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^&/VRO\ DZWX7_\ 8&O/YM62:UOVRO\ DZWX7_\ 8&O/YM62:^ZP'^[4_1_F
M>37_ (C$KGOB+_R('B+_ *\9?Y5T-<]\1?\ D0/$7_7C+_*O1,.I]B?LG?\
M)N7@'_L&)_,U\1_#[_D<_B;_ -C!-7VY^R=_R;EX!_[!B?S-?$?P^_Y'/XF_
M]C!-7S66?[Q6_KJ>CB?@1W-%%%?2GFG,:K_R6OX)?]C.G_LE?I(.E?FWJO\
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MZM'#!/:W9WQ8D \M0 ,+COGGTKO[_P"-4FA6?B.WNM-5M2TLVZ6<)G_X_1*
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MBJCO*VOK\K!11169T!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRT;@CD$?4>U>L5SWQ%_Y$#Q%_P!>,O\ *O2?O+EEJCG3:=TS[N^$7C=_B/\
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M0.Q]PV/B/2=5:U%EJEE=FZA-Q;^1.C^=%G&],'YEYZCBN9MOBOIEY\2Y?"$
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M#2[6.2>V6TD=8P"\*C"QG_9 XQ534/AWX6U+2=/TZ\T*PN-/L.;6"2 %8?\
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M-=?^S19?9?AA8-_:,U]YA9MDSJP@Y^ZN.@[\UV.C_#[PSH.HW-_IVA6-G>7
M*RS10*&8'J/H?05=\.>%='\+)/'H^G6^G)/(995MTVAF/<UG5KQG"4(K=I[+
MS[>IT8;!U*=2%2;3LFMV^VNOH[K;4VJ***X#V@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>glyc-20241231xs4053.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4053.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  N 2$# 2(  A$! Q$!_\0
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M]I,&GP2S2P6ZA(S,P+!1P!D < 4@.6\'7-MH2>-[EE$5K:ZG-,RQ@<!849L
M59TGQE?SWFA"^LX8;77(VDMF@D+-"0GF!9,@ Y3N.A&/>M?3/"UKIIU4>9+<
MQZG*TUQ'<$,I9EVM@ #@@ 8]JKZ7X*M=+N;"7[1<W2Z=&T5E%<,"MNK#!Q@
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)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>glyc-20241231xs4054.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4054.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !% 2 # 2(  A$! Q$!_\0
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M7U[_ +[C_P#B:/\ AM_X_?\ 15M>_P"^X_\ XFO(_P#A%=>_Z &K#_MPE_\
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M(S*2O]Y2.&Z\D5O_ /!54@_M=:ACMH]D/_'37G?["(Q^UY\,C_U$6_\ 1,E
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M4XY"\GN:^F/^">_PM\0_"']FO2-#\5:1+H>NF\NKB>RF92R!I#MSM)'W<=Z
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* I+$=:**!'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>glyc-20241231xs4055.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20241231xs4055.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  C -@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z:U.KPW
M]LC]I.P_9<^">J>+)5BN=:FS9:-92' GO'4E-PZE% +MCLI&1F@#YR_;@_:?
MU?Q)XZE^"OP\\4KX4M+"U;4?'GC.(G&BV( W0JZ\B0AE!"_,S21QJ<LPK4_X
M)>>!=1L=)\=^-M.N-?LOAMXANXH_#6E^(;LSW5PD(99-0E_A1YB1D)Q\I'*J
MA/CWP'_8L\.^'O@9>?&C]H;Q5JTNEZL!XIUCPP'$-M<.'=K<W)'SS,PDR(@5
M :7'-?3>B_MOZ)=6?PF\/>%/ =[-XE\7QQ3Q>$Q-':OHFD#/^F3$*42,1*'1
M/EW+C!'&0H^L:S]<UNP\.:3>ZIJEW#8:=90M<7%U<.$CBC499F8\  #K7PI^
MT1_P4Y;PHGB)?A)X:L_&%AX=N8K34?%.J7!CTQKA\XM;8*5:XF.&("D<1NP#
M*-U=5J/[3FC?'^]\(? ?7_ =WXB\0^+]&CN?&FFZ=>/;1>'(657;SGQN# E?
MDW*PW*"=S $%8^KO /C[0/BAX1T[Q1X7U*+6- U%#+:WL(95E4,5/# $8((P
M0#Q7S-^W[^UAJGP7\/:3X"^'D<FI?%KQDXM-*MK90\EI&QV&?:?XR3M3/&=S
M'A,'E_VC_P!M;1/V5;-?A=\'O"5CK^L^&=,$U[ 9/+TO0;.,  3L&!:0Y4;=
MP)+KDEF"GB/V?T31=2N?VKOC_;%O'GC"2*Q\'>%[& R7,4# )%'9VQ;<TLB\
MKDY"$LQ!=C0%CZ#^'DNG_L*?LEV]_P#$[Q+/J%[8(]]JMY/<M<37=_.Q<P0E
MSEV+':H&,X+' W&OC*/QK\7_ /@H"^K^,O$_C0? K]GC296W7*77D?: #]SS
M,KY\@P 68A%)PJEL@WOVQ9_$7[;?[<&@_ ;0I)H/"/A8K)J\\?W4;:'N;ACV
MVHR0H#_&3_>X]_\ VM/^"?\ H7QDT'X<^'],^(/_  K7PAX;C72K306A$MI,
MS'Y&13*F;@XQD[BW/?.0#YJ_8[@\/VO[<VF>'_V>KWQ#=_#[1;*X/BG7-4OS
M-#JZ;<!_+"JBKYAC$9 #$Y;H#7ZV+TK\E+']JWPY^QIII\'?LZ> X/&6D6VJ
M1Z;K?C#6F??K>I$D>3;",@N0,X*@J,\*<AG^A/VQOVR+S3]"LOA3X,NK;0?B
MAKUBDFOW,URKV_A&T:(/<O/.,+O12P!'( R!N* @'V_97UMJ-NMQ:3Q7,#9V
MRPN'5L$C@CKR#7+:?\7?!NI^-/$'A.U\1V,WB#P_;1W6JV2R<V4;\JTC?=7C
MG&<@$$CD5\F_ K]IWX'?L]_L87^K>#=;O_$FA>#YWT^1;M6BN]2U&4F0;%?[
MJS,S.O'RJ"2"5.?"?VP_V:/A1%\*IOCEXC?Q9\//&GC5%G'@>UO4N7O=0F&Y
M8=K)N&"0[\X49  )4$"Q]B_%7]M_P7X%^+_P]\ :-J6B>(+[Q%<LVIWO]LPP
MVND62J2TTDI)4N<-MC)!;81P67/O_A[Q/HWB[3%U'0M6L=:L'8HMWIUREQ"6
M'4!T)&1WYK\AH_V(_A!^S)\ =!\;?M ?V_J7CK6G)L?!FC7:Q/-(0I2UPJ[B
MPR/,<-A=^ "<;O5?V&_VE-&^%>G?&5+KX26'PS\$^$[?^T=0N]-U2XNF6[!V
M16,GVB1]]PP++\A4!D(91D8 L?5O[8'[9.@?LL^'8(5M'\1^.=4A=](\/P'E
MPN=TTQ'*1+@DG!)VD#H2,;_@GQ\8/BG\>/@_J'C7XF)8QQ:EJ4C:(+.U\@FU
M  ;C/*!PP5B23@Y)XK\_?@=X8U_]LCQQX]^+WQ(O7\)_#^69F\2>)KJ38D>G
M1[2NE6;D<;L(LCCG8 O)D*O^C'C[]JKP5\#OV5M)^(=EHMWI>E3V4=KX:\-W
M=L+2YN&P5MHA%D[$*J'SVCYQGB@#@O\ @HI^V_%^S)X*7PQX7N$F^)6NPG[*
M% ;^S;<Y!N6'=B0513U.2>%PW@OB'X]3?\$\/V5=.\-->RZO\?/'(;7M2_M.
M5IIM/EG4 SW 8DED5 BJ>KJQ.0"#\R_$_5;CPY^TUX0O?'MG<>.OBHTL>OZ[
MI\"F8RZE*BMIVDJHZ)$HMPP&<;W49V@'K=.\*^'_ ![\=-<\9_&'4X;W1O D
MHU;Q]KRN)!J6K.2(='M0#M\M#'Y05,[O+F.[!4J ?=__  31^&?CGP]\)M2\
M>?$?7-:U;Q3XYEBU 0ZQ>/.8+10WD':Q(1G$C.0,?*4&!MP/L0=*^ ?@-_P4
M+\>_%+]H!/".K?#6P\)^"7TJ76?M-U=-%=:9IZH7BNKIF(1$8;#C:N ZD$C!
M/ ?#[_@L'K0U&/0O%GPN?7-:O;\0:9-X5F=(;V%I-BM&DH9G)YVE3AN/NT!8
M_3+5]4M-$TN[U'4+B.SL+.%[BXN9FVI%&BEF=CV  ))]*^;/V5OCWXV_::\=
M>+_&MM#!I'P6M6?2O#MM-;?Z9JDZ. ]Z9<\)PZ[ ",L!G*$GY?\ ^"DG[7VA
M^)?&$'P)L-:N=-\.Q2K-XSU33XS-.Z)\_P!@@1?O2':-VXA0Q4,0 ^.Y^'O_
M  4B\#^'?V:]*G\(_#^]T[5([[_A&?"O@_[0K-?&.--LOF*HPBATWG!.YL9)
M.: L?H#<7$5I;R3S2)##&I=Y)&"JH'4DGH*^;OC%^W!X,^''Q(^'G@K1M1T7
MQ'JGB;45COIEU>&*VTFQ'^MN99<E00,E4."^QAG.,_ ?Q2U/P]^T[\(/&?QK
M^+EWJO@G7=*U#_A';&Q\(ZB9M-\23HG[M+>.8R?,I(#O&Q0A-V =V7^&OV$/
MAM\$_@#H/C'XVVFOZQ\1?$<RIH?@+1KD03W<T@7R;0H$,F_+ R,"-@;&-P 8
M"Q^O'AOQ3HOC#3?[0T'6+#6[#>8_M6G727$6X=1N0D9'IFBOSN_X)M_$SPO\
M)/@1\2/%7B/0[/PC#'XG&EQVFE+//<74VT>5:1QEW,LH9RB[1N8<MG&04!8Z
MO]H?_@KKX$^$OBW4?#/@_P .W/CV_L&>"YU!;M;6RCF7C:C;6:4!L@D!1QP3
MUKX(^+W[9>L_M0_&WP;XT\<>!9=9\%^&64#PCIL\GD2G(:3=*4;EV5-V5Y50
MOO7V\O\ P2PUR[\SP5/\1+#3?A$+UKS[!I6B0QZO>CS-\:W5UMW2%<X#,6 V
MJ0GI]R_"KX4>%O@MX(T[PEX.TF'2-%L4")%&,O(W\4DC]7=CR6/)H#8_)+XY
M?MM>(OV\-;^'/PV\">#1H,D6J&\N='U2Z%Q9WLD2[HEEVJF^)%61BA7D]C@5
MP?PNTWXZ_&/X6?&'QKI%G?VU[<P7=]XG\<W&\7NJPQH#_9=J% $:XWLZQCD!
M%.%55/[5W_PE\$ZIK%AJMSX3T:35+"X6\M;XV$0GAF7.'60+N!^9N_\ $:ZE
M($CC*(BJI))4# ))R3^9/YT!<_*W]EOQ+K'Q.^"_@OX4_ ;X>S:*EH([[Q!\
M4/%-C'*FFZ@R_P"D36:\AIP2RQ,&!50!A>6'SU\)?B?\4/@IHOQNT[P!X5UG
M4/B$;RY;Q%XWOXB]QIFGPMR1DX$[N7=F8MP1M&1N'[J65I!86R6UK#';P1C"
MQ0H$51GL!THCL;>%[AHX(D:X;?,50 R' 7+>IP .>PH"Y_/Q8^%O''@/P3\,
M-:\7>$+W4?!_B_7I]2DTNVWKJ/B6: QLGVERK-Y3>:1&O<&=U&6W']5_V6OV
M>?&.K^)XOC1\<72Z^(4T!BT3P]$H6T\,6C# BBB'RK*5P&/) [EBQKZS:"*9
MXG>)'>)MT;,H)0X(R#V."1QZU-0%S\E9?VC?#_[!O[3O[0VI>)?#.JZ_XYU_
M4HY=$10L-L]E)NEW-,V6"DL@^56SY>.#TX+XQ^._CI\3?@_=?'CQU%>6::K>
M#P_X+\/V$$B0Z>+E'$U['&26#&-3#'(<NS2E@5"KG]?/%GPL\&^.M6T_4_$?
MA31=?U#3\_9+K4]/BN)(,]D9U)'//'?FNH:)"@4J-JX(&.!CI^5 7/P/\1^%
M_C-\#?$FCW5[X9M-%'@[PJFIV2M"R6>A&Y^47#,V!)?-(W\1<^:54?+$JKP/
MPCT&ZU'Q7/>ZUX:U[Q_\1=6>.?1?#%Q;SM'J$DN)%OKQSAI(02KA0?WAY=E0
M'?\ I?\ %Z)_V\OVM]/^&-A.;GX1?#.=-0\3S!CY.H:CDA;8#HV!N3)Z#S\?
MP[OO2WT>QM)XYX+*WAFBA%LDD<2ADB'2,$#A1_=Z4!<_&+XJ> O$'['OB+X-
MZ/XP\+R^.);^^N/&>IZ3IJXM=4UTDI;VQ"H0RP#;\JKSYTN 584SQM\0?'GA
M+]K[0_%?Q]T34O%WC1-)BU7PIX&TV(FTBO9GVVML5)^58R&=B@=FD0 DG<1^
MTTUM#.\3RQ)(T3>9&77.QL$9'H<$C\:HW?A?1M0UNSUFZTFQNM7LD:.UU"6V
M1YX%;[RI(1N4'N : N?ASJEM^T7\6?C]\3/%FNZ7YGC?P7I-Y/=W,]NSVV@B
M.)F6.S W*)BNX0D;CN8R!MP#B+Q7\#_B1H'[&OA7QAXPL+[1/ %OKUNS>&;2
M-X[G4XY_->;4[MF.0Y"Q0Q;A@*P(QG+_ +NA I)  +<GCK3+RS@U"UDM[F".
MY@D&'BE4,K#T(- 7/SV^%/AN\^.OA>R\?_$S08OA5^S;X)@%]X<\"!MB7PAR
MRWE[WD5<952!O8YP027@_9W\-:U^W1^T#/\ M!>,=.DM_AIX7E>V\$>'KL;A
M-)&>+@I]W((#$C^/:HR(\U]V?$?X8^&/BYX7?PYXOTF+7-#DFBGDL)W<12-&
MP=-X4C< P!VG(..0:W](TFRT'2[73M-LX-/L+6,106MK$(XHD' 554  #T H
M"Y^,G@_P?K/A_P '?'3]K3Q.D]MX@34KW3_#"3':T=_/<>1)=+D9)AWE4QT9
M'/5!CFKCX3>/[;QO\,O@MX1\(IJDNBZ7#XPU47T+-9W6H74 E-Y<D</% OE0
MJG(9HG4;O,VU^P/Q\^!FB?'_ .$&O?#[5I9--T[5$4_:+1%WP2+()%D4$8)#
M*"<]>:[3PGH*>&?#>DZ2L[W9T^SAL_M4P DE$:!=S8XR<9(]Z N?DU^PE^S%
MX_\ V@+'7;SQ_!/IWPZU'66U'7[JX\R+4_%MPAREL\AP_P!F1B[-MV[F<@9(
MRGEJ?$_XL^*/&GQ@\5>$O T[^)?#D,MA;ZW)$-G@W1X7*"UT^+ 2&<C(W+E]
MOFE5!9GK]SJK6EC;63SFWMXX&GD,TIC0+YCD %FQU/ Y//% 7/POT?\ 8H_X
M5'XS^%/B'X^:EJ.C^!/&\>Z[U#36V3Z=>2 LEM>.V3&'5AN< XRX.-K&O1?V
MG?!7P^T3]JS4?!.K^ O%FNZ!I&A:9:> ?"O@<K!%?(Z*\[22[68J\CR!G169
MF+$G/-?KCX_^'OAKXH>&YO#_ (MT.Q\1:+.ZO)9:A")8RRG*M@]""."/ZUJ6
MNCV-DUNT%I#"UO#]FB94 ,<7'R ]E^4<=.!0%S\6_B)JWB3X/?M$_#Y_C/X4
M8V&C:$NK>"OAGX7AWV-M<M*T=M:.<Y+"1/,DD'F.S*JG.>._\??$+XS_  $^
M)W_"R?B;\/Y?&?Q)\<^'6M_"CV0<V_A29WD1K1(0KAW"/$Q .[YL9)9S7ZNW
MWA31=6UFPU:^T>PO-5T_=]COKBV22>VW?>\MR-R9[X(S6O0%SX+_ .">O[#^
MN?"W0M)\9?%222Z\2P/-=:+X=G</#HK38\V=E'RFY<  G)V+@9SPI7WI10(*
M*** "BBB@ HHHH **** "F2@-&P/0\&BB@#YK_8.\$Z)X-^'OC=='T^.S-SX
MTU<S2!F=Y-DY1-SL2QPJ@#)]3U)S]+T44#84444""BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990587402032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GLYCOMIMETICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990587731840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,720,178<span></span>
</td>
<td class="nump">$ 41,792,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">371,276<span></span>
</td>
<td class="nump">1,997,904<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">11,091,454<span></span>
</td>
<td class="nump">43,790,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,176<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">11,091,454<span></span>
</td>
<td class="nump">45,316,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">329,304<span></span>
</td>
<td class="nump">868,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,381,744<span></span>
</td>
<td class="nump">5,225,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">66,844<span></span>
</td>
<td class="nump">741,558<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,777,892<span></span>
</td>
<td class="nump">6,835,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,844<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,777,892<span></span>
</td>
<td class="nump">6,902,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at September 30, 2024 and December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.001 par value; 150,000,000 shares authorized at September 30, 2024; 100,000,000 shares authorized at December 31, 2023; 64,483,958 shares issued and outstanding at September 30, 2024; 64,393,744 shares issued and outstanding at December 31, 2023</a></td>
<td class="nump">64,484<span></span>
</td>
<td class="nump">64,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">499,613,448<span></span>
</td>
<td class="nump">494,835,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(494,364,370)<span></span>
</td>
<td class="num">(456,485,212)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">5,313,562<span></span>
</td>
<td class="nump">38,414,401<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 11,091,454<span></span>
</td>
<td class="nump">$ 45,316,475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990590169856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">64,483,958<span></span>
</td>
<td class="nump">64,393,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">64,483,958<span></span>
</td>
<td class="nump">64,393,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990582023088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from collaboration and license agreements.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 14,259,756<span></span>
</td>
<td class="nump">20,071,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">18,249,318<span></span>
</td>
<td class="nump">$ 19,213,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Restructuring and asset impairment charges</a></td>
<td class="nump">$ 7,530,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Restructuring and asset impairment charges<span></span>
</td>
<td class="text">Restructuring and asset impairment charges<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">$ 40,039,378<span></span>
</td>
<td class="nump">$ 39,285,293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(40,039,378)<span></span>
</td>
<td class="num">(39,275,293)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of asset</a></td>
<td class="nump">1,224,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">935,275<span></span>
</td>
<td class="nump">2,375,873<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">2,160,220<span></span>
</td>
<td class="nump">2,375,873<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (37,879,158)<span></span>
</td>
<td class="num">$ (36,899,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average number of common shares outstanding (in shares)</a></td>
<td class="nump">64,477,249<span></span>
</td>
<td class="nump">63,342,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average number of common shares outstanding (in shares)</a></td>
<td class="nump">64,477,249<span></span>
</td>
<td class="nump">63,342,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss and comprehensive income for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990582093008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 54,378<span></span>
</td>
<td class="nump">$ 462,461,251<span></span>
</td>
<td class="num">$ (419,585,792)<span></span>
</td>
<td class="nump">$ 42,929,837<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">54,377,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">35,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="nump">24,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting', window );">Exercise of options and vesting of restricted stock units</a></td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">116,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting', window );">Exercise of options and vesting of restricted stock units, shares</a></td>
<td class="nump">169,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 9,823<span></span>
</td>
<td class="nump">28,697,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,707,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="nump">9,822,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,524,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,524,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,899,420)<span></span>
</td>
<td class="num">(36,899,420)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 64,394<span></span>
</td>
<td class="nump">494,835,219<span></span>
</td>
<td class="num">(456,485,212)<span></span>
</td>
<td class="nump">38,414,401<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">64,393,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">75,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="nump">28,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting', window );">Exercise of options and vesting of restricted stock units</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">5,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting', window );">Exercise of options and vesting of restricted stock units, shares</a></td>
<td class="nump">61,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,697,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,697,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,879,158)<span></span>
</td>
<td class="num">(37,879,158)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 64,484<span></span>
</td>
<td class="nump">$ 499,613,448<span></span>
</td>
<td class="num">$ (494,364,370)<span></span>
</td>
<td class="nump">$ 5,313,562<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">64,483,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options and vesting of stock units exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options and warrants and vesting of stock units exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of share options and vesting of stock units exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of share options and warrants and vesting of stock units exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990582029392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (37,879,158)<span></span>
</td>
<td class="num">$ (36,899,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">35,174<span></span>
</td>
<td class="nump">153,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">46,654<span></span>
</td>
<td class="nump">8,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Asset impairment</a></td>
<td class="nump">365,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">402,649<span></span>
</td>
<td class="nump">856,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock for services</a></td>
<td class="nump">75,375<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,697,546<span></span>
</td>
<td class="nump">3,524,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,678,948<span></span>
</td>
<td class="nump">846,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses', window );">Prepaid research and development expenses</a></td>
<td class="nump">603,737<span></span>
</td>
<td class="num">(553,737)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(538,811)<span></span>
</td>
<td class="num">(102,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">156,187<span></span>
</td>
<td class="num">(1,766,449)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(741,558)<span></span>
</td>
<td class="num">(983,045)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of assets</a></td>
<td class="nump">46,654<span></span>
</td>
<td class="nump">8,627<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(31,098,078)<span></span>
</td>
<td class="num">(34,879,903)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(9,972)<span></span>
</td>
<td class="num">(21,394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">20,028<span></span>
</td>
<td class="num">(21,394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,707,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">5,398<span></span>
</td>
<td class="nump">116,497<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,398<span></span>
</td>
<td class="nump">28,823,508<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(31,072,652)<span></span>
</td>
<td class="num">(6,077,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">41,792,830<span></span>
</td>
<td class="nump">47,870,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 10,720,178<span></span>
</td>
<td class="nump">$ 41,792,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in prepaid research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990586124032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of the Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Description of the Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">GlycoMimetics, Inc. (the Company), a Delaware corporation, was incorporated in 2003. The Company was previously developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation. In July 2024, following feedback from the U.S. Food and Drug Administration (FDA), the Company determined that the regulatory path forward for its lead product candidate, uproleselan, for the treatment of relapsed and refractory acute myeloid leukemia would require an additional clinical trial. The decision to not conduct an additional clinical trial did not relate to any safety or medical issues or negative regulatory feedback related to the Company&#8217;s programs.  In order to conserve its cash resources, in July 2024 the Company reduced its workforce by approximately </span>80%<span style="white-space:pre-wrap;">.  The Company also initiated a strategic review of its business in an effort to maximize shareholder value. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Following the strategic review, on October 28, 2024 the Company entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement) with Crescent Biopharma, Inc., a Delaware corporation (Crescent), pursuant to which Crescent will become a wholly owned subsidiary of the Company (the Merger).  Upon completion of the Merger, the Company plans to operate under the name Crescent Biopharma, Inc. The Merger is expected to close in the late second quarter of 2025, subject to certain closing conditions, including, among other things, approval by the stockholders of each company and the satisfaction of customary closing conditions.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrently with the execution and delivery of the Merger Agreement, certain institutional and accredited investors have entered into a securities purchase agreement (the Purchase Agreement) with the Company, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase, immediately following the consummation of the Merger, shares of the Company&#8217;s common stock and pre-funded warrants (together, the PIPE Securities) for an aggregate purchase price of approximately $200.0 million in a private placement (the Private Placement). The closing of the Private Placement is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement (in addition to other customary closing conditions) and is expected to occur immediately following the closing of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the exchange ratio formula set forth in the Merger Agreement, upon the closing of the Merger (but prior to closing of the Private Placement described below), on a pro forma basis and based upon the number of shares of common stock of the Company expected to be issued in the Merger, pre-Merger Crescent stockholders will own approximately 86.2% of the combined company and pre-Merger stockholders of the Company will own approximately 13.8% of the combined company. After giving further effect to the Private Placement, the pre-Merger Crescent stockholders (inclusive of those investors participating in the Private Placement) are expected to own approximately 96.9% of the combined company and the pre-Merger stockholders of the Company are expected to own approximately 3.1% of the combined company. The exchange ratio will be adjusted to the extent that the Company&#8217;s net cash at closing of the Merger is less than $1.0 million and will be based on the amount of proceeds actually received by the Company in the Private Placement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990588293888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_GoingConcernAbstract', window );"><strong>Going Concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. During 2024, the Company incurred a net loss of $37.9 million and had net cash flows used in operating activities of $31.1 million. At December 31, 2024, the Company had $10.7 million in cash and cash equivalents and had no committed source of additional funding other than the expected Private Placement. Management believes that given the Company&#8217;s current cash position and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date that these financial statements are issued without the closing of the contemplated Merger and Private Placement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the contemplated Merger and Private Placement does not close by the late second quarter of 2025, the Company may seek other strategic alternatives or liquidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990588492720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Accounting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restructuring Charges</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company recognizes restructuring charges related to reorganization plans that have been implemented by management.  In connection with these activities, the Company records restructuring charges, as applicable, at fair value for:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulate when the payment of benefits becomes probable and the amount can be reasonably estimated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-time employee termination benefits to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the detail of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">contract termination costs when the Company cancels a contract in accordance with its terms; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to be incurred over the remaining contract term without economic benefit to the Company at the cease-use date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">For one-time employee terminations benefits, the Company recognizes the liability in full on the communication date when future services are not required or amortizes the liability ratably over the service period, if required. The fair value of termination benefits reflects the Company&#8217;s estimate of expected utilization of certain Company-funded post-employment benefits.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">As described in Note 13, during the year ended December 31, 2024, the Company incurred severance charges of </span><span style="color:#212529;background:#ffffff;">$7.0</span><span style="color:#212529;background:#ffffff;"> million in connection with a corporate restructuring, including a reduction in headcount.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company views its operations and manages its business in one<span style="white-space:pre-wrap;"> segment.  The Company&#8217;s chief operating decision maker is the president and chief executive officer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company has not generated any product revenue since inception.  </span><span style="white-space:pre-wrap;">The Company has no ongoing operations, is not actively performing any research and development, and is preserving cash until the contemplated Merger and Private Placement.  If the contemplated Merger and Placement does not close by the late second quarter of 2025, the Company may seek other strategic alternatives or liquidate. As of December 31, 2024, the Company had no material assets besides cash and cash equivalents and only had </span>six employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies of the Company&#8217;s single reportable segment are the same as those described in Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The chief operating decision maker assesses performance and decides how to allocate resources based on net income (loss) that is reported on the statement of operations and comprehensive loss as net income (loss). The segment-level financial information is the same as the financial information presented in the statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The measure of segment assets is reported on the balance sheet as total assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net income (loss) is used to monitor budget versus actual results. The monitoring of budgeted versus actual results are used in assessing performance of the segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company does not have intra-entity sales or transfers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December 31, 2024 and 2023, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, <i style="font-style:italic;">Fair Value Measurements</i>. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#8212;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#8212;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#8212;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) either on a recurring or non-recurring basis as of December&#160;31, 2024 and 2023. The carrying value of cash held in money market funds of approximately $8.3 million and $38.8 million as of December&#160;31, 2024 and 2023, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did&#160;not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash balances with financial institutions in federally insured accounts and has cash balances in excess of the insurance limits. Cash equivalents consist of investment in United States government money market funds with major financial institutions. These deposits and funds may be redeemed upon demand and the Company does not anticipate any losses on such balances. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash and cash equivalents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i>. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company has elected to account for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A discussion of management&#8217;s methodology for developing some of the assumptions used in the valuation model follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividend Yield</i>&#8212;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility&#8212;</i>Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company bases the expected volatility on the historical volatility of the Company&#8217;s publicly traded common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8212;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8212;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,<i style="font-style:italic;"> Income Taxes</i>. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when necessary to reduce deferred tax assets to the amount expected to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&#160;31, 2024 and 2023, the Company&#8217;s net loss was equal to comprehensive loss and, accordingly, no additional disclosure is presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted this standard for the year ended December 31, 2024 and the primary impact of which was the additional segment disclosures included in Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company&#8217;s financial statements.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40), which requires disclosure, in the notes to the financial statements, of specified information about certain costs and expenses. This ASU is effective for public entities for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact ASU 2024-03 will have on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990588208512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Net Loss Per Share of Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share of Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Net Loss Per Share of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#8217;s stock options and restricted stock units (RSUs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average common shares outstanding, as they would be anti-dilutive: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options and RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,043,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,981,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990587341632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5. Prepaid Expenses and Other Current Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">The following is a summary of the Company&#8217;s prepaid expenses and other current assets at December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,420,642</p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 234,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 401,442</p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 136,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 175,820</p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,997,904</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990587135120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6. Accrued Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the Company&#8217;s accrued expenses at December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51,306</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,824,689</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,561,913</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued consulting and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 790,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 439,192</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,825</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 399,763</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued retention</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,049,105</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,487,258</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,381,744</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,225,557</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990586902624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Operating Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company determines a lease exists if the contract conveys the right to control an identified asset for a period of time in exchange for consideration. Control is considered to exist when the lessee has the right to obtain substantially all of the economic benefits from the use of an identified asset as well as direct the right to use of that asset. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less on the lease commencement date. If a contract is considered to be a lease, the Company recognizes a lease liability based on the present value of the future lease payments over the expected lease term, with an offsetting entry to recognize a right-of-use asset. The Company has also elected to use the practical expedient and account for each lease component and related non-lease component as one </span><span style="-sec-ix-hidden:Hidden_-J90KSXgGUSREtmuyxhLCA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span><span style="font-size:10pt;"> component. The lease component results in a right-of-use asset being recorded on the balance sheet and amortized as lease expense on a straight-line basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a term similar to the term of the lease for which the rate is estimated. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The Company leased office and research space in Rockville, Maryland under an operating lease that was subject to annual rent increases (the Lease). The Company paid a security deposit of </span><span style="font-size:10pt;">$52,320</span><span style="font-size:10pt;"> to be held until the expiration or termination of the Company&#8217;s obligations under the Lease. In April 2023, the Company and its landlord entered into an amendment to the Lease (the Lease Amendment). Pursuant to the Lease Amendment, the Company and the landlord agreed that the lease term for a portion of the premises, consisting of approximately </span><span style="font-size:10pt;">30,000</span><span style="font-size:10pt;"> square feet, would be </span><span style="-sec-ix-hidden:Hidden_QkjKoOCR1UixNvOHv0BEAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extended</span></span><span style="font-size:10pt;"> from November 1, 2023 to January 31, 2025. However, pursuant to the Company&#8217;s strategic review and restructuring plan adopted during the year ended December 31, 2024, the Company abandoned the leased space and determined that its right-of-use-asset was fully impaired. As a result, the Company recognized an impairment charge of </span><span style="font-size:10pt;">$0.4</span><span style="font-size:10pt;white-space:pre-wrap;"> million, during the year ended December 31, 2024, representing the carrying value of the right-of-use asset.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;white-space:pre-wrap;">The Company&#8217;s lease of the remaining premises, consisting of approximately </span><span style="font-size:10pt;">12,000</span><span style="font-size:10pt;"> square feet, expired on October 31, 2023. There were </span><span style="font-size:10pt;">no</span><span style="font-size:10pt;"> additional operating leases as of the year ended December 31, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The components of lease expense and related cash flows were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating lease cost </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 450,274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 944,963</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 516,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 602,416</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 966,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,547,379</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating cash outflows for operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 789,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,017,770</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Maturities of lease liability due under these lease agreements as of December 31, 2024 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Lease</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Obligation</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,401</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,401</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (557)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_vgZVo8BJJ0aed1tCmLrUPw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Present value of lease payments</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,844</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Supplemental information related to leases were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Operating Leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10.0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets obtained in exchange for operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 872,892</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990587135120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2024, the Company&#8217;s board of directors adopted, and its stockholders approved, an increase in the total authorized shares of common stock from 100,000,000 to 150,000,000 shares with a par value of $0.001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">At-The-Market Equity Offerings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In March 2022, the Company filed a shelf registration statement with the SEC, which was declared effective on April 22, 2022. On April 28, 2022, the Company entered into an at-the-market sales agreement (the Sales Agreement) with Cowen and Company, LLC. Under the Sales Agreement, the Company may sell up to $100.0 million worth of shares of common stock. During the year ended December 31, 2023, the Company issued and sold 9,822,930 shares of common stock under the Sales Agreement at a weighted average price per share of $3.01, for aggregate net proceeds of $28.7 million, after deducting commissions and offering expenses. There were no<span style="white-space:pre-wrap;"> shares issued under the 2022 Sales Agreement during the year ended December 31, 2024.  As of December 31, 2024, approximately </span>$66.0<span style="white-space:pre-wrap;"> million remained available to be sold under the terms of the Sales Agreement.  The shelf registration statement will expire on April 28, 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990591062064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9. Stock-based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2013 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan effective in January 2014, and the 2013 Equity Incentive Plan was amended and restated by approval of the board of directors in April 2022 and by approval of the stockholders in May 2022 (as so amended and restated, the 2013 Plan). The 2013 Plan provides for the grant of incentive stock options within the meaning of Section&#160;422 of the Internal Revenue Code (the Code), to the Company&#8217;s employees and its parent and subsidiary corporations&#8217; employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards (RSUs), stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company&#8217;s employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one <span style="-sec-ix-hidden:Hidden_rkMRBeyC_Ee79e86m5b6WA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">forty</span></span>-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 90 days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Authorized Shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The maximum number of shares of common stock that may be issued under the 2013 Plan was originally 1,000,000&#160;shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. Upon the amendment and restatement of the 2013 Plan in May 2022, the existing share reserve was increased by 2,619,622. Beginning on January 1, 2023 and ending on (and including) January 1, 2029, the maximum number of shares of common stock that may be issued under the 2013 Plan will cumulatively be increased by 4% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares as determined by the board of directors or the compensation committee thereof.<span style="font-size:12pt;"> </span> The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is 20,000,000. As of December 31, 2024, the total number of shares reserved for issuance under the 2013 Plan was 14,257,627 shares, of which 1,070,346 shares were available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Stock Options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A summary of the Company&#8217;s stock option activity under the 2013 Plan for the year ended December&#160;31, 2024 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,273,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,756,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,722,543)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,304,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,561,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,024,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2024, there was $915,970 of total unrecognized compensation expense related to unvested options that will be recognized over a weighted-average period of approximately 0.3 years. The total fair value of options that vested in the years ended December 31, 2024 and 2023 was $2,919,122 and $1,710,938, respectively. During 2024, the Company issued 3,250 shares of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">common stock in conjunction with exercises of stock options granted under the 2013 Plan and received $5,398<span style="white-space:pre-wrap;"> in cash proceeds from the exercise of these stock options.  During 2023, the Company issued </span>100,960 shares of common stock in conjunction with exercises of stock options granted under the 2013 Plan and received $116,497 in cash proceeds from the exercise of these stock options. Total intrinsic value of the options exercised during the years ended December 31, 2024 and 2023 was $4,091 and $82,300, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has granted stock options to purchase an aggregate of 2,459,275 shares to certain employees under the 2013 Plan, the vesting of which is subject to performance vesting conditions relating to the achievement of specified regulatory or commercial milestones. The maximum fair value of $650,266 associated with performance-based options granted under the 2013 Plan has been excluded from compensation expense as the completion of the performance milestones was not deemed to be probable as of December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock Units (RSUs)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An RSU is a stock award that entitles the holder to receive shares of the Company&#8217;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#8217;s common stock on the date of grant. In January 2021, the Company awarded RSUs under the 2013 Plan to all of its employees. The RSUs granted vest over four years in equal installments on each anniversary of the grant date, provided that the employee remains employed by the Company at the applicable vesting date. Compensation expense is recognized on a straight-line basis. As of December 31, 2024, there was $9,541 of total unrecognized compensation expense associated with these RSU grants that will be recognized entirely in the first quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of RSU activity for the 2013 Plan for the year ended December 31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 117,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (58,581)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,443)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issuance of Shares to Directors in Lieu of Cash Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2023, the Company&#8217;s board of directors amended the Company&#8217;s Non-Employee Director Compensation Policy to include an election to receive unrestricted shares of common stock in lieu of quarterly board and committee retainer cash payments. The number of shares to be issued to an electing director is determined on the last day of each fiscal quarter by dividing the dollar amount of the compensation to be paid for such quarter that is subject to the election by the closing price of a share of common stock on the last trading day of the fiscal quarter, rounded up to the nearest whole share. Non-employee directors who made such an election received 13,127 shares of common stock in lieu of cash compensation earned for the quarter ended March 31, 2024. All shares of common stock issued pursuant to such an election were fully vested upon issuance and are classified as &#8220;Other Awards&#8221; under the 2013 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In June 2024, the Non-Employee Director Compensation Policy was amended to allow a director to revoke his or her annual election to receive unrestricted shares of common stock in lieu of quarterly board and committee retainer cash payments.  The decision to amend the policy followed a significant decline in the market value of the Company&#8217;s common stock in May 2024. Without the ability of the directors to revoke the prior elections, the Company would have been obligated to issue a significantly greater number of shares than in prior quarters in lieu of the fixed cash retainer payments. Each of the directors who previously elected to receive unrestricted shares of common stock in lieu of quarterly board and committee retainer cash payments for 2024 revoked their elections in June 2024, and as a result there were no additional shares issued subsequent to March 31, 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inducement Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;">The Company&#8217;s board of directors previously adopted the GlycoMimetics, Inc. Inducement Plan (as amended to date, the Inducement Plan). The Inducement Plan provides for the grant of nonstatutory stock options, restricted stock awards, RSU awards, stock appreciation rights and other forms of stock awards to individuals not previously an employee or director of the Company as an inducement for such individuals to join the Company. Unless otherwise stated in an applicable stock option agreement, </span><span style="-sec-ix-hidden:Hidden_36PO8EraXkq8olRkBZDjHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="font-size:10pt;">-fourth of the shares subject to an option grant under the Inducement Plan will typically vest upon the first anniversary of the vesting start date, </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">with the balance of the shares vesting in a series of </span><span style="font-size:10pt;">thirty-six</span><span style="font-size:10pt;"> successive equal monthly installments as of the first day of each month measured from the first anniversary of the vesting start date, subject to the new employee&#8217;s continued service with the Company through the applicable vesting dates. Upon termination of employment by reasons other than death, cause or disability, any vested options will terminate </span><span style="font-size:10pt;">90 days</span><span style="font-size:10pt;"> after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate </span><span style="font-size:10pt;">10 years</span><span style="font-size:10pt;"> from the date of grant. The Inducement Plan was amended by the board of directors on multiple occasions to increase the number of shares reserved for issuance to </span><span style="font-size:10pt;">3,000,000</span><span style="font-size:10pt;"> shares as of December 31, 2024. As of December 31, 2024, there were </span><span style="font-size:10pt;">299,108</span><span style="font-size:10pt;"> shares available for future grants under the Inducement Plan</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A summary of the Company&#8217;s stock option activity under the Inducement Plan for the year ended December 31, 2024 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,590,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,690,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,610,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,452,908</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, there was $235,087 of total unrecognized compensation expense related to unvested options under the Inducement Plan that will be recognized over a weighted-average period of approximately 0.3 years. There were no options exercised under the Inducement Plan during the years ended December 31, 2024 or 2023. The total fair value of options that vested in the years ended December 31, 2024 and 2023 was $919,184 and $601,586, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has granted stock options to purchase an aggregate of 584,200 shares to certain newly hired employees under the Inducement Plan which options are subject to performance-based conditions. The maximum fair value of $825,353 associated with the performance-based options is excluded from the unrecognized compensation expense under the Inducement Plan as the completion of the performance milestones was not probable as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The weighted-average fair value of the options granted under all equity incentive plans during the years ended December&#160;31, 2024 and 2023 was $1.49<span style="white-space:pre-wrap;"> and  </span>$1.96 per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.25 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.25 years</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.79%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">78.36%</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.17%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.60%</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Total stock-based compensation expense associated with stock options and RSUs was classified as follows on the statement of operations for the years ended December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,271,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 909,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,425,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,614,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,697,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,524,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990588298816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">10. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">The components of the gross deferred tax asset and related valuation allowance at December 31 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,811,786</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,746,869</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Research and orphan drug credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54,937,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,152,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Capitalized research costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,861,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,748,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Capitalized start-up costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 339,138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 532,931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Patent amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,699,628</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,324,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Accrued bonus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 704,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 222,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87,097</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Gross deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170,722,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 161,562,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (170,722,283)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (161,351,398)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Net deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_458vb9MY1EioLUCUnC-NFg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211,287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (211,287)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Gross deferred income tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_eA0MLaJIrUmo4aiKeTHJNw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (211,287)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred income tax asset/(liability)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hdWUWzn18kiagf-L_qnDbQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_NTBSQbNInE69YpwADs5_rw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 12pt 0pt;">Based on the Company&#8217;s operating history and management&#8217;s expectation regarding future profitability, management believes the Company&#8217;s deferred tax assets will not be realizable under ASC 740, <i style="font-style:italic;">Income Taxes</i>. Accordingly, a full valuation allowance was recorded as of December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had $351.8 million of U.S. Federal and state net operating losses, $10.9 million of research and development tax credits and $44.1 million of orphan drug tax credits available to carry forward. A portion of the net operating loss carryforwards will begin to expire in 2025, the research and development tax credits in 2025 and the orphan drug tax credit in 2033. Under current federal income tax laws, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s tax attributes, including net operating losses and credits, are subject to any ownership changes as defined under Internal Revenue Code Sections 382 and 383. A change in ownership could affect the Company&#8217;s ability to utilize its net operating losses and credits. As of December 31, 2024, the Company does not believe that an ownership change has occurred. Any future ownership changes, such as the consummation of the Merger, may cause a limitation on the Company&#8217;s ability to utilize existing tax attributes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company files income tax returns in the U.S. federal jurisdiction and the State of Maryland is the only significant state jurisdiction. The Company&#8217;s federal income tax returns for tax years 2005 and after remain subject to examination by the U.S. Internal Revenue Service due to tax attributes available to be carried forward to open or future tax years. The Company&#8217;s Maryland income tax returns for the tax years 2007 and thereafter remain subject to examination by the Comptroller of Maryland. In addition, all of the net operating losses, research and development tax credit and orphan drug credit carryforwards that may be used in future years are still subject to adjustment.  The Company is not currently under examination from any taxing authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company did not have unrecognized tax benefits as of December 31, 2024 and 2023, and does not anticipate this to change significantly over the next 12 months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense is as follows as of December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">U.S. Federal statutory tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Orphan drug credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Executive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990708149792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_ResearchAndLicenseAgreementsAbstract', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_ResearchAndLicenseAgreementTextBlock', window );">Research and License Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">11. &#160;License and Collaboration Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Apollomics</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020, the Company entered into a collaboration and license agreement (the Agreement) with Apollomics (Hong Kong), Limited (Apollomics) for the development, manufacture and commercialization of products derived from two of the Company&#8217;s compounds, GMI-1271 and GMI-1687 (the Products) for therapeutic and prophylactic uses (the Field) in China, Taiwan, Hong Kong and Macau (the Territory). Under the terms of the Agreement, the Company granted Apollomics:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an exclusive license, with the right to sublicense, to develop, manufacture and have manufactured, distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise the Products in the Field in the Territory; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a non-exclusive license to conduct preclinical research with respect to Products in the Field outside of the Territory for the purposes of developing such Products for use in the Territory. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company did not recognize any milestone revenue under the Agreement for the years ended December 31, 2024 or 2023.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company and Apollomics also entered into a clinical supply agreement pursuant to which the Company agreed to manufacture and supply the Products at agreed upon prices. Apollomics has the option to begin manufacture of the Products after appropriate material transfer requirements are met. The Company did not recognize any revenue under the clinical supplies agreement during the years ended December 31, 2024 or 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ResearchAndLicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research services and license agreements, including contracts and arrangements to be performed by or for others. Includes contingent payment receivables or liabilities for achievement of specific milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ResearchAndLicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ResearchAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ResearchAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990587253856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">12. Employee Benefit Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company has a defined contribution plan under the Internal Revenue Code Section&#160;401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. For the years ended December 31, 2024, 2023 and 2022, the Company matched 50% up to the first 6% of employee contributions. All matching contributions have been paid by the Company. The Company&#8217;s matching contributions vest in full immediately. The total Company matching contributions were approximately $211,000 and $248,000 for the years ended December 31, 2024 and 2023, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990591071648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Asset Impairment Charges<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract', window );"><strong>Restructuring and Asset Impairment Charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">Restructuring and Asset Impairment Charges</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">13. Restructuring and Asset Impairment Charges</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July 2024, the Company&#8217;s Board of Directors approved a streamlined operating plan that included a reduction in the Company&#8217;s workforce by 26 employees, or approximately 80% of its headcount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">Employees affected by the reduction in force are entitled to receive severance payments and Company-funded medical insurance for a specific time.  During the year ended December 31, 2024, the Company </span><span style="-sec-ix-hidden:Hidden_gisLThAx_kmBXJrqV8ibaQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recognized</span></span> $7.0<span style="white-space:pre-wrap;"> million of charges for severance and related benefits.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following is a summary of the activity for accrued severance costs for the year ended December 31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Severance accrual, January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Charges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,026,614</p></td></tr><tr><td style="vertical-align:bottom;width:83.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,539,356)</p></td></tr><tr><td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Severance accrual, December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,487,258</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The accrued severance liability of $3.5 million is payable within the next twelve months and has been included in accrued expenses on the balance sheet as of December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company also completed an evaluation of the impact of the restructuring on the carrying value of its long-lived assets. Our evaluation determined that indicators of impairment were present within right-of-use assets and property and equipment. Where impairment indicators existed the Company evaluated the identified asset group and separately compared the estimated undiscounted cash flow for each asset group to the net book value of the related long-term asset. The Company calculated the amount of the impairment by developing a fair value estimate of the asset group that was compared to the carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company recorded $0.4 million of impairment charges related to its facility operating lease and accelerated depreciation on property and equipment during the year ended December 31, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990586648064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Accounting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Restructuring Charges</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restructuring Charges</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company recognizes restructuring charges related to reorganization plans that have been implemented by management.  In connection with these activities, the Company records restructuring charges, as applicable, at fair value for:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulate when the payment of benefits becomes probable and the amount can be reasonably estimated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-time employee termination benefits to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the detail of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">contract termination costs when the Company cancels a contract in accordance with its terms; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to be incurred over the remaining contract term without economic benefit to the Company at the cease-use date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">For one-time employee terminations benefits, the Company recognizes the liability in full on the communication date when future services are not required or amortizes the liability ratably over the service period, if required. The fair value of termination benefits reflects the Company&#8217;s estimate of expected utilization of certain Company-funded post-employment benefits.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;background:#ffffff;">As described in Note 13, during the year ended December 31, 2024, the Company incurred severance charges of </span><span style="color:#212529;background:#ffffff;">$7.0</span><span style="color:#212529;background:#ffffff;"> million in connection with a corporate restructuring, including a reduction in headcount.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company views its operations and manages its business in one<span style="white-space:pre-wrap;"> segment.  The Company&#8217;s chief operating decision maker is the president and chief executive officer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company has not generated any product revenue since inception.  </span><span style="white-space:pre-wrap;">The Company has no ongoing operations, is not actively performing any research and development, and is preserving cash until the contemplated Merger and Private Placement.  If the contemplated Merger and Placement does not close by the late second quarter of 2025, the Company may seek other strategic alternatives or liquidate. As of December 31, 2024, the Company had no material assets besides cash and cash equivalents and only had </span>six employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies of the Company&#8217;s single reportable segment are the same as those described in Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The chief operating decision maker assesses performance and decides how to allocate resources based on net income (loss) that is reported on the statement of operations and comprehensive loss as net income (loss). The segment-level financial information is the same as the financial information presented in the statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The measure of segment assets is reported on the balance sheet as total assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net income (loss) is used to monitor budget versus actual results. The monitoring of budgeted versus actual results are used in assessing performance of the segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company does not have intra-entity sales or transfers. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December 31, 2024 and 2023, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, <i style="font-style:italic;">Fair Value Measurements</i>. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#8212;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#8212;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#8212;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) either on a recurring or non-recurring basis as of December&#160;31, 2024 and 2023. The carrying value of cash held in money market funds of approximately $8.3 million and $38.8 million as of December&#160;31, 2024 and 2023, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did&#160;not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December 31, 2024 and 2023.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash balances with financial institutions in federally insured accounts and has cash balances in excess of the insurance limits. Cash equivalents consist of investment in United States government money market funds with major financial institutions. These deposits and funds may be redeemed upon demand and the Company does not anticipate any losses on such balances. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash and cash equivalents. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i>. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company has elected to account for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A discussion of management&#8217;s methodology for developing some of the assumptions used in the valuation model follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividend Yield</i>&#8212;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility&#8212;</i>Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company bases the expected volatility on the historical volatility of the Company&#8217;s publicly traded common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate</i>&#8212;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term</i>&#8212;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,<i style="font-style:italic;"> Income Taxes</i>. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when necessary to reduce deferred tax assets to the amount expected to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&#160;31, 2024 and 2023, the Company&#8217;s net loss was equal to comprehensive loss and, accordingly, no additional disclosure is presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted this standard for the year ended December 31, 2024 and the primary impact of which was the additional segment disclosures included in Note 3.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company&#8217;s financial statements.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU 2024-03, Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40), which requires disclosure, in the notes to the financial statements, of specified information about certain costs and expenses. This ASU is effective for public entities for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact ASU 2024-03 will have on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that have been adopted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990591077776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Net Loss Per Share of Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options and RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,043,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,981,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990591093296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of prepaid expenses and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,420,642</p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 234,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 401,442</p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 136,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 175,820</p></td></tr><tr><td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,997,904</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990664537440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51,306</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,824,689</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,561,913</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued consulting and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 790,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 439,192</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,825</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 399,763</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued retention</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,049,105</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued severance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,487,258</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,381,744</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,225,557</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990588283600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense and related cash flows</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating lease cost </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 450,274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 944,963</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 516,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 602,416</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 966,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,547,379</p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating cash outflows for operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 789,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,017,770</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities due</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Lease</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Obligation</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,401</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,401</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (557)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_vgZVo8BJJ0aed1tCmLrUPw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Present value of lease payments</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,844</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_LeaseQuantitativeDisclosureTableTextBlock', window );">Schedule of supplemental information related to leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Operating Leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average remaining lease term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.1</p></td></tr><tr><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"> Weighted-average incremental borrowing rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10.0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets obtained in exchange for operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 872,892</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_LeaseQuantitativeDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_LeaseQuantitativeDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990715766448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average fair value of options granted under all equity incentive plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.25 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.25 years</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.79%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">78.36%</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.17%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.60%</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,271,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 909,981</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,425,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,614,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,697,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,524,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">2013 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of the Company's stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,273,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,756,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,722,543)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,304,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,561,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,024,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of RSU activity for the 2013 Plan for the year ended December 31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 117,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (58,581)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,443)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of the Company's stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AGGREGATE</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WEIGHTED-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INTRINSIC</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AVERAGE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REMAINING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">VALUE</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OUTSTANDING</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXERCISE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONTRACTUAL</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IN</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTIONS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRICE</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TERM&#160;(YEARS)</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THOUSANDS)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,590,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,690,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or expected to vest as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,610,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,452,908</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990588214832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of the gross deferred tax asset and related valuation allowance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Net operating loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96,811,786</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,746,869</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Research and orphan drug credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54,937,994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,152,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Capitalized research costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,861,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,748,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Capitalized start-up costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 339,138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 532,931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Patent amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,071</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,699,628</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,324,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Accrued bonus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 704,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 222,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87,097</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Gross deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170,722,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 161,562,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (170,722,283)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (161,351,398)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Net deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_458vb9MY1EioLUCUnC-NFg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211,287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (211,287)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Gross deferred income tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_eA0MLaJIrUmo4aiKeTHJNw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (211,287)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred income tax asset/(liability)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hdWUWzn18kiagf-L_qnDbQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_NTBSQbNInE69YpwADs5_rw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">U.S. Federal statutory tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Orphan drug credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Executive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990588216624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Asset Impairment Charges (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract', window );"><strong>Restructuring and Asset Impairment Charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of activity for accrued severance costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Severance accrual, January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Charges</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,026,614</p></td></tr><tr><td style="vertical-align:bottom;width:83.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,539,356)</p></td></tr><tr><td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Severance accrual, December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,487,258</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990587414368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Oct. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of reduction in workforce under corporate restructuring</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing', window );">Net cash at closing of the merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_SaleOfStockAggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=glyc_PriorToClosingOfPrivatePlacementMember', window );">Prior to closing of private placement | Crescent Biopharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Parent ownership (as percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=glyc_PriorToClosingOfPrivatePlacementMember', window );">Prior to closing of private placement | GlycoMimetics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling ownership (as percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=glyc_PostClosingOfPrivatePlacementMember', window );">Post the Closing of Private Placement [Member] | Crescent Biopharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Parent ownership (as percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=glyc_PostClosingOfPrivatePlacementMember', window );">Post the Closing of Private Placement [Member] | GlycoMimetics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling ownership (as percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum net cash of the company at the closing of the merger for the determination of the exchange ratio of shares as per the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_SaleOfStockAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of shares and warrants to be issued by the entity as per the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_SaleOfStockAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=glyc_PriorToClosingOfPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=glyc_PriorToClosingOfPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=glyc_CrescentBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=glyc_CrescentBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=glyc_GlycoMimeticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=glyc_GlycoMimeticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=glyc_PostClosingOfPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=glyc_PostClosingOfPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990591013504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_GoingConcernAbstract', window );"><strong>Going Concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax', window );">Net loss</a></td>
<td class="nump">$ 37,879,158<span></span>
</td>
<td class="nump">$ 36,899,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="nump">31,098,078<span></span>
</td>
<td class="nump">34,879,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,720,178<span></span>
</td>
<td class="nump">$ 41,792,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss and comprehensive income for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990589086816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Restructuring and Segment Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment </div>
<div>employee</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance charges | $</a></td>
<td class="nump">$ 7.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts', window );">Number of positions remaining after restructuring and related activities | employee</a></td>
<td class="nump">6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions remaining after restructuring and related activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990586627536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Carrying value of cash held in money market fund</a></td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 38.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value levels 2 or 3</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value levels 2 or 3</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value levels 2 or 3</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value levels 2 or 3</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990588451216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Stock-Based Compensation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990708148128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember', window );">Stock options and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">15,043,815<span></span>
</td>
<td class="nump">10,981,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990587918576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember', window );">Stock options and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computation of earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">15,043,815<span></span>
</td>
<td class="nump">10,981,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990581952944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,420,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">$ 234,696<span></span>
</td>
<td class="nump">401,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">136,580<span></span>
</td>
<td class="nump">175,820<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 371,276<span></span>
</td>
<td class="nump">$ 1,997,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990587886672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 5,381,744<span></span>
</td>
<td class="nump">$ 5,225,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990586653632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent', window );">Lease, Practical Expedient, Lessor Single Lease Component [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_LesseeOperatingLeaseNumberOfNewLeases', window );">Number of additional operating leases entered during the period | lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment loss | $</a></td>
<td class="nump">$ 365,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=glyc_RockvilleMarylandMember', window );">Rockville, Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Deposits | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=glyc_FirstPortionSquareFeetRockvilleMarylandMember', window );">First portion of Rockville, Maryland lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_SquareFeetLeased', window );">Square feet leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=glyc_SecondPortionSquareFeetRockvilleMarylandMember', window );">Second portion of Rockville, Maryland lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_SquareFeetLeased', window );">Square feet leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_LesseeOperatingLeaseNumberOfNewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of additional operating leases entered into during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_LesseeOperatingLeaseNumberOfNewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_SquareFeetLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Square feet leased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_SquareFeetLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedient is elected to account for lease component and nonlease component as single lease component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -SubTopic 30<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=glyc_RockvilleMarylandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=glyc_RockvilleMarylandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=glyc_FirstPortionSquareFeetRockvilleMarylandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=glyc_FirstPortionSquareFeetRockvilleMarylandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=glyc_SecondPortionSquareFeetRockvilleMarylandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=glyc_SecondPortionSquareFeetRockvilleMarylandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990588407040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Components of lease expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Components of lease expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 450,274<span></span>
</td>
<td class="nump">$ 944,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">516,344<span></span>
</td>
<td class="nump">602,416<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">966,618<span></span>
</td>
<td class="nump">1,547,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows for operating leases</a></td>
<td class="nump">$ 789,183<span></span>
</td>
<td class="nump">$ 1,017,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990586742960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Maturities of lease liability (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of lease liability due</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 67,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">67,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(557)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">$ 66,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Operating Lease, Liability, Current, Operating Lease, Liability, Noncurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990664562160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Supplemental Information (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990587884512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Offerings (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2022Member', window );">2022 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="nump">9,822,930<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share</a></td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock sale</a></td>
<td class="nump">$ 28,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_CommonStockValueAvailableForSaleUnderAgreement', window );">Common stock available for sale under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2022Member', window );">2022 Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_CommonStockValueAvailableForSaleUnderAgreement', window );">Common stock available for sale under agreement</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_CommonStockValueAvailableForSaleUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock remaining available to be sold under the terms of the agreement at the end of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_CommonStockValueAvailableForSaleUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOffering2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990587784304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Incentive Plans (Details) - 2013 Equity Incentive Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 09, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment', window );">Period from date of termination that any vested options shall expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 915,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for unrecognized compensation expense related to unvested options yet has not been recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,091<span></span>
</td>
<td class="nump">$ 82,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,398<span></span>
</td>
<td class="nump">116,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,919,122<span></span>
</td>
<td class="nump">$ 1,710,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">Stock options vesting based on performance | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense', window );">Maximum fair value of option excluded from the unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">Upon first anniversary of start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percent of shares subject to option grant that will vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">Each month after the first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percent of shares subject to option grant that will vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.083%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract', window );"><strong>Authorized shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,257,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,070,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions', window );">Maximum number of shares that may be issued pursuant to exercise of incentive stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares of common stock</a></td>
<td class="nump">2,619,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee', window );">Maximum percentage of shares of common stock issued and outstanding on the immediately preceding fiscal year, or such lesser number of shares as determined by the board of directors or the compensation committee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of common stock issued and outstanding on the immediately preceding fiscal year, or such lesser number of shares as determined by the board of directors or the compensation committee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum fair value of option excluded from the unrecognized compensation expense under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of maximum shares issued upon exercise of incentive stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=glyc_StockOptionsVestingBasedOnPerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=glyc_StockOptionsVestingBasedOnPerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990588185360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Company's Stock Option Activity (Details) - 2013 Equity Incentive Plan - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>OUTSTANDING OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,273,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,756,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,722,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,304,882<span></span>
</td>
<td class="nump">8,273,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>WEIGHTED-AVERAGE EXERCISE PRICE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="nump">$ 5.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>VESTED AND EXPECTED TO VEST</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,561,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>ADDITIONAL DISCLOSURES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Outstanding options exercisable at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,024,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price exercisable at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average contractual term outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average contractual term (years) exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">Employees | Stock options vesting based on performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>OUTSTANDING OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">2,459,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=glyc_StockOptionsVestingBasedOnPerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=glyc_StockOptionsVestingBasedOnPerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990582612480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of RSU Activity (Details) - 2013 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Restricted Stock Units information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for unrecognized compensation expense related to unvested options yet has not been recognized</a></td>
<td class="text">3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>NUMBER OF SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period | shares</a></td>
<td class="nump">117,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(10,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(58,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period | shares</a></td>
<td class="nump">48,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>WEIGHTED-AVERAGE GRANT DATE FAIR VALUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period | $ / shares</a></td>
<td class="nump">$ 3.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">3.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited | $ / shares</a></td>
<td class="nump">3.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period | $ / shares</a></td>
<td class="nump">$ 3.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Restricted Stock Units information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to unvested service RSUs | $</a></td>
<td class="nump">$ 9,541<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990664515952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Non-employee | Other Awards | Director</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock shares issued</a></td>
<td class="nump">13,127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=glyc_OtherAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=glyc_OtherAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990582030208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Inducement Plan (Details) - Inducement Plan<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment', window );">Period from date of termination that any vested options shall expire</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to unvested options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for unrecognized compensation expense related to unvested options yet has not been recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 919,184<span></span>
</td>
<td class="nump">$ 601,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember', window );">Stock options vesting based on performance | Newly hired employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense', window );">Maximum fair value of option excluded from the unrecognized compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 825,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember', window );">Upon first anniversary of start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember', window );">Each month after the first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments', window );">Number of monthly installments | installment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of monthly installments for Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum fair value of option excluded from the unrecognized compensation expense under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=glyc_StockOptionsVestingBasedOnPerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=glyc_StockOptionsVestingBasedOnPerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990582479104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Inducement Plan - Stock Option Activity (Details) - Inducement Plan - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>OUTSTANDING OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period</a></td>
<td class="nump">2,590,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="num">(29,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period</a></td>
<td class="nump">2,690,800<span></span>
</td>
<td class="nump">2,590,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>WEIGHTED-AVERAGE EXERCISE PRICE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period</a></td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited</a></td>
<td class="nump">3.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period</a></td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>VESTED AND EXPECTED TO VEST</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Outstanding options</a></td>
<td class="nump">1,610,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 1.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>ADDITIONAL DISCLOSURES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Outstanding options exercisable at end of period</a></td>
<td class="nump">1,452,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price exercisable at end of period</a></td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average contractual term outstanding</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average contractual term (years) exercisable</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990715768864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Weighted-Average assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of the options granted</a></td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="nump">$ 1.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">101.79%<span></span>
</td>
<td class="nump">78.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.17%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990586657008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,697,546<span></span>
</td>
<td class="nump">$ 3,524,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,271,655<span></span>
</td>
<td class="nump">909,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,425,891<span></span>
</td>
<td class="nump">$ 2,614,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990586702448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 96,811,786<span></span>
</td>
<td class="nump">$ 88,746,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits', window );">Research and orphan drug credits</a></td>
<td class="nump">54,937,994<span></span>
</td>
<td class="nump">53,152,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_DeferredTaxAssetsCapitalizedResearchCosts', window );">Capitalized research costs</a></td>
<td class="nump">11,861,613<span></span>
</td>
<td class="nump">10,748,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_DeferredTaxAssetsCapitalizedStartUpCosts', window );">Capitalized start-up costs</a></td>
<td class="nump">339,138<span></span>
</td>
<td class="nump">532,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_DeferredTaxAssetsPatentAmortization', window );">Patent amortization</a></td>
<td class="nump">27,071<span></span>
</td>
<td class="nump">42,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation</a></td>
<td class="nump">6,699,628<span></span>
</td>
<td class="nump">7,324,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_DeferredTaxAssetsAccruedBonus', window );">Accrued bonus</a></td>
<td class="nump">25,356<span></span>
</td>
<td class="nump">704,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">18,394<span></span>
</td>
<td class="nump">222,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="nump">87,097<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
<td class="nump">170,722,283<span></span>
</td>
<td class="nump">161,562,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(170,722,283)<span></span>
</td>
<td class="num">(161,351,398)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">211,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211,287)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred income tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(211,287)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset/(liability)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetsAccruedBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Accrued bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetsAccruedBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetsCapitalizedResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences capitalized research costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetsCapitalizedResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetsCapitalizedStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences capitalized start up costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetsCapitalizedStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetsPatentAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences patent amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetsPatentAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from research and orphan drug credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990588208512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - NOLs and carryforwards (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits available to carry forward</a></td>
<td class="nump">$ 10.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits available to carry forward</a></td>
<td class="nump">44.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=glyc_FederalAndStateAuthoritiesMember', window );">U.S. Federal And State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 351.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=glyc_FederalAndStateAuthoritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=glyc_FederalAndStateAuthoritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990587852336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research credit</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent', window );">Orphan drug credit</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(5.10%)<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent', window );">Executive compensation</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(24.70%)<span></span>
</td>
<td class="num">(30.80%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to executive compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990708145520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Company matching contribution percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer match contribution</a></td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="nump">$ 248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percent of employee contributions the company contributes a matching contribution</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990586219168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Asset Impairment Charges (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract', window );"><strong>Restructuring and Asset Impairment Charges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Reduction in workforce under corporate restructuring | employee</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of reduction in workforce under corporate restructuring</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total charges in headcount reduction under corporate restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Restructuring Costs and Asset Impairment Charges<span></span>
</td>
<td class="text">Restructuring Costs and Asset Impairment Charges<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Impairment charges related to our facility operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45990587781136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Asset Impairment Charges - Severance cost (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(3,500,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee severance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">7,026,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(3,539,356)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Severance accrual, December 31</a></td>
<td class="nump">$ 3,487,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>103
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MBX,T [!_(X3>5\P$W?^"\"]02P,$%     @ HHE26BNL"O0E!0  3A4  !@
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MSJV\HFBP0,ZU2.]7(L^85+\T':5^=E?(=]74]XJVSWJKO6A8?$W7M&1FIF5
M6?[GX ,\A1"9@BF!Z:AK=@Z",830_@&UHM(VK[5>"<G_99F9K>+E*5?*5K&F
MLZVUTN;"-BM4@SFK-"L61N0)7.^5&BNS_=D\=6Z!-LG^ ?4'SCS__T#[*=[V
M!FBX.9B)HC"[]][\H@#V9]B=/^,$7W'J9/<<A/[8C\DX">(?&;/&GR1D;$3G
M=?_C!K?;[H2^'W?4PF5&DIX5C[<M$1[L/J:76<9M;37ER>X<3GAI=I,5-^7*
MN76&W=XL24)$#.(#P$Y3WRH&2GI ;UL:_&I+4Q=U3C6SNYLE3[FS[\?=;N7$
M8" F<1$\A.NR#4(_-GAQ#]Z=,XGA[F9=_I6CN#IAN_H<1(+P4 <<AB3VD>]#
MU(-XV^C@X4:G(UC-_#Z:@>.PP=WK.RQ[FGUOY[#+GC3^0>4=+Y79""Z-*SR-
M3 RY/KQ;WVA1->=?"Z&U*)K+%:,&NC4P[Y="Z)<;>Z36'J%._P-02P,$%
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MR2A7 O!]RIC<OB@#S:W0X']02P,$%     @ HHE26CL7;3Y:!0  <AX  !@
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6S%66V3VC80_BL:VNG+3(BM%[^E
M'#,).).;-LDU7-KI1\6(PQ/;HK:X2_]])<,9+ D'$J7] K;9?7;U[%KL8T\>
M>/VQ63,FP*>RJ)JKT5J(S3//:[(U*VGSE&]8)7]9\;JD0I[6=UZSJ1E=MDYE
MX2'?#[V2YM5H.FFOW=33"=^*(J_830V:;5G2^I\7K. /5R,X>KSP+K];"W7!
MFTXV](XMF'B_N:GEF=>A+/.254W.*U"SU=7H.7R6HM:AM?@C9P_-T3%02_G
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M]2RY3JCD2G3*?S6;WWCPYS+P%4:Y^$N;_NQXDE#1.6^: 0P%C=3]OW@9XG
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MXC\=%C@]GZA2XA\QLC$:_L*$@!A,/<>.$VH8*R2;3# 0"UM;BNQ@[N<7LQ.
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MMSPAOHBXE#+PY2@Q-C,.+P&6#]T3NR76JMR:9!#C?5 1B') U&&E"!I5,>+
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MNGBFV0_<.N[>/=].-4\6U6COC(KC+2KR0NH'<@?32B'#K6M*P;60;YJ.3ZP
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MZVK^2'=0C:<!>+]P,(OXA1;(OP=[^]]02P,$%     @ HHE26GHAQ: ] P
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MX1AMR_4DO-7M]=6(NE("JA,632-3\)\3PU7H2@2[B\9(1=Z1=Q?3M]W4;'2
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M&VESVS;VKW"\22>9860>HHY<,XJCNMIIG(R/=/<C1$(6&HI0"=*R]M?O>P\
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M(ANSD3]&-2]6[=T%XTI9JW;NYU9PH( FX/M:*=N\T +MC?/5_P!02P,$%
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M@._64./ALZFP>@J0,J<#L6)/;%6<1/R$Y02F^1D463$[@3<]!#J->-/_&^@
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M\XM'<-XVPC=6ZA7C.F<?G,->N*]J+BU6W[/;DML5N*N)QWCD-1$M]DW$3E_
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MZ#H=GYTDL;6[A3=UN/\MC<?;9'BD<PXL&>#WPAC?+2A _P_!XF]02P,$%
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M^F?3V"&R'Y:]H45K!]1*:!QW=EOB_P6D"<#S0@B],\P%PQ\K_0502P,$%
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M':$A(MTR(MW&0 K2< F2Y6AV:+QH!/C!\<(KU?-^\7C1C/^[QXC_QXM?,EY
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M0H %+RLYK), W0T'XLC!,$==B+]UR0:D0_*,+;(\4QD,(5V,8"\[[4J4FGY
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MDD79;8!D@UPW4-^WC,GC@^Z@/+*=?P502P,$%     @ HHE26@?G\B67 @
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MU/8+=OE,'%ZNA/&_L.UL!Q'DK;&J[IR)0<UE^++'K@Y[#J,/+S@DG4/B>8=
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MS]H YDT T3,!A!&Z$UR7"MWR'/)C@&^RZ5**]BG-HT%B"MDEBL,/* JB44]
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MT0>T:+\TXBMT.>QJ!HI0)J\UP=-BAJ[>7B>NTLK-^F[6J7QH5>(3*F>0W:#
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M,^#S)>?J^487T)[1SOX#4$L#!!0    ( **)4EJDH4,)^P(  .,(   9
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MV./J88Y_(2"- 7Z?"Z&W$[-!^U^3_ -02P,$%     @ HHE26L8- <>B @
M%@<  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULG95A;YLP$(;_BL6F
MJ9/20@B0J$N0UJ;5)K5;U*S;AVD?'#@2K\9F]I&T_WZV25#44J3M"]CF[GV?
M WR>[J1ZT!L )(\E%WKF;1"K<]_7V09*JL]D!<(\*:0J*9JI6ONZ4D!SEU1R
M/PR"Q"\I$UXZ=6L+E4YEC9P)6"BBZ[*DZND"N-S-O*%W6+ACZPW:!3^=5G0-
M2\#[:J',S&]5<E:"T$P*HJ"8>1^'YQ<3&^\"OC/8Z:,QL96LI'RPD\_YS LL
M$'#(T"I0<]O")7!NA0S&G[VFUUK:Q./Q0?W:U6YJ65$-EY+_8#EN9M[$(SD4
MM.9X)W>?8%]/;/4RR;6[DMT^-O!(5FN4Y3[9$)1,-'?ZN'\/1PGCY)6$<)\0
M.N[&R%'.*=)TJN2.*!MMU.S E>JR#1P3]J,L49FGS.1A^K4"19&)-;D!4YPF
MI^268JT8,C.1!>%VF7!&5XPS?"(G<T#*N'X_]='X6Q4_VWM=-%[A*UYSR,[(
M:#@@81!&Y'XY)R=OG\GX!K^M(6QK")WNZ!7=?N"\AB[41C+JEK1;X5Q7-(.9
M9_YU#6H+7OKNS3 )/O0 CUK@49]Z:NJ/NYB:K-AEV=VT39-Q% RG_K;#+&K-
MHEZS;QLPN[5 4%V636YR9!ETV\6M7=QO)Y'R+J?XA5-/<4GKEO2Z+>S'$4BV
ME-= :/[;[!C3,K +('D!<!K'XV[_<>L__@?_]N^KZ).ET%T8XY<?.9E$43?'
MI.68]'(\V\8#<G/X_P=DB13!XEB^:R:HR!CE9"$U<XWQY]4CVBZ[XD"N1%TZ
M)2E^=<'_/\5EK91A&)"^H"]29$U<UR[SC]J</3%NJ5HSH<T[+PQ.<#8V+U4U
M7;B9H*Q<YUM)-'W4#3?FX )E \SS0DH\3&PS;8_"]"]02P,$%     @ HHE2
M6LQO\&)) @  _P4  !D   !X;"]W;W)K<VAE971S+W-H965T-# N>&ULK91O
M;],P$,:_BA4D-"36_%V!DD1BK1"30%2K8*_=Y)I8<^Q@N^WZ[3D[:=2BK R)
M-XGM^'G.OXOOTKU4C[H&,.2IX4)G7FU,._-]7=304#V1+0C\LI&JH0:GJO)U
MJX"63M1P/PJ"J=]0)KP\=6M+E:=R:S@3L%1$;YN&JL,M<+G/O- [+MRSJC9V
MP<_3EE:P O.C72J<^8-+R1H0FDE!%&PR[U,XFR=VO]OPD\%>GXR))5E+^6@G
M=V7F!?9 P*$PUH'B:P=SX-P:X3%^]9[>$-(*3\=']\^.'5G65,-<\@=6FCKS
MWGNDA W=<G,O]U^@Y[FQ?H7DVCW)OMM[DWBDV&HCFUZ,)VB8Z-[TJ<_#B0!]
MQ@51+XC^$$31,X*X%\0.M#N9PUI00_-4R3U1=C>ZV8'+C5,C#1/V+ZZ,PJ\,
M=2;_WH*BAHF*? 7,AB;79+5M6P[XIPSEY$YT-\6F_&H!AC*NWZ2^P=#6P"_Z
M,+==F.B9, LH)B0.WY(HB)(1^?SE\OA<[B/P0!T-U)'SBU](/0;4.23C#K:X
M9KJE!60>5H\&M0,O?_TJG 8?Q_#^D]D9;#S QI?<\P=WE:&\ICNDK@"+SY:W
MI>>6GAA0#;EB@AR JO&_>SE"2!HI3$VFI*2'L63._Z:WD<DEFS/R9"!/_HV<
MB4(=;_9:*K2S6<"K &/0G?D'9VZ[X2X/)F'J[T[!+N_I3NV?E*=MC=^HJIC0
MF/T-JH+).^P-JFLWW<3(UE7L6AJL?S>LL4.#LAOP^T9*<YS8)C#T_/PW4$L#
M!!0    ( **)4EJQ>Q8GUP,  +<2   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;*U877.;.!3]*QJVL]O.=,V7C9VL[9G$M+-]R&ZFGG:?%;B )H"H
M).QT9W_\2H Q.(2&CO(02T+G2.=(7%VT/E+VR!, @9ZR-.<;(Q&BN#9-'B20
M83ZC!>3R2419AH6LLMCD!0,<5J L-1W+\LP,D]S8KJNV>[9=TU*D)(=[AGB9
M99A]OX64'C>&;9P:/I,X$:K!W*X+',,>Q)?BGLF:V;*$)(.<$YHC!M'&N+&O
M?7NN %6/KP2.O%-&2LH#I8^J\BG<&)::$:00"$6!Y<\!=I"FBDG.XUM#:K1C
M*F"W?&+_6(F78AXPAQU-_R&A2#;&RD A1+A,Q6=Z_!,:00O%%]"45__1L>[K
M608*2BYHUH#E##*2U[_XJ3&B Y \PP"G 3B7 .\%@-L W$O _ 7 O %45INU
ME,H''PN\73-Z1$SUEFRJ4)E9H:5\DJMUWPLFGQ*)$]N]H,%C0M,0&/\-??A6
M$O$=_7XJ_!U%P$@><_36!X%)RM_)AU_V/GK[YMW:%'("BL8,FL%NZ\&<%P:S
MT1W-1<+1ASR$< "_^P'>&2$PI?)6OG.2?^N,,MYA-D.N_1XYEN,,36@<[D/0
MPN<#</_U<'=$C=LNIEOQN5,6\R\J8&BI:JKY,)4*-]>\P %L#!E/.+ #&-M?
M?[$]ZX\AFW22^9K(>A;.6POG8^S;'<TR&8ZX<O(]X@F60R!<BH0R\N_@GKT=
M)9QJ9$WF560J9A^V]L*J_];FH>O20$_KLF?/@D5KP6*"!05FZ(#3<G /C1)-
ME5Z3+3N"K)EEV1>R?]2K)]EK)7NCDM7;C_8XE6M]$S, >;")(;VC+%/UZB3S
M-9'UW%NV[BWUA9VE3@MUDOF:R'H6KEH+5Z,;\!/G)<X#0#1"0>_]RV7N)QO)
MJ4- N>"GR#1D\.I97+A:.<Z5>Q$_=L_[74:8T2G_I"%7K2%7HX;<,R+%%L!J
MI4-":X)51X [NPP7N]%1INX0360]0VSKG*E9HY;<Q#(TQ5A M2<*1@. D*.(
MT:S>+(C+"#:8E=7$BXY5SFHY<*CLQJ<PU2]=;'W#.JFM_>J##.&#3%_Q0PI(
M?BQ53J%2)I$,X;& /S["U'#5L'77P?,&#W==X_:=<\[..9//0_0?NL-/)"NS
M0:-&"2<;I9/-U\76-_.<E-L:LW);:UJNE<W7Q=;W\9R9VZ]/S7_V=9X_>P'M
MYS%09T+OZV*K33,[7_H9L+BZ,>$R*2AS47_TMZWMK<Q-=1=AGKO75SKRTS<F
M.4<I1!)JS9;2%5;?DM0508OJWN"!"D&SJI@ EAZK#O)Y1.4>;BIJ@/:N:OL_
M4$L#!!0    ( **)4EI"H1$PD <  , U   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;,V;76_;-A2&_PKA#4,'M+5$VW*<)0:22-HRH$#0HMLU+1W;
M6B71):DD'O;C1TJR/FR%C;=ST5XTLJ3SD.)[2(JOI*LG+K[(+8 BSUF:R^O1
M5JG=Y7@LHRUD3+[G.\CUD347&5/ZI]B,Y4X B\N@+!U3Q_'&&4ORT?*JW/<@
MEE>\4&F2PX,@LL@R)O:WD/*GZY$[.NSXF&RVRNP8+Z]V; .?0'W>/0C]:]Q0
MXB2#7"8\)P+6UZ,;]S*D<Q-0GO%' D^RLTW,I:PX_V)^W,?7(\?4"%*(E$$P
M_><1[B!-#4G7XVL-'35EFL#N]H$>EA>O+V;%)-SQ],\D5MOKT<6(Q+!F1:H^
M\J??H+Z@F>%%/)7E_^2I/M<9D:B0BF=UL*Y!EN357_9<-T0G0'.& V@=0(\#
MIB\$3.J R7' _(6 :1TP?6T)LSI@]MH KP[PRK:O&JML:9\IMKP2_(D(<[:F
MF8U2KC):-W"2F\SZI(0^FN@XM?RD>/3EG=$F)G<\TPDK62GY.W*?1Y ;W<E#
MRG))WOB@6)+*G_4QZK@3$GPM$K4_.D\?_/S))V]^_/EJK'0%33'CJ*[,;549
M^D)E7/*!YVHK29#'$ _$^]^(IQ; 6+=,TSSTT#RWU$K\P/9DXK[5UTOI0'WN
M[-&_L_R]+=RWA_L0->'3@?#@]>&3@?#P%95W%B;<G5J:<M)DVJ3D35[*M"T3
M\.[V---NA&#Y!O1PI<AJ3[KG/;!]N?OFB8GX+;F)X\2$L)3\"CD(_==/9)1R
M60B00_E656DZ7"4S:E_*'8O@>J2'90GB$4;+GWYP/>>7(;$Q83XF+,"$A4BP
M7I),FR29VNC+!Q )C\E:\(S$3 'A:Z) Z(&ORA6U98JP?$\>02J=('QG=DLB
MMRQ-"3SO$@%#>6 M]=P\P(3Y]O98.+H9]D.I'6#6(D2"]32?-9K/K-<8&-4J
M>7>E_$,"6A'G"H@)\^T7YSID#TP,*HA9C1 )UE/0:Q3TK!?Y.1<0\4V>_*V[
M9-0=VW6/U-N@[T%39OJKXJ3(^WUW2&UK<>>JC0GS*]BLA)F[]L?EPITMYL[5
M^+$K+6:9(1*L)^V\D7;^J@&9"RW<_U!9]P)%MDR2G.M9'L L2PZPH0RPUNK<
M#,"$^?;VFI"LN@-U+UX<N3&K$R+!>LEQT23'A?5B[W,E$KW(C,@C2XMRLC[(
M#<\@HD0.BVNEGBLN)LR_..G>4V?A'G7NTY,NZ,0Y&@)"I'KUA%DTPBRLPMPQ
MN24[P2. 6%9W4P=!C$C2+/ILXZ^5?JY F#!_<=+VL\GBXDB@ZB2O<Y+K>M/%
M_$@AI(KU%'*==N'M6#4JUSF2)%(6$/\'C>SX<T5"I?DUK:O A,Z.)TG4,D,L
M6E_.CH_B6N4,62+:85!6XE9SX*!Z5MK9ZF'2_)K6[61TX2Y<XV'T!3P]T9V[
MSF)RU"%#K/KUM:&M-M3>U;I]J10ER3>D,KVJ54=IT>81D'](D.U2OH=A/\%>
MT-FR8=)\5%J 2@NQ:/T$:*TG]SOTGEQ4\PF5YJ/2 E1:B$7KYTKK0+EVR^4#
M>TZR(B/KWH!>#1YZAH[2(C[,UVH+WUX5#:8&JA]5T[K#L#=SJ.?U1V$?M=0
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MTRSA.SC!_!&-&5>=&7<^X*"!K?W^O:*KYHW/=V^SXHKDU@JT _CZE$&$[32
MJX:.[1U]_J[3C@D*C<"<A*6ISEHG"N+645'V6OY_B](].JRG();YE41J)6NF
MBG-[^;6\]@3%8;^:7MR9'HC0S4RB!!;:M''9T=2BN(84+XIG^='_F2M]D<B'
M*WUU V$FZ/\7G*O#BR$H+X/#?P!02P,$%     @ HHE26D4_Z,]\ @  Q 4
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MX9Q$R>4:(Q]3V4#\OB2$[V_D /E!YN!_4$L#!!0    ( **)4EK?4! 6+ ,
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M$HN5YJR$.TG4JBBH?!H!%]70"9SG#_=LD6OSP4OB)5W %/3#\DYBSVM4,E9
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M-!8UV\SQ-P*DF8#C<R'T<\=4MN;')/D-4$L#!!0    ( **)4EHX.!\G.P,
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M0.*B%,>Q+944#6BG+>VLH?5>H74]=,.HS 6ZI!ED?P+8*H8N$&\?R,P;1%Q
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M"-R-.((Y  \8$D7F/;CS/@I6[ZE@_1_:X5]02P,$%     @ HHE26I>*NQS
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M3TALG^<AQI$I,\3$$Q*+YQGA:1MJJ,KE8$SYF)AX0F+Q','\S)W4K10'F)B
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M&[/\ZQ?H[36M==D<\EGWE<+D$U!+ 0(4 Q0    ( **)4EH'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ HHE26CR<K2ON    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ HHE26IE<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "BB5):
M]$MSM;0"   C"   &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ HHE26BNL"O0E!0  3A4  !@
M     ("!]PH  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M **)4EJX@39HOP(  +8)   8              " @5(0  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " "BB5):_?K-!]8$   A$@  &
M            @(%'$P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ HHE26CL7;3Y:!0  <AX  !@              ("!4Q@  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( **)4EK/3?/.#08  *P9
M   8              " @>,=  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " "BB5):(L+H]XD'  #;$@  &               @($F)
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ HHE26GL4Z]/E
M P  /PD  !@              ("!Y2L  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( **)4EK*WU10K1(  !LV   8              "
M@0 P  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "BB5):
M>B'%H#T#   E"   &0              @('C0@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( **)4EK^3TO;H (  /@&   9
M      " @5=&  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ HHE26AHDY5G6 @  $ <  !D              ("!+DD  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "BB5):!5/5K3H(  "R%@
M&0              @($[3   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( **)4EH#R%YE! 0  &D)   9              " @:Q4  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ HHE26L1[G]L&
M$   DS<  !D              ("!YU@  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " "BB5):D6R(VM('  !]%@  &0
M@($D:0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( **)
M4EHJRSEY:@0  )$*   9              " @2UQ  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ HHE26A,)W78V P  6P<  !D
M         ("!SG4  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " "BB5):>.4.*^H$   <#   &0              @($[>0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( **)4EK6WIS7A1,  +4\
M   9              " @5Q^  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ HHE26C"IF@14 @  @04  !D              ("!&)(
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "BB5):GVS\
M(X4"  !S!@  &0              @(&CE   >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( **)4EI,8*#XN0(  +T&   9
M  " @5^7  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
MHHE26@:45+K= P  :PL  !D              ("!3YH  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " "BB5):PT9OT\0%   >%0  &0
M            @(%CG@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( **)4EHPLI]3@ 0  !8-   9              " @5ZD  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ HHE26GY[=RAV @
MK04  !D              ("!%:D  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " "BB5):R@/R\$ $  "^%0  &0              @('"
MJP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( **)4EH'
MY_(EEP(  .@&   9              " @3FP  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ HHE26I"&5LR? @  1 8  !D
M     ("!![,  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M" "BB5):WQTK61$#  #&#   &0              @('=M0  >&PO=V]R:W-H
M965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( **)4EJNL(AMOP(  '8*   9
M              " @26Y  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L!
M A0#%     @ HHE26NG[2Q=S @  XP4  !D              ("!&[P  'AL
M+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "BB5):(XQV=Y$"
M  #5!@  &0              @('%O@  >&PO=V]R:W-H965T<R]S:&5E=#,T
M+GAM;%!+ 0(4 Q0    ( **)4EHQW!FMD (  (P'   9              "
M@8W!  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ HHE2
M6HON[V,* @  _P0  !D              ("!5,0  'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " "BB5):HW>Y,QT$  "O%0  &0
M        @(&5Q@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( **)4EJDH4,)^P(  .,(   9              " @>G*  !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ HHE26L8- <>B @  %@<
M !D              ("!&\X  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " "BB5):S&_P8DD"  #_!0  &0              @('TT
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( **)4EJQ>Q8G
MUP,  +<2   9              " @733  !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ HHE26D*A$3"0!P  P#4  !D
M ("!@M<  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "B
MB5):TTTU]+,%  !3(0  &0              @(%)WP  >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( **)4EH14O2J[0,  !@.   9
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M970T."YX;6Q02P$"% ,4    " "BB5):)JWCEN\"  !#"P  &0
M    @($:^@  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M **)4EH$-U\.1@0  'H0   9              " @4#]  !X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ HHE26GB#^IJF @  I @  !D
M             ("!O0$! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " "BB5):.#@?)SL#  #1"@  &0              @(&:! $ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( **)4EIHG#P"\0(
M  H+   9              " @0P( 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ HHE26GJEU#YJ P  UPP  !D              ("!
M- L! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "BB5):
M6\B,1\0"   2"   &0              @('5#@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( **)4EJF*M-^5 ,  *X5   -
M      "  = 1 0!X;"]S='EL97,N>&UL4$L! A0#%     @ HHE26I>*NQS
M    $P(   L              ( !3Q4! %]R96QS+RYR96QS4$L! A0#%
M  @ HHE26J',O-?/!   QB0   \              ( !.!8! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( **)4EJ\ =;!X $  .P@   :
M  "  30; 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M **)4EH4U''DT $  *T@   3              "  4P= 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     _ #\ ,!$  $T? 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>81</ContextCount>
  <ElementCount>233</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementBalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureGoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Net Loss Per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock</Role>
      <ShortName>Net Loss Per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Research and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureResearchAndLicenseAgreements</Role>
      <ShortName>Research and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Restructuring and Asset Impairment Charges</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentCharges</Role>
      <ShortName>Restructuring and Asset Impairment Charges</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Net Loss Per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables</Role>
      <ShortName>Net Loss Per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureOperatingLeases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Restructuring and Asset Impairment Charges (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesTables</Role>
      <ShortName>Restructuring and Asset Impairment Charges (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentCharges</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Description of the Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureDescriptionOfBusinessDetails</Role>
      <ShortName>Description of the Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureDescriptionOfBusiness</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureGoingConcernDetails</Role>
      <ShortName>Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureGoingConcern</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Summary of Significant Accounting Policies - Restructuring and Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestructuringAndSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Restructuring and Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40305 - Disclosure - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeasesDetails</Role>
      <ShortName>Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Operating Leases - Components of lease expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Operating Leases - Components of lease expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Operating Leases - Maturities of lease liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails</Role>
      <ShortName>Operating Leases - Maturities of lease liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Operating Leases - Supplemental Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeasesSupplementalInformationDetails</Role>
      <ShortName>Operating Leases - Supplemental Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Stockholders' Equity - Equity Offerings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails</Role>
      <ShortName>Stockholders' Equity - Equity Offerings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Stock-based Compensation - Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails</Role>
      <ShortName>Stock-based Compensation - Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Stock-based Compensation - Company's Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Company's Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Stock-based Compensation - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails</Role>
      <ShortName>Stock-based Compensation - Summary of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails</Role>
      <ShortName>Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Stock-based Compensation - Inducement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails</Role>
      <ShortName>Stock-based Compensation - Inducement Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40906 - Disclosure - Stock-based Compensation - Inducement Plan - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Inducement Plan - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40907 - Disclosure - Stock-based Compensation - Weighted-Average assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Weighted-Average assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40908 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail</Role>
      <ShortName>Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Income Taxes - NOLs and carryforwards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail</Role>
      <ShortName>Income Taxes - NOLs and carryforwards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Employee Benefit Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail</Role>
      <ShortName>Employee Benefit Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureEmployeeBenefitPlan</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Restructuring and Asset Impairment Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesDetails</Role>
      <ShortName>Restructuring and Asset Impairment Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="glyc-20241231xs4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Restructuring and Asset Impairment Charges - Severance cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails</Role>
      <ShortName>Restructuring and Asset Impairment Charges - Severance cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>glyc-20241231.xsd</File>
    <File>glyc-20241231_cal.xml</File>
    <File>glyc-20241231_def.xml</File>
    <File>glyc-20241231_lab.xml</File>
    <File>glyc-20241231_pre.xml</File>
    <File doctype="S-4" isDefinitelyFs="true" isUsgaap="true" original="glyc-20241231xs4.htm">glyc-20241231xs4.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>glyc-20241231xs4007.jpg</File>
    <File>glyc-20241231xs4008.jpg</File>
    <File>glyc-20241231xs4027.jpg</File>
    <File>glyc-20241231xs4028.jpg</File>
    <File>glyc-20241231xs4029.jpg</File>
    <File>glyc-20241231xs4030.jpg</File>
    <File>glyc-20241231xs4031.jpg</File>
    <File>glyc-20241231xs4032.jpg</File>
    <File>glyc-20241231xs4033.jpg</File>
    <File>glyc-20241231xs4034.jpg</File>
    <File>glyc-20241231xs4035.jpg</File>
    <File>glyc-20241231xs4036.jpg</File>
    <File>glyc-20241231xs4037.jpg</File>
    <File>glyc-20241231xs4053.jpg</File>
    <File>glyc-20241231xs4054.jpg</File>
    <File>glyc-20241231xs4055.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="385">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="7">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>110
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "glyc-20241231xs4.htm": {
   "nsprefix": "glyc",
   "nsuri": "http://glyc.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "glyc-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "glyc-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "glyc-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "glyc-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glyc-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "glyc-20241231xs4.htm"
     ]
    }
   },
   "keyStandard": 202,
   "keyCustom": 31,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 19,
   "memberCustom": 15,
   "hidden": {
    "total": 26,
    "http://fasb.org/us-gaap/2024": 24,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 81,
   "entityCount": 1,
   "segmentCount": 34,
   "elementCount": 366,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 385,
    "http://xbrl.sec.gov/dei/2024": 7
   },
   "report": {
    "R1": {
     "role": "http://glyc.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://glyc.com/role/StatementBalanceSheets",
     "longName": "00100 - Statement - BALANCE SHEETS",
     "shortName": "BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://glyc.com/role/StatementBalanceSheetsParenthetical",
     "longName": "00105 - Statement - BALANCE SHEETS (Parenthetical)",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "longName": "00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://glyc.com/role/StatementStatementsOfStockholdersEquity",
     "longName": "00300 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSdHWh91dUS21LGrb3eG2g",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSdHWh91dUS21LGrb3eG2g",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://glyc.com/role/StatementStatementsOfCashFlows",
     "longName": "00400 - Statement - STATEMENTS OF CASH FLOWS",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://glyc.com/role/DisclosureDescriptionOfBusiness",
     "longName": "10101 - Disclosure - Description of the Business",
     "shortName": "Description of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://glyc.com/role/DisclosureGoingConcern",
     "longName": "10201 - Disclosure - Going Concern",
     "shortName": "Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "10301 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock",
     "longName": "10401 - Disclosure - Net Loss Per Share of Common Stock",
     "shortName": "Net Loss Per Share of Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "longName": "10501 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://glyc.com/role/DisclosureAccruedExpenses",
     "longName": "10601 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://glyc.com/role/DisclosureOperatingLeases",
     "longName": "10701 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://glyc.com/role/DisclosureStockholdersEquity",
     "longName": "10801 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://glyc.com/role/DisclosureStockBasedCompensation",
     "longName": "10901 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://glyc.com/role/DisclosureIncomeTaxes",
     "longName": "11001 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://glyc.com/role/DisclosureResearchAndLicenseAgreements",
     "longName": "11101 - Disclosure - Research and License Agreements",
     "shortName": "Research and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "glyc:ResearchAndLicenseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "glyc:ResearchAndLicenseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://glyc.com/role/DisclosureEmployeeBenefitPlan",
     "longName": "11201 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentCharges",
     "longName": "11301 - Disclosure - Restructuring and Asset Impairment Charges",
     "shortName": "Restructuring and Asset Impairment Charges",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables",
     "longName": "30403 - Disclosure - Net Loss Per Share of Common Stock (Tables)",
     "shortName": "Net Loss Per Share of Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://glyc.com/role/DisclosureAccruedExpensesTables",
     "longName": "30603 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://glyc.com/role/DisclosureOperatingLeasesTables",
     "longName": "30703 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://glyc.com/role/DisclosureStockBasedCompensationTables",
     "longName": "30903 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://glyc.com/role/DisclosureIncomeTaxesTables",
     "longName": "31003 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesTables",
     "longName": "31303 - Disclosure - Restructuring and Asset Impairment Charges (Tables)",
     "shortName": "Restructuring and Asset Impairment Charges (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails",
     "longName": "40101 - Disclosure - Description of the Business (Details)",
     "shortName": "Description of the Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_7_31_2024_kOgWP4JoZ0qcll1HUFWAMQ",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_28_2024_TP4f-xHx2E2A5iRUPIKLLA",
      "name": "glyc:MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://glyc.com/role/DisclosureGoingConcernDetails",
     "longName": "40201 - Disclosure - Going Concern (Details)",
     "shortName": "Going Concern (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestructuringAndSegmentInformationDetails",
     "longName": "40301 - Disclosure - Summary of Significant Accounting Policies - Restructuring and Segment Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Restructuring and Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:SeveranceCosts1",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails",
     "longName": "40302 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)",
     "shortName": "Summary of Significant Accounting Policies - Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_fba-gQlZbEu4aT4dU-Zdgg",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_fba-gQlZbEu4aT4dU-Zdgg",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails",
     "longName": "40304 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details)",
     "shortName": "Summary of Significant Accounting Policies - Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
       "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_J7qgUFtkl0Wo9KigpKzqfQ",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
       "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails",
     "longName": "40305 - Disclosure - Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details)",
     "shortName": "Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_goAAe-HQTkGa8mwVYUZwOg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails",
     "longName": "40401 - Disclosure - Net Loss Per Common Share (Details)",
     "shortName": "Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_goAAe-HQTkGa8mwVYUZwOg",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "40501 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
     "longName": "40601 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://glyc.com/role/DisclosureOperatingLeasesDetails",
     "longName": "40701 - Disclosure - Operating Leases (Details)",
     "shortName": "Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "glyc:LesseeOperatingLeaseNumberOfNewLeases",
      "unitRef": "Unit_Standard_lease_a1VBadA-40-Zv384mN5EKA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "glyc:LesseeOperatingLeaseNumberOfNewLeases",
      "unitRef": "Unit_Standard_lease_a1VBadA-40-Zv384mN5EKA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails",
     "longName": "40702 - Disclosure - Operating Leases - Components of lease expense (Details)",
     "shortName": "Operating Leases - Components of lease expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails",
     "longName": "40703 - Disclosure - Operating Leases - Maturities of lease liability (Details)",
     "shortName": "Operating Leases - Maturities of lease liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://glyc.com/role/DisclosureOperatingLeasesSupplementalInformationDetails",
     "longName": "40704 - Disclosure - Operating Leases - Supplemental Information (Details)",
     "shortName": "Operating Leases - Supplemental Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "glyc:LeaseQuantitativeDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "glyc:LeaseQuantitativeDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
     "longName": "40801 - Disclosure - Stockholders' Equity - Equity Offerings (Details)",
     "shortName": "Stockholders' Equity - Equity Offerings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_1_2022_To_3_31_2022_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_U4gkV-b8YE6xJmFs08VMbg",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
     "longName": "40901 - Disclosure - Stock-based Compensation - Incentive Plans (Details)",
     "shortName": "Stock-based Compensation - Incentive Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg",
      "name": "glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg",
      "name": "glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
     "longName": "40902 - Disclosure - Stock-based Compensation - Company's Stock Option Activity (Details)",
     "shortName": "Stock-based Compensation - Company's Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NeI1DrJAfU2Pdw5yL4hyCw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails",
     "longName": "40903 - Disclosure - Stock-based Compensation - Summary of RSU Activity (Details)",
     "shortName": "Stock-based Compensation - Summary of RSU Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_KEVqEI1mz0alUnOYmZkAMQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails",
     "longName": "40904 - Disclosure - Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details)",
     "shortName": "Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_glyc_OtherAwardsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-V6DN7K7xkqKAShmvSchFQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "unitRef": "Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_glyc_OtherAwardsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-V6DN7K7xkqKAShmvSchFQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "unitRef": "Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
     "longName": "40905 - Disclosure - Stock-based Compensation - Inducement Plan (Details)",
     "shortName": "Stock-based Compensation - Inducement Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_t2wb_CLKRESBcc-YEXDRlw",
      "name": "glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_t2wb_CLKRESBcc-YEXDRlw",
      "name": "glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails",
     "longName": "40906 - Disclosure - Stock-based Compensation - Inducement Plan - Stock Option Activity (Details)",
     "shortName": "Stock-based Compensation - Inducement Plan - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_QC2B5nm5zE6wl4KPu8GzAw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails",
     "longName": "40907 - Disclosure - Stock-based Compensation - Weighted-Average assumptions (Details)",
     "shortName": "Stock-based Compensation - Weighted-Average assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
     "longName": "40908 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail",
     "longName": "41001 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)",
     "shortName": "Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail",
     "longName": "41002 - Disclosure - Income Taxes - NOLs and carryforwards (Detail)",
     "shortName": "Income Taxes - NOLs and carryforwards (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_SHUtEQJ4gEmeTUN1FXH1Jg",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_SHUtEQJ4gEmeTUN1FXH1Jg",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail",
     "longName": "41003 - Disclosure - Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)",
     "shortName": "Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail",
     "longName": "41201 - Disclosure - Employee Benefit Plan (Detail)",
     "shortName": "Employee Benefit Plan (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesDetails",
     "longName": "41301 - Disclosure - Restructuring and Asset Impairment Charges (Details)",
     "shortName": "Restructuring and Asset Impairment Charges (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_7_31_2024_kOgWP4JoZ0qcll1HUFWAMQ",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "Unit_Standard_employee__mI-PxD8qU-9RiyVThW_0Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_7_31_2024_kOgWP4JoZ0qcll1HUFWAMQ",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "Unit_Standard_employee__mI-PxD8qU-9RiyVThW_0Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails",
     "longName": "41302 - Disclosure - Restructuring and Asset Impairment Charges - Severance cost (Details)",
     "shortName": "Restructuring and Asset Impairment Charges - Severance cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w",
      "name": "us-gaap:PaymentsForRestructuring",
      "unitRef": "Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20241231xs4.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r25",
      "r28",
      "r603"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r520"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails",
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r520",
      "r659"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r556",
      "r557",
      "r558",
      "r560",
      "r610",
      "r660"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r207"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r248"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive securities excluded from computation of earnings per share",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r69",
      "r84",
      "r99",
      "r128",
      "r130",
      "r141",
      "r142",
      "r149",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r289",
      "r293",
      "r317",
      "r381",
      "r432",
      "r495",
      "r496",
      "r520",
      "r541",
      "r572",
      "r573",
      "r619"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r86",
      "r99",
      "r149",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r289",
      "r293",
      "r317",
      "r520",
      "r572",
      "r573",
      "r619"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets measured at fair value levels 2 or 3",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r513"
     ]
    },
    "glyc_AtMarketOffering2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "AtMarketOffering2022Member",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertains to the sale of common stock under an at-the-market sales agreement under a shelf registration statement filed in March 2022.",
        "label": "At Market Offering 2022 [Member]",
        "terseLabel": "2022 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Accounting",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureGoingConcernDetails",
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r82",
      "r488"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r45",
      "r97"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r45"
     ]
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r533",
      "r535",
      "r536",
      "r537",
      "r538",
      "r556",
      "r557",
      "r560",
      "r610",
      "r657",
      "r660"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r420"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r34",
      "r420",
      "r438",
      "r660",
      "r661"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.001 par value; 150,000,000 shares authorized at September 30, 2024; 100,000,000 shares authorized at December 31, 2023; 64,483,958 shares issued and outstanding at September 30, 2024; 64,393,744 shares issued and outstanding at December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r383",
      "r520"
     ]
    },
    "glyc_CommonStockValueAvailableForSaleUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "CommonStockValueAvailableForSaleUnderAgreement",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock remaining available to be sold under the terms of the agreement at the end of the period.",
        "label": "Common Stock Value Available For Sale Under Agreement",
        "terseLabel": "Common stock available for sale under agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans, Other than Share-Based Compensation [Text Block]",
        "terseLabel": "Employee Benefit Plan",
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred income tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "verboseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r73"
     ]
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]",
        "terseLabel": "Restructuring Charges",
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "glyc_CrescentBiopharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "CrescentBiopharmaIncMember",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Crescent Biopharma Inc.",
        "label": "Crescent Biopharma Inc [Member]",
        "terseLabel": "Crescent Biopharma, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of prepaid expenses and other current assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred income tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r63",
      "r266"
     ]
    },
    "glyc_DeferredTaxAssetsAccruedBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "DeferredTaxAssetsAccruedBonus",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Accrued bonus.",
        "label": "Deferred Tax Assets, Accrued Bonus",
        "terseLabel": "Accrued bonus"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_DeferredTaxAssetsCapitalizedResearchCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchCosts",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences capitalized research costs.",
        "label": "Deferred Tax Assets Capitalized Research Costs",
        "terseLabel": "Capitalized research costs"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_DeferredTaxAssetsCapitalizedStartUpCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedStartUpCosts",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences capitalized start up costs.",
        "label": "Deferred Tax Assets Capitalized Start Up Costs",
        "terseLabel": "Capitalized start-up costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred income tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred income tax asset/(liability)",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "glyc_DeferredTaxAssetsPatentAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "DeferredTaxAssetsPatentAmortization",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences patent amortization.",
        "label": "Deferred Tax Assets Patent Amortization",
        "terseLabel": "Patent amortization"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_DeferredTaxAssetsResearchAndOrphanDrugCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "DeferredTaxAssetsResearchAndOrphanDrugCredits",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from research and orphan drug credits.",
        "label": "Deferred Tax Assets Research And Orphan Drug Credits",
        "terseLabel": "Research and orphan drug credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "glyc_DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.",
        "label": "Deferred Tax Assets Tax Deferred Expense Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "glyc_DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating lease right-of-use assets.",
        "label": "Deferred Tax Liabilities Tax Deferred Expense Operating Lease Liabilities Right Of Use Assets",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer match contribution",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Percent of employee contributions the company contributes a matching contribution",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Company matching contribution percentage",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "auth_ref": [
      "r567",
      "r658"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r209",
      "r240",
      "r241",
      "r243",
      "r507"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per common share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r117",
      "r119",
      "r121",
      "r122",
      "r123",
      "r127",
      "r284",
      "r287",
      "r303",
      "r304",
      "r378",
      "r389",
      "r490"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per common share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r119",
      "r121",
      "r122",
      "r123",
      "r127",
      "r284",
      "r287",
      "r303",
      "r304",
      "r378",
      "r389",
      "r490"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Loss Per Share of Common Stock",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r124",
      "r125",
      "r126"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Provision for income taxes",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r510"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. Federal statutory tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r255",
      "r276",
      "r510"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r510",
      "r555",
      "r604"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "negatedLabel": "Stock-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r555",
      "r604",
      "r606"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r510",
      "r555",
      "r604"
     ]
    },
    "glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent",
        "terseLabel": "Orphan drug credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research credit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r555",
      "r604",
      "r606"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for unrecognized compensation expense related to unvested options yet has not been recognized",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to unvested service RSUs",
        "verboseLabel": "Unrecognized compensation expense related to unvested options",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to unvested options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee severance",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "EmployeeStockOptionsAndRestrictedStockUnitsMember",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to stock options and restricted stock units.",
        "label": "Employee Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock options and restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://glyc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r78",
      "r90",
      "r91",
      "r92",
      "r101",
      "r102",
      "r103",
      "r105",
      "r110",
      "r112",
      "r114",
      "r129",
      "r150",
      "r151",
      "r154",
      "r192",
      "r274",
      "r275",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r340",
      "r388",
      "r394",
      "r395",
      "r396",
      "r406",
      "r458"
     ]
    },
    "glyc_EquityIncentivePlan2013Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "EquityIncentivePlan2013Member",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the 2013 Equity Incentive Plan.",
        "label": "Equity Incentive Plan 2013 [Member]",
        "terseLabel": "2013 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_EquityInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "EquityInducementPlanMember",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to inducement plan.",
        "label": "Equity Inducement Plan [Member]",
        "terseLabel": "Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to executive compensation.",
        "label": "Executive Compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Executive compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r314",
      "r513"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r314",
      "r513"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r313",
      "r314",
      "r316",
      "r341",
      "r342",
      "r343",
      "r499",
      "r500",
      "r503",
      "r504",
      "r505",
      "r513",
      "r515"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r196",
      "r201",
      "r307",
      "r314",
      "r341",
      "r503",
      "r504",
      "r505",
      "r513"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r196",
      "r201",
      "r307",
      "r308",
      "r314",
      "r342",
      "r499",
      "r500",
      "r503",
      "r504",
      "r505",
      "r513"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r307",
      "r308",
      "r309",
      "r310",
      "r314",
      "r343",
      "r499",
      "r500",
      "r503",
      "r504",
      "r505",
      "r513",
      "r515"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r313",
      "r314",
      "r316",
      "r341",
      "r342",
      "r343",
      "r499",
      "r500",
      "r503",
      "r504",
      "r505",
      "r513",
      "r515"
     ]
    },
    "glyc_FederalAndStateAuthoritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "FederalAndStateAuthoritiesMember",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the U. S. government and the designated tax department of the state government entitled to levy and collect income taxes.",
        "label": "Federal And State Authorities [Member]",
        "terseLabel": "U.S. Federal And State"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_FirstPortionSquareFeetRockvilleMarylandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "FirstPortionSquareFeetRockvilleMarylandMember",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to first portion of the Rockville, Maryland lease.",
        "label": "First Portion Square Feet Rockville, Maryland [Member]",
        "terseLabel": "First portion of Rockville, Maryland lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Assets",
        "terseLabel": "Gain on sale of asset",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment",
        "negatedTerseLabel": "Loss on disposal of assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r442"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_GeneralBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralBusinessMember",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Business Tax Credit Carryforward [Member]",
        "terseLabel": "General Business Tax Credit Carryforward",
        "documentation": "Tax credit carryforwards which include, but are not limited to, investment, alcohol fuels, low income housing, alternative fuels, alternative motor vehicles, hurricane relief, disabled access, renewable resources electricity production, employer social security, orphan drug, new markets, employer provided child care facilities and services, biodiesel fuels, low sulfur diesel fuel production, distilled spirits and the advanced nuclear power facilities credit."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "glyc_GlycoMimeticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "GlycoMimeticsIncMember",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to GlycoMimetics, Inc.",
        "label": "GlycoMimetics, Inc [Member]",
        "terseLabel": "GlycoMimetics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "glyc_GoingConcernAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "GoingConcernAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Going Concern"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r208",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r208",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r159",
      "r311",
      "r312",
      "r315",
      "r391",
      "r393",
      "r443",
      "r486",
      "r514",
      "r629"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r159",
      "r311",
      "r312",
      "r315",
      "r391",
      "r393",
      "r443",
      "r486",
      "r514",
      "r629"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r255",
      "r256",
      "r263",
      "r271",
      "r510",
      "r608"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r255",
      "r256",
      "r263",
      "r271",
      "r510",
      "r608"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r252",
      "r255",
      "r260",
      "r261",
      "r262",
      "r264",
      "r270",
      "r277",
      "r278",
      "r279",
      "r280",
      "r404",
      "r510"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r253",
      "r254",
      "r264",
      "r265",
      "r269",
      "r273",
      "r401"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "verboseLabel": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in prepaid research and development expenses.",
        "label": "Increase Decrease In Prepaid Research And Development Expenses",
        "negatedLabel": "Prepaid research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Nonoperating",
        "terseLabel": "Interest income",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r551",
      "r563"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Issuance of common stock for services",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r519"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Components of lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense and related cash flows",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_LeasePracticalExpedientLessorSingleLeaseComponent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasePracticalExpedientLessorSingleLeaseComponent",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Practical Expedient, Lessor Single Lease Component [true false]",
        "documentation": "Indicates (true false) whether practical expedient is elected to account for lease component and nonlease component as single lease component."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "glyc_LeaseQuantitativeDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "LeaseQuantitativeDisclosureTableTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental information related to leases.",
        "label": "Lease Quantitative Disclosure [Table Text Block]",
        "terseLabel": "Schedule of supplemental information related to leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r339"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r339"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of lease liabilities due",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "glyc_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Two",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "glyc_LesseeOperatingLeaseNumberOfNewLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "LesseeOperatingLeaseNumberOfNewLeases",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of additional operating leases entered into during the period.",
        "label": "Lessee Operating Lease Number Of New Leases",
        "terseLabel": "Number of additional operating leases entered during the period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r615"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Operating Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r32",
      "r99",
      "r149",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r290",
      "r293",
      "r294",
      "r317",
      "r419",
      "r491",
      "r541",
      "r572",
      "r619",
      "r620"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r64",
      "r385",
      "r520",
      "r554",
      "r568",
      "r613"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities &amp; stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r81",
      "r99",
      "r149",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r290",
      "r293",
      "r294",
      "r317",
      "r520",
      "r572",
      "r619",
      "r620"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities measured at fair value levels 2 or 3",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r611"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail",
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r203",
      "r249",
      "r310",
      "r346",
      "r390",
      "r392",
      "r399",
      "r411",
      "r412",
      "r463",
      "r465",
      "r467",
      "r468",
      "r470",
      "r484",
      "r485",
      "r498",
      "r501",
      "r506",
      "r515",
      "r516",
      "r517",
      "r518",
      "r529",
      "r574",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ]
    },
    "glyc_MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum net cash of the company at the closing of the merger for the determination of the exchange ratio of shares as per the agreement.",
        "label": "Merger Agreement, Exchange Ratio Determination, Maximum Net Cash at Closing",
        "terseLabel": "Net cash at closing of the merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "terseLabel": "Noncontrolling ownership (as percentage)",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Ownership Percentage, Parent",
        "terseLabel": "Parent ownership (as percentage)",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Carrying value of cash held in money market fund",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of the Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r77"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://glyc.com/role/DisclosureGoingConcernDetails",
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash flows used in operating activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r47",
      "r65",
      "r79",
      "r87",
      "r88",
      "r92",
      "r99",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r120",
      "r149",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r284",
      "r287",
      "r304",
      "r317",
      "r387",
      "r440",
      "r456",
      "r457",
      "r539",
      "r572"
     ]
    },
    "glyc_NetIncomeLossAndComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "NetIncomeLossAndComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureGoingConcernDetails",
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss and comprehensive income for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss And Comprehensive Income Net Of Tax",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that have been adopted during the period.",
        "label": "New Accounting Pronouncements Adopted Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestructuringAndSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r562"
     ]
    },
    "glyc_NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestructuringAndSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions remaining after restructuring and related activities.",
        "label": "Number of Positions Remaining After Restructuring and Related Costs",
        "terseLabel": "Number of positions remaining after restructuring and related activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total costs and expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r492",
      "r561",
      "r563",
      "r564",
      "r565",
      "r566"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r519"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails",
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Asset impairment",
        "verboseLabel": "Impairment loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Maturities of lease liability due"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease payments",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash outflows for operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r336"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Non-cash lease expense",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average incremental borrowing rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r519"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of the Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets",
        "terseLabel": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r83",
      "r380",
      "r496",
      "r541"
     ]
    },
    "glyc_OtherAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "OtherAwardsMember",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to other awards.",
        "label": "Other Awards [Member]",
        "terseLabel": "Other Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r569"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "negatedLabel": "Cash payments",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r552"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "glyc_PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of common stock issued and outstanding on the immediately preceding fiscal year, or such lesser number of shares as determined by the board of directors or the compensation committee.",
        "label": "Percentage Of Total Number Of Common Stock Stock Issued Or Outstanding Immediately Preceding Fiscal Year Or Lesser Number As Determined By Board Of Directors Or Compensation Committee",
        "terseLabel": "Maximum percentage of shares of common stock issued and outstanding on the immediately preceding fiscal year, or such lesser number of shares as determined by the board of directors or the compensation committee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ]
    },
    "glyc_PostClosingOfPrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "PostClosingOfPrivatePlacementMember",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the scenario post the closing of the private placement as per the terms of the merger agreement.",
        "label": "Post the Closing of Private Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r180"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r420"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r180"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r420",
      "r438",
      "r660",
      "r661"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at September 30, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r382",
      "r520"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid research and development expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r152",
      "r153",
      "r489"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Prepaid research and development expenses",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "glyc_PriorToClosingOfPrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "PriorToClosingOfPrivatePlacementMember",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the scenario prior to the closing of the private placement as per the terms of the merger agreement.",
        "label": "Prior to Closing of Private Placement [Member]",
        "terseLabel": "Prior to closing of private placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r87",
      "r88",
      "r94",
      "r99",
      "r104",
      "r110",
      "r113",
      "r114",
      "r149",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r284",
      "r287",
      "r288",
      "r291",
      "r292",
      "r304",
      "r317",
      "r379",
      "r386",
      "r405",
      "r440",
      "r456",
      "r457",
      "r511",
      "r512",
      "r540",
      "r550",
      "r572"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail",
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r195",
      "r203",
      "r235",
      "r236",
      "r237",
      "r249",
      "r310",
      "r344",
      "r345",
      "r346",
      "r390",
      "r392",
      "r399",
      "r411",
      "r412",
      "r463",
      "r465",
      "r467",
      "r468",
      "r470",
      "r484",
      "r485",
      "r498",
      "r501",
      "r506",
      "r515",
      "r516",
      "r517",
      "r518",
      "r529",
      "r533",
      "r570",
      "r574",
      "r612",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://glyc.com/role/DisclosureEmployeeBenefitPlanDetail",
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r195",
      "r203",
      "r235",
      "r236",
      "r237",
      "r249",
      "r310",
      "r344",
      "r345",
      "r346",
      "r390",
      "r392",
      "r399",
      "r411",
      "r412",
      "r463",
      "r465",
      "r467",
      "r468",
      "r470",
      "r484",
      "r485",
      "r498",
      "r501",
      "r506",
      "r515",
      "r516",
      "r517",
      "r518",
      "r529",
      "r533",
      "r570",
      "r574",
      "r612",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r486",
      "r495",
      "r627"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "glyc_ResearchAndLicenseAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "ResearchAndLicenseAgreementTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureResearchAndLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research services and license agreements, including contracts and arrangements to be performed by or for others. Includes contingent payment receivables or liabilities for achievement of specific milestones.",
        "label": "Research And License Agreement Text Block",
        "terseLabel": "Research and License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_ResearchAndLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "ResearchAndLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Research and License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSU",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Reduction in workforce under corporate restructuring",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Percentage of reduction in workforce under corporate restructuring",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesDetails",
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "terseLabel": "Total charges in headcount reduction under corporate restructuring",
        "verboseLabel": "Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r161",
      "r162",
      "r571"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r162",
      "r163"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r162",
      "r163",
      "r164"
     ]
    },
    "us-gaap_RestructuringCostsAndAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostsAndAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Costs and Asset Impairment Charges",
        "terseLabel": "Restructuring and asset impairment charges",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_RestructuringCostsAndAssetImpairmentChargesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostsAndAssetImpairmentChargesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Asset Impairment Charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentCharges"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring and Asset Impairment Charges",
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesDetails",
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r544"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve",
        "periodEndLabel": "Severance accrual, December 31",
        "periodStartLabel": "Severance accrual, January 1",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r163"
     ]
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "terseLabel": "Impairment charges related to our facility operating lease",
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r53",
      "r384",
      "r397",
      "r398",
      "r403",
      "r421",
      "r520"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r101",
      "r102",
      "r103",
      "r105",
      "r110",
      "r112",
      "r114",
      "r150",
      "r151",
      "r154",
      "r274",
      "r275",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r295",
      "r297",
      "r298",
      "r300",
      "r302",
      "r324",
      "r326",
      "r394",
      "r396",
      "r406",
      "r660"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "verboseLabel": "Revenue from collaboration and license agreements.",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r128",
      "r131",
      "r132",
      "r140",
      "r142",
      "r144",
      "r145",
      "r147",
      "r193",
      "r194",
      "r347"
     ]
    },
    "glyc_RockvilleMarylandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "RockvilleMarylandMember",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to Rockville, Maryland.",
        "label": "Rockville Maryland [Member]",
        "terseLabel": "Rockville, Maryland"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_SaleOfStockAggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "SaleOfStockAggregatePurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of shares and warrants to be issued by the entity as per the stock transaction.",
        "label": "Sale Of Stock, Aggregate Purchase Price",
        "terseLabel": "Aggregate purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate net proceeds from stock sale",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r115",
      "r204",
      "r545",
      "r559"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities outstanding",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of components of the gross deferred tax asset and related valuation allowance",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r510",
      "r604"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of RSU activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r162",
      "r163",
      "r164"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of activity for accrued severance costs",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r50",
      "r51"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r208",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of the Company's stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r57"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted-average fair value of options granted under all equity incentive plans",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "glyc_SecondPortionSquareFeetRockvilleMarylandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "SecondPortionSquareFeetRockvilleMarylandMember",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to second portion of the Rockville, Maryland lease.",
        "label": "Second Portion Square Feet Rockville, Maryland [Member]",
        "terseLabel": "Second portion of Rockville, Maryland lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "terseLabel": "Deposits",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r408",
      "r409",
      "r410",
      "r464",
      "r466",
      "r469",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r487",
      "r502",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r533",
      "r575",
      "r628",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r143",
      "r145",
      "r493",
      "r494",
      "r497"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestructuringAndSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Severance charges",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Authorized Shares Disclosure Abstract",
        "terseLabel": "Authorized shares"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of monthly installments for Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Number of Monthly Installments",
        "terseLabel": "Number of monthly installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Restricted Stock Units information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested at end of period",
        "periodStartLabel": "Unvested at beginning of period",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "NUMBER OF SHARES",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested at end of period",
        "periodStartLabel": "Unvested at beginning of period",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "WEIGHTED-AVERAGE GRANT DATE FAIR VALUE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Expiration Period After Termination Of Employment",
        "terseLabel": "Period from date of termination that any vested options shall expire"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-average assumptions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r208",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum fair value of option excluded from the unrecognized compensation expense under the share based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Fair Value Of Option Excluded From Unrecognized Compensation Expense",
        "terseLabel": "Maximum fair value of option excluded from the unrecognized compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in number of shares of common stock",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of maximum shares issued upon exercise of incentive stock options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Maximum Shares Issued Upon Exercise Of Incentive Stock Options",
        "terseLabel": "Maximum number of shares that may be issued pursuant to exercise of incentive stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Common stock authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "ADDITIONAL DISCLOSURES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Outstanding options exercisable at end of period",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price exercisable at end of period",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value of the options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "OUTSTANDING OPTIONS",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "WEIGHTED-AVERAGE EXERCISE PRICE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "VESTED AND EXPECTED TO VEST"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Outstanding options",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock shares issued",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Upon first anniversary of start date",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Each month after the first anniversary",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r213",
      "r232",
      "r233",
      "r234",
      "r235",
      "r238",
      "r244",
      "r245",
      "r246",
      "r247"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationSummaryOfRsuActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employees",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "ShareBasedPaymentArrangementNewlyHiredEmployeeMember",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Newly hired recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Newly Hired Employee [Member]",
        "terseLabel": "Newly hired employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Non-employee",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r210",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percent of shares subject to option grant that will vest",
        "verboseLabel": "Vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average contractual term (years) exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average contractual term outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "glyc_SquareFeetLeased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "SquareFeetLeased",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Square feet leased.",
        "label": "Square Feet Leased",
        "terseLabel": "Square feet leased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r34",
      "r37",
      "r38",
      "r78",
      "r90",
      "r91",
      "r92",
      "r101",
      "r102",
      "r103",
      "r105",
      "r110",
      "r112",
      "r114",
      "r129",
      "r150",
      "r151",
      "r154",
      "r192",
      "r274",
      "r275",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r302",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r340",
      "r388",
      "r394",
      "r395",
      "r396",
      "r406",
      "r458"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r408",
      "r409",
      "r410",
      "r464",
      "r466",
      "r469",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r487",
      "r502",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r533",
      "r575",
      "r628",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationTables",
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r129",
      "r326",
      "r347",
      "r400",
      "r407",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r441",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r534"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r115",
      "r204",
      "r545",
      "r546",
      "r559"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationTables",
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r129",
      "r148",
      "r326",
      "r347",
      "r400",
      "r407",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r441",
      "r442",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r458",
      "r534"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for services, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r33",
      "r34",
      "r53",
      "r402",
      "r458",
      "r472"
     ]
    },
    "glyc_StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options and vesting of stock units exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options And Restricted Stock Units Vesting",
        "terseLabel": "Exercise of options and vesting of restricted stock units, shares"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options and warrants and vesting of stock units exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options And Warrants And Restricted Stock Units Vesting",
        "terseLabel": "Exercise of options and vesting of restricted stock units, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised",
        "positiveLabel": "Shares issued from exercise of stock options",
        "terseLabel": "Options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r33",
      "r34",
      "r53",
      "r219"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r33",
      "r34",
      "r53",
      "r406",
      "r458",
      "r472",
      "r540"
     ]
    },
    "glyc_StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of share options and vesting of stock units exercised during the current period.",
        "label": "Stock Issued During Period Value Stock Options And Restricted Stock Units Vesting",
        "terseLabel": "Exercise of options and vesting of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of share options and warrants and vesting of stock units exercised during the current period.",
        "label": "Stock Issued During Period Value Stock Options And Warrants And Restricted Stock Units Vesting",
        "terseLabel": "Exercise of options and vesting of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_StockOptionsVestingBasedOnPerformanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://glyc.com/20241231",
     "localname": "StockOptionsVestingBasedOnPerformanceMember",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationCompanySStockOptionActivityDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a stock option award with vesting based on achievement of performance conditions.",
        "label": "Stock Options Vesting Based On Performance [Member]",
        "terseLabel": "Stock options vesting based on performance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets",
      "http://glyc.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r37",
      "r38",
      "r49",
      "r422",
      "r438",
      "r459",
      "r460",
      "r520",
      "r541",
      "r554",
      "r568",
      "r613",
      "r660"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://glyc.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r98",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r301",
      "r461",
      "r462",
      "r473"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://glyc.com/role/DisclosureGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "terseLabel": "Going Concern",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credits available to carry forward",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://glyc.com/role/DisclosureIncomeTaxesNolsAndCarryforwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r567",
      "r618"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIssuanceOfSharesToDirectorsInLieuOfCashRetainersForServiceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureRestructuringAndAssetImpairmentChargesSeveranceCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r162",
      "r163"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r71",
      "r72",
      "r74",
      "r75"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://glyc.com/role/DisclosureOperatingLeasesComponentsOfLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r519"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://glyc.com/role/DisclosureStockBasedCompensationIncentivePlansDetails",
      "http://glyc.com/role/DisclosureStockBasedCompensationInducementPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted-average number of common shares outstanding (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r123"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted-average number of common shares outstanding (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r123"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "SubTopic": "30",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>111
<FILENAME>0001104659-25-014838-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-014838-xbrl.zip
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M?F)$:A6R/.O^,N;V;R&EYW96E&ZS#1$D)$3UM,W@[9O!Y49^"T!"@J,KMZ*
M$E(2I!9(K:D5)C]"=PK)F>UM!GF-->AUV8MDMLL?+=9!,B:HA.[N=@;8W0,@
M'<^6H@A'/S'9-FX'M2U'I<*4!+G-9)G> DE$3;GAYLNBDA*L7S(M%?2X_OGY
M>5>EQH0NZ =A2KH;I.@3HD-R%Y,QSZ#3.^N@%8GI+L_5W0^^[O)]RZRJ].J
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M7X4XVGMP99D)%>4@4K RJ)N@YD3KOGG13=<$FB+@'_3S3^=\^B]02P,$%
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M\>!A. *S;Z/1TTS )S+QJ;YM/5:W28?=-DY7%2MKKCG/K$#/:2\T;4UUUN]
MTW6")\P\F-;\![^V0750J*D]0_.J%3SLG$(6/]K?$RDUS:]/O2^?S\]5Y;S;
M5=6^HGY6(D)'+&" X_(3RPS*]XVTG W/L;W:J<NOP1:1UL:D?[UJJ2W@.40(
MFWE2C?2AK\S-LC=KC&P2 VZN6MVC<T)'L'1D3GZ,_N>A%\VDH?C '6H8;TB4
M2J,KF,$55UY)..1G+,ER>9RRLQ\?D ?C<9YVRI&S <R71>GSWGT?O#^0\8$
MV;ODDC"<[9^%!!<CK7=TTB*VE\%3)(7TU!3)ZK/1RV/CV 3$IFZF5(S)_+L#
M&8HL2O+RR$^2L/0^;7U9/5\PO8;8]#,;("UMD\CLT*[=W>S16)S\=/)G6%PD
M19RA<T7M]TYA7[PZCUI>$0K9(ZN(_/F!5#*A)*SQ,I'+71XDV2D<Z+KMD4#_
M4=MHSR8L&+>F)I:7RCP!4\:Y_.C> :O8@P9W^\Q,WR!N!0#*/K*)1RSA8EH^
MQ_F9FD)T"90\0;B$;!<.: OSR<MY-;(+$,K>N@OC]>R$<;R?"-[S]Q(+<X*1
MG;Q'[*_A,SQY$\LI*26A3Y"2U!DI+FBRAU%#>[7R%QASEPCVDC6%1BY<LC?(
M@6&@K4B/&C+NK*&V1BZ5+ST03D_=%$9%X,D>%DWITKX%C9&&+1("."3$]U8>
MVRUU ^=(1UEQ47'&IM!=$FG)Z<VOG;WM"E7W, AML8ZPD+G!H9O8X#![&CR-
M[D</3S,PN063Q]%T\'0W>9B!P<,-&$[N'Z>C;Z.'V=V/$1A/9@?; 9'<]4*?
M_'J [G9K&L6XCWO[AB29S)^TMSU;%\IYY(9+PG,["-RWHOA+5QGM-3-]W'@_
M*VKO\RF::0F6HHU4#!Y/R'1D/N\L%V+HN#'AHZ@>,A>.>+)*PG(YNI)TEX8L
M(?-_D-Z%&OW$ND'.VG98;#&9;Y?:U S.\S,UC.T28'D"ZE/-0.W\7-&<TRZE
M)(Q6]-*\P&1F+SB25,1=D$X2YD0IR"$O%UFA@VT?G[LIZ2FPI]/C,]9B:#LN
M-5WF/>Y6:PUA&L8.EQI>9+(J4$)<*U^4GJ)*P7<N:VFCGFJ(9>QHH44/L% <
MQ@I9B #4Z,&5_,"Y(%=#Z"Z#4D(O3:P6$G71/;@W\ 6:]IK::3[!N7D:0J\X
M1@DWU4V)Y)8';XE&AK9%#%1W?R)W.?0<E_1DF'1HID<O::!>BOPSD@/Z"B7)
M:@C"W7A=V/E;_T&GM*+GZGEFK_H%LU?#P>P;N!U/?LI[4(="WCMAP'IKI+O0
M\$\@Q!]$4CY"C&R#L(SI:N\-W/X,61^]Z4O-6D!ZAG-[LG.O"1V[\F-/JT&7
MROR([1=$S.=Z\YTT@3LK;&[^$<#L/97\!<1;U86B]K^<PJ.<QIIB<W?55";[
M^B?!-4=NSG!_ET 2DZB)F+0E[5RDLC-Y ]<8ZMO3\1E<1I,TG<U"K+*O:N_F
M%6<:O3Z"J(8HP]T\FAH)CHF78U%RX0QL7N:FVT %+12.,-JG/D45VQBWF_;@
MF;E-R=)T4Q#&SK-"+M.YK<'*QB[Z.WHS I<9%!?SL4RCI#Y\<SF7M3>Y<QR/
MWA8QF;.M)B1L_JEA3-R@<VOC&<0O2(?.! ]-#:VR_(=0&4VWFNK*\$WFDT0>
M9K;4,$Q<M)*U-SDU<0PJO:6S?]+3\K7S+H#:)_BSM#XA,3+VSYD'EY2EWA>0
MN<^C3&%-MY8:M>);TY=#1:09&]0R$>3.VN];296BFFHCM>O$MY +:<<L2;![
M!S*Y?<M>OJ::2#4%!#-6ROOI@)*'.$5,8B_KA[0*'AT$AG&HN4SNKB3]=%^2
M=='L<=2JHO::,?BH10\!^]+.?&:HZ\YZ@4Z59:Z4 B0Q%&F7N7A5)OMD.L&E
M0V@X=&-!REPPO2FX8$9=H 1)C*HF:E,7RBJI0L+==R2,8ELVGNR!3F2GWP,0
M- _N AIO'=4T4>A)VG+V3K?(TBR]0N^44H DIB)M[\2K,MG/N48=ZFY>.7(V
MFZ-/2LTGB0'51&-^3\2O -EW<J2C8A//SG?+8-L@2=-"+W3:,'T^FOI:)VQD
MD=O^<[;Y'*[.. M=PL*G#V"&AU1>R7B[KLVN1_EN4L0.,C;,]I5S105ML!.'
M_.%7 H):@&89@-4#_(K MB:ZNW8K&;#G MG^XXOX7VGWX(I?A\V5XZ27.XM<
MXYUV%=CIW(X &]EW/N=!DKT_8WBG4(<D)GPVH4/];_ZU9ID9WC>E@KADGU1A
M<$1::7:&./Z>HIZ?Y#J6*KSRXRHY'*F_\R[[&3^>GOF3TMOOF</J@,GJ(X]V
M5=(^F#T&9E#KKJ<%M&8@\@7!(]^23 \CP?1I^$TP(7*3N%V,/]NQ;WW.$XQ$
MM(15NOI(MR_H).E@1?_*:/2ERI+$'XCR&KL]NC;<TO?OZ1BYMI^&J1O N @R
M:09PPI\QY7'^GY5NMO,?!\Y_5]?.^<-M=>]@D,5@T+L'$DX]?'[2=I@B6G9"
M:5K?GN#9S2M3:MF]Y0\-(QK]%Y&42!='VU?4?E\ZCOB$EM7Y\7S$F,_]Y<2^
M8\'85V('^(&"WHA@#X3WIU=HOL![VW*7F=^O*5F<-,W\0*&O*/22_KQ^9U'S
M1[TY'(FJ)*>WMU( )@:=P?8EH2Z$R0("86B2[90UF\KV!0*A1" 4*? U\KJ:
M?04[D3UNR:LG"U,?_63VGCS9MV6F)97$(7!R$#^#S8E&]I@M 80U-5X.66))
M6!2FAH/5;'SOCM==GT4@L>_BSFW\JF&#F^SL$N(:.I?. K)IY+ !0=@'-HR,
M#>@)J?W+\='?]#L6&G:_K]EE@FF[SWGS-H'EZH /O'15@M_@/%4I@F.9/P3#
MQ8CKOX./E]5'$LA:L9/Y7'PFLS6724ZL!_[*+2^AD;..$[Q>:M8-]A9#D@)Q
M-M6\ II+LC#J U]2P4LW^67O^+/0.; JY377&*HJ@><V"JE"]23@Z'Y*TB:N
MH07G20]2O<"X_CXI7?7BW1G1@;1PX"LO>#V,?P[VVK8\/A<2S= $>DNB++QC
M0C8GP'9><0_-:>(FL%L"8>'=$+(QFYPYYZ4YF5-VSBO,O7&"E?Y470 L7&0I
MO@(B+TM,">3'B:Y^J#!GSHWJT-06][D1"06BT+V+]HKZZ7HJD<0N2I.=W<,?
M4#\RKL!.H6Y;.D'!"KJ&[BN$%KTXWR,&O+F%!OU@2)B>GBZE)X_9 =/P8U#^
M"\$5V<36CKT5V;ADP!<-A+(!7[A(/D#%8*NTH82)M]*OT:8KEW[% 5D>,;W=
MYSWW6KI(QB/W2NFBQ1D>N#ZA(<.QQ!F=5PTEQ]MJ5U'/3S*7(<Y[M+L[E!YD
M7WGDP<V^ T+<UIA(8$9\7P63RBKRP]B2D )D/X#% Y@\]*>$@^GB"N:3+.S#
M& XG=,%[X^N*QH40[!8+'B'6D\?U:BCQ79O%H?"?9K5M] 9UCP*)SN/RH'NP
M:03LD63/9G ,9'=Y@;^-<T#OO%ZPKU7E&=.196B ^<F@L<+UPA-\+I5'!\$Y
MZ^TC:W%'F''2S;.N8N/ZHT=13C*Q</A^4%@)LB\L5F]4T2::<Z"G_HH^C-'5
MH!;9+^/G4<.0795V9Y5?+*FYE@]C@%5U4G)A-6T*]6MG2ZP_R_?;_P%02P,$
M%     @ HHE26F%-5,X0*   ?<@" !4   !G;'EC+3(P,C0Q,C,Q7V1E9BYX
M;6SM?5ESXSB6[OM$W/_ ZWGHN0].+UG559E1V1/RDMF.L2U?V]D]_51!DY#%
M*8IP$Z33ZE\_ $A*% 6 X +B4-9+55K$<I8/!^=@.?CM/]\6H?.*8A+@Z,O!
MR8?C P=%'O:#Z/G+09K,#G\]^,^__)]_^^W_'A[^]]G]M>-C+UV@*'&\&+D)
M\IT?03)W'O'+BQLY-RB.@S!TSN+ ?T:.<W+\X=.'XP\?G</#O_ FSEQ"J^#(
MX6V=?C@I/ISGK>'HLW-Z=/+KT>GQZ<_.I\^GIY^/?W+N;HIR-Y2R65!7, RB
M/SZS_SS1_AS*840^OY'@R\$\25X^'QW]^/'CPX^/'W#\3*L?GQS]]\WU@S='
M"_<PB$CB1AXZ<&CYSX3_>(T]-^'B*55_>XK#HH&/1ZN^I"787X=%L4/VT^')
MZ>''DP]OQ#_(262?-3HIBK.O@:)\B9=5>3]952@7_ODH^[@JND5*+JZ33Y\^
M'?&O!W_Y-\?Y+<8AND<SA__T.5F^H"\')%B\A*Q7_ML\1K,O!\_ATJ-<G_YT
M<IKQ_.\/"54X0]+J'V0Z>TBP]\<<ASX%Y.4_TR!9'CBLB^_W5RMJ6%,?/+PX
M8A^.M)OAC&E)]Z@C9Q<!\4),TAAQ.CCFS_'B!46$X^C1?0H1J6-,MQ4;?%T@
MXL7!"R-C.CM+21 A0BY0X@9A [[4K5C15[I8N/&2 BAXCJB=\=PHF7@>3J.$
MVL,[' 9>@,A7-XC_YH8IND$NJ\5!UYC[/OJ"*R,Q9@T)J:8SN%*ZPPG59^"&
MX?(B"-,D>$4/R$OC(*$?#0E+KT\;,KM%R34FY [%5(T+'#W,768D&DI!W8H-
MOJ8O*':9"J[I&&ZA5UE]:S/:QLR:_7<ZFZ&8DM@"M=HMPIG!KZA7%;&1<Q>Z
M44N6=1N%PS7[MQLM'_C7*9^W)QXEF"JK)Q'H] !''BM[>T_2G@6A;!J.!*X(
M25F$0:<<9F7)([X(8N0E."97T76 TNGLW"7S>T9Y1,?W5QP_H/@U\)J;=6,$
M ))FY*<>]_"8!>C-J@@;A<JU.=NBWP\<V8A_O7QC_^QK".GU84,F=$+$"_3H
MOB%RBT,RB?QS-XZ7,QS_<&,_GR'UV==LS@:GE[0X7B)TAB(T"THC59\[11,V
M.+I')(E3+TF9"T=%/2$$)5=T=@]B-@3/J;5^IH$;>J6N+;7?YY@DC?'<I8^F
M,N%L%X+1'W!NY%-L,:BE),&+R5M +O""SD47:.:F84(..EH-C0XT&)BYY(GS
MGI+#9]=]R1A!R%\<7;[1<)$$3R&ZC-(%#T0PG5F)#NFL=5*L-&[UP7@Z0I1$
M]@OKD' V.8NLZPW*W=@KB,__6::?Z0^1A?L!I3%^8?_C?1XA@F9'>?FC'P$-
M,0XC.N;Q#Q3K45_%1AC'J_98AX?Y'Y3RDU\/3TX.3S,55?O2YF354Q E1WZP
M6/5&X_5V))=6=]FR\\^</MY:=Z+HOQDX<'3H9W#KD41!V[T2S$>)&7KSIGL@
ME[=TN$"+I[:(%=.ZV6YW0N>4IMA+G]#A2@P]DBMLO40T!4@0!9EABO[8Z!<Q
M\^4CO^B94=O1[+%^BYY#[&UT%[*M(ARW-H/LE[45S'_X_3IPGX*0+]!-GNB<
MYWJK@1:Z3RC\<J HD00)8UE8XFAX7C87LPJJEN=I'-,YN\*67N&<P[K"&\RN
M(3.)-]FFD"X:SM'=<IS.8KQ0:P8WY'!-]&='T*Z38*>NO930=C"/>UPZ!;S$
M 8[I]R\'QP<.CNFD]>7@!!(N;G'D-8'&=GDU.LKEQP00*9_M,5)N4@,FIU9@
MD@5QJ[U>B3G4+)V+K+:T!3XW8AL6N1!I@"/AO44+%7DT:J'YX,G@KZLJW)*N
M"I+[&+?;(ZV&"><1.ZV(SX?:+\>5(9CY/D<"YZ>[4]0EF!U^G*QDG6T:L24L
M'+$]<D9=961HE<V56U/6@D6H$'*Q$;_D'"K+Y)Q)RIB<_&118F8!]-2"];@K
M3W_*AME$*&FP8C+Z=XM(G)0T3O]::YO^\?MYNDA#E^T$7LYFR$ON$!W[_G0V
M\3.B!-!N4B67E%X5("P+T=ZLDB;;]L=#(UWBEF(HCQ.=#MEPT>W(^/AI8#79
M.OBMNT"",2/ZE$MG\Y-%LH6X%W^LD&X?QT+YXAKRR[@L-\#P5ZT("6</Z1,)
M_,"-EP]NB/(3J"(?I*Y<X7_(R]G@;DT#4\!T]AB[$:&>K<PTZU<H^-6H8-%%
MJ=4:;L'SAJ\BZX$!7Z=EVT[+O1L]BZSLUN\Y\Z7?AZ3P9B.2*]-X(XKQ-K[8
MP]^V$+&*ZC*P5E49D#:J0#.?Z)\I\]5?Z7\>:5<2XZDH53*=PE(P^!+;R[IR
M<MY@6$>56K ^?U63*&B6&T1Y<Y!0_3=$V#*K ,F"+[D$-K[8HUF(4N&W3;KM
MHU$D6JRFO8RZ4G6&M$HU2.B:1 GU&*HG^"_?O##UD?^5"H.M;*2)FUVPN73C
MB!VGIE$;/RMYMA0W($#K #WEFC#:$Q@=22,[W>)*:<&(_H; #&XLL?)(-T@A
MLQSUE$$R)JM[9F?+U3__&J"8:GN^O$:O*!38A6:5<A7H5K(IA/)ENVTBA4.W
M5=VJ2/3JVAO4#16.NXFE/%CU>F;CKF&/D ;A78Q?4)PLV4)7,HE\MC_QPN@_
M6THBH@8UBO5!G1J0>)?&3 UJU/$.(XYJHDS<AO^-Q=7ZSOB:JTXGMM>>5AM]
MWQ!^CMV7>>"YHOFJMEQU\W>[W% <H>=J_^)U@[IR!4?R<@ V?J7JP/H<"C=^
MJPWSM0-Y@Y#F@@F[E"*Q^L)O14RP^<W&FA?WCJL7BB9QS!8?^6Q\MER7N7.7
M_*@,(WM->^0K=\!,=E&,&"-=6(S'A)C!@\AR(^HJT\''HY'^(0WE;Y25!/%C
M8:EH>47Z/1>?X+MM+H2C4E%"Q(G],2$7/-;AI@SKK:88M(5-V':6'AGQT]E5
MY >O@9\*'25EF9Q[21E;7/P]2.;W*.3&@\R#ET=\&27L5J\(J2UKRSBOJVT/
MX6I%XJZ2*(\ 85=L%#3N I+MKISH+5+!"<:,1LE<:LJ2<'@4CARMLFH^[8\*
M'57A9KR61X*B>38>:IJU/3^<LWQ1*'YQ:=0O.3FG*E(<LQ06&>JD!WI)8V].
M_<7)<XRXE*OT",'=N%YQ2D2_GL5CI2JEX?;,;YPD%?3!SYWHMPW/^#^Z;Y,T
MF?/;%U*[+RNT80JW"X%@2F'HY<6DC-E'>HU&L#9SVT:]VNC:GHL:@X1E2M]Y
MC/P@*2<]$;G^=>4*)UA>#@IW4CNO65K%*0R;7J\LW)3;#9=>UCQWZ^N:M>W(
MK#,#>RARXP +T"XM]_M)12[*DD-QE'?[/2(OR.-YL(7X5I85<Z8JW?9JIXYP
ML4;_':]P2G.4; %>03"[PEE+J%4#?XVCYT<4+^YR3XME/PV2;$?OG/+TC%D^
MP2O*7%%"9/X[MK8%KA[: R5+":W"8=BQM1:RK&VOZRWM[K# O? QF$GHS'CY
M[G<'AJV:EJT[ZY/(I[^A^%6T.J!92PIOC7HV/$S:]G2V09MRT$O+2_E6UN@Z
M</65@34I&GP(UK)0'FI*T@=W1:<_6/+9>? B<4$WO@L=M*T20U,N=30K)=34
M]^-4RL2%I;T-ZD)6R"M<1P%9%2#*,WH(DWDHTG;HOXI2DG4U+4C.W?'QQ^-C
MYW!]JH;]^W'R>'ES>?OXX$R_TK^FY__UU^GUQ>7]PY^<R____>KQ'P?Z*38+
M) R;,(2_GR(QWM5"1W9(U,AIHEFG8*#?U0EA7KXUID7SD%C\Y4FGAI-U'IS3
MK6$]K)IT$K+4E#6CENU,E)HZJ4O 4L,-'-7D+W\P>R>\\*LH9T@EFWFDU/I0
MY[G!2O+AZ&#B^T'6\YT;^%?1N?L2)&ZHU$=-G2%U<]I1-S6LP-%3_C:"7]QO
M4BI(5GA(S7SLJ!D9#W!4LCX;0.ED"P*ULWZIH!E5\(31FM/(%M7"Z3UW %12
MS_( ?_9PE%#?]#+D]:B/GYW@7G\/,4'^EP,:ZEGPU60^]9:JM@L"L&>Z2MLF
M?JVX[?AJ8!WPIU^F:<*>NV0/E\I4L%T.@-W2U, V[8 4P.#!GN)!_@5?:LDR
M@_$+=]G/ZW=WY*:L41M#*NZGSD-'GR_P2LV V%&KTD8 >-^MP*RA<2G/O:E\
M^Z40]HN2H=(S2"P/[=]==NV"IZ3E2Z>!ER"?E_E.M4'R9!@579OJ9$@L_-QF
MB)MBW!(@,H":1D2G7BR:![-#J0Y.G:0&?D[A\KM%/_B7-@Y"J>Z0$/FS*<>@
MQ ]XY670;*F]K<K '8 M-K4G?A,J[3[AFYOEP=CQ7X:8VD<SGQN<Q,%HO./,
M;6JZ'LD</?'_)R7\4!)YQ))5;,[?4_7.]CWZ9QJ0($%Y;)/)XAYY^#E3.9>V
M=.G?=+=#0O#7+IZ!>5' 0=LM2K+[$]>8R'R'2IDA]?BIBQXK=-<*_;>C'DY^
MU#WWRY?=*V]W2@Y^?#S^=/S1.7363?)3(+350XX\I]RN\Q]9R_]O?_##Q&,%
MXB(C.M:Q23B<O39EGAE9(1CG-F0/+,BH[DWH$C\TVQFB)H_B('A%K/O3XY./
MP@UEG0H 8D%)6ANLQX!IQ[_HOORP?;VT1:4![$1JBEI$_7ZS?K]9KZ4J;X[\
ME+^E(4PZM1&P>71$4U8YYX^4HS-*TQ\RU?;0,( AJ F*'IB%$X"LN;G%T2L-
MQY$P4&\)AU9MCN=00C<^(8) G&FN#&D60F?Y7 A)%]EOK8U$ET[&<P2B9\8A
MXN9R\1+B)2H67B1)#<,P3_;#KB;Q19E_45'P11K^%*P^A'KO#_QN^P R&'J%
MY@(1+PY>,N+.4D+9)N2"'4\-]59H?CH^.3ZIKM"46G7PS$GFR"G:=OXC;QWN
M*LU*NQMW]_CR>4CAD>M,M833I(4>S(7)+!205GB:*V:5W$',6O^6>XCT&;87
M?VHQ59M2P\A2Q!TSG8_XG%HABHKIC/[]2HFD47H6KLN7)71K6EP-T@+/:J5"
MER$36J!CL(T*=*I9C$\;RE^'F\&-3Z,KX#;LOFQ-H+W=K[!D3^2Z=]<AV'8A
M3B0WVXW8D/.8^H\LKTF 7ZA'O7"O(D]N.E2E+5MLB?I7=D)%N@&Y?J/_P3<4
M"4G@$:5,924M6^ Z><K(MANA:[[+K5%^>),L6YQK9Y(U6+2KJJ:/C#>I"&/'
M5NL=\29LV=TZUW$PZPH#V.1M\' [KF?(\F5N:8ZDNNU)O:K6-BR;<"9>+M0P
MEN/;TE0P=9LR0-(0B(9"?!W],@P60<0^9\N?]+]>QD<M'MJV#&!3LRUP>N$?
MSE;%31!Q2JY8UG7*VLJ;RVEUG]'9\LZ-Y8!HU * /<RVBF_$Y\@4?(LC9LVH
M,$.V/,*+=%&WN#T .Y-&E2_FVO1IKQL4/Z-X]8#"Y9LW9T^DW;/-K0M$R>4F
MB'9XX[X%BW1QBY)SE\PGQ6*8*-3LWB: ?<.FNNZ)<^/7>DHAPC.E\YEYFWEF
M6.I\>M4-,-U* &Y(MM*8!FN#'[%/%PN79>U]")ZC8!9X[)%<SV-/F["[0#@,
MO  1X8O4S;9Y/QZ?;AW$S_IF6[REWIUU]T[1/RW,2' X#4Z9"/C[P2O930A!
M_*KS=> ^!2%5%R(Y*_XTND=>&N>.&K7.<?'GF4L"Y6YQC^T/.]TW>XI=QG5-
M93"[S[W#H#SGZTK#JGO7\%E[M=KUVH"Q9M8,Z$*]ZK$+0[U7T4N:$,[7B7)!
M35D#P*I:*\ *U2=B$)RR3ALKZQ3 OHY199V"59;X3I)6#0 +&T:4]1&6LCK,
M\W4+W3WW86U%W(BLA##I[G2-;V$]XWDE@G7H)4&5HCPD^VX**PKVX2R1EGC6
M5VQ=)4@3@BGMULD CHIO<(26-V[\!TJ^II%/)MGSA)1+5?*1VEH 5K2-*[E6
M"#!7U\1I+IHNK_W4:7DM2XIQ)DB* 7U][8)IAXDN2N+@*65$LYO5JB4S=17S
MQSKOV3J]Y!1MZ1N8M2L=$1<'/$OT&TZ1H2-D892T]=7^F=DM1&R(<Z#\_C4"
MS;>1I"*M?+=\=E:@_D*F%4+A9'*1C+.U5:\+#)LT8"WJ:\YE>8Y7VZ+Q16GB
M-&@3EA?W&66O<ZZ+E.\<7[Z]!#$OG)W8D1TM[:]] %%@-^ST* LX\4)KILKN
M>'%1G3**6.H#]L;K2=^(TN@00"AJ"6(:PH$9O=SAA.6.HH9_>1&$*<LB]<!"
M-A[5-0UB?NX4Q)1(<0I:G#4Q\&.9$63XFU !^UMZOGSSPI2J]"L=2@SX:9(G
M+"B>J*)V,\MNL!0WH-CJ-]HCF!BK/O^@43G83=@K)*PVIV%]-1C[_P,,F7J<
ME,5B(I%?D<FD/F.T(K]?\T8 '!/01>\Z$6!S-O?Y 0?*#SB^ +*C=9DLF"-E
M9NHMV@80.&KF+>^'WZ$=]5N4L 3=E(S\/5U&3#/7^Z?M+$RT58<UZ]!VG:QA
MA[<\ C]Z=66NHT;UTC3UT\FHS,;>CZ_-,M4G]/9QP#X.V,<!^S@ X/#4QF]=
M]-!?\]9BCKXE)$X#T,_$LH]T=C/2,8G!D<9'4^K%N6RSX!K14*3AIL0OVY'1
MJCTG:Q!^0'2-"$&(4UM*KJN*;I0U!DPZ^PWAY]A]F0>>*[H/6%,63%B@H8"M
M9+/;[ R?<#8S_V5*Y EGY67M'["JQ=-*^G(N#+C+]]3!>PW"$-VX\3)T(U_N
M%$N+VDXK6P>1E;\KY<!T'H*O04R2.QRS-A_^F=*9Z"M"20/9-VS =J)9;8TT
MY,M$B@A$/4Z_BVZ:MF#QB$DSY31ES.[%%.'\5A?RU=:R%LEI\K-QQ40UQ8\O
MVLK8V72=2WQ-GD@2NYXLGM*N#2!B:JUK#?;@G!/D--XQJIC-84?+_(#MAU%.
M</Q F0@S$; (#D?R)&HMV@&P.-<0S9NZ;LPP'*WG4?KR KVP5'^RK:QJ*3"C
MLI7&MM@QGNAJ-3MS,JMGL25E !QV;2%D"3-P("_BZ9)&>@F*/#2=90OMC_B2
M+_@TF+X4;0"X7-G)P#5BUO1@$I%3Y"N]13^R)3?1"-.L""#?7]MAI\DAG+&X
M2>K5XL4-8GX*A[\G+QQZZBH 4O]U&&EJW@8_W\^V%^<XI,R2[''B[+_3V0RQ
M"]<-%\I_W5XH+_?P)R=KG?Z<_V/5#_SU\Q$<S!_U.Q&M#\4KN(!SKW/_+D1%
M:1IL]:8]B9<Q2;)$$841HB7$"=!J2P.(;IN]_U#+D9V[^A 3(M2=)MZG0!@X
M!<(^ZT%/60_V-TKV-TJDVJG&!;<X034+_G65 *PHZNI/S0B<X#J_[,'HY<>K
MR"1-YI2V?VTM0&K5@.#':"&OK"TE1R!5=>?&TYA#T>?W_8O#<?4JD]<$,;@Z
MJ$[.&1P5<D*O"$F1?\%??<A2@62HNT4_^"?Y/*97&<"60'-%ZC('2)><M(QD
M_O!&S2!4E >P]-]"8W)^ "EI'=2>8QI%^"A+P7.//!2\LDR1I2BW?@%%IPT
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M\BHB"9VB>*BK]J!,]3EF*]@4@ .)%"P0JR\^3F8)BMD[?$%4)+?E[JKL#.-
M'4,X+SX.2#:3ZPY,W+O]/JQL3V,T$S3D)V57#Q.@^#7PD%BHMSAZI18>9<:>
M/&)JULO?SS%);G'R#Y3<(P\_1^Q*5GE]67:F<9B^(9ST'QJK XGV'> X&[)?
M<9S_Q,K)GDL>F@@(MR%V!MD2&<.!>&M13XLGIFE8&!!$KO)YB(OEBKU]'9'
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M"V$:6@\+:!\5Q*4K7T)/V@3,^Z1@MX(DDU#O4^H[!/>M+"LV$-^0B#%[)[!
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MT3Z[T#Z[$!S4%8$A=252+J=I,D?QX]R-;!SNZ$K-F'<PS1S[Z"I18)LX;43
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MX;/L--:G]Q25!F",-'-[BJB'<U0KS^"@,$4;)79[;57(,@3U*$U/I0P,RR/
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MO-X'/P@7YK%<I=13/O9GI+M!L3?L9HPQF<&!X5V,/81\\I7*LWQ:YO(-Q5Y
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M<4-GW,[=SP;JTPQ53[R.WE-^8V<>C!.)8B)XB2 I8=P(9V<K#]"TEDB$)8K
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M.V_'JR7/&YU6V1BWMS;K6'V!7=<2KW^VR*O_"EJ0)<6!LE5_'$G+I>L>=H>
M5QNYH!O?]:T\BRDVAU=,QTOVS]:]OMP0M^>I=:O=U1>M\'I<@ZP&@D] E'"J
M=CQM3.VL^%;'4]#YG7-V.LF<T5FE^2.WB3+IBQOMJ[#VRO1XVKUU6$>7YMGS
MQ].,^6^<8M)MHDF9[:5%B9(+G@OFAAN#E_X2OWX7Q7<T?O)=95*5OC20 XZ.
M1:JS? \"B(%*2PW]V1/B58(N$?S(3?:&AK/,B_KP%S8Y6TMKARD- Q0!).2;
M$]Q68(>DW@XVD4,N>J0-'6HBL\2.%IMT  \%A=FA1YL>8\!'M2@86OP8RS2=
M &3 $D3Q<K<))?G?UGN>7F<9>G]UXM@)>5I+GI;.=].L[/#'T$^3W]CO3G<T
MHS'!B3#CVK1X*VR< _(7Q>/I.^3=,2^,"_XJWGA$0@;^;O(YDX+_\"1X\I;<
MI0\@":&?:>SZ4%#&$T@(SXIYVLDPS1XF3_N\&)^5U?-%5H]9-,CDXF^4<\GX
M#Z5L64LN'<G$FW1:06KA538(87#* U@:LW%I1&GXCCX%B8EV[#EH&)?Y34(&
MK-HV"PU@,<]IR(3"VJ_UB_OZKWL2LFGCAEDH>T?R.J8AFS;6GH>P1F6OZ3/_
MBTXT5NZ+<XK1LD#7Z&O1<79Q$X7X(T9;&3/1 %60Q+ =5+&1,F]3WH!GX48$
M!0)2-;'@M/,LP4!A@\[AU/G"@4K^,<.G. '!M"5Z(H+5N.EXP=+7MCG5M)Y.
M6/35;4)UE1PI #KS[>;4UM0(=,YD4SFU)6<6T!PQBOG:9@==^VG%*U_=_*"M
MY1B1R9G/#I/;4B<".9/Y87);SC+2N/3^ZY"DX/?)?:1X#\8M"3KR], T3#A$
MW-)_'/S$3VEV4T58_9:ZT6/(J? )6K&;FX MSGEH:KM7WV:.RQ-O&&4RS;6?
M:-U<GF>AEK.W( .Y<5[X4YDEG)(\\H<E"\B,'E/V9WYW"TJ($DD22T](D5N6
MX_P9Y\Z3CN?LK52.D;.M*PQZW 8WC-5J5*D*(S? "Q#U8AHH<3!B@<0VUS2O
MDZTT_5)ZMG,GV;X+HN>D>SZ^NBZXO:J+OHKL>R?M\?I<)ZG-Y-H[7][]2MY=
MK?]Z9PGV0<&;.'KR/>J]??G()J/+L"A@NG13_XE->;1M4&L1PCW4]6US-,OT
MI(+7+0;H,@3;@2?)F9*'%_(-\"5^^"TIJ_Z6O,FGG+N=!]P6K%2:P2F(VX"3
M&UZ*JF$)66F V_U/=9'=NOPK7G>MD='8LI%O^((#SXU\D]4B6QZ5#+MF1H["
ME,D9^+S6H*B/:<4I#=O"UG*SLJ>%#6GH^@&M+*?O(S,S^DBL<#O]F/95QKL,
M\<$+1*-JJY\#K! *P*H0BYQ@'?P9UQKDB<8/48_H%U*;QX7-BRI"[+?P;Q?,
M?1 6)E'-ZN87&^A[0?=,9+_N&%+1!#?:U>DCHY3\=[SH4BNE=I$(B9B5A<I4
MVDSB,.\=/P2D68=W3D#7&X8US)?3EQNF#T_$O0<L4%BB<V?<3M;/!K+[=>N)
MUS%[RJ\[R(%-/E.S7<B%G^RCQ,^K(^=,">=*"K83%^Z=V":\?#$S@,>- 370
M>9UH80DX^:<3V.&^#>LL&L-)$FKGU42QOKJ"X]++W=[Q8Y[N3QTU:>F"&_^Z
MZ"NC7E-[O%C72>KAX3U.?4%*^KQ0N96%RJ@:+\$]B5\0M;2)&E5'Z2/:"B=5
M];N%NFCK#=L&<O,O=Q#7^R=?/*X^P^T$U94I#3)SPJSN=E'C6#N-N6!;#TV,
MX1WG>19MSAA7PMDNLKN@ODMNJ7=PK>W7)C?.=12>\?!(P*];44'6!GKD#]*R
MRG32PWDI2=@Z/@\<7YE0NR\-W+BA91$9-'H1P(L8>FJ8>!@IKGT[<C8*.:L>
M@<N)G*L5L+!G%USY.>'6Y=OC6Y<*FRD;XX:"9AU/,H2?M,3KW"WR#LH5WG3#
M&(Z38=Y;U<YXTSCP6+HCN@F<7^2^H.)_I1.A[-)TR\%Q+P*XG;B_+2J3>>?>
M>)U=0P?MZ2I_0?!-SNQ;./TK-P-%82J[][LF-,GY%N O 3.(@"5?V02^\^ '
M]HY!3PUP$].]XWL7=$/CF'H90K/ES3K=TIAOA90; %UB<T../C9J1I$NE.:$
M*+WT,8PN&>]\4<']B[,580:SVX3NQT26C)1;(PLJ"+B)N#FT#TP4"0.4&M[2
MA#)'VS+5+N@3#2)^")3I>XPB TGAQ! 3]BD2 &C20?[@?ZA6PU'$DU%DG_E-
MG''G?N.5_ N'FO8IOW4KY8S)98FT.6_^8%_BGD/PU)!KU5(W70<.CG7>TG6C
M0Y@F;'\.E[P[3UZG_7 B;V_-FQ=J1YWFM"93B6YX^96S(1D?)!LZT]H7:NYK
MU;3GS?&!@6*YG>QCH-.N,_1IA?ZM;GW4;V:>K9+>O',#)R*QPN/?IFV0*SM@
MPNZ\4ZJ>.:O]5Z,[3A_6M4/#+DC9=W8[GW9-AN2[]&MV/%*F,K9^A2L.[">1
MJPS\'GY?OMD0UQ2DF*7M/=!X]JK=]QQ=9AD;#1MNM4UNCZOC3X\[Q8%B^NA%
M "=^ZMM"+Y4!WO60A@X3IBZP%&V>V"C\%'\#.54:G_B-LE:,4B? 9HH>1K")
MF)=AEBYR:%*89D*S1- .MNF I U49H>H7709"5D+UOB3PHQII=(,EI/"B,M<
MD(31_<?!CVGEF=<R]-H>@O8B@!L^^MNBDG2F<V^\<*&A@_;A2L8*D@IDS(KG
MH OQ'G3!#UQL/PJ=TB9,_*T#1_M=7X1.E3C*I=1+WC%OJ7D+V@4D>E% CA+]
MK7&4FZIK=\0XH:&$_BFLX$7@,Q#@)K\<GP J>F2QLF24)#,*'LCHOJ(:O"1#
M#QC];:&W&\$+%QHZ3+C[P!3*&,LDE5"&CV3OH;#!.S]T0M= **.9T"Q!HX-M
M.H!' Y79@4@7748"DX(U_E#&F%8JS6 ]OVVQ_BK?<I[SMY7\#5>'=9NJ'VZP
MZ*RY:B-2VPDO%'07W<SZ6GZK*[B(I\S6MQE3*.\K'BHCJG5=;Q)1R.MCZ-'X
MDOTB9-@$3S+J7XG"%BTILB;+U;]Z?09S/.>(.(8MWHY6AAC.#>E,JST4*!85
MA,P+?W>I2I4E*1<"D;P2GH<(6+'96H RE6H&BK016>5 W/NXP8M6],#8WQ9Z
M^S6\D*6APX3[,TS!GK%,PH,]>\DD&R0[-# "_#_$P9^< $[5RL*J\(=*I=6C
MEB*EV.D-R0QL5Y]=_A[_UDGI:K.ARF#1Y$+@!BP[WT0&O6DEP N<ENR@G?Z"
M"; 0\"O)L9#+/(LF3K7V\VF/K'!TS4,5>8V8JT! !R*4L(+F,_M.?$80EO-#
M,3? %^'_H*5@LYL/"IM=9)FCW\?180]/@?T$*AOYX8%ZV=50]39^8A%>\5R@
M^3V,S00]^;_2>4#7"O9G@1+I<]$)EYWWE*4GI?ACX+]X*K4*&R^%S>X;U6+^
M@E!((;/)GH>-9\V[U(G3+\&>#_31#T,8Q"JK3I,Z/'YTPBRU\3E3.0I\C__
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M<=S#XDNK0N/+<']($PX(;QJ?6S7WF,G@5VM;.]1/F\]@8#<(;6*Q(\@O"&=
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M=?H !M(([9FD?.)GM.7T01#,2[-$G6E$(KXL<#CO[\9PLSKD&4EIL<01).U
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M\T?LD;Y%8;"G@N[L@?K63WY_%U-ZR78*[,.F4\&T@N\7!-)-EA\-HNN8?B$
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M;=T2X5YEMHML?$-D;:%9J^NULZ.-Z\WV7C,<P:=:MX[CLLO,1G.-X(;']((
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M+&O.X>C '&Y4_]ITG=VFCX[/''#H^2QVD=7['OC8\8Q62@&8H6]D?XOVO _
MQ='QV/=&")BXKO^&#65"0J/C"@F]=LRW.]\E ;IV$'R@Y?2;'<S"%@QA-=<Q
MI0_ \3T';92(',Y ] : AT-?8S0U?EP!M-C&>XJT_ .2&@Z:1RMN; M!X4,+
M!BD8A2'Q+:),831A[NF?L$D5;-9<RA\!G@^1X3KWPT@1&ZK[$.4)(3MCS/8
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MW/F>(V 0-L6+G#H=C0].#(! *_6O(6Y8.E\,W7[ 4573^8\0$#Y2L,"L,PA
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M@-<X0+>X5GHR(Y*'/_*@=228:2A4%G31DB7#>LJ)PHQK[S6YV-,VY)#1D"F
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MPY'=.8\DG16S<O-KO_>UP_YX!WXN)DD*EZ=GE\E"X*1EE\'4N7X8!VB>"YT
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MUV:C,\*@WO&4PZ6@E-*F:"-/#AA^ H85]%F5_2:S/A^W.,D[^E].$ BWU">
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MB*&)!JGG_:W]#E?QBLK]PG?C^,\85E$"]628:<6:[ %NVCW!VC<[)TB6TMO
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M]X/1D!; U:8^?-Q7&D'9GWS$W*SL8#'7;E [G>M&YX1E8E0J6$/>7!%@\ /
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MQT1DTV@)@J>E[741GMEN-,9IBAKD2E01!?Q6ZE#I)DZ@"6?)?]+G0Y)+\<P
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M+]_QG]MFO_/Q?#J-,)/CF>:H.0GNSP213K3$*[6>9;\'?B@]XIC>4U% ^TA
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M=[V3? 2OB ^> S"+1;>5I<R" MO*K]:Z:\M!?>_VF6QL:X_4WSSIS%B&AJS
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MWK^_7D5)DA5G.WDZ;UX]VWWYTGQ496<+_5E99TT&[U*E>=1DYRG>>\V3K2?
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MS\./T_;]0%*F_TEF>OI*<39$(*FN36*&C+0?UZ;]>#[2?FPJ<?P#\+I[)/[
M#J,C(\@]4U>/@!%$V)B(9"IG:E/0/1D5<*!89U$\9'G?('KE;_%M@E<>YHD2
MGITN+Z456&$ZPDI3/MI0&VWO$^VC*B@P?%X$="HKW8J$+YBPLI7PBQ6W\6^?
MS14S)3/?QV7=3(U+HZ=;&0G80%ZL 4M)&4B;;Y=ZOICPDE9<I<"U.9G-.4;/
M*)*>\B[5UCCCIDT4$*ODKWHX *:#:5(>YNZR**_+H:WFOG^C^Q$/^GD5)QZ8
M]<% VYARUT#7="&$Q5:+]D+]+?>K)9(WV;56\<)U'O[YCRVH'4>_Y#'RJ)QJ
MX_6-E@O7*:0R3$L$TK=I]3R!$+D=6"T?QC.A^XQXV.^X:^VJQF;A$"ZAX% ^
MBO2G5>)ZPO)61*IIYV2):!6DOX7-/L*L]!L?CC"K$69UGV!6CUW3W(=BW:-$
M8TD^&H:.3Q:?7==XOU(/C8'SVP;D?8]BP@SCF\5F=,]68+,.%!)J3=11U;"P
MPR!U<N3'P2^I]!>=@40-@3'8O>48;E&%)+6D<D#]FMDJJ!T\$B-S52S3*G)5
M@2G:X,H(FUS(2YY>+,"[H_MW7LJ4U\*KQ25N#7&#\+$+*@#4+J3_:\0$>(5'
M.C5G^V0]!4J]URD;RIH&;)">X5-GK:& H9G-"MT10;BJL:<"I935S_U?XUSP
M*PTD[50UR\":AD[6K_*J2/0&\<(!=;1TG%E:0%4-HIA(T*(4"U-_5'M)QIX=
MV4>>TVCN%IPG*9754Z*R3VJP5*43U>L0D9[='1*M'E9V1XV:,L^+=VEV'-XK
ML[1Z)?%8X$M:2\/Q!BS3MXKT*]H?]%1>B?UG\/Y)I"FFFD6&;CX<]87G?O-0
MX3+$'^@S<[/Q$*[FE[6WPTDJ"Z13M_:$<21&)73[Z.+OT7R ML<;3*]09>QF
MK;].K6 AMS[D4!YM/=-T)+9NJR)Y<,"4%'# A!V!87&MD<G,OT72M/*B!Y@6
M>K6MD8R!R31@EY=5S;>8Y5'Q)>SV02#48:-J---T2EUH6.NMLLI-F*\+_0G7
ME7U?Z0<I-];1!$8*DQ2RIZKW*-(M'-'<4^B(K]#%)"%O7Y)A4:'\9)86*8*.
M46N8DM30 5T. I;Z6D&IZ"-7,<+36HH#Z]PC.7R:L\RK0S2AV^[WFH,U22-8
MKQLV?GEKRF]_,5.P1710$11$LSHM=$.K=#YGNA,]F<)VY1%VR<#[1Z&"G;PW
MD'1E<"X(CSMV@WF4'"/;.Y JFCZZD7]'-_)SVH"#A[;N)HJ;2GX["1\+[1+U
M;Z\A0@+/Q51JP,>44_E^+S>#ZLW#U>_PI2J/\?R5%&D E?KJ(62:KWN$-./2
M,\4FL$>&B9]-P[60%B[#V<;_&$(U,=&I&5"? 43'6G&:QW%;,::'"Z45 04W
MY8%'7SI<%,;A]I!, T\I53MQ+(!*HX3M+O#Y*C0+2C$+8(H0^CR+ZJSFTA#6
MW7D:V\:1H_,ZW3F)AS,CZDU0Z)HS;>_'H\&F0:.P>BSNQI_,</>)S,&-VACT
M"!T*-X&-+'1Y8EOVH>H&=KM$@KC\K\ER#6>H[-0X!FW,"6VD9]BX+V^_T.X[
M1F.#8_!DSS$DM-G^/.T'^WM$1H93<F!'VKK!:U6J^8H)J6,IV;XA[_9^J@JQ
M*&(44[MHK/SB7K=)9G@QD6JYE2*OCB27F_"92!0_C>J:.T0F5"3ZAUN$&M?$
M& =F<#"^V#\C*H 6=JL/K863(9,6(Y+4F"K-ML7$&O[5+6$#NS?Q=7MW]*:0
M&_0_J3\N[3J';6_ ]:=CH!\EI9T3B\R@?X=03:F7B"B+@8M'3/&U,<4O1DSQ
MIKK@ _D#M.%V?B&&(]67]1%CB#N2@&=!@(>#==_<4J.TK^4@,,A7*0KKJ[B@
M=J(@YRF(UI3,98^NFTZZJ3[*@RWN.SYBZ#=O18M-2NY+-X-Z RSCVLVQ41#Q
M"K)Z2=BL5@COY(_$PIVP3NLKT= *=;@+7Z17<KC!P70$A-TB(.S9" @; 6'?
M&Q!V776@>_@,%SQ< 4'WH>=B_7)'/6'4')*N(O0($8]="\^C+&>#&8U418QK
M\=EZ 3^,#]HZ:H"3D&-KUFWR+&TI*EDN5VE11PJ9P9+8M84S&S.BHJ*[PZ]D
M.V79D,6K@/OK Y.=/E'=3MSX?N&:T.8Z@#+WA^A_#UN;49\9A4,6I+'VZ&Q7
M+]1A2:^)K"!;>OTJ2YNA9F_*T1NXMC?P<O0&-D_(X8"X+0_&1=Y0_2]V3NI&
M.A!'@:P+?%:(*_AQ>PT/,>#8J3Q<J_=./'R"0;? FV-BK$JQKU3J?LC_,%@\
M4(W1BLB@_B64S!X+@X('PH6(W')HZM5W]0H.3#F?@Z.35F<(+$,D(6Y3N6>>
M_7>K_U$YQ-5AE_Y("MDI0F./C8 ;YZG58>SV,(I(%8[3*X0B)/(U<LTT]S;Z
M7BEL4+:LT8@D?)-;P.<>J9YI":-T'+ABNK6;8F*G +7]!.,+>^TJ&8SJ*D#K
M(=;5_#":(?N1HE )K)>=3UWB@W6_L;*QL ,:2@=&)+>Z[/43:5H,]DG;=*P1
MA%@RM%6KVZFRI]8#@U[?14N1'A3OFN M!FQ%6CL4_\J<M%L"JD3D_N[AP>'.
MOC*;3C'!VE:82CIK\\A8*H.)R^"??G]1_&IMCU&O?-6L%0.+T,0EN6+5Z9J#
M!B_-P5IN@. ('KTMNSV_U#?K-W7/B: XC=Y<D38P%><](TLM(:$_DS%-0,T:
MV:!_;Z/'=5VL^A$W<2K\W,C"T&+8G0-G:7.1"AVC?5OUSL[PW =Z\[<.Y1#J
M-E#^[01[[=[*3U"X>.G^#@R4\+>IE]3;=CM1TI:*8BE_MJ'[!*_&BF9[+<V\
MQWG)Y""ZT7C9G;F!^1DA:(^Q6K:OY854SVJ3X4U)3:!'U-G?$W7V%AF--JZC
MOO,ML+_W\@:9C\G1M,\UZ-TKO!<.]G9?/.4[;^)37#_[H/'">?#AHMBB"Z(-
MG2%;3IHZ.LGH3RU8V/M/DYVG U3%#VXE?]EZ)?=WGQYNOI)'-TC0]PC3K;+S
M-FE\3[%:1H[7D5\/A4M*:,+* -@9GZGM4MW&B@3_+?1BN6K-#P]OLN8G6Z_Y
ML]V]_<W7G%JV<X>V'G(WO]64!?8_4JW9>WXW#1A2:1<V^H<]-*3-E$I5_PH]
M5]?O$(NVG\LD85VL2T%RO*UB?29;[Z-N0T=!#\N7OI)$6OV(S.9+MZI.7;*@
MV#VYHF#,XUOR[>R78W_VDIIK8P!Y'5Q'!H'D-6A>XW\GL C7/Z!ZO3;/[4[=
M+K_/L(ELQ<U^E;E-<1^DI?::_5I3HPL]R.>QS7:S"'3ZK;B[+!:Z1&H/T2)&
MG6W4W^>,XO322B_!*JML)B"O'!NS!Y.3DY/I9)]Z_DX.IKQM[YYJ^*:R87OA
M  KAV>;"P96@N(U!&K=17@=QBD&AN1P,QFWC1L48'L=B""C]5UE900+CG?-Y
M*"O9%#!Y2/G[*L EL1]#':W%@SO6=4EO^Z5.:#_='"0*0!U,:: %K)QZMBO<
MS,?P3"001H,PRKW^="5VMT#VF=YM5ZB. P0XI+[:.#J-*(<?-'3LK203C9FJ
MT,$8C07M@/%.4R+CH]+-Y+D';2I#CU:K$D2,HKK5/W7$"WQ1E$L5LYW?!I_Q
M");0;_Q\!$N,8(F'"I;P!8BOURF*IC(G%S9U=EE1W&T)HDAPY!%:"FRH-P',
M2]WTZ E?.S09U?(HZ8M6 84!I=.+)0][-866Z99@#"V)ZDM"\]4%E4>EYUG9
MUF 7UN70JSU TV%KVV'_Q>[SEUO9#A5I2E1P[7+);8(EV:>(0W2ZSS?S=:ZN
M8T.CB9TE5.SM_4:4L")V%VO=UO+ZBCX_9AK::3ZT1(9'R_;_1=GFR%97M[F&
MZ3C4%:FRBX?]&=L>SF W)3@4JG\3FDYIGM,_#K0HLJ(50T%;ZW83I"I=1AE%
M1^Q'<3N^62JH%<2+D('<E,-#KENPTJ@U@TRM+-(JJJR:HJDYV>0P;. HK)D=
M%:C?Z-&#D\D%A.MF,E2>0*13X.9*E6.VO(J'=^#_O,9YWWNQG:^0+5<,4=-G
M.@I6!$5CT%D.OJZ=UY<4/"Q#VR,$ODN7C1M.\]:SO&6P=4"JUA$CTNW^UUZF
M'!>#N8^M( 6>#?RPWV$'WR=M:D<LWNZC4(B1X"WDG(?;"Y->\<7R.K,Z@3E&
MBR=UJ)NX/7 -2$=T/C<:4*51647WK.I%MNK<9U">JTE4?FF?/GIPX>DWMQR>
M_B9,*7IZMRX?PSI]+NS_-8WR9A$C=. =N&W!R4D8_+;[<3<DQAW)BJ/Y*:'P
MW'ENJ/M?^O%$;BX*?\@7MQ]3?*TC["%8+A>H^4+.N6_ZMO?^%4,F7.. %:.V
M>[>#JO_GWR*3FR$NBJJT-X:]/E2MS;':2+']#:78%K'3W> =LK.W%8AC-8A,
M8F,9VS8W2.OT+>_6A9<FHEL)#0.NA%C,6!J4RCO!"E,-%>S X?Q LZC*]FS!
M:1Z)1]/>(&E;43B9-20-G4!)L7F/V249>YP3C!FI(E^3@Q#:/!H\[ <GBM_>
MVYPO3^B-,[UG(%ZIA9%"KCV=1-/)CU-U?MQ^U-B]LTRX;0+Q) AYFORX#O8/
M)PF3B^\_P[_$H=!)20-#PFTF@S*9*$PH3/O\5Q@-"DE;,F+4GC(4"#FS^DO,
MLZ1E#C/-B&HDBS1&!;,(C.CR,E6D9XTVKX<?KAWF3!Y_0@86W?("[D\E"DLP
M:^"*O/?I(%OJ5@JDZ6EPAH6%A:T92P2"30.N!L6UJU6I>.;0ZAH^T"+ ;\LD
M$Q)+YX8/[D0?7\.X^G&+5,]-<O]]$*MM=01K1/%IV!=\I4^5XR-6K@?I+*L<
M+]X<>;J))R*>AW^$"DG-<(0 U0;Q!/$): L*V,*G+,[TL=)8=A>OW@W<V$=*
M+*,KQLE/JDWTTS=&_'?0MH-M-CBVQK!_XN1/2\9;7A3#)]B*X4XLRXQZ(,,,
M[Y@0$TVC%M.#0^N$G"C>BH$V*PBD."[Q4_2$)1SD([Y#%DFTV)CK%Z?5[(UN
M!+IG7'U2A/F@:O@:Z[BL.:.;HIA(!<FL]HMU42V<BAJ7@$D@$EBRU!R3^E.Z
MZ9K IO<2.!Z#=O6.P["E?#.$NW87-D&YZXZ&\ZP"&QC^=TF&5\8Y2JV)&FP&
MWL[@24;'>+K'D%-R)WI6,&/N\A9SER_&W.68NWRHN4OBEC52AJ309V.N'C%Q
M\_Z/3Y^2K(PXG8?^XCG+'](&<T7B1$9%-]J)2DB"%#:FB6(;DA["[(3-5.D@
MR$RQA"[18#D82L!D5L/MB9/+$X]DZK-:D+JWH(JR6@,>0]%OG,M@Z8DM7LL<
ME3X"=MA-ZK,;DG()YD6>6NZ. ^\1@['/^ML5XVZ$RS]&WL,W"%G"_1@K\Z9O
M#P2ZO-A"!:-)J"AFKN:C.^G#]O4^2WC;HNX3;9H + MLHB^I00F[<$9S/)6)
M%M6FV4B@"@XI\ZC[#4^[%8R$1+!)U6RV VV/U:^P*0);=PZ5JL,2,4L9@T;4
MI;Y_8%&4^3^RJB*UA\U05Y$;,+XXY<";[:M/A,-6PWM57O=^ED3:^#RK%-2R
MC6^_2C+$;A2\CE3CIFQ9D)A9G'9XYD*7.)><NQY>]+;03;+5XE(DFV<#5Z;7
M?^MQI%4/F9YS([-MGM3M14!SQ8Z.[CTJ74%=XF55,TE/XW>'F7G3M\-[3HS:
MN(CV#;BI=ZC&A6X<^M14U4U_8P*2N5?TOQWV18\MJG JB_-HA46':YNGEY55
MK]@W=?!J;^75?-;_ 1EE+!!=!LU6P%#5.2VWXJ&AT3@+JU /$=>A*Z(70C!%
MJF(27>@*C1J+I*9W=#=L1G!D.:4?L2QW&PJQ)<KDLM+G@G#%[EMUR!H=#FT,
MT]:UZF)$)023$UD=_+XS.DKSU!XJ>:" U6,FZSNKLH<G;F.IIENKG)34$4,-
MG[I*H!0.>D<)J@5;:NB85G1V!FXO'K.>$FC8*YRXZ)XME8VS3T7TE0ZVA'MK
M9@5547-%F:IDC2U'U+NJ^F.C6N,(+(*<"Y.UD%*D<&HA5<LHV)%\7QP8GTZ%
MHO9>3J\TGU->:R5_NW,&!_.X1^:$_94"&Z-10E=0242+(5-X68?1UKXS# 17
M&6;-"4V%09'J.GCOK?7IOGKM.',Q><=8 H^+H[&K\[GE1_1%U5FH&*A(S16N
M6F-3266UUGKD+CY__7(RFW:IEW!+@]%1@G=R%ED\#41$A3.$:'C:HSR+H?5W
ML$CSI*?!" H!<Y&*"&+,O[E<H?Q&HQQ9CO+O$,[?QM'H2#X_8:NJ4HY@!6<E
M%N.;\G]MT*E30SP%9!""N LM'>QK_4%1WV>8AY:MA'>:IU7M[FM%!1+Z&N8*
M>2GWW-A8N<:P78$RN5BDXA$CU9B;G7)9-J?JM":^L[[5*'#S#BGQ*R:+]O[M
MS V+:! X&IN=5A+,(-!8O"A%=SCSQU.*1ZSS%?ZD3C7>RWKE]2'T ;+DNPY!
M9_.>W?)M-D#&6EWB*H(J<%(&-_*]W!Y<H&NMCE^J@&CSYX2.H=6=$D;)Z(DA
MR]/14/ HY55)S1=V@)279ZSGMWU_V]&%61<Z[N'DQE13!VK"HH%5=T_NU9OV
M1MMDY/B[-L??CR/'WZ;AN7\P.Y/=<>O(<8?_!@3@#S&VVZ'R^PZAW5.O.RY(
MN,W#M<>:P<'U"WMB>;:W;W$[>$Z6>!4P.&IM00TG$\/"2NV<5GF:G'%!EDU8
M&Y-7;]3"BM/LJB<S 3Q1+0AW;JB*R<[!^RL:AD)QD0Q:BMH RZ,+#0J;2>-A
MT:'P%6D+K#>7D/28E[[%O/3+,2\]YJ4?:E[:Y12LG!H;B=)B=QYFM E."CP-
M&%2R&QR$+C@FP# 9A^<39,P XU!H!(CX&C<6X_*35F>VX7J=_')B+X8JT$3@
M@[( H=A-$.P&[_OH^PPC9&1'EDSVG#[ 6(<3UZ4<G:+9)@IS%/L6^P_:WV?9
M7+=%DY@U+VJP3%'N*VPAN@@&MIL9Q@C%#_5B;Q_UT++-.6PUA!*8]K&OK%GA
MKN/:%S-GC98&QX1GVQQY34%S)[,FH5GWAOV$C]J+4PI5^W*4XZ(-=F0W[/@D
M[8YQ];V]0\42!D@)M\-O[>6<E'Y_SM[KW,[(8<\NTU>8=L\2TG$9HP8W&D=)
M]:S-VTH=N;6SAS:(NK8&CTQ9',8,4:9)Z-H@L.II(?7GB\L5?H$-L:T@^BYX
MCM(VIN[)$KK)!#C*Z;G58YK(1+[JHZJ Z)5[Q[99E!5LGT2/-DWKD>CR,1)=
MOBW!YE6UMQN9ZY':B):@("K46!I&XDZE=A0326D+;4)5%@A"LG;[](J.#M:S
M*%,$HT%J^=[>".@/2-]H/@/(W=#I,X>9A7$C?^N-'-^#C<Q;Z&U6QU6Z\5Y>
M1QYHY:)"CL6;G2@LX2"M!0]D[S[^IS*BE,%A]5[ACL@NJSG?N\"DKOBO.E$5
M!F[25%_$Z3&GJU=;9'CTOD=NZ[%O\N0>;/)3-[/^&5N8;=:C=4C(LK% "$\I
MO."=:%C,):@3*B,+CU>EF#3M\:@T&2;:]1"Y](ROMNP*<,3.V4^9U4S"J7^M
MP]\T,OUSJWD#O37GCVRCT1"]-ZE5(V..C^"/Q!J5+SM.3-GI^ZJ-R#P]0ZBL
MJM E1Y'YX]+J'!N#A\%9"[.7<1\EJV)8E]U4TJ-/V]/2V,ZX$"PB[G5J^B$>
M7Q\"&VR7;#>JX 9ET9BOW[S$;2'&42]/,7ZA$(/V&:-$;<C<B#%[.C6F.Q%D
M8SAPJ1XN;;"*TVX4T'>:K/)0IRZ4ZZ&S0HA1U2.HLM3A.K5ONE)_4U$K_G[.
MV3I.A0HXTQ[E2GJ2%>6@2][_HU!*!!$>,72>81\O0(%C%E(A_MDWC'NZ*7N3
M0>@:G7+T43]R@32:EKBU9GB(X?R5R[3"AC8M)EGHS_.T2(B/K-)QG0PD,<U9
M*N.1]I<6%P)APW0E%_FEG&<DDQBGN!:F36Z)4J@%D#X.BH8*2^$J+ M<1###
M[ON^1JCJX"PBJ"G3%6S@YT8X'46IF"LU/TLP3\%>NK0I3)99G:2X4+27SLN<
MRO:6)6:B&CA^6=,B4C;!Q"L5]\N"T4WF5=0FKQ$L.CBV>93E;47Y*Y#^Y)7@
ME@4-J-]7EK@>O(>.>"2M;J.#/\+4,.E&^/ UXCH'[W &:P_[.ST#Z8C:CMDE
MYFV.[X\^3*N:5EQKZ7I7#"?Y>'A(YUF9&[XE@@?(?.B^>>H;?;0F]?3ZXD(=
M"77!BIA+J8F8T)J&/:U@0_/TVJ$W+<BP6J[ &.'K\ .7#14_04T55=&9V"OR
M$?;[P%VA\/^TP*I)(FQ#/%H<_C3#U+6899#"P8SIVXNR^@+")J; "J[BJ+=O
MOW;ESO7V6VT$;\M @9(-V<Q :45%JHY)V1!CC;JI@LK;NAZ->T%0'AQ,TNGD
MZ=3HF.0[L#P]=N\NO0?>W3\-.G=3GTY)TP$\+0@K*7@ KPR$-;74XQY[.7-Q
M(_$1J,4YJ%>0B*$5"$&BTK,"GNBZ65:EB:J=P#RZILZP>RXHG!A"\DN#GS3
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MFI^P;$&OP= [D"!>L98Q]=9@<S5IK&).0ME@1BLW5O?%UP%G^PQY;;#.@R2
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MM;*&DPC,0B?$)JQ3G<-IOA;%FA5)KHIZY:A2--<:&[W>TQ&RU3Z#4-23BE6
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M=7#8,^:[^/!]&P'W$A]N]NRPVO]63].,H3!^K@LYLH0;NM:TH)4,[DDWP<#
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MGI5M?<COZN(RC-8C>7HP5=Q2#$Y@0\(249?;:.Q:"(83 /8X3C#7V3DKA A
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M]B)!=S<<ZT6^O5+2K_UT4OQD"UL[)>,J.19R7)%5?8DX"&KXC6LWF=LW'?.
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M5_CC2\L'F=S5957=:%;5'TVANDBCR5495$]'Z60%_\R*>?S+_P=02P,$%
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MR]RBA(R_SR?8FES!<"ZCO-C[BTNC*MD(#A Y@V.YC0D0:4-JS.<=S,\X9 3
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MRLN"^AH\PC4@/RAKF0WR@<EP(K1N&JN>\F^4)[(1<!YEI&-065/WK3'&*M[
M68KMY;4D?'\!9Q\Z['H].!F,J>3@R:+?--$XU1!)4:-V3*\4)?;V*!'HB_+#
M#':J*%:,"#,-&L4"CN$&U0']OO:+PM]QE%T/A)*] >T>9_60F(L_M_T=L?_Z
M'PPI9<!96(B%'SKJ#/RT@[+OQ_!!AB$ /TYD/#$#S60@='+;/DR;HCM3]E,5
M-V;-0AN#!8WT8B3 $E 7'Y.!V'OYZAUNO+!TF=(G!;/ #[3E).OU5)*@ W0(
MX!LXL%]N#W\UJRFQ"9)@/\6J:5CY@LSI.JDC-E80L=%=/&)#8[.?E*\U._4U
MCJ&_'.C2P <\Q; (/S2!$0J=_.8"YA$?W0E<B#[<'$#(IOCGW_;>[!X= UD8
M3=PAQ4 FHJM4*/I9'/H)4)@*JI)3(UZL&>]$CBAZ]3_X%JTV2^#/;I:*,(*[
MCS=WC/354WTX0AN8P#=W(.&BX:!#)4.X/XGCR==A"[A$,UGK>T\!HL!Z\W'A
MX(&)(@BZ$WJ!7/#?TT9A]3Q=%Y<!L*$- OB"S%/$&D9PFR,*K@ "_._,CW7$
M"G%/?-BR"9?ZW,"^O6 B*-9*^&G"$&C65VK%5ZJWT)7Z<XZGG)EG!U^W-8;X
M?0Y88KQ1.O":8VL29#3MJ_-#L<QU]S%:Q.-Q_YW!.OH3Q&X84LL<?F70J!88
M-.)= <' \5[M[YM[?1)Y]L9_CL;JAAEGSN>]" X*+VBL1H#L2"VB>*/QM@3*
M.3F:$_.P/*8VIX,\G6],Y,00_C:Q&LV]]VI8$851C*X8Q' $0)D\6%T:9VI+
M4&#GSUM:#M\2N("?M_::K[<$O?KSUL%N<_<?6S9"2?:^78/$%GJEF-#B)[LL
MBD.:6A7MH/D&5LQ: =R\4!6DB5*4% LM#QZ3O/=N]" QR6^F#W=K%2:I!PU#
MKM[$K<3IK'-Z*%H8#$\B/Q ,D)"!2NWMBHF2<:)# (&,Y'[N.\3;A] .\?]O
M5DDT1F5>2?>!V*6^266+P1TK6&+?2P8\#>*[24.>>%9))5"_+NRUA%@'#JXY
M.7"%<*W"5S:Y;B2O0>"@*#72Y0YE,):31-_N=W"77EFK!W^W6XI;>YZI>#-P
M>DY.N/5A+&.ZCW1?70&510H?55U4+7H#(Q-T2L)],HBRP$/1.<D"+>OC.%&,
M\KJ(QB"+R^^@4 -*1C':4*YE[!FM&']2_3Z((4G)C$(R$@G2BJ1J5$M [E"H
M8Z/V#&)/U$TEB/I]>0.:##(45&N&/&B*&:&DRMPJZ32T+&_6,P#Q#?\&J=Z/
MO,+<!@#M_I2"@Y<]2@!6V^.!0O4"%8I$HK'EVN^#/L%Y/0B..-<_=ES3DM8=
M;C<M$72U<@-TY0625K/4K@($0$7(&$WL&$2086+GY70<W?YR3J4;4[MEA0@D
M0!0Y7<E03W"P"U-.8$MX40EW-(!\5_OK1'J5&/1L\ \DX^MKQ!!8\2?IQ^)7
M&7\#M>XW&61*;'L*M232!:75;?.E[I2,-&6[#NN_N2(JMD=!!NN$W="AB&J1
M.0%$#JR.Z$!BAW1I#6="0% _'6,/1;Q/OR:\+$90(\B \8,4#P=!I['-N(H+
M N81)CFF,H!);4@1LGV@[;#C9 >F[RGE)>+O0'4:0(L;[@9A.:#E\R;($$8#
M JCY+3Z<P!_ZJ=AF\R%=!#X:HJ:<.*#A!D<,8QB-9H<-G: 9ISK]&@[ES$U(
M<]-)\ON36]<:9BJ-!:1/\WK+F&^UC@5TG891=FB;9N *?1X^R-DK;_ZU9K40
M9(075C5$#*K4%,]04V00+J,O(NQ<G1'W',[ ^-MI)JW)'#T.&8,>2,=O,"B8
M- M>I#H%<1'+_WZ=@CAO"F+985;G(&Z8^6V)'$0KZC"!Z6=!,"DPV2K6#Q0K
M]0/F)1(P!T4M?J84LR,TAV9!0E:QFB+Q.Q":;^H7R:B\T>:NIX@G2WL^[N^C
MG>$Y+9.6HGO!8,>>D-WH1C4%2#5&.C6Z1)@-NXR'. ^LB%?8*/UHG*%&+"'%
M&Y[V2'5B^2A4^$RJ4SCIC1H'']E5T-9JUHWB+'@YGQG_9"##:Y2;0)8*TS@*
M&JR 3&F5UAD/WR-1*B"11A<)TNI0DFP$1!+06 4J-N[OKB)MF DHO[UVYS])
MVE-;;,X%F>4C^/8=<VDM:RXB !W4LN:\LF;+825UQ8N-I.!3TF8VXW#6B"94
M;@M0Q*#+3R^S.^B>#5' *"(@X"Q9S(H<L'(""BU(?'V.7Y "/P:DB)]%*=)H
M%"[<@AX6@[45$ L-"9FF$D4<$G,Q^"D1CPB]%E=QTP$G=\-.;/M]9CKGQE:'
M<2',[7:083W^9L3'I?>!1ANS%V3I"=P\566*9#%XC&<HY&@4  ?KHOE9FE?P
MYQQ!@"\G6FRY&D590FK1*4@+0#-Z-&[(IK^G@"8G=X.7P6-5@V[1;HVNRA0+
MH/@A0A.%L3[<GT;YBA5CI'C,D63YR&J;A8PI]$Z ^&4@";0.X6HKK53$*97=
M*T,YL55<1* 2% =E6*U"]+"H@SZB[N3('I _M\ERZX-=&YJ)?WKIWX6W842U
M9'R VBRG!6ZAR[9QA'8_ECT=6DGK1M3#W_IJK&+>W=[NKJOJ6-.QDPN:([D(
MY)B5P(2(8,BVY=RT7+TJXU[RDR0CS8^*]4R*R:<(2<+):2^(1#Q(V))*<C:"
M8<+AH[H4&SJ35)QHP9K?8,RYB4BW=+[Q8@F?@ZCX+0>1P<K8H1"K?I8 W/@R
MOT /D_NT!C#[,NSW""HXU!SM/T8RU@0![?;D]>D"3Y=,>-C4(8>1=E$X6RGY
M(QH(<O<BX4FCRPS(2*V>KMU$\@AT]X150^ 8XI+<VH P W^46TT,)ERRX]1;
M0/JI"- L$DJL3\;"$;]!\0QOC@X:4]0&V68WO_H>:,^:=):9)CL=N315T5]B
M7V[ )Z;U-MH57D,A+*633M"',N4TA17?JD?SUB@POZ!1;_2U*1W>4PT-K[?Q
M]+=11V?6T9F/%9VY_]2B,SL1N^HI^, C:;L0<^#I N "BV9ZP('#8/(@T9FS
MTXZ6HPI3!?@+\7E3H8CKJ%@WLSKT_BN3 &GIX'X=A%D'8=K*LE9_ZY,Y(LFZ
M"4B(,L8@S.T\UFF)7-(6+--'FNX(O_/GEKJF"8XE=$+""CIQ3\G$Z,08750U
MK^/HQ 2SF*.1M"*Y_!8[CC\?)?"[M]?4^]MHX>@I*JI3?M1'4%0[Q?".6Y75
M^774BM#?N5#>F+Z ="84]3A0\*^R&J^KYVH5-Q$'V]KH>["M=K@X<6..S$*^
M7B:\!7^+E<Y(-B&Y.$CYOHAMS+N$^<-(N[3S9TLA-#M'HF EK'9/N!$[*$^4
M0CUMP*\)]P$P: ^W#D$NK] <PEF4X@DF*<#&)E='L;J.X%,#0RNGU/Q1['-8
M9<5N&N+&CP*,I:4C"@D/AR.5Z@A5_ *QJN>G,O\&[Z6,@1^R\3=&9;^/!<O1
M$HK5L E"B3&HD94Y3ZY5Z1C-"%,F16V2=/A!@1%,ECE_?SA4'L8*8[8IAL20
MEX'WC,&M-?E;,?GS-H#\Y6X(CN__B@=_JB3;GD[Q6I(P?2_2YZ%@ L.Q_3O!
M('^\[9[8=C(-='8V>2E<X]W^/E"U[8,=-[!XY]:+BC('T!(*3 <L5SHLNI+@
MEF\26N[0*&BOA0Y]CUV^@%3Z1*(S#&O7FZ1S(KP[5;4C2D2N(M!_.XH;QLF#
MO5QPLQZ>0J/B:1M_<ZK09T>+_*A"6$8/[_Z.F[^ATS;05!\JSATH5IO8$/+N
MA'/>3=]K2K1B2J0V@!*YIVPOV")DYR[N/>L6.39W)VS-3UP:4/(#V_6MA,_>
M)L, -5UH5[CN:U!?0TJ[ZJGRRC41G0IJ7@0TLX%AJ.D44>&J(PEZ_$(;4L@J
M(A*Z $O=T.*(V/+2YX<M4)DD2T9N"Q'CJ]&;FS%%=3 XUB"BAV@$($<^@=7)
M*7.3\UA<LQ1P$4#:_#A*C<JQ+><O)9'?73H\8\H651!QFXQ%W&1.0#8P@ "=
MW/:(1A@)H9U/F!)$IV(Q>2;V[MPB#,"<C@-\"C)P2N1D1Y\8^O_)UF$%8@1\
M'],C Y4B5]H&U4@G95;(Y/F+.]..1SHOG$7Z(<8#$!OWS8W0]H4>GH))#J.<
MO7RGC?NT"&+B-J=A948A&\".7NQWV2["" NKLW@R$VKF<,X-"C_X3G #8OMX
M9^9] 28Z ($EP0$!GSBE%S$!TW_+V9HE38A4*)/W.!6(H!_H97&L00,7C(;"
MW+8>,'\04>,$XY\Q<(3^!'+J84:RN?9X<V*/PUE,]BC?-@(\ZG:I+G_2S1*@
M&!R,@V$9F/J,)5E(94NTG@^R$:9L,A1TJA\_BD\.X:L8PV:PGU)IOT=B^^-L
M* )V YVQ^9V!D@@.$.RH?%%"P-O>VP'D[X/LRM#;WN=LXZ&?> K/B=I W43!
M#6+<$'@WT,LL'OEIADG1'D9*852*.3 :I!_+S(.UG<Q>6U_Z01:3,QMD5(H<
MP_P*1 ZS7WW$4]YX.X9,=,R:E]%!<.A6 E1)^P#@2UC%Z>Q57,/98Z[X-8AF
M3-TPW:.?!;A_C!#*>ND]CJ[RQ!#(K=E+L@JW,0=8>%A+P92A8#O96=Y68*Z$
M>6!$-@R5Y GO#4+Q"/0"R@#6U,_.GFCMB!."E[&+V*]Z090@5L"B7^*RZ(!-
MV!R@(5XMLI3$^3)I<ETV"2YFCWX=1_$W$,.9D> I%I2&.O1_$1+_J@[]GS_L
M24<UF7"\3Q2.=\GA>'4:P(;IO9N0!I"'X%_$$18'\41'%P&YE]%MQ*.1QR%1
M*-PS-<UKC#10)/"N@>D-)B,4;'HZ[=4IJ,CU2F!U9(B*1BJVO FC:0L/;V/O
M0A:D@LE]9,K4[G_NJK9XZ8IY;W/526$/RQ3L6$KE4%K4IL4X]D%RMDJU%BI'
MYL!LU99[-CPQ!Z_S,A9KX>DP>=<16QK3*)URJ*KWH$M)D-Q=BAXGZ5:#]S9T
M6Q4XSE%IL2>Z0!O/U1L(UUD*[(G%HAS4L2AU+ H0:2(>IMM/X:IRDH4MEF05
M&*[=RSD).OG"5F@P-,.0KD^ZBH*\B7S/I%UX4=8%9:&<XFS27NZHB84K(]^.
MGHI*@=7.A.>9?N#*X<"2+C2*S"]2(0*: F6YR\Q/=>&(46HY8HG#%HO@EDQW
MNFR2TW&;+TI,UB1S&8J,SR0?\&W#ZV,-KWRCINI9EWG^/?GP+=K,0G%AA4((
M+I HES59#"H--,LS=&>(:&R,<])DRS*+]I/2<P>[+SPYT?Y2L^#?^8&]7?[H
M%*N;9;TIXX;KRIB6,*G(5ERV8<[(,F29JX>FA[YO1'7G8T(A+63DM 67C9>W
MA% <A)23S:)'IR&\#"OID-&3'0_=0(;?JAS7NEI@Z0TN$3:*QBI.\H30E#-"
MN8P%&OLX833)_#2OB6?K'U;>A&HQ%Q2GX2@-)LX]+9_#K6";OJ_:7X2/#B5Z
MB*:11PK8%.P2-E)*[;0XS!<6M\4)NX6]/$S6I=]WZ 2LSRSU3I)!]?N,M5N&
MZ$="EP(Z2U+K3BN"CC)0Y<36-BR=G299"6D>59* 3'C6N]9V1"_>"WK]+,:M
MS0% ,OY2-7,0QB9LC_]&#C$J%6C :3UY?D@5^XWRI&&3.P(=V00O>04_F 9=
M+:,\Q\A3?2T IZUTXHF/DZ6#3:?*[A/K(S<KFT+<\D%E7EJF;G"7&VX<48$]
MED*(5!Z3H$?76.U4KG076*H9"0(CU\9RJM]6D(\\D+P<JT7[U-'A>J?6?3UE
MW'@8LLO>6+.;@I\?;WL5]1M&L.Z\0K%ISI);970Z/YKCM-LZ+PQ0HI"S(F"=
M"! -<5Q8F<<:]0B^*L8#Y'FU0J?4OM)[B]50DB15J!DU(RF]1-^K1B4+E M#
MI4R(PG3R?N'!AN7=9:G*2HC(PN*,Z#8%XZ)'_YH)?>6<>&I=M&E0]93\#LU6
M9RNV5-/PYQ@^2^51,*BIQPW)S^")4RT<S4_ CZU*P1%'J5N NJ0*QK;.N2G.
MJ_%]FLX6Y.G2;^[%KJ3$4R(QDB^4[HC%^$@-P\H>3A%72<S"7/@N"X)431Q+
M29??=:.3'%H%<O2-'ZAK?I>H"@?+%TI.E,-"*J9N4,\H34B #$1]&5.,%2U'
M!_H%$M,GL.!%D7ZP_A6-0\<87LMISS\PM?5=@7;)+)8+TB3S7^W.P&VMF#IC
M%"*D<0(;N%C,"*GD)H</CFEO]Y\WIOD+U?2D $+'5)&;)W2-(CS'+L7DIR9:
M)Z'Z60W1&_@!A9"B>.SI3Q6Y2!ST*V$>. XSJ!^;81\^'?'9H\ ]<,#EIQC5
M2IU*T"P9JVL?Q$U6CVPP(TC$P718.2M&^ W<]RRF^#5QW",,VGM_<,#"[Y#C
MG.]ITRW.,+\MEXPO->JM'/46PSTVI 5<BXPMY1C0ETI**PP*:DJ4I58!3+0$
MUA<][JFI3;6E]B';>:^; F*+H8JOV2R*;7PB,G0!8N\\##&Z!0&64>8;8L!M
M"^]6Z!NL'I8RM&3U_>\%G!OF6VG:#9RH%>9'4YCK( Z[XU=U$,=S"N+XD73"
M_@;HA,>%P/1"M,%BNJ'K.^/X3 XQ8!N'ZQ8J&5'0?XIV'-(8LD#&KG)I)<DJ
M5H%*2DA>4#(Y<UMJLJQ0XHI?VS%6C[/7&X"S3I+>8C@ZASUB*LG51JB4FNSD
MMA"* DEJ0\;C&C)(G V 5W'E!5>OR'6%0J5C(CQ,8(Q\.,JZ(%ESCN&4SK!Z
M9=@M7NP2O7*>%FVF>A/;>A"TI*<3$+#M#*1&^6F6FH 5K!B#V56XL< W=0EP
M6PF&K?C)P :\J.\]:FAR]!A]SI\]7B]HG;FEN4S-UE9T)H,-8&MGD3BW1<F1
MXES"D]<A3"W:'(NS1#Y-I]+]U75\;ZC=NZD.$0MNW2CZEKB^JT+T@A,,2N6A
M80]D"79=[H"O4RF@>;Z)8<1WFP0:>86 2+NSL&1VP7V5.^10TI2Y8R\QY>G=
M^ /LBQL-V98]9=!P-U6UK_KRK9W1/\+E^Z*N$5L6B%7*>_H:% MXC.FPOSN:
MTS0XD=\)["R$O>:XG4<$NRT<LM!YU7)P0O^>B6QRGR]UWT/'L5YZR?1JFZ$8
M29>B7+$BA[-SNIU4^GW8-94ST('=<$"2$QLTH^5M+/H*#D<W=^ T+4=^">28
M36PSTK/=H**RV3<?9L>IC%(.89QAI,1H+*>&246SQ#S.X'KG8>1^Y_;C->7K
M/_/"3KD[F ]H$?)/BUU.CQ<'A?[ZD\J48B@(-U;QP[\H7,.Q\<I9P#/-Z:OZ
M9K@%8"3-2)9CMPMS7NJC7.:DJG9IG?V^B*/L=9W]/K=5S*(A"]VAOO"$E&TL
MK@.H?L'*XKE6%I]U3OP46>F4DPBH-Y!I E* %_$?#;-;M>V<9.3Z;=%K-T/M
MGJ5A-\2VW.%,N8CD7)HJSQ:781AEII4)=8JWCB7*,^=_;0&GPO<LSHY,31KW
M(6/I;#A)0#,?YA$IP-AYRO9!BL58QK$&0#YP(5T]YX)Q(<^=:]P'7"DE-)^8
M,<\P)Q1,$@XS+O%7(Y"3<P8AIUM C>4HKRV4TW*N**97R4C"O:Y8=$#3;\-5
M#^!:AM$04*-7BDHDH9\J5\XVZ]CY9RZ_@5WC>(E&,="&%T^90E2(Q[GWT^S7
M-QE'(.*EVM13J,AFI^2;@*DF[E$UN"ZRB3['"#]@NKG)R')F<K289=M+@TE(
MBV_77  LO@Q3[;V;R@4DF%O;EJEFQ^6;*R]<:0(V>\VT<VV;O"%>J-X\" 2Z
M39KNGS5M.=/A1X7]4VQ\#R'@L:1\G8%,&,6X5EBIKV/2HKPL%Y,9:2X?+\+#
M;?G=S"BG"'894WW4$8CN+'EB22H9RF!" @Y."L*L[AF&OT<CH&OPH>%6&,+
M3(0X51BB6%9=_\]=7B'N_5/[[/)87&+'[?W]5WOF$@+( .T3TSDI,?6"*&Z&
MY6&=B+;#!0LQZI4#3WM9JDH5F$% HP1".&Z#V%*[]1<X"F [\AK'*)R)VU/*
M:.2&JL_R$?E#HE,@_8U>6 +&_GD-HZKJ: O<^5)$@JV7[1Z$6S8QM,%K6F1&
MU?E%-C(%WW1"9>W,7Z,S_W7MS'\$9WZM1BTBM[^IU:BY';7RN_A58J7.Y%EK
M1T_1Z+H)%<.P*@'FO)#V/*_A]2RRK@B?(_30N#F5XC>[#:[NC$GE)\JV09'
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MO!_0S8KOA65?-<FX=3_N+7)E5NSA5E&EX1?<\F$3R2AU:BH=VJX[20'SB;*
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MUD5[;N#;S*TO>0:R7!1.N+(ALL;16D9Q' Y3;#$#M0RN [6W$0'6KO++X,'
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M)C=\5-A6F_ROIIPQ='_:V"UM[[7 2WI1RVYT\HM-TXY13X8.C[LCU>$PC:\
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M16Z2H(QQP 3EWF53.KDHO6WFEDJ,XYT6&*]W0V!<2MGR=5%V/&=0_;P"(<*
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M([=WC#;GT/VH!>0-*2HD2<P9*%!,7L/_HUG1@."\S6'BQF9*0X;KYX.9P *
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MY RIB ^%CI^,";01(XS:4C2*V9_8)RTN<Y/9 ?R3:):8D/%2#WDJD3GUZ='
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M>SA)HJ$93A1F2KNU#B)A.R<4YB"_P"+YLRCQ+EX5M7W%#UA2Q_<$6,\/+HZ
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M8>("/N))-2\X.Y#!4"Q*OQCI?M=)@@EAB(#*[R"67!7:YCA1BCFFK<-+ZM+
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MFI._42E:'V]CMK:YJ%N$48.V%DT'6R)6+ B L*=OF[^D8?A88"XGMD(<GO>
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M=T@Q"A.CPVC]!"W^F@ONO<#=I*F 0"HZ74S Z>"N[J.66@$#AI.NED53H5Z
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M0G;A/1M'?IL35($-7'V/?.L653*:@.!_4@ ##6#\"FX+^HWZ<=]I2M<T0\O
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MZA[=S)J:P_4S[U,V8"S%"<5!"[>G'H6U@N5FZ-N"Q[FXAL,E#2*FP,B!!?.
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MVNR#Q[M_WG)K&<P@Z*E#)&)G:5.09@(&7!,P('2"]CJSM[T\ (:R<I+HPAX
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M9WGV<MR.3NF,T^2@W2*EONF\IG1@!Y9_X ;';GE;O,-M-C(<E5_$%PJI 3>
MMZWI&QO,39U5V"#L+7\_M'=SC*WRA#>NQHJ^;*: /"<N*_H#;B%U31=/[#,I
M=3V%I3.X.KRD?\!,8"Q7N+C0I3 _H8_MZ'U1X=J9"B:.W^.7P%'410%_,1GC
M!C:3 G5"7^BBAGU"XPFPIR&< 6)'-%I<KQIH?N;/Q1115O *TK9[7Z4%K5J=
MER#'%#FTAC<0\%JX2&G&L%XCX(!R4=%56@QA#$1]IG6<>NYW>^ZWMS+W>PN2
M9O0ISN)RQ@SPQR(#4<;23?L*]!D1'8]I/&.)*;=L,1IBDX::Q,/UU^=[+P;
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M;V+VC3M#4SE#SD\I*S0!M5]S9%!"*[-V+ONIV?:C8-O/>*_"^+S@;KKI579
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MB^5F6J9L4AD!97OD0-(C9>%WG0.4P>_0[B*.PDY3;=DX$AV3=6![J[#$!PL
M^5$T_Q@1T^F\PXC3HAY6:TK6;Y]M6)/U]KM+_<Z%V9-9?5(C#"1>G==P1QE&
M\Z3XB;P0(89IC2_^5AZR=:677DJO5Y(!)=IO>XW[L*<O$-A7AY?N#O0@0;R_
M/.]+FEJZ(V=PX92:KX=C$&)R9 5>311*@C2$UB*8+AV1GIQO@^PIS,/%BXI
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MR2C6%!$/:S4M537?I,<X+*G+) S?HMA%^YYK$J+YS"R:+>\*S4\UX0<4NH^
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M@G7R@YC H.*\ 76H8*-3]QKN;JI&E'&GF[I]>WL;:G/CV6903K#?_8[=?_F
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M,&0S.2YH=&WM77ESVT:6_RK8S&9'FJ*LPT=LV7&5+"L3[2:62V(FE=K:/YI
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M<Y""^+>%KVG,0Y*+,*WC8CI3^?S5;DTD<;#_<ANF$JEI!!=O'LTRK8Q.HJJ
M:>/1S8LZ4I&-(D7*1!<Z3XLR^E<*<NZ]B+P*%_E#FBL2?GD2'4]2/8Z.XKBH
M\PJN*1("/$"D@$N6:6Q^_>=%IL/%1[.Z-+6"%<"2JTD*,EM7%4Q4799:4]1T
MXW,\LJ]NGM*L+*Y@LQ,^DSC60&NFCB=R4G T:9X Z\1@[6B.ORHC \2JJKK4
M0(Q9<?TI(Q.WN@V_X62TXP$<@0X)(<WIGW@\\&6617$QG;(N99!HWNI8HAU[
M'.W8_+&<P#;'&$*-WL(>AV?S*&+O_<6DJ#,^G[RH_!)@ Z^ ^@T>"\ZZ.5($
MMRD=,_&YHX_@'P7\MKQ.C8Z (*=PNS@,C[^?E7@'B63;PPWH_?"DAK<1%<./
M5-4>WP!ORH JHJL"%.97:8,F>.%I!<<;P\K5",X'&4#T:C=]C?<;3B0OHG%1
MQC1]33-X,.IJ2+\D-;-,S0_3',]T9Y05\8=P. R+\;_ANL!.D+1G%>/QLZYH
M]5V7$.QD7@#+SUYV!+_W'W'$F\7RJC#Y>^'!^/M'T:^3-!/" NX:W!X^?KI"
M=&9PRO.HU+.BK"R]R)U#ZMW_[J419GWR4<<U49'EU5L;%4PG9PV^#%3%S TO
M0333I6'Q0PLX.8NF:AXEFOD;+!J)<J)@\O10 @O1!CZMJTE1IO(/^ G(JUF1
MBWH$G^*("KAC##0&AUK"0<-'IHA3#Y2Q.VMO^1 O$OR_BL9UENU40 0A:[.R
MTO[\E.XR;0.\HTAH'G0O$[J8 \LG\""9V77P"'>HR%AT?JDN-9XZLD[>(3\#
M'# W=49R%[:1OQ_5!@X!;%*%H_+BMZXGFK[T"T'>HLJ*_N'XVKNBPITP%4P=
M!\7YP=W7EP7\BPD.C\-/J]1PU=*BAEU'"%#*,6AB'/0^7'$-U#D/9V.**"MX
M#^@0@Z^2@M9=YR6H)T4.HZ'$ *X(@H_F#"L> Z\2P4*BKQC!'(C23(OP>SYU
M>SYUL#:?>@,*9'2A,E7.F54- S%/)#Q3<]9A<LNBHA$^9.@AO #_^?C)W@!8
M"M[[: ZZ_  ?(B)"H@>ULDQ(UVSK$8ZG$:VJ,L'GR@)>:N*)3FJA0E./?H?;
MA72A9C,@'!H:=*LZ9H+!'^'8$U@3T+BQ-X'TF'"RM*"1#D>$.:<%*&)P"ZY2
M. 4<:U8@A@)7JA*D$Q;Q>>?4@3#B4H<L9.&M\"2+W @$.^[K)3 *& UO,#";
M4L.]*%F-1T4@=9QSDQR]00CUZT?"VOO+=^O+]WCMRW>4YS40V9LBKPW?ON.;
MA4N@,@ E$^O&ZP#$4X+6C;]2*&EH9"#N,<X3+]\(WQ)5L.,:A260XN.GW^(K
MB/\&Q^\EIY:?V^%XB#N1\R9)><B3EFWUM!S]%HKE</-@DT!!($,E7&JX$R#?
M_!:H*5K*N%I__?&F(_- V=ID,2H&E>V*%7G8[_!0>']-I T*W=1,V!H,;:VQ
MU:V0L[H9%1'\*P^.FB8FTAUN%RV/E(S%$3UE ;N]-R?/G_5SV4N?%W#@=.\%
MYK;Z-7>=/0[U20"]A$B6*-J]@9)O@',V=H1^6Y4J-TAVA_4,"#"&ZWZ[Y?)_
M)Z7#)JKXPV4)UR!I7=U@,YI?R/$!CV\>9]>>R4<!/%P^"='A;?3W#/39G1$H
MG1]VU!CVY%!EUVINY ">/W]T\,1%H/BSO04\^9>*4N^ATSUT^H&@TY]=?L/-
MVF5"CKPQRU41]4<H&4,]QZI8,Y4FZ#^#&8-]4TTP#4>5\.#^TVIB)6FL,HTF
M#$EID-E95EQ;X[OY'2@$UY,4'O<OCV@[M.E-W=MKVT_6UK9/_EV#J'L4X>\O
M&B9E65SAJ;.6]*9 0Q2=V"DHU%51F@</@]"4VOXV.R.=&WJ&;(>TJK2V\^65
M/$30BN?1#(BDI"\KL*OC=$;^.G%TM_P-ER7&=U"/-1507E3,G%=H5L.U0T-%
M17E-\06\PQ-5ZO89.?,<?5>P-SQ4J6?P4\TQKKU';/YT/84>MCGH]EF-\]1$
M.-$66#89&F)HG,%$B[IR/C8_B<8+"];0#:9E8*@<=7%E4K.]^5,YXVUL4!'Z
M[@IVU,Y*=."Q9Z7)O=K6)SEQ8%7Z(ZB1&.Z8E1A<1-\/[0)N%]PF<>*-55J"
M251^ (,,+EE-Q*GDE^N<6<%N%\NQF3JV8,:)YCB+MV_DYKJK(;<!#-"TPI6B
MT\B9:]NA<2>;PP1X!<985%QAD ZVHBYWB&VSGVB=O3GP=&7'Q2')O\N+&:>E
M(:,:GBR->-&ZQD-[$C\O]50ALRW=2+"HQ\]DJV&SJ@GY6($>LPPM.H.OTF!X
MNB_#MZ%75Y.*/"!K'G^'%L$@M%K)+8#I1&E>PQY+5&PQ%EA-P JXY,\"]YR=
M:$*";=E>@WB]Q*T.3A%/U5UG%HQ)I*[Q:%V4=]!)-V2_,Y?'>#W><]C)]QD0
M*Q*,@B<Q(#LNBRE[*Y!&\4_<YC2/LYKN,BX*9'.LC4'_.CP^V+@W3E:!<V_>
M6"$(WB3\%YQ0DHH;E"393??!13IR!+XQ4$ NJQR-CQ$L<3"1YC*N*5(MS)'N
MI;&.RR4WD:- >LHS!;X!9]OK/+?7>9ZN[][7N1X#]]M]CTHLOAKCA:P#W=G7
MV& 3"U<VX %X=YA*X;B!0J9 6BC&56F5 .M5%U<5 A]XPG(G35V2G\P^'UW"
M]R5%2:<J@9==J3130I[+)'D8]-.>&;W5%3QLO!U@7^TG&S %ORHW5V2.93JJ
M@R"$2HGIL;#  <;!DP.WDXMSIWV>Z+PQE2U0%$; (J;!CX,H@S^8G#+T$]Y<
M.&@.#H['%%M,3=4 <31.J[U?S<=GP([B^8#1*M;KN\ _0^YNI0+J627( .;B
M2)+XZVF1P*4<1%D*'&' ')D"@GC(&<='QR2M_6$0#1&(0DA O,[TYIYYW)IY
M/%O?8/J(QH6.SG4Z'=6E(='+O&,A2EC:WQ EDS^=/I4 ,,O87*-010U$\]!(
M5G%-T0+&0"&9 <WFFB)[3+/B+\=[13H)PP4("Y#[R]BRT5A0(JF4R#WT3ELX
MR@\#H!;]'.< %VZ6S:VB.W=C\FU@6B1M6:.6!;P0Q1O%UI6'T-$6P"1L.0^R
M$O!NVZ7WM'M[VOUN;=K]J8B5Q]]02!;TC2D%@8OR0Y3)]XZ'@HI=5)JTZ.AG
M!50:3VJCJ\IT48CH1B4J/Q+J"N$4CNBK4ET!7T-:L(B.02=/;K-AA__(M4["
M>#:]&HS@_%+S;>!Y+RP*[PVASJY+U+UR#'DAP:+# Q$MUNG!S+Q'6_P9JGR^
M?L"WVOD5Z<WCJU\*J' <#04UZ(CVJ"(>BG*.5?(;,)DNR*HJHNJ!#7M.M<J%
M>X:.(WP(J<G!%=%%$PA786'$\/)"R'J5[A<B%BW)'F75A,Q#FO_OQ<BAO4AE
M&0C8C;AC5=8QVA2$L?)^+:17JPZ0*G*M85LLN*Q]<?B'H>I)8+0<KB'Q;Q(=
MK)'&.H&WP9C!G5HT#K?66_!VPTB4([ G(*A>&VP/CA%?7>09L1.>0L)(,903
ME)5D+["'.".,SDM,NLZY!<_]@:#33O1V YZ2*5.!:4[J5C ;>^)\UI\/.*7S
MC@2!_5.Q(JYP$8Y+ZTR.#;7,F^Y/PZ5@.;NA<5"K9A& UP,Q]U7T> ^WSPC=
M@25]Q0BG!6[;<0(W /3:][/.4PH]D-6#2/(,_@[[\3E%[;^6D/@WKP_ZT'<?
M^NY#WWWH^RL-?:-TZ1"G T':$I);1 PJ7YQX@G@YD(9U1C!8Y51&_$4+7(:2
MK:BKZ%B!^40*Q:PN8?&Z2TE\*&-CR'(9'D%5(/304=S1)MN@KUI4'TQ6*+5H
M7J0D4@A0-"U24<GG/>6\)WO:QFLC"$Y>U-JMBLU>+TQX$/<K:)TF35)56H55
MP;LR])B;J)Y)("D\AP[ELJG.A58D+U%3$HFFWU@_A6F9L"@@4>4+3%YM*MX5
MQ/&G\+7+*:J5C$:$5$K"!^Y#;U?>WJY\L;Y=&<<E!NG.?!8%VY -Q5CL <U:
MYXWTTM1$F6)L,L!6NKV &T8J7?!XDR].9C>J,2FDQHS5*Q4+VPG#ATOYTE8*
M[Z/@ @-O,88<T"S&Z*U#$0-+8%/,%SR+19CB&Z[,9><YP@VO%?DM@?W-=>6=
MG(F]2YO/-NTZZ2"WL;]FMT_JVUO[GEW 1>* U'O%/F8;8(O.Z@J3JQUQL3LA
M15A.7I5%%KVGF%#'M5R P3B'C.FT6KUTW;+$B;YP*Z#MO4ZT0GA:&;U-C6(3
M;ILP*VO,DN+E=!5B-:/$4O0K2-"Y1,$X)N %/+@9J@<##;C6Q^@(B9U=+3EA
M%]HA[([[854;Y\5QS(OEG[_E8&/I*^M#99R*GBG1A+S_A5,3*?>>U2&6D93C
MW1&+'%B\'W%0#BDBA$E"F6XH! ]E*L4MOE2(Y5@(:'!(A1$1[-9BU8#B?TY/
M0/8]1KGLUL'C$)*#LON#7#M&TO!I4M(Y8PR$VXO7@R@T);J*T,B,)RN&'$0B
M* 2',A;_AL7-&'>'9G*'7*Q/=F@*2A<J.L#$8]J9C7/9"W_L1XUC/^>S:B+;
M&A+JID<YH$L0GI*IC>4D+!PO-]#3,W8M163(+Y.+T99-"S&3HJRT RCAQ=4D
MRN'V2W3]ICEM+R-1/*M\!_V$P<7@%]USJ8Y0.I!,V)SH^139)&M('_GHF]=;
M:MOYG.B/X5*U"_V\K $YD%V.1:L(Y&6ZDKD:J9AH4U0JES1S'J()&KL2BL-1
M=VC4;N!;%T6NF>M9ZLLZ0T"=I'K:6"KZ[N&$\P GMP#F(-R<#  KL%FB/F^4
M8(+-J=)'S,',>G?KI8OX#<!JNT9^-?!2FB<1;%O[UB"SID,2X^^:RDR0!3G2
M.F>(Q<W;.5%BCS=.R%:I2)I8PEON2<?[[EES_"O=Y]$M[O-<,@ PF\^92$(A
M3*"$/@UEX@QA>"YPP%_GPL"7$5,1@S%D/#,06J8 E\]#T*S=,0:HD.Q_.W./
MG^HIY5-12MRBE(L%^*WH490W6NII6D\=<Y$S#)!IBEU'[J1L=*IDMXP$P=A"
MYNB8:,X6V.DT,5*4K))'6A$IG6?3/!T!M;ZI$\RP/0=5)H_)*T6Z14SSW'_Q
M_"G%:2W@=K.52<[>G!\U];-N-X8HZ1C(F443K3*4=8@5%N9?;AG[+ [I/D:3
MBNML66BU/:,&\-U^*8=1-M""':D/7D@0.#"(.<K</!A2X(*BD*.<8'PXND&6
MI/PB*"ECFQ.D1$H(]W&T=;3=EO8=H/1.";GUQMI0! HE\Y)8UN)^MHBJ701%
METZ^+SS[$C=[ZYAG2=BQAJM3T.G\(86E3!\5O9>HZ.,^*MI'1?NH:!\5_4JC
MHBR:2- OM_[29MP@J&[E<M'$Y$LKA+2C9Q8U#8ZJ6I-P#;7#H?2:BL=6([:R
M[9S!KEP1S.0J+7 CFQD+F;J&AVTNP\ ]2#!\";-<B#9X\-W^,ROYW]<C&"+Z
MD6=Y(1E@H.:)![9#LY)$1UZS<P)27H*8^_:SA-)KL[E59ZR]0S:).!TP&IJ.
M4TP &Q57+M'@(AR<0DX\QL"';D/0'I"<]9JN*!K%J$ T?99X']J.BZ1/V;YC
MP&7],HHK BZ_LK?T<PZVL*' 87"B[W]B1<%SB:Z&F9?6][MJ-4NB'N24UWCC
MPS2@=6,A:\5!UO)K4\)6Y=W;G$.M;3Y9[^+^*SLZVBYNE[UF/0]XAJLB0^%Y
M;R@$Q/)P?P^="2)_>H*X+Q]I&Q,-K!DYQ:7E9>0]D6**Y&$/\C$I WEG1*70
M6XGB42.#N\ZO&+M$*0>!(X&4F;">P^*8IJ%2P![(ES;/?3%V&4"UF98ID5-F
M0#D5.9#T6-MZJRY6RH5FT#\C,<5.CV[I8XZ.R;HR">NPQ =377X034]A,6NZ
M[S#CI*A'U>!A[C;LR6;?NT_O7<!#DO=]6F.A012='T%&&2[H2%"+O! EAFF-
M!7\K^==&W<L@@S:HF8\VV%][CWN%_0X*^_KUA+LQ(8_NKU'X7U%XMK6IE2=R
M#@*G3%D\'(,2DR,K")I64*HAFC2NDD@'-)2!T<B>FCFO**C2G+"38&<A<R)Q
M8]#BX>?>P0T%HRC."D.I?63#V>S6]V51R7T]>K@.'EV[$L:/V'"P554% [ZB
MIX-U4_RP$OS.*DE8]YQ,&?C)9OGD@>//8.T:;;/F4^.*<RSNCR0=VD".5[?8
MC<=J&Z'#$_9,@3*%(4%+%H1WM^0"1JFK>U\&Q!K+:XUS+649[W(F4'2?FO@
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M4%SW2O!]P5U75_ ""KWT.9CG%'T'JPCKL2& M5G>R]F(_)66\&-7YTKK54_
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M/5#+%[*(A0R"LPNH+:H>(RYOA P$R%$K-:E6MM'Z R_[]SJ/+6L4M[NOHLZ
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M$7&W"_7T\=[[B/<^Z^.]?;RWC_?V\=ZO--[+7MY05CIQY*JF9MB*'K5249M
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MG4+L*JBVV^F.L-,1QU]N>]W0!HS'8,=(B63Y3$(""/C G ")15U/)$>J64<
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MI4)M,\6A\4M.37TN*C('[)5;WJ"Y)\K;$^7Z/>!/)*T>:X6$<441'R[CFM
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MJP(XT@VQYMU1D<SACTDUS5[_/U!+ P04    " "BB5):VES;91E3  !+M (
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M43H#_C0-?.\T&>_X7N"]@ZM]&V3"&Z?9+,T"O._>UMWW7+UKE2W_-9Z/TX]
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MBP6*<T7Q&E2O*<@G,8V22(UQ48Z\$Y!([3(*Q[N]!A8ZWTYOD;_DY2B/PB@
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M1GDAS0IRE.<>4F=&8_R^<[%C.R".0:X '>_]].J5[]G> 74ELC*6%P0&+N.
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MN6?,"HR 38Z6OW1F)!Z5&565KU6%]Y94'CD6)[-@\*9=M(<2E0#7'FN/KTA
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M)6,CY7;NCN;*/B<J9YG'E.59F8CO_1-LSF@"YB7_TYT8B.H9J*/T5C5'F2(
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MDEA1\YNP4&U+6<+18G$5Q/IU3/?C-#<;K9,V>CFR;CER]11R1*MN=_&"-GL
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M]<QUD=S,Y@[F^TS%M@8I<_?'6"_E6Q !/#Q>6OFOO,I>B'U:+7=D8C]R48J
M$GXB)?0IE \JJV >B#Y?8";4_0J5Y3+C-C5U3 _%2)%3E-.ISKPG! *CX#/D
ML( QR2QE**3^'J[['EYOP#T\2;%[.##U4T?KNX,"$#%14[=03[+S6KVIID ;
M((/%L'*@*&-)=YNQP*$)BY1Z@S()QX4LM;:;RM&5,*&6B8)(9Q/2U8.EU$0
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M2=G']Z,TG,-_KHMI_,O_!U!+ P04    " "BB5):P02H'?TS   ^4P$ &0
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MIRRK!>IP.(?B^%*Q(?<$OA\"@Q!]NCC] ^$+/NF,'P [\*GFV];J_QHNX &
M1;T:_5!J]/#OJ$:_@T=1I2$]>A5WRV]I.093_]$A:%TSNU3_#/1IKT"#-JO9
M?9A5$]BE:D*Q-QR M29TS'S'?IDP*M689QWWN63O!JBGK)R2HNRB-1C"1?7S
M7%6@@N^ WICH$8C'A(-\Y$$VXB#&W][QTLH[G<%4=XZ.=Z,);,!X)7/!Z/^M
M4G&'&(W>)W)]5O!M8^[N+=T;V-!DPW4TM/Y/HE)^+<Z+QYLZ+R[@P$MOT]U_
M=]XU_(&FN$6CA,GD98%>1#CC5T!"<5D8NZ5  YKH>C$:MPKGX2%+/"U+K=T:
M>?5;LD(_NW4@!RD9TRH' 9A.R727D&_+*7UC$'6!;,.6<"FB8NJ##M,*K$]T
M%:@HKPAPAVQ@K(!!M6C!^W Q- +[R4,!SX&?HO\76,D^^Q_(3FT]A!QI!G9_
M5N$T-=%PM&/T*$/6AMX1F&=1E3Z"4\^A\;Z"K7<+>Y^CZ&=W16IWM^4@W_#>
MKD&L&$TJ.(8X-1A28H_]<A%'P0'8"?U!FQBQ E.3QIIB"K1SN,5PT26L-%*I
MB8"-OM=E!/>_HCN@Y)>K''.1-^0$$Q2+-A87M;]$F(J_@7+I0/:D):X4@Q'>
M_;,;.HMDZYAF;[4%T7J+R!G8BLKLD<-#G%$K[,UQ38MN7!R2(HZ\F%%J+$88
M<GC26(G.=(V'_BG\W.B)0M%A_$@H4)_*5I/,IJ@?T'"6H<"T^"JM0*:Z+\.W
M89Q1DUD[H* '_BZ&JS@(O6"D60"MP^LJV&.!E,QC;\HQ6.XW_%D0]G$33<@E
MM&BO08^XP:T.3A%/U7, =BDED;K#H_5PK4$GW9"#D8440O:0-<!.OLV 6)%@
M%#R)**F1*28<U$$:Q7_C-J=YG%5T_W%1H([$VEJ,^,+C@RV)\LC:<$7KW'(A
M(MY8_ M.-4DE)$>"^;X[Y./UP"L2?M1=<#G..M*]P)-,"MZH(LB9,&&ZR]8%
MT1;<7@8UZ G/%'@-^GG[R-6FRM^3C2-7.@=;HK0';]&1C#-!(,WJRN#&X8@&
M4YIC$ ''P9O*] V$ K0U :)$/4,9IZ6XV+ XVA'[R(L2#F K0UY^]WQTPV!8
M8)\3E<#+;E6:*2'L+@[4!KWHFO6]TB4\;&NOO7MU/=F !=6K\G-%5FS2816$
MTE5*+)9%$PXP"IX<^)V<GSOM\UCGC:GL@"HS!-8S"7X<!'#J@\DI<R[AS05B
M8'#,:$38FM26#8AFX[3:^]5\? IL+IX-&+#J0O%SW+H+ (&*H &)PS(#R19_
M/2D2N,>#*$N!EPR8_Q,@!@\Y8WS0B'2#^C"(A@CO*"0@4 !Z<\]V-F4[3S>V
M.3^@':6C*YU.AI6Q)/Y7YSIS*!GCQJ$[@,X219\*=(IU@5RC\$=-2?/KD2#C
MBL ?#*!& @5JSW7L'2DN3H@WDG0G!MH1BBZOKW'+S&7AC$1FD._HO;9 EA\&
M*&_Z.<X!+9ULYA3RF1^3[Q%3,6GU&K5!X*(H4@F5AEB?BBTGV@*8A$O0)0L(
MN8);>D_U&U/]=YM2_<]%K-8#S%*$';2C"<&G"O,^RF2,P&$W*4I-=@(M]'?X
M51=9B1(7^O="]**_*:51M\!&D8 <@'+0*0+:7-_#+7.MDQ $1J^.QRJ_T7R%
M>,ISZ\'+1GCT.X-*8HX 2*1R=#0A@-0YFUAV].#&!R#E9YN2\EFY]QL28)VU
M=BI)"*/HNO;WKD[I9R6Q;!3(;'7<DQIBG>&F2KH* S&,HHE6N3#KT&V'#R$=
M^A0(='8%6H!P3.*O>2$78IF2&F9!^$5DY9BL9IK_'\70P[))MQH(I)V8<6FJ
M&,TF D/77D6D=*>WD,YTIV%;'!R\?>7XAZ&.3/#Q'"XPB0N25*PZQSJ!M\&8
MP6V<MYEW5EOP;L-VEB-P)R 92"Z,$1PCOKK(,V)$/(6$(=THEC"]U%_].H4+
MXQJU@"9&D#N4^Y\(*Q+<?U,"-QAHIBR":V9SF",^<3[K;<>"=MZN53&AS0"3
MEPDZXZ-^> ;ZT$">+4#)+ R7'S\6F7#H1<)Q#XOI83$]+*:'Q7QL6,SG5G?G
M)([F]+2EVEO#S^\L$DL2"9U/;+J@<H9Y[:6#&(C6$ZGDEM-9YJR$#OE_3QY7
M6SNL\I20M.0<Q)SK3".$F7[7(8 'DB!#J5OR8U3B."D6\[=@755&V2NJ@8-H
M88%QCD55"L0#%9-I9># =9>RN4WFSKQKAH\!!L23#_V6%"YVV<+H^Q<]"U,8
M&;[BHC@4NA6UCO1ABB%,N'Z+NP:V5F,P\6C>1'#Z//L",0U2G-*@XMHT295Q
MVK&"=V48@;!1-95@7@NTTB;IINX8&KN\1$UYJ9I^XWPPMF5IHUL)]<O ,M>V
MY%W![+X4OO8)SI62T8C: KA/[\G9W/Q]OK'Y&\<&PZ=OZHS+U4W=-MB+_F#V
M="^E-5D6TYI+$=Q)=^=2-9"^YR((Y*&4%0PK3#*M,$'C5L7"U<+@[T*VMY/"
M^RA8PVD8B  (J!U1&<[-BB$^,')F<_[6(JS1$J[,%R;P)!]>2/+F G>=Z;)V
M_29N?[<$N-%)(RN7@N@O]<;U# XWO=7OX$IRJ/"M8A^^"X]&;ZK2HE+BR)3]
M)RFBP/+2%%GTEJ)U&S*!.925]U+93F6J5A5VW%7 >(33-AP72;3")" 3O4JM
M8B-[ES!1*ZR$L!5T\6(UI5H=Z&P1L('1'H(*#W[..S:=(N?\$)W=?[789Y43
M-J8-=^BXJTZW\^XPSUY9MM=\"&QK?>O<V(R#TE,EJF#MR.)B#%2JB?5!EO]4
MV*<C^CQPF5C$XSF(C*@Z"5[[H1#0EJD4C^5&(59H+A#%H3!&W+!_D-4>BOAZ
M'0@%S AU#K\.'H>00BB;@KWI B'3;K$\$@6>J#HE6HS0N1"/EPPYB$24"<YI
M)*JZPV59?S>G<C=]=%=V: (*)2IQ(&9BVIDMD0/O:F(X:Q##%9_@.@#-AMR]
M;V .^Q.LS#"%LO2'S1+P]E,!;Y/39Y&TCW9<ZJ,=%Z;4'C2'#$*3@@)<1C 8
M]\UI=Q%9X_GF>^BD#2X3O^C3E)D+Y1=)K4\G'.<._^/(1_FHF4G-_UHYVM[4
M.-$3S\J?1X?FL E!ND%;'VW4ID!#K%2YE/OA(9IHQULA2QQUCT;M1FQVD>V*
MQ2^,OJDR1()*[0L77,?H"IQ_'@ \YW!!!/B4 6 %KFQ&74B#\*T=J1',&NUJ
M%_#41W,'8.K>(2,<U"H#3R+8MO;50BE AR06\QT5%R.S>ZAUSFB=^[=SK,33
MT3@A5YLL:8)@U]R3CO=]&@7X:[KTPP>[]#/)<<+<=V]""ADQ%1.V.I3(4P2,
M>@\<?YV+*%A$<44,QJ*M.880/,4IZ_QTS?HH8\X*J;;D9E[C]7IR>F!RBM<B
MIW=S"'17] !+,1@]2:N)9U-RT %<4K'GSA^G\P4;]HJ)RYG=#!S5%.7>X92]
MLDA:F]-#244CO?C-)$^'0-(OJ^0&=)HKT)SRF)R"I,K$-,^CY\^>4$S>8<ZW
MH=;<FY=7*Q@_M0K9[3\2VP/CDM-HK%6&DA8A]B)ZS(YUS^(+_<=H77*U69>1
MX,ZUD2_BOI0#- W8:T>242VB".4:1 5D;C6J5W"O8F>@E.*T"O0_+:B\@1BY
MC,UOD%$I)8:,HIVSW;:NT9'+T2F?=UXZTY#0S61I$R\,][,/LC]PD/U1'V3O
M@^Q]D+T/LG]U07:2S"V5IET751MOI\Y)]5,4VSOG+.\(%-^(<TIZ('](K,2]
MA(3_8GLT;09Q@M*E/JU3C-"TQ'P-=%RC]L$1=&>DKJ"*>&1G4QG9:02Z=KVO
MW%>4A)G<I@6>;#,=)U-W\+!+U!GX!RG'1&)>[T2K//[NZ*G3!MY60Q@B^HEG
M^4Z2*4%=%&=SA[8E><:\9N_OI*0;<4"XSQ)*HL]F3L5QQA490.(&P:!V.DHQ
MEW)8W/HLFG?AX!3_XS$&=00^!'K"'7 .XB5U/1E)BG;6 G](VY62S-4-^]PW
MZ0N+9&U<FGM))$L*GWSI42PV.Q@'03?C1RPT?25!\C#]V==#6;+B!:$ABEQH
MY!5A=MRJ :.5@D4K.?(IC[&L_?E<_$"[-,O>I]_[8];TZ?_>KFB$![TLQA82
MQ6<-IK$0/CJ\W^<A(K&GM,_J2&XC,$$P()^Z<9R4/$%2IYMB%4&2-!44V./R
ML:U:$5&CB$.5WS)TCM)K E66E+"P#,S\F+:A"L$.R9>NU,5\>#D AO(EH>QJ
MF0'E#^5P5T;:-0'PX6RNTHJ^)@GA=KJ]31WB]2S>5TI9A2%OE<HU1Q _B!JK
ML&,,<1M85E)4PW+PY7"6/-F*N1ZM,-<Y #'%2R85%E)&+>(#B&O+5:$)SI,7
MHL\QX;,.U"H/X% :)LBQ#YIQH66]%?OSMS_+K;KJ7YAUM7%GCVX$TPI64Z^*
M?&RE=XU3O )Y;5*6KN>@*.;(O().?2MG+J/-ZFLO=4"X.?4!F6XS^1YU@30G
MC'-TF2/+)8ENT:3EYUX#MP"K-\X*2YG"9,B[-/NWIBB%=YQM6\/#KOU</43)
MUJ2KGR^9(4M:U;F3^&%IW@QKBF&/)+)OX2?;P/V/5Y14Y;BPVM462:TO?C2_
MXY(K[;S"M>;,KFW6P"G/)&'G*.C%&-UVY$>9,XXL[:#NJV6"BQ/+:ZWW;F89
MGTPF22UU1O76I%(OXM\K9U/7V3YXJU5RFTK[52Q$6%F[Z$1<D455EH7)]:SV
MN(^+- Z:NU'H&V/9^.,$0^FH_4_1NN$F8OBN ON'^6LACB9"V#2T/5\$H3V=
M7AQ]=,MX#7%T/4[!OGVK#)RN/R+VN5]1"&:MJC&N<:?+(_.Y<DBPZ&D=8FQ\
MKC@C&>!M<B7TUBWVMJOQ&YX93&G"S+$9MH$_UE(>EM+YVA640A:,TZ1K&\[=
MUX!M0>+]*D*W:@>?O[=ZB*N=&/: <5<1040%7F<I]#0JFD5$?$M"#B0QP#)<
MDBNV0W<XS&"Z;Q<#ISK-A.KCM%X?%-/#.22L'%!#P(EZKZ.*,P*X>RZMS6%A
M)>XE*0KA.7,M;ZHBSK$^^<%*DVXUI"32,K5[IP>]/##HY7$/>NE!+SWHI0>]
M?'V@%T0)>\LN%.:HYDQ15GO15*J<2Q7KR;!(4I]3AO'7*6,V0O&(*6SP $LM
M'&18,H*4RQ$LD(5.NPY%>*]2?VR8^3KU%H&J;^J,\2N"IX#EA34U$2F^?C%&
M;^7RXUHB\?/EZ7(?XDG  LY90P/5T@9J*Q$NIVYBCK^@;O+BCN +'ZC>(O>X
M%X<(UXD84FZ^[X@KQ;==\B?2XZ*D>AZ&D3YD,MXZ+SZE6AA\G>"S2J-R.R5?
MU1TU;2<-#UM/<]%(BG,MP%>WTA13BLW)0:!SAQMP4S/K7&4TT ?^[X';%KB7
M\(G%"&Y5!FDB;B5P8;&78TO9?@][E^GDAO8LN-^-8G#4RB:NS[^KYBOG/=/1
M#/S!T)C!4FP3[S"@/!C2?S7CQL@E,!  28"%:]1LGF@M!@K6;K4Z8Y/!PEY'
M5 _$O9LP\!CXX_HPJ/EC>AS5.2D-=4O.V<T2"XX&1B5'X4)Z@'/V82""I>4I
M&5UX<7V!Z\IPU#811 D;5T0$WLLTY^O,;+'&56EO/W\<;#5W.*(&T4(@(YU@
M%O0 +BVY1@P5$LT$@D9W7&H$EC.NU3MSV6O=XTJ7R\VO1?==Z"IKS1O34;(X
MA$QJC%KO%:.]*3!I(!%72R.L)S[2VE7^MZ65,2+DW9@53X?3[6B*QFE=A&-0
M5^7H. O7LC6TDT-K-PS[;8\S%<3&/OGS>CG\0'(X^4N1%N#6H_4$+7DG/%:8
M/4M8-RK%NE (#R3>J2S)/BP[HR; D6P4J\K6,+VFY)M0"7F!%Y)J1]0MM0F$
MLRPM?.!ZMZC2P578US4I\)*Y.?C9TFWT_EN#):]F_JIS"B.]VX>2*%\9WIF)
MHR?<A;"0PD#4B2D% PK_*=<)-[5C;/%"YI')091_#@E));G$^X] F #'[<0O
MM66P6K_G9?]1Y;'CL1*!J%M], R'V)PAXN!</0O\5?8UV!T/%K5C3AGFM=^Z
MKB[2$YIWOUT'KH^/;QP??[1I?/Q'^)?.T9<-IX=5T*[5!]W'Q[^P^/A+S(L\
M0YUO#\X/K"=DFW\%&D[,27FSV16O%@1J(DHN!0WE$ZD2-J=C-();Q%SN,!2Z
M!>FX;P4:M48C)Y86:"YBE7W@OU0WT(5)I_X2R=:Y&&2 :G<ESX'C^R259X<_
MUA(@T;5)AE8*!Q520CY:>0)H9=#."Z%"CM0-K@0*2"<<&(%3<:]Y_/SY\_ U
M@W:;+633UL>/V54SP351 <2&$C\0%;XP5*$3<?W!R[?@;"]X-G 9ULRWGJ\C
M7^]+>&A'CP<L]QP5!8(Y)1&*.<J^M0.</AFSS>NQL&:[+XCIA+%/KJ\C9X@]
M?1F\0I%!1'/*X$2U<84]PX!?7>.44J+<W-GN_8^C_<-#>AB9 /]$:L8H-TR'
MUN)'\;I4:P?KPQ"\"&+7Z[)14N'5)97!,:CWW&"/+&3JD](N,M!-CGAQ'#V"
MH51,X)O _X=?.Y_C!S''FO.[-[&,S5TX-<W^&S#>5$:QQT):.='0NP/9:>NV
MFOCD%(^-FU@2K\;+0ATL!VXWX'C1M"V#0HT>P=D ^?MC1_[@([,-'CM #T>K
MHJ[BU@V848(XZ. DF\0L_JN%![D?_9H+H31#M50ITG-YUHFQ>HA)I>]-7B<8
M2M*B UJY<@]P$=PM\W>*2@L,9PV#&7?/.6(2*;(Z7T" 2[G5#IU&#3<JQ?GY
MN=5EL"JDPG->U7HX+#0OFCOK=P\+9 3 X6'*Y$ %=%VGAG#/7%,F!]!:!-J:
M\$6EU "5Q54FCH8E1SJ(%BR62([BXF$K*&NKR;1.<22SY$,ZD??@NK3)FPFB
M?1C[@</83_HP=A_&[L/8?1C[JPMCUVKBA!)C,VR)%,BG072#F<PCE5*R)6SO
MU.AR7C@%RJM3MT0<6K;^\!5M^ZPNW<!ZVR*YR5*>)*6NL8.4%8I-NG@)K$"/
M@5VA<LG[@2&8 )%]W:')\=BC"I9AQZ@P+9P$QVOJ,'W8T) Z,"X3^X%^)I7U
M46<D%DV^8]0*5$NYF5<M%L=OAEC#CB-<UI567'$^%&]9%/AJ*#V8'(G&1JV$
MSD]MWM&R#2&81SMJ%_T-8$ZNFJG+Y*RME,[@+$PI-1&204W"1:>F.9PM.@CV
M>L=5B2H&ZO>Q28<P4&WK$(@1YS$3V[?1G VCNX'YXKT@A\_/&LX6#\IN/+W*
MDUQSPSG;V=ZAV2#Y8ZQ28\0P'ILBAT.[2=%")6M/H+;.ULK8XD-#,:V;ZU[R
MFRY=Z/T*B:;2OG#)EF2/7%Z]6\-_UBXM@R0@-F>4VF5^ R*S[;@LPU5N"9(I
M6M7,G)$L!I[X-5Z06+O$C2]H5=ZB%'>C&)42+?L<X9RO*4+P5U(6SA+<,?%W
MKQP7&,W[D!CY((6' KZ\);4F'E$<9=7KN4- (=;/AE8+9B)HW2/KE'J:P.SF
M6)A+U,A2URBH[5-L%<H)O($$T,@Y(Z PM2=5V%VC"Y, .5B46H*ZB,,/53T2
MDNU .D<="C2R81_1'W-TW*@XHZ(1J8'ANKRC,W!!-NM?A9GDC<JAGU\:76D7
MM#JCR:^1)X9:8_MQUO2D'97WKL][_*D@"US2#.5X4""-N_D0RB[X=9A92CY6
M.4L.J[GBR(V8?Q&DT^2ZY!ZQ.K'W3'!'"@LM\*<'97U;).O"1\ZI[4;<#3VR
M']()-AI9HWW;IOO[IS8%;>7\".B%Q*M# 0OZ'4<A4/W3Z+G/74^X%99'N,&U
M7^-V@MZ"IR,7QX=&?1-L]YZ6CA?.S#9GGFPG:&LU=2'L(T>%BYLAA![NL3'<
MX_'FQ>9J8Z8'>6P!R&/I_I^Y^DLN^[T.$+<K,K74-)8\01%^!RH-VAT16[)B
M3BZ'*+1MWR8D;9%*Y($1=>5+5Q5^-60$OA9]$\?HFD#417L*>0U]X!Z6W; 5
M/RLI_Q06R G\2 N@*D7NI>:]N^@BX @/25FF)RZMON%@J(=O&;T.R:>R!I C
M% .M[6DZ)>:5S6[/XSV;&ZI\08_4H:Y;/+AVJFZ7F[]RCI^Z@'NCFTKI*[H;
M5] ];$=#H?I<4R?X ,N^8-\]&*(N0AF(6*_.)QK8!1Z$LO7:8"[U6;BU<9 ^
M;-0B87I2:JAM2G-OZD**L-'Q>*^:^A\0]#_ -T1!9Y?ZS:T>+PE#^<MQ5S^=
M&A8T=[A$QQZQ$NTX#(/#+.S67HBARAQ(G+UV0:L8KWD%'8 Z&O2D:'^D[$IV
MS6-ZF?%Y:_B=$37N@<;?A1:A#!#7ZI,[((C1ZG,<B&@[N6)-%6ZX%M:"K.EF
MU]" D(-:R'.52QMULAS".LR\F*/+E N@%GA5@5\D(']2Q"1+/1-I#<51FB'=
M@%:UM!XG\, X@:<]3J#'"?0X@1XG\-7A!-@G'LI/+Z)\9>],@=*(ZJSH6Z#<
MDV9%_=6:+?8:7S5:KXGHCNZ4]9(V#'O7+MO%*D @Z[ERKU,'PM1"U+T;TZB5
M>T7UW$1G;+V$/9KAJX)9+U4X))7(PW/K-^_H#PC9]+E863K2;-+Z9*4;4!W0
M-QY =4.P,*6?)11_=5/9;71?(/;,:4WAG$B=::U0''2!T9:E_UMA9S+)GX+9
M<N%ZGB_/4![O=>//V]GNNN$L6);HTHAKM=3@.O7#.@<'UJK 2 @[.3HM?N?Q
M8,UZL6-%,L/;\VS8X\%$T=P3&XW@O"ZIP%>H[BAQ28Z3Q3&=.>.OR$&A=F!A
MXYTZW;9X(Z#2A.S 7%Q% <).X#340E_*&&MQQ\*2FD#P!>UBL1*9APLW#(QK
M0^FG,U=7 E_FG=G[> A[V<YXM[^?'ST5>?G]I*"4H7P*]%BX_-W6!230#:;L
MBM&G16BU:6+1)?,2<P$[\.Z3^;R<%!M*#M.;"DO+,.HHY=:Z(&WN?_.@F5$4
MQ@15PFV6,7@(5)[GVOBX7Z/=>@V HK?.5EOKA0KXQY(DO=3M/'M'&VEN<E/K
MP.&HE0^PPC4[WAFBRS%46MR)!PG4K4E)-HJT\J1HZCQDD'T.DGP5U+M3/ILE
MU]0_RQ!2A4M<K+*%/ HY(QC<9ZI,8*'&K],V$(M4$]%(JXY[$GA"0!L[ZP(7
M, (6J<Y%L*R>2STTE](;MUM&:"IJA'4=3*\(WBECX(XQF)8O.CEY\X*P(MQX
M5&"1C72_J386:]V,FMRH*TT0HRP^^M*^L-V!AU60C>@O2PI6=.$I.\)%8!U/
M%JXDIP=.N_?EM'&"$CAPL-<^Q+MQB/?)IB'>W^HV<*>$*> "W&L424?(=R%Y
MJ0W:"2M$S^O%2(P!==4@,?ICA+6F0ZLL:%<GW>JX$UT-NN?K$'2Y\\@98/29
MNNNHH:OBNK#47(^SI-!LO=$]5%@UEJLS<V<R)\C]<J<%S)5UD5HFTZBH=R#D
M0YJE8:#.W6D"1<_5664(NRLBYBN M9SG^.?+ GOG.%'#'?_"P:F4.%44\D51
MPDGW5V[S*_=TTRN'+<BKZ9JM""0:R$T:36W%+8V\+,U-;[5D E*[(UP@.5O<
M#&NJYIS_&*Z70;)*BNE\^JPK\'_?6*AAN;;?(ZX*@#V5N.)/<M!\"J>ZQNH;
M&?G!^GY1H,S%XPHL/4+1 S]X781O;KZ5AV:SMWL+Z+;>$* YY5H]*G0-=;4O
M7 @?Z"KF/]3EG=:=*;?]M=W\VGZWZ;6];&1LT9%<U-#\U:_R=;MW17'#7@XR
M*SXC7N]LBHDUZ8?H;!6P'I-CN_/ P/>F:'=U6T+.@U /9241["Q=ZC4>Q[*N
MEJL5C+Q;RW8XM+IKQML*]6B=:"MJ-*;YU'74!RV-G7@![:N#4-EHQWFKL'I!
MB:5!8)NI>$**YKY.=I=>Z<#$753FPST"$RFR1K%1O(/D852NRW(?KW[@>/5W
M?;RZCU?W\>H^7OW5Q:L%:CN0GJ6#9M%8$]W":Q)T3W47IA(#%%V5Z/&I;=4!
MATQ)@ %O<CG3.G$B>LW>+PT]FG<4)/4XG2Z3N]N2&?M*)/@ZY>4DL'&#D-&<
MC3&I=(7V31OL')0%RT,L*3PU9QL-.%V3O"WPIYWK+ 9#<1Q0R@[#T>,K&3#H
MGGSEM1*A@06)\=RY%Q$%"+4&@XK;_X:MQUO++)M:DI[O+=P:K5& MD4!8"].
MTK LGN2ILF<5-O./"N:?I'%8QLQM-"F/5*D:3$>#NX?MT%TDF%XR*?([K;*2
M"M$VMWK!ALC&^<)ZY 4*G#S!;^BD'.!A;L/9WOQ4>]Q;I1M;I<\VM4KKII*K
M6Z"O)3Z$[#!O-<'R=;7(,FJT#.QV6_CZ=BGZ1 =(.74%?F$+S3IS+G#%+BDT
MM,1B(C,P2#&D9^K")H-H7-QAG83!O+,6I\VS)<>LM+LB1A>4-.]TO[CIB',T
M=^W): -&(S!DI Z]?"8!%P3O8&*(A /OQI*UUZPE@HYF1G6Q\*1TB\+<@$3]
M4W)G\94H!/ M.!2)Q8DV-YIS,/G--'XJ=>I'U$%!*O-50[1!L<UC-G,&L(0,
M8:JE.*Y@<W1I@RHQ(^!68[^74H/:Z F6:?8E[PGHP4DPBSI"T"E6)AXKRPG&
M=:GMU-0;N)#7<1E$7)62DF^M;&9)$0FS< (8CAW405+41:2U>QBSWH84R%7:
M57-X?*NFO5D7<AA&<YF5,+FH?=#=_C"?(8,N61')#KU$S@Y*F+JO)B&[H5SQ
M=[K9U ,=60/G#Z/0\M5L[4#:#M)_!MD!]#<2,O.2*89.RY+*IR*OL;W(VUSD
M/=\X9*G@\$ NG"' 8TW)!XR4GG:.LQI<TRC!@OS&-R*NN':IPY))<5+6_+B#
ML?!$')J83]CS$1UZ(Y5F%&*0EU)G38H24(22>6BS$P<UQ01RXZ95F6]K,M\3
M4P2XK&LX"UXAX]1M$.9")9[#NMZ>HA!;1,G GZWB,WR'.Z9EJ(4##IM@?YK&
M'@?#-9LB7"_#[7"9BX0QDH0IQ*5Y50$#HJ9BCN$/P7$"^F529;Y5S)^(PPD\
MN+<^D:V/J/S5BWQ\N.E%EO")H%O6*333+"QMEH+P5BG2O&@H(E\==U\]5]Y"
M%!*QL^D>@,5&*,,LTS<< ZAR[5:;:290,A@]:H(>#BU-E[),#G]4RQ)7!KOS
M_K=2.R5RV;$LU,-2$U<35!NQ_Y&@Z+F&-]8%YB "FX8,&K;%_8L:-/4U!OY3
M.4("6P0BV4V+1.J2D_.\F#Q,_'RPB:(=(#0/[0_9_UI&"^RCO]D;W^RC36_V
MN4=YK=<;:%)121SRQS"6#'1%;/D%9%*,O"['?>T1LBDJ7 #/I+!A%!LJB9)%
M=6@FBL<Z?N]<'K,:!:0_H&"PH;0087)/-VI/OZ 8N.J531P]WQ0WK'+X)NK_
M+ ZB7W/J)_>N)"/)75:I,D@U4+PB\@KK;_;DO#$Y'V\LJ*0.!5;Z":/ :X@L
M7\: T"2SEOI!3!,K&A'4A'TK5'H^XL9*ND0<<JMBZ@'U!T2M%$24T=P'E9DY
MM>+(Q?0OJ?^\X*8#&4I7 +%MV!, _SU6";W6<A"Y.;3Q0^<COG_84&'1]&JX
M&7ZF3:/)N,MSJB<F?@3I<3Y7'A:N2KO5O/1P;[F!N)S!.!WBG6JHF:A<-OHY
M2FI6V,\Q7)IKP]6U.->?LT ]>%07KAW 6T 5+=.8,L@4L*=B5-Z!U!STX?@'
M#L<_Z\/Q?3B^#\?WX?BO+AP?P_,%BM0LM:6@QX>53:DC,,;A2%B3^U+?A!(_
MKSNPI,U.YZ!AFF:1KC$E367L>V&)V\I9P;#!"?86\P6\4)QR5]T2=>G:S461
ME+H665W0B/I"@K4K'MHZRT64'YHHS<[U268MP&5]6E_82.9]&NT,FQ,*P<"D
M9^5L;:?.,,9D7%&[1+.:J^OEYXE*>"R81^NP_=)Y-%A(L+7M]D(+"K_3&F'R
M\6ZME3G;EH-9H&H5=Y(*6_<_QEPOLE XJ)_ B=U*!8$6;+#>.PD1T4S#X%CI
M4\M.N:=<LMO,2AA2;1[7.[A==13= 58[W:CES10"LE,L=%;G)C25-VD/KK'E
M-=!UW0\ (X1H,8$^ALD=Y)CITBOGM$K)AQ12N-$YANS;?;HY@ 4;$0^<J[?6
MC(>(*T5$BK@=FZ8<9R"CMMHQFW >0J8IZ)2%M? *Y_[ +<-_T]N"#@[-NKSD
M+)J2T6#5I+<!_X(-N''KTS=$7-<(B%@'Z]W.NNAT<=D*V)E<^58*_#P$^$!8
MWO*\_1;ZIY',RJ&-RI6Z99"'8*@EQ31M],<8:\48YSK/*E93G\C:D=F%!.\;
MS\=:TE^!R7'5;'3GUXF.XC&D]LZ((G! >W+9$C3<5-(=F/U_KK*X&-'+=GAY
MK$&8)R=3NWQE*MX(,X";ZX7G;]2W I;>^):3V"C\0.(SZ+=<4FN^I$;W8WV"
M7/M )=YCS^+<6]Z^^@$O>LKYT1+7:+RP#D]A 0G8Q3I,A2^0\GJ?/"YYK])R
M&65%\1[)@M("Q ?6EB<$/&F(!&YQZ-Q\6[:L%2WK?J)K$,H[Q)1A[Z2/X#+Y
M*K9PQ8FB041O^-<W**%A3&YSZ5PH[(J(BRQ34ZM/W'^$,T7I+8X2-*1(L<W+
MIF>"?1^A7V+>RU!ZQXV,QI3PHDS<Y[>(8XI5)GO"WA@9Y<GAM^'FR,O<1@5V
M7S XHAQ'67'G=LC]O7=GU/2$W33 GY)[W2?B%Z(7NY^J(67GZ(_B2UF)#-9U
M^LD_RZ3?\\^QYP>EP4NPSN;+]92M.)I^H,A!$CE_YN+#^0A;<F /HO\L0!/%
M"/)_IS"1G!>Z'D$M6A-!QD#[0=[R2=?5..I5#_>O'2CZ83_S:;X&Q?3D(<[S
M;WM6GW1AUPAZ/>'&;NDD.K]X\S<_BP/20QR#W)+I?273F-/&S\@/*Y7 @VHI
MR<GV!S2W<U:]WMWK@+W>O15[_G?0NU\J,U1&12]3.QVK2:]W?[%Z]P.<Y!=T
M2KV6]Z6K"/!:X XPQ^-O>M'5JPM__SU?4[H\WC]Z\HE9,N+#3Z)U)<?C)_O/
M'F^9:G-T?'#\Z.#X\/AQK]%\G;*R95W_A73FOR?^^7F/?^[QSSW^N<<_?W'X
MYWN7O#HJ[Q,50QU^')&W(:QR:QHA'-5P+/[7TE#"YR^Q=JXJJ^\K:'(W3DN]
M!UIBK$^F1I/9<^J+K@G^#BOB1=@$F5/14CLN<DQ!ID)@'K.LL$0:P=NDYD@'
M9+I59*B1%#CP];\85"\I:;Y\B4L$L)@&B]G?])^W0+:%L5UXZ%1;5ZR(JGXA
M<%EJ&%&Q>Y]%0+!IKMPBG4HP72YHHH+UAN)TZNJ129&7-/?X[6BLS*2UWE/8
M,K=GB UU!=5@5<"2</%YP?!XZF)R$E&?9Q6-=%;P;F'39D*)IS;1> A40/"V
MR*CLQH3J[9:5F:8EI?D!)6@L2>4/B 89&54E-!<W&5>>(P#)8UE"/&BW'#E!
MJ>#/U5^P=Y=D(1*ZM8EN=XG&;G!<6)I7DK/PZ!"[^UGI^.?0Y7E18C$]+"J>
MNV8?TEL,%\A(<QX/%W K\P==#PXMUS? 7Q%?.R#,_JC*<*.PX485EQ_M3/%8
MW$1NTR+S@.00SC]?5<%G6>S8I761W1UP6^0^#KHM+*_NX&LX-VH8MK,^!O0)
M$$J<%3:H0]^L@)8BH-G7?_93""KS:;AML<]8  X><\L3.(&/ %[]^\B2XR]-
MEG#7QA0),B]-D:U<MS-L[H-T+M55VRVN=73!-1;??IS*BG\?TGGTI9-.]):Z
MG*]+0:2$(*$<'>]-X*=CZ98.W!1.EFA*.CQB"D4UF00Y)3H:I09KIE#-)U]]
MG_(JHKD)]N2WA/P>?VGD5R3W*L$UJ2&1<=T*0J!A194K))I*>G\!-1T]?_:4
MFNQ)X:Z>6I90RY,OC%I>I=:7Y]J /2DJQZ3R.@VU! I*_*!(-HD>4=I96G=_
M/#[>T;L[CW8;K2E[LEI,5D^_,+(*>B)M*/9466?I<C_5NFZ\;O1<>HLMF\ ^
MVN&\1K:XA.AV6[W4I8.PV%!!7>!6A>*!,V.<-/6CD$2U)^0=4+7]DV YJLI5
MCZ$AA\IB&F"&29E@+UP#,8(*^++(*QO6]%8Q6G=[\):](35[DT?H.O$S0WK&
MU)WOV)0&>UAS6;>CPV_I=8G3",2*PIT]^NX43%+8ESPF0RU(W+8P:7A7-I-B
M;J0>+*HZ#-N"1:O@277#.9:2#*UMRZ\A?H!@=V*O<>#/;G1Q8]04#"DNIDZY
MTF50MPNS+GUS/^J?RC6X?%6 #C^+>Z N08 CR8LE/7U28%-X]TIJZ.7_"HKD
M<1._L88;(8X9[/:5(-4XMT+9+/H93@8K.E-6.5?MLZX'=4>R+U4)]$5JV=1&
MHY_,!K=WBXI[1CO=?<6LS[C<;54GZ#GL$@[[W9?+81T'W)S3BJLS]!;Y/K)X
M:V_P94#OQ'VQXH)KJ!',PHWM&\ V6K;7OD%R@HV:93."JKL-\Z5FU^[S<-GU
MFY#B88RGXG1;,@:YV/R#@9<0/N2R]NT%M]N0>)ZJ1VC.VP%S<6><4<TQ\;'F
MW@U8RP^:@/@!MZ0UR3ERL=5LU.7>\]T!.Q8G.IDYP[3>:&!LL&[<3M=333S4
M;A\7GV_M6Z6"**DMI80).R9]J03=V40FH Q6#JAN E8Z$,Y=KW\_BBZ;[#RF
M7I"+IY94QBD7P3B#QJ]]4K\44)9B@%R!1"[(_A>,5<#J]Y\0K/!7D0FW!9#]
M/<"$@V&1S.!?XW*2??]_4$L#!!0    ( **)4EH?)FF<I70  /)T P 9
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M3XR]-9![_^*29B]+EZRU8G]V<FRMV$!L [$-Q/;XEVX@MH'8!F)[M"LV$-M
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M.#.<6D@X.;N4+.D"+!FH88WA%"1%S-^TJ<-#N63(#\FHYRJ_-1\+-W?QJ Q
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M8Z9ED62+L'PEV'LI_%@G8,YQ=\A=AM2ITFVD&Z N@(2:LG>VH*_^N*B$\80
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M%=XV",Z) [C[/CW'9W0.[7 AM_76<E6Q3\D@>#(ZB':W?-OZ:*4HW#MX:3F
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M6F]LB<6]]*YO]I=H0F.E<<."!L.CBT?IKC*.]!1;]BUTN OQ1:ELFX-R>K"
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M90])MB%J,D[T/6?QBI2]K#*#,T&,+LO%,PL!>QK[);+,/X\>T0_LGT=!Y$-
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M)%]$7\.4W<TPLZ;5@T'.?E\X"9C0KHG">@P3O2Q-\0879C9^'5,QF?*>C.-
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M1D*3AM)7<3@F%F\X@@?"0D$5.%J29-^_M?H#M_@[SO86AP4BR[1<LW&6S2_
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MWI@OC&^(:L2?E2CB?O"&X3"X>1T?@M_+_.XUZ)\,KWMQ_@102P,$%     @
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M@H5E(/=Z3:^SRE'%F&-+YN*]6<N^=OL;4$L#!!0    ( **)4EK?RIRV!%(
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MO-*8V, _E;8A@8O2&\,D-B5)&(-B][FO0'D%QKZS(ZAI:L/MR7-))I&JQL5
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M_R(LAQQT!U5EN<F,:I:8(LLM#P\"@]D. @T:Y,%N%\>6F+8M@6S\B8&)C8>
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M,VNXCN9PI5RIDH#+]7OE1BW]>ZD';Z>=WT8[OV>-_.[:^$-IX!WM>SUQ3M#
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M1WL$M4F*=N_OKLV'=&+<1(MP@_QC5$OQ.>+0'Q/2 'TWA*0PV1:"&U%WGC\
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M\5/TU^@6-Q_RS?\=[1U'_S=Z-0*#X>C9#R_XX\GH@9GL\#IT(7V]M ZS21L
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M]O3LIQ^/SC\<S8+3C\=[VSK>M_]\?_3KQ;:.[BC*<J0H%QK^6<UU$1Q\-PN
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MG<A\HFZ")W@*J0%\A@X!/ZP6%=)T:,^^PCN&9QR&0?\*KWBGH2D%K_]=I[H
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MTZJ<R,SGDIEOQB SQUD*+)NNWEL1"$:D-I>M@]:Z)8T;PH?5^+:T*&^BFKJ
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MS[S12G;P[>N^R=IUHU?G&'211N+@"#D#CHW]WJLK%8/ 6N@*XX<PQCG.V4X
MNC$,9[*J/XI5_<5D59^LZI-5_:$"!1OCC!'7,%5#[I27+(FTE:RWZ(VU*I@G
M]Z->CT^4)D:#8[.04*;98!>!7BQ0]KO6-D*77V>RK)VXL]"%XU>4^\SAT#,#
M"F,ROXV%7X'8AW;(B/RVIN--G&_F&;3[! PG*"C@U<@:8@K;M3S?"\GU@XV1
M#VWDN&UML(WRL8@+F(CS--,405L2L7DO."('"?RXF@4A6KSQ3^<B(2MDD:5Q
MV'8/T\QL5*L9<$.F1 6)7S)^>]7,2"G\9-29]?N[R '^J_0#!\3RS<KSIM8\
MD<5+;I5=FIDMP4'R/IO@ .LQ;ZU5RW#?CD?@8 *.3&\?5;>%/>$*3:2;PY=/
MHJ=/#IZ:PWA;.OV(^D3;TW9[F(23OKUHC\\(?GAHL,-C!#=LFO[CN14??7N_
M)#3?UF+SO3T[.G\7G/T0O#L]/SF^/)L0^G87H>\C\U D 9= DO$^,0C5R%X+
MQ]L=_AY).NV,(V?O'(0D, '>TN9M<'A=;)96J+\XBLW /)F*(_:%NU:RGNB#
M)G0]7&1./O),X80H6);H8+4A__3DOVNXJZC?/A209D3(%W2DL/''21Y].QJC
M\0@C_)!=S75UHW4;J'$ ]:GK3?5P&A%T)DZ;1@3:0XXMQE0'M$R3:X5/!BR$
M>]^(,G.5V%@.WDVW@_![[&T>VSQZMX\EFTCS-&V*R.:%\7.A"1/2B>NV?X:<
M;(1NFR.W<3V,^"Y6=^,F8&PI&:9 YKBC?:U"6 L*3TC%,H371ZQC!88>H&@
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M/ QE1M9IPT5,6PY>U5-D,X-&(&HX",).$36:+# 06T; RKRW*-N$ ./O*G?
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MB,B@JDJ%2QW1I*0:MA2R\IY"MR/&"[:0)FBB5,2:)8PC6[S[5PEV/VX6\;[
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M[5B-3MPX$'X5WR)**VU^%[B0+"O=4;B>=%05T =PXMF-U<2.;(?=O:>_L9-
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MHL 5#J+!0\.]MU&T27,\A7_T-NB!1X^PUW2:8]&U!C);@Y]"[$+?_SY7'?S
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M-$RF-[NQ&XO]"5MW#!?Y4[R_ %!+ P04    " "BB5):./ UXI$)  #1=
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MJCDTIO-?FS7AK*5#/7$$UKOQ<XU5G-+C"9WTT+CX1X?&5;"8S9_^Q!$7,#S
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M;2TSO-)V['?NJ&T;4D*.)>X2[FG_IW%Q.;W2!K%AUXKC6B!,*X;BXJI+INT
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M$P*'6?-^:+I=,+FMT6JL'&N6[81>"S8VUG1=P#0>XN71<$QYB#Q@W_L$@>:
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M!YX[F'8+D'E5_'(&3_O K,GAA1IUJ@9))7Q?Z\:CO1OM=6RC X_Z<HM7]X3
MP<JB=[1)_P+?=6:>OL=W(#^O6&914Z)P")(&X$*;W=<TO%NL%&?-WD"5'6)1
MN&PX+%M3[O';ZD'GIH]@'BRH(W>@NCI^D=9:=#(-"@]+7DLWUC.)M[-BB57K
M*#.8A6&[0]8C[<$U+7>(^^!#'.#?%GEP-8M[-1>%&!A>Q8,Y7V;F?9F=]V4N
M^J60YY6KX6:B2P#K""";;- "M2=G IA^8J=B;,:<@88M4T !I"Z5K]DL:\+@
M1DF)$D<NCI6O,XC&/->87S@-DL330.=4C'[YD?R> DGJCI:3SO]\\T@ ]D"C
MU.:8&4;8!0N^-V*;MVR<(90^,8C%;Z!G??R\.TG"+60.O#5X/;QH>@[ TNCK
MR"2 3-:G!B$YB[G4#N@Q+EQC5(BGF.$.9XEH94^,],HG9GIQ6L0/[&%O%&&D
MNP#1T!%FAFQ@8R 9KKE='NQW0)7#'F,892?,B^,M $4*T1Z]),$!+)78GAE-
MZ6'Z.$POQ0O'\4W$HY@1>3"16?',$;0TG)B,PW\<#-#YM+GL>9\W:#-4,I6'
MP,.8"WI:3BTZW&F0!3-)D#O!HRS3W0AYN'1?JU:+^E0+0J8J6JK&S^^CQL--
M/&F?2H!HS45<D!Z)@;#&[/<1-N"//K^"(*?30VDR//<5XH@8JN9I?PXH1XRC
M&%2+4'F:C<D%(N ,BUZI5Y$5"F":$F"!)?PZK,L*9VM!R)@?=L3F.N8XWRF"
MRC6B10VLX '-?R\3%@_3HWE/V-1LN>@$!6W/T0+' .N*A9M8;Q'[2E#8_"=2
M(B<<U8J-LG!:; IEJ24U+BI5J2P4JV7A2#JO2%=24VB=%EN"5"R="KQ[4+U1
MJ]>:Q?.F4&NWSMD+1[4K6A!T7*PTA%8-*^_HLT=2LP5_P\CP![QP?$ '+Y:O
M*LWBT;D$STXM"'^NP*.1"B[\$M=8K,/D5S A74^S#?_R5A,7%FVN(<%7%U*U
MS/<2?28RSU6M)<UI(39GMCU%<,53.)$CHS'0('VPS#R67'R$\R<S/PYGRT#P
M%QC0UM 4]0RK9HCI>!%V[WS!:3HBPNF6558O5C[UAAAIL0YSBQ,*:5$ P-<4
M8*Y'8GLV+T\S A:'G9:G*Q)H6,<PN'+FY[^L75-']3.985Q',W"-6JP^<K4A
MYVI8/A6T"-EY^>>=:V/NQQ+ 'DV$&OKXEJ46P4]E7VE]K87^M: _U.M,O69K
MH[?!V7,8PO[\F[&FSU88GS&"SQC!9XS :X6AR-E43U&5CES(ISKI@ICOY-5"
MOJ.D4LE,-Y%5DDKJU5IA;*072C?U\V*UV*HU;H4J*+EOJRQY%:K468%EJ^C?
M6J_LU, Z=F:\H;)*^R33-Z.W-BPH;YUWP<-T56O0Q-9_!@1NK 06+0YQK!FP
M=/CKVP$KK%Q_[9&26?)$+$5CKG:P<&,]EU:^C6GRCF.'EA+9\+Q'07$<>1E?
MJW9H8Q;\6OOS:T>WW^,V9<&+-KX TR/_;;H =ML+9MU2$+%$7,5\I/FQM$B%
M^BQ?^(X2ZI3VLET$5>O!$NEM!EZ)U-IN?NH6\5PAFT%F:\(^>('EL22,Y8M\
MSKP!S5'_TXJSM<ZR7^^@^4[*YVY]J^/V# J;.GM[U?OX4UW^5)<_U>6W59>3
M65%6NHEDIR!VY4Y:)'*GF^GE.CDED>RIJ5RFV\ONI[K<D(ZEAE0MH?N[)A3+
MY4JK4JL6SX5*];C6N"CBI[=5H=?62?RF"R24CA!*AP39TV.2".N 5UTF04L.
M6/DA"]4QW9K)#(Q1$NR<A"*!^RNQF:JIN/22(S_Z8G9ITCK]-3PEOH.3@NBQ
M^C0&ZMVYM$Y_W:_>Y>12*6@*1KI JD3XNMKU:1,EWC<?T=_YC19HHDBE82'O
M.C:,6UG47TN#8*A/THLO%.J'#37W.Q!FV^@="$4<A!Z;.?YN@1:%XHB@:^-P
M7Y/IQ#<AF4[%Q&1"G+XH@SJ3AP!$!"2JG=Y&M_/RLN8SJ A0I7?"\233LE;>
M=7@81 DP-(VY.@Q-L@W*#A(,:M:R;6+0#1-L$2X*<SW3JVX<O#K+CYU;IH%I
M$O!DC_;!1=Q3&/1<R]#L =7>F4H("(T+I^88L[;9-V&BB=P]PGH>PZ(U&OCC
M!#2W8M"#&"=D>K?@9FV2!=.[GVZ^/;&-#8'[\LV(/0PPM8*(+<P'V.,GWDM]
M $+QSCOM/C3Q3XL]\*Y_&\HJO3Z--;.CK9ZVKB2G$21Z60SF1- 4[F$XG?OU
MP[111_D&<#^F[?[\V@F5 %EC>BCEPT$#.P7 !1Q;7<VL1SJM@+ )SVSGD22>
M#\2YY7)N<4VG1;Y=@FF/<5IZZU EF)MU[V.!TBZ<!,-@G0 %U#B%E)C9M/GX
M/ID1_C)4S1[I\@3T.H-$DK^63[/MZFDFV:>E\VGI?%HZ[\'2*9!$,D<R8H>(
M^70G37J%3E=1NYU40LZFE922369E;NFP-QB0]Z-G=HLFXM2.\?*SEE1M[;H-
M\JJUO>'-5F&JDUW'C)(<_>;YEU^)H^4WYS"^S$<I9!9=*C-%OJ'!T;W=T\VQ
M!S+O<PR+! \9)QP#D%8R(2XA(H0O=VT3KP-^99$1>G [4;C\(I\(S-\)R&=V
MQR]KV@UIO1Y"\QL@=",D<D;@E8>.GFA)LBIXZL(+;C[_3![L7Q4Y?1/7)L@-
M]*3#?X$13'J]%\=W5(CZ4. &3VSVEL= S[AL2TWTHS6+U7*QVKR6&LWB4:W=
M:IU*%U+C1&ITTJE$)I_>3AGQ1V?YIFQ\@4[ [O:D4\QH*)O1VRR\.0FB&O>J
M]#<M:*EPBD)>T[1G4=<>DU)P96FS?7%1;-QV\HET+B=N1SK!: (?[GED\K9H
M%_\@E@*X.I-:]4:E),&I+U>N*F6I6@[Y[#NY@IA()K:C"S:Z0(>G7,6;(!H5
MV#%'>6/JR7Q4GH&W-_/+FSN%M)A/I+:CBO MT.^:3V3_($91*K9I0*]QB\EP
M#>FDV  V<0*G^!K^.J_5SN!3LU7<CB2"T6FNG>"/+_ )8GR&X-;M9Y+.WO&-
M0O*C\@U0'OE]4_P2J4H5+Y>J';.KI?B7M>,M?6B@FDY?9[7T^JK%Q4SOF1D5
MTG\0,PH,GD(^DQ.3VU/."QDU;TP+A0_,2AC&BB<-B8J!CIA*Y[<U>0,*$/P!
MWS,3 %C\05S 1UFS(9V#5E!NU0+&((J%?'9+L@@&%OC(F-/T8=F%F'F>Q;O'
M)!*1]>5*0Z)&1^WX& S2!KK12K5&O=;84FN-:A+^\ >"-P&U>?D4H-6>U*ZD
M1K58+4GOFLED_B@FXV<RAEP6OGD"/(%6S&^KO,[/DPR9/[0C *W)!\W5I[ 7
MHJL]Y$P?5I.)\ [I1BJ! 7R%;1?J4K7)/&^8=)?;!6?RAQ?"X[]K'I3]DYRT
M$6Q6:U7IHGY>NY4DCQ]X6-T%K<#P,6]\G^'LD&[VC\=D\W\&C[EL5UJW841B
M?2N5.COA,73X"*$(.,'N//UO3"9XK?L?PW%*#:E9 @-H@6 2"YE49DM/+Q_Y
M1832_C&7W(<UK3Q$3@LA2B')1"XOYI])(2\@?=Z:&OXDRPEX?@MLX",) T/M
MHXM*B[IHBM@QK'8<2(]M0\MT=($.+_CCT^(SUI3L!5W]>\AG/FS4V>L?5ZV)
M8 Q7B\UR\9)BLM)LMM'FY0]LG;E"1P>]%SMBQJC!S29A]")XT_B-[-XW!WH>
MG;PO#A203A+06FRW3FN-RB^IW#PM-H!M@* I-I%\=D Z24XZP20"G47PIMD1
M^>PAY\E]?,Z3 M0VI"N0&Q)E"LWZ>:7E_=S9 ?FD./GP23CKH=-\#+Z3_Y.L
MIX!PTH!43XV5SN$_:'9[=+-E="I".&E..+ZN[,WR8?E-_@_@-QDJKLH50&@#
MK)[C2JD8HIP=D$W&%U=T$B$\RP=A.,_SZKU7AI/%9"L4'NA[\SE-KI!*Y;<,
M)43H)LOIALDGZM_[L'SFPX:> FK) 2ZE9KWN$TI2S,+_[X!0<IQ0</2/P5#^
MJ 2[@$3R?DI-)'3 ?]\!I>0YI? \K&@ X8/REL*'#3D%A%- ':;\L]9N5#&5
M*F QJ<*VA0,1NBEX*DPPQP=A-,\3/.^+T40\M$?M9J4J-9N=5":53F]9<Q09
MT>M<Y(W\P1A),O$\LWJ/"<.+ @5$ 1I9MK"E;N*-QNFAN2.">&/L_U$%2)%S
M?5&L%D]8BFZYTBRUFTU,HL.JZ%TDP?CWM_BS^'03S,:KI(OGM\T*7M,C'%<P
M!0_+4$JU*DOKH\\ Z;7/Z4T^0JTN-:AF\^$8T3-S0O>8[GQ&M(3FD 9VQ)CV
MEN;>F,"R?Y(#.2""X]KY>>V:91KSRH9\-I=*;.G,"086_)$_;F%#\IGY%GM,
M(26IT2I6JK0\!<_V::6.Y0R\7*5>;+1N6XUBM;DE5V*C"Y'A.6-A]3!T!H%.
M42RQKB'\KCL0HT?TACNTY(O5=]T)(IG[DVRQ=I6& X!\&C6:LXDR1:HVI;*'
M4R9NMJ,I?W2TT@4ZON!/$%!-(-$^;HN(9/[#\J5JK87QAY6DM!T-T=$QQ>OM
MB.FM*>=/"FN503=N5.J(M'#"(%AHI6*]TBJ>TS!49TN?0&CTV5Q!/@$+='TT
M]E/XL,F"5.=H5)I(,(W*R6FK63OF&9\1"MI2+?)'1X)AX^-?WEVXRZF(%>UY
MR<T[)+"WIJ8_B275&Q40*'7.>N:15JG926:W3'WW1X_>L3Q-5Q^,'Z42'S@<
M-I=</"[0R633Z>R6@8[%Q.(-_Y[92DK\DQP^"^@$[&E/EV76]*XI9?<&^_YQ
M%_'#-M8ZETZ*Y[P0II-,),3LEH%U.I# 1WK?7.-/RM*1;NI2H]7L%/+90F)+
ME8./\>$._8?UL%QC*<)MK5TJ5H\KU?)%#4M9@G:MZ41JZ[Y'=&@!Q@;KI(K.
MD[* PW\4YTGJF:U9WQ=S"(EZ+RVJ66MX=0)5,":J%*/;D4IH=#_K"C2*1E"(
M$,S01 <=NW8JVHWQPS&=Z7R,[_36C3V]^F%/KC#:DV7LS9U0"^]$2*;Y'40)
M_PHB[?,2*(:4STN@7O 2J"$,QNFD$$^R;>_Z5J@]X0+\<BI22*GI;DKL=$F&
M=-+I7J%3R.:3G5PWE<BH,DDFTH4O/W9X&=6.6?NN+GN*H'86L[,L\*5N<J+'
M+AE/9H*#M\>W##U3'WY?F^6*]/3RDB^$^.^;:(C1VXV0FZUUO\P<!.SO=4?/
M!OS:>O1+@&4.]_,E*MB?TDVK%@E]5*JEIA_5YW<!;"=VZ>B82Q D";S@W0+A
M6X[>E [7L&..8[--JU[K>+\P214-@SP5.YED012SV]$-F+! -\7#H&,X#>S2
M6MC:L=].G.;*U1HGQ6KE%[6"#^AWM&()7BK3%VE;B5;M)9PJ;T0[Q9>@G;WE
M4)2<CCJ%7"&9>A8Y'1T*M7JERE-1SMNE2MG/$&"7*+V6A_:-Z.;H@_.<4D<L
M))+9+6^J8$12.J29;NS>61JJ"\?SA&:[7J\U6B][D\$;D4?ISV,KY4XADTDG
M"L^AF') ,0M;X>V:;MX>JLM)J?S!.8T$XBB73FY9(,+H1@KHYAP()=:N?TBN
M(OUY7.6XDTSE"]OF"3#J.#X4L$"$-0RB?3;+4K-RPH(]^+$I-2I24RC29N)7
M-7KQ5JE6O<*7\.+T>D,ZEAH-[)'WBNFUG];4SBD*R>&D(Z:SR>R6[: 919V$
M-)LH985LI5I@/$EEK\JQ1:N1IEZJ5+V[,>;E=A_@[W$<#\@0NZ4%/1HKU9D&
MCB^2#O-&I'CR9_$[)*W33CX)PO!9QMGIVU+GG)Z0'YMCGGY@CHDRN-+)Y@KP
MO^?09.50*-;KC6(%V^'P2H2O3=[Z$>Q,+[FS+)T7K[$/[8E4E1JT3CR@/?CI
MVP=B;Y4_@+TQ[/\,<22OH.2H4JN#P+HH<@Y"\VUX"^LJ/H%7+:"7\O]^0);Q
M\Z.Q#(;GLW7Q[-_8PQLSMANE4]IT&KW2VR!\K[![]L<<[/,%#AN.ZWJC=G,K
ME(J-\D<\Q.<S:/;RYT*AZJWCK^'4F%"\.Y1 1#\&N2YB7"R0X<K,E742KOP1
M,^$(NS\@G3R>)1ZNDIEXPD^U,DR#^' 29-<QA820F [%OP!%_E^A90I=(O0T
MG:A"=R+(0V*H\(^SP[P]73-( /!D;CK5*A^0X(RNY,U9 HKJ6AK,<4KT1X)'
M .>3#3LV.^DV"9*J9H]T><)0$5YQ%&8OLN#$^NM]GRF,GSF,GSF,+Y_#^ (I
MBUZN8"Z=RV32J4XB*_<ZZ40AU^FF9;G3+:1S2267R,ABAN<*LC<NVU*3IL73
MWF'-:[R(^*C6;@4=GM*I1(9>:;Z[!,-EJ4>4'E"!\NAA<1X2'<:Q@%/U /6'
M[FA$+$6VD:+];?$F971C MU9I,-4=Y=IW^%JB*EBB)E=:7-H6G, )@J& IX4
M H^.!\0B@CTBBM9#34J?"(;I$/5 < 8@"4U=-\= )H)FX/YE) ]!-E0!GA2
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MG1"&)5]+P?$.!'>$MDF$WH&6[D(6:XC\;4)U,P"99BR@<]\DH>HR4DX,5 A
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M;/$Y>LX6?>&*A@E.PQ<!6X_L'/6V 8G!G&0RQR.TUG%WN"+..1_.'(;EU_&
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M8+CP#).";+HZ6]D'3WR2I/O,D#W5]%%2RZ"-8EO@=&@+[+8:F%>C.EQ+&;8
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M3$Z7C=;PW-BSQ@N)"@-7:31#9B5B%[F*]D4_:+LKK9D2Y& ^,<%7*F;=W%<
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MBNO1P8OYH9K0P&E"1J'B7;07E%OPUSMG\&!P-6])BKE@/(BXPW'DN</6^]Y
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M/)U;40D/3!Z\%3E=)&H>O#7W]J]L(B*AO4( C.#\-+'1[6F&QRH)UU (#_"
MGRX*,.SR%2($WQ#OPOK6#OGCV,>;G.@=G-#7=9D0';X<T%L[B(]CMV[G&GZ
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M!<XMO!V38W6I68KQZ==1?.$M$>;=N8B/ +ZO_/Z^FO06 OGG@U,2Y+]YAV^
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M&_A%+.MG2WD&6Q&D-?=3G2%7H]R(OYR=_G2J[\0N@2(E#7MQ3CL959&]=\T
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M"ZUVV+0GY/>3T['G-OO/F/\>171(1'71)J<K.-O15'V]@ V3[-!*VO?UFQ3
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M8E2/)/"&%Z9C@M%6BH K#B_Z9B!HC2NEU/L2X!L>-M38]&YF;X((&"+!(<@
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M>QG!(8]=/HQ?\NR,N\]QW<C+9T?/#FZU;.0VI1I&N^<.MTMV=U4?T@7Q)P$
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MV6RG;D4>%++M3+E"7=!2RG)&9CG9"!G +L.WJ,T17N4&O[R18JD9VZ:B =/
M2T+4@^3'Y(OT%@J0!3=E9B\RIDI&.Y,?DQ%8H]/3+KTZ+S/XMICIL#2;''[;
M,+?[K[]RW?M_L#]YL6'_!^IN[F,7!U[?W,F1Q&@[1-^K$=$W(OI&1-_C0O3=
MM1LFA<[,FO"^1"K F2W)8X?ZQ%(/G%'Y]'O-4F#J]/3]^%%8 OAY9\02X'WH
M^E=CHSU)ZWX,=0>6")D\JOR<:0I-2&/@:N5IRGL&;M['8Z7^!,N_]]MJT$K=
MQ#S_MBCRXO\+7N?Y9QC:9\IP"P9DLEM*>FWR.M:>"7VTV].'#6/)MX];MDR*
M2P<N2N2(ATN2R6ZW";I@9(T>(I5Y1):0&\P$C%*W=VCX9A)Z7*4JQMJA4B%3
MC@'(H5%%/\'_,I)II1EEW ]I2LW0DFOV?YB?>,YD2.93H5244ZEIBZLS]-%Y
M9 #/F?XS3DI"6V&M4G>]'-<P;675"4+0Z18BI>\)WFZT,S[OA%!L41"+_HW%
MWT/];FR3"0;(@ JC? 4VFHC#H*L'UY 5BKH27TM=Q'BLFEYHRTY*MI>7GD>#
M_;.WV9-7/\R-1$R?KU XDB1R&.KGZ0W=MGE8@T'V&HMB6![@2VT"VK)O_ET?
MO4H7"# EMISCTS"HLRI)@X.7^TS480/KO?0KC^@6.*NGMG6M[\Q^5.=,*8V_
M^LB,9/UAU!)#&O2]@^.C787#VA5B[AGP2IM]$?74.WZG9UWHF3J2A@D8[I^7
M,($.UQOG?G>CWJO!?MJ]'#8W+<N+D.\,5;..0N7JZH'FT0AMH3,?58<-D=G(
MI9XT^.YP?]^&W((G/%H^Y;!IWQV]F#C-@_#(YDQ@B,'E)*\1;RJ4(WX#*8HT
MX[HFVGZ4A.>IH\%_R;&!$)F LUG!YQZW!6Q!G+RDL=33[4[NCG)0&'G9I'Z\
M*$>G+L.D#9K15^KEJ,E.=!4^B95'!S-5H5/&CY=O@SQFV^C*SLFR/O6?4</-
M, -]">\MUEZAOZ:'D\5.&AM%XI>6^?4>0\E%.;Z%,?[HE%;YPULJ,U&)43:H
MH!HJD\ZO45HT.>KZQ:IO&PDE-<L?%ST[>,D$42?AU*80<DO?ADCZBM\7/#1\
MJNQNV2#\:#@ -VVO2;X*=[32H"'BR(J^%+;BX,6CO5"IX8ZYV:JR<H4]HQ@[
M_NFNP,<:!OCLX'AW1LE05^2?;3^Y=YYAI4F,O ;)AR_NBP5&SHUC[#%232$Z
MA@AZB!@K0K):'!DWMGNGID6-FN)%B%TWCDE&=/S&D/.*&*,/!-)58Q3C<I&W
M6A^6F,W'!QM_M91.N]I5[6ML:$<]ZR&'^N%.$OA-"Q2)<)CQ]H=%$L,R$S+M
MY>'^D47QKGJ#NAIRMSU$D,?T'+XG86@,U,TXY.E%][ CL1_:HY_XX>%6- Y_
MTBBF+?3 Y(4',F:#N&N"^7(-VCL\GAP^_T]W\1K@/&=5G(?G\, Y;*Y>4/WO
M/<0#_L#1]DM8I(TQ;//[: K>4%VI'S4>TI^BES7QT82-N7$0N!^F>#C9/]CA
MA!T :'ONUYWS("[S>+)_/.[PU[S#SX\GSX\>XQ836M,',V_25)M2/?V+T'W-
MG,)[ID4"U\K?57J!]F:$5TR4E7O;W#/3&]Q=#?(YN,31SN!$V"T<@+Z5HL H
M&'CV-GJ$J_5?_W'P?/_']G^W7,$M%.;.!:TW8W[KBWER_M5+WO5K#(9DS1J/
M-]?>WY"\?9#[PA>ZZUP&!@KRPW]@_\+Y?*ML_7T)77(3Q\:-F",KOTX6_BK)
MPO_^/KG%$]M>R$=S0+=T[VZV3'(G/&QY>^!K.(K:5LND[X-1UJYU)]SY.GCA
MF1>3PT8$;X]_='OFQ__F640M!_Z1P(9GMWT>OTJYN9M(R3T86L&1AX2]D> \
M>S7*RIW)RL:8RP-;D;_\]721J'G0,B1#3.=@):FDU]Y(7/\V=/$N[OK[5L^G
MBR(I8>:8TWN3U^#FK$>3Z?ZU]B[6Z+X4^='+4:)VH-L?\R)I=?]:U^2+MA\M
M[(ZE^KB&[_ZTSF:+T6 :C>LMC>N#459&X]J(PR<L,ZH+-*?/5(8T+/](J#Q)
MF]8(RR&H%+=G9NU\PFV"$")SB_KY6["Z7T?%-"JBX'52KA;1<K2/1HO[5BWN
M6P^=C!+UU5O<?U.9*J(T.!6"1-+S>;'*J<7QF9IA8[>B'1T83?"M:H2P.^-;
MZ;IGHE3E#]^L&=9:HGM,A.X<C/#8EFV4K>TSG]_&*HV&?><E^@'Y2H._1\7E
M[:<Z'[-Y,5KUHU7_V"3JJ[#J;S,?^M5IZY-4?0$W!P,Q43K+;ST.\VCD9(R?
MC_'SAR,KC\V0OETM^RV8R6<U#";X.2^BT4H>K>1;U<S'QZ-$C5;RK>IOOYO]
M ZGW'XEX-Q+Q'NR/3+PC$^_(Q#LR\6[-I//;Y&P2O%,Q94+?9[-\J8)/T1<4
M-&I7%'6TQ6K0ZQP<[JH3RDFI^],SVUFLJBA)-?]1*8Q^55*E\'MAX6U4>7I9
M3+<K,O&^'OYXC?7!2L]"<P9/%8R=FNL@_[ L%W\\H>Z#7]8!]?%!,J/OX=]$
MLU8+H6P]_<-I@D!\KPZ)V)\UC%JW9W*[*1%S6)(1$5</=2%W[7%[$L!+^(%K
M;H$KZU6HO#B/LN3?]!8]+60TE&5>JB@3FJTS6?&CYR^?1$\MT5"L)L%)6=9+
MGZ8)FP7*')"W-@IHL?_.S7V9"LOVG0B>.)VB98)/F7B+.^3.\G,8I0JHWU1>
M!&E>EDP72OV[-!&H9A#TGMUF>*6?P\Y3^^HE=FUBX5*Q%CF''8G&/1<A25A(
M*A"2V< A0@)>M5,Y+5!0PYL*ZL,D"/N8E)^#=Q%!#IKJZOF.M-7K?+AQ!3)Y
M.2?^(BJ0&S,H8"KPR;+,9PDU!-$,I8EM4RH<7_Q#& TL'E(#3T 2 KR0F(W9
M%3[+P4OD@W!6Q :W30/ED&(W*3QA4Z5YP9#4&/F944MD]7+*IY7'B1T&D:UL
M)J1B."QN"*[Y(S43\UJ8LIMCL31D],3;Y!R[8U;<C[0"'_U6:TQ2#__69\YZ
M-&/GX8X1?[U]3-_9)ISZ(!$'>@P"LRZIC[SP[B$=)1]+-/:QKY^<13KZC599
MNO=?*BV"8FJ4@/_B#DJ>QM&MC+FA/-T'^4K?#J'1)Z'365A_%![^/=&^.[24
MJR*9J;&W]BCAXJ:"S+[5AM9'%"IKH&GSR^7\QX:DU%<:>9_=]K:P@Y]5Q>(U
M3"L\"M\H?%;X7)[PH8X-]]Z2 ?O&]#32<UEW!UO$L2(F?E;38)6:<.2I94I_
MEQ1E94PW.%ITR*@+'9.K=[@YQA"+?(^P,82-'>JZ7N<1$;MO V_%WH?YE%B0
MX<.E,CWSRHX6I)V-$T8=,.H U@'O.XXQ&5JEY_ST<WAGTDRAB/!^TJX3-E67
MGH\4EH&;K9RO;6_4G#OAU-CGD5M@TR$!\4?-013F?];H6SE-:#"P8!\?JVG%
MW6,*Y"0(P,-0&4DZ$<6?ZWY!W%H!7;)95&/+$MA "@%ABWHX3AQ(R#MG:#H9
M>>H'7HJ]$N"FK8:_9>W$\;R-YXW/6R.F6'I,Y%.,F8'@@D\"URQVFY*@  8#
MX6=\G\%E?(-#BR=AZH5-*%:'\@R')L.X(/9<HVB"TWE>FF3ACYM!5>'FUV=B
ME/=1WJV\GV%856R/@4B>WQ:NW3B.>ZSH-C6EWQK%]GJ($Q12TP@'MK?0<;Z(
MN[PGV3RM%1J\\/UEX#3,Q>N%S3#WT;K',K;Q*>B0XD/M2*C'X0.2]OU1V!^*
M<O>,!D_:O=_H:'&A8#W^#284J.=,S1.GF9/((GI88./45&UINFYAS[RB7"0K
MQYQ9*+'.\'8!_PKE/1ENVN6'E'V/K;O#RE5Z)DWZCT@;X$#I[T/>PML$U.PT
MF-W1CG6,;'^SFN(312=8(J15(C7HU<H@T6U]-[LE.N9WH;AW4HH=F.!V6HY&
MV"AMFZ4M5HZDI0E8_#'ZW3TMCXSH>1'ET08:96T;64M51!=C9*5.6P^],90+
MQ&>D.K\A027!UGR35H5G9(XFQ#=[T*Z>'!](B8.?@.W#?0<&TPS4R=$$,B6<
MZZ2Z43H'#(T1@KX9@GXP0M!'"/H(07]<$/3QLOVF+MM6FC3.X37HJ9?U;*;*
M<EXCG SAR_42\67NA8N1Y8QO4FIJK,Z3F0L."#NBXZ]S##>+@X:MD;E??5EC
M@#!.2FI#J+LCL]L655T BS$*,,IP5W1Z024+E,M#%!E;>-EYL$"N_V(=@G#K
MOU/;;8P]%VCS)?_&CZV*/*YGF!?$!^%!."=R0'P8IAGE]^0*9K7BCR79K":$
MCYN$MZ_&^@.8>)EPN'JF5GPZ.$5:LJ6+9+(U'0=ZFOX2'@,*GJ'K&42S1:(N
M"#NWC!+J+X\CFH.;Q9CM\52,IZ)/LY.^)6G#?/L2<_(7*LU72V$Y1G!^7-3G
M 8AOC&H72W'\9S ,BZ Q93TMJX@QR0Y\90X&/>9%@M;[+^&@U!D)H8'54/I2
M VHN%RJC9V-5@?]=I_) /\"<&#KOYSFAX7(X7 7?'>S_3;&*H)AQA($\R!!F
M#R>8SI!"-9'AK4;S=M<#3M5Y$2T)%6/!UZZVX&M)S;&;^Y@N'8_>P-&;1TE:
MFH#&FI%6YY$.920$5*7PQ2]1&4=_.M%H%G(TA4JZ2_#,Q6!"8;%,U0"G"@0&
MQ#PI^;YB$*<!3S>_P<^(=+E/#O<+VGR<*953R0'*TI3OV!@)#(Z/O3UKF3HG
MIP+FF"QA!V$4WV0L4T>AQC#F-ZL$3" 2#42\F-(ZU@AIQ,>Y]V><U],*SB$"
M<AHG<NB:PUI5N#]3%9554%TB<T@ 9[M:E!9B@==XX]R:VDVL)42U\$;-%-7N
M'1V$P>'^X3/"'$47H+7T;3M5 HN8!&_!\$6DGN,(>B"03IR$E#1JES*T']\*
M;,N ] 0U&*Z=-2/B'$N'/<N!; IZ*C^M;Z'U"(RRW6[51PM[/.$=)YS],]]7
M%!^1#Z-V'!%3VG3KILIX<>E81#<*6%/ $M1"JT+-TB2CJ8)".U?!-,E7BP@^
M/%,U+8&IM29;<B *@M5U7$" 1A\&&DJZ)'35YX^H:'4 !-Y94;UY2"9?3:AN
MKO_D&G 2=CVVH,(25!,_,0$56PLTE]I1=J3H0/"G>7#X$+0?=4R% R%\ Z :
MGR6KB!'A$=Z6K.K;\1,W%".QE'E>2%TY+*Q2=)CF=547XYD;SUSCS!FKP 0"
MT(*A<)LYA@$=0S*AW-"!UNUS8:#QPBP@F#5BN74Z6P#<PX7;S.;@G)F+1(P5
MBK,8/0%/)Q</#P[_D\4[(#F=8CL3@J+#3ZP)I8]Q,QSDG5($\'8M#5UI;KP(
MHRH6F^L5)9G\?4SV5)F'[4=J!<2G>JK<I4%5!X(_'M7QJ+:N1\?(3S&UM%(9
M-V\3 BCV/'0,A/!:<K!!"#_N[>\?A";"82^9N'FKX0/@60NK%9S(I'5O1AD=
M9;0AHZ*34_0*4JKZS'I*.]EX^Q 5T3E)+Y>!$N9>?O8KY8]L47;IWP*>@VS2
M1/8*8/JGHK>R%&\1'2O<[CMTH_A)XR'=/A0N'(_.>'0DBH[<;3'3T7E@A 3M
M%;)2VA9)&DGQI@8DH$W2'6LZ+_)+OAS0N)&;P66XDPN!5+QCTV M7C)#_@5%
MU@Q,.3KG^B(X>?C4:C%*\2C%C0O  &OL39!?9N0Z2\$96AQ9Q1E'15E4^1&Z
MSJDF=YP$GS"$C#YLAXYU8IC"I(%"#-9*A7X$2K@\DB!AXE7K7S.4!_ZU E''
MAH?F4W2E",E!R*!:')Z9G!2%,7E<JIAQD=$5*U4E5/(*7@U85N PC;G2\7PT
MRBK.ZS2BN)1F?$$IG#&=H53LO'MS0L+*0DJ!KH(C.' 28%&\I]35(A=V#31-
M4I6=5XMU&%0PY#T&LY$-@PH^6R@YCW4&SGV<S&CW6S85GEUM5?'9TJ82YW2H
M3MOXN/P)@J@+W4#<-4\.2M&Y['"F&Q=7$P#A..<T%.TSTRBX@K4!;PI[7V6<
M'ZM =##;Q+$[?'(TVW!N-\SRCG#ZS7#ZPQ%./\+I1SC]XX+3/T[X2E?EX@AE
M^:9MM"8/Y]9%U!U<4!<YGA7,^FF$6M?36]"V&!P3AQ-Z9/T;);5+4CN9P3Q,
M?7\>N =N/T+L1VG;5MJ&\6QS X@3@@"1._@L(N<Y!NG0<%N61^W]N:B\A!)<
M\^@B9U<8V5&83Q)<U71,0XV2*I+ZH<BQMQHF<2P\<KJ9I0)#?MQ7AB/DV2PO
M5I(/(ETY7:?19:FCB/H=(,F@/=^ 07E)X9?HTC#4?T8="XKUSSIAR[G/F)!6
M*SK8;C2SY@".*J0=KIA;M6JPDE&-RRJ-N,RC4$MDO\-/4;">D@?CX1@/!Q^.
M$PR &%()*Y%#=*/FA+0I'<,&Z2,8M1G""5)?1.D($OLC/K^!/48B[]S#L*4N
MQ2,3Q\ !* CYL$RJ <?-?^W<T$'"W,= _'@*-ALS)*33(H^XX57!AT2N#J2>
MU@Y;5"ZX] [_@D%OD#'.:/6H>%N@E,_ 8G+*%C95$\AED&07JF14W4HU'P8C
MQ)@FXRG8D (QPI(!"N4C>D(R /PYPZ7:(JJ#>=0T3>%(Q9?B'?)P:INVZSOU
MB5CUI8V4R:7(O^FV=5KHP?I@G%^WTN,[_;I=ROPN7,E?!WJ-/=^FU=@0YR[&
M"P/0D[!7^$#<<[('HE@*0[D/&FE1EDRS*#-8!0(9/-!>9C:!=*(32 ^F!>,0
M"W(N9XH[#>;8\.ZSE$BT4W^D!!"$5Q781L)-YO'UZ%)1N+TH'N:F<4FG\*/^
MS(&NG[B:L[EW1_L/8N]XGVBUYTE*!CO7 *2F#-5!))APBA>PZU/Y3I7K)-AD
M>34*R,5I*506+:WB,5+V6I=#A-CV<*)5C*!XO#"D;FRWY9!3Q']&L4(E)=OI
MJ,/U$G9:C^:__N/@^77_:X;\7DH^;(6MV'9&^%N+Q7/J6##L;HGF*7QUGA3R
M53IB,A.S&*V)8TW&5*G,+]W0(F#6 IN%59($!U.5@'U450+ZET#@")C5W[)3
M,MED)?TNNL<O,!9Z2-\<*%??\QK)W,M;DGG'D^0C_"8N(71(Y6SFW:J>&/8_
M-972[KLN(UCLF$ Z>H'M[TL8!-(%+!H\[[:]C@RE$3#GA^HF.G+VT#A?107J
MQ8>I^$X<'/7)#*[CC+;F$]H52RJ.?B#:S[90[4A65&0&=31,BKAS!3."+FTA
MK);KB*<LIP8_C6IT3Y#J,\LF"B?48_]L]Y*"=ULD2D9/+F)+&D =7_]&: W$
M9,!:JU5CT3^P$XJEAT]$4_WMY.2#*)RG,+P0@X;85$F%S8L55@5YU /$X\!+
M^?=N@RWI:=/JG:M[#&8@]UAE9OO6@%,,^Y$(M5124L6)<2#8+LUR).? TY?M
MV0HV?H[00[';3/U-J3^OG?"J+J@Q:>AA>+3M9W:7 E&%3B=U/[N]'W1ZX7'N
M&GE=ZR00.^\^Y':*<[:('9;Z'X(GR=,VKD]6V L>$'S0*V]>1G^@I618CB]R
M[G="*+Z^8-^/\,:N5Z9P7M"Y<L('^D;1+;K,9W3;B,%W."_A!\4* QQHR5E3
MW%@:2RI)-XLX)=XPK+0RP96>^YIO_"?)1=<RFFB-#03"9D5+?6JY8?/"^WW/
M>UC'=UL+> 62C=)GG-#9+'##T[5WW_0KH(AO&^M7>QT,='LI-F6(RH-09_0=
M>_Y:LNQUX.F*? U\U\R57+08%<@\2@IVE_5))]OA2[*DFDWPKXHU#E-_!-47
M& OG>1ZS3$M32)2H*#LG,*F\'?MZ%U3AK\,&MEZTNXLI:IF\:'33TV,&IX)#
M%WH)>3]9O"0N,.,F05186](0/(B$>_S-8^UN1<PTY-IJ&26Y)3XAEEFL6Z@[
M::)5E,1P>>W)Q3 )SJ1#^%;.]F]9!+H$1_&AR%$Q+B,$%\%56+*@LL2^,XP0
M[[-Y+L:0ZYRKM%27S%>1;?+(^9*S,TCL(R<M%--#PHL])(C?T0CQ&R%^(\1O
MA/C=R.V""S=*2M#!']GNP[OL38*V.R:,M$W.OVSY8 <[\L%^,_&4-W\[_:D9
M^O%;3DFQ(7+R400:K1TS:6OL]G>%FO2TK,(G7_^I$A,ZD]\>/C_4USY.Z6'Z
MZ&2U%DG))HH(#/SM[[HG:-/D.Q5:. YG>E%>[U<-P3I\=:MA:3M;F,-KC/</
M1)^9N$$C%RAVHV6-P NR26>5H!P,;@&>$HJS[1CJA5DDBOYY'53!%8[0YL5(
MF"[S"FU4P&4IF8+Y>XY=0#(;V2$YP5B6[Q 8HI6P1VY=YV6+KLY)H2>AK=:N
M@?!LP8O)8N$21 ]/8B%ZX?RW/7%,U ;M,WW#AAO$@F_(%CA(%?H=4:FY#.=U
M0>Z '@:,CSN/@9S]DI<3#IP>T@./,+K7[#@]I$>JCD^<@3F+)O'/BAI,L%-@
MMWS@<;BY%#_43G#GY&BD76LC/1YM"M2^M'O3K11W[M$@=,=]J+MI]BSS:+T-
ML[L^_%U_KWDW$<O#U;O@],^*9.H=P^MD%.]0<PVE)T&1;9.?O"M=YUF?"+=B
MW,@/BR2&6Y; !2\/]X]^=-'Z9AAQ4J[2: UV::9^3$%4]\1=&'[-=4=/>(GM
MAC@ZAYN=PV>/RCGLWXWCR<N7S=V0GWVC?M]7Y0Y%01+_SU]^/SYZ_BIZ/GWU
M^XNC^.CW9T?[+W^/CO9?_1ZK9_LOCN:OCI^_//@++P1_X^>3C__W]M.'C^]/
MWY[\\N;-^W^\?_/VES?O?WGWZ\>?3SZ]__67WU^\.M@_W)<OW?$!O)H=S3 P
MC 9BT.N'>K52Q2PJ47YY6@'-*X")!7IF@3,U-)9WE_IJM5SW:G<L78&P2L,O
MG>2FOCH%V-"7%O_;3_\ZU>GMW<UT)D RK\YH8/K(M3.K\BD:0F1G'C,_;BC.
M0UD%<<39EB**Y<DVXAQE68ZT"6X608?6HU(:TF]8T9!X\[_;GQR\"%;8: 4,
M,\56Z=5G<Q-PPE7_2RMU?.6)WN<0^;]V57<CF*_5+*I+G75JU\$-'\^RGOY!
M%(%Y,$]KL#TCVWE'GF;0BW0L<:;E%L^VL) AE],+EVBHB0]ND/(K1E-2'S_^
M^XZ6NTFJFER@AR3$J98'P:Z3MRH,Z%;@J%&[%_Z9Q*-6]11<$U"4A!6*=S2_
MDU*36V@\'<S!\YF# YH&.\V66:F%Z6IBOASH5MBHP^S')87.2@Y(VP#&J@=1
M<$D9UG  !<;'&[.MH8L%PZ]J=7W[V*U=;3JL[_VK3JWC<;L_4GHV>(.G22,"
M!T,KH4#&+HD\Q6:)T_5]3J$ #[^L"!'B1/$XU[Q92U+V?!<K[Z^_PT0>[VHL
MG:OG=&/UE>BN1MDW[B?E4_YG]_ ;*I_11@R,IWB?R7537Q<*%S-J165JGI#4
MYY<9+,\B6=&=PE1:0U%K/W);2OY?(F7E%C&H*T73/I@BI;-&0+O1ECGYJU&F
M-WRP[9%BXVVX C=\;#=W1?+7.U#0U\RYO$DNDA@!UKMS^]HM\[C@'6RS-"J8
MWATQ*,SLCK"\6 ]:0]P&+G/<14-W9]ETX8F$_;GR\_KK]2=@T%1HEU!;)'WJ
M\'/4LR.D\<,Y507U^1(D-8RC.0A$T:D_:X?+K@$7$F/8*8"R-!4L:RYUI &<
MP2>R/<W'W8%A,ZDAIBP.ZA46U@993?U8X*-MA. 6;^U$0X5=K9M"78"N]489
M<@%BA*X$X:HJ<$;D >Z_D/HK+SG1XB"2L=:WA6]DM-2&I8B56A+$2B%/X*Z]
M WLFZ!SDSMGH/A/VJA.W5FX*/YMGCD4^@Z4(W1*9WO/2?P:[WVFH!5K')?2O
M&*?.0S"=B,.T# /(2%!*WX6U%A05%9@0*0UE 1V+!OV]^@)JMY13XC:6 (/)
M/JKS8-I);CQZUN8G:;K.64JJNSLM.AVW^<24/4>F,<&[.R$WSC'UI&X>4O[D
M^![S)R\GA_WYDY<O3?X$LQYC_F3,G[3S)R^.U;,7L_VCWX^?OWKV^[,X/OX]
MFJF#WX^.9M'^].#%B_TX\O(G']^?_=^[D]-/OWX\^_W5LX.7^T>/+%."$PAD
M!KNSC(?=CD'$/VAN 7/#K2.Q5Y5=)$6><9T!-[O-I)I,N&9-GT[L9I1=Y.D%
MM8JV?5.H,CG$@@3*-#"J7K]SJM:Y1"R%-P(L#@LEU\:LQM1;/]6B52C2YZ"C
MIEB5.T=.W-DVP.^0"JS+!?&[F/II6V7-@6@FC)4J:PL!F8+5< G_G1/7"S8H
MIB952,R>8_6*XHK[;4*(D^!?=AQ16G95?'<OQ>8Y3H(/*86O&VYXP\7^)\6S
M<!BGH.K>@< %/^/$''A]+["$HP_HJ![!334HA-OX_G/J_5,TYSK!%^S> ^XD
MG.08-?R;3>5;5@&WR9?Y#@QD(>W2T+R0/03-_JQ+FB7*Z720-FXE: DG.L;D
M2,-=H#H#X3W&J[:W73-6?Q0>_KTT=S(N-F6<)IVHH?O2O+\VDZTO=;+5/_1T
M^U#4S??4;7V=M[BF#LG^.G+]?5Q?P<_!:KQ3TZ*."@E!'SS3$=9576"Y(T4'
MZ'E@WL/JG8LZ$3*>4%(J)B5'N@+VI)Q+F1"R=&,Q;V'#!^);E)NK@T/0*459
MZ9^?U5.^!ZCX5"Z>3!;&F7Y#U B"RI64<$]=+O*46Q%(3W=0P<C\W]*U&K)9
MUL4%N&A48^T!"O&7WO@(/ILLEW#-45B_D3-J?A;'@_7,)E,)VQ(@+C7BU) I
MM9)"./?[3:KTKA4Y4[C6[N(U7NA]0-:M_:5;7$#*G:X[7S]!D[>OU-]/^^I8
MLH8#6(D*/>]7CH$D*Z7FK%.G&$N"?'6K[%B2"5=+9<M":^^(, Y'AN%PM86L
M&4UQWR62(KK:KJ/?70<KA",#3?X7L:K$I.*MDW6!!;Y<*#JE>/BP4[!84@2R
M-9-HK9ZM;J1I)V(JS>'K?.A-1XR*.481C:J$ (F&0Q0(0D#C-JMT2/R]QC8-
M:A-]-%P,#FZ-@H5IX-A;*M!P0.XHCM8I5VJ.ZJWTF@XZHY^)"5DWFS8G95&O
M)(22L8Z=49FEMP6PUN2_FS8']@ZT+)I#4M<7"S*8 !O$^LUY;U3RI< RUA$Z
MMGU2,<)&/2A2'$F6L4SR1K$(#=ST#D6<CM8A"U9>,8)!?9$T/8I'OE;JCH;)
MN[2=<6(Z?ND59)\7-A+S8'Q*W<Z4(6PB!L;H*@7-$=//#$>0&R8SCT8-CIDU
MQD3)N%#4,#RGCSFW YRM.U2)[4:FOH #5TRU$\2I@Z9%UZF.B+_$"67V%/[?
M3<3NYO;L^Y8IXEM6IKN;JPB9D\2K7=?<:13;WJTQV=&D/BE;Q2'-XAU;,M0L
MT@B18&Z6T.2==5HB057CB@CUZL%H*7>,@E%577'?4#.[=&M$$NG2VQC<BLTL
M,I2 ,TZV]0.O76SQJ>,M;M[VZHQM/5>D0P31%L<!]J/.NUIS\;3E^UH2'6B>
M*\?"L=UV'NKAQJU[^V6VP&:-P4=<.Y-/;5(<R8<\,PUME1B+#%%^78J3)E1Q
M(#)SKYJ *V#3M78S_+F'=A+=IJ_/Q!.16CA#.IVE<4R/]MDQ]9)IEC*YZPF=
MCBU73\4-<^_$\U.9L$3%4C(7?6;J<.+W(*Z;GFE(FI72ACKB'')Q(@73^L$Y
M'N1;@4FQC"P721?:TX-N!0?/)J\.GKW:,F3WMGM 382E-5$R)&!UG7^*K'O#
M<5R>OD&<82_',CA!=E%Y$<%(0F17P6:_>8?H2&:2U/A!N+^_/PD&!4U2L."*
M.J >V$TDZ-%WCNL=2Q2T<>^Z9#!$^..M]JOGDU?[_ZEU871^CO CD*>N)>@"
MQC2EU@ NVDTV@B>4325/92\&GU T0M*.>M!O#44;VE%"7R2-#ETZ*\J>!>8@
M#%$F.0LD*OAIV%%.>=MK?#0YN,D2WVAIGX9=GCY>FLN5N/@FE\TT?*C'TV29
M\'3"/O2LJ ;63OI"FRKR'_01^.Y@\C( _9R2P_V>U3Z3KP\_-2DEL ]/>'%X
MK)\1=ATJ?;0?2Q;Y^9A%'K/(#S^+?-=VJ+$)B4W3U(JTE*)H?"<@;7LU%VI/
M:YZFSK;]*;A6).Y4]*UZ%&'$@VU/M;&%^65%;6=[%?2VI0R[*NC .X14IJ'P
M&[2]M3KF^\:]-%LA#"\$;]P )PC;VL^K%P.YF9/.H(C;SQ@\]JT''%[1#3'"
MY-#,^]_.-MHA],ZL9Q4XD*3GO=1!3<X]1Y8QQHEMIM+FA$NTQ"]+W(1W#\0/
M3AR/5AA@$?D/%_!Y7B5DKE.<&WY/)CSHOZ1<J+CC_IT$9V LI%&!/"5WNOH(
MG\2(W8-:?#CW2O@*.7[8,CP-+I/M+,4U8S.XMLF/=*-^I)X?<AC I6SMWZDF
MU'BK^BUZ-%ZS!+ID/TWC/[M\+U;.'0Z8<U/X&[Q)CYC\&H?P*9?#@LZD3=13
MQ<B>I_ET%,\-#VY!H],S!(>0WD_78$Q%P:.[7N>A/=VW30(';2!<V)Q_LRVD
M+TGV=6,D-T35O+]V&)%]W7*]A"O<83<:N-]IT63%_-P[YC'/RS8I\782_M5+
M=P/SW;&H<;ZJ^E\J:^[YS&8L(MAN#X9N>;6)5I=.V(HPQE*%@Y:R3P8QQIEC
MZ;5.'O@47B^(NGSN1FLY7ZV_X&!PFA'=3:GG*C'=X;F JY+F,,U@ 1%(4XO(
MV"[^[1N+MWT/.$OAY?U0?\ 4\OI\X6Z!GU-SM\K,>8CI -0#B%FQ1N](&4O6
M$/U2OK?<K6YZGTFS^S0$(RJA<?GG&IQ)CT@\!Y/J7 =&NY+9G'M"YKER8"U9
MZ+2(\H*@18<;4UUBZX4>2-1F6TD?TNZK(/@[6#X7N#TZJ%2M5U+O3ALBLDXV
MCR/<H&J07!X_%^G44<_D3#>+,W01Z5&EY/#IJ1ROTID8-V;E>#NR+0%B8_)E
M,J/"M!QYV6=N84;9(V;V659O;B6T8-+5!6,/HI*A72">L5I2+E VBNK]@X6*
M4FPXA)<OR37<<S.T;O]05"_#/R?0@IT74?:?&\K^2%/VNPSVAK*_Z2)9_$II
MGD]5U*AR*5.U&3\8. (=MJ2/+8JR$K^.I%W+NH=1Z90NW%"O*(^"!'UB@NDY
M:E.''VKE[\UTFM>S'D;9/X[0)GF'&U>33BMKY-_#M4[8T:Z+3)1=7,\:C<"<
MR6J8WU#=K(-/@W7'P-)#O1]:Y).4&.PQT?Q0 R\Q=>IF7\_O7[A;%?_IBK$"
M#V+GPO$=EA4XF#\[CV34M82RI&\$4U',5$T*"U1>DE=JMLCR-#]?.W"6-)G#
M<LT2 MTS&0E[]1<NS3UE,%3&3O^L)K?==%/W@/]7=L\IA),FGSE+8AYJTZ4:
M.>13:)H)<%,\Q.A,54I-LSL:^J#%WW59>AGG5L]D'?D@N-P*J82ZI= A_F\A
M/UB*;?L>+FK,9498^' .JMR#!9E"#2Q'K CZ$;HA%EU9H!_91DVQLF88'D47
M9%4=T.<5=LAV8Y+FAVW($N9<-+4)O*M>@E"<.,VG36FA-#KL)QX:(@:R3$-*
MW^4_T*$>^^9^4QU#7?O)I#\= "45)<$]0*9:A5<_]<:E%I,"L 6[R:+[=,5L
MNR,@5@;15\:FS:/PL?!1+CH#>Y^@(&$;@1D&G]7:5GUX5=^HSU1!13$"'W4^
M.,K8*&-="FZZ[I ;\J/0I(&+4C>E0H(Q]Y-%CEV T!?5RA!^!.)6TI?3B-(Y
MX+ZAS+J6IF86()(!\S@70LUO%_,(/Y-4HPB/(MQ0D^ :DURB/C3% 0,B\@A0
M."]&%,Z(PGGX*)Q1V7Y3RE;(@<HHW911'"_H46989G2"@\N4)84AM48SF_9P
MBV%T]&8#+0 HS]E"2H$L.Q>F+_%1(*@E\2T^($G<'P5Q=X*X@B_G,4QFC__F
M!;HQN-DBDICTBTZ[>PMU$3SDJ?%-?^\I .1BR2_\M!#'/;U4(\7<\9@4%(V/
MO5ID)X)+YW!!"'JP9S@T6V>-%K&V;S7\A6A8!)T"0\9RDIH=-P[WZWJ_:9%'
ML0[)>MM QQZY;;IQ"[8)P<::+(WG7T5EY;)Y\^;3]>7,M0=W&FG>= /JM=F/
MT,\4T*KR2B59"<XR%3G,T@BK@SGB[F1.,,%[+@54YQ%^@=.#=JD>;OJLM>B4
M[BA;><EN'JE,"7RV+PM"M39"Q&"H'W++02C(!!*7Z=KTA98*'#<[Y?7KC=6T
M8HA-0?@/F)_***4:%06FK26(9DOII5#?"5B8NA\1_MYJ(S]76AB6Q.%OV?S.
MSM$B_4T@PX$BXC9US1FHEEF14"U/D\!&;Z[)K+D13%/M;_-N#EBX@Z^&X7'F
MPQ3N)$&#3\Y BR&R(/-+G,+@N\-]<(YT_4[PA)\D.9\R^.[HQ<14]U"V4[>V
M1BQBDM=ENK9=KMVJ+X/!< %[F"\XY0H_ZOO]2UYI*!VEZV:SHN;%XU[SJ#)0
M*63PN:<X^N&>#7O(5HK0:!+H1F>]I$&H^@$^?RJ8 NF3C8OME))YG5YZ0#:?
MVK_:](;2FGI**$SIMMJ61&AH0%CN=:F0XK4TTB4@+/, 'G07_GR;)95RC^U6
MD_2=!?VYV@/+P)LU(7W8C2?)1$U" E5TV\(X4%F YC-Q'AMJ-)_NJNS#R=N:
M)=/UZ @\-#2]/=J6:P 2@JOAK<)%[IU/P%+-Z"(O^'&J6*(8>"0&MAM,\RUT
M495=-]70[1/RT9W[PL!7BGLK74\F7$UY'9%HU2J)C#0^"T84MY%!BVR5ER6I
M+;-4M)!D)L$R85*@?0?C;I!EM#*4BR5Q7@W?A(T6%(1ZA>O;KF;G3M'M4_+E
MPTUYB&T2GG:A,CJ^-'1S&:,^=NY<,4X-H['W36GR0Q42!.43"R3/W.T$?ZU@
M,Y.L&.WE>B3)HO!0$#85+8/MJ- F<=0:W$"+9)J81^$<'.(<H0U*P;(G1)]#
M-XT\,TBPS-U_N&$6'I?/^MHD Z@!LDEZ=%+[4#"7]B;K*JDTL@/,"U662"0&
MPSY'[2I?4KQ$)%L&E(PGVCG!W0IA1XK,6S"B3!.=WU>X9LN;M01\B(KH')NQ
M-0RE#0VYA^SLJ6KR]%G#V2XY_ 7?+485_(88%'+L$3US&2$.F">06ZUW_>IY
M:"])Q^CJ8BLP]=<'DWU;>)[7E853;E.S$!GMZ.*$>5K]E?Q"F8>\$\4,/1#V
M]3Q:A'F4%)V]Q8B/C D1]! SYZTXC@FC@<U:T&]4W+0%-&7--?7_0_4./Q'Q
M\<# ._SHH$8?_-^XJ!_K5&EBRF<.;:#^Y,G,J ^!4^_643KQO$,$[KGD_5M,
M79]4?4%H)+JQP_$W$4(?===GX?]%ZX9:N/-E?)UE=STH?^'])<:#YO]>X(;&
MO.KD<%!?$/$MG0:DM(4G0ZK CD.ZL*4N>T:Y4*D3-PJ>Z$HHK*C2Q&C<(D1W
M)>*H5..+3XG1$!^K48%DC##*L"*[!0&-KCL7><]83[I5N"F2P9;3U'BN3]E;
M<*M<YXPI=:"<0QH>U]HMR*'KND&[.3A@I]V&K,#VC>T&@CAYD.89C@\%L3F
M$WL'-DO>6J/Q*JRUW:ZY(_&I%=4+.P>D-:*M9!K7%:Z8@-NA2<$L%B+ SF7R
MN;6*"N%K\4<]3U*);YT*[]!'ZOA)A+I@.?/77^[]7W-QQ244[G.)*GC58O;K
M!_L>:;>8JO.4R@3ZW1,ZC'HWFEOQ6$A'7HYPAQ'N\/#A#@_/X.J\<AIW!E'X
M@3L1;]#4R4U#^[[+0;P/J+5!,V&7!]*8J U%]XE'F&-1$O[8]:JELQ :"Z[O
MO%MKK[LF8T,DXQ8-!1.0I1*\#I:M:]@*)R7%J?IV5=N:#4_2W4&7\1/O;/?Y
MG;::1&!O]@P*"D2EK$,YEF=\@PG]S3E&M-M YGT3C:A[R'K#!WCV%Y8(>T88
M&X/:C#.V^=G;4VV:Z1YK2 E;EQ3^R33O/9M]XBSY4CWBHT8I9BGV%31+BRUN
M_W_LO7N3X\:1/?I5&+L;#CL",QK)3UD;-V)6#Z_W6JNYDGSOWR )-N$A 0J/
M;M&?_E:>S*S**A1(]HRD[OD9?SBLZ6830"$K*Q\GSYE+ORA/*E:56XQ:G"8:
M"\:<OWOQ6\EO/OX$I;"56[ZJV992MSNZF]GWL84O5KE8Y:V^]:&L!ZJAD&[4
ML/K#J\2\MD0K'[O/G$/^[L6?4!TR'*JG0]DP>..A[+;+J,=BDU=MDFI&C;)U
MN%^K6^3*G])T<!6RJTRUI\\7; HK0F=IIZ;4BE2M_74MVNI!9@YLLXG.'(4)
MUO(_INW U$Z_KO4K1FZ:N2^NJM4#E;6 =PMB=.XAW*?UXT*876Y),%4X(*E5
M^.)M0UR1O=N<P%GP2FB4LJWZ4TW#S4.O)!^[0UL.RUY;]AKOM0"D>MBWP<"1
M=>W(;%'!C10E/+54E>2D+GD4?0CM T#XL&7Z0N&FR?)WV8VAS(<Q_42^)!JI
M1@A\QI:#?__KC7QK^#8FH#=;BS<&*5]1A6(%Y@OJT%%[S^(\U -)C45YY._*
M.^5,V%+%N5Z/6F.??(5$>YTPR.$;T&LD!\#5<0R2PPEP N-G,(9]VU>3;R.:
MG8X,Z'!.+V<1,E*3]H"FV#WY"HPIF7OI"U/*UX>FTWUK",_S&*VQ.5 VG]X5
MA#_<:U^US>',ZX8=[L&X4B:J&W'.^ (#^".40'GD?E6T>/)LP8DN8P&+I_.>
M+FH3.4?WZT]D_PMAC'-=C!H-(!OO&6@(Q7WHFFLAS'GRH>UO(E0/"*_0XI0@
M)O2[O *-_YVP(>HO;G"(Z?5_IT[1P Q,A\WN2M#(G!.GC^W$<8-6Z7 R +@/
MN#X)>LQWUR:%ETBMMA='8LLM']HH!E4XR9G?M>2SN%YDZIU<6%6^YLL59)RH
MS,73XZ@D[!5('AB&:$KH#(QAU3R;38FD')7SS[Z09:<1R@?BM61,BB 7X_NE
MO>#VZ6H].L_3].VQRH+:0H-_VJ5EP,PZM:4(34X?-#;Y/IOAN4)DOJ.UFT6&
MY;"96_<:-EX=C@5S:@R;[-S)J*,GBAKOD_#'0^BV]0[)B(#327=:-3MEWL[M
MPL.(;,7]_='24;5=CB;5]-1=IDZ?AYBUOY.G;==\<6W9L@*FWAP]<O61"UNP
MWKA5*!?J7O\]I+TX3"DXHZ$13YVHL-3PYVDPF+6DJT9C *T1W3!PHA!S=O>^
M;IN1% C/TJP#6%J)@05"IP>C&:PR<!K!] C>E.&-P,010IH(.C$<H5>@'B0S
M.!R%AU0Y;S26)IQ>O6--(D.'<QE$@W8B;4*1YH3 +;YQ6QT9OR7Z430\"H3V
M?:G$F3RXVH]\IQL(]MY53X0U]3[:3T8)(.4(2&8( =2,_ZNEK<G@<WEN"CB"
M><S%#.&D9JI*,AXZB@J6/<X#71( D9=-,'5J(>1URUP*N*QIFQ=*VW'#C5F,
M3UZF)_=]X:)D(,2PN@D-&MLU=4<>#R71T;FID@>-U^*)C(""B]AUR%NF2/)!
MM,:4O8_D <#-WEHG,J/N71.2CAB?^7'K+C"3 :$J9P"SK\ZQ:A>9LT*IS\#S
M([T-SWXVIXF5ON!YHN^)DXR?3W@!"^O4Y:CC6[GJ+<G=E7X^\WSU;/Q@D%>?
M+LBK!7FU(*_>$WFUFI#&SN@12.G-;9&#NRL7SPC_?LJNSX1HB#J&*L0S[0-1
MLI&V=!@<( T<'+1AI/_:U$BL?Q++/<R)9MX^]_C$P\MS16&J"BK"2-<?TQ[4
M&P\4N9B8]$P07AXA2(;:NF?RUBX*?,Q;!=[>158&_[;YJ'3G<K"$.#'@?(Q*
MY3R%=HXM29X'20H*K>&S1/@7YFVG?Y.H/L\M<KK$N(K][I]FJ9]K>G]9JA-O
M.K#BXYV7PK^^->^45N:^E?EWF08GB1#ZN>QU&5]"+3TD[GZTTCUW>5=%(B+3
MYF4R"9#*886A:H0]G6?]</:G><?%>_8ILV2K/%(9&"Z><G0G="EFGGN&"EX?
M?+J#PWM]-YD^E3R+=O>D2!&-Y>L<_E_-W'Y(W&:<4CH/S%S&<Y/_[R8CFY_F
MBR7>9N?=GZT.KTQ)FPIE.E2OG:S'J!K_+&OUC(1U*5W]?%]7N]67/K'ZAA.K
M: FQB=S&OD>%8KC\5^_AT)[KT?&YO"3*)27GGK-2:%#4_:8=J1;E/E.[]%^5
M$K$9I.DN9-"G2G$DP*!'3"O^AZ$0#,0WZGG>#<RKOHFXVT3V\DG=^_^WKP\S
MJO,L?L*%'%&,9TV8VE1=_9R]1!YY1;:>RDB Z!0RQHAE=JM&\!ONOKMC&6])
M/N1.>OG(KMQ0X;0<C+T>Q\;7(H^ ]A3\)OM>>%%231^4ZC;.ZW'^Y-\F/FM^
M7C?4SCDGX_T73[BK11&4F,1H[2#LE!<KX@72PDE@))^HPWEFB9GZ4K,5I#46
MU%>+)JT3<BEN$3$^X'Z/VPCD1-,O7I\#F9"&9YY("*@5&M+V0?CLG'KDNVLA
M'[EXYES>8X,H*^+!A2],8OOIUL[X??7K82A7*V;&V;#"J'$KY>K4HA,@'&Y\
M)5A51U4U\C-:8A2CYMO@U".R/Z*:D' $*FPUT2&QJ-.IJWQP28P5&5'3<K5W
MGE*53#52HN*M6Z$Z.*&L+*K$H&9\Y+F> /]5!<$2T*:#@DXZ[4J79X7:HAR=
MYGUZ6E5J2)%Z#DR@HB53-:LLLP%R+FNQG"[XWU^62EE7&0WL:=7#?0P#840(
MC]VH^K[96\H^X-/K*]E(;1*?6?4\%T'?<ZBWKPZLI"-S($1AR'I#W,LPKY8C
MI;GWGG^[VXJ[8!=>;UY@^>7*&%LN1<F/O7-X?=MKIW:$O[]M$%I2B2%F\!,9
M0$!*.( IA--I2CATBTE.2>DN2I;>^BS2R7HG&X[6_9FZGK^5#_U8#WZS"I9/
MSIH9K;=B)=!]%7N*FI \MJ]Y_YI:5/B5B2LZ1K)0T2IM'7H:1M8[Q=D2@-C/
M0?#WS3B@5&TMA9,.MVBQ'DOT"4L):C\>M,;"3V]Z'4.^'VC?4Z8G["\W2T'Q
M^)A_)5YR(R 70W.*^JO$(T5FE]ICS2!4^W%#/%$NPP6%GMN[['YM%,1,:\Q-
M[E:W)G8W;\\VJ7G?5=1AWW@A)6Z:-U,2A2( )7<]!P57/ H$9.IYB,95YL+7
M1:E76YZ)WGA;FJ%9_Y8?F&[UHF1F5*+VE=G#!\,C\<FKI9NY=#.7;N;[MBV(
M]+LA<)8+R>HM WX, ]-EL!7^'7SFMJTX\J6F0..3/&2O5$CT_(2:IU'MM:\J
MF 4[]6=$^Y N3?(($M;GDJJ4E\FO2Z[=!8'9TB?5Y9DSCO1:DXM<7,-G&7=.
M^,3]NH23_W!.59F#K.I%C=/90UU%?$E)F]D*>\+%4?&C;Z6G0(?AH78)S[;,
M'M<HI;&F<\,BU7RY\D@"UUS"IT*Y)Z&ES#T:!9K@FZ8IQ[8B-0N2X+ZOJ;'$
MKW>HCX*VP_7M79JA@LS-(!B*QGB9?(Z*[CR>M0DB:PHA&X3!Y5 SU).'C/K
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M@0AU5L<, &2+E9AH-ES^TBC9Z**-YE(T]W[Y1)Q?R>1XQIYJJ:J5WW=7.L!
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MHE(72G"_7+$+?W2IWD6)-''E/_@P)3H++A^7=! Y.Z]BIQ;1H=(5Q1,%]=)
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MM(;T%%ONR^S3RAWV\2UF%T Z"G+F"%:&,9G2LXF^@T<X?AA=\%UUA[-PLY,
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M[X+AP;\52J.)\D2@QC>)9>@Y9(*\Q<86&[MF8SQAY=E:50IA$ISF"S?N<"9
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M\G;:U-AYNI#"-Y#TFVSFH!P"$27MI+-\H:5BT^P\\WWHS^8 ;9[D?<JP(!J
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M)%*XWM:3$H&GHNRVBC]+.4R1#]&'A;Z1YV"$D"3]BR)UL>5FHTC:$'AQ4*V
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M\6AX.'HDYL@4K>82"X0HDMUM_,SK/#?%V'.X0I&,5F&TTG"]5G8]68VSQWB
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M+T!B6_K!A4NN#XDOLT*P%D&/S%?YW?SXV3#EJ_C0QKJ^GXUI,TA)BY70(0<
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M]G1*:^F%NOG(\]DZQ??"O7SDN/7D<JV**;6K+3<I1CJ5< :YY1^$Z($/.LJ
M]E01:.ZTQBB_=C_N[J1V*B,(G\\'%I:;-1Q[@D3'/6<2IVP(E1[VVT#/(\KI
MG;E&4I"<O:G>K7G/-54B.6IF3G@Y<+,,<TS2=:1G1RXNW'58+G?M(M,U^,GT
MF[[Q=2RN6S!Y*8M.SH8JH>^I.J8UE79=SI<V9#*$MJKX%1)A*6NU+CQM6NHO
M](.+0[C]_ ^W)8EP]4+H*<LU\ZHLN$=+OS*:CWF+6\(S,@R05'D#Q!2!_0AE
MI^&W#5? E;V67W[:)<R^J@P5\87<*-=."I:1:8C4:@P8L'JBED0@^+75O\!0
M'&JKETK[J&$]',Y)=;60)%3^4"Z$TH:^#I0V&',<CI:P;)HTX9WJ=XL\@-14
M,L3U]ABXP%O_M;N1%K1PE8M3:TE%F!5L]ED#4QTH@[E4Q?>H*8%+JMFC4G'&
M_6@#O4YRD_114*-)0X.<SUPQJ1^B/$#+Y\5<[=QY22;\26$'88;GKP"<'//N
M4%ZBOCEN)@EW:A$*QAY;X/GJX$<(\C'_(.D\XI$$14X5J0#C"/\V=A/8._3Q
M>PH46"$>!U=K9U.];>CI[,L@?37(R)Z840VGX/YN6Z@5KDM1!\@N1GEP9_:6
M&K]LW0PF0NP1LD+Y)I*?Z$XM5^T!Y:E^K'L>N"C/G"T&!G?%-KUT6]J?TO[X
M#4Z:2ZEK$+]NV:S#,0^7MY;^J[AS]U&3?)I8RF>@R$8Y%C1D@>NSQ=F3B_[1
MM_P/Y8,40XE3A6GA=5H8"@O=X)4+)/C ':+KP2&;[^N2T;345QYD->79&:'5
MY#;H]]-@J7497</"C>"8]>FQW[*H?@@-&R\_.YO2MV_4/+C>2F";F?I)X(UL
M&UDS,6NJ85M%DZ'U09J_$01&@E50IP&M,-G^0E?)SP7?X3LRD^]16Y\I/>>.
M+_U=-$U$DYTGR*9P&'++B<O;$2^7DC=C92]V+B>G5I4!%<CS:%0X;;?-0NFX
M)IGE_(WT+UQH(\A .R954OEQXV()0CX0'D CG&E[02M2>'8B:O7M2XJ':H%V
M/A5&P-;\L%R\WCFY^T(+A<4-I[,\/%SJ S%?G^V&E1(<_M/E "(E@S"8'<.!
M^E]"Q01(3-0)%D9_Y$@:WT1Z&^2**:2(QB<Q(FPE&L-AP07\7!SBG_[EZKL6
M4[WJ<%3@P.J_ZS2VC^!U2TI?HP91+)])M+XN%B,LYY'1+_+-A<\!V 3O:[><
M-//=4M_KC@0&4&F*)[Y9^24-^9PK;O0J/=T_W89;2_E;O%/05YVPU$F;.=S#
M$;H&IGXL?+GTVP@%I.DM\BN^S9I*\52#S-W7:QI6YFUV6Y1,]9/YM,:Z0?"9
MFSQ9[*U8N4B%EKCAR,(_$K^SR8;@F>WL8+;ZR4*%ISB>.X#7Z<QCX/SB)#@U
MA.W4#9ERC'LVVXC!UIN5C4-PB+%Y\S9ZS;[,OS5[#M$>VI-7F(F;XA'0=CRE
MD]:T*9H -)REN\WV;&:3T*=,1&0C-FV0U,P<&)?@3P@V2N\"I+"!%Y6+, 1D
MRP>QV>T:R!-A@/.4%%T)B7(L/<,&9%FV2T;U[0#,TX2F\!(EY]Q7D]-[$09W
MD=U,JWDA8R OC],UP\X<>_YICP*A!.XEO8(N:SX4"H+FUSCY@<O.V9SG=#Y?
M?E//M4'X1ODA:GU:BHZ9W$$050G7 4ZY7">:NLU0!K*(9/U>7[N4FD4>C'LS
M5N$9D;P3(K?G(1O:[Q1:UCWFS$Z3M75):]MK0F(4$ 00-M<;=+MY/[J'R*!S
M(.(#6GX0<+!_5 0;;F3*5F$EI\BP^T=@1";3-L)]$960MM6NXFBT.NR\'6T.
M9:VS&1=%,F!<6PC6=;EI 'K>BY9&J?==V6T/@C<]$HT8 #PT^3!2##4.U*DN
MS+N1VXM0;0M[Q3)W]V__U[9"KX/2/5]#SQ9&O05?WD4+3\5B:G-$*>3SS@K<
MZJK3.)0>FFYKV1KA(X0KPQ#98EN+;<W85BSFFD"#.7^MW2U=Y#?_ % WOUU0
M-POJYOFC;A9O_*_MC>.QE)XY]21Q&O8A0Z2,A@6<EZ-],:8Y8S)Y\)'$V-!A
M?H#.+_KVD)E(SWFT3D5U;3&NQ;AFC.O0<A5%6@6+I2R6,F,IBN\($Z!2T#33
MBM0 &[M^Y+&;]=C7$,K!$&)U=UX8L!8#NY7&\YI6\@WM@P^#XFHZ\;<INXZF
M@I,L'BAX=!A]3PWLN@KQSBS+NCH0_7F_>BA[BW_#5'(0J4*'/.X^\+>!=$@0
MM]4VWY L&1*OF( 43)4^WI8'E5DD56!Q,VV1]);BF?1)<3] ,+GMK*L5$0SY
M_J.' !*<QC:R9JP+/8F$-.NQ)$T7R/R!-!0B_)KA]U7R' $ODP PJ?/D%J[/
MOD?J%V>;1,VFZO.-NAP;A'OPJ?7U>JN8% B0[!R,.T$E*U0\^WS G(:>-3",
M@DWUUFY?)(/H&108S (O$B#0KNY_J1[MH_31LR !0KP>#M4&K:PW'>'(AO.'
M*F ^OP$ H*%N>N!YT^%P,TD@H\_4;1VJC2<RR$ZKLJ4#YK)QJZ8XE^DW*(2=
M#)C;F^H8B8:O:\OM='Q:I1<NL0!$$Y\"\::;HE. MZ1[QK'K@PK!NX\P*Y 7
MX]!/+7<RZ1M79+^]\83^$>:\(904A$0HTK,F3P]:#DINE6W.JLC>9#2S)U<"
MI+F%["O'&J8,*Z7S5#T-N L8##>@[!@G=P4D[X&IX+S:U0>&7>.6!;\>T;9,
M;[J$D5J<P9R@3JRP$IPN#A;C9T[B9U8H<O;71.=W8\=(8 [VA_U$3\C3^&1T
M>IX0J1HLHZ\V/&O@_AM6=T6 A3?MU7/-O<Y*>1!PB0H!1H!<41NYZFL9FL^\
M]4NG'^[I (!]4U$TPI-#P& S># '/U,0";-6LCO:G>7BC J#O?N,;H[WB) 5
MQ(X<@*@U;?)V=9"#6#;C9/_-!028;$1!M)8MH]!/48QSFU[P:+)/[-*J+-%T
M$7D(SAB\OP93MPJ?!L-=%:EC."I%'(B>LI#I/OT;[#_[OHP1^'?.^/*J@73.
MEE\=OS-&T?4#8]V&O0@(D/ ,];ZJGM]"-C+0?/H9[!]U8.Y68PHIO)\9;D !
MIM(!%^@81Q?Z=?2."D57*^/0CP3@%MH!S NY__YA)#!5*R/'XGF)SZ\9?O7O
M'__AU6=G9[B4]U2B:B7(7,()T6QQ*+@GH3Q3B#]@\:>IC+YC=>C9UQ/LBZ&V
M1T_F4/;1]T^<.LR51FQ6!%0L$_VH+T=RSJ7?5NYK_$1+;T(<PVDG!"^XF/(_
MZ)49;+9NMV=&X6*8!</,],7,)/8&S(O*XK$+E**5/Y4,996[*N&-"?K&LRZ'
MDL#J!!5F>#V_._,EA?)4W7[F\4%-H+%^J\)_%#X.YY.@7/&"1F7M<J_.^;N/
M_\1F<716OU?(N[@2\%8)HAWS;@6C10?RV)$'R(+BWC;M@Y!QLP&[I7<I+VXS
M<;_R_G=UUP_LEMY6,D%XS\B.GI-8]A4(%\3=4!7?A4$S(4+AT;%7KHACB4>^
M)]'PCL?NP[TD@'K<:-^/)>@6$5L7JWL7FFY!9BU>3JTO#HWI<Z//\>7BLE'H
M[:5.8&982)? #'?DC$>W:2@2Z#(R61T]!0]P#E%L-L5ETQ1>R^#C0-"BY07#
MU@Q54VPNYFV4\92893=E@8QBR<\QA@+#%T9ED[2PQ^CX;#@1<YR^LO1#-P>X
MJ)19(E+_AO(K'^RP*;NN?8@3+/-6S6G_B['W? O/[^VJ B&['?O1L1TIJ& 4
M4VW-PY:Y0]N/': C@6X@BC(NK$X2OXG7DWVA,^;H_H9REYBB+._+U3?-ZKOJ
M-%1$F,@NZ^,_%*M/7GW\,6_ OU7E_OSBNR/YF]<$>=V4[@"[Q[MY[<SXU_0A
MNJU/7GT6?78SX*<??_8;+@*Z@TUG/IWA<!DN^0.5=R,G$"@<HYZV&*W[$IP<
MP1*5(U&^@D<#^S (8S@+'LIS?@&[223E1WGES_5ZYC2GY_C[=V^^_T;"@</9
M$*O2+)F=R9$HTL5FSI7@,61BK=QB9RAIHFRT9'T*)6GT3*6^17M?V;7Y4+B,
M?K>@JA94U?-'5?WL7$8AOD[U5F:]@$0'/!U89(*NX "9Y/%H:$&IG/4U)=J1
MQ_^MB[^4/X#X=SC-IK@&K] %(>40-$1D!#!S@YSV(\46;CF92;YPH/F6[6QK
M0V8VLT6?;+',#Z3G;E$+H;6GF'V^QW;VJ^)SO%#V<TM9*?K,1YK:P0BKC%BR
M&="[N?PJ$/0^FWGOP$"2I>HQH[!E/++G<FI)(NA#1_</K=^ 99^JNY(Z(Z1X
M(^_(/?SW'0D'E-W;U3=4J*\0B@L;I1=MIJ'(DWH08AS!<#_^NZLHEQ;>@X*#
M:>Q:#&#39#1F;X<7&"C686D-NTDTC&X:\4)%=M9'U%33Q*:-8GC]X4YR!+>[
M&V\#,25#S82^2,?"&A7FTCRDK5&/Y\OU_.X:F',WI$&6YFZCN+@/^ YANXCO
M$PF?Z\T(R?G @;VM7?Q%T=>4#+O S]IQ\"P7:0^L8)H02_\;(0(,=<Q4T(+!
M 7H)TCZOE3S,3HZ:1YZV<U&-(QX5=^\TW$F,;W?#7@;^-&46O@L0D=AD?;:H
M =Y;&MMK*O26M)V$';&U+.>20'J>\N8NQRJ.04O4+CVWSG0]-L*(X'YA%$F?
MO@Z?I:V]Y)KA8T$+J%[6,[2 U0B_1HU5!+E*.?N4ER2MA@][[+-C51(] PDL
MA)=;^)3>MO\TKS]5<Z\DXA2^<F%;$/ Z@C=0=(N/]42^=;<9C[A7:X5KG_E
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M*(L+!S8C$'U^9A*WH"UM*9"NM5W*0#@B+:SX#/>-(2IRRV)]. Y5<4F2R\Q
MDH2]:B++VG-#?\,*R5FB9U&3G?[<:HO&!$G0F'U:E_K:/"VG.?L6Y;#LN1'X
M5MEH"G],JR01LUZ6[#<#$DFJ+4D-[Y; *0\/ ^C/8/Z8S-UC_(!6$J\<,U!-
M<MO1XVW8RBUVSFQLQ'^/+584@6*5FOY9'<[DW%"(H;=3Y5-#:=+>P#6[0B1[
MN=KG P "T5#4[EGAM(#X?'?X]]%B<#1 M'V@^[ICJ_4UM(L'F#_# NGI);PB
M9XC"^Q/JK_YM^N*QE*IN*\L.L;"E'6GZQ75J)A#;ZWK0L:)1%EP+/EH#J"V"
M;$  $TWX$PLC")70.1NA[UE6M6R%KHHV>:B9YF!YK*G 9'386WG3,.>PI.%7
MH6I! #'/1 _S^E"ZNK]?NKI+5W?IZG(4);*5H0P/-U1H99R=?\E3].:0BMLM
M'8CG. R_ )Z_23 \A&U1EPDM1VU=1;<BY:!!<2["-1X=MY(_9G+<F2S24\H;
M_O< /)3_](-4ZTHY=]6C\O(]58DX/1-K&@(<&QFBDSI$::-IGV!>CB9RK)@W
M!86(>6WT;COFIBI?1@*_E_OF5V<._ C,.=RAWM6UB%0U'@CQFM<3)-18>J70
M??*]++#@-B^T4LVX^:XBBG^7 ,A#1GJC'(]8N'0D.VO!^=$=I4>SOSZC[>W6
M6I^E?(&#"7'+!HB"M%;)8%P?CS!O?50MF;TFV1L-'0K UC-T;,NC.S.CG3ZX
M]7 ?D]]P'V!PB]%49Y\([*HJ@[ZPEHW E?I;/"NFAK[U-1F2K-K5#(F@^"WR
M!E* XA970G::J^+.D'ER?7.2N?'J]A*%1R0 'GQ"H%?#%CH=ICK6/2AV73C(
M\TWHL#0[KA\C3*-&GS0!G%,G?("+-S==E0D:XW!?R]&>8D_P,Q('_QPC%C]W
M43IB5)?.SSE9 SX89K(M&:BLCJ=#>R;SPUIEWL)<%H:C%9>&R3TT%9ING(A-
M+L>G: _1:7I?#\U,^?=)BS J1)]OREJQ 6>*56=6#YD9[;"Z'7L:B^;?0$9D
M;&H*-$3G1ZO?<5Y")^_,!(W;V0=*GN[2[C-MFP&D = W#HH=\8N5@N8HF"J;
M<B5[BJ8;7NS;AX!;D2/?V<!#V[V5,=SK*"!+#,PEDW [D]H//0;H@2D,JOO-
MH66NX"N%K\0!Z++./%ZA\XDXK/5N?&00O\_NY>IO(0"<E*\"K9?&5_R,_-3/
MH77^L$?7 ZWR?*F9Q6=02F QBMAFN&+2N#7>X-Q^V+=!1BATPG)PP&R,A>ZA
M3$;>=96(;3@'1?AR[8G._FD"%\I:GVV.8:X"E_/?31P">F&.U:O2_9CC-7HZ
M8K.@,\'+O,S<S2VN;0;5P8_+4]!A$:PN8'78O0@W+H7L-:.3-GL*<_+SJ#X.
MHM5:0Y\QR0"24KJ"'+=AJZK\$?XZFSA("4CD'+GZ]CBW/^?RGT4B0;.R<'@>
M3<KO@!>* WCQ']I"K,.FXQ'3,R TDVAP^L;(R6$*YT(M*R +W;]= -]4L_%Z
M;>6F+S^#O-GH.3+H0FUN62*Z('M#B0BKMY4;??I "?5< ZF_7BL97I1"Z%$]
MM>L16+&\F)TJL_@WYOL&[@SED@^J!%3)].3V3QKSJ$'1PZA?IR> RGMD&OZ,
MG=;UN<S#TG=Y8S9D_)>E)LS$D2H"F@)^M,B(GQ LR6R.4I(]:O4G,\& UDBJ
MA]G2S8JF/ZF?P"Y;,$BB\47_W%<E^4W2-6]E@-:B'$C,,*DPF6-3N4%V%,V,
M7A:X/)S[028!24V'SF'%%TC$H7= 7K\RZ<V0Y#_&9O,=#Z\Z->4,:FF/M9NW
M EN+[2'"1^.2YEK(4P7-GY>#\W)IA'FK5,/> YO-_HID?$_M($GA#,V,L/E+
MG8_46OK"E%XXT S*D[9?>8&SP("B C3?O^=PLT:PMK^\9,IG=#B+2)COO,SB
M/_NQ]^0&[(]UEG?^,D =V %6C']/!IPQJA)$*]V64=F1\+C^*5^N_AX-9[ I
MTNIZX2GI RK9O93$/(QO,L\7!?&)6=&*N.^MA2 K)HP#!EW6A-_RZ> 2J6=[
M#&5.[T"(I(BRM !B&G-1ZE/$%9< RV>HL6=M>(A[S$],'A0'3GU5O;5UZ%FZ
MIVGFB G1CBCO4-).E\:GBV/CP06:YA:KI#%X)8-,R73V-3EEGZRG*YXP.B J
M<*<DX.I47_5E^#B3%0$M$(8P"]+AS'!@.DBQ 1IB"URW^_,6,&"7&1QKKT)/
M3W>HMG?8QM'GUK6@F!*&'Q7]%.+ 7(Y#WF&.Y\6_+7TZ:E*,Z<N:@[:/LJ.%
MO0*I2;GAG%3K=O[1$7&CK&NZT:L[NLZ1KY,=4X&R+.K..#73CPS[#M45SZ(7
MG2H)ZU?I,VP/W&0^KO?C]GKYH328_[ TF)<&\[]*@_F]&%WSE'"3 TJ L>OS
M"GM/FL,M&FM2#D6SFB.H*!PP5224M+3P3_4L#OUMN^U82"FLCXM]!,H57? 4
M\J.B](;W)_F$%@DM(DA^3O%@R=G-]K[N5<>[%;Z3".(S<ZYC192Y8O+TF,06
M_AHSAI,OLV&!$%M?*N/+*NNMOUQ]X;+%>M!\R\70)"5>!*8[B^7F\AGJBD!3
MF4(GEP=0VIXIR,X%'08R,+6>F]CIM'\;5+-)8:KB* L6(>5%][A? L"-.A%G
M[ 'X34E\?4#J?SB;0CU5*9.N41G=)X6WVYI2)PRF7.?;L[ ^A,:GCE1-P5J7
M9.N]*"MW3)I+M@H;$[O-C&%!(KIG>CS)!<=&_V'#;[O24$F4=SYY#1Z5MP;;
M%Q_XGFX4Z3LC[U*"$E*T-_'01!4QI/!-&\CRM(W+.QKPEI8A\F[;'[F02^'&
M2+$,Y45NS2.<//5DHL:3[0*9A&HZ[VB7(6O%L^L2S(4,\A%+8K/A*^G,LV/Z
M_39,B;TV4M_9E?N"PL'/X[#U&WC*OZ'81A,WAQJCD%^3-%S7?ZCLP%?9(T 2
M?(.@-VUE<+=%?LY0 M.IV67%V8N F3&C?$:O?G)Y;*N85%P'<O.AO<98CUZ\
ML!#O_!4YJN&)/KC?0 %B_ER8A;F2HVXNTU0B2^IO,"6&B)O"8(;BI>YNR?=,
MWUG^A((,/Q6:(*+[<E>!)H].O7)S+J"-WFW?5M4)GW9F7!WP7U1"<%E0X:VO
MX!*M2W?Q>ZIZM7+8E4(S:XN717B1M@%/Y;)J+P=M8,%BD$BU^NJ+UR88LWO
MV<G&,#Y.AYCE&[[\^K5(6'*.;K^#9_2X$CMW$K]<?576A[&S(<I4YUW$RN/7
M*D^<QS-E7446Y(3F=?3%N3B4J05EJ,_?%DI!@GH_S_DQ7'5F702Z9ZDM<U=O
MF\.9IZ#=U5$&J8$8I6YUX,;MQQ,-^^A#13P*$6SA+K_*EC::+J(3/13'-!&3
MQN???J,SB_4$5PJ3J7LE5WZY^@[M#) *3%ZL..!>J=0,-PP(5&&X[A7[H@PV
MIJ_0E$.9/GH2QLPL/!F4ANA=>0+:AL(163 @%7H*-94J,7ZK'C'"6YPI?V67
M7WY@*53./K6]?6>YXZ!H'302@GM!G53HJPG@S&D0<,?R3?%GW7^IRL7Z7*AQ
MT.&57Z$9\$*.BUY.0M]9*+19 ;,]MEN<.(2&"N17C&F@-:D\KG%L CLVXG'J
MF37$M0+?P7\-^,&/]2:!46U<_.>>U6V,GAN)BEN&[8S;2;]@WM>@:R+,GLH]
M8(9IQKZZ&@"GJR2>H\]<3L\FQGD!.(!3@>$!GOB /\[CSM;1Y!@:T.C2[B3@
MK$](&BTF2E R#;MRKJ=849GI&F=&,65JIV4:B%.7.!DM#S21I$F"2)7Y1!J%
M(D(-_IA035^_NX+/VA@=S9N+:M_WY$#CUB:7[S%,5=+OZXH;-#N&3"4A U$6
M5X627&OYHG%O]C"<[2N+^5D8:A41QF8,%V@NVA5;WO(I+(N.C=8][29\BS!<
M5(V[6T_?'U;-/><P"NK7<FBVG?V2*0V&]Z[P;0.]2SR4.9(,!"!$YL'2>1]V
MU3^"/R/L5OC[ES:OLIY=>K2AU4U)ITM$S2Q86#&Q3C6D,&=.);,3'^OFHH4Z
M+CL.G_< .)D(4-?8?C&%,?XD0)>;6QQFS<UA5P2S]8ZN'\;M%*Y ANGG23Q9
M<' "=#?>JA&0S)ZI2G"BJB?NW13B6(QGS/G-W21$8\J$S&?CB($ZQD<^(O@F
M?;M;8QZ4J'Q8JPSH:HL@<//?3;ZZ'HYA?*6C0Z2+W2CNDP?\S83$/;#\SP6)
MEDMP$A&=$ OVN00WVDP3M!@CW4QIT+S)V2S*G(0$+F/MB)E&K;Y%KLW<EHX2
M=]=L-OHLRQQ?,H]0!IEM@.!^\WW3G0AU\07/[%+V6/KN:4]#/Q?6_]8:;\O7
MP-^'S6>)I(3:J*\4(R.79!\S,_+_SH6(Z+[?O9PAI:-)LOZ+#V3/G#PJ*! )
M%:0!P#2T01JM.@_NUW+,?/GW0HX:-A(E.=SA7.1NES.L_DBTHZ+VZSSA*1!=
M]]80@-11-VB-$'2V6@R(+RCNG-HPL5'5.T&5^P@=.L05Z]>@VE;W 'R!]JLQ
M@'0">%LUD&VUXU"KYQFFY#$02E4/N&]W]4]>O2I>O7J%3.V^WHX4RGTH+?,_
M+BWSI67^K](RGS]@RZ89!12:*P>^QPFJ@$-R9#A.#91R?L360HDF10%[9@IG
MEA)^1VY^<C:/O:\7\K TB,'S4;//^32,\EXU%*0RDD7JD,T2> R7\[GW%8MB
M>I+1E71%P"@HU(>&3[$0K.V$TK";Y$M/%"#_10\-3MAYS818-;<:E 2Z_(J;
MB[X$<_%M*.6CJ01::5D&=%"OW%RG""^0JA,NZ1P.?"*6DG)S-2YC4WHB:I&J
M]_8K]T'E==@UWR%7>CE(B^[^8._6SU1[H_(_29Z+N\#4>^<;92D-4QN4^Z>Y
M$@K0H_K*7*GFXU>9CWWY=_[N+_\>[2GY?F'?4YEQ@LW5/Z;%',W95H>6"/56
MQZH2#:Q-5R-;P#-E#,&W OU;BF0_W<KN:A$@;[5RB*I^M/U[<^U_N/U=[VJJ
MR7QCXB+[><U@2<)/KIZ\6#]#%48D41 @1;A=VT6/0$A1DQ/1((^OI,JW6^A-
MC"4N>V"'3"'BAY&*(TG)B;H9;DWQ Z)GZP6>70?D#&YQ+KY[2D[IV<E8@\#(
MOZ=<:ZG@%Y*^3O*LL0"4P6C[MI3EB^9FF^#I"?U2 73$D;Q8O:])1#LUK"K/
M>C'_:QJ']_ZO0PQ/7QNY/OF(]QS!;_JKE6Q,QQ;ER_R-6"MFTN6MM=P#1@3T
MMK2<1!G*B%W>L2O 7#*VX)ZFOQD70EV4KD@&%+C6]I:\BOO_?["EA6D-UG*$
M-6_*GY:'Y">O#KB5>^KD.>$,RXSLCLY*#E7OHL(F&-..5&T)VO<V<D<HR8>:
M)1(1Q4]S1^T\J6Z8[_>[B>4!J;E9E7)DTA6KN!G?=C?')4^KA%QZ^_<AG.ZE
M2(NQ7-'57%S+':9=]4+)B<! DO&MOE(@9&]'$*@*;KTRHU"TAMLM8.YCXXQF
M12@_JNNR1^?; 10OEZ#[*V X3HK=% \$IS!O%6B+S1B,Z:K$U0;/$A@8M/M*
M2[NT4O_K/FCXCVRP4ZM<*%6:OZ>G$A4T9VCHBO-WB@@:O*4?(!-G)E_7>.[K
M/H /@8Y@WTD_7?4T>SW*\%G<M=68D6L2T1,D-_U$A^0,=T0NORKGWN$DP;([
MVA> 7G_]-P:(/-8GV&\H /NY18FHY01G4R7?]5 2L-AOBPR^:ZZ>:O 566\D
MSJ;(.2)T<84E"CE8(QZ2EBRHSA$?:C^WS!(XT@&][<J'"*S#A3>9T#&';[+5
M0J JP C&5*(-A+<(;$QNS@4S,N7Q\AWZ-/-N+,$)-J\\[0+- PE.<V1N:]5H
MVH;D5'8*+?X6&86LKI'JHZ_@!#WS-I_K^7\3O*EF&IR.U]?](-:ZC8%.3QU)
M9/%-S%#-CU9YB8NGQ@_ZPLX<-ZG)3SFFH5;(,%$;SB!!I^@RU'SD'?>L7EYE
M7G:8S52AI,8%9!T% _0+[>1& 0^:Q$?F<?]^TL"FW<'0@YZT++AW*Y*OBEP0
M#($-VJ31R]\8*U]D>H*L'4L)3 * D%,!?=;)GX<CM&19Y=S6#2"16;R^40_W
M^J0'7SSK +E.09VA"QK?14J$?V19'EVQV9M0-;[PF-[[THY(,[FNJH_KL>N9
MBD B&((29;(^0#HU/>);.2.:>DQ#^#8CE4,N>;V748KS[P6H%[(=1L+4/9?F
MA%30P]W-">;/#F&J*LUGYD&2J9)Q.]F@V+WFNXAI/_-]YPL/\_/<&HX]__RF
M\+R;G SV/*#[M]_#P3(3UEV3X$F_KCKTU0,!X=/R^D43,6>UEQ"?<V=!?9M+
MW@%N&CXW"Y+W,%C^]N=ZDE\<9T@HN*-M&>'"\K[J,?2@<:B J6),"!'7Y?/D
M*7^D;NC-CHSX K('RAP>1?>^G!N3VG4!(*977TTT#GYDL$LFU/U06M!_6EK0
M2PMZ:4$KR,P*UH:XF#UT%P;X C]1C:J%>T.-.? G10K%,'(?97(0&D30G_$&
MI?4DFQ ;Y@6<W:FO_JS_\=E[K85+]:L7LG<_?OG)']4*G)4,[?'/M#;ZHZ$]
MP9_CKEX<RK-SFG_>U3]66_N6=%^SF0^=^]\VV6-T/OS;1_87[_4(&(9R!BC.
M#G[/W>MG#WOGQ%^X/;&AC?30E:?/S V(]<F-_NK?/_W#'S_][#\_&K;VON(/
M37?IN][RC5N<TZH+25_6[C[SCH >YB-Z!1_AG2T&]:]N4'%'@*$P+Z@9!_D]
MRJ.K@RA#8;C0P_) W;EWGJJBJM.^ MU[NT%%V_T1DI:-QJQ[=U%HB;K_)S9
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M]+NRJ?^I3:'L*W4O9=4^T$WLZY,P11&3"=L=O>J*%F)?'?PYG-"X\9%4'X]
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M_(E%$W1'TOXTF7PR$K((-8@OH2>#@W1&,^#"Y4^B%39596)HOY;3!#'@'[G
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MEC+G559.E]3R5QI!6=LBAZ2CW^O >)R!E72B2;?M%<>Q2D=IYM1MGO?\:07
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MU^9)-K?'"'WTGRM9THG6RX0VA@^0UA#R>;1)0OHCT"A$Q7"\4RU$*];/I?V
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M8\_3B%("'RG0/PGX\UU1>Y;0QX4;E N/^<Y<,542Z<MC_)3\[;U'88R'@4X
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M.2XPMY9LCOD%@L]SZ"4\7=*_HB(ET.%FTQ/S@S0"-"M"Q])UMS6?@5_8]#Y
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MFF7%8P(:NKL4@2!1)7.1A'=L#A0P99FD5$NU)'MOY?L$QRF[[5%86:,8TM.
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MIS<1LK.+@0HU>:;:3OSWOWYODVH\;YN%H].=4\CHB!' [;:DHZ5/BS.BS*V
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M (X0*3/74 @)]M7 @KX-HM>ORCV7/F<:.8R3"K]J><JU@9QQ63<E-)/<B:_
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MW?&,:Q>"_!M85M*6H*= -56-*^4) DV8QOJY*$Z &];5G^%$XQ%7^;DT(OF
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MV ^-6KQJD<BUQ'HL6"H43G"7#,+SQ?>_J*:?(C$NQA2@#R#K=#Z+9"L?P;8
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M-YOFMND-\J!=\KZ).14Q(:O>##F"V:8UL6P$G$P:G@_@HN*:@T-_T^.'&)K
MG+H&N!8):B(!IV8@8:GL!J]O?!8CG$DN2*(*&YR"9\D%<#X?I&%!"]N^+&'G
M![,.N08RH"<UTC/\491BG^'%+@$J_ZG2I+]"EO3C*$;_VU,Q^JD8_<]2C/[-
M<(R9)4+8GJB36M[WNME1.?549<ZU(-@(".ZXJYBFY4$K+M]0%$;U7 ?EB43
M"<O6X',/]TK?Y=EHHEY<1(6E=<3)3^65*>K8-])*9V>!)2G_@2H(#ZS0ZFAX
MPG@T2OK:"U 0+Z"LR[5GR7-M#2@P9,^'R$7[^J[(:86C[9#5]=X'SDED.+V4
M?]Y*/0]\2*X/XPT,C^B'(0D[8^=M>))N=:3W8+;1OCDTM7+4%,*_2KAF-(7"
MSU7,B"8CBSTQF+N>CM^WC;2D,!3QDDV2;"_0/FF58JQ5^,4J ")H!XI$9*C&
M=CCOT%CF[=X/8TPUQN9FWA8D1%CP/-DVBA!_[)CMNQQVX\;A<@)3V#3->Y<"
M'ZQ74],.*R?T20(!7;=7><*H2O@(RLYOA<#R;<2AT!)X341;:RR;U[2;"-&S
MXUJ*6,/_C"@>^L&78>38U7Y'$!1*H_ _P\\7G] /1*;N]9O7*A%?1>-"&H/+
M,%9$K%,#@$0_^:L-ZMN>@,%OW(C23;_9[\/XVVV"W7[Y^>=_-C7ZO[Y]\XV[
MF30;@&MG#?.T7))>&?_3(O-ZO+YE[BZ;5-_%9_U.X4.7O%4Y!4ZQ8."$EYK.
MC6?,3('@0*!0A8L_7_P(C!%>G9Z=.[]=R89[4Z2S6N\>_B8O'!])50!U22<[
M=PE==Z-XI'.-=; VW;$O0P DN=I$:'-\$;W';5@D7! O< 04U(7\>5O[X2P\
M- 3(8A7"G<C\Y"]>)L^M)7<\<K>/9'H7/?;SQ1=Z,@7[^>*E9Y%DSD^H5E#_
M/LV00_3L.3LZC!1#:7>O:TZDCEE7K)D^C <N\]/0WJ#4%++)KM N5S2;U1D=
M,N=9PT'6];%6>9MR/'-=CXZ\"!_7UD8 M9OM]IF< ]LR CJM-ZA(=T4L=T9L
M0%W'*P5FQ"[=!TKXV*D([O$;*WYQ_F8N9-:UG!AY!@-RBE\4YE2%3^?H[+IQ
MS6ACI'B,XFY8>>[[L0H:[D9,[Z"AU4::X'\),\M"JX%.'H=[\'TOA>495$SP
MHN05TY]-UNR@?#[IBB2.&&TZ)Y]-Z4'04.Y$&=V/SYZ42I:O^BL;;R8!CPQ_
MXGV.3L.HLH;O)(.)ON9!^I]!P4;("O#=21T'#2(0H\6"H9K E4 TO@T^?Z<S
MQZ(_J 2)3*<S9*K!*"NHLM0**OKM>!RUK0)EZ<FX(D]/9]$H^DKNO G[S@H[
M2.&TJWA9/2I(N+ATAK51V@)!-'N_65M+[;+J;,H.6W)K7(,*A0R3/F V?C$0
M>*SNWT2N6>+ H2P.,V<@\O3=,FDPBII0JM+M+MXMM[*J3.D4[2#K-"0CW<K*
M+>V^J+3L"GT,9LJ$_J1&Z)[M0'P[+'>_ 0-KW6XC??SI;'"(:J05Q<D>NKU*
MHQ0<H-T0FZ:+] P/Z/J^QHXKY&G3UBD>;DX/S&=P>>*]?GA:"58Q+>0:RB!?
M(KX^]C=-N) V$X73E?@PW-FJ4 RF\YE#.U;:@\KDG&Z)H-8@ZZV/D.LC=!L9
M8(_/'+LJG7M7Q#G;'0]4!JI[<C&@A-6(AJJJT@:+-&&8X9YO3ND[^@;4$&QK
MF7P9CC\F"-YIY2-&TY,>2NWS-/ 17T"(6C5&V)GI7K"S<G6R .'=E]]^K_$!
MLOF:$M+JQ47H1=_$3"7%-@OCV6GG+D<\Q]4QG+E5)%I;8.AB] V2'974W=:B
M1.KV]U:N#+UVL,\#J0.^':6GT1F%>!W]YY+/!2:RB@QNM"3Q>>-H_&0JPD/M
MM((R=MVVT";^097I>PWOF5*&):'DLIG\!/N<=S+39ACCMA<,5X7D$\HI+KU6
MF:.K.[&"5$6_?M\T!WQ;"U?AJ^'502L4"XJ@S1E1DX.>W*X3PH2:UK6?JDID
M916@2O]9.&)R 6X%#N1I2YG8J9#N/)1\>;H/5EC:BY(,ENS]: _AN3ES)I#>
MM*B8 %GA;L" 5KI6M?$X%L^#H\/'*W?9QN2F<B*NOO[V+;_4UV_>#N9U%5&]
MT\Y9IWINB,YD)Z3P$,$AI#2 O+0<PB076.?3'[5]B*A+PW<('MI5A1-VWQT!
M08MXW4ER>CK+&1AN,D T,+^?7+=/3L(N%B%&!',E'QO-<#<$V4-[R_L]Q['>
MN[ "<S1]N>S:)G-/3+F.JO$]JTR<*J$R=Y?FWCB;KUMN>'-G;NNSXN3@S[R.
M!"1=?M!JJ[B]P12>)/<_>0&V5&R3MAO_%V7.N$ \7J_[^I;=5O_ EAA1HO9>
M]+W454EN7DV>]I*NNVEW2(0M'/D!09#D$6G7P27'#=1+IB])\[5>9CIRL[E\
M<5,8!(ZLXGJQ;<813%:K<%P(+*N'*NHV>L+TL#^%/28NC [;T+3_(%7["GW^
M>_-ZQ#XOP;1UTVW#S02>$!YLS:N U5WSX@#78G9:(&0O,7V_B);Q0R@H#&(9
M3%\^+]WDM&UD[; AN/%^#S[XM3",4=<0'<@?2WW_WY_J^T_U_:?ZOA>O.V^:
M?6?9&8=Z @9BAWF.*D-4<GR,"?%']ME4+@>@0V98==>S6RFG5K24CS5CE&J[
M4"[,E%9;U99PS>U;<E9Y75!V+VP$XJRA<.VAZ<B50]4Y*P8^9I8F*F)Q"._B
M3L<!Z?')VB.Q9[91U[8O<I65].R;$,Y,@NTB_;0Y\DL@!DT_HUKL:X AD#08
MI7&U^ *QU8LTVH5]44"W-H6<4L]X Y0)NFGA=,^A]KDA=U*7'T)$P1Z*5N?K
M=7T8!>>QO^*=T\2Y2K-OS&/0'=1]((\@_XY.JB(8VRD@H,"N&B.$C,&2M.DE
M5WU'OYNA7$SD)/8$ _<RD25P_.\'8;&$^:*62,FI27E:_#E)X?REG=_"A1+_
M7P67C#^\?%5D&Y#/7('['7;O7SYK_Z?6526GTP$,2BD?2K/ F;()<98@V_U)
M<Z&Z9'?36N3&.>S/<3I@U2)15Y@W^(_=RDX9%3/\>$$Y*M$WXN2SIT8[)V@
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M.1&:&X%1-;[;MCGQ<!P$]HUZ.S5U;$F/-QUK4)9\V)L(U' <F]UA-)8&=%K
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M<58J46>::2>JTLP:2G)4NW#TA3I$A=^B'%648DLZE)1OJE7^+./U?:Q)W->
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MQ48*WMG=(7[F&P2^V7 < 2]VG3\PGA>TSDQ8LBKHL3OAH[)IE3/,D\R+JU2
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MMSKZ#G&:D\ ES=WR0IQ:#\&:A+(-*6FM6(]:=Y.T<=TTRAKG Q!7=-\B5W\
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M*EZMDS8AKL!G8L08[IQ=R]D.,89, 4D S6^,&BK3?ID01T-M+Z?_SHC$(Q+
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MS432U9K(-ZW#Z7:*39K !1"O(I6(L($M^HF,U,-U1X5VBF_2$95T,KJ(J:3
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MF;"_2X_-^'I,92+%O;3TK_8=1LE$@EG(,$Q:MQ.$>STR((V?:IH7>""7X_6
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M\GK='1C\S30$QN<M?3)LRE?D!QOH11 #Z)#==@-BT1 _2L\XS!9J-E&U.N]
M T>G?V1&FQ)/N+2Z*^B'L XU)W\='KU^SXW+=!W)W47,;#OH^YX\ZB,^/LL_
M OY-@WO<,[D4^@"X>+^6HY:45CI2+V'6"8L>'+-"S@24S+(B?W@ZE(>0KEK?
M$@B<3OUFMS/NBOH\TR<H+R,E7,R(?P1%PC\_%0F?BH1/1<)?P7^09!C9&3!]
M,HH@EO(,Q EWKF,0A>_ZP*F3L')4EN*,G-]=GYYOOLM"0#"QVP(W.Z\T5(E4
M6<L<O\=@COO(RDM])L2GJ92]2Q6M,NMYW(L;^P]AZHR'&X*KL:N$N$6$&$-
M=;1,3PEN'^[5C,)8&%YUPT>4,'M6Y@'P@W5:#;7/?;]?[)"8=HLJ>DB\VBIQ
M=8G2VWI3@=4IH9J6/2,H8RN+)YV8@$T?UL7ZAJ.XCO+8-6IZ7M8D-H@EI4(C
MC3$/ )&BA7Y2;*45U9![(GG?BB3[J(XN3>B5!118#!7#NS:4.Z7R*4G4TCI\
MW\BJ(>^DTF.]$D8P?/?0R5K"%7;M* QKUY2&^42> PA@N_FG?E%5R9*2'U,;
M*UP07D%.US==6L6\I!(RAH?LD8B-%;+TPOGCQ4^=Q?CT@;(&7S3#H1T;;1OC
M9(AU"ID]V#7U@,Y=VE)[4<,6 B3X?&+EV&''(BAAP.QUJXB3$/$_+8U0JEF3
MH=((3LT#R"?O*.7+T%!G:Q5\F?8WW]<^RPV[N#6\A64C/;7*GSA$ 3B7A._Y
M$@;Q3^\PXKQ&?0^MH4(JQ?[[\X!<4GN9OO'=#XN;XY;VH3C_<-76XF3S2ZWK
M'10:>QXOM64<\LN3^4\H1,*]PO!O-](V7BWVU,[)YI#2R<!1A-^$8V+8!1,M
MRJ!A-U$,LSON+5-">4S:(ST&2-SN%"ULB]$.(SR=ZPS5Q]]K;X4VP1<DFUU
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MA"6'U6'T7TV3HJ_(VV)( 25#8WIT>'6O_*U_R*2]-9A >:-(E$7YHE>^%BQ
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M>)/P-N#WV1KC'P3=R&AOZKI<9ICQIAQ"^ (J1D4[1IDZ5BL:RD"]]0;<<S:
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M#LQ+LE+14Y#1M@>K-[*66DY<3:P4@G7T:X_9C!EK\V TB$R0LUYON1!AI1\
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MF=N3@+U14NJ+DB.) S.':ZOQ:';NYI7OYB*U=A&\9VO'VM2>>6S/10I+-CJ
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M_=NWV=^%$].W)H/R!VCW<O)PC$"3^ Y2% -KKRI T\OT!SC_/ _B7LX_E(2
M(U#ZUZ^R7%>POGW^#.@-NZ+03X ( IV!Q+W.L0]/;<P?W:)_XR$!"7YFE_^%
M53ZSGT%1O,0@%-J*PSMW=O+@TVW='B907:C+%)Z.VPG5E;4[LBWU$W4?XR_M
MIYU?:/II78Z[S:"?(O88H@ QO]E9^=JVCPRI,@EU^KN%IBG'[H)XN5(0P%$*
M/T0-PB$9TN)HT?G>*WMH6'WE\AAAD587>&![#^8>]0_DW9*!\J<3TY=>$4</
MH.(-\4P@P\3HI(>A"^R.J5*EZ-RW NE3& $!ZKX7B9"E ,S$R\:_M6Z@/[=)
M#9G0 4GMB,,GUYC5D+#G]NE G@;HO-SN#]P(C6G%_H;O8.F/:5\!K5X*:,+C
M#@W8]$XI"*,K-0BU8_C=:F?LJ,L*-ZMFX%A7T"PG4(G"I$EC!C-"3=OIRX$]
M9O)V8KN><W5^"B?D/:J@TDK0A4 XREFS2<F-Z?)Z9UYE$N7'"H"+??3JW)6S
M?RFHSZ@\I5LW&W((T%N "B&G:B1.^MO%RI-KO."L%U=^!IW4W[G%?_$!."/C
M^K@<Y*"^@IJKLZGF:JJY.OR:*VXADQZ?G=T_.7WXZZ/D-/GU_EF:_IJLTB>_
M/CAY?/_QXR>+AZ=GCX(6,N]^?/[V]?-G+\]_^OGY\W<O?_G'RU]^>OG\7Z]>
MG/_RR[_<AZ]>?&4M9.RT9CRO&<]A]O*7&4QM]NK%C";G_F(_"6^RMU;V_NO'
M5S_]\/S-I^XL\U$S_>;O/V#S>G@T7J6OP72XO9XWUI]HKY@U=\"5_]D8]'?%
MGKHT&"F948/,3_7_V#S]P9PBIL1):^W$3_L.^O_9['E26PDM<.V='6"/XW:#
MMAPRL_Q6-E5!9F,R@\*="HT/\KQNLE+FPS)O:GN\H05MD5OK]0CM1_D2];$H
MJ1([I0@=I#BX91U[7<,OI.>"!7.%5 GVHV%?]OKZ^HB<U4^_OOK_AT=Q9#<;
M1C'&T0$+&3S>763I@'?3%&+@KGE1<H2MU\UB;5W:WQM@[Q%NQ*MRVVEVGT%G
MPB(=Y<*4U,A0-PCN:3C+=!:.8@6>FI$WU=W6[TMH4 VX9@R\;$?L/'H!UL)F
M@76>FT@S?[#:_RB4[.%Y9Q"9J6KH&$'M2ZHBJR\CE&?ATI38K")9E,WG.="?
M2OE\KB@$78N_-37T./K8V^)U4P%A[*BMO-U;9$,C'2=UX,)^=X.F'\Z2'LH+
M!1F7($?T*=(\G]1J</G<TVZ.[)N_GU#?T.&$TI<;SCDE*F=WLKM$&%A##W9.
M15XFE>G&M_ ^+[GMAOUA0- YZC?XD@5B]DK4L< R$J,^F;VU$[./.P=:[Y6I
MP*=_"X^X*]$5O#<J P%JS!^X1NRGQW\5:1TU)JO)(#:!$\FLO9("Y2("L3**
M16@>(L@)!^IPI;KOZ3[V(\B4H-_\9N=;(V7(X)(L+ZEG^O!U>VZOIP^S\_D,
M[MQP)Q+[^!1C*5B=#)WD<$"#]P&%@.YD+ U"2;:2 J_N(D:X7F25]$(P<?9/
M3*?]!MJQSQX\/'MP)[F+[\1_7]R=*S"R7?T[\#R.Z/,C</]G+T5.7S-_E.HX
MQM^7O\Q^*8]F)_SWNT_]\?N(#/J?2U>='J:NLJ=;"7?II=V0K0W\8\18"LL-
MB#>*,/K44E37:%D+__+,*A![BD6$T%@LEA5FH>!'OO?9*%432;["H6^VEV4%
MJ1-\OI5O0T?JY,'Q_/@8_T>F#;_$?NL0#*V;&V8^B[B^L:K[!RBZ$8HLV,US
MO[1O8>UF+V7W1FJ/TTE[W/RXGGT]VB-ZW.&/S"&7( <L,*'1":XW>=9EW1?$
M 9Y=4D7:J@AT ':J1$TDQZ'"JW9AMM?0A_'+G\LOIT^8]ZY&9_Z/*(,?T>P9
M8]4XYQU(>7->>"QTIU::5Z;@DF3J0NL$Q/>WL?]6%M)MH?4M[B?9 *P"\GQ@
MW:5# 0%'0"^)./HX,#9?H%_^7 9(8<6R0GRAZD728P])^R=!(G:3O=J"G<]2
M0UQ-P,A=YF![#0Q?*]<W?#)H'&_Q9(Q4JV>36KVY'KM_6&KUN4O0/LL3>X1>
MOO05TO,O:U=\V;?!$;YM2RIZ?2D-4\[@?',U.W<MBEY9I\>GCX&C$V!A$FQ%
M[+YR<@D< (\@2 *CH@%AYOL'IPTT.\@)*@2_<%B&.<%O_.]-4N49Q.!-LKU$
MO\\>/[;-H29UC7T\M:KY@05KAD('7QRI:.Z+HL$N.U=9BIQ=@(P*O'*$3DE;
MLI10/JZAJ%V.\)D4>T!@!\[?&A9L+KA9]K9UM(M%4#SY$B<.XP$VVE&/L()!
M"AD:AU#BK\'K-5E:MR?%R\%=@Q%*\$D!C]1X#PY+ ;])( 8MLEIFQ5:,E.<5
ML.3]1[+>/(7TE#W2/_WT&FRKN-5J_6<B10:&QPO(OT"XC4%D($0@UA#GR:RI
MADVE,BB<G>WL09YQFN4'LS3H"Y^=2/8O/'"O*ZN)KB'W=EE:^7]6 OBVQH%E
MM0<9DD'%\S&40*%VZ.J=D<,KX,;0^TL!\#[#A8)@P T4QX/)0KFY1#X\K ,B
MCE]H;V?EQKIYZV0.P8 CE%4QI0OX!EC<KW.KT[4HT1?PXY$"]' 2H)OOV*.O
M58">,U$02]+KIEI>8IBI+4C/W[Y^/5:$'DTB=/,]>WR0(C2'Q#D$H-*KK(;R
MU$529];Y=MTLH#RKJ.F*2BH,"5&Z'R[ T"@L$H! FP]FV5 ?,6&SQ7L2HISV
MX2;E5#T6SEQGR.6?8Q^R@.M6RZ;Z^)D>STAQ?3R)Z\WEX\E!BBN)JD.AC,K^
M8WBJ,. 9)L K":E2 LSH*C3!S) )5QD7K;)>)<AQ!J_S:14 ]R >9Y5<(7'S
MB  8N6_[0__@I7[+A1I#L:S0IE2K,O)</''G@DIYHV?C*X!:WY^@UA/4^O"A
MUM,M$\$>'1_6-?.."?4IG4*UO;XREXJCB?:<>!<@QK@BA(]IQ2;' "NYPB^X
MT4)8)5U&Y>JH1ST?9*'[\P06KQ6=/"$ >I#$1I2!;B-8]@8.&1.MT6#]@ ;=
MQ^H+X;\H_#[NNWTX7M7QZH]BG2@VBP6#4#@G)8,(0M^_+6"6C$O3N<%& ]:\
M:>.SVST@%H5$&;6=8R=/ J@F2E6TU NP/4P][1M/[+.E[<=.]>P/3C46_P=M
MZ+*T:I88^6UMF=]:MFQC"V&-;V;'@(L^%,..F)[<-*&LRX<-5,&B+N;D4H#+
MIAJG-X;J1%+T-LN5_57P>%R$<O7#YZIQ^H-@[G#X0WD<^R=)9-5?H&R):'4B
MQ4 TFDK&S8$#*,8 =VM"</=9+?UT/V]W:RL-_Q>K:$\>MXIH#\3F&F-1],G*
MI;7)%$Z$V*R6>5))=N=C$.2W8CVT,=J=ED]0%Y-D<)DXB-+"U%0I#_A2&"09
M(1C+X[*E6&O<=EG1@(9OG\4!0P".:)OJ9$@]O7CU!G0-QR &OTK@ OAV._^]
M!W&$TE$OJVPQBLVAS\B>=,ZD<VZ@<XCRQI]"(A&*G]@1QQ/K-E7"Y\9&)^I
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M)N+(9FNP.5P]I+U;[-PDXC1N/NX/9..DY;(AU\D.E4C6I.C4A2Y&M>!Y:\R
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MIV:9I4'"T@_ !\Z^,CYB^^8IA3BE$/\L*<1/#X\G6^#)@:.)."P&_C4G_-J
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M9R>\!69'MN 720FH-)ZL0S1+C$$:EUH>K@8*D1NM>V'K?_!<%FH9>J;OIJK
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M'0J;G@=%( J&1;=\8P,(3CF @ ,(FA] T"#U5$JIR( ^J9G(G^:R5]$F!5<
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M?VM>-!.=FF9T/J/-4@6H;1V[JZHQ*FWD%K9R+FSTML\2+]5?4HRC4Q8':1[
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M@DMQM0I%] 2\E8#%Z>YXP\"B)Y1LGNQE=TD1?CB@L5V)C6>V]X3"C>3P/FU
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M8C6X1\*%[QI(JE6K!2O[F[P(:#+:XJ+?/]RJ-?0S2+@$;4?J8GI-%P"1[[U
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MSXR\7I5LYISO4(L:.NGU5WQ#)[W^NFKHI->+WI\9>KV V[UW]1DE,NY*<GW
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M8\0[JH =6'3P;7>-=WW!WJ(7^%VFP3:*DWHH*@93<4'0ZT[6.J)@[^^"+ J
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M19,V6.4@='01&G\H;Y%A3JMN48CZJ)I.$_@3R(./=ODV<+]A:N8=9:,*#[=
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M8:@$2(WM4YYW(!-?8]_<53#8"!*$"!+!4^4FP;>RHMK!7\PFL%AK;;_]Y^G
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M7PCB)YYXW4;GW2FWD1=_<NI&G?X\VMT[VCM\4,?</;FM')HWO>_'5QG5H):
M?N=$IY"@5G :?06=J]!2W>?T.J3+[Y?-N]>^T:VRJ\J^H_FE&Q=L ;X#1]@Y
ME8LG_4[2JVVOC7<\K\]59U/<+4JN=%F9>)20#2:-Z<RUW^M!W+(R&F^[[FU6
ME1F2^,AD&0,71 ]AD26:T%F-7=4$,%#M<O;%_%:C"6<F?":F<_ 125*\:4.^
MVA0R97<5P_ SB^T^7+= 5-BR=$'\T7??9*K(J)0EVMPD>R9;7T0)OL/A%-(D
M8;%3CE,TD+^C=1=LS>1%JX1HJ6O] ,/9XYQ%JDI6(S:SP:OT5@XE+;8A3_*
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MG1@_L/>+T;6.*B"VO<'>UE"R7EL^EU;0_Y$70!SW!1!] 41? -%'QS9*#)R
MRISKB2@]Q.6MT>%W!W #W-P4H#,RRWV.'7MFT]2./E=KG>0&Y"2!0S;46F*_
MJVLD979A"&<*[\Y M]BJL[H*D]:U'6BNJ6$,MZ$>,X"CGW^Q$0E4=TCL?Y<%
M"<$;$1+E&..J)K6>]:8(Q/ZJ"?:V*,G?<FJ0'ND$!J=!;$&-J@$Q"Z.S(=H7
MCDC:7,CX=JK(4KK&D48;:4Y]P56618C-#4I@7;#4Z'/"EMEDFJ7L*>&R;3,+
MMRU,&T"N&UVE!4S7C2SB@Z[5[44:6].@U7JK;BS\P]UVJM589=DN%=W;U!K'
M3JC9O?4[%')0BF\N>4.83!"/XX[D!$,8^%2[P]%UK,=.U%?\2G3UXS%?>DR]
M3+-YCX8V.(&S3-P(,@HV#BZSEYB>WZ:]H:U%$3:!]0X9CH_P,'/]WY7M!J0Q
MITG?H.5_F^6?069B-UP:&#7YG6H:X,GE\#:0EH6T$RKTN,)Z.MD@XV9H7S)W
M1SI(*S28DD"6R6P0^$RB!+6WDTMPVJM0\\QVUVF_?LN>/AZZ>8Z9;V A$]#U
M5\A>%$"*F,X&L]AVN_/@];E6-\R'20OE3CS%M,)D'/+;Y181L#T3+*GD^7+9
MX&T>@RF88B89]N<A2@3;D\%,VQ=TRYTL4@PFL>&]-3/@<;8'P0DY,=T/>?+8
M7AG(=]9]?[N2\SZ#9!:,U525:+X2N1&;L7"KV/0Y0[+(M?7:9MVWPVZ*PP2^
M]L@7L:VO/?P.V;(:!=![[G_R=DWS#CWM6O9F$L)\;NY1P7IJ#<^=2EW9J6+.
M]6T)7^_YA1R.>#=0!JI_G!ZO2HP&4 3!$9*$CEMDB5"8O""2K%;<\51?P3E2
M\A\0 GIAHQWJ-6827*WV81< /_LYZ^AZY@C5MJ@8!.=C;]J(!UNE)DRR^C0Z
MUL&0P"SOC<)+'NM8+G_KSM,@SKWW9)9/X*$DZ1HK$+Y5QEDM-WBH_:N/;7LB
M/=5$, %5)6<Y8_",LJL4R"H*>$&<&,R:^:22#D2\?.[XUDI9=(4?U[=W[E#M
MH;3'YG84K&EJHB+-;;^QX$*F:BHN2"M@C6 86_MAP836<^<62P:3^1R3V?0O
M88AI-=%Y5H'UI*3M78$!/"0<KCT1/&/@;',KFR5VR<?0<@W;"8B:C/00%&"R
M@KXW CJ#DQ95$A19)QYOM$4O0 +7!^Y%%,4U1GGG<Y@?F$1X=*8RIP7C[ZE/
MN$R@\\"&*Y'VZF:#]6H6[_$W5YN9LA0(FO_XR4Q>P)'_/#X^.#QZ]A,['M=;
M#F_[V_+4UE?R_HE\4"L4NY/MPZCK> ;3*A]=(]=>UH?1@']Y$-DI=L0T#2JC
MNT)[&[1Q> Y)TG07-2R6<.F-V61A[0F$'3CNPB7,AP)?$\?R7$NNXPILGQUR
M7?WTRPG5DV Z ZA5THPN<N17UR:^#&HW!I^L<SSV( 7AC7?,;&M+TK#<#NKC
M!#T"3W+, F+IUKYJH+;<L3N"PZN_=B6&@GPT&@&RI%:B%K%RWD077();KGBT
ML_5MB)5F2 H3.B)87[_CO4%\G%^=^?LP-V'=4\N8U-P% /^2I4:@BYMWI%I1
M?\+;:SCN.Q[:*^,I<L\=_4@,_V];U\*B1DZ/OF5[U7U^-9K0R8IOFW\RW_(
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MRH::O-'#MBXS4^_G3CMT.UZYJR^![ M*)=H L*G3[$:GV-GO%5ZBJ.+Z0 N
M]T'7K>'6#6KIGP"B,1HLMFN%B):V4(UCE:VV-6Y%FBH\^.5$W89HYU5I@JOV
M(!]MS[7;' =-35U7&$1U/0Z\,LXB$IF:^K6:2C$7BKZSN%AZW^%/$!$PX79O
M*D]B3;CV&=+]2@B;W*"PJZ3.67B;C#&JZV43T%6LJ"T?K"9'?PFA50MPM;85
M2D3W3#.<E# T9$.1OZF O15&A:5&JXH"RU7.;?\0[I/!U4%9F:H" =K0[L9:
M.YI<ZD2AQ?#&!CT6%%AJ_B1J;3F!N=WMO(I!T$%'29'YQ.1<75M<& -1P0-,
M9_@FKGT 1;99[E>K6J;W#'"V!I\;*=QB!#TF:J6<#:Q^:)X&PI,]/D+KX=-^
M0(N#@?E1H(]&>07_+33R8V">1.=J1D1NNC(&%.7[K)GR&3 _QL228464!5?.
M6"\&N;M&FW2;;[]B#YWI2(W,( (JM#T:I:NGZ7RT8"2GK2,[;O ";HE@6;4M
M,W>1-G<$&89$-[$8RJ(-9XR(624EM=5MCKC=>XSZ6R6(89K:JR*>:AA<<0?K
M*6G./H7#Y4%D4S+J<ZE:Y][N-8PKE0X;QY+<JL4W8.;1_Y(.#MB8UN XLQ?+
M[;P\O\-A-K6>]A4:G17;W '8](,S?461"YC. ^YE;RVP9CAVD?(I]QLQP*9$
M4WC7"!Z&VUE3A1E=P+%I@[IX__J+W%_D)I*&-3V K*Y0O3(XS=B0>T8 M($@
M5' 754?3$GST4."GZ:,%2-/8 1Q5Y';'XGEP&FWI!C]MJJ5D+<FL,:VXSC_F
M-0CJ<Z/)<FC;H_,]"FN+ 7C)4'3*=KOE=DOF=K-G ;+N;+3:W:;9/0\&=S)M
ML-SHG]?*=@["27_'^SLN&0;H9^(N,W)96+8XXDC:QV+Q$(JW^F+:3P1XAC^E
MUC0S%ND6J@R__E<&_PRPS+G*C6G<^%5/ESU=FN1LD!43:O,KY#,%-LF-[(56
M4&Y4I"]>50H5*JU%)XKT$)@?L6GN 9;GV:V6\5XU'L>'7?,)%3\DR>*59_ 9
MK4E_F:*+D6B8<=,F<>FT&\27PA!_W3\,,=K2$W1/T SB&('Z'P;8;&.8Q,5U
M@T$:IUT-UQAR^C!Q8[07K@3#Q.D#();Z1+KO2=IQ85-+.WUV5$>EG.;C\);&
M2W!HU)"D2XAI,P#/M=W0I&RE7#;!@8//\DL!4<ERV^"PA?KT;/?%21WYB/0K
MZW099FE5>!=PFF>PN!U4HLB+6.M(\!N9=<BS<9IS2!<-><>MNB(%3,'/9B%?
M7E#2R#4ZQF%UO8E6S*$_5X-^Q6H<>FXF56KZ@L"[I0U@Z'I$K=\DM.VIPMJO
MPK.,-'(2TY,"?;T9GIDW_0*U0S9^<T$+X>8E\(,L<28+FJWHY\2LJ.D=$07V
MC%K!H4/,[MJ(_,ST^+&)[M[3/5?KN9IP-4=/M*$+ J>@"TJ>($(B\%T_,9#G
M33:BKJ*.&\BY0#5"H=2I&QN.'$I-G,,6IA,SN8XQ>M+M2==U4Z*-?@7V.IG0
M8V1Y"7"^%+WR8!')O^?Z+3VR[T178 ]?AX]BRY&J;G?0-$MW0(U,J@+]+#*!
MN1%);,HM'HG> ]^3-GWDSG^:ZQU:P4^_./2VG)A>!J1XA5;G0+7G)OO<X/18
M'$G=Z!%ZD?#RZ'NC.*)C;U+?'O]WN08;"GY%BK&CWOBBI.X["/?F.HL:4388
M" %P&YX&[SVF/Z-5>5DRE672L9A1HF(*Q*'L* KRE=E N8P.= )W4I3!6X7M
MM8U^22%W40PY[NT$_MDE[ZKOJ[W>[9KN_X0?'].HXRJ->@[0<P#)I46R# V9
M"[Y[GDU0?K$SA<-:!,\!Y@90M$;,*+\B'NX,MLIKMBLT$:EV\D?HVHI\-0HS
M"_'5YXZ)*R$I8Z1AEHGO1 &Z0"^*85CJ"GYZA5&#+1*1/$?Z<2$VZU3%45#1
M5=%?XJ+DR(04U@73+,&6D%(B Z818]B#Z92-MVL0^BCCN4Q(SGM7SH62,)DL
MC[OGS7Z?1MRG$6]^&G$OP+Z- /MY@Z26DX&9U<F9_S][;]K<-I*LC7Z_OP+1
M,_.&_%Z8K7UQGS,1M"2[-6W+/I*ZY\S]X@")HH@V"'"P2-;\^IM+5:&PD91$
MB:!4$1,]%@D6:LG*/9]LRE]JC/ B0CRY*#WG=AR'PE62BB)81#] 7-C.&B.T
MC$P%ZJ=T >)+;I,XNO9C%!J#NX6EGE6[K-JE$@IAEY%21A[FJ\:8Y0<?W(Z!
M+K'%9DF5*/+UL19!JS-L\:3:LTSX:)2?Z'/P*;449RG.B-]30@Y25AA[7 U2
MA$M-RD*V940"BKA$*2:@R\0MC5D:DQ!8*C68XG&Q'XSN5,J':1>A3\8UF9_.
MI92FEO*%JEB9X3DM&6@V#<227@62-KQ3[L$I6-_2<Y'$=UZH4$;9\2!#P:DC
M(U#PH^2:8]5MVERE>(78Y#!/X>P%<T3I@[=2UY*E#GNB"\LLDUP"?;+ 3M%T
M<<9>$?OQ6P)+52R&%I*V1&N)5L'/J2")RL5&(8XUT!$&%GS.0VXBJT(!D 16
M>D+U@6N A,8*"JRFFA-MPAA'A\ATTU+IBEDKIL6G<7ACI%@B8?JQ(D!JT!DG
MXAI]-8_$^GCVNO!2M?9#2\*=#<.RH]*+B..P16;U&5[X8.)\8!0Y%DKZY7U,
MW6&?ZYMY]>5ECI".L:299)2N-4>MZ474F^O]>4A5.>Y"]VK*C5+R,NDMN8J\
M @VU>"EYR:%Z9RO(K4ZU+M+J-560+Z-F7/$?FZQFKU"WJDQG59=JJ?F0PM+/
MMK#47NO7=JT?DX-J*M&NLTPTB2;CT5'D72TAF, 3/-7MO;^IGQ724/.$BC@U
M,",\C>I&FFJCFGH+#V$&NO#?.0NA6\QA1RVRVYQ6,?/[P&$D1AI?>1(%%H8$
MMB!;!^/8B5]8+ RXA1H#%G=0GA\SS<HNM6C7;WY9-H3&+T^(H3'OE"R;M&Q2
MICS=GR,NO3;?5N9;BEV<8KM0F6^)T1*C4<37J0I3[<6?7V4U@X[7H7)@QU8.
MV,H!6SE0$PE'5B*L6B(\6UGW;<0!TP)!>=EUW5U2=BQEOYR:SD:*7:!F<Z/_
MAL%[NE>\N?%>3NTA59RSBH],7\XC"HK4,/9*VRM]OY0\DP#+V7BUK#N=="<]
MJ7/\2;8%EZ7'9TV^.U*V3.#_]T_G<71);)U1,[[M[QP>;.W^).V1):;G5:RJ
MH\6:S<#TWIKS>^9>,L4L3[WA>$Y3'\K':\DF].&9)!B@JBK"^+:IJXH>A^H-
M]4$'B7)ZH-I:;[M"R5T1QG[P+Q'(+/>D@"AOZA'2&)*;C9D'#/*:81$]X!-)
M).[(%4[%DAY]'D0W(-8ICC/PHN_T<]TVE_-E= ,F>!(!:$ 38O4]R&9-EQ+2
M:';AG<3NDW^M*.G+"NU56IC,$)#@@BR097'8'0SF%)+3$ 2M=TT=QOR<H1M'
MWC (D8D(F30YF>21S.!P,2>,<E> Z+3NB-08 7$/5<25:^:,K%WG*QBC<0JB
M?X.N^(B)&2_X&_R]^>A9A#&CNY8G,Y63)O-!2'V&581^D>]ZAPHZUA\/97Y(
M*#R)-]D\J>896-77WB(N7,Z3"&%PD>S0-S(EMPQ<&40D]XI$=L/E'F25B%-#
MWCNCT>*/,"_9TJ>ESP>;9M? PY&8_" =YHP2S("ZUS&R_2)IR*#(*LFVLFQ+
M?9;Z9B;%BF'.FD4%VS 4B.W-":V9X9+2YK^1'LO.0#,CW,0>;"1,6XIGB5 1
M(8ODD*#7R8>Z?"_ <U;@%=9T/W*P:'5[\Y<&'DS?;/WB3(2G:IU*')VM6]3&
MX0;2+TC1-]*QS6PLS&G'?Z*SO$7-,9& [S^H.=+$X[H3LB-4\:#AYY>.[D@X
M\"Z?/-:56E_Y!$V(GU'-A0O#_@W;![>/LP^6V4KXL2>OYK3XT=\QXK[*_, ?
MNPCS1+NDZB"1]R9HGI4/N/;+YG/#7T>PJ6,O'#7%(%0:B\+K29L/N&&D6;AF
M3</-H8:%!4Y9%;HR"A!HIRFCAL;L$FT8TRR1!ZW'+**@#.E$YJGI.@JS@,*D
M ^IXH4[T:R+>'DN88EVLZS;7\&I0.]4IW*SC11]8'-Z@S+".J5<FKUM*+F;T
MMO/@9]?>Y%X%244S3MDD3%X3K$+2F9H803#KJ9KJF#+&LR9FZ.K7%LRQH4[I
MG>-L!#+""W89+'@X5GFE6&&9(Q/F%%37N8[AH"/TG6'3)ODAC"NO.&:F35UU
MHPVO&(>?C=IJ(P&5RZR;/<$J+3N535F& 5MY\"V0."6*).DXF)9WJG!*$\1Y
M47*RJ4M.S-*-<C(LJ?U8#(9_W,19_8D:IV\0(K.=_/#<1E#;]$JEMSFJ+-RX
MA$$6?@G5GJ3/MRV%I)GE]<?CK4VL5B&RU,E9Z\MR<QV+Q:)M#U%L*;W9-5AS
M0U9;B1<G,IE-LV;JJ*7X>26[)5%9S-+K'Z7 *Z7O0<;7R- @\DZ8WE71K98G
MJ++&\7>L&LN%RH09>0'6NR??1::^X-^IM.E9#$HB+[1S#<(L*?AT'?[W<3;I
M.B1@[]H$;)N W?T$[.<VY,[C# U*+8%+GBI0;,6(>-@ P__J>T/A@W\F\0TF
M%TIV54$_PI)/X"^^A(?4'*OTA8EE0!@8DTFY!ACXN:>UD(EWYZB 6(N7"',G
M$U8H"NV%T(&:LA7P"QS4<![/"V.PO9F- ]!6>?1J( V;,GK."'/+E(NCR8OB
M2B6QF*=$B /5./90%QX9&"&^X'PVSH6^CF,?Y09-![F0!A!I\A/H<4=L'6/#
M()7P0>A+,A..<V!1E*4B= T9)Y4\TXL5!M]%>,?8W?ABSLB[S F%*'&^D'W2
M$$;?H+-(*>44I^DGWBT":P4C:XJ_/N6-:+0Q\(<%_T@CS'Z$Q 3R!2LN?"],
MRU*1(6IQ#HIG3@3K.OB&I;Y54]]<S@ML$-/PZXQWX"'JK/3^(D,="H4AT<!-
MR6R0ZGZ(]>/H(\:$(JZ0E [>.<&"@2!\GC(4'@T:^/F04.'\O&2^-RRHYKH)
MO5M[)^R=8',Z(SL:2/4VUO8ON[5\,',0MSDF4$"IAU%U2GMND@K,<XE*1;WB
MK!!3EW)-K>V:TD\K<12M4H%PD!<.GT#<N$PBBA BDZ&?D8HSX@M8ONV<&D"I
M?/$\Q5)VS6[1%%DSI,D;K[:WRMZJBJ1!1[<@PF9HP!JM.C*GA6 Y1TS7L!_X
MG49#PE"B-,H(699I4%]=4)%&WDV<J'::IB6$%RIF/%6I6,FZL_:W#41V*^#&
MM2?#V^(82^M/)4'(HFX3$7((*292;R)F#%.5)/(CZE/+A9G31-P$<9Z&Q<C^
MFJ7LJ,!=V1*OAN1!!Y3I^<  _BMH<,Y1$'(((VIGQG_]'/Q]ID/#V="8RXF
MEXIH2&X6<HE++D/> .UO;\MS& CR-U%QKL]XB^9X>S#>B)WGP,FF>8)95ZG,
MM]GP9!3N"2U(U]D8J%@?9P,Q7AMC*?L!>XNTQM^@@\N!39&@7&P<VFWW]VBS
M@^X!D'>&CC1Z69 YB&]+^)3BQBNCGW/CY>\B#,8X&B'52H<;%S-0A;"&<AYI
M-'1>G*H@IGC"K4!@;4[NT&D\-&\)P]YPSVJ8?GBS-0HIOZ1UOW%6(Y 45#W2
MX.P*C"X*)<.+?UGS>Z'#"6</(X,I1L$:+3)=%LV>\;,I(7]A*#(0MS*]IZ9-
MEAR;.GNEM+!VH- 6^'J@M&%!:4C.!O8X[GYQ3 ;EL9-M9'P9%*Y6R4!+WV78
M>6^44W\6JF0TP4T+WBO+Q_UB1H:I.O2FRFG/]Y? V$56V,B\%3)+TE]-]M)5
M(P@Z(KQ+C'YYE0RO,Y7L(8+ %/,7-B34?!0[ J'@'#P_F:V$&64Z?N@CJC7Y
M9INT/PI;MGJ_FM/>WS#YBMH-4ZB;<"-R9D.*ZOCF?!=B6ON1<70L*(5?3>6;
M44O54CBEJB)UN37U0=/YF49O>T4&Y2>(RV1QAVA#_, 4"U0)&(4_+2(9RH-C
ME(35"QN:VTMXC0TF>-E<\OL>A<:%8#A_3D4ZIKCVMZ/=_<VC(UG\N\JR7YJB
M4YZCPY-<607P[^3<:F:E#6T;BG8-]>)?C"66 ^T5"Z@H(JZ'X!MD/@::5-@#
MQ83$,G!U'(3S!JAOX ;FO3;DE2_PVS>T^J1\*J5LGEG>SA9@A2KS,-!SC>87
MPR 9YA,,***F5MG0%66K,D1=!L,5EH>,9%+XLJ)S@!PN6+_>*#.WPI#RI$7H
M7#N#S8])9R56[R\<$"P4QON&!-UEZD:N=#17HWEN.<G-*UBY#X(PC*<3F=HF
M4Q2QZK!$#^7\;BG^2(:Z+4.4+30#=+U-++E-0LEMM3-D @[U9OEW+NT+UG-=
MZ:L?4@&S\B'"5HIP))WYQGE/A,0WQ'LA?/8L)@B0/\C]:X%E]Z#G<409H^I#
ML(]3E4V'"/113HB(7H).'0-NWU!!14+6K$PJ96.%P3XU(H\T@3Q"C&:;V,##
MU2",)H3/J!HGIV8OG.^4!)CYQ#K,?'ANY;=:S3T_DUXL3T*3*1*J\$'L+DT>
MA?L1K[O@E9SD6&Y"'7*TPHB.ZE'-*B*J0F[ *>S*9S**\Z3):2*3,;@"OE@=
MC,$49"[2)450F7QZH2-J-4<V:NE:5GH9&'&A^^V1M!Q+%V.VI,'<YI3;0Z(6
M-7-1O6H.5V>SS?9LMIG--K/99HLRZ/I5+YAT50&Y+Q.V*46O+_R@M>(%TS5:
MM>/FE(T%1-7#LCAPG%H61V.JA@VV66I7U*[24XON,24SO70%-/ERQI'_9\XP
M8*GV]#9%,=H:1Z:QH>PUFK-#K,=0?3]5M42=J1LM+'4V<$D-)D^J3/>032YQ
MCM)?6T\0P:4J_\Z,U.#R/-8KS'<VJBW;%R%ATF)91RDB@Y(T5":<] LGBYSP
M P[&-:):Q.!\3OTQ&6:S=XJP-EMD.79M7!)3;PT'=9/7.QO2^F:[C]%-9+$1
MWV(\6:]TCO>YQ=A?<FG&^L.<R!>*M"X+QYK35[4%*_,CEUV]&.4=@.P@0SEO
M=3$7$0$,C[*/*1*(](SGW'C R!T]A&*G3HY%4AN>'VX&NBJ$8,@ /D-=4U$M
M"RLW'I6^+1D=5^%>?2%A>%E6B21%V]WBV]&]?5MCE^0R&]Q5@\T\TAL9$V*'
MM=ZE6KW(\1BX!NY/BKD7Q-@*!S*^ .[?!NHO[(<-[YC7R'0'.6L%%9'*A(<W
M/>>J]J9+N)UX^3_+?:7X'MS3L0@IV4![;NC?U&&:"UZD(XS"GM?8D)99 'I;
M)/I@Y'P <<-^F\NWNT@WLO6M+_NXX2D7!'19%+WVAS+,+3M1<7 QBLWXXNZ>
MX1(J_'+%R$5KN,4GN1I_W5>]R???5?2N#S CK;ZWO(7E76O)0R*JI;<;E=E!
MN22)<T?*\8+!7;6#>Y'*9]Q-=#'^&2=&3FJIVKG6(%%;M*6>>:ZZI92T@L@7
MH5"%T822XJ5O9:TUQED\$#/ZPCYB,D"86",EMQRC7%\I!4?SZ<J\!(A\)#V:
M&;DV*8@RI()<V,>-'RIJX,=3B9V[",^17TA>]E .Y#H;=^K]0T0@Y;Z86N3K
MHT4>'.G!8"N+]DA5]V8IV0-S2+Q;3U?\!HEJ?(%IPF*BUNL%J!=+UASHQI-F
M_XM+(3%4<+;;^]OJO$X^'G]RV^=0B3A%I)*@\!C&4SKS6>-R5L=_VK:(4U."
MI"5D1GSXCO8 HYN4AQW*,(U>L]R.:GB\M T-,)4&#4B2H).A]@O$)8MMEHO'
M9N*J]V:FBJO-JFKXL]R5LN#&N!<]YZ+0Y;0D*,)K])III@,GD@68Z XR7P3O
MA.1'0R_G,.H G>J!W!VJ2#3)Z':,2>4^;Z-$MJN\Q%,J0G/K4%Y"!W2ZZQPN
M9@Q*S^HUN=,BDT=%[&,G3QE=&-NV>ICVI#5X$J=QPD0U"L)*^QO&GJ(DN#2.
MHS8=87:75I<51-8$B9VY\EP)$V9*KZ=@'.M!NLFV86>88FH@:*:416:$\Q32
M:W7V6>U)&5(M@<%(\'$U3OG6/B23C6YP+.=@:%F8/>.SH4)]A$R+G0#<>% =
M,FZ>96\66+OJ<4(A)YJ$$-^9@12DJMD;I_\A'TMRLUFH^:Q\;5 X.(S297-S
MS)R>,Z#72:2SG6"*9ZIM"RSZ1%F]7@=R>RI3I>W4DR41IJ=+WWV14/2=3/S1
M^MD'"LW*!TZUVHQS@.^3.+]F-IH&/PBP-B*7"AIOI=[+"M]GWI <2V]J(\!9
M'LD-I_W*VB6I:8*H!L-=RSW-LP)Y)'>%<0B"<Q*B)X9S5B2X+H@12A:]I90-
MK2U[;:DPLUD5-BT8(X\!?BG2\B]G+-[52=:$[Z=Z%<Q$,W&-1!LT\%0/)N26
MH%H&$]C+,$8\%H1T\0:(%4\0)[XW\:[Q'W_F_O6$1>6(DJ>E*J1X^XA:) SC
M5#)8=-5$-%ZA.>K&"5(EIQ_1TWZ0#K YC'P#M6]-N(2FJKE( *-@XDI' $:O
M4' 8+:8H>0J;,:!C@1Y1T(A#H NLP$\";&&#C=I\^(<TCKCCB/%+,GN2@'#Q
M0*^GG) $J4$C-\0ZFZ70>A4Y!>A 4X>3%&<6R%[EZ3T.TC ABL5@X@F9)^AV
MQ"T1OJ8B2GW 7!,M-V>05,_YP)S97^SY^1</%"@0MLSAY.V3(Y$21WG!HSP<
MX1^EL11IF%+&*"NDG45CBYU&+.'+M UG4K^TKKZMSWKOUB>Y8M\F5]CD"IM<
MT92YCB$OUM=HMPLM&GF4RM!54I/J/ @7M:CS5%4$5;6$6*&L%S7K3='+1AW*
M=:UIK1-%@Q+I^3=>T:U%"^"B,E4B&H)ED K*,,: 233+8US+S'Y_AQ"4JW%L
M/DY$T5Y/8*-ILS4?Y_13UK"5Z"F.LM[[T55*2-4W[.E0T% "Z9K*GSE1PC4N
MF<C>C1>$7%/<%&+"/SGVBO89-H4@H@/K$(PHV.3DCLR&WWN7/9G:+FD0;2@)
M8XJ''F2YRD<L[4T/[ ]M*#;N&P%$LJ-NFB?#,:8:H=/T!SNV[H"KJ'@!;&_(
MNZ6!S..H6<3K%ILZ*FD*_X5/Y6[^D9A'H8ZGX616[]_I%^:Z-A16[."9U_0M
MK3A_B##G.X!,SYT$3M2AO=2([;7!EVF=4^:^W]=K0D1OV!;D 66P":-"K;0\
MF_3V^M* )BKHC*CT6$!0. ^+9FFIL\%%KQR2I8"SQ[T) ZK/4-]67(M<-"U_
M$54\ARU.^WL3NH5*L:1,I+R@9UY&9CG,*,.P!@&WN<DU&,"&&70C/;B<E\$I
M4M0JR"WYT-\L%J=Z*,.7%4(Z[L/-BBB^->&$-JK3QF=DR06K$_;^V/MSG_L3
M!J-,-@7X,X^8E,&V&P<#69*D$-^)C#F';N"QR^YA#-ZF+5LBO2>1IEX6I+)V
MSK TIQB$]XU,LA*024L@8[T2?+\:TJDY+#.OQ;5*HC.JU*UE\/IN6H.;Y![F
MK_9$X?.A](/ '3OW4M_[MYG;@HY#G48V(R_5R-"B@/XBOZ%F.CBS?$H^*4QW
M2XVK7DGO-%+7^M6\M3<2FX8ZEOB5F(^L>^?$-)_4L(8U9]R3;+%HS RN8R7>
M*[^'A,JCF783'$]1L4)WQ4CWP\#WM72JRR#YK'9U14&%V6JNS?Y8*->R"_*T
M07SN[#>D[]-V:YP.<GP4(#YHJTTQY2JGD"WL"WHV@F$P15=>$&&++X8')',L
M#ED!]H&O4$N95&19J/<.> >ZH<V.,F3*&0>V48:U*-)09=[!VV$8X!? 8VX"
MT+R%PLNG3,6)PK(KLKHD3@LE4X^H\@137C52AT0$84O5R%*L)W4UK4F66LU;
M%*60!J5W8JU!I0*M%BJ7)3O5R51&-W.HCK4>F.$.'#/(&/P=C^!/)F>$2.I
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MJ_@^RAQ7VZ5LDAN.X$K2#OM?/4[N4D=8$& F4+%A.2R=?'[;U0 5#)8K0YU
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M%EJQ(R(<+*F0S&H:A\&0[/=IZ&& HS&EZ5Z0LI1,%U#Z$W)&WV2,;7D$*GY
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MH3,5B=*8,NQ4PVIEMR-EJ 0JYC%CSXK<N&P<IV;Z9T!IK'"N.*MZ6I \5:8
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M4=Q$AX1MG>I<1V-Q#+Q0N9^,410D 4QB9Q\5-"00<I3\.U=)S[".; RT%D1
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MUFI !P4.$^4E# KH!@*'Y\S#.[JM9JW5U0T$= .!%XF+1KW5T^JANH[A)A&
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M];Q)+2XFMR/3M5WOPT\-^M]']<3Y0\[CZ-7U'E<ADE:W#D\>N=Z8>X!.AT<
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M-;CPM1>MQ*^7 ,( (M\%JK9@T[ ?D.%C@(X#T";9:HU"LLHBZ'EPE\=)^R$
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M=(^ NAV)]H@J[EWO!U"@B3$)&3T6KCB&7CAX-"SRF85Y1JX+W9[&/)],\-E
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M=\#EZ#-XY /]G0&2O(5X<EN0=W?5EK\1!M5^T6WQU.G+TE6UG&U%)[@L$10
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MI"PX9@8AF8R"WY%TN(<,G3!TYS$4EADV:SU)37O<;;]E[Q3J$\;8/S$:=!T
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ML9RD,GLK[8NO%]_.E1VKCGE#>XR^/M!_O@CP W*_/.0.I-<5YS4$9*DNN<K
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MYD,JZO<?=45&F<M%8\W4+;+0;4U997J\2 3Y),P[ZV N:BKE9B)\X=ORUXZ
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MT(#U_N!!VKH&A'._A@IZ#N0M(C@6?H-JFS^ S6WAN^OQ\_%+$_@,'NSQ.PO
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M-6< _\_JWLCF=>\=8/>I-4>KAURR!VL&ZA= *G0%$R;FT=BR0^E4 T:$.HB
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M^RQNE\[0J=KQ27+'-ZF^R:].@'FCP^= //)\ /P:-T!()Y>,MC(QO##/R?O
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M:JD"3L'1XZ/GNPJWG:#V"VI;4B_'L$O1W\$&KK'FG/_YCS(K\BO.3_V<5-@
MYQ(<ZNJW/"FL]'X5X7WZP\:J@W94,;MS,W1NV@?G/3:Z&>=)=%*D58;VS9ND
M^A3]!&(-MH,<'A@*."3+Z#T8&'2^OO+9>?:ME8[]JE%D6H@0PHV+Q T6R'@;
M;MG+Y=^Z/1P82X3*A9=YA+F1_"H7I-](4B49(UJ3J("YM4Q!1:K>L04<A1N
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M>0>W]_&!GZO=Q\$2;V8-$WI28;F0P-2MD^'S0+YXOMU*G"@V=#2UV9RXW3A
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MA,+:XF32*KGE#IGM*WL3XDJ-:0=D2:K<*:-,CK[CHPL"^<PBSI"'A+L#L\9
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M0?#0'(U^S,LY2.DLB7DESHOQX.SBB Q8NEZ)0R Z<<U0\*%4(P["(7,A.']
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M2LF](WB2 R1+LSSJ!STD.T%ZP6T@:6J7@OAZ66W>Y/_Y6SZ<T\:R"Q\1O.0
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MQF/&2%;=>Z:#W$I^U.ETOSU_>T!UI0BC!%ZGU=&<@#9''1P=74(.D,XIS<X
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ML GY_!?O@<I.-# \W:I'Z;E).*[J@[L*9[;T)/B0';7UO5;'OO0:-J$$7B_
M(4]THO?AV;"CBHX$"Z1(\"BN9)+SH[X$=Q+(I9DZUX=)@S[@FES2*O:%DRKU
M3W1!QI(DCEB5N..DH>FT2(#$&Y^V]]Y=]:FFX&"2AF5G.-7BUH\*]7_]/!PY
M#:[ABPJ>8U-/<EIFKVD!5S4%HPHK-. =8ME_=/$GP(0VMO>\,0-[IYE/2,P=
M+ARS5LG+A'92@&C6986GBG@L":>6"&!!& ^7MV=:NBN0P0X&-88"%_N@I4E8
MG@5]4)0/<SZ1Q"C\Z=-Z[J8')NZ%-U)MNT+SIVXF0Q\;+'KJUT%> 1 MR4W
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M=6Y>0QV-+.0YRVRF5<G CN$7*/"(5:C.Z5JYJ[B344QN9NZ<@LO NQ^[AFJ
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M$^6KC1L4"+6IE3(MO8[$=4T:3&<XI(F$+-J!UE56A6524HMP!+U"89)>WWE
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M&64\OXVBX"6EZSDAY3668LK"N;G*CU FL0E39EN)J/OE#/7&+N>G#WG3UK\
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M1Y?S.WHDA7Z]64;X(7&?YM[@#HX<P7N*9MV[:"WF)7D=[',_$U-A8F$E)<(
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MF7XG4R)(VW=G/_WPYL?BZ)19C.LP_B I_R*>N'FUI;Q4N%_*>8=K"JJQDK:
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M,3_M<HMQQ#$9%-2YLJIWUJ7$&VP<K!HJSU&@%LFE%G8-:W5S74 QJ(F,X;S
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M_Q][[]H<MY%MB?Z5BIF8$U($2.OA1[LU<2(H2K8U;=FZDCQ]XWX#JU D6E5
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MY#,FDCJ0&K0X[NSN*V1;<I[WB^Q^D1V+(XUH0G0I/*,LA.W?BC+?BAAI!:P
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MI^Z Q<?*9P32O*Y7>Z66\V:NR6N]<)PC8,G*<L\PI#YM15)R%?01L9<8.7C
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M^?1^.]H"'^OM?CM30A36/B:WU5T5\^Z:=M)QW)&-9K7P>$*J Y$)#'(.R;!
MH%[AT)>75C#G\5@M]T-+/!++17EY20UG@R3AC!PRU,^<^L[(CND;5!J0=?/D
M?T!E=)VFKMR$15+V67>S;N&+_>JR(L@$X%'2+>NKXCE_?"YGIO/M/':Z7QOJ
M#1M/*H=85>\L'2L;.[2><BIWQ>HVM$/HOFCR],GUC5EHKQ-5.<#4RM=-2Z+>
MI%$\?;(0"I"PS85X,YUYQ.L$V)+:EU$F& ]8X[3IDR<NSYIS"LWL="49RG8-
MA,6G#$3IO3\426@ND^$8:],DT5X@@QIRJZ+O.TE%@V,4@!+TUGUBSWJ_V6CW
M<(KQFQ0VI4M]E_Y?NIS7YU<A-1<@*1#*TN,'=N42E+:^P\G"K8RUMP[=A9?E
M3@J"3,X4Z(<MIQ6>UBG3]X-!Q'!C)3OY! K@Q1W9A]<IVJ&Q^2G'Q,FPB[ .
MG*^HFK$O:E++@-#)A#3<SZ; J;@<^KRDQO.M>><(#\)O>1S4B<@.9%]=8\_G
MQVW=H-)D]![!CJGS.0T7%)L8PX'YW2(X0,NEPML; 4ZH'Q,+",!)<(-2 K99
M'L32L7BRQA@B7XPLMO G04K*9-(UQ<?=PWZ>Z*K*XP0)-:=20&/,GCE\=2B<
MA.I8YBS 83?<QN/O!;<A)T,)ASR9MOU&JN2E<H:[25E=IZ.5-M(;HK''\PK&
M-,W*OF>>.LDJ<V-OK-#+Q(*'FEMBYX]XOK9*SZN[%;!YGIL5?HFT!*0N2D5^
M4WFN/RK/$35V;LJ^US$XE$H=A)<?Z;Y6AWW.[7;]Z"%>C,P,\$N@WZH"4"F@
M)IC9Z :T(/T@4P/'ECB%TNO5J%8"K/&!-2\9]ACG!HD;I(5F:)#GQ)LUXIDP
M$S;!6J@0+<T7Y2+1?_]#==&%FWT=\49I97/P6FKQ,9G%C8*LZ4" N]2NJHT8
M U%75.Z[M-I>-4U[S9/,<G;ZW'/ZX6Q, BT(3V3<N+JDD$BI)*=1\R^,A0U%
M#,N!K!$=I EDG&B#M&#6A"N/H&/BA<<&R^5Y=9.:W1G[Z5K<3 _R(IG>K4W^
M=SJIQ]Y9Q%(U(?<Q6[F:-U_FF(>NZBU%ZR=4NV(2N.!3E8>KDQ?)"8>F&Z'.
M\A'_*8[X%RV]O3).22*%-,9DFO3W'@#O]DJ?S'W^6ZY[I#"S7 _I&@-.9C*L
M/^[K%2*.'Y*EJV[:[@-38H7\'&]4*L/S(R$!<9*V@I H\F+2H]R1ATJVUN?S
MY@AQ$@!L*BC.H_ B--\H'-'TH<H-^A!AX:MT%*-9/5W\]8J8M\>3#;^<(OX=
MG17MOM>#6"]$'KBN2+%X@'(I,$XQI^&UT79;ZUS=D:<Q@R;BB-0QLIDGC3,<
MM.*9N.)M+ ^<_A0E%WCIG((C8>I8NS8JT]-I".[B [J),)>[/<AT><6,#OEX
M;7$:LE:1^7TWU@C->TS^><X!_> ?] _^5> 'H*],1$R*_A%VQ"KBE!RXJ);M
M=M0#5(IL3P.>02'0XX4DN+.CBCXQ(ZP&<SY3-Z:YL?<]!FRW_CI&%"/$$]<1
M!T]?>.0T@^N638UE)7I:3A^F\/&HL@*L0ER4>7M/?$A'8G-Z4O@X*;H:Z\DQ
MY>'F0\CYG"Y^)FK"C>)K-/+*RO(*KV1&F'Z>J<;58[/'Y_Z;/TPU^,E]-?B^
M&GQ?#88"ZP1\HG2IA11P:BY@:0:+HWM. 0:54([C.6$^RGDEPQVA7$PS.**$
M"V*4IMX\[1J%4%FRZBNQV](CQE&:0E&3*T?@VB.0';J9LHZ!$*CS., (>VL-
M3:9]*D[8-P<Z)(8IM88A"Y$FK-Y"I]#;#RGT-"GXW9[AP"R^U=B'?EPILR%=
MN8&,SW5EA;#_*R_Q7T,:>I'=(,<><!(\$ F^-1=@\>M^H*#!$$S1G_R?7UW<
M'75H[/_-1 AG2YM1?SA*#X-RO>)H=G057GTYS,%JBL<28GU%X8JX%6GEM#O1
M>LW!B(6&]$5P5/%/;E\NK'>YL'A;?(ABL2DOJ@V^O$LG:'G)OTLN.6KS747:
M"I WJ$5M,-WS8J\+4G#-5-5"ZD'\OY9X \L56 !Z&9CZ4[X7!6?1,D[0!0^$
MUW>NH3$CJY;N#&'@-A*V\)4=M?[9!VF.:T+CR2 RI;3 ;09M>.ZK]1&D7=LG
M7XZ"_ZZDZA/)"JJY"VM@W]3_9\\N6FD4;D0NS>"-FK4!#4+-WIAD78'>5H_P
MC@+'OTK")9DW"HLGK)(_O#CSF996'J.1'+@,(5C<0<'-Z;RL[$?2:1#9*;/V
MQBGVFLPI$P(*W#1M@J4!1<; W+8+:ZW5KBMI0&ZDFN^SO#A7K067=K[%2$EP
M%"6BG6_/.L60Y228O2NCC<:IE1,LCRU4N.L/?.R\^N7%[4_,P.?1<]_1<ID
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M681UU5UF:E,%##U[2?G :'7'7%^?D;^0%+S"@8>^RUMU<V:[3Z@@[+J<*J.
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MZG@Y?T'43OFHB%"O]2W3L8ZF0R> #F,\(M2()L",1*[26K/A=_E!!QCD%^S
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M#E8CP>V(B=V)LN2>=C"= D4-+!6]$AQ-A+..^.[@!%D=LUSPTL'V, 1=S^?
MAG/LU7DUB4= 6C(A:7?_M9U?NPD1@7T?$? 1@>Y'!*(@'OWYEW\=C0]&)\?]
MX;^&QX='_SK8W3W^U^GI:/ROT?AT.()_'8A^_Q?>"'[B_:__//_\\</'M]\^
MG%]\//MT]O[MQ[>?OEV\^7!Q_MO%Q8?/G\X^O8&/Y4,/? /O)ALY.0U;@&$V
MP2O0%T2.2-CPE+,LA;UFEB<_N0C,,@-8)_SO[-=_7GRX"#Z_"]Y]@*6??SC[
M-3C__.G-AV_J-U_?7OSVZ[<+DL+WFAN^_/.7MU_/\)47ZY/FRYUD_\PJY=O
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M;O\@VPODPLGN'Q6_A\N7CS#1()>Y 7B0#CH054,@*Z&0151,;$=LH1-N4/:
MQ)A2FK?5U!@M/YF1[4Z8TX% BY=A,+5&/I\UT73+GEK*+WEU2*?"FQR<9W*9
ML#DZGY_2_ZSXZ)D*6M.!GG\]0_IMMA$[)RT(A*9L/$:__G3^(70RFO3/]>\*
MD\\1NDC4?+?Z+_<=]<E2E.J*D2AT08SB:%3=:G%K6K:JLW*E/F9/P3*Q2"'X
M#*K20.22,YR&3%2++FV;Z.P'U'C0 %'IR@/B+E@]>%M-AZSSG3&<@E%VE%;S
M]MV%UFJHP:-2@5G64?FD*ZR6Z]*+U:$.Z"V%"ZE$U[DEN<D2/#8#=D]/1U--
MF(NKBZPD!.'F";B4E&E5!N?!?,XUC)H6@1Y*CR[#3G.=T%I;4 <"G=^H[A Y
MOV$%:XQU.@*ZSG0Q&7V8QP.E21+8GGN93UHOL\,8RY85\UU1L4"N?\,<%Y1&
MI &W>R"BT16Z.AO.!M X[21^J@HJ9"J]K+DCZZ7($M# RFI*17=VNTN6W3HX
M*5$G*= ;P9<9V:K7^#)0F(MX%$><U%IG8J.ZNH$ODMD(%I9-&L&+]6A_C3.N
M9PIY5S^DPUY-=^(-; AYN%B8I^(@1\F]YLJO)"N$DNVD<Q8"14)-PA^&JL\B
MW5>%GP@/<P&$JMT*B7M95@GJ^M*EJU?S)1<[Y_+1=^R;3B][P;N6]4A%7;Y!
MA:3M7!OG)$I.S9GBWML_=M7SC0FZ'OB@JP^Z=C_H^NA"2;L;[*0HUX*HFWRJ
M.D<FS9C'R$"A1%;\0T.LE)(SCRMI6UI!.M.223% U9D6SWPZ8YM;,3#9JJ6P
M&:A.' =+BXT9D\*GXT7.AS;',Y$]4+;*C+A=DQ5;N!SN5A $,^T@.5)4B WW
MDPJK)9ZOCH:1<BP]Q-=YII),ZSX=-&H)V(:LOKKKI,A J471!C>J]62H2<B"
M3;2T1Q)7LKJBS10]K*\65U (\;UA&CLF/&B720QGCWID!W3 <]4LY6P(&\OM
MD+^ :C)46947EOGR]VIT:0+";U7$M"/Q(A7?,'E9.D72"AY3Q0;8J7/T.TH=
M_XZ1<T74DBVT1<Q#NPDZH9"#K0[F<CNRLZREM$%+(G,<,@,XH5 3D>-O*?EN
M*+Y8D#G^_NSLB\H7YM(18Z 6"X+Z&B3#)6.X?E2'KP/B8?!OY]P;5S?B;#YV
M_,JX0C3%Z1?&?\28"1(M@?*Q\5#@DJF8&EEFE\1U6A] CX[QU G]#]4HMI@(
M4=JI"LV9Y&AP5T(!?F.B7R'K_JQG:,\I!E]0J*!^6KC7];N/!,%Y_B:/  [
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M)#;O#Z[A!XUV DEVC0EHC3;6:GIA$*?#I*+N @J/7P/ETPQQ;!Q*P!!JK"*
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M',&T7,8E F'CCO5W7W^-B^]JZCWZ;.]U\"4ANYM:AA1"+'G\/*H(E0VLBD]
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M1R%C]L+F(#-\@U<.%I#(Z2CPW7=OSNS5*-&=53E,H8'K1A.#,R<&8DX?B<+
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MJKRH*)CBNJC0?SNJN:@*CLI@6B.KCZ!*PG:X/^'6>N@H9#4^'>KDE29]HBO
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M/\<C 8T0=H'_R@7'&2B1@)*6J-I L)O-I7(MTW?P>?CV_<<OF);#H?>8LK#
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MWD$^\HJ!E*YAGV[$,++8I?YI- !+L"KK.K2MRSZLKZ$[:WYHT\KZ(8J*6UJ
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MU :(IYWJU/>:7+1*<IFE>YKZ#4:1@^/@QQE[IM"[8U0P.)NP:937U99Q:$_
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MCV T0C?=31"3[N)37#F8,%^F8?9]1\JD41E#O@(X5H06/X;.)LFDB"RI[G-
M/N>9P_@PI\&T8W_TVH]&.U$X"M2@[0EI3\@B EA:LS<9BAU]!M#-'Q?HS"A2
M966:.(^I'-@R7LMXBS >3\44>T$.&VEW/G(7?-F_(F><'0WQLFF6!\K$:[FN
MY;J[*01B*M5$6:5<$5;@5;8._RG0/@7ME/L])O_MUUR[%QC^]"<(R6P8#JQJ
MP@[W@QZ2[YBXJ7(SD((Q2(IHZ/4#Y8XF+(T]3[;NR%\!TW ^A?%S+#VE L9A
M)@MMRP"W1V0QP2RW/\4IQL YR#WJP@_B:T%T946&?V L8 94X7]* SXAH4(Y
M$DA\%+#?PL68:.5A!]^'O_[Z\=(;^!,#&-3EFS FFPYWN)02G,EJ /XV+NDG
M\$_L@=$E?5I_17LX[G4XK(@@G!-E(UI8)U90;#21"9$$&6Y9F%W3Z9D+G &-
M)_7AWXL!?47Y\!2HJH0"4O=475RHQ@V.CS.\O5RJK19VU!Z.]G#,"E@R$-%H
M3;KL'SE7+"-1UXN\+Y-:!Z?ET99'[R; =1,.1\_I< B;<1H!VIT#^D>$7;.[
M3V*+.7KYX%\KO(Q^O"A"K!A5CT0+%]00 L1DSLOHVDYM@1O\@-LBX\8A5IB%
M+8XZM47<-69FT_JOF\X+D1^VL<OVL,P\+!;J21(/\+C 9['4:HQ:?C+U(];$
MV=S5^0F&2<$^ $[]'K#GW>?P)\.U+9R* 8YH=4H!@;7[.PIAQ(S>2%/,%^-/
M2<H"V 4J3:EEZY:MY]X!IE@S8L3)@V);N3K=S%2A;MFJ9:OYJD4IM: ?D,":
MT=/+>,*Y(1DUK.DX]A>J*_Z/'9VUH5M[E;]F<S %SD-*\U*EK$&OH$1;$*5&
M]'Z].'< KZ#BP#\.5$NT!,., :969D5*HX&^- Z+L<ILF=$^C=?6GIOVW,PX
M-QPGE_3*"5MSH!9?QTF47&DO(5MZ=DAR7ENF;<C,.&XS,]K,C,W/S%B_F-YM
MI?2:I;3D?"9E7YP_(-6!D**L#) NK?1G2J6UN\L8T5[RBZ.PQ'^@? %CZQ'B
MU;(%7>,/O2/*_;UM/9C?XT/A:.HF3BP"71\D,?Y,+]: U)W,;8&LA9C8"@9]
MP#URQ\K#A52^"21%'/0\"H93_8),PM Y&.^9U<1'8A"4,=YQ&P:A1RK&CBPF
M.QUYQ\3;80D^^[H8=:<CVR807W7I2HF1ZQ!&+F?(.]G3==YDE:(RTK'[#D\S
MR?68MF>:@:?=ZEC60^+HMO !E._5Q]R<U#B\JUV1B)ZSDOK[]F0P[_S&#R,%
M]:8TLG(W):1VUSL;#$#> =&BJ94(3;.* X>\5CZ\G3F!F6^TLXHFZ*$Q-G#_
M3X8RKK0*Q!)'Y6P(C(+L5)FRVDN@G"&6E2+L)0[N$F0,L@/:*]*&JKH=4K(&
MR'_MWW"$#3<ES',J<0-#X.>Y81L' &$BU,^JG!QO A9^2&5QK$1TR4Q6H6V[
M!Q4>"O:JV4V)J')'%L#L)*:8W,(9RZ[#"?EZ4Y*\FA%#;&@P-(@36KBDS&>!
M-0Y1D,4PVH78V,U7+FEQZE'1E$!J'OA4 0$^C$GL/NON%/UAO_;,C#0JG((-
MEP),[C\SU*"U665B./M&ZIL(.?2?^=BIS>[( FZ2"#?K*@WD:J"IJH5AI@^\
M#C]3JJ5<+$BS-&QPWZO,#2QZ@/Y+3/O&.@J>K] \5/M MYG#07 =.*'O9(#+
M%CN9H?#5(4AL;OH-]TX([#_,Q,29*H%8J1ES2[<>&N=\_3(V2-\:6$:)=KR.
M*=9T9M^/9O&_"!SA?M@&.-U7Y"!Q_+Y KH7=OAWW(J+#RS6LPABHFEU[<)D4
M K\F9A5/M*N2Z)1)+JL"4POH"JDDEY$8J;FAX=<KW"R9.?X2R_DCGK1$ULB_
M2=*RR();S2)=B&5<U"-$QV8R&L'A'BB"@\5T%:!,<,ADX\O@"T.P . .H5."
M ^&\89@\4!T):;5V@JA66"10U8B' $,_27.+/F87[#"66/HUA*7R(]:&EX3L
M+9T)DEFW8:9:_34,#ZL)HM&ZKK/[]GWSWE!]/L2'  %5C363C([97*7*0W"5
MD"@<BE9'^$!@+ELAP(*>5(*D( +9(E UKN0**5PN!X>$RY!#E,#N@9_A,GD]
M8WCAVJJ A5M8DV"AD;ZZQ$:E^=J]2I)1Y1E',^@'TI_1+B,$]].8>4R(TU!N
MC(O-Z%M5#W"9!COG44)BZIVYJ/+D*J [E*15\\5(N^RK^YEI-;\"B=$[LP*]
MM*%8: '+"SO?$.7$W'(UJG)?S<4%*F DN8F96QY!R1X@]G&IX2@7D:1%* )[
MW'>]&$]X*"T023>7[;E-$R3>C.DB?]-KXL^61HMH5%"(TJJW8*ES18REI6)'
M/73L%[Y5@Q_7/D8MZ01HSE%$256K7M  DQCE"Y99*Q<?VM1J:>BT2GT&!7RV
MMA3)\)DX]9Q4W0>JGW;7ZHF7?NI?)5B5EFZ2,ZWEK:]:XMPFL.30H$JS4C;K
M#"1H/QE.O:;5L)10?\4MP7_FT5 F2@T&)1[A @-6PQ.&):6 62_?[G"%AG]=
M_/JN(^&9F8U9JW-\>WZ_Z>T)8,7#4BK9 $2BGB _5$7)<'O5BGK5M89'[T6,
MLQ5$S)C!\'HN>/QO M",6<2CB:&4(:N6*%7/1;<@96!C3US.DE/:I')_!.-)
ME$P#-M[M];)!#:H;""*<!>D[^@+%;,($)H =C'F'&ME6+"L2':2B$IZ-#0JE
MZG>]W^</5+KD\=G/T@D;YXR-Q9FJETS5G?YTI_P;RNDPZ_#-D5.HCTH:9PB+
M(J.[G@-4Y5WUN\]%S A0M1,'5TG.D4E6?5_XJD[9!U:+S2JD(M=+5_$-?J#Z
MB'<2;M#GB1%4J#1P14&&'7)05+1MRP0$0S'75Z2MY!(>!6L6@X8(NT7R7<-:
M#(@%GE1KA545$_SAY[T]JRRI=2K)@\:/'!S5/;)GBMB)DT4A:A3?U59;Q'&M
M6+">9N;4OP5U&->F #EVG5#\('9*S).=<8BMT..K*-@9AE?DXK$+H%$]NC#-
M\C)6DYP2,&DU,9, T_6H:BPY%E&$P/]:+ FZ.]S0"9;+X!HPMNFBI!:<XW%!
M%U(]GSV2COZ:^P4W'UEEFJO5==2SG9(LM T.ZP"BRH+,0(04B6C[*#)X"VLU
M=KQQ,D2;%52@;!JCOP9/9T#&*Q]MDU_$E$-/#$YTZ&#.V5-06S1;N45$CC4X
MDKN:&G2(E-!C#M:C9BS9L91FS(MSURR,A:R!09[2"R3RW!?DWJK@%RJ+[1=#
M(&+7NW _*E)-'?R$G%5!+)YS\I.2P #&\[T_P9)Q[5GEZPM*]8CSV\2Z&9Q\
M<;8'JG_7#.*H_YI=D+)$L&O_AH]@X-WHUN-8)E/<PL, !"'[0T:J"B;/L>O]
M&RW[^DN9/"!\4*G8K.<K#038$&YZDB!2.X0\:5M3T?"DC9NW<?/-CYL_M-'D
M7V&%X)PT+\<6Z(@Z4ELT-Z@3EYT&&2*5#*/PAM5F(\0XF#>!LP;GIW2397!7
M4ITA.V&;#(,(0QY!O&.A?TDFA>PX!:F45<027PAF(,:GL2I']P<O>DW.O(6T
M=*)Y1?%EZJK+^(4OO6L9J4<9 +#ZVR2-AL!7@=9P49?"6MC:.-'&%/%FA^L"
M*[IQ%(":.\1#5<*Y(3>!/"B4-:D<7F8?JC>L473LHA!!3>UO&FJ<Q(D)HBRV
M[3IT:N]YC?'[(GO)+[SHUQ 1785\$+ DN-RA<\WQES@SM!+FC#/#9'[Y1+9O
MC.,^X-[9P4 ,83<<%V-9S_%36*?*=[>P84,T\L&GNXG<W5B1RO4S(,0%G8*C
M41B%QEW\(A2>,]^D_!K^:_!C@M4+(]R?09B+U:HEI'!1W>'0>OI0V7&DM%%X
MQ\(9Z#]8FRV4KDIY.B.AFC"59;>K(=0SA,L,*C!,0198792$N=X4:W+(& O-
M":O@T@8-)9]5-@%CF4/W<TOM"Y5WU!>@W-7L'\[1SX&-#"1H-0[RZX1:"*E-
M($-#(KGP$$(AL"1^Z2C(DLL_ZSB9S?EB[]JNG^O \9.)G\ Q#C-C=#N[,BQM
MR[!V7V;3"7_("+.-YP#$FS4WQUHI49=+M.GW\/Q>V"=VF7,ZXA+_UGDE*4C
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M/O;.NX2K>5@C6GU#@V$@!0MP-EC*%HM7657'Z.-GDS2,K$]+)V9_\-\BY'S
M^7RWR)Z]A<GEUT76O&=4$QEKR7X$#HUSO^G)EV9[WW[Z]MM+X=)J30NG5M>
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M!-\D MLC+S7TT9RA&15@1G=8VTZ)AFMFAY*B?_K[^^6F<#QG"EWO?4X7'4B
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MY?8Z #Z!:S3>J;?CPLP!$O/,+9M(N7,MRZ?6;FUTVHIY#K=63#D<7#.K=B[
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M&DO%7]S :9ZJB2G_E3B=M/^FY!IBGY:,<GC</3K]JXV$*'E[+!>"-3Y">4=
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MD/^PY>JM:X:X?J;>;YEZ[4R]\7T**UF$E.:)R9#7X40:J$D+GHYIJ$3Y@!8
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M?K$'5\<+<1/"T91SS.%NQ(,68$,B%B IGVQ?$70 CX5#GZY9Z78TP/M4IKU
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M[M>N]^O9V24G@!CZYGX853">,KXZ5?:4)E% RG7@<#7C+?;9W<^YV7S!J51
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M)MT6M,/CEB)9(Y>Z^=J]W0>M(_)T>70-0=='+?*Q07)TE76Y6S9]PBO>)FS
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MCEE_#61.*_671V]LX?-2G,VQZN^@Y?J+81&KOCNOTCXH\=G3JP3FTLKMSR,
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M]MG;Q2AQ'?#KQO>.EWW/2YP$_L+^6, _IT^.![_VX54@GY_8*%YX\1,?5G=
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M-E.H.JVO ^=Z%SA:1Q8Y_2U9F *A*9X3"L<@(L"4)<9O<2ZY)8%?XSV@"W<
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M)B_=\KI5&UTHWHN,  /U;S;MHNCS+#M?FG]\A+>QI8 >ZM>H[>3*Q:$0QL@
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MU%Y&1BZ.$:;9/36QK2S3J@XAIG]QU]%['_$8W3901,.]Y>SG6N 7_1J ;Q!
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MXST#/Q35EF,RGTSZH/R&*<5-FF0\X_N P=[^SL8+2I=P5$B1@I2#BP+CNV4
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MIMM7ZOU.1H5'\C$&P.!)DWR(@%2#VFO,"1DR56<CQK[X['R<?R!C:XMI&LS
M!DX%:Z;@@*>I<IG"D<O5TV=CGK4VTQ8\L!A&*FJHU '<6,QZD_[D1LF_DAK
MCA'+[CS,SXILY3*LJJI*)1/]P)'7*+UR4E]C([J;E0**E'VDS4ST8,)(!C]J
M,'I#FX&K >,I$V_,3S^1'0U5+S&WM 0H]UM5$7H7,\9[-4D$@A%51J).S/W
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M-ZJ4TDOT)ISB[$^H$;M(^)<U\A2%NJNW%U7(5WH\\GUAJJNLVVC63A!W+K+
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M_$9)2G><VMV.\Z6-:- -D?8DK@CZP*TBSAC8RJ)D\ :\= 5D%4/FQ15&&X6
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M^@:=(W-HZHRTG0>US3R(9 *;EK];YRP$ &><0 ZD9D'"J)RZ'T# EX\#OG'
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MF&B#<ZW-T1H2S^DA;D"C%P-J,[>V;L-$WK </.1,-Y&*"M ]LG6+7(Q8.P%
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M<V#>LG  C H)M)-WRHDM5 UT;2U5^V1,:7HVWRZI^D?X.U+L[\3^SL'X.YP
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M!>/V(T<XO_[)T5QV>E$/ 88&2?9V])+#:1W3 %MK@XA#A&IDOUH=/PL0V:]
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M[F(&ZSORQKXQ@S7[M@36#X?>=AKJ#[#E2[+LZ+7K8BV_5Q&N-!Z^RH8_/+6
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MNS&OVSQRG_"'__V5^O510,B$&GR_S.<-?O3,((;0-28XZ?EB4'VF"MC*K><
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M^&Y/;-_[C8RGMGO3)WSEM4CX=5T?&:F?[5Y>-G)M8:(_>I-[Y=)I(@LG:,/
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M'8=G8LD02X8C"N^\13*D;>OARG7Z:O$<C,<)3KZQQ2Z6#+B_0)85<*.EK'C
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M\^\=BF\M7,2W5SDOI!^]\'AW640"R3TQ*LB#F"#WI$BBWXMR$=03!_BW1&+
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M!RM<[Z[7ZG1[^6%_LE;*Z\BP*Y>ET:5LQH_#RJI3+UFC6JW)-E?=)ULH&:+
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MLKA$RS90=>#?_,F6W^]5C0JO%<,KGLV8<L5LK=E''=5_,0@K!S/\",NPT;F
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M>\BDY*FB*7CBY&',7_EL"B^9;P$QQ3& X(OPZ FYR/C0T,83TC&M9Z(U A,
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M&J0O@?4S<W4:3@EE2I.SFP+*',TLW&F.F9\^E5"WUBE/JO.5E7ZPTH5!_BO
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M)QJP)F8-&20\NK\?HTX/#>YY]-CNW(ZD;K04EX?F!?;C_M8+MK?>Z T#9^&
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M)6T@/ID,Q87O9@$9"-)>L:T3&#G?3>N[C*ONNLCP9YYT-HJU0_;D>U0@&=?
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MOEA;ZO@I#H: ::Y8!E)!7EODV/<!6LN0  GS^M8@1BQX0C:X2S:(NK9I,?U
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MN )TQ$LZMN052X3":_M6)/Y<82FI[W@R( 7TZ*NHT#M1S<<TZF52:MM;IQF
MEC;$"G&6M#@NL^87=(_FPI+.-[7!>L:(XU]_$T0B1-!1+SE!_%P;+3>2D3Y&
MR[P7KTR[<0K'PX-2KYU,1S@\"]!"X40H1GMK D+ M#!@ E5: F/AZ3XV,90%
M$#:\NL8F_*X9(]@&$'1[B:!A<TL7P (1$!/&C\>Z. 8V#I0:]],3"%.M]?R
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MCTR[;^'Z'@6VB;M?\?XBV;\W"NPGLL<3 RZ6FDXI5JPN:_IJ4V,&:>9]9/\
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MUZ;M$.L./</"31AB%\"-C1&.H.4+(-=*DPS_B21<+A6Z##@B+@>RR :I W\
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MO,H.'1X  -[#,-X5L&O@,BX\,>*5S8'(FB%>4NY'I$R@SFS1O'&0;O0TJAS
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M5-]<VC"$E\<0UT"/?'?/XDS1ROVE%&<^O5+YHEEG 97"'Y@_!GGL>P#WGN"
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MW_PGO%K^=PF\N+$YR8KIDXFX=:VN\#9QV:!WCAQS_-9V*?FPZWC656(U_(V
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M BN2=:WB9X&@M<1Y?=,&,Q55/GP'$B;0!48TX;L^"@'1KP[>OWI*H!2EUKO
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MX2_R$F"90"5H.NP24\4 E_HHSC')H:1EVY8TG50GUCZ3KA6\R!Z@M$4=&H+
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M]T!.)#)B"B3U_A])>N,)*QX6?HO:;74)IAR3+NQU=HOS*.2%!DELY+_""J]
M=/X.=8DLNMIXKA;IO0:[ "OPM*Q&]4I-9EN8C4M9 =R9C',PN-<+&*($('=A
M:Z='!B9.@GEC@@NC,R/0&F,B%]1GH9#XU#(V95N5^(13:O#U3#3^'9/-70C
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ML7DM(F_(3:-71I$?1%AA"F].=RD353!I$,IZ2&H*2P/M;!>;13H) FA5-@P
MIH.6Z&OXA+_@CQJP(_6Y'?"V/V:2D-[(OAD3ZU*='A9^3@9(56O)]%;Q<6!S
M6+YB49,YBS_$X7U7<T:J:9^87T%U+Z[+J  KKJW"JAG,PZ?1'(> #\8N'Q$A
MBJ7Q*SFJ6G2_>LTJEQ5L%<1'6/1Q,A46CXAV>'A4O<D2S7$40RY*!@NMRAM9
MHS)Y;C'?+N[H086Y8@),#=3@?U._-RR]&9;(:X!BADHAL1C'&5>,+7A[Y%(Y
M6K(Q2'PK.$O+&K!>)!J= I"IF-A-,;W-!,X>X',(FO>PH[AFZ1@GOZ@1I31
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MU!0F&5_#P;!R^N_^E25(XK89SZ*# P?=:.:_!6+*M]YZ2I2*U(/S!S4(!2E
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M_$1H%^5*@@!8L"E7UK5V(%T$; 1(GA-^281MZMKB@1P^"DHH#TWS[+8*@\1
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M:ORID>WDT_VR^F\5%8D;\"V C,S P"KQ?"0QY!D# NBS9C94:P]0C@D@/].
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MRG]@YK:->>.! :0$\OLK3NT& 6\.NDV#DFIA.YB3+-/=7<QH9;.0BW1;_,:
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MF5P<ONJ?R[WG\^SQM+W>[W\'<6<V$>/.Q8SU2##5S_UF.SZH'21Y,W2W(1A
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MGO9X7E_!XNB#K"'S AIN=JN0WO@/^-'T0Q!$PA88@35P<GKC>3T%KU4RFQD
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MSVR=>&G9/V\$PY6H.XN3RS7*+,O/(.(BRW*M.U.O->R>.F*I?^;DA.((\XP
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M%.#;_*\V#T]K.HU"F^-'GL%%LQEF+ 3E U>N<X[@)UQ"NJ3).D>3J+YF6J6
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M8N*VP/LKLR(@-*W,0@0:LG]08]O@0,?>9PQ=F IR<$E!>(T]!#NUR(OJF@#
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M/,TQ>ISS%8A_2'H(YUKJ;&^-6Z1[_V(P#&Y*O-!!<.<+S,F#21@JEVI:4./
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MD_,JN4M#3))&IR^Z=J(JHHP:BWMC;F]A<=1-Y"HG<I?1C."4)Z:CA+U?2"+
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M7JL#8#?'G?MT_!Z_.O4"/ZHQO6,X?'9Z<GS>]G_\E:#H_N8C2NU=(X"SL1$
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M8MD7R*VK=;TE-;QT3[AUV.=AF0EAT3A1VW*,EOKW+$#E'7S5R3Q: <7-9_2
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M)AC1WED-O0+;=Q@^Y9W0*$#A0[:6K>UT1JH*"#GKC#&5L8PT"+I?U [EJ,>
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MC4[;OVR7OG\,-LKX?$!A8,#E@!D"Z;[UHFC%_9@%&J$BO."<'9\KS&S>T"A
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MTV"/ +@=V.,9=S8":\^_7)3%G H>5!AE BK\DWJ=:2>$_O<54J@$&:58* 1
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M.8R%!^%NNROU$I?::WHR7&<!Q<NS')FCC8\-LNS@Z4SIA5'ZD-K@ LRQ^,1
M$JTR2)]3#^+=VM<V2V1K%>5,>!:6OZ7E:M7<:-?_ZMXH$M[6?O=_N#@^.;\X
MVQ]I>GRR[Z#<3HO:F,?+E'X2J_LN8G7CDUT;;4*QQ5ON+$%=,6AP,&AJ<)2V
M\>O;1TA_?%IPWVO!I1*ZPYH!:#6[#96'XOQ/0F7$=(;]]>WHG5??7Y0N* Q
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MXW.D4R3!KDLCDL?B398NISC-OR&S#48-P"HBLJR^?Y]-G?#^&:?_Q8HYNY,
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MOCP*,'=!6,"F.Z8=-%;W>N, X_>*H%+<%LX_SA_P7[?Y1Y0G62P05!#PE45
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MVSI7DG,B%HI$[- $*II5@=V&)"2;2-+23-0S*,X%G8R/\2E/("DDE05CZ*9
M,2B:)7YX10K\<;T_F9[5M^*^3WF(]0H$I/ &_ZHP[8]^X_[6<7\[P:]Z%(6O
MSIWB)-7:8R[<BU_D$V .U,W#;K&#Z=-4MD'7\"UA57NS7LWJ>ZSI4(G'5W<\
M)IR5+DL+,P_2>V^<_T5_@BCU[/EIIE7/N:\UQN6/3H$$4V+2M2FNE<H5,4&S
M&XZ7L#1\#OA&AE5==9@'X*%TTJE6C0&/7K03I*Y1B$$P#=J85\S+ Q3&VSEG
M=OCP<*Y<<0>!_!;\\=: 59*R,B$:_0Z8E;)5;3=<GYB/PF%:4@_BFPR\"7D*
M[8?+XQ<7>^U6<;YO-D\'^/62.!R/F,5CR2?B&G6@D]O7G-+>$*EATUN8Z!<I
M3E!$J5B));[+3]YB$4U4V-R#!5GX@U[6_<#='K"&X#I#(2%?YE,4Z&MQ:1^&
M7GU7K_*>DZ/8Z7$H%<4;1?+);\#45-<LJ(J_ P[G-V%F>-3>WJD9 \G:=OT1
MWVFX%DCV]=^?/RNWQC'LCQL)&;KZWXN'T6MI #'H5G*6\_/#"I&#MF6:L;^7
M]I; 4T^CPU)1)"P2%<:'F4CPD=2",+4ZVI-=9.'V;??ETVX/ES_R3_\@DLZ'
M\8L7QV>G>SQ0+O9]H+C)&/%L/-XC) &8[26$&B#?'+/5![!J\W6K(BSVKX<,
MO7+G1C&"N7A7.,>8Y93@3Q%5V7XDTG:AN[G%6"H5.G#J1@<KMK.@FP7(@'6U
MBIT_%6%M#PW@Q-X5( HCR(-S/7NZ&@@[@6D26U HH3QL&CSQ)HY+K-#&5!-*
M6!5 R'4?DQ4R0G^ZT*.=E1P<H_7=OM-G=4&"$S"-P0,/[(4=&KM5_DGQZW@!
M.ZA'>$A=V5=&3'LTD6XB8'+6A"TB9-J@8T:[,E,0XX(NC+C(9/OI/33I!]X7
M2/#?=:T^/K[$KC8#G)N;8D&87YP#/K%,'_6^91]L.'IEUCCX*>[>I">5)$M
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M]*B;QP$R]$<>2H,R6+@, I*#"3X>N/=Z.ZG=!Y6#?K!<=A\8!$1M],@LB/8
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M)PAV,FX+3,3E^R1I#=Y^4<HE1>D CJ,X-8<#N]<#BVV.V*;"K&!F^9(]1)J
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M5'<O)^ I(A<"Q"5V,)WF=[0HF53Q6HHU'60HN(4:(YLX5-M!"><*F>*P<E5
M E_OK"K&H-U#-7UHI?XR0F[Y4=P8NK!HJ*3(2%ZDF+/HLO\M3KIOXJ:ZW%G&
MX;UC\Q.(_XQ";#ALKGD(OF9-@74F*5$G9+#KV<B2T]?*2!=P%Y+VK"CRZ?LE
M[1)-R(B.57A3PHVMJ@A,Y*S<SHXJ8W0S.9!K?N#_[A76;<-E&E'7MRTR\5@T
M@5:HD4N <33/;2:2O_7N@BJ[[(5LDO71U<G@QBH)UI;[&P)LW+5XH68O>AF
MF[_7KS:E$GFJUE$&.:0#P!>CG,!)\DLEL3^47E:Y/FN XOD!H'@ *#Y'@.(W
MV19TDMA0=!',9FEDA55$1 BAS>P67ZVDB#DSW/X\Z!L+6V=!+)(3%=//ZE)?
MK?@JE1QE5JJ%8%Y\OHT.O;J*O/?Q/D?#C%0HZZ^#^GH:Z@MS1I@O(JNCR,=4
M]RA6D5?G2':1U$>P[GH:E8Z\M<8C\PMVN"S$7<"A2AV$0>L^1VX4FCH4?8[D
MQHZD9=PP'S^:+BI-+R="FS2 3&"X+%=_<\XXFVKOG@=P=6OKR:U$:;#E"),]
M?%47?XVD#G!\>]L(-W\G4FTPD=? @XC3\AG'\?/J@Q1]?[PY/3N]O.X+5&_D
M:M_A$%R/Q"[(TP75_UH2/1WC"G[,A_4RJU?TX> B->;.V670)6@.[?AJBH1C
M,V"+;OGP]C600>/D+06 AQ%6)H0&E_V<Y_(-(QB!([ZK3C[V8V8*.%I4=Z3C
MK:^L^MIS5H5R-6+\-)*+H" C2)XS<TJZ@ZR1K1VB/C\;O#H^\==)>F]LP:=B
MX?Z<6<#PF/>>5B3 X8+JY118NRF4 Q[^W7+*%A0$P9;3NTR5O>$>464>OY,0
M<F,7,9.&[QBT63 Y&R8+K"B IW"LQVST9&++$66/_=$_P<0K;Y5$4UHXD>@F
M'$FFCC#SQ"RC<)JIPC3-^$SC-3%N#?R-K@:E%O,Q'3[8SF.B#W+'@'8ZPQ?@
MCPL,%+9:(C;N9K0:I;@3\H^3#R?))!\C Y9B\?PI>W0$'6_^_OJG-#@:."H&
MC6,\%\[%LES4RUQ=<$3QV9%-,L+Z5<R>AM_S\X7X%4UH/^3'\9)@.:9C]U#E
MF2I,I3A&T#/@7R*^9XJ$9A*M*NK1<@;YG9&%U5D6)W.=@' !GH";E\R*!FI2
M^N!WVYR?;,F7K;F:.D3*$*9><(TS/3T.0,X:)Q_POR$P2*>+DOJQ%UBK7M&F
M:!G$)KT]]O(9_ Z@HB,^$E31/J[RACDI%SEQ,0&XS.Q![-U5+3]LY&MBQG2-
M4OCB$+ZJ6NI8>)[YSM'@5)Q+0.313F#3RCG01(V3IH ,8^P]8(I&%D*JABE!
M() ^8UBP7(:X.3>YX%^P8(:O CM0*LC:$:M97B]:IL:M4QH;5HIR)5)*LH7\
MF(;RXR1Y-[&I&2+[^QF[04!& )U<4#3N3Q)5^+"L'VCN3)5NX2,4C?>#\80Z
MP4G[M>]IX 7F\$89[.W(LN.\9:Y[^!ODBS R/LREPH:R*LB#RN:#;S5T*+DT
ML;!-"])QZ@"1^F;S).UNJ59W>056]\$/G9G>(M(2(<J0UZ/S<$SJ"%FFU/:A
M:!S2GU).+5Q0_$M!]HV&%V!6BMS98ZI;646\7;F"Q?N_,;O"$A!:&DOFJ6L)
M0W&#.3_%,)!22[(MGN0;KEHNGB2_1XHK/$BYBZH#&MKC\JKF0#.U+(O%2DDS
MP8?@.#JV1W6Z!OX^9^8RKV7;OO4J47CY9 _T2C%E6\DVA2Y^U":A,@,[AKCM
M"ZW5C)4CX$]$'\?8N,XMDGF*.,58) Y!=:Q2H<,G"%2Y]76L2M5I=>L2T6_,
MC9X-\YI^?3Y ;^W"QTN@!;>EI2 Y<->%.#-G# 1*E-E-(KZK/ -D/1BT\1$9
MSVQ+YTI&_:-]GST!C?:T0N/16M1%]##J4 6_0CF0?U Y F?=/UY=75R?ONPO
M>-%[+]E871FOD4 3GFY XS=[@:Q5BA@X$CPIQP"5&5%6&K^Z>*R2CN(+E##X
MU!@BB2J?*+LA97[#5:MK'MIQ]I?:P&Z6 %% QB6Y6!LK_<C5R9?L@;'#J6T@
M+XYX=G8M0I"<O3#P[#I1CJ$3$3NO-!\2WRT4X2:0B;.B;4V&AW6QBT7*$1?9
MK)MYC^O1D/.;A,%)K1M\T=J&:.I3#P$H\,EG,OJL +#D1 (6U.2I>YFNSOQE
MZG[[?:: /11\R<Q_ (J(NM*O>6[(CQ19(%B(11/4C>9B/X.)3PZ1)JIR\^6E
M"!%P:@DZ8FS\?-Y>W \D+J(R&+?"/'-H.#A3"G:2%36TPUK:3?';2)$';I=A
M9^6P1BXU?CCN'_@F<\/]$ #=6'V'P76KF3O-M6!RZ^Z,"%AQ&Y?@_?'N,6]!
MA6QJNUV7Y\T+=7& 71Q@%]\O[.(KA:7?:Z.?31EG\:/$G5M)NP450-M2T>D;
M\'Z-NN(HQ=:26+_F%_RM9YPOL#"H]@R<D(> VKD48])?S$VCO[!&RI/3W1X$
M3]!:,9AC;W2X$UX@?5,=VI9>^#<LS;;E^V/W#=&W#=4:9=0V$5 L1@!U<*^<
M70[L+H=*G^W$(?4)I(:!UJ7VE$F$O(&5"YD;:*?A4/W"^;869Y6VE:FF&>77
M#0=H,>^-/4N&2&-C+GY=MW0,I7)9GOL6NZR#'/B<,77'5*L0H]+XDLEOWLVS
M:\ND$^XF1L"@N1?BW\GF*<VSYNQ=X9>&*XR51O9368#LQ0)C0MZ,ZF(NT%LQ
ME#V[SG]61]3><J#[1A<$?2L 106!-AU,S!J"K8NC#98@<Q) LE!9SSY'P4ER
MJQ)5C:ZDBZ5D%]6Q%,^Y].&Z4Q?9JT-9SKXF?]7N=&_#FXI\*,@D&;&)FZ4"
MG+J#!]_E)YAO\X*[FD- S?5P[O9T[L9R[G[P,X:^ J?C"'U*9HQJ]?5\7% ^
M5%QI"4I&Z]F=G3B5T-@R[,H4CYR"$,4&@HV5)=9L]X)4_>[/7.;+NB-*BO#9
MLH4W[5/XE4_=,"?K?Y+7'/3FU-LN<1,:V7MO])[=[F,_VI/R?^HC6RUG%):;
M8+6W&>B1NR[M.PJ_C'%!RJ/LDU:11_AC.>[J9BBY:"KTI?9^2QS],/;42O#A
M,[1'<INP^K)AK1]50NDQW/S4[CSUDF'A=80!VO82K?G-<7>UN-74XC94M:W0
MWZ?R/=TJ&];9,"2LR_:H)P^2<4^2<73LT-GKF2</6[)_(M##FN_G&M@[ - 2
MQ;!CP0_6GK/A&FLSA 2@6T;THK:O8P7:EN)R4_RK257<L4U:"7F/*(,BP\(#
M_LK4UKSXO)-I +6#"6AN2 L9'></^;2:"_*#\5N0P/)2.[IWN.6VP41OVO$(
MG\Q.P9@M[667/DWC9#YK*+!9;34  </A+APHW>.Z!(!L2GGJ,2?1\NDD;6\:
MY'RY41-4[C>NS=YP.;XSGZ6)\5&(*A6X\D89AQH9%IF72^Q)G]50)*=ZJ[@=
M--N%0:%RQ(8&[ X^PW7(/>;4&896R3*5[F2IM,^$1W<V$L:?$[$"&F%U 2GI
M((??OC5'V4X6,#)_F#DCT/ A0.^GD=L D"3I_,-]L],O,@2[#+FO\? -QF]R
M9$3>E/KD0,/GW9:,7GC+#PUF]1JOD.=#%.:4#I<+:I,$_[!%H %W<%L2^%UR
M5:J# 6D0]5LJ6HSP]VN" MVDO!WDL)WB+4X0^U7.R!>1RL) MZ6.C;IV]UGC
M]<O@5 HQLI@+!HS&$[2NAT9Z/AX[,BL!,O,Q\TEW!:G/75K_7#8+#OKJ=LN;
M>G@G3:60%U$]AJQ<38N5,: W#B/M$UO3=(\SG$)?)A=_MC$_JT,K? RV_Q69
MQ"1J]?H9="UM3-PH-+G*0_W%$]NID)_G.39'DK0"4>]1%PN6#'388(-\+;/=
M83ONK=L$[87%O//)M#9=P)=L:P%D%T9 ,PR'Q>,0TCM$A]QE-BMK0*$9X&V?
M+7>85$MCEEQ$P7"@<3BH'XU_K548VR>:O1OC*VNJX/&(2^+YL\*#7)M5@)RW
M91R #QK7T'B'67 K:@OPTPV%C1F9/V38/)$)$!?*$E2][&REXIS)\_%09\F\
MPC)E ,"&6D[0B2Q8X,>!8/&JA((^ABSJ0D$'Y%IXQ>L<Y88Y*G.6L*Y]>E3^
MAA$^ !RGBB6QJ_61U2)KE$C -,W?,9M;U"3R[4..NQ6.!-%W4SB<<A7!\U=5
MS[EO!'$%2]!]VF';&6X?<O3[F53(IC5\PG&X,]BXE(L-S686G^$5*&G'+!(W
MQZ1%>A.T+W#(<'&[SN9Q!U.?QFH+M("W,H +2./O<#GDC/FVB:("7"#\7 H\
M+$\  %%*)"EYULBZRP.R[H"L^WZ1=6M2]Q1UL/699H]R)VM]BZ7.9P#09UGI
M2Q+G>5KJ$$MFR6K6%@RCIK;= :4F'VD*NVNQ#P"57H "CA1A70X2S89L)P/6
MJVW+58,2_UP9[6GL"5%/1G]+)A=G8]1NY3+%M910)C.C;(OYE/5:0_$U36O5
MBJ1TQK=\C>Q3HL(9EO2H9D)5P -_-L,<(HC.1MW)5HZ8ZT0,X'A\X8T>10";
M:UZ -^"94"9:YR*X^HWV*5 UTKL?@]X 2_DV@"5KWBF24(4VL;%H,D1C=0R-
M,5"V16O&8'D'@=</2L4#9F #'<KUA]R]CA1&^'D)0.L:38(CI_O"UE[7V$G,
M2;$9A)TZ()B_0PL\[#JZX_UC!BJ49.J ,J70QXNS\[/+\_[*.<_[+N?LIEMZ
MPE6<.H)!E.Y0YD[A$U=_%8T/(N4)Q""@HM C8!@G,']5*<E1( 4TYA>;0S@S
M;\(U$_^^$.BS16TQ^N;HG0JKF[NQE+ 85]FIQW(='#U7N?,;OHD/113WO,*2
M/;@4A7320*[R>"5?-TJQW2@'1 6UKE"$4N:37[)FG/V+F8'>Z;G*6,W@(2)[
M:_WU(..T;;2OF]M+A?X8;0*! MK%O_9\N0FZ;/#W^[4D93;N@#QE6Q'C,/U!
MG( F6GYPT)U[T9T#ISO;M>%I4!Q^=9H@Z4^0EN9+&+"_H=12@>>9^<\EARTY
M*$7>*[&E?$:7DFRS.*O_8OVIA)*NX/<!GP](T*!2XPLP=I9E:R(Y*)>;7S=
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MQPJ2EB9_FDN^D+W68#5PB(V,F!JWT_WU./4B[QCX;0.Z8F<W=IJPH>W6QRD
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M*DBE;3/SU_#BH/-OR1F>*,O5BN:=L@0$J "0[!E1!P!Q9B8IT"9G3>V*S4;
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M^)Q#_FDYPQ:8\"+"M)]=FN/-(P^_B.K.1::@-Y19TRF<$.H09<Z0^3YKQWA
M'#5+L'I2=&47SWSMBRT9ZIPA731CWS@JB0"5JZ2 @2UCV,*X6@ZA% RM!I[F
MT-KH=%AIN3&.1=P#(Z8J81Z08F+K$FG9;+IRLZ5 Q0M$/&*W@N)5WEZD%.B*
M&SEV&?'<:&"]D7/%;#ESISI[,&.@UC!@D@=O<1GR-4/QJ>@DLZ(YR4=5-4<,
M!EU6VU]]JZL=\*A#%'99VU#%AF4]X75]>IBI+[/S(7J)A3>1A(DRO*.YD]3)
M.QL#YT =139!(7!U$P:)2& =\#)[P<N\E"!YO"-. =5%V(!/3C[L&P>)75_7
M2D>JF\,>]K.'O04I)VN#VS[1Q^%@]'"Y2?BZ@E1L VZ#%I8(FZZU,@ZMEA;
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MY=)CL2&_#FBH7/3N?WUX3R$ZB*39AQWK^B9CU GFWQU?+'IR65X_\O(> ,)
M@]=\?/GR].KJLL<][!UD^TN5N/7P-L]&U\AB;UQ@#UL^J[WERR54=-U4>EZ*
M8M<,Z->A. LKXXA)R[&F(+GTKQ@<Y(IB1Q# ,JYP#4&[!QN^AS,]:XLLX*DP
M'NR,E_QIEKL9$Y ](3JO&1(W"E&>Q%SKW.\> 2\ VF2*2=YS<P3^#7;C_?1E
M<RJFR.7L&>0.T"(BX"/0HYSW%[]\>=([E$BMBI6,]F[9:+SG/N-)(5Y-"G&9
M:\GQ;$D+J8?^LS(W\@C(%Z!3[K1-K(;N7V'V$=$-Z(%Z81Q?O2_T+D?I@FZ=
MM^=%]-L!TC43D2^&,XE2Q-Y<OMPO0ZQ_AGH'OH04L;_?KZ7J"^6-94ZT?)7>
M*IL-^,?<0=L^7H(UT^-R]XZH: $J&V_EVQ^[BBTCD*F[)G13HD 3RMIV1/(U
MM7*ZE;#,Q^O+P4U_2):7)T\EY<T+D]B5"5MC1+_4+G-?<L)ZK!*@N_##JCIV
MUUO7BZ1];7FJ#XD"3E23-XQ4!KC3X/K\9M"G-.P](?C:YPU6BQ,OI,0S02<!
M553GS[_HH$1"DM>W-A <#T[V$I*\WE](TLT_V3(ZJ3#3D9S4OBO].P,G\6%^
M01!E\97C)AVQ$,N7\?7"'[<CX_MEHU4U>>\3-GP<G+V\[!&+>=U_$$36!BN7
M_=6)XC%_- _.V/,+OM_29XB+H11H#:CV;LS.IF[FB=?YL?5<]C [H(]61#:
MN@S-'/A5,2',C/<<:O(##SB2/NE>G \_CY'$&!&+E0$Y:5KI[X*H!'P-/3]#
MB'TQ6D*5 V&N"J$G093!-B_H7I-@$L?^-G(LH_@?TB)?NI//8P.ET7W(NG/T
MF=U VT&]*#.Z#X7E\L"R[#R9&;-J5B [HN#7I\29SHVC[NZ JP1>=K12CR4V
MP0V[R&\B+#!<CP66KI335==9@>QDL>WQZ-['-)317&(NC"Q9"[.0JYSM:(IP
M"K.,J5[R8*A\\C:,-( #LR4K+ [>43JB[*[-16\CFL+*IO7GOQUGZ[A>3^'
MMW[-TLH&:OQ#'SVRCQB&0UWJR%F'U-\T'#I1)T&PKIO-D+K!V=7^603^[9BZ
M81# UQQBKD>ZHYHBL4@J9ONQ;:P$!LF?;'JN10"(IH'HI'^TC[U^<3W<U/U<
MS6S]U4R.@#D',7]H,#0+:(H'1:!IB]=$@"L2?,V4Y;"%JB(:G^5<K@OTI*K&
MKH5+0)W6+B:F\\YCJO5!P_4CS;H!INQNY+AHB%LJ'Q\_;UC!Q0%6<( 5/$=8
M 8<6"7D)F;=J\EK8]3[>W)R=G_97.WK=?VI3+0P=#%Z:J%NFM E#62FG[.<'
MN_TOP,OZE=B:ZM*K3%CS?..^%XL.S.QV+>*\MLNVN.KFZOJ\QT+BZ_Y3<NV"
MJG:\T"+>_9B(+4%*;="$+)*-&8 ?GEY;A,QKP<;D$@Y)>U_DD^0MD5&:%?G5
MD8O01S_:7JB_.HY8S^_ IZ^\>@1+>=6%Y-YS,3ESP'UOO=FO3P:N^>_W,^FS
M[W'2%]_CI"^%# @D\-IJ3C6\ZY.K,(-(<?:"20-=!9.58[IIA@ZF8 E8H^O2
MH75,R\N,UTI+8;Z3QB-7<162%?9"O_&]"4Q@>I C96PQ&V @QYV8G#N"N%Y?
MT:?7U,2W C3?0*132R/,($TR.!E<7%R^.+-D"\BA>G)]\]+\[?X8D+QW5/-!
M<#KJ*VO6Q)5+PNJ\>_\A=J@7]^U"XW7C8581]7H_4E=P7UON7<#=1#J)Y\D@
M[&VWNMN :/L*JB%)='S@\GEL6_OT>-&[!9V/QN6)2222 Y'DU'R\.;_YAC[L
MAE9KU_V#P'ZI-H5JK3OSH:!6.=T$ R%4E)!Z(,NHP<?FL+!JW+4HRF50T\Z_
M5NB^/R@Y_=K<64 [7=R\O+KZ=LGBC=O9.\@L!H#D-4IXD:+!B37?;[EPBF*N
ME13Z LB:+1DU=_'R\O3;U3MLW+VG@E6+%-%VEU)N7/&$FZ%2\3UIRJ!4]&?(
MG"YGL.-X5\UCWV%Q)+[AEDKXPVR(KMYW#'18X*TIWMVGK" 71 DSLN_2[>/$
MJNF [L?0Y!N@<%T+%T%8W3Q)A-7-$T58!5?_R:&JM%AZLE J-<@]X:FN3J_.
M!E>]!6IOG@^>2J3Q 4[UG.%4?F78 4UU0%,]&315!^YW%V#5%C)*<%5;780#
MK.KKP*IXL;\VJFK#8P^@JF<+JNILT'# 5,4Q59<'3-4!4_5OAZFZO#D_?WG3
MHW?V]#%5'5;35X!7D4%2U%\)9Z7\]=DW0%Q=GM[<7%[W>%2>(.*J V_W?<.N
M #9@\5;MQML*3[411A7 F[8$0-R<#-:B1((OG^V$KK@YN>A$5SS!O+B$ &M7
M(-Q(&KE9UR.^W9O=<WW<V?3;ELF7PB1.I5M?QMJI0></XI5<</TY).1T0[#.
M3FPZV^_#.[;<4VB[E1"?3J^YY_4)<Y[M+SDXU<V]39?[V6?Z5CSY?'D^.+_<
M;P=67X0_A?3S>I_VJV:?-[C/ZY//TCOI5+7Q^GA^?36X^+H)YVWS0L:XW5MB
M2$W9R_.TFK]]'%S=O+SIC^_,+$KO^87(8AG#Q#/\N!F4ZA*V1:,4(;OEYO)
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M1T>="-JLL;*IX&17J0598?+) 5>[V['Z=8<:"L9]T5NOP_I$?J%2V\&O/3/
M.!&Y+9+@@A5V> A4COK^J=$/?9]6XXUE'X(M/2SY7I9<N(]4<<0PU_PV-H2'
MUHU@YD4JU.$7(HAZ[]JNNYT].K%6 MC 1T/QM/L<^VF%IOX7BL,8BG3_LTXF
MRQI$H#][R:/8DC*D%0KB+KZLY3]O+)6J(QZ2+[0!M6/>B7VA.[Z3TF:TV0KX
MS+JFD.M" 8<X:&\!@7L_( !=<B#ALIPN8G4^3L*H [DT!VI*^9O,O)=PL%Z
M$IL]9N)S9;#'T-#TZ/ST.!EG*^XN"<%%<QQ&6$ $=@XS:Z%9(5@19B2:U-4L
M+$;OL%M:PE$-'>Y$L0"L*%BW!5<.V6-Z.)=/YEQZT>#X3D/W==UM=)1GB-(%
MGH+/>3TB0@)SQ.H1L66HOO>JY?UH6>?>D5'8]L.!/!Q(6H/.6L>#+OQWV>(O
MT86%?[DWF%8:HDH^KT.YDB7NZIB-X#GN+>!:; ZX[B<V$:"-MHI(M"_D(0[Q
M["[H]2$.T1\'\W<=AR !( BM?^,(Q-[! SM$/&(%%[L$.((HD@IK>#8[;*O7
M8.!@NCUY,86F6_&,PQA\X$(L]<%-_'<XB"T4F^NXL>_HQ.&<_?N>L^YPQ$&=
M/?_=_3J1B+8-M'/\P;RCKQ#$GW\-\_4-X'(@'#5E+##5N*X(COO&;XX0X5DS
MYC<PXQUNV9YOV9^N>A,--74P_E9EM?%OJ:SI?V!_G?9$\!NHQ K@DE:4WD[-
MG^'N&._U>_+BHA#PEM;1BP:D$>N7C0O;?W#V=[OMFZ6&ZJ2?(G(J:$BB2*S)
MUSY<LCU,_M+VLR+RH<.:?_O)7YV<VYL8+9\AR:;ND5!QTDVZ \-QDIF;DS)=
M!?(43#E:YZ[4<M$8<9-,\SNHO:V699-/%61'8?35U:>:X UWGX*-W6RP2"$&
MHRH:K$^U8YH4XZ5QGL #:EUXEQA.?LH>I;HH*EV\)@KS+.2,\OY;T9(D/^;Y
MH>=7?_K\W-7T]=@O 0O>S9UJBIJ]^R?N7_%F!2Q((K<U-;8>;Y]#1=LMD[V6
M8L4[I&B3@(=X2=JAX6M<264E)!R0+F<E5>-DBJ/4H%(_;\Y,8Q@^MFB8+YAK
M1X994W I); >FZ,PJHLA25<5TS%BUXA(S?A$U$351#,_W5Q<G9_U2?S4.W7I
M6\L)$*. >D=6>_Y@"[QR;W,B)3X^8<[3NW-I.&)+G(EMA@0GRO29YH21?_Z]
M>AJ6::IW$0JW9>]KTC&0<\_P[L4*>%O75?U_)>^%=S]IJB6<6/ &)U#Y=;)7
M V$04VF][M+@Y/I8;Q.%BJC&<)Q/BI+!)L+6 7\""S@'4E,CNE 3-=+CDZ1$
MLZP?0!%N(0=M0XD:^M^6ZUN=62:T[1X<*%/SI:=R'UQ$PBQUD8/-0!R6A!6"
M?TR+;%A@EP?0WY,Z6R(5-?P#/H9F;&:A<)Y?G/]/E8OB.'7LDJUK5^*9#,8M
M,HY7HU2C\4*:CX.SF].SKVLWK#<3>J>MEI5X%;ID35\^ 2_.&B;$M]19I=U\
MXQ %WI_7>(A0[3U"=6.M))#%DSPG[$[.5QBB.T0O'&U8&54VW07ZUGJ>9X7E
MG2!Y3^\!YP]5J;P_M<RM1.BD&>2(R%AX.Y]WLY>7APK]0X7^H4)_*R7>303\
MS@.)><()PD".C-JK!= QY-[C:M^;!HHQ(55AY]C#MO2R+9/C2/I*PSHVMF6C
MSMP*^]%-_)9"N4I5 C/=&,/S]1AQ-:OD=O2O94%2*/FMKHQ$RJ;D 2:C^ZR\
MRXDBM5S4U52W-28CA3/0J@8PI,&:+XW[-X)&?V5I=.PH'Z?01@[:U%'C(]U#
M>39;EMB!9AQ,B7)Y1\Z5]QGP8"SC.GLLC\-\EZ4(S:?FRT>#L^-D9B9SWT26
M-PQX6WI+-#$: 4)(Q (\:I?*"U8CP^JG_%]+HIARRU;5RJYJNK\'/729SU#W
MH:3CH<T^(E%:T_5\6I@='O.,S-*;4[C$;R",'/JS(G[749H<IQ%\>#L]F%K^
M5?-=HPRC!*R\RLI3/:KJ%,N9;)Z202EDFIJ#MEJ[TGH!"P$HQQ<1NC@"$Z^Q
M/*##*=@/$TY=FO^COO0Y-(B$F?W'^=EI:JYV<K0MP7E':E3SG??FBW>3([]K
MR9&6]O:(V9Y27JQ#G_4W%BO$Z<X$U7=\9Z1L<(OK$I5">(9?;'>(+T_I$(,$
M1Z&!T@YY/Z'_9T'@+R+WQ*P"D/T:XW,.TI@NZ\_9*NC,P$@'K_3)S(UA7T7$
MD,<>P2,OA5)P?5$!6&W.8]$R(6R1)B*DYCEXL:M8Y4HKEQQNRKD]^]#/U\SJ
M/\Y@1>!_O=W&;DKL+6YCI"W6P4K;'WMRZJKCON7]WNYZNZ.<?($[=CA"?1RA
MNZ]BZ$MO)62D%1C'1C).<[C2N(D?&JR=M>- ,/U%IKL\K2?;70^A!P.^DR]J
M=Z'QC&SH_E5M-]F\$9B.;!YRGEDQQ4HSV)''>VS_2?X53TM9(,6!Q;O'E!7?
M):ON7,,=F]@O9L,E]&(,<6]@!RLLVJAJ%D$.1C4.4%^TN1HC\/#)5-."L1!$
M !]O2-[ NZ93_IL(*.@D@X>,#ICD=/(2H0B:^D//P?P:0+\8-VX.Y[#GU*G3
MX:UCJ&(D>O^@IA1:^R0BH(-C<#3A.'F[K#KS6]C$?OT(WS%G UI.8#&MWV,<
M<H%XWBG.P\4_G4\SI\K(_24^"G\;G0_B9XZQDT128WTL ,_+<CESND!%4>8U
MF#GP18Z+$(.96!5PYO^6E9]@JK<SLP:C+&$(BAGBR.A!6I\Z7U3'& UCI.2&
MN6RQ,O/I$A"L=8Y3&%G020^*JYLJ7]#6P/6 .AP=:2#ML?T2#Y)@/Y+@3&LD
MB8&HJ$6@6PYHE]Y%MD5%P Z9+S#@#X+K#1C%4*TZ1AV+X3*Q&J38-=N  11M
M;-1]48^6LV8!]3"-#X8_['PO1F,G4T [!+FV"]4P]W0':OE[<('&Q4,Q!G6'
M-Q]*(+)9=F?^4SR'IU'X\AT? K 19M3ZTKRZ*K'G2 ; TQ/P=P_JLR_UZ23L
M09$^Z2VS-\D8Z1FIQW2-)XYQ/56[XR#F<4<B=)S![J\+Y NJEI%.5B*;O7(W
M2FBEZ#%TM:F-.=9W!39DK2&"&2$&2>5E08_=;@@F>18*-ZE#OF95/*\>GUW4
M$G3$TN#)Q"P6QA6MW0)T1(LINRTU]X.%.@9L38;$1D3D.<V*6:J:A\WK"O)?
M:,7<F>\:!U1ME_E"D^>?5)<SPO,#;K\V6_SG<GPG"RYJC4'_GXSFBSWRB)TV
M ):4>9TF,VSS;AP5%Y6&"'(-Q7_FORHSVQ'\"1:S6N5YBC'(8@R5S:E;##.I
M.QX)3?6]JCIX<.%?',7QMSQ5PY6>[X;C\]=/3Q@01Z85>X0*%I);G2*S8!#E
M@NX+P)#EC@W;OY'M%$HL][@4//YI]D@$/.#J%W22;"(@_3=:_9/DK94DR@$?
M?2JK1W,?X4)07=YG53%D8^Q-I++EH+/V':^KP=W# -Q=G4U1,FT\"49FKU0&
M"HZL^7ZC]S;UCH3CC%4$$)$4WM'_R#UNYQ@.GD+?9X4);[/$F)S9%*R<H=EY
M\[-[JH80&!W4++(^!*6IDP:\IR@5H'B.6LN;@[7(O0/#?%A^Q,#\4=7=NW L
MGY!7MI@[3;@\F.N"S:CO&?YW.#E[I>&8Q'K,3HM9H3H#-Z$".= R[;$4^L22
M#3SO"J;K0P73H8+I.58P4?4V2Z'!X.>B&>73:5;FU;+YS=;-?SR[NGIY<[.O
M,FX?,CHXV9LT]J:?N/E[,HJ6[)>J_( 4!]FTFKSW">"-,?F'T+_W1YECA&O?
MM?!FD5[(*L'%>A\ARK<K95<Y^1WY)]9SZGO=5&PE"'Q+=[=9PUX@*>Q1;O3^
M!*%QY#<WBWJ)7V ::^"F#:W_D!/'46LQ%OO'HC;>^ELAK$U@7U,<7E5.5XP_
M(08&=E,I_E743*NA^3-B#^/0@@-8[VM/Y5;Z";Q-P]57Y]8LW!@6[^/-^>G-
MV7F?5Z1W5BF[&.KT>P=LEF&&*X/OY6,'7PJ)A%6 :0B(3KPC$LQK7QA]2^ H
MR052N-<CJ3X7;&NM@)VV=SW\V!_+FE9)MF6&"CE2@XS@%1TXVBX*Y.^5<XH6
MBY$X]QOV@=,#T3U((2F0R5ET<4DDE"._USP!""LYU=K8%()^*3$!Z;U5(9KM
M?A&] $P7+Y<@)[X2F%.I)3;XZ'6Q0"(%8[H#"AKHP\UD)A9!L-U%T/+JCPS4
MP,?K\\OKE[T*J]ZY;6@E^N*Q$0+V;AZ;6\AN6.HB9DYD ?H(8[?E<_ O)M.&
MW%@US8U6%OR??TVJ1SE#J7>:(13-25$7KL>?GB2_5"ZPS>3J'-IT)$^ZWP:F
M9<P%KU.*2J10./Q03/,[E(F<!(AU9R*CPEQ>8ZUDJ^ZW03Z WH8)I[_P/I(-
MU3Q'9"%V!,"UK5WMV:8GOY)!PV"F^ %V$3 BP2X)CWZ[!PK D[,H:D. +XO%
MCGTT)R\P,Z(W;^-K>CORW:P/OU1>?G<(]&PP5CA>F.SE<X^F+J0@U^=Z4C&+
MO_1T$%^ZO6/J5' "=/.#S0/SSV#]-^9.>LB"S+:3T6;ZTGS-[.UH*2DY9[A[
MXC_(G=G3Q>/T&I,HEF8S,%Q(+%0A9"OK'XX3$W=K,<)!(=VRC147&"(&1MC2
M8TLS3DR=VU5[#;'DO(8KT+S]3&7]S7#U=MJGLKGH6]G0(ND.!GJ=7B5VI4"F
MOP4H?UV59A<P5S0K&M !74:U(/OIWC>C^]R<(DB@YI_OBV$!&23E%S:I.F]D
M):@\8@V\DHP]:WN9H"46Q6+)*8:<)I5Y(VF61I@V.<@M%&*%[LE'[V.(7(8H
M<3,>B#G9RX!N99U-4TA+$ !AF"\>J31L%0:X8Y5E E6>8>L1T9R\2O#?WZN!
MS9E(H.4H03]!0CUT_J4;I>SB> =*RPA-.^3T,0;P':QYM/$B1DC>TD4DD?-&
M5P%YG]Q:; '_^1@$+K#RUW-X)5E\M:5^):Y,N&ED(_%)APJ/^=+\I*'8DA>!
M/+L<R!UZ\_?7/W5YZ%8% 2,JG"1N1R 2*[7^!^<1 X4- $BNAB 10WU[])>5
M, &LI$BQ)L,&I2*A*("6?W;\,!F>/J4EW>"/$!#B1NG!18[1Q3(O%MEA_ID[
M2;M0DA9F_=N;'V$EC1!QDVN6@"(J<@J>#0L>LCR0Y0_%O& ^JK=QRSCQ@DA6
M01NG]+^7QJ89%[AG'\_.;BXN7_:I.B_[5IVW7H^)5XE>GRZ5:'?L#A!F)5Z<
M5+8$CA8WN/&E%2$MIMFCC3!]6'#)[QOCD#P:9]K8>OE=5H_1+N0OX0_PLL_
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M"X;8HEBT>VOUA:(VLE3@LE*9!::<PS1S]_"+Z10.O\ZQ BU59[Y,@3')-=/
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MS4'?8PIIVI ;PD[H<DH)B9QU\JKM !MN[X.]O7LWNKT'Z/\&0VZGOT&>"R4
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M6Z[!@3L>Q$1).R_V]HB9$WWACC2>,[ X^X-]_P=$(W@G&;ALWZ_!_R2+*",
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MOZ#NF*A;FEY5\JAQ]:=P^%&I/V[@B$!M -'O%=NW32O9 ; I.7L65^%6EV_
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M_&IQ.&C6-9JDMN8W^4XKU!B]YE&$AU-YK:S'4;I-'5[@_I?7O5ONQK"DFID
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M@$J*0^OO;G,I\3GJ2^>^;NXL6Z0D\VU]+AWV_#E26TO;Z=/]3<B]\>RA4]L
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MYGE'&^DS1)R*.*QFT=? _C7-(NZTKL-'< "7FZ:?-W(_FH6G'5P4N!4H@Z*
M2@8@7R,.&HHW*( -BE N@XXPJB5(13#"QI8BC !$,"^XLAM*FB*YO_G!JH4Y
M[*)W%^@(<])7DQ8%]P:&B(&+:TBC<$Y1CD8HX)M!AZ9;K>60QV >C-<,Y=&Y
MXDZHQ^.:0)4Z$F%_NTFSXNO,6CQI;:Y^1^W569B^C:XX '))+*"Y&^+D5_K-
M'.[ ;_6BZ>/.,()=(OE<Y5BFT;4_\A34/65<IO("/"78[FI\C82%S>3ME 4G
M\NK>#"J,VJ:)\8V'K*\ZM$R['V?8-YA8^V.@=3B%KYN\)L>]KJ\7JULH0=*\
M5H)B(O12A]).YW.]J6/(>A_DSFL/ID*JHE.RR+O>-S/DU_0QMN8=X_K[C'0"
M\")DPZH^B"P%:3GC@%Z*4AJKZP0MZ)@AYJJ>3(PS&H<WPA&F3[<_*U64X.OP
MVE[K U]3G6)A5*E7IVCH$:)>A+@'%W)M&EO(AR>&1=LP06^ROE;.;15?/TL1
MHQ1*E+:;_[@W>468O_G;OK<N7C&O0_C?4='VHO<+O&$_E@OL3[C[V=+>'U&0
M)XIM!V$&3M::2Y# 4C+F363,&+1XOYD"MCC81)=4T3FCP!/9+6#@DA<K2OXJ
M:G9:L 59S6!,.4D=/,)?P(OD%];CH8$\J,)SHW=B;#36O&7TV=TC\CO0[U%C
MMV:C#H)MTE1PZ:$3X&<7E[G1>@H-VS<D5\@"'\C&P>8-3$ !3?RVZ=F!!\A1
M) 3Z42S!-67:"QUKQYUJ>A<P/C305R<LJ=$NL)/:W=#"=2#C8": 44E"V CN
M*E<8^T61@*>*:D5[;*;F'"$I$[A6/-(-Z(A>N-@G$,7X3HJ<BU\8MF%%GNR]
MK3LJ,'5/SH5C9EGB7T3SA[A$4(%*AQ@)^B-)4=?,$W% &D,GU&)<,BR,^LE@
M0?ZQY9=PX*!$5=9FH)<\KJ=A@ [.LE+^RX&V-*Y;;-"XF(S27/Z KS/$<XS3
MV'P"^KUKLVHHAYOG40ID\(MB^D<\M@:W,(UIH(GA@PE*4V+TI9*H/:<@H3$A
MP7L9'F3*E<)K4S$DCK[R-I%]5;Z]J.^- ] BCQY[XQCR*W^0UE1J3[+[:@$U
M\(H3%_]$?\C/2[JS"O1JRF?A;%D+L'S0X?W=(;P_A/>'\/XW&S+[:V/(L*Q-
M<T]+.=3=4#[DV76O30,Z@9_[T+1;BTQEUUIF=6D<;M>5J$/3:6M=D>L4"OUP
M+OU$L%;+O9&=*04' \?P)O:(ZGH*[\4D]W*9*$YC@S2];]))X&1TSR2[S[RD
M=-YM7KB.)O>3=:'48QO]0SOC:S]=2O(?/OX%77.%JW:+8DU:,S^1;)J((ZH%
MY.9KJNT8KF-_%(9E#5JQ&6]TH 6!I_>13\WSS':^9ARE6>7'[GIU\E6IX[+M
MVI!W7)/+V?2<76+\S8TQOI=A;15*<GK:T/&U.3RRD5$MG$X+#+0EMIZ&UA8Q
MQ (Z98WN?U5126-6Z@3*23&ZF8,.Y>E.G!]BP1@DG@9,@./;[)O@X#7<5KCM
M0$<;=+SC.LMLA)O\K>F,E-E-#@:Q?DR#Y=&$L-11S)6;JIF*DM#04?/=#DWE
MQL'1[=20,_.WO^QPXG0]*-Z;.4'YB<26\3NP,FAO0[TRA^#Q$YP5J/3:U1&N
M_ *T$%%;QH/.W(:\ XYSEH!7=.Z:!$6PC,7(D["9#@R#9<&_T<E80(.2-=MR
M$F\%G: @B6'0&[2CN<7;)%<:1!,7WA#&Y, M9-KPPKBHI^90*5U=H.-X1&@?
M,>8E!T:;EG$]0?]W#%.WW%;B"]&,+:/.MW@Q"D[[YLL\\J9%$KKI99?=HZ57
MC)GO3AANO]D]%EX'\Q-LL(;!BYBB'6C.HHFL>D!O:RG&GZZ+&']?!*?P3]#!
MZ-M>(>[?H6X(@QMMG%V X7E^X8+\1-FJ0J-K,?,ZYR@N.^ L!R2:-)%8)(F+
M=)3:FC71%PEM&]FE.<.3K7W-T5HE29""EWDN-44+K(>%X[;D$5'(!N?7W)_4
MN*55@/^%+:JPE/Y:TN*S=:'%UQ+2MP5TCG.$]\VG3.8)C+.C'VD&RBBL?\.F
M]D12*8 ^RM+J0GNHX@SY/0J[S$$8L!"/+U1"Z;;CU'!<XMU'AU9#0<<OUO0
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MX+I9/4Q4:-,D_ <$.['BPI8&2?%#,TNWGC^5(X.!U2;!GWUUY*0O&](H;=*
MEWY]_\%CC+99*;:$2,(D9LT7(\+.$3C:L*02J9ZBK\5^GQK$?T;4E55%[JWW
M/U9=8%6IH]UX@H.Z)H\XL5=?)W4!><7UA"_.\,)30SR<T>7%7%$]E[$@Q760
M1P.K-R;]@%U5W&5"8ZIX]"8F#ZY_&B8CZ6REPJ_T![Z,4CFM/!'7DZ$8C>5P
MT/Q&0(!H1'%<G:,TJ@B8JP"VB)LWI,O:N8O,BC3]<O\W-KAT]]QA8JI,P6T=
M5 7*0J=^,X$Z8JQ!I]'Z4O#Y^ ;W/Q]W;KGMJ9%45@E@X!LT.I'LTQJ?LZ<@
M3IN*"I'G9ORN,>F+7U."%]'WA?<^D:+1_&-5(%-_[- )][.2+&#JHH1\;Q D
MW,1>,6A5\*/UJ#49W\38')"A'9(M$9FMYI3W.I:$"P72@;YP&L#F1DMM>*X%
M>Q>0FYMHF8Z.PUEP#<:X 4PR@A[IWB=5](1(HI BK.VOUMYM?I9<N)1)0>4O
M4V+I<+#5D, 0F2$MMQSYK2!02,GCHJ/V60-WOI5RDS1-8!;D.*"163&<NJ@6
M]9(+%^*+L8$-?)(N4)ZV.>4;=<I=V,[;&9B,'!]>, V0*\F:!-D-A_&L'L:-
MQPLW/YO8U&VQ)GL8L2"H(-JX6Y5Q-%([)8-CZXTE.Q8CO1(M$[YL"@+[#06X
M$>V2GE,JN&;JQW,GK^(%*ZZ^C*-)*KVFTH"U=F-2$UP(F'?HH(+5#+#5<R\*
M/>\KEXR*X@%%VR.=C5#WX;+_ES1FBUW92&JV7EXSO&IG":]:PJO^NO"J"59A
M1SD4!QMMDH%1S1Z.#.]6H'GA,NW>9,//3&N^!A/KYC[.5(05"DNJ3UZ+L=M,
MP-L9:E"B42VHX3T5]_.,A1,N*:^8S^"<SLERCG94C_95]IZ$H0<)%KI)"J>L
M1I8;3Q"67R3MF!1JDTLB32.U;H%*Q#".QBKH*6G7=R [BXPJ\.IXM5.6\@7=
M+;/KC5/A$L^GU:/'CR,Y^K"/--@^=Z'TM:O-J"H\:LZ7R/!,;!U263U)63%[
MD \<Z\J$FRQD.+U0,F9B-QE">!101Y!0-PCC>)M4E$49^=/?C(T]645N;H(L
M0+HQZW4QP-%\8R]PW3LE5R9Y2/^HHFL58)C>!RO" JFY=BG,>"P33J2FK^-/
M#/R)9S/D.B2,&(CM2*&%#""]4#5KY8IU7(>T/CWRY:!\P.ZS7(4I].Y .R)^
M,;K)N=%!SCA!+C'5_B9)R&KY0I&A2=IQ\G%4.: 0N]UZ5!&CD,))Q+@4'L<T
M=1,ZZ"3KEE6VP"J-.&J?5P%6E3?,(BI,5:OGUN;R<NL\T>:;4F,8<A*(+0M'
MPDBD8?N)U_9Z]H6J0VA?4L?1$#0Z"&\PE%SW[8$&5"2:,(%+8>'I$*M?%U@C
M1+*..(IBI;#/.>T%E0+7"R,%U,W\:J"'6AI,3!]61;_L+'B2VTE<J/)C)KV?
MQ7^N@#6!UO><B%)8#2M6AU429B070#F;1260WA.L)IAW,R3-%\T 4ZZ0U?]9
M(8NO^>74Q;4ZQZ#?0^:EADEC-8A&^8^P=C66CG9^VS(OCFJU<%STB(V"G)NN
M!$/L.&YJ1 ]A3&[81=]@$([<?_#^VR 9,"LWH/D>>36#"!:)KFT>63V0A6&E
M\??,7K0X$4XW46[>(0"3ULS$T1I,$;^/9O$LDRW$(^8,J,B$Z9<MB,*@D++6
MTDV($L MST8=D.CF...NX1RMYN2$.B&N2I*!)PO##Z2_7F2DGCH:RPG&/<55
MX[#TCRH-C917?Q4V+%,&[$IO1V'#_$GO$)=Z<\*&UBD(I.XO$3JA_>K%8EV@
MD:S" HT[;J=.CA4>FP\+3E-N.G(<NNR-NIDF:&Z"!;T,4R>QDE5IFL*K.A<*
MDTX>Z9Y+H&9RQF@U@7AI+J0+.]FC*_BF'4)(2L-;,'U"Q#P)>"F!Z="B;ZZ:
M Q?7;=UP!XBW$(:KKP"9O:!(+'727L -EQ"N<1%K8_6O\.!H#UKGH+JMI9QK
M!.J(]38%%A-[K>74%E16WRR*K#ZCD)"QS(^8:I(PMI4EJ?P2-IS$G;BD&JR#
MDO--#C[%%4$.KFRN>N^4;O8><S70!RK7MY!PFI?""MS'5(*#[_61YD<H^Y((
M\Y(#RO(85:58C/"Z5"5J4T"=+A_RL(0N)H7:).!*TESG3M3Z -H)_S<,H9$P
MI U.-DM4ZC/IQ?;O0>H6D@"(-B?5E3)PDA51B94WRH67H%:2Y*8SF7KIJ@%
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MZ7&H"ZO+TQ^2-& BL)M64=USF4<^9;R;>, ]ETS_*_WE*BD47)8XQLZ6X2!
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M(R5$,6A5 \1E,!AW9(?@PB0/JR&FXH9VK$.623EEA# V7NQV1:[A+E\$+*.
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MKY V]Q.EH.[3:[7\DIO1PD2D'U11R"8QQ_%1^+!J7KQ91'OV\N3\\P6Z*A;
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MMR8)BU8X];/G/^_LK<]2&0W;<2]*%LA[R[IQ8L>Y=V+:.)]*71VM9).A<^R
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M&0%7*OC)-Y8_IICC=9R&K7*171MXQY0GD0#I;A<-Y2-LJ=3^0C=H4P<6&8/
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M]/@"=+&SXW54TLPB7]N)_H '>-_E_>!']P@JQ!.LZ-WX33N!;<]$8#M[EM-
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M:>#W$G*_A-S_I>#;2\C]ZSNS)>1^";EWU@"FAS*1Z%^+=D0_+@3_N?#=CPO
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M8H\-QZ27"F=N'6F_=J0&7?OR0F[C+RGCMJ;)N)<5*6=9B3J4SE<9Z61O,%1
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MDME0<\9X!-3 Q[&6,PP8%@,:#Y7&]AS MBJU-)5JK9U*H9\X"4'LR8'(235
M\X0S4<$PYY"BI*EA4=I%=#OS6:0C(SJ\@%K&X7B@2!<JNJ@J\;5BNPYBVUXO
ML37'#C;P@<Q%>,I5'J:##4%&PKOXG2/M/M5Y1G3-Z8.EZ"!R9N!<$'%#N/'Y
MZJ@1S;Y3R<YC^LVZR8T@G].]"JK/DEJA]S&FQA)3C:Q]RQ]*LC,6-E+)^K$(
M[B(6R/%G'CF2[WG[PN\FUJ#(7)N,Q,&8OSD/S.Y57!5%2Q=D;9R1XY"?+XBT
M1 62,5.*+!0=GNR-,7Y?M6[%.>MVE31O8[JSRC;G#4ID<<*W)YJ,RQ@G?M-"
MSSI 3V=CH,> FZ(NH8=I1OP!<K13*>BOE/]F>F+:Z2.GLZ,":!,LX@.,&.,3
MN2?908D;)/=,LH\CD6@^X3SC-_(CF?I4(ABKNFY ITXFQJ4ROE"N%\C;L!E$
M&H4L1CC0[=0$AO2YG#8S,1$#>_GK[YGA#!P8/4D2@=$(18L)D;FMGP/#U\:+
M,KV5-R$]B?AYK@1^RSUNM:Q+80%R!0#972^ ?*(91B=^/ U%IRS)OA9+9H7L
M_%8@.2]TI**EF9UB@FF6%-BN.0!T_?V:!#V7P!,C7=(<P]?6E D5!MSIIS%6
M7<784\L1W0NY/\W*7^2P:ZKA5\PU=: QW$'HI0)W8>!#/XH3K&2(L4#('^>Z
M[= ]&,QC N\@#PR+W,3L,6H8YTT;,QB8O4/@*I%,PN R('W2K9XR9HE,2GY<
M;I<!2'+Z:PT'NY(=U]MT-(A3"J$O&GL8CXO*X/%('-XF,UIV,B*C-U')47R"
M>3(L+WG<C*-4W+[*7H)T[DI;ABR402Z$/T>%B.L3"<.YA[5G>A)K<8$RIQJ#
M.G?$X9 1[7-5]9I9+*6R!V;:2-)WRTIF8:MU.98FTQ3%/8AH$8 ">9W2_RO@
M5.'.(G=G;["(U'*4O;7B(S3C+QO %]2-N]S/< H64!:0VFB.L99-E[3IDIN8
M+OGF9:W9K:B\_RY7N$M2*!D1G(;P)S$L\GO,23&NW N0)YSFFCA1$)V0$IKC
M8>5QW$IBV"&3[%:SW3-)227LWV+%\PR^7+,+#EG LK=W^9[7+"G7!<845_3)
MG*[@-U9]7O. 7(''<A$,\O2%J='W:9T5"Y?B*UYT*#.Z.,RYBR@=!!A"T(3=
M9?S'TD,/\#'F8YEB1/3J&6$\,3'0R'/CH^B,(O0@LMN0F($E+3\U<IY&&,O)
M-UC&=Y!)31.2G,N5\ME_(!:Y%TJIBL7<8(%VD+'P#$4WFD*G S$0#!H_^49>
MJ"2BKSQ/$&T\ 6=YI"_C1?DH32+U5G4ZU8\ZTEX?595Z22@U#D]\5\GP#I6!
M?5QW_VJ:1 53V@"[_ !P&8?C\$ZUUU3_IFCA.W%TWL%"/7IJZ=^S?AR.TX2_
M5\Y+?B5RQ1S)Z+7FWZPW.CNX ,)XR^R9H_9J%\%P8<OK\<@ZD&-!_W\]C9 Z
MK@)MTWN'>H<[RFR<O5:K;UB9J_JF.L]^=#C_*U_221\3Q&1-Z!+U:_7+)=:I
M_.?KK4:5LFVR@)WQV(M\8NK*+](;:B*%!Y:^2H\TIQ8?5($B<Y$6[3^];8JV
MADLT1_M6(U0K6L-,.77<]+E6X5+6H5EWJ6?44;/9?O]CUNI^@>$O1Q=F[]K"
MV[+8=!ZUS]YB/CJ8<P)^Y_W)=:=Y[+K=YX5U3A21&;EB%S+7_S./;B2!^"4/
MHQL6^/\K.>(&=)O$*";Z%1QD,$XDV\51S6DVFFV9.$3-5\$-S1%PUQ3?C5>O
M.3]SO.A6[[I*^\YI&$TK?W%^7G,^?3JMY6G^?O+#Z8C!1(S'JM9APN.D!7).
MG.QR[OXABXX?YHK2!H^2H^S72S$O'3W?,.WM6^W="NW55U%?PKJ\4$9A?Y%6
M?^3]*&71@\K5([7N6+5><[5NU5VKRTO79?G,@YA[![ _$?.2=Y(P+I=1\+<_
MTS!Y_^CKQ,?>_R Q8I0DT_C=X>'=W5T=WE"_"6\/3R)OY-_R^) /;EAT")K+
M#MUFI]4].CX$&]EUCUOP3[?=<$%MCPX'W4ZOUVH,^'W+K8^2R2M<PB\&2[+!
MQB4GQ03]SK>?.\^UG]M[3$E1UW/1$Q!W_-DL'-)$K*=XS0"H<DF%:GDBM:.#
MWYR]C_Z89_ )"WC0ZKJ]WGYM3J$Q_.]7%A@@V4&0=-M; R5-"R462MQ.YZC5
M Y.^T>BV.\>'-Z!K!VCB-SH-]QX 9; T1"F QTDQ07<NN, /9L'$!@+/9Z9
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M*]TXB7POT97;OP=^4@YY57_LY(Y%@[>/@+6V,0*V6?AU;/'+XM=\_%I:2HK
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MQQ<\KP*O82OPWA+&VKL'7-;.FD-!@&%S(RU*YQLLS<ZZ8F,>E]')-":.GI,
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MG*<?N2JN208E!H]/Z*?]N%SU*?*'M3@7OUI=N&1#/0U@ANJ<O-6WH 'W!FC
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M1M0(V9ZPU9F_CDO+T8U94*%OEZT!\+Z#"Q@I)XEZOC^O$&HT0)*^MV:F!-(
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M&L!RA:2X&G#F,U6$P GG@5D^^JB^PVV4;O86^P C6*@T+2JCGW-@[8LZ>87
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MS"S,_UF$B.1F#BD9)1D9)3,M-2WS_UBNNP ,MP#^1+(D1'P 8@8B$@:BZSX
M\,9.,J+_$L#_(T3$-S:24]RBI**^4:B_#2 F(B$A)B7YC]4WH\$WXP!2!C+&
MNS+JY$R&KRCX/)COAR;EW>)_7-/-8C2.%I!][1E&2<7*QL[!*2@D+')/5$[^
M@8*BDO*3IQJ:6MHZNL8FIF;F%B\L[=[8.SB^=7KGY>WCZ^<?$!C^(2(R*CHF
M-CDE-2T]XU-F5GY!85%Q26E9>>V/NOJ&QJ;FEI[>OOZ!P9]#OR8FIZ9G9O_.
M(5=646OK&YM;VSN8H^.3T[-S[,7E?W 1 4B(_E_Y/^)BN,%%3$I*0DKQ'UQ$
MQ'[_46 @);LK0\ZH;DCQRH.)[W[H+>;'27DUW93\LD9HEM>>XU2L G(K@IC_
M0/LO9/\]8&'_5\C^/V#_/RXD@(:$Z,9Y) P $.#*.#]6!) ?^V1L#!!H&E!D
MXB"^8JJIP\]>(<6!G>CMNN2ZS"D0^CGV6G$V/0TG>ID"46U;5,6>!HMIB#FU
ML.X7L63R0LJX?BX5V2F7TVJ(=0Q^CADH9S198;O7$7<<G'1X&=6'H'(ROC /
M).32-(W0]FP"(\P0J^=AA8H\PI->6[-$SG].W.<4>K?IY"6,+@\<+F(:Q*@(
M)*2Y ]4VL*$.VK0[]@,5"8DR[PMA&@&5O//8.L4%E_&=TO[ 80+1;@NLIF1G
M/*.FK;%5'?]<NY9^;/JO@7$5G.K"RNPJHTU_14N!0(^A3%\/H$YQEKZ\GTRY
M/R(*HB&,+TI@_<JT"J'J$R7I\JA]6J+$9?I#N,\@KGZL[%C*)X5KPN1-7D+A
MRF8;['B74XRBQU9J4L6I1"BO$*(>[+ ,Q4@+@@OHON(X%T@?>"!K_ Q^GQ<(
M"OYA\Y9@-E17UV!^3O0_[Y$A-*M9UK>UZ@UGY(-4&7OT6G&EE1*OR7*<_O%5
M3V6AX>RPOS#.R4/RSRO#S@F!![Y'R6M (3*[D%L.ZS6SH8C ">9R$_U^&WX$
M0UQ>!$+>J= >.Z)7'0]D18VYKKOO?:80L?(#2%T.7J;T![-\=?+-DLPD2TCE
MH[9@>\W+WL6" 4?67P.BE>GR) 9#Y5[4ZQ2S-S?A@#G,K#^MLP%>0U7]]5)(
MHVO _:*R4# ?2').!LOC3$/.:+IR&J,CZ798\F3CO3_6V.N;LG'JVKFA;^/3
MS-.JQ]EGA?=+N9W7K'(Y81.<XJ_LQWFV<DBT2OJ5>*X!_$8:.$O_:T#O_?K.
M&"@'AS0@N2;2V7=A1X=,,Y@L,->PE,":^X>G?$1$:O6QQVF<6G-";3,_R;;U
M-2 >RE+HOZN? IX1MVL+#45:'=X]-=LI;G/LN08T5'^0-ZK9F5%H4?D0X40<
M%QUZH&/[""\V@Q?&B/40%(PE(ZI>0'(/M"0%@*:*_$=53N.5&HN&;_=*XGKL
M[(8H!W1.K@$AT,'545+LCS,[##$V_%%+.JZWFO<%Q]"]NFL 64^B6B(%RPF\
M!Q+'">H'T<?-LQZYO^Q9^*O=->RV61RL/O#$CV5V)]WCW8,)I(TZ=W_%3R.+
M(L"W,"52GGK,81\"L)O[ Y$@T6:SHN#U54>HJ\+SXV8*Z2!H9QYK54/<&%$C
MEFZI5W"X$\ 4\2S?=B+9+7P!+I5U=(#XT1CB\4?1RQK1"XH.=.\;I>VMV*XB
M_CXG1XI':ZL=29^ITGO8>)Y4<6CTUTTCBCZ@C$3?^SVS%,E/>O4_#4EK1!\H
M6AG2"Z'_M\O9M_'0?X!1GB,@^T2#6T>H)>-C>;(F13O4'<-).#^+PF+<5ZR4
M%KQI97Y[RKD>)92<UP8Z8K50-A:!HA6?,WKJ85$9GUZO1Q2V)[>M[;-L;J[%
M7SW4P&SNVZ^2=W0V*VM]6/ZX!\@54N%)RF-/PDPCB-M;P*&V#%CW96X'?85G
M5@D:+FLC><$QCL).:TP]YUW<8M-U]+1S6&>#NLF3K>3% >1=YO?EB8#SW=,B
MC%FZO#OM3H/]K[@X)WZRP/@R+J.^57LSR6PYA ;!4>V.>,(M71^(JEE]RN'Z
MG&14&F'X[S7@@S*>CA[9>69H.Q:7G:STQU]AK[XTY57E=@7Q$'.,$/VB$KOP
M274@HJ0]@%U)."JBE9OC3>IW[_WY(V81;D QF K,\8+!)IC]C4E=9&N#ZI-1
M%6,TJ(L@!=PF<-8<LS-L6@[<3?(:\?RTT>;5#Z_1*$M=]#>&-'W_HI1(??CI
MWEG2^]XC^5/1D':1]]I=BE59%N53=?%?$ H,&:]DQ,[KIG%[A!.H X$?NXY6
M<#\K]')&JCAFY%[=YRL@9(DLAN^(M:)G]S66P=&7>ELPT097IOW2EUD/DS8L
MI56U/E$,[QX3Q?M4%]!PL$MT[\C8VF#8SMS0YGT"60$5Y&EEBM< Q)7*K7D"
M:1-R*;HJS3;"$;?UXAQQP0/];O'[_C7@S;<_P/6<\L767#5_N%'K529,5/SQ
M?KT4V2[[/>6?W$)1BB](Z*@'/])[JM6?N7WQ(5M(E>WE3><P45;./C#^J50=
M2> E_.&10\NG2,2!8MI =]@,G9($(/OLX"<[YGSM=F<:V&R?8"%4C_FD3,>D
M)N[5W5YVG74PM*PJVU1DJO#;9'**)>BX9M/>/W.EAI["\O,'^PKC.;4RU:R@
M@NV/FD[O%$<,/)"%U;=QTO\[J?VW.PG%0%;9>)M@!62 1+6^L+94]3[S[)]K
M0(U::N-W_XP^QK!SSU\?W5U2PH]K2'%9YU+QK!,0J"3&Q%!GO=7BEVGH@'3A
M*5[L-_SU@B[U:"2;V=A@K550SQN[;M<NADOS//!"CTFC6=+R+/3BRRW5U#>$
M0/XM$Q44^WG9G8.<?\_;151I S;;H-/+PI"H)1YY"8&RQKIVWT1>O)O9Q1CN
M&*+SU$]$X.5Y=>XUX.T2O4[)HI.MQ/?'0J$S]RQ\V)4T+WU8]F#4&!4>,?1,
M;ODC/TH4V0!L-Y$=1M[TGK!6HG/>.90C1(2CJG]?NW70#KS@IF4.KY?PX_EK
MJ'%W^3F185OI?>H0+0HY?:&N]N-]" UAJA/]O-4]ZO+J,$*-:]YR-W"AX77K
MK*0![J&.T@+7.]!,4]>0\-OM/ZZ:"<^>7MS[5FLO2.8;W,.B;0W0*JU2,,8Z
MKN Z6>?\8Q]*U3C[CC;96L+V"TD]DXEZPP\AR<J-^[*8S552E!%B ":9S*M;
M-L:?O$@'?O;H*]-I]3,L&\X3;SO1P?>6AQ-#5YYSM[:U/7+ V=5M3,OKMA]U
MDW*$:Z_2Q8^L4_LT\Q)6E.*"6Y473MO@W_#8E;GY+<W#%/Z0=^I\V1\UH)TX
M&-0*X]<]&J&L5K.\\&8+F8VL\)T G_FO+W!H"K[?T7H%(>_'>>&#WUN"[MA8
M\P6C6%-<NF%-L<WOYX)=3$'.Y,F=QCK3\=R9.%X'\"&1P3&;PQZ^_B(8[46@
MLD>I BT:PU=9ZC.B3Y1LC)QQ>AZN?N^4V9"=8J%3542H<$A1!_>LN(KQ5XN=
M%OLI/Z3KGI@<&T-V170O[PQ[O(2UF&[^4O7C/,4_0<59SQ(572:' <JS:^ ^
M\+P7"A:%N@8P.<W8*CD'B:EJ^O/&.\U4L+#\-$SA$":9:5Z_:E-3>2"+&CJ^
M!KS\9@W?*C_A3WTMD%J5#', ,S#OP8;)S;:<5-9H&_WD,5)XILVS4&PHIL 2
M\T%-;G;>*K:'W7;.<D+D@:P,1:K&*,H:O@_'!>X2;F-N"$"X&E>;LG>+%_OA
MZ7!TNOEQT""CHBC@H(]SS8+SJ J-^>$,&T@L- G(O&1K\D)F"1F\[T)-=+))
MP)VD$$C[?\A+_^$!_3LB:45-83KB/3D?^(53F2]#(:[7@&[0C0XGWA_1[PN3
M::N;!NJPCI*M/1BF2>A\_Q(G77)P26*Y>A_9%.A6D.SD[B R9>1;CZ@]NJ<0
MGY1U#$\$<4,5T$S=YCQ\&)IFDGO.=@R_9Y//$BBJR[8HA#KE"/PW.ZBK24.U
MI@4;T%='6,V!S7MTG_/G8ZIJK@$VT>)65V/UB7?(K)B;OU9DF)GL:-[)K8K?
M^>JF.%HI/?*YX8#CI+K_C_!9)O8<C1G)7Y3%N'C\N#7L'W9/DE<B&\54!KB2
M=CZQ.N/'GE<3QJX!-(?U",;Y%QIEV^<#_9LUCV/>$XM14C'ZY@32B5D;$!=S
M\HS7S:8(L9A\013,/%JX5?(F<'8MJA\\;X6"1,&$_'OU)ML\!!MR[<K_6<T_
M:O'Y=@ME?M>$B<< 4&4!6P1Q8V[HT>\EK-B-2U"FXUP%3")E0O6SGL%MDN,X
MT6.^VQPAPD7$)BKDW![8V=Y.-#@72;]*/U#-X#\Q/]!R,?/R>UUC\HV3V7UE
M'Y(K/;5>$]E]D:-ZU>"S%'H-J#^/45%=U?ELBO7O=(S:&Z(*0 :\3<VTX[6/
MM%C76?,>9.E!F[97;%5:FY[(G2759F@&'S9Q*E17VF.#^CCAL=Y!^N9Z;;'7
M /VV&(?&EM!S@5(M&EI_Q'X[1KBODY)  L%&]03FGAG\X-YOT_.^FVC-S]3D
M^E[+77>MA-(D*VRAE16INSE&*RI%%J*6FJ_A%MDA=@T(@T*],8<#-:ACE/MM
M;C^<C$M_SJYVWE%C3.,UX)OIB*^4Y<7#OLY&K0$</9.SV7?L!2KL)MQ>QSNE
M+XF*QP.&$,( /_FMR>%O)M^4[WT;#'[VQ22_Z-]5Y#^*0/?L3R,'M##YSOUY
MS J3'UZ<@O<:,'5_$G0IV=+Y =+0.0!GQEN@;1/*L(MZ?Q0,9R1<W2HC/[MT
MO 'S?:LRD]945PFW&A7IZY$T<@;?YX^.;]#:-?_4N<AL^H!4AD21 M><WP%'
M2FUS9Q=RGJ7QU.0M6>CF3:Q21$0]BS22@4@0?G)FYW!A'&-5@-Z+UC\WGAJ$
M>[N8AK"//C.?F1BP 2M6)Q(4_HZBC5%5*2AG1>U)]T)&W9HUXBM!8X3I1?-N
M["DZMSU!EWY?0M7P.+,$I[*%@B?-7>IIG;L%1]U^&> Z?7>-<VC<QRK8[=<,
M841=ONCWX[?_O$4U-=ZM)?WL#Y@Y"-HNKHH'L_G[SO;S\'1,2MK1<O?9RS8J
MJD:?<SMWPZBQ69LK-[1:JHVCXO?KF T^1C"UL$N0]$9'DK==2BM@M<WN+!SK
M<'F6HZ)>=$_?K-^+-QXZ,:#T<Q!#E]]<WKU@$KE[I +M244-QQ54Y$VV["#>
MQH=ITKVS/ *'YK*@, .)XNXVYI8_GFEG=F<J4P(.#[><I_I_2B24L"_GG+9!
M[K>H<K*L1!>73P;>[V=.K==27^UL$.X76_H !$!UJK;=UW9J^>8LGP&=8G4,
M%E +FMKGQ)T/.E^[A[""@ 2I8??JBA_^[D\;.1/PCSY*<75,17SRBE1R&*"D
MTM0(GK_A['?'JN2KYZ*,LA8$4G /G]>W?]0LQ(?&)O_=4H/5'X/QC+,#K)9:
M?9UL6-_5IWKM=@:1&Y,2OQ-(&DX,_T6D^(UQ7HJ+>1]=UM_#F\^.K9556I34
M7((+MAIX@)-?OT^*5Y[LLK.],9NIB4:I;[$\ IC?0^6&J]%BXTJW9Y'7@"CQ
MPU-:M77)2O<&EZ;8I[QEC))T]Y5YQ)H70KNNG")=U!9*T/+'Y6#OD1\H"%94
M>QXMJ\X^XO.S\\1J]NXU@+0H[&$G-53GQ6L=-MSCR74?&M"TSJY-%)Y%V@U[
MYZM7O+-'+CY*$.:YE4.%L<U;#O;J1ZJP1?6V/!M_4C;JY&D\Y"1;\X4YS+Q4
MXB?WY>SD\E:%INWVL2=ND&9]V.RL^40+SXP HWUS,25@,.V@$UW5C-+,W5HJ
M!HC?P7#$LA+'*-1._FQVC\?G+DX:^^@=(+P!S N\0+7M$>HO)G'\T%OH:\ ^
M"4;PI/HV-LE[2R*D)5A>]JQ2AV*1H?GB$?=E-@^%Y54,^B#.;N4/X[#>I$1!
M[>3>J@5O8X1O.5\\@,QKPRN!4[J[Q(_;2J[@4,&X&1NUJM<:_/ L9LI=ZHV%
M2R7^^218S)-1OGF8RRN':!]2JH=S@(VL &Z(^Z2&P,UE5K;#YU</0[BWP:OT
MB5F$#*YAM_/%N^E3VBC1HDVQIL1"FK/J<M#*5([XJUPL6,X6OCUB>>+AC9Z^
MJS<_M>X[]BLERW/=? IWN%*=@+^'X>_UP(9W-S:TI"<\K-,+<"**?WBOEX:%
M A&(]\#.%]I"5:X*5+1XOCDT>KUP=L#.V] G[X!D \.SURT\(!60VO/NSTMS
MYRN"B/!36DU:RU7JS!*%!S5U;Y\TO"?:C/UUE0]_<Q.4A''T$\FF#$Z#5I<(
MU_I*E?+?!;5-O#%LH!XXL5A?]ZK3BK->II?&EK=I\8[FPC/0S5.UU .)-7N0
M+E$]CW4W3GHJ4> <*S'PGGS*"]=@G$WG-1M[)D5_DRFK/YQ^T;,<.Y$ Z4S+
MOU'W\WA%U>=&O%;VLHWIF,=CQ/EH_BSD*A3JBH8\ZL!P5YXBXE1D'&@RC'L_
M5;U$*-)A%-P"D(,\V>95-VE5O@/D[)<CF+L"^Q'@]<WI]7BU7(RP'?^+3Y@.
MWK[-85%/"D7^>&)G%P.JW)HTJ/@A3^FG*>@O6<L<65P@'MR*3< ]WK&T5GA\
M^ Q]8:/\2V3(GC$[X /](>M#\$3'Y54*R"&!>AD26C<?;L>R&5M_BW'U&F":
M1J+7' FM4_Q5'GYSYA-7I7+W\-0X/>P ]>]GN]\2'K%W$Q5XUM*\"?0XK?Z[
M%-4A4H,Q#VL#E6U/!.?_.AO@R$\S4"?3N@98FUU\* )3/LX&MLQT%$[,>'K^
MFY^2:U5U^*6G_WB">OZ%YFS8A@R?](FH)JTGG [&Z ]949S>QPL7].?-[9@[
M7*XB::+;)HB38_V?/]J25A5K<+S[G5RK4G9D. VIU5R=HX^<'=MI-,: ^@+3
M$F-PICM^EZEE[B5(;)5.E7V29WF<DKCV9KPO<:=NU'XN[F'2$79)"ZBO[$Z0
MAWQ:NMT&$HX#.=$S;"49I!_MV KD3 OZ"/"K]!$'/SJK+IHD4&JM]EL#>;9*
M"/_6KP&<."Y[<7GMB<M^ W/["_[$SS<Q:P,>HX_*$4-W]@%IK?P1/1FL+9$)
M02ED^W7D\JGW1/U%Z4D9?E8/0>8K8PG3M@K\N)G>8B]<:O449*YU176S:RD\
MD#Y<GO8QK=&N/F-D<X/FT^ CV7B2GUTNYNNC^R,XD#.0XZ,2(Q*^55BM<*].
MQGC=S\Q7ZG;VUPROPJO$:X#SPI.S@)G!R#;-XW_^= <N>DS$;R;6A#.? Y<)
M1P2^CIZ;U![V+AW&>Y52Y<.MMB&&H_X\K)37''$N$-WW\5?0*<O&4CUB[ZT*
M?-GFX2I%F$L,YEF@"^,[9:@BR?/XI\T^P.,Q^M_F_4C'07H&IVL Q6EGQ'G1
M(?2AAYP?ZYB![G") 2*=.G=9)>P+0JU^FM.DIOY5;%YARGG&CL/&MD8/G'_W
M$"OP5\VQ7SJ 8[+FPMI\,2LJRCNW]M_05:;]AHM=4U?F"#W4O#L7K3,"645<
M]39= [IBKTBGX*@>^.7&TL]91&;G&3*G1%\J%!C;>>N5#OS=/B6GW-O1F"(R
M#G7K@,H!>A;<$V"4W*<BNBS[+.7L2(O;MX,#S5'TW4L7#R4H" ,!H!-G\WW_
M79O,UO/MZH,"+K6)4XZUNP3@3&QZ+-K@>Q7)ZGGO-T@L#WW'N,,=X9<"]=E5
M3XT0+; O"7XGO2FMJJ(%PN1%W.-?=#V^41B\V]X:O;DTU;'FMK0S!S N[-?Z
MPO%G=K7.(>HZLK^?Y@R6STY_'VI1LY+(0B.08LO4_F<__:.>V.0(_[".'DMC
MTVV+&'4$]L"IAJ]RX6_7, R-Z)*XN3VH!L,1;VNS?JZ3_34@W4WF:'@0O+H_
MRK)D2<T =->#?3M5H1%T>BDJ3B=XB-9KV=_I9-H6#U_,2Y4T4%="(;-3*%Y*
M:\GS-:QD'?NHQ5]4HX1[KO2ZD8-XH0ZF)?=UT&<50RGI1C^2%I[5=J858/_5
MPU6#K*1G&.3N\U)99 KA!R%+:Z?DY- V\SV)T(0"^7+8?5KH/L;J#-Y:/Q45
MTT9E.4/@T.C]VX>C^K[6)K$#;QX;9Y^WVQ1[M?M2M,V P99^-6H7".+?JD\R
M4'L%'O& *$$EKTHDJHKC=#!97Q0,GZS'G>DGM0;J=A[]:;XT'WO@EV2MB:")
MDW-3X,\CLP@,4YZNMYONL1.Q>S6J:8Z?3=$ L;UE51-#'^3E[_@.!Q2_NZU:
M^9M&MD/!Z!9/5 Y]E1AF%-78Y7Z'\+.3H?*PLKA57Y0ZR2L/FS^N*VQDRG6B
M8_*&155+)1Q2%QST^H=\ MVDS8^FVJE*B1LNX%%KI5>:;E$(>5QQ"Y3@^\HC
MN4=GV[]]UJO<>VKT#YP:WFV,]RC:0B-W<QC&\>K!0-I2*X.S?/4=NUZ:7,/0
M_1<D9UCL%TSX*N+#B;^;A(I@_K]=UB&)R$3*K%59WE]M@^*:]'<?D7>,SL!?
MCH8B]^?__5FV"G*ZX[M>T]K4^%AGQ+<PQ!'-L@!]>/6E@QLOE*J_ KJU':@Q
M %#08\M4 MA=.:]W6NZEBP'RUZFD,L^W'/*,+H>?;%9C165)L7?R&#UN2M32
M06'@T9_=B)LK;K5M%G@-Z+T&Q'*ZXBF#7@5XN;I[N.$KDNKN1YKQ?& 4VU^*
M!M&HR&",=<*?8=QBG*JWT;^$]8*FQ>-X2<F7$_L(/N8KA]V'%'CAL+.E[D6>
M&O0>6ZUXQKW7$4\K"JBL4L:8+F:Y/'1>+G(B%\^EDEJR!]?.]YG0X;97'PGR
MR'_8P(T@"<4_5WE?WSUB^$[RFV8P;&CL,DSLI/K,YBJO[A )7%DOKG8;9JUQ
MC@LV&PYY]8F^3=6T)4QL#'87*HUN[-<7Y5;HS^+.B!:_FZK/Q59S:/)>IBEH
M.:L;#>R2 D!%IZI\I"C]S7I[&U,T^=*M!.WO2WI%<O 23/WCK3U,[#B3SE&S
M37D4E \:'%&."!^_<34%_RB31H8A542T4(M&:G)AX7J((B^*?Z;C(Q!M<G-0
MCU[Z.W8O=O5[PL_J@S.#T6QG0;-M^E[<2Y'XNP'5UL_^R '?QH\*%*[7?CYN
M5:VQC,/=P3.)  DL5=$4UNP6P$W;#S]H)"P&Y+<?3-0D%R@VH"1&.?_S)+O2
ML\/&@0SR$B1]@;:AKUR=7[LEG31MO* F)Z& QLN,%D%7*F#()188!?X5Q@U!
M5T#>6-!;;F WH:+.I)2@\)X?&F68&,*H^NU$K M(06"#RF DNM!142?Z])!D
M&GWN/.*U'K!1:Z/K*-1L*1%&CY5:C2B%L& A>K,A\_4'KNIICU0 *%K$(,]T
M/Y<!C[R]E/V!VI<$)0&4PRE(H4/FAE-HMAECM%8.RE8L5"2*L6X21OSN?K!&
M_8<7PH?EQ%_O\?,+Y-"C;.!X)JGEF1HOE-YAC()9!FL@;?WGOTY'RLNVVMA%
M8Y4]0_R3,I101\88R $T5SO9;VN6L7)( ]F-NY?D?3[5,<U7"^T3IQ7S'N1W
MG^F(KJO3$[,P8DX4X7L4PZ7-8$H! "@"Z'KJ*Q,*.._WKN3]*FH?2E!2NO=G
M#^J#"X0-F2^QNKS&#(97JAPR;X]=^)E1]T(>*?5@PG9'*#SZH1YHIK-.S.'>
MD@"2I;V]XUN^0'_)6+WIF_2%:T#<L,M!/&:2U+$>UF[K?]B;KIPT>5"_?W_^
M.2E]K7X0IU[*Y)I$#BQM$*IUE:MV!V_YI1CC^,%[X?5R&-E2^NNF;O9K@.4'
M&?R.-':K)^-[WY,L8))1D=\?"@>HU"H(*QJ5<$HK9"'G3K[5(H%+)EN?GLK0
M#:<@%;K])BA9]=L6'"M<W8=@@5I@ U9O&'FK>=/,*4=] Z6'R#SGUP0U[51H
M^=<S+H<6;J8SR:O<MH?5A=)8D$&NN7;?L#V\5-]S57H)^O@H-P/4'V_>Z 3Y
MVZ+:ITR7C?3-0?=O/"FR"O"H\W L[VNZZ[7$7MHWV_.+9Y1>OZ3][PKEXG':
M:#\BQI;O<\]2'22FOE4CTJI2H<^/S5 +)/([A5&!*#P^\6\U#(@V!<;\'4(O
M?9!=.F>#X ,[]J;A;W(_<!Z4^)6] ]+7Z;5K'IAEK:Y:Z#C9).KQ!*98G.76
MYG;I/][9F)GMLN5L;FZ 2_KG$2&%3MY7IJD-LBRH]%*;R9Q-!61IPG[ENZ>;
M-:\MU63LYZ* 2-"J6<U-<7O;*9#ULZ-]8</79">/W[6R,07/%#+Y:9N\QGRJ
M$ZX!;LTLH'>''$>R&\@U1T*F(*S,GWZ9K?<P0KE^H&P%2.G40I[G03%7W/0C
M_IN*5;B+2HX" $ZU?KH4?@T@Z1#V']BX!AB-0\5604P&O2-P-25)[H\OW9Y?
M* XHFPMRV8O*KYM]>:CQS:+1P"A6?R<0'IIFCX9$S8=IYKK?K. RTR%TU0Q_
MW;U*UH%%W%138&&+> Z?8-8%:<DIGRQYX-&8'\DA7>#L@J6+AY5591O#K?R(
MITZ<\:3/I2DFO@U6;<\&9E]:LYWMESW.UY&P^T(S7NWPAO0[SYIY[N/V9_)@
M)_T])T7-=[^Q0 +E@Z[&?F+Z*Y(?2>&Y)XE+N997Y%/TEV2#5Y[N:\X?;C8/
MQ9.@&_M:XB]-TY-6%KSZ92F:GZ8^OOQ0EOQ \\_0G?D/W):MPZFT1&9K#&&J
MY36F[>U.IKJS7/Q#+$P8\^7=>U<5=3R:\!7AE,XK^<"KVD-;J1+"Z!(Y5!5E
M(;6'%U[9!;.()P11FA&O/?!\<\M*%?Q<;"[EHUK:>&*_N'6!R+<7%B-?0(X>
M)X8: 1O=VH%&XX\8]!A_-KEE_JRFP6[C%+8[&546K#0M3CJ9B8$C2@PV#/&4
M@*U@+L^'LVTF6@+9$8,N9JGE!O'-RZ=*->R!%N5N:6\79-= 49 ZQ^@.EG=+
MZ!BH5FUKTMT+UC/3/WUB.=3P49.35Z-5SCMP.FP4&".9P4+(*.TNM=3[->K6
M'8IO =I9+*I@(5^AVA-_TEM+^KU-&%A^9>O3!16< @W2CC5;T22KP.Y@,U>[
M+LZ*RX3D+QN+)+@-GN2GL!<4DUD']32V94=@M&-TCJR$;[*/DW=C7SO\\[%:
M_\!&]]!A3FH"YY?!V<4.,[3[?M:ES^B9>Z(<=9SS3X)63L]](&C_<1\#EO.L
MFAH:C*:/2]) Q(BCLE$/9MW7= NSB>IK1B>:=UXY&V)1)8N!)K+BDL++69V.
M!1 ^8$PNF8H2AF^AN+F!5;F,75]S ? QT(V;*X@3'9= OYJ[AQ'.+-)%+D6E
M_:@5N-]#@3.\VAIMP4"LGWBQK 7EI;TQ'+![OU1:*-/0 QA2*ZZ)T*+E;+G?
MMU[W;1C9W02^*+BLZI3M5F'#0;!^+YY&]4D/K>"J6(JI'!I'IVBJ\;?,Z]_"
M)"94C $96M.N\BSSK0^.OF4'HI18?OD/+IN'J[PO.N5F99<<M6H%_M/+M:ZF
MP+ LJSVXRJA#4/UREZN.]LVZ?UPOKY3.NNQ(_/2ESLA#&,LD^_/RO<]QN!$%
M<]GNZD5->;L%M1?0R<D#M2X#& :_]21[Y0<D)PK%E@!E@*_]]3^M]R^XP&\Y
M*IC]!AMF,C,A=$_ 41">#EG_U<.]2[5<^^I(ESLQ%6VE=I<M'T&5WB;#[_J]
MCL4"_XXDPJ.^@1R')-V&($=JOXRS)Y*R-O"4;#%V$^J89RW>62DOTR;Y[6,H
MBBV2P>W>]6M()/!9[OWV#_//8(HL@EH2]UQDCU8)J&66M-P!?]C=N?D_&"I]
MMVL #CB4^"J@.>0V^YJUY@=MKPS^#O_J,7A(EE^,'#R,0%.#B5CS6^2/T@N5
M$DY4YW6<'[!^OR9)]*KW-CCP@KX'Q("77::FCUODPKB'^AS>?F=9U0J7^)+0
M&278;-7G0Q5=N]\U[#?*[;R]- ?JX3P/!3G"2;9R!&.UY8/T@(OS!G/)<R_F
M4!&(<GY1G!WWMZG^=C7GHRT[L-=(G84Q@8=RE>(6"?#68VJ[W-/B5OIY_D'+
MDA"X8R<S9)M1M2/O_J =2Y]K9-2?]Q'=IX#<D>9V8=TIIK/#61^AR8/(; )S
MI'SKD=60U$9N!DRF%=D*0?Y8R2G 0);-8[Q5!2WUC8>M6K5OV$]5NM BOUKK
M=ZU9E@_-P94/]]^8^#I&X=]>I>%IT:@SJ^99J$2>>K'_?,\9@_,#-<$?QMP7
M+?$%=0A)/VDW3\I!86ZQG:5(6R$X!UX>7=4N5IB\$VA3OY9PNR?#/^TSSYQ0
MASSV,\[D+_XMEB4(W=H;2!]=@BVJ1 HE>>0)98KKVPF9.B;KL+L>C9$KC?)C
MJNM5*%=JE@^)L7!UR>1K@/WVV9FF]NR[YD3YQUU!*+GR8T]!XR "$?<!(KX>
M%'D-H&QSQ>G@W5JP7QSSE2TE\NJ;IR7[VY+H^3=DONSF#.9MLNQ"OG_9*"G%
MD]:S'=LL_GT2[$6>X>'O.?%"_,-3=96TP<?.6>C.;B#M#04H[9!<\A_L-LM:
MNZV:XG2NW)Z1R7:9U_K*C=[ >:<29- P(8>5D)!8J:L+)=8@O<6H..5-51"B
MEKIK8MT69],I&:YGE0O$FV#S5NC#(8WZU=$J3A7J7[?!R^$.C2E/#ULTFW^"
MDW36Q( ]!5@(1J_[&L#>Z5:"H0_WB?;9EU'A=>4\8K=5K17O2[N8!C\6^S$#
M%4>.[B^0+9S%7.7E7P-ZZ(8V_\W%N.+'?3ZV?KI]I[-2J\C?I@XQWV9M\1;^
M>OP:L$)'>?;92IV[\Y,CZ)[]'3\[#%[,O\GSX@CT^_-#_&@^7J^B)$I.0LLD
M;?IN;4/R^O!)3YE:QS2&8B]3K609D=#B\*-\B%^XO_(^RA1^_\$=-[[,6!%Q
M^&:*8TE1,!'NS<*..QIL."ZG9Q7WQ[B/J;=0B[M"2,LTK<NOBX+(7" +/1H'
M^C'R RWV!$V1> )F]Q\=8,1JF=1!]H*&&%<?!KV0X2(8%;Y*=45ULD3PF%*P
M$J2.)C&4[Z[HF]8NPKE.R#LEY*X!U%!62(@::/HTP/LS/([AW67,!!*)+:[<
M#%AJHF3L /^&M\8[-LI?1CDI_T-6E-YZ8?Q^+X #6 2#8]V729RO 3_ L6V&
M)=@7+FH";SN$.J;EYC=KC@Z+;X]PV]$F[%7DA7 ,RON_T)2!CB '3_%4.:U
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M3Q#)$2%M>P9I7UDH1MO&,-^3ZZMHPH?XRF6HX3%2N/-P1#^GG5.N5-+24">
M[_>CL#D W;^I5,,7!>^+6Z+856F9C8GRI=DX7(*=? &?@[PW8N]9D-]YH[0[
M=%KRX8YNK$@QR;-;GC)AFI3<3D]U^1BN 70R&LPAIOI? ?[,JWD9W*7YB5^?
MVAEVX]J=C*1+_AIJ@)]3)%BE7$R(Z[:%P?)C13]1?<Q?2[SR,GA#NI;S-C^$
M]%'S(*PXZ[49;[(.!7^62,E+>D%M?N&<MM,2%IJO]".Q]XB <RE*0\*[8(N0
MX#D!7)9(7@A^7(.%ZS?]]=S_ E!+ P04    " "BB5):E4H4*633  !Z"0$
M%P   &=L>6,M,C R-#$R,S%X<S0P,C<N:G!G[+P'5)/;MBC\(2!($4&03E1
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M?/&=U3P7S=3]%^ 74>0?U,#0LF7P9CM$GA7$M^S07>>/3<-_5GE'!-9WQXF
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M!JK";D25_'PHM<Q6SLA$+G'+RSP-6ZX/"7^"?S@$4]KHK+IO20J[=(F%,N"
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M -P !-S//0Q)'YLR%C[*4L1$Z[2#D<0/.P:;[#K^#5V&5]CSO=SW3$+2#V@
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M'>"VI1@W1BI=;A&%0-/;I-XTNLGKEX^#Q&"O1+NN>L6,ET)3O_"GKI\FZY'
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M,O;;$:O"+*)CE]1/0+=3%?AMTR^/YCAK?I'.M7Q5&A/J_XK.NRA>;3R.U&M
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MU.%'E ;/GGVK)^IO<DEE:Y*^16]0IOP%*BP=&,??-7?_!PQ(##<=5?*M#2V
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M2>L[SKM"LM_Y-GT-*M@/.!; #^9B;S+0>:F_6*C5/ /S&%.44<-_3R"*VH2
M4W'-$W$(#D;3B:G):DT77JTVZ5>PHO,].Q^)%$52(\&S&WZ]@>3^%(?B@@9V
MCF.PMY1Z#]P6ALK3;C<*)7Q.5WCU_.I42U/SYIH_?DJGO0$<)K=+%M+NAHS1
M '64P)(-:,$(G^X5UU.!1A?/,V\KW_KN\]IZ1T(;MHQ'"9+ 730 RZYG=#HZ
M5EU)KL/0L>,PZ"@N+KV@*76,WZZ)%#?UA-5.S[9*5O[,:M31[6&Y5+-A=SG1
M>=D+5F#AF!/ [TW^<W)K];,S0C )HG*XHAPCU%-O=+/4FEEM=#@G,B?^Z>-M
M'F6Y6U_1VB37?)<&AG8:@'4Y?:[ML"8KQG+?T&-^3O8C][K821TAW2+NX4NF
MIM; JQ1W4KM,7:<,1)?(L$Z71Y$>+*T0"D/BBO$C2E:_N^7M&"+[8#N1X(29
M9@O"P#HO4:X#59']8<Y=V S/ I\T2VD#<3Q8MLE/[)15KQLYU_OJ>_'Y@R!Y
M>>T3/'FSD& (?PN/\T,I@N>;.0+,LJ%Y?>HWA%W.XY)J5&E?WZE:O'J/Y :V
M]!G3>[;F&"'06=@)4AFA'<?01H;0KV)?:$H0,HP.R\.]?"6= V8S-!W?+36&
M!!OD7+[Y].!;H]Q4A?+:%![%2:KKK.7'A&K*35(@)%=_E]6/Y6CN<X?9"2]C
MNBPN1@JX;IWUOCQ9)Y*^00.XSD1B-]O0K[&%)3B;T#JBQ>AH84:!FG8BG!KX
M)@96SI0II?);.+F?PD6Z@N_U1&I>)-7A^T5O$>P6BO)EXUL$"5.]MF*DM[KC
M_M[OYJPNS5Y,AC2.+#0,(!%G:M#1#\5)MBF)6*WWT,".3ZN'[[.UK<2W."CO
M!F_'MS9ZGZ&+"MA*\.WWH6N;.:>$9H'_0'!2I.98X&JQ#/<(NV&81\-WN$]B
MV8754J4!8HK1GS?$6$.$I'K7$4YL49HB/UXTEEW?D#)TQ7M4CTVS?VJI@LC=
M'<IC\%TKJ5:/6U%>]VZU]XHW] -52ZS5XR'1*/X=0W_],1E%])F99= $7/+V
MFNR&6PI.@KWM9$*XY+>.A'9A%M\9P1;FU</IDEGC<S -=\GACFSF9&IWP<KC
MO,KZ6NB>ND \%Q^6?@SP.NZM"\C_3E3]"/7"L3\^UR+H'##>H383T2),S"([
M\UYU&;M.&'#UF4^URG$R\>O^<IIU(R][-_0XX^.D6)&('RCW1]Q;1)6#-8%.
MAYV=M1G^1<ZUVP\_O[YVD2'!+V+TM5C\@VSE$W;E281H/*C#,^+8/+##+[+P
MZC3]6%N,;L\^/^217Q_&G,:.K+8U^MJ8^9Q^=!9N 0K6I"<UMLY4AI7-1NM5
M#\]E&6'7%]X9X4>F;-5X-1WZ)Y]/^2UB$^_Y0Q0Z-S%NFYS0P%F)]NHQF%ZA
M4XLTT7ZJLYCHD>>B'FUS^1VRMEKRJMU;EH_T4U/:*F7H$%#UDUO$X38JVR!<
M'ABK"HQXG^4!'[;G!EO;=;@(Z@I?'H05"80-G3GU/"C0T'//A:@3LL,6JEK7
M?J 8V02>-: KJLTJ42@HH+#F]<7H?KSGZ*?KCK$%'X>3=#!+HFP.>A7##M-C
M"TLG&R<9#<.4<59]*5@X 3'TT%%+WO:D-^,)L-#V%\?G'M=_$+*>XNOBFL!$
M<->T0!.ISHM0TCT&WNK$@<[,.*<L%[KXK5)STIWCT_HZ'B4_!TNX9#YI%NUX
MJ$%*)=[!>R01\K3'W"D,'Y;33[=4S6GXZX?*"9^9/S#]-MPO /9BI;I>4;O9
M==6GFS0Y*]?-%GELJBX<A_',G@RNM=?T7VM>?/C06#:'6TKDHGF=4Z5L;<PY
MSM,JZOA&# ?L,BF),#QW"3VW&5:+!4;E$843G M=&OPC//.K4_C6S?-YKTAJ
MXY*<+\RU)3Z_M:/$G)=!0LZ!8B!5=:V;40JNU(OA'77G?'Y.DI0[T)Y,,[8"
MJ0^^&9]$IUCS/@[K_BZO.\?C"2&".S'GJ8.6?S8E7YL[KZ@AI4_(Y(5?',LP
M#,-;-";LA;W691)7\SYQP*T@5/9*TAV\YT**QD.82*)&1)V8"\3K.33 F0Y-
M&:+B.)?!WH-9I'3M]6M7Q1];,IY,5#G[RY&NA61'0'8(<Y&2B.%=UM6UIA!H
M[=8OY\$O"C?"QJ;99$4ZBK$&G!UGAT>7I$I>9G,15A^0.HF\[2B.]2)2_?54
M'.3T2EW*?6BZD.3$2GI2VZMJ4\X64S'W+_:&?<;WZ:7TY9!PI>:C=RW\K@&+
M'9"S%)61FHG>E99+8Z=<_40L'_&/_0BNU&]EO7KSNY==:AC&$<U'"MR[2V1X
M=;%A:+P[@-2<OK=QY9=U='3:@RJIMU-MR2O-6@ZKJ*J!6,J).<P)4N,7:YTP
MRJ-#8/C3'V)#OJM%->?Z<GQ\W"_'MJ6(;!QX:TE=FY;)W%\[(M^RG88YCC0I
M%,%,/I/J9S]7JR@Y[]KI&!I8[1RP'PU>U(Z6O-&SO#57]AS%U"1#?"CWBJI
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MG,INL@A2T_DT.'3W4T5MI9Y@8UF3P7D'#;U6/LW=@"A V.6G(?XIT<)S*5A
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M2"SP,F4XEVJLU4:PJ@-:J,[[S1KD>(_E*<>A$P?U45(=3KSEBI&Q;OZHW"F
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M29UP?OI,P-OD+9&TC>/1EH'H@XEZVDO7;WDLLS?2CZ\$Q%^]%/;J]MW?H:<
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MN#0V-PHXU^>HTTHXADM3W>;'/WX7B&(G21V?6X?0@83<0'($A:3ZX9C@JGA
MX^BX.5:<Q>@>@+9)Y9R*&O\-I=Z@#[>"#+MTD _.X"DA:T41]6L6+&34N"F6
M5%Y45T-9#7\^/@4X+1B,#1.W27^PG#L?&T8E)(N.]5>2&\0(0FKI=R_*-ZY
ME\XP0,QT:Y%^8D\4>H,AL?4( &FQ5ZHV$:KEE:G3U&EW)3MQD$J<*B(B)<&+
M,@RIB8X$NYP"+FTJ:]8=@@3;IRW:467N,&E;1\:ZEX?FJY[2ND*IAAPT?KT=
MT*7H3. V&)^^BY6*;!>J'XK&#+@Y)1LTI@V.5?U,C+C]WE=ZX:)/)^A@<ZD:
MTA,$NA,V',8S+3Q6*?LD;\ENJH'QS_-30'/GH!OY9BBH'A=<3&9FUDS=,_XT
M"A*!E7=3:"8\0:,!&"N7!:J]G*8?+"]'/+4$)Z:GD/0@OE^0*V3N(IA5]W/[
M/IWQ?$8-/M^^R?<=L;$KF=3^^\::YZ]HK>OI_*!2 XJ']5.N?QHG4Q%"<#2Q
MGJGSQ] >KL*3!?+)TT^U(I<$19M[4Q2!N^:OR;)MI$:<%9*7;(I<+EB\D8R]
MD-(P?FL'KNMF/Z4LSY!VI6OYTP(ZP9>*MX!>/P38!9G=H//"]*$1D6$J8_67
MR#(,"2BI9_=-=:F#$U^-54X 6TT47@Q]^Z8L;3<];D:\_61.T\WKJK=E#T><
MHKU12<S%\R\4 ><2S-RE-,R%LD" Z#[SRE, =?]X75!$0Z/W*0 ?JT<-D?F3
M^/RI$]_G>^";Q[<V;49 Y\G\=9^GO3Z,RR8SN*7<^_T-\^B/3^05F<EW230F
M^CY'2UM!9T22[VI65Z.RQ]&OL4U3V(ONBX6J#Z6$?KY3;E ;%O![.6-F&WU\
M!<X[&C"@;^O%L B=;O 4:J L3E:AL+'1/CPU+.0>-NA3!39X<07,P70,[!S*
MW@L2KLOLUB6<Z4#$-=OYKRWP> 7D;=D7)XNW#6# Q+!7I,8^9?:7JLP(;([9
M$;?-E:Z)A;9.;Y9>=OX;HM2Y -Y^UD!T+LLH^2EF?H'*<MSC0)+KM^!5HODE
M+J5K1$$RCA7+);HEBL_7GGA6E-[W9')_\_)]HB5?9:6-C=M4%?VCPI;VQ;O<
MUW,R9WC>--X-P40GVY%RECT$>]CF//,*+#=>Q\=XR.E,J41J'.J).20D^>0>
M3.2^75D4(>DI_#_-G5D\%(K?QD>%(B;[;I3!B6S'OLWD+[*$),J2(4F(DF4&
M8T;)'$M(0EEFE+W%8 RRS*0Q),EN[,M(=F:$!F.\G:MS][[GO7K?B^?S^5T_
M-\_G>_$\O^3?*0NEUE#D2O-F@\[V3_8OI3B>*]28!@LDEA>R1\'K1P&:D$KC
MV,#L8IT?P#&*_)^LT7U3))0+:X(7Z:2;/.=]*(\[D0'?US'ZC=RF5Z$C=2!)
M= A0: 11.27G;,.0^&MUOJ\VYKNP1][;U]WJ&]D(?Q>7)\):S4*85ODU- -/
M:4QOF]3IH.G7V-%O&#ADVM<6E*$U_KA1#Q$Q@8NTK_K+7C-A6NR$,=*IJ=$]
M;1(++GVF]@%<M2E>C/4R#5RT>B?X8_\%2G@4>.WNG(ID9P5AHD3I-<27F9ZL
M>PC 0*7(=R9C6C,\ DB@?E,@WW+52$(:S_!H?ILU[+G-O*QL&,UT""K)EF2%
M,<B<$VO>ZEMF>MN3SK8U#;6#E_Z@.0?"N:3UW;0;LN  ;P;O<(O=W,;JBG\Q
MFW\ (LDV8-1VEJYP3A.DFX=7_9Y:+)S+G)CH4A1')C*^MN'RY-3(#/)J$F/@
M$TJ#0%O=:AK-<WA9&=ZB\=,)&VMBEY7FMA;\\DFH[#,K7JG=4.<O73]L%+]
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M.,57?WU=].\M^/^QUG-%_CF@]EH;CI<C/HD:,+[81I9A$3JP:C#!:5;>E4/
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M==^_^_'XW6_.'V;.><UYO<YK>3[/.8/VC;8 '+<P,3<!&(X   /]!Z!]!XP
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M+/?)59N=G4T)M7TOXW-%2T!&#!O;)0Y=!<>#N'<VXR#<<#T,IWQ;KHC&XY
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M/#MD#0"JYM6)5%[$ )7CL'2<CHP%X&8MNT6PBE[[O' +A]^J3@JKO^SD/>X
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MJ-88&-,6>%XWAB4 K["0D]!9P.@Z%G1X9?-ZAMUD57VS3.L-NW1SXH;Q#,N
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MY^+)^S,W=LQ%K>YA3B6-YF1=NG=<2)7QH^2.9&PRX8<E4;&5D*I]GC#U 2D
M&XCD.IC9,],R%'*O5S&KLBPZ9B5]YK'J1TN@7]SJR#E=E@5?1FP9SIO0L+=X
M-,UST9]TZ;O5Z(ZO@GVTG^)ZY:OHDK 3@LR69MB01=4+71\"46QM*ACE&#0_
M&%HII>>TV5W(/;ZNGN1$OO+HL/AR,E0AX1;C\5[UNX;25[GF'S',M&\NFJ[/
M4D^1$F@ VV8LW/L-19OP>++B5F1D:1=GK\A#=H2-.N]KNV QA5W&*4:A#O;#
ME#8%3*3.HFOZR\JU0OE&4K2_/]>[@[>_QY]*.S)>?L_,I*/^ZN"6V=6C1^7%
MAW/T)6%&%]L.GP2C2)? =Y\JJG.X"F]@"'O)&V_?UAM62!#"#>,+'872NB[>
MN+=PZW[]7G\7I\6:$TEQ@=/P($S)WX\"+INUUGV8EV72D/8T:5<FVTTMF"SX
MVTT:?ZF0E>#?IWR"E-(5X!29-6CF@*N\[%.1F+IM"GH:L/3HK<"7L8^MT6+V
M'10]? 9%$L&(WXNW.["Z&.2KSZFGM&1LGW/;('F(!<"8!!A4!079&!_Y%[N#
M?U^PI_[!5M51_G\P\F^CG6A #-VM/[VG(\%O4"L:,!97_1JZ5$TZ#:(\4QP^
MC*^;/Y1W.LB-CN.W,8BAP]HC_ZM;6Q(-\$''95)L0=S?^\*O3GUN?H*J-R7>
MQQ CGW]N]4+I[CO^2/]:2;[D"$NY1N+#?H>P"=.K@,PSDQ9+'A^SIR4JC8/"
M8@G2)P.^K-O_'.Z$<% X2<\JO3IX",&C^$MEW=LS\SY3XV%<&F@<_YU,\:3+
MHO#2*?87=R+7-9AE'Q C'";KZ%QDM5$DMR+2MW25^*D#VOHI5[X(LJE6PV#:
MK-'_@;"-21TWY8?PM,G*O#]WZ=*4HN/3I$Z 3=7\5(?W8<?&;9(1F=,(HQ!Y
M=]->,-#[0$;PX&&%[.=>KV[7H06@MT3H+(O&-KBS4H%H-5D_?_27ON0(!?*2
ME+XL:B317#$P2=1JA+D.M=Z1Y2EA4A#@2"^YJ@"J?(C-'FL>9H8;X=&]SAPI
M=!X2:T40+ZCKFX,6**TJ\<@"O*D#9ISQ+!*[VYNXV&**#^%P&A\:K52IJ[QP
M>L?;KWZ3;W!HG[G'J8_1;S_3)*3\"T60,78%A#>#[$M2E6A 39;UH6Q,5,VN
M727Y(EQYI%ZG4NL:*05CI7.U+N=E4UW+I&]QOC!#C_3K^S>BA223I_ 9'_R9
M*09-N=P<I%8C@MA(VICQ*Y^KLRU<1QVD>5GTH%N-YDTD.2C9B^('%L6FU3&^
M@1P^-,N[K#].'-IIV.]8WFA#:%2\(D5@T/1EOP>)6R,K/OL.PYVR_.RS\.E^
M[JAAUNO'U3-FCV)Y@CW(E8\J/JDS9TSFRQ=%,]/]\2]-( '+\>FM[H6P /^3
MR7>FZ_MMMN7!K\+R**?RYP^99&A /[*[L<QXPM[$MOS%^K!W49L]E4\1>H$Z
MFKU# ]@A)"L-] &K.1U"T( XZ*YCJ/1WI?ZZ43=K#)K_]U0^+I7/[9.,M>2Q
M,B'IK6J'MV>N!?UX^O94:55,,K;C) 6"M^Z.</"#NR\6*/1D#J-D(#_.^BMI
MK]L&?B,>+: CH\7Y6'T%1\O0!1K MXJ0CN=E0D_O*4CW6AO\YKJFOV!G7!!I
MI-AFSWPLLR1><^Y5E(YU^8Z&!AVW.<XL-Y>1W$W:O^Y"/P8=JO8)-C6W-MVO
MZ1%)K563B&+(_V2=2!7,(O?80:L=1*OY#/:TSUIJ;TQ(.?2^Q:=2?O/$\NJ(
MC;!8_P,Z^I<MZO^7.]R#$+PM>%_3&47F]$8?7*W?5837TP!F:1J0[4'GL^\F
MG]& 5QP0VW^53_Q7-X8/E)L$O\8%<+R;%$$P(4B99!Y<H/JUZL48O,\H\'C,
M;U8[V1@_2<"2)WH2+=^A  \@720;0IT:4W6MBWM>0GE)1Y9Y/&YQT/%BMXDR
MR_1\>#EOK/ G3QFF =03]L/,:C'DM&>G/V$ G-1O/(ZNR[L,Y;MU6,#RR%.-
M#3&#<-DGB6KM?K]H_FW__?"B4B59&]%% SAV02"**N@XQOJ'RXQ/:I3WN[;T
MR32I3_Q/#J<O"7/4K1M>E+1_1IU#B<$9R;8D" ;UL$/(DE[X3%.J-31R67UQ
MKK)U28OR-V]W^MX-,;S.RY*='1V#O+RY0W9U&HC0^>Y5K2AW36QR^T50L*Z
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MYTC7"0V-E8CO;F?P>0GJ('9H.'?W9]"-!,<IW8N+')KOM3,3GN!\BY!/OZ;
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M_T4OP0'B?_O>A2)!VK2-P!*K(:[??5)QMDOSY,WFG@H):W%F&(1R&B*('+D
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M"O(SV$7&&'Z-"I8=^H<'<S%NW/(.8F&IY6BJUC)VWH )H-!;E=T=^)+^!;=
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M*687V#T\&G@OQD.O<I&Y_MFMDCFK\#(KNCXV?Q!Q-^0Q,-M8A=F2HV39>")
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MD"J#%U@%(W=/K80G3""\4#.B"O?;N"V8#FRS-7SD\$+,SLZZ6#G2T%AITZC
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M_"(H2 ?I D$! 0'I*#58:"(@*J!4!:FA2 \0B(* U @(* I(1RF1$KJ$7D1
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M6O4*IR05/3K6XDU.+'+EPP7&+8[==W\N/*SF[?*XK6=@R-9IX5\V6>WZ>>
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MQ]L/YJ>/70_VE)-QM+:L'H9A-?Z67O ' 0[PO+$5;X27SV53M;<3 F' T^G
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M>.7*$"ODU>W7!E^N>G&L)6]MB\ZEA< I _GMZRCKTII4Y;B>2O8\R^AR>N'
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M;7Z:P2AQV_.6S*NK%FWZ-E;]15KM?(\]57256M/88$*8+<->V2TFB.1*4O7
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MX253E;_B3EECR/3+9,,_D?LE$H&='VT'Q3'PP;EQ>OM]%/C=R<R>'[B];C[
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M'7WU:^VWWG3CL]TS"<J]OV*X]_?]]B]A^DLM]C$9O/"C#+)Q>_Z%LQWYN%8
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M$H"-?WN+^K]G#^O?E!C@P:V&.<5Y*CQC# QE,S,J%,KZMJ,:#W392IL>$9>
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M=525K*?PC\RR]HTBWQ7:R<PUT0&B_1]0RSTM^9U_^YA,0(S$6TS@BZ'B4,2
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M3_A;E 'U&;[]!'1R&D(@D&'[\1:H*VX<T#*^!#0=7P)80.BH<_Y+P%,YUTL
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M%):#=WIZQW!Z/=&HJWS.6,PI1GF/\#[O%L<W^?S\C5K8UGZ>9C:DUHQF3:M
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M@D<@O$[C]=E4_',D_/R&&18A/PJS!)(;@VNC\LT+-A_?:GC7ZY!M?.N]L0>
MZMONR/>BV4<-@VNO_CC'&7TL%(%> OZ<',(L+GC@)VSU!O S4B V_1)@22E
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MG,,2)Z*1,V>5I,B3#-.;?WD6GYC4GLHD*[.0K'\&THTYO((LD+.%1$\ 84B
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M.DA=B:\33^;^Q7O^AJ_):@F&?:^,?Y&^NN9Y9#NPZUW0/3\%0@UV[#R;U\)
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MXS1 ,8[#JF)D:3*&L?CA^9JU4+@-D&R@R.Z ?,=TZ*,BVVRURUO_X-W"W;Y
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MH4II\R\)P#GP<(=: UT66A#VD_=1]+WZ<X7,UZ^:F+HLUU:%P;6]N)MH]_D
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M?T:<(IXY1[1K'#]?OVTQ;(Q=8.L1^K)3M_@JZR6[:,'XR+>D.3\!^)$V'"I
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M3)U@&C;Q5FD\+B<)<;1.H )^MAQFNZ.?9#@R*U!.@ 4!O@=@+;3CY>&1LS#
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M[EU%PNS-_T.,X-DV&7H+PX40RIA3$VH+J:$5^P.&.?&^!9-L)8Z79V>B&:A
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M&]BNZ02=FFV !4_ =B,Q.%F29E!T-E[(VJCJBY(1IX6_:\*2QC/,:S_[3VP
MX"\WD+0]<!,T3W>"L;LC!<;-V[<I\0Z:+[(:;S$7&Z).<WX64!'2\4K-W>%
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M8Z281AF:[).77UQI_CZ]<:_H)QPV5"*5KXJ\.@8*Y#,$?R[?Q8WZ-R$=J;I
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M,@=D_UQB@X?O2?Q1/;'[_8FD_).+P@[SPV<!-UCCZP?[WIWD,75$%V17WHF
MU@LW=Z1?AS$#BFAWO?J9.TPB&PIK;F73LEANLDY758TZ_][7%QNOSIF,[CZM
MR% ;KJZL;(AG-Y3?W>*0!@3M/+Q+56LLUQK@V6JS%T?0.P_[XCKH72HFW4O^
MKI1A-$I:00MP3(@TAYBFSCS+JMOG#WBL)<RF[*[DGH\:)<2[B8TWFYU)!:RU
M-<I.)<>V6T5-&LQH%@X,BM^ER_E0/*"6&%+Z#H-JSP)W(E@FFG6*6HIPSQ-I
M'V<\$[O1MJMRETKUZ0?(R.= M.#0VIL.TYRJ+/DL.,3'%IG\R\3.."*4:\M>
M=>AHUE9?'OEL^%VO+RZ&1GZ8$_;A2<2/O=A1#$<KF!FJ.6QK6_/>>$3V3B?'
MP_%=.JF^]HAJ@!%93R_O/=85F\^2_8+E#;*8\<WZXGL(2,UJ6L*I<+ZB<@B2
M -4BXHE/&P??@J\0=#"(8)/R>^23LRD2\.TO!S<^H!4'R*AX%HXN-:AX'F']
M3KJ!;\MO*(XER?(.?]X8B#^YI=WO$YR3QR=% J1(%I, O[DO0AD-8;N;M_30
MN NTKW4$/".'[=P 9Z4N/B,!Z(W-MO#IZ'PBRP21&4S0PGLOVFEV$;EC!X[;
M:;R"G;VDW%>,: .?..D.S@T:=;48_""J8)QWC.5P$>5X>6XU&Q5OQ3'W6(-O
MAS/? 9Q&0>03S3*+GETAP8N"QV*%W>[%KG70&5=4!E/E1L,C'T7<]5,KY]+0
M<9O2#2MY>VY,8?*B<X/I]]EIAR^<FQJ1)CG>F?-,T5^5ZJ[=]D@QZ@^J0'[M
M#.\:RM>7^FJQ'U+BH=J+W$7$$*E,,*_FP  "%S[GJZMI*21-P<RV?*G0UNV)
M:/>WWM-Q^&1.U]QUK'.X*HRALF06(H^;*!LR]K^1.IQY4SPWR2.:M\I> E.U
MM%J)R3=MR>Z[YFO+C8W[R8U2>0Z:IZ*B#[^W#5F7# <S3W<C>+#G-771AX/T
M&Y:6'@[?1_,![ $S53( :6/>TAP._9<)>OJBLT7]T^XJ68'V-U-M/@9Y?8J+
M37DY,:B]%X(X]TBD79Q:P\EA,]"7CGXOXUAT,OW;O7(FR9<TX]U=5]L9\(^0
MY2_!5Q!RFT"Z0]MSWL-/H*LNRF$2<I%H=YH.AV\O?T3]Z''8I7?9 E;+EY<&
MR%AC/H?R#A^VL#Q,ZHV=^G$MK5>QY^%EGO>]PIRS&W:^(I9K*;'#_?K'JE/7
M?HF[F'TH',O7:YL(GIR<=76&;=GZ!FFEO_4!AA/YWG?F,#&^AHJ*'/A,J]WL
M3\R57F@,WTBD%L)&]'+*#1&'CI/=;!1:N>L];L-3(%O^B?MXRNQG8IQT"V0'
M"A38,=0G5Q#P>=R/*5B4JN:BA$ GQM5!.T<]SU:T^FH3RK779'^9*?M(IXL$
MX)5+>BO/QQUM,2)[U# $9]ZG+75^=D"34^^X7J)-1950P]0^CNMSE^">FJBR
M"3R=F0KXI3#NI,WB@0U'9345?FH*W;0K*U^;_TT$!1QWV"ATSU_>R/2#^SH6
M?:U+WOGCU5?1P%CY(Z+D!T>J1$.5I:2DFC/PE'<[EUIVN:]S01>&JBK*M/+!
MXW?38R&[ !Y45,#>TFH^EJH[$QR[)_O35J6)[*K!HYO/8XTE?B;\TM;6Z]8'
M,Q' 8U #K/3/KH,-OW=@FVNQD]UBU\ .@DYO>P:":3X^R7S8;)GLNM-$K+M=
M"^$<*(V?+3"5!G.TU1T>$AA#1ZHAM'O3 K:9 ?EIP792M]W13CP_$YJBZWFW
MWN!#L!%=4T4[#&D<09UC.!37F]K1]=WVWL3KNM<>0[]<Q"?E">(=R!2\HP8[
MGMF>MW6K!&'15)W,]O">V6</.D;^IHOD&$+_X K\13/G'QM$@2S5!KDWW)^3
M'KM3Y#S]G;M84N!,*=8I@8.A'+J!T1\J2NIMOA3EA>Y[NDLXC\X-'4I&*VNE
M)9UI$?2K1DT<([8UC"44:;:O/*&:J&?\C64D2+3 @/(_.<F9!D97LV7LO19
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MP8&''*-<\^+H"FV\(_E1A=YKT>I$929SS$"!7E^^G]^PV@@8LY2H]#!?^UI
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MW=N=%]FHM^YI+V%KP7L$@3__B%Q.= 5:@[)>/O_K66A(%&A>B @<![)"[Y(
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M7%/*R7/5]\<EDO^ U<K'.T@JUD@20P+(=']M5\SH[S521H+^%;' =V)!?20
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MT;G" V/ES8&Y"8DNU=?&\L,I2KS<ZJE'P.U!;#)"E< ]!'60R[.VMQ/3\:8
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M!(:( U;;Y/V8FI+)K-2S=IP-%BJ";DY;8Q)N;1S17=CD)VKA]_!?(;+8G4L
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M2X M(QGI%"K_8]=%0&H@;]]/;(Y1OGU[@+F8Z,ZOQM&7W$YWP#I-AO0%DY>
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MQNN8Y(RV(M#0-/X^5Y*-2P"CDDAQW7"D\-B.PDF\8TN18L!?K9H&_<<&^I>
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M]H1_'^AI'8W=MQY#*A?97VE7I8?<S@RJ<?)U:7UXY"^H=RR\U'5!?/UKG-#
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MNXX-^D_.32:/S[S7K4VM9AP5+-=FC;XENSCS [MX3E3ZOG =G]_!N**5VWO
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MI'<CYHT&W[J9QGU&M+MZS2H_4CMI>2;Z0KL-)"-^P>IK&4=Y@H@&.8%)G!2
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M#!>X6;'F +TI=P;@CSLD=Z!!/PQ[2PY#)Y&-IZ'PY3CS,\"4\<I11-H8T>5
MLK<U"J0[?GPKXBXB5?''/U589:/IVD[GDVD#?T+66HF$SX>> 1Z74S\_ \30
M(HZ7SP#'5\I/E@Y)24,<9X 6!G*@*7WV^5C9P0?G9W:?&?SVPQG *_!HTI)\
M9' ^0ZI@-F> >!A1=!]XS&_XF;=FXPS V;J\H$CK1TT.9UVF+G/]M=#AC]B7
MJT(<G@N2T /;45#%$"D8>1/>:GT&R-( &QGVM?[CD= (LORIT<$CX*&Q?]CY
MN'_)!?V36^L88LX B]FU?"<,'5[URZ9:;'ZUOYM:IR!ZOD.!N"<K()OF9 J"
M@&0GO%W9^3'N#/!QZ^$>=[(U2<JB"3YET;WE?QGUL!A<;?ZC?^B-B^$P0_9J
M3L2_3\%5'DW\O"_Q!WIV_D#/&6 C#_PW]E">IGN< T;J$=<VW"%L*)PLNU$"
MX;,KZ+G[)LY$AW=Y:W!%(/IA8'1'<_1.1]+[&2T^2%W55T$WECR6]U2>=96K
MD/7W52F=/2-K<T#JF$(-[.\Y+<ATIC+)_AS)+N&$R0T(<CS-[C->_YKMS&IX
MF..Y0Y@>PP17<[VL39MIJ(MC#P,2DS8#'EP[?N^Y-RN#2 9A&)K/== G?07D
M[AD@V.W7Z%_V$KE^O@B^JD?!,A:W?LG)>?HM6&Z _Q&V8+DG5*:BM5'8TYO9
MT2:?3.JM_9[&+)B&OFJ+K^NOB_24//" 3B7.V=>6%>]_D4CD2M%9[SV_)"MR
M_^T[(#^/CCP&"OC/RLI_7D>R3DYHA)76.G7F9'# C8\6KW7R92.&@9$@^D5B
MYB)DB^U)Y<_[>XX%SD>V0KN%:U.GD+V=YQ6MN'*$1YX#8=38?*8UB?^=#/4X
M[[I/!&DA[/ZW_'#"FN\WTF0BR&&1U)%N"AR?/<SVDRO8@;=,^;&,>\2Z1G+X
M&E3%Z/:<6]R+U)([9X#*R21^LBA:\D9A;]#<FR&+KA5@ NP,\"Y^/6GRV#^3
M<AYL^BCZK@7G[2B_+=Q#3!'Q[:*)GZP^_[B-HM_RA^;0HF/ZA/UI>C8/%Z&:
MEBFR;3O>\ZTN0Q#TQ>EQXEB?7-TQ[\<60;N<5DW0M?\RS?LW^1;QE=AU(G,7
M+_ +E9GF=Y.W&3^^/\EL6T1K:"NL4NY!"*)X$23-:5:91-.F2;K^_))&.I!H
MJ]QBN-$H!8SRCZ<A;9XB2+1P''PI(3-R_^7]V?7X@C*[C3:MJ63CIT..4^?8
M<L'A9*P-^:"2&+@XQ]WE Z'^-KZE_UO^>L+/YN)#@P1%;"IE5DZ$X'\P+:%_
MXUPF.[&$W,D./KZ/7FM?A>P>8CW2,H2(J=C^$Y-DB;LZ^2)@ZTH,1W:[6R;6
M0MS%/ ,L*(1( "MW#O)QOAW]JPQQ1!"$:/JWP3?RX,<<"+?3TC/ LAM.^C0
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M4/M%RUI9PP'0=<6K1&I,9B022"R6Y\M#89+%SK6\1XF!DWQ"]*(%Y[2/-3_
MZ0S@5-6QY%]&36]"&JB<MD4+?4TC?*M%[_P.:WUKP8\D!MYZF[M7QNZ3%OG1
M_R%8<X,LBUL(=GI3-]FLE+_&SGP&^!IQ3'ADK'NH?'\(HX79N6*'O#C"B^IL
M5,E(L$G-8YMT$7$8B"ZDC(.L[ 0@+^"&N@?$NC,D\?,);[$\_B<&]54-H2_K
M- QU0MAF/M]X[PF0X?<8A(24GN;]DG,:,@X6L]24V/$5!CXSGE/VO:#K+.'6
MMB3(_X[SM4_0(TD%& 0##GMU!J#VOT$,ZL=,IBI6+7+7?U"VO=VO K&%<M._
MO7?E005YA_.Z82N,GSC@B+^CU23\B7KDH.0YKXGT9_7RT-S< &F&7Z8.+8*Z
MT\7"A$O&?Q5N+O$O6([]*;\T]?^%;O__MY0?K!I_"L%E4;\2").W/U?BEW.0
M#>5KC>)U0LX[? '  NQ#<\$2\H2^8K&KO (F:6(_S&S)9,VIBVJY7'7UK^(C
M\4<6JI"DTW1YSD5XV.\SP"O\8)(C5BR"7;S/JUBMK'/E-$/*E2]Z#BRXG+/U
M_(6?[RM&A*;K^\AXNQ[6-1V=!W&-BKD5XZ*2OAP($:>W+=7)TB@7)ZSZ3][U
MML68?'_;C5T4>Y2\T?7HRE[)3VFY%73]&3W(6B+S.^0E8C^>MDU6. F7$*=<
M;&)"L6N_UW^XJ-.N.T\[6R--*,%E?I 8HEPW'D>RCCJ3P%^;?1R#?]1^M?8-
MO_R4?TG R8UHF!_2Y6?NY-G0']WAYYI2..#H!+,NU>4VOFC$=V^T)UOY@L:]
M1QOF:R>F]^OPF8'/\I[2A[U@?W0QZ-'QB>$(D+[5YMR[08'JPY48LWMF-AV7
M.]>99DN^VP"<_+H\!KW+%[J1%+B5&,=;M7BV<,LR96;G*+$W1E) O=AN=UWN
M(6-);\^]1VO6&?T,LM</?V\XMC+O.6]=BP1*W5#PBL$CRL\-TJ)NAW"QC."=
M$M?O1$S(=NZXB^GO5IQ)FR+5:4XU1&OHRIHXU+([D>[B?=UW!<*^J]X=MML[
MRO'KCQ%9\IK,F)5.,QM=NK7/3]Q;9.W?E8HNT7)8126_N'O(4OEZJ+1;+7%R
M3Y@R\533-4EANZRF57\R'\_0,:/X32)UA\F>3;88\$DX=34W[</8L@AW9KX[
MC7*P]<V_=B_O[("E8#>)2CBT"9'3'AO#OG9L&''/XY-E*4267':A3_C'8G5F
MLWR1SO-+?-O'O^L1P:T<'KHAC,303C)PU FFO-B[\Y',6S]1/G/E1JWUI2T<
MYDL.TI-Y:L]<1;-Z37@\3JU$OTQ6\X _EF#&VDD2)F9;XM54$]?GK[P3*^/?
M%1.Y<Z.:(3):[27?9U^TB_&=O/):"6T-LW?G_N;!_^L";ZZ=LY3[2CXT]%RT
MV3-L,C#-V<W0AY\VW/YTY%4G;AIFH;9NJ1QD%.*]>LE6/T]0[9PM!CUN:LJ/
M>:HA(/ZW1F&2$$(9V*!JM S%Z[&Y1@-?>/8X;YBDD@_-:0/;':<7E%EU%=5_
M2[\3&3M.I:\"0^"^HSLR.9%W-XP+N^FDY(:N_31]-USM9W@XZ4F(>,3H]JLY
MTM6$3][%K" ^]S5,\+10XI2]@PTWM4J^/7:[84+"5V)WL2[N'I.'4D=BGT'
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MXI,K('>-";%QN O]U(M3L !Y&IU@1>]CV&\ST5!0?"^EZE>5#SK-_E[*MS/
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M)F&EDK%G@'"?Z!BW.Z',!;%YJQIW:Z-M,.56XJY@9X [YR!D9OB-0='_S--
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M%@(I4\ZW! IVK!;[H'B1Z/B60]TCW4!WU,P"8'-_WJK<S_NQ+EJR!A\RNF!
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M(Z>(5\DJ>H*]_P#&MZB@#C/!/P@\'?#F:>?PWX>L]*N)QAYHPS2$>FYB2![
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M!V'.X[,6@O9$=:?5X=^$V#<$U]*$-ZA30K[SB[+@&PB;&,9HGRT;?H*?IV<
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M729<&T]GY#?<-#_*]6;-36LSY1*YEZZFPS!L=(RR/)IVY08X^?FT9WV6G=*
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M@0-FN-YT46A9;'7"!T6(_1[/(OUOL_!Z@'3"C 3B_#&XJ1/!V.Y61BCL$G6
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M<]PR?A)0;]"Z=P]W-2TUTF<NWBTK#7_F-VA<^C<0TM/A7#8%M>\W:V5J@C?
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MI6JTJI&>%D4. ;D*C,F]GX'62_1$!0?>.Y#XG6D,BQ:H;9J N4=XB62B48C
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MM7P3Q]Y2Y8+3;FK]W>]6$B ESVRVQU>K)8N<'DXG[?>_RM$$+@OEI</S0DU
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MJ*0G]7@_R)2RE"#9&W)[IIXGMET6&"TX5BD<-F=OY+%4*,+D1538S#W1?T:
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M56>->\=$EF0_W-N'BD$U.$]EIS/OS.4UHX;7M/IJ$U2T>?3&K>0%]X;TKP!
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M:T_;>K3,,)@F-;""TCL)IU@>C>R0P.H&7@KW*@8FUZS-[1I_9_J(7!*^'%_
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M!_EW%1J?8P7K+I?2X_.O()FD<=_0RJ,YV_ 3MW&ER=.\'X6=4%0^X=0!MYZ
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MR!Q9"MO./YCG_QKVZ K@A@Y5BT$WCY;"R[<8Z5"X(BZU@0[0"L^N%&8_&B0
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M,RQM;EHK@ :LF718G<TNS3A@F)*Z[7<J#_@]6SZ2*,2 0S,2^I0.QAJL1PK
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MI<P$XY#9V.AA&[,_>%8=-:P5PD-4WOC/2=S^CV(L>%[[B+4KXH]]M%(U_V5
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M[CYDX\"4,GS'GZ>FX8B*,3W*S=UL?OZAL@#L9>HS1A?[%WD^V"VJYVE914P
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M E:)7['B&K?V6J+ST+JL;*!+O(#2TKL  0"')+N95O2"+S:UCS#8'02)\Z-
MU8E,Z9^LFOOO=WJY.-Y^\ 8+VF0Z,KR/+BY_9FRRZU&DZG85Y0%;K\W!"/4?
M0")SA9$6H[6GJJ'3"]#8L:FY7^YQ6O>NY;3[=#*/=\,9</[59? KG9FL-C2
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M=KG.D0\BH* REGN'4B(VZJLJ;SFBHNQVHC61D572C 7!:_Z\YYBU?W=75 _
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MG7#0.8FUEJ"VP]_'!5/EC8_6:%=H_X[D!J<8JETT)QN]N!3Y"6^S;P@3\D)
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ME<WF 4I<XP^<LLX@!1[8C5K/+7=#+Z];AQ@'XZ5\=ZV^-M4_=ZUW>T*H<;G
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M^]^W)S4'KCX>P9?^$V"'%MMJ+KR*'_^Q9*\6\91E:JLZYFJ?QIUP:T@!F96
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M%3U/U)6^2MZB$2M5R#*H_2AV11)$8;+XG,K'_(T.8>LH<GQH6-SZ?E<ZYL2
MU$^Y3M)1V5<S=M/!UF44#S*F9HB$F%W6MV50@L$4XK+E.FC$!&[UO::HD0U;
MAZ($P!CKMF%?=2 >Q@J[JE_8X55MD[64+[YUL>ED(D'?Z9WRFN2H/'S"[?^B
M[3V#FOJBM]$H""A-I'>5IM*D2Q>5+B"]$Y :8D!ZJ*%(;P(""M*E"2'2>V_2
M2RC2(?2>4 .$</G=>>_,.W?^]\[]<C_L+Z?,VG/66GL]SSEG/ZN]06PQ^H56
MZ0A%*%30W??YJ:3%DI9+)L>;?[,*',0R+J9GP#M-7(50K4XYUN!A6Z2,=(E
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M]LQV4Z>,AZW+9)O.V^8/60Q@X55CO[92#"RM^R(_7+_>J *?F'&QEZRLJ%<
M8< NG"!KQ.7B"SAL(PF,+%SY*/E3D?JOYMU@MVW@.WS[U"A4>3DU-N"I(]6=
MZQPO-ZBM#'WPO2=ZL"4>=I,+<*_/CW&<H#^GM8B4MW:\@7453.H2L9JDB"8^
M(ZL=A01W>[E9.Q?BX%4_.#M5%G%$(U,MUG)P4 =[_\^L$<4+D0.L,MF\XW1M
MUX3A@.$%HNX(@>4^^\$3*_<2IX2-]'E[3RE&]<D64L7&.LLR[Q@AU8PAQO'
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MRIM5V1JX[%#F5)8?,?2YXJ&Z,%7#!^)^2LGM(7_PE=@\V$N>2$:$NV5:&,A
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M91=A%.R]X3970$! YQ*ELQ\,X[J+TOLC$\ ZMF_1^3ZCY][@L NOX.\BAJ&
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M"7B,X_>59>^BK_FZY#@M%59"]ZO8;I=EJBR/.8F#/,8?.=4H"(#VF!NNQ/U
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M%T*<#V;Y*Z?+N,S,*OM<DQ[9\A5(1/L#OV,TN\ILNKCII?U2Q\VW9RU9HUX
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MH(>1QIEZ9.Z[1L!1& KTMX><4,+"K@E5;P!]13> D'J_&\"S\YX; (Z<[ ;
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M&IPFSN]0=].F[$!^<M<Z1'E6D#MFT:Q/>&J?%(OCO7.<SE^9M2HN.+D\'6"
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M7,.#35-,EJ3#BS_?M9ALS!-V]V_:_0O5E@]$F&;X[XC@']D"[I@E^DTB:^0
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MS)BA[2I_F[ MMD 47NRX![#Y=@%Z!6VR!N2_;<J9\)?.VY9O7T^^-QOWSBQ
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M/'!=60(6M4"V/14>%22(]R2 VN._R"\A\ 9$7V_*BET+^)W+^;><"+'C9Y/
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MR'8XIA7L,2./=6#6/ZBU)--[Y,':\]49\MM-OVVE3![<_)K%D#[+*"B54TX
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MA1-+8OYVCDT'M+$Z9HB2?^KQY:5B"?#6DYLF"\\"JA$]0"!->B&5<ZVQ)S^
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MM4AXVU/MZU1GU0V=VHT9Y'15]1_EDS- (T+;"/8-T1S9XT6M1###VQPT]8E
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M8:_BIL\ CC21?TA7P&"X:J6"&&7]P GV66CRR0?\O8[(H;H0T6-]FC[5T)F
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M@%DKM)^H$G:WSY-3[Y(X\FYOZYI1G;*QC9E+/QJQ63L'!W\,EO-_YQ=+Y0$
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M-I[__$8AVNA] SH.S7;J% <K^JM"NI]S=+HQR+KV6/5FCZ;<O5N]1>\7EL2
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M\[)1B5-B0Y1"";%R>WJ%IZS@X6_('C4Q@?-^>4+7Q'-:&?EIG7I##XZ'GM]
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MBP@"$7R3?\GK*.HZ%.%[?XX0HB1RA\;[8@4I+"_7DQ(3*HF3A#&V9YK+\2<
MCTNMJ"U7/"VQIL1"2&"NX@Y[<<[G5 VQHZ*T"?OJ]2_N#CXB)@^;%VK<Y.M_
MSQ:^2^DH_8V=,K16ZGOHS6Y85+=G%C4<<?1D8?W&S>:-ZVM9!?[9G$KW7ZZ3
M-?[YI.I$!!!I9IM^3]&<V_J*T8]-49][J@"KAY*P#W)[G%_/*D,A9 D^K._E
M,8(T:W>U(G6F(5NH"2G_^$\ <6T XIH-?@I?8^8KMLU"K/UJR5&66;1G3[O8
M/JX(I;AE=>JFZB"J NL9^&_/0E5).B;=KFP)@\EL%%B?! G<E'=X58+2EBQ
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M6?N>0SD#$3PTRK:;IXU]/ZRJ,"_L:-THOWI&I(,K6^75M5;GU>/$>"@,TXN
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M*->B?]BUJO)O,!I6X#L"LZND27>JX\U9]UCK$9V?PP$UNPTX8HI4^&>NGBF
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M"I,O->;+1OM65 7.O\ !2=[<6P7C,0A;13M5BKO0O%G/KH[O7F^E:\.8U".
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MV5!,C<D3Q4AHQA;HE,)&)</;* 21ZI'@SQO-WR3XG!O2DE?;H!IKT;?59#.
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M,LN;*.L;D4GT,S]Y:JE?F2VQLX"C7$TE97K1PA6% X"]TF:A57NHMH/+VT=
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M8=.2M%XNEU!-,NI,ZH+F [#K:SPZ75?1A[V[>/K)\9[U"B*NJ>$D&]T*7N#
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M)[4D4CRG$O;)TY'F)E49;00G(EIVH##VBKB8D-1XRT^P2VQ<H/8%KXDSSG_
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M?*&MY:"/.0,TIZD5W@D36JTHMG)GCRIC^_0S,CP(I<Q'R:PH6T>2D?E2#^+
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M)SAI&JK_<SR%084XTC[ZYZM+"1Y:V/L2UL8986\-HRT[D'?9)+D4<*.&A/J
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M<G1"*[?I/3TQ]IKNC[$L<1 (+Q$'Z'"=3D-TU9R>6PW<_RW/,\]<1R#)(_@
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MN:H)VDZYJROF-(!G'%SQE<5MS"ENOV 7,&B-H7@6X1ZOM BI:9J0S+%V>S7
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MT9U<>RK*U5I5ELYR*13G0&2;Y.\=XH"[[("[Z;Y8*/7@2"+&(H.0X/7=L&!
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M1++:)(+75#F;/8P*?0;&V'(#$N"*[&6GVU S48O/6HO%?8N6B=!T=9F5X*]
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M;A.'GM!_FQ/R>YTPO[^T'N"!NZNT[7Z]T%! G*$RGK39)]%0?P.>:>TF+W@
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MN;:75[+-'=O\TW]>:A?[9X)=S]_(,=H<=0:WIMKBY!0_AT#Z(\2@L3Z57%0
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MMT,X^:7[EZ]*W$=Y&!:)RC^-/^:?LS!%'XM5OAO;Z95"N<VT-J_8?&A6'L_
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M&L09FT&O4#F!52>BZ<;"YXF>Y8Z0FI:3=2=2+)Z9T=/#&7^CDAW,FA81>RR
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M/+AQG?YGA]B9*0?^2ID-\W?*6!^KKV#",;NSQ:/KUWR(]L9[:_BJ#)G4H=:
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M9&3A9&%E8^?@X#C/S,7-R<Y]D9V#_3<1*FK*&9JSY\Z>/<?.Q,C$_G\\R-\
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MWGOVFL]%<)$!UCV6IYMW3?XYJMX)P9+S:2D+$KXOSVX$D?$,9C>Z??;_QU.
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MB<%%X2X@[5F"+G"!>-;/@R"-#6Q&$2Z.R#EI8+3?R=.D*E:GM$X$3Z66%/(
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M(D@7D@%':_.9]1,)7'DJ&;AO7'54T*T;;SC=Q1\!B9H]+S$Z:87['(D] 0O
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M%_VN3BLR[[ZQE6/(:$.\SS4RD('8\MR"V 1P-#:85I4*-^9<OZB4_>#+IS?
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MJ6"0DH>5M8WM$P^.U=U'/6]3V%X:NN\#VGA\ME"N*@'*-+B5M4#QJAW>=KG
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M>54V7>7FB=)RC/\6'OEG[2$ YRS/ZV2&_C$2*-RA5RASZO/K\(>&OG;VX 7
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M9O]-V#=@K@\D_/T:TXXMR)LE>.M6I9_:RIR9OF^5;W -5=/W/%L#RCV?;-S
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M(U:UK9]=BVX'G8=;](A-?5@^$I<\\)51":SRT).'Z%99CX4\T'EM#OX*X(<
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M@)!2(")25,QQ1Z?:$RAB-#4!S)G\<[_L5N?P2PX%IX:6'T// _YCT%LSB/Z
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M: TNU5UU.BIC'2-=W6H!2JT'M*$TZE.RAK=.IG9O,+*,+)D\KV/0)U67GVE
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M,^F:HW)6>U&F-)W:_1$]YWL=!I0Z<VXMN\]''UPRKA]%8/5=+2 ]?_AL^WQ
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MOXZ/=,ITCM5]<-&$E0"%?WPDV@F?BC#B%QII^RFTJX^>$9QJ/VU"VS@.MY)
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MJOX=C7ZZ^R7;B-6L+CXXM?KD;X6+R9$@8H-U9F4EY0+0?0'X2R2#N&%:]>-
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M^E)\97O^_/#(QTK9\L!MR&C4;#O:"UH\$<9J^/#*_V  +Z;^-U!+ P04
M" "BB5):NC#+2CWF  !I'P$ %P   &=L>6,M,C R-#$R,S%X<S0P,S8N:G!G
M[+MW5%-OMRX:FG00I4A7 1%0$.DU(M*E"TB-%*5$0 0D0" J M(%!906Z4U
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M7=2/1^VBV$_E-BT)>EV:H@2_TOY[AQ=;)C._SR&[DTK0;6%@@^O6G6C6!M9
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MU N3P_]Z (CLY9,Y?9.0:];CP-UY"L IB6".T*0 <NW-*  DC!1"XLE+VLY
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M?( ;R2N6;)J:LJ^R5'8M<\E6=M[*RO\Y/=E_6%?9E!.Q".1?(ZN,(6;SO#A
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M[CFG:J>G*&5=8EA4X!#A;A-J*7'-.^E2/Q6!_/=CNC[W 6?*TJ]2[RX9A\S
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MUE1,.X$MZU<H(Y-8*FJ^%;FW"5Z$V!':)HYG>1[4TZ2KM$X^QY]Y.+F%_>*
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MN]3P.$7AX"9][3:5<ZCITW:E!*>96EK[6P9@V0C7CV;&&TP"@>/YE&?-;?5
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MUU:=VY-X.[%5N\ZA\?GB1#UF2;VEK5T^+\<!Z&ZHKRF0B ) ;4#%%8%&')K
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M8.*VSAP/.,>L-XB^%#Z\7XTHI-SK;)S.SM#,6UPO<O*P9O<NQVF31HB=:71
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M4'1(@B&',_2B'[1RC@[88\/V[5$__\%@]W4ZP!<1"G>9.IQUFPM]?T:B :_
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M*(W)Z*43/MM8,S5F5\C9>GX](JR3WQB_';8EZ*T-U<]9D2]\R<0I72#B>@N
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MR;%(@U&9L/43,W!_&E\_>/5><O=. &[G/EZUH=S'_OM81>ZZ16(S0J@?2 =
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M)H(ZT=T[PJS5?BDR,7C%C:<0CCU$+!50/CVI$.DC)<0:,<N<LN**>HZNWEY
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M%$P%W-57H0)HA$\#^N%,!BH M$ %O)6BW)\=54'541AV"LBJB+DE,AF:29)
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M2A*]XZ,5A\C7P5&V8H1DAS)*3C_ZJD(XS5:*-E[RJY<GS_/K&IP^@M8BH$6
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MN$X)P@K$A?/N"]R@)#Q!QEBTQ$O>7HNMKN6]] ,5-/ H+;,#<^]&C3W%DN2
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MN1994.^SID,![5[U0Q#MK$RZ;4.;@:6_OE]96J^53IB(OI3$_1676L'(V7,
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MYL0*$E<\S?W H;<]EMKSU=,8JG215)2FQ607O?9KYJMD\*Q2DNP#C_MH\ZD
MOFIM\[JT*3^]4T0=2A(.^LB?2!XH(JL3]MOQTRO1J?XK'F9&;?C >(^!/W:*
M+GY73)*&_Q[37=1+L@*5F Z!%8_@/N(@X7>\IV(%%K]'C'+Q\"A/0]K6BR-\
M$OG77AQQ$#CPY'J3R<JF+P=EV UQM47PR!]VXCM2TRJ#=NP2,\D&OVW Q\Q!
MBI?P$IL]XN[X>7AJ^3?+\D0CK_8=Y)\W(D<(>.47U!LO6((SU!C,CLY;!3+K
ME P%.N+:0R!OUI/]Z8Y-;21^ET),U:$H$?KE1K&^9:XM;2Y-3@*\AU>>5'IZ
MOSG'<,8/J.:0B9OM@TXJ>+<:M*+,4M\%E>"1G81T7'0K+DG'&C\-D>H!SK-9
M6VYR(9^UM&0] "Y=MW_JFVRDRLV?IA"/J$]Z[^'AU7EPO.?N)['\L=KK1) =
M>PY ='%YP:X@XLS(3OA(7SV.])9H+[\=OX]$-;"LI([GF[< (,07[$:6)$2A
M$3 ^B&]_X!QX'AV<\3Y0?L'GD@+3_&^Z<J(04@X_ONM07KN+Q2ZZ&.,[>,4&
M&>D#.Q^T):NHM#N)Z,K7B<_;OLB/9/+./OY'8=]>%FA$7"7EV*$[7/$+EHTM
MS]HG_$+O6O<ZF=.VE/_BT>?WG< U#U1I'D;HWSJJ_R<EC?ZH^&ON=QHIA_B!
M].$OI!V%T=K/H+M(G36WTF]%*&5N>>(6FZV>S ]_5>OF]ZN)P!FCM&,IDH2#
M.,6"&/72G$];%(Z)EVC/)<IWVTZ"GWR09D$*X,KWW\OYJK(<9'Y2:MD6185D
MY;BR4&V@3P!U"G[VPCW+EG-GK'LSM.%<S^\[J%93@!/KZP)"94AQN-,#!M+]
M@\%@<$*'"E-LFN6/6 ^Q1S]"BJ\]9$_SG6I>[UOT*5\N70AI_W> +%X*]?1#
M*IY]@9IH[QY_AI3U@CA:D02FZF*M0W1\)5% _,;9ZO>#OCMJF+SQ<F[0%MZX
M/_AB-;"2=&QF2[G4\PM+%G[]^B',&I.:<EU#CSI]PN*#%5E@#@H\Y;<E,?'!
M]YA9;D42]VA;Z7[D9=W^ ME_5*M/8BY:)GFMH,(;JTUG=_WYM&YA&!)<Y=K$
M++N=55?#I4:K=T-SGDV1"JJ[OF/X?V&(&L/B1=\8Q\ #YP V3;D5C6H99E;W
M3&M%3#%2-\W^,<NX&,_S\5+LOW@$JHN=+(9'#F,.!H+/,B,\?,4RKK74OV%3
M5G@7^I81!J?,=;%V,! 45A')?ET<I+#&;YHW"Y%YV)EDB36KIO#A_;7^ZL;+
M8(F6%]!WQ)IVG%A_.4@-*G>6JS12DGRR 6>WF=]^.EQT=[KH?8I\RKWE=S^U
M\CL_K!.3U!Z?'!S;6:[[MQB<;(9FK8 3\NDO B(,"^9P#2:G7!L1R!AN']1Z
M?$2]S%UUP ^%D0+QR^8)!@391+]JH$DZW6X+.X5P;]-2)@ 1T%U+31K%)@&Q
MXWL&^.#CGC;G_*0J-Q];F^5[I7>_)B1 KS7&?J)./ (U@8D/\!:1Y%!L05S;
M[X3#3FU+M.?1Z4*HT:I)G'.FZK.4RDR:3P#!@D7!#,1LA7C(JV7IS&RP.7K3
MHC'C7W"!G6MP=7Y+64]HV:).B//;\$<UTK\T?20VG\?0F%RO=%;^+!T9^%;K
M4+Q>_TT]M9#$YH_6[W1U2CUDFBDH0Q%4H[F>Y ]KBXF^F?\\_D%;2)3%XM]/
MK]2XM=HMQL!,51VZ6 1&>S6@21MQL[EEVB/3)F9&D=3/YJP?^WWDKR1J,[?)
MMS<\)R^O-:2LIEEZM-*UE=C)B>_J@R- 6BTD]$41:I0SJ#Z>V*&!JQ"+QZV:
MX+NG;_-7O<%6.=UT\N<6>"B'KN6",A-\<4T74E\33I!]1GBO8BT6Z>G/8./%
M5)K%PE55&9OMFD4CJ2!++W]?,*AZ/2PW,&UKN;*I>;\MK5)LXM2MW'IS[KIZ
MU-%99T8C5\L XVS_VR]#:KJ8?$>J3(PJSZ9J;:(V5HN$PC)JKR1WE9,-8JSK
M26$U6Q6AI>< )YN'<P2CX4%QVTM/0H#N_$Z<IE=^N?/9GA7!;D,:!NPUYS0E
M@G"<@@)SZU.-7=>V8*RA]WNW52VESDJWGKU/'=2W#<]KB_?N?I8Y9?[ON,43
M1QRI.S9S:]:O&"AK^L50KL^3(?WDW>/O5VC#?XOXJ%7.$HSB''!G7L3%+(L6
M=$WCPD<RE]>7YG1_A^N'4<5 @DQ*:D;_QY>D)7D] 7=9[#$*'LMKW!\J.(VS
M2/3ONNQVK#+(U\ENB^]WU&LU[;\=D&4"[5[E#E =-W4-U6^"#&FQ[Z#724G/
M]]L*_$V>"-09URK^$B^*!_S_@02CM.($W:CUZ<=SP,HG)'_<-Q8(FRM'\MKB
MM]J2K$^UV4JB*D#\TTZIUS?NK5QE<$%Z<7O_BS^Q"[9X)4:Q.P=$P4J?[FQ+
M<YC8OBK4Y7A*]5\ 70$4?@Y(XR(P4+JYS@$G1D<9IU+PH5:HYCG@ZP/MX2;M
MU\!_-\$L7;O@KG/ 5&!5[;PCQ7 :^_LL#$MY_K-K$;YW,#&R1^XRF]TLBE]5
MHA<O>O??(,'\^%\E,8= :2^!H"[$1\3JPMGE#0.N#@^&/D%!]>:ZH+_RE2OA
MJ?>OG(XFIO2)-<]4J$^O@=&_GI0,UXR75##K@&FWS@&-!0-@%C*09.'O4K.P
MA12=@YI3@!T=;=-%SGF7[[H*#W*$/[S/N67W!,Q'N4$60(/D7O.> V)CDM?P
M8]%M@P4A_HX"#7%\U(ZW(7P^OB1O.P25B:L_#'/<XBCK(8B:71(BU$1A^:KE
M&1V?-T^7SNS35F<;D12&']Z7K1CPO/8*>8F0%--_N8M$70-!H5@A-0LVZ!M(
M [.R <\YTP[=\,^W5&Y-)][YKG2XO&= <+0@Z> [FZ0OJQHUA 1=SG%7&MZ/
MI\MHCN,.1)6X:$H9L42T9RUVMC,^ZURP$1Q$T1OZ8 [ZNQ@@+OJ\I16U/ZU=
M!W<M$S+SGL""1*[4:R?<(.R!E0QPVO'@:\B;F_ET!*Y^18)=2^+A$&;A*64D
MFB%)9OUIWG#EGPXHL//$(LQJ$W.$V'WN["\6>[F0@Z*4]*:J1EKXT9ZS39R.
MFO-Z7\N/>UNY]$OYM(_'S":;W,'5Y(ZX#)LWB&E(GM-S_QN5U\(U$":FZ._7
MX1RP&V1N4F<-!-Z/E#06<#58:2_@T.-O9K7*"7*@.]9O$'/ Z*EI(G3R#5:.
M45X)V?N=*UK!!@AV2)DA0>#P[?:)&41K[W 1A#''--@L23I$!M&D/7IQ54O!
MZNRAI\SCQ\M:<&:9S\0OQ+IC&[\J1CA*G2ZJR5#8<+;)W>.BL+,HV)UC,3JU
MW@#OEU5L(/W."J"Z!!W<>/\Y@-=-O0!ASDP/,1L(CD[+5N2UU:A]:7J_\@=
MLERSXZWE>GVPA=WI/5*ER45:'/"*N*Y<X'0**JOY('.-:&*$53X'4+=E)EZ$
M5B3O$#;7[?36=  R/VO70MU[0VO7O\13%\I017Y)0@6N',3!Y"\R&&=>;234
M6"LJ_[U?0@ 7ZU5B9.83%[<: $HL-S_C%PF.L^@_N$*VJ9_HT%D5[]#QP 'I
M;7?B>+?J[K;Y;5U-N6TYY$P3]C<]U]>ZX]H4[,_4V8G[0IUD?2AS(46$S(ZW
M&%@M!7)M/MV),$H9>9-N(/1%;B?#G"JFP<G"V=&=,:E1>8Y0?.=^N.KJO:CG
MU "JGR^1M%-(6?+;'.QX7P$?(K8Y?11GJ'<JLE6_.7%%V%R57>XI@^I.6!.$
M>JZMO2L1S(8$SD-]\>OG@$0X5FB&+%%FL[R5_:/MC=SC)*EWSP8_.U#G7F*V
MGK*4;'[ZVVA1Z<!E^EN&Y1(1]+,(^6(.>0>"'.^'-RQ6!3=_ASX3I<P;-_3#
MIA/>KI)\"E2.Y>Q- @G@59E6?!<.C)!&"NF5VD!4;+*7I@T1>BU>345MEQI
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M#)?R[-)67,8 !S.U:2E\6VT>"Z[!!?%'HZ8,209W)X3R<5>D-[1O7T_Y9!%
ME\:ER1:<;C>63K!8K1[OE8U5SGZ56N.&O#&YOX?60RL9,_,QC"RH7?W+(VU+
M&_29'C)XY45 >D_%BIB 9V;S[+^%II9_<>;&A<3GG'_&=^L(X<<#^<IS4.TO
MD&/+.1G3\3TY4L@ 4L!.P;SI!=;J&'7:RI[>O>;D!T@_$O*KD9S)X_EC<'1F
MZ"BJY*<>+UYE\#]VR MHGF)E>[R8H7R335H:NJ?/)V<.UF=J98XD(M%<[(\
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M>O?U-4@,#VHIA939V=0R_C0N>7(2.1)TJ]I#H3A-NC_MTL*/U,_[IM\& =0
M/S:H3%T6SO\X";G@)UMS>*^PJ65D_?9]LUN$P4"GU1JYNP@F M>><ZWV.S(0
MIZ7,?!5B*N!B%#)O,]"6DQF42E1J:NJ@'DVMO_I7KO':6_T!EYVN9OM.L6@R
M\Y>?6_E ?&=I5UG3_$R'E=:PI;[Z=T?ENG'^$,< C*5BR4.Y'K6::?VS5 ^H
MM&_Q+Y+78/98C+]'B7)<X-NO-N.BBX49)?0,A:RJ+EYY=,+EJIROEHF6.??Q
MF5F?(+XXL=A&=RD;";^%#^N6LD*=+6D/?9$23S^]][KQ^!.__^5W$X<)YP#>
M)4NR')R],Z-^23I\,<=R/W)B_P9;I21^9[.OVAOC->CA.7CZ*+T?(U":5^)&
M3+/%##G[38WP/%@ROWN7/ZP@JZS3TQZJT(*/Z;FJR8H-"7K5TC"=E)=K.LRK
M=]+ (F\42J=5J= #I+U9EZ#?CE9BU#$+,1"FX?4XC"58']BJTCZT^3:D2;]7
MLOO\UK;77^0BR"4I_N1''6O2Y:GZ/8^CKI$ZO2>D\=KOBH9@LXDWU5"%FE\,
M[CR%;2[?D@I )N\]!OF O9 #6W0,Z XIH1?&2S"OQ5&Y0T9K!$ _M$;>)#OF
M5O([O'QNNQ9RN&.WA,!+&4\U,6JMSQUIZ3V:OJ5RG5?W1^R+%ACJ9J#R4G>^
M!'#E8<YMWO6&[;:8>26&V9E/<8^I'7VX4V\;)G>LT@D#\_PDL&9N&-?)8_)>
M:^_F!MMC6TSED4U3ESO8N4VMB_0ZY+NF ,Z ^'5:24OO0?ZLDX?\5O[8AMI/
M@&-*^8WD>S1O=67C81(D) 8UB!$=RRG;:EM/3O1WM]J3^3AY0[JI_C%BJ7R(
MFT_?!-.6<Z$&J.WPR,IB=\%;LTWZ_A)%V>ZM'^DR'6]\07$_C57]35U@/8V&
M<;BVG0-BE3JM-[;70-7%R@A%\8<#L<T&%8.!L S)4AZ-/Q08&&\HP _][ +*
MW#K;VPNU:)_!0J5P=O>.@-%RVW,;J^8=D_MB7*S+WUG*HZRL)A(UOFKNGY:I
MCLI$$$9,YS3-LYD*+R?V$J\."PC^JQ&<3-6?EXKZ.4K!KB*ERKZ2))PYK"\M
MN:%/(EX3 Z_+:8:Q#%W[PN[.HAUU%Q ?<Y_$Z56TN,7>%=LD-5F,NGT]9?AK
ME7?_2OB'9S3Y,((:+J<B)N.@B\QU#@!\F$3I#NCI^H>:?YDT.@?XHBG4?/B
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MZ%@)FXR_ 0QE35S5-[(UO"I]I% _!6G?,YUEL"'O9+>=0%Q'@5RUQ?YYWYV
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M8Z2/6<;6=ZV$1A8D&>NM+ =_6CQ/XJUKZ?H6GJYU U  %UTE(9@L0_1QB3<
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M]=EL)X',/J%N,'_\U=-G]".$#41R-8;XO6!!8K@N&^3LCBW5$']6W*AT4=)
ML^S-I"Q"@G>9O3RT'//L/V37>C$OE&NI<058_.\S_WI1R _3ZD<:>3GP)6N
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M^J]]OF")%46=FU;%W>W_W93P<Z@=F@^3&BIA:JL:/63C,LG:T;M'E[PBE?4
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M3R9W:A=2DX(FV8TK]CI63,T.NR=KB;4D*)'EZ3K@0C$U[>O[M6"A=-NM=5[
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M:++_JR18OJ[<-ZAZ(&;PI0?930!K#EE:4':M2+=]X6$XB0M#ID@9=WR_U]S
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M#.)U,BZU12JW7GM13KS&_0E^<T_ ,L%G_[$1)46K1QM9FR.7NCY&*Z0O1CS
MEDVB+JUWJ2?F9M.LF5EIXLT8JYBA>_=?EXC>M&5=E=N=(0[[#;<%P=CMP:6&
MM7VA4'6OLOE!ADXMS@KOCMM>- H3K9!_&E80,9PG/MSA%T2D,^L^BJ"P>!=3
MMC)5MCEY/WV_WKVDN8LSB*BD9$=6E0BT9^5, \R.70$<O&K'H$\L\K?,!/ A
M%2!OGU3DA7/IOHW]<H/]TO E6HE;YC'%!@#.4!ZC:-^-),C_-,?K=7#S83]N
ME-%4I\O:_ZH'/N>XFV"79<3,Y]H>V!SAY/I\V [Z%'^S!$]MB D]72RQ\Q1W
MYK[0S/RD8BZQV216(NP'H*/S'79MBMO+0X<XKY1XB(3)Z10XY&.&<B"?%P(^
MJXOO/S#Y,K:?/ UT,&*AJ+Y%^L;YN@XL,4':VC%XL,H415AMJY1. Z+!.O Z
M_P'(R<26_]E)S\7/F#"*&<_2[W-70<!=^DW,H6APA/$^,CZMM;\^>&(64O8M
MV8C_3P1C_SK0257-B9/&0&)Y:0;< Z.<A++=S*_XJ24<VY29.>LKVL50U[SI
M*2!6.Q9X@R>5:^>:!16ON8J;\(A=(6\YP* KU1B%N\O^J(BND7,7?#_T6X^<
M!C>0U_<F)4?#OU"2GRU7@-JPA-+YK3JSVQA$ZZJ\NL$$72T85$#Y8.;&H&6"
MC4/>R]C27.>UI/9#[?I]CU\@JA\J*R(TH*QG;=/BYGA5H.9O2:Q)AS57#CC1
MR&#XJYP+P@08JWTDVJ@5TE;MM=0)9[<_KP+I.$KJ9W$%"&]ZOD\<]7TX-Z_^
MC.V^]G<Z%KXXXV5PFW4V,WVX @NFIA+/T8-LLLT6JD^JF)E_B330D.T7WG?Y
M>7F46%X\OJYR\#7,) UP7O]F:M)X?,^+=;FQ+O: \H"9^B\[%9KN9_  !Z"_
MZX6 \JM^N>F=#00'WO*XPXQT3)Q+Q:@1RX1+MZ+-/2_;@,X5O+UE[93HKCK*
MEZVK)3$Q=N]__F;S%6,7"U]YWHJEK<?1U>; K98&+#9V<+"W/NGP]=K&@>,'
M\NG1*)4 SQ1FC_E^JEC6/]$LY8!AF#M!!W6J2F0BP""G_EMY]?BO#X*MFUS'
M^#//M#<%<L;<S JLEOUY0LQKP])_X+TO/A!'4%!!7X]B%7BANB?83LEC4SHA
M;N1=L&K["6G:J4UPI,:QS\1"(MC\^Y\2A;Z)*P %47!;D;V%V@X]S#A[A-)L
MMOL02Y10>Z7?T:]O,>6'5(F"26\3;X7TIAIGAT/?,&>O^"NU9!%F;M8WZ\6E
M+,P$>K.MN9F3XGW:<3"6RZ06+JR(YI2$/=24O)53LAY4])ZW+J+\1HU;-\<G
MO8$7;-?:UJP2JZ?7U#(-=^C/;TX#0@BRI'DMU7<XK4-'IOE)C\JRR-,*)WP,
MZN<G+M4^V@R57P, ?2U!"/U8#K@R+&5<&VM8!MZ?V.#+?.FEST82R$<Z6E3.
MO;NZ$9Z#M])'U5Z*F&"&P[(+::7AM4[L3X37A$+M[]YI-3QQ$5P]I'ZU$D=V
M[=8W)"K"84]:IN5,RS6XRBLI<#6I&AX K6_J=Z0I[V+( <MNAHMRD\XM>AC^
MWM2TZ>F%28=%A:,?B< 9)LN8)3H%W/.@I0*=2)WV5Z,&.2"4=]M+W,BL"RQA
M3K->6TG4FB^2TV5Y.?94'BJ(UF#I6'R"7UHY#"<*H]9^XRVL5KZ4UZA;E0[0
MMI[DTDZ($VVM;61_^\#I*RODITX70-V*9.(+S',][*TC$<Y8!2[Z5Z@'338-
MZ5H"@[?4IX,376=668F<^CKM'L#%Q049>82?DT%=_9N3JLA5(AM48AQV!_^.
MGMZ>8?[A9Y>C("_7XW[3.0_&/;4=#9C?[#:"'@4EQ2Z985FB:SG,V?$^W<;1
M")XZF?E*#GV:]T(TLNV/C$BB,^Y\9IV;6GE#RWZ@GQ*15^_C7&ZRXS[WYF0G
M_D3BWRZ6U[0*G[_(]ALK__5\*;*TY0ZH^)KF7/ _:YP?]&22!N19Q4 'A*EX
M7<D>4W U^(1"M4KQH&6##L5H@]F\TWDSGM;$+J.D$5]V4P4U(P6;$</RNS0G
MY/7G(>M:Z08%R_NHL@C<X 6/W?_B[;RCX7Z_?3^"$()$[Y(H*:(D>F_1(@PA
M.A.]3!!], BBMR!("!*]BS+J,/I$!-$9##-:]!EUPN#ZKOO7_9US[KEGW77.
M'WO-6GM]_OC,Y_GL_;Q?S^=Y]H::$-H*H3QCXCMJ9HWPEJC34T'*C &F3]J\
M-MKDT8.'(V-M/HIP1X0<\45K5!LN0#ZX='Y$#() ^DW[5<AQ"GWQ?A/MFM?V
M089[L@T;#Z0F:A-*\$D><>A'K:,PNIM?((&3,*=Z"]/W01G.1DRT?=]E.=<J
M-I_4G32V'R(<FBI88/XS9[.M[)6-DOAYA9]=[//25.-D'#.!#%,()7?X:P1]
M"!?Q >X2D"3DJT0/;CI.6U!S"L7R;%L]W9UD+;>T^DF2,D/RH6R@6D<=G_0=
M40]K3 S 4L<#;V@OP\9\J=N$5+5?HCL_O-"1XT*;_4T"VJ@.KDSW32WFHO[Z
M*6]5(Q<+L,<IEP#JQ!".\ZS#*[3(>6T9 #ZVHWS[WGVAS<_4LXG["&VR?A+=
M *(DB!U_QA?G+(%8%#*2P;C='=N)/(/48P6V0<T#OLC/X=_NJ9)(/_9,2D\_
M4QH XQ!89,^W\@T=;]^:0?Y*[L>XY'B^M@ASK^;% "=>9I24^_W;D??E0BP?
M/F8,\&"I [H=>B#^UCZJ/G8^9U)X)/TZB09MZ<)JEP93'CB2WM.S;BF9_N#[
M[Q'9?VJ:XB[B;IQQ7*RWC!+"Y28^ZE\/B?RZ@>883T7JU,?U#['6]5#MZ&L/
M*.4X&Z@#F'1,&YOAX^Y?&UHE39[V#W!UZJX)\$:1=CS:823!G?3GO6]"T#C6
MP1'3>BV*)7R1JY"X'Y:O4[WTMG?[O"Y8<,(E6!#;+,3YV]@11RJD70,DI,I"
M5F/8B>W 3<'O%T+"+P%Z\(D&@H>[^,E3"_F*/*&8KCL^Q$W!D>M_IB\$OD^O
MU28>Q?,Y?VU;]ZJXR21_T*7@8EJ1)SIR]H3(1=#&T)CT*K$T(&BTJ>8SK8 G
M?W8M",^C_L[DAIE(#WN#Q(@A>*?M=JQ(Q,6#\1!N@BH8Q#*/^CCN;@%L4:>W
M]V+[%-8?&'="-Q=U-1TJ.2N]O^! O&H9M86U321^C'@R((K122+,C<^?3HEV
M LCU*0#D@!#3FL(NAX_EHZ\>2=78157YW_ J.#@XMDX-C0SE(=)A]VY;P&4E
M4P*;6%Y:%#S'*-_YT+Q>%0(G\!SO$=26:V[-.3>>KDYE!_ETW;F8K N"K-B-
MJJ4T,.S%X2K/1,YQ2MTM=/&!ZADPW)Z%11MD!1SDE\LF"<!KP:,,)WB*_ 8?
M]L#L%Q<O 8 !VZ)@@U,>!PP-<X\%?*JJ@7!O8D^988$D\ZVL]TRPX$#('2*8
MH';VQ#53N]Q:(+O2=5B8?_R08!V0)^_QI%J5;E!B(F3(?'(Q)H04PJ./2*\6
M7AV_=\#OG=KKF48@ =% 7 VQH?$(!J)F:;Z5*](LR'277[__0>:[<J"*M0 U
M!:>ZF:J'UK'LYL2Q9ZL\XH)*"E_1<PEH:-\++\8]1<]7?TRK^MT!"_)JB^E_
M2AO(WG,>Y7L)B,R[^1ANF<<F+]D*;ZI71KV]& (/Q95W_>V<2U4/ULP[-KD@
M\& T@C/_^;'>.];C&-D#K7B>NUHE:Q!<OET,Y34(?ZXP)= IXXXZFAB%/KD?
M)@NOS?!\U%Y5E ($120L2_007Q&$%RGT$ATS\2!UOX0/?>1-Z:O;G8 ']R-:
MFZWBOUZ,YEV'M4L+991X5^8H8B&,=W,I (S0X%VV:$78*5<Y :@U+>$F]1(Q
MCFEK'X^7J*Q+^!3;K\4EUKD%4DCN1E(;:-!I)&U*R"S[004Q=-&!>?%P)YXH
MJAQ!@]?]ZNT)93'D"P<BEBEQ9V(8I2AY=0P/=7$FEDN/QER+PPU>>_UGWZQI
M;G/5 )RCP!*2RW-;XGWHG'ZOC4[7ASDZ_8 N(M@+/L?>]#8_[F&,H)S6[X8K
ML)P;N)[C0//QJ=98JVJ8BI_,X^ AYU'EFXG,3V!&#PY)K^7]]QY>(D%:0P5P
MUM\<RF87("::S;!)X8O%X)N-!G66\^N*/N\2Q-9SD%D3K3CKB.":KNIYYV-#
ML*CRU"AHX-KG5('A%5H-U2]?$J9VF"S'=@5Y/_!00=DN 92_N#DO >\MM"XZ
MPPWDS9UFEL]DM3C>OO[4*;,NO65H#17'Y7X3J#Y1Y!R_'VQ]]_K7,?,"CF;D
MLS3>-=+?TX:6(_$7?!"=?[XV(S /\!J)F)&&U#NR,*)QAPN7W]\$*3M44L )
M];VD,%QHYP4CGGHK2^1]@YN@B7.OQOY8OW3A;(+=6^YW=-W%>1A01/6A@HY&
M9H^L499QT</<XU^HDG3/NS+"RYR-04=E\OQXN2ZT8DM+$PX9+ZYT>^0-*9 [
MK;3'9Y2T4YC7KH$G<+/L8/AD+132\O+/VRQD%P]@"\TY?DBCV74JL9M<4FHA
M)[,]FCH?>)]'!#/5L$KPP.@DWG\^9H];^X1R3']J:6K.\6R_R@'8C*\6K92[
M_:,ZM[[Z:$&VQ_#[>+7'CEO-7M-YZIA+.G_S#$FHD/;@#AE#TKLXA<)%E,W/
M-G;6SL[./N@)KN)8&[<7F=?K34#J_(9;! 5A=:K\NK%@<G^8]O,4[C4RG(GT
M64O-M]+R2+-Q7774$C:[37J$$<J+,[G*L4(FO=Q,8[XY&C]LJ;.WQ--_^_9K
MK?@C70_R$D$D$@@VPE,14@+S7L\%#<YW(W0GR'<\-CW]$\,*>?=#Z3<K_F2W
MK0_4I8W+KF<%O;G/.)FD.(()C?J&"XG%M%5QCQB.'<9@+$QK;,Q4Q5^[O66]
MQ<$K<U0*!^'\.R\!MR3DW#1[0QC&)-I59TB8AHZR=.Z%_;9/TJS%MID_8ES+
M&7?PJC!'WL5>98\06OP.+!(1 Q<KVM*?^>!F!V_09K[IIZ])FI3S\ X!N-1F
MQ6 T6D44+.@JW$SL..Y[7& JS %PMR<EP\D<<Z?/O.3^Z#T\M69C[QG"05!:
M"B4?XCQE>>_C)@#9R1IRJ*]-$MAG:Q*W#TLM:KES))^5W(T@@Y,LU=S6J?ZC
M2#/JDVBKW%7S>+L@29D.3:7\5V5=NM_;2O-X]TL6ZL^Z/HR]0MG=N/-71T",
MY/B=%[N";8DS_9"R(P6-<:VK@:RI_E97UYA8G+N&5>'TO)=0+\;-"+C!AWMX
MIKVUIP#M^]G&7%K.DM4>E5<X5&YE/6>Q\:';G;\CRT'KY1TI-K8!%".M/T."
MD:Q3S&&5JXO-^)&<W%^;))G"))1/2@H?67_OPR51LK(_RLL2GS6JF-(O 3<$
M/C9-^]TWJC]SR^*=MX@='XH$R;%-R^C/2/]8I^ 2U WX2O&_(UPBB1P@&U?@
M5&D*<F5IE#QI/$#/,K(8XY]7\9%G>E'H>[5P)APQ!;ZC>E@U5F8!-@\>+O$N
M40MR$_[F'L\W%?OHLZWQ\)3#L+*T]/WJ!]?.&:?9F( Z4X]]P^1,K>?0E?0-
M]-D!QBJ<\2<IWR&\S?*_R3?_"[4@%5G/ZQ K6R$LEX 9]H._,/NLJ7]UG%52
MG,&4-/_FZH9BGPCF$N(O ?<H8A!;_:!5*QKOQ=NA*\IXEG/((+%B5'0S./;L
M?NA "X3BHBN6. 35Q)U=:"K%(HY%=4'N(0.+^^[6))> [[:A8J#;1,5+0,H(
MUN,\@<%DR"%OCPE175(02[@]/ZK.=%B2Y<U>0\Q A(..Q4HN!D"%$44A;IN(
M??.+&Z$SPWEG_"&IM.G[ 4B\S<9I_7@/E.>)<WX<CO;[OU,;XK_#2,-PS%7+
M5FJ]W'S1O2CUHJC/'IY-+[(H!E]\=@?>EW>3N1L@C2P)5F?RSI1K-3Y\4J0[
MGBR8EIE-A544<6:WAN'.>I^ZLKL5G<UM- DQ6%E4%HNM2@DVOP4WE;>F1W94
ME<S/6O4*P)H3OV4\U;J9(*K)W3O!P7,7*BJ;N)/9G7R-8&<4W:E31C Y,[\$
MF(Z]J>I8]-&/-,T<2IQFD_N4?G_#A"B%I\;2]=+=(IATTRV/;(>+^ ;1J)F/
M/W:#+ZB[L5V3M[:MT[R[<&"CM80)6%[PW7MW<1TO%7WH1G^FVA>5T":^#/:7
M@$]5)-Q*T]BZ0_968S=HF@.;-VO78WT'+Q5>$*_;T( +C:YRS[>21;GLK&L7
MSC6:KB9&7&=]T[B=@^3[+?>%(JJ#%W()0'8(C(9P#"RS^61_<C^"U, M2F8L
M8H]8M]>T"DPCHN*DW,Z^O%?R!PB#!74)@\MF1,]O?Z2RJM."2O\$9L;Z9$[[
MRCVX&EO47"]NA)?\%XD.%O2@5,ZB$7!*=0DXAA*"2PDZ6KAQ@CNE>,X]->'<
MQVL9Z" SRKNY,LL.'\3L=^7J%ONR:HN@5#CF9*=O9BB(>;^<%;W<ITI;!^&4
MJNZ=YGG6/-$?%+] GN[>$[]9%%_7GW\E!N-ZNCL$)N1U2PE16WUO(>;KAA&J
M>-IT1Y^SN1_P>O[AG"!GU0$WU@]BJBLM+T1Y4P/WN CC6(K.JI>#+UKP.R-)
MFC%0L4H0=?:"(HKB>WM]HUED[[4'G?L<;T%")SO\BMYI>0ZXY.T-W$&7E G#
M1@A[+'1.1AS/M'U@U<=4&7V2@=<4:U5G\']&H@6P Q@ILIUG=7 0-&CTN*1Z
MM&HW93W'A!7'_15ZA%*VW-A29OKHE+P4"L*0U]ZU8+.8"_!JKZ;E;Q1900T1
MS_"AD?;3>XY-8]L9.C+Y6I1)$W^#7K$.DP;$K6Q+"[8E6:B>?POA(VHVX/R2
M&3OXS@R=3623O@4O#4EV[>ZN)>%W"APMBF\C>7ZP==NG=M+D=[0W$'PQ;7(+
MS+LT @_61QN.Q[8YQ4(+4-^51T44*!,IY(FP0=>\>E!/HIWZZ&$97/H[RN6:
M0RU8KBW>I6K*6.C1X]K6#N1C[9<SBA_)1[A_0]WPFLB.^SC:^%)"$9P>I F?
MD$AS<7$2G(>U=^=SKAG%>YT?&4O+O>N_+KI](0D9@+IA<FQ'>A4%I@\53'IY
M9NMTA:-='+[JN/>]8RY"HA8R/4[GTVWI5.).@Y0)!A@>JL&BCN2O9AOK.K5N
MD@-"$^5J[KUB&BS27;Q\*:F!N>#/=>>?.MAG7'^[/H&\H<X&US2BHMJ;(3L"
M]_F_)OPP?ISJ=0O@_>.K,"0W$>^/1#/BHU%$BZHM?>H(Z/%Q8A'*&N+_ZIDF
MA+>NK?%\FWY'[]E<_<%->\,0&J(EH03+Y=_9NK"MR <?@VO?94_OJ (76VSH
M]_\9X3#5YLSW,G&7;/;J3%6^U[ZL<IZCR VQZ]/&7@VRY]SF[2'^7L'CV"PT
MVDQI2INIQ9OQS:R,O;X>L$HD2LD)&!UR"__,^NX848RFHX1TD+\V8"V#0RKM
MW$Z%NB6)?GZEOSP &7AM/3UD%,0 5UNBXX%\/K3(#C+Y3@CPK[#X.:4_\,B2
M?YCQ;T)1HUVYDP?4*6NU0Q!$&._AYL*?7&GK91FB7?%6'M51NY?I[O;KIC.)
ME1OLHN^[RY\];N+Q/$EI@!*S3NWZ0#>(_,O!JKLGEJ-W)H2K#Y&CZQD:KZV'
MYH+4NCB9UZ?117B*[BOTAQ1K%T[ZQ%2CW>XMJW@-+_LFG$'_Z%%B&N\K:$C?
M>]=R(!(GK[N\&&E^,ROX) $8]WJJ@W.SM6YNT<6OC#QRM5#43;2_]MWO[WG7
M9?S/1],&F#2[ T/CKKB'#:H^?:C$I;W4EJU$[<RR7]4>6=_CJS3KZ.#R+$:U
M6[2S,,B[;4^8/%@;RQ-IS8 WTM>L</YN7<CNT)_,FO*%O#['P#$^7-J&_5I@
MPEMU;]F3[1[<8&]KW.(F-ZNV>\84!S.D1O@>_5PO0,O>Z -% D!1@XS3BX;$
M>W4DWEIJJD.00&K6 F]E%VT;APN6,]8UA%DYY)J@BQ;8<KQ(']@J$[444ZH)
MX\AI%+ WC\F,<&%%ST,RGRT8S&XA9\CT)XK//_4HZ^ELIC^WF7)[9%!3C.(-
M D^?9-90=0EF#APC$001\N =_ KY-I): *;)EN)D[.*&I56$#.712BR\G#-
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MPP./_>*YBK^5\N? !L**/XK?2==B7^> MV^2//X:L?A'#CC;A&G/3:G>J,!
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M2KANL&**8QU_[J?7L=<$G6+YJ%M?V"_[/]?Q"&<V1K/];K I7V!MR%$[4Q%
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M0?_;S_38Z^CV8)=NB/UX8Y,5L>8T[66N#1_&W[&P5;@:M1=D4?++K:9WD7$
MZR;58WS! 6M#2(HN+ RCPFY0-:%E'AYP^B #KYXZIP2U$CO*.1/EGDZ/MFRO
M-,9MEDG,\Y'"5I^1/6HJ]A(L_ZW('NH 1J!.LMJ'BP)/O5S&VIZE4+P:&8KD
MY XRD2J"DEC=6P<^Q%JLU8_79)U.C6_CRJ,\X%SANUY!])"RESU@W_$1;VTU
M[M15C]#=/PWCNPBK85#W(KOO(AT$9#DIK^9!/C=0D2W(-?WMEI9I>.7S,$[G
MZ_[^AWL6&8@&51XZU^K3X*J+)B=_\H_Z&_Z#"E6_TIP&!25EW\XN+3,5+@)V
MK)%&=6Y^>]OUB]5%]N&L)Z;SUX6:Z17?>O]P?[2"N!X*DQ<*+G:]X)V0D!N,
M?]^:=&Z7Q !^%-P?)V%5D73NG37VLEL;O0 E(DH(K.-%G[H>E-0%S6[56%T]
M1=_YG[BK2%/07+:N=ZE1]EF/UXCLZ".?S9W\-'!12T*=K):22R==B/='<BQ0
M($U:R1MSBLOJ3"W<JTK/DW1VEI7^K&8._@W:M=FP$HE09!G$Y#%;$9+.>DU:
M=\O\'1O3)'H-^C^]I'Q4"C! JFP"S4?PZUUE4,]@R!@DZYA+F"""\IFMPC8_
M0P'.>Z0%.)=SVL'"KO05>VX.BQ><L^/]:G2N_FMK'MOH$?#ASB6 K.$2P+ >
MW\<M,(:H-S#1&AO7-Q&S__%+K![PVFZ"O;.1,%F])809M.+M,3[Q/QW^<E)>
MA_[KV6VT3+8CP_-\;"J$4C.@0F$J$\NE]BQ\64_WZ2ZU3Y*:^ /19B>R"KOF
M];@U]PZZS6/%)SA8<7+9)GMP;GK1H'O6Q$,VU JN,CKB0Z!M.37M=$[K8M/?
MXWN5M:/!;B$96\*Y\17J%7FHNZ'??:9T%8='S%O;,GXZ^\IA:*KJ>]^N%B$%
MQWG,#<^4%T#.@4S]*5][2EW-,[X)9TUU$RBGGEGNF@'N?CRB&(.-=%IP!#/H
M1@"GA+>/XCEBA:>-G0L^%V4 CR*77QM%;""?CT=@[CGUO+0"9S:=F MM+08<
ME#LZ.719 JZ5;E,\Y_P>[["(R,-\GQ 3.-_PL?#Z"UI'Z'!^)V2@F? \"2*^
M%3IYC2ZGP86I*!7HN/*8HK)6RD?R]0K_"ASQ]=1A6;405!/SPV>PS&< )L?@
MX;^N^2"1FG5^B<GCE_%:$R[H!?YZ&1;<ME41G6S5&(<V-:1>#8!6E'&N2U>>
MT86_L8<W3T%U0JL7.O*$L\'B>$U66.1$67?IW^P\N(LW!M6VJ'>>L:BP:U*/
M5#6.']MK\D=858%]YU$$PV4A;Z2Y].21 CT->_?:@]7ZVPL!(_<^>%FL FC?
M!X-;*CTH(%Y*E 2[%Z,VZ25QW0M"4R:LCE2B-ZJR,*78M7FFE&V;9>F7<:5[
M@N"M_>\&ZDR??_]G5>ZA3\X<0@>FB"*7@.\2ZP>N Q(S(0MHADEQ)0X"-3:]
M.L>WPKGU$="F0MV%+4 (F[8[%$;D?4QG@ZR"A$-#",'WHKCY$\6&IYL^BIXF
MPMG/$EJ?FSI[;8$OG-)C@"AK9+#E22_H[RWY*_%N_?02\.A*^D2>7,GQ*$CH
M7B^"J&M/*,!6)R[G<"_W<--(<3_$,U?GV<,:ZAJ]&VJ[G/ANDEAGH.IS!-!(
M]&*=/S$[\UWH-FO>K^G>4#K$BC<A^TJ@DTV>7 *Z/,CGH7($(,:#9N%[4+ML
MO[3C(R^IY<<DQWS)W1WD>%1HCRS4%M^8A_TAO.VCZT78-'?\?N>IQ<^J2=:D
M]R'I!VR6RT=Q67M-N25%,;I=ICL/JBF)083@O+]LF$L @OX2@!</[3XC7.E4
M-7FE$RSH0J"CP!J9[30S-1FZ B->75";HW3\_)R/2_#  R.KBS];7G_'ATN'
M]:U'0Q]"?:T,+5*9D\AM3NZI!M8SD4ZL*S!.;]Q9H?K+B=:>B@,:(8P#(3X3
M$LQQ#VHH-_\[FH/]1W9K6@:[Q[$10ED?%:R]*N1Y)PJ-GF+.<%D\*XU[JNOC
M".]9YNE9T.RG=S9/^BA_5O5H?5@R:F?GY@\-2K.TCQZ!J(\V#XND[+UL2XP9
MOY16_.@EI.!10DK=K<&+4;D>#8M6\6I\Q_1:;EK2;T=Q_DF#Z.\['1);@9DQ
MOA5:1Q*U=:.'>$'=H&^_BEV>',@E=O:+C09-8G 1EJ&T9GQ^DGY2(U7JI?/=
M3>.6M]GSL!FJ.AT*HH(6U@2':E?VY%XS6^9^!:^Q!V].=,+- G>75VN>*QG'
MK5X"A+<.Y6^<AQ2V+$RA!*M3@Z<M+.<G0I[^X>9H^*[['(O=/P:KMWUR.?;2
M7NU+<O!EFT&89YH1QC%5M]WF?K5/\&9,>B1D!7],JY1<+ZQCXGETM/4'G*9(
MBL][#QOP#:4SWT!]/,WX3)[8*Y5Y_8G;8QV8Y5NUFM)-UY*D"R[(0>_8(-B;
MO['6P;-8J/6>Z].9.=3\]MV5)QITV6DG:F_EXGZ*E\H(MBN8_/4AZL7:/DEY
M7\45&%2S6G6$*&@RA$]?B!+ /:,;V],L+".A;T2^Q0,; Q:W"2-??A;<E=UW
M1:?@U7I:T<6/=T2@_<$ROLXK3]*3=+SF_,.#Z<BX\\)JY,?A),M*Y-9_V*?B
M'4I<I48A@5S,NS\W__37RD/N/0LN$?SP%,YPFA2TK!Z5/[BT('=F.T ,\DDN
M6E"QNV7 #^M\M,V26EKX=MY?WH?,V2#;(!Y]NGBX_>C3O.Z#GX7+8 L=!0^W
MG"/W,XNB]N!!=?QP2C5$':I]LTZ]4!PHE2WO0-O+QWSG($F)O6M,40("-I%Z
MA/!H@+B9'QD?_]1Z@4NJTVRFZ=FPD,V,=M^6)Q6.Q51\'-^[4WLF]'%O3/(5
MJA 7+(N%!VD2U+$#$FFEZ%F5F_L;8C,CCT][F])TY(3E^X5%RY'Y-0M,Z;(^
MCH4K.W.&%;<MF+2[11,/IW7I-'^'2$(L>E'I18DY?6.P%4<=EUTA^SBVVD%R
M/P"]W"7 ? T.Q!\/[!ZV@6BU#N1/4\T:3B2]* 4L,<0R4<:4%_$8O<8I:T#C
M1Q5VEUO:3!MFWDU>*>G+:UNF4XO41$_:M*\0']2&IO:H+U.S#L8+[=9K4R>:
M'?*2PC(WR!A?$K76&AITM'\HO6F";/9JGNTH4]K=Z,ANAR9;X:.3?!!D%JB!
MT.-8Q[:TGTVPALCB+/]^+2-K(%/Z_;X].B1F<O)S3;<"<I9Y?/MI?''>14!,
MX^Y"UW'Y(JO\W0#LCL!/05U>X%0&VN.I3E#92N,GSZXH^[/$/'V5ZGMSF+U>
M'25R==>L]^/K!F*-'U'UE17@!$K%&48I:VW2#D$JG]*?-P:V0BX!TT<3VS4Q
M?:H-!91HR7&-2T!-1H=&9B]/<L84-\75P*0N[^P%BI]85+!1F_V@1/,E+$5U
M8;37&H4ZQ)RS:(J*BF&AO@%!7/"GB^B>8FU.XWR#?3:DHIZ7XDO(GJ5"31>0
MO@O#Y:1K 18,BJ\*H7G)IS/]^>7MID=6_=@>+J! ):%M:0JA%$O4D<QS\*AP
MN;CC_*5]N,H3S%5/$DW?PRR_NBOSH[K&*3+D2O(PA>1<W7'SP7GCZ[R&U<G"
M*B<'O(_5=JM+2,R&QX6<^8;2;8EVJMW^#9\%8>3.2ZL^,&\]IX>C])(&PP=D
MV1]P71,A,G]A,XLI$KZOZUEE(;%0_"/V^IUO34\N;H?+3C-".0(PH!C_UE[<
M3!ZEY9_:&:L13^_Z[5AZ[O+.7<-W,O+7P+GG6?(*?-.M_8TGFOK?:X7RG4^>
MV067:XTT!ZY[+9W=1M6F/Q+._A+(?^!Q<6,4>#LNT4$CU!58/"!''+=0O 1X
MHHAJA /,2#3[O#G_4&-M%5A@'CU40@C5S3@%@_7?.GV\(\<@[ST@TRE=!E?
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M#US1)2#* 4=!_.<?+WF'1@9&,AV9!(](2,UW$GC+-D'U>?T(LC\=W),B]W'
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MLBEW)9@6'*CG\]M_]WNS#EN&MFTI<X@;&JWE_)?/;/+<#)D%[?LBKN3V-DT
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MS:Y.7O4#O1^;?S@)_)$M_V]#C^9R]E\ 4$L#!!0    ( **)4EIWSB<W31H
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M "N((A2B#!P0@4!%(*P> ,[6DQ/R+P'^+9 #;!VYN'EX^?C9"QJ%@0,0*/0
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M9+2U4 $X3/,#:RXR'F+#&,%]7MSO/)$.CS0BC17AOU[%#Q0.YSC.^1ZUVQI
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M[.[V+63,'P']JU?N@6AB!XZJ0/J%RG%/./Q+2O U(#SDBU"\EV.FOAG6;R[
M>!;O3;NT@I4E@M(O9NPJYSKUWV8?^B;8HO:E:O(NTDDZYUIG+Y#8-.*%I-@L
MPK(3#RW\DF#72F=KZ49G UQMU_3/#JCF$#,ZK38&%7/:=FI9P!V\<+P-9;';
M(<A<FB)1317:=T]-;9C3)*GY9O/5;?+;GGRO*&06 "6LYY1N%,+3%K;[V#1D
M-8BN<MEC=W5"B5\4=!AO]+1R9*K?%U]?L!_U4I+("(FY.B958>U(ZR)(''H3
MAYI"[)2 G<^O"")WKE M#4.ZS"M?3EL 2++V%<5$,<@Z6H2.+8_7H/S52,(+
MS]MX5ZRXDB-,1[7EA#+-+N6(0095(.C2!8H].JUHH1^>4Z+#J#1U^7MGTG J
MHBKEGI9N*[U6V1]$G*Q+_E(7?T/_5RQ^]0758N<EE:OTG\0O,G,/4HFRO"D[
M>!A=X[CI7XOMGSMI2RLEU;+!JQK04V-M&A475V2LGIA$/?([V!D6&'H3D0&\
M=X$V @$E!006T%BX.@(C0PFSE[:R\*OPV^;P0II%=^R63?#,G)* ^,.(NMO2
M\KEF=5Z;MG-J4"(Z&4UQMH<%W@KCCH^H;Z' <[=B!!]4G'!K>Q QT"8-.7=_
M;DJJ<^A4;YPPFP]2$H?16\Y;%2S@ZD]V,ZO^ 4\H1]:IH.5,3ZCFFLI?05"9
M][C70Q:E9&K?;/YXS0)*LNC<S .QF?0HA(^N:8C<[5YY.>^"FYU.)X0Q_4$
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M?-0[KP/Y/6R_X,"RIO\+4$L#!!0    ( **)4EH!A&$NT1(  ),3   7
M9VQY8RTR,#(T,3(S,7AS-# U-2YJ<&>=EWDXU-_;QS]C[-L8QKY,0J10UC :
M2[;\+$4DI!I+*D26P9B)1"%;17Q#MH2RQ*08AK$E6_8LF1D3+<A,:GR^6>;1
M[WK6Z_K]\3S/^YS[K_L^Y[I?USGWN>[#^<"A 6(G;>QM  @7 $#V!L"9 ZP
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M@H36>35B \:,,CZ[9A ,EB>^SV1893582=%O/N?O#>< K25<.>9 LWI&T\#
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M8RTR,#(T,3(S,7AE>#$P9#,R+FAT;5!+ 0(4 Q0    ( **)4EJT0T/=5C4
M .N= 0 :              "  0LX 0!G;'EC+3(P,C0Q,C,Q>&5X,3!D,S-A
M+FAT;5!+ 0(4 Q0    ( **)4EJ8%+2$!BT  )H^ 0 :              "
M 9EM 0!G;'EC+3(P,C0Q,C,Q>&5X,3!D,S-B+FAT;5!+ 0(4 Q0    ( **)
M4EKBL=KM^D8  *9L @ 9              "  =>: 0!G;'EC+3(P,C0Q,C,Q
M>&5X,3!D,S0N:'1M4$L! A0#%     @ HHE26F3BPXU]/   C=H! !D
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M9#,Y+FAT;5!+ 0(4 Q0    ( **)4EK:7-ME&5,  $NT @ 8
M  "  6+Y @!G;'EC+3(P,C0Q,C,Q>&5X,3!D-"YH=&U02P$"% ,4    " "B
MB5):P02H'?TS   ^4P$ &0              @ &Q3 , 9VQY8RTR,#(T,3(S
M,7AE>#$P9#0P+FAT;5!+ 0(4 Q0    ( **)4EH?)FF<I70  /)T P 9
M          "  >6  P!G;'EC+3(P,C0Q,C,Q>&5X,3!D-#$N:'1M4$L! A0#
M%     @ HHE26OZ9MN">>0  X:,# !D              ( !P?4# &=L>6,M
M,C R-#$R,S%X97@Q,&0T,BYH=&U02P$"% ,4    " "BB5):->K][K\"  "W
M!@  &               @ &6;P0 9VQY8RTR,#(T,3(S,7AE>#(S9#$N:'1M
M4$L! A0#%     @ HHE26G&2G;(5 P  \@8  !@              ( !BW($
M &=L>6,M,C R-#$R,S%X97@R,V0R+FAT;5!+ 0(4 Q0    ( **)4EH.:N'<
M;08  /<;   8              "  =9U! !G;'EC+3(P,C0Q,C,Q>&5X,C-D
M-"YH=&U02P$"% ,4    " "BB5):W\J<M@12  #:- ( %P
M@ %Y? 0 9VQY8RTR,#(T,3(S,7AE>#-D-BYH=&U02P$"% ,4    " "BB5):
MD&9E(1HQ  !+= $ %P              @ &RS@0 9VQY8RTR,#(T,3(S,7AE
M>#-D-RYH=&U02P$"% ,4    " "BB5):K>MNOEP$   8&   &
M    @ $!  4 9VQY8RTR,#(T,3(S,7AE>#DY9#$N:'1M4$L! A0#%     @
MHHE26F*SY>A%!   KA(  !@              ( !DP0% &=L>6,M,C R-#$R
M,S%X97@Y.60R+FAT;5!+ 0(4 Q0    ( **)4EI 9N-E400  *P2   8
M          "  0X)!0!G;'EC+3(P,C0Q,C,Q>&5X.3ED,RYH=&U02P$"% ,4
M    " "BB5):?_55.1,$  !&%   &               @ &5#04 9VQY8RTR
M,#(T,3(S,7AE>#DY9#0N:'1M4$L! A0#%     @ HHE26CCP->*1"0  T70
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M;'EC+3(P,C0Q,C,Q>',T,# X+FIP9U!+ 0(4 Q0    ( **)4EJ52A0I9-,
M 'H) 0 7              "  <=G$0!G;'EC+3(P,C0Q,C,Q>',T,#(W+FIP
M9U!+ 0(4 Q0    ( **)4EI?VWE"C9T  -S.   7              "  6 [
M$@!G;'EC+3(P,C0Q,C,Q>',T,#(X+FIP9U!+ 0(4 Q0    ( **)4EIS>_:Y
M*.X  +<4 0 7              "  2+9$@!G;'EC+3(P,C0Q,C,Q>',T,#(Y
M+FIP9U!+ 0(4 Q0    ( **)4EKX9O8O#D<  #51   7              "
M 7_'$P!G;'EC+3(P,C0Q,C,Q>',T,#,P+FIP9U!+ 0(4 Q0    ( **)4EJV
MU:-X-8D  #R3   7              "  <(.% !G;'EC+3(P,C0Q,C,Q>',T
M,#,Q+FIP9U!+ 0(4 Q0    ( **)4EI_B_Y@?$@! -A2 0 7
M  "  2R8% !G;'EC+3(P,C0Q,C,Q>',T,#,R+FIP9U!+ 0(4 Q0    ( **)
M4EI*@_"4%,X  &3C   7              "  =W@%0!G;'EC+3(P,C0Q,C,Q
M>',T,#,S+FIP9U!+ 0(4 Q0    ( **)4EJFB.K=.!(! /H; 0 7
M      "  2:O%@!G;'EC+3(P,C0Q,C,Q>',T,#,T+FIP9U!+ 0(4 Q0    (
M **)4EJ>9W$#'K\  );.   7              "  9/!%P!G;'EC+3(P,C0Q
M,C,Q>',T,#,U+FIP9U!+ 0(4 Q0    ( **)4EJZ,,M*/>8  &D? 0 7
M          "  >: & !G;'EC+3(P,C0Q,C,Q>',T,#,V+FIP9U!+ 0(4 Q0
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4!08     +0 M #,,  #OM!H    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>glyc-20241231xs4_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:glyc="http://glyc.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="glyc-20241231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_SHUtEQJ4gEmeTUN1FXH1Jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_ZY2boBNI1ES9pXTrZe4dfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_TkPU169fb0a115F1Jhn1kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tjhcHjf3qUCUEAGiJHVx7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cIbtCfNf7EazwoGlwZilVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MVa3Xane0EWGuB31zaHGLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_74z7jNQFhUKDHc5lm0MsVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KsS5cukmYkiHF4C6-dXYBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YguH7JjiPk21kMLGoxNsYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wERsIdAgWE-wQCQ81ui9CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AwOVplV_P0mDzPrhrPFQXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSdHWh91dUS21LGrb3eG2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_onqX81APG0Ghn54y5zgaMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_glyc_OtherAwardsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-V6DN7K7xkqKAShmvSchFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:OtherAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K4GuybjZVEmN-yz3jNQQZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_QC2B5nm5zE6wl4KPu8GzAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NeI1DrJAfU2Pdw5yL4hyCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_SGKk_W-IqEa8wgIaEyiQyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JTfAygcVu0yXRQjZySO8fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_V8Yc464DDEuqsw28B2LXXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_KEVqEI1mz0alUnOYmZkAMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_g8Jzg9x9fkCHME1NaPv5rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_svfYtyytSku_5hVzJCGpwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_R_eQJnbT5kGlzY8X-rGidQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_VaSlxAOYBU-VdhWjQiAv6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_l6-d0WjB2EWKO9FwgF6G9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_31_2016_srt_StatementGeographicalAxis_glyc_RockvilleMarylandMember_BcWT7OTHpEyojUQYM5l-wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glyc:RockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_U4gkV-b8YE6xJmFs08VMbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ezQHd-wQf0--shnHTiwUGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_31_2024_kOgWP4JoZ0qcll1HUFWAMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_M5J3K2r_hUe_T0x0UXRjpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_VcdbkkEL90CR6p-GileFsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_glyc_FederalAndStateAuthoritiesMember_0VDyvQ7ZGE6FKTRNibG9Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">glyc:FederalAndStateAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TMq5bdXLv0uPMiT_XpYChA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_R9ETDiIjiEmYnIZRVb5HJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_fba-gQlZbEu4aT4dU-Zdgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_DKDfj7hCjUu3mShq3nI3Gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_28_2024_srt_OwnershipAxis_glyc_CrescentBiopharmaIncMember_srt_StatementScenarioAxis_glyc_PriorToClosingOfPrivatePlacementMember_9Nw2kINcWkOS08dTHYx78Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">glyc:CrescentBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">glyc:PriorToClosingOfPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-28</instant>
        </period>
    </context>
    <context id="As_Of_10_28_2024_srt_OwnershipAxis_glyc_CrescentBiopharmaIncMember_srt_StatementScenarioAxis_glyc_PostClosingOfPrivatePlacementMember_vPM54hGTmUeMioQHoVKWoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">glyc:CrescentBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">glyc:PostClosingOfPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-28</instant>
        </period>
    </context>
    <context id="As_Of_10_28_2024_srt_OwnershipAxis_glyc_GlycoMimeticsIncMember_srt_StatementScenarioAxis_glyc_PriorToClosingOfPrivatePlacementMember_Tm8848Kss0eZks2g6Tisbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">glyc:GlycoMimeticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">glyc:PriorToClosingOfPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-28</instant>
        </period>
    </context>
    <context id="As_Of_10_28_2024_srt_OwnershipAxis_glyc_GlycoMimeticsIncMember_srt_StatementScenarioAxis_glyc_PostClosingOfPrivatePlacementMember_A1VjOonYZ0mFZlFMgXfwHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">glyc:GlycoMimeticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">glyc:PostClosingOfPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8hSvq-SHI0KxvBm4TVYLQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_wZeRx6oRpUKbM_22ALjCXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_J7qgUFtkl0Wo9KigpKzqfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_v6lQTXiXUUmyixAKiaaFgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_mfEME_8KIEOUdPf0enFlBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_J_TWX_FgbkyiMy1gXdMchw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_29jmlAx-Ok-3Yvf3ByU8Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_YUjaMxLsuk-X-7qE4Kk97w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Fj8fd_U170aoblyabwgvVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_gI4hA-RNTEmj4Ln9TxOBNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_goAAe-HQTkGa8mwVYUZwOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_vGzIZ8H2gUCh6mmnJZxOfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_8LGYnV6fdkuBJAJjiuhDlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pj61R-BVG0mAA7jRopE9Lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qaEaEVpgsk2gHQo8gXVEfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_T5bkeU0TREKgcAs7V6M9TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aWlLHTyMG0CvFZ6zPAULSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_R7XVHwnd7U6Sd_9oTQ_uFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EjDnsR2epkyuZXXhTKnIHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2023_srt_StatementGeographicalAxis_glyc_SecondPortionSquareFeetRockvilleMarylandMember_XXtFnEFv6EaiyeUhpgD3cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glyc:SecondPortionSquareFeetRockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2023_srt_StatementGeographicalAxis_glyc_FirstPortionSquareFeetRockvilleMarylandMember_omYj33019EaIg4e-nOCwbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">glyc:FirstPortionSquareFeetRockvilleMarylandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HyhkPdyGmU6UnG8nxVmM2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-09</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_GranteeStatusAxis_glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_nWojf5k1XEuW7zoLkHsxkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">glyc:ShareBasedPaymentArrangementNewlyHiredEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_1XsemFUZukWboPPsX0QU9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">glyc:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_t2wb_CLKRESBcc-YEXDRlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iGa9kvr1_0OCIlThV88zBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityInducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_28_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8BLdTfohekutDmOuRqt3RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lEn5z0QjVECg-jhVCra21w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_28_2024_TP4f-xHx2E2A5iRUPIKLLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <instant>2024-10-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_SmdQHOUz5UqCH4SGTEpEHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_Lgi28lfrs0-59NK1_KFagw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOffering2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_lease_a1VBadA-40-Zv384mN5EKA">
        <measure>glyc:lease</measure>
    </unit>
    <unit id="Unit_Standard_employee__mI-PxD8qU-9RiyVThW_0Q">
        <measure>glyc:employee</measure>
    </unit>
    <unit id="Unit_Standard_installment_xM6my3fUa0iIeeFWVwoxkA">
        <measure>glyc:installment</measure>
    </unit>
    <unit id="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_sqft_c5PYJCWbn0-rXPVafi2irQ">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_hVrhBvSi7EWHtMESRprj8Q">
        <measure>glyc:segment</measure>
    </unit>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      id="Hidden_D7vkSyJr-EqQ_vMdm49tQQ"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      id="Hidden_iYvC6zUDDkeqXWNTByTQFA"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g"
      xsi:nil="true"/>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      id="Hidden__sNpJ6kWbEi0MrQEFcD_Vw">http://fasb.org/us-gaap/2024#RestructuringCostsAndAssetImpairmentCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Hidden_e7QLV2rjm0K6BIn7F2EDZw">http://fasb.org/us-gaap/2024#RestructuringCostsAndAssetImpairmentCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="INF"
      id="Hidden_Cl5USwoH3E2-Yiysk554yw"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="INF"
      id="Hidden_wYseKlUGHEeUkGQbXltD3Q"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      id="Hidden_458vb9MY1EioLUCUnC-NFg"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      id="Hidden_eA0MLaJIrUmo4aiKeTHJNw"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      id="Hidden_hdWUWzn18kiagf-L_qnDbQ"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      id="Hidden_NTBSQbNInE69YpwADs5_rw"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_svfYtyytSku_5hVzJCGpwg"
      decimals="INF"
      id="Hidden_rkMRBeyC_Ee79e86m5b6WA"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.02083</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      id="Hidden_vgZVo8BJJ0aed1tCmLrUPw">http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Fj8fd_U170aoblyabwgvVw"
      decimals="-5"
      id="Hidden_wztLkP3Lm02MgfrAQ67r5g"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_29jmlAx-Ok-3Yvf3ByU8Qg"
      decimals="-5"
      id="Hidden_L7HqH2SU6UKyZQDrUHawow"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_gI4hA-RNTEmj4Ln9TxOBNw"
      decimals="-5"
      id="Hidden_OZBgsrfjlECTU_mCo2b-RA"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_YUjaMxLsuk-X-7qE4Kk97w"
      decimals="-5"
      id="Hidden_dvRw_F9A4E-8M7P2Y-W2Tg"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Fj8fd_U170aoblyabwgvVw"
      decimals="-5"
      id="Hidden_dPj4OlAFHU2hlppffVMjow"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_29jmlAx-Ok-3Yvf3ByU8Qg"
      decimals="-5"
      id="Hidden_TfZ5_WmvLk69osJya5oqwQ"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="INF"
      id="Hidden_i4KFkDItQU-W7JjpHj8jIQ"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">64483958</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:LeasePracticalExpedientLessorSingleLeaseComponent
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      id="Hidden_-J90KSXgGUSREtmuyxhLCA">true</us-gaap:LeasePracticalExpedientLessorSingleLeaseComponent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="INF"
      id="Hidden_GQx9LJBBZk6tvQkeC5S2pg"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">64393744</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_VaSlxAOYBU-VdhWjQiAv6g"
      decimals="4"
      id="Hidden_36PO8EraXkq8olRkBZDjHw"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.0025</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Hidden_QkjKoOCR1UixNvOHv0BEAQ">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Hidden_gisLThAx_kmBXJrqV8ibaQ">http://fasb.org/us-gaap/2024#RestructuringCostsAndAssetImpairmentCharges</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tc_3sI6Ro4BHk6YmGfxcbTz3g_6_1">0001253689</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tc_XfHy7xS8SkOi7WvG1PgsfQ_7_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Narr_iDrnSZ41mk6K4nMcDQ3qGA">S-4</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Narr_3ND9X9pXrkmq0YXsmPTYLQ">GLYCOMIMETICS, INC.</dei:EntityRegistrantName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tc_U9qblJHfckOn8rQVg4th7w_3_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tc_rmeuyciYBEiZAELZG5Zctw_3_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tc_gOrkuzVz4k-QXMtGtysk7g_4_3">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_SPkIRmvvh0a3IHfM6kUusw_5_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">10720178</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_9Fz_vlWSi0-bbUKD9zBHxg_5_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">41792830</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_qHd5gnjvTUKm8-4Twn54Ow_6_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">371276</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_KLfXYyp7I0C_9Ec1M8Ek6w_6_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">1997904</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_nrUW36OjaU2nm8OjupMHFg_7_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">11091454</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_O2KoUj2FD06TS_m-j8o0Ww_7_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">43790734</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_SPijyfs8oEGUufpgrwVSQg_8_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">603737</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_ayeIpoH2m06cx_bQGsxKvQ_9_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">767828</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_OPqhrbkAukCxKbCThYzCqg_10_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">154176</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_oa8WdRJcikakexQCunKeaQ_11_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">11091454</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_7WiAfwCh5EGj7GmQgI-o1A_11_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">45316475</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_rlEUEOYcB0GTQjycjNAzig_14_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">329304</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_3Ef7xU3XI0uX9TiKbxBXmQ_14_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">868115</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_iJD_29HcgE2F96fve7p-Xw_15_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">5381744</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_UK2mf8ZX6Uq-3T_Z57hFng_15_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">5225557</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_CZaQqYT78EW3JcatvycrtA_16_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">66844</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_O4PfqiXw00e9rVyMz9z51A_16_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">741558</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_AlUoh1TmXkOA1CvWAhRDlg_17_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">5777892</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_bm_aBXBC2kKO59n6XeL9_w_17_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">6835230</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_z6khm8IR1EizY5MjKMArWw_18_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">66844</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_muVA0PSsfUGt1C51TIgUDA_19_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">5777892</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_e0pq4y7FYEaVL2YbhJXFlg_19_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">6902074</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="INF"
      id="Narr_IO9VJMlr0U-0EQFveRtV9A"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="INF"
      id="Narr_fluDUpV6WUa0RUzjLhdL-Q"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="INF"
      id="Narr_ZdP2RK25kkuhAhAWEEl5tA"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="INF"
      id="Narr_SANV6k2Y-U6PsIzIGdIM_g"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="INF"
      id="Narr_PDDVB7an3UOSalP61Hft5g"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="INF"
      id="Narr_8HDOJDuqKEe536HoB0_tJw"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="INF"
      id="Narr_dvcyNbGvRUmqVT_Ps4QTaQ"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="INF"
      id="Narr_GslEKzpbzESe6oSc6mBCYA"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="INF"
      id="Narr_9cET6geSOkuPBEuzDXyYSg"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="INF"
      id="Narr_OLz91RwF-0msvvlbpZMOUQ"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="INF"
      id="Narr_e1gCBcPXnUKyC_3zUJuwBw"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">64483958</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="INF"
      id="Narr_-pKn8X6ruEGEuYSBEQ1o9g"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">64393744</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_KHC3gzZmykyKliK8CtJr7Q_22_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">64484</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_7mBaYnraY0qvlQyISIKugA_22_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">64394</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_Cbu5SH0yQ0ec9BP4SqZlAg_23_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">499613448</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_93kmGRz8PE-WhBMOW9S_yg_23_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">494835219</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_QNyMra1B10CjC9EkPL4JLw_24_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-494364370</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_hdDjgxvI3kOH5f5beXoNHQ_24_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-456485212</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_34h9fJJQAU2wijuwY_JsSw_25_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">5313562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_7-iH3lquVECKqD4TcV7yUA_25_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">38414401</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_7ZAufyOMxkqU7W_z_6BYPA_26_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">11091454</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_cSw76EKY5EiBAkJLHsVODQ_26_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">45316475</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_F-Cw2CQJpEi7oM0wtu6fPw_3_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">10000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_pCCOb7ElSkSiI-kDqT61PQ_6_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">14259756</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_86UKYotXX0iu2HGgA27AjA_6_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">20071656</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc__ysYXgIBpE2lhs8lXDLYNA_7_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">18249318</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_iybAW4zWjUqP0_xTuuwDnQ_7_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">19213637</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_qAtIpe4Z1UKwT6HR8iGqlw_8_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">7530304</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_lEB6IiddKUGAiL3goE1dxw_9_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">40039378</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_7roZKtshcEGavv-06Vr3fw_9_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">39285293</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_M1RjkVfIo0SJmWmLx8RXjQ_10_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-40039378</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_AEu9wQS9Q06Q2e3wRL7zdQ_10_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-39275293</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_c5gETDvMgky2aXbhFN7biQ_13_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">1224945</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_kdRFO4OZIUCwlU6EMGSSfw_14_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">935275</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_9fc1_emdiEqIOfWPXNITAg_14_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">2375873</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_szUW8OEeWkWFm_DKWAds4Q_15_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">2160220</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_tg2OtdbSbE6bh5O1W-TuPg_15_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">2375873</us-gaap:NonoperatingIncomeExpense>
    <glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_CpeZYxqGa0S284TXQo1vcw_16_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-37879158</glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax>
    <glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_4mtU8YvdI0ynV2447Y7avA_16_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-36899420</glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="2"
      id="Tc_LzAQ6Qkqb0aIj1j2jY-EcQ_17_3"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="2"
      id="Tc_LzAQ6Qkqb0aIj1j2jY-EcQ_17_3_2"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">-0.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="2"
      id="Tc_8n4rMnqbFkCaJLppmd1H_Q_17_6"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">-0.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="2"
      id="Tc_8n4rMnqbFkCaJLppmd1H_Q_17_6_2"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">-0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_Uis9b_WaR0KEbQD3GoDeew_18_3"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">64477249</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="INF"
      id="Tc_Uis9b_WaR0KEbQD3GoDeew_18_3_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">64477249</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_-1PXRwQBcEmaUjrOUXxoow_18_6"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">63342465</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="INF"
      id="Tc_-1PXRwQBcEmaUjrOUXxoow_18_6_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">63342465</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSdHWh91dUS21LGrb3eG2g"
      decimals="INF"
      id="Tc_1MMzetM0IEutsnBor_PYEg_4_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">54377798</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CSdHWh91dUS21LGrb3eG2g"
      decimals="0"
      id="Tc_-pluQKDEA0mNBLop7cBiug_4_5"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">54378</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YguH7JjiPk21kMLGoxNsYw"
      decimals="0"
      id="Tc_qelV2FPJEUGd9XDsOR81aA_4_8"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">462461251</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KsS5cukmYkiHF4C6-dXYBw"
      decimals="0"
      id="Tc_0CDH1MxBV0GhkUK2rb6_zw_4_11"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-419585792</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_J_TWX_FgbkyiMy1gXdMchw"
      decimals="0"
      id="Tc_PwIImXdCdkiDgU6WS-TEEg_4_14"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">42929837</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw"
      decimals="INF"
      id="Tc_3kYr6GybxkyWd6dqxOet1A_5_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">9822930</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw"
      decimals="0"
      id="Tc_kKyQiZxCOkGn7q8siPpUlQ_5_5"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">9823</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aWlLHTyMG0CvFZ6zPAULSQ"
      decimals="0"
      id="Tc_ACnBp6XXw0y1JfIxp3Xf1w_5_8"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">28697188</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_IVzuRDbzpUGuVb8y5jB69Q_5_14"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">28707011</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw"
      decimals="INF"
      id="Tc_ShCA2FdEfUW5YTCNIpQhYw_6_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">24001</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw"
      decimals="0"
      id="Tc_NljEnEsIJkmDYYikxjwbNA_6_5"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">24</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aWlLHTyMG0CvFZ6zPAULSQ"
      decimals="0"
      id="Tc_YSspGZp_XUmOJo01i9L7UA_6_8"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">35976</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_YUcPMe4dokyh3Y6vqJ7amA_6_14"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">36000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <glyc:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw"
      decimals="INF"
      id="Tc_vwfrMFH8B0yVo70hjwgH3A_7_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">169015</glyc:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qaiGCf5W7keBCnHBr162Fw"
      decimals="0"
      id="Tc_Iz68AjSc4UajqpK5HuosBQ_7_5"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">169</glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aWlLHTyMG0CvFZ6zPAULSQ"
      decimals="0"
      id="Tc_L9FCBFJxUEKKWqenrv2wjA_7_8"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">116328</glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_K3TWkrnwI0aXlYOPYota1Q_7_14"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">116497</glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aWlLHTyMG0CvFZ6zPAULSQ"
      decimals="0"
      id="Tc_QwRhj_jSHUuY2UGy9PTpGQ_8_8"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">3524476</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_EQmE7TuWEkGGedE4pZaQ0w_8_14"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">3524476</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_R9ETDiIjiEmYnIZRVb5HJA"
      decimals="0"
      id="Tc_k2zbovJPPUyTPHzf1nGgDg_9_11"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-36899420</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_IAJ7goqt8EiVJ9xikyun1g_9_14"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-36899420</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AwOVplV_P0mDzPrhrPFQXA"
      decimals="INF"
      id="Tc_ICkawatOLkOWhb8YWSgXuQ_10_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">64393744</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AwOVplV_P0mDzPrhrPFQXA"
      decimals="0"
      id="Tc_ONa0iKZ2qEGGVQy1jYDtnQ_10_5"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">64394</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_74z7jNQFhUKDHc5lm0MsVw"
      decimals="0"
      id="Tc_iLiP3IBB0k6tnX5F75rrmA_10_8"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">494835219</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MVa3Xane0EWGuB31zaHGLw"
      decimals="0"
      id="Tc_x4QJTvEE6ke7oZOpsHOEkw_10_11"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-456485212</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_rQdVxJO7vkyznbS3ahYi6w_10_14"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">38414401</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EjDnsR2epkyuZXXhTKnIHA"
      decimals="INF"
      id="Tc_o_4Yw8nU10KzKmFOUwHe0A_11_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">28383</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EjDnsR2epkyuZXXhTKnIHA"
      decimals="0"
      id="Tc_KHEXJNF5LkqT74tq5YrlzQ_11_5"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">28</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_R7XVHwnd7U6Sd_9oTQ_uFw"
      decimals="0"
      id="Tc_-Jrbc_FPfkaKjsQ9YXbk3Q_11_8"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">75347</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_2ElXK3YjjU2I3Cmngz9Pqw_11_14"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">75375</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <glyc:StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EjDnsR2epkyuZXXhTKnIHA"
      decimals="INF"
      id="Tc_Vu75B2l1fUyFikiWQVY9OA_12_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">61831</glyc:StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EjDnsR2epkyuZXXhTKnIHA"
      decimals="0"
      id="Tc_DrfTU35O5kCl25zQbYHqug_12_5"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">62</glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_R7XVHwnd7U6Sd_9oTQ_uFw"
      decimals="0"
      id="Tc_Btw_Z23oHUmTEJcmZCslsw_12_8"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">5336</glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting>
    <glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_BKBjHIWCJEi0P96PTPhqlg_12_14"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">5398</glyc:StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_R7XVHwnd7U6Sd_9oTQ_uFw"
      decimals="0"
      id="Tc_RFzzXQAaM06KqG1XMZGS1Q_13_8"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">4697546</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_Ga8TJh2lUkWbwN8W4BI71A_13_14"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">4697546</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TMq5bdXLv0uPMiT_XpYChA"
      decimals="0"
      id="Tc_7aRVhtNcqEyQXsLa3HRHeQ_14_11"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-37879158</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_N4-zd0Yd1UCYYh18mxT5ZQ_14_14"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-37879158</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wERsIdAgWE-wQCQ81ui9CQ"
      decimals="INF"
      id="Tc_aCykOlh71EaTqYn_-Etndw_15_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">64483958</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_wERsIdAgWE-wQCQ81ui9CQ"
      decimals="0"
      id="Tc_gopNyXiwq0yCuYX1JtPxsQ_15_5"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">64484</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cIbtCfNf7EazwoGlwZilVQ"
      decimals="0"
      id="Tc_9NejIKbjQ0OW40plXOEFLw_15_8"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">499613448</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tjhcHjf3qUCUEAGiJHVx7g"
      decimals="0"
      id="Tc_Uzl020Xc50WmMRdlV2NRtg_15_11"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-494364370</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_KcbeWeRoFEyzPycluPD3dw_15_14"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">5313562</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_1bmzZqWWUUWEo-ekCklZFg_4_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-37879158</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_jnY01y2MaE6Naq8ShIXWlw_4_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-36899420</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_-Mf38Kx2sEq28Gfm07w2cg_6_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">35174</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_jRjhOFylgE-D6jNRd6mkhw_6_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">153301</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_JOxdljmr8UauVTbmB64zTQ_7_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-46654</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_q4ag3jT450-iKaZEWRv1Ag_7_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-8627</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_o0P4nCJqL0itv1vK4Pargw_8_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">365179</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_w2bgoOqV6Em3zm1jAKI6Tw_9_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">402649</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_o7BwnDaZRkeHwDW0IWp-LQ_9_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">856238</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_ltZa7CHwE0KS-YKSYV5x4g_10_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">75375</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_uqQBuZJe50S9Dj66aTYlbQ_10_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">36000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_P8EkwiuKR0iurzO-IxkOvA_11_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">4697546</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_U5aLZYEuak6e5D4RW6IlWg_11_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">3524476</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_sY3yX021sUqDO2aceJI59A_13_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-1678948</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc__l1OKUKqykKkjeDfdN1JDA_13_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-846182</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <glyc:IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_EsdXnVoXjU23bZ0GIP8EkA_14_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-603737</glyc:IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses>
    <glyc:IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc__lm7Jb2rUEyLh56nqVVmNA_14_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">553737</glyc:IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_AhNCX6HldE2nVycLPtzhLA_15_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-538811</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_S6ACkXDEPkyl3dxSYr34Zw_15_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-102076</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_Ktt3ZbKdL0u8ZvYU3_OxhQ_16_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">156187</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_FeELrMHWH0qw6s2bN5Ov6A_16_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-1766449</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <glyc:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_9ddRdh2FcUa3k3J4-u81IQ_17_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-741558</glyc:IncreaseDecreaseInOperatingLeaseLiabilities>
    <glyc:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_veLaRQ_ST0ODaU0m785rPg_17_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-983045</glyc:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_IAAf5GWsJEqyggHYqFXItg_18_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-31098078</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_80nS7thnv0KSTp8vqf6W2A_18_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-34879903</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_Mvj3AHHlokaHvA1taUYEqg_21_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">9972</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_M5dC30ccm06BUrw0aCB2Dw_21_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">21394</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_DA-qGczUfUmHXPmFjKdhhQ_22_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">30000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_tiSioC6IuUGtTiqLn8Y9kg_23_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">20028</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_yp3k_4mfg0KJI8hTzS2_6w_23_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-21394</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_Oviwx4C-T0atq6uLkRBu5g_26_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">28707011</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_1P_J4kbU00qIgI1XfFx0PA_27_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">5398</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_WKFCoYlmOkaWiCsD41ZgzA_27_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">116497</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_9-hqzOHbRUGo0byQSCYRIA_28_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">5398</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_Bf-hxJFCdUOrG0C4NId6WQ_28_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">28823508</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_YNIwL-9wq0SHJPHOA9bMWQ_29_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-31072652</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_poRqBeJNcUiXeaJ6e6WiFA_29_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-6077789</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_6-gKtrHqUUO6kPKTTiImGg_30_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">41792830</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2022_J_TWX_FgbkyiMy1gXdMchw"
      decimals="0"
      id="Tc_xWQKthPPS0SxXZu6Kra60Q_30_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">47870619</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_o9PL3pAUWk2fH6hniXt1DA_31_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">10720178</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_zKxx4g_bYUOJxSCpIwJ29Q_31_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">41792830</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_OrN3nI-x30CsdNsTy0YoeQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Description of the Business&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;GlycoMimetics, Inc. (the Company), a Delaware corporation, was incorporated in 2003. The Company was previously developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation. In July 2024, following feedback from the U.S. Food and Drug Administration (FDA), the Company determined that the regulatory path forward for its lead product candidate, uproleselan, for the treatment of relapsed and refractory acute myeloid leukemia would require an additional clinical trial. The decision to not conduct an additional clinical trial did not relate to any safety or medical issues or negative regulatory feedback related to the Company&#x2019;s programs.  In order to conserve its cash resources, in July 2024 the Company reduced its workforce by approximately &lt;/span&gt;80%&lt;span style="white-space:pre-wrap;"&gt;.  The Company also initiated a strategic review of its business in an effort to maximize shareholder value. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Following the strategic review, on October 28, 2024 the Company entered into an Agreement and Plan of Merger and Reorganization (the Merger Agreement) with Crescent Biopharma, Inc., a Delaware corporation (Crescent), pursuant to which Crescent will become a wholly owned subsidiary of the Company (the Merger).  Upon completion of the Merger, the Company plans to operate under the name Crescent Biopharma, Inc. The Merger is expected to close in the late second quarter of 2025, subject to certain closing conditions, including, among other things, approval by the stockholders of each company and the satisfaction of customary closing conditions.   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Concurrently with the execution and delivery of the Merger Agreement, certain institutional and accredited investors have entered into a securities purchase agreement (the Purchase Agreement) with the Company, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase, immediately following the consummation of the Merger, shares of the Company&#x2019;s common stock and pre-funded warrants (together, the PIPE Securities) for an aggregate purchase price of approximately $200.0 million in a private placement (the Private Placement). The closing of the Private Placement is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement (in addition to other customary closing conditions) and is expected to occur immediately following the closing of the Merger.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the exchange ratio formula set forth in the Merger Agreement, upon the closing of the Merger (but prior to closing of the Private Placement described below), on a pro forma basis and based upon the number of shares of common stock of the Company expected to be issued in the Merger, pre-Merger Crescent stockholders will own approximately 86.2% of the combined company and pre-Merger stockholders of the Company will own approximately 13.8% of the combined company. After giving further effect to the Private Placement, the pre-Merger Crescent stockholders (inclusive of those investors participating in the Private Placement) are expected to own approximately 96.9% of the combined company and the pre-Merger stockholders of the Company are expected to own approximately 3.1% of the combined company. The exchange ratio will be adjusted to the extent that the Company&#x2019;s net cash at closing of the Merger is less than $1.0 million and will be based on the amount of proceeds actually received by the Company in the Private Placement.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_7_1_2024_To_7_31_2024_kOgWP4JoZ0qcll1HUFWAMQ"
      decimals="2"
      id="Narr_WsU-vnKEdUSvjMUd7OXYwg"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.80</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <glyc:SaleOfStockAggregatePurchasePrice
      contextRef="As_Of_10_28_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8BLdTfohekutDmOuRqt3RQ"
      decimals="-5"
      id="Narr_oMXzMEOV5UKLRSAh5yVhFA"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">200000000</glyc:SaleOfStockAggregatePurchasePrice>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_10_28_2024_srt_OwnershipAxis_glyc_CrescentBiopharmaIncMember_srt_StatementScenarioAxis_glyc_PriorToClosingOfPrivatePlacementMember_9Nw2kINcWkOS08dTHYx78Q"
      decimals="3"
      id="Narr_DSlkiuawYkm_a26x-BB17A"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.862</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_10_28_2024_srt_OwnershipAxis_glyc_GlycoMimeticsIncMember_srt_StatementScenarioAxis_glyc_PriorToClosingOfPrivatePlacementMember_Tm8848Kss0eZks2g6Tisbg"
      decimals="3"
      id="Narr_HyEOqVyHZkmzeJr6NZgAdA"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.138</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_10_28_2024_srt_OwnershipAxis_glyc_CrescentBiopharmaIncMember_srt_StatementScenarioAxis_glyc_PostClosingOfPrivatePlacementMember_vPM54hGTmUeMioQHoVKWoA"
      decimals="3"
      id="Narr_7hCm6FOPmEGp5tG6BzRj8Q"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.969</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_10_28_2024_srt_OwnershipAxis_glyc_GlycoMimeticsIncMember_srt_StatementScenarioAxis_glyc_PostClosingOfPrivatePlacementMember_A1VjOonYZ0mFZlFMgXfwHQ"
      decimals="3"
      id="Narr_I3L3-XjH00-6ztbJnO51Iw"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.031</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <glyc:MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing
      contextRef="As_Of_10_28_2024_TP4f-xHx2E2A5iRUPIKLLA"
      decimals="-5"
      id="Narr_dfBGOr9GK0-4tOecBEjUDw"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">1000000</glyc:MergerAgreementExchangeRatioDeterminationMaximumNetCashAtClosing>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_mDK2eTsX8Equ19CULvKmVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2. Going Concern&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. During 2024, the Company incurred a net loss of $37.9 million and had net cash flows used in operating activities of $31.1 million. At December 31, 2024, the Company had $10.7 million in cash and cash equivalents and had no committed source of additional funding other than the expected Private Placement. Management believes that given the Company&#x2019;s current cash position and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date that these financial statements are issued without the closing of the contemplated Merger and Private Placement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If the contemplated Merger and Private Placement does not close by the late second quarter of 2025, the Company may seek other strategic alternatives or liquidate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="-5"
      id="Narr_9IE5Clszwk-_caMrkoB1ag"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-37900000</glyc:NetIncomeLossAndComprehensiveIncomeNetOfTax>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="-5"
      id="Narr_Xs8_rC9YeEacVi2Ygat7XA"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">-31100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="-5"
      id="Narr_1x3JX6FXlEGRZSCfMaL9Kg"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">10700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_3wPu-2rmfk-ao69-4QfZtw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Accounting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restructuring Charges&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company recognizes restructuring charges related to reorganization plans that have been implemented by management.  In connection with these activities, the Company records restructuring charges, as applicable, at fair value for:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulate when the payment of benefits becomes probable and the amount can be reasonably estimated;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-time employee termination benefits to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the detail of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;contract termination costs when the Company cancels a contract in accordance with its terms; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;costs to be incurred over the remaining contract term without economic benefit to the Company at the cease-use date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;For one-time employee terminations benefits, the Company recognizes the liability in full on the communication date when future services are not required or amortizes the liability ratably over the service period, if required. The fair value of termination benefits reflects the Company&#x2019;s estimate of expected utilization of certain Company-funded post-employment benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;As described in Note 13, during the year ended December 31, 2024, the Company incurred severance charges of &lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;$7.0&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt; million in connection with a corporate restructuring, including a reduction in headcount.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company views its operations and manages its business in one&lt;span style="white-space:pre-wrap;"&gt; segment.  The Company&#x2019;s chief operating decision maker is the president and chief executive officer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company has not generated any product revenue since inception.  &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company has no ongoing operations, is not actively performing any research and development, and is preserving cash until the contemplated Merger and Private Placement.  If the contemplated Merger and Placement does not close by the late second quarter of 2025, the Company may seek other strategic alternatives or liquidate. As of December 31, 2024, the Company had no material assets besides cash and cash equivalents and only had &lt;/span&gt;six employees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies of the Company&#x2019;s single reportable segment are the same as those described in Note 3.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The chief operating decision maker assesses performance and decides how to allocate resources based on net income (loss) that is reported on the statement of operations and comprehensive loss as net income (loss). The segment-level financial information is the same as the financial information presented in the statement of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The measure of segment assets is reported on the balance sheet as total assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Net income (loss) is used to monitor budget versus actual results. The monitoring of budgeted versus actual results are used in assessing performance of the segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company does not have intra-entity sales or transfers. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December 31, 2024 and 2023, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements&lt;/i&gt;. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#x2014;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#x2014;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#x2014;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) either on a recurring or non-recurring basis as of December&#160;31, 2024 and 2023. The carrying value of cash held in money market funds of approximately $8.3 million and $38.8 million as of December&#160;31, 2024 and 2023, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did&#160;not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December 31, 2024 and 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash balances with financial institutions in federally insured accounts and has cash balances in excess of the insurance limits. Cash equivalents consist of investment in United States government money market funds with major financial institutions. These deposits and funds may be redeemed upon demand and the Company does not anticipate any losses on such balances. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash and cash equivalents. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company has elected to account for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A discussion of management&#x2019;s methodology for developing some of the assumptions used in the valuation model follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividend Yield&lt;/i&gt;&#x2014;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&#x2014;&lt;/i&gt;Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company bases the expected volatility on the historical volatility of the Company&#x2019;s publicly traded common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt;&#x2014;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&#x2014;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,&lt;i style="font-style:italic;"&gt; Income Taxes&lt;/i&gt;. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&#160;31, 2024 and 2023, the Company&#x2019;s net loss was equal to comprehensive loss and, accordingly, no additional disclosure is presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted this standard for the year ended December 31, 2024 and the primary impact of which was the additional segment disclosures included in Note 3.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company&#x2019;s financial statements.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40), which requires disclosure, in the notes to the financial statements, of specified information about certain costs and expenses. This ASU is effective for public entities for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact ASU 2024-03 will have on its consolidated financial statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_UkHir6x9xk2vxit3Kp1_2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Accounting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_J9j-P7GQTEG-THBn7NsIbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restructuring Charges&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company recognizes restructuring charges related to reorganization plans that have been implemented by management.  In connection with these activities, the Company records restructuring charges, as applicable, at fair value for:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulate when the payment of benefits becomes probable and the amount can be reasonably estimated;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-time employee termination benefits to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the detail of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;contract termination costs when the Company cancels a contract in accordance with its terms; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;costs to be incurred over the remaining contract term without economic benefit to the Company at the cease-use date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;For one-time employee terminations benefits, the Company recognizes the liability in full on the communication date when future services are not required or amortizes the liability ratably over the service period, if required. The fair value of termination benefits reflects the Company&#x2019;s estimate of expected utilization of certain Company-funded post-employment benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;As described in Note 13, during the year ended December 31, 2024, the Company incurred severance charges of &lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;$7.0&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt; million in connection with a corporate restructuring, including a reduction in headcount.&lt;/span&gt;&lt;/p&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <us-gaap:SeveranceCosts1
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="-5"
      id="Narr_IFL8Hhu0Q0mB7Yn2fG4g8w"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">7000000</us-gaap:SeveranceCosts1>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_YhMrBQ5I8kGebIlZaJzy2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company views its operations and manages its business in one&lt;span style="white-space:pre-wrap;"&gt; segment.  The Company&#x2019;s chief operating decision maker is the president and chief executive officer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company has not generated any product revenue since inception.  &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company has no ongoing operations, is not actively performing any research and development, and is preserving cash until the contemplated Merger and Private Placement.  If the contemplated Merger and Placement does not close by the late second quarter of 2025, the Company may seek other strategic alternatives or liquidate. As of December 31, 2024, the Company had no material assets besides cash and cash equivalents and only had &lt;/span&gt;six employees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies of the Company&#x2019;s single reportable segment are the same as those described in Note 3.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The chief operating decision maker assesses performance and decides how to allocate resources based on net income (loss) that is reported on the statement of operations and comprehensive loss as net income (loss). The segment-level financial information is the same as the financial information presented in the statement of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The measure of segment assets is reported on the balance sheet as total assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Net income (loss) is used to monitor budget versus actual results. The monitoring of budgeted versus actual results are used in assessing performance of the segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company does not have intra-entity sales or transfers. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="INF"
      id="Narr_j1WNv8TmgE6SQbkBYtO4rQ"
      unitRef="Unit_Standard_segment_hVrhBvSi7EWHtMESRprj8Q">1</us-gaap:NumberOfOperatingSegments>
    <glyc:NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="INF"
      id="Narr_uAGZGrqAHUCM-50Tb68h5Q"
      unitRef="Unit_Standard_employee__mI-PxD8qU-9RiyVThW_0Q">6</glyc:NumberOfPositionsRemainingAfterRestructuringAndRelatedCosts>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_pIIAqmyQ10SwnFzr34FAsA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_EnMOcIBjkkm8iEBE5l_O1Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_SaqvaaoLcE2uK6glQyquDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December 31, 2024 and 2023, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements&lt;/i&gt;. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#x2014;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#x2014;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#x2014;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) either on a recurring or non-recurring basis as of December&#160;31, 2024 and 2023. The carrying value of cash held in money market funds of approximately $8.3 million and $38.8 million as of December&#160;31, 2024 and 2023, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did&#160;not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December 31, 2024 and 2023.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_gI4hA-RNTEmj4Ln9TxOBNw"
      decimals="-5"
      id="Narr__d_yhJ-oD0aNRl43OP6h8w"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_YUjaMxLsuk-X-7qE4Kk97w"
      decimals="-5"
      id="Narr_trGjuQVoTUemQBjn6dj7kA"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_fba-gQlZbEu4aT4dU-Zdgg"
      decimals="-5"
      id="Narr_P9TGVhuBPkSVj5n-77jcqg"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">8300000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_DKDfj7hCjUu3mShq3nI3Gg"
      decimals="-5"
      id="Narr_frTkgxEaW0qentSpjPqRaw"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">38800000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_X8NOhsbxN0ysmDpXQlh9aQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash balances with financial institutions in federally insured accounts and has cash balances in excess of the insurance limits. Cash equivalents consist of investment in United States government money market funds with major financial institutions. These deposits and funds may be redeemed upon demand and the Company does not anticipate any losses on such balances. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash and cash equivalents. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_FmZKeXPWMkOqxtBVtBGfFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_aVhmciKEbkqwpxMlc38z4g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. The Company has elected to account for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A discussion of management&#x2019;s methodology for developing some of the assumptions used in the valuation model follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividend Yield&lt;/i&gt;&#x2014;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility&#x2014;&lt;/i&gt;Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company bases the expected volatility on the historical volatility of the Company&#x2019;s publicly traded common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate&lt;/i&gt;&#x2014;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term&lt;/i&gt;&#x2014;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_mfEME_8KIEOUdPf0enFlBA"
      id="Narr_wGtAz6_V_UqcRGQXpx0D4g">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_v6lQTXiXUUmyixAKiaaFgA"
      id="Narr_fXAYDmx6a0qwHxDWUa3vIw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_J7qgUFtkl0Wo9KigpKzqfQ"
      id="Narr_xqnKkQrTeEuaLVNLA3Zb-w">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_wZeRx6oRpUKbM_22ALjCXw"
      id="Narr_PdYpxt1wKESkiMzNPuDdqg">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      id="Narr_ZkMbhdMmHkG31o70E1fPFg">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Narr_-qErDbDdcEuyxqBrF_pumg">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_IEUTIlcm8US-4fGuhBST1Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,&lt;i style="font-style:italic;"&gt; Income Taxes&lt;/i&gt;. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_boG8GcvAO02NbFnup6Clvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&#160;31, 2024 and 2023, the Company&#x2019;s net loss was equal to comprehensive loss and, accordingly, no additional disclosure is presented.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <glyc:NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_MAqtkCbiPEmOARemV0tqDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to provide enhanced segment disclosures. The standard will require disclosures about significant segment expenses and other segment items and identifying the Chief Operating Decision Maker and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all entities on an interim and annual basis, even if they have only a single reportable segment. The standard is effective for years beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024 and early adoption is permitted. The Company adopted this standard for the year ended December 31, 2024 and the primary impact of which was the additional segment disclosures included in Note 3.&lt;/p&gt;</glyc:NewAccountingPronouncementsAdoptedPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_DfB-jJQJ_USJAlsP3rjvCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the Company&#x2019;s financial statements.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40), which requires disclosure, in the notes to the financial statements, of specified information about certain costs and expenses. This ASU is effective for public entities for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact ASU 2024-03 will have on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_eW_efL3eYUWHhcX4K7dgsw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Net Loss Per Share of Common Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#x2019;s stock options and restricted stock units (RSUs).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average common shares outstanding, as they would be anti-dilutive: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options and RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,043,815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,981,357&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_PxHQ_cpYLU-3b3P1AK9-xg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options and RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,043,815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,981,357&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_goAAe-HQTkGa8mwVYUZwOg"
      decimals="0"
      id="Tc_rfonpt__g0it9Z4w09vv0A_3_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">15043815</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_vGzIZ8H2gUCh6mmnJZxOfg"
      decimals="0"
      id="Tc__G-dJ6Zy8kCEQe6yXOj_qg_3_4"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">10981357</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_MaZ3pHOmeEOV9H8gLvdC1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5. Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"&gt;The following is a summary of the Company&#x2019;s prepaid expenses and other current assets at December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,420,642&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 234,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 401,442&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 136,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 175,820&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 371,276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,997,904&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_OevvqNtBpkekpLJGH7WH7A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,420,642&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 234,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 401,442&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 136,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 175,820&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 371,276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,997,904&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_eB7wlcTAIUGl6dCkda8jOA_3_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">1420642</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_dPjQFt2cuUGjoUzW6OUaoQ_4_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">234696</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_qqejFxnx50u32ZFd8_mKHA_4_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">401442</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_RMfa2FXEVk6uJD7kdFaBqA_5_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">136580</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_q-a3OD7Az0GUkYh6ErHGKQ_5_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">175820</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_ZM2dNNCeLUuE7wapOkZthw_6_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">371276</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_ya-6CR10OEOUe2zTyjTDYg_6_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">1997904</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_vujzQZgS0ES6iQLJY12CVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6. Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following is a summary of the Company&#x2019;s accrued expenses at December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 51,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 1,824,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 2,561,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued consulting and other professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 790,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 439,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued employee benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 3,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 399,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued retention&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 1,049,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued severance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 3,487,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 5,381,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 5,225,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_SvBn8Do5Tk2pW9R22EaNrQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 51,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 1,824,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 2,561,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued consulting and other professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 790,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 439,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued employee benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 3,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 399,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued retention&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 1,049,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued severance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 3,487,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 5,381,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 5,225,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_rbEYSJWmNkem7Bo8nX1l3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company determines a lease exists if the contract conveys the right to control an identified asset for a period of time in exchange for consideration. Control is considered to exist when the lessee has the right to obtain substantially all of the economic benefits from the use of an identified asset as well as direct the right to use of that asset. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less on the lease commencement date. If a contract is considered to be a lease, the Company recognizes a lease liability based on the present value of the future lease payments over the expected lease term, with an offsetting entry to recognize a right-of-use asset. The Company has also elected to use the practical expedient and account for each lease component and related non-lease component as one &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_-J90KSXgGUSREtmuyxhLCA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; component. The lease component results in a right-of-use asset being recorded on the balance sheet and amortized as lease expense on a straight-line basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a term similar to the term of the lease for which the rate is estimated. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Company leased office and research space in Rockville, Maryland under an operating lease that was subject to annual rent increases (the Lease). The Company paid a security deposit of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$52,320&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; to be held until the expiration or termination of the Company&#x2019;s obligations under the Lease. In April 2023, the Company and its landlord entered into an amendment to the Lease (the Lease Amendment). Pursuant to the Lease Amendment, the Company and the landlord agreed that the lease term for a portion of the premises, consisting of approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;30,000&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; square feet, would be &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_QkjKoOCR1UixNvOHv0BEAQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;extended&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; from November 1, 2023 to January 31, 2025. However, pursuant to the Company&#x2019;s strategic review and restructuring plan adopted during the year ended December 31, 2024, the Company abandoned the leased space and determined that its right-of-use-asset was fully impaired. As a result, the Company recognized an impairment charge of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.4&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; million, during the year ended December 31, 2024, representing the carrying value of the right-of-use asset.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt;The Company&#x2019;s lease of the remaining premises, consisting of approximately &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;12,000&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; square feet, expired on October 31, 2023. There were &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; additional operating leases as of the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of lease expense and related cash flows were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Operating lease cost &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 450,274&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 944,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 516,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 602,416&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 966,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,547,379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Operating cash outflows for operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 789,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,017,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Maturities of lease liability due under these lease agreements as of December 31, 2024 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Obligation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value adjustment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (557)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_vgZVo8BJJ0aed1tCmLrUPw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Present value of lease payments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66,844&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Supplemental information related to leases were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt; Weighted-average incremental borrowing rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Right-of-use assets obtained in exchange for operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 872,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_5_31_2016_srt_StatementGeographicalAxis_glyc_RockvilleMarylandMember_BcWT7OTHpEyojUQYM5l-wA"
      decimals="0"
      id="Narr_ksjXTnAFiEuo-Xd84SmMCw"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">52320</us-gaap:SecurityDeposit>
    <glyc:SquareFeetLeased
      contextRef="As_Of_4_30_2023_srt_StatementGeographicalAxis_glyc_FirstPortionSquareFeetRockvilleMarylandMember_omYj33019EaIg4e-nOCwbQ"
      decimals="0"
      id="Narr_NfA-fWBGK0aVRVnYNBebYw"
      unitRef="Unit_Standard_sqft_c5PYJCWbn0-rXPVafi2irQ">30000</glyc:SquareFeetLeased>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="-5"
      id="Narr_NbAW9omDZEWV-Auv8-jjYQ"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">400000</us-gaap:OperatingLeaseImpairmentLoss>
    <glyc:SquareFeetLeased
      contextRef="As_Of_4_30_2023_srt_StatementGeographicalAxis_glyc_SecondPortionSquareFeetRockvilleMarylandMember_XXtFnEFv6EaiyeUhpgD3cw"
      decimals="0"
      id="Narr_4oObz8p5HUipCcdp8i3QZg"
      unitRef="Unit_Standard_sqft_c5PYJCWbn0-rXPVafi2irQ">12000</glyc:SquareFeetLeased>
    <glyc:LesseeOperatingLeaseNumberOfNewLeases
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="INF"
      id="Narr_faj-MIL3J02Oo9-xCeOrgg"
      unitRef="Unit_Standard_lease_a1VBadA-40-Zv384mN5EKA">0</glyc:LesseeOperatingLeaseNumberOfNewLeases>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_aYOrq7BwIE-FT8uIPrGGuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Operating lease cost &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 450,274&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 944,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Variable lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 516,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 602,416&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 966,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,547,379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-top:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Operating cash outflows for operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 789,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,017,770&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_fG4zE6_Ue0OVYr9TNNKyUA_3_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">450274</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_G-xFLQjXw0i_x8mSv3jWXA_3_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">944963</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_gMafY8WfbkmP2PFUneZ8Aw_4_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">516344</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_8xvBDUNaOkKuHigCuQC2FQ_4_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">602416</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_Fp3lxTtAGECshBv5g52msA_5_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">966618</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_IzyJA7m_uU6XQfVigpFSAw_5_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">1547379</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_Hh5SPdB0SEewV7hso52A2g_8_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">789183</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_q6qKJ4fsC0W8MnGM9VpD8Q_8_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">1017770</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_TDiqXlS5OUO7Sc8FuMGxKQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating Lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Obligation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67,401&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value adjustment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (557)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:83.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_vgZVo8BJJ0aed1tCmLrUPw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Present value of lease payments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66,844&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_yaVAQAdYYUGspUBtdiVKHg_3_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">67401</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <glyc:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_tR5bk1AK_EqnU5TGvSUx-w_4_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">0</glyc:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_HMo-eyyLpEWyOLMnQTsO2A_5_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">67401</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_QGvES4cuOk2-SfZcsp8sdw_6_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">557</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_ML6C769akk67p_V-Xbv4ZQ_7_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">66844</us-gaap:OperatingLeaseLiability>
    <glyc:LeaseQuantitativeDisclosureTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_LxkWj2gfUEy5Ge-ZVRloow">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Operating Leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt; Weighted-average incremental borrowing rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10.0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Right-of-use assets obtained in exchange for operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 872,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</glyc:LeaseQuantitativeDisclosureTableTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      id="Tc_G2YvdnKOcEqYqr68ozJFSQ_3_3">P0Y1M6D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      id="Tc_Ejrlv50iyE-rbA4d8d9gnQ_3_6">P1Y1M6D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="3"
      id="Tc_y9S6JX9c5ECgLxQMhEoinQ_4_3"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="3"
      id="Tc_MJrGJZbFmk6Ii-mwIuUOew_4_6"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_c71QRzLCNU2qd0KWKbXhXA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2024, the Company&#x2019;s board of directors adopted, and its stockholders approved, an increase in the total authorized shares of common stock from 100,000,000 to 150,000,000 shares with a par value of $0.001 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;At-The-Market Equity Offerings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In March 2022, the Company filed a shelf registration statement with the SEC, which was declared effective on April 22, 2022. On April 28, 2022, the Company entered into an at-the-market sales agreement (the Sales Agreement) with Cowen and Company, LLC. Under the Sales Agreement, the Company may sell up to $100.0 million worth of shares of common stock. During the year ended December 31, 2023, the Company issued and sold 9,822,930 shares of common stock under the Sales Agreement at a weighted average price per share of $3.01, for aggregate net proceeds of $28.7 million, after deducting commissions and offering expenses. There were no&lt;span style="white-space:pre-wrap;"&gt; shares issued under the 2022 Sales Agreement during the year ended December 31, 2024.  As of December 31, 2024, approximately &lt;/span&gt;$66.0&lt;span style="white-space:pre-wrap;"&gt; million remained available to be sold under the terms of the Sales Agreement.  The shelf registration statement will expire on April 28, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="INF"
      id="Narr_FNNuyG9GZUqT8sj0pCZUuw"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="INF"
      id="Narr_-Z4S6SUXtE-s6f2wC6VomQ"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="INF"
      id="Narr_YHFyO4_TikCZ66sIKToK4w"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="INF"
      id="Narr__9hYxjfGXUW8IDK0YL8ETA"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <glyc:CommonStockValueAvailableForSaleUnderAgreement
      contextRef="As_Of_3_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_Lgi28lfrs0-59NK1_KFagw"
      decimals="INF"
      id="Narr_F5bxiXMbAEGJMO5BPcbFig"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">100</glyc:CommonStockValueAvailableForSaleUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_U4gkV-b8YE6xJmFs08VMbg"
      decimals="INF"
      id="Narr_wL-Eod6UdkiUmvHAIOrk7A"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">9822930</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_31_2022_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_onqX81APG0Ghn54y5zgaMA"
      decimals="2"
      id="Narr_48mDFMm72ku8gh4a_EnqqQ"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">3.01</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_U4gkV-b8YE6xJmFs08VMbg"
      decimals="-5"
      id="Narr_LlyJUv4BrU6xna_tK0dVgA"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">28700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_TkPU169fb0a115F1Jhn1kA"
      decimals="INF"
      id="Narr_wwfiZ-xIIUKdiYS64K5rJA"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <glyc:CommonStockValueAvailableForSaleUnderAgreement
      contextRef="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOffering2022Member_SmdQHOUz5UqCH4SGTEpEHw"
      decimals="-5"
      id="Narr_LLUWum23VkK2hwSEy4K6WQ"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">66000000</glyc:CommonStockValueAvailableForSaleUnderAgreement>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_D5cvRzuUMkqaD4ymZTb1Xg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9. Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2013 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan effective in January 2014, and the 2013 Equity Incentive Plan was amended and restated by approval of the board of directors in April 2022 and by approval of the stockholders in May 2022 (as so amended and restated, the 2013 Plan). The 2013 Plan provides for the grant of incentive stock options within the meaning of Section&#160;422 of the Internal Revenue Code (the Code), to the Company&#x2019;s employees and its parent and subsidiary corporations&#x2019; employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards (RSUs), stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company&#x2019;s employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one &lt;span style="-sec-ix-hidden:Hidden_rkMRBeyC_Ee79e86m5b6WA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;forty&lt;/span&gt;&lt;/span&gt;-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 90 days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Authorized Shares&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The maximum number of shares of common stock that may be issued under the 2013 Plan was originally 1,000,000&#160;shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. Upon the amendment and restatement of the 2013 Plan in May 2022, the existing share reserve was increased by 2,619,622. Beginning on January 1, 2023 and ending on (and including) January 1, 2029, the maximum number of shares of common stock that may be issued under the 2013 Plan will cumulatively be increased by 4% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares as determined by the board of directors or the compensation committee thereof.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt; The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is 20,000,000. As of December 31, 2024, the total number of shares reserved for issuance under the 2013 Plan was 14,257,627 shares, of which 1,070,346 shares were available for future grants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock Options&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A summary of the Company&#x2019;s stock option activity under the 2013 Plan for the year ended December&#160;31, 2024 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AGGREGATE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;INTRINSIC&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;REMAINING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;VALUE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OUTSTANDING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EXERCISE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CONTRACTUAL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(IN&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OPTIONS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PRICE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TERM&#160;(YEARS)&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;THOUSANDS)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,273,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,756,875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,722,543)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,304,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested or expected to vest as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,561,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,024,978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2024, there was $915,970 of total unrecognized compensation expense related to unvested options that will be recognized over a weighted-average period of approximately 0.3 years. The total fair value of options that vested in the years ended December 31, 2024 and 2023 was $2,919,122 and $1,710,938, respectively. During 2024, the Company issued 3,250 shares of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;common stock in conjunction with exercises of stock options granted under the 2013 Plan and received $5,398&lt;span style="white-space:pre-wrap;"&gt; in cash proceeds from the exercise of these stock options.  During 2023, the Company issued &lt;/span&gt;100,960 shares of common stock in conjunction with exercises of stock options granted under the 2013 Plan and received $116,497 in cash proceeds from the exercise of these stock options. Total intrinsic value of the options exercised during the years ended December 31, 2024 and 2023 was $4,091 and $82,300, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has granted stock options to purchase an aggregate of 2,459,275 shares to certain employees under the 2013 Plan, the vesting of which is subject to performance vesting conditions relating to the achievement of specified regulatory or commercial milestones. The maximum fair value of $650,266 associated with performance-based options granted under the 2013 Plan has been excluded from compensation expense as the completion of the performance milestones was not deemed to be probable as of December 31, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Restricted Stock Units (RSUs)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;An RSU is a stock award that entitles the holder to receive shares of the Company&#x2019;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#x2019;s common stock on the date of grant. In January 2021, the Company awarded RSUs under the 2013 Plan to all of its employees. The RSUs granted vest over four years in equal installments on each anniversary of the grant date, provided that the employee remains employed by the Company at the applicable vesting date. Compensation expense is recognized on a straight-line basis. As of December 31, 2024, there was $9,541 of total unrecognized compensation expense associated with these RSU grants that will be recognized entirely in the first quarter of 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following is a summary of RSU activity for the 2013 Plan for the year ended December 31, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Underlying RSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 117,157&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (58,581)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,443)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Issuance of Shares to Directors in Lieu of Cash Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2023, the Company&#x2019;s board of directors amended the Company&#x2019;s Non-Employee Director Compensation Policy to include an election to receive unrestricted shares of common stock in lieu of quarterly board and committee retainer cash payments. The number of shares to be issued to an electing director is determined on the last day of each fiscal quarter by dividing the dollar amount of the compensation to be paid for such quarter that is subject to the election by the closing price of a share of common stock on the last trading day of the fiscal quarter, rounded up to the nearest whole share. Non-employee directors who made such an election received 13,127 shares of common stock in lieu of cash compensation earned for the quarter ended March 31, 2024. All shares of common stock issued pursuant to such an election were fully vested upon issuance and are classified as &#x201c;Other Awards&#x201d; under the 2013 Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In June 2024, the Non-Employee Director Compensation Policy was amended to allow a director to revoke his or her annual election to receive unrestricted shares of common stock in lieu of quarterly board and committee retainer cash payments.  The decision to amend the policy followed a significant decline in the market value of the Company&#x2019;s common stock in May 2024. Without the ability of the directors to revoke the prior elections, the Company would have been obligated to issue a significantly greater number of shares than in prior quarters in lieu of the fixed cash retainer payments. Each of the directors who previously elected to receive unrestricted shares of common stock in lieu of quarterly board and committee retainer cash payments for 2024 revoked their elections in June 2024, and as a result there were no additional shares issued subsequent to March 31, 2024. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Company&#x2019;s board of directors previously adopted the GlycoMimetics, Inc. Inducement Plan (as amended to date, the Inducement Plan). The Inducement Plan provides for the grant of nonstatutory stock options, restricted stock awards, RSU awards, stock appreciation rights and other forms of stock awards to individuals not previously an employee or director of the Company as an inducement for such individuals to join the Company. Unless otherwise stated in an applicable stock option agreement, &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_36PO8EraXkq8olRkBZDjHw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;-fourth of the shares subject to an option grant under the Inducement Plan will typically vest upon the first anniversary of the vesting start date, &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;with the balance of the shares vesting in a series of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;thirty-six&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; successive equal monthly installments as of the first day of each month measured from the first anniversary of the vesting start date, subject to the new employee&#x2019;s continued service with the Company through the applicable vesting dates. Upon termination of employment by reasons other than death, cause or disability, any vested options will terminate &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;90 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; from the date of grant. The Inducement Plan was amended by the board of directors on multiple occasions to increase the number of shares reserved for issuance to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;3,000,000&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares as of December 31, 2024. As of December 31, 2024, there were &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;299,108&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares available for future grants under the Inducement Plan&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A summary of the Company&#x2019;s stock option activity under the Inducement Plan for the year ended December 31, 2024 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AGGREGATE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;INTRINSIC&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;REMAINING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;VALUE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OUTSTANDING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EXERCISE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CONTRACTUAL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(IN&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OPTIONS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PRICE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TERM&#160;(YEARS)&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;THOUSANDS)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,590,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,690,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested or expected to vest as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,610,833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,452,908&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, there was $235,087 of total unrecognized compensation expense related to unvested options under the Inducement Plan that will be recognized over a weighted-average period of approximately 0.3 years. There were no options exercised under the Inducement Plan during the years ended December 31, 2024 or 2023. The total fair value of options that vested in the years ended December 31, 2024 and 2023 was $919,184 and $601,586, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has granted stock options to purchase an aggregate of 584,200 shares to certain newly hired employees under the Inducement Plan which options are subject to performance-based conditions. The maximum fair value of $825,353 associated with the performance-based options is excluded from the unrecognized compensation expense under the Inducement Plan as the completion of the performance milestones was not probable as of December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average fair value of the options granted under all equity incentive plans during the years ended December&#160;31, 2024 and 2023 was $1.49&lt;span style="white-space:pre-wrap;"&gt; and  &lt;/span&gt;$1.96 per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6.25 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6.25 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;101.79%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;78.36%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;4.17%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3.60%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"&gt;Total stock-based compensation expense associated with stock options and RSUs was classified as follows on the statement of operations for the years ended December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,271,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 909,981&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,425,891&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,614,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,697,546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,524,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_R_eQJnbT5kGlzY8X-rGidQ"
      decimals="INF"
      id="Narr_HTIiFCDFH02ab3eY1glEHQ"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      id="Narr_rrP-5GDbkECleMCVE53DBQ">P90D</glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      id="Narr_z80koursWEOqAaSs515pTQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HyhkPdyGmU6UnG8nxVmM2Q"
      decimals="INF"
      id="Narr_gtTjAHtEHUGkXOzkjWIumQ"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_5_1_2022_To_5_31_2022_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JTfAygcVu0yXRQjZySO8fQ"
      decimals="INF"
      id="Narr_OZXUq2BcQUWMfLtAg7rxLg"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">2619622</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <glyc:PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lEn5z0QjVECg-jhVCra21w"
      decimals="2"
      id="Narr_2YQJ-x7spEqQ9V7r9uuWQg"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.04</glyc:PercentageOfTotalNumberOfCommonStockStockIssuedOrOutstandingImmediatelyPrecedingFiscalYearOrLesserNumberAsDeterminedByBoardOfDirectorsOrCompensationCommittee>
    <glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions
      contextRef="As_Of_1_9_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HyhkPdyGmU6UnG8nxVmM2Q"
      decimals="INF"
      id="Narr_qGJWjaASBUCXSxvyJVWJIg"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">20000000</glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lEn5z0QjVECg-jhVCra21w"
      decimals="INF"
      id="Narr_TlVpehOPD0O7_C0V6mEMfA"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">14257627</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_lEn5z0QjVECg-jhVCra21w"
      decimals="INF"
      id="Narr_PqVor98H30iH1CdjIzyUTA"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">1070346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      id="Tb_LXioFO29nU-RzGomSQWCgg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AGGREGATE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;INTRINSIC&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;REMAINING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;VALUE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OUTSTANDING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EXERCISE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CONTRACTUAL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(IN&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OPTIONS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PRICE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TERM&#160;(YEARS)&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;THOUSANDS)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,273,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,756,875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,722,543)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,304,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested or expected to vest as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,561,952&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,024,978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NeI1DrJAfU2Pdw5yL4hyCw"
      decimals="INF"
      id="Tc_UJS24dE_5E-xrXQy9Nicuw_6_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">8273800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_NeI1DrJAfU2Pdw5yL4hyCw"
      decimals="2"
      id="Tc_UJq5DCiVS0mI5zVocUmykA_6_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">5.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_M5J3K2r_hUe_T0x0UXRjpQ"
      id="Tc_yB-KoSpCOkS_PhV9SZq1MA_6_7">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      decimals="INF"
      id="Tc_6zcV04TOukSwIM8wqrO9FA_7_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">5756875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      decimals="2"
      id="Tc_VoTsSi3V-0aqh0QWhZBhPA_7_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">1.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      decimals="INF"
      id="Tc_22S8fj3RuEGDSed0yzN1Eg_8_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">3250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      decimals="2"
      id="Tc_h2GXTZj0UUuJAOwkqUPmrw_8_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">1.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      decimals="INF"
      id="Tc_BYbZQO8PJUSbYPnGuZTa-w_9_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">1722543</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      decimals="2"
      id="Tc_SYj1od5UuEaJjcRZlMPxdw_9_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">6.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA"
      decimals="INF"
      id="Tc_ndSL-rNaF0eanqVgDW5MMA_10_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">12304882</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA"
      decimals="2"
      id="Tc__EMYfCjSEUu0_-ygulvgTQ_10_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">3.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      id="Tc_Of7bJHycmUy5e4FLbIoGnw_10_7">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA"
      decimals="INF"
      id="Tc_R1CphXnSRUGuR8-ztCpY-Q_11_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">6561952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA"
      decimals="2"
      id="Tc_opJFFtgYok2RgCoMKqNYzg_11_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">5.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      id="Tc_tLXuIIj5pUSSE7-2lQwIKw_11_7">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA"
      decimals="INF"
      id="Tc_QM7GvykNuUWHCc9v_DNubQ_12_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">6024978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA"
      decimals="2"
      id="Tc_sqQjH8hjXUOakHNW0oPTrA_12_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">5.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      id="Tc_Lg3oEwGtHkSFu4MeFOZdPQ_12_7">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_5is67PkAokC7pr6jUxHiPA"
      decimals="0"
      id="Narr_LKsC-Z5_-kGkK2RR4zhqKA"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">915970</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      id="Narr_i0QJy7CfJkGRIF9cGyr8MQ">P0Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      decimals="0"
      id="Narr_2os2zItJoE6eMcTBB3fAgA"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">2919122</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_M5J3K2r_hUe_T0x0UXRjpQ"
      decimals="0"
      id="Narr_0pDAIN-K6kO1an1E4TYWQg"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">1710938</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      decimals="INF"
      id="Narr_ZlUkZHjUmU24dF7S73v9TQ"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">3250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      decimals="0"
      id="Narr_HDjaopC0gEGs_FWJqwp3Gg"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">5398</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K4GuybjZVEmN-yz3jNQQZg"
      decimals="INF"
      id="Narr_MO9stUoHyEmBnCg4h5hkbQ"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">100960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_M5J3K2r_hUe_T0x0UXRjpQ"
      decimals="0"
      id="Narr_0bfYMhAwBk6NAbo8njw-HQ"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">116497</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      decimals="0"
      id="Narr_M0-fT3DaYka6e2kUpFYEVw"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">4091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_M5J3K2r_hUe_T0x0UXRjpQ"
      decimals="0"
      id="Narr_xrcXdM9iKkq5JtPkWtNV4g"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">82300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_1XsemFUZukWboPPsX0QU9g"
      decimals="INF"
      id="Narr_1jpWGL3gHkG0V0RUUPxrAA"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">2459275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense
      contextRef="Duration_1_1_2022_To_1_31_2022_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_1XsemFUZukWboPPsX0QU9g"
      decimals="0"
      id="Narr_hN2aHHNGOkCtQn5HW8ontA"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">650266</glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_l6-d0WjB2EWKO9FwgF6G9Q"
      id="Narr_zuYVkcuLdkOlvH3IVdOwBw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_8hSvq-SHI0KxvBm4TVYLQw"
      decimals="0"
      id="Narr_odbHe08F9UKGY1q_Jmcrqg"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">9541</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_z-tBV49hdU2uaqCIgKa0rg"
      id="Tb_vVGul5J0N0GMy5SeTWoaZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following is a summary of RSU activity for the 2013 Plan for the year ended December 31, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Underlying RSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 117,157&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (58,581)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,443)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_KEVqEI1mz0alUnOYmZkAMQ"
      decimals="0"
      id="Tc_asifWdC55k2WRTTiWkoLvA_4_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">117157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_KEVqEI1mz0alUnOYmZkAMQ"
      decimals="2"
      id="Tc_xBfffg0ovkOnCYCDo8tVUw_4_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_g8Jzg9x9fkCHME1NaPv5rg"
      decimals="0"
      id="Tc_kvJIbLyp3kaRP5KSKmvB8Q_5_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">58581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_g8Jzg9x9fkCHME1NaPv5rg"
      decimals="2"
      id="Tc_G3xar4mc906PpfENspJ1Ew_5_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_g8Jzg9x9fkCHME1NaPv5rg"
      decimals="0"
      id="Tc_nHMMmWJ2E0ygkIszcu4-uA_6_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">10443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_g8Jzg9x9fkCHME1NaPv5rg"
      decimals="2"
      id="Tc_Gu_Lx0q7O0WFifwvUb2ZyA_6_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_V8Yc464DDEuqsw28B2LXXw"
      decimals="0"
      id="Tc_hxqLICvJl0-3PnwXedqDgA_7_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">48133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_V8Yc464DDEuqsw28B2LXXw"
      decimals="2"
      id="Tc_VOqCZuuy3UOjV8cZtiPX1g_7_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_glyc_OtherAwardsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_-V6DN7K7xkqKAShmvSchFQ"
      decimals="INF"
      id="Narr_87U4pN69okG6IJBmTL6W0g"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">13127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments
      contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_iGa9kvr1_0OCIlThV88zBQ"
      decimals="INF"
      id="Narr__V5J-0qjGE-GXVrczHKv7Q"
      unitRef="Unit_Standard_installment_xM6my3fUa0iIeeFWVwoxkA">36</glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfMonthlyInstallments>
    <glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment
      contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_t2wb_CLKRESBcc-YEXDRlw"
      id="Narr_cAXNJGwbWEyta6a__xuhdg">P90D</glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2020_To_1_31_2020_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_t2wb_CLKRESBcc-YEXDRlw"
      id="Narr_mabCi1fPik2FP7S6CMPYQA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_SGKk_W-IqEa8wgIaEyiQyA"
      decimals="INF"
      id="Narr_J4yo16oIQ06B43NUYhZhaw"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw"
      decimals="INF"
      id="Narr_D4FOp6cmIUiI5UBLS1Pi4Q"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">299108</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw"
      id="Tb_E6PXnE2M2keALVPrnkYpBQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AGGREGATE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;WEIGHTED-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;INTRINSIC&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AVERAGE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;REMAINING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;VALUE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OUTSTANDING&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EXERCISE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CONTRACTUAL&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(IN&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;OPTIONS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PRICE&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TERM&#160;(YEARS)&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;THOUSANDS)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,590,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,690,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested or expected to vest as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,610,833&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,452,908&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_QC2B5nm5zE6wl4KPu8GzAw"
      decimals="INF"
      id="Tc_I1kZTotZxEascCAqI071-A_6_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">2590400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_QC2B5nm5zE6wl4KPu8GzAw"
      decimals="2"
      id="Tc_tm4uOGoSG0i2dwRos6hHjQ_6_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">1.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K4GuybjZVEmN-yz3jNQQZg"
      id="Tc_kx-rMZpea0GrRmpH970yeg_6_7">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw"
      decimals="INF"
      id="Tc_2nDRNou_p0i6QhVylaU26g_7_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw"
      decimals="2"
      id="Tc_7KNfcZ-ipkaw3Eaj6Q2Yuw_7_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">3.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw"
      decimals="INF"
      id="Tc_Xx4mrRdXPU2Yaz_jhYf2kg_8_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">29600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw"
      decimals="2"
      id="Tc_2EjGdWcFP0K4ZfFbhAmNmA_8_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">3.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw"
      decimals="INF"
      id="Tc__kN4BEerwkOzFMuSOJFXeA_9_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">2690800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw"
      decimals="2"
      id="Tc_h1vRShqyFECuceMJ9xG0sw_9_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">2.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw"
      id="Tc_hRiRlzDhsECCwS13bl4Z1Q_9_7">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw"
      decimals="INF"
      id="Tc_ThAkgUalCUy0EHPoGDDCyA_10_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">1610833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw"
      decimals="2"
      id="Tc_pgCkNPbccECs-gwMlkdQ0Q_10_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">1.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw"
      id="Tc_4JZM1yaEjUCdDkWwed9xzA_10_7">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw"
      decimals="INF"
      id="Tc_TkuV0H9E_UmSiB5etaG4CQ_11_2"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">1452908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw"
      decimals="2"
      id="Tc_n5wCAvmhfke30GBMaETpQg_11_5"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw"
      id="Tc_GFAuLXUNzkGKdCnBXLSVeg_11_7">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_yZ29hO768E6SVWZgEjuCXw"
      decimals="0"
      id="Narr_DX4XaJ6v0EmWq8DgzGp-IQ"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">235087</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw"
      id="Narr_R8WPynz_qkqe1uEql6XdrA">P0Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K4GuybjZVEmN-yz3jNQQZg"
      decimals="INF"
      id="Narr_yY7D-NEe-EqRiELtwgIhWA"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw"
      decimals="INF"
      id="Narr_OR9rLjo-Q0OpFu-S2KLZtQ"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_dHDagezCU0y9PamdVtU_Iw"
      decimals="0"
      id="Narr_UUFyaq8Y8U-iraSobymAeg"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">919184</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_K4GuybjZVEmN-yz3jNQQZg"
      decimals="0"
      id="Narr_pY7NjX7600-bLYVBD3U0Gg"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">601586</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_GranteeStatusAxis_glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_nWojf5k1XEuW7zoLkHsxkw"
      decimals="INF"
      id="Narr_jJVBGAXwbk-ZwYVBpYpiug"
      unitRef="Unit_Standard_shares_C9I2C3j5M0GdUEDwJht1vg">584200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_glyc_StockOptionsVestingBasedOnPerformanceMember_us-gaap_GranteeStatusAxis_glyc_ShareBasedPaymentArrangementNewlyHiredEmployeeMember_us-gaap_PlanNameAxis_glyc_EquityInducementPlanMember_nWojf5k1XEuW7zoLkHsxkw"
      decimals="0"
      id="Narr_rkK7xif1Q0uxLSDr47My5g"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">825353</glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFairValueOfOptionExcludedFromUnrecognizedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="2"
      id="Narr_Ie02c_HdE0epPgIbxTugrQ"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">1.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="2"
      id="Narr_MqbGu7mIjkOTWq68EXDnPQ"
      unitRef="Unit_Divide_USD_shares_C3IdtxdQjkmEjJX8-_BWLQ">1.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_RrE_KVJO6EyAFWrVwkWsPQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6.25 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6.25 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;101.79%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;78.36%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;4.17%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3.60%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Narr_3VbY8vcxZ0C7W7GxuSgy7w">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      id="Narr_09bU5Cjj6EeOvPrxzPAbDA">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="4"
      id="Tc_B2uq0B5V6Ey3jCq3DjLcfQ_3_2"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">1.0179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="4"
      id="Tc_u4eS3lMhl0aSMgXLiI7DzQ_3_4"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.7836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="4"
      id="Tc_vLokT55USUORdNa8ci8nKQ_4_2"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.0417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="4"
      id="Tc_tU01-mKyGk6Br7ZG36LKxg_4_4"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="2"
      id="Tc_oGFLxYlPakCdKoWLohvHTA_5_2"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="2"
      id="Tc_MOC0YaJOgkiMz_WGvipHLg_5_4"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_Iqy1DRH6Ek2Ua_sGrKkLfA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,271,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 909,981&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,425,891&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,614,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,697,546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,524,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_8LGYnV6fdkuBJAJjiuhDlw"
      decimals="0"
      id="Tc_nj0DPGFhM0OIvDxB7lEHWQ_3_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">1271655</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qaEaEVpgsk2gHQo8gXVEfQ"
      decimals="0"
      id="Tc_WnzEqdq__0aV2L0FmPQojA_3_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">909981</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_pj61R-BVG0mAA7jRopE9Lg"
      decimals="0"
      id="Tc_XnI_CkZ5nkqXb-eVzRmHXA_4_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">3425891</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_T5bkeU0TREKgcAs7V6M9TA"
      decimals="0"
      id="Tc_DKW4SA31n0i7gPKpz7z0Bg_4_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">2614495</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Tc_NGpqav8bwkShY3rq4b7Law_5_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">4697546</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Tc_usqjmpgtdE6qradX8H6nqQ_5_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">3524476</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_N7QFPfTgE0OB2MvBjUJIJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10. Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;"&gt;The components of the gross deferred tax asset and related valuation allowance at December 31 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred income tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,811,786&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,746,869&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Research and orphan drug credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 54,937,994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 53,152,849&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Capitalized research costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,861,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,748,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Capitalized start-up costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 339,138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 532,931&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Patent amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,071&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,541&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,699,628&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,324,617&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Accrued bonus&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 704,974&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 222,452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87,097&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"&gt;Gross deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170,722,283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 161,562,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (170,722,283)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (161,351,398)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"&gt;Net deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_458vb9MY1EioLUCUnC-NFg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 211,287&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred income tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (211,287)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"&gt;Gross deferred income tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_eA0MLaJIrUmo4aiKeTHJNw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (211,287)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred income tax asset/(liability)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_hdWUWzn18kiagf-L_qnDbQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_NTBSQbNInE69YpwADs5_rw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:6pt 0pt 12pt 0pt;"&gt;Based on the Company&#x2019;s operating history and management&#x2019;s expectation regarding future profitability, management believes the Company&#x2019;s deferred tax assets will not be realizable under ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;. Accordingly, a full valuation allowance was recorded as of December 31, 2024 and 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, the Company had $351.8 million of U.S. Federal and state net operating losses, $10.9 million of research and development tax credits and $44.1 million of orphan drug tax credits available to carry forward. A portion of the net operating loss carryforwards will begin to expire in 2025, the research and development tax credits in 2025 and the orphan drug tax credit in 2033. Under current federal income tax laws, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s tax attributes, including net operating losses and credits, are subject to any ownership changes as defined under Internal Revenue Code Sections 382 and 383. A change in ownership could affect the Company&#x2019;s ability to utilize its net operating losses and credits. As of December 31, 2024, the Company does not believe that an ownership change has occurred. Any future ownership changes, such as the consummation of the Merger, may cause a limitation on the Company&#x2019;s ability to utilize existing tax attributes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and the State of Maryland is the only significant state jurisdiction. The Company&#x2019;s federal income tax returns for tax years 2005 and after remain subject to examination by the U.S. Internal Revenue Service due to tax attributes available to be carried forward to open or future tax years. The Company&#x2019;s Maryland income tax returns for the tax years 2007 and thereafter remain subject to examination by the Comptroller of Maryland. In addition, all of the net operating losses, research and development tax credit and orphan drug credit carryforwards that may be used in future years are still subject to adjustment.  The Company is not currently under examination from any taxing authorities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not have unrecognized tax benefits as of December 31, 2024 and 2023, and does not anticipate this to change significantly over the next 12 months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense is as follows as of December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;U.S. Federal statutory tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Research credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Orphan drug credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Executive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_clWfYZ6iXkeaA_E1kRHvIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred income tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96,811,786&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,746,869&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Research and orphan drug credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 54,937,994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 53,152,849&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Capitalized research costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,861,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,748,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Capitalized start-up costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 339,138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 532,931&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Patent amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,071&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,541&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,699,628&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,324,617&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Accrued bonus&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 704,974&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,394&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 222,452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87,097&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"&gt;Gross deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170,722,283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 161,562,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (170,722,283)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (161,351,398)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"&gt;Net deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_458vb9MY1EioLUCUnC-NFg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 211,287&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 42pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred income tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (211,287)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"&gt;Gross deferred income tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_eA0MLaJIrUmo4aiKeTHJNw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (211,287)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred income tax asset/(liability)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_hdWUWzn18kiagf-L_qnDbQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_NTBSQbNInE69YpwADs5_rw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_ZDnokC04KEWEX5uv1VrTkA_3_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">96811786</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_baARxDLKS0Wbw_AGTVq3gw_3_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">88746869</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <glyc:DeferredTaxAssetsResearchAndOrphanDrugCredits
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_rWw9GddD0ECpO1GPfhugbg_4_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">54937994</glyc:DeferredTaxAssetsResearchAndOrphanDrugCredits>
    <glyc:DeferredTaxAssetsResearchAndOrphanDrugCredits
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_T8jjW0B9iEqUZS9_RvVzHQ_4_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">53152849</glyc:DeferredTaxAssetsResearchAndOrphanDrugCredits>
    <glyc:DeferredTaxAssetsCapitalizedResearchCosts
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_AmJudaOL6U-ImZYhs5Z1Pw_5_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">11861613</glyc:DeferredTaxAssetsCapitalizedResearchCosts>
    <glyc:DeferredTaxAssetsCapitalizedResearchCosts
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_q6QICf0Kw0GzmxyF9B1W_A_5_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">10748355</glyc:DeferredTaxAssetsCapitalizedResearchCosts>
    <glyc:DeferredTaxAssetsCapitalizedStartUpCosts
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_Jxw1pw5FBUmaFBAyDBb7Lg_6_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">339138</glyc:DeferredTaxAssetsCapitalizedStartUpCosts>
    <glyc:DeferredTaxAssetsCapitalizedStartUpCosts
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_5j8aPN5VhkS2q1JsO3-HjA_6_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">532931</glyc:DeferredTaxAssetsCapitalizedStartUpCosts>
    <glyc:DeferredTaxAssetsPatentAmortization
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_Y0JSrPvMhUelJD7IWDN8Tw_7_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">27071</glyc:DeferredTaxAssetsPatentAmortization>
    <glyc:DeferredTaxAssetsPatentAmortization
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_fC6PHW_pek2J8Fc78wR-Aw_7_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">42541</glyc:DeferredTaxAssetsPatentAmortization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_-uq3BFe3_kOiFoSkPTm_0w_8_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">6699628</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_6mJCxkOtFUWT9gYsMlN1qQ_8_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">7324617</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <glyc:DeferredTaxAssetsAccruedBonus
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_Ukqn6RTaF0Oc_yvCekRwZg_9_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">25356</glyc:DeferredTaxAssetsAccruedBonus>
    <glyc:DeferredTaxAssetsAccruedBonus
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_kOgbwWjR6kefcLB-TZ20Dg_9_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">704974</glyc:DeferredTaxAssetsAccruedBonus>
    <glyc:DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_M8jZJzuC6kyo8hd2mEif4g_10_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">18394</glyc:DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities>
    <glyc:DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_-wVz8ScKlE6AdhpHGZFQag_10_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">222452</glyc:DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_ExAPkmET4EOzia5UYoTcLg_11_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">1303</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_zLraCGwcPU-n-78GJrr7Hw_11_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">87097</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc__IN96E77C0u6onPQicHcgQ_12_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">170722283</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_k-DPVlohAEm9fTNcGFV0pA_12_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">161562685</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_bk36nn77rU6r9Iesa1M0cA"
      decimals="0"
      id="Tc_VztajSA3IU6hQarm-2vncA_13_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">170722283</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_k0t_6uZ--0izypP1N7uM6w_13_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">161351398</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_zuXTqXwRM0-xzdkVZhYvYQ_14_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">211287</us-gaap:DeferredTaxAssetsNet>
    <glyc:DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_wrhNKk_5f0un-0p2EbKQ6Q_17_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">211287</glyc:DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2023_6XqwbMeWrEampvKQIXgP0g"
      decimals="0"
      id="Tc_U-O52ygDIEe58cVXAUl4eQ_18_6"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">211287</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_glyc_FederalAndStateAuthoritiesMember_0VDyvQ7ZGE6FKTRNibG9Aw"
      decimals="-5"
      id="Narr_2l35p4RuaEW5wXKFKX9QrA"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">351800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_SHUtEQJ4gEmeTUN1FXH1Jg"
      decimals="-5"
      id="Narr_l0IydJu6FEKeXs-hwhFK2g"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">10900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember_ZY2boBNI1ES9pXTrZe4dfQ"
      decimals="-5"
      id="Narr_r07-u5CIEEaFn6uJ-mEF6Q"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">44100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_7lBQwdP6V0-9MgK94qTekQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;U.S. Federal statutory tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Research credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Orphan drug credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Executive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="INF"
      id="Tc_OlPTayhd2UG0fewcEhOaUA_2_2"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="INF"
      id="Tc_Zb9G51HHR0-o-SYUWAKdPQ_2_4"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="3"
      id="Tc_Q1_Cl-cVL0Oi9ssfKoNCsw_3_2"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.059</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="3"
      id="Tc_pTRAna_kOUmknnk2yIF0vw_3_4"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.063</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="3"
      id="Tc_ToFo-UdXT0-PyUnxQnZoYw_4_2"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="3"
      id="Tc_isHK5a9VBEiFlr9A8pJQfQ_4_4"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="3"
      id="Tc_1sEM1LWAB0qaOuXBIKYWBg_5_2"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.041</glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent>
    <glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="3"
      id="Tc_KUjbCdnTLUaFz0ajNatKdQ_5_4"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.041</glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="3"
      id="Tc_uplufujew0io8a3rtPxqAg_6_2"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="3"
      id="Tc_7JgUV2vGBUqoXJoxXouZ9w_6_4"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <glyc:ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="3"
      id="Tc_pwPTEh4iTEqoiAQJT1nnSg_7_2"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">-0.012</glyc:ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent>
    <glyc:ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="3"
      id="Tc_Ntwt_OvUNEGbRJHCbjW_qg_7_4"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">-0.001</glyc:ExecutiveCompensationEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="3"
      id="Tc__IdO7ltvnUynhtswjiYPXw_8_2"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="3"
      id="Tc_oiyoy-YOQEKcUfxmFHa-UA_8_4"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">-0.035</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="3"
      id="Tc_1WVDi5Pc10KqtL9o_Nabpg_9_2"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">-0.247</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="3"
      id="Tc_yqKPWFhbVkWZPzKLs96M8Q_9_4"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">-0.308</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <glyc:ResearchAndLicenseAgreementTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_W2Y32F_P0UWwhDoI1sy-UA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;11. &#160;License and Collaboration Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Apollomics&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2020, the Company entered into a collaboration and license agreement (the Agreement) with Apollomics (Hong Kong), Limited (Apollomics) for the development, manufacture and commercialization of products derived from two of the Company&#x2019;s compounds, GMI-1271 and GMI-1687 (the Products) for therapeutic and prophylactic uses (the Field) in China, Taiwan, Hong Kong and Macau (the Territory). Under the terms of the Agreement, the Company granted Apollomics:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;an exclusive license, with the right to sublicense, to develop, manufacture and have manufactured, distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise the Products in the Field in the Territory; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;a non-exclusive license to conduct preclinical research with respect to Products in the Field outside of the Territory for the purposes of developing such Products for use in the Territory. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company did not recognize any milestone revenue under the Agreement for the years ended December 31, 2024 or 2023.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company and Apollomics also entered into a clinical supply agreement pursuant to which the Company agreed to manufacture and supply the Products at agreed upon prices. Apollomics has the option to begin manufacture of the Products after appropriate material transfer requirements are met. The Company did not recognize any revenue under the clinical supplies agreement during the years ended December 31, 2024 or 2023.&lt;/p&gt;</glyc:ResearchAndLicenseAgreementTextBlock>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_mkFmEtqwR0KaVgUNOAqKAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12. Employee Benefit Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company has a defined contribution plan under the Internal Revenue Code Section&#160;401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. For the years ended December 31, 2024, 2023 and 2022, the Company matched 50% up to the first 6% of employee contributions. All matching contributions have been paid by the Company. The Company&#x2019;s matching contributions vest in full immediately. The total Company matching contributions were approximately $211,000 and $248,000 for the years ended December 31, 2024 and 2023, respectively. &lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2022_To_12_31_2022_wZeRx6oRpUKbM_22ALjCXw"
      decimals="2"
      id="Narr_0LnrwBTv0UeOFXLVZ973ag"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="2"
      id="Narr_5s3fVTehYkWUda3DQTFzTA"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="2"
      id="Narr_s6MxVL5fxkqRw1W9mY5aSA"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_mfEME_8KIEOUdPf0enFlBA"
      decimals="2"
      id="Narr_nwbMcFj2NkSlo6uMjHB0cw"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_v6lQTXiXUUmyixAKiaaFgA"
      decimals="2"
      id="Narr_6UBrG75ZeEyuHXk8-LM5gA"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_J7qgUFtkl0Wo9KigpKzqfQ"
      decimals="2"
      id="Narr_xwHkhc7i2UWjQEGLoy7WzQ"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="0"
      id="Narr_NIOC4Ha9sUCCWSwE1S2IoA"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">211000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_U-z7BUsnE0a-0j0uHgJnMQ"
      decimals="0"
      id="Narr_7BCDiAN7rkWx643UFmEX4g"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">248000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_EyiT-XRdGEarCWjUnij6eg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;13. Restructuring and Asset Impairment Charges&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In July 2024, the Company&#x2019;s Board of Directors approved a streamlined operating plan that included a reduction in the Company&#x2019;s workforce by 26 employees, or approximately 80% of its headcount.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Employees affected by the reduction in force are entitled to receive severance payments and Company-funded medical insurance for a specific time.  During the year ended December 31, 2024, the Company &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_gisLThAx_kmBXJrqV8ibaQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;recognized&lt;/span&gt;&lt;/span&gt; $7.0&lt;span style="white-space:pre-wrap;"&gt; million of charges for severance and related benefits.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The following is a summary of the activity for accrued severance costs for the year ended December 31, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Severance accrual, January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Charges&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,026,614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,539,356)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Severance accrual, December 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,487,258&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The accrued severance liability of $3.5 million is payable within the next twelve months and has been included in accrued expenses on the balance sheet as of December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company also completed an evaluation of the impact of the restructuring on the carrying value of its long-lived assets. Our evaluation determined that indicators of impairment were present within right-of-use assets and property and equipment. Where impairment indicators existed the Company evaluated the identified asset group and separately compared the estimated undiscounted cash flow for each asset group to the net book value of the related long-term asset. The Company calculated the amount of the impairment by developing a fair value estimate of the asset group that was compared to the carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company recorded $0.4 million of impairment charges related to its facility operating lease and accelerated depreciation on property and equipment during the year ended December 31, 2024.&lt;/p&gt;</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="Duration_7_1_2024_To_7_31_2024_kOgWP4JoZ0qcll1HUFWAMQ"
      decimals="INF"
      id="Narr_UVKsDPquIE2XIYuX2oTk0Q"
      unitRef="Unit_Standard_employee__mI-PxD8qU-9RiyVThW_0Q">26</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_7_1_2024_To_7_31_2024_kOgWP4JoZ0qcll1HUFWAMQ"
      decimals="2"
      id="Narr_zhG_gkLWe0yajFuaNUyZGg"
      unitRef="Unit_Standard_pure_9Fci5qc3REig8LNR07gHvw">0.80</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="-5"
      id="Narr_D4AMwF0y3UOxWeUyzvU5rA"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">7000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      id="Tb_7A76czkgPUW14mKVnH1i3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Severance accrual, January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Charges&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,026,614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,539,356)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Severance accrual, December 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,487,258&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_VcdbkkEL90CR6p-GileFsw"
      decimals="0"
      id="Tc_FVmJgmDdXU6zf0GOhvHbEQ_3_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">7026614</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_VcdbkkEL90CR6p-GileFsw"
      decimals="0"
      id="Tc_M-hqlI4p20a7bXkOriOilQ_4_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">3539356</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="As_Of_12_31_2024_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_ezQHd-wQf0--shnHTiwUGQ"
      decimals="0"
      id="Tc_NgG6PitMoUmXYTuin2Ztsg_5_3"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">3487258</us-gaap:RestructuringReserve>
    <us-gaap:PaymentsForRestructuring
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="-5"
      id="Narr_EUBYEPiN70ObOPYnojkYZw"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">3500000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_HMjXnbFqmk6Gt0r-iDIh1w"
      decimals="-5"
      id="Narr_IodTW4eoE0qM6dPD_f_vUg"
      unitRef="Unit_Standard_USD_TcSySYK7lUG2p_8mbK50-g">400000</us-gaap:RestructuringReserveAcceleratedDepreciation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
